<SEC-DOCUMENT>0001387131-21-003140.txt : 20210304
<SEC-HEADER>0001387131-21-003140.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210303194819
ACCESSION NUMBER:		0001387131-21-003140
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		21711765

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>txmd-10k_123120.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:txmd="http://therapeuticsmd.com/20201231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_078_XDX_P%2D%2D\Clients\TherapeuticsMD\2021\q21%2D01733__10%2DK__IXBRL\txmd%2D10k__financials.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06A_Sqft_8_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06C_N_5_Number -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<body>
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0038" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2019-12-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_us-gaap_LicenseMember" id="xdx2ixbrl0170" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:IncreaseDecreaseInSecurityDeposit" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:WarrantGrantedInRelationToFinancingAgreement" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:WarrantGrantedInRelationToFinancingAgreement" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember" id="xdx2ixbrl0588" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember" id="xdx2ixbrl0590" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P5Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_custom_BijuvaMember" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_custom_AnnoveraMember" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_us-gaap_LicenseMember" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_custom_PerformanceStockUnitsMember" id="xdx2ixbrl0748" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31_custom_PerformanceStockUnitsMember" id="xdx2ixbrl0750" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0794" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl1028" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10057632</ix:nonFraction>
    <ix:nonNumeric contextRef="AsOf2020-12-31" id="xdx2ixbrl1634" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric>
    <ix:nonNumeric contextRef="AsOf2019-12-31" id="xdx2ixbrl1635" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="txmd-20201231.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-01-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_VitaminsImvexxyAndBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsImvexxyAndBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_BijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_KnightLicenseAgreementMember_custom_BijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:KnightLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-04</xbrli:startDate>
        <xbrli:endDate>2019-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-03</xbrli:startDate>
        <xbrli:endDate>2019-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-05</xbrli:startDate>
        <xbrli:endDate>2019-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-05</xbrli:startDate>
        <xbrli:endDate>2019-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-062019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-06</xbrli:startDate>
        <xbrli:endDate>2019-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PerformanceStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_PerformanceStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_PerformanceStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MultipleTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MultipleTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUSPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ForeignPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ForeignPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticPatentsNonApprovedBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUSPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUSUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUSDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ForeignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ForeignUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ForeignDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTopicalCreamCandidatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ForeignUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUtilityPatentTx009HRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ForeignPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DomesticUtilityPatentOperaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-27</xbrli:startDate>
        <xbrli:endDate>2021-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period3Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period4Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period5Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period5Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period6Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period6Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period7Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period7Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period8Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period8Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period9Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period9Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period10Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period10Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period11Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period11Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period12Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period12Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period13Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period13Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-05_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-08_custom_LenderWarrantsMember_custom_FinancingAgreementAmendment6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-092020-11-13_custom_UnderwritingAgreementCantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-09</xbrli:startDate>
        <xbrli:endDate>2020-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-092020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-09</xbrli:startDate>
        <xbrli:endDate>2020-11-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-092020-11-20_custom_UnderwritingAgreementCantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-09</xbrli:startDate>
        <xbrli:endDate>2020-11-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-28_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-24</xbrli:startDate>
        <xbrli:endDate>2019-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-05</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember75219000">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_WarrantMember75219203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_WarrantMember75219203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Plan2019Member_custom_PerformanceStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-17</xbrli:startDate>
        <xbrli:endDate>2020-06-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriodIndefiniteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_AmericanInternationalGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:AmericanInternationalGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SupplierOneConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SupplierOneConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_SupplierOneConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-07-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CatalentMember75224546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_KnightLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:KnightLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-08_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment7Period1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment7Period2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-11</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>txmd:Number</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <ix:relationship fromRefs="Fact001446" toRefs="Footnote001448"></ix:relationship>
    <ix:relationship fromRefs="Fact001698" toRefs="Footnote001760 Footnote001761 Footnote001762 Footnote001763"></ix:relationship>
    <ix:relationship fromRefs="Fact001705" toRefs="Footnote001760 Footnote001761 Footnote001762 Footnote001763"></ix:relationship>
    <ix:relationship fromRefs="Fact001712" toRefs="Footnote001760 Footnote001761 Footnote001762 Footnote001763"></ix:relationship>
    <ix:relationship fromRefs="Fact001719" toRefs="Footnote001760 Footnote001761 Footnote001762 Footnote001763"></ix:relationship>
    <ix:relationship fromRefs="Fact001699" toRefs="Footnote001764"></ix:relationship>
    <ix:relationship fromRefs="Fact001706" toRefs="Footnote001764"></ix:relationship>
    <ix:relationship fromRefs="Fact001713" toRefs="Footnote001764"></ix:relationship>
    <ix:relationship fromRefs="Fact001720" toRefs="Footnote001764"></ix:relationship>
    <ix:relationship fromRefs="Fact001726" toRefs="Footnote001765"></ix:relationship>
    <ix:relationship fromRefs="Fact001733" toRefs="Footnote001765"></ix:relationship>
    <ix:relationship fromRefs="Fact001740" toRefs="Footnote001765"></ix:relationship>
    <ix:relationship fromRefs="Fact001747" toRefs="Footnote001765"></ix:relationship>
    <ix:relationship fromRefs="Fact001727" toRefs="Footnote001766"></ix:relationship>
    <ix:relationship fromRefs="Fact001734" toRefs="Footnote001766"></ix:relationship>
    <ix:relationship fromRefs="Fact001741" toRefs="Footnote001766"></ix:relationship>
    <ix:relationship fromRefs="Fact001748" toRefs="Footnote001766"></ix:relationship>
    </ix:resources>
  </ix:header>
</div>


<!-- Field: Rule-Page --><div style="float: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%"></div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>
<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>Form
<span id="xdx_90D_edei--DocumentType_c20200101__20201231_zwLPhTg2rvKl"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font: 12pt Times New Roman, Times, Serif"><span id="xdx_904_edei--DocumentAnnualReport_c20200101__20201231_zQSi7LbKbAgl"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font: 12pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>For
    the fiscal year ended <span id="xdx_908_edei--DocumentPeriodEndDate_c20200101__20201231_zzmm4o951RG9"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2020</ix:nonNumeric></span></b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%"><span style="font: 12pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--DocumentTransitionReport_c20200101__20201231_z2BHfpU7sQBb"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="width: 95%; text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 12pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>For the transition
    period from ______________________ to ________________________</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Commission
File Number <span id="xdx_90D_edei--EntityFileNumber_c20200101__20201231_zjwV6yqeZlw"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityFileNumber">001-00100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid"></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>
 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p>
 <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img src="logo_img001.jpg" alt="" /></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityRegistrantName_c20200101__20201231_zbGdf4doEdGe"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityRegistrantName">TherapeuticsMD, Inc.</ix:nonNumeric></span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>
 <!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid"></div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;
<span style="font-size: 10pt"><i>(Exact Name of Registrant as Specified in Its Charter)</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 35%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20200101__20201231_z45xb9XvWyG2"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 35%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20200101__20201231_zCbLIdTyFQC5"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityTaxIdentificationNumber">87-0233535</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or Other
    Jurisdiction of <br />
Incorporation or Organization)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-style: italic; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">(I.R.S. Employer
    Identification No.)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20200101__20201231_z55AxgQEcjO9"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressAddressLine1">951 Yamato Rd.</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20200101__20201231_zxMXB3JaoTzb"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressAddressLine2">Suite 220</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20200101__20201231_zTqKueygDWag"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressCityOrTown">Boca Raton</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20200101__20201231_zRyeC9AgYHAg"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20200101__20201231_zJjBFBojmvX9"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressPostalZipCode">33431</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--CityAreaCode_c20200101__20201231_zJBjBrgfermi"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:CityAreaCode">(561)</ix:nonNumeric></span>
<span id="xdx_90B_edei--LocalPhoneNumber_c20200101__20201231_zpZB9prnPmZ8"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:LocalPhoneNumber">961-1900</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Address,
including zip code, and telephone number,</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>including
area code, of Principal Executive Offices)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
        of Each Class</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
        Symbol</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of Each Exchange on Which Registered</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20200101__20201231_zXUaihCdvaZh"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--TradingSymbol_c20200101__20201231_zhuEUlflq3be"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:TradingSymbol">TXMD</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--SecurityExchangeName_c20200101__20201231_zNlrtwEWCo86"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(g) of the Act: </b>None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20200101__20201231_zQakorg9n37l"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric></span> &#9746;&#160;&#160;&#160;&#160;&#160;No
&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;&#160;&#160;&#160;<span id="xdx_902_edei--EntityVoluntaryFilers_c20200101__20201231_zXd7yS72zwe6"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_908_edei--EntityCurrentReportingStatus_c20200101__20201231_zkOucy4qiIE"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746;&#160;&#160;&#160;&#160;&#160;No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20200101__20201231_zDAWkgrOaXei"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746;&#160;&#160;&#160;&#160;&#160;No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
<tr style="vertical-align: top">
    <td style="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td>
    <td style="width: 52%; padding-right: 45pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 10pt">&#160;Accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">&#160;&#160;&#160;<span id="xdx_900_edei--EntityFilerCategory_c20200101__20201231_zH6VYDsdu8u2"><span style="-sec-ix-hidden: xdx2ixbrl0038">Non-accelerated filer</span></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></span></td>
    <td style="padding-right: 45pt; text-align: right"><span style="font-size: 10pt">Smaller reporting company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntitySmallBusiness_c20200101__20201231_zPwlcsGsv6qg"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 45pt; text-align: right"><span style="font-size: 10pt">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20200101__20201231_zeN2HbSfdYU8"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
        <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--IcfrAuditorAttestationFlag_c20200101__20201231_zPFFC5UKkQSg"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></span>
    </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; &#160;&#160;&#160;<span id="xdx_901_edei--EntityShellCompany_c20200101__20201231_zYpn25f9HMQd"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate market value of common stock held by non-affiliates of the registrant (<span id="xdx_908_ecustom--EntityCommonStockHeldByNonaffiliates_iI_c20200630_zBz5ibblan7j" title="Entity Common Stock Held by Non-affiliates"><ix:nonFraction name="txmd:EntityCommonStockHeldByNonaffiliates" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">246,062,968</ix:nonFraction></span> shares) based on the closing price
of the registrant&#8217;s common stock as reported on the Nasdaq Global Select Market on June 30, 2020, which was the last business
day of the registrant&#8217;s most recently completed second fiscal quarter, was $<span id="xdx_903_edei--EntityPublicFloat_iI_c20200630_zBvE7wCCzC89"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,578,710</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 1, 2021, there were outstanding <span id="xdx_90B_edei--EntityCommonStockSharesOutstanding_iI_c20210301_zVxUMUdf0hs"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-03-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">387,825,545</ix:nonFraction></span> shares of the registrant&#8217;s common stock, par value $0.001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Documents
Incorporated by Reference</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Portions
of the registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders are incorporated by reference
into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange
Commission no later than 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 12pt"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0; margin-bottom: 0"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0; text-align: center"><b><b>THERAPEUTICSMD, INC.<br />ANNUAL REPORT ON FORM 10-K</b></b><br /><b>Fiscal Year Ended December 31, 2020</b><br /><b>TABLE OF CONTENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: center"></p><table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a001">PART
I</a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a002">Item
1.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a002"><i>Business
</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">4</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a003">Item
1A.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a003"><i>Risk
Factors</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">26</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a004">Item
1B.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a004"><i>Unresolved
Staff Comments</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">54</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a005">Item
2.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a005"><i>Properties</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">54</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a006">Item
3.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a006"><i>Legal
Proceedings</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">54</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a007">Item
4.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a007"><i>Mine
Safety Disclosures</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">55</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a008">PART
II</a></span> </p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a009">Item
5.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a009"><i>Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">55</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a010">Item
6.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a010"><i>Selected
Financial Data</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">57</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a011">Item
7.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a011"><i>Management&#x2019;s
Discussion and Analysis of Financial Condition and Results of Operations</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">58</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a012">Item
7A.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a012"><i>Quantitative
and Qualitative Disclosures About Market Risk</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">73</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a013">Item
8.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a013"><i>Financial
Statements and Supplementary Data</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">74</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a014">Item
9.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a014"><i>Changes
in and Disagreements With Accountants on Accounting and Financial Disclosure</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">74</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a015">Item
9A.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a015"><i>Controls
and Procedures</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">74</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a016">Item
9B.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a016"><i>Other
Information</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">75</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a017">PART
III</a></span> </p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a018">Item
10.</a></span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a018"><i>Directors,
Executive Officers and Corporate Governance</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">75</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a019">Item
11.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a019"><i>Executive
Compensation</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">75</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a020">Item
12.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a020"><i>Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">75</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a021">Item
13.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a021"><i>Certain
Relationships and Related Transactions, and Director Independence</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">75</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a022">Item
14.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a022"><i>Principal
Accountant Fees and Services</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">75</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a023">PART
IV</a></span> </p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a024">Item
15.</a></span> </p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a024"><i>Exhibits
and Financial Statement Schedules</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">75</span></p>
</td>
</tr>
<tr>
<td style="padding: 0in; width: 1in; vertical-align: top; width: 90px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a025">Item
16.</a></span></p>
</td>
<td style="padding: 0in; width: 459pt; vertical-align: top; width: 765px"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a025"><i>Form
10-K Summary</i></a></span></p>
</td>
<td style="padding: 0in; width: 27pt; vertical-align: top; width: 45px"><p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">78</span></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-align: center">&#160;</p>



<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->

     <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: justify; text-indent: 36pt">Throughout this Annual Report, the terms &#8220;we,&#x0094; &#8220;us,&#x0094; &#8220;our,&#x0094; &#8220;TherapeuticsMD,&#x0094; or &#8220;our company&#x0094; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: justify; text-indent: 36pt">TherapeuticsMD owns or has rights to trademarks, service marks, or trade names that are used in connection with the operation of its business including TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, ANNOVERA<sup>&#174;</sup>, BIJUVA<sup>&#174;</sup>, and IMVEXXY<sup>&#174;</sup>. This Annual Report also contains trademarks and trade names of other companies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: justify; text-indent: 36pt">This Annual Report includes our trademarks, trade names and service marks, such as vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>, BIJUVA<sup>&#174;</sup> and ANNOVERA<sup>&#174;</sup> which are protected under applicable intellectual property laws and are the property of, or licensed to, our company. This Annual Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report may appear without the <sup>&#174;</sup>, &#153; or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#x2019; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: justify; text-indent: 36pt">In addition, this Annual Report includes market and industry data that we obtained from periodic industry publications, third-party studies and surveys, government-agency sources, filings of public companies in our industry, and internal-company surveys. Industry publications and surveys generally state that their information has been obtained from sources believed to be reliable. Although we believe that the industry and market data below is reliable as of the date of this Annual Report, this information could prove to be inaccurate as a result of a variety of matters.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><b>Statement Regarding Forward-Looking Information</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties. For example, statements regarding our operations, financial position, business strategy, product development, and other plans and objectives for future operations, and assumptions and predictions about future product development and demand, research and development, marketing, expenses and sales are all forward-looking statements. These statements may be found in the items of this Annual Report entitled &#8220;Business&#8221; and &#8220;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as in this Annual Report generally. These statements are generally accompanied by words such as &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential(ly),&#8221; &#8220;continue,&#8221; &#8220;forecast,&#8221; &#8220;predict,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; or the negative of such terms or other comparable terminology.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have based these forward-looking statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date of this Annual Report, but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, research and product-development uncertainties, regulatory policies and approval requirements, competition from other businesses, market and general economic factors, and the other risks discussed in Item 1A of this Annual Report. This discussion should be read in conjunction with the consolidated financial statements and notes thereto included in this Annual Report.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have identified some of the important factors that could cause future events to differ from our current expectations and they are described in this Annual Report in the section entitled &#8220;Risk Factors&#8221; that you should review carefully. Please consider our forward-looking statements in light of those risks as you read this Annual Report. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we project. We do not undertake to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><b>P<span id="a001"></span>ART I</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><span id="a002"></span>Item 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Business</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Overview</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><i>Our Company</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">TherapeuticsMD is a women&#x2019;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a novel patient-controlled, procedure free, long-lasting contraceptive to advanced U.S. Food and Drug Administration, or FDA, approved bio-identical hormone therapy pharmaceutical products for the treatment of vasomotor symptoms and dyspareunia We also have a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our women&#x2019;s healthcare focus.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our portfolio of products focused on women&#x2019;s health allows us to efficiently leverage our sales and marketing plans to grow our recently approved products. During 2018, the FDA approval of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our pharmaceutical products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was approved by the FDA in May 2018.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In April 2019, we launched our FDA-approved product, BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bioidentical 17&#223;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus, which was approved by the FDA in October 2018.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In October 2019, we began a &#8220;test and learn&#8221; market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was approved by the FDA in August 2018 and which we have licensed for commercialization in the U.S. pursuant to an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council. We paused the full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic and resumed this initiative in July 2020.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have also entered into license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In July 2018,
we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight
an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Knight received the first regulatory approval
in Canada for IMVEXXY and BIJUVA in the third quarter of 2020.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In June 2019, we entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women&#x2019;s health, to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: justify"><b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><b>Impact of COVID-19 on our Business</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our business has been, and we anticipate that it will continue to be, impacted by the coronavirus (COVID-19) pandemic. Despite the ongoing COVID-19 pandemic, we remain committed to the execution of our corporate goals, demonstrated in part by the increase in product revenue throughout 2020.&#160; We resumed the full launch of ANNOVERA in July 2020 and launched the new consumer marketing campaign for IMVEXXY in August 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">At this time, the length and extent of the impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. We developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments in our sales and marketing infrastructure, protect our balance sheet during this period of market disruption, and meet the needs of our patients and prescribers. This contingency plan was designed to monitor the COVID-19 pandemic and adapt to the length of time that COVID-19 may impact our business, which is intended to allow us to conserve our financial resources during the COVID-19 pandemic.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">COVID-19 has accelerated telehealth, online pharmacies, and retail pharmacies utilizing home delivery options.&#160;&#160;These are areas where we have been developing relationships with industry leaders and emerging technology companies and we believe we are well positioned to capitalize on these trends. For example, contraception is an important category within telehealth and since 2019 we have been working with leading online telehealth platforms that focus on directly prescribing and filling birth control to patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><i><span style="background-color: white"><i>Cost Containment and Spending Cuts</i></span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We reduced our operating expenses at the beginning of COVID-19 pandemic, and we continue to identify areas in which we can further reduce operating expenses in the future.&#160;<span style="background-color: white">These cost cuts and reductions included permanent cost savings, as well as the interim cessation of certain spending that may be restarted in future quarters. These cost cuts included:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Negotiating lower fees or suspending services from third party vendors;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Implementing certain hiring restrictions;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Delaying or cancelling non-critical information technology projects;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Eliminating travel, entertainment, meeting, and event expenses; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Reducing the size of our sales force and eliminating certain staff positions.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="background-color: white"><i>Employees and Sales Force</i></span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">We continue to monitor the COVID-19 pandemic and adapt to the impacts it has on our business. As interactions with HCPs continue to be challenged during the fourth quarter of 2020, we continue to utilize digital engagement tools and tactics and virtual detailing to remain engaged with prescribers and distribution channels to supplement live interactions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our sales force continues to support HCPs remotely, when it is necessary, including the sales forces&#x2019; ability to continue to provide HCPs with access to patient product samples, product marketing information, and information regarding patient affordability programs and support services.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our sales force is in regular interaction with HCPs, including conducting live and &#8220;virtual&#8221; educational programs with providers.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our sales force also continues product training, including sharing best practices, in how to operate and create impact in both live and virtual world.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="background-color: white"><i>Remote Pharmacy and At-Home Delivery Options</i></span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">As of the date of this Annual Report on Form 10-K, we are providing continued access to our products for patients.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our products have broad distribution at all major retail pharmacy chains across the country.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our vitaCare patient model assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice, including via home delivery retail pharmacy options. We anticipate that home delivery pharmacy options will continue to be attractive to patients during the COVID-19 pandemic.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We anticipate that vitaCare will continue to support patient access to our products during the COVID-19 pandemic and will help sustain refill trends for our products given vitaCare&#x2019;s broad use by our patients.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We have also engaged with independent community pharmacies and multiple third-party online pharmacies&#160; to help ensure patients have real-time access to both diagnosis and treatment.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We have developed relationships with industry leaders and emerging technology companies in the telehealth channel, a channel that has seen accelerated growth because of COVID-19. Recognizing the importance of telehealth particularly in the contraception category, we began developing various telehealth relationships in 2019 to ensure access to our products.&#160; We provide information and links on both Annovera.com and Imvexxy.com for patients to connect with these telehealth providers.&#160; Among those relationships are leading online telehealth platforms that focus on prescribing and filling birth control directly to patients.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="background-color: white"><i>Supply of Products</i></span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of the date of this Annual Report on Form 10-K, we do not anticipate a shortage of our products due to the COVID-19 pandemic.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We currently have sufficient inventory of finished product in our contracted warehouses to meet anticipated demand for IMVEXXY and BIJUVA through the next six months and ANNOVERA through the next three months.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We currently do not foresee any interruption in our contract manufacturers&#x2019; abilities to continue to manufacture additional products to be used. Our contract manufacturers have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products and there is currently no interruption in the supply chain for the active pharmaceutical ingredients for our products.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We currently have uninterrupted wholesale and retail distribution of our products and are actively working to ensure that there continues to be an adequate supply of our products at pharmacies for sales to patients.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">While we currently believe that our COVID-19 contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, the effectiveness of, and ability to widely distribute, the COVID-19 vaccine, the duration of &#8220;stay at home,&#8221; quarantine or &#8220;social distancing&#8221; orders, the ability of our sales force to access HCPs to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients, thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are uncertain and cannot be predicted. Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that we may face.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our business may also be affected by negative impacts of the COVID-19 pandemic on capital markets and economies worldwide, and it is possible that the pandemic could cause a local and/or global economic recession. While policymakers globally have responded with fiscal policy actions to support the healthcare industry and economy as a whole, the magnitude and overall effectiveness of these actions remains uncertain.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Our Business Model</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">At TherapeuticsMD, our purposeful and continuous partnership with HCPs and women is at the heart of our strategies for delivering innovative solutions for women. From pregnancy to post-menopause, we believe the only way to truly connect with and understand women and their healthcare professionals is to ask questions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Healthcare has become increasingly consumer driven. Therefore, patients are seeking more information, control, and convenience, which places additional time and financial pressures on HCPs and as a result HCPs are looking for improved ways to provide better service to their patients. A study by IMS Health Inc. concluded that HCPs desire fewer but more encompassing relationships with companies that can provide more valuable information, deliver more relevant services, and better respond to specific needs of their practice and patients. Our goal is to meet this challenge by focusing on the opportunities in women&#x2019;s health, specifically the OB/GYN market, to provide a better customer experience for healthcare providers, payers, pharmacists, and patients through the following means:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We offer HCPs a comprehensive product line of women&#x2019;s healthcare products across a woman&#x2019;s reproductive lifecycle.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our hormone therapy pharmaceutical products are designed to respond to both healthcare professional and patient needs in the marketplace &#8211; low dose, FDA-approved bio-identical and convenience where needed.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our contraceptive product is the only long-lasting, reversible contraceptive option that is patient-controlled and procedure-free.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We believe the attributes of our prenatal vitamins will result in greater consumer acceptance and satisfaction than competitive products while offering high-quality products with differentiating ingredients. We focus on improved patient education, a high level of patient compliance, and a competitive cost of products, which can result in lower cost of care for payers and improved outcomes for patients.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">At the forefront of our sales approach is the philosophy that the healthcare providers should recommend or prescribe products based only on what is best for the patient. In general, a better outcome is achieved by providing patients with the best products and care at the best value. We believe having a portfolio of high-quality product options that can be recommended or prescribed by HCPs, and reimbursed by either government or private third-party payers, is the foundation of providing valuable options to the patient. We are dedicated to enabling healthcare professionals to advance the health of women by offering new treatment options and giving voice to women&#x2019;s needs and health concerns. We are committed to partnering with women&#x2019;s health advocacy organizations as we create and commercialize solutions to help women transform how they experience reproductive health.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our sales model focuses on the &#8220;4Ps&#8221;: patient, provider, pharmacist, and payer. We market and sell our products primarily through a dedicated national sales force that calls on HCPs primarily in the OB/GYN market space. In addition, our products allow HCPs to offer an alternative to patients at a co-payment that provides patients a cost that is competitive in the marketplace. We also believe that our combination of branded and authorized generic lines of prenatal vitamins offers HCPs, women, and payers cost-effective alternatives for top-quality care. We supply our prescription products to consumers through pharmacies nationwide. Our fully staffed customer care center uses current customer relationship management software to respond to HCPs, pharmacies, and consumers via incoming and outgoing telephone calls, e-mails, and live chat.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We believe our sales force has developed strong relationships in the OB/GYN market to sell our current products. We have established relationships with some of the largest OB/GYN practices in their respective markets. By delivering our portfolio to similar customer bases of women and OB/GYNs, we believe we can leverage our already deployed assets to increase sales of our products and achieve profitability. We leverage our existing infrastructure, including our sales force, to efficiently commercialize our FDA-approved pharmaceutical products: ANNOVERA, IMVEXXY, and BIJUVA and our VitaMedMD and BocaGreenMD line of prenatal vitamins. In addition to our focus on direct selling from our sales organization, which currently targets approximately 128 territories, we utilize other commercial levers such as non-personal promotion to HCPs and direct-to-consumer marketing as appropriate to drive awareness and education of our product portfolio. Finally, we partner with strategic partners and licensees to commercialize our pharmaceutical products in specialty segments of the birth control markets and in non-U.S. markets.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of December 31, 2020, we marketed and sold ANNOVERA, IMVEXXY, and BIJUVA under the TherapeuticsMD brand, our prescription prenatal vitamins under our vitaMedMD brand name, and authorized generic formulations of our prescription prenatal vitamin products under our BocaGreenMD brand name.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Our Growth Strategy</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We believe that the relationships our national sales force has developed with OB/GYNs, through our prescription prenatal vitamin products and our FDA-approved pharmaceutical products, will continue to grow as these products offer HCPs new opportunities to serve the needs of their patients. By delivering our entire portfolio through the same sales channel and demonstrating how these products can help women as different needs emerge throughout their lifetime, we believe we can create efficiencies and synergies to further our growth.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Exclusive Focus on Women&#x2019;s Health Issues</i></i>. We have steadily developed relationships with many of the largest OB/GYN practices in the country through the sales of our prenatal vitamins and our FDA-approved pharmaceutical products. We believe that our singular focus on women&#x2019;s health issues enables us to continue to build long-term relationships with women as they move through their life cycles of family planning to post-menopause.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Focus on Hormone Therapy Products</i></i>. We continue our focus on the commercialization of FDA-approved bio-identical hormone therapy products designed to (1) alleviate the symptoms of, and reduce the health effects resulting from, menopause-related hormone deficiencies, including VMS and VVA, and (2) fill the large unmet need in this segment of the market.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Deepening focus on other parts of a women&#x2019;s reproductive lifecycle.</i></i>&#160;With the acquisition and launch of ANNOVERA, we are demonstrating our intent to provide effective and innovative products for women at all lifecycle stages.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Penetrate
Compounding Market with FDA-Approved Products</i></i>. BIJUVA is currently the only FDA-approved hormone therapy combination
product that is bio-identical to the estradiol and progesterone produced by the ovaries, and will provide a proven
alternative to non-FDA approved compounded bio-identical hormone therapy products, and potentially at a lower price to
patients since most insurance companies do not provide coverage for compounded products, which are not FDA-approved and
supported by professional societies. We continue to work with independent and community-based pharmacies that currently
compound bio-identical hormone therapy products to help introduce patients and prescribers to our FDA-approved products. Our
BIO-IGNITE program is focused on supporting the synergistic relationships between community pharmacies and HCPs so that
offering BIJUVA, IMVEXXY and ANNOVERA as appropriate treatment alternatives is economically practical for independent and
community-based pharmacies.&#160; A dedicated team of Key Account Management, or KAM, is focusing their efforts on growing
BIJUVA through our higher writing BIJUVA prescribers and our BIO-IGNITE partners.&#160; As of December 31, 2020, there were
approximately 260 BIO-IGNITE compounding pharmacies that were dispensing BIJUVA, IMVEXXY, and ANNOVERA.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Multi-Channel Marketing Emphasis</i></i>. We continue our emphasis on large group OB/GYN practices that provide opportunities to reach large patient bases and that are receptive to the data and savings we provide. In addition, we work with strategic partners and licensees to commercialize and/or market our pharmaceutical products in non-U.S. markets.&#160;&#160; In our U.S. markets, we have broadened our channels that allow for wide patient access.&#160; The proliferation of digital technology has dramatically increased the amount of information available to patients and providers. We believe this makes patient/provider engagement and experience a more important factor for life sciences companies and that providing patients and providers with important information on a real-time basis is a critical piece of serving this market. As an example of the impact of technology on women&#x2019;s health, products such as ANNOVERA can be prescribed to patients via online platforms, and other direct-to-consumer telehealth platforms. Subject to state telehealth and prescribing laws, prescribers affiliated with direct-to-consumer telehealth platforms can prescribe or offer products to patients through a convenient virtual platform.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Multiple Distribution Partners</i></i>. We have multiple distribution partners, including large chain pharmacies, independent community pharmacies, mail order, and compounding and specialty pharmacies. We believe that providing a higher level of customer care through unique programs targeted at each of these distribution partners can produce better outcomes and value for the patient, provider, and payer.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Geographical Expansion</i></i>. We continue to adjust our marketing footprint in the United States and sales team, which currently targets approximately 128 territories, as we continue to commercialize ANNOVERA, IMVEXXY, and BIJUVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, serif">&#160;<b><b>Industry and Market</b></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Women&#x2019;s Healthcare Market </i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">According to the GBI Research (a provider of industry-leading business intelligence solutions on a global basis) report &#8220;Women&#x2019;s Health Therapeutic Market through 2018,&#8221; the women&#x2019;s health therapeutics market is one of the most attractive markets in the global pharmaceutical industry.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">According to the BBC Research report &#8220;Pharmaceuticals for Women&#x2019;s Health: Global markets&#8221; post-menopausal osteoporosis, pregnancy disorders and management, menopause, endometriosis, and polycystic ovary syndrome (PCOS) are the largest segments within the global market for women&#x2019;s health therapeutics. Women&#x2019;s health therapeutics established a very strong presence in the global pharmaceutical market over the last few decades. The market is expected to grow moderately, mainly due to patent expirations of blockbuster drugs such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and several other. However, the launch of new drugs in the market, and novel drugs under research and development in the late-stage pipeline, has the strong potential to drive the market during the forecast period. The global market for women&#x2019;s health therapeutics is projected to grow from $31.5 billion in 2019 to $41.2 billion by 2025, at a compound annual growth rate (CAGR) of 4.7% for the period of 2019-2025. The menopause market is projected to grow from $5.7 billion in 2019 to $7.7 billion by 2025 at a CAGR of 5.4% through 2025.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Menopause Market </i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Menopause is the spontaneous and permanent cessation of menstruation, which naturally occurs in most women between the ages of 40 and 58. In the U.S., there are approximately 42 million women in this age group with an additional 6,000 women reaching menopause age every day, or over 2 million additional women per year. Classic symptoms of menopause are VMS (including hot flashes and night sweats), vulvovaginal symptoms (including dyspareunia and vaginal dryness) and sleep disturbances. These symptoms are caused by the reduced levels of circulating estrogen as ovarian production shuts down. Common treatments for menopausal VMS and vulvovaginal symptoms of menopause range from prescription medications, including hormone therapy and non-hormonal options, to over-the-counter supplements and lubrication options.&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Hormone therapy is the most effective treatment in the United States and Canada for relief of menopausal symptoms according to the North American Menopause Society, or NAMS. Approved FDA prescriptions for menopausal hormone therapy in the United States dropped significantly following the Women&#x2019;s Health Initiative, or WHI, study results published in 2002, which found that subjects using conjugated equine estrogens plus the synthetic progestin medroxyprogesterone acetate had, among other things, a greater incidence of coronary heart disease, breast cancer, stroke, and pulmonary embolism. This study caused a significant change in hormone therapy prescribing habits.&#160; Since 2002, many women and HCPs have chosen compounded hormone therapy, a bio-identical solution for treating VMS, and the use of local vaginal therapy increased during this time. The FDA recommends that women with moderate-to-severe menopausal symptoms who want to try menopausal hormone therapy for relief use it for the shortest time needed and at the lowest effective dose.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Reproductive Market</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Contraception can be defined as the deliberate prevention of pregnancy by interfering with normal process of ovulation, fertilization and implantation through the use of barriers, drugs, medical devices, or surgical techniques. The contraceptive market includes non-hormonal methods, such as the non-hormonal intrauterine device, or IUD, contraceptive sponge, diaphragm, cervical cap or shield and condoms, and hormonal methods such as oral contraceptives, injections, implants, hormonal IUDs and vaginal ring and transdermal contraceptive products. Hormonal contraceptives can be composed of synthetic estrogens and progestins. Contraceptives containing both estrogen and a progestin are referred to as combination hormonal contraceptives, or CHCs, and contraceptives containing only progestin are referred to as progestin-only, or P-only.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The most common synthetic estrogen approved in the U.S. for use in contraceptive products is ethinyl estradiol (EE). There are 10 different progestins that have been used in contraceptives sold in the U.S. The progestin component provides most of the contraceptive effect, while the estrogen component primarily provides cycle control, for example, minimizing bleeding or spotting between cycles. The progestin exerts its contraceptive effect by inhibiting ovulation, or release of an egg from the ovary, and by thickening cervical mucus. Thickening cervical mucus helps to prevent sperm entry into the upper genital tract. The estrogen component, in addition to providing cycle control, makes a small contribution to contraception by decreasing the maturation of the egg in the ovary. The latest data from 2017 to 2019 from the Centers for Disease Control and Prevention, or CDC, indicate that approximately 65.3% of women aged 15 to 49 were using some type of contraceptive method with approximately half of these women in this age group using reversable prescription contraception. Most women who were not using contraception had reasons for not doing so, such as seeking pregnancy, being pregnant or postpartum, or not being sexually active.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The U.S. contraceptive
market size is expected to reach $11.6 billion by 2025, expanding at a CAGR of 5.3% over the forecast period, according to Grand
View Research, Inc. Increasing awareness about long-acting reversible contraceptives, or LARCs, is expected to augment the product
demand, thereby driving the market over the next few years. According to the National Center for Health and Statistics, the use
of LARCs in the United States has increased nearly five-fold in the last decade among women aged 15 to 44 and we believe that
this segment of the contraceptive market is attractive given its current growth trajectory. We believe that the increasing awareness
about long-lasting reversible contraceptive options will grow incremental product demand, thereby driving market growth over the
coming years. This is currently led by IUDs. The market leader in the IUD market is Bayer with the following products: Mirena<sup>&#174;</sup>,
Kyleena<sup>&#174;</sup> and Skyla<sup>&#174;</sup>. The remainder of the market is dominated by oral contraceptives, which is
represented by one major brand, Lo Loestrin<sup>&#174;</sup> Fe by AbbVie and a variety of generics led by generic manufacturers
such as Teva Pharmaceuticals, Mylan and Lupin Pharma.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Prenatal Vitamin Market</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">According to the CDC, there are approximately four million births per year in the U.S. Of women giving birth in the U.S., the U.S. Department of Health and Human Services reports that approximately 73% received early prenatal care in the first trimester, while 6% began prenatal care in the third trimester or did not receive any prenatal care. Most HCPs encourage taking a prenatal vitamin as the recommended standard of care. Prenatal vitamins are dietary supplements intended to be taken before and during pregnancy and during postnatal lactation that provide nutrients recognized by various health organizations as helpful for a healthy pregnancy outcome.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The prenatal vitamin market is highly fragmented, with dozens of companies selling hundreds of competitive products. Prenatal vitamin products are marketed as either nonprescription products or prescription products, with many companies marketing their products through both channels. According to Symphony Health Solutions, during the 12 months ended December 31, 2020, approximately 4.9 million prescriptions for prenatal vitamins were issued in the U.S. resulting in total sales of approximately $290 million.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Our Contraceptive Product</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>ANNOVERA</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In July 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year), which was approved by the FDA in August 2018. In October 2019, we began a &#8220;test and learn&#8221; market introduction phase of launch for ANNOVERA. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic and resumed this initiative in July 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The segesterone acetate component of ANNOVERA was classified by the FDA as a &#8220;new chemical entity,&#8221; or NCE, and thus ANNOVERA has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. ANNOVERA is a one-year (13 cycles) ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone<sup>&#174;</sup>, or SA, and ethinyl estradiol, or EE. EE is an approved active ingredient in many marketed hormonal contraceptive products. Segesterone acetate, an NCE, is a potent progestin that, based on pharmacological studies in animals and <i>in vitro</i>, does not bind to the androgen or estrogen receptors and has no glucocorticoid activity at contraceptive doses. SA has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">ANNOVERA can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (one year). ANNOVERA releases daily vaginal doses of both active ingredients (SA and EE). The claimed release rate of 150 &#956;g/day SA and 13 &#956;g/day EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro release.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. In accordance with the post-marketing requirements, the full protocol for the study was submitted to the FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">We believe that ANNOVERA will compete across all the contraception options for women with focus on those women seeking a long-lasting option without a procedure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">For patients, ANNOVERA provides a single, long-lasting, reversible birth control product that does not require a procedure at the doctor&#x2019;s office for insertion or removal, empowering women to be in complete control of their fertility and menstruation with a 21/7 regimen. We believe that ANNOVERA is a unique alternative for women who have previously chosen other forms of birth control. These include nulliparous women (or women who have never given birth), women who are considering an IUD but would rather not have a procedure, women who are between pregnancies but desire protection without a long-term commitment, and women who are not satisfied with oral options due to the daily usage or potential side effects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We believe that the strong initial commercial net revenue per unit of ANNOVERA and commercial insurance adoption provide us with an opportunity to deploy additional financial resources to maximize ANNOVERA&#x2019;s consumer-focused commercialization strategy and leverage the ability of doctor/patient choice of contraceptive to override insurance company formularies when necessary. As part of this strategy, we are pursuing distribution opportunities for ANNOVERA to provide women with additional access to ANNOVERA, particularly during the COVID-19 pandemic, with multiple direct-to-consumer telehealth platforms that extend the reach of ANNOVERA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Our Menopause Portfolio</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>IMVEXXY</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In May 2018, the FDA approved the 4-&#956;g and 10-&#956;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#956;g formulation of IMVEXXY represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY 10-&#956;g became available for commercial distribution in July 2018 and both doses were commercially available in September 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">IMVEXXY is a small, digitally inserted, softgel vaginal insert that dissolves when inserted into the vagina. It is administered mess-free, without the need for an applicator, and can be used any time of day. IMVEXXY provides a mechanism of action and dosing that is comfortable for patients, with no patient education required for dose application or applicators. &#160;Additionally, the dose packaging for IMVEXXY is designed to optimize compliance and convenience for users. IMVEXXY demonstrated efficacy as early as two weeks (secondary endpoint) and maintained efficacy through week 12 in clinical studies, with no increase in systemic hormone levels beyond the normal postmenopausal range (the clinical relevance of systemic absorption rates for vaginal estrogen therapies is not known).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As part of the FDA&#x2019;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked the sponsors of other vaginal estrogen products to participate in the observational study. In connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material on an annual basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Based
on prescription data from Symphony Health Solutions, the FDA-approved prescription market in the U.S. for the treatment of VVA
symptoms includes seven products (including branded products and their generic equivalents), which generated an aggregate of approximately
$1.8 billion in gross sales on approximately 6.0 million prescriptions for the 12 months ended December 31, 2020.&#160; Approximately
$436 million in gross sales were generated by PREMARIN<sup>&#174;</sup> cream (Pfizer), the leading brand in the market. ESTRACE<sup>&#174;
</sup>cream and Vagifem<sup>&#174;</sup> are now mostly generics which generated approximately $ 1.1 billion in gross sales for
the 12 months ended December 31, 2020. These three products are localized estrogen therapy which is the most commonly used method
for the treatment of VVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>BIJUVA</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In October 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS (commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA have the same molecular structure as the hormones that are naturally produced in a woman&#x2019;s body. We launched BIJUVA in April 2019.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">BIJUVA offers the convenience of a single-capsule combination of two hormones (estradiol and progesterone), which may improve a user&#x2019;s compliance. The estradiol and progesterone in BIJUVA are plant-based, not animal-sourced, and does not contain peanut oil unlike other FDA-approved progesterone products. BIJUVA provides a sustained steady state of estradiol which reduced the frequency and severity of hot flashes in clinical studies with no demonstrated impact on a patient&#x2019;s weight or blood pressure. Additionally, through clinical trials, BIJUVA has demonstrated endometrial safety and greater than 90% amenorrhea rates, while providing no clinically meaningful changes in mammograms, or in coagulation or lipid parameters, and while providing clinically meaningful improvements in quality of life and sleep disturbance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In January 2020, we submitted a New Drug Application, or NDA, efficacy supplement for the 0.5 mg/100 mg dose of BIJUVA to the FDA for review and potential approval. The NDA efficacy supplement used existing data from our Phase 3 REPLENISH trial for BIJUVA, for which we announced results in December 2016, together with additional information and analyses. On November 5, 2020, we withdrew the NDA efficacy supplement. We currently intend to file a Formal Dispute Resolution Request, or FDRR, with the FDA that disputes the FDA&#x2019;s requirement that the efficacy supplement meet approval standards that have not been required of other approved drugs in BIJUVA&#x2019;s therapeutic class. There can be no assurance that we will prevail with respect to the FDRR, if filed, or that the 0.5 mg/100 mg dose of BIJUVA will be approved.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Estrogen (with or without a progestin) is most commonly used to treat VMS due to menopause that is a direct result of the decline in estrogen levels associated with ovarian shutdown at menopause.&#160; Estrogen is a generic term for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such as estradiol, a natural ovarian produced estrogen.&#160; According to NAMS, the most effective treatment for VMS due to menopause is estrogen therapy.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Progestins are used in combination with estrogen in menopausal women with a uterus to avoid an increase in the incidence of endometrial hyperplasia, which is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an increased incidence of uterine, or endometrial, cancer.&#160; Progestins include the naturally occurring hormone progesterone and several synthetic progestin compounds that have pregestational activity. These agents are used for a variety of indications and conditions.&#160; Progestins alone are also used to treat women with secondary amenorrhea to create withdrawal bleeding in these women who have not had regular menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">According to Symphony Health Solutions, the total FDA-approved prescription market in the U.S. for all estrogen and progestin drug products for the treatment of VMS generated an aggregate of approximately $2.2 billion of gross revenue on approximately 23.4 million prescriptions for the 12 months ended December 31, 2020. The three primary hormone therapy products are estrogen, progestin, and a combination of estrogen and progestin, which are produced in a variety of forms, including oral tablets or capsules, skin patches, gels, and emulsions. For the 12 months ended December 31, 2020, gross sales in the U.S. of FDA-approved branded and generic products for estrogen-only amounted to an aggregate of approximately $1.4 billion on approximately 13.7 million prescriptions. For the 12 months ended December 31, 2020, gross sales in the U.S. of FDA-approved branded and generic products for progestins-only amounted to an aggregate of approximately $389.2 million on approximately 7.8 million prescriptions. For the 12 months ended December 31, 2020, gross sales in the U.S. of FDA approved branded and generic products for estrogens/progestins combined amounted to an aggregate of approximately $431.7 million on approximately 1.9 million prescriptions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Based on the Symphony Health Solutions data and the uses of these products, we estimate that sales of FDA-approved combinations of estrogen and progestins (the addressable market for BIJUVA) were approximately $1.3 billion in the United States for the 12 months ended December 31, 2020.&#160; Based on various reports, including data recently presented at the NAMS Annual Meeting, &#8220;Knowledge, Use, and Prescribing of Custom-Compounded Bioidentical Hormones for Menopausal Women: It&#x2019;s Not What You Think,&#8221; by JoAnn V. Pinkerton, et al., we estimate, that U.S. sales of non-FDA-approved compounded combination addressable estradiol and progesterone products approximate $1.5 billion per year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">With the approval of BIJUVA, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method to show how BIJUVA is released from the capsule in an in-vitro setting for quality control assessments. The development of this method and validation were completed and submitted to the FDA as required in our approval.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our hormone therapy pharmaceutical products are characterized by safety and efficacy profiles that can be consistently manufactured to target specifications. This provides an alternative to the non-FDA approved compounded bio-identical market. We believe that our FDA-approved pharmaceutical products offer advantages in terms of demonstrated safety and efficacy, consistency in the hormone dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The largest competitors for BIJUVA in the FDA-approved market are Pfizer (PREMPRO<i><sup>&#174;</sup></i>) and Premarin, with sales of PREMPRO<i> </i>and Premarin constituting the largest branded products. The remainder of the market is represented almost exclusively by generic products (estradiol, the generic version of Estrace<i> </i>oral, and generic micronized progesterone). The leading generic manufacturers of these products are Teva, Mylan, Sandoz Inc, and Amneal Pharmaceuticals. None of the competing FDA-approved drugs for the treatment of moderate-to-severe VMS due to menopause are a combination of both bio-identical estradiol and progesterone produced by the ovaries. The market for non-FDA-approved compounded hormone therapy products is generally considered very fragmented because the products are prepared and sold by individual compounding pharmacies. We believe that BIJUVA represents the first time a combination product of estradiol and progesterone that is bio-identical to the estradiol and progesterone produced by the ovaries in a single combined product has been approved in the U.S.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Our Prenatal Vitamin Products</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We continue to manufacture and distribute our prescription prenatal vitamin product lines under our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD Prena1 name. We will continue to support the vitaMedMD and BocaGreenMD products as they are important products to our core customers and help provide us with continued access to sell our women&#x2019;s health portfolio.&#160; Our current prenatal vitamin product line features a unique, proprietary combination of FOLMAX&#8482;, FePlus&#8482;, and pur-DHA&#8482; and includes the following products:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i><i>vitaTrue&#8482;</i></i></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i><i>vitaPearl&#8482;</i></i></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i><i>vitaMedMD One Rx Prenatal Multivitamin</i></i></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i><i>vitaMedMD RediChew<sup>&#174;</sup> Rx Prenatal Multivitamin</i></i></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i><i>BocaGreenMD Prena1 True</i></i></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i><i>BocaGreenMD Prena1 Pearl</i></i></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><i><i>BocaGreenMD Prena1 Chew</i></i></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">For the years ended December 31, 2020, 2019, and 2018, approximately 16%, 20%, and 93%, respectively, of our consolidated product revenue was generated by our prenatal vitamin products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Commercialization Model</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are commercializing the products in our portfolio through a common model focused on the belief that providing good experiences for both HCPs and patients will drive profitability for TherapeuticsMD. Given that our portfolio focus is exclusively on women&#x2019;s health, we believe that each new product launch will allow us to further leverage our existing infrastructure and build out our reputation as the premier women&#x2019;s health organization in the U.S. Below is more detail on our commercialization model:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>HCP Education </b></b>- Initially, we focus on the high writing and high potential HCPs in each territory to gain a full understanding of their prescribing behavior and practices. Our focus is on driving initial prescriptions of these writers for each new product launch and utilizing the time to also pull through on our portfolio of existing products. Once regular writing is established with the initial group of HCPs, we expand our reach to a larger set of HCPs writing in the category. We educate HCPs on our products primarily with our field sales organization supplemented by non-personal promotion. Our sales force currently has approximately 128 territories targeting approximately 20,000 physicians, which includes the most significant part of the addressable markets across our product portfolio. As of December 31, 2020, more than 5,200 HCPs had written at least one prescription for ANNOVERA, more than 21,500 HCPs had written at least one prescription for IMVEXXY and more than 7,100 HCPs had written at least one prescription for BIJUVA, the majority of whom are also IMVEXXY writers, thereby demonstrating the value of portfolio and focus. In addition to our sales organization, we leverage non-personal promotion (multi-channel advertising) to HCPs designed to drive awareness, education, and action. These efforts are designed to allow for pull through of the sales organization&#x2019;s efforts and identification of new targets that have interest in writing prescriptions for one or more of our products. We believe this will drive increased prescribing for our products and lift the overall writing universe and our products to top of mind in the HCP community.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>BIO-IGNITE </b></b>- In addition to our sales organization calling on HCPs, we have a KAM team to support our existing BIO-IGNITE pharmacy partners and additional pharmacies that wish to enroll in the BIO-IGNITE program. Additionally, KAMs are focusing on supporting current prescribers of BIJUVA. As of December 31, 2020, there were approximately 260 BIO-IGNITE compounding pharmacies that were dispensing our products.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>Payer Access - </b></b>With the ever-changing payer environment, we believe it is critical to maximize breadth of coverage as quickly as possible to not inhibit patient access to product. We do this while working to negotiate the best possible contracts for us. Many commercial payers employ &#8220;new-to-market blocks&#8221; for newly launched products until the payers have the opportunity to make a coverage decision based upon their internal review of the product. When a product is not covered, the patient is responsible to pay the full price for the medication, which can significantly limit utilization of the product. As we seek to increase the number of lives covered by commercial payers, it is our objective to continue to seek unrestricted coverage. As of December 31, 2020, we have obtained coverage for the majority of commercial payers by commercial payer lives for IMVEXXY and BIJUVA and continue to seek unrestricted coverage from the remaining commercial insurance plans that we have not yet contracted with to provide affordable access for patients. For IMVEXXY, we achieved unrestricted coverage with the top ten commercial payers of VVA products by commercial payer lives and we continue to sign new agreements with other payers to cover IMVEXXY. In addition, as of December 31, 2020, four of the top eight Medicare Part D payers of VVA products, based on covered lives, were adjudicating IMVEXXY. For BIJUVA, through December 31, 2020, we have achieved unrestricted coverage with nine of the top ten commercial payers of VMS products by commercial payer lives and we continue to sign new agreements with payers to cover BIJUVA. Although Medicare is a small percentage of the VMS market, as of December 31, 2020, two of the top six Medicare Part D payers of VMS products, based on covered lives, were adjudicating BIJUVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">For ANNOVERA, we believe that its unique characteristics will assist us in pursuing favorable commercial payer coverage, including only one pharmacy fill fee per year and no office visit or procedure fees. We have made substantial progress in achieving unrestricted access to ANNOVERA through commercial payers, including having achieved adjudication with six of the top ten commercial payers by commercial payer lives as of December 31, 2020, and we continue to pursue discussions with several of the country&#x2019;s largest commercial insurers to further expand coverage. As of December 31, 2020, approximately 62% of the commercial payer market covered ANNOVERA with unrestricted access under pharmacy benefits and approximately 74% covered ANNOVERA with step access.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010, or the ACA, mandates that private health plans provide coverage for women&#x2019;s preventative services, without imposing patient cost-sharing requirements, as recommended by the Health Resources and Services Administration, or HRSA. HRSA guidelines require private health plans to cover, without cost-sharing, at least one form of contraception, or product, in each of the methods, or classes, identified by the FDA for women in its Birth Control Guide, which currently includes 17 separate classes. For classes with more than one type of treatment, private payers need only provide no-cost coverage for one product in each class and may use reasonable medical management to determine whether and to what extent to cover other products in the class. We believe that given no other vaginal contraceptive product offers contraceptive benefits for an entire year that it is possible that FDA could determine that ANNOVERA constitutes a new class of contraceptive, which could allow for coverage of ANNOVERA by private health plans with no out-of-pocket cost for patients. However, there is no assurance that FDA will make such a determination and it is possible that other FDA-approved products could also be included in such a new class. For instance, the FDA may find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. To the extent ANNOVERA is not the only FDA-approved product in a designated class of contraception, private payers may choose not to cover ANNOVERA or may require patient cost-sharing obligations.&#160; Recently, some states have amended and expanded requirements to match the standard set in the ACA mandate, specifically requiring coverage for the full range of contraceptive methods, counseling and services used by women and eliminating out-of-pocket costs and limiting other health plan restrictions. As of January 2021, 29&#160;states require insurers that cover prescription drugs to provide coverage of FDA-approved prescription contraceptive drugs and devices.&#160; However, the Trump administration implemented new policies that permit certain employers to claim a religious or moral objection to the birth control coverage mandate under the ACA.&#160; Originally, the religious exemption applied only to churches, but the Department of Health and Human Services extended that privilege in 2017 to family-owned, non-publicly traded corporations whose owners state that paying for birth control would violate their religious beliefs. Exempted entities no longer need to certify their objection or otherwise notify the federal government of their decision to stop providing coverage. Health plans sponsored by certain exempt religious employers and non-profit religious organizations that have religious objections do not need to offer contraception coverage through their health benefit plans. In July 2020, the U.S. Supreme Court issued a ruling in the case styled <i>Little Sisters of the Poor Saints Peter and Paul Home v. Pennsylvania et al</i>., upholding the legality of the Trump Administration&#x2019;s religious exemption to the contraceptive mandate. As of January 2021, 21 states allow certain employers and insurers to refuse to comply with the ACA&#x2019;s contraceptive coverage mandate. Prior to his election, President Biden stated that he would undo the religious exemption expansion if he were elected.&#160; To date, the Biden Administration has not issued any Executive Order, regulation, or other policy change to reverse the Trump Administration religious exemption policy, but such action may be forthcoming. We anticipate that any impact on contraception coverage due to religious exemption will be low; however, healthcare reform continues to attract significant legislative and administrative interest, legal challenges, regulatory and compliance requirements, new approaches and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may repeal the contraception coverage mandate, affect our reimbursement or impose additional coverage limitations and/or cost-sharing obligations on patients, any of which could have a material adverse effect on patient usage of ANNOVERA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In February 2020, we entered into an agreement with Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the public health system, to market ANNOVERA in the U.S. public health sector. As part of the Population Council License Agreement, we have agreed to provide significantly reduced pricing to federally designated Title X family planning clinics serving underrepresented women. We also have agreements to market ANNOVERA to the U.S. Department of Defense, the U.S. Department of Veteran&#x2019;s Affairs, and in Puerto Rico.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Obtaining and maintaining favorable reimbursement can be a time-consuming and expensive process, and there is no guarantee that we will be able to negotiate or continue to negotiate reimbursement or pricing terms for our products with payers at profitable levels.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>Supply </b></b>- We take active steps to ensure our products are available in all classes of trade and delivery systems. We offer our products through traditional chain wholesalers (Cardinal, McKesson and AmerisourceBergen) and independent retail pharmacies, community compounding pharmacies with our BIO-IGNITE program, and online pharmacies. We continue to develop unique opportunities to sell direct to pharmacies to streamline distribution and better control costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>Patient Affordability Programs </b></b>- We have affordability and adherence programs in place for patients so that we can support appropriate use of our products by patients. Our co-pay assistance programs allow all patients to access our products at a reasonable cost.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We continue to support our patient education and affordability program that allows all eligible patients who enroll to receive IMVEXXY and BIJUVA at a reasonable cost. When a product is not covered by a patient&#x2019;s commercial insurance, the patient is responsible to pay the full price for the medication, which can significantly limit a patient&#x2019;s ability to pay and subsequent utilization of the product. For IMVEXXY and BIJUVA, enrolled patients paid as little as $35 for a prescription with commercial insurance coverage and as of January 1, 2021 pay as little as $75 for a prescription without commercial insurance coverage. For ANNOVERA, for commercially insured patients, we offer patients assistance for as low as $60 for an annual prescription. Many patients will not need a co-pay assistance program for ANNOVERA given the requirements of the ACA at the federal level and similar laws at the state level.</p>
</td>
</tr>

</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We continue to dialogue with the FDA regarding the potential inclusion of ANNOVERA as a new class of contraception for women in the FDA&#x2019;s Birth Control Guide, which would require private health plans to cover ANNOVERA with no patient out-of-pocket costs as part of the ACA. There is no assurance that the FDA will make such a determination and it is possible that other FDA-approved products could also be included in such a new class. The FDA may also find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. Eight states require insurance coverage of prescription contraception with co-pay regardless of inclusion in the FDA&#x2019;s Birth Control Guide and 11 states, plus Washington D.C., require coverage of prescription contraception with no co-pay regardless of inclusion in the FDA&#x2019;s Birth Control Guide.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>Patient Adherence</b></b> - Establishing compliance and adherence programs that make getting on a prescription medication and obtaining prescribed refills easy and convenient for the patient and HCPs is a critical lever in our commercial model. Our focus is on minimizing complications in patients filling their first prescription and engaging with them throughout the life of their treatment to ensure patients stay on and use therapy for the appropriate length of time. We have delivered effective patient engagement programs for all of our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><b><b>Consumer Communication -</b></b> Another critical level in the commercial model is consumer outreach. Our initial focus is on those patients who are already predisposed to seek treatment, such as those patients new to therapy, and those patients dissatisfied with their current therapy. Next, we are focused on expanding the market by energizing patients who are experiencing bothersome symptoms but who have not been motivated to seek treatment. Methods of communication include online and offline media and span branded and unbranded communication to ensure we drive action from awareness of symptoms to desire to speak to an HCP to acquire a prescription.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>License Agreements</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>License Agreement with the Population Council</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within 30 days following approval by the FDA of the NDA for ANNOVERA. The first commercial batch of ANNOVERA was released during the third quarter of 2019 and we paid the Population Council a second milestone payment of $20,000,000 as a result of the commercial batch release. The Population Council is eligible to receive additional milestone payments and royalties from commercial sales of ANNOVERA, as detailed below.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We assumed responsibility for marketing expenses related to the commercialization of ANNOVERA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are required to pay the Population Council additional milestone payments of $40 million upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $200.0 million, $400.0 million and $1.0 billion.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; border-collapse: collapse; width: 80%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 70%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Annual Net Sales</b></b></p>
</td>
<td style="padding: 0pt 5.4pt; width: 13%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><b>&#160;</b></b></p>
</td>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 16%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><b>Royalty Rate</b></b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Less than or equal to $50.0 million</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">5%</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Greater than $50.0 million and less than or equal to $150.0 million</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">10%</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Greater than $150.0 million</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">15%</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of ANNOVERA that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt">The Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post-approval study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. We and the Population Council formed a joint product committee responsible for overseeing activities under the Population Council License Agreement. We are responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt">Unless earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#x2019;s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may also be terminated for certain breach and bankruptcy-related events and by us on 180 days&#x2019; prior notice to the Population Council.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt">As part of the Population Council License Agreement, we have the exclusive right to negotiate co-development and U.S. marketing rights for two other investigational vaginal contraceptive systems in development by the Population Council.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt"><i><i>License Agreement with Knight</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.5pt">In July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight paid us $2 million in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is also required to pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 28.8pt; text-align: justify"><i><i>License Agreement with Theramex</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In June 2019, we entered into a licensing and supply agreement, or the Theramex License Agreement, with Theramex pursuant to which we granted Theramex an exclusive, perpetual license to commercialize BIJUVA and IMVEXXY for human use outside of the U.S., except for Canada and Israel, or the Theramex Territory. Pursuant to the terms of the Theramex License Agreement, Theramex paid us an upfront fee of EUR 14 million in cash. We are also eligible to receive up to an additional EUR 29.5 million in cash milestone payments, comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Theramex Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments based on net sales of BIJUVA and IMVEXXY in the Theramex Territory. Theramex has agreed to submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY in certain specified markets within certain specified time periods and we may terminate the Theramex License Agreement if Theramex does not submit certain of such regulatory applications, submissions and/or registrations. We may also terminate the Theramex License Agreement if Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. Pursuant to the terms of the Theramex License Agreement, we agreed to supply, or cause to be supplied, BIJUVA and IMVEXXY to Theramex. We and Theramex have agreed to form a joint product committee responsible for advising and overseeing activities under the Theramex License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Preclinical Development </b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We currently have placed on hold our four preclinical projects: a progesterone-alone transdermal cream (TX-005HR), a combination estradiol and progesterone transdermal cream (TX-006HR), and a pair of transdermal patch product candidates (TX-007HR and TX-008HR). <i>In vivo</i> and <i>in vitro</i> proof-of-concept preclinical studies were conducted to assess TX-005HR and TX-006HR with respect to penetration of the estradiol and progesterone, and successful opposition of subcutaneous estradiol on the endometrium. In addition to menopausal treatments, we are also evaluating various other indications targeted to women&#x2019;s health and wellness. We may, in the future, engage with a financing partner to advance one or more of these product candidates. We have also placed on hold our oral progesterone and estradiol formulation (TX-009HR).&#160;Previously, TX-009HR showed improved bioavailability in animals.&#160;In 2019, TX-009HR was tested in a Phase 1 study of healthy postmenopausal women and was well-tolerated in that study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Sales Concentration</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We sell our prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. See Note 13 to the consolidated financial statements included in this Annual Report for a discussion of the concentration of sales of our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Seasonality</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The pharmaceutical markets in which we compete are not subject to seasonal sales fluctuation. However, our net revenues for the first quarter of each year can be negatively affected by the annual reset of high-deductible commercial insurance plans.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Manufacturing of Our Products</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have sourced and qualified third-party contract manufacturing organizations, or CMOs, for the commercial supply of our products. The regulations for manufacturing of approved drug products are significantly more stringent than the standards for manufacturing supplements or drug product for clinical trials. Our CMOs are responsible for the manufacture of our products in accordance with our specifications and applicable regulatory requirements. We have entered into long-term supply agreements with Catalent Pharma Solutions, LLC, or Catalent, for the commercial supply of our IMVEXXY and BIJUVA, and QPharma for the supply of ANNOVERA. Under the terms of the agreements, we are obligated to purchase certain minimum annual amounts of each product. We may terminate the agreement for a particular drug for certain specified reasons. If we are unable to obtain sufficient quantities of drugs or receive raw materials in a timely manner, we could be required to delay our manufacturing and seek alternative manufacturers, which would be costly and time-consuming.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have a multi-faceted risk management approach to ensure continuous supply from our qualified CMOs for the commercial supply of our products. This approach includes oversight of the manufacturing processes, regular Good Manufacturing Practice, or GMP, audits, a review of their business continuity plans, management of finished product inventory and safety stock, and second sourcing as appropriate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have also sourced and qualified manufacturers of the active pharmaceutical ingredient, or APIs, to be used in our drugs and drug candidates. We follow a risk management approach for our API manufacturer similar to that followed for the commercial supply of the finished drug product.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We use third-party manufacturers to manufacture and package our vitamin and supplement products, as well as meet applicable contract and regulatory requirements. We currently obtain all of our vitaMedMD and BocaGreen products from Lang Pharma Nutrition, or Lang, a full-service, private label and corporate brand manufacturer specializing in premium health benefit driven products, including medical foods, nutritional supplements, beverages, bars, and functional foods in the dietary supplement category. As a result, we are dependent on Lang and its subcontractors for the manufacture of our vitamin and supplement products. In addition to manufacturing, Lang also provides a variety of additional services to us, including development processes, prototype development, raw materials sourcing, regulatory review, and packaging production. We believe that Lang maintains multiple supply and purchasing relationships throughout the raw materials marketplace to provide an uninterrupted supply of product to meet our manufacturing requirements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have experienced no difficulties in obtaining the vitamin and supplement products we need in the amounts we require and do not anticipate those issues in the future. We believe the terms of our agreements with Lang are competitive with other suppliers and manufacturers. At present, we believe our relationship with Lang is excellent, and we intend to continue to use Lang as our third-party manufacturer for most of our vitamins and supplements. Although we anticipate continuing our relationship with Lang, we believe that we could obtain similar terms with other suppliers to provide the same services in the event our relationship with Lang terminates. Accordingly, we do not believe that such termination would have a material adverse effect on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Quality Control for our Products</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our products for the U.S. market are required to be manufactured in accordance with the FDA&#x2019;s current Good Manufacturing Practice, or cGMPs. Our third-party suppliers and manufacturers are also responsible for continued compliance with cGMP requirements. We have executed quality agreements that delineate the responsibilities of each company in the quality assurance process. To comply with these drug commercialization standards, we have personnel with pharmaceutical development, manufacturing, and quality assurance experience who are responsible for the relationships with our suppliers. We have contracted with Catalent, an established manufacturer of softgel drug products, to manufacture the commercial supply for both IMVEXXY and BIJUVA. We have also contracted with QPharma to manufacture the commercial supply for ANNOVERA. For the prenatal vitamins, our quality assurance team collaborates with Lang to monitor the cGMP compliance of Lang&#x2019;s contracted manufacturers and packagers. Although each of Catalent, QPharma and Lang have received Form FDA 483 observations from FDA inspections in the past, we are not aware of any open FDA investigations into the manufacturing and/or packaging processes at the facilities that are used for our products.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our quality assurance team establishes controls that are designed to document the manufacturing process and ensure that our contract manufacturers meet product specifications and that our finished products contain the correct ingredients, purity, strength, and composition in compliance with FDA regulations. Depending on their roles and activities, certain of our contractors are subject to applicable requirements to test incoming raw materials and finished goods to ensure they meet or exceed FDA and U.S. Pharmacopeia standards, including quantitative and qualitative assay and microbial and heavy metal contamination (as appropriate).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Distribution of our Products</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We distribute our products within the U.S. through our third-party logistics partner, Cardinal Logistics, who ships to national wholesale distributors such as Cardinal, McKesson, and AmerisourceBergen, regional wholesalers such as Smith Drug, Anda, Value Drug and RDC, and alternate distribution partners. Wholesaler product inventory is monitored daily and sales out are monitored weekly. We are subject to compliance responsibilities under the Drug Supply Chain Security Act, or the DSCSA, and the Prescription Drug Marketing Act, or PDMA, in relation to distribution of drug products in the commercial supply and dispensing chain and drug samples to HCPs, respectively, and are further subject to state laws on these topics. National and regional retail pharmacies along with online pharmacies are also an area of focus to make sure our products are purchased and dispensed properly.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Customer Service</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our goal is 100% customer satisfaction by consistently delivering superior customer experiences before, during, and after the sale. To achieve this goal, we maintain a fully staffed customer care center that uses current customer relationship management software to respond to HCPs, pharmacies, and consumers. We believe our customer service initiatives allow us to establish and maintain long-term customer relationships and facilitate repeat visits and purchases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our representatives receive regular training so that they can effectively and efficiently field questions from current and prospective customers and are also trained not to answer questions that should be directed to a customer&#x2019;s physician. Having a quality customer care center allows our representatives to provide an array of valuable data in the areas of sales, market research, quality assurance, lead generation, and customer retention.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><b>Our Return Policy</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We sell our prescription products through third-party logistics providers, wholesale distributors, and retail pharmacy distributors. We accept returns of unsalable prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration. Our vitamin and supplement products and IMVEXXY currently have a shelf life of 24 months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of 18 months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Our Quality Guarantee</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We proudly stand behind the quality of our products. We believe our guarantee makes it easy, convenient, and safe for customers to purchase our products. Under our quality guarantee, we:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Ensure the potency and quality of our products; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Help HCPs and payers by delivering information on patient compliance and satisfaction.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We value frequent communication with and feedback from our customers to continue to improve our offerings and services.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Research and Development</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Historically, our product development programs have been concentrated in advanced hormone therapy pharmaceutical products. We have engaged, and may continue to engage, in programs to provide alternatives to the FDA and non-FDA-approved compounded bio-identical market for hormone therapy. Our programs have sought to bring new products to market in unique delivery systems or formats that enhance the effectiveness, safety, and reliability of existing hormone therapy alternatives.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Intellectual Property</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our success depends, in part, on our ability to obtain patents, maintain trade-secret protection, and operate without infringing the proprietary rights of others. Our intellectual property portfolio is one way we attempt to protect our competitive position. We rely primarily on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to protect our products and to maintain our competitive position. We are diligently seeking ways to protect our intellectual property through various legal mechanisms in relevant jurisdictions. Where permitted, patents for our hormone therapy drug products have been submitted to the Orange Book.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of December 31, 2020, we had 38 issued domestic patents and 39 issued foreign patents, including:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">15 domestic patents and nine foreign patents that relate to BIJUVA as well as three domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">12 domestic patents (ten utility and two design) and 18 foreign patents (eight utility and ten design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">One domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">One domestic utility patent and eight foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have a pending patent application with respect to our transdermal-patch candidates in Brazil;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Three domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Two domestic and four foreign patents that relate to formulations containing progesterone, which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Australia, Canada, Europe, and Mexico; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">One domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">As of December 31, 2020, we have a
license to three Orange Book listed patents relating to ANNOVERA. These patents will expire in 2039 and establish an
important intellectual property foundation. In addition, we have a license to six U.S. pending applications relating to
ANNOVERA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The sponsor of an approved 505(b) drug product, which approval is the first permitted commercial marketing of a drug with that drug&#x2019;s active ingredient, may apply for a patent term extension (PTE) under 35 U.S.C. &#167; 156. The length of a PTE is calculated based on the &#8220;regulatory review period,&#8221; which consists of one-half of the time between the initial effective date of the Investigational New Drug, or IND, for the clinical study(ies) supporting FDA approval of the drug and the date of the NDA submission, plus the time between the submission of the NDA and the date of FDA approval. Any period of time during the regulatory review period in which the applicant is deemed to have not acted with due diligence will be deducted from regulatory review period calculation. A PTE may not exceed five years, and the remaining term of a patent as extended by a PTE will be limited as necessary such that the remaining term does not exceed 14 years from the date of the NDA approval. Only one patent may be extended based on a regulatory review period, and a patent may not receive more than one PTE. The rights provided during the term of a PTE generally are limited to the approved use(s) of the product.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of December 31, 2020, we had filed over 138 patent applications with the U.S. Patent and Trademark Office, or the USPTO, with respect to our technology or our hormone-therapy drugs and drug candidates, and over 193 international patent applications with respect to our technology or our hormone-therapy drugs and drug candidates, including Patent Cooperation Treaty (PCT) and national-stage filings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We hold multiple U.S. trademark registrations and have numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of ownership of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all the areas in which it is used. Federally registered trademarks have a perpetual life so long as they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We intend to actively protect our intellectual property with patents, trademarks, trade secrets, or other legal avenues for the protection of intellectual property and to aggressively prosecute, enforce, and defend our patents, trademarks, and proprietary technology. The loss, by expiration or otherwise, of any one patent may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive and time consuming, even if the outcome is favorable to us. It is possible that the patents issued or licensed to us will be successfully challenged, that a court may find that we are infringing on validly issued patents of third parties, or that we may have to alter or discontinue the development of our products or pay licensing fees to account for patent rights of third parties. See &#8220;&#8211; Pharmaceutical Regulation &#8211; Regulatory Exclusivity&#8221; below for information regarding our intellectual property and challenges thereto.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As we continue to develop proprietary intellectual property, we will expand our protection by applying for patents on future technologies. As we examine our current product offerings and new product pipeline, we are in the process of modifying and developing new formulations that will enable us to gain patent protection for these products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">While we seek broad coverage under our patent applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor to avoid infringement claims. In addition, patents expire, and we cannot provide any assurance that any patents will be issued from our pending application or that any potentially issued patents will adequately protect our intellectual property.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Government Regulation</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In the United States, the FDA regulates pharmaceuticals, biologics, medical devices, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including federal and state consumer protection laws, laws regarding pricing transparency, laws requiring the implementation of compliance programs, laws requiring the reporting of payments or other transfers of value to HCPs or other healthcare professionals, laws governing the financial relationships between manufacturers and HCPs or other referral sources and industry stakeholders, laws protecting the privacy of health-related information, laws restricting items and services of value provided to patients, and laws prohibiting unfair and deceptive acts and trade practices.&#160; See also <i>Item 1A. Risk Factors &#8211; Risks Related to Our Business</i> for a discussion, among other things, of the extensive and costly governmental regulation we are subject to.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Pharmaceutical Regulation</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The process required by the FDA before a new drug product may be marketed in the United States generally involves the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">completion of or reference to extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA&#x2019;s Good Laboratory Practice, or GLP, regulations;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">submission to the FDA of an investigational new drug, or IND application under which the holder may begin conducting human clinical trials, provided that the FDA does not object; the IND must be updated annually;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">submission to the FDA of an NDA after completion of all pivotal clinical trials.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">An IND application is a request for authorization from the FDA to administer an investigational drug product to humans. We have submitted six INDs for our hormone therapy drug candidates.&#160; The INDs for TX-002HR and TX-003HR were withdrawn in December 2019, the IND for TX006-HR was made inactive in October 2020 and the INDs for TX-009HR was made inactive in December 2020. The INDs for TX-004HR, TX-001HR, remain active. The IND for ANNOVERA was transferred from the Population Council to us in May 2019 and is also active.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in the clinical trial. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from a central or each clinical trial site&#x2019;s institutional review board, or IRB, before the trials may be initiated, and the IRB must monitor the study until completed and re-assess and approve the study at least annually. There are also requirements governing the reporting of certain clinical trials and clinical trial results to public registry and results databases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Clinical trials are usually conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess safety, characterize pharmacokinetics, and assist in finding the potential dosing range. During Phase 2, the drug is administered to small populations of patients to look for initial signs of efficacy in treating the targeted disease or condition and to continue to assess dosing and safety. Phase 3 clinical trials are usually multi-center, double-blind, controlled trials in hundreds or even thousands of subjects to assess the safety and effectiveness of the drug.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">During a clinical trial, we are required to inform the FDA and the IRB about adverse events associated with our drug candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group reviews unblinded data from clinical trials and assesses interim data to make recommendations regarding the feasibility and appropriateness for a trial to move forward or continue to completion. We may also suspend or terminate a clinical trial based on evolving business objectives or competitive climates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information is submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application includes all relevant data available from pertinent preclinical and clinical trials, including, among other things, negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls and proposed labeling.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Once the NDA submission has been accepted for filing, the FDA&#x2019;s goal is to review standard applications within 10 months of the 60-day filing date for new molecular entity NDA and original BLA submissions, or within 10 months of receipt for non-NME and original BLA submissions. For Original Efficacy Supplements, the FDA&#x2019;s goal is to review the application within 10 months of the receipt date. The review process can be extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Post-Approval Regulation</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Since regulatory approval of some of our drug products has been obtained, we are required to comply with several post-approval requirements. As a holder of an approved NDA, we are required to report, among other things, certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, to adhere to product sampling and distribution requirements, fulfill post-marketing study commitments, and to comply with requirements concerning advertising and promotional labeling for any of our drug products, which include, among other things, standards for direct-to-consumer advertising, restrictions that prohibit promoting products for certain uses or in patient populations that are not described in the product&#x2019;s approved indications or that are not otherwise consistent with the approved, FDA-required label (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available products for off-label use if they deem such use to be appropriate in their professional medical judgment, manufacturers may not market or promote such off-label uses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Also, quality control and manufacturing procedures must continue to conform to cGMPs to ensure and preserve the long-term stability of the drug product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are, depending on the nature and scope of their activities, subject to FDA and certain state agency requirements relating to establishing and maintaining product quality. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. For example, Catalent, the CMO that we have contracted with for the commercial supply of our BIJUVA and IMVEXXY hormone therapy drug products, was issued a Form FDA 483 in 2019 with respect to its softgel manufacturing plant. The observations and associated corrective actions identified in Catalent&#x2019;s response to the Form FDA 483 related to our BIJUVA product. The current inspection classification status of that Form FDA 483 is that the response was adequate and Voluntary Action Indicated. Voluntary Action Indicated status indicates that objectionable conditions or practices were found but the FDA is not prepared to take or recommend any administrative or regulatory action.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We rely, and expect to continue to rely, on third parties to produce clinical and commercial quantities of our drugs and drug candidates. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution or require substantial resources to correct. In addition, discovery of previously unknown problems (for example, through adverse events observed in the post-marketing context, or in Phase 4 / post-marketing studies) with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could delay or prevent regulatory approval of our products under development.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><i><i>Regulation of Compounding Pharmacies</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our hormone therapy pharmaceutical products and product candidates may compete with unapproved hormone therapy products supplied by compounding pharmacies. Pharmacy compounding is a practice in which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored to the medical needs of an individual patient. The medications created by the compounding pharmacy are not approved by the FDA and are therefore not reviewed to evaluate their safety, effectiveness, or quality.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">For
approximately 50 years, the FDA left regulation of compounding pharmacies to the states. In 1992, in response to
various safety concerns, the FDA issued a Compliance Policy Guide, which announced that the &#8220;FDA may, in the exercise
of its enforcement discretion, initiate federal enforcement actions... when the scope and nature of a pharmacy&#x2019;s
activities raises the kinds of concerns normally associated with a manufacturer and.. results in significant violations of
the new drug, adulteration, or misbranding provisions of the Act.&#8221; Thereafter, Congress enacted the Food and Drug
Administration Modernization Act of 1997, or FDAMA, which sought to clarify FDA&#x2019;s regulatory authority over
compounding pharmacies. FDAMA exempted &#8220;compounded drugs&#8221; from the FDA&#x2019;s standard drug approval
requirements as long as the providers of those drugs abide by several restrictions, including that they refrain from
advertising or promoting particular compounded drugs. In 2002, though, the Supreme Court declared this provision of FDAMA to
be unconstitutional under the First Amendment, effectively reinstating the pre-FDAMA regime. Shortly thereafter, the FDA
issued its 2002 Compliance Policy Guide 460.200, which states that the FDA will exercise enforcement discretion to exclude
compounded drugs from the new drug approval requirements except where compounding pharmacies act more akin to traditional
drug manufacturers.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">To further clarify
the FDA&#x2019;s jurisdiction and following a prior history in which states were primarily responsible for the regulation of
compounding pharmacies, in light of industry changes to large-scale compounding operations and concerns regarding product
quality and patient safety,&#160; Congress enacted and President Obama signed into law the Drug Quality and Security Act of
2013 which, among other things, formalized the relationship between the FDA and large-scale compounding pharmacies allowing
for certain compounding pharmacy products to be offered without FDA approval requirements (e.g., an NDA or ANDA) and the
requirement to label products with adequate directions for use, but requiring that the facilities and products meet FDA cGMP
requirements. To qualify for this exemption, a compounding pharmacy must register with the FDA as an &#8220;outsourcing
facility,&#8221; subject to FDA inspection and other requirements. The FDA does not exercise the same authority to regulate
compounding pharmacies as pharmaceutical manufacturers. For example, compounding pharmacies are not required to report
adverse events associated with compounded drugs, while commercial drug manufacturers are subject to stringent regulatory
reporting requirements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Regulatory Exclusivity</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">A Section 505(b) NDA applicant may be eligible for its own regulatory exclusivity period, such as a five-year or three-year exclusivity. The first approved Section 505(b) NDA applicant for a drug containing an active ingredient that has not previously been approved in any other 505(b) NDA (a &#8220;new chemical entity,&#8221; or NCE), is eligible for a five-year NCE exclusivity period starting on the date of the NDA approval. During this period, an Abbreviated New Drug Application, or ANDA, or 505(b)(2) application for a drug containing the protected active ingredient of the NCE product generally cannot be submitted to FDA until the end of the five-year exclusivity period, except that such applications can be submitted at year four if the product is covered by an Orange Book listed patent and the ANDA or 505(b)(2) NDA includes a Paragraph IV Certification challenging such patent. Additional exclusivities may also apply.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The first approved Section 505(b) NDA applicant for a particular condition, or a supplemental NDA approval for a change to a marketed product, such as a new extended-release formulation for a previously approved product, may be eligible for a three-year Hatch-Waxman exclusivity if one or more new clinical studies, other than bioavailability or bioequivalence studies, was essential to the approval of the application and was conducted or sponsored by the applicant. Should this occur, the FDA would be precluded from granting final approval to any ANDA or 505(b)(2) application for the same condition of use or change to the marketed product that was granted exclusivity until after that three-year exclusivity period has run.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Additionally, any ANDA or 505(b)(2) NDA that references the 505(b) product must include one of several types of patent certifications. If the Section 505(b) NDA drug has one or more unexpired patents listed in the Orange Book, an ANDA or 505(b)(2) NDA must include either a &#8220;Paragraph III Certification&#8221; or a &#8220;Paragraph IV Certification.&#8221; A Paragraph III Certification identifies the expiration date of the listed patent and requires FDA to withhold final approval until that patent has expired. A &#8220;Paragraph IV Certification&#8221; states that, in the applicant&#x2019;s opinion, the relevant patent is invalid, unenforceable, or would not be infringed by the commercial marketing of the proposed ANDA or 505(b)(2) NDA product. The sponsor of a Paragraph IV ANDA or 505(b)(2) NDA must also provide the holder of the marketed product NDA, and the owner of the challenged patent, with notification of the Paragraph IV filing along with a detailed statement of the reasons the applicant believes the patent is invalid, unenforceable, or would not be infringed.&#160; If the patent owner brings an infringement action against the Paragraph IV applicant within 45 days of the notification, a statutory stay is imposed which prevents FDA from granting final approval of the Paragraph IV application for 30 months from the date of the Paragraph IV Notification. Generally, no more than one 30-month stay may be applied against any specific Paragraph IV ANDA or 505(b)(2) NDA. A 30-month stay can be terminated early, and the Paragraph IV application can be immediately approved, if the district court rules in favor of the Paragraph IV applicant that the patent is invalid, unenforceable, or would not be infringed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 20, 2020, we received a Paragraph IV certification notice letter, or the IMVEXXY Notice Letter, regarding an ANDA submitted to the FDA by Teva Pharmaceuticals USA, Inc., or Teva.&#160; The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY.&#160; In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY, or the IMVEXXY Patents, are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. On April 1, 2020, we filed a complaint against Teva in the U.S. District Court for the District of New Jersey asserting infringement of the IMVEXXY patents, arising from Teva&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Teva&#x2019;s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed. We intend to vigorously enforce our above-described intellectual property rights relating to IMVEXXY.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On March 17, 2020,
we received a Paragraph IV certification notice letter, or the BIJUVA Notice Letter, regarding an ANDA submitted to the FDA
by Amneal Pharmaceuticals, or Amneal.&#160; The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a
generic version of the 1 mg estradiol /100 mg progesterone dose of BIJUVA.&#160; In the BIJUVA Notice Letter, Amneal alleges
that TherapeuticsMD patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of BIJUVA, or the
BIJUVA Patents, are invalid, unenforceable, and/or will not be infringed by Amneal&#x2019;s commercial manufacture, use, or
sale of its proposed generic drug product. The BIJUVA Patents identified in the Notice Letter expire in 2032. On April 29,
2020, we filed a complaint against Amneal in the U.S. District Court for the District of New Jersey asserting infringement of
the BIJUVA Patents, arising from Amneal&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that
the effective date of any FDA approval of Amneal&#x2019;s ANDA would be a date no earlier than the expiration of the BIJUVA
Patents and equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed its answer and
counterclaim to the complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has not been set.
The complaint which we filed automatically precludes the FDA from approving Amneal&#x2019;s ANDA until the earlier of 30
months or entry of a district court decision finding the BIJUVA Patents invalid, unenforceable, or not infringed (&#8220;the 30-month&#8221;). On February 25, 2021, the District Court entered an order temporarily staying all proceedings in the BIJUVA
litigation. The District Court stay also extends the 30-month stay for the period in which the BIJUVA litigation has been stayed. We intend
to vigorously enforce our above-described intellectual property rights relating to BIJUVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Dietary Supplement Regulation</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our currently marketed prenatal vitamins are regulated as dietary supplements. The processing, formulation, safety, manufacturing, packaging, labeling, advertising, and distribution of these products are subject to regulation by one or more federal agencies, including the FDA and the Federal Trade Commission, or the FTC, and by various agencies of the states and localities in which our products are sold.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Generally, our nutritional product formulations are proprietary in that in designing them, we attempt to blend an optimal combination of nutrients that are intended to have a beneficial impact in prenatal women based upon scientific literature and input from HCPs; however, we are generally prohibited from making disease treatment and prevention claims in the promotion of our products that use these formulations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The Dietary Supplement Health and Education Act of 1994, or DSHEA, amended the FDCA to establish a new framework governing the composition, safety, labeling, manufacturing, and marketing of dietary supplements. Generally, under the FDCA, dietary ingredients that were marketed in the United States before October 15, 1994 may be used in dietary supplements without notifying the FDA. &#8220;New&#8221; dietary ingredients (<i>i.e.</i>, dietary ingredients that were &#8220;not marketed in the United States before October 15, 1994&#8221;) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been &#8220;present in the food supply as an article used for food&#8221; without being &#8220;chemically altered.&#8221; A new dietary ingredient notification must provide the FDA evidence of a &#8220;history of use or other evidence of safety&#8221; establishing that use of the dietary ingredient &#8220;will reasonably be expected to be safe.&#8221; A new dietary ingredient notification must be submitted to the FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a determination could prevent the marketing of such dietary ingredient. The FDA recently issued draft guidance governing the notification of new dietary ingredients. FDA guidance is not mandatory, and companies are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations. However, FDA guidance is a strong indication of the FDA&#x2019;s &#8220;current thinking&#8221; on the topic discussed in the guidance, including its position on enforcement. The draft guidance on new dietary ingredients is expected to be significantly revised when published in final form. Moreover, Congress can amend the dietary supplement provisions of the FDCA to impose additional restrictions on labeling and marketing of dietary supplements. Such action would have material adverse impact on our business and growth prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The FDA or other agencies could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products or ingredients in such products. Such actions or warnings could be based on information received through FDCA-mandated reporting of serious adverse events. The FDCA requires that reports of serious adverse events be submitted to the FDA, and based in part on such reports, the FDA has issued public warnings to consumers to stop using certain third-party dietary supplement products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, DSHEA provides that so-called &#8220;third-party literature,&#8221; such as a reprint of a peer-reviewed scientific publication linking a particular dietary ingredient with health benefits, may be used &#8220;in connection with the sale of a dietary supplement to consumers&#8221; without the literature being subject to regulation as labeling. The literature: (1) must not be false or misleading; (2) may not &#8220;promote&#8221; a particular manufacturer or brand dietary supplement; (3) must present a balanced view of the available scientific information on the subject matter; (4) if displayed in establishment, must be physically separate from the dietary supplements; and (5) should not have appended to it any information by sticker or another method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject our product to regulatory action as an illegal drug.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In June 2007, pursuant to the authority granted by the FDCA as amended by DSHEA, the FDA published detailed cGMP regulations that govern the manufacturing, packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all manufacturers, and the FDA is conducting inspections of dietary supplement manufacturers pursuant to these requirements. The failure of a manufacturing facility to comply with the cGMP regulations renders products manufactured in such facility &#8220;adulterated,&#8221; and subjects such products and the manufacturer to a variety of potential FDA enforcement actions. In addition, under the Food Safety Modernization Act, or FSMA, which was enacted on January 2, 2011, the manufacturing of dietary ingredients contained in dietary supplements are subject to similar or even more burdensome manufacturing requirements, which has the potential to increase the costs of dietary ingredients and subject suppliers of such ingredients to more rigorous inspections and enforcement. The FSMA also requires importers of food, including dietary supplements and dietary ingredients, to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The FDA has broad authority to enforce the provisions of federal law applicable to dietary supplements, including powers to issue public Warning Letters or Untitled Letters to a company, publicize information about illegal products, detain products intended for import, require the reporting of serious adverse events, request a recall of illegal or unsafe products from the market, and request that the Department of Justice initiate a seizure action, an injunction action, or a criminal prosecution in the U.S. courts. The FSMA expands the reach and regulatory powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and regulatory powers include the FDA&#x2019;s ability to order mandatory recalls, administratively detain domestic products, require certification of compliance with domestic requirements for imported foods associated with safety issues and administratively revoke manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The FTC exercises jurisdiction over the advertising of dietary supplements. In recent years, the FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in consent decrees and the payment of civil penalties and/or restitution by the companies involved. The FTC also regulates other aspects of consumer purchases, including promotional offers of savings compared policies, telemarketing, continuity plans, and &#8220;free&#8221; offers.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are also subject to regulation under various state, local, and international laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and drugs. For example, Proposition 65 in the state of California is a list of substances deemed to pose a risk of carcinogenicity or birth defects at or above certain levels. If any such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient linked to cancer or birth defect risk. Private attorney general actions as well as California attorney general actions may be brought against non-compliant parties and can result in substantial costs and fines.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Other U.S. Healthcare Laws and Compliance Requirements</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#x2019; rights, among other topics, are and will be applicable to our business. We are subject to regulation by both the federal government and the states in which we or our partners conduct our business. The healthcare laws and regulations that may affect our ability to operate include:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully offering, soliciting, receiving or providing any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce either the referral of an individual or in return for the purchase, lease, or order of, or the arranging for, any good, facility item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as the Medicare and Medicaid programs;</p>
</td>
</tr>

</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">federal civil and criminal false claims laws and civil monetary penalty laws, including, for example, the federal civil False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (e.g., public or private), knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which impose obligations on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the federal physician sunshine requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare or Medicaid to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. In 2022, the Sunshine Act will be extended to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in 2022 for payments made in 2021). In addition, Section 6004 of the ACA requires annual reporting of information about drug samples that manufacturers and authorized distributors provide to healthcare providers;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">federal and state laws requiring pricing transparency or limiting price increases, which are in existence today or are anticipated to be in existence in the near future, may limit the ability to raise prices, require disclosure of price increases or require disclosure of the wholesale acquisition cost of pharmaceutical products to governmental agencies and consumers; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers or even self-pay; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be provided to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to healthcare providers or marketing expenditures; state laws requiring a license, registration or permit to engage in manufacturing and distribution of prescription products or to engage in the practice of pharmacy; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Pharmaceutical company interactions with HCPs, patient advocacy groups, and patients, including with respect to product and patient assistance programs and other education and support initiatives, have been and continue to be, the subject of regulatory scrutiny for compliance with fraud and abuse laws.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations could be costly. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third party payer programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the HCPs, providers, or entities with whom we do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government funded healthcare programs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 24; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition to the fraud and abuse laws, we continue to monitor the potential impact of proposals to lower prescription drug costs at the federal and state level. For example, on May 11, 2018, President Trump laid out his administration&#x2019;s &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products.&#160; Following on this initiative, the Department of Health and Human Services announced a drug payment model through the Center for Medicare and Medicaid Innovation at CMS to lower Medicare Part B payments for certain drugs to the lowest price for similar countries. Beginning January 1, 2021, the model, known as the Most Favored Nation (MFN) Model, will test a new model of drug payments whereby Medicare will pay no more for high cost, physician-administered Medicare Part B drugs than the lowest price charged in other similar countries. The MFN Model may be subject to industry challenges but we expect that drug pricing will remain a priority under the Biden Administration. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, U.S. Department of Health and Human Services, or HHS, or by other federal, state, local, or foreign regulatory authorities, or the repeal of laws or regulations that we generally consider favorable, such as DSHEA, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The growth and demand for eCommerce could result in more stringent consumer protection laws that impose additional compliance burdens on online retailers. These consumer protection laws could result in substantial compliance costs and could interfere with the conduct of our business. There is currently great uncertainty in many states whether or how existing laws governing issues such as property ownership, sales and other taxes, and libel and personal privacy apply to the Internet and commercial online retailers. These issues may take years to resolve. For example, tax authorities in several states, as well as a Congressional advisory commission, are currently reviewing the appropriate tax treatment of companies engaged in online commerce and new state tax regulations may subject us to additional state sales and income taxes. New legislation or regulation, the application of laws and regulations from jurisdictions whose laws do not currently apply to our business, or a change in application of existing laws and regulations to the Internet and commercial online services could result in significant additional taxes on our business. These taxes could have an adverse effect on our results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the European Union and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Human Capital Resources </b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We believe the
growth of our employees drives the growth of our company.&#160;Therefore, to ensure the continued growth of our employees,
our human capital strategy is measured around four key pillars; attracting talent, engaging the workforce, developing
leaders, and promoting our culture.&#160;To attract key talent, we offer a competitive benefit package, 401(k) match, paid
time off, referral bonus, and an employee stock purchase program (ESPP).&#160;&#160;To engage our workforce, in 2020 we
refined our compensation approach to match our company&#x2019;s size and stage of growth.&#160;We introduced a new framework
as a foundation to our talent and reward programs, to clarify career paths, to promote pay equity and pay for performance,
and to ensure pay is competitive to attract and retain talent.&#160;To develop leaders, we provide self-directed learning and
company leadership training.&#160;Such leadership and self-development progress is measured through our learning management
system, and we evaluate our leaders according to their achievement against goals and company values.&#160;To promote our
culture, we actively seek feedback from our employees to create a culture where they feel engaged, appreciated, and
fulfilled.&#160;The feedback from our employees has earned us recognition as a &#8220;Top Workplace&#8221; according to the
Sun Sentinel.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Employees</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of December 31, 2020, we had 400 employees, six of whom are executive officers. Our sales force currently consists mainly of employees with a limited number of contract sales agents who call on 340B entities, the Department of Defense, and Puerto Rico, with the sales management being employees. Additionally, from time to time, we hire temporary contract employees. None of our employees are covered by a collective bargaining agreement, and we are unaware of any union organizing efforts. We have never experienced a major work stoppage, strike, or dispute. We consider our relationship with our employees to be good.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><b>Our History</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On October 3, 2011, we changed our name to TherapeuticsMD, Inc. On October 4, 2011, we closed a reverse merger with VitaMedMD pursuant to which (1) all outstanding membership units of VitaMedMD were exchanged for shares of our common stock, (2) all outstanding VitaMedMD options and warrants were exchanged and converted into options and warrants to purchase shares of our common stock, and (3) VitaMedMD became our wholly owned subsidiary. As of December 31, 2011, we determined that VitaMedMD would become the sole focus of our company and services previously performed relative to the licensing agreement discussed in the following paragraph were discontinued.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We were incorporated in Utah in 1907 under the name Croff Mining Company, or Croff. Prior to 2008, Croff&#x2019;s operations consisted entirely of oil and natural gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the spin-off, Croff was a &#8220;shell company&#8221; under the rules of the Securities and Exchange Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America&#x2019;s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders of America&#x2019;s Minority Health Network, Inc. acquired control of our company. On June 11, 2010, we closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsidiary. On July 20, 2010, we filed Articles of Conversion and Articles of Incorporation to redomicile in the state of Nevada. On July 31, 2010, we transferred the assets of America&#x2019;s Minority Health Network, Inc. to a secured noteholder in exchange for the satisfaction of certain associated debt. On February 15, 2011, we transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of associated debt and in exchange for a licensing agreement under which we subsequently sold subscription services and advertising on the Spectrum Health Network for commissions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Available Information</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are a Nevada corporation. We maintain our principal executive offices at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431. Our telephone number is (561) 961-1900. We maintain a corporate website at <i>www.therapeuticsmd.com&#160;</i>as well as various product websites.&#160;The information contained on our websites or that can be accessed through our websites is not incorporated by reference into this Annual Report or in any other report or document we file with the SEC.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We file reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any other filings required by the SEC. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, other filings required by the SEC, and all amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.&#160;These reports may also be obtained directly from the SEC&#x2019;s website at <i>www.sec.gov</i>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><b>Risk Factors</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>I<span id="a003"></span>tem 1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Risk Factors</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><i><i>Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with all of the information included in this Annual Report and our other filings with the SEC, before you decide to purchase shares of our common stock. We believe the risks and uncertainties described below are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition, or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</i></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our business is subject to a number of risks and uncertainties. The following is a summary of the principal risk factors described in this section:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our financial condition and results of operations for fiscal year 2020 were, and our financial condition and results of operations for fiscal year 2021 and beyond may be, adversely affected by the ongoing COVID-19 (coronavirus) pandemic.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our level of indebtedness and the terms of the Financing Agreement,
dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, or the Administrative
Agent or Sixth Street, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time
to time as guarantors, or the Financing Agreement, could adversely affect our operations and limit our ability to plan for or respond
to changes in our business. If we are unable to comply with certain net revenue and minimum unrestricted cash covenants and other
restrictions in the Financing Agreement, the repayment of our existing indebtedness could be accelerated.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We may not recognize the anticipated benefits of the proposed disposition of vitaCare Prescription Services or any other divestitures we may pursue in the future.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We currently derive all of our revenue from sales or licenses of our women&#x2019;s healthcare products, and our failure to maintain or increase sales of these products could have an adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The commercial success of our existing products and other pharmaceutical products that we may develop, if approved in the future, will depend upon gaining and retaining significant market acceptance of these products among physicians and payers.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We may not be able to complete the commercialization of our pharmaceutical products and development of future product candidates if we fail to obtain additional financing.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our dependence upon third parties for the manufacture and supply of our existing women&#x2019;s healthcare products and our pharmaceutical product candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Licensing of intellectual property involves complex legal, business and scientific issues, and disputes could jeopardize our rights under such agreements. Additionally, our current licensing agreements contain limitations and restrictions that could limit or adversely affect our ability to develop and commercialize other products in the future.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
<td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></p></td>
<td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">If our efforts to protect
the proprietary nature of the intellectual property covering our hormone therapy pharmaceutical products and other products are
not adequate, we may not be able to compete effectively in our market.</span></td></tr>
<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our products face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Our success is tied to our distribution channels.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><i><b><i>Risks Related to Our Business</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our financial condition and results of operations for fiscal year 2020 were, and our financial condition and results of operations for fiscal year 2021 and beyond may be, adversely affected by the ongoing COVID-19 (coronavirus) pandemic.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our business has been, and we anticipate that it will continue to be, impacted by the COVID-19 pandemic. During the fourth quarter of 2020, all of our products remained affected by the COVID-19 pandemic, primarily due to our sales force having limited access to healthcare professionals and our patients deferring visits to healthcare professionals in certain areas. While we have developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments in our sales and marketing infrastructure, protect our balance sheet during this period of market disruption, and meet the needs of our patients and prescribers, the severity of the impact of the COVID-19 pandemic on our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Stay at home, quarantine and social distancing orders and closures and restrictions on travel have negatively affected the ability of our sales force to access healthcare providers to promote our products and the ability of patients to visit their healthcare professionals for non-emergent matters. Our sales force is continuing to use a hybrid model of office visits when necessary and digital engagement tools and tactics and virtual detailing, which may be less effective than our ordinary course sales and marketing programs. Increases in unemployment could reduce access to commercial health insurance for our patients, thus limiting payer coverage for our products, which could lead to increased use of our co-pay assistance programs and negatively affect our results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our future results of operations and liquidity could be adversely affected by, and we may require an increased level of working capital as a result of, extended billing and collection cycles as a result of displaced employees at our company, payers, revenue cycle management contractors, or otherwise; delays in payments of outstanding receivable amounts beyond normal payment terms; supply chain disruptions; uncertain demand; and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that we may face.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 27; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Additionally, although we currently continue to have uninterrupted wholesale and retail distribution of our products and we do not anticipate a shortage of our products due to COVID-19 at this time, disruptions may occur for our customers or suppliers that may affect our ability to obtain supplies or other components for our products, manufacture additional products or deliver inventory in a timely manner. This would result in lost sales, additional costs, or penalties, or damage to our reputation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our business may also be affected by negative impacts of the COVID-19 pandemic on capital markets and economies worldwide, and it is possible that the pandemic could cause a local and/or global economic recession. While policymakers globally have responded with fiscal policy actions to support the healthcare industry and economy as a whole, the magnitude and overall effectiveness of these actions remains uncertain.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We may also experience other unknown impacts from COVID-19 that cannot be predicted. Accordingly, disruptions to our business as a result of COVID-19 could continue to result in an adverse effect on our business, results of operations, financial condition and prospects in the near-term and beyond 2021.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have incurred recurring net losses, including net losses of approximately $184 million, $176 million, and $133 million for the years ended December 31, 2020, 2019, and 2018, respectively. As of December 31, 2020, we had an accumulated deficit of approximately $879 million. We have generated limited revenue and have funded our operations to date primarily from public and private sales of equity and private sales of debt securities. We may incur substantial additional losses over the next few years because of our commercialization, research, development, and clinical trial activities. As a result, we may never achieve or maintain profitability, even if we successfully commercialize all of our pharmaceutical products. If we continue to incur substantial losses and are unable to secure additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, refinance then-existing debt obligations on terms unfavorable to us, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our level of indebtedness and the terms of the Financing Agreement could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to comply with certain net revenue covenants and other restrictions in the Financing Agreement, the repayment of our existing indebtedness could be accelerated.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Under the Financing Agreement, we have incurred a substantial amount
of debt, which could adversely affect our business. In April 2019, we drew down the first tranche of $200.0 million under the Financing
Agreement and in February 2020 we drew down the second tranche of $50.0 million under the Financing Agreement. On March 1, 2021,
we entered into Amendment No. 8 to the Financing Agreement, or Amendment No. 8, pursuant to which we, among other things, repaid
$15.0 million in principal under the Financing Agreement on such date and agreed to repay an additional $35.0 million in principal
by no later than March 31, 2021, in each case plus a 5.0% prepayment fee. Our high level of indebtedness could affect our business
in the following ways, among other things: make it more difficult for us to satisfy our contractual and commercial commitments;
require us to use a substantial portion of our cash flow from operations to pay interest and principal, which would reduce funds
available for working capital, capital expenditures and other general corporate purposes; limit our ability to obtain additional
financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten
our vulnerability to downturns in our business, our industry or in the general economy; place us at a disadvantage compared to
those of our competitors that may have proportionately less debt; limit management&#8217;s discretion in operating our business;
and limit our flexibility in planning for, or reacting to, changes in our business, the industry in which we operate or the general
economy.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The Financing Agreement requires us to make certain payments of
principal and interest over time and contains certain minimum quarterly net product revenue requirements and several other restrictive
covenants.&#160; We are required to achieve total minimum net revenue for ANNOVERA, IMVEXXY, and BIJUVA equal to at least (i) $17.0
million, $20.0 million, $23.0 million, and $26.5 million for the first, second, third, and fourth quarters of 2021, respectively,
(ii) $30.0 million, $35.0 million, $40.0 million and $45.0 million for the first, second, third, and fourth quarters of 2022, respectively,
(iii) $50.0 million, $55.0 million, $60.0 million and $65.5 million for the first, second, third, and fourth quarters of 2023,
and (iv) $70.0 million for the first quarter of 2024. Among other requirements of the Financing Agreement, we and our subsidiaries
party to the Financing Agreement must maintain a minimum unrestricted cash balance of $60.0 million, less the amount of certain
payables.&#160; The Financing Agreement also contains covenants that limit, among other things, the ability of us and our subsidiaries
party to the Financing Agreement to (i) incur indebtedness, (ii) incur liens on our property, (iii) pay dividends or make other
distributions, (iv) sell our assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay
or prepay certain permitted indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions.
These and other terms in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to
grow our business or enter into transactions that we believe would be beneficial to our business. In order to maintain compliance
with the minimum unrestricted cash balance requirement of the Financing Agreement, we anticipate that we may need to raise additional
capital.&#160;We cannot guarantee that future financing sufficient to maintain or exceed the minimum unrestricted cash balance
will be available in sufficient amounts, in a timely fashion, or on terms acceptable to us, if at all. If we are unable to maintain
the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements or otherwise comply with any other
covenant of the Financing Agreement, all or a portion of our obligations under the Financing Agreement may be declared immediately
due and payable, which would have an adverse effect on our business, results of operations and financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 28; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our business may not generate cash flow from operations in the future sufficient to service our debt and support our growth strategies, especially in light of the COVID-19 pandemic. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including under our current debt obligations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We may not be able to complete the commercialization of our pharmaceutical products and development of future product candidates if we fail to obtain additional financing.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We need substantial amounts of cash to complete the commercialization of IMVEXXY, BIJUVA, and ANNOVERA and the clinical development and commercialization of future pharmaceutical product candidates. Our existing cash may not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected on these programs. We may attempt to raise additional capital from the issuance of equity securities, collaborations with third parties, licensing of rights to our products, the issuance of debt securities and the incurrence of debt, in each case to the extent permitted under the Financing Agreement, or other means, or a combination of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management and may divert a disproportionate amount of management&#x2019;s attention away from our day-to-day activities, which may adversely affect our ability to conduct our day-to-day operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We cannot guarantee that future debt or equity financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly delay, scale back, or discontinue our commercialization and product development efforts.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The Financing Agreement does, and any agreements governing future debt financing, if available, may, include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products or grant licenses on terms that may not be favorable to us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing commercialization and development efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We may not recognize any anticipated benefits of the proposed disposition of vitaCare Prescription Services or any other divestitures we may pursue in the future. </i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have commenced a process for the divestiture of vitaCare Prescription Services. Additionally, we may evaluate other potential divestiture opportunities with respect to portions of our business from time to time, and may determine to proceed with a divestiture opportunity if and when we believe such opportunity is consistent with our business strategy and we would be able to realize value for our stockholders in so doing. There can be no assurance that we will be able to sell vitaCare Prescription Services. Any divestiture or disposition, including the potential disposition of vitaCare Prescription Services, could expose us to significant risks, including, without limitation, fees for legal and transaction-related services, diversion of management resources, transaction execution risks (including risks resulting from buyer financing and due diligence contingencies and other closing conditions), loss of key personnel and reduction in revenue. Further, we may be required to retain or indemnify a buyer against certain liabilities and obligations in connection with any such divestiture, and we may also become subject to third-party claims arising out of such divestiture. In addition, we may not achieve the expected price in a divestiture transaction, including the potential sale of vitaCare Prescription Services. A divesture of vitaCare Prescription Services may be subject to various third-party consents. There can be no assurances that we will obtain any necessary consents of governmental authorities or other third parties that might be required in order for us to sell vitaCare Prescription Services or effectuate any other divesture. If we are unable to consummate the divestiture of vitaCare Prescription Services or do not realize the expected strategic, economic, or other benefits of that or any other divestiture transaction, it could adversely affect our business and financial position.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We currently derive all of our revenue from sales or licenses of our women&#x2019;s healthcare products, and our failure to maintain or increase sales of these products could have an adverse effect on our business, financial condition, results of operations, and growth prospects.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In 2020, we derived all of our revenue from sales or licenses of our women&#x2019;s healthcare products, including patient-controlled, long-acting contraceptive, hormone therapy pharmaceutical products, prenatal and women&#x2019;s multi-vitamins, and iron supplements. We cannot assure you that we will be able to sustain such sales or that such sales will grow. In addition to other risks described herein, our ability to maintain or increase existing product sales is subject to several risks and uncertainties, including the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 29; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the presence of new or existing competing products, including non-authorized generic copies of our products;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">supply or distribution problems arising with any of our manufacturing and distribution partners;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">changed or increased regulatory restrictions or regulatory actions by the FDA;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">changes in healthcare laws and policy, including changes in requirements for drug pricing, rebates, reimbursement, and coverage by federal healthcare programs and commercial payers;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the impact or efficacy of any price increases we may implement in the future;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">changes to our labels and labeling, including new safety warnings or changes to our boxed warnings, that further restrict how we market and sell our products; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">acceptance of our products as safe and effective by physicians and patients.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">If revenue from sales of our products does not increase, we may be required to reduce our operating expenses or to seek to raise additional funds, which could have an adverse effect on our business, financial condition, results of operations, and growth prospects, or we may not be able to commercialize all of our pharmaceutical products or commence or continue clinical trials to seek approval for any other products we may choose to develop in the future.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>The commercial success of our existing products and other pharmaceutical products that we may develop, if approved in the future, will depend upon gaining and retaining significant market acceptance of these products among physicians and payers.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Physicians may not prescribe our products, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our hormone therapy pharmaceutical products and patient-controlled, long-acting contraceptive, by physicians, patients, and payers, will depend on a number of factors, many of which are beyond our control, including the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the clinical indications for which our hormone therapy pharmaceutical products and patient-controlled, long-acting contraceptive are approved;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">acceptance by physicians and payers of each product as a safe and effective treatment;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the cost of treatment in relation to alternative treatments, including numerous generic pharmaceutical products;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the relative convenience and ease of administration of our products in the treatment of the symptoms for which they are intended;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the availability and efficacy of competitive drugs and devices;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the effectiveness of our sales force and marketing efforts;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the extent to which the product is approved for inclusion on formularies of hospitals and managed care organizations, including any access barriers such as prior authorizations and step-edits;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the potential inclusion of a new category for one-year multi-cycle hormonal birth control methods in the FDA Birth Control Guide, which payers may rely upon as guidance for coverage;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the availability of coverage and adequate reimbursement by third parties, such as insurance companies and other healthcare payers, or by government healthcare programs, including Medicare and Medicaid;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">limitations or warnings contained in a product&#x2019;s FDA-approved labeling; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">prevalence and severity of adverse side effects.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Even if the medical community accepts that our products are safe and effective for their approved indications, physicians may not immediately be receptive to their use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. Labeling approved by the FDA may not permit us to promote our products as being superior to competing products, because the FDA applies a heightened level of scrutiny to comparative claims when applying its statutory standards for advertising and promotion, including with regard to its requirements for supporting data and that promotional labeling be truthful and not misleading, and there is potential for differing interpretations of whether certain communications are consistent with a product&#x2019;s FDA-required labeling.&#160; If our products do not achieve an adequate level of acceptance by physicians and payers, we may not generate sufficient or any revenue from these products and we may not become profitable. In addition, our efforts to educate the medical community and third-party payers on the benefits of our products may require significant resources and may never be successful.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i><b><i>We are subject to extensive and costly government regulation.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The products we are currently commercializing, including IMVEXXY, BIJUVA, and ANNOVERA and our prenatal vitamins, and the pharmaceutical products we are developing and planning to develop in the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly or indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing, formulation, safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products under various regulatory provisions. If any pharmaceutical products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 30; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are also subject to additional healthcare regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal and state healthcare laws and regulations include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The federal Anti-Kickback Statute, or AKS, prohibits, among other things, persons and entities, including pharmaceutical manufacturers, from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of, or arrangement for the referral of, an individual for, or the purchase, lease, order, or recommendation of, any good or service reimbursable, in whole or in part, by federal healthcare programs, such as Medicare, Medicaid, TRICARE, and the State Children&#x2019;s Health Insurance Program. This statute has been interpreted broadly to apply to, among other things, arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. The term &#8220;remuneration&#8221; includes kickbacks, bribes or rebates and also has been broadly interpreted to include anything of value, including, for example, gifts, discounts, waivers of payment, ownership interest and providing anything at less than its fair market value. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The safe harbors are subject to change through legislative and regulatory action, and we may decide to adjust our business practices or be subject to heightened scrutiny as a result.&#160; For example, under a final rule issued in 2020 and to take effect January 1, 2022,&#160; OIG revised the AKS&#x2019;s Discount Safe Harbor to explicitly exclude reductions in price offered by drug manufacturers to pharmacy benefit managers and Part D plans from the safe harbor&#x2019;s definition of a &#8220;discount,&#8221; meaning AKS immunity would not be available for such arrangements, and as a result potential AKS risks would increase unless arraignments were restructured. The failure to meet the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not meet the criteria for safe harbor protection from AKS liability in all cases. Liability under the AKS may be established without proving actual knowledge of the statute or specific intent to violate it. In addition, federal law provides that the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, or FCA, described below. Violations of the AKS carry potentially significant civil, criminal, and administrative penalties, including imprisonment, fines, civil monetary penalties, and exclusion from participation in government healthcare programs.&#160; The compliance and enforcement landscape, and related risk, is informed by government precedent, Advisory Opinions, and Special Fraud Alerts.&#160; For example, on November 16, 2020 the OIG published a Special Fraud Alert addressing manufacturer speaker programs signaling that such programs will be subject to an even higher degree of government scrutiny for potential AKS compliance concerns.&#160; Our approach to compliance may evolve over time in light of these types of developments.&#160; For example, we are currently evaluating the impact of the November 16, 2020 Special Fraud Alert on our speaker programs; if we are required to materially change our speaker programs to comply with the Special Fraud Alert, our speaker programs may be less effective, which may have an adverse effect on our business, financial condition, results of operations, and growth prospects.&#160;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The FCA prohibits entities and individuals from intentionally (or with reckless disregard or deliberate ignorance) presenting or causing to be presented false or fraudulent claims to Medicare, Medicaid, and other federal healthcare programs, or improperly retaining known overpayments;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 54pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9675;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Violations of the FCA carry penalties of up to three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim. Suits filed under the federal FCA can be brought directly by the government or be brought by an individual (known as a &#8220;relator&#8221; or, more commonly, as a &#8220;whistleblower&#8221;) on behalf of the government, known as &#8220;qui tam&#8221; actions. Relators bringing qui tam actions under the FCA receive a share of any amounts paid by the entity to the government in fines or settlement. Qui tam actions have increased significantly in recent years, causing greater numbers of entities, including manufacturers, to have to defend a false claim action, even before the validity of the claim is established and even if the government decides not to intervene in the lawsuit.&#160; Companies may decide to agree to large settlements with the government and/or whistleblowers to avoid the cost and negative publicity associated with litigation. Criminal prosecution is possible for knowingly making or presenting a false or fictitious or fraudulent claim to the federal government.&#160; In addition to the FCA, many states have enacted their own false claims act statutes that address similar conduct and that may apply to claims for items or services submitted to any payor source, not just government-funded programs.</p>
</td>
</tr>

</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 54pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9675;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Although we do not submit claims directly to payers, manufacturers can be held liable under the FCA if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers, promoting a product off-label, marketing products of sub-standard quality, or, as noted above, paying a kickback that results in a claim for items or services. In addition, our activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under the FCA. For example, several pharmaceutical and other healthcare companies have faced enforcement actions under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product.</p>
</td>
</tr>

</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 31; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The Civil Monetary Penalties Law, or CMPL, imposes substantial civil monetary penalties against an entity that engages in prohibited activities, including but not limited to violations of the AKS, knowing submission of a false or fraudulent claim, employment of an excluded individual and the provision or offer of anything of value to a Medicare or Medicaid beneficiary that the transferring party knows or should know is likely to influence beneficiary selection of a particular provider for which payment may be made in whole or in part by Medicare or Medicaid;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 54pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9675;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#8220;Remuneration&#8221; is defined under the CMPL as any transfer of items or services for free or for less than fair market value. There are certain exceptions to the definition of remuneration for offerings that meet the Financial Need, Preventative Care, or Promoting Access to Care exceptions. Sanctions for violations of the CMPL include civil monetary penalties and administrative penalties up to and including exclusion from participation in federal health care programs.</p>
</td>
</tr>

</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Health Insurance Portability and Accountability Act of 1996, or&#160; HIPAA, imposes criminal and civil liability for knowingly and willfully executing or attempting to execute a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including third-party private payers, knowingly and willfully&#160; falsifying, concealing, or covering up by trick, scheme, or device, a material fact or making any materially false, fictitious, or fraudulent statements in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. State laws may also govern the privacy and security of health information or other personal information in certain circumstances.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, also imposes obligations, including mandatory contractual terms, on certain covered entities and their business associates with respect to safeguarding the privacy, security, and transmission of individually identifiable health information. Our vitaCare Prescription Services subsidiary is a covered entity under HIPAA. HITECH also gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA laws and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. The Department of Health and Human Services Office of Civil Rights, or the OCR, has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. The OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $5 million.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">According to the U.S. Federal Trade Commission, or the FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure constitutes unfair acts or deceptive practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#x2019;s guidance for appropriately securing consumers&#x2019; personal information is similar to what is required by the HIPAA Security Rule.&#160;&#160;&#160;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Federal laws require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The Physician Payments Sunshine Act imposes annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under certain government healthcare programs (with certain exceptions) to annually report to CMS information related to certain payments or other&#160; &#8220;transfers of value&#8221; made or&#160; provided to physicians and teaching hospitals, or to other entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Numerous state laws may also require disclosure of transfers of value to healthcare providers, pharmaceutical pricing information and marketing expenditures. Transfers of value to certain other providers such as nurse practitioners and physician assistants will also need to be tracked and reported under the Sunshine Act beginning in 2022.</p>
</td>
</tr>

</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 32; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Analogous state laws and regulations, such as state anti-kickback and false claims laws, and other state laws addressing the pharmaceutical and healthcare industries, may apply to interactions between pharmaceutical manufacturers and healthcare providers, sales or marketing arrangements, and claims involving healthcare items or services reimbursed by commercial third-party payers, including private healthcare insurers and health maintenance organizations, and in some cases that may apply regardless of payer, i.e., even if reimbursement is not available; further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance program guidelines (the PhRMA Code) and the relevant compliance guidance promulgated by the federal government (HHS-OIG) in addition to requiring drug manufacturers to report pricing and marketing information, including, among other things, information related to gifts, payments, or other remuneration to physicians and other healthcare providers or marketing expenditures, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information and the use of prescriber-identifiable data in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For example, California enacted legislation &#8211; the California Consumer Privacy Act, or CCPA &#8211; which went into effect January 1, 2020 and, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information, and creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. The CCPA was recently amended by the California Privacy Rights Act, expanding certain consumer rights such as the right to know. It remains unclear what, if any, additional modifications will be made to these laws by the California legislature or how these laws will be interpreted and enforced. The potential effects of the CCPA and CPRA are significant and may cause us to incur substantial costs and expenses to comply.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Many state laws differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts. Moreover, the number and complexity of both federal and state laws continues to increase, and additional governmental resources are being used to enforce these laws and to prosecute companies and individuals who are believed to be violating them. We anticipate that government scrutiny of pharmaceutical sales and marketing practices will continue for the foreseeable future and subject us to the risk of government investigations and enforcement actions. For example, federal enforcement agencies recently have shown interest in pharmaceutical companies&#x2019; product and patient assistance programs, including manufacturer reimbursement support services and relationships with specialty pharmacies. Some of these investigations have resulted in significant civil and criminal settlements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Efforts to ensure that our operations, including our business arrangements with third parties, comply with applicable healthcare laws and regulations could be costly. In connection with the commercial launches of IMVEXXY, BIJUVA, and ANNOVERA, we have grown our compliance program and are in the process of developing a program based on industry best practices and tailored to evolving risks as we launch additional products, identify new distribution channels and target new patient types. Although effective compliance programs can help mitigate the risk of investigation, regulatory and enforcement actions, and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state fraud, privacy, security, and reporting laws may prove costly. We cannot guarantee that a government agency will agree with our interpretations and it is possible that an enforcement authority may find that one or more of our business practices may not comply. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government healthcare programs, and the curtailment or restructuring of our operations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, and could result in related stockholder suits, any of which could also have an adverse effect on our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, from time to time in the future, we may become subject to additional laws or regulations issued by federal or state agencies. Federal and state elections in 2020 have changed which persons and parties occupy the presidency of the United States and control both chambers of Congress and many states&#x2019; governors and legislatures. These changes will likely result in new agency priorities, rulemakings, and legislation. We anticipate that the new Biden administration will issue a number of Executive Orders, which may alter the policies of the previous administration. Additionally, certain agency rules and policy statements of the prior administration may be rescinded.&#160;Further, the Biden administration may propose substantial changes to the U.S. healthcare system, including expanding government-funded health insurance options. We are uncertain of the impact or outcome of these potential Executive Orders, rescission of rules and policy statements, or new legislation, especially any relative impact on the healthcare regulatory and policy landscape, or the impact they may have on our business. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have an adverse effect on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 33; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Market acceptance and sales of our products, including IMVEXXY, BIJUVA, and ANNOVERA, and our prescription vitamins, will depend on coverage and reimbursement policies and may be affected by healthcare reform measures. Government healthcare programs and third-party payers decide which prescription pharmaceutical products they will pay for and establish reimbursement levels. Payers generally do not cover OTC products, and coverage for prescription vitamins and dietary supplements varies. Many private third-party payers, such as managed care plans, manage access to pharmaceutical products&#x2019; coverage partly to control costs to their plans, and may use drug formularies and medical policies to limit their exposure. Factors considered by these payers include product efficacy, cost effectiveness, and safety, as well as the availability of other treatments including generic prescription drugs. Our ability to commercialize IMVEXXY, BIJUVA, and ANNOVERA successfully depends on coverage and reimbursement levels set by government healthcare programs and third-party private payers. Obtaining and maintaining favorable reimbursement can be a time-consuming and expensive process, and we may not be able to negotiate or continue to negotiate reimbursement or pricing terms for our products with payers at levels that are profitable to us, or at all.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In both the U.S. and some foreign jurisdictions, there have been several legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Payment or reimbursement of prescription drugs by Medicaid or Medicare requires manufacturers of the drugs to submit pricing information to CMS. The Medicaid Drug Rebate statute requires manufacturers to calculate and report price points, which are used to determine Medicaid rebate payments shared between the states and the federal government and Medicaid payment rates for the drug. For drugs paid under Medicare Part B, manufacturers must also calculate and report their Average Sales Price, or ASP, which is used to determine the Medicare Part B payment rate for the drug. The federal government sets general guidelines for Medicaid and requires rebates on outpatient drugs. Each state creates specific regulations that govern its individual program, including supplemental rebate programs that prioritize coverage for drugs on the state Preferred Drug List. In the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government provides reimbursement through the Medicare or Medicaid programs for such products and services. In addition, government programs like Medicaid include substantial penalties for increasing commercial prices over the rate of inflation which can affect realization and return on investment. The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest and states have begun to take action to increase transparency in drug pricing through mandatory reporting requirements. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations, and additional legislative proposals. Our results of operations could be adversely affected by current and future healthcare reforms. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, any such cost-reduction initiatives could decrease the coverage and price that we receive for our products from Medicare, if any, including IMVEXXY, BIJUVA, and ANNOVERA, and could significantly harm our business. It was historically unclear whether products approved to treat moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause, such as IMVEXXY, were excluded under Medicare Part D, which resulted in limited Medicare coverage for such products. A clarification issued by CMS in May 2018 indicated that drugs, such as IMVEXXY, that are approved for the treatment of moderate-to-severe dyspareunia (as well as drugs approved for the treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy associated with menopause) are not excluded from Medicare Part D coverage. CMS&#x2019;s clarification, however, is no guarantee that such coverage will be obtained for IMVEXXY and obtaining Medicare or other government healthcare program reimbursement for any new pharmaceutical products may take up to several years following FDA approval.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our ability to commercialize ANNOVERA depends on coverage and reimbursement levels set by government healthcare programs and third-party private payers. The ACA mandates that private health plans provide coverage for women&#x2019;s preventative services, without imposing patient cost-sharing requirements, as recommended by HRSA. HRSA Guidelines require private health plans to cover, with no patient out-of-pocket costs, at least one form of treatment (e.g., one product) in each of the methods (e.g., classes of contraception) identified by the FDA for women in its Birth Control Guide. To the extent ANNOVERA is deemed a new class of contraception by the FDA, such a designation could allow for coverage by private health plans with no patient out-of-pocket costs. However, there is no guarantee that such coverage will be obtained, and it is possible that other FDA-approved products could also be included in this new class. For instance, the FDA may find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. Pursuant to HRSA Guidelines, private payers need only provide no-cost coverage for one product in each class and may use reasonable medical management to determine whether and to what extent to cover other products in the class. Private payers may interpret the statute and its associated rules in ways in which they decline to cover ANNOVERA, even if we believe ANNOVERA should be covered without cost sharing under the ACA framework. To the extent ANNOVERA is not the only FDA-approved product in a designated class of contraception, private payers may choose not to cover our one-year vaginal contraceptive system or may require patient cost-sharing obligations. Some states have amended and expanded requirements to match the standard set in the ACA mandate, specifically requiring coverage for the full range of contraceptive methods, counseling and services used by women and eliminating out-of-pocket costs and limiting other health plan restrictions. The prior administration implemented policies that permit certain employers to claim a religious or moral objection to the birth control coverage mandate under the ACA.&#160; On July 8, 2020, the Supreme Court held in <i>Little Sisters of the Poor Saints Peter and Paul Home v. Pennsylvania, et. al.</i> that health plans sponsored by certain exempt religious employers and non-profit religious organizations that certify they have religious objections do not need to offer contraception coverage through their health benefit plans. This exemption could be overturned by the new Biden administration through an Executive Order or other policy or regulatory action. Further, despite our progress with commercial payers, there is no guarantee that we will be able to retain our agreements or obtain new agreements or that we will be able to negotiate favorable reimbursement or pricing terms for our products in the future.&#160; In addition, healthcare reform, including potential repeal of or changes to the ACA, continues to attract significant legislative and administrative interest, legal challenges, regulatory and compliance requirements, new approaches and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may repeal the contraception coverage mandate, affect our reimbursement or impose additional coverage limitations and/or cost-sharing obligations on patients, any of which could have an adverse effect on coverage and reimbursement of our products, and our business, financial condition, results of operations, and prospects could be harmed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 34; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">To the extent we obtain coverage for our products by state Medicaid programs, we may be required to pay a rebate to each state Medicaid program for any covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program, and to comply with all Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. Moreover, federal law requires that any company participating in the Medicaid Drug Rebate program also participate in the Public Health Service&#x2019;s 340B Program, which impose additional reporting requirements and price concessions. Manufacturer compliance with 340B Program requirements can be costly. In addition, if our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration or to low income patients of certain hospitals, additional laws and requirements may apply.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We expect to experience pricing pressures in connection with the sale of our products generally due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, the scrutiny of pharmaceutical pricing, the ongoing debates on reducing government spending and additional legislative proposals. We cannot predict whether new proposals will be made or adopted, when they may be adopted, or what impact they may have on us if they are adopted.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The availability of generic products at lower prices than branded products may substantially reduce the likelihood of reimbursement for branded products, such as IMVEXXY, BIJUVA, and ANNOVERA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, we could have difficulty achieving market acceptance of our products and our business, financial condition, results of operations, and prospects could be harmed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Future legislation or regulations may adversely affect reimbursement from government healthcare programs and third-party payers.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">There have been efforts by government officials and legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. On May 11, 2018, the prior administration issued its &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Following on this initiative, HHS announced a drug payment model through the Center for Medicare and Medicaid Innovation at CMS to lower Medicare Part B payments for certain drugs to the lowest price for similar countries. Beginning January 1, 2021, the model, known as the Most Favored Nation (MFN) Model, will test a new model of drug payments whereby Medicare will pay no more for high cost, physician-administered Medicare Part B drugs than the lowest price charged in other similar countries.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">While drug pricing was a priority for the prior administration, we expect that it will continue to be a focus of the Biden administration in 2021 and beyond. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The ACA and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have an adverse effect on our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Further, if a federal government shutdown were to occur for a prolonged period, federal government payment obligations, including its obligations under Medicaid and Medicare, may be delayed. Similarly, if state government shutdowns were to occur, state payment obligations may be delayed. If the federal or state governments fail to make payments under these programs on a timely basis, our ability to sell our products to government payers may be limited and/or our ability to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 35; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our dependence upon third parties for the manufacture and supply of our existing women&#x2019;s healthcare products and our pharmaceutical product candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We do not currently have, nor do we currently plan to build or acquire, the infrastructure or capability to internally manufacture our existing women&#x2019;s healthcare products, IMVEXXY, BIJUVA, and ANNOVERA, or our pharmaceutical product candidates. We have relied, and will continue to rely, on third parties to manufacture these products in accordance with our specifications and in compliance with applicable regulatory requirements, including cGMPs. We have entered into long-term supply agreements with Catalent for the commercial supply of IMVEXXY and BIJUVA. Under the terms of the agreements, we are obligated to purchase certain minimum annual amounts of each product. We have also entered into a long-term supply contract with QPharma AB for ANNOVERA. Under the terms of the QPharma agreement, we are obligated to purchase certain minimum annual amounts of ANNOVERA. We depend on Lang, a full-service, private label and corporate brand manufacturer, to supply our vitaMedMD and BocaGreen products. We do not have long-term contracts for the commercial supply of our vitaMedMD and BocaGreen products, however, in certain circumstances, including our failure to satisfy our production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased by Lang that it cannot use in another product category that it then sells.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Regulatory requirements could pose barriers to the manufacture of our women&#x2019;s healthcare products and our pharmaceutical product candidates. Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated product under their own name, are ultimately responsible for compliance with manufacturing obligations even if the manufacturing is conducted by a third-party contract manufacturing organization, or CMO. All of our existing products are manufactured by CMOs. These CMOs are required by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements. The CMO that manufactures IMVEXXY and BIJUVA has previously been inspected by the FDA and received Form 483 observations with respect to its softgel manufacturing plant that is used for the manufacture of the commercial supply of IMVEXXY and BIJUVA. The CMO that manufactures ANNOVERA has previously been inspected by the FDA and received Form 483 observations with respect to its facility that is used for the commercial supply of ANNOVERA. We believe that corrective actions to address the compliance issues identified in the referenced Forms 483 have been implemented by the CMOs; however, the FDA has not yet reinspected the CMOs to confirm that the corrective actions were implemented as described to the agency in the respective Form 483 responses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, our regulatory submissions may be delayed or disapproved, and our marketed products may be affected. If these facilities are not in compliance for the manufacture of our products, we may need to find alternative manufacturing facilities, which would result in substantial disruptions of our sales of existing products and significant delays of up to several years in obtaining approval for our pharmaceutical product candidates. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. After generally suspending in-person inspections due to COVID-19, the FDA announced it would resume domestic facility inspections, although the agency continues its general suspension of foreign facility inspections (although &#8220;mission-critical&#8221; inspections may be considered on a case-by-case basis). Because of the global pandemic, decision-making around facility inspections by the FDA (including preapproval inspections) continues to evolve. Failure by any of our manufacturers to comply with applicable cGMP regulations or other applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, violation letters, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have an adverse impact on our business, financial condition, results of operations, and prospects. We do not currently have alternative manufacturers, and we may not be able to enter into a long-term agreement with alternative manufacturers, or do so on commercially reasonable terms, and if we do enter into agreements with alternative manufacturers, those alternative manufacturers may not be approved by the FDA, any of which could have an adverse impact on our business. We also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products and proposed products to the delay or other detriment of our products and proposed products, or otherwise do not satisfactorily perform according to the terms of their agreements with us. Finally, we could experience manufacturing delays or interruptions as a result of the ongoing COVID-19 pandemic.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We also do not have long-term contracts for the supply of the active pharmaceutical ingredient, or API, used in IMVEXXY, BIJUVA, and ANNOVERA. If any supplier of the API or other products used in our products or pharmaceutical product candidates experiences any significant difficulties in its respective manufacturing processes, does not comply with the terms of an agreement between us, or does not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant interruptions in the supply of our products or pharmaceutical product candidates, which could impair our ability to supply our products or pharmaceutical product candidates at the levels required for commercialization and prevent or delay their successful commercialization.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 36; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Even after the approval of IMVEXXY, BIJUVA, and ANNOVERA, and even if we obtain regulatory approval for other pharmaceutical product candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">With respect to IMVEXXY, BIJUVA, and ANNOVERA, the FDA may still impose significant restrictions on a product&#x2019;s indicated uses or marketing or to the conditions for approval or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for IMVEXXY, BIJUVA, and ANNOVERA contains restrictions on use and warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the Risk Evaluation and Mitigation Strategy, or REMS, explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. IMVEXXY, BIJUVA, and ANNOVERA will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance and reporting, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&#x2019;s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. As part of the FDA&#x2019;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen such as IMVEXXY. As part of the FDA&#x2019;s approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. Foreign regulatory agencies often have similar authority and may impose comparable requirement. Post-marketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our pharmaceutical product candidates once approved, and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The holder of an approved NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of certain clinical trial results on a publicly available database.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, manufacturers of pharmaceutical products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA&#x2019;s cGMP regulations and other regulatory requirements, such as adverse event reporting. If we or a regulatory agency discovers problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws, and are subject to review by FDA. If the FDA raises concerns regarding our promotional materials or messages, we may be required to modify or discontinue using them and may be required to provide corrective information. Should we fail to comply with these requirements, we may be subject to significant liability including civil and administrative actions as well as criminal sanctions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Commercial products must now meet the requirements of the Drug Supply Chain Security Act, or DSCSA, which imposes obligations on manufacturers of prescription pharmaceutical products for commercial distribution, regulating the distribution of the products at the federal level, and sets certain standards for federal or state registration and compliance of entities in the supply chain (manufacturers and re-packagers, wholesale distributors, third-party logistics providers, and dispensers). The DSCSA preempts previously enacted state pedigree laws and the pedigree requirements of the Prescription Drug Marketing Act, or PDMA, and its implementing regulations. Trading partners within the drug supply chain must now ensure certain product tracing requirements are met that they are doing business with other authorized trading partners; and they are required to exchange transaction information, transaction history, and transaction statements. Product identifier information (an aspect of the product tracing scheme) is also now required. The DSCSA requirements, development of standards, and the system for product tracing have been and will continue to be phased in over a period of years, with FDA indicating enforcement discretion on certain aspects due to the COVID-19 pandemic. The distribution of product samples continues to be regulated under the PDMA, and some states also impose regulations on drug sample distribution.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party suppliers fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">conduct an investigation into our practices and any alleged violation of law;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">issue warning letters or untitled letters asserting that we are in violation of the law;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">seek an injunction or impose civil or criminal penalties or monetary fines;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">suspend or withdraw regulatory approval;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">require that we suspend or terminate any ongoing clinical trials;</p>
</td>
</tr>

</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 37; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">refuse to approve pending applications or supplements to applications filed by us;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">suspend or impose restrictions on operations, including costly new manufacturing requirements;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">exclude us from providing our products to those participating in government healthcare programs, such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Recent government enforcement has targeted pharmaceutical companies for violations of fraud, abuse and other laws.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, pharmacies, and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical products, including certain discounts, or engagement of speakers or consultants, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor. Our practices with respect to interactions with healthcare professionals, including but not limited to consultant relationships, speaker programs, advisory boards, and scientific/educational grant programs, as well as our arrangements with pharmacies, may not in all cases meet all of the criteria for safe harbor protection from AKS liability. Moreover, there are no safe harbors for many common practices, such as certain educational and research grants or patient assistance programs. The safe harbors are subject to change through legislative and regulatory action, and we may decide to adjust our business practices or be subject to heightened scrutiny as a result.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, several states have recently enacted legislation requiring pharmaceutical companies to establish marketing and promotional compliance programs or codes of conduct and/or to file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Several states have also adopted laws that prohibit or limit certain marketing-related activities, including the provision of gifts, meals or other items to certain healthcare providers.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only those claims relating to safety and efficacy, purity, and potency that are approved by the FDA. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the product&#x2019;s labeling and that differ from those tested and approved by the FDA. Pharmaceutical companies, however, are required to promote their pharmaceutical products only for the approved indications and consistent with the FDA-required, approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and the FCA, exclusion from participation in federal healthcare programs, mandatory compliance programs under corporate integrity agreements, debarment, and refusal of government contracts.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate federal or state fraud and abuse laws or other applicable requirements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Federal enforcement agencies and private whistleblowers have shown and continue to show interest in pharmaceutical companies&#x2019; product and patient assistance programs (PAPs), including reimbursement support, co-pay support, nursing, adherence and educational services, referrals to other providers, donations to independent patient assistance charities, and relationships with specialty pharmacies. Co-pay assistance programs are intended to assist qualified patients with private insurance with any out-of-pocket financial obligations but must exclude any government healthcare program beneficiaries. Several investigations into patient assistance practices have resulted in significant civil and criminal settlements. We offer co-pay assistance for our vitamin products and IMVEXXY and BIJUVA, including co-pay assistance and free drug sample packs for IMVEXXY and BIJUVA, and potentially will enter into similar programs for ANNOVERA. While the OIG has approved certain independent charitable PAPs that help financially needy beneficiaries, advisory opinions on this issue have primarily focused on charities that provide assistance to patients who cannot afford cost-sharing obligations for prescription drugs. A key element for the OIG has been whether the charities are sufficiently independent from drug manufacturer donors. In May 2014, the OIG issued a Supplemental Special Advisory Bulletin regarding Independent Charity Patient Assistance Programs, or the 2014 Special Advisory Bulletin, which updated its 2005 Special Advisory Bulletin relating to PAPs. In the 2014 Special Advisory Bulletin, the OIG stated that although PAPs provide important safety net assistance to financially needy patients, these programs also present a risk of fraud, waste, and abuse with respect to federal health care programs. One of the three factors set forth in the revised guidance was that the PAP could not limit assistance to a single product. In September of 2014, the OIG also released a Special Advisory Bulletin on pharmaceutical manufacturer copayment coupons, specifically stating that manufacturers that did not comply with the law may be subject to sanctions if they fail to take appropriate steps to ensure that such coupons do not induce the purchase of Federal health care program items or services, including, but not limited to, drugs paid for by Medicare Part D.&#160;Failure to take such steps may be evidence of intent to induce the purchase of drugs paid for by these programs, in violations of the AKS. PAPs have also been the subject of Congressional review. If we fail to structure our patient assistance and support programs to comply with applicable law, we risk becoming subject to government investigations, and potentially, facing penalties or consequences for violations under fraud and abuse laws. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government healthcare programs, and the curtailment or restructuring of our operations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, to the extent we, our subsidiary, VitaCare Prescription Services, or our other contractors or agents receive or obtain individually identifiable health information from patients, healthcare professionals, pharmacies, or other individuals or entities, we could be subject to criminal penalties if we mishandle individually identifiable health information in a manner that is not authorized or permitted by HIPAA. Claims that we have violated individuals&#x2019; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. In addition, VitaCare Prescription Services&#x2019; activities could be subject to regulation and enforcement by the federal government and the states in which VitaCare conducts its business, including state licensing of pharmacies and pharmacists and as a result of potential increased scrutiny of innovation in hub services.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Some of our products can be prescribed to patients via a virtual health platform, such as PlushCare, a direct-to-consumer telehealth platform offering primary care medical services, subject to state telehealth and prescribing laws.&#160; The federal Ryan Haight Act substantially limits the ability of prescribers to prescribe controlled substances via telehealth.&#160; While this federal law applies only to federally controlled substances, the permissibility of prescribing other non-controlled substances via a telehealth encounter is addressed at the state level.&#160; Constant changes to the telehealth laws and regulations as well as state pharmacy and prescribing laws and emerging enforcement priorities by state legislatures, licensing bodies, and attorney generals&#x2019; offices, make it difficult to predict our ability to effectively provide patient access to our products via virtual care offerings. There have been recent waivers of telehealth restrictions, including many of those pertaining to electronic prescribing based on a telehealth encounter, in order to assist in expanding access to care during the COVID-19 pandemic. Many of these waivers are tied to the federal public health emergency declaration but some state laws have different expiration dates. We cannot guarantee that prescribers will be able, or willing, to prescribe our products to patients via a telehealth encounter and any limitations on such remote prescribing at the state level may impede our ability to expand access to our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Licensing of intellectual property involves complex legal, business and scientific issues, and disputes could jeopardize our rights under such agreements. Additionally, our current licensing agreements contain limitations and restrictions that could limit or adversely affect our ability to develop and commercialize other products in the future.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are currently and may in the future be a party to license agreements of importance to our business and to our products and product candidates. Disputes may arise between us and any of these counterparties regarding intellectual property subject to and each parties&#x2019; obligations under such agreements, including:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product and product candidates, and what activities satisfy those diligence obligations;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the scope of rights granted under the agreement and other interpretation-related issues;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">our obligations to make milestone, royalty, or other payments under those agreements;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the agreement;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">our right to sublicense patent and other rights to third parties:</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the ownership of inventions and know-how arising under the agreement or resulting from the joint creation or use of intellectual property by our licensors and us and our partners;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">our right to transfer or assign the license; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the effects of termination.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">These or other disputes over our obligations or intellectual property that we have licensed may prevent or impair our ability to maintain our current arrangements on acceptable terms, or may impair the value of the arrangement to us. Any such dispute could have an adverse effect on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">If we fail to meet our obligations under a license agreement in a material respect, the respective licensor could have the right to terminate the respective agreement and upon the effective date of such termination, have the right to re-obtain the related technology as well as, potentially, aspects of any intellectual property controlled by us and developed during the period the agreement was in force that relate to the applicable technology. This means that the licensor to each of these agreements could effectively take control of the development and commercialization of the applicable product or product candidate after an uncured, material breach of the agreement by us. This may also be the case if we voluntarily terminate the relevant agreement. Any uncured, material breach under a license agreement could result in our loss of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for the applicable product or product candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 39; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In July 2018, we entered into a license agreement with the Population Council to obtain exclusive U.S. rights to commercialize ANNOVERA. The agreement requires us to commercialize this product and enter into certain manufacturing agreements, make timely milestone and other payments, provide certain information regarding our activities under the agreement, and indemnify the other party with respect to our development and commercialization activities under the terms of the agreements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, our current licensing agreement with the Population Council contains limitations and restrictions, including limitations that could limit or adversely affect our ability to develop and commercialize this or other product candidates including the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">we cannot sublicense the rights licensed to us without the consent of the Population Council;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">neither we nor
the Population Council may develop a competitive product (as defined with respect to each party in the agreement) for six
years from the date of the agreement; and </p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the Population Council owns any program improvements, as defined in the agreement.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have also entered into licensing and supply agreements with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA&#160;in Canada and Israel and with Theramex pursuant to which we granted Theramex an exclusive license to commercialize BIJUVA, and IMVEXXY outside of the U.S., except for Canada and Israel.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Sales of our products in the U.S. and our rights to receive royalties with respect to our products sold outside the U.S. could be adversely affected if products manufactured outside of the U.S. or for sale outside of the U.S. under the terms of these licensing and supply agreements are reimported and sold in the U.S.&#160; In addition, our rights to receive royalties with respect to our products sold outside the U.S. could be adversely affected if our licensees fail to diligently pursue approval of our products, or opt not to sell our products, in certain jurisdictions where they are not required to do so.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>If our dietary supplement</i></b></i></b>, <b><i><b>hormone therapy pharmaceutical products or patient-controlled, long-acting contraceptive products do not have the effects intended or cause undesirable side effects, our business may suffer.</b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Although many of the ingredients in our dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human consumption, they also contain innovative ingredients or combinations of ingredients. Furthermore, our hormone therapy or patient-controlled, long-acting contraceptive pharmaceutical products have been approved by the FDA based on its assessment of the safety and efficacy of these products. While we believe that all of these products and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects if not taken as directed or if taken by a consumer who has certain medical conditions. In addition, these products may not have the effect intended if they are not taken in accordance with certain instructions, which include certain dietary or other labeling restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations, and prospects could be harmed significantly.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our products face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Development and awareness of our brand will depend largely upon our success in increasing our consumer base and maintaining adequate pricing through our exclusivities. The pharmaceutical and dietary supplement industries are intensely competitive and subject to rapid and significant technological change. Our products face intense competition, including from major multinational pharmaceutical and dietary supplement companies, established biotechnology companies, specialty pharmaceutical, and generic drug companies. Many of these companies have greater financial and other resources, such as larger research and development staffs and more experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly and may be more effective in selling and marketing their products. They also may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the products that we sell or develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. If we are unable to economically promote or maintain our brand, our business, results of operations and financial condition could be severely harmed. In addition, our efforts to provide an alternative to the non-FDA-approved compound bioidentical market for estradiol and progesterone products sold by compounding pharmacies may not be successful. Finally, loss of exclusivity may provide opportunity for competing products, particularly generics, to erode pricing and siphon off our consumers.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 40; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 20, 2020, we received the IMVEXXY Notice Letter regarding an ANDA submitted to the FDA by Teva.&#160; The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY.&#160; In the IMVEXXY Notice Letter, Teva alleges that IMVEXXY Patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. On April 1, 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set.&#160; The complaint which we filed automatically precludes the FDA from approving Teva&#x2019;s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed.&#160; We cannot assure you that the complaint filed on April 1, 2020 or any other patent infringement lawsuit that we may file will prevent the introduction of a generic version of IMVEXXY for any particular length of time, or at all. If Teva&#x2019;s ANDA is approved, and a generic version of IMVEXXY is introduced, our sales of IMVEXXY could be adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On March 17, 2020, we received the BIJUVA Notice Letter regarding an ANDA submitted to the FDA by Amneal. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of BIJUVA. In the BIJUVA Notice Letter, Amneal alleges that the BIJUVA Patents are invalid, unenforceable, and/or will not be infringed by Amneal&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The BIJUVA Patents identified in the BIJUVA Notice Letter expire in 2032. On April 29, 2020, we filed a complaint for patent infringement against Amneal in the United States District Court for the District of New Jersey arising from Amneal&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Amneal&#x2019;s ANDA would be a date no earlier than the expiration of the BIJUVA Patents and equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed its answer and counterclaim to the complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Amneal&#x2019;s ANDA until the earlier of 30 months or entry of a district court decision finding the BIJUVA Patents invalid, unenforceable, or not infringed.&#160;On February 25, 2021, the District Court entered an order temporarily
staying all proceedings in the BIJUVA litigation. The District Court stay also extends the 30-month stay for the period in which
the BIJUVA litigation has been stayed. We cannot assure you that the complaint filed on April 29, 2020 or any other patent infringement lawsuit that we may file will prevent the introduction of a generic version of BIJUVA for any particular length of time, or at all. If Amneal&#x2019;s ANDA is approved, and a generic version of BIJUVA is introduced, our sales of BIJUVA could be adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">In addition, we cannot predict what additional ANDAs could be filed by Teva, Amneal or other potential generic competitors requesting approval to market generic forms of our products, which could require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby harm our business and financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Failure to obtain regulatory approval outside the U.S. will prevent our licensees from marketing our hormone therapy pharmaceutical products in non-U.S. markets.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have entered into licensing and supply agreements with Knight and Theramex to commercialize IMVEXXY and BIJUVA in non-U.S. markets. To market these products in the European Union and many other non-U.S. jurisdictions, our licensees must obtain separate regulatory approvals. We have had limited interactions with non-U.S. regulatory authorities, the approval procedures vary among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval or clearance. Approval or clearance by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by other regulatory authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA approval or clearance. For these non-U.S. regulatory approvals, our licensees may not obtain them on a timely basis, if at all. Our licensees&#x2019; failure to receive necessary non-U.S. regulatory approvals to commercialize IMVEXXY and BIJUVA in a given market could have an adverse effect on our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, by seeking to obtain approval to market IMVEXXY and BIJUVA in one or more non-U.S. markets, we and/or our licensees will be subject to rules and regulations in those markets relating to our products. In some countries, particularly countries of the European Union, each of which has developed its own rules and regulations, pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a drug. To obtain reimbursement or pricing approval in some countries, our licensees may be required to conduct a clinical trial that compares the cost-effectiveness of our pharmaceutical product to other available products. If reimbursement of our pharmaceutical product is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our licensees may be unable to generate revenues and achieve or sustain profitability with respect to any given market, which could have an adverse effect on our business, financial condition, results of operations, and prospects. If our licensees obtain approval to market IMVEXXY or BIJUVA in one or more non-U.S. markets, we will have additional pharmacovigilance reporting requirements for our products. To the extent that the non-U.S. markets in which our licensees distribute our products have different pharmacovigilance reporting requirements than the U.S., there is a risk that the marketing of our drugs in those countries may increase the number of adverse events reported for our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 41; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our success is tied to our distribution channels.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We sell our products to wholesale distributors and retail pharmacy distributors. During 2020, three customers each generated more than 10% of our total revenues; revenue generated from these three customers combined accounted for approximately 63% of our total revenue during 2020. Our business would be harmed if any of these customers refused to distribute our products or refused to purchase our products on commercially favorable terms to us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We rely on third parties to conduct our research and development activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful in obtaining regulatory approval for, or in commercializing, our pharmaceutical product candidates if these third parties do not successfully carry out their contractual duties or meet expected deadlines.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We do not have the resources to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our on-going clinical programs for our pharmaceutical product candidates, as well as for the execution of clinical studies. Although we only have oversight of certain aspects of our CROs&#x2019; activities, we are ultimately responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards. Our reliance on the CROs does not relieve us of our regulatory responsibilities as sponsor. We cannot assure you that the CROs will conduct the research properly or in a timely manner, or that the results will be reproducible. We and our CROs are required to comply with the FDA&#x2019;s current Good Clinical Practice, or cGCP, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic and pre-approval inspections of trial sponsors, principal investigators, CROs, and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of our pharmaceutical product candidates to a statistically significant degree, our clinical trials will require an adequately large number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly, if our CROs fail to comply with these regulations or recruit enough patients, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, we do not employ the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot control whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs may also have relationships with other commercial entities, including one or more of our competitors, for which they may also be conducting clinical studies or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our pharmaceutical product candidates that we seek to develop. As a result, our financial results and the commercial prospects for our pharmaceutical product candidates that we seek to develop could be harmed, our costs could increase, and our ability to generate revenue could be delayed or end.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We typically engage one or more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources and expertise to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation of clinical trial data for submission with an NDA for each of our pharmaceutical product candidates. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can affect our ability to meet our desired clinical development timelines and can increase our costs significantly. Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, results of operations, or prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i><b><i>Our ability to utilize net operating loss carryforwards may be limited.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of December 31, 2020, we had federal net operating loss carryforwards, or NOLs, of approximately $761.7 million. Subject to applicable limitations, these NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce our future federal income taxes otherwise payable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 42; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Section 382 of the Internal Revenue Code of 1986, as amended, imposes limitations on a corporation&#x2019;s ability to utilize NOLs if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percent over a three-year period. If an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be carried over to later years. We may be found to have experienced an ownership change under Section 382 because of events in the past or the issuance of shares of our common stock in the future. If so, the use of our NOLs, or a portion thereof, against our future taxable income may be subject to an annual limitation under Section 382.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On December 22,
2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or
the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing
the U.S. federal corporate tax rate from 34 percent to 21 percent and imposing new restrictions on the use of NOLs. The Tax
Act reduced the corporate tax rate to 21 percent, effective January 1, 2018.&#160;Management assessed the valuation allowance
analyses with respect to our NOLs as affected by various aspects of the Tax Act and determined that a full valuation
allowance continues to be appropriate. Additionally, in order to address the impact of the COVID-19 pandemic, the Coronavirus
Aid, Relief, and Economic Security Act, or the CARES Act, was enacted into law on March 27, 2020. The CARES Act includes
several significant business tax provisions that, among other things, includes further statutory amendments to the rules
governing NOLs, as amended by The Tax Act. The CARES Act limits the NOL carryover deduction in taxable years beginning after
December 31, 2020, to the lesser of the NOL carryforward or 80 percent of the taxpayer's taxable income (after considering
the deduction for NOLs arising in tax years beginning before January 1, 2018), which may restrict our ability to offset
future taxable income with NOLs and increase our future federal income taxes otherwise payable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our operations are concentrated in Boca Raton, Florida and interruptions affecting us or our suppliers due to natural disasters, the COVID-19 pandemic, or other unforeseen events could adversely affect our operations.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our current operations are concentrated in Boca Raton, Florida. A hurricane, the COVID-19 pandemic, or other disaster or unforeseen event resulting in significant damage to our facilities, or causing illness in the personnel operating our facilities, could significantly disrupt or curtail or require us to cease our operations.&#160; It would be difficult, costly and time-consuming to transfer resources from one facility to another or to repair or replace our facility if it is significantly damaged, or engage or hire new personnel due to the COVID-19 pandemic. In addition, our insurance may be insufficient to cover all of our losses and may not continue to be available to us on acceptable terms, or at all. In addition, if one of our suppliers, such as Catalent at its manufacturing facility in St. Petersburg, Florida, experiences a similar disaster or is otherwise impacted by the COVID-19 pandemic or unforeseen event, we could face significant delays in obtaining our products. Any significant uninsured loss, prolonged or repeated disruption to operations or inability to operate, experienced by us or by our suppliers, could adversely affect our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Any failure to adequately maintain a sales force will impede our growth.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are substantially dependent on a sales force &#8211; both those directly employed by us and those engaged through our contract sales organization &#8211; to attract new business and to manage existing customer relationships. There is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our success in recruiting, training, and retaining direct sales personnel. New and future sales personnel may not become as productive as expected, and we may be unable to hire or engage enough qualified individuals in the future in the markets in which we do business. If we are unable to hire, engage and develop enough productive sales personnel or are required to hire or engage more sales personnel than we expect our business prospects could suffer. In addition to utilizing a contract sales organization for part of our sales force, we also utilize this organization for certain sales support functions, such as fleet and sample management. We currently intend to insource at least some of these functions and personnel in the future.&#160; If we are unsuccessful in insourcing these functions or personnel, we may face delays or additional costs in commercializing our pharmaceutical products, which could adversely affect our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Other pharmaceutical companies with which we compete for qualified personnel may have greater financial and other resources, different risk profiles, and longer histories than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we offer. If we are unable to continue to attract and retain high-quality personnel, our ability to commercialize IMVEXXY, BIJUVA, and ANNOVERA may be limited.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of December 31, 2020, we had 400 employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial, sales and marketing, and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional pharmaceutical product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our pharmaceutical products and compete effectively will depend, in part, on our ability to effectively manage any future growth in our organization.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 43; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><i><b><i>Risks Related to our Intellectual Property</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy pharmaceutical products and other products are not adequate, we may not be able to compete effectively in our market.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability to maintain adequate protection of other intellectual property for our hormone therapy pharmaceutical products and other products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in patent laws in the U.S., such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">These risks include the possibility of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the patent applications that we have filed may fail to result in issued patents in the U.S. or in foreign jurisdictions;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">patents issued or licensed to us or our partners may be challenged or discovered to have been issued on the basis of insufficient, incomplete, or incorrect information, and thus held to be invalid or unenforceable;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the scope of any patent protection may be too narrow to exclude competitors from developing or designing around these patents;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">we or our licensors were not the first to make the inventions covered by each of our issued patents and pending patent applications;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">we or our licensors may not have been the first inventors to invent or file patent applications for these technologies in the U.S. or were not the first to file patent applications directed to these technologies abroad;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">we may fail to comply with procedural, documentary, fee payment, and other similar provisions during the patent application process, which can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">future pharmaceutical product candidates may not be patentable;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">others may claim rights or ownership regarding patents and other proprietary rights that we hold or license;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in development, testing, clinical trials, and regulatory review may reduce the period during which we could market our pharmaceutical products under patent protection; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">we may fail to timely apply for patents on our technologies or products.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">While we apply for patents covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or have received patents in our areas of product development. These entities&#x2019; applications, patents, and other intellectual property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture, or commercialize our pharmaceutical products. In addition, if third parties file patent applications in the technologies that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings with the USPTO or foreign patent regulatory authorities to determine our rights in the technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged in the courts or in post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent claims or adverse changes to the scope of the claims.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">If we, our licensors, or our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their uses, companies may be dissuaded from collaborating with us. In such event, our ability to commercialize our pharmaceutical products may be threatened, we could lose our competitive advantage, and the competition we face could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 44; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, mechanisms exist in much of the world permitting some form of challenge by generic drug marketers to our patents before, or immediately following, the expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as &#8220;at risk&#8221; launches to challenge relevant patent rights. On February 20, 2020, we received the IMVEXXY Notice Letter regarding an ANDA submitted to the FDA by Teva, and on March 17, 2020 we received the BIJUVA Notice Letter regarding an ANDA submitted to the FDA by Amneal.&#160; The ANDA submitted by Teva seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY, and the ANDA submitted by Amneal seeks approval from the FDA to commercially manufacture, use, or sell a generic version of BIJUVA.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In the IMVEXXY Notice Letter, Teva alleges that IMVEXXY Patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033.&#160; On April 1, 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set.&#160; The complaint which we filed automatically precludes the FDA from approving Teva&#x2019;s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In the BIJUVA Notice
Letter, Amneal alleges that BIJUVA Patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of
BIJUVA are invalid, unenforceable, and/or will not be infringed by Amneal&#x2019;s commercial manufacture, use, or sale of
its proposed generic drug product. The BIJUVA Patents identified in the BIJUVA Notice Letter expire in 2032. On April 29,
2020, we filed a complaint for patent infringement against Amneal in the United States District Court for the District of New
Jersey arising from Amneal&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective
date of any FDA approval of Amneal&#x2019;s ANDA would be a date no earlier than the expiration of the BIJUVA Patents and
equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed its answer and counterclaim to the
complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has not been set. The complaint which
we filed automatically precludes the FDA from approving Amneal&#x2019;s ANDA until the earlier of 30 months or entry of a
district court decision finding the BIJUVA Patents invalid, unenforceable, or not infringed. On February 25, 2021, the District Court entered an order temporarily
staying all proceedings in the BIJUVA litigation. The District Court stay also extends the 30-month stay for the period in which
the BIJUVA litigation has been stayed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We cannot assure you that any patent infringement lawsuit that we may file will prevent the introduction of a generic version of IMVEXXY or BIJUVA for any particular length of time, or at all. If Teva&#x2019;s ANDA or Amneal&#x2019;s ANDA are approved, and a generic version of IMVEXXY or BIJUVA is introduced, our sales of IMVEXXY or BIJUVA could be adversely affected. In addition, we cannot predict what additional ANDAs could be filed by Teva, Amneal or other potential generic competitors requesting approval to market generic forms of our products, which could require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby harm our business and financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our business also may rely on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached, it could adversely impact our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We may be required to file lawsuits or take other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, including with respect to Teva&#x2019;s ANDA and BIJUVA Notice Letter, and Amneal&#x2019;s ANDA and IMVEXXY Notice Letter, which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents, or those of our licensors, do not cover the technology in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents, or those of our licensors, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications, or those of our licensors, at risk of not issuing. Moreover, we may not be able to prevent, alone or with our licensors, misappropriation of our proprietary rights, particularly in countries in which the laws may not protect those rights as fully as in the U.S. or in those countries in which we do not file national phase patent applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, if securities analysts or investors perceive public announcements of the results of hearings, motions, or other interim proceedings or developments to be negative, the price of our common stock could be adversely affected. The occurrence of any of the above could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 45; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><i><b><i>Risks Related to Ownership of our Common Stock</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of December 31, 2020, our executive officers, directors, holders of 5% or more of our common stock, and their affiliates beneficially owned approximately 25% of our common stock, inclusive of vested options and warrants to acquire shares of our common stock. These stockholders may be able to largely determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to largely control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal control over financial reporting. Due to our current filing status, we are not required to have our independent registered public accounting firm deliver an attestation report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control over financial reporting or our independent auditors are unwilling or unable to provide us with an attestation report on the effectiveness of internal control over financial reporting for future periods as required by, or voluntarily followed under, Section 404 of the Sarbanes-Oxley Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i><b><i>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of the Financing Agreement preclude us from paying dividends, and any future debt agreements may also preclude us from paying dividends. Any return to stockholders will be limited to the capital appreciation, if any, of their stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Some provisions of our charter documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Provisions in our articles of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult to remove our current management. These provisions in our articles of incorporation and bylaws include the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">authorizing the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our board of directors to increase the number of outstanding shares and thwart a takeover attempt;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">prohibiting cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">advance notice provisions in connection with stockholder proposals that may prevent or hinder any attempt by our stockholders to bring business to be considered by our stockholders at a meeting or replace our board of directors.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, we are subject to Nevada&#x2019;s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 - 78.444), which prohibits an &#8220;interested stockholder&#8221; from entering into a &#8220;combination&#8221; with a company, unless certain conditions are met. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, beneficially owns (or within the prior two years, did beneficially own) 10% or more of the corporation&#x2019;s capital stock entitled to vote.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 46; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><i><b><i>General Risks Related to our Business</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our business may be affected by unfavorable publicity or lack of consumer acceptance. </i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are highly dependent upon consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer acceptance of a product can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use, products themselves, or marketing campaigns for our products. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry or any of our products and may not be consistent with earlier favorable research or publicity. A future research report or publicity that is perceived by consumers as less than favorable or that may question earlier favorable research or publicity could have an adverse effect on sales of our products and our ability to generate revenue. Adverse publicity in the form of published scientific research, statements by regulatory authorities or otherwise, whether or not accurate, that associates use of our products or any other similar products with illness or other adverse effects, or that questions the benefits of our products or similar products, or that claims that such products do not have the effect intended, or that question the marketing of our products, could have an adverse effect on our business, reputation, financial condition, or results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our success depends on how efficiently we respond to changing consumer preferences and demand.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our success depends, in part, on our ability to anticipate and respond to changing consumer trends and preferences. We may not be able to respond in a timely or commercially appropriate manner to these changes. Our failure to accurately predict these trends could negatively impact our inventory levels, sales, and consumer opinion of us as a source for the latest product. The success of our new product offerings depends upon several factors, including our ability to achieve the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">accurately anticipate consumer needs;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">innovate and develop new products;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">successfully commercialize new products in a timely manner;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">competitively price our products in the market;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">procure and maintain products in sufficient volumes and in a timely manner; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">differentiate our product offerings from those of our competitors.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">If we do not introduce new products, make enhancements to existing products, or maintain the appropriate inventory levels of our existing products to meet consumers&#x2019; demand in a timely manner, our business, results of operations, and financial condition could be adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We may initiate product recalls or withdrawals or may be subject to regulatory enforcement actions that could negatively affect our business.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We may be subject to product recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of any of our products. A recall, withdrawal, or seizure of any of our products could adversely affect consumer confidence in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products would require significant management attention, would likely result in substantial and unexpected expenditures, and could adversely affect our business, financial condition, and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We face an inherent risk of product liability claims as a result of the commercial availability of our current products and the clinical testing of our pharmaceutical product candidates despite obtaining appropriate informed consents from our clinical trial participants. Additionally, in light of the history of product liability claims related to other hormone therapy products and contraceptives, we will face an even greater risk through commercialization of our products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failures to warn of dangers associated with the use of the product, negligence, strict liability, or breaches of warranties. Claims could also be asserted under state consumer fraud and protection statutes. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our existing products or pharmaceutical product candidates. Regardless of the merits or eventual outcome, product liability claims may result in any of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the inability to commercialize our products or pharmaceutical product candidates;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">difficulty recruiting subjects for clinical trials or withdrawal of these subjects before a trial is completed;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">labeling, marketing, or promotional changes and/or restrictions;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">product recalls or withdrawals;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">decreased demand for our products or products that we may develop in the future;</p>
</td>
</tr>

</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 47; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">loss of revenue;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">injury to our reputation;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">initiation of investigations by regulators or actions by state attorney generals or the U.S. Department of Justice;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">costs to defend the related litigation;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">a diversion of management&#x2019;s time and our resources;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">substantial monetary awards to trial participants or patients;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">exhaustion of any available insurance and our capital resources; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">a decline in our stock price.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Although we maintain general liability insurance and clinical trial liability insurance for our products and product candidates, this insurance may not fully cover potential liabilities. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the development and commercial production and sale of our products, which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>If we use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our manufacturing and research and development activities involve the controlled use of potentially hazardous substances, including chemical, biological, and radioactive materials. In addition, our operations produce hazardous waste products. Federal, state, and local laws and regulations in the U.S. govern the use, manufacture, storage, handling, and disposal of hazardous materials. Although we believe that our procedures for use, handling, storing, and disposing of these materials (all of which only occur at third-party sites operated by our contractors) comply with legally prescribed standards, we may incur significant additional costs to comply with applicable laws in the future. We also cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced. Also, even if we are in compliance with applicable laws, we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur liability as a result of any such contamination or injury. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources, and we do not carry liability insurance covering the use of hazardous materials. If we fail to comply with applicable requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs, or capital expenditures for control equipment or operational changes necessary to achieve or maintain compliance. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, and may adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our ability to compete in the highly competitive pharmaceutical industry depends in large part on our ability to attract and retain highly qualified managerial, scientific, and medical personnel. To induce valuable employees to remain with us, we have, among other things, provided stock-based compensation that vests over time. The value to employees of stock-based compensation will be significantly affected by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific, and medical teams may terminate their employment with us on short notice. Although we have employment agreements with several of our key employees, most employees are employed on an at-will basis, which means that any of these employees could leave our employment at any time, with or without notice, and may go to work for a competitor. The loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results, and financial condition. Our success also depends on our ability to continue to attract, retain, and motivate highly skilled scientific and medical personnel.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>A failure to maintain optimal inventory levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our ability to maintain optimal inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some instances, our products have unique ingredients used under license arrangements. If our manufacturers are unsuccessful in obtaining raw materials, if we are unable to manufacture and release inventory on a timely and consistent basis, if we fail to maintain an adequate level of product inventory, if inventory is destroyed or damaged, or if our inventory reaches its expiration date, patients might not have access to our products, our reputation and brands could be harmed, and physicians may be less likely to recommend our products in the future, each of which could have an adverse effect on our business, financial condition, results of operations, and cash flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 48; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Delays in clinical trials are common for many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval or commence or continue product sales.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We may experience delays in future clinical trials for our pharmaceutical product candidates or required post-approval clinical trials for our approved products. Clinical trials might not begin on time; may be interrupted, delayed, suspended, or terminated once commenced; might need to be amended or redesigned; might not enroll enough patients; or might not be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in obtaining regulatory approval to commence a trial;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">imposition of a clinical hold following an inspection of clinical trial operations or trial sites by the FDA, or other regulatory authorities;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">imposition of a clinical hold because of safety or efficacy concerns by the DSMB, FDA, or IRB, or us;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in obtaining required central or local IRB approval for each clinical site;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in identifying, recruiting, and training suitable clinical investigators;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in recruiting suitable patients to participate in a trial;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in having patients&#x2019; complete participation in a trial or return for post-treatment follow-up;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">clinical sites dropping out of a trial to the detriment of enrollment or due to a lack of ability to enroll a certain number of patients in a trial;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">time required to add new sites;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays in obtaining sufficient supplies of clinical trial materials, including suitable API; or</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">delays resulting from negative or equivocal findings of DSMB for a trial.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Any of these delays in completing future clinical trials could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenue from our pharmaceutical product candidates, or continue to generate revenue from our approved products subject to post-approval clinical trials for our approved products, subject to the trial.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Clinical trials are lengthy and expensive with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results</i></b></i><b>.</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. Failure can occur at any time during the clinical trial process because of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors. New drugs in later stages of clinical trials may fail to show the desired safety and efficacy data and results despite having progressed through earlier clinical trials. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our future clinical trials may not be successful or may be more expensive or time-consuming than we currently expect. Before approving a new drug, the FDA generally requires that the safety and efficacy of the drug be demonstrated in two adequate and well-controlled clinical trials. In some situations, the FDA approves drugs based on a single well-controlled clinical trial. If clinical trials for any of our pharmaceutical product candidates fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA will not approve those product candidates and we will not be able to commercialize, which could have an adverse effect on our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Future legislation, or the absence of such legislation, regulations, and policies adopted by the FDA or other regulatory authorities may increase the time and cost required for us to conduct and complete clinical trials for our pharmaceutical product candidates.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The FDA has established regulations, guidelines, and policies to govern the drug development and approval process, as have foreign regulatory authorities. Any change in regulatory requirements resulting from the adoption of new legislation, regulations, or policies may require us to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols or clinical trial applications or the need for new ones, may significantly and adversely affect the cost, timing, and completion of the clinical trials for our pharmaceutical product candidates.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, the FDA&#x2019;s policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval of our pharmaceutical product candidates, or impose more stringent product labeling and post-marketing testing and other requirements. For example, in the past the FDA has indicated it would regulate prenatal vitamins containing greater than 0.8 mg of folic acid as a drug under the FDCA. More recently the FDA indicated that there is no specified upper limit on the amount of folic acid permitted in a dietary supplement. If the FDA were to seek to regulate products with higher amounts of folic acid as drugs, it may require us to stop selling certain of our dietary supplement products and otherwise adversely affect our business. If we are slow or unable to adapt to any such changes, our business, prospects, and ability to achieve or sustain profitability could be adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 49; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We may be required to suspend or discontinue clinical trials because of adverse side effects or other safety risks that could preclude approval of our pharmaceutical product candidates.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Clinical trials may be suspended or terminated at any time for many reasons. A clinical trial may be suspended or terminated by us, our collaborators, the FDA, or other regulatory authorities because of a failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or negative or equivocal findings of the DSMB or the IRB for a clinical trial. An IRB may also suspend or terminate our clinical trials for failure to protect patient safety or patient rights. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe the clinical trials are not being conducted in accordance with applicable regulatory requirements or present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate any clinical trial of any proposed product that we develop, the commercial prospects of such proposed product will be harmed and our ability to generate product revenue from any of these proposed products will be delayed or eliminated. Any of these occurrences may harm our business, financial condition, results of operations, and prospects significantly.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our business may be impacted by new or changing tax laws or regulations and actions by federal, state, and/or local agencies, or how judicial authorities apply tax laws.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In connection with the products we sell and intend to sell, we calculate, collect, and remit various federal, state, and local taxes, surcharges and regulatory fees, or taxes, to numerous federal, state and local governmental authorities. In addition, we incur and pay state and local taxes and fees on purchases of goods and services used in our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. In many cases, the application of tax laws (including the recently enacted Tax Act) is uncertain and subject to differing interpretations, especially when evaluated against new technologies and services. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">If we have incorrectly described, disclosed, calculated, assessed, or remitted amounts that were due to governmental authorities, we could be subject to additional taxes, fines, penalties, or other adverse actions, which could impact our business, results of operations, and financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We may not be able to maintain effective and efficient information systems or properly safeguard our information systems.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our operations are dependent on uninterrupted performance of our information systems. Failure to maintain reliable information systems, disruptions in our existing information systems or the implementation of new systems could cause disruptions in our business operations, including violations of patient privacy and confidentiality requirements and other regulatory requirements, increased administrative expenses and other adverse consequences.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, information security risks have generally increased in recent years because of new technologies and the increased activities of perpetrators of cyber-attacks resulting in the theft of protected health, business, or financial information. During the COVID-19 pandemic, in particular, cyber-attacks increased as companies shifted to remote work environments, including several high-profile, sophisticated attacks impacting government agencies and security firms alike, the impacts of which are still being uncovered. Despite our layered security controls, experienced computer programmers and hackers may be able to penetrate our information systems and misappropriate or compromise sensitive patient or personnel information or proprietary or confidential information, create system disruptions or cause shutdowns. They also may be able to develop and deploy viruses, worms and other malicious software programs that disable our systems or otherwise exploit any security vulnerabilities. Outside parties may also attempt to fraudulently induce employees to take actions, including the release of confidential or sensitive information or to make fraudulent payments, through illegal electronic spamming, phishing, or other tactics.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">A failure in or breach of our information systems because of cyber-attacks or other tactics could disrupt our business, result in the release or misuse of protected health information, or PHI, confidential or proprietary business information or financial loss, damage our reputation, increase our administrative expenses, and expose us to additional risk of liability to federal or state governments or individuals. Although we believe that we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities. Our remediation efforts may not be successful and could result in interruptions, delays or cessation of service and loss of existing or potential patients and disruption of our operations. In addition, breaches of our security measures and the unauthorized dissemination of patient healthcare and other sensitive information, proprietary or confidential information about us or other third-parties could expose such persons&#x2019; private information to the risk of financial or medical identity theft or expose us or such persons to a risk of loss or misuse of this information, result in litigation and potential liability for us, damage our brand and reputation or otherwise harm our business. Any of these disruptions or breaches of security could have an adverse effect on our business, financial condition, and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 50; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our failure to comply with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">European Union member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the European Union, which was formerly governed by the provisions of the European Union Data Protection Directive, was replaced with the European Union General Data Protection Regulation, or the GDPR, in May 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the non-compliant company, whichever is greater. The recent implementation of the GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#x2019;s attention and increase our cost of doing business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On July 16, 2020, the Court of Justice of the European Union issued its long-awaited&#160;decision&#160;in the case Data Protection Commission v. Facebook Ireland, Schrems, or the Schrems II Decision. The Schrems II decision invalidates the European Commission&#x2019;s adequacy decision for the EU-U.S. Privacy Shield Framework, calling into question personal data transfers from the EU to the U.S. While we have yet to determine the full impact of the invalidation of the EU-US Privacy Framework on our business, we anticipate increased legal and technological costs as we evaluate any trans-Atlantic transfers as well as the impact on any business that we may conduct in the EU.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the European Union and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our employees and business partners may not appropriately secure and protect confidential information in their possession.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Each of our employees and business partners is responsible for the security of the information in our systems or under our control and to ensure that private and financial information is kept confidential. Should an employee or business partner not follow appropriate security measures, including those related to cyber threats or attacks or other tactics, as well as our privacy and security policies and procedures, the improper release of personal information, including PHI, or confidential business or financial information, or misappropriation of assets could result. The release of such information or misappropriation of assets could have an adverse effect on our business, financial condition, and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 51; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><i><b><i>General Risks Related to our Intellectual Property</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>Another party could develop competing pharmaceutical products and obtain FDA regulatory exclusivity in the U.S. before we do, potentially preventing our ability to commercialize our pharmaceutical products and other products in development.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We plan to seek to obtain market exclusivity for our pharmaceutical products and any other pharmaceutical product candidates we develop in the future. To the extent that patent protection is not available or has expired, FDA exclusivity may be the only available form of exclusivity available for these proposed products. These FDA exclusivities can delay the submission or the approval of certain drug applications. Potentially competitive products may also be seeking FDA exclusivities and may be in various stages of development, including some more advanced than us. We cannot predict with certainty the timing of FDA approval or whether FDA approval will be granted, nor can we predict with certainty the timing of FDA approval for competing products or whether such approval will be granted. It is possible that competing products may obtain FDA approval with exclusivities before we do, which could delay our ability to submit an application or obtain necessary regulatory approvals, result in lost market opportunities with respect to our pharmaceutical product candidates, and adversely affect our business, financial condition, and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>If we are sued for infringing intellectual property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or commercializing our pharmaceutical product candidates.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our commercial success depends, in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration or other agreements we have entered into with regard to our technologies and products. We are aware of numerous third-party U.S. and non-U.S. issued patents and pending applications that exist in the technical areas of our pharmaceutical products, including compounds, formulations, treatment methods, and synthetic processes, which may be applied towards the synthesis of hormones, for example. Patent applications are confidential when filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications remain unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently unaware with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products or product candidates. Therefore, we cannot ever know with certainty the nature or existence of every third-party patent filing. We cannot provide assurances that we or our partners will be free to manufacture or market our product candidates as planned or that we or our licensors&#x2019; and partners&#x2019; patents will not be opposed or litigated by third parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture, or methods of treatment related to the use or manufacture of any of our product candidates, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. There can be no assurances that we will be able to obtain a license to such patent on favorable terms or at all. Failure to obtain such license may have an adverse effect on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">There is a substantial amount of litigation involving intellectual property in the pharmaceutical industry generally. If a third party asserts that we infringe its patents or other proprietary rights, we could face many risks that could adversely affect our business, financial condition, results of operations, and prospects, including the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">infringement and other intellectual property claims, which would be costly and time-consuming to defend, whether or not we are ultimately successful, which in turn could delay the regulatory approval process, consume our capital, and divert management&#x2019;s attention from our business;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">substantial damages for past infringement, which we may have to pay if a court determines that our products or technologies infringe a competitor&#x2019;s patent or other proprietary rights;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">a court prohibiting us from selling or licensing our technologies or future products unless the third party licenses its patents or other proprietary rights to us on commercially reasonable terms, which it is not required to do;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">if a license is available from a third party, we may have to pay substantial royalties or lump sum payments or grant cross licenses to our patents or other proprietary rights to obtain that license; or</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">redesigning our products so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">We are party from time to time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that our technologies, processes, or products infringe on their intellectual property. We cannot predict whether third parties will assert these claims against us or our strategic partners or against the licensors of technology licensed to us, or whether those claims will harm our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. If we or our partners were to face infringement claims or challenges by third parties relating to our pharmaceutical product candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our partners to curtail or cease the development of some or all of our pharmaceutical product candidates, which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i><b><i>If we are unable to protect the confidentiality of certain information, the value of our products and technology could be adversely affected.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We also rely on trade secrets, know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this competitive position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees, independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims that a third party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming, and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets, know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 52; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers or of other third parties with whom we have obligations of confidentiality.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As is common in the pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual property rights, which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><i><b><i>General Risks Related to Ownership of our Common Stock</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>The market price of our common stock may be highly volatile, and you could lose all or part of your investment.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The trading price of our common stock on Nasdaq is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above the price you paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">changes in laws or regulations applicable to our products or proposed products, including clinical trial requirements for approvals;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">unanticipated serious safety concerns related to the use of our products;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">a decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">adverse results or delays in clinical trials;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the inability to obtain adequate supply for our products or the inability to do so at acceptable prices;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">adverse regulatory decisions;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the introduction of new products or technologies offered by us or our competitors;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the effectiveness of our or our licensees&#x2019; commercialization efforts;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the inability to effectively manage our growth;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">actual or anticipated variations in quarterly operating results;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the failure to meet or exceed the estimates and projections of the investment community;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the overall performance of the U.S. equity markets and general political and economic conditions;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">additions or departures of key scientific or management personnel;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">adverse market reaction to any indebtedness we may incur or securities we may issue in the future;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">sales of our common stock by us or our stockholders in the future;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant lawsuits, including patent or stockholder litigation;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">changes in the market valuations of similar companies;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">the trading volume of our common stock;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">increases in our common stock available for sale upon expiration of lock-up agreements;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">effects of natural or man-made catastrophic events or other business interruptions; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt"></td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">other events or factors, many of which are beyond our control.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 53; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, the stock market in general and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i><b><i>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</i></b></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which might cause our stock price and trading volume to decline.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><b><i><span style="background-color: white"><b><i>Future sales and issuances of equity securities, convertible securities or other securities could result in additional dilution of the percentage ownership of holders of our common stock.</i></b></span></i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="background-color: white">Our stockholders may experience dilution upon future equity issuances, including convertible debt or equity securities we may issue in the future, the exercise of stock options to purchase common stock granted to our employees, consultants and directors, including options to purchase common stock granted under our stock option and equity incentive plans or the issuance of common stock in settlement of previously issued awards under our stock option and equity incentive plans that may vest in the future.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We expect that additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell equity securities, convertible securities or other securities in one or more transactions at prices and in a manner we determine from time to time. If we sell equity securities, convertible securities or other securities current investors may be materially diluted by subsequent sales. We may also need our stockholders to authorize the issuance of additional shares of common stock under our articles of incorporation if we do not have sufficient authorized shares to raise such additional capital or issue future awards under our stock option and equity incentive plans. New investors could also gain rights, preferences and privileges senior to those of holders of our existing equity securities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>I<span id="a004"></span>tem 1B &#160;&#160;&#160;&#160;&#160;&#160; Unresolved Staff Comments</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">None.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>I<span id="a005"></span>tem 2.&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160; Properties</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="color: #212529">In October 2018, we entered into a lease for new corporate headquarter offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which the lease on 7,561 square feet commenced in 2018 and the lease on the remaining 48,651 square feet commenced in August 2019, or the full premises commencement date. The lease will expire 11 years after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which commenced in May 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><b>I<span id="a006"></span>tem 3.&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160; Legal Proceedings</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">From time to time, we are involved in litigation and proceedings in the ordinary course of our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On February 20, 2020, we received a Paragraph IV certification notice letter, or the IMVEXXY Notice Letter, regarding an ANDA submitted to the FDA by Teva Pharmaceuticals USA, Inc., or Teva. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY, or the IMVEXXY Patents, are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. On April 1, 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 54; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On March 17, 2020,
we received a Paragraph IV certification notice letter, or the BIJUVA Notice Letter, regarding an ANDA submitted to the FDA
by Amneal Pharmaceuticals, or Amneal. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a
generic version of BIJUVA. In the BIJUVA Notice Letter, Amneal alleges that TherapeuticsMD patents listed in the FDA&#x2019;s
Orange Book that claim compositions and methods of BIJUVA, or the BIJUVA Patents, are invalid, unenforceable, and/or will not
be infringed by Amneal&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The BIJUVA Patents
identified in the BIJUVA Notice Letter expire in 2032. On April 29, 2020, we filed a complaint for patent infringement
against Amneal in the United States District Court for the District of New Jersey arising from Amneal&#x2019;s ANDA filing
with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Amneal&#x2019;s
ANDA would be a date no earlier than the expiration of the BIJUVA Patents and equitable relief enjoining Amneal from
infringing the BIJUVA Patents. Amneal has filed its answer and counterclaim to the complaint, alleging that the BIJUVA
Patents are invalid and not infringed. A trial date has not been set. On February 25, 2021, the District Court entered an order temporarily staying all proceedings in the BIJUVA litigation. The District Court
stay also extends the 30-month stay for the period in which the BIJUVA litigation has been stayed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b><span id="a007"></span>Item 4.&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160; Mine Safety Disclosures</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Not applicable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><b><span id="a008"></span>PART II</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 72pt; text-indent: -72pt"><b><b><span id="a009"></span>Item 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><b>Market Information on Common Stock</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Since October 9, 2017, our common stock has been listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC under the symbol &#8220;TXMD.&#8221; From April 23, 2013 to October 6, 2017, our common stock was listed on the NYSE American under the symbol &#8220;TXMD.&#8221; Before that time, our common stock was quoted on the OTCQB.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of February 1, 2021, there were approximately 171 record holders and 28,853 beneficial owners of our common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Dividends</b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Historically, we have not paid dividends on our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments of any cash dividends in the future will depend on our financial condition, results of operations, and capital requirements as well as other factors deemed relevant by our board of directors. In addition, the Financing Agreement contains covenants that limit our ability to pay dividends or make other distributions on our common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><b>Performance Graph </b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The following line graph compares cumulative total stockholder return for the five years ended December 31, 2020 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on December 31, 2015 and includes reinvestment of dividends. Measurement points are at December 31, 2015 and the last trading day of the fiscal years ended December 31, 2016, 2017, 2018, 2019, and 2020. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</p>
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 55; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, serif; text-align: center; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><img src="txmd10k001.jpg" alt="(GRAPHIC)" /></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The following line graph compares cumulative total stockholder return for the five years ended December 31, 2020 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on December 31, 2015 and includes reinvestment of dividends. Measurement points are December 31, 2015 and the last trading day of the fiscal years ended December 31, 2020, 2019, 2018, 2017, and 2016, and each of the following quarters ended therein. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: center; text-indent: 36pt"><img src="txmd10k002.jpg" alt="(GRAPHIC)" /></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The performance graphs shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. The performance graphs will not be deemed incorporated by reference into any filing of our company under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 56; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a010"></span><b>Item
6.&#160;&#160;&#160;&#160;&#160;Selected Financial Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth selected consolidated financial and other data as of and for the periods indicated. You should read
the following information together with the more detailed information contained in &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the related notes included
elsewhere in this Annual Report. The consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018
and the consolidated balance sheet data as of December 31, 2020 and 2019 are derived from our audited consolidated financial statements
included in this Annual Report. The consolidated statements of operations for the years ended December 31, 2017 and 2016, and
the consolidated balance sheet data as of December 31, 2018, 2017, and 2016 are derived from our audited consolidated financial
statements not included in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
        INC. AND SUBSIDIARIES</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(in
        thousands, except per share data)</b></span></p></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Consolidated Statements of Operations Data</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2019</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2018</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2017</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2016</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify">Product revenue, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">62,872</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">34,141</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">16,099</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">16,778</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">19,356</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">License revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,506</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Cost of goods sold</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,975</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,335</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,737</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,637</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,185</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">48,897</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,362</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,141</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,171</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Operating expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sales, general, and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">192,964</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">174,113</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">115,989</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">57,703</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">51,348</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,432</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,792</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,299</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33,853</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">53,943</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,042</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">613</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">294</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">213</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">204,438</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">194,518</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">143,582</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">91,769</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">105,424</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(155,541</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(151,206</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(130,220</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(77,628</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(90,253</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Other (expense) income, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,983</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,939</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,397</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">703</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">378</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(183,524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(176,145</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(132,617</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(76,925</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(89,875</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Net loss per share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.67</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.37</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.46</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Weighted average number of common shares <br />
outstanding, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">275,649</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">246,353</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">225,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">205,523</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">196,088</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consolidated Balance Sheet Date</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(at end of period)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">181,610</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">265,986</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">211,984</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">143,230</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">142,472</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">237,698</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">194,635</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">73,381</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,929</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,647</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">305,611</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">256,785</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">114,460</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,321</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,983</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total stockholders&#8217; (deficit) equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(124,001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,201</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">97,524</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">129,909</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">127,489</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Other Data:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Capital expenditures (for the period)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,598</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,892</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,322</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">827</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,241</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Working capital (at the end of the period)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">69,166</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">155,411</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">145,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">126,233</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">124,428</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 57; Options: NewSection; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a011"></span>Item
7.&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>You
should read the following discussion and analysis in conjunction with the information set forth under &#8220;Selected Financial
Data&#8221; and our consolidated financial statements and the notes to those financial statements included elsewhere in this Annual
Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties.
See &#8220;Statement Regarding Forward-Looking Information.&#8221; Our actual results may differ materially from those contained
in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the risks and uncertainties
described under &#8220;Risk Factors&#8221; elsewhere in this Annual Report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD
is a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan
of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise,
and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions
range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also have
a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our
women&#8217;s healthcare focus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and marketing plan to grow our
recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned
our company from predominately focused on conducting research and development to one focused on commercializing our drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts)
                                         for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
                                         activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was
                                         approved by the FDA in May 2018.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         April 2019, we launched our FDA-approved product, BIJUVA (estradiol and progesterone)
                                         capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol and bio-identical
                                         progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe
                                         vasomotor symptoms, or VMS, due to menopause in women with a uterus, which was approved
                                         by the FDA in October 2018.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif; color: #212529">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         October 2019, we began a &#8220;test and learn&#8221; market introduction for our FDA-approved
                                         product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first
                                         and only annual patient-controlled, procedure-free, reversible prescription contraceptive
                                         option for women, which was approved by the FDA in <span style="color: #212529">August
                                         2018 and which we have licensed for commercialization in the U.S. pursuant to </span>an
                                         exclusive license agreement, or the Population Council License Agreement, with the Population
                                         Council, Inc., or the Population Council<span style="color: #212529">. We paused the
                                         planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19
                                         pandemic and resumed this initiative in July 2020.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have also entered into license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         July 2018, we entered into a license and supply agreement with Knight Therapeutics Inc.,
                                         or Knight, pursuant to which we granted Knight an exclusive license to commercialize
                                         IMVEXXY and BIJUVA in Canada and Israel. Knight received the first regulatory approval
                                         in Canada for IMVEXXY and BIJUVA in the third quarter of 2020.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         June 2019, we entered into an exclusive license and supply agreement, or the Theramex
                                         License Agreement, with Theramex HQ UK Limited, or Theramex, a leading, global specialty
                                         pharmaceutical company dedicated to women&#8217;s health, to commercialize IMVEXXY and
                                         BIJUVA outside of the U.S., excluding Canada and Israel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Product
Portfolio</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are focused on activities necessary for commercialization of IMVEXXY, BIJUVA and ANNOVERA. We continue to manufacture and distribute
our prescription prenatal vitamin product lines, consisting of branded prenatal vitamins under vitaMedMD and authorized generic
formulations of some of our prescription prenatal vitamin products under BocaGreenMD. All of our prenatal vitamins are gluten-,
sugar-, and lactose-free. A prenatal vitamin option that is both vegan and kosher is also available for women with special dietary
needs. We believe our product attributes result in greater consumer acceptance and satisfaction than competitive products while
offering the highest quality and patented ingredients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>BIJUVA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bioidentical
hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS
(commonly known as hot flashes or flushes) due to menopause in women with a uterus.&#160;The estrogen and progesterone in BIJUVA
have the same chemical and molecular structure as the hormones that are naturally produced in a woman&#8217;s body. We launched
BIJUVA in April 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 58; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
late January 2020, we submitted a New Drug Application, or NDA, efficacy supplement for the 0.5/100 mg dose of BIJUVA to the FDA
for review and potential approval. The NDA efficacy supplement used existing data from our Phase 3 REPLENISH trial for BIJUVA,
for which we announced results in December 2016, together with additional information and analyses. In November 2020, we withdrew
the NDA efficacy supplement. We currently intend to file a Formal Dispute Resolution Request, or FDRR, with the FDA that disputes
the FDA&#8217;s requirement that the efficacy supplement meet approval standard that have not been required of other approved
drugs in BIJUVA&#8217;s therapeutic class. There can be no assurance that we will prevail with respect to the FDRR, if filed,
or that the 0.5/100 mg dose of BIJUVA will be approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>IMVEXXY</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2018, the FDA approved the 4-&#956;g and 10-&#956;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe
dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#956;g formulation of IMVEXXY
represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY 10-&#956;g became available for commercial distribution
in July 2018 and both doses were commercially available by September 2018<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">IMVEXXY
is a small, digitally inserted, softgel vaginal insert that dissolves when inserted into the vagina. It is administered mess-free,
without the need for an applicator, and can be used any time of day. IMVEXXY provides a mechanism of action and dosing that is
comfortable for patients, with no patient education required for dose application or applicators. IMVEXXY demonstrated efficacy
as early as two weeks (secondary endpoint) and maintained efficacy through week 12 in clinical studies, with no increase in systemic
hormone levels beyond the normal postmenopausal range (the clinical relevance of systemic absorption rates for vaginal estrogen
therapies is not known).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the FDA&#8217;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the
risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen.
In connection with the observational study, we are required to provide progress reports to the FDA on an annual basis. The development
of this method is underway, and we do not believe that the costs will be material.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>ANNOVERA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA (segesterone
acetate and ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free, reversible prescription
contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year), which was approved by the FDA in August 2018.
ANNOVERA was classified by the FDA as an NCE and thus has five years of regulatory exclusivity under the Drug Price Competition
and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA
is a one-year ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone
acetate, a 19-nor progesterone derivative also known as SA and EE. EE is an approved active ingredient in many marketed hormonal
contraceptive products. Segesterone acetate, an NCE, is a potent progestin and ANNOVERA is the only product with segesterone acetate.
Segesterone acetate also does not bind to the androgen or estrogen receptors and has no glucocorticoid effects at contraceptive
doses. SA has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA
can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, or
OCs, ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes
ANNOVERA for seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then
re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (one year).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA
releases daily vaginal doses of both active ingredients (SA and EE). The claimed release rate of 150 &#956;g/day SA and 13/day &#956;g
EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported
by data from 13 cycles of in vitro release.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of
venous thromboembolism. In accordance with the post-marketing requirements, the full protocol for the study was submitted to the
FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided
that if the costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will offset against
royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational
nature of the study, we do not believe that the costs of the study will be material on an annual basis. The Population Council
has agreed to perform and pay the costs and expenses associated with two post-approval studies required by the FDA for ANNOVERA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 59; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2019, we began a &#8220;test and learn&#8221; market introduction phase of launch for ANNOVERA, with 36 of our existing
sales representatives currently promoting ANNOVERA in addition to our other products, and our 23 regional sales managers and 12
compounding key account managers, or KAMs, introducing ANNOVERA to top targeted healthcare practitioners outside of these 36 territories.
We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic and resumed
this initiative in July 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that the strong initial commercial net revenue per unit of ANNOVERA and commercial insurance adoption provide us with
an opportunity to deploy additional financial resources to maximize ANNOVERA&#8217;s consumer-focused commercialization strategy
and leverage the ability of doctor/patient choice of contraceptive to override insurance company formularies when necessary. As
part of this strategy, we are pursuing distribution opportunities for ANNOVERA to provide women with additional access to ANNOVERA,
particularly during the COVID-19 pandemic, with multiple direct-to-consumer contraceptive platforms that extend the reach of our
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with the Population Council</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
July  2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#8220;test and learn&#8221; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding
the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing
initiatives into subsequent quarters. <span style="color: #212529">We resumed the launch of ANNOVERA in July  2020.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within
30 days following approval by the FDA of the NDA for ANNOVERA. The first commercial batch of ANNOVERA was released during the
third quarter of 2019 and we paid the Population Council a second milestone payment of $20,000,000 as a result of the commercial
batch release. The Population Council is eligible to receive additional milestone payments and royalties from commercial sales
of ANNOVERA, as detailed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
assumed responsibility for marketing expenses related to the commercialization of ANNOVERA. We are required to pay the Population
Council additional milestone payments of $40 million upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliated
and permitted sublicensees of each of $200 million, $400 million and $1.0 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net
sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Annual Net Sales</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Royalty Rate</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: justify">Less than or equal to $50.0 million</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Greater than $50.0 million and less than or equal to $150.0 million</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Greater than $150.0 million</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first
arms-length commercial sale of a generic equivalent of ANNOVERA that is launched by a third party in the U.S., and thereafter
will be reduced to 20% of the initial rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by
the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post-approval study required
by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval
study exceed $20 million, half of such excess will be offset against royalties or other payments owed by us to the Population
Council under the Population Council License Agreement. We and the Population Council formed a joint product committee responsible
for overseeing activities under the Population Council License Agreement. We are responsible for all aspects of promotion, product
positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year
vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unless
earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the last-to-expire
of the Population Council&#8217;s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous
period of six months during which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population
Council License Agreement may also be terminated for certain breach and bankruptcy-related events and by us on 180 days prior
notice to the Population Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 60; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the Population Council License Agreement, we have the exclusive right to negotiate co-development and U.S. marketing rights
for two other investigational vaginal contraceptive systems in development by the Population Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with Knight</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted
Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License
Agreement, Knight paid us $2,000,000 in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in
the third quarter of 2020, and is required to pay us sales milestone fees based upon certain aggregate annual sales in Canada
and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada
and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or
registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified
time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate
the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods
or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement, Knight is prohibited
from exporting IMVEXXY and BIJUVA to the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with Theramex</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; color: #212529">In
June 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the </span><span style="font: 10pt Times New Roman, Times, Serif">Theramex
<span style="color: #212529">Territory. Under the terms of the Theramex License Agreement, Theramex paid us EUR 14 million, or
$15,506,400, in cash as an upfront fee in August 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other
applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the upfront fee,
which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and benefit
from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive additional
milestone payments comprised of (i) up to an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals
for BIJUVA and IMVEXXY in certain specified markets and (ii) up to an aggregate of EUR 27.5 million in sales milestone payments
to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones of BIJUVA and
IMVEXXY in the </span>Theramex <span style="color: #212529">Territory ranging from EUR 25 million to EUR 100 million. We are also
entitled to receive quarterly royalty payments at a rate of 5% on net sales of BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Theramex is responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all regulatory
applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY within
certain specified time periods. We also may terminate the Theramex License Agreement if Theramex challenges our patents. Either
party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain
specified time periods or if the other party files for bankruptcy or other related matters. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
significant portion of our historical operating expenses have been incurred in research and development activities. Research and
development expenses relate primarily to the development, support and maintenance of our drug candidates. Our research and development
expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, and consultants
that conduct our clinical and preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash
share-based compensation; the cost of developing our chemistry, manufacturing, and controls capabilities, and costs associated
with other research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred
with respect to drug candidates that have not received Investigational New Drug Application approval from the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table indicates our research and development expense by project for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2020</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2018</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 41%">TX 001-HR (BIJUVA)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">2,085</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">3,848</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">11,790</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">TX 004-HR (IMVEXXY)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,311</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,522</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,890</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">ANNOVERA</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,990</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,637</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Other research and development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,046</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,785</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,619</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,432</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,792</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">27,299</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 61; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenditures have been reduced as we refocused our resources towards the commercialization of our approved pharmaceutical
products. We will continue to deploy limited resources as we develop our drug pipeline, continue stability testing and validation
on our pharmaceutical products, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory
authorities on existing submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><span style="font: 10pt Times New Roman, Times, Serif">The
costs of clinical trials may vary significantly over the life of a project owing to a variety of factors. We base our expenses
related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research
and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory
testing, regulatory submission and response work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Comparison
of Years Ended December 31, 2020, 2019, and 2018:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Year
ended December 31, 2020 compared with year ended December 31, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2020</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Change</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 41%">Product revenue, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">62,872</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">34,141</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">28,731</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">License revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,506</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,506</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cost of goods sold</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,975</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,640</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">204,438</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">194,518</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,920</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;&#160;&#160;&#160;&#160;Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(155,541</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(151,206</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Other expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,983</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,939</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,044</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(183,524</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(176,145</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,379</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. We
launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third
quarter of 2019. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic
and resumed this initiative on July 1, 2020. Product revenue for the year ended December 31, 2020 increased approximately $28,731,000,
or 84%, to approximately $62,872,000, compared with approximately $34,141,000 for the year ended December 31, 2019. Despite slower
than anticipated growth of our product revenue due to the impact of the COVID-19 pandemic, product revenue increased primarily
due to continued ramping of sales of IMVEXXY, BIJUVA and ANNOVERA during the year ended December 31, 2020, as compared to the
prior period, partially offset by a decrease in prenatal vitamins sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Sales
of IMVEXXY increased approximately $10,887,000 as compared to the prior year and sales of BIJUVA increased approximately
$4,517,000 as compared to the prior year due to a higher number of units sold and increased net product revenue per unit.
Sales of ANNOVERA increased approximately $13,445,000 as compared to the prior year primarily due to a higher number of
units sold, partially offset by slightly lower net revenue per unit. In addition, during the year ended </span><span style="font: 10pt Times New Roman, Times, Serif">December
31, 2020, our prenatal vitamin sales decreased approximately $118,000 due to decreased number of units sold partially offset
by an increased net product revenue per unit as compared to the prior year. In addition to our product revenue, during the
year ended December 31, 2020, we recognized aggregate license revenue of $2,000,000 from two non-refundable milestone
payments from Knight under the terms of the Knight License Agreement, which we recognized at the point in time upon the first
regulatory approvals in Canada of each of IMVEXXY and BIJUVA. During the year ended December 31, 2019, we recognized license
revenue of approximately $15,506,000 from the upfront fee, which was a non-refundable payment, payable to us by Theramex
under the terms of the Theramex License Agreement, which we recognized at the point in time when Theramex was able to use and
benefit from the license, which was when the knowledge transfer of regulatory documents occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the launches of IMVEXXY and BIJUVA we introduced co-pay assistance programs which allow eligible enrolled patients to access the
products at a reasonable cost regardless of insurance coverage. We expect that our product revenue will improve in the long term
as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA, and
ANNOVERA prescriptions at pharmacies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cost
of Goods Sold</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Cost
of goods sold increased approximately $9,640,000, or 152%, to approximately $15,975,000 for the year ended December 31, 2020,
compared with approximately $</span><span style="font: 10pt Times New Roman, Times, Serif">6,335,000 <span style="background-color: white">for
the year ended December 31, 2019. This increase is attributable to a 84% increase in product revenue as compared to the prior
year, an increase in royalty fees of approximately $672,000, and an increase in amortization of our license fee related to ANNOVERA
of approximately $2,246,000 as well as an increase of $4,085,000 inventory charge, primarily related to BIJUVA, as compared to
the prior year. Our gross margin related to prescription products was approximately 75% and 81% for the years ended December 31,
2020 and 2019, respectively. The change in our gross margin between the two periods is primarily related to the change in product
mix and its related costs including inventory charge, amortization of license fee and royalty fees described above.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 62; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs included the following items as a percentage of total operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended <br />December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2020</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify">Sales and marketing costs, excluding human resource costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">44</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">45</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Human resource related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Product research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Professional fees and consulting costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating
expenses increased by approximately $9,920,000, or 5%, to approximately $204,438,000 for the year ended December 31, 2020, compared
with approximately $194,518,000 for the year ended December 31, 2019, as a result of the following items:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended <br />December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2020</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Change</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 61%">Sales and marketing, excluding human resources costs </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">89,286</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">86,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,827</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Human resources related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">66,969</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">54,120</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,849</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,432</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,792</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,360</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and consulting costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,260</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,913</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(653</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Other operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,491</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,234</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,257</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">204,438</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">194,518</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,920</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Sales
and marketing costs, excluding human resources costs, for the year ended December 31, 2020 increased by approximately $2,827,000,
or 3%, to approximately $89,286,000, compared with approximately $86,459,000 for the year ended December 31, 2019. This increase
was primarily due to higher expenses associated with advertising efforts to support the significant initiative related to the
launch of ANNOVERA in March 2020, which was subsequently paused as a result of the COVID-19 pandemic and relaunched in July 2020,
as well as continuing to support the commercialization of BIJUVA and IMVEXXY, which was partially offset by cost cutting initiatives
put in place at the beginning of the COVID-19 pandemic, including reducing consulting and agency fees. In addition, we recorded
product samples expense of approximately $7,100,000, during the year ended December 31, 2020, primarily related to BIJUVA. Sales
and marketing costs, excluding human resources costs, also increased as compared to the prior year as a result of higher sales
incentives due to the increase in product revenue, which was partially offset by lower physician education, training and travel
expenses caused by restrictions on in-person speaker programs due to the COVID-19 pandemic. In addition, during the third quarter
of 2020, we onboarded our outsourced sales personnel which decreased sales and marketing costs, excluding human resources costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Human
resources costs, including salaries, benefits and taxes, for the year ended December 31, 2020 increased by approximately $12,849,000,
or 24%, to approximately $66,969,000, compared with approximately $54,120,000 for the year ended December 31, 2019, as a result
of an increase of approximately $11,964,000 primarily related to higher employee count which increased from 348 in 2019 to 400
in 2020 mostly in sales, marketing and regulatory areas to support commercialization of our pharmaceutical products which included
onboarding our outsourced sales personnel and an increase of approximately $885,000 in non-cash compensation expense included
in this category related to employee stock-based compensation during 2020 as compared to 2019, partially offset by cost cutting
measures implemented due to the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Product
research and development costs for the year ended December 31, 2020 decreased by approximately $9,360,000, or 47%, to approximately
$10,432,000, compared with approximately $19,792,000 for the year ended December 31, 2019. Product research and development costs
include costs related to manufacturing validation and early development trials, as well as salaries, wages, non-cash compensation,
and benefits of personnel involved in research and development activities. Product research and development expenditures have
been reduced as we refocused our resources towards the commercialization of our approved pharmaceutical products. We continue
to deploy limited resources as we develop our drug pipeline, continue stability testing and validation on our pharmaceutical products,
develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory authorities on existing
submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 63; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;
Since the project&#8217;s inception in February 2013, we have incurred approximately $133,120,000 in research and development
costs with respect to BIJUVA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;
Since the project&#8217;s inception in August 2014, we have incurred approximately $49,572,000 in research and development costs
with respect to IMVEXXY.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
a discussion of the nature of efforts and steps necessary to complete these projects, see &#8220;Item 1. Business &#8212; Research
and Development.&#8221; For a discussion of the risks and uncertainties associated with completing development of our products,
see &#8220;Item 1A. Risk Factors &#8212; Risks Related to Our Business.&#8221; For a discussion of the extent and nature of additional
resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see
&#8220;&#8212; Liquidity and Capital Resources.&#8221; For a discussion as to whether a future milestone such as completion of
a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined,
see &#8220;Item 1. Business &#8212; Pharmaceutical Regulation.&#8221; Future milestones, including NDA submission dates, are not
easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of
ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Professional
fees and consulting costs for the year ended December 31, 2020 decreased by approximately $653,000, or 5%, to approximately $13,260,000,
compared with approximately $13,913,000 for the year ended December 31, 2019, primarily as a result of reduced recruiting and
consulting fees, partially offset by increased legal, accounting and other professional fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">All
other operating expenses for the year ended December 31, 2020 increased by approximately $4,257,000, or 21%, to approximately
$24,491,000, compared with approximately $20,234,000 for the year ended December 31, 2019, primarily as a result of increased
insurance, dues and subscriptions, rent, depreciation and amortization expenses, and write off of intangible assets and patents,
partially offset by lower other office and travel expenses due to travel restrictions caused by the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss increased approximately $4,335,000, or 3%, to approximately $155,541,000 for the
year ended December 31, 2020, compared with approximately $151,206,000 for the year ended December 31, 2019, primarily as a result
of an increase in total operating expenses to support commercialization and launch efforts related to our pharmaceutical products,
a decrease in our license revenue as well as write off of inventory and product samples due to the COVID-19 pandemic, as described
above, partially offset by increased total net product revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA,
and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA, and ANNOVERA will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
expense, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Other
non-operating expense, net increased by approximately $3,044,000, or 12%, to an expense of approximately $27,983,000 for the year
ended December 31, 2020, compared with an expense of approximately $24,939,000 for the year ended December 31, 2019, primarily
as a result of increased interest expense related to our Financing Agreement partially offset by the loss on extinguishment of
debt of $10,058,000 incurred during the year ended December 31, 2019. For more information regarding our Financing Agreement,
see &#8220;Liquidity and Capital Resources&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Because
of the net effects of the foregoing, net loss increased by approximately $7,379,000, or 4%, to approximately $183,524,000 for
the year ended December 31, 2020, compared with approximately $176,145,000 for the year ended December 31, 2019. Net loss per
share of Common Stock, basic and diluted, was ($0.67) and ($0.72) for the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 64; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Year
ended December 31, 2019 compared with year ended December 31, 2018</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2018</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Change</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 41%">Product revenue, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">34,141</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">16,099</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">18,042</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">License revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,506</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,506</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cost of goods sold</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,335</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,737</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,598</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">194,518</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">143,582</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">50,936</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;&#160;&#160;&#160;&#160;Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(151,206</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(130,220</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(20,986</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Other expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,939</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,397</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(22,542</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(176,145</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(132,617</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(43,528</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. Product
revenue for the year ended December 31, 2019 increased approximately $18,042,000, or 112%, to approximately $34,141,000, compared
with approximately $16,099,000 for the year ended December 31, 2018. Product revenue increased primarily due to an increase in
sales of approximately $15,194,000 of IMVEXXY in the current period, partially offset by a decrease in prenatal vitamin sales
of approximately $5,155,000. Product revenue for the year ended December 31, 2019 also included sales of BIJUVA of approximately
$1,836,000 and sales of ANNOVERA of approximately $6,167,000. The revenue decrease related to our prenatal vitamins was primarily
affected by lower number of units sold as compared to the prior year period. We launched IMVEXXY in the third quarter of 2018
and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019<span style="color: #212529">.
</span>Since the launches, revenues related to IMVEXXY and BIJUVA have been greatly affected by the co-pay assistance programs
that we introduced to launch these products, which allow eligible enrolled patients to access the products at a reasonable cost
regardless of insurance coverage. We expect our product revenue to improve as commercial and Medicare payer coverage increases,
and plans complete the process needed to adjudicate IMVEXXY, BIJUVA and ANNOVERA prescriptions at pharmacies. In addition to our
product revenue, during the year ended December 31, 2019, we recognized license revenue of approximately $15,506,000 from the
upfront fee, which was a non-refundable payment, paid to us by Theramex under the terms of the Theramex License Agreement, which
we recognized at the point in time when Theramex was able to use and benefit from the license, which was when the knowledge transfer
of regulatory documents occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cost
of Goods Sold</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of goods sold increased by approximately $3,598,000, or 131%, to approximately $6,335,000 for the year ended December 31, 2019,
compared with approximately $2,737,000 for the year ended December 31, 2018, primarily related to product costs attributable to
our prescription pharmaceutical products, as well as royalty fees of $308,328 and the amortization of our license fee of $778,692
related to ANNOVERA. Our gross margin related to our prescription pharmaceutical products was 81% for the year ended December
31, 2019 as compared to 83% for the year ended December 31, 2018. The change in our gross margin is primarily related to the change
in product mix between the two periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal operating costs included the following items as a percentage of total operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended <br />December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2018</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify">Sales and marketing costs, excluding human resource costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">45</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">43</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Human resource related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Product research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Professional fees and consulting costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 65; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating
expenses increased by approximately $50,936,000, or 35%, to approximately $194,518,000 for the year ended December 31, 2019, compared
with approximately $143,582,000 for the year ended December 31, 2018, as a result of the following items:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended <br />December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2018</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Change</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 41%">Sales and marketing, excluding human resources costs </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">86,459</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">61,845</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">24,614</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Human resources related costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">54,120</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">35,003</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,117</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,792</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,299</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,507</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and consulting costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,913</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,252</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Other operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,234</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,774</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,460</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">194,518</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">143,582</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">50,936</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing costs increased by approximately $24,614,000 or 40%, to approximately $86,459,000 for the year ended December 31,
2019, compared with approximately $61,845,000 for the year ended December 31, 2018, primarily as a result of increased expenses
associated with sales and marketing efforts to support launch and commercialization of our pharmaceutical products, including
an increase of $7.4 million related to advertising expenses related to our pharmaceutical products, an increase of $6.5 million
in consulting projects including costs for outsourced sales personnel and their related expenses, an increase of $6.0 million
in marketing initiatives related to the launch of our pharmaceutical products as well as an increase in costs related to physician
education, conferences and travel expenses related to product commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Human
resource related costs, including salaries and benefits increased by approximately $19,117,000, or 55%, to approximately $54,120,000
for the year ended December 31, 2019, compared with approximately $35,003,000 for the year ended December 31, 2018, primarily
as a result of an increase of approximately $16,844,000 primarily due to higher employee count which increased from 241 in 2018
to 348 in 2019 primarily in sales, marketing and regulatory areas to support commercialization of our pharmaceutical products
and an increase in non-cash compensation expense included in this category of approximately $2,273,000 related to employee stock
option amortization during 2019 as compared to 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development costs decreased by approximately $7,507,000, or 27%, to approximately $19,792,000 for the year ended December
31, 2019, compared with approximately $27,299,000 for the year ended December 31, 2018. Research and development costs include
costs related to manufacturing validation and early development trials, as well as salaries, wages, non-cash compensation and
benefits of personnel involved in research and development activities. Research and development costs decreased primarily as a
result of certain employees and activities that were previously classified as research and development being transferred into
operations as they began to support commercial and launch efforts after the FDA approvals of IMVEXXY and BIJUVA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;
Since the project&#8217;s inception in February 2013, we have incurred approximately $131,035,000 in research and development
costs with respect to BIJUVA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;
Since the project&#8217;s inception in August 2014, we have incurred approximately $48,261,000 in research and development costs
with respect to IMVEXXY.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
a discussion of the nature of efforts and steps necessary to complete these projects, see &#8220;Item 1. Business &#8212; Research
and Development.&#8221; For a discussion of the risks and uncertainties associated with completing development of our products,
see &#8220;Item 1A. Risk Factors &#8212; Risks Related to Our Business.&#8221; For a discussion of the extent and nature of additional
resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see
&#8220;&#8212; Liquidity and Capital Resources.&#8221; For a discussion as to whether a future milestone such as completion of
a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined,
see &#8220;Item 1. Business &#8212; Pharmaceutical Regulation.&#8221; Future milestones, including NDA submission dates, are not
easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of
ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Professional
and consulting costs increased by approximately $6,252,000, or 82%, for the year ended December 31, 2019, to approximately $13,913,000
compared with approximately $7,661,000 for the year December 31, 2018, primarily as a result of increased medical safety consulting
fees to support commercialization of our pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All
other costs increased by approximately $8,460,000, or 72%, to approximately $20,234,000 for the year ended December 31, 2019,
compared with approximately $11,774,000 for the year ended December 31, 2018, as a result of increased contract labor, dues and
subscriptions, information technology, travel, insurance and other office expenses primarily to support commercialization of our
new drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 66; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss increased approximately $20,986,000, or 16%, to approximately $151,206,000 for the
year ended December 31, 2019, compared with approximately $130,220,000 for the year ended December 31, 2018, primarily as a result
of an increase in total operating expenses to support commercialization of our pharmaceutical products, partially offset by increased
total net revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
expense, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
non-operating expense, net changed by approximately $22,542,000, or 940%, to an expense of approximately $24,939,000 for the
year ended December 31, 2019 compared with an expense of approximately $2,397,000 for 2018, primarily as a result of a
one-time charge of approximately $10,058,000 in loss on extinguishment of debt and increased interest expense related to our
Financing Agreement that we recorded in 2019 as compared to 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Because
of the net effects of the foregoing, net loss increased approximately $43,528,000, or 33%, to approximately $176,145,000 for the
year ended December 31, 2019, compared with approximately $132,617,000 for the year ended December 31, 2018. Net loss per share
of common stock, basic and diluted, was ($0.72) for the year ended December 31, 2019, compared with ($0.59) per share of common
stock for the year ended December 31, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We have funded our operations primarily through public offerings
of our common stock and private placements of equity and debt securities. For the three-year period ended December 31, 2020, we
received approximately $198,642,000 in net proceeds from the issuance of shares of our common stock, par value $0.001 per share,
or Common Stock. As of December 31, 2020, we had a cash balance of approximately $80,486,000. Subsequent to December 31, 2020,
we received approximately $47,300,000 in net proceeds from sales of our Common Stock in January and February 2021 pursuant to a
Controlled Equity Offering<sup>SM</sup> Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald,
and approximately $97,100,000 in net proceeds from sales of our Common Stock pursuant to an underwritten public offering of our
common stock in February 2021, each as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On November 10, 2020, we entered into an underwriting agreement
with Cantor Fitzgerald relating to an underwritten public offering of 23,437,500 shares of our Common Stock. We granted to the underwriter
an option, exercisable for a period of 30 days, to purchase up to 3,515,625 additional shares of Common Stock, which was exercised
in full. The net proceeds the offering were approximately $31,703,000, after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us. The offering closed on November 13, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On November 27, 2020, we entered into the Sales Agreement with
Cantor Fitzgerald relating to shares of our Common Stock. In accordance with the terms of the sales
agreement, in January and February 2021 we offered and sold an aggregate of 28,600,689 shares of our Common Stock having an aggregate
offering price of $50 million, resulting in estimated net proceeds to us of approximately $47.3 million. Sales of our Common Stock
under the Sales Agreement were made in sales deemed to be &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated
under the Securities Act of 1933, as amended, or the Securities Act. Cantor Fitzgerald was entitled to compensation at a fixed
commission rate of 3.0% of the aggregate gross sales price per share sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 11, 2021, we entered into an underwriting agreement
with Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of 59,459,460 shares of our Common Stock. Pursuant
to the underwriting agreement, we granted to the underwriter an option, exercisable for a period of 30 days, to purchase up to
8,918,919 additional shares of Common Stock. The net proceeds to us from the offering, excluding any proceeds that may be received
from the exercise of the underwriter&#8217;s option to purchase additional shares, were approximately $97.1 million, after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on February 16, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with Sixth Street Specialty
Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and
certain of our subsidiaries party thereto from time to time as guarantors, which provided us with up to a $300,000,000 first
lien secured term loan credit facility, or the Facility. The Facility provided for fund availability in multiple tranches:
$200,000,000 was drawn upon entering into the Financing Agreement while an additional $50,000,000 was drawn on February 18,
2020. An additional $50,000,000 was previously available to us in the Administrative Agent&#8217;s sole and absolute
discretion either contemporaneously with the delivery of our financial statements for the quarter ended June 30, 2020 or at
such earlier date as the Administrative Agent may have consented to. Subsequent to the pause in the full launch of ANNOVERA
caused by the COVID-19 pandemic, the undrawn $50,000,000 tranche under the Financing Agreement is no longer
available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
August 5, 2020, we and our subsidiaries entered into Amendment No. 5 to the Financing Agreement, or Amendment No. 5, with the
Administrative Agent and the lenders party thereto, pursuant to which we modified the minimum consolidated net product
revenue requirements attributable to commercial sales of our IMVEXXY, BIJUVA, and ANNOVERA products, which requirements are
effective beginning with the fiscal quarter ending December 31, 2020. In lieu of a cash amendment fee, to induce the lenders
to enter into Amendment No. 5, on August 5, 2020, we issued warrants, or the Lender Warrants, to the lenders under the
Financing Agreement to purchase an aggregate of 4,752,116 shares of Common Stock, pursuant to a subscription agreement among
the parties, or the Subscription Agreement. The Warrants have an exercise price of $1.58 per share of Common Stock and an
expiration date of August 5, 2030. The Warrants may also be exercised via cashless exercise pursuant to the terms thereof. No
registration rights were issued pursuant to the Warrants or Subscription Agreement. On November 8, 2020, in connection with
entering into Amendment No. 6 to the Financing Agreement, or Amendment No. 6, we amended the Lender Warrants to provide for
an adjustment to the exercise price if we conducted certain dilutive issuances prior to December 31, 2020, or if the
volume-weighted average price of our Common Stock for the fifteen trading days ending December 31, 2020 was lower than the
then-current exercise price. The issuance of the shares of Common Stock in our November 2020 underwritten public offering at
a price per share equal to $1.1856 triggered the automatic reduction in the exercise price of the Lender Warrants from $1.58
to $1.1856. On January 13, 2021, in connection with entering into Amendment No. 7 to the Financing Agreement, or Amendment
No. 7, the Lender Warrants were further amended to provide for an additional adjustment to the exercise price if we conduct
certain dilutive issuances prior to March 31, 2021. In connection with entering into Amendment No. 7, we paid the
Administrative Agent an amendment fee of $5.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 67; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of the filing date of this Annual Report on Form 10-K, our cash
balance was above the required balance by the Financing Agreement. Based on our current projections, and recent equity financing,
we anticipate that we will remain in compliance with the minimum cash balance covenant for the next twelve months from the issuance
of these financial statements. In addition, we have reviewed numerous potential scenarios in connection with the impact of COVID-19
pandemic on our business and we believe that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary
course of business for the next twelve months from the issuance of these financial statements. However, if we are unsuccessful
with the commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if such commercialization is delayed, or if the continued impact of
the COVID-19 pandemic on our business is worse than we anticipate, among other circumstances, we may consume funds significantly
faster than we currently anticipate and our existing cash reserves would be insufficient to maintain compliance with the Financing
Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY, BIJUVA, and
ANNOVERA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Financing Agreement requires us to maintain certain minimum
quarterly product net revenue requirements and several other restrictive covenants. On March 1, 2021, we entered into Amendment
No. 8, pursuant to which, among other amendments, the minimum quarterly product net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA were revised to (i) $17.0 million, $20.0 million, $23.0 million, and $26.5 million for the
first, second, third, and fourth quarters of 2021, respectively, (ii) $30.0 million, $35.0 million, $40.0 million and $45.0 million
for the first, second, third, and fourth quarters of 2022, respectively, (iii) $50.0 million, $55.0 million, $60.0 million and
$65.5 million for the first, second, third, and fourth quarters of 2023, and (iv) $70.0 million for the first quarter of 2024.
In connection with entering into Amendment No. 8, we repaid $15.0 million in principal under the Financing Agreement on such date
and agreed to repay an additional $35.0 million in principal by no later than March 31, 2021, in each case plus a 5.0% prepayment
fee. Additionally, we have agreed to make quarterly repayments under the Financing Agreement commencing with the fiscal quarter
ending March 31, 2022. See Note 8 &#8211; Debt for information regarding our debt maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other terms in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to grow our
business or enter into transactions that we believe would be beneficial to our business. If we are unable to maintain the minimum unrestricted
cash balance, achieve any of the total minimum net revenue requirements or otherwise comply with any other covenant of the Financing Agreement,
all or a portion of our obligations under the Financing Agreement may be declared immediately due and payable, which would have an adverse
effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
net days sales outstanding, or net DSO, is calculated by dividing gross accounts receivable less the reserve for doubtful accounts,
chargebacks and payment discounts by the average daily net product revenue during the quarter. We also disclose gross DSO, which
includes the calculation of gross accounts receivable divided by the average daily gross product revenue to distributors during
the quarter. For the three months ended December 31, 2020, our gross DSO was 61 days compared to 55 days for the three months
ended December 31, 2019 and our net DSO was 132 days for the three months ended December 31, 2020 compared to 141 days for the
three months ended December 31, 2019. We anticipate that our DSO will fluctuate in the future based upon a variety of factors,
including longer payment terms associated with the launches of IMVEXXY, BIJUVA, and ANNOVERA and changes in the healthcare industry.
Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and
reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with
the COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses,
it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
need substantial amounts of cash to complete the launch and commercialization of our hormone therapy and contraceptive drugs.
The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Summary
of (Uses) and Sources of Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Years
    Ended December 31,</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2020</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2019</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2018</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: justify">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(159,470,335</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(165,697,595</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(106,811,781</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Net cash used in investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,597,907</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(23,912,694</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,497,857</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.6pt; padding-left: 12.6pt">Net cash provided by financing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">80,724,313</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">188,826,925</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">162,787,087</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 68; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
principal use of cash in operating activities for the year ended December 31, 2020 and 2019 was to fund our current expenses primarily
related to supporting commercialization activities for IMVEXXY, BIJUVA and ANNOVERA, sales, marketing, scale-up and manufacturing
activities and clinical development, adjusted for non-cash items. The decrease of approximately $6,227,000 in cash used in operating
activities for the year ended December 31, 2020 in comparison to the year ended December 31, 2019 was primarily due to changes
in the components of working capital partially offset by an increase in non-cash items and an increase in our net loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
increase of approximately $58,886,000 in cash used in operating activities for the year ended December 31, 2019 in comparison
to the year ended December 31, 2018 was primarily due to an increase in our net loss coupled with changes in the components of
working capital which were primarily due to the launch and commercialization of our pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, a decrease in spending on fixed assets, patents and trademarks resulted in a decrease in cash
used in investing activities for the year ended December 31, 2020 compared with the same period in 2019. In addition, during the
year ended December 31, 2019, we paid $20,000,000 to the Population Council in connection with the commercial batch release of
ANNOVERA, based on the Population Council License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, we paid $20,000,000 to the Population Council in connection with the commercial batch release
of ANNOVERA, based on the Population Council License Agreement. In addition, an increase in spending on fixed assets, patents
and trademarks resulted in an increase in cash used in investing activities for the year ended December 31, 2019 compared with
the same period in 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Financing
activities currently represent the principal source of our cash flow. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Our
financing activities for the year ended December 31, 2020 provided net cash of approximately $80,724,000 which consisted of the
funding from our Financing Agreement of $50,000,000, </span><span style="font: 10pt Times New Roman, Times, Serif">approximately
$31,703,000 in proceeds from the sale of our common stock and <span style="background-color: white">the exercise of options to
purchase common stock of approximately $271,000, partially offset by the payment of deferred financing fees of $1,250,000. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 10, 2020, we entered into an underwriting agreement with Cantor Fitzgerald, as underwriter, relating to an underwritten
public offering of 23,437,500 shares of our common stock. We granted to the underwriter an option, exercisable for a period of
30 days, to purchase up to 3,515,625 additional shares of common stock, which was exercised in full. The net proceeds the offering
were approximately $31,703,000, after deducting the underwriting discounts and commissions and offering expenses paid by us. The
offering of 23,437,500 shares closed on November 13, 2020 and the offering of 3,515,625 shares closed on November 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
financing activities for the year ended December 31, 2019 provided net cash of approximately $188,827,000. The cash provided by
financing activities during the year ended December 31, 2019 included approximately $77,031,000 in proceeds from the sale of our
common stock and approximately $109,000 in proceeds from the exercise of options as well as funding from our Financing Agreement
of approximately $200,000,000 partially offset by the payment of financing fees of approximately $6,652,000 in connection with
the Financing Agreement and the repayment of the MidCap Agreement of $81,661,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
October 29, 2019, we closed an underwritten public offering of 29,900,000 shares of our common stock at a price to the public
of $2.75 per share, inclusive of the underwriters&#8217; option to purchase additional shares of common stock, which option was
exercised in full. We received net proceeds from the offering of approximately $77,031,000, after deducting underwriting discounts
and commissions and offering expenses paid by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Critical
Accounting Policies and New Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Critical
Accounting Policies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with accounting principles generally accepted in the United States, or GAAP,
requires us to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements.
We consider an accounting estimate to be critical if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">it
                                         requires assumptions to be made that were uncertain at the time the estimate was made,
                                         and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 69; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
                                         in the estimate or different estimates that could have been selected could have a material
                                         impact on our results of operations or financial condition.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
base our estimates and judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our
observation of trends in the industry, information provided by our customers, and information available from other sources. Actual
results may differ from these estimates under different assumptions or conditions. We have identified the following accounting
policies and estimates as those that we believe are most critical to our financial condition and results of operations and that
require our most subjective and complex judgments in estimating the effect of inherent uncertainties: share-based compensation
expense and income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue
Recognition. </i><span style="color: #212529">As of December 31, 2020, </span>our products consisted primarily of prescription
vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, BIJUVA, which we began
selling in the second quarter of 2019, and ANNOVERA, which we began selling in the third quarter of 2019. As a result of the uncertainty
surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales
and marketing initiatives into subsequent quarters. We resumed the launch of ANNOVERA in July 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have
one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised
goods to a distributor, and two performance obligations related to products sold through retail pharmacies, which are to: (1)
transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather
than as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring
a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods
or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all
of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been
satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement
of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent
to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined
based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns,
chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed
on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current
liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate
the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method,
depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable
consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount
of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our
historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject
to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal
arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts
of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates,
we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become
known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Share-Based
Compensation. </i>We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value
and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation
rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods
of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance
with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including
the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected
dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds
whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which
our stock price is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock
price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar
to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated
volatility is based on historical stock prices over a period equal to the expected term of the awards. On January 1, 2020, we
began calculating the expected term of our stock-based awards, which represents the period that the stock-based awards are expected
to be outstanding. Prior to January 1, 2020, the average expected life of options was based on the contractual terms of the stock
option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends
and have no current intention to pay cash dividends. The assumptions used in calculating the fair value of stock-based awards
represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As
a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different
in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated
in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s
requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted
ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based
payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments
granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded
the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value
basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 70; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><span style="font: 10pt Times New Roman, Times, Serif">We
grant performance-based stock units and restricted stock units for shares of common stock to employees. We value our restricted
stock units and our performance-based stock units by reference to our stock price on the date of grant. We recognize compensation
expense for restricted stock units based on a straight-line basis over the requisite service period of the entire award. We recognize
performance-based restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance
and over the requisite service period beginning at its grant date and through the date the restricted stock vests. The number
of target shares that vest are determined based on the level of attainment of the targets. If a minimum level of performance is
attained for the awards, restricted stock is issued based on the level of attainment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Income
Taxes. </i>We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates
expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled.
We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation
allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions
are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized
uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes
in recognition or measurement are reflected in the period in which those changes in judgment occur. We recognize both interest
and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2020 and 2019, we had no
tax positions relating to open tax returns that were considered to be uncertain. Our tax returns are subject to review by the
Internal Revenue Service three years after they are filed. Our U.S. federal and state tax returns since 2011, which was the first
year we generated net operating losses, remain open to examination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
determination of our provision for income taxes requires significant judgment, the use of estimates, and the interpretation and
application of complex tax laws. In the ordinary course of our business, there are transactions and calculations for which the
ultimate tax determination is uncertain. In spite of our belief that we have appropriate support for all the positions taken on
our tax returns, we acknowledge that certain positions may be successfully challenged by the taxing authorities. We determine
the tax benefits more likely than not to be recognized with respect to uncertain tax positions. Although we believe our recorded
tax assets and liabilities are reasonable, tax laws and regulations are subject to interpretation and inherent uncertainty; therefore,
our assessments can involve both a series of complex judgments about future events and rely on estimates and assumptions. Although
we believe these estimates and assumptions are reasonable, the final determination could be materially different than that which
is reflected in our provision for income taxes and recorded tax assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Segment
Reporting. </i>We are managed and operated as one business, which is focused on creating and commercializing products targeted
exclusively for women. Our business operations are managed by a single executive leadership team that is chaired by the Chief
Executive Officer of our Company, who oversees all operations. We do not operate separate lines of business with respect to any
of our products and we do not prepare discrete financial information with respect to separate products. All product sales are
derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>New
Accounting Pronouncements</i>. <span style="color: #212529">In March 2020, the Financial Accounting Standards Board, or the FASB,
issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference
Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting
impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank
Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally,
contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment
of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022.
Our Financing Agreement currently include the use of alternate rates when LIBOR is not available. We do not expect the change
from LIBOR to an alternate rate will have a material impact on our financial statements and, to the extent we enter into modifications
of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the FASB issued ASU 2018-13 which eliminates certain disclosure requirements for fair value measurements for all
entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed
the amendments to Accounting Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims
to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate
the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal
years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt
either the entire standard or only the provisions that eliminate or modify requirements. We adopted this standard on January 1,
2020, and the adoption did not have a material effect on our disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January
1, 2020, we adopted ASU 2016-13 under a modified retrospective approach for all financial assets measured at amortized cost. There
was no adjustment recorded for the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit
losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, 2019, and 2018, we had no off-balance sheet arrangements that have had or are reasonably likely to have
a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that are material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
the ordinary course of business, we enter into agreements with third parties that include indemnification provisions, which, in
our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners,
clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified
parties for losses suffered or incurred by the indemnified parties with respect to our drugs or drug candidates, use of such drugs
or drug candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required
to make under these indemnification provisions is sometimes unlimited. We have not incurred material costs to defend lawsuits
or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to
these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of December 31, 2020, 2019,
and 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally
relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other
appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by GAAP, an estimate
is made of the loss and the appropriate accounting entries are reflected in our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Effects
of Inflation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
each of the fiscal years ended December 31, 2020, 2019, and 2018, our business and operations have not been materially affected
by inflation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 72; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of contractual obligations as of December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Payments
    Due by Period</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Total</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>Less
    than <br />1 Year</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>2-3
    Years</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>4-5
    Years</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><b>More
    than 5 Years</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify">Operating lease obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">15,615,418</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,334,582</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,856,432</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,989,992</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7,434,412</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Long-term debt obligation <sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">187,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">62,500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interest payments <sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76,034,635</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26,487,847</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">47,913,975</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,632,813</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Purchase obligations <sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,923,559</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,984,374</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,141,093</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,133,647</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,664,445</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">374,573,612</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,806,803</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">243,411,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">74,256,452</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,098,857</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 0; margin-bottom: 0"><div style="border-top: Black 1pt solid; font-size: 1pt; width: 20%; margin-left: 0.5in">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9pt"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: #212529"><span style="color: #212529">Reflects amounts payable under the
Financing Agreement as of December 31, 2020, which provided for the outstanding principal amount to be paid in four equal quarterly
installments beginning on June 30, 2023, with the Financing Agreement maturing on March 31, 2024. In connection with Amendment
No. 8 to the Financing Agreement, entered into on March 1, 2021, </span>we agreed to make quarterly repayments under the Financing
Agreement commencing with the fiscal quarter ending March 31, 2022. See Note 8 &#8211; Debt for information regarding our debt
maturity.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9pt"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interest
                                         calculation is based on interest rates in place on December 31, 2020.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9pt"><span style="font: 10pt Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes
                                         manufacturing purchase commitments described below.&#160;The amounts presented here represent
                                         our estimates of the minimum required payments under our agreements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual
Property Licenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have license agreements with third parties that provide for minimum royalty, license, and exclusivity payments to be paid by us
for access to certain technologies. In addition, we pay royalties as a percent of revenue as described in Note 6, Intangible Assets,
to these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purchase
Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels during
the first contract year and a higher number or softgels after the first contract year. If the minimum order quantities of specific
products are not met, we are required to pay Catalent 50% of the difference between the total amount we would have paid to Catalent
if the minimum requirement had been fulfilled and the sum of all purchases of our products from Catalent during the contract year.
In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum number of units of ANNOVERA
during a contract year. As of December 31, 2020, we have met our minimum purchase commitments with our manufacturers related to
fiscal year 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">See
Item 3 &#8220;Legal Proceedings&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Seasonality</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
specialty pharmaceutical industry component of women&#8217;s health is not subject to seasonal sales fluctuation, however, we
anticipate that high deductible and annual prescription copay resets under commercial insurance plans at the beginning of the
calendar year will affect our first quarter net revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a012"></span>Item
7A&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
had a cash balance of approximately $80,486,000 as of December 31, 2020. We hold certain portions of our cash balances in overnight
money market placements all of which are fully available to us to support our cash flow requirements. The primary objective of
our investment policy is to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies
credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 73; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest
rates. To minimize this risk, we intend to maintain an investment portfolio that may include cash, cash equivalents and investment
securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt
securities and commercial paper, all with various maturity dates. Due to the low risk profile of our investments, an immediate
100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Amounts
borrowed under the Financing Agreement accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70%
or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.20%. Considering the total outstanding principal balance
under the Financing Agreement of $250,000,000 at December 31, 2020, a 1.0% change in interest rates would result in an impact
to loss before income taxes of $2,500,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a013"></span>Item
8.&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Reference
is made to the financial statements, the notes thereto, and the reports thereon, commencing on page F-1 of this Annual Report,
which financial statements, notes, and reports are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a014"></span>Item
9.&#160;&#160;&#160;&#160;&#160;Change in and Disagreements With Accountants on Accounting and Financial Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a015"></span>Item
9A.&#160;&#160;&#160;&#160;&#160;Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as
of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and
Chief Financial Officer concluded that, as of December 31, 2020, our disclosure controls and procedures were effective to ensure
that information required to be disclosed by us in the reports we file or submit under the Exchange Act is (i) recorded, processed,
summarized, and reported within the time periods specified in the SEC rules and forms, and (ii) is accumulated and communicated
to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Changes
in Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
was no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Inherent
Limitations on Effectiveness of Controls</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and
procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of
a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented
or detected. Further, internal controls may become inadequate because of changes in conditions, or through the deterioration of
the degree of compliance with policies or procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under
Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">pertain
                                         to the maintenance of records that in reasonable detail accurately and fairly reflect
                                         the transactions and dispositions of our assets;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">provide
                                         reasonable assurance that transactions are recorded as necessary to permit preparation
                                         of financial statements in accordance with generally accepted accounting principles,
                                         and that our receipts and expenditures are being made only in accordance with authorizations
                                         of our management and directors; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">provide
                                         reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
                                         use, or disposition of our assets that could have a material effect on the financial
                                         statements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 74; Value: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management assessed
the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, our management
used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated
Framework (2013). Management&#8217;s assessment included an evaluation of the design of our internal control over financial reporting
and testing of the operational effectiveness of its internal control over financial reporting. Based on management&#8217;s assessment,
we believe that our internal controls over financial reporting were effective as of December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This&#160;Annual&#160;Report&#160;on Form
10-K&#160;does not include an attestation report of the Company&#8217;s registered public accounting firm regarding internal control
over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting
firm pursuant to the rules of the SEC that permit the Company to provide only management&#8217;s report in this Annual Report on
Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b><span id="a016"></span>Item 9B.</b></td><td style="text-align: justify"><b>Other Information</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Amendment No. 8 to Financing Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 1, 2021, we entered
into Amendment No. 8, pursuant to which, among other amendments, the minimum quarterly product net revenue requirements attributable
to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised, the amortization and prepayment terms of the borrowings under
the Financing Agreement were revised, and the Administrative Agent consented to a framework for our potential disposition of our
vitaCare prescription services business. The minimum quarterly product net revenue requirements attributable to commercial sales
of IMVEXXY, BIJUVA, and ANNOVERA were revised pursuant to Amendment No. 8 to (i) $17.0 million, $20.0 million, $23.0 million, and
$26.5 million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $30.0 million, $35.0 million, $40.0
million and $45.0 million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $50.0 million, $55.0 million,
$60.0 million and $65.5 million for the first, second, third, and fourth quarters of 2023, and (iv) $70.0 million for the first
quarter of 2024. With respect to amortization and prepayment terms of the borrowings under the Financing Agreement, in connection
with Amendment No. 8, we (i) repaid $15.0 million in principal under the Financing Agreement on such date, plus a 5.0% prepayment
fee, (ii) agreed to repay an additional $35.0 million in principal by no later than March 31, 2021, plus a 5.0% prepayment fee,
and (iii) agreed to make additional principal repayments as follows: (x) $5.0 million on each of March 31, 2022, June 30, 2022
and September 30, 2022; (y) $10.0 million on each of December 31, 2022 and March 31, 2023; and (z) $41.25 million on each of June
30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, plus the prepayment fees described in the following sentence.
In connection with Amendment No. 8, the prepayment fees on principal amounts being prepaid under the Financing Agreement were revised
as follows: (i) 30.0% of the principal amount being repaid through March 31, 2022 (excluding the scheduled $5.0 million principal
repayment on such date, which is subject to a 5.0% prepayment fee); (ii) 5.0% of the principal amount being repaid from April 1,
2022 through March 31, 2023; (iii) 3.0% of the principal amount being repaid from April 1, 2023 through March 31, 2024; and (iv)
thereafter, none, in each case subject to certain limited exceptions, including with respect to a repayment in full of the obligations
under the Financing Agreement. The foregoing summary of Amendment No. 8 does not purport to be complete and is subject to, and
qualified in its entirety by, the full text of Amendment No. 8, a copy of which is filed as Exhibit 10.25 to this Annual Report
on Form 10-K and is incorporated herein by reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a017"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><b><span id="a018"></span>Item 10.</b></td><td><b>Directors, Executive Officers, and Corporate Governance</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item relating to our directors and corporate governance is incorporated herein by reference to the definitive Proxy Statement
to be filed pursuant to Regulation 14A of the Exchange Act for our 2021 Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><b><span id="a019"></span>Item 11.</b></td><td><b>Executive Compensation</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the
Exchange Act for our 2021 Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><b><span id="a020"></span>Item 12.</b></td><td><b>Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the
Exchange Act for our 2021 Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><b><span id="a021"></span>Item 13.</b></td><td><b>Certain Relationships and Related Transactions, and
Director Independence</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the
Exchange Act for our 2021 Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><b><span id="a022"></span>Item 14.</b></td><td><b>Principal Accountant Fees and Services</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the
Exchange Act for our 2021 Annual Meeting of Stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><span id="a023"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0in"></td><td style="width: 1in; text-align: left"><b><span id="a024"></span>Item 15.</b></td><td><b>Exhibits and Financial Statement Schedules</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">(a)</span></td>
    <td colspan="2" style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><b>Financial Statements and Financial Statements Schedules</b></span></td>
    </tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: top; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statements are listed in the Index to Consolidated Financial Statements on page F-1 of this Annual Report. &#160; &#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No financial statement schedules are included because such schedules are not applicable, are not required, or because required information is included in the consolidated financial statements or notes thereto.</span></td></tr>
</table>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 75; Options: NewSection; Value: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 6%; font-size: 10pt"><span style="font-size: 10pt">(b)</span></td>
    <td style="width: 93%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibits</b>&#160;</p></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>



<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 8%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 17%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Date</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 69%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Description</b></p></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm">2.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">July 6, 2009</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm"><span style="font-size: 10pt">Agreement and Plan of Reorganization among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#8217;s Minority Health Network, Inc., and the Major Shareholders <sup>(1)</sup></span></a></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm"><span style="font-size: 10pt">2.2</span></a></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">June 11, 2010</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm">Agreement and Plan of Reorganization among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc. <sup>(2)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">2.3</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">October 25, 2007</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization <sup>(3)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">2.4</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">July 18, 2011</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">Agreement and Plan of Merger among VitaMedMD, LLC, AMHN, Inc., and VitaMed Acquisition, LLC <sup>(4)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm">3.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">July 20, 2010</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm">Articles of Conversion of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm">3.2</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">July 20, 2010</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex3-1.htm">3.3</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex3-1.htm">Composite Amended and Restated Articles of Incorporation of the Company, as amended <sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm">3.4</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm"><span style="font-size: 10pt">Bylaws of AMHN, Inc. <sup>(7)</sup></span></a></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">3.5</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">December 17, 2015</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">First Amendment to Bylaws of the Company <sup>(8)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">4.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">Form of Certificate of Common Stock <sup>(9)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120002086/ex4-2.htm">4.2</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120002086/ex4-2.htm">Description of Securities of the Company <sup>(10)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm">10.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm">Form of Common Stock Purchase Warrant <sup>(11)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm">10.2*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm">Form of Non-Qualified Stock Option Agreement <sup>(11)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119004545/ex99-1.htm">10.3*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119004545/ex99-1.htm">TherapeuticsMD, Inc. 2019 Stock Incentive Plan <sup>(12)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm">10.4*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm">Amended and Restated 2012 Stock Incentive Plan <sup>(13)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm">10.5*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm">2009 Long Term Incentive Compensation Plan, as amended <sup>(14)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120004409/txmd-def14a_061820.htm">10.6*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120004409/txmd-def14a_061820.htm">TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan <sup>(15)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002306/ex10_7.htm">10.7</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">October 23, 2011</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002306/ex10_7.htm">Common Stock Purchase Warrant to Lang Naturals, Inc. <sup>(16)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm">10.8</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">February 24, 2012</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm">Form of Common Stock Purchase Warrant <sup>(17)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm">10.9</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">January 31, 2013</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm">Common Stock Purchase Warrant, issued to Plato &amp; Associates, LLC <sup>(18)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex4-1.htm">10.10</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">August 5, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex4-1.htm">Form of Warrant to Purchase Common Stock <sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex4-2.htm">10.11</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">November 8, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex4-2.htm">Amendment to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August 5, 2020 <sup>(19)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-12.htm">10.12&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">January 13, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-12.htm">Second Amendment to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August 5, 2020</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><a href="ex10-13.htm">10.13&#8224;</a></td>
    <td>&#160;</td>
    <td>October 4, 2011</td>
    <td>&#160;</td>
    <td><p><a href="ex10-13.htm">Warrant issued by the Company to Robert Finizio</a></p>
</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-14.htm">10.14&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">February 18, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-14.htm">Amendment to Warrant issued by the Company to Robert Finizio</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><a href="ex10-15.htm">10.15&#8224;</a></td>
    <td>&#160;</td>
    <td>October 4, 2011</td>
    <td>&#160;</td>
    <td><p><a href="ex10-15.htm">Warrant issued by the Company to John C.K. Milligan, IV</a></p>
</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-16.htm">10.16&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">February 20, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-16.htm">Amendment to Warrant issued by the Company to John C.K. Milligan, IV</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-1.htm">10.17***</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">April 24, 2019</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-1.htm">Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC <sup>(20)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-6.htm">10.18</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">December 27, 2019</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-6.htm">Amendment No. 1 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC<sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-1.htm">10.19</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">April 17, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-1.htm">Amendment No. 2 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC<sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-2.htm">10.20</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">May 1, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-2.htm">Amendment No. 3 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC<sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-3.htm">10.21</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">May 13, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-3.htm">Amendment No. 4 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC<sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-4.htm">10.22</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">August 5, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-4.htm">Amendment No. 5 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., Sixth Street Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC<sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-4.htm">10.23</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">November 8, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-4.htm">Amendment No. 6 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., Sixth Street Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC<sup>(19)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-24.htm">10.24&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">January 13, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex10-24.htm">Amendment No. 7 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., Sixth Street Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><a href="ex10-25.htm">10.25***&#8224;</a></td>
    <td>&#160;</td>
    <td>March 1, 2021</td>
    <td>&#160;</td>
    <td><a href="ex10-25.htm">Amendment No. 8 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., Sixth Street Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC</a></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-2.htm">10.26</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">April 24, 2019</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-2.htm">Pledge and Security Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc. and TPG Specialty Lending, Inc. <sup>(20)</sup></a></span></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 76; Value: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="width: 8%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-5.htm">10.27</a></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%"><span style="font-size: 10pt">August 5, 2020</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 69%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-5.htm">Subscription Agreement, by and among TherapeuticsMD, Inc. and the Subscribers identified on the Schedule of Subscribers attached thereto <sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-1.htm">10.28***</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">September 28, 2018</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-1.htm"><span style="font-size: 10pt">Commercial Supply Agreement by and between TherapeuticsMD, Inc. and QPharma AB </span><span style="font-size: 10pt"><sup>(21)</sup></span></a></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118003401/ex10-1.htm">10.29**</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">April 20, 2016</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118003401/ex10-1.htm">Commercial Supply Agreement by and between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC <sup>(22)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-6.htm">10.30***</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">September 29, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-6.htm">Amendment No. 2 to the Commercial Supply Agreement, between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC <sup>(19)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119001471/ex10-20.htm">10.31**</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">June 24, 2016</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119001471/ex10-20.htm">Softgel Commercial Supply Agreement by and between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC <sup>(23)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-5.htm">10.32***</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">December 1, 2017</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-5.htm">Amendment No. 1 to the Softgel Commercial Supply Agreement, between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC <sup>(19)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-6.htm">10.33***</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">September 29, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-6.htm">Amendment No. 2 to the Softgel Commercial Supply Agreement, between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC <sup>(19)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118005976/ex10-1.htm">10.34**</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">July 30, 2018</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118005976/ex10-1.htm">Population Council License Agreement by and between TherapeuticsMD, Inc. and The Population Council, Inc. <sup>(24)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113001675/ex10-31.htm">10.35*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">May 8, 2013</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113001675/ex10-31.htm">Agreement to Forfeit Non-Qualified Stock Options between the Company and Robert G. Finizio <sup>(25)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-2.htm">10.36***</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">October 5, 2018</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-2.htm">Lease by and between 951 Yamato Acquisition Company, LLC and TherapeuticsMD, Inc. <sup>(26)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-1.htm">10.37*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">November 24, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-1.htm">Amended and Restated Employment Agreement between the Company and Robert G. Finizio <sup>(27)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-2.htm">10.38*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">November 24, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-2.htm">Amended and Restated Employment Agreement between the Company and Michael Donegan <sup>(27)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-3.htm">10.39*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">November 24, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-3.htm">Amended and Restated Employment Agreement between the Company and John C.K. Milligan, IV <sup>(27)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-6.htm">10.40*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">June 1, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-6.htm">Employment Agreement between the Company and James C. D&#8217;Arecca <sup>(6)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><a href="ex10-41.htm">10.41*&#8224;</a></td>
    <td>&#160;</td>
    <td>October 30, 2019</td>
    <td>&#160;</td>
    <td><p><a href="ex10-41.htm">Employment Agreement between the Company and Edward J. Borkowski</a></p>
</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><a href="ex10-42.htm">10.42*&#8224;</a></td>
    <td>&#160;</td>
    <td>November 22, 2019</td>
    <td>&#160;</td>
    <td><p><a href="ex10-42.htm">Amendment to Employment Agreement between the Company and Edward J. Borkowski</a></p>

</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-3.htm">10.43***</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">June 6, 2019</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-3.htm">License and Supply Agreement, by and between TherapeuticsMD, Inc. and Theramex HQ UK Limited <sup>(20)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-3.htm">10.44*</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-3.htm">Form of Indemnification Agreement between TherapeuticsMD, Inc. and each of its executive officers and directors. <sup>(19)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120010302/ex1-1.htm">10.45</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">November 27, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120010302/ex1-1.htm">Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated November 27, 2020, by and between TherapeuticsMD, Inc. and Cantor Fitzgerald &amp; Co. <sup>(27)</sup></a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713120002086/ex21-1.htm">21.1</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713120002086/ex21-1.htm">Subsidiaries of the Company</a><sup>(10)</sup></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex23-1.htm">23.1&#8224;&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 3, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex23-1.htm">Consent of Grant Thornton LLP</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex31-1.htm">31.1&#8224;&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 3, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex31-2.htm">31.2&#8224;&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 3, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex32-1.htm">32.1&#8224;&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 3, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex32-1.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
    to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex32-2.htm">32.2&#8224;&#8224;</a></span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">March 3, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ex32-2.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">101.INS&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">101.SCH&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Schema Document</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">101.CAL&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">101.DEF&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Instance Document</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">101.LAB&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Instance Document</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">101.PRE&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a&#160;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Instance Document&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">104&#8224;</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">n/a</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and Contained in Exhibit 101)</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><sup>&#160;</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="width: 96%"><span style="font: 10pt Times New Roman, Times, Serif">Indicates a contract with
    management or compensatory plan or arrangement.</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">**</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Certain confidential
    material contained in the document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
    treatment has been granted with respect to this omitted information.</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">***</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Portions of this exhibit
    have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely
    cause competitive harm to the Company if publicly disclosed.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 77; Value: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-size: 10pt">&#8224;</span></td>
    <td style="width: 96%"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#8224;&#8224;</span></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Furnished herewith.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on July 10, 2009 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on June 14, 2010 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-K for the year ended December 31, 2007 filed with the Commission on May 1, 2008 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on July 21, 2011 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2010 filed with the Commission on August 3, 2010 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(6)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 filed with the Commission on August 7, 2020 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(7)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on June 29, 2010 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(8)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on December 22, 2015 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(9)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form S-3 filed with the Commission on January 25, 2013 and incorporated hereby by reference (SEC File No. 333-186189).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(10)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-K for the year ended December 31, 2019 filed with the Commission on February 24, 2020 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(11)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(12)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form S-8 filed with the Commission on June 21, 2019 and incorporated herein by reference (SEC File No. 333-232268).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(13)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(14)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Registration Statement on Form S-8 filed with the Commission on October 15, 2013 and incorporated herein by reference (SEC File No. 333-191730).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(15)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an appendix to the Definitive Proxy Statement filed with the Commission on May 4, 2020 and incorporated herein by reference (SEC File No. 000-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(16)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on October 24, 2011 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(17)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(18)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(19)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q filed with the Commission on November 9, 2020 and incorporated herein by reference (SEC File No. 000-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(20)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 filed with the Commission on August 9, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(21)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2019 filed with the Commission on November 8, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(22)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2018 filed with the Commission on July 30, 2018 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(23)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-K for the year ended December 31, 2018 filed with the Commission on February 27, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(24)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2018 filed with the Commission on November 8, 2018 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(25)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 filed with the Commission on May 10, 2013 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(26)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2019 filed with the Commission on November 8, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><sup>(27)</sup></span></td>
    <td><span style="font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on November 27, 2020 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a025"></span>Item 16. Form 10-K Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 78; Value: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 60%; text-align: justify"><span style="font-size: 10pt">Date: March 3, 2021</span></td>
    <td style="width: 40%; text-align: justify"><span style="font-size: 10pt"><b>THERAPEUTICSMD, INC.</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font-size: 10pt"><i>/s/ Robert G. Finizio</i></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Robert G. Finizio</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the date indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Capacity</b></span></td>
    <td style="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Robert G. Finizio</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Chief Executive Officer, Director</span><br />
<span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Robert G. Finizio</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ John C.K. Milligan, IV</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">President and Secretary</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">John C.K. Milligan, IV</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ James C. D&#8217;Arecca</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Principal Financial Officer)</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">James C. D&#8217;Arecca</span></td>
    <td></td>
    <td>&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Michael Donegan</i></span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Chief Accounting Officer</span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>Michael
        Donegan</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">(Principal Accounting Officer)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Tommy G. Thompson</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Chairman</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Tommy G. Thompson </span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Paul M. Bisaro</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Paul M. Bisaro</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ J. Martin Carroll</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">&#160;J. Martin Carroll</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Cooper C. Collins</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">&#160;Cooper C. Collins</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Karen L. Ling</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Karen L. Ling </span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Jules A. Musing</i></span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Jules A. Musing</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Gail K. Naughton, Ph.D.</i></span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Gail K. Naughton, Ph.D.</span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
<tr>
    <td colspan="3" style="border-bottom: black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><i>/s/ Angus C. Russell </i></span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center"><span style="font-size: 10pt">March 3, 2021</span></td></tr>
<tr>
    <td colspan="3" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Angus C. Russell</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="vertical-align: top; text-align: center">&#160;</td></tr>
</table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 79; Value: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; width: 93%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Page</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-2</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb001">Consolidated Balance Sheets as of December 31, 2020 and 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-4</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb002">Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-5</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb003">Consolidated Statements of Stockholders&#8217; (Deficit) Equity for the years ended December 31, 2020, 2019 and 2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-6</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb004">Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-7</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb005">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-8</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Page; Sequence: 80; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<p style="margin: 0 0 8pt; text-align: center"><span style="font-size: 10pt"><b><span id="a_002"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></span></p>

<p style="margin: 0 0 8pt"><span style="font-size: 10pt">Board of Directors and Stockholders</span></p>

<p style="margin: 0 0 8pt"><span style="font-size: 10pt">TherapeuticsMD, Inc.</span></p>

<p style="margin: 0"><span style="font-size: 10pt"><b>Opinion on the financial statements </b></span></p>

<p style="margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">We have audited the accompanying consolidated balance sheets of TherapeuticsMD,
Inc. (a Nevada corporation) and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, the related consolidated
statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period
ended December 31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020
and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020,
in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Basis for opinion </b></span></p>

<p style="margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">These financial statements are the responsibility of the Company&#8217;s
management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are
a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks
of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis
for our opinion.</span></p>

<p style="margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Critical audit matters</b></span></p>

<p style="margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">The critical audit matters communicated below are matters arising from
the current period audit of the financial statements that were communicated or required to be communicated to the audit committee
and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate
opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>

<p style="margin: 0 0 8pt; text-align: justify"><span style="text-decoration: underline; font-size: 10pt">Calculation of variable consideration related
to sales deductions</span></p>

<p style="margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">As described further in Note 2 to the financial statements, the transaction
price of the Company&#8217;s revenue contracts is variable as it is calculated net of estimated product returns, chargebacks,
rebates, coupons, discounts and wholesaler fees (collectively &#8220;sales deductions&#8221;). We identified the calculation of
variable consideration related to sales deductions as a critical audit matter.</span></p>

<p style="margin: 0 0 8pt; text-align: justify"><span style="font-size: 10pt">The principal consideration for our determination that the calculation
of variable consideration related to sales deductions was a critical audit matter is that auditing the estimation of variable
consideration requires significant judgement and the amounts are material to the financial statements taken as a whole. These
estimates require the consideration of key assumptions such as expected return rates, estimated level of inventory in the distribution
channel, expected coupon utilization, and expected insurance coverage levels, all of which have estimation uncertainty.</span></p>

<p style="margin: 0 0 8pt"><span style="font-size: 10pt">Our audit procedures related to testing the calculation of variable consideration
related to sales deductions included the following, among others:</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We
                                         evaluated the design and tested the operating effectiveness of controls over management&#8217;s
                                         calculation and review of variable consideration related to sales deductions by verifying
                                         management&#8217;s controls over the completeness of the input data, mathematical accuracy
                                         of the calculations and evaluating the reasonableness of key assumptions used in the
                                         calculation.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 81; Options: NewSection; Value: 2 -->
    <div style="border-bottom: black 1pt solid; text-align: center; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: sequence; type: arabic; name: pageno -->2<!-- Field: /sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We
                                         tested management&#8217;s estimates by performing one of the following procedures based
                                         on the sales deduction being tested (1) developing independent expectations to corroborate
                                         the reasonableness of management&#8217;s estimate, (2) testing management&#8217;s process
                                         to develop the estimate, or (3) reviewing subsequent events or transactions. Our procedures
                                         included reviewing subsequent information related to coupon and rebate settlements. We
                                         used historical sales and return data in developing our independent expectations and
                                         in testing management&#8217;s process. We tested the completeness and accuracy of the
                                         historical sales and return data used in the calculations by agreeing total sales to
                                         accounting records and tracing a sample of individual sale transactions to supporting
                                         audit evidence, such as purchase orders, shipping documents and invoices. We also evaluated
                                         the average assistance paid in the co-pay assistance program by vouching a sample of
                                         transactions settled during the year to source documentation. </span></td></tr></table>

<p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0 0 14.2pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Forecasted debt covenant compliance and going concern</span></span></p>

<p style="margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described further in Note 2 to the consolidated financial
statements, the Company&#8217;s Financing Agreement contains covenants that, among other items, require the Company to maintain
a minimum cash balance and meet certain minimum quarterly product revenue requirements. The principal assumptions used in management&#8217;s
cash flow and product net revenue analyses used to estimate future covenant compliance consisted of the forecasts related to revenue
growth, gross profit margins, and sales and marketing expenses. We identified the evaluation of management&#8217;s forecasted debt
covenant compliance and going concern analysis as a critical audit matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The principal considerations for our determination
that the evaluation of management&#8217;s forecasted debt covenant compliance and going concern analysis was a critical audit
matter are the significant judgment by management when evaluating the uncertainty related to the Company&#8217;s forecasts
and a high degree of auditor judgment in evaluating management&#8217;s forecasts for at least the next twelve months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audit procedures related to the evaluation of management&#8217;s
forecasted debt covenant compliance and going concern analysis included the following, among others, (i) testing management&#8217;s
process for forecasting financial results for one year after the date the financial statements are issued; and (ii) testing the
completeness and accuracy of underlying data used in the forecast; and (iii) evaluation of management&#8217;s covenant compliance
assessment and their disclosure in the consolidated financial statements regarding having the ability of the Company to continue
to maintain liquidity and meet the Company&#8217;s financial covenants for at least the next twelve months.</p>
<p style="margin: 0 0 0 0.25in"><span style="font-size: 10pt"></span></p>

<p style="margin: 0 0 14.2pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0 0 14.2pt"><span style="font-size: 10pt">/s/ GRANT THORNTON LLP&#160;</span></p>

<p><span style="font: 10pt Times New Roman, Times, Serif">We have served as the Company&#8217;s auditor since 2015.&#160;</span></p>

<p style="margin: 0"><span style="font-size: 10pt">Miami, Florida</span></p>

<p style="margin: 0"><span style="font-size: 10pt">March 3, 2021</span></p>

<p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: sequence; type: arabic; name: pageno -->3<!-- Field: /sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmdb001"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_111_pp0p0_ziXn3VuxlSQ3" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td>
    <td id="xdx_494_20201231_zv5VStNk2DR8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_499_20191231_zd8xghoYHoh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zH2f30UGYq2c" style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0">ASSETS</td>
    <td colspan="8" style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zxpHD4pqy4C1" style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Current Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--Cash_i02I_maCzCIn_maACzhOp_maACzstX_zyC7si2rfBpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; padding-left: 0.25in">Cash</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,485,784</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">160,829,713</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzCIn_maACzhOp_maACzstX_zGwstmV6Ofqf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.45in; text-indent: -0.2in">Accounts receivable, net of allowance for doubtful accounts of $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20201231_zExYMHLRfTM9" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,117,854</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20191231_zgvTSjaYaZLl"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">904,040</ix:nonFraction></span>, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,381,701</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,395,958</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--InventoryNet_i02I_maCzCIn_maACzhOp_maACzstX_z5J8UNrfIN22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,993,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,860,716</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzCIn_maACzhOp_maACzstX_zLzyRUMFQUH1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,543,397</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,329,793</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtCzCIn_maCzYME_zuCYt3JkO8I8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">128,403,969</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">208,416,180</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzYME_maAz1Nq_maAzWf0_zkt2gkvDI2Gk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0">Fixed assets, net <br /></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,942,224</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,507,775</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherAssetsAbstract_i01B_zqBbd5iIHCL1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Other Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--LicenseRights_i02I_uUSD_maCz2j8_maOANzLHW_zF7PpB8OWW4l" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">License rights, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,196,916</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,221,308</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCz2j8_maOANzLHW_maOANzqut_zZoQnmZmXGNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,247,723</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,258,211</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCz2j8_maOANzLHW_maOANzqut_zqxKLR4wVad9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Right of use assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,565,700</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,109,154</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OtherAssetsMiscellaneousNoncurrent_i02I_maCz2j8_maOANzLHW_maOANzqut_zGVJT1NX7Pck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">253,121</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">473,009</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCz2j8_maCzYME_zl0EgfhM56Jf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total other assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,263,460</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,061,682</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--Assets_i01TI_mtCzYME_mtAz1Nq_mtAzWf0_zJPVgaVpyRj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0.6in">Total assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">181,609,653</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,985,637</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_ziyfKZFp1vig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0">&#160;LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zWMKV0lQ6c98" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Current Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzO2e_maLCzuvw_maLCzfS7_zegV5Qlo4rri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,068,327</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,181,212</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzO2e_maLCzuvw_maLCzfS7_zJdr9dII7bs8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Other current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,169,869</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,823,613</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i02TI_mtCzO2e_maCzNLB_zqpkcEWGpU93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">59,238,196</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,004,825</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LongTermDebtNoncurrentAbstract_i01B_zCzSjb2qM68k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Long-Term Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LongTermDebtNoncurrent_i02I_maCzMsH_maLNzL7C_maLNzfsd_zidPcsN8lnub" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Long-term debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">237,697,531</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,634,643</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzMsH_maLNzL7C_maLNzfsd_zBOJ3guSUJok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Operating lease liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,675,477</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,145,049</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_i02I_mtCzMsH_maCzNLB_zM7Qauhm9bh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total long-term liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">246,373,008</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">203,779,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--Liabilities_i01TI_mtCzNLB_maTotalLAndS_maLASEzVV6_maLASEz7xL_z1D39F3Cx1j9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.6in">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">305,611,204</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,784,517</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CommitmentsAndContingencies_i01I_zHfiMarNeGq7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Commitments and Contingencies - See Note 14</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_i01B_zC90H2s4La6f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Stockholders&#8217; (Deficit) Equity:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_maCzutK_maSEzCg6_maSEzUwc_z7kcwWcLpwF5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.45in; text-indent: -0.2in">Preferred stock - par value $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20201231_zM14s6lzfqa6"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20191231_z3PZcxO1Cg91"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>;
    <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_uShares_c20201231_zZ7k0zLHOdM6"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_uShares_c20191231_zY7AJbpEI8Ug"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_uShares_c20201231_zbPds0gUvn6b"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_uShares_c20191231_zkRpyWD1Jtg9"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_uShares_c20201231_zOFQSj5VPT0d"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_uShares_c20191231_zAkfeFH3nC4a"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0133">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maCzutK_maSEzCg6_maSEzUwc_zMXp3Isr6ndh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Common stock - par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20201231_zdK4UFaFXuC5"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_uUSDPShares_c20191231_zdcTSXKTakua"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pip0_uShares_c20201231_zwqtpMWPjuXg"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">600,000,000</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pip0_uShares_c20191231_z6IKXMsNEtok"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">350,000,000</ix:nonFraction></span> shares authorized: <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pip0_uShares_c20201231_z2BwNxKr9lC6"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pip0_uShares_c20201231_zLuvBJPFdQN4"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">299,765,396</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pip0_uShares_c20191231_zhFkozqPN2f2"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pip0_uShares_c20191231_zawfSE82MND"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">271,177,076</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">299,765</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,177</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzutK_maSEzCg6_maSEzUwc_z2JkQDB4foC9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">754,644,100</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">704,351,222</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzutK_maSEzCg6_maSEzUwc_zFXc01ejmog2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">878,945,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--StockholdersEquity_i02TI_mtCzutK_maTotalLAndS_zZV2oaxUaEje" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total stockholders&#8217; (deficit) equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">124,001,551</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,201,120</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtTotalLAndS_zo5fBYVo3GXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0.6in">Total liabilities and stockholders&#8217; (deficit) equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">181,609,653</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,985,637</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 83; Options: NewSection; Value: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmdb002"></span>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_pp0p0_z2PBUfJBu9Xg" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 0; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20200101__20201231_zb1YzhMalth" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20190101__20191231_z9hRHmUupUK5" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20180101__20181231_zoCU52XG9B7f" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 0; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Year Ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 0; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2018</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-right: 0; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left; padding-left: 0; padding-right: 0">Product revenues, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zTYTdEegdgmh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,872,280</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zrqbMXQCNrXk" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,140,537</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3yEVLAskgfj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,099,460</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0; padding-right: 0">License revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zDEiiKJdxY76" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_uUSD_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zfUzOU0QTCYd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_do_uUSD_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z85w54ZYEZZa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0170">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzfld_z0xAEYPXei5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-right: 0">Total revenue, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">64,872,280</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,646,937</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,099,460</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_msCzfld_msGPzOxt_msGPzWhe_znyjzCZX7pZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0; padding-right: 0">Cost of goods sold</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,974,977</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,334,585</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,737,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--GrossProfit_iT_mtCzfld_maCzyty_zZSobrC3CJv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0; padding-right: 0">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,897,303</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,312,352</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,361,808</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingExpensesAbstract_iB_zRAHQSRsRu13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; padding-right: 0">Operating expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzrT6_maOEzIey_znguufd8wKif" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-right: 0">Sales, general, and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">192,963,967</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">174,112,612</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,988,954</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzrT6_maOEzIey_zg21o2Jqt8z2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-right: 0">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,431,907</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,792,212</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,299,138</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_i01_maCzrT6_maOEzIey_z6MnJvjUd9gl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; padding-right: 0">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,042,170</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">612,786</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">293,886</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OperatingExpenses_i01T_mtCzrT6_msCzyty_z420YaokIOdh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.4in; padding-right: 0">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">204,438,044</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,517,610</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,581,978</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.4in; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_iT_mtCzyty_maCzYA2_z7rStxv9vRtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 0; padding-right: 0">Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">155,540,741</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">151,205,258</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">130,220,170</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zO2butQx77G9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; padding-right: 0">Other (expense) income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzyG4_maNIEzifo_zSSVFjT2TVs3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-right: 0">Loss on extinguishment of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherNonoperatingIncome_i01_maNIEzyG4_maNIEzifo_zdwqmErxcqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-right: 0">Miscellaneous income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">597,647</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,500,106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,280,844</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--InterestExpense_i01N_di_msNIEzyG4_msNIEzifo_zdqPlMcszsZh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in; padding-right: 0; padding-bottom: 1pt">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,581,043</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,382,215</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,677,834</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzyG4_maCzYA2_zZGKxCRGnfZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.4in; padding-right: 0">Total other expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">27,983,396</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">24,939,741</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,396,990</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.4in; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzYA2_maCzwgn_mtILFCOzbiS_zWJr8VztOAi6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; padding-right: 0">Loss before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">183,524,137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_msCzwgn_msNILzHqI_zY2uenM1TLag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0; padding-right: 0">Provision for income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NetIncomeLoss_iT_mtCzwgn_zuAjBMJ2FMF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0; padding-right: 0">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">183,524,137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--EarningsPerShareAbstract_iB_znfpIyw9V5t" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; padding-right: 0">Loss per share, basic and diluted:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pip0_uUSDPShares_zPkzM7hVVBi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0; padding-right: 0">Net loss per share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.67</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.59</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0; padding-right: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_z0cKI4V5A6vj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0.25in; padding-right: 0; text-indent: -0.25in">Weighted
    average number of common shares outstanding, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">275,648,552</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">246,353,318</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">225,026,300</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 84; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmdb003"></span>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FOR
THE YEARS ENDED DECEMBER 31, 2020, 2019 AND 2018</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zAbAjtvNm0t8" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zIjQryFzKS07" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zEGAElUFGaR" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Additional</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zB8JuNB3VqDi" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B9_zVevJb3OsMr4" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Common Stock</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Paid in</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Accumulated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Shares</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Capital</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_439_c20180101__20181231_eus-gaap--StockholdersEquity_iS_zx1HzRgGgvij" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 35%; padding-left: 0">Balance, December 31, 2017</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CommonStockSharesOutstanding_iS_d0_uShares_c20180101__20181231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4s2f2xs0MKe" title="Balance at beginning (in shares)" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,429,642</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,430</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">516,351,405</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">386,659,120</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,908,715</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20180101__20181231_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zfchiMYA62Ri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Shares issued in offerings, net of cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20180101__20181231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6PI8Gje9Sv2" title="Shares issued in offerings, net of cost (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,578,430</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,578</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,889,219</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,907,797</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20180101__20181231_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zS2gBm5bB1ga" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Shares issued for exercise of options and warrants, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20180101__20181231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRgqRczDXHQ5" title="Shares issued for exercise of options and warrants, net (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,454,367</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,455</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,660,753</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,666,208</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20180101__20181231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zVnCClHbzPL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,658,561</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,658,561</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_43E_c20180101__20181231_eus-gaap--NetIncomeLoss_zIgccWv7Md4i" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_438_c20180101__20181231_eus-gaap--StockholdersEquity_iE_z9UghBmylcba" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0">Balance, December 31, 2018</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesOutstanding_iE_d0_uShares_c20180101__20181231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRLJZHCYGOh3" title="Balance at ending (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,462,439</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,463</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,559,938</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">519,276,280</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,524,121</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20190101__20191231_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z9bhAkOP8JRb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Shares issued in offerings, net of cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5jpyHPxshPi" title="Shares issued in offerings, net of cost (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,900,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,900</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,001,358</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,031,258</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20190101__20191231_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zjqaHUtE6Mwj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Shares issued for exercise of options and warrants, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znxFFHzPNYqd" title="Shares issued for exercise of options and warrants, net (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">814,637</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">814</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,842</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,656</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20190101__20191231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zDbAg5XwgTc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,682,084</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,682,084</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20190101__20191231_eus-gaap--NetIncomeLoss_z3xnZ0TbJSca" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_43B_c20190101__20191231_eus-gaap--StockholdersEquity_iE_zxM1viMfv4K5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0">Balance, December 31, 2019</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesOutstanding_iE_d0_uShares_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJlRpGWUx2ya" title="Balance at ending (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,177</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,351,222</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,201,120</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20200101__20201231_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zya8dhOq8Kp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Shares issued in offerings, net of cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRa0tkWY2kAe" title="Shares issued in offerings, net of cost (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,953,125</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,953</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,675,682</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,702,635</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20200101__20201231_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zbaLJfWkRCr9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Shares issued for exercise of options and warrants, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_uShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYzP9JOfmZ65" title="Shares issued for exercise of options and warrants, net (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,182,195</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,182</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,496</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,678</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_436_c20200101__20201231_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_iP3us-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_zmgedKIpJwY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Issuance of shares from release of restricted stock</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_iP2us-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_uShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbmjjt4w6jn3" title="Issuance of shares from release of restricted stock (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">453,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">453</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20200101__20201231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_iP3us-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zHPg2VlSIU5i" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Warrant granted in relation to Financing Agreement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,668,161</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,668,161</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20200101__20201231_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z2vGvzBb8LPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,678,992</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,678,992</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20200101__20201231_eus-gaap--NetIncomeLoss_zyZOvgguDcbf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,524,137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,524,137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_430_c20200101__20201231_eus-gaap--StockholdersEquity_iE_zMeugyHBTzmd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; padding-left: 0">Balance, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--CommonStockSharesOutstanding_iE_d0_uShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1csFwlWLge6" title="Balance at ending (in shares)" style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">299,765,396</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,765</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">754,644,100</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">878,945,416</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">124,001,551</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 85; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmdb004"></span>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_pp0p0_zVMRwuyhxOF4" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_493_20200101__20201231_zHhjYeICjlGk" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_496_20190101__20191231_zOMna6XRW01d" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20180101__20181231_zIa2gDsMEIp6" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Year Ended December, 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2018</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zZa0uwHJEy01" style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_uUSD_maCzyMU_zxQN6FfAJgs4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left; padding-left: 0.25in">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">183,524,137</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zW3FR5nckJdh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in; text-indent: -0.2in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--Depreciation_i02_uUSD_maCzyMU_z3NC8Kg75f73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Depreciation of fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">772,624</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">415,193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">181,412</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AmortizationOfIntangibleAssets_i02_uUSD_maCzyMU_zKEu24tMCdlb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Amortization of intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">269,546</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">197,593</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,474</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i02_uUSD_maCzyMU_z90LpMoUgwve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Write off of patent and trademark cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,131,776</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,864</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_i02_uUSD_maCzyMU_zQZhn7NHDbIk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Write off of deferred financing fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">275,379</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--NoncashOperatingLeaseExpense_i02_uUSD_maCzyMU_zrvf0HC6Kevi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Non-cash operating lease expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,405,443</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,062,318</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--ProvisionForDoubtfulAccounts_i02_uUSD_maCzyMU_zfT8qSSp2Xhj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Provision for doubtful accounts</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">213,814</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">307,438</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216,022</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseImpairmentLoss_i02_uUSD_maCzyMU_zzmNQMfmA9Ih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Lease impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">136,832</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Inventory charge</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InventoryWriteDown_i02_maCzyMU_c20200101__20201231_zXK666o0kUI2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,204,818</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_uUSD_msCzyMU_zfD0nga5a1ti" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">Loss of extinguishment of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_uUSD_maCzyMU_zQxaZZysxFn5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,678,992</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,693,662</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,661,967</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--AmortizationOfIntellectualPropertyLicenseFee_i02_uUSD_maCzyMU_zVFnecxxPY1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Amortization of intellectual property license fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,024,391</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">778,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AmortizationOfFinancingCosts_i02_uUSD_maCzyMU_zjbp3W5GfM3h" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Amortization of deferred financing costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,256,429</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">856,302</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">269,859</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_uUSD_znpOG2xecHBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.5in">Changes in operating assets and liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_uUSD_msCzyMU_zOwSJc1I06R3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.6in">&#160;Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,199,558</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,639,575</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,951,041</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInInventories_i03N_di_uUSD_msCzyMU_zuSLiXDEpZh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.6in">&#160;Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,337,189</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,593,046</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,782,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msCzyMU_zYWQu0EFGdje" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.6in">&#160;Other assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,429,443</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,880,048</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,657,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzyMU_zz6m0Z3jUxWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.6in">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,887,115</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,562,629</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,646,241</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maCzyMU_z1QWF9LQIEBf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.6in">Accrued expenses and other liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,903,947</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,675,008</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,107,947</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_uUSD_mtCzyMU_maCznNm_zkrbUkfKq7Qh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">159,470,335</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">165,697,595</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">106,811,781</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zLkvwipzHQVl" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--PaymentsToAcquireIntellectualPropertyLicense_i01N_di_msCzVCV_zxjaGFtzQzD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Payment for intellectual property license</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_uUSD_msCzVCV_msNCPBUzmFA_zWy6YHWGAHO7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Patent costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,390,834</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,441,989</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,105,407</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_uUSD_msCzVCV_msNCPBUzmFA_zHEyd2G309b3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Purchase of fixed assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">207,073</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,450,285</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">217,040</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_403_ecustom--IncreaseDecreaseInSecurityDeposit_i01_uUSD_maCzVCV_zoQ9EGUW3qIl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.3in">Payment of security deposit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="txmd:IncreaseDecreaseInSecurityDeposit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,420</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="txmd:IncreaseDecreaseInSecurityDeposit" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">175,410</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_uUSD_mtCzVCV_maCznNm_mtNCPBUzmFA_zWmOleZVCb6e" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash used in investing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,597,907</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">23,912,694</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,497,857</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zCWkfvqrMHDa" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ProceedsFromStockOptionsExercised_i01_uUSD_maCzHmj_maNCPBUzz91_zHo1r8OnG4C6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Proceeds from exercise of options and warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,678</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,656</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,666,208</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzz91_zQYznRnE4PW3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Proceeds from sale of common stock, net of costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,702,635</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,031,258</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,907,797</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromLinesOfCredit_i01_uUSD_maNCPBUzz91_zaqIDznMJFGd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Proceeds from Financing Agreement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfOtherLongTermDebt_i01_maNCPBUzz91_zMvl8R5mGdy7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Proceeds from Credit Agreement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PaymentsOfFinancingCosts_i01N_di_uUSD_msCzHmj_msNCPBUzz91_z2mCRspYxTah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.3in">Payment of deferred financing fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,250,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,652,270</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,786,918</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--RepaymentsOfLinesOfCredit_i01N_di_uUSD_msCzHmj_msNCPBUzz91_z0BIbp2OQ0d8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.3in">Repayment of Credit Agreement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,660,719</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_uUSD_maCznNm_mtNCPBUzz91_zDPCubcv1wZk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,724,313</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">188,826,925</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,787,087</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_uUSD_mtCznNm_zFqO9dNDKMk2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">(Decrease) increase in cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">80,343,929</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">783,364</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,477,449</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_uUSD_z8qW6HmVO5u4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 0.25in">Cash, beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">160,829,713</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">161,613,077</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,135,628</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_uUSD_zf19cSWu06l6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; padding-left: 0.25in">Cash, end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,485,784</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">160,829,713</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">161,613,077</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z90krIRFpSG3" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of cash flow information</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--InterestPaidNet_i01_uUSD_zzw2s0aMeMh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0.25in">Interest paid</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,849,236</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,787,903</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,890,166</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z7uNOhqg8AGb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Non-cash investing activity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--WarrantGrantedInRelationToFinancingAgreement_i01_uUSD_z7epOfyIaIY4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2pt; padding-left: 0.25in">Warrant granted in relation to Financing Agreement</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="txmd:WarrantGrantedInRelationToFinancingAgreement" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,668,161</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying
footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



<!-- Field: Page; Sequence: 86; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="txmdb005"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_80B_eus-gaap--NatureOfOperations_zTDSbu1RScr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline"><span>NOTE 1 &#8211; <span id="xdx_826_z2TojvhJBQk9">THE COMPANY</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TherapeuticsMD, Inc., a Nevada corporation,
or TherapeuticsMD or the Company, has <span id="xdx_90A_ecustom--NumberOfSubsidiaries_iI_dc_uN_c20201231_zQUiSrPNfplb" title="Number of subsidiaries"><ix:nonFraction name="txmd:NumberOfSubsidiaries" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">three</ix:nonFraction></span> wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or
vitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation,
or VitaCare. Unless the context otherwise requires, TherapeuticsMD, vitaMed, BocaGreen, and VitaCare collectively are sometimes
referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221; TherapeuticsMD<sup>&#174;</sup>,
vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>, BIJUVA<sup>&#174;</sup> and ANNOVERA<sup>&#174;</sup>
are registered trademarks of our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Nature of Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">We are a women&#8217;s
healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy
prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership
to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled,
long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also manufacture and distribute branded and
generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. Our portfolio of products focused on women&#8217;s
health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. During 2018, the
U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products has transitioned our company from predominately
focused on conducting research and development to one focused on commercializing our pharmaceutical products. In July 2018, we
launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal
pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched
our FDA-approved product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol
and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our FDA-approved
product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free,
reversible prescription contraceptive option for women. Although we expected to commence the full commercial launch of ANNOVERA
in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch
of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as the pandemic began to negatively affect our
revenue growth. We resumed the commercial launch of ANNOVERA on July 1, 2020. On July 30, 2018, we entered into an exclusive license
agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize
ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement,
with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and
BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply agreement, or the Theramex License
Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada
and Israel, or the Theramex Territory.</p>

</ix:nonNumeric><p id="xdx_81E_zRozT4xEbWMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zItv4Oy2b268" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 2 &#8211; <span id="xdx_829_zMY7YMirPiNd">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zbWuVh9adzo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zCCnWITYyUYi">Principles of Consolidation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of our company and our wholly owned subsidiaries, vitaMed, BocaGreen and VitaCare. All intercompany
balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="txmd:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_848_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxel2fnrUmS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zdZGAt846502">Risks and Uncertainties</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to be subject to risks and
uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues
to be highly uncertain and difficult to predict. We continue to provide an uninterrupted supply of our portfolio of products for
patients. We have sufficient inventory of finished product to meet anticipated demand in the near future. Additionally, we currently
do not foresee any interruption in our ability to continue to manufacture additional product to be used beyond this period and
have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products. During the year ended
December 31, 2020, we recorded an inventory charge of $<span id="xdx_90F_eus-gaap--InventoryWriteDown_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_z3beEO1Oq3Rb"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2020-01-012020-12-31_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,204,818</ix:nonFraction></span>&#160;which was primarily related to BIJUVA and resulted from the
impact of the COVID-19 pandemic on our business, which decreased demand for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the early phase of the COVID-19 pandemic,
we have been using substantial virtual options to ensure business continuity. Our VitaCare Prescription Services patient model
assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice,
including via home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple
third-party online pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time
access to both diagnosis and treatment. We continue to support prescribers&#8217; needs with samples and product materials through
our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for live virtual e-detailing of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of our response to the COVID-19
pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented cost saving measures, which included
negotiating lower fees or suspending services from third party vendors; implementing a company-wide hiring restriction; delaying
or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 87; Value: 3 -->
    <div id="xdx_23D_z5dBtQODEz24" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zMkkEFv5iLgl" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zxdmzYUnx8q1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full impact of the COVID-19 pandemic
continues to evolve. However, we remain committed to the execution of our corporate goals, despite the ongoing COVID-19 pandemic,
as demonstrated in part by the increase in product revenue throughout 2020. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity,
or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our operations by monitoring
the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic
has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression
that has occurred or may occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we currently believe that our COVID-19
contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of
the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity
of the pandemic, the duration of &#8220;social distancing&#8221; orders, the ability of our sales force to access healthcare providers
to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients,
thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are uncertain.
Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable
amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs
that we may undertake to address financial and operations challenges that we may face.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="txmd:LiquidityPolicyTextBlock"><p id="xdx_849_ecustom--LiquidityPolicyTextBlock_zBQndKwXmNy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zvBKo3cmFt66"><span style="text-decoration: underline">Liquidity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the filing date of this Annual
Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement (as defined in Note 8 -
Debt). On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement, or Amendment No.
6, with the Administrative Agent (as defined in Note 8 - Debt) and the lenders party thereto, pursuant to which we
temporarily lowered the minimum required cash balance from $<span id="xdx_907_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z6zi29hmeiHl"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">60</ix:nonFraction></span>
million to $<span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z8O7p4TL3t4e"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">45</ix:nonFraction></span> million through December 31, 2020. After December 31, 2020, the minimum cash balance reverted to $<span id="xdx_908_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201231_zHQCHcqSC1ej"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">60</ix:nonFraction></span>
million. Based on our current projections, and recent equity financings, we anticipate that we will remain in compliance with
the minimum cash balance covenant for the next twelve months from the issuance of these financial statements. In addition, we
have reviewed numerous potential scenarios in connection with the impact of COVID-19 pandemic on our business and we believe
that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary course of business for the next
twelve months from the issuance of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, if we are unsuccessful with the
commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if commercialization is delayed, or if the continued impact of the COVID-19
pandemic on our business is worse than we anticipate, our existing cash reserves may be insufficient to maintain compliance with
the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY,
BIJUVA, and ANNOVERA. The Financing Agreement also requires us to maintain certain minimum quarterly product net revenue requirements
and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA were revised. See Note 8 &#8211; Debt &#8211; for a description
of these covenants. These and other terms in the Financing Agreement have to be monitored closely for compliance
and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.
If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements,
or otherwise comply with the covenants of the Financing Agreement, all or a portion of our obligations under the Financing Agreement
may be declared immediately due and payable, which would have a material adverse effect on our business, results of operations
and financial condition.</p>

</ix:nonNumeric><p id="xdx_858_zLVm9OdIocal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQduWR076XSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_z0kdb43Ciy2g">Cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain cash at financial institutions
that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20201231_zQ3AOk9yMPC4" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per bank. We have never
experienced any losses related to these funds.</p>

</ix:nonNumeric><p id="xdx_85B_zuuw5lOMJAxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 88; Value: 3 -->
    <div id="xdx_23D_zxy0erBkjOg8" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_z6OhVIPgdc4d" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zKLil86ZXez2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"><p id="xdx_84A_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z0PXW0Wks4q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zoeKDk3UUjUg">Trade Accounts Receivable and Allowance
for Doubtful Accounts</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are customer
obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks
and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection
information, reasonable supportable forecasts, and existing economic conditions and we record an allowance that presents the net
amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent receivables against
our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances
of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful
accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves
may be required. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws,
coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption
associated with the current COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced
significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying
amount of trade receivables in the future. At December 31, 2020, four different customers represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeMcWBPAkK27" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zFblFmC1C4tf"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19</ix:nonFraction></span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJYlkjf6rLea"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zrz7FpodhDjb"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>% of
our gross accounts receivable. At December 31, 2019, four different customers represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zQd80LlYI9Lb"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zTuZYhyAeing"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%,<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zUl1Y7LTCLuh"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zwAnBdJ6IQNc"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>% of our gross accounts
receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock"><p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zr4gbPw0pdZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Allowance for Doubtful Accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%">Balance - January 1, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20200101__20201231_zkKUwDVtxyf2" title="Balance at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">904,040</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase in allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IncreaseInAllowanceForDoubtfulAccountsReceivable_c20200101__20201231_z2ElkvKerBU5" title="Increase in allowance" style="text-align: right"><ix:nonFraction name="txmd:IncreaseInAllowanceForDoubtfulAccountsReceivable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">422,137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Recoveries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_iN_di_c20200101__20201231_zqIFO0vWPGR5" title="Recoveries" style="text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">181,514</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Write-offs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20200101__20201231_zo2AETyNBur8" title="Write-offs" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,809</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance - December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20200101__20201231_z98bXEewnbJ6" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,117,854</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A6_zU3AskfXE1Nd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zA9T6GNGbCQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_866_zNPe8jcvuR3d">Inventories</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories represent pharmaceutical products,
packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products
are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for
excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value.
Obsolescence may occur due to product expiring, product improvements rendering previous versions obsolete, or decreases in demand
for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Pre-Launch Inventory</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-launch inventory costs associated with
product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial
use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined,
then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during
the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Inventory Write-Off</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate inventory quarterly for short
dated and excess inventory. During the years ended December 31, 2020 and December 31, 2019, we recorded an inventory charge of
$<span id="xdx_902_eus-gaap--InventoryWriteDown_c20200101__20201231_zfLrLmKKSFud" title="Inventory charge"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,204,818</ix:nonFraction></span>&#160;and $<span id="xdx_905_eus-gaap--InventoryWriteDown_c20190101__20191231_znwcXFB4i4a4" title="Inventory charge"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively. The charge recorded during the year ended December 31, 2020 was primarily related to BIJUVA
and resulted from the impact of the COVID-19 pandemic on our business, which decreased demand for our products.</p>

</ix:nonNumeric><p id="xdx_856_zfohqwWieDZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zLEBTqL1leIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zODjpnlN2nFa">Cost of Sales</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of sales includes the cost of inventory,
manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. The Population Council License
Agreement requires payment of royalties based on the sale of future products. Such royalties are recorded as a component of cost
of sales. Additionally, the amortization of license fees or milestone payments related to licensed products are classified as components
of cost of sales to the extent such payments become due in the future.</p>

</ix:nonNumeric><p id="xdx_850_zBo09VWnaBog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxr4m9jKAlg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_861_zqMgBOxm7Gkd">Fixed Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We state fixed assets at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives
of the related assets, which range from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zwStNlSSdvcc" title="Useful life of assets::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0588">three</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zQYPap4IV4Hh"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">seven years</ix:nonNumeric></span>. Leasehold improvements are depreciated over the shorter of their
useful life or the term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We capitalize software and software development
costs incurred to create and acquire computer software for internal use, principally related to software coding and application
development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable
that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized
in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into
service over the estimated useful life, generally <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zz4odzWls18g" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0590">five</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zXJarThY0hD4"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">seven years</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 3 -->
    <div id="xdx_231_zNttKjFkaMLl" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zrfVmjsxsXhb" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_z7jjTUArfpQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zCOuXAwCqboi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zHNQkewR0Dw8">Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted the provisions of Financial
Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, <i>Intangibles - Goodwill and Other</i>, or
ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications.
In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent
using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December
31, 2020, we had <span id="xdx_908_ecustom--NumberOfIssuedPatentsDomestic_iI_uN_c20201231_zUgBdjjhjVOi" title="Number of issued patents domestic."><ix:nonFraction name="txmd:NumberOfIssuedPatentsDomestic" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="N">38</ix:nonFraction></span> issued domestic, or U.S., patents and <span id="xdx_90A_ecustom--NumberOfIssuedPatentsForeign_iI_uN_c20201231_zaGjxEbi1Ww2" title="Number of issued patents foreign"><ix:nonFraction name="txmd:NumberOfIssuedPatentsForeign" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="N">39</ix:nonFraction></span> issued foreign patents (See Note 6). We capitalize external costs,
consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review
intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1pD2jkvUF3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_z9aHXGYIYrjg">Impairment of Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review the carrying values of fixed
assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate
that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant declines in an asset&#8217;s market price;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant deterioration in an asset&#8217;s physical condition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant changes in the nature or extent of an asset&#8217;s use or operation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant adverse changes in the business climate that could impact an asset&#8217;s value, including
adverse actions or assessments by regulators;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset&#8217;s use; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If impairment indicators are present, we
determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#8217;s carrying value
for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are
largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate
the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate
to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise
of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held
and used. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#8217;
fair value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based
upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform impairment tests for intangible
assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change
that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for
assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also evaluate the remaining useful life
of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment
or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining useful life is changed,
we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of indefinite-lived assets
is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment
test. During the years ended December 31, 2020 and 2019, we <span style="color: #212529">wrote off $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20200101__20201231_zXt7gpxpg4Qa" title="Write off of patent and trademark cost"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,131,776</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20190101__20191231_zWv3D9gcdwq8"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,864</ix:nonFraction></span>, respectively,&#160;in
costs related to trademarks and patents. </span>There was no impairment of intangible assets during the year ended December 31,
2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 3 -->
    <div id="xdx_238_zybYptwrIKEk" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zMgjYtO6ulIl" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_z3SEA0NtgEs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z38d8DPCPpkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86F_zlLEgNREqtec">Fair Value of Financial Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of December 31, 2020 and
2019 (as disclosed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value
Measurements, </i>or ASC 820<i>. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for
identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 1in; text-align: left"><b>Level 1</b></td><td style="text-align: justify">unadjusted quoted prices in active markets for identical
assets or liabilities;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 1in; text-align: left"><b>Level 2</b></td><td style="text-align: justify">quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 1in; text-align: left"><b>Level 3</b></td><td style="text-align: justify">unobservable inputs for the assets or liabilities.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2020 and 2019, we had no assets or liabilities
that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zBlBozfK2Pa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zjtSmTJjiblk">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize both interest and penalties
related to uncertain tax positions as part of the income tax provision. At December 31, 2020 and 2019, we had no tax positions
relating to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our U.S. federal and state tax returns
since 2011, which was the first year we generated net operating losses, remain open to examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_ziINyPlLXYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_zk32UZu6u9Sh">Share-Based Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, <i>Compensation-Stock Compensation</i>, to value
options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our stock-based
awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January 1, 2020, the average
expected life of options was based on the contractual terms of the stock option using the simplified method. We utilize a dividend
yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. In
addition, the terms of the Financing Agreement (See Note 8) preclude us from paying dividends, and any future debt agreements may
also preclude us from paying dividends. The assumptions used in calculating the fair value of stock-based awards represent our
best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.
We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance
with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 91; Value: 3 -->
    <div id="xdx_232_zzEkiCy8GmBd" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zDbtIYcP6MX9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_ztGZug1vlzre" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We grant restricted stock units and performance-based
stock units for shares of common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20201231_z2GxITWehrV5"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, or Common Stock, to employees. We value our restricted stock
units and our performance-based stock units by reference to our stock price on the date of grant. We recognize compensation expense
for restricted stock units based on a straight-line basis over the requisite service period of the entire award. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the performance restricted stock vests. The number
of target shares that vest are determined based on the level of attainment of the targets. If a minimum level of performance is
attained for the awards, restricted stock is issued based on the level of attainment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgShP7jOATyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_860_zQ2ipGElfXOj">Revenue Recognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 606,&#160;<i>Revenue
from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer obtains control of promised goods or services.
The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these
goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the
transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for
those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify
the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance
obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Prescription Products</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: #212529">As of December
31, 2020, </span>our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began
selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we
began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed
the commercial launch of ANNOVERA on July 1, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our name brand and generic prescription
products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription
products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations
related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service
for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription
product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or
service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the
customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on
our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional.
We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services
sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price of a contract is
the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will
not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that
supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and
the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ
from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would
affect net product revenue and earnings in the period such changes in estimates become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 3 -->
    <div id="xdx_232_z5lkKebbvSjk" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zYW2dmN2upve" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zlhofrmViBzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of six months prior to and up to <span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z3ySKQtvDA47" title="Return period of unsalable prescription products"><ix:nonNumeric contextRef="From2020-01-012020-12-31_srt_MaximumMember" format="ixt-sec:durmonth" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">12</ix:nonNumeric></span>
months following product expiration. ANNOVERA cannot be returned before the expiration date and expired ANNOVERA can be
returned up to <span id="xdx_909_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zmR0T8rgRole"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_AnnoveraMember" format="ixt-sec:durmonth" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">12</ix:nonNumeric></span>
months past the expiration date. Our prescription vitamins, IMVEXXY and BIJUVA currently have a shelf life of <span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--VitaminsImvexxyAndBijuvaMember_zT2KiZyFAJs3" title="Shelf life of prescription products"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_VitaminsImvexxyAndBijuvaMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">24</ix:nonNumeric></span>
months from the date of manufacture and ANNOVERA currently has a shelf life of <span id="xdx_908_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zzAsj5sOc8Ha"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_BijuvaAndAnnoveraMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">18</ix:nonNumeric></span>
months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of product revenue in the period the related product revenue is recognized. Where historical rates of return exist,
we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched
products, for which the right of return exists but for which we currently do not have history of product returns, we estimate
returns based on available industry data, our own sales information and our visibility into the inventory remaining in the
distribution channel. At the end of each reporting period, we may decide to constrain product revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the
expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic
products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the
customer&#8217;s consideration. Since our returns primarily consist of expired and short dated products that will not be
resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the
initial sale (when recognition of product revenue is deferred due to the anticipated return). Return estimates are recorded
in other current liabilities on the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We offer various rebate and discount programs in an effort to maintain
a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates
and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on
a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenue at the time the product
revenue is recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor
fees are recorded in other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units
sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors
fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates
relating to invoice discounts and chargebacks are deducted from gross product revenue at the time the product revenue is recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of commercial launches for our
FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket
costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with
our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. The variable consideration
is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average
assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time
up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription
products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain
variable consideration for our prescription products to an amount that will not result in a significant product revenue reversal
in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates
of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by
insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently
available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 93; Value: 3 -->
    <div id="xdx_23C_z9LJt1ms1z09" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zKQCAeFQ7Kgd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zrkY4TcP2FDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIeQdb0LePU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Prescription vitamins</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zIUJyq1Gpgyb" title="Net revenue" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,767,644</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zm4kXwTPfFzb" title="Net revenue" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,885,493</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zRSEpLOd3G4l" title="Net revenue" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,041,259</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zJfE6V5ja3Mc" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,139,387</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zVZkVbCvPFNg" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,252,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zvBbyNZlnXLl" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,058,201</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGYUHrnBZE1" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,353,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zLSGvlHRufNg" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,836,443</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--BijuvaMember_z1JXyWuYn72d" title="Net revenue" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayMzasE8eb6" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,611,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zYvSCX7ojjG8" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,166,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zjpw8uaRoM46" title="Net revenue" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zydUwtLaPfM1" title="Net revenue" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zEuVRJerfvu7" title="Net revenue" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSl8MRsNl7Jf" title="Net revenue" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_zQyorgOoNb95" title="Net revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">64,872,280</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_z2VgHc6SD9Wj" title="Net revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,646,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z9pXHF47yUB2" title="Net revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,099,460</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zf7LBTNOj0Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><i><span style="text-decoration: underline">License Revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front
fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the right to use functional intellectual property is transferred to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">License Agreement with the Population
Council</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2018, we entered into the Population
Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a &#8220;test and learn&#8221; market
introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. <span style="color: #212529">We
resumed the commercial launch of ANNOVERA on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Population Council
License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNmM0XbdrIkf" title="Milestone payment upon FDA Approval"><ix:nonFraction name="txmd:MilestonePaymentUponFDAApproval" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>&#160;within 30 days following the approval
by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_902_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRlIviFCHJSa" title="Milestone payments (payment after release of first commercial batch)"><ix:nonFraction name="txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>&#160;within 30 days following the first commercial
batch release of ANNOVERA. Both milestone payments of $<span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zHvxx9ISU3ic" title="License rights acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction>&#160;</span>were recorded as license rights in the consolidated balance
sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became commercially available for use.
The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our
cash flows, which is estimated to be the remaining patent life of the product, which expires as early as December 2032. The cost
is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the years
ended December 31, 2020 and 2019 we recorded $<span id="xdx_908_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20201231_zU0ennHdqNG" title="Amortization of intellectual property license fee"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,024,391</ix:nonFraction></span>&#160;and $<span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20191231_zoFDDXXJ6XF8" title="Amortization of intellectual property license fee"><ix:nonFraction name="txmd:AmortizationOfIntellectualPropertyLicenseFee" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">778,692</ix:nonFraction></span>, respectively, in amortization expense related to the
license fee which was recorded as a component of cost of sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Population Council is also eligible
to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible for marketing expenses related
to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based
royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as
follows: (i) if annual net sales are less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zB1xl9STslZj" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="-2" unitRef="USD">50,000,000</ix:nonFraction></span>, a royalty of&#160;<span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zHDWWmUGwgea" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of net sales; (ii) for annual net
sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zT2XmmFVoWge" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="-2" unitRef="USD">50,000,000</ix:nonFraction></span>&#160;and less than or equal to $<span id="xdx_90E_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zTAI4ux2XhT6" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="-2" unitRef="USD">150,000,000</ix:nonFraction></span>, a royalty of&#160;<span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zC6XNUaPEozh" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of such net sales; and (iii)
for net sales greater than $<span id="xdx_90A_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zt1yVxYQsZOk"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="-2" unitRef="USD">150,000,000</ix:nonFraction></span>, a royalty of&#160;<span id="xdx_90A_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zBs9xrl0NxU4" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of such net sales. The annual royalty rate will be reduced to&#160;<span id="xdx_90D_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zQetXhTVEaka" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent
of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to&#160;<span id="xdx_908_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zXp9UntycC9i" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>%
of the initial rate. We are required to pay the Population Council milestone payments of $<span id="xdx_902_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRb6ERjPJGr9" title="Milestone payments upon specified levels of cumulative net sales"><ix:nonFraction name="txmd:MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">40</ix:nonFraction></span>&#160;million&#160;upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $<span id="xdx_904_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z0nEr1VekSOf" title="Specified level one of cumulative net sales for milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">200</ix:nonFraction></span>&#160;million, $<span id="xdx_906_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zTUERTX9tZt7" title="Specified level two of cumulative net sales for milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">400</ix:nonFraction></span>&#160;million&#160;and
$<span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zUELoe4agUhi" title="Specified level three of cumulative net sales for milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="-9" scale="9" unitRef="USD">1</ix:nonFraction></span>&#160;billion. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval
studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such
post-approval study exceed $<span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z4kNf57Lbi3k" title="Maximum costs and expenses for post approval"><ix:nonFraction name="txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid" contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>, half of such excess will be offset against royalties or other payments owed by us to the
Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a joint product
committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible for all
aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired
clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.
The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational
vaginal contraceptive systems in development by the Population Council.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 94; Value: 3 -->
    <div id="xdx_230_zzcJUoyucJGb" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zTYh4aZq3sSf" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_za5nXEt5MQU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless earlier terminated, the Population
Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#8217;s
U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during
which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may
also be terminated for certain breach and bankruptcy-related events and by us on 180 days&#8217; prior notice to the Population
Council.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="text-decoration: underline">License Agreement with Knight Therapeutics
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2018, we entered into the Knight
License Agreement pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.
Pursuant to the terms of the Knight License Agreement, Knight paid us $<span id="xdx_90D_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zUD7dpRngPs2"><ix:nonFraction name="txmd:MilestonePaymentReceivedUponRegulatoryApproval" contextRef="From2020-01-012020-12-31_custom_KnightLicenseAgreementMember_custom_BijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> in milestone fees upon the first regulatory approval
in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is required to pay us sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory
applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in
Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain
specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement,
Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="text-decoration: underline">License Agreement with Theramex</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: #212529">On June
6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR <span id="xdx_900_ecustom--CashUpfrontPaymentReceived_pn6n6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zJCFLkOukmJf" title="Cash upfront payment received"><ix:nonFraction name="txmd:CashUpfrontPaymentReceived" contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="EUR">14</ix:nonFraction></span>
million, or $<span id="xdx_902_ecustom--CashUpfrontPaymentReceived_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z92lh37so5V4" title="Cash upfront payment received"><ix:nonFraction name="txmd:CashUpfrontPaymentReceived" contextRef="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,506,400</ix:nonFraction></span>,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_909_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_z7IqI8sc6G2c" title="Regulatory milestone payments"><ix:nonFraction name="txmd:RegulatoryMilestoneAdditionalPayment" contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">2</ix:nonFraction>
million</span> in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR <span id="xdx_900_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zoyAeZAvCZb8" title="Sales milestone payment"><ix:nonFraction name="txmd:SalesMilestonePaymentsInTranches" contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">27.5</ix:nonFraction>
million</span> in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory
ranging from EUR <span id="xdx_909_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zcUhRqEMr4S6" title="Sales milestone"><ix:nonFraction name="txmd:AnnualNetSalesMilestone" contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="EUR">25</ix:nonFraction></span>
million to EUR <span id="xdx_904_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zAacOzdvIPjd" title="Sales milestone"><ix:nonFraction name="txmd:AnnualNetSalesMilestone" contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="EUR">100</ix:nonFraction></span>
million. We are also entitled to receive quarterly royalty payments at a rate of <span id="xdx_909_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_uPure_c20190506__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zq6e23cqcAxe" title="Quarterly royalty payments percentage"><ix:nonFraction name="txmd:QuarterlyRoyaltyPaymentsPercentage" contextRef="From2019-05-062019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
on net sales of BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory. Theramex is responsible for
all regulatory and commercial activities for BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all
regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA
and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex
challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party
that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zenh362Wo67i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zv3nAQnaW9M8">Segment Reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single executive leadership team that is led by the Chief Executive Officer of our Company, who oversees all operations. We do
not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information
with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business
as one reportable operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="txmd:ShippingAndHandlingCostsPolicyTextBlock"><p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zxpqbr2bmcbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86B_zmyttqWPgYYk">Shipping and Handling Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_84E_eus-gaap--AdvertisingCostsPolicyTextBlock_zdhmPYMiEK52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zyINHvbwxSv4">Advertising Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $<span id="xdx_90F_eus-gaap--AdvertisingExpense_c20200101__20201231_zJaZR6tmsl89" title="Advertising expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,799,313</ix:nonFraction></span>, $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20190101__20191231_z2WkwD8JFvA" title="Advertising expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,045,571</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--AdvertisingExpense_c20180101__20181231_zTk92CW5pAXb" title="Advertising expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,682,746</ix:nonFraction></span> during the years ended December 31, 2020, 2019, and 2018, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 3 -->
    <div id="xdx_237_zpLSD5CRzrB" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zE2V14bG75Hd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zmIPTdNeThZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbIx9lxZUof7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zs115znl8Fgd">Research and Development Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development, or R&amp;D, expenses
include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory
supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory
experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken
by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house
staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking
work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations
as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.
We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity
has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses
and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion
stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion.
We charge revisions to expenses in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGxe5iUgOs2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86C_zY8NoTbthJw6">Earnings Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We calculate earnings per share, or EPS,
in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic
and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period.
We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options,
warrants and restricted stock units and were excluded from the calculation of diluted earnings per share because their effect would
have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could
affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zxZw0sPuvJN4" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.5in">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Stock options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuoTVoVLv1X4" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,781,930</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA3iPFU4QS93" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,030,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zln2FQ1cG1xg" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,872,824</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6a7Q8G2kyz" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,534,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAcN8G1ZGnC" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,832,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrW6K1PYpl3j" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,007,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zw7hkCKqtWXe" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_custom_PerformanceStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,403,951</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zeOF1BJWYdDj" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuGGGXBHxbSc" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCzVK1LkrEla" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,061,024</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziCDxmGKrzz3" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7UbyYPGZJCl" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,040,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231_zJ9z974o0Fec" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,781,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231_zEaiLOIhKlld" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,102,805</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231_ziJUIS60zymh" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,920,395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zZpXowcWtFb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_z2CF8RaRZ6B4">Concentration of Credit Risk and other
Risks and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially
expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial
institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not
experienced any historical losses on our deposits of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of credit risk with respect
to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors.
Credit is extended to our customers based on an evaluation of a customer&#8217;s financial condition, and collateral is not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_845_eus-gaap--UseOfEstimates_zSN8ER4xhn9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_z9q28YO8Zn8d">Use of Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 96; Value: 3 -->
    <div id="xdx_23C_ziaaiNkSZ7yj" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zYIj5p6b6lpa" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zat2dlFU4To6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znmqU4R9pzrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zhOmlAltG07g">Recently Issued Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In March 2020, the FASB
issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference
Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting
impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank
Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally,
contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment
of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022.
Our debt agreements currently include the use of alternate rates when LIBOR is not available. We do not expect the change from
LIBOR to an alternate rate will have a material impact to our financial statements and, to the extent we enter into modifications
of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In August 2018, the FASB
issued ASU 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public
entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting
Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness
of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information
to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December
15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or
only the provisions that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not
have a material effect on our disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In June 2016, the FASB
issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments.
The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be
presented at the net amount expected to be collected based on historical experience, current conditions, and reasonable supportable
forecasts. The amendments in this update are effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the first quarter of 2019.
A modified retrospective approach is required for all investments, except debt securities for which an other-than-temporary impairment
had been recognized prior to the effective date, which will require a prospective transition approach and should be applied either
prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13 requires expanded quantitative
and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January 1, 2020, we adopted ASU 2016-13
under a modified retrospective approach for all financial assets measured at amortized cost. There was no adjustment recorded for
the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">Other recent accounting
pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants
and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</p>

</ix:nonNumeric><p id="xdx_854_zxqwplGFy472" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zajTsxMknFXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 3 &#8211; <span id="xdx_825_zwwj3ViuRwyj">INVENTORY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z4VIWKaJ1hnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zGhhd5wdffZa">Inventory consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zmsSAMGBKAy9" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20191231_zIAXW9h947I8" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzQbM_maINzicc_zTwzl9zMR9lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Finished products</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,350,580</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,976,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzQbM_maINzicc_z6ccfz20W1y2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,182,059</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzQbM_maINzicc_zxy3xVRWrBDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,422,589</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,701,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryNet_iTI_uUSD_mtINzQbM_mtINzicc_zj3NQdbZOL56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,993,087</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,860,716</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_zBhj3909m1Ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_819_zBvgKpj7nJAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 97; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_804_eus-gaap--OtherCurrentAssetsTextBlock_zsdeEMek8hk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 4 &#8211; <span id="xdx_82E_zj6xO6iAAHJ6">OTHER CURRENT ASSETS</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zyDotqxUZZjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_z3E7SUgITetf">Other current assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zWlfmIhVR7h5" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20191231_zaPuNRXP6zbe" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_405_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zTX1UGrHOIDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Prepaid sales and marketing costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,308</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,583,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_maPEAOAzRrD_zWdzxiUe5Nw1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt financing fees on undrawn tranches (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_maPEAOAzRrD_zV5AAuUETA53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,568,269</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,812,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_maPEAOAzRrD_zPdNfb7f2uod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,331,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,595,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zbM6X4J7YOFk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,639,720</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,787,482</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_mtPEAOAzRrD_zWmZJ6fH1651" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,543,397</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,329,793</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_zwVTX4gg8gGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_817_z1lBOtDKKoF8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEdVbqz1aUZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 5 &#8211; <span id="xdx_828_zus5oAUiLXD7">FIXED ASSETS, NET</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwalxkNjwlpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B3_zpzb2OwFhoZ4">Fixed assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20201231_zJIfVFMJGDmk" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20191231_zpgoHHfaLpb7" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Accounting system</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zXVawOStxG4d" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">411,550</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zm9EPO4CUHbk" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_znRbalwMXMfg" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,704,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zPIVpZNZNZac" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zwDDCVnUTvF7" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,406,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmrLBXnu01Rb" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,406,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zFRX5JHfIGq5" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zBAJ6spUyCOd" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zvn7rxfAzVGc" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,121</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zebvqVsbkxsi" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,788</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_zHwmcCITGIVc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,683,671</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,476,599</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20201231_zaTLGDdVBvm2" title="Accumulated depreciation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,741,447</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_zHp8qjyh7OHj" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">968,824</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_zlvcHLtLDnNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,942,224</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,507,775</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_zM3luYgKygP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense for the years ended December 31, 2020,
2019, and 2018 was $<span id="xdx_90D_eus-gaap--Depreciation_c20200101__20201231_zS1VPS1vozdg"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772,624</ix:nonFraction></span>, $<span id="xdx_909_eus-gaap--Depreciation_c20190101__20191231_zRbjcLOUYLJ1"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,193</ix:nonFraction></span>, and $<span id="xdx_903_eus-gaap--Depreciation_c20180101__20181231_zF184FoseAS6"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,412</ix:nonFraction></span>, respectively.</p>

</ix:nonNumeric><p id="xdx_814_zeHSUIeifpNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_801_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zKVHVcTGWZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 6 &#8211; <span id="xdx_82D_zJtKxGSrqsl1">INTANGIBLE ASSETS, NET</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z4clAvQB88J8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B4_z8NdkXyYT5Xc">The following table sets forth the gross carrying amount, accumulated
amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross<br />
Carrying<br />
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated<br />
Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net<br />
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted-</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average<br />Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Amortization</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Period (yrs.)</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Approved hormone therapy drug candidate patents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zSYuKPdQIVDd" title="Finite-Lived Intangible Assets, Gross" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,044,552</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zALv2sZjcEfe" title="Finite-Lived Intangible Assets, Accumulated Amortization" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">748,627</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHAO8XCZRci2" title="Finite-Lived Intangible Assets, Net" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,295,925</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlsvJLAC4KM7" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">12</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z8bRYnrmuxok" title="Finite-Lived Intangible Assets, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,628,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zc3zWfX2t3Qb" title="Finite-Lived Intangible Assets, Net" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,628,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zdVboSaMaXWj" title="Indefinite-Lived Trademarks" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2020-12-31_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">323,341</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zqphpEFgOJJa" title="Indefinite-lived Intangible Assets (Excluding Goodwill)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2020-12-31_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">323,341</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zDv0mJvaJSk9" title="Intangible Assets, Gross (Excluding Goodwill)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,996,350</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231_zR3YedimwWm7" title="Finite-Lived Intangible Assets, Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">748,627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zP2E2mjJ1Due" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,247,723</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 3 -->
    <div id="xdx_232_zRV5oIqUyW38" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zAG4a0q4cf6c" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zGr9QCdBMMv6" style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross<br />
Carrying<br />
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated<br />
Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net<br />Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted-</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average<br />Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Amortization</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Period (yrs.)</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zKnJASx50b3l" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,463,082</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxvVB9iunx1f" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">478,983</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zReVzPUfDAE5" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,984,099</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z7kwhX16V0ng"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">13</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zk3uT2fprYog" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,979,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z6mTdKWmF8Rj" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,979,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zR8Me2QAcuwk" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zwrOWh3L3gqk" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zVTewfUNILE3" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,737,194</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zraYe4cYgmJf" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">478,983</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_z3ErTi9gGA5e" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,258,211</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_z7k1K2akQEU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We capitalize external costs, consisting
primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone
therapy drug candidate patents using the straight-line method over the estimated useful life of approximately <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zr99z1YZYDPe"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> years, which is
the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time.
Trademarks are perpetual and are not amortized. During the years ended December 31, 2020 and 2019, we <span style="color: #212529">wrote
off $<span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0i_c20200101__20201231_zwHJkluFg3Uj"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,131,776</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0i_c20190101__20191231_zp3BudRUttAi"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,864</ix:nonFraction></span>, respectively,&#160;in costs related to trademarks and patents. </span>There was no impairment of intangible
assets during the year ended December 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, we had <span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zb84hNxk4FZj" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUSPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="N">38</ix:nonFraction></span> issued
domestic patents and <span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zQ3GEY3Tbpy4" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_ForeignPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="N">39</ix:nonFraction></span> issued foreign patents, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zE7TGDHXeao2" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticPatentsBijuvaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="N">15</ix:nonFraction></span> domestic patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zyesTFzuOuTd" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_ForeignPatentsBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">nine</ix:nonFraction></span> foreign patents that relate to BIJUVA as well as <span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zcvIvUiInO1k"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticPatentsNonApprovedBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">three</ix:nonFraction></span> domestic patents
that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation
and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel,
Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zVwtAja4g67f" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUSPatentsImvexxyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="N">12</ix:nonFraction></span> domestic patents (<span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zGVAz1QFsWyg" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUSUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">ten</ix:nonFraction></span> utility and <span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zbnT7XnsLmH7" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUSDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">two</ix:nonFraction></span> design) and <span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zIWLh9HLxNVe"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_ForeignPatentsImvexxyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="N">18</ix:nonFraction></span> foreign patents (<span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zqPNDL7iLvYi" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_ForeignUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">eight</ix:nonFraction></span> utility and <span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z6jnUS6IcUPh" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_ForeignDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">ten</ix:nonFraction></span>
design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned
by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign
design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection
through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil,
Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_zk4t8lH5kPj" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">One</ix:nonFraction></span> domestic utility patent that relates to our topical-cream candidates, which is owned by us.
The domestic patent will expire in 2035;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zmitEfPyOK3f" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">One</ix:nonFraction></span> domestic utility patent and <span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zrGKH3tQ6Is" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_ForeignUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">eight</ix:nonFraction></span> foreign patents that relate to our transdermal-patch candidates,
which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We
have a pending patent application with respect to our transdermal-patch candidates in Brazil;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zf050oudVsD3" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentTx009HRMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">Three</ix:nonFraction></span> domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate,
which are owned by us and will expire in 2037;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zCmiPjTgtIq8" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">Two</ix:nonFraction></span> domestic and <span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zySWeuiKXGy" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_ForeignPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">four</ix:nonFraction></span> foreign patents that relate to formulations containing progesterone, which
are owned by us. The domestic patents will expire between 2032 and 2036. The foreign patents will expire no earlier than 2033.
In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Australia, Canada,
Europe, and Mexico; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zPGQ1AFmuwK3" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentOperaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">One</ix:nonFraction></span> domestic utility patent that relates to our OPERA information-technology platform, which is
owned by us and will expire in 2031.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 99; Value: 3 -->
    <div id="xdx_232_zvhA5kd7AK2c" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zQXHUqkx6rD9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zOkQf0r7fOLa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Amortization
expense was $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20201231_zD2ORwFbcPEa"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">269,546</ix:nonFraction></span>, $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20190101__20191231_z1SPBGHDSzl5"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">197,593</ix:nonFraction></span>, and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20180101__20181231_zkaSaHWfOPJg"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,474</ix:nonFraction></span> for the years ended December 31, 2020, 2019, and 2018, respectively.</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z33kdLUjHoci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span>Estimated amortization
expense, based on current patent cost being amortized, for the next five years is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20201231_z1JUp7oWRApk" style="border-bottom: Black 1pt solid; text-align: center">Estimated Amortization</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zZyWjdNjBbcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: right">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,669</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zj5ls5NSbUHl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,669</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zozl23CkGf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,669</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zXrb5arYeYK8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,669</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zY4MKUsYBGvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,669</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_zA8ImBbyKVl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_817_zjqsS61gNlee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zWTtJcOhdnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 7&#8211; <span id="xdx_82B_zlEeOlBd5rY2">OTHER CURRENT LIABILITIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock"><p id="xdx_89A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zWFG7m1cBZL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B0_z0igxA9SVRpb">Other current liabilities</span> consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_z1xo8tvfSIge" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20191231_zWIqwsQfSZPe" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zaTCBg7RazSi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Accrued payroll, bonuses and commission costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,758,073</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,040,278</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zeyV3oadnasd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,770,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,316,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zNcBXHLzhL6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,285,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zhYdjdiDEsF5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,353,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,463,878</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_zQ7aXpeBqyMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,632,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,347,122</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zMwLBfP5Q63d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">898,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zIPy0XfuYiHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">925,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zBo2rNF1j4zj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,253,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,501,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--AccruedRebates_iI_maOLCz3D1_z9a5LrouC4Vl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,010,588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,916,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zZe36SEC1cHe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,339,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,480,225</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_mtOLCzij0_z5oEs5EK70W1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,169,869</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,823,613</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zaOWz2G0v393" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_81E_znyykLZbVns5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_809_eus-gaap--LongTermDebtTextBlock_z0Lc13j7mEA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE
8 &#8211; <span id="xdx_828_z7KQ3ZogzQ47">DEBT</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2019, we entered into a
Financing Agreement, as amended, or the Financing Agreement, with Sixth Street Specialty Lending, Inc., as administrative
agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party
thereto from time to time as guarantors, which provided us with up to a $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zT0AXzKGg7Vi"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000,000</ix:nonFraction></span>&#160;first
lien secured term loan credit facility, or the Facility. The Facility provided for availability to us in three tranches: (i)
$<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zpthIp6Cwi0b"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span>&#160;was
drawn upon entering into the Financing Agreement; (ii) $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zsyWnBAMTlqi"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>&#160;was
drawn on February 18, 2020 following our achievement of more than $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0i_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zdKLAwDNebQf" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000,000</ix:nonFraction></span>&#160;in
net revenues from IMVEXXY, BIJUVA, and ANNOVERA for the fourth quarter of 2019 and (iii) <span id="xdx_90E_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zhlT40GNMH74">$<ix:nonFraction name="txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>&#160;was
previously available to us in the Administrative Agent&#8217;s sole and absolute discretion either contemporaneously with the
delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as the Administrative Agent
may have consented to. Subsequent to the pause in the successful full launch of ANNOVERA caused by the COVID-19 pandemic, the
undrawn $<span id="xdx_90E_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zXcnPtbRWxn"><ix:nonFraction name="txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction> </span>tranche
under the Financing Agreement is no longer available. Borrowings under the Facility accrue interest at either (i)&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zPVeV0wuGvT2"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">3-month
LIBOR</ix:nonNumeric></span>&#160;plus&#160;<span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3dms8Czlin3"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span>%,
subject to a LIBOR floor of&#160;<span id="xdx_90E_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zMjzo8Midjnf"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.70</ix:nonFraction></span>%
or (ii) the&#160;<span id="xdx_906_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zHBzFBbDJ7y2"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">prime
rate</ix:nonNumeric></span>&#160;plus&#160;<span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zxSSBmgdEwab"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.75</ix:nonFraction></span>%,
subject to a prime rate floor of&#160;<span id="xdx_907_ecustom--PrimeRateFloor_iI_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zAS0ri0fVuc1"><ix:nonFraction name="txmd:PrimeRateFloor" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.2</ix:nonFraction></span>%
as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. Prior to entering into Amendment No.
8, the outstanding principal amount of the Facility was payable in&#160;<span id="xdx_907_ecustom--NumberOfInstallmentPayments_iI_dc_uN_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zxNsII45QZWi"><ix:nonFraction name="txmd:NumberOfInstallmentPayments" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">four</ix:nonFraction></span>&#160;equal
quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. In connection with Amendment
No. 8 we, among other things, (i) repaid $<span id="xdx_905_eus-gaap--RepaymentsOfLinesOfCredit_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDXzbY67F1Eh"><ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15</ix:nonFraction></span>.0
million in principal under the Financing Agreement on such date, plus a <span id="xdx_909_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0MgY7Uekn96"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>%
prepayment fee, (ii) agreed to repay an additional $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodOneMember_zMKCEXLiRjDd" title="Principal repayment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodOneMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">35</ix:nonFraction></span>.0
million in principal by no later than March 31, 2021, plus a <span id="xdx_90C_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodOneMember_zGuOlDVYVIxc"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>%
prepayment fee, and (iii) agreed to make additional principal repayments as follows: (x) $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodTwoMember_z25NpNlTyoCj"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodTwoMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5</ix:nonFraction></span>.0
million on each of March 31, 2022, June 30, 2022 and September 30, 2022; (y) $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodThreeMember_zB8ECcvYo9je"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodThreeMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10</ix:nonFraction></span>.0
million on each of December 31, 2022 and March 31, 2023; and (z) $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn4n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodFourMember_zBNRx6eCQbCh"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFourMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">41.25</ix:nonFraction></span>
million on each of June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, plus the prepayment fees
described in the following sentence. We have the right to prepay borrowings under the Facility in whole or in part at any
time, subject to a prepayment fee on the principal amount being prepaid, which was revised in connection with Amendment No.
8, of (i) <span id="xdx_908_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodFiveMember_zrqBEU9y1o61"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.0</ix:nonFraction></span>%
of the principal amount being repaid through March 31, 2022 (excluding the scheduled $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSixMember_zR8lTtRCB5Ik"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSixMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5</ix:nonFraction></span>.0
million principal repayment on such date, which is subject to a <span id="xdx_908_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSixMember_z54PxhVRbOhc"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSixMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>%
prepayment fee); (ii) <span id="xdx_900_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSevenMember_zwTMAbnLn6wk"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>%
of the principal amount being repaid from April 1, 2022 through March 31, 2023; (iii) <span id="xdx_90F_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodEightMember_zAyMpw7mPmJk"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodEightMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>%
of the principal amount being repaid from April 1, 2023 through March 31, 2024; and (iv) thereafter, none, in each case
subject to certain limited exceptions, including with respect to a repayment in full of the obligations under the Financing
Agreement. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility
fee equal to&#160;<span id="xdx_900_ecustom--FacilityFeePaidPercent_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z21h4l8uOn5i"><ix:nonFraction name="txmd:FacilityFeePaidPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>%
of the initial amount borrowed and were required to pay such a facility fee in connection with subsequent borrowings under
the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition
to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants
applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a
minimum unrestricted cash balance of $<span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z1AjjsD6Du04"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000,000</ix:nonFraction></span>,
and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and
ANNOVERA products beginning with the fiscal quarter ended December 31, 2020. Pursuant to Amendment No. 8, the minimum
consolidated net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised to (i)
$<span id="xdx_90C_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period1Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zFPcOQ5sNoQ2"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">17</ix:nonFraction></span>.0
million, $<span id="xdx_906_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period2Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zzw9yTflbxr6"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">20</ix:nonFraction></span>.0
million, $<span id="xdx_906_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period3Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zGYPtvUkiZwe"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period3Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">23</ix:nonFraction></span>.0
million, and $<span id="xdx_908_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period4Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_z4Ku9yQcdFw2"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period4Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">26.5</ix:nonFraction></span>
million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $<span id="xdx_900_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period5Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zgtcrDt0j6F7"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period5Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">30</ix:nonFraction></span>.0
million, $<span id="xdx_90B_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period6Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zQLwyBo9FNV6"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period6Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">35</ix:nonFraction></span>.0
million, $<span id="xdx_90A_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period7Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_z3x0ztv50Mfb"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period7Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">40</ix:nonFraction></span>.0
million and $<span id="xdx_905_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period8Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zDk7k2am9BRb"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period8Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">45</ix:nonFraction></span>.0
million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $<span id="xdx_90B_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period9Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zNtl5cfKYZPa"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period9Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">50</ix:nonFraction></span>.0
million, $<span id="xdx_909_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period10Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zeCtuhVGyR99"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period10Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">55</ix:nonFraction></span>.0
million, $<span id="xdx_90E_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period11Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zakn57nHjtud"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period11Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60</ix:nonFraction></span>.0
million and $<span id="xdx_902_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period12Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zg5BaqQj9XUg"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period12Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">65.5</ix:nonFraction></span>
million for the first, second, third, and fourth quarters of 2023, respectively, and (iv) $<span id="xdx_90C_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period13Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zXpp1CJAd8r4"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period13Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">70</ix:nonFraction></span>.0
million for the first quarter of 2024. Pursuant to Amendment No. 6 (as defined below), the minimum required cash balance was
lowered to $<span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_znJdXV3fEqu2"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">45</ix:nonFraction></span>
million from November 8, 2020 through December 31, 2020. As of December 31, 2020, we were in compliance with all covenants
under the Financing Agreement. The Financing Agreement also includes other representations, warranties, indemnities,
restrictions on the payment of dividends, and events of default that are customary for financings of this type, including an
event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent
and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and
payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and
its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon
exceptions, by a first priority perfected security interest in all existing and after acquired assets of our company and its
subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect
subsidiaries, subject to certain exceptions. Also pursuant to Amendment No. 8, the Administrative Agent consented to a
framework for our potential disposition of our vitaCare prescription services business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 100; Value: 3 -->
    <div id="xdx_238_zRCvBEuFBAwh" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_zRXnyymOF0T3" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zhW0XVBMHBKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2020, we entered into
Amendment No. 5 to the Financing Agreement, or Amendment No. 5. Amendment No. 5 adjusted the covenant in the Financing
Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our IMVEXXY,
BIJUVA, and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant was effective beginning with
the fiscal quarter ending December 31, 2020. In connection with Amendment No. 5 and in lieu of a cash amendment fee, we
issued to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zI61F8GEjRN2" title="Number of warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-08-05_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,752,116</ix:nonFraction></span>
shares of Common Stock with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z5GIH5eJwp6j" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-05_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></span>
per share and a ten-year term, or the Lender Warrants. The Lender Warrants were issued pursuant to an exemption from
registration under the Securities Act of 1933, as amended, and no registration rights were issued. The Company concluded that
the modification accounting model is applicable to this transaction and recognized the fair value of the warrants as a debt
discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 8, 2020, in connection with
entering into Amendment No. 6 to the Financing Agreement, or Amendment No. 6, we amended the Lender Warrants to provide for an
adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted
average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise
price. Pursuant to Amendment No. 6, the issuance of Common Stock by the Company in the underwritten public offering at a price
per share equal to $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20211108_zEgMmvRCIOY4"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-11-08" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.1856</ix:nonFraction></span> triggered the automatic reduction in the exercise price of the Lender Warrants from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zt920nnHIO94"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-05_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></span> to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201108__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zJUrhQg1Hbf6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-11-08_custom_LenderWarrantsMember_custom_FinancingAgreementAmendment6Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.1856</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2018, we entered into a
Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as
lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as
amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zVPDmAPSJpG3" title="Line of Credit Facility, Maximum Borrowing Capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span>,
or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in&#160;<span id="xdx_903_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uN_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zbWTZ2h6yAjl" title="Number of tranches under term loan facility"><ix:nonFraction name="txmd:NumberOfTranchesUnderTermLoanFacility" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">three</ix:nonFraction></span>&#160;separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts
borrowed under the Term Loan bore interest at a rate equal to the sum of (i)&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zbB61kc3itwg" title="Debt Instrument, Description of Variable Rate Basis"><ix:nonNumeric contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">one-month LIBOR</ix:nonNumeric></span>
&#160;(subject to a LIBOR floor of&#160;<span id="xdx_904_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zD5trAgIz9Nl" title="LIBOR floor rate"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.50</ix:nonFraction></span>%)
plus (ii)&#160;<span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zfzZnx0M4x9b" title="Debt Instrument, Basis Spread on Variable Rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.7</ix:nonFraction></span>5%
per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2019, we terminated the Credit
Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $<span id="xdx_90B_ecustom--RepaymentOfDebtWithNewCreditFacility_pp0i_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zS0oG7kt7oUj"><ix:nonFraction name="txmd:RepaymentOfDebtWithNewCreditFacility" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,661,000</ix:nonFraction></span>&#160;was
used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of&#160;<span id="xdx_903_ecustom--PrepaymentFeePercentage_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zq5316yBeWVb"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%, a repayment fee of&#160;<span id="xdx_906_ecustom--RepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zW8j96OpNqrh"><ix:nonFraction name="txmd:RepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%&#160;and
other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement,
we recorded $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0i_dxL_c20190101__20191231_zx1FLKRkKzI6" title="::XDX::-10057632"><span style="-sec-ix-hidden: xdx2ixbrl1028">10,057,632</span></span>&#160;in loss on extinguishment of debt in the second quarter of 2019. Interest expense for the years ended
December 31, 2019 and 2018 related to the Credit Agreement was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0i_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z1Q40lF5lODh"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,816,747</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--InterestExpenseDebt_pp0i_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zt9DarYAfUi1"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2018-01-012018-12-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,407,975</ix:nonFraction></span>, respectively. During the year ended December
31, 2019, and prior to the repayment of the Credit Agreement, we amortized $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zMGagYlPtuma" title="Amortization of deferred financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,146</ix:nonFraction></span>&#160;of deferred financing fees as interest
expense in the accompanying consolidated financial statements. During the year ended December 31, 2018, we amortized $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zBfbp3pfViZ1" title="Amortization of deferred financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2018-01-012018-12-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,859</ix:nonFraction></span>&#160;of
deferred financing fees as interest expense in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As
of December 31, 2020, we </span>had $<span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0i_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z5ejBrpNZnYj"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2020-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000,000</ix:nonFraction></span>&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated
financial statements. Since the inception of the Financing Agreement, we have incurred $<span id="xdx_90C_eus-gaap--DeferredFinanceCostsGross_iI_pp0i_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zCSFoFqVSN05"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2020-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,902,270</ix:nonFraction></span>&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
were allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to the two
tranches of borrowings that we received of $<span id="xdx_90B_eus-gaap--DeferredFinanceCostsGross_iI_pp0i_c20201231__custom--DebtTrancheAxis__custom--TrancheTwoMember_zgxjvZuF7T9i"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2020-12-31_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,626,891</ix:nonFraction></span>&#160;have
been reflected as debt discount upon each draw and are amortized to interest expense using the effective interest method. In
addition, during the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of
$<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0i_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zZ4SOZlWM6pc" title="Fair value of warrants"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-08-05_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,428,178</ix:nonFraction></span>
as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the
Financing Agreement. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value to the debt discount
of $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0i_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zGkmiNugi5nk" title="Debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,983</ix:nonFraction></span>,
which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement.
The public offering in November 2020 triggered the down round provision underlying the warrants
granted in August 2020, as modified in November 2020, which was immaterial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the third quarter of 2020, we concluded
that the undrawn $<span id="xdx_90B_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zbKv5T4ySVBg"><ix:nonFraction name="txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" contextRef="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>&#160;tranche under the Financing Agreement is no longer available to us. As such, we wrote off $<span id="xdx_90C_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pp0i_c20200101__20201231_zTTCFlRoUJ0g" title="Write off of deferred financing fees"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,379</ix:nonFraction></span>
of deferred financing fees associated with the unfunded tranche, which were previously deferred as assets until such tranche had
been drawn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 101; Value: 3 -->
    <div id="xdx_237_z5yWb2i4zzT5" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_z2ZJaGKZPJC3" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z68CgTAF9l4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2020
and 2019, we amortized $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zauQQjdQEBi2" title="Amortization of deferred financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-01-012020-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,256,428</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zhgLPwwxNhH4" title="Amortization of deferred financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,156</ix:nonFraction></span>, respectively, of deferred financing fees related to the Financing Agreement as
interest expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement
is due and payable quarterly in arrears. Interest expense for the years ended December 31, 2020 and 2019 was $<span id="xdx_90F_eus-gaap--InterestExpenseBorrowings_pp0i_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zE095bRo9O8e"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2020-01-012020-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,049,236</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--InterestExpenseBorrowings_pp0i_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zsb7QUeW8Pf2"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2019-01-012019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,709,166</ix:nonFraction></span>,
respectively. The overall effective interest rate under the Financing Agreement was approximately <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7YiWUjSjGK5"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2020-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% as of December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zPwkD1Td4woa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B6_z2o13kQ2qy38">As of December 31, 2020 and 2019, the carrying
value of our debt consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Financing Agreement</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zwMTUNoEabB4" title="Long-term Debt, Gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2020-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7jLOiHi86Hh" title="Long-term Debt, Gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20201231_zJZIcl9hA7Q3" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,302,469</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zwN3DhrO3tLa" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,365,357</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--LongTermDebtNoncurrent_iI_c20201231_zBq3vAz9k4rj" title="TOTAL LONG-TERM DEBT"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,697,531</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--LongTermDebtNoncurrent_iI_c20191231_z7cAUqfBdSZ1" title="TOTAL LONG-TERM DEBT"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,634,643</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_z9QIONfH9CBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zxHfodBnKX38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zxEhXGMEwQB">The following table reflects our aggregate future principal payments
under the Financing Agreement for the next five years, as amended by Amendment No. 8:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_z3X51nIyMpud" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_iI_d0_zYdZnuq1q9g6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_iI_d0_zAXeX7sTPnMe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_iI_zcu09OXQhgR7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: right">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,750,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_iI_zE0O6fqRfQ1c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_iI_d0_zy2jDUsGPtmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" contextRef="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zh4LGFfHc1Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><p id="xdx_810_zTDqoWFaCCQ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zevvxjX5Eo33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 9 &#8211; <span id="xdx_826_z9KCoir0Pphh">STOCKHOLDERS&#8217; EQUITY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, we had <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zadL1y9Kiw6b" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span>
shares of preferred stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zL5auj1mcSdd" title="Preferred Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, or Preferred Stock, authorized for issuance, of which <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20201231_zMdkPuF07txb" title="Preferred Stock, Shares Issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20201231_z4ktvPaYuNxd" title="Preferred Stock, Shares Outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of Preferred
Stock were issued or outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, we had <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zETZF7pENal" title="Common Stock, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000,000</ix:nonFraction></span>
shares of Common Stock authorized for issuance, of which <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20201231_zPgGFQklb5Ac" title="Common Stock, Shares, Issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zdycJgL6WmRk" title="Common Stock, Shares, Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">299,765,396</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock were issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During 2020</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWL7lnRBYlMi" title="Shares issued for exercise of options, net (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,182,195</ix:nonFraction></span> shares of Common Stock were exercised for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDzhsgKiugrc" title="Shares issued for exercise of options, net"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,678</ix:nonFraction></span> in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 10, 2020, we entered into an underwriting agreement
with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201109__20201113__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zqGbZGoDAHMb" title="Shares issued in offerings, net of cost (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-11-092020-11-13_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,437,500</ix:nonFraction></span>
shares of Common Stock at a public offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zCzbiIckQG02" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.1856</ix:nonFraction></span> per share. We granted to the underwriter an option, exercisable for
a period of <span id="xdx_909_ecustom--PeriodExercisableUnderwritersOption_dt_c20201109__20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zk0suB4XaUz5" title="Period exercisable underwriters option"><ix:nonNumeric contextRef="From2020-11-092020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt-sec:durwordsen" name="txmd:PeriodExercisableUnderwritersOption">30 days</ix:nonNumeric></span>, to purchase up to <span id="xdx_906_ecustom--UnderwritersOptionGrantedInPeriodShares_c20201109__20201120__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zanMzhITS889" title="Underwriters option granted in period shares"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2020-11-092020-11-20_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,515,625</ix:nonFraction></span> additional shares of Common Stock, which was exercised in full. The net proceeds
the offering were approximately $<span id="xdx_90E_ecustom--ProceedsFromIssuancePublicOffering_c20201109__20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_z4NSlubpzt65" title="Proceeds from issuance public offering"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2020-11-092020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,703,000</ix:nonFraction></span>, after deducting the underwriting discounts and commissions and estimated offering
expenses payable by us. The offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201109__20201113__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zDzDIsb2ctVc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-11-092020-11-13_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,437,500</ix:nonFraction></span> shares closed on November 13, 2020 and the offering of <span id="xdx_906_ecustom--UnderwritersOptionGrantedInPeriodShares_c20201109__20201120__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zFcL6LKPQKF3"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2020-11-092020-11-20_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,515,625</ix:nonFraction></span> shares closed on November 20, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2020, we entered into a
Controlled Equity Offering<sup>SM</sup> Sales Agreement, or sales agreement, with Cantor Fitzgerald relating to shares of our
Common Stock. In accordance with the terms of the sales agreement, we were permitted to offer and sell shares of our Common
Stock having an aggregate offering price of up to $<span id="xdx_905_ecustom--MaximumCommonStockOfferingPrice_dm_c20200101__20201130__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zH0MJ3E4LRni"><ix:nonFraction name="txmd:MaximumCommonStockOfferingPrice" contextRef="From2020-01-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">50</ix:nonFraction> million</span>
from time to time through or to Cantor Fitzgerald, acting as sales agent. Cantor Fitzgerald was entitled to
compensation at a fixed commission rate of <span id="xdx_907_ecustom--FixedCommissionRate_dp_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zhUMSLPVsvdj"><ix:nonFraction name="txmd:FixedCommissionRate" contextRef="From2020-11-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>%
of the aggregate gross sales price per share sold. No shares of Common Stock were sold under the sales agreement during the year ended December 31, 2020. As
further described in Note 16 - Subsequent Events, on February 8, 2021, our &#8220;at the market&#8221; offering with Cantor Fitzgerald
terminated following the sale of the maximum $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_c20210101__20210228__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zbwaDJBp2gCf"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-02-28_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">50</ix:nonFraction> million</span> of shares of Common Stock in January 2021 and February 2021 pursuant to
the sales agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 102; Value: 3 -->
    <div id="xdx_237_zmRNbH9skLic" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zomYXeWaa2yg" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zANXCoKtO97l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During 2019</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2019, we entered into an
underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters, relating to an underwritten public
offering of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z2h9oFSnHer5" title="Shares issued in offerings, net of cost (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,000,000</ix:nonFraction></span> shares of our Common Stock at a public offering price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zMNfU5hFd5c7" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span> per share. We granted the underwriters an
option, exercisable for a period of <span id="xdx_903_ecustom--PeriodExercisableUnderwritersOption_dt_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zrY70L9cq1Hi" title="Period exercisable underwriters option"><ix:nonNumeric contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt-sec:durwordsen" name="txmd:PeriodExercisableUnderwritersOption">30 days</ix:nonNumeric></span>, to purchase up to <span id="xdx_903_ecustom--UnderwritersOptionGrantedInPeriodShares_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zsItt7AIR0J4" title="Underwriters option granted in period shares"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,900,000</ix:nonFraction></span> additional shares of Common Stock, which was exercised
in full. The net proceeds to us from the offering were approximately $<span id="xdx_905_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zsecvHzmeRng" title="xdx_907_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zSAbRt90BdY"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,031,000</ix:nonFraction></span>, after deducting the underwriting discount and
offering expenses payable by us. The offering closed on October 29, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019,
certain individuals exercised stock options to purchase an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwLg2siMkLFc" title="Shares issued for exercise of options, net (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,619</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMS273NxSAG4" title="Shares issued for exercise of options, net"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,656</ix:nonFraction></span> in cash. Also,
during the year ended December 31, 2019, stock options to purchase an aggregate of <span id="xdx_900_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20191231_zduc4iYxQJSe" title="Number of stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,097</ix:nonFraction></span> shares of Common Stock were exercised
pursuant to the options&#8217; cashless exercise provisions, which resulted in <span id="xdx_905_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20191231_zO0sMCeCS4zg" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,834</ix:nonFraction></span> shares of Common Stock being issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During 2018</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2018, we entered into an underwriting
agreement with Goldman Sachs &amp; Co. LLC, as representative of the underwriters, relating to an underwritten public offering
of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zmq2OsvdXGFj" title="Shares issued in offerings, net of cost (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,745,098</ix:nonFraction></span> shares of our Common Stock at a price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zT0g1eBP9hU7" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span> per share. We granted the underwriters an option, exercisable for
a period of <span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dt_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zdsxWOgxQfIf" title="Period exercisable underwriters option"><ix:nonNumeric contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt-sec:durwordsen" name="txmd:PeriodExercisableUnderwritersOption">30 days</ix:nonNumeric></span>, to purchase up to <span id="xdx_901_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zMLZnLxOtWjb" title="Underwriters option granted in period shares"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,911,764</ix:nonFraction></span> additional shares of Common Stock. On August 2, 2018, the underwriters exercised
the option in full. The net proceeds to us from the offering, including the exercise of the option to purchase additional shares,
were approximately $<span id="xdx_901_ecustom--ProceedsFromIssuancePublicOffering_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zRqydcYEtCy5" title="Proceeds from issuance public offering"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,908,000</ix:nonFraction></span>, after deducting the underwriting discount and offering expenses payable by us. The offering closed
on August 6, 2018. In connection with the Knight License Agreement, on August 6, 2018, Knight entered into a subscription agreement
with us, pursuant to which Knight purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zbJWmNdIxBQd" title="Shares issued in offerings, net of cost (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,921,568</ix:nonFraction></span> of shares of our Common Stock concurrently with the closing of the underwritten
public offering of Common Stock at a price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zDjJWk4XjBGd" title="Shares Issued, Price Per Share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span>, for proceeds to us of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zXhW1Xh38PNa" title="Shares issued in offerings, net of cost"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2018,
certain individuals exercised stock options to purchase an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxzVFySqaZB1" title="Shares issued for exercise of options, net (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,444,526</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQFrePRJZdI3" title="Shares issued for exercise of options, net"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,666,208</ix:nonFraction></span> in cash.
Also, during the year ended December 31, 2018, stock options to purchase an aggregate of <span id="xdx_901_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20181231_zkDhw48ZgHMj" title="Number of stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of Common Stock were exercised
pursuant to the options&#8217; cashless exercise provisions, wherein <span id="xdx_901_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20181231_zc4Sui8Vqqvc" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,841</ix:nonFraction></span> shares of Common Stock were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Warrants to Purchase Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, we had warrants
outstanding to purchase an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231_zG6yWauvexhh" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,534,687</ix:nonFraction></span> shares of Common Stock with a weighted-average contractual remaining life of
approximately <span id="xdx_90C_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20201231_zQF75OpByNNi" title="Weighted-average contractual remaining life"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:duryear" name="txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife">7.25</ix:nonNumeric></span> years, and exercise prices ranging from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zuOiOyQJYNCc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span> to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zToPRD7Gv3T6" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.20</ix:nonFraction></span> per share, resulting in a weighted average exercise price
of $<span id="xdx_90F_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYD8KlOza87c" title="Weighted average exercise price of warrants (in dollars per share)"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.55</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,
including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with Amendment No. 5 and
in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders under the Financing Agreement the Lender
Warrants. The fair value for the Lender Warrants was determined by using the Black-Scholes Model on the date of the grant using
a term of <span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zFq1ZymDuLh8"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">ten years</ix:nonNumeric></span>, volatility of <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z25U0CWNsN0b" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">68.8</ix:nonFraction></span>%, risk-free interest rate of <span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zoTOEUcWjUJ3" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.34</ix:nonFraction></span>% and dividend yield of <span id="xdx_901_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zRsf6BxHzLX5" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%. The grant date fair value
of the warrants was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zFA7i4iPEnWh" title="Weighted average grant date fair value, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction></span> per share. The warrants vested upon issuance. We concluded that the modification accounting model is
applicable to this warrant issuance and recognized the fair value of the warrants as a debt discount. As a result, the fair value
of the Lender Warrants is being amortized to interest expense over the term of the Financing Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 8, 2020, in connection with
entering into Amendment No. 6, we amended the Lender Warrants to provide for an adjustment to the exercise price if we conducted
certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen
trading days ending December 31, 2020 was lower than the then-current exercise price. Pursuant to Amendment No. 6, the issuance
of the shares of Common Stock in the November 2020 underwritten public offering triggered the automatic reduction in the exercise
price of the Warrants from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zSSM7TXC0RUl"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-05_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></span> to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201108__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zNIemvC7rTHc"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-11-08_custom_LenderWarrantsMember_custom_FinancingAgreementAmendment6Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.1856</ix:nonFraction></span>. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value
to the debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zv62SeJgagZ9" title="Debt Discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,983</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019,
we granted warrants to purchase an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zETZ3fmKAQpd" title="Number of shares under warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-01-012019-12-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of Common Stock to outside consultants which vest ratably over a
<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z6KPq0u7PX4l" title="Warrants vesting period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OutsideConsultant2Member" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span>-month period and have an expiration date of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zGptuM3Xzy1f" title="Warrants expiration date"><ix:nonNumeric contextRef="AsOf2019-12-31_custom_OutsideConsultant2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">February 13, 2024</ix:nonNumeric></span>. During the year ended December 31, 2018, we granted warrants
to purchase an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zivTQmjh9yl8" title="Number of shares under warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zy7SCWdnFgk3" title="Award vesting period"><ix:nonNumeric contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span>-month period and
have an expiration date of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zrd4iPyErWB3" title="Warrants expiration date"><ix:nonNumeric contextRef="AsOf2018-12-31_custom_OutsideConsultant2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 15, 2023</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 103; Value: 3 -->
    <div id="xdx_23F_z1jE3wTuOV85" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zwZMO9aNt3D7" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zXjVyRUaFse4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded share-based compensation expense
related to warrants previously issued of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgQNHXusCNkc" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,446</ix:nonFraction></span>, $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXXQ3RiS3qW8" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,970</ix:nonFraction></span>, and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2PY20UsVsXe" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-01-012018-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,136</ix:nonFraction></span> for the years ended December 31, 2020, 2019 and 2018,
respectively, in the accompanying consolidated financial statements. At December 31, 2020, there was no unrecognized compensation
expense remaining related to unvested warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="txmd:ScheduleOfWarrantRollForwardTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zQIEBlKA5QB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Summary of our Warrant activity during the year ended December
31, 2020:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Shares Under</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Warrants</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Life in Years</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Balance at December 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRRfJbOqoFuf" title="Number of shares under warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,832,571</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zV0mPa5GYoF6" title="Weighted average exercise price warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxLMoeHGv0sh" title="Weighted average remaining contractual life, warrants outstanding" style="width: 12%; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.95</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zI9HnHhuALE2" title="Aggregate intrinsic value, warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,447,929</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyYJ8fQEKFIb" title="Number of shares under warrants granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,752,116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9MnAk7PDqsa" title="Weighted average exercise price warrants granted" style="text-align: right"><ix:nonFraction name="txmd:WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhpZv6rBSF6f" title="Cancelled/Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh9SXiF0REug" title="Weighted average exercise price warrants cancelled/forfeited" style="text-align: right"><ix:nonFraction name="txmd:WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.35</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRmnrBa1Ixka" title="Number of shares under warrants outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,534,687</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYMBmVblsfE3" title="Weighted average exercise price warrants outstanding ending" style="text-align: right"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHkKR2Z3kSue" title="Weighted average remaining contractual life, warrants outstanding" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne">7.25</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB7D2SbhQIng" title="Aggregate intrinsic value, warrants outstanding ending" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,219</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zToiBI49G18d" title="Number of shares under warrants vested and exercisable ending" style="text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,534,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHtFFJEiNjzk" title="Weighted average exercise price warrants unvested ending" style="text-align: right"><ix:nonFraction name="txmd:WarrantsUnvestedWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOhy3RAC7XNl" title="Weighted average remaining contractual life, vested and exercisable ending" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms">7.25</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLUCFsclWND7" title="Aggregate intrinsic value, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,041,219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zQsBOyx2o9ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock"><p id="xdx_896_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zD2LR7eyNHaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average fair value per share
of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018
are set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzzohakCd7ib" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdGcFn7jkUsb" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zfDz6mG7bx2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_407_ecustom--WeightedAverageExercisePriceOtherThanOptions_pii_uUSDPShares_zfh5i8004uWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Weighted average exercise price</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:WeightedAverageExercisePriceOtherThanOptions" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:WeightedAverageExercisePriceOtherThanOptions" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:WeightedAverageExercisePriceOtherThanOptions" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.16</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_z2wJm8856j8j" style="vertical-align: bottom; background-color: White">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.79</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_z5fuJJ2oCdj6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.34</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.52</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.36</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_zt1cBcLV5i3e" style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">68.8</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.8</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.12</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zDTGR0r3w2kl" title="Term (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrntf4TgaIXi" title="Term (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjrWxfC1bd4j" title="Term (in years)" style="text-align: right"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_zqNSt6wazfbg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_zdc3kPZnDLWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Warrant exercises</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE9Ev2PWsAr6" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> warrants were exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019,
warrants to purchase an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zNcbcQhbK0Rd" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> shares of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise
provisions, which resulted in <span id="xdx_90B_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlzOamFaa91c" title="Number of stock issued in cashless exercise of warrants"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,184</ix:nonFraction></span> shares of Common Stock being issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2018,
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbV1UI0mn4P7" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> warrants were exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Options to Purchase Common Stock of the Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2009, we adopted the 2009 Long-Term
Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants
of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock
options and other stock and cash incentives, or the Awards. As of December 31, 2020, there were non-qualified stock options to
purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zCN6cUIpt71c" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,285,205</ix:nonFraction></span> shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2012, we adopted the 2012 Stock Incentive
Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive
for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
As of December 31, 2020, there were non-qualified stock options to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zdfGIErC8jUf" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,305,974</ix:nonFraction></span> shares of Common Stock outstanding
and an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOVaX8pE4ZDe" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">890,000</ix:nonFraction></span> restricted stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan, no future
awards may be made under the 2012 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 20, 2019, we adopted the 2019 Plan
to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and
advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted
stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan.
Generally, the options vest annually over <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dt_c20200101__20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zsk1eY9FOX24"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_Plan2019Member" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">four years</ix:nonNumeric></span> or as determined by our board of directors, upon each option grant. Options
may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified
expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20200101__20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zhdZtjjsJZm3" title="Award expiration period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_Plan2019Member" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten years</ix:nonNumeric></span> from the
date the option is issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 104; Value: 3 -->
    <div id="xdx_23C_z1mvQ5v8tPi" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zLgStBoYoydk" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_z0845r5vnkI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_znGkjdUJ2LJ4" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-12-31_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,583,565</ix:nonFraction></span>
shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) new shares, (ii) unallocated shares previously
available for issuance under the 2012 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012
Plan), and (iii) unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding
&#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221;
under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the
underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of
the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction
of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration,
termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of
December 31, 2020, there were non-qualified stock options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zc4sTBvUvO6" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,190,751</ix:nonFraction></span> shares of Common Stock outstanding under the 2019
Plan and an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhB3nGTXUDuk" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,171,024</ix:nonFraction></span> restricted stock units and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zTkUUzrcTerl" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_Plan2019Member_custom_PerformanceStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,403,951</ix:nonFraction></span> performance stock units outstanding under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zK73YAIvjLQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. <span id="xdx_8B3_zFjG7qlKfWp9">The ranges of
assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Weighted average exercise price</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdRKOCY194Fb" title="Weighted average exercise price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm1q20xQpHlc" title="Weighted average exercise price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU0RGQJ0eQP4" title="Weighted average exercise price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zidH9LoM7wI8" title="Weighted average grant date fair value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsks95RV0Fla" title="Weighted average grant date fair value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3zmIglYQXQd" title="Weighted average grant date fair value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd5Gy8sGeof8" title="Risk-free interest rate - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.34</ix:nonFraction></span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJwEaTnpPMOa" title="Risk-free interest rate - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.68</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEeyhRC6N5vb" title="Risk-free interest rate - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.64</ix:nonFraction></span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNDhpRN2P563" title="Risk-free interest rate - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.54</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9AZUWqOxlb4" title="Risk-free interest rate - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.38</ix:nonFraction></span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyc3vOPXLIJc" title="Risk-free interest rate - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.89</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z54cPeUNn1fc" title="Volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.53</ix:nonFraction></span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4QToulRpY67" title="Volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.92</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z136BI8h4gZk" title="Volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61.25</ix:nonFraction></span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX63SVikg5oj" title="Volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64.49</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEXhJmbtOxaj" title="Volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">59.45</ix:nonFraction></span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKWp9HvkneX1" title="Volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64.04</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zfErmA5yB31f" title="Term"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zjHnM7guZ3Td" title="Term"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.8</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zEwpZpbrrsA" title="Term"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zr8jstVV9iL7" title="Term"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.5</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjogRE4kyEX5" title="Term"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.1</ix:nonNumeric></span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zS49ZdephDu4" title="Term"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUS3Mu5ASo8f" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zma4MpsEpOE1" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVWNjv8rptFg" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A5_zzknt228Iyx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTUGf9YtZhZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of activity under the 2009, 2012
and 2019 Plans and related information during the year ended December 31, 2020 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Shares Under</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Options</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Life in Years</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Balance at December 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zOWxDl2OmMV" title="Number of shares under options, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,030,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFZbBzcvewna" title="Weighted average exercise price, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.65</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zHq1IWLmGAm2" title="Weighted average remaining contractual life" style="width: 12%; text-align: right"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.84</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231_zUcEtCZBuQpj" title="Aggregate intrinsic value, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,668,171</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zGMx6F3D6ZKh" title="Number of shares under options, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">736,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zvSF7LkOHy4g" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200101__20201231_zPI1pUWgipxb" title="Number of shares under options, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,182,195</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zDu6VR4Q0aC6" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20201231_zuosgxVLzVWl" title="Aggregate intrinsic value, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,738,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20201231_zdi9BU3pwUO5" title="Number of shares under options, expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">386,609</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zD9L6LV7Wfme" title="Weighted average exercise price, expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zejaUJeR5ZR" title="Number of shares under options, cancelled forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">416,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_z8yQlXeRfJ45" title="Weighted average exercise price, cancelled forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.80</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20201231_ziOsw50js328" title="Number of shares under options, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,781,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zmkwoS8XeKLb" title="Weighted average exercise price, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20200101__20201231_zOHq9IcPTqY5" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:duryear" name="txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">5.20</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20200101__20201231_zYyeO6L5dF0h" title="Aggregate intrinsic value, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20200101__20201231_zKXVf5SnUPX8" title="Number of shares under options, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,862,681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zZveoHdWBtgj" title="Weighted average exercise price, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.06</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zgoGIzgv0bdg" title="Weighted average remaining contractual life, vested and exercisable" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.59</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20200101__20201231_zrblXPQD82Pg" title="Aggregate intrinsic value, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,443</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20200101__20201231_zOpLSxrBy8Si" title="Number of shares under options, unvested ending" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,919,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zAcpuOCuOwCa" title="Weighted average exercise price, unvested ending" style="text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zrd64DCGRALe" title="Weighted average remaining contractual life, unvested" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">8.29</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20200101__20201231_zq2yZIhCwPhi" title="Aggregate intrinsic value, unvested ending" style="text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,810</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zCYrATHIvmp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, our outstanding options
had exercise prices ranging from $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20201231__srt--RangeAxis__srt--MinimumMember_zoxuNelaib64" title="Range - exercise price of options"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2020-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.38</ix:nonFraction></span> to $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20201231__srt--RangeAxis__srt--MaximumMember_zePcthb9sHvi" title="Range - exercise price of options"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2020-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.92</ix:nonFraction></span> per share. Share-based compensation expense related to options recognized in our
results of operations for the years ended December 31, 2020, 2019, and 2018 was approximately $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_z5eLMzIWM6Ke" title="Share-based Payment Arrangement, Expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,235,585</ix:nonFraction></span>, $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_zDurT9OhxWUh" title="Share-based Payment Arrangement, Expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,798,707</ix:nonFraction></span>, and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20181231_z13vmzA2ilGd" title="Share-based Payment Arrangement, Expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,091,294</ix:nonFraction></span>,
respectively, and it is based on awards vested. At December 31, 2020, total unrecognized estimated compensation expense related
to unvested options was approximately $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20201231_zMJtixXviPte" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,238,000</ix:nonFraction></span>, which may be adjusted for future changes in forfeitures. This cost is expected
to be recognized over a weighted-average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc8lTcI89ZJf" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.9</ix:nonNumeric></span> years. No tax benefit was realized due to a continued pattern of operating
losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Restricted Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted stock units granted under our
2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common
Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares
vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 105; Value: 3 -->
    <div id="xdx_237_zypuZk3dD9j4" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zGesjzBdxekl" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zEy2gaqF9jVk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Performance stock units will vest if certain
performance targets are achieved. If minimum performance thresholds are achieved, each award will convert into Common Stock at
a defined ratio depending on the degree of achievement of the performance target designated by each individual award. If minimum
performance thresholds are not achieved, then no shares will be issued. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at its grant date and through the date the restricted stock vests. The expected levels of achievement are reassessed over the requisite
service periods and, to the extent that the expected levels of achievement change, stock-based compensation is adjusted and recorded
on the consolidated statements of income and the remaining unrecognized stock-based compensation is recognized over the remaining
requisite service period.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2020,
2019 and 2018 we recorded $<span id="xdx_908_eus-gaap--RestrictedStockExpense_c20200101__20201231_zVYrOOwEv5Zf" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,399,472</ix:nonFraction></span>, $<span id="xdx_900_eus-gaap--RestrictedStockExpense_c20190101__20191231_zXpFpaBNf6Oa" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,628,407</ix:nonFraction></span>&#160;and $<span id="xdx_908_eus-gaap--RestrictedStockExpense_c20180101__20181231_zGK8BUbXaM41" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,132</ix:nonFraction></span>, respectively, in share-based compensation expense related to
restricted stock units and performance stock units. As of December 31, 2020, we recognized performance-based compensation expense
using our assessment of the most likely probability of attaining quarterly EBITDA break-even which would result in vesting 1.5
times the base number of performance stock units. At December 31, 2020, total unrecognized estimated compensation expense related
to unvested&#160;restricted stock units and performance stock units&#160;was approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20201231_zPACtXFqzIGl" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,989,000</ix:nonFraction></span>, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of&#160;<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNPihaeACL2j" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.6</ix:nonNumeric></span>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zIPEnR0HqOs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule of restricted stock units and
performance stock units</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Restricted Stock Units</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Performance Stock Units</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number of</p>
                                                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shares</p>

</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Weighted</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Average</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Grant Date</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Fair Value</span></p></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number of</p>
                                                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shares</p>

</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Weighted</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Average</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Grant Date</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Fair Value</span></p></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Balance at December 31, 2019</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpell54xGhm4" title="Beginning balance, number of shares" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEI5qekRZA2" title="Beginning balance, weighted average grant date fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znrSniegE5g4" title="Granted, number of shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,152,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLTIusfAgI23" title="Granted, weighted average grant date fair value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDUff6ykhbVl" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,585,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zl46URc21r1j" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Vested/Released</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrr6E2e496V4" title="Vested/Released, number of shares" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">301,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFn9vJyGoWp7" title="Vested/Released, weighted average grant date fair value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zE4tbr4OSqu9" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">151,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeCG9cEPaTsa" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQSChyti9sO5" title="Forfeited, number of shares" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,294</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoOzrrMk41L8" title="Forfeited, weighted average grant date fair value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJm02Iv3Hx3g" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,294</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znKJMmPU6OO4" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Balance at December 31, 2020</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJAZPd398kKk" title="Ending balance, number of shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,061,024</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxuh3DzApZT2" title="Ending balance, weighted average grant date fair value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2020-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____zKNcfa9MpK0g" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember" id="Fact001446" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,403,951</ix:nonFraction></td><td id="xdx_F22_zJX5trdtnZEi" style="padding-bottom: 2.5pt; text-align: left">*</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjEJORWN5x1i" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F06_zr1lKch6hv28" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td id="xdx_F12_zfnzvpgq2c4h" style="text-align: justify"><ix:footnote id="Footnote001448" xml:lang="en-US">The number of performance stock units (PSUs) represents the base number of PSUs that
may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the
Company&#8217;s achievement of break-even quarterly EBITDA.</ix:footnote></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A7_z0vsJ8mm2Gn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Employee Stock Purchase Plan </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 18, 2020, our stockholders approved
the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan, or the ESPP, which reserved <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_z3J4010UkTAb" title="Common Stock, Capital Shares Reserved for Future Issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,400,000</ix:nonFraction></span> shares of Common Stock for purchase.
The ESPP permits eligible employee participants to purchase Common Stock at a price per share which is equal to <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zCffGAHUkuyd" title="Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>% of the lesser
of (a) the fair market value of the shares on the offering date of the offering period or (b) the fair market value of the shares
on the purchase date. During the year ended December 31, 2020, no shares were issued under the ESPP. We recorded $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zd2BdH7smUMi" title="Non cash compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,489</ix:nonFraction></span> of non-cash
compensation expense related to the ESPP during the year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DefinedContributionPlanTextBlock"><p id="xdx_802_eus-gaap--DefinedContributionPlanTextBlock_zFSunyPavn81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 10 &#8211; <span id="xdx_822_zV4M5n5r0Z5k">EMPLOYEE BENEFIT
PLAN</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a voluntary defined
contribution 401(k) plan covering all eligible employees as defined in the plan documents. The plan provides for discretionary
matching contribution, which is equal to up to <span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pip2_dcp_c20200101__20201231_z4ZnpvC3Wxph" title="Matching contribution percentage"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="From2020-01-01to2020-12-31" format="ixt-sec:numwordsen" decimals="INF" scale="-2" unitRef="Pure">four</ix:nonFraction></span> percent of each eligible contributing participant&#8217;s elective deferral
not to exceed $<span id="xdx_90E_ecustom--DefinedContributionPlanMaximumEmployerMatchingContribution_c20200101__20201231_z35XromJ4aFd" title="Maximum matching contribution per year"><ix:nonFraction name="txmd:DefinedContributionPlanMaximumEmployerMatchingContribution" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> per year. Employees who elect to participate in the plan are generally fully vested in any existing matching
contribution after <span id="xdx_90E_ecustom--DefinedContributionPlanVestingServicePeriod_dt_c20200101__20201231_zE31kIc8aJjg" title="Defined contribution plan vesting service period"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:durwordsen" name="txmd:DefinedContributionPlanVestingServicePeriod">five years</ix:nonNumeric></span> of service with the Company. Contributions by the Company under the plan amounted to approximately
$<span id="xdx_900_eus-gaap--DefinedContributionPlanCostRecognized_c20200101__20201231_zq9ueVwtyqA5" title="Contributions under plan"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanCostRecognized_c20190101__20191231_zlQ9Y8g2va2b" title="Contributions under plan"><ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,000</ix:nonFraction></span> for the years ended December 31, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 106; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zgkAzeD7GxXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 11 &#8211; <span id="xdx_820_zfvddJ7t15mc">INCOME TAXES </span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYaE2QoEmhYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, (loss)
income before taxes includes the following components:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-bottom: 1pt">United States</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zguCFyRPD1ik" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2020-01-012020-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,524,137</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zC3C21UWS0Xc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2019-01-012019-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_z7ehvKbVq99j" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2018-01-012018-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231_zjsoXl7n8sM7" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,524,137</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zoHfrzFGf7Il" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">177,144,999</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zC7zcbxEydWh" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zOSqzGVVKmM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For
the years ended December 31, 2020, 2019, and 2018, there was no provision for income taxes, current or deferred. </span>At December
31, 2020, we had a federal net operating loss carry forward of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_zq31T0Xo72di" title="Net operating loss carryforward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">761,701,546</ix:nonFraction></span> available to offset future taxable income
through 2038. Approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zIgTBYApSvne" title="Net operating loss carryforward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,775,332</ix:nonFraction></span> of the federal net operating loss carry forward can be carried forward for <span id="xdx_90B_ecustom--NolCarryForwardPeriod_dtY_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zPEimXBmSl9l" title="NOL carryforward period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember" format="ixt-sec:duryear" name="txmd:NolCarryForwardPeriod">20</ix:nonNumeric></span> years and
will begin to expire in <span id="xdx_909_ecustom--OperatingLossCarryforwardsExpirationYear_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zaNAPu9Qd669" title="NOL carryforward expiration year"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember" name="txmd:OperatingLossCarryforwardsExpirationYear">2031</ix:nonNumeric></span>.&#160;The remaining $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriodIndefiniteMember_zIxqWuvl0Mle" title="Net operating loss carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,926,214</ix:nonFraction></span> can be carried forward indefinitely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjRPx5ggl1H3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation between taxes computed at the federal statutory
rate and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20201231_zNMMJonDbVr4" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20190101__20191231_zdl9tOiJ8FOd" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20180101__20181231_zX2FXwBwhHO3" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_maIT_zak6HihgVW0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left">Federal statutory tax rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPure_maIT_z8NNHPmmKKP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.1</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_maIT_zBQUuhjCjVE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">27.0</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">22.5</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">31.2</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
<tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pii_dp_uPure_maIT_zz1X9yLFzn27" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Excess stock benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.1</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.2</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp0_uPure_maIT_zIdMSs7oCQN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal income tax rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2018-01-012018-12-31" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Pure">-</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td></tr>
<tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPure_maIT_zABe7zYzkFvl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Permanent and other differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.7</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_uPure_mtIT_znjLm1h5T7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2019-01-012019-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2018-01-012018-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zlBVXbMJQjDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes result from temporary
differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYnj1A9WQn2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of the net deferred income
tax asset as of December 31, 2020, 2019, and 2018 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_ziSVdkEpnGI8" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20191231_zSgCwboagMPk" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20181231_zUg3mP0nvgG5" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhQAL6kZqtHd" style="vertical-align: bottom">
    <td style="text-align: left">Deferred Income Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzcsC_zzDrXcGjVRfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 0.125in">Net operating losses</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,008,131</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,555,975</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,419,113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGzcsC_zEiqUd5lJmid" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,251,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,913,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,464</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetInterestCarryforward_i01I_maDTAGzcsC_z6p6IREdlPh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Interest expense limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,991,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,389,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetInterestCarryforward" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,173,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcsC_zxB7OY1bHfb6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Other, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,818,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,662,037</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,658,573</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGzzfO_maDTAGzcsC_zgclBwHpui5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">R&amp;D credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,347</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,347</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,347</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzcsC_maDTANzEH4_zfcLcbgF6Ze3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Total deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,257,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,707,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,078,111</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzEH4_zZkjhxFogA86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,257,029</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,707,056</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,078,111</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzEH4_zj2p6EyLBNkk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred income tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2019-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2018-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AD_zi1rz11aMPyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that it is more likely than not that we will not
generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and
as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The change in valuation allowance was $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zLmxywPf2218" title="Change in valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,549,973</ix:nonFraction></span>,
<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20190101__20191231_zt72pgKfIapd">$<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,628,945</ix:nonFraction></span>, and <span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20180101__20181231_zttrJOfIoFXc">$<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,295,443</ix:nonFraction></span> for the years ended December 31, 2020, 2019, and 2018, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Unrecognized Tax Benefits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020 and 2019,
we have no unrecognized tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_81A_zDfbpUhKB74i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5CamXjNc75e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 12 &#8211; <span id="xdx_820_zo07iBxRMRQg">RELATED PARTIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2015, J. Martin Carroll, a director
of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with
Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by
independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During
the years ended December 31, 2020, 2019 and 2018, we were billed by Catalent approximately $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zVm6hPfLoVV5" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2020-01-012020-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,036,000</ix:nonFraction></span>, $<span id="xdx_901_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zg6gFtOrBz3d" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2019-01-012019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,101,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_z2ZNfZ7eAiNe" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2018-01-012018-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,111,000</ix:nonFraction></span>,
respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation
testing. As of December 31, 2020 and 2019, there were amounts due to Catalent of approximately $<span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zbqpkgTDXzKl" title="Amounts due to related party"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2020-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zdKHYABU1L82" title="Amounts due to related party"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span>, respectively. In
addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 14, Commitments and Contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 107; Value: 3 -->
    <div id="xdx_23C_zIdzHOMWZTc8" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zZrUIO9dO9jg" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_z76RTzpVG6Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2020, Karen L. Ling, Executive
Vice President and Chief Human Resources Officer of American International Group, Inc., or AIG, was appointed to our board of directors.
From time to time, we have entered into agreements with AIG in the normal course of business. Agreements with AIG have been reviewed
by independent directors of our Company, or a committee consisting of independent directors of our Company, since April 2020. During
the year ended December 31, 2020, we were billed by AIG approximately $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zzyCrYe9ReK5"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2020-01-012020-12-31_custom_AmericanInternationalGroupMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,000</ix:nonFraction></span> for various insurance coverage for our Company.</p>

</ix:nonNumeric><p id="xdx_813_zQs5qqGFFlPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zuDcSZ4RlZ68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 13 - <span id="xdx_826_z35jNAzObWC2">BUSINESS CONCENTRATIONS</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We purchase our prescription products from
several suppliers with approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zeEinaQ0hK1j"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_SupplierOneConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">36</ix:nonFraction></span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_za4bwRzBEWz8"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">30</ix:nonFraction></span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zLH0VN68v2Ue"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% of our purchases supplied by three vendors each, respectively, during the
year ended December 31, 2020, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zBVb9Z4VrFTc"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_SupplierOneConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">24</ix:nonFraction></span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zEsyU2IWwZ"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">27</ix:nonFraction></span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zlmj09UzW6ih"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">35</ix:nonFraction></span>% of our purchases supplied by three vendors each, respectively, during the year ended
December 31, 2019, and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_z9SVCfUYyj59"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_custom_SupplierOneConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">43</ix:nonFraction></span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zgJB6p6poND6"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">33</ix:nonFraction></span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zIa2Opf9NUh7"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% of our purchases supplied by <span id="xdx_90C_ecustom--NumberOfVendors_dc_c20180101__20181231_zoqdVHpUOswi" title="Number of vendors - suppliers"><ix:nonFraction name="txmd:NumberOfVendors" contextRef="From2018-01-012018-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">three</ix:nonFraction></span> vendors each, respectively, during the year ended December
31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our prescription products to wholesale
distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies,
hospitals, and other institutional customers. During the year ended December 31, 2020, <span id="xdx_90F_ecustom--NumberOfCustomers_dc_uN_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNYx6Nf73YJ2"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">three</ix:nonFraction></span> customers each accounted for more
than <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc7eOy3RzJrf"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of our total product revenue. During each of the years ended December 31, 2019 and 2018, <span id="xdx_90A_ecustom--NumberOfCustomers_pii_dc_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlBpaKn0s3Fa" title="Number of customers - revenue"><span id="xdx_908_ecustom--NumberOfCustomers_pii_dc_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zG9xZsjDqgi2"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">four</ix:nonFraction></ix:nonFraction></span></span> customers each accounted
for more than <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziq6KhIb9My6"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkPdSXcgA7Qc"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% of our total product revenue. Product revenue from the <span id="xdx_90A_ecustom--NumberOfCustomers_dc_uN_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zfGBxDZHe9Il"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">three</ix:nonFraction></span> customers combined accounted for approximately
<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zSzTHiudfEo1"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63</ix:nonFraction></span>% of our product revenue for the year ended December 31, 2020. Product revenue from the <span id="xdx_905_ecustom--NumberOfCustomers_dc_uN_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zs3KhhmU7X93"><span id="xdx_90F_ecustom--NumberOfCustomers_dc_uN_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zf0k5M0OFwo"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="N">four</ix:nonFraction></ix:nonFraction></span></span> customers combined accounted for
approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4QgXcOXV1n7"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">73</ix:nonFraction></span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJmCIM6Ax7c1"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">76</ix:nonFraction></span>% of our product revenue for the years ended December 31, 2019 and 2018, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
Cardinal Health accounted for approximately $<span id="xdx_908_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvduzlursID4"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,489,000</ix:nonFraction></span> of our product revenue, Pillpack, Inc. accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYpMsmVD0Rk6"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,228,000</ix:nonFraction></span>
of our product revenue, and McKesson Corporation accounted for approximately $<span id="xdx_908_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJHNKFHoTVEb"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,862,000</ix:nonFraction></span> of our product revenue. During the year
ended December 31, 2019, Pillpack, Inc. accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgruKxhYV437"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,676,000</ix:nonFraction></span> of our product revenue, Cardinal Health accounted
for approximately $<span id="xdx_904_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLDsfaP4ydAj"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,551,000</ix:nonFraction></span> of our product revenue, AmerisourceBergen accounted for approximately $<span id="xdx_900_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zN8XF7vDrkPf"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,927,000</ix:nonFraction></span> of our product revenue
and McKesson Corporation accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYrhcixy4rQf"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,911,000</ix:nonFraction></span> of our product revenue. During the year ended December 31, 2018,
Pillpack, Inc. accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkpyx6JbhKed"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,075,000</ix:nonFraction></span> of our product revenue, AmerisourceBergen accounted for approximately $<span id="xdx_903_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYyVDJDrVbcj"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,246,000</ix:nonFraction></span>
of our product revenue and Cardinal Health accounted for approximately $<span id="xdx_902_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6j8c0vpq6o6"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,308,000</ix:nonFraction></span> of our product revenue, and McKesson Corporation
accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1ZBlyidCPC"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,610,000</ix:nonFraction></span> of our product revenue.</p>

</ix:nonNumeric><p id="xdx_813_zFJoBw6gwEIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXO01roVpH79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 14 &#8211; <span id="xdx_82C_zPpozXAS9B3c">COMMITMENTS AND CONTINGENCIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Operating Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 842, Leases, effective January
1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office
space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease liability for all leases that
have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The
lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured
at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any
lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the
present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying
lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments
based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in
effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our
portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of
the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in
the initial lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We lease administrative office space in
Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a&#160;<span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20130701_z0WXKmWBbBPc" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2013-07-01" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">63</ix:nonNumeric></span>-month
term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space
in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with
the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May
1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement
with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease.
This addendum became effective beginning November 1, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 108; Value: 3 -->
    <div id="xdx_235_zJA4jfpEMqqd" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zDdmuld5piP3" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zhIApB7O3tMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2018, we entered into a lease
for new corporate offices in Boca Raton, Florida. The lease includes&#160;<span id="xdx_906_ecustom--NetRentableAreaLease_iI_uSqft_c20181002_zFnEgLSZDql9"><ix:nonFraction name="txmd:NetRentableAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">56,212</ix:nonFraction></span>&#160;rentable square feet, or the full premises,
of which the lease on&#160;<span id="xdx_90E_ecustom--RentedAreaLease_iI_pip0_uSqft_c20181002_zfGSxuLSVrj5" title="Rented area lease"><ix:nonFraction name="txmd:RentedAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Sqft">7,561</ix:nonFraction></span>&#160;square feet commenced in 2018 and the lease on the remaining&#160;<span id="xdx_906_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSqft_c20190801_zjpwDKA9I8f3"><span id="xdx_90B_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSqft_c20190801_zog8N3qcuDWa"><ix:nonFraction name="txmd:AdditionalAreaOfLeaseOccupied" contextRef="AsOf2019-08-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft"><ix:nonFraction name="txmd:AdditionalAreaOfLeaseOccupied" contextRef="AsOf2019-08-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">48,651</ix:nonFraction></ix:nonFraction></span></span>&#160;square feet
commenced in August 2019, or the full premises commencement date. The lease will expire&#160;<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_zViRcxSFO2g3" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2019-08-01" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract">11 years</ix:nonNumeric></span>&#160;after the full premises
commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of
the lease for&#160;<span id="xdx_906_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20201231_zaEY7Lw5PSwk"><ix:nonFraction name="txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">two</ix:nonFraction></span>&#160;additional consecutive periods of&#160;<span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dt_c20201231_zXhfcFQyY4S2" title="Lease renewal term"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm">five years</ix:nonNumeric></span>. The extension option is not included in the determination
of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent
periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses.
In June 2019, we entered into an agreement with the same lessors to lease additional&#160;<span id="xdx_904_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_uSqft_c20190601_z1xbIP2gkEXj"><ix:nonFraction name="txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea" contextRef="AsOf2019-06-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">6,536</ix:nonFraction></span>&#160;square feet of administrative
office space in the same location,&#160;<span style="color: #212529">pursuant to an addendum to such lease, which commenced in
May 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Supplemental lease information (Details)" id="xdx_887_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z0qHaQXgGYsf" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Supplemental
lease information as of:</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_zvsQK6mhd6H6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2020</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20191231_zwCekJDFreEk" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2019</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zgSJwi8HN9p8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Right-of-use asset</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,565,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,109,154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zRmUVpY5KQNh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term operating lease liability (included in <span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20201231_z7Yt0tyMkr3g" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"><span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20191231_zPu4jiwRNLTl" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1634"><span style="-sec-ix-hidden: xdx2ixbrl1635">Other current liabilities</span></span></span></span>)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,253,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,501,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zmGRt1AS3nWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,675,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,145,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zQrO6eP9Cye5"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">8.9</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zkuU70CWQ0Ne"><ix:nonNumeric contextRef="AsOf2019-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">9</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zUT9oLVC6zUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.30</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.25</ix:nonFraction></td><td style="text-align: left">%</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Supplemental cash flow information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>for the year ended:</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20201231_z4Kvyri66KD7" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br />
2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190101__20191231_zjEikObZOm47" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2019</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeasePayments_zoHM3doKuPbk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,617,645</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_z5mz9Do3uNtb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,171,471</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSRjabTl3LOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the undiscounted
cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Years Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_znBA6Qv3YUQh">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zNaAzI5TOiV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,334,582</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_z9806I5Zru21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,413,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zDS4sf6wjyhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,443,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zhk5xpIRSuR6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,476,534</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1WK_zuFZz9rMrOi3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,513,458</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zQhlQPsjm8p2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,434,412</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zVDcOeTVXDne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Total undiscounted lease payments</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,615,418</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWCSU7W9F8H9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Less: imputed interest</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,685,947</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z9oRF49fzBAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Present value of lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,929,471</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_z8ieqkvdIXni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
operating lease expense related to our real estate leases was $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20201231_z5xfuW4RwL2d"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,325,844</ix:nonFraction></span>, and variable lease expense was $<span id="xdx_904_eus-gaap--VariableLeasePayment_uUSD_c20200101__20201231_zcGqvKe2xly6" title="Variable lease payment"><ix:nonFraction name="us-gaap:VariableLeasePayment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,578</ix:nonFraction></span>. During the year
ended December 31, 2019, operating lease expense related to our real estate leases was $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20190101__20191231_zxvkbCxhX6M7"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,558,794</ix:nonFraction></span>, and variable lease expense was
insignificant. The rental expense during the year ended December 31, 2018 was $<span id="xdx_900_eus-gaap--OperatingLeasesRentExpenseNet_uUSD_c20180101__20181231_zwfEDtYwxmm2" title="Rental expense"><ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,068,275</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Intellectual Property Licenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Population Council License Agreement
provides for future milestone payments to be paid by us for access to certain technologies. In addition, we pay royalties as a
percent of revenue as described in Note 2, Summary of Significant Accounting Policies to these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Purchase Commitments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have manufacturing and supply agreements
whereby we are required to purchase from Catalent a minimum number of softgels during the first contract year and a higher number
of softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to
pay Catalent <span id="xdx_908_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_uPure_c20201231_zHlmLgK99v5e"><ix:nonFraction name="txmd:SignificantSupplyCommitmentPercentagePayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the difference between the total amount we would have paid to Catalent if the minimum requirement had been
fulfilled and the sum of all purchases of our products from Catalent during the contract year. The minimum purchase commitments
for Catalent for the next five years are as follows: 2021 - $<span id="xdx_90B_eus-gaap--PurchaseObligationDueInNextTwelveMonths_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zyEGNj5aMty6" title="Minimum purchase commitment, 2021"><ix:nonFraction name="us-gaap:PurchaseObligationDueInNextTwelveMonths" contextRef="AsOf2020-12-31_custom_CatalentMember75224546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,458,000</ix:nonFraction></span>, 2022 - $<span id="xdx_90F_eus-gaap--PurchaseObligationDueInSecondYear_iI_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zEEMNRZaUOnj" title="Minimum purchase commitment, 2022"><ix:nonFraction name="us-gaap:PurchaseObligationDueInSecondYear" contextRef="AsOf2020-12-31_custom_CatalentMember75224546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,000</ix:nonFraction></span>, 2023 - $<span id="xdx_904_eus-gaap--PurchaseObligationDueInThirdYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zCgZbR9fhbO8" title="Minimum purchase commitment, 2023"><ix:nonFraction name="us-gaap:PurchaseObligationDueInThirdYear" contextRef="AsOf2020-12-31_custom_CatalentMember75224546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,991,000</ix:nonFraction></span>, 2024 - $<span id="xdx_90E_eus-gaap--PurchaseObligationDueInFourthYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_z1TeeOZUex04" title="Minimum purchase commitment, 2024"><ix:nonFraction name="us-gaap:PurchaseObligationDueInFourthYear" contextRef="AsOf2020-12-31_custom_CatalentMember75224546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,347,000</ix:nonFraction></span>,
and 2025 - $<span id="xdx_902_eus-gaap--PurchaseObligationDueInFifthYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zvF6Tplc5KH4" title="Minimum purchase commitment, 2025"><ix:nonFraction name="us-gaap:PurchaseObligationDueInFifthYear" contextRef="AsOf2020-12-31_custom_CatalentMember75224546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,786,000</ix:nonFraction></span>. In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum
number of units of ANNOVERA during a contract year. The minimum purchase commitment for ANNOVERA for 2021 is approximately $<span id="xdx_90E_eus-gaap--PurchaseObligationDueInNextTwelveMonths_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--AnnoveraMember_zFZp6NjwV9J1"><ix:nonFraction name="us-gaap:PurchaseObligationDueInNextTwelveMonths" contextRef="AsOf2020-12-31_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,526,000</ix:nonFraction></span>.
As of December 31, 2020, we have met our minimum purchase commitments with our manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 3 -->
    <div id="xdx_235_zD1ItUFFNrvh" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zWTjKEwAY4o" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_ziSMLeNnfTTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Legal Proceedings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we are involved in litigation
and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would
have a material effect on our consolidated financial condition, results of operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Off-Balance Sheet Arrangements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, 2019, and 2018,
we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Employment Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into employment agreements
with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including
a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the
term of the employment agreement.</p>

</ix:nonNumeric><p id="xdx_81B_zaWwUU1Ar4v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:QuarterlyFinancialInformationTextBlock"><p id="xdx_806_eus-gaap--QuarterlyFinancialInformationTextBlock_zQazNNsFg25" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 15 &#8211; <span id="xdx_829_zc0nkY9To9kd">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zfXZTA46Uurc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BC_zWmViDIqFdz5">Summarized quarterly financial data for fiscal years 2020 and
2019 is as follows</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20200101__20200331_z6rrFh6OByEd" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20200401__20200630_zZCpBW64XMCh" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200701__20200930_z1pUNMwR3iT9" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20201001__20201231_zqnyUQTcCaf6" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands, except per share)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">First <br />Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Second<br />
Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Third</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Quarter<br />
<sup id="xdx_F5E_zJhND2Sl5J81">(1)(2)(3)(4)</sup></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Fourth<br />
Quarter <sup id="xdx_F52_zdpoaQjMzzkj">(5)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zTaRWi9Bojzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Revenues</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,701</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zTmPSvKBesW2" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30" id="Fact001698" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,343</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20201001__20201231_fKDUp_zhou96xStL1h" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-10-012020-12-31" id="Fact001699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,577</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--GrossProfit_pn3n3_uUSD_z8GEljnynhu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--GrossProfit_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zs1jjBIXEGlf" style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-07-012020-09-30" id="Fact001705" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,064</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20201001__20201231_fKDUp_zyYD68qP7L1d" style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-10-012020-12-31" id="Fact001706" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,996</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_uUSD_zRDlTSpwFoXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">56,849</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">51,976</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zLc9X0tXDuF8" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" id="Fact001712" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">32,611</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--NetIncomeLoss_pn3n3_c20201001__20201231_fKDUp_zhBCouQ7SyT6" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" id="Fact001713" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">42,088</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zvJ1IxwcGY59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.21</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20200701__20200930_fKDEpKDIpKDMpKDQp_z2VZ6BcRKMdj" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-07-012020-09-30" id="Fact001719" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20201001__20201231_fKDUp_zXBzDesZKu5k" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-10-012020-12-31" id="Fact001720" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.15</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20190101__20190331_zLItBRipd1b6" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190401__20190630_z7lyNgKXa7a3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20190701__20190930_zzkGCPzdaGPd" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20191001__20191231_zdHCdsnhGRia" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands, except per share)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">First <br />Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Second<br />
Quarter <sup id="xdx_F56_zuZyx7yGIx28">(6)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Third</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Quarter <sup id="xdx_F5A_zgkjBnBWNqJg">(7)</sup></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fourth<br />
Quarter</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zQUf9wuYvpl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Revenues</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,947</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630_fKDYp_zhoa6OAP7HIa" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-04-012019-06-30" id="Fact001726" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,079</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930_fKDcp_zl2c2NZrJHA8" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30" id="Fact001727" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,719</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,902</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--GrossProfit_pn3n3_uUSD_zPfRErpHlX4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20190401__20190630_fKDYp_zUm7MmC9lhve" style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-04-012019-06-30" id="Fact001733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,830</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20190701__20190930_fKDcp_zT6E6UN8L0Rh" style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-07-012019-09-30" id="Fact001734" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,275</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,023</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_pn3n3_uUSD_z6k5bp7JoxL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,506</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20190401__20190630_fKDYp_zGWN8WPLUUE8" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30" id="Fact001740" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,237</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_pn3n3_c20190701__20190930_fKDcp_zgG2QV0213Pc" style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30" id="Fact001741" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">31,967</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49,435</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zjxeUGUvBbe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190401__20190630_fKDYp_zX8xMvGJPwJ8" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-04-012019-06-30" id="Fact001747" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190701__20190930_fKDcp_z8zBgJdMGhQ3" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-07-012019-09-30" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></td><td style="text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(1)</td><td>During the third quarter of 2020, we recorded $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_znlN4bjOneM9"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30_custom_KnightLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2</ix:nonFraction> million</span> in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(2)</td><td>During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3p0_dm_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zzstULDejUfg" title="Fair value of warrants"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-09-30_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.4</ix:nonFraction> million</span> as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(3)</td><td style="text-align: justify">During the third quarter of 2020, we wrote off approximately $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20200701__20200930_zbp5nfI78fAa" title="Write off of patent and trademark cost"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction> million</span> in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(4)</td><td>During the third quarter of 2020, we recorded approximately $<span id="xdx_902_eus-gaap--InventoryWriteDown_pn3p0_dm_c20200701__20200930_zzpUeya085Mh" title="Inventory charge"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">5.7</ix:nonFraction> million</span> in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(5)</td><td>During the fourth quarter of 2020, we wrote off approximately $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20201001__20201231_zzyk86lmPAse"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.5</ix:nonFraction> million</span> in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(6)</td><td>During the second quarter of 2019, we recorded approximately $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_z3r1bzKRWu15" title="Loss on extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" sign="-" unitRef="USD">10.1</ix:nonFraction> million</span> in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(7)</td><td>During the third quarter of 2019, we recorded approximately $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zT1eC19R11qi"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember" format="ixt:numdotdecimal" decimals="-3" scale="5" unitRef="USD">15</ix:nonFraction>.
                                                                 5 million</span> in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of
                                                                 Significant Accounting Policies.</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td id="xdx_F0A_zfLFhuE5BfRf" style="width: 0.25in">(1)</td><td id="xdx_F17_zPuPm7yI0if8"><ix:footnote id="Footnote001760" xml:lang="en-US">During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td id="xdx_F0D_z9vclAeXaBF" style="width: 0.25in">(2)</td><td id="xdx_F1C_zTsLEb9IsUs1"><ix:footnote id="Footnote001761" xml:lang="en-US">During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td id="xdx_F03_zF1DY0Wx71Nf" style="width: 0.25in">(3)</td><td id="xdx_F1B_zkzvmv0xaEa8" style="text-align: justify"><ix:footnote id="Footnote001762" xml:lang="en-US">During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td id="xdx_F02_zwANq9PitIP1" style="width: 0.25in">(4)</td><td id="xdx_F10_zMH9wMYnGo54"><ix:footnote id="Footnote001763" xml:lang="en-US">During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td id="xdx_F04_zNdRKYs8T8h6" style="width: 0.25in">(5)</td><td id="xdx_F17_zi3pMoIBCvwb"><ix:footnote id="Footnote001764" xml:lang="en-US">During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td id="xdx_F00_zxjQ2fGLDGwc" style="width: 0.25in">(6)</td><td id="xdx_F1E_ziFSieJPBL67"><ix:footnote id="Footnote001765" xml:lang="en-US">During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</ix:footnote></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td id="xdx_F04_zC6OWyYFKqnf" style="width: 0.25in">(7)</td><td id="xdx_F18_z8We1Rc08aQk"><ix:footnote id="Footnote001766" xml:lang="en-US">During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</ix:footnote></td></tr></table>
</ix:nonNumeric><p id="xdx_8AD_zcP7mDJijidd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><p id="xdx_813_zBnaWkcyOsEc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 110; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_z8Co9uv6xHPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 16 &#8211; <span id="xdx_829_z8OTVS4HZLaf">SUBSEQUENT EVENTS</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period from January 1,
2021 through February 8, 2021 in accordance with the terms of the sales agreement described in Note 9- Stockholders&#8217;
Equity, we sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20210101__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrwrgLMhjjF" title="Shares issued in offerings, net of cost (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-02-08_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,600,689</ix:nonFraction> </span>shares
of Common Stock for net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_uUSD_c20210101__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfDdQ7PzRq98" title="Proceeds from sale of common stock, net of costs"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-02-08_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">47.3</ix:nonFraction>
million</span> through Cantor Fitzgerald who acted as our sales agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 13, 2021, we entered into Amendment No. 7 to the
Financing Agreement, or Amendment No. 7, pursuant to which, among other amendments, the minimum consolidated net revenue
requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA for the fiscal quarters ending March 31, 2021
and June 30, 2021 were reduced to $<span id="xdx_90E_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment7Period1Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zDLs5c4qRHb2"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">18</ix:nonFraction></span>.0
million and $<span id="xdx_904_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment7Period2Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zSriJ7OOLta5"><ix:nonFraction name="txmd:MinimumRevenueRequirementUnderCreditAgreement" contextRef="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">22</ix:nonFraction></span>.0
million, respectively. On January 13, 2021, in connection with entering into Amendment No. 7 to the Financing Agreement, the
Lender Warrants were further amended to provide for an additional adjustment to the exercise price if we conduct certain
dilutive issuances prior to March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2021, we entered into Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA. See Note 8 &#8211; Debt for information regarding Amendment No. 8.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2021, we entered into
an underwriting agreement with Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zY3ih7pRKQT3"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,459,460</ix:nonFraction></span>
shares of Common Stock. Pursuant to the underwriting agreement, we granted to the underwriter an option, exercisable for a
period of <span id="xdx_909_ecustom--PeriodExercisableUnderwritersOption_dt_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7BB1HF48HNh" title="Period exercisable underwriters option"><ix:nonNumeric contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember" format="ixt-sec:durwordsen" name="txmd:PeriodExercisableUnderwritersOption">30
days</ix:nonNumeric></span>, to purchase up to <span id="xdx_90A_ecustom--UnderwritersOptionGrantedInPeriodShares_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgnNBDHFfuv3" title="Underwriters option granted in period shares"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,918,919</ix:nonFraction></span>
additional shares of Common Stock. The net proceeds to us from the offering, excluding any proceeds that may be received from
the exercise of the underwriter&#8217;s option to purchase additional shares, are expected to be approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztrhJARpXUs6"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">97.1</ix:nonFraction>
million</span>, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The
offering closed on February 16, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 111; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>

    <!-- Field: /Page --></ix:exclude>
</ix:nonNumeric></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>ex10-12.htm
<DESCRIPTION>SECOND AMENDMENT TO COMPANY WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.12</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND
AMENDMENT TO COMPANY WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
SECOND AMENDMENT TO THE COMPANY WARRANT (this &ldquo;<B>Amendment</B>&rdquo;), dated as of January 13, 2021, is by and among TherapeuticsMD,
Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), Tao Finance 1, LLC, a Delaware limited liability company (&ldquo;<B>Tao
Finance</B>&rdquo;), Redwood IV Finance 1, LLC, a Delaware limited liability company (&ldquo;<B>Redwood IV</B>&rdquo;) and Sixth
Street Specialty Lending, Inc., a Delaware corporation (&ldquo;<B>Sixth Street</B>&rdquo; and together with Tao Finance and Redwood
IV, collectively the &ldquo;<B>Holders</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company issued Warrant No. 1 to Sixth Street on August 5, 2020 convertible into 712,817 shares of Company Common Stock (the
&ldquo;<B>Sixth Street Warrant</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company issued Warrant No. 2 to Redwood IV on August 5, 2020 convertible into 1,188,029 shares of Company Common Stock (the
&ldquo;<B>Redwood IV Warrant</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company issued Warrant No. 3 to Tao Finance on August 5, 2020 convertible into 2,851,270 shares of Company Common Stock (the
&ldquo;<B>Tao Finance Warrant</B>&rdquo; and together with the Sixth Street Warrant and Redwood IV Warrant collectively, the &ldquo;<B>Warrants</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company and the Holders amended the terms and conditions of the Warrants pursuant to that certain Amendment to the Company
Warrant, dated as of November 8, 2020, by and among the Company and the Holders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
on November 13, 2020, the Company sold 23,437,500 shares of Common Stock at a price per share equal to $1.1856, and, pursuant
to Section 3(b) of each of the Warrants, adjusted the Exercise Price of the Warrants to $1.1856; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company and the Holders wish to further amend the Warrants on the terms set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Holders agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment to Warrant: Adjustment to Exercise
Price For Subsequent Issuances</U>. Section 3(b) of each Warrant is hereby amended to add the following language at the end of
such section:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;If
the Company shall, at any time or from time to time after January 13, 2021 (the &ldquo;<B>Second Adjustment Date</B>&rdquo;) and
on or prior to March 31, 2021, issue or sell, or in accordance with Section 3(e) is deemed to have issued or sold, any shares
of Common Stock for consideration per share less than the Exercise Price in effect immediately prior to such issuance or sale
(or deemed issuance or sale) (&ldquo;<B>Second Adjustment Trigger Shares</B>&rdquo;), then immediately upon such issuance or sale
(or deemed issuance or sale), the Exercise Price shall be reduced to the weighted average per share consideration received by
the Company for all Second Adjustment Trigger Shares so issued or sold (or deemed issued or sold)
from and after the Second Adjustment Date and on or prior to March 31, 2021, as determined in good faith by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing Law</U>. This Amendment shall be
governed by and construed in accordance with the laws of the State of New York, without regard to principles of conflict of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Other Amendments</U>. Except as expressly
amended herein, each of the Warrants remains in full force and effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Counterparts</U>. This Amendment may be executed
in any number of counterparts, each of which shall be an original, but all of which taken together shall constitute one and the
same agreement. Delivery of an executed counterpart of this Amendment by telefacsimile or other electronic means (including email
with a &ldquo;pdf&rdquo;) shall have the same force and effect as the delivery of an original executed counterpart of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[<I>Signature
Page to Follow</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, each of the undersigned has duly executed this Amendment as of the day and year first above written.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">COMPANY:</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 25%">/s/ James C. D&rsquo;Arecca</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">James C. D&rsquo;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">HOLDERS:</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tao
Finance 1, LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Joshua Peck</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">Joshua Peck</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Vice President</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Redwood IV Finance 1, LLC</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>b</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Joshua Peck</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">Joshua Peck</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Vice President</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sixth
Street Specialty Lending, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Joshua Easterly</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name</TD>
    <TD COLSPAN="2">Joshua Easterly</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>ex10-13.htm
<DESCRIPTION>WARRANT ISSUED TO ROBERT G. FINIZIO
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.13</B></FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-13_img01.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>


<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-13_img03.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>


<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-13_img05.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-13_img07.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>


<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-13_img09.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-13_img11.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>4
<FILENAME>ex10-14.htm
<DESCRIPTION>AMENDMENT TO WARRANT ISSUED TO ROBERT G. FINIZIO
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.14</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
TO WARRANT</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment to Warrant (this &#8220;<B><I>Amendment</I></B>&#8221;) is dated as of February 18, 2021 by and between Robert G. Finizio
(&#8220;<B><I>Holder</I></B>&#8221;) and TherapeuticsMD, Inc. (&#8220;<B><I>Company</I></B>&#8221;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recitals</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
in connection with the guaranty by Holder of a line of credit issued by 1<SUP>st</SUP> United Bank to vitaMedMD, LLC, a Delaware
limited liability company and wholly owned subsidiary of the Company on March 6, 2011, Company issued to Holder that certain Warrant
No. 1 dated as of October 4, 2011 granting Holder the right to purchase 204,571 shares of common stock, $0.001 par value per share,
of the Company (&#8220;<B><I>Shares</I></B>&#8221;) at a per Share price of $0.2444 (the &#8220;<B><I>Warrant</I></B>&#8221;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
pursuant to Section 11 of the Warrant, neither the Warrant nor any term thereof may be changed, waived, discharged or terminated
without the prior written consent of Holder and the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Company and Holder wish to amend the Warrant in order to allow for a cashless exercise of the Warrant.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, Company and Holder agree as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant is hereby amended to add Sections 2(e) and 2(f), to read in their entirety as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
lieu of, or in addition to, exercising this Warrant as specified in subsection (a) above, Holder may from time to time convert
this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares
or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Purchase Price of such Shares by (b)
the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to subsection (f) of this
Section.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Shares are traded regularly in a public market, the fair market value of the Shares shall be the closing price of the Shares
reported for the business day immediately before Holder delivers its completed Exercise Agreement to the Company. If the Shares
are not regularly traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable
good faith judgment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as amended hereby, the Warrant remains in full force and effect. This Amendment may be executed in two or more counterparts, each
of which shall be deemed an original, and both of which shall constitute one instrument.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THERAPEUTICSMD,
                                         INC.</B></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 10.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By<U>:_/s/
        James C. D&#8217;Arecca</U>_________________</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 10.1pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
        C. D&#8217;Arecca</FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 10.1pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Financial Officer</FONT></P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 10.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ROBERT
                                         G. FINIZIO</B></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 10.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 10.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By<U>:__/s/
        Robert G. Finizio</U>_________________</FONT></P>

</TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>ex10-15.htm
<DESCRIPTION>WARRANT ISSUED TO JOHN C.K. MILLIGAN, IV
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.15</B></FONT></P>



<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-15_img01.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-15_img02.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-15_img03.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-15_img04.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-15_img05.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><IMG SRC="ex10-15_img06.gif" ALT="" STYLE="height: 1056px; width: 816px"></P>
<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>6
<FILENAME>ex10-16.htm
<DESCRIPTION>AMENDMENT TO WARRANT ISSUED TO JOHN C.K. MILLIGAN, IV
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.16</B></FONT></P>
<P STYLE="margin: 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt; text-align: center"><B>AMENDMENT TO WARRANT</B></P>

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">This Amendment to Warrant
(this &#8220;<B><I>Amendment</I></B>&#8221;) is dated as of February 20, 2021 by and between John C.K. Milligan, IV (&#8220;<B><I>Holder</I></B>&#8221;)
and TherapeuticsMD, Inc. (&#8220;<B><I>Company</I></B>&#8221;).</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>Recitals</B></P>

<P STYLE="margin: 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">WHEREAS, in connection
with the guaranty by Holder of a line of credit issued by 1<SUP>st</SUP> United Bank to vitaMedMD, LLC, a Delaware limited liability
company and wholly owned subsidiary of the Company on March 6, 2011, Company issued to Holder that certain Warrant No. 2 dated
as of October 4, 2011 granting Holder the right to purchase 204,571 shares of common stock, $0.001 par value per share, of the
Company (&#8220;<B><I>Shares</I></B>&#8221;) at a per Share price of $0.2444 (the &#8220;<B><I>Warrant</I></B>&#8221;).</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant
to Section 11 of the Warrant, neither the Warrant nor any term thereof may be changed, waived, discharged or terminated without
the prior written consent of Holder and the Company.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">WHEREAS, Company
and Holder wish to amend the Warrant in order to allow for a cashless exercise of the Warrant.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
Company and Holder agree as follows:</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant is hereby amended to add Sections 2(e) and 2(f), to read in their entirety as follows:</P>

<P STYLE="margin: 0 0.5in 12pt; font-size: 10pt; text-align: justify; text-indent: 0in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
lieu of, or in addition to, exercising this Warrant as specified in subsection (a) above, Holder may from time to time convert
this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares
or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Purchase Price of such Shares by (b) the
fair market value of one Share. The fair market value of the Shares shall be determined pursuant to subsection (f) of this Section.</P>

<P STYLE="margin: 0 0.5in 12pt; font-size: 10pt; text-align: justify; text-indent: 0in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Shares are traded regularly in a public market, the fair market value of the Shares shall be the closing price of the Shares
reported for the business day immediately before Holder delivers its completed Exercise Agreement to the Company. If the Shares
are not regularly traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable
good faith judgment.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as amended hereby, the Warrant remains in full force and effect. This Amendment may be executed in two or more counterparts, each
of which shall be deemed an original, and both of which shall constitute one instrument.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="margin: 0 0 12pt 12pt; font-size: 10pt"><B>THERAPEUTICSMD, INC.</B></P>
        <P STYLE="margin: 0 0 12pt 12pt; font-size: 10pt"><B>&nbsp;</B></P>
        <P STYLE="margin: 0 0 0 10.1pt; font-size: 10pt; text-align: justify">By<U>:_/s/ James C. D&#8217;Arecca</U>_________________</P>
        <P STYLE="margin: 0 0 0 10.1pt; font-size: 10pt; text-align: justify; text-indent: 0.25in">James C. D&#8217;Arecca</P>
        <P STYLE="margin: 0 0 0 10.1pt; font-size: 10pt; text-align: justify; text-indent: 0.25in">Chief Financial
        Officer</P></TD>
    <TD STYLE="font-size: 10pt; width: 50%; padding-right: 5.4pt; padding-left: 11pt">
        <P STYLE="margin: 0 0 12pt 22pt; font-size: 10pt; text-align: justify"><B>JOHN C.K. MILLIGAN, IV</B></P>
        <P STYLE="margin: 0 0 12pt 22pt; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="margin: 0 0 0 22pt; font-size: 10pt; text-align: justify">By: <U>John C.K. Milligan, IV</U></P>

</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>7
<FILENAME>ex10-24.htm
<DESCRIPTION>AMENDMENT NO. 7 TO THE FINANCING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.24&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 7<BR>
TO FINANCING AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 7 TO FINANCING AGREEMENT</B>, dated as of January 13, 2021 (this &#8220;<U>Amendment</U>&#8221;), to the Financing Agreement,
dated as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<U>Financing
Agreement</U>&#8221;), by and among THERAPEUTICSMD, INC., a Nevada corporation (&#8220;<U>Company</U>&#8221; or &#8220;<U>Borrower</U>&#8221;),
certain Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party thereto, and SIXTH STREET SPECIALTY LENDING,
INC., a Delaware corporation (&#8220;<U>Sixth Street</U>&#8221;), as administrative agent for the Lenders (in such capacity, together
with its successors and assigns in such capacity, the &#8220;<U>Administrative Agent</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Loan Parties have requested that the Administrative Agent and the Lenders amend certain terms and conditions of the Financing
Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Administrative Agent and the Lenders are willing to amend such terms and conditions of the Financing Agreement on the terms
and conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B>, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U>. All terms used herein that
are defined in the Financing Agreement and not otherwise defined herein shall have the meanings assigned to them in the Financing
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>New Definitions</U>. <U>Section 1.01</U> of the Financing Agreement is hereby
amended by adding the following definitions, in appropriate alphabetical order:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;&#8220;<U>Amendment No. 7</U>&#8221; means Amendment No. 7 to Financing Agreement, dated as of January 13, 2021, by and
among the Loan Parties, the Administrative Agent and the Lenders.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;&#8220;<U>Amendment No. 7 Effective Date</U>&#8221; means the &#8220;Amendment Effective Date&#8221; as set forth in Amendment
No. 7.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;&#8220;<U>Cash Collateral Account</U>&#8221; means that certain Deposit Account with Bank of America, N.A. identified by
account number 4451020473.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&#8220;&#8220;<U>Specified Payables</U>&#8221; means the aggregate amount of all trade payables aged in excess of 60 days past
the applicable invoice date and all book overdrafts, in each case as reasonably determined by Administrative Agent.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 0pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Existing Definitions</U>. </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Section 1.01</U> of the Financing Agreement is hereby amended as follows:</font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The definition of Excluded Account is hereby
amended and restated to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">&#8220;&#8220;<U>Excluded
Account</U>&#8221; means (i) Deposit Accounts and Securities Accounts the balance of which consists exclusively of (a) withheld
income Taxes and federal, state or local employment Taxes in such amounts as are required to be paid to the Internal Revenue Service
or state or local government agencies within the following two months with respect to employees of the Company or any of its Subsidiaries,
and (b) any payroll accounts, health care reimbursement accounts and employee benefits accounts, including any accounts containing
amounts required to be paid over to an employee benefit plan pursuant to DOL Reg. Sec. 2510.3-102 on behalf of or for the benefit
of employees of the Company or any of its Subsidiaries, (ii) all segregated Deposit Accounts constituting (and the balance of
which consists solely of funds set aside in connection with) tax accounts, fiduciary accounts and trust accounts and (iii) any
Deposit Accounts and Securities Accounts, amounts on deposit in which do not exceed $100,000 individually or $500,000 in the aggregate
at any one time, (iv) any Deposit Accounts that contain accounts receivable arising from any Governmental Payor where Administrative
Agent may not under applicable Law obtain a security interest in or lien on such Deposit Account receiving the proceeds of such
accounts receivable; <U>provided</U>, that amounts in such Deposit Account referred to in this subclause (iv) are automatically
transferred on each Business Day into a Deposit Account that is not an Excluded Account, (v) the Cash Collateral Account, or (vi)
the Deposit Account with Bank of America, N.A. identified by account number 4451288202.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The definition of Permitted Indebtedness is hereby amended by deleting &#8220;and&#8221; at the end of clause (m), deleting the
&#8220;.&#8221; at the end of clause (n) and inserting a &#8220;;&#8221; in place thereof, and inserting a new clause (o) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;(o)&#9;Indebtedness
of the Loan Parties in respect of credit card programs in the ordinary course of business in an aggregate amount not to exceed
$200,000 at any time outstanding.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The definition of Permitted Liens is hereby amended by deleting &#8220;and&#8221; at the end of clause (p), deleting the &#8220;.&#8221;
at the end of clause (q) and inserting a &#8220;;&#8221; in place thereof, and inserting a new clause (r) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;(r)&#9;Liens
on the Cash Collateral Account securing Permitted Indebtedness described under clause (o) of the definition thereof.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Section 5.1(a) (Cash Reports)</U>. Section 5.1(a) of the Financing Agreement
is hereby amended and restated in its entirety to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">&#8220;(a)&#9;<U>Cash
Reports</U>. Promptly, but in any event within 5 Business Days, after the end of each week commencing with the week ending January
15, 2021, a report (which report may consist of bank statements) of the current Cash and Cash Equivalent balances (including the
balances in each Deposit Account of each Loan Party) of the Company and its Subsidiaries, which report shall identify (i) unrestricted
(other than restrictions created by the Collateral Documents) and restricted Cash and Cash Equivalents and (ii) those accounts
that constitute Qualified Cash; <U>provided</U>, that at any time the current Cash and Cash Equivalent balances of the Company
and its Subsidiaries is less than (A) $75,000,000, the Company shall either (1) on each Business Day provide a report of at least 95% of the current
Cash and Cash Equivalent balances of the Company and its Subsidiaries (the &#8220;<U>Specified Cash</U>&#8221;), which report
shall identify unrestricted (other than restrictions created by the Collateral Documents) and restricted Cash and Cash Equivalents
(or, if greater, all Cash and Cash Equivalent balances required to satisfy the covenant set forth in <U>Section 6.8</U>) or (2)
provide Administrative Agent with electronic, read only access to such Deposit Accounts of the Company and its Subsidiaries which
contain the Specified Cash and (B) $60,000,000, the Company shall immediately notify Administrative Agent in writing of the current
Cash and Cash Equivalent balances (including the balances in each Deposit Account of each Loan Party) of the Company and its Subsidiaries.&#8221;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
6.8(a) (Minimum Qualified Cash)</U>. <U>Section 6.8(a)</U> of the Financing Agreement is hereby amended and restated in its entirety
to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;(a)&#9;<U>Minimum
Qualified Cash</U>. At all times, Borrower shall not permit Qualified Cash to be less than $60,000,000 <I>minus</I> the Specified
Payables.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Section 6.8(b) (Minimum Revenue)</U>. <U>Section 6.8(b)</U> of the Financing
Agreement is hereby amended by amending the table set forth therein for the Fiscal Quarters ending March 31, 2021 and June 30,
2021 such that the minimum Product Revenue for the Fiscal Quarter ending (i) March 31, 2021 shall be $18,000,000 and (ii) June
30, 2021 shall be $22,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the request of the Loan Parties and in reliance upon the representations
and warranties of the Loan Parties described herein, Administrative Agent and the Lenders hereby waive any Event of Default under
Section 8.1(c) of the Financing Agreement arising out of the Loan Parties&#8217; failure to comply with Section 6.16 of the Financing
Agreement solely as a result of the failure of the Loan Parties to cause the Cash Collateral Account to be subject to a Control
Agreement (the &#8220;<U>Specified Event of Default</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The waiver in this Section 3 shall be effective only in this specific instance
and for the specific purpose set forth herein and does not allow for any other or further departure from the terms and conditions
of the Financing Agreement or any other Loan Document, which terms and conditions shall continue in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions to Effectiveness</U>. This Amendment
shall become effective only upon satisfaction in full, in a manner satisfactory to the Administrative Agent, of the following
conditions precedent (the first date upon which all such conditions shall have been satisfied being hereinafter referred to as
the &#8220;<U>Amendment Effective Date</U>&#8221;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Payment of Fees, Etc</U>. The Borrowers shall have paid on or before the Amendment
Effective Date (i) an amendment fee equal to $5,000,000, which fee shall be fully earned, due and payable to Administrative Agent
on the Amendment Effective Date, and (ii) all fees, costs, expenses and taxes then payable, if any, pursuant to <A NAME="a_DV_C93"></A><A NAME="a_DV_M117"></A><U>Section
2.7</U> or <A NAME="a_DV_C95"></A><U>10.2</U> of the Financing Agreement.</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Representations and Warranties</U>. <FONT STYLE="letter-spacing: 0pt">The
representations and </FONT>warranties <FONT STYLE="letter-spacing: 0pt">contained in this Amendment and </FONT>in <U>Article&nbsp;IV
</U>of the Financing Agreement and in each other Loan Document shall be true and correct in all material respects (except that
such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) on and as the Amendment Effective Date to the same extent
as though made on and as of that date, except to the extent such representations and warranties specifically relate to an earlier
date, in which case such representations and warranties shall have been true and correct in all material respects (except that
such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to &#8220;materiality&#8221; or &#8220;Material Adverse Effect&#8221; in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) on and as of such earlier date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>No Default; Event of Default</U>. No Default or Event of Default (other than
the Specified Event of Default) shall have occurred and be continuing on the Amendment Effective Date or result from this Amendment
becoming effective in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Delivery of Documents</U>. The Administrative Agent shall have received on
or before the Amendment Effective Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
this Amendment, duly executed by the Loan Parties, the Administrative Agent and the Lenders; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
an amendment to each Warrant to Purchase Common Stock dated August 5, 2020 issued by the Borrower to Sixth Street, Redwood IV
Finance 1, LLC and TAO Finance 1, LLC, in each case in form and substance satisfactory to the Administrative Agent and duly executed
by the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Material Adverse Effect</U>. The Administrative Agent shall have determined,
in its reasonable judgment, that no event or development shall have occurred since December 31, 2019, which could reasonably be
expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_Ref24471569"></A>(f)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Liens; Priority</U>. The Administrative Agent shall be satisfied that
the Administrative Agent has been granted, and holds, for the benefit of the Administrative Agent and the Lenders, a perfected,
first priority Lien on and security interest in all of the Collateral, subject only to Permitted Liens, to the extent such Liens
and security interests are required pursuant to the Loan Documents to be granted or perfected on or before the Amendment Effective
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Approvals</U>. All consents, authorizations and approvals of, and filings
and registrations with, and all other actions in respect of, any Governmental Authority or other Person required in connection
with any Loan Document or the transactions contemplated thereby or the conduct of the Loan Parties&#8217; business shall have
been obtained or made and shall be in full force and effect. There shall exist no claim, action, suit, investigation, litigation
or proceeding (including, without limitation, shareholder or derivative litigation) pending or, to the knowledge
of any Loan Party, threatened in any court or before any arbitrator or Governmental Authority which (i)&nbsp;relates to the Loan
Documents or the transactions contemplated thereby or (ii)&nbsp;could reasonably be expected to have a Material Adverse Effect.</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions Subsequent to Effectiveness</U>.
As an accommodation to the Loan Parties, Administrative Agent and the Lenders have agreed to execute this Amendment notwithstanding
the failure by the Loan Parties to satisfy the conditions set forth below on or before the Amendment Effective Date. In consideration
of such accommodation, the Loan Parties agree that, in addition to all other terms, conditions and provisions set forth herein
and in the Financing Agreement and the other Loan Documents, including, without limitation, those conditions set forth in Section
4 hereof, the Loan Parties shall satisfy each of the conditions subsequent set forth below on or before the date applicable thereto
(it being understood that (a) the failure by the Loan Parties to perform or cause to be performed any such condition subsequent
on or before the date applicable thereto shall constitute an Event of Default and (b) to the extent that the existence of any
such condition subsequent would otherwise cause any representation, warranty or covenant in this Amendment, the Financing Agreement
or any other Loan Document to be breached, the Required Lenders hereby waive such breach for the period from the Amendment Effective
Date until the date on which such condition subsequent is required to be fulfilled pursuant to this Section 5):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On or prior to the date that is 30 days following the Amendment Effective Date (or such later date as agreed to in writing by
Administrative Agent in its sole discretion), the Loan Parties shall deliver to Administrative Agent (x) Control Agreements for
(i) each Deposit Account identified on <U>Exhibit A</U> hereto and (ii) any other Deposit Account with respect to which a Control
Agreement is required to be delivered under the Loan Documents, in each case duly executed by, in addition to the applicable Loan
Party, the applicable financial institution, (y) evidence that the Deposit Account identified by account number 898049551890 has
been closed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On or prior to the date that is 5 Business Days following the Amendment Effective Date (or such later date as agreed to in writing
by Administrative Agent in its sole discretion), the Loan Parties shall deliver to Administrative Agent Collateral Assignments
for Security in respect of the trademarks, patents and patent applications identified on <U>Exhibit B</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Continued Effectiveness of the Financing Agreement
and Other Loan Documents</U>. Each Loan Party hereby (a) acknowledges and consents to this Amendment, (b)&nbsp;confirms and agrees
that the Financing Agreement and each other Loan Document to which it is a party is, and shall continue to be, in full force and
effect and is hereby ratified and confirmed in all respects, except that on and after the Amendment Effective Date, all references
in any such Loan Document to &#8220;the Financing Agreement&#8221;, the &#8220;Agreement&#8221;, &#8220;thereto&#8221;, &#8220;thereof&#8221;,
&#8220;thereunder&#8221; or words of like import referring to the Financing Agreement shall mean the Financing Agreement as amended
by this Amendment, and (c)&nbsp;confirms and agrees that, to the extent that any such Loan Document purports to assign or pledge
to the Administrative Agent, for the benefit of the Administrative Agent and the Lenders, or to grant to the Administrative Agent,
for the benefit of the Administrative Agent and the Lenders, a security interest in or Lien on any Collateral as security for
the Obligations of the Loan Parties from time to time existing in respect
of the Financing Agreement (as amended hereby) and the other Loan Documents, such pledge, assignment and/or grant of the security
interest or Lien is hereby ratified and confirmed in all respects. This Amendment does not and shall not affect any of the obligations
of the Loan Parties, other than as expressly provided herein, including, without limitation, the Loan Parties&#8217; obligations
to repay the Loans in accordance with the terms of Financing Agreement or the obligations of the Loan Parties under any Loan Document
to which they are a party, all of which obligations shall remain in full force and effect. Except as expressly provided herein,
the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of Administrative
Agent or any Lender under the Financing Agreement or any other Loan Document nor constitute a waiver of any provision of the Financing
Agreement or any other Loan Document.</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Novation</U>. Nothing herein contained
shall be construed as a substitution or novation of the Obligations outstanding under the Financing Agreement or instruments securing
the same, which shall remain in full force and effect, except as modified hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Representations by Administrative Agent
or Lenders</U>. Each Loan Party hereby acknowledges that it has not relied on any representation, written or oral, express or
implied, by Administrative Agent or any Lender, other than those expressly contained herein, in entering into this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Release</U>. Each Loan Party hereby acknowledges
and agrees that: (a) neither it nor any of its Subsidiaries has any claim or cause of action against Administrative Agent or any
Lender (or any of the directors, officers, employees, agents, attorneys or consultants of any of the foregoing) and (b) the Administrative
Agent and the Lenders have heretofore properly performed and satisfied in a timely manner all of their obligations to the Loan
Parties, and all of their Subsidiaries and Affiliates. Notwithstanding the foregoing, the Administrative Agent and the Lenders
wish (and the Loan Parties agree) to eliminate any possibility that any past conditions, acts, omissions, events or circumstances
would impair or otherwise adversely affect any of their rights, interests, security and/or remedies. Accordingly, for and in consideration
of the agreements contained in this Amendment and other good and valuable consideration, each Loan Party (for itself and its Subsidiaries
and Affiliates and the successors, assigns, heirs and representatives of each of the foregoing) (collectively, the &#8220;<U>Releasors</U>&#8221;)
does hereby fully, finally, unconditionally and irrevocably release, waive and forever discharge the Administrative Agent and
the Lenders, together with their respective Affiliates and Related Funds, and each of the directors, officers, employees, agents,
attorneys and consultants of each of the foregoing (collectively, the &#8220;<U>Released Parties</U>&#8221;), from any and all
debts, claims, allegations, obligations, damages, costs, attorneys&#8217; fees, suits, demands, liabilities, actions, proceedings
and causes of action, in each case, whether known or unknown, contingent or fixed, direct or indirect, and of whatever nature
or description, and whether in law or in equity, under contract, tort, statute or otherwise, which any Releasor has heretofore
had or now or hereafter can, shall or may have against any Released Party by reason of any act, omission or thing whatsoever done
or omitted to be done, in each case, on or prior to the Amendment Effective Date directly arising out of, connected with or related
to this Amendment, the Financing Agreement or any other Loan Document, or any act, event or transaction related or attendant thereto,
or the agreements of Administrative Agent or any Lender contained therein, or the possession, use, operation or control of any
of the assets of any Loan Party, or the making of any Loans or other advances, or the
management of such Loans or other advances or the Collateral. Each Loan Party represents and warrants that it has no knowledge
of any claim by any Releasor against any Released Party or of any facts or acts or omissions of any Released Party which on the
date hereof would be the basis of a claim by any Releasor against any Released Party which would not be released hereby.</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further
Assurances.</U> The Loan Parties shall execute any and all further documents, agreements and instruments, and take all further
actions, as may be required under applicable law or as Administrative Agent may reasonably request, in order to effect the purposes
of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">11.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This Amendment may be executed in any number of counterparts and by different
parties hereto in separate counterparts, each of which shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement. Delivery of an executed counterpart of this Amendment by facsimile or electronic mail shall
be equally effective as delivery of an original executed counterpart of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section and paragraph headings herein are included for convenience of reference
only and shall not constitute a part of this Amendment for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This Amendment shall be governed by, and construed in accordance with, the laws
of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Loan Party hereby acknowledges and agrees that this Amendment constitutes
a &#8220;Loan Document&#8221; under the Financing Agreement. Accordingly, it shall be an immediate Event of Default under the
Financing Agreement if (i) any representation or warranty made by any Loan Party under or in connection with this Amendment shall
have been incorrect in any respect when made or deemed made, or (ii) any Loan Party shall fail to perform or observe any term,
covenant or agreement contained in this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any provision of this Amendment that is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the
remaining portions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Remainder
of page intentionally left blank.</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered as of the date set forth on the first
page hereof.&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">BORROWER:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THERAPEUTICSMD, INC.</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 25%">/s/ James C. D&#8217;Arecca</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">
    James C. D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">GUARANTORS:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">VITAMEDMD,
        LLC</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ James C. D&#8217;Arecca</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">James C. D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;BOCAGREENMD, INC.</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ James C. D&#8217;Arecca</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">James C. D&#8217;Arecca</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">VITACARE PRESCRIPTION SERVICES, INC.</font></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ John C.K. Milligan, IV</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">
        John C.K. Milligan, IV</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">President</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">                                                                                                                                         <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIXTH
STREET SPECIALTY LENDING, INC., <BR>
as Administrative Agent and Lender</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">By:</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">/s/ Joshua Easterly</FONT></TD>
                                                                                                                                                                                                                                                    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>                                                                                                                                                                                                                                                                        <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
                                         Joshua Easterly</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">Title:
                                         Chief Executive Officer</FONT></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP
    IV TALENTS, LLC, as Lender</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">By:</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">/s/ Joshua Peck </FONT></TD>
                                                                                                                                                                                                                                                    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%">&nbsp;</TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
                                         Joshua Peck</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
                                         Vice President</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TAO TALENTS, LLC, as Lender</font></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">By:</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: 0pt">/s/ Joshua Peck </FONT></TD>
                                                                                                                                                                                                                                                    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%">&nbsp;</TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
                                         Joshua Peck</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
                                         Vice President</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>8
<FILENAME>ex10-25.htm
<DESCRIPTION>AMENDMENT NO. 8 TO THE FINANCING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: right"><B>Exhibit 10.25</B></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: right"><I>Execution Version</I></P>

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>


<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 8</B></FONT><B><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO FINANCING AGREEMENT</FONT></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 8 TO FINANCING AGREEMENT</B>, dated as of March 1, 2021 (this &ldquo;<U>Amendment</U>&rdquo;), to the Financing Agreement,
dated as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<U>Financing
Agreement</U>&rdquo;), by and among THERAPEUTICSMD, INC., a Nevada corporation (&ldquo;<U>Company</U>&rdquo; or &ldquo;<U>Borrower</U>&rdquo;),
certain Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party thereto, and SIXTH STREET SPECIALTY LENDING,
INC., a Delaware corporation (&ldquo;<U>Sixth Street</U>&rdquo;), as administrative agent for the Lenders (in such capacity, together
with its successors and assigns in such capacity, the &ldquo;<U>Administrative Agent</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Loan Parties have requested that the Administrative Agent and the Lenders amend certain terms and conditions of the Financing
Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Administrative Agent and the Lenders are willing to amend such terms and conditions of the Financing Agreement on the terms
and conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B>, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U>. All terms used herein that
are defined in the Financing Agreement and not otherwise defined herein shall have the meanings assigned to them in the Financing
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>New Definitions</U>. <U>Section 1.01</U> of the Financing Agreement
is hereby amended by adding the following definitions, in appropriate alphabetical order:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;&ldquo;<U>Amendment No. 8</U>&rdquo; means Amendment No. 8 to Financing Agreement, dated as of March 1, 2021, by and among
the Loan Parties, the Administrative Agent and the Lenders.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;&ldquo;<U>Amendment No. 8 Effective Date</U>&rdquo; means the &ldquo;Amendment Effective Date&rdquo; as set forth in Amendment
No. 8.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;&ldquo;<U>VitaCare</U>&rdquo; means VitaCare Prescription Services, Inc., a Florida corporation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;&ldquo;<U>VitaCare Business Assets</U>&rdquo; means the assets and property (other than cash or Cash Equivalents) that
are part of the Loan Parties&rsquo; VitaCare prescription services business as of the Amendment No. 8 Effective Date or are acquired
by such business after such date in the ordinary course of business.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;&ldquo;<U>VitaCare Business Asset Excess Amount</U>&rdquo; means an amount equal to the excess, if any, of (i) the aggregate
amount paid by the Loan Parties to acquire VitaCare Business Assets after the Amendment No. 8 Effective Date over (ii) $[***].&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;&ldquo;<U>VitaCare Sale</U>&rdquo; has the meaning set forth in <U>Section 6.9(b)(i)</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<U>Amended Definitions</U>. <U>Section 1.01 </U>of the Financing Agreement is
hereby amended by amending the following definitions as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The definition of Affiliate is hereby amending by adding the following sentence at the end of such definition:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;<B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Notwithstanding
anything herein to the contrary, in no event shall VitaCare (following the VitaCare Sale) or the acquiring entity in the VitaCare
Sale (or any direct or indirect parent or Subsidiary thereof) be considered an &ldquo;Affiliate&rdquo; of any Loan Party.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The definition of Permitted Indebtedness is hereby amended by deleting the &ldquo;and&rdquo; at the end of clause (l), deleting
the &ldquo;.&rdquo; at the end of clause (m) and substituting &ldquo;and&rdquo; therefor, and inserting the following new clause
(n) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
incurred by a Loan Party or any of its Subsidiaries arising from (i) customary indemnification obligations or (ii) revenue guarantees
or other similar obligations, in each case as (A) provided under the definitive documentation related to the VitaCare Sale and
(B) consented to by the Administrative Agent in writing (such consent not to be unreasonably withheld, delayed or conditioned
(it being understood and agreed by the Administrative Agent and the Lenders that such consent shall not require any economic consideration,
other consideration or any repayment of the Obligations (other than any payment required by either <U>Section 2.8(y)</U> or <U>Section
2.10(a)(ii)(A)</U>, as applicable) as a condition thereof)), except that no consent will be required in the case of clause (ii)
above if such obligations are satisfied solely in Capital Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The definition of Permitted Investments is hereby amended by deleting the &ldquo;and&rdquo; at the end of clause (h), deleting
the &ldquo;.&rdquo; at the end of clause (i) and substituting &ldquo;and&rdquo; therefor, and inserting the following new clause
(j) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(j) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
contribution of VitaCare Business Assets by a Loan Party to VitaCare in connection with the VitaCare Sale.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Section 2.8 (Repayment of the Loans)</U>. <U>Section 2.8</U> of the
Financing Agreement is hereby amended and restated in its entirety to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Section
2.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Repayment of Term Loans</U>. (x) On the Amendment No. 8 Effective Date the Borrower shall repay $15,000,000 in principal
amount of the Term Loan, (y) on March 31, 2021 the Borrower shall repay $35,000,000 in principal amount of the Term Loan so long
as the Borrower shall not have made a mandatory prepayment in accordance with <U>Section 2.10(a)(ii)(A)</U> prior to such date,
and (z) commencing on March 31, 2022 and on the last day of each Fiscal Quarter ending thereafter, the Borrower shall repay the
principal amount of the Term Loan in the aggregate amounts set forth below, in each case which payments shall be applied as follows:
(a) <U>first</U>, the principal of the Initial Term Loan until paid in full, (b) <U>second</U>, the principal of the Delayed Draw
A-1 Term Loan until paid in full and (c) <U>third</U>, the principal of the Delayed Draw A-2 Term Loan until paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>


<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fiscal
    Quarter Ending</B></FONT></TD>
    <TD STYLE="width: 25%; border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
    Loan Repayment</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$41,250,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$41,250,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$41,250,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2024</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$41,250,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the Term Loan, together with all other amounts owed hereunder with respect thereto, shall be paid in full no later
than the Term Loan Maturity Date.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Section 2.10(a)(ii) (Asset Sales)</U>. <U>Section 2.10(a)(ii)</U> of the Financing
Agreement is hereby amended and restated in its entirety to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the same Business Day of the receipt by any Loan Party of the proceeds of the VitaCare Sale, Company shall prepay the principal
amount of the Term Loans as set forth in <U>Section 2.11(a)(ii)</U> in an aggregate amount equal to $35,000,000; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
later than the fifth Business Day following the date of receipt by any Loan Party of any Net Proceeds from any other Asset Sales
(which, for the avoidance of doubt, shall not include the VitaCare Sale) in excess of $5,000,000 in the aggregate in any Fiscal
Year that do not constitute a Permitted Product Transaction, Company shall prepay the Term Loans as set forth in <U>Section 2.11(a)(i)
</U>in an aggregate amount equal to such Net Proceeds in excess of $5,000,000 in such Fiscal Year; <U>provided</U>, solely in
the case of this clause (B), so long as (i) no Default or Event of Default shall have occurred and be continuing, (ii) Company
has delivered Administrative Agent prior written notice of Company&rsquo;s intention to apply such monies (the &ldquo;<U>Reinvestment
Amounts</U>&rdquo;) to reinvest in or to the costs of purchase of other assets used or useful in the business of the Loan Parties
including capital expenditures, (iii) the monies are held in a Deposit Account subject to a Control Agreement, and (iv) the Loan
Parties complete such reinvestment or purchase within 365 days after the initial receipt of such monies, the Loan Parties shall
have the option to apply such monies to the reinvestment in or the costs of purchase of other assets used or useful in the business
of the Loan Parties (including capital expenditures) unless and to the extent that such applicable period shall have expired without
such reinvestment or purchase being made or completed, in which case, any such amounts not so used to reinvest or purchase shall
be paid to Administrative Agent and applied in accordance with <U>Section 2.11(a)(i)</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE <BR>
IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Section 2.11(a) (Application of Prepayments of Term Loans)</U>. <U>Section
2.11(a)</U> of the Financing Agreement is hereby amended and restated in its entirety to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Application
of Prepayments of Term Loans</U>. Except in connection with any Waivable Mandatory Prepayment provided for in <U>Section 2.11(b)</U>,
so long as no Application Event has occurred and is continuing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
mandatory prepayment of any Loan pursuant to <U>Section 2.10</U> (other than <U>Section 2.10(a)(ii)(A)</U>), in each case, shall
be applied as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>first,
</I>to prepay accrued and unpaid interest on the Term Loan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>second,
</I>to pay any Prepayment Premium payable thereon; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>third</I>,
to prepay (A) <U>first</U>, the principal of the Initial Term Loan to the installments thereof on a pro rata basis until paid
in full, (B) <U>second</U>, the principal of the Delayed Draw A-1 Term Loan to the installments thereof on a pro rata basis until
paid in full and (C) <U>third</U>, the principal of the Delayed Draw A-2 Term Loan to the installments thereof on a pro rata basis
until paid in full; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
mandatory prepayment of any Loan pursuant to <U>Section 2.10(a)(ii)(A)</U> shall be applied as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>first,
</I>to prepay (A) <U>first</U>, the principal of the Initial Term Loan to the installments thereof on a pro rata basis until paid
in full, (B) <U>second</U>, the principal of the Delayed Draw A-1 Term Loan to the installments thereof on a pro rata basis until
paid in full and (C) <U>third</U>, the principal of the Delayed Draw A-2 Term Loan to the installments thereof on a pro rata basis
until paid in full</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>second,
</I>to prepay accrued and unpaid interest on the Term Loan; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>third,
</I>to pay any Prepayment Premium payable thereon.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Section 6.8(b) (Minimum Revenue)</U>. The table set forth in <U>Section
6.8(b)</U> of the Financing Agreement is hereby amended and restated in its entirety to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 25%; border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Fiscal
    Quarter Ending</B></FONT></TD>
    <TD STYLE="width: 25%; border-bottom: Black 1.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
    Revenue</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2020</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$17,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2021</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2021</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$23,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$26,500,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$30,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$35,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$40,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$45,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$50,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$55,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$60,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$65,500,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2024</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$70,000,000&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Section 6.9(b) (Fundamental Changes; Dispositions of Assets; Acquisitions)</U>.
<U>Section 6.9(b)</U> of the Financing Agreement is hereby amended and restated in its entirety to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i)
&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any Asset Sale of VitaCare (which shall include any VitaCare Business Assets sold or transferred by a Loan Party in connection
therewith to the extent such VitaCare Business Assets are not contributed by such Loan Party to VitaCare in connection therewith)
so long as (A) the proceeds thereof are not less than the sum of (y) $[***] <U>plus</U> (z) the VitaCare Business Assets Excess
Amount (of which not less than the sum of (y) $[***] <U>plus</U> (z) the VitaCare Business Assets Excess Amount shall be in Cash)
and (B) such proceeds shall be applied as required by <U>Section 2.10(a)(ii)</U> (a &ldquo;<U>VitaCare Sale</U>&rdquo;) (it being
understood and agreed that it is intended that the assets and other property to be sold pursuant to the VitaCare Sale shall be
sold free and clear of the Administrative Agent&rsquo;s and the Lenders&rsquo; security interest, subject to the execution and
delivery by the Administrative Agent (at the Loan Parties&rsquo; expense) of such release documentation as may be reasonably requested
by the Loan Parties and reasonably acceptable to the Administrative Agent); <U>provided</U> that, if following any VitaCare Sale
the Loan Parties retain any interest, directly or indirectly, in the VitaCare Business Assets pursuant to which any Loan Party
has any primary or contingent obligations payable in cash or Cash Equivalents, any obligations of the Loan Parties with respect
to such retained interest shall be consented to by the Administrative Agent in writing (such consent not to be unreasonably withheld,
delayed or conditioned (it being understood and agreed by the Administrative Agent and the Lenders that such consent shall not
require any economic consideration, other consideration or any repayment of the Obligations (other than any payment required by
either <U>Section 2.8(y)</U> or <U>Section 2.10(a)(ii)(A)</U>, as applicable) as a condition thereof));</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
merger or other reorganization of VitaCare pursuant to an &ldquo;F reorganization&rdquo; in connection with the VitaCare Sale,
as consented to by the Administrative Agent in writing (such consent not to be unreasonably withheld, delayed or conditioned (it
being understood and agreed by the Administrative Agent and the Lenders that such consent shall not require any economic consideration,
other consideration or any repayment of the Obligations (other than any payment required by either <U>Section 2.8(y)</U> or <U>Section
2.10(a)(ii)(A)</U>, as applicable) as a condition thereof)); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
other Asset Sales (other than (A) subject to <U>Section 6.9(d)</U>, those constituting Permitted Product Transactions and (B)
any other Asset Sale in respect of the Products or the Product Patents) in any Fiscal Year, the proceeds of which are less than
$10,000,000 with respect to any single Asset Sale or series of related Asset Sales made within the same Fiscal Year; <U>provided
</U>(1) the consideration received for such assets shall be in an amount at least equal to the fair market value thereof (determined
in good faith by officers of Company or the Board of Directors of Company (or similar governing body)), (2) no less than 85% thereof
shall be paid in Cash, and (3) if and to the extent required by <U>Section 2.10(a)(ii)</U>, the proceeds thereof shall be applied
as required by <U>Section 2.10(a)(ii)</U>;&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions to Effectiveness</U>. This Amendment
shall become effective only upon satisfaction in full, in a manner satisfactory to the Administrative Agent, of the following
conditions precedent (the first date upon which all such conditions shall have been satisfied being hereinafter referred to as
the &ldquo;<U>Amendment Effective Date</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Payment of Fees, Etc</U>. The Borrowers shall have paid on or before
the Amendment Effective Date all fees, costs, expenses and taxes then payable, if any, pursuant to <U>Section 2.7</U> or <U>10.2
</U>of the Financing Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Representations and Warranties</U>. The representations and warranties contained
in this Amendment and in <U>Article&nbsp;IV</U> of the Financing Agreement and in each other Loan Document shall be true and correct
in all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties
that already are qualified or modified as to &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; in the text thereof,
which representations and warranties shall be true and correct in all respects subject to such qualification) on and as the Amendment
Effective Date to the same extent as though made on and as of that date, except to the extent such representations and warranties
specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in
all material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that
already are qualified or modified as to &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; in the text thereof,
which representations and warranties shall be true and correct in all respects subject to such qualification) on and as of such
earlier date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>No Default; Event of Default</U>. No Default or Event of Default shall
have occurred and be continuing on the Amendment Effective Date or result from this Amendment becoming effective in accordance
with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Delivery of Documents</U>. The Administrative Agent shall have received on
or before the Amendment Effective Date (i) this Amendment, duly executed by the Loan Parties, the Administrative Agent and the
Lenders and (ii) the Amended and Restated Fee Letter, dated as of the date hereof, duly executed by the Borrower and the Administrative
Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Material Adverse Effect</U>. The Administrative Agent shall have determined,
in its reasonable judgment, that no event or development shall have occurred since December 31, 2019, which could reasonably be
expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Liens; Priority</U>. The Administrative Agent shall be satisfied that
the Administrative Agent has been granted, and holds, for the benefit of the Administrative Agent and the Lenders, a perfected,
first priority Lien on and security interest in all of the Collateral, subject only to Permitted Liens, to the extent such Liens
and security interests are required pursuant to the Loan Documents to be granted or perfected on or before the Amendment Effective
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Approvals</U>. All consents, authorizations and approvals of, and filings
and registrations with, and all other actions in respect of, any Governmental Authority or other Person required in connection
with any Loan Document or the transactions contemplated thereby or the conduct of the Loan Parties&rsquo; business shall have
been obtained or made and shall be in full force and effect. There shall exist no claim, action, suit, investigation, litigation
or proceeding (including, without limitation, shareholder or derivative litigation) pending or, to the knowledge of any Loan Party,
threatened in any court or before any arbitrator or Governmental Authority which (i)&nbsp;relates to the Loan Documents or the
transactions contemplated thereby or (ii)&nbsp;could reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Term Loan Prepayment</U>. The Borrower shall have prepaid $15,000,000 in principal
amount of the Term Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Continued Effectiveness of the Financing Agreement
and Other Loan Documents</U>. Each Loan Party hereby (a) acknowledges and consents to this Amendment, (b)&nbsp;confirms and agrees
that the Financing Agreement and each other Loan Document to which it is a party is, and shall continue to be, in full force and
effect and is hereby ratified and confirmed in all respects, except that on and after the Amendment Effective Date, all references
in any such Loan Document to &ldquo;the Financing Agreement&rdquo;, the &ldquo;Agreement&rdquo;, &ldquo;thereto&rdquo;, &ldquo;thereof&rdquo;,
&ldquo;thereunder&rdquo; or words of like import referring to the Financing Agreement shall mean the Financing Agreement as amended
by this Amendment, and (c)&nbsp;confirms and agrees that, to the extent that any such Loan Document purports to assign or pledge
to the Administrative Agent, for the benefit of the Administrative Agent and the Lenders, or to grant to the Administrative Agent,
for the benefit of the Administrative Agent and the Lenders, a security interest in or Lien on any Collateral as security for
the Obligations of the Loan Parties from time to time existing in respect of the Financing Agreement (as amended hereby) and the
other Loan Documents, such pledge, assignment and/or grant of the security interest or Lien is hereby ratified and confirmed in
all respects. This Amendment does not and shall not affect any of the obligations of the Loan Parties, other than as expressly
provided herein, including, without limitation, the Loan Parties&rsquo; obligations to repay the Loans in accordance with the
terms of Financing Agreement or the obligations of the Loan Parties under any Loan Document to which they are a party, all of
which obligations shall remain in full force and effect. Except as expressly provided herein, the execution, delivery and effectiveness
of this Amendment shall not operate as a waiver of any right, power or remedy of Administrative Agent or any Lender under the
Financing Agreement or any other Loan Document nor constitute a waiver of any provision of the Financing Agreement or any other
Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Novation</U>. Nothing herein contained
shall be construed as a substitution or novation of the Obligations outstanding under the Financing Agreement or instruments securing
the same, which shall remain in full force and effect, except as modified hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Representations by Administrative Agent
or Lenders</U>. Each Loan Party hereby acknowledges that it has not relied on any representation, written or oral, express or
implied, by Administrative Agent or any Lender, other than those expressly contained herein, in entering into this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Release</U>. Each Loan Party hereby acknowledges
and agrees that: (a) neither it nor any of its Subsidiaries has any claim or cause of action against Administrative Agent or any
Lender (or any of the directors, officers, employees, agents, attorneys or consultants of any of the foregoing) and (b) the Administrative
Agent and the Lenders have heretofore properly performed and satisfied in a timely manner all of their obligations to the Loan
Parties, and all of their Subsidiaries and Affiliates. Notwithstanding the foregoing, the Administrative Agent and the Lenders
wish (and the Loan Parties agree) to eliminate any possibility that any past conditions, acts, omissions, events or circumstances
would impair or otherwise adversely affect any of their rights, interests, security and/or remedies. Accordingly, for and in consideration
of the agreements contained in this Amendment and other good and valuable consideration, each Loan Party (for itself and its Subsidiaries
and Affiliates and the successors, assigns, heirs and representatives of each of the foregoing) (collectively, the &ldquo;<U>Releasors</U>&rdquo;)
does hereby fully, finally, unconditionally and irrevocably release, waive and forever discharge the Administrative Agent and
the Lenders, together with their respective Affiliates and Related Funds, and each of the directors, officers, employees, agents,
attorneys and consultants of each of the foregoing (collectively, the &ldquo;<U>Released Parties</U>&rdquo;), from any and all
debts, claims, allegations, obligations, damages, costs, attorneys&rsquo; fees, suits, demands, liabilities, actions, proceedings
and causes of action, in each case, whether known or unknown, contingent or fixed, direct or indirect, and of whatever nature
or description, and whether in law or in equity, under contract, tort, statute or otherwise, which any Releasor has heretofore
had or now or hereafter can, shall or may have against any Released Party by reason of any act, omission or thing whatsoever done
or omitted to be done, in each case, on or prior to the Amendment Effective Date directly arising out of, connected with or related
to this Amendment, the Financing Agreement or any other Loan Document, or any act, event or transaction related or attendant thereto,
or the agreements of Administrative Agent or any Lender contained therein, or the possession, use, operation or control of any
of the assets of any Loan Party, or the making of any Loans or other advances, or the management of such Loans or other advances
or the Collateral. Each Loan Party represents and warrants that it has no knowledge of any claim by any Releasor against any Released
Party or of any facts or acts or omissions of any Released Party which on the date hereof would be the basis of a claim by any
Releasor against any Released Party which would not be released hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN
EXCLUDED FROM THIS EXHIBIT BECAUSE IT <BR>
IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF<BR>
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further Assurances.</U> The Loan Parties shall
execute any and all further documents, agreements and instruments, and take all further actions, as may be required under applicable
law or as Administrative Agent may reasonably request, in order to effect the purposes of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed in any number of counterparts and by different
parties hereto in separate counterparts, each of which shall be deemed to be an original but all of which taken together shall
constitute one and the same agreement. Delivery of an executed counterpart of this Amendment by facsimile or electronic mail shall
be equally effective as delivery of an original executed counterpart of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Section and paragraph headings herein are included for convenience of reference
only and shall not constitute a part of this Amendment for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This Amendment shall be governed by, and construed in accordance with,
the laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Loan Party hereby acknowledges and agrees that this Amendment constitutes
a &ldquo;Loan Document&rdquo; under the Financing Agreement. Accordingly, it shall be an immediate Event of Default under the
Financing Agreement if (i) any representation or warranty made by any Loan Party under or in connection with this Amendment shall
have been incorrect in any respect when made or deemed made, or (ii) any Loan Party shall fail to perform or observe any term,
covenant or agreement contained in this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any provision of this Amendment that is prohibited or unenforceable in
any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining portions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Remainder
of page intentionally left blank.</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered as of the date set forth on the first
page hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BORROWER:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Robert Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CEO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GUARANTORS:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VITAMEDMD, LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Robert Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CEO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOCAGREENMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Robert Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CEO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VITACARE PRESCRIPTION SERVICES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John C.K. Milligan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: John C.K. Milligan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIXTH STREET SPECIALTY LENDING, INC., as Administrative Agent and Lender</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert (Bo) Stanley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Robert (Bo) Stanley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP IV TALENTS, LLC, as Lender</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAO TALENTS, LLC, as Lender</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Vice President</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>9
<FILENAME>ex10-41.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT WITH EDWARD J. BORKOWSKI
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.41</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-transform: uppercase; text-align: center">EMPLOYMENT
AGREEMENT</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in"><B>THIS EMPLOYMENT
AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;), by and between TherapeuticsMD, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and Edward J. Borkowski (&ldquo;<U>Executive</U>&rdquo;) is entered into and effective as of the 30th day of October 2019 (the
&ldquo;<U>Effective Date</U>&rdquo;).</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>,
the Company and Executive now wish to provide for terms and conditions of Executive&rsquo;s continued employment with the Company,
pursuant to the terms and conditions set forth in this Agreement.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration
of the premises and of the mutual covenants set forth in this Agreement, the parties hereto agree as follows:</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">1. </FONT>Employment
and Duties.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(a)&nbsp; <B>Employment and Term</B>. The Company
agrees to employ Executive, and Executive hereby agrees to serve the Company, in accordance with the terms and conditions set
forth herein, for a period of three (3) years, commencing as of the Effective Date (such three (3) year period, as it may be extended
pursuant to this <U>Section&nbsp;1(a)</U>, the &ldquo;<U>Term</U>&rdquo;), unless sooner terminated pursuant to <U>Section&nbsp;3
</U>hereof. Commencing on the third anniversary of the Effective Date, and each anniversary thereafter, the Term shall automatically
be extended for one (1) additional year, unless at least ninety (90) days prior to such anniversary, the Company or Executive
shall have given notice in accordance with <U>Section&nbsp;8</U> that it or Executive does not wish to extend the Term.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(b)&nbsp;
</FONT>Duties of Executive. <FONT STYLE="font-weight: normal">Executive shall serve as the Executive Vice President, Operations
of the Company, shall diligently perform all services as may be reasonably assigned to Executive by the Company&rsquo;s Board
of Directors (the &ldquo;<U>Board</U>&rdquo;) or the Company&rsquo;s Chief Executive Officer and shall exercise such power and
authority as may from time to time be delegated to Executive by the Board, the Chief Executive Officer of the Company, or the
designee to whom Executive reports. During Executive&rsquo;s employment, Executive shall devote Executive&rsquo;s full business
time, energy, and ability exclusively to the business and interests of the Company, shall be physically present at the Company&rsquo;s
offices in Boca Raton, Florida during normal business hours each week (other than permitted periods of working remotely, paid
time off (&ldquo;<U>PTO</U>&rdquo;) and on appropriate business travel for the benefit of the Company and shall not, without the
Company&rsquo;s prior written consent, be engaged in any other business activity pursued for gain, profit, or other pecuniary
advantage if such activity interferes in any material respect with Executive&rsquo;s duties and responsibilities hereunder. In
Executive&rsquo;s capacity as the Executive Vice President, Operations of the Company, Executive shall do and perform all services,
acts, or things necessary or advisable to manage and conduct the business of the Company, subject to the policies and procedures
set by the Company, including, but not limited to providing all services, acts, or things necessary or advisable as may be assigned
by the Chief Executive Officer from time to time consistent with Executive&rsquo;s role, including, but not limited to: providing
advice and recommendations to the executive officers of the Company and the Board of Directors to assist them in continuing to
transition the Company from a development stage to a commercial pharmaceutical company over a variety of functions, including,
but not limited to, human resources, finance, legal, research and</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify">development, and business development; interfacing
with investors; providing advice and recommendations regarding potential transactions; providing advice related to functional
planning, corporate processes and structure, and identification of corporate gaps and solutions to the same; and providing advice
and potential solutions regarding Company risk. Except as otherwise agreed in writing by the Company, it shall not be a violation
of this Agreement for Executive, and Executive shall be permitted, to (i) serve on any civic or charitable boards; (ii) deliver
lectures, fulfill speaking engagements, or teach at educational institutions and other institutions; (iii) subject to any applicable
Company policies, make personal investments in such form or manner as will neither require Executive&rsquo;s services in the operation
or affairs of the companies or enterprises in which such investments are made nor subject Executive to any conflict of interest
with respect to Executive&rsquo;s duties to the Company; and (iv) serve, with the written approval of the Board, as a director
of one or more private or public companies, in each case so long as any such activities do not significantly interfere with the
performance of Executive&rsquo;s responsibilities under this Agreement, create a conflict of interest, or create an adverse interest
or position detrimental to Company.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in"><B>(c)&nbsp;
Policies</B>. Executive shall faithfully adhere to, execute, and fulfill all lawful policies established by the Company as are
communicated to Executive by the Company.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(d)&nbsp; <B>Place of Performance</B>. In connection
with Executive&rsquo;s employment by the Company, Executive shall be based at the Company&rsquo;s principal executive offices
in Boca Raton, Florida.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in"><B>2.&nbsp;
Compensation</B>. For all services rendered by Executive, the Company shall compensate Executive as follows:</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(a)&nbsp; <B>Base Salary</B>. Effective on
the Effective Date, the base salary (&ldquo;<U>Base Salary</U>&rdquo;) payable to Executive shall be Four hundred thirty thousand
dollars ($430,000) per year, payable on a regular basis in accordance with the Company&rsquo;s standard payroll procedures, but
not less than monthly. The Board or a committee of the Board shall review Executive&rsquo;s performance on at least an annual
basis and may make increases to such Base Salary if, in its sole discretion, any such increase is warranted. The Board may reduce
the Base Salary without Executive&rsquo;s consent only if such reduction applies in the same or greater percentage to all other
executives of the Company at the Vice President level and above.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(b)&nbsp; <B>Annual Short-Term Incentive</B>.
Executive shall be entitled to participate in the Company&rsquo;s annual short-term incentive compensation program, as such program
may exist from time to time, at a level commensurate with that being offered to other executives of the Company at the Chief level.
For calendar years beginning on or after January 1, 2018, the percentage of Base Salary targeted as annual cash short-term incentive
compensation for each calendar year during the Term shall be eighty-five percent (85%) of Base Salary (the &ldquo;<U>Targeted
Annual Bonus Award</U>&rdquo;). Executive acknowledges that the amount of annual short-term incentive compensation, if any, to
be awarded shall be at the sole, good faith discretion of the Board or a committee of the Board, may be less or more than the
Targeted Annual Bonus Award, and will be based on a number of factors determined by the Board or a committee of the Board for
each calendar year, including the Company&rsquo;s performance in connection with, among other factors, the clinical program, regulatory
filings, commercialization and/or sales, and Executive&rsquo;s individual</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify">performance. Any annual short-term
incentive compensation earned for any calendar year shall be paid in the immediately following calendar year, as soon as practicable.
Except as set forth in <U>Sections&nbsp;3(b)(ii)</U>, <U>3(b)(iii)</U>, and <U>3(b)(iv)</U>, Executive must be employed by the
Company on the date on which short-term incentive compensation is paid in order to receive such short-term incentive compensation.
The 2019 Targeted Annual Bonus Award will be paid to Executive as if Executed were employed for the full year and will be at target
or higher.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(c)&nbsp; <B>Long-Term Incentive</B><FONT STYLE="font-weight: normal"></FONT>.
<FONT STYLE="font-weight: normal">Executive shall be entitled to participate in the Company&rsquo;s long-term incentive compensation
program, as such program may exist from time to time, at a level commensurate with that being offered to other executives of the
Company at the Vice President level and above. Executive acknowledges that the amount of long-term incentive compensation, if
any, to be awarded shall be at the sole, good faith discretion of the Board or a committee of the Board, and will be based on
a number of factors determined by the Board or a committee of the Board for the applicable performance period, including the Company&rsquo;s
performance in connection with, among other factors, the clinical program, regulatory filings, commercialization and/or sales,
and Executive&rsquo;s individual performance. Any long-term incentive compensation earned for the applicable performance period
shall be paid within the first 2 &frac12; months of the calendar year immediately following the calendar year in which the applicable
performance period ends. Except as otherwise set forth herein, Executive must be employed by the Company on the date on which
long-term incentive compensation is paid to receive such long-term incentive compensation.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(d)&nbsp;
</FONT>Stock Options. <FONT STYLE="font-weight: normal">The Company will grant to Executive by the Board of Directors as soon
as practicable, pursuant to the Company&rsquo;s 2009 Amended and Restated Stock Incentive Plan, as the same may be amended from
time to time (the &ldquo;<U>2009 Plan</U>&rdquo;), and the Company&rsquo;s 2012 Amended and Restated Stock Incentive Plan, as
the same may be amended from time to time (the &ldquo;<U>2012 Plan</U>&rdquo; and, together with the 2009 Plan, collectively,
the &ldquo;<U>Plans</U>&rdquo;), stock options to purchase 250,000 shares of the Company&rsquo;s common stock (the &ldquo;<U>Previously
Granted Stock Options</U>&rdquo;). The stock options are subject to the terms and conditions set forth in the applicable Plans
and in the stock option agreement(s) previously executed by the Company and Executive. Additional options or other equity compensation
may be granted at the Board&rsquo;s discretion.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(e)&nbsp;
</FONT>Restricted Stock Units. <FONT STYLE="font-weight: normal">As soon as practicable following the Effective Date, the Company
will grant to Executive one million (1,000,000) restricted stock units (&ldquo;<U>RSUs</U>&rdquo;) under the 2012 Plan as consideration
for Executive entering into this Agreement, which RSUs will not vest in whole or in part until three (3) years after the Effective
Date, at which time the RSUs will fully and completely vest, subject to Executive&rsquo; continued employment with the Company
and the terms and conditions in the 2012 Plan and an award agreement to be entered into between the Company and Executive.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(f)&nbsp; <B>Executive Perquisites, Benefits,
and Other Compensation</B>. Executive shall be entitled to receive additional benefits and compensation from the Company in such
form and to such extent as specified below:</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in">(i)&nbsp; <B>Insurance Coverage</B>.
During the Term, and as otherwise provided within the provisions of each of the respective plans, the Company shall make available
to Executive all employee benefits to which other executives of the Company are entitled to receive, subject to the eligibility
requirements and other provisions of such arrangements as applicable to executives of the Company generally. Such benefits shall
include, but shall not be limited to, comprehensive health and major medical insurance, dental and life insurance, and short-term
and long-term disability.</P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in">(ii)&nbsp; <B>Reimbursement for Expenses</B>.
Reimbursement for business travel and other out-of-pocket expenses reasonably incurred by Executive in the performance of Executive&rsquo;s
services under this Agreement, including, but not limited to, industry appropriate seminars and subscriptions and applicable licensing
and continuing education expenses. All reimbursable expenses shall be appropriately documented in reasonable detail by Executive
upon submission of any request for reimbursement and shall be in a format and manner consistent with the Company&rsquo;s expense
reporting policy. Company will provide for Executive reasonable (i) temporary hotel or rental housing, (ii) rental vehicle, and
(iii) airfare for the period of time in which he commutes from his home in New Jersey. The Company will reimburse Executive for
reasonable, actual expenses to relocate his household to Florida.</P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in">(iii)&nbsp; <B>Paid Time Off</B>. Executive
shall be eligible to accrue PTO and utilize and carryover from year to year such PTO, consistent with the Company&rsquo;s policies
and procedures in effect from time to time for officers of Executive&rsquo;s level.</P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in">(iv)&nbsp; <B>Other Executive Perquisites</B>.
The Company shall provide Executive with other executive perquisites as may be made available to or deemed appropriate for Executive
by the Board or a committee of the Board and participation in all other Company&#45;wide employee benefits as are available to
the Company&rsquo;s executives from time to time, including any plans, programs, or arrangements relating to retirement, deferred
compensation, profit sharing, 401(k), and employee stock ownership.</P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in">(v)&nbsp; <B>Working Facilities</B>.
During the Term, the Company shall furnish Executive with an office, staffing and administrative support and such other facilities
and services suitable to Executive&rsquo;s position with the Company and adequate for the performance of Executive&rsquo;s duties
hereunder, which will be reviewed and provided based on the Company&rsquo;s needs.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.&nbsp;
</FONT>Term of Employment<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(a)&nbsp;
</FONT>Termination Under Certain Circumstances<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;
</FONT>Death<FONT STYLE="font-weight: normal">. Executive&rsquo;s employment and the Term shall be automatically terminated, without
notice, effective upon the date of Executive&rsquo;s death.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;
</FONT>Disability<FONT STYLE="font-weight: normal">. If, as a result of incapacity due to physical or mental illness or injury,
Executive shall have been absent from Executive&rsquo;s full-time duties hereunder for six (6) consecutive months, then thirty
(30) days after giving written notice to Executive (which notice may occur before or after the end of such six (6) month period,
but which shall not be effective earlier than the last day of such six (6) month period), the Company may terminate Executive&rsquo;s
employment and the Term, provided Executive is unable to resume Executive&rsquo;s full-time duties at the conclusion of such notice
period.</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)&nbsp;
</FONT> Termination by the Company for Good Cause<FONT STYLE="font-weight: normal">. The Company may terminate Executive&rsquo;s
employment and the Term upon ten (10) days prior written notice to Executive for &ldquo;<U>Good Cause</U>,&rdquo; which shall
mean any one or more of the following: (A) Executive&rsquo;s material breach of this Agreement (continuing for thirty (30) days
after receipt of written notice of need to cure, if, in the Company&rsquo;s determination, such breach is curable); (B) Executive&rsquo;s
negligence in the performance or intentional nonperformance (continuing for thirty (30) days after receipt of written notice of
need to cure, if, in the Company&rsquo;s determination, such breach is curable) of any of Executive&rsquo;s material duties and
responsibilities; (C) Executive&rsquo;s willful dishonesty, fraud, or misconduct with respect to the business or affairs of the
Company; (D) Executive&rsquo;s indictment for, charge of, conviction of, or guilty or <I>nolo contendre</I> plea to a felony crime
involving dishonesty or moral turpitude whether or not relating to the Company; (E) a confirmed positive drug test result for
an illegal drug; or (F) a material sanction is imposed on Executive by any applicable professional organization or professional
governing body including, for the avoidance of doubt, an accounting regulatory board.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)&nbsp;</FONT>Termination by the Company Without Good Cause<FONT STYLE="font-weight: normal">. The Company may terminate Executive&rsquo;s
employment and the Term at any time without Good Cause.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(v)&nbsp;
</FONT>Termination by Executive Without Good Reason<FONT STYLE="font-weight: normal">. Executive, at Executive&rsquo;s option
and upon written notice to the Company, may terminate Executive&rsquo;s employment and the Term without Good Reason (as defined
below) at any time, effective on the date of that notice.</FONT></P>

<P STYLE="margin: 0 0 12pt 9.35pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(vi)&nbsp;
</FONT>Termination by Executive With Good Reason<FONT STYLE="font-weight: normal">. At any time during the Term, Executive may
terminate Executive&rsquo;s employment and the Term for Good Reason. For purposes of this Agreement, &ldquo;<U>Good Reason</U>&rdquo;
shall mean (A) the assignment to Executive of material duties inconsistent with Executive&rsquo;s position as the Executive Vice
President, Operations (including status, office, titles and reporting requirements), or any other action by the Company that results
in a material diminution in such position, excluding for this purpose (i) any action not taken in bad faith and that is remedied
by the Company promptly after receipt of a Notice of Termination for Good Reason (as defined below) thereof given by Executive
and (ii) any change in status, office, titles and reporting requirements following a Change in Control of the Company in which
the Company ceases to be a standalone public reporting company, provided that the material duties of Executive following such
Change in Control are not inconsistent with those of Executive immediately prior to such Change in Control; or (B) any material
failure by the Company to comply with any of the provisions of this Agreement, other than a failure not occurring in bad faith
and that is remedied by the Company promptly after receipt of a Notice of Termination for Good Reason given thereof by Executive.
A termination of employment by Executive for Good Reason shall be effected by Executive&rsquo;s giving the Board written notice
(&ldquo;<U>Notice of Termination for Good Reason</U>&rdquo;) of the termination, setting forth in reasonable detail the specific
conduct of the Company that constitutes Good Reason and the specific provision(s) of this Agreement on which Executive relies,
within ninety (90) days of the initial existence of one of the conditions constituting Good Reason. A termination of employment
by Executive for Good Reason shall be effective on the thirty-first (31st) day following the date when the Notice of Termination
for Good Reason is given to the Company; provided that such a termination of employment shall not become effective if the Company
shall have substantially corrected the circumstance giving rise to the Notice of Termination for Good Reason within thirty (30)
days after the Company&rsquo;s receipt of such Notice of Termination for Good Reason.</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(b)&nbsp;
</FONT> Result of Termination<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;
Except as otherwise set forth in this Agreement, in the event of the termination of Executive&rsquo;s employment and the Term
pursuant to <U>Sections 3(a)(iii)</U> (&ldquo;<U>Termination by the Company for Good Cause</U>&rdquo;) or <U>3(a)(v)</U>&nbsp;(&ldquo;<U>Termination
by Executive Without Good Reason</U>&rdquo;) above, Executive shall receive no further compensation under this Agreement other
than the payment of Base Salary as shall have accrued and remained unpaid as of the date of termination and accrued but unused
PTO consistent with the Company&rsquo;s policies and procedures therefor in effect at the time of such termination for officers
of Executive&rsquo;s level.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;
In the event of the termination of Executive&rsquo;s employment and the Term pursuant to <U>Sections 3(a)(iv)</U> (&ldquo;<U>Termination
by the Company Without Good Cause</U>&rdquo;) or <U>3(a)(vi)</U>&nbsp;(&ldquo;<U>Termination by Executive With Good Reason</U>&rdquo;)
above and after the first ninety (90) days of employment, (a) Executive shall, for a period of twelve (12) months following the
effective date of such termination, continue to receive Executive&rsquo;s then current annual Base Salary, as provided in <U>Section&nbsp;2(a)</U>,
(b) Executive shall receive an amount equal to Executive&rsquo;s Targeted Annual Bonus Award for the calendar year in which the
termination of Executive&rsquo;s employment occurs, which amount shall be paid to Executive in a single lump sum, which is unpaid
on the effective date of Executive&rsquo;s termination, and which shall be paid to Executive when paid to other similarly situated
executives of the Company in accordance with <U>Section 2(b)</U> hereof, (c) Executive shall receive, beginning on the first payroll
date occurring on or after the thirtieth (30<SUP>th</SUP>) day following the effective date of the termination of Executive&rsquo;s
employment under this Agreement and for a period of twenty-four (24) months thereafter for a total of twenty-four (24) monthly
payments, a monthly cash payment equal to the one (1) month cost of COBRA continuation of the health insurance benefits for Executive
and Executive&rsquo;s immediate family as applicable, as the effective date of such termination, less, the one (1) month cost
for the same health insurance benefits for Executive and Executive&rsquo;s immediate family as applicable that would have been
incurred by Executive immediately prior to the effective date of such termination if Executive remained employed with the Company,
(d) all unvested equity compensation of any kind (including, without limitation, stock options, restricted stock, or restricted
stock units) held by Executive in Executive&rsquo;s capacity as an employee of the Company on the effective date of the termination
shall vest as of the effective date of such termination, (e) Executive shall receive payment for accrued but unused PTO consistent
with the Company&rsquo;s policies and procedures therefor in effect at the time of such termination for officers of Executive&rsquo;s
level, and (f) Executive shall receive payment for any annual short-term incentive compensation earned pursuant to Section 2(b)
hereof for the calendar year immediately preceding the calendar year in which the termination of Executive&rsquo;s employment
occurs which is unpaid on the effective date of Executive&rsquo;s termination, which shall be paid to Executive when paid to other
similarly situated executives of the Company in accordance with <U>Section 2(b)</U> hereof.</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)&nbsp;
 In the event of the termination of Executive&rsquo;s employment and the Term pursuant to <U>Sections 3(a)(i)</U> (&ldquo;<U>Death</U>&rdquo;)
or <U>3(a)(ii)</U>&nbsp;(&ldquo;<U>Disability</U>&rdquo;) above, (a) Executive shall receive an amount equal to Executive&rsquo;s
Targeted Annual Bonus Award for the calendar year in which the termination of Executive&rsquo;s employment occurs, multiplied
by a fraction, the numerator of which is the number of full months of such calendar year during which Executive was employed with
the Company, and the denominator of which is twelve (12), which amount shall be paid to Executive in a single lump sum on the
first payroll date occurring on or after the thirtieth (30<SUP>th</SUP>) day following the effective date of the termination of
Executive&rsquo;s employment under this Agreement, (b) all unvested equity compensation of any kind (including, without limitation,
stock options, restricted stock, or restricted stock units) held by Executive in Executive&rsquo;s capacity as an employee of
the Company on the effective date of the termination shall vest as of the effective date of such termination, (c) Executive shall
receive payment for accrued but unused PTO consistent with the Company&rsquo;s policies and procedures therefor in effect at the
time of such termination for officers of Executive&rsquo;s level, and (d) Executive shall receive payment for any annual short-term
incentive compensation earned pursuant to <U>Section 2(b) hereof</U> for the calendar year immediately preceding the calendar
year in which the termination of Executive&rsquo;s employment occurs which is unpaid on the effective date of Executive&rsquo;s
termination, which shall be paid to Executive when paid to other similarly situated executives of the Company in accordance with
<U>Section 2(b)</U> hereof.</FONT></P>

<P STYLE="margin: 0 0 12pt 9.35pt; font-size: 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)&nbsp;
In the event of the termination of Executive&rsquo;s employment and the Term pursuant to <U>Sections 3(a)(iv)</U> (&ldquo;<U>Termination
by the Company Without Good Cause</U>&rdquo;) or <U>3(a)(vi)</U>&nbsp;(&ldquo;<U>Termination by Executive With Good Reason</U>&rdquo;)
during the twelve (12) month period immediately following a Change in Control, then in lieu of any benefits or amounts otherwise
payable under <U>Section 3(b)(ii)</U> hereof, (a) Executive shall, for a period of eighteen (18) months following the effective
date of such termination, continue to receive Executive&rsquo;s then current annual Base Salary, as provided in <U>Section&nbsp;2(a)</U>,
(b) Executive shall receive an amount equal to one and one half times (1.5x) Executive&rsquo;s Targeted Annual Bonus Award for
the calendar year in which the termination of Executive&rsquo;s employment occurs, which amount shall be paid to Executive in
a single lump sum on the first payroll date occurring on or after the thirtieth (30<SUP>th</SUP>) day following the effective
date of the termination of Executive&rsquo;s employment under this Agreement, (c) Executive shall receive, beginning on the first
payroll date occurring on or after the thirtieth (30<SUP>th</SUP>) day following the effective date of the termination of Executive&rsquo;s
employment under this Agreement and for a period of eighteen (18) months thereafter for a total of eighteen (18) monthly payments,
a monthly cash payment equal to the one (1) month cost of COBRA continuation of the health insurance benefits for Executive and
Executive&rsquo;s immediate family as applicable, as the effective date of such termination, less, the one (1) month cost for
the same health insurance benefits for Executive and Executive&rsquo;s immediate family as applicable that would have been incurred
by Executive immediately prior to the effective date of such termination if Executive remained employed with the Company, (d)
all unvested equity compensation of any kind (including, without limitation, stock options, restricted stock, or restricted stock
units) held by Executive in Executive&rsquo;s capacity as an employee of the Company on the effective date of the termination
shall vest as of the effective date of such termination, (e) Executive shall receive payment for accrued but unused PTO consistent
with the Company&rsquo;s policies and procedures therefor in effect at the time of such termination for officers of Executive&rsquo;s
level, and (f) Executive shall receive payment for any annual short-term incentive compensation earned pursuant to <U>Section
2(b) hereof</U> for the calendar year immediately preceding the calendar year in which the termination of Executive&rsquo;s employment
occurs which is unpaid on the effective date of Executive&rsquo;s termination, which shall be paid to Executive when paid to other
similarly situated executives of the Company in accordance with <U>Section 2(b)</U> hereof.</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(c)&nbsp;
</FONT> Release<FONT STYLE="font-weight: normal">. Notwithstanding any other provision in this Agreement to the contrary, as a
condition precedent to receiving any post-termination payments or benefits identified in <U>Sections&nbsp;3(b)(ii)</U>, <U>3(b)(iii)
</U>and <U>3(b)(iv)</U> of this Agreement, Executive agrees to execute (and not revoke) a full and complete release of all claims
against the Company and its affiliates, in the form attached hereto as Exhibit A (subject to such modifications as the Company
reasonably may request) (the &ldquo;<U>Release</U>&rdquo;). If Executive fails to execute and deliver to the Company the Release
within twenty-one (21) days following the date of termination, or revokes the Release, within seven (7) days following the date
Executive executes and delivers the Release, or materially breaches any term of this Agreement or any other agreement between
Executive and the Company while receiving such post-termination payments or benefits, Executive agrees that Executive shall not
be entitled to receive any such post-termination payments. For purposes of this Agreement, the Release shall be deemed to have
been executed by Executive if it is signed by Executive&rsquo;s legal representative in the case of legal incompetence or on behalf
of Executive&rsquo;s estate in the case of Executive&rsquo;s death. Payment of any post-termination payments or benefits identified
in <U>Sections&nbsp;3(b)(ii)</U>, <U>3(b)(iii)</U> and <U>3(b)(iv)</U> of this Agreement shall be delayed until the first payroll
date occurring on or after the thirtieth (30<SUP>th</SUP>) day following the effective date of the termination of Executive&rsquo;s
employment under this Agreement, and any payments that are so delayed shall be paid on the first payroll date occurring on or
after the thirtieth (30<SUP>th</SUP>) day following the effective date of the termination of Executive&rsquo;s employment under
this Agreement.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(d)&nbsp;
</FONT>Section 409A<FONT STYLE="font-weight: normal">. Any payments made by the Company pursuant to <U>Sections&nbsp;3(b)(ii)</U>,
<U>3(b)(iii)</U> and <U>3(b)(iv)</U> of this Agreement (except for unpaid annual short-term incentive compensation earned in the
calendar year immediately preceding the calendar year in which the termination of Executive&rsquo;s employment occurs, which shall
be paid to Executive when paid to other similarly situated executives of the Company) shall be paid or commence on the first payroll
date occurring on or after the thirtieth (30<SUP>th</SUP>) day following the effective date of Executive&rsquo;s &ldquo;separation
from service&rdquo; within the meaning of Section 409A (&ldquo;<U>Section 409A</U>&rdquo;) of the Internal Revenue Code of 1986,
as amended (the &ldquo;<U>Code</U>&rdquo;). For purposes of applying the provisions of Section 409A to this Agreement, each separately
identified amount to which Executive is entitled under this Agreement shall be treated as a separate payment. In addition, to
the extent permissible under Section 409A, any series of installment payments under this Agreement shall be treated as a right
to a series of separate payments. Executive shall receive no additional compensation following any termination except as provided
herein. In the event of any termination, Executive shall resign all positions with the Company and its subsidiaries. If Executive
is a &ldquo;specified employee&rdquo; within the meaning of Section 409A, then payments identified in <U>Section 3(b)</U> of this
Agreement shall not commence until six (6) months following &ldquo;separation from service&rdquo; within the meaning of Section
409A to the extent necessary to avoid the imposition of the additional twenty percent (20%) tax under Section 409A (and in the
case of installment payments, the first payment shall include all installment payments required by this subsection that otherwise
would have been made during such six-month period). If the payments described in <U>Section&nbsp;3(b)</U> must be delayed for
six (6) months pursuant to the preceding sentence, Executive shall not be entitled to additional compensation to compensate for
such delay period. Upon the date such payment would otherwise commence, the Company shall reimburse Executive for such payments,
to the extent that such payments otherwise would have been paid by the Company had such payments commenced upon Executive&rsquo;s
&ldquo;separation from service&rdquo; within the meaning of Section 409A. </FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Any
remaining payments shall be provided by the Company in accordance with the schedule and procedures specified herein. This Agreement
is intended to satisfy the requirements of Section 409A with respect to amounts subject thereto, and shall be interpreted and
construed consistent with such intent. Any reimbursements by the Company to Executive of any eligible expenses under this Agreement
that are not excludable from Executive&rsquo;s income for Federal income tax purposes (the &ldquo;<U>Taxable Reimbursements</U>&rdquo;)
shall be made by no later than the last day of the taxable year of Executive following the year in which the expense was incurred.
The amount of any Taxable Reimbursements, and the value of any in-kind benefits to be provided to Executive, during any taxable
year of Executive shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable
year of Executive. The right to Taxable Reimbursement, or in-kind benefits, shall not be subject to liquidation or exchange for
another benefit. Notwithstanding the foregoing, the Company does not make any representation to Executive that the payments or
benefits provided under this Agreement are exempt from, or satisfy, the requirements of Section 409A, and the Company shall have
no liability or other obligation to indemnify or hold harmless Executive or any beneficiary for any tax, additional tax, interest
or penalties that Executive or any beneficiary may incur in the event that any provision of this Agreement, or any amendment or
modification thereof, or any other action taken with respect thereto, is deemed to violate any of the requirements of Section
409A.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(e)&nbsp;
</FONT>Section 280G<FONT STYLE="font-weight: normal">. </FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;
</FONT>Certain Reductions in Agreement Payments<FONT STYLE="font-weight: normal">. Anything in this Agreement to the contrary
notwithstanding, in the event a nationally recognized independent accounting firm designated by the Company and reasonably acceptable
to Executive (the &ldquo;<U>Accounting Firm</U>&rdquo;) shall determine that receipt of all payments or distributions by the Company
and its affiliates in the nature of compensation to or for Executive&rsquo;s benefit, whether paid or payable pursuant to this
Agreement or otherwise (a &ldquo;<U>Payment</U>&rdquo;), would subject Executive to the excise tax under Section 4999 of the Code,
the Accounting Firm shall determine as required below in this <U>Section 3(e)</U> whether to reduce any of the Payments paid or
payable pursuant to this Agreement (the &ldquo;<U>Agreement Payments</U>&rdquo;) to the Reduced Amount (as defined below). The
Agreement Payments shall be reduced to the Reduced Amount only if the Accounting Firm determines that Executive would have a greater
Net After-Tax Receipt (as defined below) of aggregate Payments if Executive&rsquo;s Agreement Payments were so reduced. If the
Accounting Firm determines that Executive would not have a greater Net After-Tax Receipt of aggregate Payments if Executive&rsquo;s
Agreement Payments were so reduced, then Executive shall receive all Agreement Payments to which Executive is entitled. </FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;
 <U>Accounting Firm Determinations</U>. If the Accounting Firm determines that aggregate Agreement Payments should be reduced to
the Reduced Amount, then the Company shall promptly give Executive notice to that effect and a copy of the detailed calculation
thereof. All determinations made by the Accounting Firm under this <U>Section 3(e)</U> shall be binding upon the Company and Executive
and shall be made as soon as reasonably practicable and in no event later than twenty (20) days following the effective date of
the termination of Executive&rsquo;s employment with the Company. For purposes of reducing the Agreement Payments to the Reduced
Amount, only amounts payable under this Agreement (and no other Payments) shall be reduced. The reduction of the amounts payable
hereunder, if applicable, shall be made (A) only from Payments that the Accounting Firm determines reasonably may be characterized
as &ldquo;parachute payments&rdquo; under Section 280G of the Code; (B) only from Payments that are required to be made in cash,
(C) only with respect to any amounts that are not payable pursuant to a &ldquo;nonqualified deferred compensation plan&rdquo;
subject to Section 409A of the Code, until those payments have been reduced to zero, and (D) in reverse chronological order, to
the extent that any Payments subject to reduction are made over time (e.g., in installments). In no event, however, shall any
Payments be reduced if and to the extent such reduction would cause a violation of Section 409A of the Code or other applicable
law. All fees and expenses of the Accounting Firm shall be borne solely by the Company.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)&nbsp;
<U>Overpayments; Underpayments</U>. As a result of the uncertainty in the application of Section 4999 of the Code at the time
of the initial determination by the Accounting Firm hereunder, it is possible that amounts will have been paid or distributed
by the Company to or for the benefit of Executive pursuant to this Agreement which should not have been so paid or distributed
(an &ldquo;<U>Overpayment</U>&rdquo;) or that additional amounts which will have not been paid or distributed by the Company to
or for the benefit of Executive pursuant to this Agreement which should have been so paid or distributed (an &ldquo;<U>Underpayment</U>&rdquo;),
in each case consistent with the calculation of the Reduced Amount hereunder. In the event that the Accounting Firm, based upon
the assertion of a deficiency by the Internal Revenue Service against either the Company or Executive which the Accounting Firm
believes has a high probability of success determines that an Overpayment has been made, Executive shall pay any such Overpayment
to the Company together with interest at the applicable federal rate provided for in Section 7872(f)(2) of the Code; <U>provided</U>,
<U>however</U>, that no amount shall be payable by Executive to the Company if and to the extent such payment would not either
reduce the amount on which Executive is subject to tax under Section&nbsp;1 and Section 4999 of the Code or generate a refund
of such taxes. In the event that the Accounting Firm, based upon controlling precedent or other substantial authority, determines
that an Underpayment has occurred, any such Underpayment shall be paid promptly (and in no event later than 60 days following
the date on which the Underpayment is determined) by the Company to or for the benefit of Executive together with interest at
the applicable federal rate provided for in Section 7872(f)(2) of the Code.</FONT></P>

<P STYLE="margin: 0 0 12pt 9pt; font-size: 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)&nbsp;
<U>Definitions</U>. The following terms shall have the following meanings for purposes of this <U>Section 3</U>:</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-weight: normal">(A)&nbsp;
&ldquo;<U>Net After-Tax Receipt</U>&rdquo; shall mean the present value (as determined in accordance with Sections 280G(b)(2)(A)(ii)
and 280G(d)(4) of the Code) of a Payment net of all taxes imposed on Executive with respect thereto under Sections 1 and 4999
of the Code and under applicable state and local laws, determined by applying the highest marginal rate under Section 1 of the
Code and under state and local laws which applied to Executive&rsquo;s taxable income for the immediately preceding taxable year,
or such other rate(s) as the Accounting Firm determined to be likely to apply to Executive in the relevant taxable year(s).</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-weight: normal">(B)&nbsp;
&ldquo;<U>Reduced Amount</U>&rdquo; shall mean the greatest amount of Agreement Payments that can be paid that would not result
in the imposition of the excise tax under Section 4999 of the Code if the Accounting Firm determines to reduce Agreement Payments
pursuant to <U>Section 3(e)(i)</U>.</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">4.&nbsp;
</FONT> Competition and Non-Solicitation.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(a)&nbsp; <B>Interests to be Protected</B>.
The parties acknowledge that Executive will perform essential services for the Company, its employees, and its stockholders during
the term of Executive&rsquo;s employment with the Company. Executive will be exposed to, have access to, and work with, a considerable
amount of confidential information. The parties also expressly recognize and acknowledge that the personnel of the Company have
been trained by, and are valuable to, the Company and that the Company will incur substantial recruiting and training expenses
if the Company must hire new personnel or retrain existing personnel to fill vacancies. The parties expressly recognize that it
could seriously impair the goodwill and diminish the value of the Company&rsquo;s business should Executive compete with the Company
in any manner whatsoever. The parties acknowledge that this covenant has an extended duration; however, they agree that this covenant
is reasonable and it is necessary for the protection of the Company, its stockholders, and employees. For these and other reasons,
and the fact that there are many other employment opportunities available to Executive if Executive&rsquo;s employment is terminated,
the parties are in full and complete agreement that the following restrictive covenants are fair and reasonable and are entered
into freely, voluntarily, and knowingly. Furthermore, each party was given the opportunity to consult with independent legal counsel
before entering into this Agreement.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(b)&nbsp; <B>Non-Competition</B>. During the
term of Executive&rsquo;s employment with the Company and for eighteen (18) months after the termination of Executive&rsquo;s
employment with the Company, which may be extended an additional twelve (12) months in the sole and absolute discretion of the
Company for a total of thirty (30) months after termination of Executive&rsquo;s employment with the Company, regardless of the
reason therefor, Executive shall not (whether directly or indirectly, as owner, principal, agent, stockholder, director, officer,
manager, employee, partner, participant, or in any other capacity) engage or become substantially and directly financially interested
in any Competitive Business Activities conducted within the Restricted Territory (as defined below). In the event of the termination
of Executive&rsquo;s employment and the Term pursuant to <U>Sections 3(a)(iv)</U> (&ldquo;<U>Termination by the Company Without
Good Cause</U>&rdquo;) or <U>3(a)(vi)</U>&nbsp;(&ldquo;<U>Termination by Executive With Good Reason</U>&rdquo;), if the Company
exercises its right to extend this non-competition clause by the additional twelve (12) months, then Executive will, (a) for a
period of twelve (12) additional months, continue to receive Executive&rsquo;s then current annual Base Salary, as provided in
<U>Section&nbsp;2(a)</U>, and (b) Executive will receive for a period of an additional six (6), a monthly cash payment equal to
the one (1) month cost of COBRA continuation of the health insurance benefits for Executive and Executive&rsquo;s immediate family
as applicable. As used herein, the term &ldquo;<U>Competitive Business Activities</U>&rdquo; shall mean business activities that
are competitive with the business of the Company, including but not limited to, business activities in the pharmaceutical industry
related to products that compete with the Company&rsquo;s products, and the term &ldquo;<U>Restricted Territory</U>&rdquo; shall
mean any state or other geographical area in which the Company has demonstrated an intent to develop, commercialize, and/or distribute
products during Executive&rsquo;s employment with the Company. Executive hereby agrees that, as of the date hereof, during Executive&rsquo;s
employment with the Company, the Company has demonstrated an intent to develop, commercialize, and/or distribute products throughout
the United States of America, Canada, Mexico, Brazil, Argentina, Europe, Australia, South Africa, Russia, Israel, Japan, and South
Korea.</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in"><B>(c)
 Non-Solicitation of Employees</B>. During the term of Executive&rsquo;s employment and for a period of twenty-four (24) months
after the termination of Executive&rsquo;s employment with the Company, regardless of the reason therefor, Executive shall not
directly or indirectly, for the Company, or on behalf of or in conjunction with any other person, company, partnership, corporation,
or governmental or other entity, solicit for employment, seek to hire, or hire any person who is employed by the Company, is a
consultant of the Company, or is an independent contractor of the Company, within twenty-four (24) months of the termination of
Executive&rsquo;s employment, and, as related solely to consultants, for the purpose of having any such consultant engage in services
that are the same as, similar to, or related to the services that such consultant provided for the Company and that are competitive
with the services provided by the consultant for the Company.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(d) <B>Non-Solicitation of Customers</B>.
During the term of Executive&rsquo;s employment and for a period of twenty-four (24) months after the termination of
Executive&rsquo;s employment with the Company, regardless of the reason therefor, Executive shall not directly or indirectly,
for the Company, or on behalf of, or in conjunction with, any other person, company, partnership, corporation, or
governmental entity, call on, solicit, or engage in business with, any of the actual or targeted prospective customers or
clients of the Company on behalf of any person or entity in connection with any Competitive Business, nor shall Executive
make known the names and addresses of such actual or targeted prospective customers or clients, or any information relating
in any manner to the trade or business relationships of the Company with such customers or clients, other than in connection
with the performance of Executive&rsquo;s duties under this Agreement, and/or persuade or encourage or attempt to persuade or
encourage any persons or entities with whom the Company does business or has some business relationship to cease doing
business or to terminate its business relationship with the Company or to engage in any Competitive Business Activities on
its own or with any competitor of the Company. As used herein, the term &ldquo;<U>Competitive Business</U>&rdquo; shall mean
business that is directly competitive with the business of the Company, including but not limited to, business in the
pharmaceutical industry related to products that directly compete with the Company&rsquo;s products.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(e)&nbsp;</FONT>Employee Assignment, Invention and Confidentiality Agreement<FONT STYLE="font-weight: normal">. Executive hereby reaffirms,
acknowledges, and agrees that Executive will be subject to the terms and conditions set forth in that certain Employee Assignment,
Invention, and Confidentiality Agreement (the &ldquo;<U>EAICA</U>&rdquo;) that must be entered into as a condition of employment
between the Company and Executive, and that this Agreement does not modify or amend the EAICA.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(f)&nbsp; <B>Equitable Relief</B>. In the event
a violation of any of the restrictions contained in this <U>Section&nbsp;4</U> occurs, the Company shall be entitled to preliminary
and permanent injunctive relief (without being required to post bond), reasonable attorneys&rsquo; fees, and damages and an equitable
accounting of all earnings, profits, and other benefits arising from such violation, which right shall be cumulative and in addition
to any other rights or remedies to which the Company may be entitled. In the event of a violation of any provision of <U>Section&nbsp;4(b)</U>,
<U>Section&nbsp;4(c)</U>, or <U>Section 4(d)</U>, the period for which those provisions would remain in effect shall be extended
for a period of time equal to that period beginning when such violation commenced and ending when the activities constituting
such violation shall have been finally terminated in good faith.</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(g)&nbsp; <B>Restrictions Separable</B>. If
the scope of any provision of this Agreement (whether in this <U>Section&nbsp;4</U> or otherwise) is found by a court to be too
broad to permit enforcement to its full extent, then such provision shall be enforced to the maximum extent permitted by law.
The parties agree that the scope of any provision of this Agreement may be modified by a judge in any proceeding to enforce this
Agreement, so that such provision can be enforced to the maximum extent permitted by law. Each and every restriction set forth
in this <U>Section&nbsp;4</U> is independent and severable from the others, and no such restriction shall be rendered unenforceable
by virtue of the fact that, for any reason, any other or others of them may be unenforceable in whole or in part.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">5<B>.&nbsp; Return of Company Property</B>.
At any time as requested by the Company, or upon the termination of Executive&rsquo;s employment with the Company for any reason,
Executive shall deliver promptly to the Company all files, lists, books, records, manuals, memoranda, drawings, and specifications;
all other written or printed materials and computers, cell phones, and other equipment that are the property of the Company (and
any copies of them); and all other materials that may contain confidential information relating to the business of the Company,
which Executive may then have in Executive&rsquo;s possession or control, whether prepared by Executive or not.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">6.&nbsp; <B>Cooperation</B>. Following the
Term, Executive shall give assistance and cooperation willingly, upon reasonable advance notice with due consideration for Executive&rsquo;s
other business or personal commitments, in any matter relating to Executive&rsquo;s position with the Company, or Executive&rsquo;s
expertise or experience as the Company may reasonably request, including Executive&rsquo;s attendance and truthful testimony where
deemed appropriate by the Company, with respect to any investigation or the Company&rsquo;s defense or prosecution of any existing
or future claims or litigations or other proceedings relating to matters in which Executive was involved or potentially had knowledge
by virtue of Executive&rsquo;s employment with the Company. The Company agrees that (a) it shall promptly reimburse Executive
for Executive&rsquo;s reasonable and documented expenses in connection with rendering assistance and/or cooperation under this
<U>Section 6</U> upon Executive&rsquo;s presentation of documentation for such expenses and (b) Executive shall be reasonably
compensated for any continued material services as required under this <U>Section 6</U>.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">7.&nbsp; <B>No Prior Agreements</B>. Executive
hereby represents and warrants to the Company that the execution of this Agreement by Executive and Executive&rsquo;s employment
by the Company and the performance of Executive&rsquo;s duties hereunder will not violate or be a breach of any agreement with
a former employer, client, or any other person or entity. Further, Executive agrees to indemnify the Company for any claim, including,
but not limited to, attorneys&rsquo; fees and expenses of investigation, by any such third party that such third party may now
have or may hereafter come to have against the Company based upon or arising out of any non-competition, invention, or secrecy
agreement between Executive and such third party that was in existence as of the date of this Agreement.</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in">8.&nbsp; <B>Miscellaneous</B>.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(a)&nbsp; <B>Notice</B>. All notices, requests,
demands, and other communications required or permitted under this Agreement shall be in writing and shall be deemed to have been
duly given, made, and received (i) if personally delivered, on the date of delivery, (ii) if by e-mail transmission, upon receipt,
(iii) if mailed United States mail, registered or certified, return receipt requested, postage prepaid, and addressed as provided
below, upon receipt or refusal of delivery, or (iv) if by a courier delivery service providing overnight or &ldquo;next-day&rdquo;
delivery, upon receipt or refusal of delivery, in each case addressed as follows:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; width: 1.5in; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 20%; padding-right: 0; padding-left: 0">To the Company:</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">TherapeuticsMD,
    Inc.</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">6800
    Broken Sound Parkway NW, 3rd Floor</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">Boca
    Raton, Florida 33487</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">Attention:
    Chief Executive Officer</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">Phone:
    (561) 961-1900</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-bottom: 12pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-bottom: 12pt; padding-left: 0"></TD></TR>
</TABLE>
<P STYLE="margin: 0 0 0 1.5in; font-size: 10pt; text-indent: 0">With a copy, which shall not constitute
notice, to:</P>

<P STYLE="margin: 0 0 0 2.5in; font-size: 10pt; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; width: 1.5in; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 20%; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">TherapeuticsMD,
    Inc.</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">6800
    Broken Sound Parkway NW, 3rd Floor</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">Boca
    Raton, Florida 33487</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">Attention:
    General Counsel</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">Phone:
    (561) 961-1900</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-bottom: 12pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-bottom: 12pt; padding-left: 0"></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">To Executive:</TD>
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0">Edward
    J. Borkowski</TD></TR>
</TABLE>
<P STYLE="margin: 0 0 0pt; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0in">Either party may
alter the address to which communications or copies are to be sent by giving notice of such change of address in conformity with
the provisions of this <U>Section 8</U> for the giving of notice.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(b)&nbsp; <B>Indulgences; Waivers</B>. Neither
any failure nor any delay on the part of either party to exercise any right, remedy, power, or privilege under this Agreement
shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power, or privilege preclude
any other or further exercise of the same or of any other right, remedy, power, or privilege, nor shall any waiver of any right,
remedy, power, or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power, or privilege
with respect to any other occurrence. No waiver shall be binding unless executed in writing by the party making the waiver.</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(c)&nbsp; <B>Controlling Law</B>. This Agreement
and all questions relating to its validity, interpretation, performance and enforcement, shall be governed by and construed in
accordance with the laws of the State of Florida, notwithstanding any Florida or other conflict&#45;of&#45;interest provisions
to the contrary. Venue for any action arising out of this Agreement or the employment relationship shall be brought only in courts
of competent jurisdiction in or for Palm Beach County, Florida and each party hereby irrevocably waives, to the fullest extent
permitted by law, any objection which they may now or hereafter have to the laying of venue in such courts and submits to the
jurisdiction of such courts. THE PARTIES (BY THEIR ACCEPTANCE HEREOF) HEREBY KNOWINGLY, IRREVOCABLY, VOLUNTARILY, AND INTENTIONALLY
WAIVE ANY RIGHT EACH MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY DISPUTES BASED UPON OR ARISING OUT OF THIS AGREEMENT.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 1in">(d)&nbsp; <B>Execution in Counterpart</B>.
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original as against any party
whose signature appears thereon, and all of which shall together constitute one and the same instrument. This Agreement shall
become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of the parties
reflected hereon as the signatories.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(e)&nbsp;
</FONT>Entire Agreement<FONT STYLE="font-weight: normal">. Except as herein contained, this Agreement contains the entire understanding
between the parties hereto with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements and
understandings, inducements, and conditions, express or implied, oral or written, which shall no longer have any force or effect.
The express terms hereof control and supersede any course of performance and/or usage of the trade inconsistent with any of the
terms hereof. This Agreement may not be modified or amended other than by an agreement in writing.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(f)&nbsp;
</FONT>Paragraph Headings<FONT STYLE="font-weight: normal">. The paragraph headings in this Agreement are for convenience only;
they form no part of this Agreement and shall not affect its interpretation.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(g)&nbsp;
</FONT>Number of Days<FONT STYLE="font-weight: normal">. In computing the number of days for purposes of this Agreement, all days
shall be counted, including Saturdays, Sundays, and holidays; provided, however, that if the final day of any time period falls
on a Saturday, Sunday, or holiday, then the final day shall be deemed to be the next day that is not a Saturday, Sunday, or holiday.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(h)&nbsp;
</FONT>Successors and Assigns. <FONT STYLE="font-weight: normal">This Agreement shall inure to the benefit of and be binding upon
the successors and assigns of the parties hereto; provided that because the obligations of Executive hereunder involve the performance
of personal services, such obligations shall not be delegated by Executive. For purposes of this Agreement, successors and assigns
shall include, but not be limited to, any individual, corporation, trust, partnership, or other entity that acquires a majority
of the stock or assets of the Company by sale, merger, consolidation, liquidation, or other form of transfer. The Company will
require any successor (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all
of the business and/or assets of the Company to expressly assume and agree to perform this Agreement in the same manner and to
the same extent that the Company would be required to perform it if no such succession had taken place.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(i)&nbsp;
</FONT>Tax Withholding. <FONT STYLE="font-weight: normal">The Company may withhold from any benefits payable under this Agreement
all federal, state, city, or other taxes as may be required pursuant to any law or governmental regulation or ruling.</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(j)&nbsp;
</FONT> Survival. <FONT STYLE="font-weight: normal">The respective rights and obligations of the parties hereunder shall survive
any termination of Executive&rsquo;s employment hereunder, including without limitation, the Company&rsquo;s obligations under
Section 3 and Executive&rsquo;s obligations under Section 4 above, and the expiration of the Term, to the extent necessary to
the intended preservation of such rights and obligations.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(k)&nbsp;
</FONT>Right to Consult with Counsel; No Drafting Party. <FONT STYLE="font-weight: normal">Executive acknowledges having read
and considered all of the provisions of this Agreement carefully, and having had the opportunity to consult with counsel of Executive&rsquo;s
own choosing, and, given this, Executive agrees that the obligations created hereby are not unreasonable. Executive acknowledges
that Executive has had an opportunity to negotiate any and all of these provisions and no rule of construction shall be used that
would interpret any provision in favor of or against a party on the basis of who drafted the Agreement.</FONT></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: center; text-indent: 0in"><B>[<I>Signature Page
Follows</I>]</B></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have executed this Agreement as of the date first above written.</P>

<P STYLE="text-indent: 0; margin: 0 0 25pt 50%; font-size: 10pt"><B>THERAPEUTICSMD, INC.</B></P>

<P STYLE="text-indent: 0; margin: 0 0 0 50%; font-size: 10pt"><U>/s/ Robert Finizio&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="text-indent: 0; margin: 0 0 0 50%; font-size: 10pt">Robert Finizio</P>

<P STYLE="text-indent: 0; margin: 0 0 0 50%; font-size: 10pt">&nbsp;</P>

<P STYLE="text-indent: 0; margin: 0 0 0.5in 50%; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0; margin: 0 0 25pt 50%; font-size: 10pt"><B>EXECUTIVE:</B></P>

<P STYLE="text-indent: 0; margin: 0 0 0 50%; font-size: 10pt"><U>/s/ Edward J. Borkowski&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="margin: 0 0 0 50%; font-size: 10pt; text-indent: 0">Edward J. Borkowski</P>

<P STYLE="margin: 0 0 0 50%; font-size: 10pt; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0 0 0 50%; font-size: 10pt; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0 0 0 50%; font-size: 10pt; text-indent: 0">&nbsp;</P>

<P STYLE="margin: 0 0 0 50%; font-size: 10pt; text-indent: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0; font-size: 10pt">[Signature Page to Employment Agreement]</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: center"><B><I>EXHIBIT A<BR>
FORM OF RELEASE</I></B></P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">This Separation Agreement
(&ldquo;Agreement&rdquo;) is made between TherapeuticsMD, Inc. (&ldquo;Company&rdquo;) and ____________________ (&ldquo;Employee&rdquo;),
intending to be legally bound, and in consideration of the mutual covenants contained herein, and other valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="margin: 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">1.&nbsp;
<U>Separation and Severance</U>. Employee&rsquo;s final day of employment with Company was ____________________. Although the
parties agree that Company does not owe Employee any further consideration, as severance, Company agrees to pay Employee as set
forth in Employee&rsquo;s Employment Agreement dated __________________ (the &ldquo;<U>Employment Agreement</U>&rdquo;), provided
Employee executes this Agreement, complies with its terms and the terms of Employee&rsquo;s Employment Agreement[[, and does not
revoke this Agreement during the Revocation Period as defined in Section 8 below.]]<A HREF="#note_ftn1" NAME="note_ftnref1" STYLE="font-size: 65%; vertical-align: 35%">1</A>
Employee acknowledges that no other compensation of any kind remains outstanding, that the consideration provided herein is more
than Employee would otherwise be entitled to receive, that Employee shall not be entitled to any other payments or benefits from
Company, and that no other amounts are due or owing or shall become due or owing relating to any obligation, agreement, or otherwise.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">1.&nbsp;
<U>Execution of Separation Agreement</U>. Should employee wish to accept this Agreement, it must be signed and returned to ________________________________
by ______________.</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">2.&nbsp;
<U>EAICA</U>. Employee acknowledges and agrees that Employee&rsquo;s obligations contained in the paragraphs 2, 3, 4, 6, 8, 9,
10 and 11 of the Employee Assignment, Invention, and Confidentiality Agreement (&ldquo;EAICA&rdquo;) that Employee signed on _____________________,
a copy of which is attached as Exhibit A, remain in full force and effect. The terms of this Agreement are in additional to and
do not supersede the surviving terms of the EAICA.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">3.&nbsp;
<U>Confidentiality of Agreement</U>. Employee understands and agrees that the existence of this Agreement and the terms and conditions
thereof, shall be considered confidential, and shall not be disclosed by Employee to any third party or entity except with the
prior written approval of Company, to Employee&rsquo;s attorney, or upon the order of a court of competent jurisdiction. Notwithstanding
anything in this Agreement to the contrary, nothing in this Agreement or any other agreement between the Company and Employee
shall prevent Employee from sharing information and communicating in good faith, without prior notice to the Company, with any
federal government agency having jurisdiction over the Company or its operations, and cooperating in any investigation by any
such federal government agency; provided that Employee receives no monies for compensatory or other damages as a result of participating
in any such communication or cooperation with the EEOC.</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">4.&nbsp;
<U>Non-Disparagement</U>. At all time Employee will refrain from and will not directly or indirectly engage in any conversation
that would tend to negatively impact Company or any of the Releasees as defined in Section 8 below.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<HR ALIGN="LEFT" SIZE="1" STYLE="width: 33%">

<P STYLE="margin: 0; font-size: 10pt"><A HREF="#note_ftnref1" NAME="note_ftn1" STYLE="font-size: 65%; vertical-align: 35%">1</A>
Employee will be entitled to a revocation period only if over the age of 40 at the date of termination.</P>
<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">5.&nbsp;
<U>Return of Company Property</U>. Employee agrees to immediately return to Company any and all property of Company in Employee&rsquo;s
possession, custody, or control. No severance shall be paid pursuant to this Agreement until all Company property is returned.</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">6.&nbsp;
<U>Confidential Information</U>. Employee acknowledges that Employee has had access to Company confidential and proprietary information
and agrees that all such Confidential Information is and shall remain the exclusive property of Company. Employee further agrees
that Employee shall not publish, disclose, or otherwise make available to any third party any such Confidential Information. Employee
acknowledges and agrees that Employee has continuing confidentiality obligations under the EAICA. Employee warrants that Employee
has no materials containing Confidential Information, but if Employee does, Employee shall return immediately to Company any and
all materials containing any Confidential Information in Employee&rsquo;s possession, custody, or control. The terms of this Separation
Agreement comprise confidential information of the Company.</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">7.&nbsp;
<U>Release</U>. That the undersigned, ________________, for good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, intending to be legally bound, and Employee&rsquo;s past, present and future agents, representatives,
attorneys, affiliates, heirs, executors, assigns and successors, and all other persons connected therewith, and on behalf of all
successors and assigns, hereby releases and forever discharges TherapeuticsMD, Inc., vitaMedMD, LLC, BocaGreenMD, Inc., vitaCare
Prescription Services and all of their past, present and future agents, representatives, principals, attorneys, affiliates, owners,
parent corporations, subsidiaries, officers, directors, employees, assigns and successors, and all other persons, firms or corporations
connected or affiliated therewith (collectively &ldquo;Releasees&rdquo;), of and from any and all legal, equitable or other claims,
demands, setoffs, defenses, contracts, accounts, suits, debts, agreements, actions, causes of action, sums of money, judgments,
findings, controversies, disputes, or past, present and future duties, responsibilities, obligations, or suits at law and/or equity
of whatsoever kind, from the beginning of the world to the date hereof, in addition, without limitation, any and all actions,
causes of action, claims, counterclaims, third party claims, and any and all other federal, state, local and/or municipality statutes,
laws and/or regulations and any ordinance and/or common law pertaining to employment or otherwise and any and all other claims
which have been or which could have been asserted against any party in any forum.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">By signing this Agreement,
Employee knowingly and voluntarily fully releases and forever discharges Releasees of and from all claims, demands and liability
of any kind arising under any statute, law or ordinance, including, without limitation, Title VII of the Civil Rights Act of 1964,
the Fair Labor Standards Act, the National Labor Relations Act, the Americans with Disabilities Act, any state Human Rights Act,
Fla. Stat. 448, or any facts or claims arising under the Age Discrimination in Employment Act (&ldquo;ADEA&rdquo;). This release
is intended to cover all actions, causes of action, claims and demands for damages, loss or injury arising from the beginning
of time until the date of this Agreement, whether presently known or unknown to Employee. However, Employee does not waive Employee&rsquo;s
rights to claims which may arise after this Agreement becomes effective.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In addition, Employee
is hereby advised to consult with an attorney prior to executing this Agreement. Employee agrees that Employee has been given
a reasonable time in which to consider the Agreement and seek such consultation. Employee further warrants that Employee has consulted
with knowledgeable persons concerning the effect of this Agreement and all rights which Employee might have under any and all
state and federal laws relating to employment and employment discrimination and otherwise. Employee fully understands these rights
and that by signing this Agreement Employee forfeits all rights to sue Releasees for matters relating to or arising out of employment,
separation, or otherwise.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In accordance with provisions
of the ADEA, as amended, 29 U.S.C. &sect;601-634, Employee is hereby provided a period of twenty-one (21) days from the date Employee
receives this Agreement to review the waiver of rights under the ADEA and sign this Agreement. Furthermore, Employee has seven
(7) days after the date Employee signs the Agreement (&ldquo;Revocation Period&rdquo;) to revoke Employee&rsquo;s consent. This
Agreement shall not become effective or enforceable until the Revocation Period has expired. If Employee does not deliver a written
revocation to ___________________________ before the Revocation Period expires, this Agreement will become effective.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Notwithstanding anything
in this Section 8 to the contrary, releases contained in this Agreement shall not apply to (i) any rights to receive any payments
or benefits pursuant to Sections 3(b)(ii), 3(b)(iii) or 3(b)(iv) of the Employment Agreement, (ii) any rights or claims that may
arise as a result of events occurring after the date this Agreement is executed, (iii) any indemnification rights Employee may
have as a former officer or director of the Company or its subsidiaries or affiliated companies, (iv) any claims for benefits
under any directors&rsquo; and officers&rsquo; liability policy maintained by the Company or its subsidiaries or affiliated companies
in accordance with the terms of such policy, and (v) any rights as a holder of equity securities of the Company.</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">8.&nbsp;
<U>Opportunity to Seek Counsel</U>. The parties represent that they have had an opportunity to retain legal counsel to represent
them in connection with this matter, that they have been advised of the legal effect and consequences of this Agreement, that
they have entered into this Agreement knowingly, freely and voluntarily of their own volition, and that they have not been coerced,
forced, harassed, threatened or otherwise unduly pressured to enter into this Agreement.</P>

<P STYLE="margin: 0 0 0 0.5in; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">9.&nbsp;
<U>Reporting of Known Issues</U>. As a further condition to your receipt of the benefits described in this Agreement, you hereby
represent and warrant that you have reported in writing to ___________________________ any unethical conduct or violations of
laws, regulations, Company policies and procedures by the Company, a Company employee, or a Company officer of which you are aware.</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">10.&nbsp;
<U>No Admissions</U>. This Agreement is not and shall not in any way be construed as an admission by either party of any wrongful
act or omission, or any liability due and owing, or any violation of any federal, state or local law or regulation.</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">11.&nbsp;
 <U>Miscellaneous</U>. This Agreement may not be amended or modified except in writing signed by Employee and an authorized representative
with actual authority to bind Company, specifically stating that it is an amendment to this Agreement. This Agreement shall be
governed by and construed in accordance with <U>Sections 4(g) (Restrictions Separable)</U>, <U>8(a) (Notice)</U>, <U>8(b) (Indulgences;
Waivers)</U>, <U>8(c) (Controlling Law)</U>, <U>8(d) (Execution in Counterpart)</U>, <U>8(f) (Paragraph Headings)</U>, and <U>8(k)
(Right to Consult with Counsel; No Drafting Party)</U> of the Employment Agreement. This Agreement and the Employment Agreement
constitute the entire Agreement between the parties hereto with respect to the subject matter hereof; provided, however, that
Employee&rsquo;s continuing obligations to the Company under the terms of the EAICA are incorporated herein and shall remain in
full force and effect as set forth herein.</P>

<P STYLE="margin: 0 0 0 0.5in; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">IN WITNESS THEREOF, the
parties hereto acknowledge, understand and agree to this Agreement and intend to be bound by all of the clauses contained in this
document.</P>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">EMPLOYEE</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">THERAPEUTICSMD, INC.</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0; vertical-align: bottom">By:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">[Employee]</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0; vertical-align: bottom">Its:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0; width: 2%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; width: 16%">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt; padding-right: 0; padding-left: 0; vertical-align: bottom; width: 2%">Date:</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 0; padding-left: 0; width: 40%">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0.55pt 0 12pt; font-size: 10pt; text-align: justify"></P>

<P STYLE="margin: 0 0 12pt 3.25in; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0 0 12pt 3.25in; font-size: 10pt">&nbsp;</P>









<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>10
<FILENAME>ex10-42.htm
<DESCRIPTION>AMENDMENT TO EMPLOYMENT AGREEMENT WITH EDWARD J. BORKOWSKI
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.42</B></FONT></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-align: center"><B>AMENDMENT TO EMPLOYMENT AGREEMENT</B></P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-indent: 0.5in">This Amendment (&#8220;Amendment&#8221;)
to the Employment Agreement (&#8220;Agreement&#8221;), effective 30<SUP>th</SUP> day of October 2019, by and between <B>TherapeuticsMD,
Inc.</B> with a place of business at 6800 Broken Sound Parkway NW, 3<SUP>rd</SUP> Floor, Boca Raton, Florida 33487 (&#8220;TherapeuticsMD&#8221;);
and Edward J. Borkowski (&#8220;Borkowski&#8221;).</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-indent: 0.5in"><B>WHEREAS,</B> &#9;the Agreement exists
between TherapeuticsMD and Borkowski (collectively herein as the &#8220;Parties&#8221;) relating to Borkowski&#8217;s employment
with TherapeuticsMD;</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-indent: 0.5in"><B>WHEREAS,</B> Borkowski requested
to postpone his starting date as an employee of TherapeuticsMD until January 1, 2020 and be brought in as a consultant for the
remainder of 2019; and</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-indent: 0.5in"><B>WHEREAS,</B> the Parties have agreed
to amend the Agreement.</P>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-indent: 0.5in"><B>NOW, THEREFORE, </B>in consideration
of the mutual promises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which the
Parties hereby acknowledge, intending to be legally bound, the Parties hereby agree as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in">1.</TD><TD STYLE="font-size: 10pt">To replace the Preamble of
                                         the Agreement with the following: </TD></TR></TABLE>

<P STYLE="margin: 0 0 12pt 0.25in; font-size: 10pt; text-align: justify; text-indent: 0in"><B>THIS EMPLOYMENT
AGREEMENT</B> (this &#8220;<U>Agreement</U>&#8221;), by and between TherapeuticsMD, Inc., a Nevada corporation (the &#8220;<U>Company</U>&#8221;),
and Edward J. Borkowski (&#8220;<U>Executive</U>&#8221;) is entered into and effective as of the 1st day of January 2020 (the
&#8220;<U>Effective Date</U>&#8221;).</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in">2.</TD><TD STYLE="font-size: 10pt">To delete the last sentence
                                         of paragraph 2(b) that reads:</TD></TR></TABLE>

<P STYLE="margin: 0 0 12pt 0.25in; font-size: 10pt">The 2019 Targeted Annual Bonus Award will be paid
to Executive as if Executed were employed for the full year and will be at target or higher.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in">3.</TD><TD STYLE="font-size: 10pt">Except as specifically referenced
                                         herein, the Agreement shall remain unchanged and shall continue in full force and effect.</TD></TR></TABLE>

<P STYLE="margin: 0 0 12pt; font-size: 10pt; text-indent: 0.5in">This Amendment may be executed in any number of counterparts,
each of which shall be enforceable against the Parties actually executing such counterparts, and all of which shall constitute
one instrument.</P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt; text-align: center">[Remainder of page left intentionally blank]<BR STYLE="clear: both"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 8pt; font-size: 10pt"><B>TherapeuticsMD, Inc.</B></P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; padding-right: 0; padding-left: 0; font-size: 10pt">/s/ Robert Finizio</TD>
    <TD STYLE="width: 6%; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;&nbsp;Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">November 22,
    2019</TD></TR>
</TABLE>
<P STYLE="margin: 0 0 8pt; font-size: 10pt">Signature</P>

<P STYLE="margin: 0; font-size: 10pt"><U>Robert Finizio, CEO</U></P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt">Printed Name and Title</P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt"><B>Edward J. Borkowski</B></P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 50%; padding-right: 0; padding-left: 0"><B>/s/ Edward J. Borkowski</B></TD>
    <TD STYLE="font-size: 10pt; width: 6%; padding-right: 0; padding-left: 0">&nbsp;&nbsp;Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 0; padding-left: 0">November 22, 2019</TD></TR>
</TABLE>
<P STYLE="margin: 0 0 8pt; font-size: 10pt">Signature</P>

<P STYLE="margin: 0; font-size: 10pt"><U>Edward J. Borkowski</U></P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt">Printed Name</P>

<P STYLE="margin: 0 0 8pt; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0 0 8pt; font-size: 10pt; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>ex23-1.htm
<DESCRIPTION>CONSENT OF GRANT THORNTON LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued our report dated March 3, 2021, with respect to the consolidated financial statements included in the Annual
Report of TherapeuticsMD, Inc. on Form 10-K for the year ended December 31, 2020. We consent to the incorporation
by reference of said report in the Registration Statements of TherapeuticsMD, Inc. on Form S-3 (File No. 333-226452) and on Forms
S-8 (File No. 333-191730, File No. 333-232268 and File No. 333-242363).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
GRANT THORNTON LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miami, Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
3, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert G. Finizio, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March
3, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Robert G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
James C. D&rsquo;Arecca, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March
3, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James C. D&rsquo;Arecca</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James C. D&rsquo;Arecca</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Robert G. Finizio,
Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &sect; 1350, as adopted
pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
                                         Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         information contained in the Report fairly presents, in all material respects, the financial
                                         condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
3, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Robert G. Finizio</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>15
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A HREF="txmd-10k_123120.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, James C. D&rsquo;Arecca,
Chief Financial Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &sect; 1350, as adopted
pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
                                         Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         information contained in the Report fairly presents, in all material respects, the financial
                                         condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
3, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ James C. D&rsquo;Arecca</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James C. D&rsquo;Arecca</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 81 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>txmd-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaqNibP9w5dzuelBtm9/Hcmqfy0gmh87kCjpZf5mwf0F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20201231" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" id="ConsolidatedStatementsOfStockholdersDeficitEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000007 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" id="FixedAssetsNet">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
	  <link:definition>00000012 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000013 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Debt" id="Debt">
	  <link:definition>00000014 - Disclosure - DEBT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000016 - Disclosure - EMPLOYEE BENEFIT PLAN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000018 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000019 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" id="SelectedQuarterlyFinancialData">
	  <link:definition>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000025 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" id="FixedAssetsNetTables">
	  <link:definition>00000027 - Disclosure - FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
	  <link:definition>00000028 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DebtTables" id="DebtTables">
	  <link:definition>00000030 - Disclosure - DEBT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000032 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" id="SelectedQuarterlyFinancialDataTables">
	  <link:definition>00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" id="CompanyDetailsNarrative">
	  <link:definition>00000035 - Disclosure - THE COMPANY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" id="OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails">
	  <link:definition>00000036 - Disclosure - The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" id="FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details">
	  <link:definition>00000037 - Disclosure - The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" id="ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails">
	  <link:definition>00000038 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" id="InventoryConsistsOfFollowingDetails">
	  <link:definition>00000040 - Disclosure - Inventory consists of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" id="OtherCurrentAssetsConsistOfFollowingDetails">
	  <link:definition>00000041 - Disclosure - Other current assets consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" id="FixedAssetsNetConsistOfFollowingDetails">
	  <link:definition>00000042 - Disclosure - Fixed assets, net consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" id="FixedAssetsNetDetailsNarrative">
	  <link:definition>00000043 - Disclosure - FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" id="FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details">
	  <link:definition>00000044 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" id="EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails">
	  <link:definition>00000045 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" id="IntangibleAssetsNetDetailsNarrative">
	  <link:definition>00000046 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000047 - Disclosure - Other current liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" id="AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails">
	  <link:definition>00000048 - Disclosure - As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" id="FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details">
	  <link:definition>00000049 - Disclosure - The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000050 - Disclosure - DEBT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" id="SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details">
	  <link:definition>00000051 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2020: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" id="WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details">
	  <link:definition>00000052 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" id="RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details">
	  <link:definition>00000053 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" id="SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails">
	  <link:definition>00000054 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" id="ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails">
	  <link:definition>00000055 - Disclosure - Schedule of restricted stock units and performance stock units (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000056 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative" id="EmployeeBenefitPlanDetailsNarrative">
	  <link:definition>00000057 - Disclosure - EMPLOYEE BENEFIT PLAN (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" id="ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails">
	  <link:definition>00000058 - Disclosure - For financial reporting purposes, (loss) income before taxes includes the following components: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" id="ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails">
	  <link:definition>00000059 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" id="ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails">
	  <link:definition>00000060 - Disclosure - The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000061 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000062 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000063 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" id="SupplementalLeaseInformationDetails">
	  <link:definition>00000064 - Disclosure - Supplemental lease information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" id="FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails">
	  <link:definition>00000065 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" id="SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails">
	  <link:definition>00000067 - Disclosure - Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="txmd_BijuvaMember" name="BijuvaMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment6Member" name="FinancingAgreementAmendment6Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerAMember" name="CustomerAMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerBMember" name="CustomerBMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerCMember" name="CustomerCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerDMember" name="CustomerDMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnoveraMember" name="AnnoveraMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_VitaminsImvexxyAndBijuvaMember" name="VitaminsImvexxyAndBijuvaMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaAndAnnoveraMember" name="BijuvaAndAnnoveraMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrescriptionVitaminsMember" name="PrescriptionVitaminsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyMember" name="ImvexxyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementMember" name="CouncilLicenseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep1Member" name="CouncilLicenseAgreementStep1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep2Member" name="CouncilLicenseAgreementStep2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep3Member" name="CouncilLicenseAgreementStep3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_KnightLicenseAgreementMember" name="KnightLicenseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseAgreementTheramexMember" name="LicenseAgreementTheramexMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PerformanceStockUnitsMember" name="PerformanceStockUnitsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksMember" name="MultipleTrademarksMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsMember" name="DomesticUSPatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsMember" name="ForeignPatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsBijuvaMember" name="DomesticPatentsBijuvaMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsBijuvaMember" name="ForeignPatentsBijuvaMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsNonApprovedBijuvaMember" name="DomesticPatentsNonApprovedBijuvaMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsImvexxyMember" name="DomesticUSPatentsImvexxyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSUtilityPatentsImvexxyMember" name="DomesticUSUtilityPatentsImvexxyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSDesignPatentsImvexxyMember" name="DomesticUSDesignPatentsImvexxyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsImvexxyMember" name="ForeignPatentsImvexxyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentsImvexxyMember" name="ForeignUtilityPatentsImvexxyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignDesignPatentsImvexxyMember" name="ForeignDesignPatentsImvexxyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" name="DomesticUtilityPatentTopicalCreamCandidatesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTransdermalPatchMember" name="DomesticUtilityPatentTransdermalPatchMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentTransdermalPatchMember" name="ForeignUtilityPatentTransdermalPatchMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTx009HRMember" name="DomesticUtilityPatentTx009HRMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsProgesteroneFormulationsMember" name="DomesticPatentsProgesteroneFormulationsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsProgesteroneFormulationsMember" name="ForeignPatentsProgesteroneFormulationsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentOperaMember" name="DomesticUtilityPatentOperaMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementMember" name="FinancingAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoMember" name="TrancheTwoMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyBijuvaAndAnnoveraMember" name="ImvexxyBijuvaAndAnnoveraMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheThreeMember" name="TrancheThreeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Member" name="FinancingAgreementAmendment8Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodOneMember" name="RepaymentPeriodOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodTwoMember" name="RepaymentPeriodTwoMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodThreeMember" name="RepaymentPeriodThreeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodFourMember" name="RepaymentPeriodFourMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodFiveMember" name="RepaymentPeriodFiveMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodSixMember" name="RepaymentPeriodSixMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodSevenMember" name="RepaymentPeriodSevenMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentPeriodEightMember" name="RepaymentPeriodEightMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period1Member" name="FinancingAgreementAmendment8Period1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period2Member" name="FinancingAgreementAmendment8Period2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period3Member" name="FinancingAgreementAmendment8Period3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period4Member" name="FinancingAgreementAmendment8Period4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period5Member" name="FinancingAgreementAmendment8Period5Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period6Member" name="FinancingAgreementAmendment8Period6Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period7Member" name="FinancingAgreementAmendment8Period7Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period8Member" name="FinancingAgreementAmendment8Period8Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period9Member" name="FinancingAgreementAmendment8Period9Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period10Member" name="FinancingAgreementAmendment8Period10Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period11Member" name="FinancingAgreementAmendment8Period11Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period12Member" name="FinancingAgreementAmendment8Period12Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment8Period13Member" name="FinancingAgreementAmendment8Period13Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LenderWarrantsMember" name="LenderWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MidCapAgreementMember" name="MidCapAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementCantorFitzgeraldMember" name="UnderwritingAgreementCantorFitzgeraldMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementJPMorganChaseMember" name="UnderwritingAgreementJPMorganChaseMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementGoldmanSachsMember" name="UnderwritingAgreementGoldmanSachsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SubscriptionAgreementKnightMember" name="SubscriptionAgreementKnightMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultant2Member" name="OutsideConsultant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsMember" name="WarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Plan2019Member" name="Plan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ExpirationPeriod20YearsMember" name="ExpirationPeriod20YearsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ExpirationPeriodIndefiniteMember" name="ExpirationPeriodIndefiniteMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CatalentMember" name="CatalentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmericanInternationalGroupMember" name="AmericanInternationalGroupMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierOneConcentrationRiskMember" name="SupplierOneConcentrationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierTwoConcentrationRiskMember" name="SupplierTwoConcentrationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierThreeConcentrationRiskMember" name="SupplierThreeConcentrationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationCardinalHealthRiskMember" name="CustomerConcentrationCardinalHealthRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPillPackRiskMember" name="CustomerConcentrationPillPackRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationMcKessonCorporationRiskMember" name="CustomerConcentrationMcKessonCorporationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationAmerisourceBergenRiskMember" name="CustomerConcentrationAmerisourceBergenRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment7Period1Member" name="FinancingAgreementAmendment7Period1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementAmendment7Period2Member" name="FinancingAgreementAmendment7Period2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EntityCommonStockHeldByNonaffiliates" name="EntityCommonStockHeldByNonaffiliates" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseRights" name="LicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmortizationOfIntellectualPropertyLicenseFee" name="AmortizationOfIntellectualPropertyLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PaymentsToAcquireIntellectualPropertyLicense" name="PaymentsToAcquireIntellectualPropertyLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IncreaseDecreaseInSecurityDeposit" name="IncreaseDecreaseInSecurityDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantGrantedInRelationToFinancingAgreement" name="WarrantGrantedInRelationToFinancingAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShippingAndHandlingCostsPolicyTextBlock" name="ShippingAndHandlingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfWarrantRollForwardTableTextBlock" name="ScheduleOfWarrantRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" name="ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSubsidiaries" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable" name="IncreaseInAllowanceForDoubtfulAccountsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" name="MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" name="MinimumCashBalanceRequirementUnderCreditAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatentsDomestic" name="NumberOfIssuedPatentsDomestic" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatentsForeign" name="NumberOfIssuedPatentsForeign" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" name="ReturnPeriodOfUnsalablePrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShelfLifeOfPrescriptionProducts" name="ShelfLifeOfPrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentUponFDAApproval" name="MilestonePaymentUponFDAApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" name="MilestonePaymentsAfterReleaseOfFirstCommercialBatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetSalesAmountPerStepbasedRoyalty" name="NetSalesAmountPerStepbasedRoyalty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RoyaltyPercent" name="RoyaltyPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" name="MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" name="SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" name="SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" name="SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" name="MaximumCostsAndExpensesForPostApprovalStudyToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentReceivedUponRegulatoryApproval" name="MilestonePaymentReceivedUponRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CashUpfrontPaymentReceived" name="CashUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RegulatoryMilestoneAdditionalPayment" name="RegulatoryMilestoneAdditionalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesMilestonePaymentsInTranches" name="SalesMilestonePaymentsInTranches" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualNetSalesMilestone" name="AnnualNetSalesMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_QuarterlyRoyaltyPaymentsPercentage" name="QuarterlyRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidSalesAndMarketingCostsCurrent" name="PrepaidSalesAndMarketingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturing" name="PrepaidManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedRebates" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtTrancheAxis" name="DebtTrancheAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_DebtTrancheDomain" name="DebtTrancheDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" name="LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LiborFloorRate" name="LiborFloorRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrimeRateFloor" name="PrimeRateFloor" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfInstallmentPayments" name="NumberOfInstallmentPayments" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeePercentage" name="PrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FacilityFeePaidPercent" name="FacilityFeePaidPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumRevenueRequirementUnderCreditAgreement" name="MinimumRevenueRequirementUnderCreditAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfTranchesUnderTermLoanFacility" name="NumberOfTranchesUnderTermLoanFacility" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentOfDebtWithNewCreditFacility" name="RepaymentOfDebtWithNewCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentFeePercentage" name="RepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsUnvestedWeightedAverageExercisePrice" name="WarrantsUnvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceOtherThanOptions" name="WeightedAverageExercisePriceOtherThanOptions" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PeriodExercisableUnderwritersOption" name="PeriodExercisableUnderwritersOption" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritersOptionGrantedInPeriodShares" name="UnderwritersOptionGrantedInPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ProceedsFromIssuancePublicOffering" name="ProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MaximumCommonStockOfferingPrice" name="MaximumCommonStockOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FixedCommissionRate" name="FixedCommissionRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" name="NumberOfStockOptionsExercisedInCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" name="NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" name="NumberOfStockIssuedInCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution" name="DefinedContributionPlanMaximumEmployerMatchingContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DefinedContributionPlanVestingServicePeriod" name="DefinedContributionPlanVestingServicePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NolCarryForwardPeriod" name="NolCarryForwardPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfVendors" name="NumberOfVendors" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCustomers" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetRentableAreaLease" name="NetRentableAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RentedAreaLease" name="RentedAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalAreaOfLeaseOccupied" name="AdditionalAreaOfLeaseOccupied" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" name="LesseeOperatingLeaseExistenceOfOptionToExtendNumber" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" name="LesseeOperatingLeaseLeaseNotYetCommencedArea" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SignificantSupplyCommitmentPercentagePayable" name="SignificantSupplyCommitmentPercentagePayable" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>txmd-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20201231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20201231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20201231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20201231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20201231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20201231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Debt" xlink:href="txmd-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlan" xlink:href="txmd-20201231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20201231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20201231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20201231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20201231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20201231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20201231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20201231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtTables" xlink:href="txmd-20201231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20201231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20201231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:href="txmd-20201231.xsd#OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:href="txmd-20201231.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:href="txmd-20201231.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20201231.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20201231.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20201231.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20201231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:href="txmd-20201231.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20201231.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20201231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20201231.xsd#AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:href="txmd-20201231.xsd#FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:href="txmd-20201231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:href="txmd-20201231.xsd#SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20201231.xsd#WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20201231.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:href="txmd-20201231.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:href="txmd-20201231.xsd#ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20201231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="txmd-20201231.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:href="txmd-20201231.xsd#ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:href="txmd-20201231.xsd#ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:href="txmd-20201231.xsd#ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20201231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20201231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20201231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20201231.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20201231.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:href="txmd-20201231.xsd#SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_txmdLicenseRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaapOperatingLeaseImpairmentLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_IncreaseDecreaseInSecurityDeposit" xlink:label="loc_txmdIncreaseDecreaseInSecurityDeposit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_txmdIncreaseDecreaseInSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt" xlink:title="00000014 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - EMPLOYEE BENEFIT PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000027 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables" xlink:title="00000030 - Disclosure - DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000035 - Disclosure - THE COMPANY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:title="00000036 - Disclosure - The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:title="00000037 - Disclosure - The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:title="00000038 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000040 - Disclosure - Inventory consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000041 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000042 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000043 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:title="00000044 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000045 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000046 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000047 - Disclosure - Other current liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000048 - Disclosure - As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:title="00000049 - Disclosure - The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:title="00000050 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:title="00000051 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2020: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:title="00000052 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:title="00000053 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:title="00000054 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:title="00000055 - Disclosure - Schedule of restricted stock units and performance stock units (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000056 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000057 - Disclosure - EMPLOYEE BENEFIT PLAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:title="00000058 - Disclosure - For financial reporting purposes, (loss) income before taxes includes the following components: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:title="00000059 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:title="00000060 - Disclosure - The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="loc_us-gaapDeferredTaxAssetInterestCarryforward" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetInterestCarryforward" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000061 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000062 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000063 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000064 - Disclosure - Supplemental lease information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000065 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:title="00000067 - Disclosure - Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>txmd-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20201231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20201231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20201231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20201231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20201231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20201231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Debt" xlink:href="txmd-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlan" xlink:href="txmd-20201231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20201231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20201231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20201231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20201231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20201231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20201231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20201231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtTables" xlink:href="txmd-20201231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20201231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20201231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:href="txmd-20201231.xsd#OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:href="txmd-20201231.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:href="txmd-20201231.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20201231.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20201231.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20201231.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20201231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:href="txmd-20201231.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20201231.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20201231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20201231.xsd#AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:href="txmd-20201231.xsd#FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:href="txmd-20201231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:href="txmd-20201231.xsd#SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20201231.xsd#WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20201231.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:href="txmd-20201231.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:href="txmd-20201231.xsd#ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20201231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="txmd-20201231.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:href="txmd-20201231.xsd#ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:href="txmd-20201231.xsd#ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:href="txmd-20201231.xsd#ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20201231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20201231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20201231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20201231.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20201231.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:href="txmd-20201231.xsd#SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapDepreciationAndAmortization_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapOperatingExpenses_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapOtherNonoperatingIncome_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapInterestExpense_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapNonoperatingIncomeExpense_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareAbstract_100" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_100" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt" xlink:title="00000014 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - EMPLOYEE BENEFIT PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000027 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables" xlink:title="00000030 - Disclosure - DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000035 - Disclosure - THE COMPANY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:title="00000036 - Disclosure - The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:title="00000037 - Disclosure - The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:title="00000038 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PerformanceStockUnitsMember" xlink:label="loc_txmdPerformanceStockUnitsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdPerformanceStockUnitsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_160" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_VitaminsImvexxyAndBijuvaMember" xlink:label="loc_txmdVitaminsImvexxyAndBijuvaMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsImvexxyAndBijuvaMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerAMember" xlink:label="loc_txmdCustomerAMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerAMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerBMember" xlink:label="loc_txmdCustomerBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerBMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerCMember" xlink:label="loc_txmdCustomerCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerCMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerDMember" xlink:label="loc_txmdCustomerDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerDMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="loc_us-gaapLandAndBuildingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandAndBuildingMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementMember" xlink:label="loc_txmdCouncilLicenseAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_KnightLicenseAgreementMember" xlink:label="loc_txmdKnightLicenseAgreementMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdKnightLicenseAgreementMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryWriteDown_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatentsDomestic" xlink:label="loc_txmdNumberOfIssuedPatentsDomestic_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsDomestic_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatentsForeign" xlink:label="loc_txmdNumberOfIssuedPatentsForeign_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsForeign_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdRoyaltyPercent_390" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_390" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_390" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:label="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_390" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_390" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_390" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_390" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_390" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:label="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval_390" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="loc_txmdCashUpfrontPaymentReceived_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdCashUpfrontPaymentReceived_390" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="loc_txmdRegulatoryMilestoneAdditionalPayment_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdRegulatoryMilestoneAdditionalPayment_390" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="loc_txmdSalesMilestonePaymentsInTranches_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSalesMilestonePaymentsInTranches_390" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualNetSalesMilestone" xlink:label="loc_txmdAnnualNetSalesMilestone_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualNetSalesMilestone_390" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:label="loc_txmdQuarterlyRoyaltyPaymentsPercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdQuarterlyRoyaltyPaymentsPercentage_390" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense_390" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000040 - Disclosure - Inventory consists of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000041 - Disclosure - Other current assets consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000042 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000043 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:title="00000044 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MultipleTrademarksMember" xlink:label="loc_txmdMultipleTrademarksMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000045 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000046 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_230" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000047 - Disclosure - Other current liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000048 - Disclosure - As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:title="00000049 - Disclosure - The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:title="00000050 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Member" xlink:label="loc_txmdFinancingAgreementAmendment8Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementAmendment8Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaapDebtInstrumentRedemptionPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodAxis" xlink:to="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaapDebtInstrumentRedemptionPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodAxis" xlink:to="loc_us-gaapDebtInstrumentRedemptionPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodOneMember" xlink:label="loc_txmdRepaymentPeriodOneMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodOneMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodTwoMember" xlink:label="loc_txmdRepaymentPeriodTwoMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodTwoMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodThreeMember" xlink:label="loc_txmdRepaymentPeriodThreeMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodThreeMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodFourMember" xlink:label="loc_txmdRepaymentPeriodFourMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodFourMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodFiveMember" xlink:label="loc_txmdRepaymentPeriodFiveMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodFiveMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodSixMember" xlink:label="loc_txmdRepaymentPeriodSixMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodSixMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodSevenMember" xlink:label="loc_txmdRepaymentPeriodSevenMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodSevenMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodEightMember" xlink:label="loc_txmdRepaymentPeriodEightMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodEightMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period1Member_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period1Member_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period2Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period2Member_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period3Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period3Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period3Member_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period4Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period4Member_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period4Member_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period5Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period5Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period5Member_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period6Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period6Member_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period6Member_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period7Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period7Member_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period7Member_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period8Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period8Member_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period8Member_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period9Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period9Member_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period9Member_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period10Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period10Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period10Member_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period11Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period11Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period11Member_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period12Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period12Member_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period12Member_290" xlink:type="arc" order="292" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period13Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period13Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period13Member_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_480" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_480" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:label="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable_480" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_480" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_480" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate_480" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmdPrimeRateFloor_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrimeRateFloor_480" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments_480" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit_480" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage_480" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_480" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent_480" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_480" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumRevenueRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumRevenueRequirementUnderCreditAgreement_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumRevenueRequirementUnderCreditAgreement_480" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_480" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_480" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_480" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility_480" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility_480" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage_480" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_480" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_480" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_480" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_480" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross_480" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_480" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_480" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_480" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings_480" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_480" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:title="00000051 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2020: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_40" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:title="00000052 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:label="loc_txmdWeightedAverageExercisePriceOtherThanOptions_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceOtherThanOptions_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:title="00000053 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:title="00000054 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:title="00000055 - Disclosure - Schedule of restricted stock units and performance stock units (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000056 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PerformanceStockUnitsMember" xlink:label="loc_txmdPerformanceStockUnitsMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdPerformanceStockUnitsMember_430" xlink:type="arc" order="432" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementCantorFitzgeraldMember" xlink:label="loc_txmdUnderwritingAgreementCantorFitzgeraldMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementCantorFitzgeraldMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="loc_txmdUnderwritingAgreementJPMorganChaseMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementJPMorganChaseMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="loc_txmdUnderwritingAgreementGoldmanSachsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementGoldmanSachsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdSubscriptionAgreementKnightMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_EmployeeStockPurchasePlanMember" xlink:label="loc_txmdEmployeeStockPurchasePlanMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdEmployeeStockPurchasePlanMember_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_510" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_510" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_510" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_510" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_510" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_510" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_510" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_510" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_510" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_510" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_510" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption_510" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares_510" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering_510" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MaximumCommonStockOfferingPrice" xlink:label="loc_txmdMaximumCommonStockOfferingPrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdMaximumCommonStockOfferingPrice_510" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FixedCommissionRate" xlink:label="loc_txmdFixedCommissionRate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdFixedCommissionRate_510" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_510" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_510" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_510" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_510" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_510" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_510" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_510" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_510" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_510" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_510" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_510" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_510" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_510" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_510" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_510" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_510" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_510" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation_510" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_510" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_510" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_510" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_510" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_510" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_510" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_510" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_510" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_510" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_510" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_510" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense_510" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_510" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_510" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_510" xlink:type="arc" order="48" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000057 - Disclosure - EMPLOYEE BENEFIT PLAN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:title="00000058 - Disclosure - For financial reporting purposes, (loss) income before taxes includes the following components: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:title="00000059 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:title="00000060 - Disclosure - The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000061 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ExpirationPeriod20YearsMember" xlink:label="loc_txmdExpirationPeriod20YearsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriod20YearsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ExpirationPeriodIndefiniteMember" xlink:label="loc_txmdExpirationPeriodIndefiniteMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriodIndefiniteMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NolCarryForwardPeriod" xlink:label="loc_txmdNolCarryForwardPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdNolCarryForwardPeriod_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_txmdOperatingLossCarryforwardsExpirationYear_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdOperatingLossCarryforwardsExpirationYear_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000062 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdCatalentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmericanInternationalGroupMember" xlink:label="loc_txmdAmericanInternationalGroupMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdAmericanInternationalGroupMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000063 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="loc_txmdSupplierOneConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierOneConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfVendors" xlink:label="loc_txmdNumberOfVendors_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfVendors_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues_280" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000064 - Disclosure - Supplemental lease information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000065 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdCatalentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdAnnoveraMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdNetRentableAreaLease_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdRentedAreaLease_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaapVariableLeasePayment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapVariableLeasePayment_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="loc_us-gaapPurchaseObligationDueInNextTwelveMonths_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInNextTwelveMonths_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaapPurchaseObligationDueInSecondYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInSecondYear_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaapPurchaseObligationDueInThirdYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInThirdYear_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="loc_us-gaapPurchaseObligationDueInFourthYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInFourthYear_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="loc_us-gaapPurchaseObligationDueInFifthYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInFifthYear_110" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:title="00000067 - Disclosure - Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_KnightLicenseAgreementMember" xlink:label="loc_txmdKnightLicenseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdKnightLicenseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGrossProfit_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInventoryWriteDown_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_120" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementCantorFitzgeraldMember" xlink:label="loc_txmdUnderwritingAgreementCantorFitzgeraldMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementCantorFitzgeraldMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment7Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment7Period1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment7Period1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment7Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment7Period2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment7Period2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumRevenueRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumRevenueRequirementUnderCreditAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMinimumRevenueRequirementUnderCreditAgreement_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares_50" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>txmd-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaMember" xlink:label="txmd_BijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaMember_lbl" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="txmd_FinancingAgreementAmendment6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Member" xlink:to="txmd_FinancingAgreementAmendment6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment6Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerAMember" xlink:label="txmd_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerAMember" xlink:to="txmd_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerBMember" xlink:label="txmd_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerBMember" xlink:to="txmd_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerCMember" xlink:label="txmd_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerCMember" xlink:to="txmd_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerDMember" xlink:label="txmd_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerDMember" xlink:to="txmd_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndBuildingMember_lbl" xml:lang="en-US">Land and Building [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnoveraMember" xlink:label="txmd_AnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnoveraMember_lbl" xml:lang="en-US">ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_VitaminsImvexxyAndBijuvaMember" xlink:label="txmd_VitaminsImvexxyAndBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsImvexxyAndBijuvaMember" xlink:to="txmd_VitaminsImvexxyAndBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VitaminsImvexxyAndBijuvaMember_lbl" xml:lang="en-US">Vitamins, IMVEXXY and BIJUVA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="txmd_BijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaAndAnnoveraMember_lbl" xml:lang="en-US">BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrescriptionVitaminsMember" xlink:label="txmd_PrescriptionVitaminsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrescriptionVitaminsMember_lbl" xml:lang="en-US">Prescription Vitamins [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyMember" xlink:label="txmd_ImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyMember_lbl" xml:lang="en-US">Imvexxy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementMember" xlink:label="txmd_CouncilLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementMember" xlink:to="txmd_CouncilLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementMember_lbl" xml:lang="en-US">Council License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="txmd_CouncilLicenseAgreementStep1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep1Member_lbl" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="txmd_CouncilLicenseAgreementStep2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep2Member_lbl" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="txmd_CouncilLicenseAgreementStep3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep3Member_lbl" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_KnightLicenseAgreementMember" xlink:label="txmd_KnightLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_KnightLicenseAgreementMember" xlink:to="txmd_KnightLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_KnightLicenseAgreementMember_lbl" xml:lang="en-US">Knight License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="txmd_LicenseAgreementTheramexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementTheramexMember" xlink:to="txmd_LicenseAgreementTheramexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseAgreementTheramexMember_lbl" xml:lang="en-US">License Agreement Theramex [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PerformanceStockUnitsMember" xlink:label="txmd_PerformanceStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PerformanceStockUnitsMember" xlink:to="txmd_PerformanceStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PerformanceStockUnitsMember_lbl" xml:lang="en-US">Performance Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MultipleTrademarksMember" xlink:label="txmd_MultipleTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksMember" xlink:to="txmd_MultipleTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksMember_lbl" xml:lang="en-US">Multiple Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSPatentsMember" xlink:label="txmd_DomesticUSPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsMember_lbl" xml:lang="en-US">Domestic US Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsMember" xlink:label="txmd_ForeignPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsMember_lbl" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="txmd_DomesticPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsBijuvaMember_lbl" xml:lang="en-US">Domestic Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="txmd_ForeignPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsBijuvaMember_lbl" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xml:lang="en-US">Domestic Patents Non-Approved Bijuva [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="txmd_DomesticUSPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="txmd_ForeignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="txmd_ForeignDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:to="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_lbl" xml:lang="en-US">Domestic Utility Patent Topical Cream Candidates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="txmd_DomesticUtilityPatentTx009HRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_lbl" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="txmd_DomesticUtilityPatentOperaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentOperaMember_lbl" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementMember" xlink:label="txmd_FinancingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementMember_lbl" xml:lang="en-US">Financing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DebtTrancheAxis" xlink:label="txmd_DebtTrancheAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtTrancheAxis_lbl" xml:lang="en-US">Debt Tranche [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_TrancheTwoMember" xlink:label="txmd_TrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_TrancheThreeMember" xlink:label="txmd_TrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheThreeMember_lbl" xml:lang="en-US">Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Member" xlink:label="txmd_FinancingAgreementAmendment8Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Member" xlink:to="txmd_FinancingAgreementAmendment8Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Member_lbl" xml:lang="en-US">Financing Agreement Amendment No 8 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodOneMember" xlink:label="txmd_RepaymentPeriodOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodOneMember" xlink:to="txmd_RepaymentPeriodOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodOneMember_lbl" xml:lang="en-US">Repayment by March 31, 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodTwoMember" xlink:label="txmd_RepaymentPeriodTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodTwoMember" xlink:to="txmd_RepaymentPeriodTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodTwoMember_lbl" xml:lang="en-US">Repayments on March 31, 2022, June 30, 2022 and September 30, 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodThreeMember" xlink:label="txmd_RepaymentPeriodThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodThreeMember" xlink:to="txmd_RepaymentPeriodThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodThreeMember_lbl" xml:lang="en-US">Repayments on December 31, 2022 and March 31, 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodFourMember" xlink:label="txmd_RepaymentPeriodFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodFourMember" xlink:to="txmd_RepaymentPeriodFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodFourMember_lbl" xml:lang="en-US">Repayments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodFiveMember" xlink:label="txmd_RepaymentPeriodFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodFiveMember" xlink:to="txmd_RepaymentPeriodFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodFiveMember_lbl" xml:lang="en-US">Repayments through March 31, 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodSixMember" xlink:label="txmd_RepaymentPeriodSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodSixMember" xlink:to="txmd_RepaymentPeriodSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodSixMember_lbl" xml:lang="en-US">Repayment on March 31, 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodSevenMember" xlink:label="txmd_RepaymentPeriodSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodSevenMember" xlink:to="txmd_RepaymentPeriodSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodSevenMember_lbl" xml:lang="en-US">Repayments from April 1, 2022 through March 31, 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodEightMember" xlink:label="txmd_RepaymentPeriodEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodEightMember" xlink:to="txmd_RepaymentPeriodEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentPeriodEightMember_lbl" xml:lang="en-US">Repayments from April 1, 2023 through March 31, 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period1Member" xlink:label="txmd_FinancingAgreementAmendment8Period1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period1Member" xlink:to="txmd_FinancingAgreementAmendment8Period1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period1Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period2Member" xlink:label="txmd_FinancingAgreementAmendment8Period2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period2Member" xlink:to="txmd_FinancingAgreementAmendment8Period2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period2Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Second quarter of 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period3Member" xlink:label="txmd_FinancingAgreementAmendment8Period3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period3Member" xlink:to="txmd_FinancingAgreementAmendment8Period3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period3Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Third quarter of 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period4Member" xlink:label="txmd_FinancingAgreementAmendment8Period4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period4Member" xlink:to="txmd_FinancingAgreementAmendment8Period4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period4Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Fourth quarter of 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period5Member" xlink:label="txmd_FinancingAgreementAmendment8Period5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period5Member" xlink:to="txmd_FinancingAgreementAmendment8Period5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period5Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period6Member" xlink:label="txmd_FinancingAgreementAmendment8Period6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period6Member" xlink:to="txmd_FinancingAgreementAmendment8Period6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period6Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Second quarter of 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period7Member" xlink:label="txmd_FinancingAgreementAmendment8Period7Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period7Member" xlink:to="txmd_FinancingAgreementAmendment8Period7Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period7Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Third quarter of 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period8Member" xlink:label="txmd_FinancingAgreementAmendment8Period8Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period8Member" xlink:to="txmd_FinancingAgreementAmendment8Period8Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period8Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Fourth quarter of 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period9Member" xlink:label="txmd_FinancingAgreementAmendment8Period9Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period9Member" xlink:to="txmd_FinancingAgreementAmendment8Period9Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period9Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period10Member" xlink:label="txmd_FinancingAgreementAmendment8Period10Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period10Member" xlink:to="txmd_FinancingAgreementAmendment8Period10Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period10Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Second quarter of 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period11Member" xlink:label="txmd_FinancingAgreementAmendment8Period11Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period11Member" xlink:to="txmd_FinancingAgreementAmendment8Period11Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period11Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Third quarter of 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period12Member" xlink:label="txmd_FinancingAgreementAmendment8Period12Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period12Member" xlink:to="txmd_FinancingAgreementAmendment8Period12Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period12Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - Fourth quarter of 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period13Member" xlink:label="txmd_FinancingAgreementAmendment8Period13Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period13Member" xlink:to="txmd_FinancingAgreementAmendment8Period13Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment8Period13Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LenderWarrantsMember" xlink:label="txmd_LenderWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LenderWarrantsMember" xlink:to="txmd_LenderWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LenderWarrantsMember_lbl" xml:lang="en-US">Lender Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MidCapAgreementMember" xlink:label="txmd_MidCapAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MidCapAgreementMember_lbl" xml:lang="en-US">Credit Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementCantorFitzgeraldMember" xlink:label="txmd_UnderwritingAgreementCantorFitzgeraldMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementCantorFitzgeraldMember" xlink:to="txmd_UnderwritingAgreementCantorFitzgeraldMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritingAgreementCantorFitzgeraldMember_lbl" xml:lang="en-US">Underwriting Agreement Cantor Fitzgerald [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementJPMorganChaseMember" xlink:to="txmd_UnderwritingAgreementJPMorganChaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember_lbl" xml:lang="en-US">Underwriting Agreement JP Morgan Chase [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementGoldmanSachsMember" xlink:to="txmd_UnderwritingAgreementGoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember_lbl" xml:lang="en-US">Underwriting Agreement Goldman Sachs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="txmd_SubscriptionAgreementKnightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementKnightMember" xlink:to="txmd_SubscriptionAgreementKnightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SubscriptionAgreementKnightMember_lbl" xml:lang="en-US">Subscription Agreement Knight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_OutsideConsultant2Member" xlink:label="txmd_OutsideConsultant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultant2Member_lbl" xml:lang="en-US">Outside Consultants Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsMember" xlink:label="txmd_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_Plan2019Member" xlink:label="txmd_Plan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Plan2019Member_lbl" xml:lang="en-US">Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_EmployeeStockPurchasePlanMember" xlink:label="txmd_EmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EmployeeStockPurchasePlanMember" xlink:to="txmd_EmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ExpirationPeriod20YearsMember" xlink:label="txmd_ExpirationPeriod20YearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExpirationPeriod20YearsMember_lbl" xml:lang="en-US">Expiration Period 20 Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ExpirationPeriodIndefiniteMember" xlink:label="txmd_ExpirationPeriodIndefiniteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExpirationPeriodIndefiniteMember_lbl" xml:lang="en-US">Expiration Period Indefinite [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CatalentMember" xlink:label="txmd_CatalentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CatalentMember" xlink:to="txmd_CatalentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CatalentMember_lbl" xml:lang="en-US">Catalent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmericanInternationalGroupMember" xlink:label="txmd_AmericanInternationalGroupMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmericanInternationalGroupMember" xlink:to="txmd_AmericanInternationalGroupMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmericanInternationalGroupMember_lbl" xml:lang="en-US">American International Group [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="txmd_SupplierOneConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierOneConcentrationRiskMember" xlink:to="txmd_SupplierOneConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierOneConcentrationRiskMember_lbl" xml:lang="en-US">Supplier One Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="txmd_SupplierTwoConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierTwoConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="txmd_SupplierThreeConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierThreeConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 3</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xml:lang="en-US">Cardinal Health - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="txmd_CustomerConcentrationPillPackRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_lbl" xml:lang="en-US">PillPack - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xml:lang="en-US">AmerisourceBergen - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment7Period1Member" xlink:label="txmd_FinancingAgreementAmendment7Period1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment7Period1Member" xlink:to="txmd_FinancingAgreementAmendment7Period1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment7Period1Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 7 - Fiscal Quarter Ending March 31, 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment7Period2Member" xlink:label="txmd_FinancingAgreementAmendment7Period2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment7Period2Member" xlink:to="txmd_FinancingAgreementAmendment7Period2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementAmendment7Period2Member_lbl" xml:lang="en-US">Financing Agreement Amendment No. 7 - Fiscal Quarter Ending June 30, 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xml:lang="en-US">Entity Common Stock Held by Non-affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $1,117,854 and $904,040, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseRights" xlink:label="txmd_LicenseRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseRights_lbl" xml:lang="en-US">License rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">&#160;LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - See Note 14</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; (Deficit) Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 600,000,000 and 350,000,000 shares authorized: 299,765,396 and 271,177,076 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenue, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Balance at beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of shares from release of restricted stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of shares from release of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrant granted in relation to Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Balance at ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Write off of patent and trademark cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xml:lang="en-US">Write off of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="txmd_NoncashOperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US">Lease impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory Write-down</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss of extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="txmd_AmortizationOfIntellectualPropertyLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:to="txmd_AmortizationOfIntellectualPropertyLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmortizationOfIntellectualPropertyLicenseFee_lbl" xml:lang="en-US">Amortization of intellectual property license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">&#160;Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">&#160;Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">&#160;Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_lbl" xml:lang="en-US">Payment for intellectual property license</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_IncreaseDecreaseInSecurityDeposit" xlink:label="txmd_IncreaseDecreaseInSecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncreaseDecreaseInSecurityDeposit" xlink:to="txmd_IncreaseDecreaseInSecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncreaseDecreaseInSecurityDeposit_lbl" xml:lang="en-US">Payment of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Proceeds from Credit Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayment of Credit Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">(Decrease) increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing activity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:to="txmd_WarrantGrantedInRelationToFinancingAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement_lbl" xml:lang="en-US">Warrant granted in relation to Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="txmd_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="txmd_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LiquidityPolicyTextBlock" xlink:label="txmd_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiquidityPolicyTextBlock" xlink:to="txmd_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="txmd_ShippingAndHandlingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="txmd_ShippingAndHandlingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShippingAndHandlingCostsPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and other Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of calculation of diluted net loss per share allocable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory consists of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Other current assets consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Fixed assets, net consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xml:lang="en-US">Summary of our Warrant activity during the year ended December 31, 2020:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock units and performance stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">For financial reporting purposes, (loss) income before taxes includes the following components:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfSubsidiaries" xlink:label="txmd_NumberOfSubsidiaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSubsidiaries_lbl" xml:lang="en-US">Number of subsidiaries</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable" xlink:label="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable" xlink:to="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Increase in allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US">Recoveries</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Write-offs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryWriteDown_2_lbl" xml:lang="en-US">Inventory charge</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_lbl" xml:lang="en-US">Minimum cash balance requirement under credit agreement before adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xml:lang="en-US">Minimum cash balance requirement under credit agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatentsDomestic" xlink:label="txmd_NumberOfIssuedPatentsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsDomestic" xlink:to="txmd_NumberOfIssuedPatentsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatentsDomestic_lbl" xml:lang="en-US">Number of issued patents domestic.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatentsForeign" xlink:label="txmd_NumberOfIssuedPatentsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsForeign" xlink:to="txmd_NumberOfIssuedPatentsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatentsForeign_lbl" xml:lang="en-US">Number of issued patents foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xml:lang="en-US">Return period of unsalable prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="txmd_ShelfLifeOfPrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_lbl" xml:lang="en-US">Shelf life of prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="txmd_MilestonePaymentUponFDAApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentUponFDAApproval_lbl" xml:lang="en-US">Milestone payment upon FDA Approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xml:lang="en-US">Milestone payments (payment after release of first commercial batch)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">License rights acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xml:lang="en-US">Net sales amount per step-based royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RoyaltyPercent" xlink:label="txmd_RoyaltyPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyPercent_lbl" xml:lang="en-US">Royalty (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:label="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:to="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_lbl" xml:lang="en-US">Milestone payments upon specified levels of cumulative net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_lbl" xml:lang="en-US">Specified level one of cumulative net sales for milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_lbl" xml:lang="en-US">Specified level two of cumulative net sales for milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_lbl" xml:lang="en-US">Specified level three of cumulative net sales for milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xml:lang="en-US">Maximum costs and expenses for post approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:label="txmd_MilestonePaymentReceivedUponRegulatoryApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:to="txmd_MilestonePaymentReceivedUponRegulatoryApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentReceivedUponRegulatoryApproval_lbl" xml:lang="en-US">Milestone payment received upon regulatory approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="txmd_CashUpfrontPaymentReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashUpfrontPaymentReceived" xlink:to="txmd_CashUpfrontPaymentReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CashUpfrontPaymentReceived_lbl" xml:lang="en-US">Cash upfront payment received</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RegulatoryMilestoneAdditionalPayment" xlink:to="txmd_RegulatoryMilestoneAdditionalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment_lbl" xml:lang="en-US">Regulatory milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="txmd_SalesMilestonePaymentsInTranches" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesMilestonePaymentsInTranches" xlink:to="txmd_SalesMilestonePaymentsInTranches_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesMilestonePaymentsInTranches_lbl" xml:lang="en-US">Sales milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualNetSalesMilestone" xlink:label="txmd_AnnualNetSalesMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualNetSalesMilestone" xlink:to="txmd_AnnualNetSalesMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualNetSalesMilestone_lbl" xml:lang="en-US">Sales milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:to="txmd_QuarterlyRoyaltyPaymentsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Quarterly royalty payments percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xml:lang="en-US">Prepaid sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt financing fees on undrawn tranches (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaidManufacturing" xlink:label="txmd_PrepaidManufacturing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturing_lbl" xml:lang="en-US">Prepaid manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS, NET</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="us-gaap_IndefiniteLivedTrademarks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTrademarks" xlink:to="us-gaap_IndefiniteLivedTrademarks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTrademarks_lbl" xml:lang="en-US">Indefinite-Lived Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="txmd_AccruedResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AccruedRebates" xlink:label="txmd_AccruedRebates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedRebates_lbl" xml:lang="en-US">Accrued rebates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_2_lbl" xml:lang="en-US">TOTAL LONG-TERM DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:label="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:to="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_lbl" xml:lang="en-US">Line Of Credit Facility Undrawn Tranche No Longer Available</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LiborFloorRate" xlink:label="txmd_LiborFloorRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LiborFloorRate_lbl" xml:lang="en-US">LIBOR floor rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrimeRateFloor" xlink:label="txmd_PrimeRateFloor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrimeRateFloor" xlink:to="txmd_PrimeRateFloor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrimeRateFloor_lbl" xml:lang="en-US">Prime rate floor</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfInstallmentPayments" xlink:label="txmd_NumberOfInstallmentPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfInstallmentPayments_lbl" xml:lang="en-US">Number of quarterly principal installment payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaymentFeePercentage" xlink:label="txmd_PrepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Principal repayment</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FacilityFeePaidPercent" xlink:label="txmd_FacilityFeePaidPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FacilityFeePaidPercent_lbl" xml:lang="en-US">Facility fee paid (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumRevenueRequirementUnderCreditAgreement" xlink:label="txmd_MinimumRevenueRequirementUnderCreditAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumRevenueRequirementUnderCreditAgreement" xlink:to="txmd_MinimumRevenueRequirementUnderCreditAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumRevenueRequirementUnderCreditAgreement_lbl" xml:lang="en-US">Minimum revenue requirement under credit agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xml:lang="en-US">Number of tranches under term loan facility</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xml:lang="en-US">Repayment of debt with new credit facility</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentFeePercentage" xlink:label="txmd_RepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentFeePercentage_lbl" xml:lang="en-US">Repayment fee percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest Expense, Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of shares under warrants outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value, warrants outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of shares under warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Cancelled/Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants cancelled/forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares under warrants outstanding ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price warrants outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl" xml:lang="en-US">Weighted average remaining contractual life, warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Aggregate intrinsic value, warrants outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of shares under warrants vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:to="txmd_WarrantsUnvestedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:to="txmd_WeightedAverageExercisePriceOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility - maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares under options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of shares under options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares under options, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares under options, cancelled forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, cancelled forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares under options, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of shares under options, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Beginning balance, number of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Beginning balance, weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted, number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Granted, weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested/Released, number of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested/Released, weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited, number of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited, weighted average grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Ending balance, number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Ending balance, weighted average grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares issued for exercise of options, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="txmd_PeriodExercisableUnderwritersOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodExercisableUnderwritersOption" xlink:to="txmd_PeriodExercisableUnderwritersOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PeriodExercisableUnderwritersOption_lbl" xml:lang="en-US">Period exercisable underwriters option</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritersOptionGrantedInPeriodShares" xlink:to="txmd_UnderwritersOptionGrantedInPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares_lbl" xml:lang="en-US">Underwriters option granted in period shares</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="txmd_ProceedsFromIssuancePublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromIssuancePublicOffering" xlink:to="txmd_ProceedsFromIssuancePublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US">Proceeds from issuance public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MaximumCommonStockOfferingPrice" xlink:label="txmd_MaximumCommonStockOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCommonStockOfferingPrice" xlink:to="txmd_MaximumCommonStockOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaximumCommonStockOfferingPrice_lbl" xml:lang="en-US">Maximum Common Stock Offering Price</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FixedCommissionRate" xlink:label="txmd_FixedCommissionRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FixedCommissionRate" xlink:to="txmd_FixedCommissionRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FixedCommissionRate_lbl" xml:lang="en-US">Fixed Commission Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xml:lang="en-US">Number of stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Weighted average grant date fair value, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Award vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Non cash compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Number of stock issued in cashless exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Award expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xml:lang="en-US">Range - exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Matching contribution percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DefinedContributionPlanMaximumEmployerMatchingContribution" xlink:label="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution" xlink:to="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution_lbl" xml:lang="en-US">Maximum matching contribution per year</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DefinedContributionPlanVestingServicePeriod" xlink:label="txmd_DefinedContributionPlanVestingServicePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DefinedContributionPlanVestingServicePeriod" xlink:to="txmd_DefinedContributionPlanVestingServicePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DefinedContributionPlanVestingServicePeriod_lbl" xml:lang="en-US">Defined contribution plan vesting service period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Contributions under plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Excess stock benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Federal income tax rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xml:lang="en-US">Interest expense limitation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NolCarryForwardPeriod" xlink:label="txmd_NolCarryForwardPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NolCarryForwardPeriod" xlink:to="txmd_NolCarryForwardPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NolCarryForwardPeriod_lbl" xml:lang="en-US">NOL carryforward period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_OperatingLossCarryforwardsExpirationYear" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLossCarryforwardsExpirationYear" xlink:to="txmd_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">NOL carryforward expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Amount billed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Amounts due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_2_lbl" xml:lang="en-US">Concentration Risk, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfVendors" xlink:label="txmd_NumberOfVendors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfVendors" xlink:to="txmd_NumberOfVendors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfVendors_lbl" xml:lang="en-US">Number of vendors - suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfCustomers" xlink:label="txmd_NumberOfCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers - revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Short-term operating lease liability (included in Other current liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities for operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NetRentableAreaLease" xlink:label="txmd_NetRentableAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetRentableAreaLease_lbl" xml:lang="en-US">Net rentable area</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RentedAreaLease" xlink:label="txmd_RentedAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RentedAreaLease_lbl" xml:lang="en-US">Rented area lease</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="txmd_AdditionalAreaOfLeaseOccupied" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_lbl" xml:lang="en-US">Additional rented area occupied under the lease</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_lbl" xml:lang="en-US">Number of options to extend lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lease renewal term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xml:lang="en-US">Lease not yet commenced (area)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeasePayment" xlink:label="us-gaap_VariableLeasePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeasePayment" xlink:to="us-gaap_VariableLeasePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeasePayment_lbl" xml:lang="en-US">Variable lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Rental expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xml:lang="en-US">Significant supply commitment percentage payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Minimum purchase commitment, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="us-gaap_PurchaseObligationDueInFourthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFourthYear" xlink:to="us-gaap_PurchaseObligationDueInFourthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInFourthYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="us-gaap_PurchaseObligationDueInFifthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFifthYear" xlink:to="us-gaap_PurchaseObligationDueInFifthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInFifthYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Loss per common share, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_4_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyMember_doc" xml:lang="en-US">Information about ImvexxyTm.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsMember_doc" xml:lang="en-US">Domestic US Patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsMember_doc" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsBijuvaMember_doc" xml:lang="en-US">Domestic Patents Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsBijuvaMember_doc" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentOperaMember_doc" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_doc" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnoveraMember_doc" xml:lang="en-US">ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep1Member_doc" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyPercent_doc" xml:lang="en-US">The percent of the net sales to be paid as royalty per license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep2Member_doc" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep3Member_doc" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xml:lang="en-US">The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedResearchAndDevelopment_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedRebates_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementMember_doc" xml:lang="en-US">Represents member of financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierTwoConcentrationRiskMember_doc" xml:lang="en-US">Supplier Two Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierThreeConcentrationRiskMember_doc" xml:lang="en-US">Supplier Three Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_doc" xml:lang="en-US">Major customers in concentration of sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xml:lang="en-US">Custome rConcentration AmerisourceBergen Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xml:lang="en-US">Customer Concentration Cardinal Health Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetRentableAreaLease_doc" xml:lang="en-US">Net rentable area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RentedAreaLease_doc" xml:lang="en-US">Rented area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xml:lang="en-US">Future rented area to be occupied for administrative office space as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xml:lang="en-US">Number of options exercised in the cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xml:lang="en-US">Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsMember_doc" xml:lang="en-US">Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which warrant holders can acquire the shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultant2Member_doc" xml:lang="en-US">A person who provides consutling services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xml:lang="en-US">Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Plan2019Member_doc" xml:lang="en-US">New 2019 Plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_doc" xml:lang="en-US">Additional rented area occupied under the lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xml:lang="en-US">Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheAxis_doc" xml:lang="en-US">Portions of the Credit and Security Agreement to draw funds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoMember_doc" xml:lang="en-US">Tranche Two as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LiborFloorRate_doc" xml:lang="en-US">Represents libor floor rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FacilityFeePaidPercent_doc" xml:lang="en-US">The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xml:lang="en-US">The number of seperate tranches under terms of the Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentFeePercentage_doc" xml:lang="en-US">The repayment fee, expressed as a percentage of the tranche funding being repaid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MidCapAgreementMember_doc" xml:lang="en-US">Represents member of Mid Cap agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentUponFDAApproval_doc" xml:lang="en-US">The amount of milestone payments upon FDA approval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaMember_doc" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DebtTrancheDomain" xlink:label="txmd_DebtTrancheDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheDomain" xlink:to="txmd_DebtTrancheDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheDomain_doc" xml:lang="en-US">DebtTrancheDomain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseRights_doc" xml:lang="en-US">The amount of license rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xml:lang="en-US">The amount of milestone payments payable after release of first commercial batch.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xml:lang="en-US">The net sales amount as defined in license agreement for step-based royalty payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NoncashOperatingLeaseExpense_doc" xml:lang="en-US">Amount of expense related to operating lease costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfInstallmentPayments_doc" xml:lang="en-US">Number of principal installment payments under credit and security agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xml:lang="en-US">It refers to the amount of prepaid sales and marketing costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrescriptionVitaminsMember_doc" xml:lang="en-US">Information about Prescription Vitamins.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xml:lang="en-US">Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCustomers_doc" xml:lang="en-US">Number of customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeePercentage_doc" xml:lang="en-US">The prepayment fee, expressed as a percentage of the tranche funding being repaid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfSubsidiaries_doc" xml:lang="en-US">Number of subsidiaires for period reported.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xml:lang="en-US">Disclosure of supplementary lease and cash flow information.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturing_doc" xml:lang="en-US">Prepaid manufacturing costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_doc" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaAndAnnoveraMember_doc" xml:lang="en-US">BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xml:lang="en-US">The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrimeRateFloor" xlink:to="txmd_PrimeRateFloor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrimeRateFloor_doc" xml:lang="en-US">Prime rate floor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_doc" xml:lang="en-US">Number of options to extend lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncreaseDecreaseInSecurityDeposit" xlink:to="txmd_IncreaseDecreaseInSecurityDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IncreaseDecreaseInSecurityDeposit_doc" xml:lang="en-US">The amount represent increase decrease in security deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementMember" xlink:to="txmd_CouncilLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementMember_doc" xml:lang="en-US">The member represent council license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:to="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_doc" xml:lang="en-US">The member represent domestic utility patent topical cream candidates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PerformanceStockUnitsMember" xlink:to="txmd_PerformanceStockUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PerformanceStockUnitsMember_doc" xml:lang="en-US">The member represent performance stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierOneConcentrationRiskMember" xlink:to="txmd_SupplierOneConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierOneConcentrationRiskMember_doc" xml:lang="en-US">The member represent supplier one concentration risk.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:to="txmd_AmortizationOfIntellectualPropertyLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmortizationOfIntellectualPropertyLicenseFee_doc" xml:lang="en-US">The amount represents amortization of intellectual property license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_doc" xml:lang="en-US">The amount represents specified level one of cumulative net sales for milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_doc" xml:lang="en-US">The amount represents specified level two of cumulative net sales for milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:to="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_doc" xml:lang="en-US">The amount represents specified level three of cumulative net sales for milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:to="txmd_WarrantGrantedInRelationToFinancingAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement_doc" xml:lang="en-US">The amount of a warrant granted in relation to financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:to="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_doc" xml:lang="en-US">Milestone payments due upon specified levels of cumulative net sales for under agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:to="txmd_MilestonePaymentReceivedUponRegulatoryApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentReceivedUponRegulatoryApproval_doc" xml:lang="en-US">The amount of milestone payment received upon regulatory approval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_KnightLicenseAgreementMember" xlink:to="txmd_KnightLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_KnightLicenseAgreementMember_doc" xml:lang="en-US">Knight License Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LenderWarrantsMember" xlink:to="txmd_LenderWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LenderWarrantsMember_doc" xml:lang="en-US">Lender Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EmployeeStockPurchasePlanMember" xlink:to="txmd_EmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EmployeeStockPurchasePlanMember_doc" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CatalentMember" xlink:to="txmd_CatalentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CatalentMember_doc" xml:lang="en-US">Catalent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmericanInternationalGroupMember" xlink:to="txmd_AmericanInternationalGroupMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmericanInternationalGroupMember_doc" xml:lang="en-US">American International Group</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksMember" xlink:to="txmd_MultipleTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksMember_doc" xml:lang="en-US">Multiple Trademarks</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheThreeMember_doc" xml:lang="en-US">Tranche Three as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:to="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_doc" xml:lang="en-US">The amount of an undrawn tranche under a financing agreement that is no longer available.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment6Member" xlink:to="txmd_FinancingAgreementAmendment6Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment6Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 6</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_doc" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_doc" xml:lang="en-US">Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="txmd_RisksAndUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RisksAndUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for risks and uncertainties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable" xlink:to="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable_doc" xml:lang="en-US">Amount of increase in allowance for credit loss on accounts receivable before recoveries and write-offs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsDomestic" xlink:to="txmd_NumberOfIssuedPatentsDomestic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatentsDomestic_doc" xml:lang="en-US">Number of issued patents domestic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsForeign" xlink:to="txmd_NumberOfIssuedPatentsForeign_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatentsForeign_doc" xml:lang="en-US">Number of issued patents foreign.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashUpfrontPaymentReceived" xlink:to="txmd_CashUpfrontPaymentReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CashUpfrontPaymentReceived_doc" xml:lang="en-US">The cash inflow from license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RegulatoryMilestoneAdditionalPayment" xlink:to="txmd_RegulatoryMilestoneAdditionalPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment_doc" xml:lang="en-US">Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesMilestonePaymentsInTranches" xlink:to="txmd_SalesMilestonePaymentsInTranches_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesMilestonePaymentsInTranches_doc" xml:lang="en-US">Amount of sales milestone payments per licensing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:to="txmd_QuarterlyRoyaltyPaymentsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage_doc" xml:lang="en-US">The percentage of quarterly royalty payments on net sales which the company is entitled to receive.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodExercisableUnderwritersOption" xlink:to="txmd_PeriodExercisableUnderwritersOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PeriodExercisableUnderwritersOption_doc" xml:lang="en-US">The period the option is exercisable per agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementCantorFitzgeraldMember" xlink:to="txmd_UnderwritingAgreementCantorFitzgeraldMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementCantorFitzgeraldMember_doc" xml:lang="en-US">Underwriting Agreement Cantor Fitzgerald</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritersOptionGrantedInPeriodShares" xlink:to="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xml:lang="en-US">The number of shares available to be purchased per underwriter's option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromIssuancePublicOffering" xlink:to="txmd_ProceedsFromIssuancePublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ProceedsFromIssuancePublicOffering_doc" xml:lang="en-US">The cash inflow associated with the amount received from entity's raising of capital by public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_doc" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:to="txmd_WarrantsUnvestedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice_doc" xml:lang="en-US">The weighted-average price as of the balance sheet date at which warrant holders can acquire the shares reserved for issuance on warrants outstanding and unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:to="txmd_WeightedAverageExercisePriceOtherThanOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions_doc" xml:lang="en-US">Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_doc" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NolCarryForwardPeriod" xlink:to="txmd_NolCarryForwardPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NolCarryForwardPeriod_doc" xml:lang="en-US">Expiration period of operating loss carryforward included in operating loss carryforward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLossCarryforwardsExpirationYear" xlink:to="txmd_OperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">Expiration year of operating loss carryforward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriod20YearsMember_doc" xml:lang="en-US">Expiration Period 20 Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerAMember" xlink:to="txmd_CustomerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerAMember_doc" xml:lang="en-US">Customer A</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerBMember" xlink:to="txmd_CustomerBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerBMember_doc" xml:lang="en-US">Customer B</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerCMember" xlink:to="txmd_CustomerCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerCMember_doc" xml:lang="en-US">Customer C</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerDMember" xlink:to="txmd_CustomerDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerDMember_doc" xml:lang="en-US">Customer D</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementTheramexMember" xlink:to="txmd_LicenseAgreementTheramexMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseAgreementTheramexMember_doc" xml:lang="en-US">License Agreement Theramex</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xml:lang="en-US">Domestic Patents Non-Approved Bijuva [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfVendors" xlink:to="txmd_NumberOfVendors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfVendors_doc" xml:lang="en-US">Number of vendors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xml:lang="en-US">The cash outlow for payments to acquire intellectual property license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="txmd_ShippingAndHandlingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShippingAndHandlingCostsPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for shipping and handling costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumRevenueRequirementUnderCreditAgreement" xlink:to="txmd_MinimumRevenueRequirementUnderCreditAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumRevenueRequirementUnderCreditAgreement_doc" xml:lang="en-US">The minimum consolidated net revenue requirements attributable to commercial sales under the credit and secuirty agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment7Period1Member" xlink:to="txmd_FinancingAgreementAmendment7Period1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment7Period1Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 7 - Fiscal Quarter Ending March 31, 2021</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment7Period2Member" xlink:to="txmd_FinancingAgreementAmendment7Period2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment7Period2Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 7 - Fiscal Quarter Ending June 30, 2021</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsImvexxyAndBijuvaMember" xlink:to="txmd_VitaminsImvexxyAndBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VitaminsImvexxyAndBijuvaMember_doc" xml:lang="en-US">Vitamins, IMVEXXY and BIJUVA.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCommonStockOfferingPrice" xlink:to="txmd_MaximumCommonStockOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaximumCommonStockOfferingPrice_doc" xml:lang="en-US">The maximum aggregate offering price of common stock shares permitted to offer and sell under sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FixedCommissionRate" xlink:to="txmd_FixedCommissionRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FixedCommissionRate_doc" xml:lang="en-US">The fixed commission rate of the aggregate gross sales price per share sold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution" xlink:to="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DefinedContributionPlanMaximumEmployerMatchingContribution_doc" xml:lang="en-US">Maximum amount employer matches of the employee's contribution per year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DefinedContributionPlanVestingServicePeriod" xlink:to="txmd_DefinedContributionPlanVestingServicePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DefinedContributionPlanVestingServicePeriod_doc" xml:lang="en-US">The service period after which matching contributions vest in the defined contribution plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementJPMorganChaseMember" xlink:to="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xml:lang="en-US">Underwriting Agreement JP Morgan Chase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementGoldmanSachsMember" xlink:to="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xml:lang="en-US">Underwriting Agreement Goldman Sachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementKnightMember" xlink:to="txmd_SubscriptionAgreementKnightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SubscriptionAgreementKnightMember_doc" xml:lang="en-US">Subscription Agreement Knight</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriodIndefiniteMember_doc" xml:lang="en-US">Expiration Period Indefinite</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualNetSalesMilestone" xlink:to="txmd_AnnualNetSalesMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualNetSalesMilestone_doc" xml:lang="en-US">Annual net sale milestones in the Territory per license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period1Member" xlink:to="txmd_FinancingAgreementAmendment8Period1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period1Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2021.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period2Member" xlink:to="txmd_FinancingAgreementAmendment8Period2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period2Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Second quarter of 2021.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period4Member" xlink:to="txmd_FinancingAgreementAmendment8Period4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period4Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Fourth quarter of 2021.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period3Member" xlink:to="txmd_FinancingAgreementAmendment8Period3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period3Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Third quarter of 2021.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Member" xlink:to="txmd_FinancingAgreementAmendment8Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Member_doc" xml:lang="en-US">Financing Agreement Amendment No 8</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiquidityPolicyTextBlock" xlink:to="txmd_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for liquidity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodOneMember" xlink:to="txmd_RepaymentPeriodOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodOneMember_doc" xml:lang="en-US">Repayment by March 31, 2021.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodTwoMember" xlink:to="txmd_RepaymentPeriodTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodTwoMember_doc" xml:lang="en-US">Repayments on March 31, 2022, June 30, 2022 and September 30, 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodThreeMember" xlink:to="txmd_RepaymentPeriodThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodThreeMember_doc" xml:lang="en-US">Repayments on December 31, 2022 and March 31, 2023.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodFourMember" xlink:to="txmd_RepaymentPeriodFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodFourMember_doc" xml:lang="en-US">Repayments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodFiveMember" xlink:to="txmd_RepaymentPeriodFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodFiveMember_doc" xml:lang="en-US">Repayments through March 31, 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodSixMember" xlink:to="txmd_RepaymentPeriodSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodSixMember_doc" xml:lang="en-US">Repayment on March 31, 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodSevenMember" xlink:to="txmd_RepaymentPeriodSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodSevenMember_doc" xml:lang="en-US">Repayments from April 1, 2022 through March 31, 2023.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentPeriodEightMember" xlink:to="txmd_RepaymentPeriodEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentPeriodEightMember_doc" xml:lang="en-US">Repayments from April 1, 2023 through March 31, 2024.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period5Member" xlink:to="txmd_FinancingAgreementAmendment8Period5Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period5Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period6Member" xlink:to="txmd_FinancingAgreementAmendment8Period6Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period6Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Second quarter of 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period7Member" xlink:to="txmd_FinancingAgreementAmendment8Period7Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period7Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Third quarter of 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period8Member" xlink:to="txmd_FinancingAgreementAmendment8Period8Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period8Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Fourth quarter of 2022.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period9Member" xlink:to="txmd_FinancingAgreementAmendment8Period9Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period9Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2023.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period10Member" xlink:to="txmd_FinancingAgreementAmendment8Period10Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period10Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Second quarter of 2023.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period11Member" xlink:to="txmd_FinancingAgreementAmendment8Period11Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period11Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Third quarter of 2023.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period12Member" xlink:to="txmd_FinancingAgreementAmendment8Period12Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period12Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - Fourth quarter of 2023.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementAmendment8Period13Member" xlink:to="txmd_FinancingAgreementAmendment8Period13Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementAmendment8Period13Member_doc" xml:lang="en-US">Financing Agreement Amendment No. 8 - First quarter of 2024.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_3_lbl" xml:lang="en-US">Payments To Acquire Intellectual Property License</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:to="txmd_WarrantGrantedInRelationToFinancingAgreement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantGrantedInRelationToFinancingAgreement_3_lbl" xml:lang="en-US">Warrant Granted In Relation To Financing Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_2_lbl" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_2_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_2_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_2_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_2_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_2_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_2_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_3_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_3_lbl" xml:lang="en-US">Outstanding Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>txmd-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20201231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20201231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20201231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20201231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20201231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20201231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20201231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Debt" xlink:href="txmd-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlan" xlink:href="txmd-20201231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20201231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20201231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20201231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20201231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20201231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20201231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20201231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtTables" xlink:href="txmd-20201231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20201231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20201231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:href="txmd-20201231.xsd#OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:href="txmd-20201231.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:href="txmd-20201231.xsd#ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20201231.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20201231.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20201231.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20201231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:href="txmd-20201231.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20201231.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20201231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20201231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20201231.xsd#AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:href="txmd-20201231.xsd#FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:href="txmd-20201231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:href="txmd-20201231.xsd#SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20201231.xsd#WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20201231.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:href="txmd-20201231.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:href="txmd-20201231.xsd#ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20201231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="txmd-20201231.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:href="txmd-20201231.xsd#ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:href="txmd-20201231.xsd#ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:href="txmd-20201231.xsd#ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20201231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20201231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20201231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20201231.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20201231.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:href="txmd-20201231.xsd#SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="loc_txmdEntityCommonStockHeldByNonaffiliates" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_txmdEntityCommonStockHeldByNonaffiliates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdLicenseRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaapLongTermDebtNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaapOperatingLeaseImpairmentLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_IncreaseDecreaseInSecurityDeposit" xlink:label="loc_txmdIncreaseDecreaseInSecurityDeposit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_txmdIncreaseDecreaseInSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantGrantedInRelationToFinancingAgreement" xlink:label="loc_txmdWarrantGrantedInRelationToFinancingAgreement" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantGrantedInRelationToFinancingAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt" xlink:title="00000014 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EmployeeBenefitPlan" xlink:title="00000016 - Disclosure - EMPLOYEE BENEFIT PLAN">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="loc_us-gaapDefinedContributionPlanTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_txmdRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LiquidityPolicyTextBlock" xlink:label="loc_txmdLiquidityPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="loc_txmdShippingAndHandlingCostsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdShippingAndHandlingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000027 - Disclosure - FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - INTANGIBLE ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables" xlink:title="00000030 - Disclosure - DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000035 - Disclosure - THE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfSubsidiaries" xlink:label="loc_txmdNumberOfSubsidiaries" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_txmdNumberOfSubsidiaries" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails" xlink:title="00000036 - Disclosure - The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable" xlink:label="loc_txmdIncreaseInAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdIncreaseInAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details" xlink:title="00000037 - Disclosure - The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails" xlink:title="00000038 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PerformanceStockUnitsMember" xlink:label="loc_txmdPerformanceStockUnitsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdPerformanceStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_VitaminsImvexxyAndBijuvaMember" xlink:label="loc_txmdVitaminsImvexxyAndBijuvaMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsImvexxyAndBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerAMember" xlink:label="loc_txmdCustomerAMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerBMember" xlink:label="loc_txmdCustomerBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerCMember" xlink:label="loc_txmdCustomerCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerDMember" xlink:label="loc_txmdCustomerDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="loc_us-gaapLandAndBuildingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandAndBuildingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementMember" xlink:label="loc_txmdCouncilLicenseAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_KnightLicenseAgreementMember" xlink:label="loc_txmdKnightLicenseAgreementMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdKnightLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatentsDomestic" xlink:label="loc_txmdNumberOfIssuedPatentsDomestic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatentsForeign" xlink:label="loc_txmdNumberOfIssuedPatentsForeign" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmortizationOfIntellectualPropertyLicenseFee" xlink:label="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAmortizationOfIntellectualPropertyLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdRoyaltyPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:label="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:label="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MilestonePaymentReceivedUponRegulatoryApproval" xlink:label="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdMilestonePaymentReceivedUponRegulatoryApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="loc_txmdCashUpfrontPaymentReceived" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdCashUpfrontPaymentReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="loc_txmdRegulatoryMilestoneAdditionalPayment" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdRegulatoryMilestoneAdditionalPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="loc_txmdSalesMilestonePaymentsInTranches" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSalesMilestonePaymentsInTranches" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnualNetSalesMilestone" xlink:label="loc_txmdAnnualNetSalesMilestone" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualNetSalesMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:label="loc_txmdQuarterlyRoyaltyPaymentsPercentage" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdQuarterlyRoyaltyPaymentsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000040 - Disclosure - Inventory consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000041 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000042 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000043 - Disclosure - FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details" xlink:title="00000044 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MultipleTrademarksMember" xlink:label="loc_txmdMultipleTrademarksMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000045 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000046 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000047 - Disclosure - Other current liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000048 - Disclosure - As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details" xlink:title="00000049 - Disclosure - The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:title="00000050 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Member" xlink:label="loc_txmdFinancingAgreementAmendment8Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementAmendment8Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaapDebtInstrumentRedemptionPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentRedemptionPeriodAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodAxis" xlink:to="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodOneMember" xlink:label="loc_txmdRepaymentPeriodOneMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodTwoMember" xlink:label="loc_txmdRepaymentPeriodTwoMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodThreeMember" xlink:label="loc_txmdRepaymentPeriodThreeMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodFourMember" xlink:label="loc_txmdRepaymentPeriodFourMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodFiveMember" xlink:label="loc_txmdRepaymentPeriodFiveMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodSixMember" xlink:label="loc_txmdRepaymentPeriodSixMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodSevenMember" xlink:label="loc_txmdRepaymentPeriodSevenMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentPeriodEightMember" xlink:label="loc_txmdRepaymentPeriodEightMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentRedemptionPeriodDomain" xlink:to="loc_txmdRepaymentPeriodEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period1Member" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period2Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period3Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period3Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period4Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period4Member" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period5Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period5Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period6Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period6Member" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period7Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period7Member" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period7Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period8Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period8Member" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period8Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period9Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period9Member" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period9Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period10Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period10Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period10Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period11Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period11Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period11Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period12Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period12Member" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period12Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment8Period13Member" xlink:label="loc_txmdFinancingAgreementAmendment8Period13Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment8Period13Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_2" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:label="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLineOfCreditFacilityUndrawnTrancheNoLongerAvailable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmdPrimeRateFloor" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrimeRateFloor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumRevenueRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumRevenueRequirementUnderCreditAgreement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumRevenueRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details" xlink:title="00000051 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2020: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:title="00000052 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:label="loc_txmdWeightedAverageExercisePriceOtherThanOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details" xlink:title="00000053 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails" xlink:title="00000054 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails" xlink:title="00000055 - Disclosure - Schedule of restricted stock units and performance stock units (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000056 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PerformanceStockUnitsMember" xlink:label="loc_txmdPerformanceStockUnitsMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdPerformanceStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementCantorFitzgeraldMember" xlink:label="loc_txmdUnderwritingAgreementCantorFitzgeraldMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementCantorFitzgeraldMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="loc_txmdUnderwritingAgreementJPMorganChaseMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementJPMorganChaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="loc_txmdUnderwritingAgreementGoldmanSachsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdSubscriptionAgreementKnightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment6Member" xlink:label="loc_txmdFinancingAgreementAmendment6Member" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_EmployeeStockPurchasePlanMember" xlink:label="loc_txmdEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MaximumCommonStockOfferingPrice" xlink:label="loc_txmdMaximumCommonStockOfferingPrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdMaximumCommonStockOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FixedCommissionRate" xlink:label="loc_txmdFixedCommissionRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdFixedCommissionRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="00000057 - Disclosure - EMPLOYEE BENEFIT PLAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DefinedContributionPlanMaximumEmployerMatchingContribution" xlink:label="loc_txmdDefinedContributionPlanMaximumEmployerMatchingContribution" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_txmdDefinedContributionPlanMaximumEmployerMatchingContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_DefinedContributionPlanVestingServicePeriod" xlink:label="loc_txmdDefinedContributionPlanVestingServicePeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_txmdDefinedContributionPlanVestingServicePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:title="00000058 - Disclosure - For financial reporting purposes, (loss) income before taxes includes the following components: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:title="00000059 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails" xlink:title="00000060 - Disclosure - The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="loc_us-gaapDeferredTaxAssetInterestCarryforward" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetInterestCarryforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000061 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ExpirationPeriod20YearsMember" xlink:label="loc_txmdExpirationPeriod20YearsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriod20YearsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ExpirationPeriodIndefiniteMember" xlink:label="loc_txmdExpirationPeriodIndefiniteMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriodIndefiniteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NolCarryForwardPeriod" xlink:label="loc_txmdNolCarryForwardPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdNolCarryForwardPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_txmdOperatingLossCarryforwardsExpirationYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdOperatingLossCarryforwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000062 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdCatalentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AmericanInternationalGroupMember" xlink:label="loc_txmdAmericanInternationalGroupMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdAmericanInternationalGroupMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000063 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="loc_txmdSupplierOneConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierOneConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfVendors" xlink:label="loc_txmdNumberOfVendors" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfVendors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000064 - Disclosure - Supplemental lease information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000065 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdCatalentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdNetRentableAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdRentedAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaapVariableLeasePayment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapVariableLeasePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="loc_us-gaapPurchaseObligationDueInNextTwelveMonths" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaapPurchaseObligationDueInSecondYear" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInSecondYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaapPurchaseObligationDueInThirdYear" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInThirdYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="loc_us-gaapPurchaseObligationDueInFourthYear" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInFourthYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="loc_us-gaapPurchaseObligationDueInFifthYear" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapPurchaseObligationDueInFifthYear" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails" xlink:title="00000067 - Disclosure - Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_KnightLicenseAgreementMember" xlink:label="loc_txmdKnightLicenseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdKnightLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_LenderWarrantsMember" xlink:label="loc_txmdLenderWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritingAgreementCantorFitzgeraldMember" xlink:label="loc_txmdUnderwritingAgreementCantorFitzgeraldMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementCantorFitzgeraldMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment7Period1Member" xlink:label="loc_txmdFinancingAgreementAmendment7Period1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment7Period1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_FinancingAgreementAmendment7Period2Member" xlink:label="loc_txmdFinancingAgreementAmendment7Period2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementAmendment7Period2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_MinimumRevenueRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumRevenueRequirementUnderCreditAgreement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMinimumRevenueRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20201231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex10-13_img01.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-13_img01.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M); !+6Q@PB)B400T/.\?P&A"&\#@AB,X01Z,., *GO'_CS<48 WZ@-T^PH
M-02"!' 8AR-&P )9% D6!V@!,BB1@#@$P@E$D.!1&N$".8!A#@I(A#*<D(!*
MQ,,?85C $[@!.TI 06?PB,(;+/$"*?QC%D6 02 0L4A+P(X:,"" ^:; @#2D
MXQ^H2 $B+O8/0( A*^$HQ E$( DJ&(&?ZB@# II0A1C0P2@R88<5L!*[2Y1
M!OD@"#6.@()6C.$*5)@!")R@ EK\% L)J,(T^)$%*$2B"J*$W3FTT( J:.,?
MA]A"$)X @G/\ QE1"((37N *9#!A 758U3HL 05*=,,.5;B#&_"0ACPLHPU+
MX((5CH '9."Q&$+H0A>L$ E@__P#$E8 @B,.D@HO8 $4C  "$L(@!5FX(RO*
M* ,< $$*<B3B$()XQ5%800E&5.-?B>C'0?@!AQ<4 B'><,(60C&)*73A"T=8
M A"\(;-D8,(0=;!"%Z:@A[2(H@UV*,,K\.@,*E@!"F)8A!N\L XR1.$)PS '
M) 1AB&]LHPN,6(0A#($)5XCL((FHW+_XD0@O)&$/EJ@%.12!B+AAXAH'88<@
M"I&("5,B$^YXQ"$T,>%-: (>C]A$+#IXE&!48A/'L 6#)QP(3A2#$93 AKYD
MP0A'"$,0DA@$)S#1B57 2F>N:$=,P-&(3A@C*\BPQ"$.,8A$;"(2ACBL!EMQ
MB41(HO\2R/N'+ 2!B$-HF5M(E$DWY/ *',JB$H: A\/F,>5' .D?^YC&,+Y!
M#6I\HT-.\Q6VM@(-/HR#'@T0Q#^X<8A_F$$%""F& UIQD"5<@2 M:,-!NJRN
M)APA(7EHA3EHX 6$M*,$;O@'-AX  6AD)1$1Z,-!;B&!&@3T*&"80!,.,HD3
M:!<M)J##0>H @$X?I1+L_1<D3'"08N3A'XDX"@VD^0]%(#8$]#A(.UR AW^<
M(P9F0,@R9( \&,0;&T,H!AK_X0\)X.(?KZ# +?XQA23HK!"Y^$<T#( *5DH@
MUT@5 "D08HEV;V,$A^*W!!X!NW^ ( &V/0@;:G 0;V"!MRS_0 @Z!M&^53#@
ML-P0@*8WG0;+)8\$+"B2CII@A7^@PP8WB-$X:F#7:PR@W?]Z10!L 3M=5$ (
M1_U'-?K@CC"(8QD,Z#0VPM"^9%A@%_\010P.<@TKZ%PFT3@ 'Q2.@&W\XQLF
M.$<Z<& '$5DA$?]PQ05XD15]V,"VTL# )=(1#WM\01[=&( >F"$-.$A@[3(#
MAR,R( MF<"$'W. '")B %3JA 1#_L,<,ZI .3UC@#EURQ0E"(8TI>$$<JEA
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M"P>!"&WS+X7 <+$#"S2R UJ $/HP Y0 .['  ?S@" > #[#3"\4@#BK@!\^
M!/Q4,\1P !PW#1D >DE !3J3"GR7# JP7^D  5PW#B;0!3K3#,YW"C%P7/!T
M )D .Z/P!350C0<1!AR@;^1@5__P"#2 $,F 1^_0 W-P$%"0!$<!";ME,?]0
M"DH0 I"C(U? !228 D[B J60/#ZP!4=Q%/&0!2"P!3IS"S"0 ,'_] ^DD 7D
M@!K+T "+0!""]B_?( &U4&X)($'_D%GM0PXK$ O_D H9X)"#L SML(<'L0T<
M=PT2P Q940Y!$%#ST !X=Q#H  [VT "<@!"&, #")Q.SX "']0P78%=]H >P
M,P>I<!!6( D'P0<)8!>!T ('T0]Q<%1<P 0Z\P<3)Q.:L %]\)(W%0$\8$QO
M5PKYD W_P \$  G_  _:\"^@X%B00 "%* S@( @%$(P'P0P"( VP@PPLQ0D%
MD%;+, SEL "(<!#@4 /G] ^.T !IU9H7%@@!X$T&<P0IAQ#S$%A%\(=>D .5
M\P];\&H'L0RKP@36"4_+\ ]<< &U6'L$_S "Z?8/2  '" $,W @' " % _$/
M>; +KF -_] (!6 7MS"<"M$+ " &L8D!(Z"4UG"1_' "5:AK*7 #Q_4O:S #
M!V$& M"=,D &:'04^- !+V 4!R$"%T ("%$%9_$OR. !*':,'B!!R& !7@E/
M1PF(DB8N4"$L^("(6?$/9/ #N3 +LX ( @")DKB&$,  ==!Y-2(' L ^'700
M;0 #"WH4HL  RP -=Z +.7 /L4@(AQ $!Y$)GZ )'*!=EV (?G!.GO !>RD3
MR'  NO /E; /?[  7CD(*XH0]V $%U &P7@FXT #T<A;%6!N,B$*$P *0Q %
M+^DH[_ ",+ "P_^ %N88 8)P#F,@ /Q$!0:7%9YPA]#@ 9>P#'O  WQG#.C8
M/EGI ]EP#N>P#0?0"%GQ#D,0#9U0 XT1#2<  6  A!\9 Z,0"H> !F_D!R3P
M$B[P .D6!2-(<-^@!EJJ(T00!.K@A7N /31@".P@!PUP"FAA$)DP?A$P#5FQ
M"F& "AO@"5U8:P?1# U@"#1S%-(@ 0GW#+5J"8>B/R^B I"##S#@ &"0#^.P
M*75P 5B@#/_@0JX@ ;!Y%.A !5;:#!  "/V #K1P%NBJKC#I Q3Z+[D@ 8>U
M"AE :EH@;3)!!QSW#TG@?/K0 T%0)+10 6605GL5B:>6%6\0"GTG!(G_T #=
M>13*X A]( !>*0WJRHH$$%@_@Q"10  T% \DT'-]1P#GM#"&T  9Q&\)\%T'
M40-^<!!1.YR:T"7<H@YH( @-P$__( P-<)3M0@3JB@XTT 3OJ01#<!#.( P'
M ;<' 0QJI@5L, .LB0EVH )*]@]>\&W_@ _>^@]^T 4"4'?_0 >T0 Y'$;53
MRRWA\ 1]D +I=A2A, 4J4 3'I0JR8(LEX%I.B@&D*Q-A, .54P@3@#PJ$ <:
M=!22@ 8A )4_5 5QD &C("))$(PR 0X8=1 &<0\(X)>L8 ":>0^OXZ++PA7_
M,J.)*!-DT .)H 9]T 4%T*(_>A#"\ 46T ('_ZLC0O!RCJHC2V #1R43KR
MV' ,2( ." !Z3G .FZ"E#[D'_/  C% .6( .;[!VB? !=N6)$-!ID+ /XD $
M.%L*FJD0Y5 &#I #OP L>]JG'YD!>!>H&+!(0L R9_(.35 #(0!ZL?L/Q/
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M$-M[%#.;%8C <B# =4?Q"[H #S7  N[0"]5X%.HPM+$K$T=+0VE'L4<Q#D[
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M/$ )OGJNH5PS@2PB VL(!)"4[=/:D ,JNU #'1!G)IP%&J!IO'#/7YD$"UL
M:WD/N9!6?YS-2: $I9P+"K +NS"G7H">,@$'YO8/3C &I! !MJLCCQ #%Y '
M!O'+_42S!]$$;U *6) #C:$*K&H/.? &8 !ZT"S-.%/-![$/"; &L",.4% $
M^V;2A>L#:A +L8 +*8">)=T VS /W2 %U_0OXK #OH --H "9Q$+!I",XM -
M#) $E0,%)A &&L"%.@($-_\0"ZL !W?X#XBNZ'[@F3@^#WH  ?RP"85P#C,0
M<FE  Z(0"VCPAV^@"N" !!^ #)\PD)$KM=,<B89P#D$0 U&W"A0J"Q+0"-+
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M2480+# (=.P$%R>(Q"W8@(+A"28?0Z# &A3"#D!L8 GH*04#4G *?&#! FR
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M"5MP 5-8!1Y8 XWK@16X!5>0!11(!E<H@!7  S"0@A*0A"&,#42@ D50!3@
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M!U"$@?CH?048-HB!A0 '&Z !<*@'%9" 2H"*5N !#LBK?]@!#1J(7;@ @D%
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MY==JY1=7P'_8AT0HA 5 UV+(@EZ  ?]#YRL@!5*H!+?^!R* @G;8!1Z  [L
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M'1Z*!@-8E)Q@.& 4)PK%_P6[@ (](,I#AYE3<D!Q &&H@07(<5Z/?I02/S3
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M 0!1HPC 'XIT RFDA!!-, L,> &:"*P8(F?H!CP.X(O_E!RA.4"]A048H9)
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M,+!!XA##%<B -3!#-3R!+#Q#"-# -W@#'#S %KV:1P$!%,S_0Y+E *)@0Q.
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M 16, 3;D QD4 1<P R*(P!1@ CGL 0@@014 06&YI<FRI<FJ94]"2J?P2<>
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M4TX400VD1AG0&3A4P@\ P1JL 1[\@3.D0A:0P1ID ?4!PQB\01\4PLJ. R>
M*4%HPQ\X 164 118@RE,S$VO@11<AC=8 17$01$49'+P0AGTP1VL 1T<@5>3
M@R>@01G0*D&$ AID@1R4PR2&01_X-!*XVBU$01(<@1H H;=4@A3\ 1[<]!'
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M 9GAE3(X0((EAS000"6X0SS<@@#\ C\ %K^OPR'4@CR@ "*D@S:H@$)M9B\
M0""L0S+\0 =<H#Q @2#LK3QD005LPSP<P3/, P+H 3P(0B# 0P@T0CS( @WX
M]4"LPQ+D@#_P>R0< CKD 0! 0F#F @Y0@Q-T@S9<P"2LPQHT C^4@=V$PRH
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M# 0X>QQO^0,:[C&"/(QJ'$YX@Q[Z8(!'(*6W[)+# #SQA>*R]X X__Z''6!
M#R9\%2%Q4$%%DF'$?_P!!]1(!$F]"][U-J,%KX %#D3@F5A,H-'KA0((@ &,
M:>CT'^$H10H*H(HN[?H?0Y"0)@"0"#N@[31A+G 3+Y,/,0@@!6R*DE^" 0QK
M@.X?HOC#/]1& EJ@H8QGA,LF7( 0:0C@$6SH@+@1H@P/R"+R>>C&B_<87EH
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MI!%N(RUH0,-$  N08@XBH&W^(0H&U X ("/1P.3^@1X@0)ONH0JXJ@ETP'S
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MR.1[M4V9H8-=0AAEA&%*F.":]BUYH(UR*K8.-^G0.&>>X:G6W#CN:66.CN.
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M KH0+JU8 P1PP(8\.L*78?3@#E!8 #7^\8[_*6RB$$501TDFX0 I).8<0@B
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M 220"E[0 4WV#]E  O40$9Z0 PVP" 5!#4%@ 7&P#/4@"0JP U_1#EO@!;B
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MR9?,QLNLQWSQ4=>,'KM !5_P!$B !$\P!$:0"[6@!5]@"9TP"KU0!930"*L
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M 47@#I4@ !)P KW #_T@!!O@"*Z@!0;@ $#@!E"0 &V C[,8 @2@".K0 D.
M"#>  $00"$W@ OL0"2<0 B!P#=!0!C<O!(A@_PDH  *B @A,< :?\ 4WL, 0
MD0Z"L (^4 .2T [1\ )5X 9J  /F% ]W( )G0 =-X 7CH @MX ,ZP CKL Y:
M@ !G  ^V\0Y$L':OL0Z2X (I\ -08 (UX ?V< Z48/$EL >:=.6:0 (^$ .
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M=9[J (%K#,KCBH*ND" ,@_CQHR!2"D  FG_TB>$"]?[Q1 (4VD%G"'G^&6(
M*?Z!YXMWVIF!@2<*8N6 !;XIR)H>TOFF D$*VB4%QP@L"(T)HBCHB Z<DQ"2
M?QH!8):"UGBAH!T\>*/*)M(\"Y4+/BEHP$$D:*$=_W:4T*"-@O"8P(51S_IG
MC F*,*B3+W!T"A<&%IA&.D"$*(@1"W@81A \5XPE@ARJ^8>7!1J@-)Q/!O
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MFIX2%!#^+$,,@,"-4?T#&UM(0@=XX(Q_R&)NR_M''CQP!7.HYARR,@AXCI$
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MH@$-4(]3T"&. >,0//7  WC8F -L_&,>/Q@ )0J2"" *T2![1(M^&="+-38
M <?H1YO <XL")" &G5 'BBGYCSAXP)+C6 (#.,"%DD'Q$(NUP6^]YPX0&%0Z
M[L#O69C_@8,3= #(9PF$ $00CGF\( *7:!4OG?/+,4C I;$8Q#].C#T7,Q.W
MX-'%;Q#I0GG(HP4#Z$4I%/ #((%G&",0 %-CP0:K,B U>C %.M6Q5T7\ PC
M.$<YP).,$$"@"F[@$GC$800)L.$?E_B%.PH+9@]THB!5F,!VN)&" F#H+.1
M!.R@X &HWN,$#[B"*_[A#$AN6 "/8"$WBK$,]1HD"QTH@3T*8@9A@@<<1)#
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MQH ;!SZ8&V0L@!+@ @>H!%ET"F7@ !^H S3 08W\M! P@1@ @MU@D08H 2-
M *X:D"HX)"M@  )0!4I@1WI<TX*XAWA<'S9M1ZN+@!3 .O HGA&(!BQ1GG]\
MGG]  QCZ!V3 @0[_",^%ZX80B  KB!%EE"?PP,4YH(,]T($&& *_](#M,(,#
M&($W,K!L< 8$*("I,DTFF 1,8(,38(!.R[N^TB,M,=0&>J (XKVS. <@D 1,
ML 04:(#W":DD@!%![0 %F(."0,I_4(0#0 $]C RG;"X(.(6"0-:KC,Q72*13
M((E?*H6S^H=HT **VL,#2(TWF(>%>08.8(#]H2!S**BS @]ZN(- "P%U, 8$
M8  <VLL<,Z[Y"Z# W$Y"8B9[  =1*H=NL(4500='T $!@(4!C$R.* ABT((%
M>)%&"$1[L(0Y&5$7\ !+J"XAV*Y_: ,NZ 0M(( .,+(/G"48\00&\ "&_[W-
M$Y0.:\"//-LS)K4'4\LV5"@ &92.0@@3^"N4@D $#V@!& (/8: TIEH%$/F'
M=X. 'R!0ZU2 1GB'+9BB>N"?)) ^()C55Q. -H$$ABV'=TBK B@$7)" !R@%
MX&  "$ 0^RR(.73:N6F&,'@ !R G:=,F+9 G>)!$M,B"[YRB=Y !"'!0<& "
M"8@$>S@"*/H[!P("; "! D@">9PW"?""<?B"XAH';D"!"(C%LW $!O@!;W,@
M)G"'(-B]])I1#]B!>T '= @"740K%2"&.?" !&"JLT@& N  0^ #7_H'5$B
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M_Q@ 4BZ(-Q@ +P"//;@ !IX%KIPPAEO(;/D'B7O)6;F#36"$(#@ >QNV+4
M"/B\?Y@&EV,&=9 P;_@-JFJY!2@/49, >],'&+"Y?] ">UB'#I&%GLL'>7!&
M8Y)#!'J*$8B $T%?>C1?.(7KS#H+9QB""1B .<"V9QL"!^  (RB&8+"""9
M.K ':\"!"5 [=/B"$" #5;@$&U@1MCL+6T !-4X''1"V<6@%!^ "?! '?JB$
M"7" $5 %7UB "8@!4P"'7!@ "H@#;X #"[  -F@&>9 !"O";30@ 1R '<6B'
MSAF 3_"&/["!8] X;T" \I"*;R "#,B!4;A"G5[N/?]HLG# !06P !"HAEAH
M $Z AP$1 F'Q!T-0  P(@]E. $L W,=@AU*(  Q8@F'X"7R(A FX@#W(AV
M @L0 %E@!U H 0OX@5OX!E\P 1SXNU_2!0# @EM@!C-0@G7(!TPP@ M  F_X
M!C%P@)*AARBP@"9HA6Q8A":PCM90@%^$!E%P@?)(AS-P  > A'3(!Q$P !Z0
M!G[8@P'@@&, !W$ !W]X@0V8@IP%AVF   DP\G?@A F( %-(AW-XA 28AED
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M"K\HQNN1T8L'/&(99TC#'KKPA]%[(Q'=N#L[-C&/_U BM/3(Q$W%T45NQ%X
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M5,$2@$$85($-M((RI$$4)($:< 416 $\9,(4),$22-<ZZ($2"$&+\ 0WF($
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M3XR"&8@$(0A "]2?'VQ 0/U#&!C #@@?-XP  Z#"@_S#$306(W@ "QS9-RR
M _ "XOW#$D@ &8S$)2##/*2  ."62%1!!GB"2-2!! 2!2,B" *2 =#7*#3B
M-"Z" A!  32"2%#!R_Q#_Q8HP!1@61;,!3O40 =@ :[\0QK @CO4 !&(1#K<
M #5HPNN9 PAX@$S0 Q3\0R <@ ^4@+;\@RET0 E P$7]0R-$0 &8@K+X0Q#D
MQB8PP /\P#*(!!2H@RJ4P3^X0PP(0";\ SQ4P=K@R3,\0 <X51L,0!/HX@(D
MP#>XR#;8XC_( @/,0./< @,0P+#\@Q4X@!W\ R5(0 FHPSLHP0<P@DBLPPYD
M@(S@ P<4R#\L PR,3#RT@ ,LPMF]0#UP0P3,U#\PPPKH ^(E@@3X@"FNP@
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M/P!#'%!  8Q"-R0<',"#(4@ !@#"*4P! W1"J-2).4S#"F" #E1#.I"#,OB
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M SP!27@!*(A$$"P !$0!L#S#1;)%!SS 0*C#RPV"2%@Q"OC*4P;!6 F" L#
M0N"" N3 M]0J -F#/^Q*(C.06IA!)N#  13"2+3!Q+H@I)##%J"GN_R#-J0
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M VC'&#1 "[1!%#2 '3!Y=FOS/[A!'I]T!+1!(#@53T@: G##,&C!2+A#$B3
M"UR!#ZR-2"P#%1P !$0 %?0M8.H  \PLGNQS,RRU-V#"-""",Q-T 8S %W2
M'RBT>H^! "R *$P"8?_#1,O(ID@# 82 %(R!#K !;>8W2//$V8I$'$# "6"!
M%OB "=QC42: "R !#!B!4U6!!"BCBW##"8BRO3Y  W0  21DER. $-S $-2*
M+T! !W1 "KCWHN"!,Y,"7VR" JR DWW!_S, 0PPT !/0NDBD[NHNT9NH P@(
M !+H@2Q83]WR03+DP )<%2JW="4H0 08 C6,\C\P^,C\0QT40 Z$1&$SP OX
M@B\\P@H< /3B"A)L Q,(P.8NBH^*;#6@ 5TW@ ^  1&@+>$LRA^T CW40 '
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MA0:F("=&!CI A<%A'5!A(I$J\2"&=?Y!I8 0M!+I#$TV<N2 &-#49R @[V"
M@VTV$F:&"%;Y!Q-^[/]QQ"*,-/KGB S.X&DD#^*(<9:-TIB@B<I$$L0 $"H;
MPP,J_@F$@0)2,5+-0H<*9"-RHF @!:5$^D>2"!BHX[#$()A5DHTS 46,C=K!
M8P*T+.2@ Z_58NR5!!3HY1]BZ[I+SWOB80L90O[90^%_FAF!@2.B5HPQ^!Y[
M  )7^A+)%0@6&%$D6K[KK(,9ZODE 09HZ<L*"=K ]H\#9.CWGT88(, ?6#K9
MR)L;/# C,!P2L.:?+LY!1QI9<-GH%!(\&%VZ8Q8H0)9K2<*"WB$L_N>0#AP
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M #284X\:=( T&VD%'>8!@]7\HQT'B(14@O%(.3#'#8KX1SEJX )S_*,2$8!
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MZ0F %>QA$CR  6Y $20! 5!,6\KA#FR%%>R@QE:A!R9A$(I@!KQ!&/Y@ 1!
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M'2WJT62J543_I:):!=L_<(F4 ,D3IPD0(*PX>HNT9YC1TZA3JU[->C6V?.+
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M29/ 8EZTL( 0.&(-"$  &2,Q@@?L( Y3#"H>1%# &#B2BG$X(P0-F 5'9,&
M$O1#&<GPQ@R%H( ZB.@=69#=T(J2" &$0#&%B\,&K* <CF!!&D;BG@?>\X]2
MW,,>;=A"/UK1!&Y-H@2RBV)1RD&%#,R0(^]0@0.H%0U#(I(?*O^0@*D:\X]@
MX%.?)F'$(-U0  (PX&'NT&0770<[:A1@ <?@2!<DT(;?_,,.W/A'-R @ \\9
MP0$7FP[)E!$!'UBF*+I P DBD(39^ (.',%% R"0H7\H UJHRZM>.S(ZV>SU
MKZ#+8>M>YY$X-  'B?"%+X[0 -VELP!#  01N"A6DQ3B  EH0 UZ](_F-4 *
M?B!#1TX!@06<@D8<Z=[WYA&^?R2# ", Q3W,T  3S&-][5,91^;'O\*APP4*
ML-\__(> 1CQA1APA!@H8$($:%")U1=G%&UAXA(YH(P4%Z%$&QY'#_H5PA(HC
M&2LZ.:BB-*( /H#=%1)0!$>48)#=W8K__GH81@,\S 4><,-)^C   D0"'"3Q
M! Z ="*5#N\/=B@!!,)EDF^$H+0TJ%IE36*++10AOY'1!"8.X0$9R,,;?VA%
M!W(@X3PT( 6DD$(9.P*(>/PA 7&4QR"7B4A)EC5=>%# #M+1!B\1!9-*[48.
M"O =$QJC T'RR"E3J60%;,$>]N#&"Q20A^0:<A36F&><C#*) *0@&RP @!O<
MH0,((. (&YM-(1G@"E[@]1^R.$ (RKA=_(@#'=OLIM[ *4Z.$"("#8!&.CM
M X7^XQDS*("6.9(,? Z%A@Q @3G:H+Z-+,(!"6#"P\I!60::!!T[6.MV3+*,
M$S#@$D=9F*%5_]L1</"#"_Q1A1%$1 P!?,W =HW  B38V24H  K_& :R3,%&
M$0P $U9K= .&8I))3((C<Z $$1KP V.80[B#A9T\:.   _UC"1+P@SRZ8(YH
MG.,?TH  "S:R#AM,X [A)1Q'V-"!!CR[*(YPPR(P^X=_X"*L_\"" E[P#GD4
M@8#Q!:S"6=/7TBW\X:@A6;;)%(<"K, 6H0C%$PK@6-XMP 1:<(%NP0@P&3S5
M R)I7@'0((1.= 04$." 'DVHT=6V-ADYJ($:8B  -+P**NSKN/SH9[^B; ,!
M!1"N_T+PA-AZ)!M16$ "#C")BH;W'V@ QC<* (%;_8,4C]+C=DT(0O\15A;.
M#"A (LATAP[PP#=7@!07/! (H6WY'2^@+PTET )9K*  FGH'*>KP  _T8B3'
M6$,)/) %<AA8BD$01Q0$,(0MWZ(&$>@ !Q:E4G)4P1J^$$ +)&42342"&SP0
MP"X848M?,. $M_U''CK0@RU P#>%PX,\S$&$#OC $*JJY2$Y,G$\-. $0@A!
M5'^<28Y(@P -8,-T)),!2:1ZR:HLRA@Z4(,D>#\&#:AR+7D0:K60["/NZ$2X
MJN$'V*TB!0WH  (ZH>89$, +,C#_/RBA@!74 X-U5C)YMA6A $X,  .+L @S
M< *!T#2\<SSKT!''D ,-,$]%H6R/1@O-E0?_,  ['"$/:N !"Q !2\ >'T$R
MA3 '@Z  .-!(;O( #0 +J-41K-81E9 *JT0'L7</,] $NP-&B=  !- -D7$&
M(+)*,] !@; ,@4  ,*!*)^A:CK85SL81?\ +V_  $= %_*!4$Q</)E  5B .
M[0 "*P<)!],1TK  /> *^Z %#+ #6:52KE4%G\  -4!ZT.$&X' $!:  J0 +
M%V02RC""LU )U20G$+>(1M%PC/B(GO8/$Q=1$K $'2$'N;,[ZJ069!"![,!=
M\@8-EK0.A< "$8 >X. \@  ,<O /X5 /WX  #0 9Y\<16N ]6^$/5" ^"+ "
MZ4 &(6090)=;6\%;_T5G$M>P $G7/PS  \L "*B 0>;0#4UC"BL  0FP8@SD
M-('P!U3D!>2$=(LR=HHS7-]U=L]0,.7%$62@ " 0#S#D 5^S!T467R;!#370
M 5IA$KIP!GN0 B/@#QXQ!QM0+!W1"@D@ KL4;_+&!DR0#'+P5/LH#>/0#XR
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MS0MG$NE0"4U0 B> !.%QS21P B(@!M) "S0P C7@!MH0"2U0 BP0!5&P PI
M;";4#2" !7\ "4"@7]M0!RTP C=P"76  RG0N\8@!01@!IBP!'GP1/*#!AQ
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M'O &N"M?4+ !_89N4+"I9<!L42$ >/4*$I #DK(& - &GC.AIFP.;Z ^V7
M.I YI- !'H &#BAO[& $)O@/0> !1L!%B0!7'7$(%% -D0$-"0 !TK'6U/Q7
MTNQ7L0Y8)$$.QM ,]( /SZ /XH#K__M #_:@#>H #-P@[,6P#L9@#_0P#]$0
M#=R #R \/.ZP$<"0#%>"']K@#_2P#\Y@#,N #^; &/Y@#,G0NXR!#Z*P".DR
M$MQ@#+O^#.=F#O,P#\8 [LCNZ_;0"_:0#]Q #/$@#L"P"+HP#\TP#]20"*J
M#\;@#,&P#/T@#LE #,2@"(B0PHT!#*^P#,,@&[F0#,UN;;&S#8<@"+^0.=P5
M#JN0":M@"XE N@QKS;^P")G0[N)P#YXP#,U.#.F]UN)@#8NP"J*0"-(@#K^0
M"KN\%>N "[Y "R,D#OPP"[B@"-X0)_7@"2H@D,-C"K+@"< @#L3@":NP"H[
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ME/_=A!SE\-[H/)*.=GBD6N]XGSGTYSH#?60<!0D*.8 C#GELD!P:?!URQM'
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M/H&'4ERC0)_SB"$"(0UOE$,9?."%-*RA#W$4XQ32D T^F&$98JCB&]D !2M
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M8(P:6.$0-3A $QYAA!XTF#;00 (#"@""%][D&AU8  <D4;^;F"'I-_'$ A+
M@$W82!UFV, C<).)'#0@!J? R1D4D 8:M8,1*Z@"%E2@!%5XY \#$$,90+ %
M-_BA!HNH8'78\8DIW" (>[@!$WSQCGA\@@DWJ$(GUI"$'GSE74.I!QZR( <X
M>,$9'FE'&$!0ARXD 14>N88:7O""U.OC([B8@@FN,),7B(%]C7M*/ )!@S*4
M00F#:* \/D&#*Q A"5MP@B26,<0)6PS"$BY_ZA3= @\PHH)2D, 0/ (""\#A
M'WK_*$ ,C+^#"83A'X40 !B0K_'H! EX@1<*AA:0 $X B5Y(M)L8!RYP "C
MCS_P  K\AS"8 ":H#"R0 "F %H^@ @\8@W\0DT 0*=O0AQ'X 2V;!%K0ATWP
M""?P@#CP"#^HI)M(@PFH N0P!R<XAW^8 PF@ H\XA53X!SH@PG\(AW:8A24H
M- -AA _0!(]PAD[P"$SP !(PAW?(AU^P-&0( 098!9"0 T7XAU>( !YXAOZP
MA3KP""N0 "O[ASL0 !MH('*X 0G 0DA0#6]8@ 7PAG\(!4N+! FX@8^P@@Z
M ?T1!U"PA']P @5@!8_PA#/0C3MP "AL&V#P@1J@D:?0_P0&F %B\ @L$( G
M@$ IX(=1 (! \ AX"((KV;=[^8=9P+9W$ $/J A\L+)X$ $%J,)_R(8$6(!%
M^0=#4  1:)(UV #(^(=$\+B.^8<T$  9N!)U4 $!< ,8$@(O,2 C2("8>@IH
M@  (4+%H2($!L 6/( ,#N NDH  7,(FG>(8( $'9. ,'6( 5**9_H )\<(<J
M>"$L,( ^P(DJ,+[;D(<6,,96Z \S8( %2#4# 88<F(+*> I;B( &L*>6,(1N
MO(]-,( &L %Z\(@DB*-UH((*.*-^ZP (@,@H*,% N( ?:(=P^ ,ZR#R!^8<V
MV  3 (=3X($-J(A_$((-, */&/\&'("SU[L)/G  &"$%!)B?=8@"#'@$<J"'
M+9B 4IB2$1B 3PA!7H  ":@$?PBY&8 &UJ$B>8B"#1B#=9"'.:@ #OL'<K #
M!R@!;5@&+]  )=B3](N8\[L<PI0;CY"#IM,!E$2.+/  ^:L'';@ S+,""(@!
M!OJ! 5BR0 C  90-//  $  22G" 'G!,H>"'9G@*8?B,'+"&(8H#"8#"="""
M 5 #X/@"#WA)V1 '(Y  GD0"4L '>"B<<* " < !69 '=_ '\O((**A!CU"'
M=+B)8."!$ @!R! *>ZB,,?  ([@)Z 3/(M2%0V@'9J"9%7. $=@#?_B'V/P'
M2%  $CC_"3X(!VX8ASZ0 !M@LYMX!FKX!U&(@!D8AOYX!)[\!RB80X^X P;X
M ?AT!Q#P #SXAV:X+V4(1+>HAY\03=*,3@B @32<A7"(S2XH  (H0W:HQ-R(
M@PO\G7^P P$H !E\"G2  0$@RW] A ,@ *!2!2OKA0/P@4&8D%V@159IS0-5
MAQR%17#XBB85 %C\!V384(_P3 '\!P\,@F[ B5+[N)L !0Z @#+\!R\X !NX
M$E'@ _VX"5/P@ 9HEJ?0T 7H%N T X]X40PD!09@ 36YB3+P !YHRZ=P@R'X
M@0)X OVH@GUH!XC\A]U\R5E@!]R0AS 0@@_$BF>H@AL0 $R4_PU(\( .2*FG
M  <KB  9J"1M@ *OFP^P> $=$("7/(*V/(0!:,R/8(,):()QH 3VR5+Y4H4'
M5)A_$ ,/N(*6& (#D#^+@%%_Z(=::,?7"PH3R %3_(=/< 5P>((-6%2/^ 8(
M* "W@ <1$( >&P]\0($#"+)_0 ,#*(+[@IJ;L 0#L %9@8(+B+9_6 0%@($)
M&84(R($V1$R(,<SJ*=C\>(ISD )4* $! *?'%  GH(8A<  AF) O2  =: 6+
M9<5_"%:'^="R$ ((J %P5"(AM 4J.  DR) X8( 7>(0M4-0FB53>#,'?/  T
M,(4:^ KRJXU=0( $.( B4#&0D$X;K/\./%B$*1  ,L@\\!1/D!@# =@":: !
MS'-+@4D&'>@ !B !>_((2!  %Z@%%,!")C.! _B#CR'04D10!86"5.0&:; !
M ["_?YC0"@6).DW!?_C0I8*"C84&*(#4-&0 !$" )XBE?=M3NOD'89"".!
M)M"WFV"#+8R'=TB"$"B /?@',F@\>'"!#BB %_@%GU38^I!2*J5.)_6(5C!&
MD0I93U  #L@!.\"P>7V*<2 "!5A4=R "'X  U7B#K^ /+B !!!"! ?P'#4V
M12$&'[B 6-!3VO0(,-B ':C'K  !%Q  _WN*.4"%0BB !H#%*  &D)!4X= '
M0S"%"$B . K_@TW8S3PP$'<(@A:( #4@DV1X@ ,XA']0@W^)'*1XA%1H@ *P
M4"[PTBI@@"+8H'\XA )X@*,%V<^<+][]ASR0 "8 )?X#!#WU@+N8@T5H![8[
MD-^,@!70A''@!W2(!@0H %GHCWF(@0-HT]9UFF8H 0;XI'_0A0(0 'MR(G7
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M@22]#1QE $M(@V5(!0%8@2\H0QZ1@ET@!QUH@"#8$ T- 4,@ @=0 I"(@P.
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M^#37CX4M[A?"D0!DHBM3L#/:1!(!$H4[#'D1PSO_8.+!"N$P!,H5X-QC0P:
MJ/://6T@P^$/$J#1(#=-?/1/%1ZT%TX1=@'#$ T23#*7-Q DX)M$DTA PT1+
M*"#$1,%P4<\5<TP$Q0Z*W>' $A.I4X4^XE"QST1,"/"&>_^P0T,"R3"T209N
M6%3)#9#]0PH J-03Q!?H$$@90^F(H, B$?U3#@X*:,)0-@LLD-(_B2B@0H)?
M6#+1'@M0-QAA"WT# 0'',-0&!G($MA 8CC@V3A<'&/_!T#1^?O,/'P(0D,VD
M$C19C \1/,$0/VFP(YHJ"W2@BTVX6"2+ S\LRI 0$B 1$:.$R8,)0W9@P$9@
M1 A !EMJE%+,,[R4(  CHYDA@1/$'K;0&H=,U$@$*1#SSRH#M*#/1%)<T(<Y
M$B$B@ KK(!;3/WO0))HF$33 RS]I>- M-:2(8\> Q5H4CQ!N_N-- UB\DX0%
MFUCT* 3,_*./" (@8A$_7Z3CSUBR,&2+ 3C LY91XI"SQ 0^691&!FHP=(@
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M0X$I1#GL@BOP0J4N0RB @BN\)<8MPRA40S6<0BB$@BI8PS@\PRZ4@SK 0BC
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M TR %% " RP + @# B0")X3 !G !+;" ?GP+.\B"!TR $%1" <P +9!#(QB
M R0!-X@#-IA! OS", 2!!2B )20"P>T!9"Q#"SQ!)A1"#)3!.*#"#QS "*B"
M/*2#)DC )["#1*2### <P"H" 31 !+B4/@1" _R!/:2 $/@""1@ $?C"$,0
M,QJ&.Z  ">#""TA #'""$"@ JAC#$@B '1A""YS GLRA&)8##6C,4<0!! @
M$6B8,[P  RR"+?EA-%2! G1 #;S!&^B  QC#*M2 "N! $;Q!$E1 (OS"$LC
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M&SC  YQ UU!!V]4$:3A &_P#.;S!@!Q&C)]+'SB GQ=!+(0#"V! 4$34#UA
M1='ED%% 5Q1%$C!  \ !0Q##IV P.0"! L3W,IP */Q#-12  @C'/T""M$'"
M!:04ZTK"<!B "[RE&U !0ZQ"!.0 EMYN#\B!**P .D1# DB XJJ""_S#,72
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MJ\-%^E$"!N"M 2&P1SOZ\(]^W.(?6NC #^"A!P',((4!VL8#?%""/&(A 1U
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M!!*0I<4#(J$]!N! %R^8Q$7BP0((0+-2H;MF@*YLWP<(X!6X6"N"X%8&2CS
M&^9LYSO1G)EUGO;,:7;S1_8Q @?LXB.XL, ..GN1*$B #A#<<Y^)AH(#V.(B
MORBH?9+Q#TT<XA]]:  *UM$.%0@@"JP9"#B*,(!__B,4!ZC!CF0Y@@AT)1-@
M^$@O,+"L5= G(8H1PRJV>^*!Z((^T\I)&R2@IUU$( +(A4<5LL$,9\PAL=G[
M[6_RZX :X(P,J+K($7+PS31X "G[&-A ?'& IM+C%&:AQC^Z(($T_*,2#%@
MT-;0,J+5H !,T)" %/\P!7+LH\QR,,8]!(J+BZ1B CCPB8W_,0@*% %*8[
M%30$B)F, QCW+ .'<5+9*STW0)/P0&QLH@E&J% "3'C+LBJA#'? @+47048!
M(%",<0QA EG8E='<<)$]>,"MH( U(_"!#D<-ZA^SH _.S.'3+DYN8:FH1STP
M,1I]#"$9J9B2G7(!L6M 4$.L8@#Z.$&/<(1!','@2YID^@]YN&"+ZHUX=QB
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MW.$8 B2>6$ >W"$9 B02U(T?)(0.EB$;&N  <N<CSF$>4(PO+") O*X!"B-
M4J$ )$ 03LLQ_B$(), /_N$4[($<TL"ZU&\P_P']VHPPT2E AF$.R  .J& .
M8,J^IB .[( .?,&/N($-T, .QL 75,$.[L .XN :?H$RS8 /+"$,O& /U@$2
MR&#_#-+ #3B&$N) #6!M(.XA#F9F("PA1J+D!D#@#O;@&5JA$^8@#O(@"5)(
M%Z@ !T@ ")+ "'C@"Q!$O7)0%YH !F# "Y"(&-  !U: !<X '<X!!%"@"<Y
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M%G; !?Z!!J[ %ZI  !A@$C A 3AA%'@?!7S? U(@GW-B!S[J'XJ  ![A"PS
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M"@?4\@\E9FC-2@$<H/E1*DAD%L0$ DB1-3 RH Q-!Q+H\8\T.7B@2&:S>%
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M\0P[*, #;]!51\8Q"QI(( 2-P(47 " +(74D#RZ(A29H<(5_@*$#;0@" SJ
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M:*';Z-B! #YWQNCDP0-76-PB#/"  DBAT-#9=[^AL^UT9P8+'T#"XCX"BRF
M0 !@R$E-,M/4IT+''%<X !K D0\=%* /9OT'(B)0@OJ:(11^*-PUQH$7K4%"
M AQP00[=<?&XSO61_Z@'$5"P@"EX51P7EX9@ 0L=HT/ &_2X@E=SYH=4 $$!
M7OY&'B3![\7] Q(*< &?3Y(S='1A&4DHP B^,8WJCB-GJVUM3M)%Q=F&P(P?
M6049%@Z-*#2  ]]8A]!K1USC1F/_!@=@T6QSD ]^E.$?^OA(%B2 A<QL0@$^
MH&.J<K:U[X;W7O^ @@3P+8\8,""#_W#O ^QACCZ,8QXVC0XYB-"!$02B'>)0
M$KHS. =ON.,Y+&# &:+<C<9RX@ QP/$_A@ BCDO@]_\0P@#8^P]GC( !@?B'
M/>3Q#[F;L1XH:Z,1/J+\WR>"%^\X1SI@T $5]$(>^/"&-G6B!P,L8'(?><<5
M)L"'*,N"&OCP:B TSWCP0$75T $)P#,?<0\XX !NE@PAT !>]@]EX&=FI1/
MP ,*H1C.,&+B8 0>0'\0X08YDP4&D 44*%-<1 LM45__X <>\'WK0A/_, D#
M  $PIA-*_P=8C\  *0 /W[  '$!ALJ  /R /R@ !#T!A5"0*$3 #Q. ^$%
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M7)DA##/0 6CP#Z/0 3,0!ES !=&1!0=@!,R #"2  (TP$ZE2%?\'7M$!!1U
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M5# '-".2QE62';!X*LF2+@F3$3 %9<  .&1Q@YEY/?D:/QF40_D#!< ([94
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M")_1P0^3E0^)@ ,>_\"4Z1!1CD,&(],.UY ##2 FCSD$W6I\0X">R@<)R8
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M!A+P/6=4!Z3 #]$0##0@ %K[$<P@6.B9S4?]#R,F"BLS!@PV#0P  C0C!A*
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M 0(%_*!EB G@$,<%&3XI)0D1?%..G3H8("0><9IY0P$/Y)#GGU9<@  ,6LC
M A>/S!E%A@,*T$0>Y98+QXT(V'B$$0BDN.>?8.Y@( (1OOE'# <$ $,?@HIQ
MH =.'GFBAG,$DN:$":IXI(TXV(%K%!X&?620*P@QYQDH+&C DV&J:<&"'Y@)
M1SES ,E@%7+^46>(#2R08YA(+!A #6#J4F>3 09H@YNZ^IG_Q(()ZAAF&$TV
M>.6>/##P0!:Q5"FA@#.BT8:1(IY9!H9+PNG(%PLP0*,?7CBXX(ID))$ @5[0
MR46""S 9)II,%!CEGBXHF&&:?*QA(@J/EELC TRXF><+)^+I:!U !K@@$')J
M\F6 70;B8X()/ ''(VL:\."-Y/XQ)0(%&+$''E<*N.0@JJNV^FJLLRZH&['@
MTOIKL,,&VR.LESN([*O-)@CM@<:A>JJ"QG&[(+8%DIOL>V*E:9R^Z/(HYTC%
M,<>O>N@:!YX_Z8J''8_&$2><>A*?JIQUXHD''72FDJ>=N=E!1YYJVW&GG'+(
M'H>=Q#M"QQW6,2_G3W/:B0>>=)8#_UP<>=BQ?!W& X?['W?0T;4C<NYQ!QY^
MIG*;&W/JT<?R=O !9V]VU+&<G7STX2<=<OJ1A_5\W/DG''?:*8=N<_(I)QYY
M\F'<G'OD8?^<=:R/IYY[ZK\^GWOJ2<>@<.SC'\70!7_^<8YNR",=^IC%*%BA
M#$B1+1JA0$4QZ"*0>X!B%-Z@23Y&<0U7S*,?'F&&*WXQBE]48QNMJ(8XQC$-
M%E8C%\/0$BMNL0U0S$(8NW!%-90!BU#L@A7J (<PRJ$,5,"B+Y%"QRQ \8O:
M+6,7V[@&+,0WOE#<00ZA:$=RXO$+4E3#%:I8A^_(QHQ!D*$.K*"),')1C6JP
M(COO &$M\O]!$'O0@A2,B(,G-B2W?P"C%WXP0R;.]SM_>.(.;4"$;_C!"#:<
MP1>*B,0:Q-"),W1B4W!#1QC84(G_S4(,>'"#'@!!RC7 81'3^P<IV. &/-2!
M$V3[!1]@F0=  ((/=1!&*]B !S#D 18"R0<EH* $.!RB+XJ @QB2\0]X4 (,
M>( #+2ZQAT[(X1-C,,0P_D&+'>R!E+F$ Q[6H88@K $,D>C"$_Y@FN38Q1"5
M $(5(B$SCVP"!V.0@R1$=0XE[& 1NMK&#I9PAC/TXQ_*P,(-FL $0+QCH4JX
MP16:D(0DO& %V1!;1STJ-J[1Y*,C):E!(B4WE)I1I2N%&TM7BM+_N[T4IC)%
MZ=K,%KAX*L=K.45;I.SF.)O6+6DB75M0R:;3K.E4;0-9*=WJICRW"55*-?V:
M5(E*MX]:M:A56ZK?A/J[K;[MJV,SJ4_#RM2O@M6H9HW;W,Z*-9B6M:L[M1I2
MF9HVM?IM;&A+'=NT:I!WR.P@J1L?6I7#RGC\+Y[A$"Q=WC$W%S:V(\$CASG2
MP0['N4,>YC '^=S!/;J65+0?#6EH1WM:K9UTIBYE;6M9"E/'T32F9H2M:VTK
MV]C>5K>[Y:UM:ZO:E.[6J;TUXW")>USD)E>YKOVM2HWKPM4N5[K+-2QOO8K4
MF_J.J&PUJ]KLBM:ZHE:\82OM>,U;MNFF_U>]3W7N6J$;W+HT%ZI4%2MRGVO;
M^Z8WO^OE;U/=V]JZ)O>Y^YTK5]M;W;06^+QG^^Y> 9S:!K.UOMH5K81Y.N"U
M+EC#!RGOACW,T_Z&6+<$9J]RY/O>V<X7D :V[W\?C&#UDEC$(I;Q@1G<8@3+
MN*HVOC"&/WSCO.[XQ>CMJH7E2N&26EC)$6[PC\W;82>?-\A:5;!)DRIE!CNU
MK%@UG%^U?-6V!;C 03;L<(7\9=1&.,M SNN8F5QE"!>9S!YE<IFWV^8W%S?.
M2+[ND?_J82/OV:5"QC.<0=QD.N>YQ(6><Y1'"V5'B]<C]EB#'ABA#56(0Q:)
MN,4M<J&+5^BB&_^_(P8E^F &7.PB%/2HA2IN,0MK_,,:=E!U*-9P"U+40A>Y
M8$47S:&*6I!"%:.@QS1>\0I8D.(7N]Y&,U9APUU<(QBZZ/2G8Z$+:[!R&[U8
M13ZD40\\[\,6K"!%+J[1YG%(XW;I^$6[%5.-6=SB%[5(1SI@D8NWC&,6OD &
M.H3Q5Z328Q2Q6 4S:!*,7N :%M?VQP6#NH]5X'H7NM!%*$AQ"U.L8A6U&#6Z
MO_&*58 1%JLP!3'4H8IZU*,?_.N?RN^1#WC4 QWVV <]VA'!-M^C?^A0ASX&
M=\!^R'P>_H!'5'_W#D__J"/@\,<Z9*X.I0\5&ZFX1M]^IXU?_.D=YIC_1SOJ
MP8Y]G$,?[>AL/E*^COCI-:C@X'D_O X/?)2Q'OA(N3[N<3XQDP,>Z"A<1_CQ
MH]^I Q\",=AI_VQ4+@?U;)'^L*&3[/C%2SK!5BX;XY_<-<N/-QL\R ,Q4H&#
M+?S#'TLP  ,PH8M2M& ) U%$ WI0B5B8@0$K* <E/""!( @0'F=X@"[L 8=2
M?4(77+A $_HQCFL400(1R 0_6B"%6*C  "30!1 28(Q*=$ !.N@&I?DT!ET,
MP@4(B%4=3I")2H# "(=TZCPL40 /[$ 9IO4'"KPYN2@XP &,^ <A'%  #GB$
M=WB'.I@ ;UB'(.B#58 #'E@#O/((>9 $!$"!_T'( @'H@TUY!CL0  DX@D4@
M @*0@BXJL7FH P50@":@N"^0@ 8X@C9H@PCX C 3"'T8@2MH QW!@3;H 1?P
M!RVH 1W@@FYPA22  1T @F-8!1 0 1+0@TGX@P?P X<CB%Z8 A@@ 2I0 1.@
M!7)(A2+  198 S; @2L !;B0!TS PC\@ 2!XIG@ A!U0 1(P AF8 E2 BV]@
M A%0@R0H@:D1"'3P@BNP SH(@D:@$QD0@1OXA"=0@@= A7R @A:0@1<  A9@
M VX8*O#:!QBX@B2P 1&8 C/P@3J@AB_  1E@@BD @30(!8.PASQ(F0&R@1JH
M 440B%_0@2\@!6M1@_\OR ,TH )A,(8Z( ,[8 -+  ,D\ -A^(0_& ,[2,8L
M&(-XF(4T, ,[ "8M&(1EN!I"F ,S4(-A@AM5.#4SJ 2)$@AY6(3!\8AS\(,T
M&(,XN$/)\((XZ,:#( 8ZN -">H,L0 1O0H<U( ,_:(,^> ,I\ *.J!I#> ,[
M\ ,T>(,^P )=J(<S*(-^]$<R((9)&(-0" 0O> ,L6 -L\(15H"!?P 59$(7>
M^8=W& 4^^ (]\ 9JP =A2 5<, 4*4LE=<(=1>(50R(64I 5ZHP99"(5:L(5,
MN 7!FK-= ,I>R(=M2(510 51< =R0(58P 5;J(51Z 5K6 =;*(63# 5;> 3_
M6SB':DB%4!@%6>"%6H@%I,P$8_"(= "%1UA)I1.'4\"%N6P&<1 %C?.%4<"%
M3( %?S"%3$@%93B\S",OS'O,TSH#!6@&@7@$$Q (.2B !W@&@4@&)! (3W"
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M6;B0!08H@8=X@0C 6T(X@!@8O%_H@ /0A'_@! _P ?_\!SNP "HP&#3H@!G
MAG\P@@$8 W @@@&8@X' AQ'P /ZX@0YH!(% !DA840$  7,XAV<@A4( GC+U
M!8&0@@GH@M+1LF 86W$@ @] UW^8A'^ A@>  ,;]AZD5@Z1Q!QF0 #'^'31(
M@070 6WX!T4XT&/P@"I(1SO@Q7_8 @E08XFRA&?JVD@ $G-P@V=JA08(@;<@
M4 8P7ZL1! 28 0XPPW](!A>(@08PDN48@PN @Z'J! _X 0NB7Q^6JW^H!Q&
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MX?F6@#/XAT"HAG50(!"0@$^05&L0H7^HA4:NXV=X  'H&:N)A$C@ @DP X$
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M>6 '.V"&%*AQK_F#3RA3%%X.7&  #F &3OAPH%(\(^\ ,K@&-&  ,DB<+SB
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MG@@(MOT;!UM6@1*I[HA3<L#+G'M]ZPEBL<!#EJAYI_:$%&$$L+[Z1$"(G(T
M@C=<!MA(YUKB<]6L#;*"$$+7)P+8\$I%W?_S'Q0/<227A##H%*4X#QC_DP<#
M,@Q"PF43S8?:4!&4@ DBVY!C4"(,X*#' QZ@,=$6'L#A6B %%/#*/Z(4<,(G
M@E0C4RD'G'"45'=XT-D_VD !00(2\"$..4T@X$(>*'03D3PV0""-0=WD<$(O
M5.75DSE7>)"':](0D (5+3"P@SVNC:+1&P)L\8Y!YKAACCA/',##&H9$! 8/
M#42@@FE/=O $%@9 ] ]3")C@! (+&51+!R7$L<(!5*BCE1N:L-."!YJL8HH]
M(3102U_+9)B' A^Y%H\2$*CP1SRYQ8=@19010,,F(APP1CT&?0'!#FI0<(N"
MT%6D# <C>&' )A+_C1'!#E)@0$M$<1301!0:Q!)1%@THX84%HQ@430H09&$J
M@O^,X8$1SG%[0!)J=%#600D!VA8"WE3UW"<>T/#.&FS@P, VALABT%XH]91(
M!#D(U6\$*!AAA!Q&-,#%/]\04( <KD%20 >P#%74408EM5133T4EEL<?@]P5
MR".3K!4_4;SZCRDX(&!:6P0\LTZ&SD SRP$/X/:<0<_X$ $J?2$SA$';+)!
M,,V4P, ?4L6";E_O?'% 9'U19AEF"7P3H#GK[#(*+P>)X("QI;IF7FL5@2-)
M.?_ <4(0.US;AVOMP$" #NPBTL$!#UOTZS_K_"$ $;!M2UY%IQ20PS1]_\$#
M@P20_"/- PWD@L\#!>@AF>$5F8T>! C<Q40R5^E<WWU]E<2 *0:%P@" >4C
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MZ 43#O!$U[@"J>A<8A$I<P!&&(01#.A UJR8+5Y0:Q'6:.H_=(%4;>BC0Z-
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MJ#Q"$=S #51!+=1"%92B%B!#(A1!$[Q &73"$?R VRD=+@1!*6;!(Z4#(]"
M$A"!'VC#.)"!#:@ [4D""7C!$]! &7!2/'P"$RB!"?1!-!01,=R $@P!$LA
M49%#$$@!%X#!$GB!.]"#'S1!$TR!&ZQ!&IS (SA#%'1 !US!&@#!'9"ATDF$
M,*1! SS %>Q"19""$C1 ![! D&A* \S!'V2 ,XJ#.HS!*-' (XC! ; !.DA%
M&GR6-;A &L"!(C!!'\0#-.A!!S0 "_3"AIW#).1 !+S (VB"$U  *5B#"'0
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M$_;:[?A.[_BB_R_=1B_MMJC<QF_>LF_[_E']XF_^ZN_^\F__^N__ G  OV\
M=ZZ#KF&OXNWPIF_VEHK]0N[S!E/S0K QY>_TTJ[].K#UKF\&+S #EZ_Y>F^#
MUJ\%A_#Y.FX%>_ (I[#V:G (<S (K_#[QK  TW -V_ -XW .ZW#^ZD8/[[
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M"4@ #]C"/L@" 4R "S##,("! @P &]!.":S @EK" R2")U!!"!P#,,R!! A
M%]#!'&Q!!$ 9*U"! O2!'Z1!#=2 /F3""=#?*I!#/Z3! (!!*("!!R@ %/B!
M"Z1 &:B#.+@"E B % C##=@ '=A K=/!%$! ,- "!P@ !_2",<@!N\/ M->
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MN>K"PR78@!$@01L0G"K$P1N4@=IW024( ^1*Q2\<01N4P2"47#%DP1ND@1
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M?_]S) 3)R,2!&XSX9C"HA;';"W(;;_\#QD (1FXEO/TKAJ #,HSL?A3[=ZV
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M SV(QC_P@8(#R.(?Y.C55T*I$4I0P#X8^84#>K [>:A  3 4R"C\\*1P%,$
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M"^N<(3^*"78*@!*"P04<[W880 1$808.0 IDKK**A08@H+ $ AU88 &8 !B
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M(W8@ WP3$[96M+@@"*HS"V1@>S B#PY !T3K(J9 0_XA'V2Y"$IB$/APH$[
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MN"%LR( #.  &UD.F/: *+H$*G4$<WB$65* !1F 72$,0]! !_^8@&N1%$'J
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M!@,0L(-/B6,?H_@'.EB0 ":(A!GZD <+(.!Y80;C%R#CA =PL NR$,))TG@
M!*Q<B73L>1X^\,#+QY(/2-?][F/Q1Q"4$X@"=* 6_Y '#B1P";+LP27B\ RS
MD']>EUG_8 GK, T<4 !\]0_UUP&MD ZT\ ]G!@82( /3P'5DL%IST0<2 '+M
M0Q8H1P _U!?[< )Z1A9=4  RP![0$ ?_T T1P 1@] ]D8'1!EX,ZN(,\F#E
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M4.@!,(AF.&  OV:JF64+/"8'Z(#_#B(@ &P6!0(  NP1&O]0"E-@!FV !CS
M ,0EHP+P;H>9%2P0 0*WBO_@HQ$0"V/!#WSX#0\*=LV0 @>0"6,I$H(0!)^
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MX^ 48W *D4"/%.@ Q0 R]U #'>"79 $/43!L7L +YP /VQ "$6 L?9$-!'
M&OL/=] !;3 68'"N_S +%G (X( *L1 .\'.[HCS*I%P6V9 AK!AT(I$).2
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M (U #L!0 A- !/C #U$P 2(0%^- #MG@ Q9@!LTQ#KG@ 1X@".0 #F!@ 0@
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MI;=%1K)OD?0/8_!/J1P1!RX$H(!6 (,;8P@ #,(WCB0H  O&" (K/B0.9S#
M [@(H0CPP3V8#($2Y\@#!4B C9+(PP@82$,RD"$;FKP! $M QAM"*Y]S^&";
MN_P'-,P CM \@@([<,:9:!34&["S@5TXC6!4$X]_! ,01@" !AXQ#F)$ AZ'
M ( 3!N$_)VB@# ;9[*'_D8T03( 2(P$'0]Q1! #LX2"1 *?_/:P @"L@01OO
MB */T1&CGZBE)D9)<K17>F1I5QN3]>G),'*P 5%ZQA4"2( V#I(( (  D.$8
M0@!*JXE?_.,4\#A&#000C&6T$1(BVJ0)Y/ (1A"  HH(,CN8< $8-X0^;PB
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MHA4#0JG9Y<\^LL_?_CP;1XKHH?&FV2/7V/@$#-  1U '8-BQ&#@%?;"&&<B
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M%S !$  !&J !(O_8 B78 1(  24 @28P@B(  B6X@BT(@B P B ( BB(@BJ
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M  P@ FV !038A'+PDC@  =FL!UDX  M @W60AUP+AXQ-\DTT<O=]].-4D(G
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MQP.<A%.0-TI$H 4G=*"@1(CQ[ $!$Y=<\0 8AU9#0@$0&&*0+CCP,(TL28?
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M0 >#'*%P0\C;F?[AAT<TYI%<P  :L/F/4W2@ ?,3QPTD4$R#2.)]&P$#!K(
M/[Q26H=T!6*E,SW_'8*,8PDST,=!DN#==A"A !9#A4'"L00&%& *J#9(9!E
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MDO79.=1 ![R8.MF",PB#-F #.43A$UC5/VBA0;##$8R#-T#  SA:_1C?#?B
M_P  WC@L1/K00PHP@",0QR/X@3R&P 'T@1:@VD)PEW<5Q#+\0 [  ""L52,<
M0 ^< _WT@00<02-"P! (00>T3$(PCJ3I@0#@5PV)HF3"Q778Q61>IF2P!#-P
MP Z8$5T&5C!P@D% 0Q]X !^0H$'T QD4  B(PSSP8OTMQ"]@X:U%0 X$0S,<
M73%(@SDDXS_  PD80"P5&S0:Q,49!"],VQ3,Y4)T0PX( "<5AF/& #T0QS.D
M0 3@T3D:Q#TH@9'5@D%P B@8!"X\0 . 0!@:P1+]0QD(T#-PPTZ:P1P=I  ,
M&_T87#@$@0<H%'&T6PF<B1L,@D%0 P<L0 BTS$;40?\$E,"+X8,./$"%$4=)
M>L5)+D0,RAS2=<#-Q20/TJ2+'431]>0E08,^) $YQ ,'><4?.$ 48%,\5,(M
MD@!&\H$ L # B4,2*.8K]$ DC % RJ<8'H ($$.I-0'?(-$_A<$:Q$ '&(%7
M/,*<_4,M((")\<Y<]N%&^$&AL=)&Q$((XA'7=8$"S%PZ4-Y>2F-%_ ,ML, V
M# $#<( G1"9FSJE15":=WNE.9$4\J  ) -P_1($#,!$P  $J>IPDH$,-O(]!
MG, 2C ,Y)(%P'L09+-HE1$ 'X!%12$'A)-HDM=\ M ""LH0VM-8U&,00L,="
M4 (&..FDT8$%O$!(-00AF /_-XR ![3"01S"!RP!M>3"$RU$/NS !+@C+2 #
M<:S!!1!!?@7!>@(#/*@#%MS:!N  -+5'GY@J!/1 =7K%$+B7023"!M# SI$7
M!=33/ZQ!(!R$(71 "FS(1A####" L?Z#'5A &0S'*E#8%OX#\LT<<>B#"$
MA_V#/>"  (PD2;084GH%$GC T-5#T>WE/WQ#:XF<+/P#+ @H2U!#!#R V.C7
M!##B,CE &AWC$]!4&H#!(!3"'7! " 2#03@"VO'#,-@J%B[$)XP!(@1"&/#
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MME.(%#C\13]076/LG#O@P[/P1D',##PX4FVS!#DDTCU0'3G<0S\XRJ2U$M]
MB_K40SW80Y^80W37PSR4P\Z-PS+, PU9Q3W 0S_< UL0VW*(1E:4BT#TPSE(
M=SZ<@\KY@ZN@PSYLGCR(;SVT S[T@S](MS[0 UN @SW 0WXO@_]V\P,WK ,Z
MK ,^E(,_H$,]Z(,_]$,^U$,Y],,^V(.K##=;N$,U^$(NP/>D <,LV +BBD,T
MF,(L6(- J,(NW,(MH((NP (IW,(J;(@][ (LZ$(HM((RU+8VU *,YX(N[,(H
MJ$)6/(,]"$0[O,(O\$(KZ$*<"$0\A$(H)(DH'+9%W(,NZ((HC%=#"(,MJ (I
MA (JE(-L2$,NH((TB ,YW *-YP(UV'%JT^DTT!"FU7EJ_T$;S)MF<-HX!+HT
M0T8-%89""/JR#*03;D0..89L_P:BSW9R;,]+_ ]MI*EOF*VNX 97B+9O:^)O
M:+JEFVVW%#I<D7IM=(6>\_&=UQ5LK_K_G"[$.)S"YOTYH NZK:N$H =ZKE?&
MK@]Z3*!%K\O&KF=Z9 R[;+B&J7N$J@O[L0]&HD\%K+-MJ^?YM+/M:4.'K?\Z
MLG<$MW>[67S[53A[KC,$HM^#(\!",X0#,UC#,&0#,L W<B [6I![1S2[<SR[
M<"S[0%[[V5;[Z?D[GHH&K@^[N(.[0QP\PL>$PJ^$O?^YN8]E/#Q!*EA"$WA#
M%G1"!\#!&*#2O ][O><[LUN+O9>\R/>[P-.IZ:7\'<LV4Y3Z8JI+J8NZLK?M
MJU^Z;9QZ<=Q\GC)&;GSZL/S#-41 )OV","P#-@R C[&XSK_V7=1\H?OQ1; &
MOK.\U3/$RE^]_]8;Q"JP 1ZX@1P@\$'(@AZL 1AT B"L@1SD04 M%QNP02-0
M@QZX 1Y,4!Z,@1P 9D&8@R+< ;M<@U=X$!ZL 1OX@1^,09S.)S840AO<@2?@
M@RIPPRV<PC;X0AT(^90)@RE<PS;<PBB$ BQX0SJXPBU4@S(8.2CD5T;=!RCP
MPC"<0BCL@C)4PRF,0BL PT", RFP0C540RZ(C3MDPAC 0CXL@U>< BJH0CUX
M0SPHPR_<2"Y@7RBX BM\OBM4@RM\_BY40S@<>35L RN@PC= &4'< RI< _:'
MPBQT#L&.0N^K C8(Q#>HPB],^668@S$0A3_L@ 9H ?MZ#D!(0/7OG_\X@^EN
MD2I63YTX?]ODG<O'3QZY@O6^Q5LGKY^\>.CZO7-W[YZ[>/KN\3/'KEV\>.KR
MP>,7[EV^<O'DQ218T*!!>"W=J6,7CF#/GNF,IFOGSAU/=/#DZ>.GSB4[>>+<
MK4O'#FI1@SO!AA4[EFQ9LV?1IE6[EFU;MV_AQBUK#=T_<'+QYM6[EV]?OW]W
MXO-S 8,;?$;MO<&@P-<P6@(4+&#V[]R>!,G6>7*PP<JP77PF!.,I[E^Q* ;$
MT.ICX<NZ?_;H3'# AU:I%R:\DB8$(8>D1WY2;%DW*H>$(K0B%?BAZQ\P21PD
M8/'EJ @!?;QN"$@@R!($(-#^W=-THD""7JO_#D02E$# "UPCZO <I\M&! 9[
M,%?ADDF/CS7_Y!F""5DVB8&(<5IIXH (]( F'$<@<,*71E 0  9<'+'" F1\
MP0*R-B*)009<1A.'GDDXZ("'-T#P09)WN.'" 09(B(:@:W( 01_YYN$$!"-(
M&R>?/21 89]_I)$@EQ+1&4.!%)3HY9]O3'#!D41<8*&)9"B3H@4USKF$!A:H
M8$45%/(0 P02VF #A4!BF<(&%^ZP)(L8D+C'DB)L4,*2(%Z@91R>"*)%3AK:
M2(*%,%SKZ1]ZLB"--&&48 &&0PA298D5!)FF#QML,.*7TKA P8A1Y!B54,!8
M;=755V%]E2Z[8JW5_]9;<<WU'UL8\*&;$O]91 $1RB$("P\>L*&=?U*Q@Z!A
M0BB@D9WZH(90<JBH (R=D,#@B;N">: #9 A2)PZ+OI)% 12*V6D1%@A*P@$X
M"'K" !;J(8@$"38AB)\=CDRC@!3P^0<5!U"8AR K)%#C'T*<Q2>%""SYAYH[
MQG%4C@-^N.<?2 QP[1\^XI,% %4/(6'02B00@2B"[D@$9@F2V,D*YFJQ[Y'F
M>!A E-$(8D$ -O[)YX<-)K$K"0&HV*F>-\XAE)TQ2'"@"H)^P?27!GY-QH!6
M@"7'!0?T*.@?7IP@B T+#E!"GG_8J9&@+2YP^)$C_N'F 0->^:>3._X)9/\"
M'A0F!Q%X_V%" 1S(6:8*#/S(+?#!\=D'" V$,(=00@2HAE!M1F@@!W+_J64*
M@J(AP !."'HG"BK\^6>?$F195=?;<<]==[-FO6OWWX$/WM9'&$@8V$ L5(>@
M3BQ),8Y_LHF$H&2B)>4?3-R9!AA"<RD@AVS,SB6"!;Y!\@$(;OG'$7F^><=L
M?&J0 )!5+2'*" _&(*B,!DY8YA]T2*  3/Q##_D@A<<648 9$.,?[W"!!])
M$"A $$G'^ <Q9A !4_R#'XEPWU?R(($M$(0*$<B"C9*!J4DXP BB,0<<B ()
M!>#+;)88!$'\X $C_,,4V""%-?XAB@840&;_F,/_ 6  #T*A@P4>J 1!IC
M)&2J Q H8AMB42)R@.,5$X "04AA $#(P@U$R00&^A .H_PC'B;P0"?,=HHL
M$.05(*C! >"HCR TY1].\,#S<@&*"V;P9_8PQ#\X<8 8G.,=RG"'%MQ7! B0
M@!W_>,8#(M W1R4R!@5[10$ZP"72\(,& S@#H>)Q P(L  7V^$<HGO>/992
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M0)!FE.  N=A'$6!!D+<FPP-B>&LR49M:8!93M:UU+>Z6V<RO$ 1Y,%">.-P
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M" -HPG;!H05?J$  B#!;/X+PCT%T0 "?4$89-%N"$'#_004BL,@X\'QC&<C
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M'Z9  N+C&Q!NBOXA'&S  R[A'PK&$\P,#10 "$@C&B(-//YA"22@#71I&4:
M 6[MU>1  IB (%Z@B/Y!"PB@'#XA!/^A$@S &8+% 6; 1OZ!'(C@2/[!##P@
MS;#!'.;A#?[A%89($0CB#0(@@AR%'Y)P"?_!#02@!WCO'ZK_X0&TKOA((Q8,
M(&TL\=_D000DP*L(0A/$@"!P09!(PPU!@(^P,(+,!AM&H)H()9%: ![(0:@(
M(17^P0@4@ P&)1@XH &D 6@2J0:&3!Y@0 (FK1BZP!B"(1CP"7"@J@H0[QM"
M0 !HSA]0@ %(I TB8.W<JH%HH 76R@')D= 8L!S14;60(0T<0 &T0!=$@0L
MH!:VP0LF( (>81\NX0 LH1Y(PQRX@ R*!A(.0 +>X!50P0\ @'4<Q1VR8 (0
M81D,H0.0X)N&9 (L8!.4*-GD00H&@ EV01LVP01" 1U\00 ,P 9L!! L  ,N
M81]F(0+0:!^PH1,<0!3P 0HL0""\_V$'%J 6&L@88. "1, 8,J8>1$$!-N /
M;LLHYL$*-H #KB$<B. #%$$=AJ$%)HT1 " 1[@$?A* *-(<=J( "CB 43($/
MS&P<C $%!B &GN$>=D$'/&$? F$#,* 3]D$/+. )"L91SN$'," *[@$5%L
MZB"K!N43)$ !4B%C7NT?9($"B( HC&_?R"$,)J $6$$=D*$)P.<?P, 3S&8<
MAN $FB(==F " HLTMJ$#'*!VOB(0'* !P.8?K*$%+(@)!@ +_F$=G& #Z,Y1
M!(<'8L<0).  V$X(S+ 5&( !MLX96$"Q_N$4#$ +)?$P:Z<=%&0&MH$@\*$$
MBJ #T[$\5?_K',TS/8,)&4R!%$BA%G1!%U!!%>)A&W*!%W[A%Z8!%6 !%>CA
M*YIA%50L"S"!%$;!$-X #EIA6<0B%\P@$L8@M @B%_X@#_3 #T)+^/YA%M"@
M#L0@$/P'&<: #_: #FZH'?2 9"0!#$A4#R1A#>( #H2A$/9 #]A #NH@$/!0
M&,X #O9@#AB!^J2!#M@@#\: .< "' J!#O; 1Y,!$W#!#)K@" [I'SRA$.0@
M"(Q@#AKE']1!#*Y@!%Y@$0BB'R2!#?: #]9 $NQ #9I!$O! #_0 #SZ!#F9!
M<H!A":H@#]B "T  #F9A4,1!'@;!"%Q !<*@&LAAC>*!$JR !5S_X ],SBS6
MZ!^@S06VX O )AXF@05>P!%VX@_-X1O(P 5HH DD@?IH@0M(P :2P!4*14Y(
MP DLP0]D@,#VQ 9N8 V.8 AN<[8,!53&@ U$( CNM!)^( YBIQW6  14  IN
M00IB@!+0X2O. .6@(0E(@ 3Z@![.@0A(0 7<PQRF@0)NZ)?4,UV#"3W5M5U=
MB[O6 EW!HL9VPOABA5[KE5+E-2S@H<_$H<_J0<KL:1SR19?<8K_2H1]^:2;J
MU2#TH26NHOC X1[8(1[<01\LXBPB,QW*063LHA_X 1T:8K8&]1Q,HASNP0;A
M 1Y<8AW6P2=:(A[:(1_ZH1[JS29P0B<H_TH<?L(EU.$>I.P?H$(=W$$<R*$?
M3 (=Z*%B[T&-@D08Q$$?UL$D]"$>_"$C/F+;/@$!HF9?W?5K=85=P79LARG9
MU.(RP^(RS?9@U=9>R^+?T!5>+;%AZVYGTW9M238RZ59OXY5O@69OS>9NQ0)?
MT4)#!U=>O79>9\NCS$(7T,=VR#9R8T5L);=R=6=M"]=M][9MX:)M-9?&/#=T
M_TUQZW831==S^_9T57=U6;=U\>QU(?/5UL$,TJ=T+?=V^8)R<7=W:P5S-?9S
M3==PVZ)U$W=SB1=M21=?CS=T4W=YG?=Y51=V\<S?.K!2>?=ZY4(:ZH('L;=[
MO?=[P3=SBS=\R?^W++275LHW?=5W?<G6;]EW?<^7>]]W?NFW?HG.?>T7?.,W
M?_FW?_T7F?#W?WEW?P6X@ WX@'O7>A%X=PEX@1WX@2$X@O.W@26X@BWX@C$X
M<BDX@SFX@SWX@X5N@T%XA$FXA$U8=T3XA%5XA5FXA>,"&KXI8QC7A6FXAFV8
MAF'8K0CPAGFXAWW8@W-8AG]XB(FXB TXB'?8B)5XB9FX?)%XAILXBJ5XBL$6
MB<?7F$17>J^X>?>5 %]7;;DX@*EXC,FXBF.8<),IBV%WB\]6@8?JBY$W+>*X
MC.FXCM75BE_+C=,6+$X++\3X;VVLC2L5C>VXD TY ?'X77NB'')!%6K_X1ZD
M01=( 17L01R<H19>X1@(>7C=.!Y0 1588:F\01=J@13T^&WMR1ZD89,/N95=
M^<\2N;6,XAWPH *F0!V^(0@"  T: AMH0 4TF8WEV%&"@0?3H1=L8 +T[1^F
M(0I<P'IL%Y4-@ATZ(0=\\Y6Q.9L!K1O.6)B!J5*+H L(HAHN0#;_X0_*9X99
M&7$'-V^L )Q$, <V "A)XQ%2$''QURCJ811Z0 JT^9\!&K6X68>]67A>S1,.
MH)GL 0$6[S6R8%$!Q!8XP>38@1OBX1?.(1[HH1R,P36881.2H<^T 1C8H1N4
M:!F*@ :@ 2F^ AB(8 IR(.C^01/R8">B01JP_V%GLP$6\'FV3""P CJHA1IX
M!AHR\WB-EB$"9,8?.  %HF83!A ;=@ )YD &EL$?NB %GJ #ID (<  +)N 0
M8 $(Y  %]H <GL,)X@ $1* 93B$&5B"@",49LL >$@ (EH6FQ2H(+@$'Z, <
MUN@(%B!C;4P<=@#EACJQ%3M7BIJ5R_;5@J (U.<*3D! M<!_K!0!"&($<H$<
M'&$ >H$9J $..L :3D$80( 6_D$02B =GJ$);& >^,$'E@0+QA!H@N%J<N$"
M_@"1:CH75&#;0($"2,0HJ $5>EI2#GNQF;NY7:6Q"SIXDLT3!D 8T* ;DJ ,
ML $0\XP>'F$,%L $,__A ##;%&#@E]1A&B:A"%@@'?ZA" KA"'%@%]+J"B0G
M&)X*$#*@%'IA%(F "XIB"Y1 4M!XC0P;L9T[P14<+Z";T$AC&7+@#9Q%$W[@
M#4;!;)XA"<! &EK@PAOA ."K$FJ@*<8A$UB %5(!!JB/"?K%'72 OKO OG'[
MJ<B!"Q9 "S[A'VC@FO_A4WZ)7L4!',"!'(B\W@X<GA<\R97<+!I\T'KB""I@
M(**AM]R;((  -_XA!DY)%@Y@>_[!#F+ (H!A #+A'W8!!ZP\OLT!!]@N"D8(
M:+!A"4+5!BK !8>@!@KV""R0C<0"'#+&' #='+8(!% .L)?\T!$=+)H<T+[_
M(A-\H*]6(#YVH@H(X!$DH0&H !X@H0+8KA^X  +:Y1DFX Y\H0H>X!<DI@_@
M01@6P!+BH1-ZP!9BQR#0(1-48&1EAP!."1DR0 [,01I<0#0Z 0;6 1SZP ON
M(F.+O-[200><P&A_W 83?=H3?-'_["OL <5(HQ&@F32"P0FJ@!?6$!@B(0P$
MX1UN00S.8!'&@5!W8!.4X05J(1;R( ]"H1'.@ V.X5OU@#J[00_"H!2N@C1L
MX8G^016J( XLX5?:\ K: 1S\X L&Q:AW8AWV@ B4P!;<2LBGE]H]?K&MW<\&
M^<>C.5]-_N3U-;EU>"=VQ'9^G""R@AUDGAWT@1M0_P(?VJ$<Y$&-/K[G$SOD
MCYKDA9YD#39PD1QTN0N, 3GI"<(<W"<=K*$._N .[L ,]$ ,]L!(><%F:\4<
M!/5>X[9AR<*Q?;[LS1/HT]B-_=9WPQAXV:+=#6(9C&$8Z'X8A($8\-X8@('$
MO;YPA7SMW=@&R;YSC8+C_]QWMDAOI_>4S;[QR1'M 5CM)9_QQ9=SXV(<Y-<L
MR.$=H'@LQD'0 =]VPR$>@KSS!5EY]VW(ZXT@_#PRO?B/'3_VCP[RCRGT49_R
M-=9X8?]M4PW0E_WW%S7/-%;:[39Y]W7(FYZPVT)Z[[;D=Q;S%W_W97_Z!XWV
ML=CY;]_YTR(?PJ[Y._>MP/_!'00=^(E\'-[ASDR_Z#/VE$O7=]*!/(<7'#H0
M_@F%G8V6='?B'8@?Y:F__X?.^@'BG\"!! L:/(@PH<)_XAK^\W>'S)TW6L*$
MXL>P8$-Q CDFW.B0X+X_*ZY@^U>N5B]3K[!M7+B0W#B8_V3^,V<.9,9QYFY^
M>[2*EK^"X\B!JTE.X+B&[V::T\?)DKV8[_XU53H3HS-21XGV)$:)D3"&Y,@A
M2P0KZ=%TU::9 ^?QW#:,-.O:O8LWK]Z]?/OZ_0LXL.#!A L;/HPX<=]N&)=Z
M5$P8I+E6"H#,FF6H!(IO#$$Z]-?,L^AQI$F_Y#=EU+P=LJQ.,S&A%SK1M&O;
MO@W_LK1I<>3>QL-#QQ.O3E!$C7OW+IVY<N3>\6LW[[BY</SBE8MWS(F)>P[%
MQ4M'+ERX=^'(R7MG[GBZI>;2]=/Q)=QCAN# =:O2),>(7P)7Z1&D12G_C#./
M&P:(,2!#WE#! S?E0 9AA!).2&&%%EZ(888:4LC8@"%M>)=._\C0QD# _% "
M/09QU$8H&1&4VTPP_A/,#%V]V,D(/6ETT'SSO0CCAYW!*.,_1\ES%"805*-4
M'2O@(PY<Y*#S3SODV )(E?+\ P\YO(V3R@CZ#&040>/T<QQ=YKS34#K\%-+#
M$70-!,XXX<@123W$C!#%/^IPP,D_JM1 S3_Z@$(#& G^_P,,&SHTDPZ(DDY*
M::667HIIIIH2U*%CF_;XDCDJQ#%D+AHH\H\[L@"""D.==(!$+!R- DDF]W0F
MSDS^5(+)*AQ=\T8*B9#2$4=AS$#E/XEH DT[_]PS2"/^I"/-6/I80XP[49[B
M!BOA_!..,^\L4P@[&1&#R44<C4/--OLPY$PAZ,C44S8=2(+2@\#H8$9ZXD!#
MRJW6M&#&,AP)<XHK[M1$2 SX(!.,.._$(\\WLT"C+3WVE'/*, (A^4\CGVQB
M0CQ$_=./*UO^L\D)Z.3"0S/@R*-$)>(LW 6",W$$#0J@? ITT$(/37311A_6
MJ9!!ZR0JJ0ZQ4X(4XCP!PBT[A/_Q3R$G9!'+/Y;,80T9*1@SY#,[+*(+!&B8
M<XT:)\BQ"Z[_'%N/UVN(4D(J]1S!B!Y*M)-C/< @$8$V__S1@B0VB&%.%@(@
M44</59B\RA22]*!$.N[T(<@A)13RCQP .%.30)4PP$PXY>3*3Q(KO),/&(;
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M1R6\P(]])& 1[[!"EJPA@EJ@C 5?$(<C/- *?+3A -X@11-HL8TH", ;JU#
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M< 8:5 $&4 ,L0 &/\ _:0 46X")>B9P9JJ$;"C3*J2DBL@+WU2,$00Y6T M
M8H#9M03%(A!%@ )4XA"2 #H&D8;_H :0,)$C6@F;, [KD 0P, [E, .A!0XG
MT$XSL5@L *,; 0Y2X W-< PGIP:RT WU@ \R\%#J< L_8$@8RJ%?"J9A>B$>
M*H>A$D#M8 O', QPD K_ [(.B4 -\? $ ^ 'W& .R1 *:Y$)?$ (^F LTS,D
MXL $%34D;A (X) /F8 -L5 )Q"0/U. *P=, <_!?_' )AI -D6(+MO"5S] 5
ML- #_[ +#0"9_X $6C 3S^ $L* #!>H0H7  <O!?N:12_] +3_ B.,!+7BJF
MO>JKORH8+<F-#M$T_Y )$& $D) '$" -[Q &%.!J>I  <4 ,Q[ "(# @7! #
M@T $0_"G+"JHA.H0;J )]" $"F $9, !6O /N2 !=O .D)  7A *\4 &EW )
M)9 -_] $N/1)C-D)5O /@Q ",_0/:0"DXD %I, ,*."J'*$(.. !!M!.=/D/
M_U[ >QSA#F7%J\#JL1\+L@HAK%AEIJ3R#T.@ C,A F1@)$40":QG ,2B+"9@
M)$: 3(F@ M\:J(.:>N/:4ZPP 8G ,F(B#DB0!EQ2 (WP#_70 TQ""PZ$#L14
MD["9#B;P8Y<08 (1!S#P#XIP/-/0 Y&B$^7 #$-P :T"/^I  RJBL1PKGR$+
MMW'[JR-+7R4K$%TP5N"@ FH@$%7PLM(@ ;D@$)K08$;R"';@!$2@L]WQ BC0
MLQS1"8P0>@X@#<IR /1#!D?+#0U@"#?!!1-0!L< /[@"CO]P!H$@$)2@!#*2
M!D10#3"@"KO ""/ #-'Y&.^  ]\%/XL@!4.RL;OZMO]R*[S#FZ%T2Y'$&D#_
MT 578"3)&P1_&[@"L0A-8!5[\ 7 L HV(!!A *C=<03(\B)(P K_P H.H PH
MU !-E0::R[D.!@@=D (GL5ZF\0^I4 =)\0^:  %#<;)[, HH@ ,ZX ,SP +[
M^B(.L0:>%*!&,+X.\;MR0[P1+,'%ZW\YVI4A(0-F(!!?L 4"85]]*[G3, &W
M0"6/H+W0$ #O=P@M]P]K, 2D>:"\,!#^H 2I5PT&P!F>T  /Y8R,H@"R( ^L
M\%WX, (*%K4;01K_H M(A0V_0 \((+CEP .C,#/N$ ^^@ +VD!2"!0X/(A!>
M<$(S80Q_)4"P"\$3C,9IG)7_9/J2&W$/J=  *T *A98#P6 -!4 #RP + K $
M'I@"1% (ZA ' = +S^ !K=8$$O )_6 $/4 ,<I,/23 "C# (G^ "H84.H@,(
MV" %'] +WY #)K ,ZX "EB,*%3 (Q^ "7;,%W<L1:S !MY0$'2"TA' %T' &
M3I"&IP !&*$DQX -(^ &@C '?D"7G:#!&R$/MR  @N ]P:O&T2S-:LC&E_(2
MPM )F\ (E# (EP )JI *F# )V> +D& )E5L+;M .Q& )C. (Z1 *8@ +]@ )
MQL ,EB )R,0TC1 &<@ )*L4-GU )@S *@% )@> (F! )Q.(*8C /_3 )D  (
M@OL/_VZ HR^""X4@"-TL40(!"UP !O@[$.?0T;Y0 H8P#H#0!%YP> -A"3(\
M$,^0K(4P%A8\S3>-T_A7S99"G*69%SRI$5:I@ VX$?8 #<90#$E=#-ZP#<B@
M#=[0#=:P#5,]U=)0#,BP#=) !Y' #=! #<R0#-10#=N@#LS!#RF'$V\A$.8P
M+W>9TV\-U^VUTY6BDW5MUW[H$*9@!$/ UWW=UT+@UX'-UUCP!=['!4* !7S]
M!4,@!G+P!7A@!D80!5%0!5 0!48@!6<P%7'-V9T=7W--*7<MVJ*M&."P#Z,E
M#-&@VJHM#%+KUIX-V[%=/\8KV[5MV[?=7K2-V[O-V[U]/_^Z[=O!+=S#;2G
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M#[8P!.NF"4.B"E/ !4.@"[O !5SP!5R0!&-P>$J3#&70!;!X!GR0!(>=>OZ
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M?[+P (N)]IC@!9P:G6:1=7A  (M8K:EVDTCN\*"+B?)8A 4&OGPX!!#_(<.
M*G@U"I\8.D!C(E3>>.( #KIY4<E./(!!HD:7L3!>[UXI@Y&H2X6FB"(Z*&:B
M1:B9*!@WZE!7FE9XP4<<8V8!QIQ8TB!$HHFN"0.7&([[YQ8S8JFVU']@0<4;
M\> IA YD)D('&7^4V>8>9,)Q!19TB$+&E%W2F8@;4-JAIE9E:E&%'W ND8 /
M0/=AIM%G= E%'_V^27!%[IQ!()I_\$&" V__TB%% FFZX<4P6>F"<;G!!0"0
M<(X<1" 8_VA%SJ1QDG>LX1T3*0<ZQA..B:7#>O_@&*\F9HX)\JH=YOC51#9(
M#J. XS__J(0K_O$,3#0,%2=@G&Y*(H]/$ $='/M'.M8Q093\HV%8J0M)QE&/
M=-BF32?)P@[>HC=>A<=9VEDAI1I&D8G((U=&T9NBF&$ >%F*4B;8T*)(=9JC
M5 ,%*T34J!+V1O,,3&9PI&,=$1:9D\RM;A,9 P- \(I8K,(&"+"!%GD6@2XH
M(@?P*]H#%K"*:/PA 3=0DDGNH09%+.!HXJ%9 111#!%LX!,=$\ ;E $#%$W$
M:$A36E&<!C57>N +_T)\00>(T#5*R:,,#(#  NQ01%LD0A41>( UVI&%8?0@
M;L."V$0^P0 >+/ H?&/ TOXA"CWL0P4,2((\AN /<T#A %:P5SG)@P@?9,(.
M*JB+6:I1!G40X 9I.83GH+$%752B [I0Q@\*L#E-3$ :9$ !+::@A?44H@J9
MB(,#$ 0''&1B!U$8XE+(88<T-((#8R#1%#ZA"!X(XA]_Z, +=( #&A" #%E
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M,3B B_ZQBDW=(@$1" ,D_,&.'B0 "O;2LW?$,))A<,!]9MG&+&\Q@3?\(Q'
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M1106E$%026G''(APCW<H0P;8T <F)O ,+M5 H<E&#3TBH(>)M.$6[*  L'W
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M.*N:.0L'$VB +6@+2@D&PR&%(2  #Y"$?Z $, ":""@!**@'?TA N6DT2Q"
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M!G$@ @$0 UPH &9I@1^HD56P@$WI!2L$!@MH+C&X@$-1! $HL2]H@&2#! I
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MB"(( G&H 24-5)/(AE#I!?;\ABK  Q60@HE0R']@2(?,!0F(!EKH %/@!5>
MAG(H&"W@SW]8 P0HG6M(AGC8@06<"$TX %L@A6M@AG(XAP4 MI'J@7;P@W:(
M!@;H!%*X!6OH!RF Q9P82DD=EQW(@G^(ITNXAP8  U9@!6]@%280UC$X 5A@
M!65(!G)0AAC0(J,$-EXP@%90![Q[_]*V!)BUK%=\39APZ84#0  MT8Q_L ,'
MN &<^(<7*  7. DB<(![%(<YJ)=K@( ($$U98( ",,ERF +INBP/" 'N.H<1
M8 "0,:*)B(()^!N2X(180P<8D( PB)(KX"ZBD (&& &JF5D)H(*)6 <6V( V
M*%A]J()OF 4/4)?Y^(!9^(=#R#:G2;9\2 $/H- &/5+EF( 2P 9^\ (>.(Y&
M08<>. #=^H=,D,KU6(85*($ZM(<8P  ?G$\P2(9Y  $@Z =3: *3U(YWX %#
M8* %8+O<^(8G.(E^, $%H)\E> ##808NP(DW.0'N*H8/P!%:@(%_$(0,"#AY
M.(%JX <!$/_-0S@!=D4-,,  9 2&(BB&%SB"B?"'''"&?Y"!@+.+%."N?^@!
M>]B%"HA=1] U5%  +4D&"O@%L=6[?,@!4YB(7DA89O" 9ED2$7B'8C@!JM$%
M&8 B'L4!D(DX!F ?7G" 6$$$EXJ#$# <<7"#>-R.8^@ ']"2B="%4>"%":@7
M60  D]R##,@$>? !$P"'3L  1DB'?X.!>""''^ 1$Y !1[N /= '84B BWF$
M#-"$_\"#"P"#/*!%WKF!*$"A?FR40"B"N[P"!9V()E#2&L##4C$'%O@".&@3
M9B" DU."A-0[;9" 9JDX8'@%!]C,?Q &HS4*A32)1SB NIFW+5#_S7^(A5(P
M %K\AWG(AG4(UHEPA0, @Z51AQG8@Y-P!4I @7KX!V]PJ&=!#0>KEWC:A'-P
M@*B8B.)A FMJ@P^=B&F@AUE @2("@7(3ARF  DG(A6S)UX.Y5T >Y#LQB7=0
MA"T( 1_0 F9\AT60@13(@39P!DM @1DX 3>@!CL(@2MU SPH @/(A&YP 1\(
M@2[0AG'0@@5( #'(@@4 A%4=ABX@@ =8 F4PA!1(@1\@A @4AWWHA!80PDB0
MA"P8@$*8B%3( 0]X@C10+?%X-Q,( 1Z@!>IXATM8@!P@@#"@CGTH@P-X 3!@
M RK LDS@@26H S P@C08!V0@@ASP!7) _P6L088XX($'Z -NH 8@R($9P(,Z
M0($C )%[2 $*&+6)F(<LB(D88 53>  <8 4\FH84()I_& 8UX  L<(,]& +1
M ,L!> 8V ( 0B)KL((<BR($P" (!R(/P6 I@0 ,8@ : S88' )%0$  $N $5
MX-KI8AL_S.DS, ((\ 5UN((<Z(0@^  MX(88  (WV($(-8?<B(8>&%@=B 40
M-0 \V 8U$(-_F 4!B(,Z; 8$< -D6(/ +8<H* %O> 8KN 9S  0 *(6I$  G
MP(5];H1_4 $U\ 1U((,1J$,ZH!%L4 )4>(=:$(!O,(=! ,I;Z %@$Z,T4 *&
M&X0-N -DZ 4 ./\Y,3@ =5 % ^  .& "+*-7J<"##;@":D &16@#=% %#5"#
M<E"!(8@'>$ !!L@'OY//)9B *LB&;1@ CC*#"*!%2+X#%%",62@% %C!+(@
M+?!C/%  $<!J/,DRO1($1)@8L["$3;RT#3B.9] !QSH!.)A6DT $ .!!3JB
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M ,"!.PP! -C!/X"C("## <1!#;V).31)IM'B*0@ &]A#$%@ %AQ!%IP%/HS
M#<0"%LA /#@#"QAA.KS -20##!2#5XQ#)V2 %S"!$5B#"5"#*D3 )D @ 5 #
M)'Q #,R"*10 &%X#%Z "&)  ,2!!#B2>-B1!+]@"!-Q"*!@ %<A! U@#&@3"
M+?P '/P#/H  (7A"#LC YQ5')PC %=Q!">2 -KB:&;1"'P#!/+2! (0!"JS
M'$B &M1!" #!'SS! ?A!5!K! MS#+ZP "?\(7Q'( "W< R&HP2U$@1!8SA+
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M4(,#W,(_)$(-;(09E$"L5<P_1$,)*$ D( $ J$ 4$L(^_<,S*, -D$,F_VB
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M7"C\3*I(2&HEJ\0?[$ ]5$,!I,<E+,#3<<,?M,$@],!:Q($*O,D5=,$CZ8!
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M-CKDP"0([PM @16  "Q.!3B,P!ILQ!HL02T= !AZ+G(JID840:K^@@[44%C
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M1NQ(&D!V'!BA1L"#*B2 G/W#&<Q 63-#!&SO/T2!%7S# E#4O1N# MB[+2A
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M:& &-2C#/VYA@"F$ 00#T$1_=H&!,8 A BMX!";:T Q3M" <0K##,LQP!/H
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MT?^>U#%26&@,,@$--H$<W%$LQY)4V!$^)* 4M/(%)8\LXRT=L1 +W[(BF,7
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M,"MC&5P!&:YA/H*A&I !&;P!&J@F&;+.)AQA%N"2.=.!%.Z BNXT<-]R%/:
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M7!S&M3$=T<$?DIAR*P(0- !QBE,;%B! R"$&TD =,.$ P@ =&($"#*'_'+3
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M$RX@1_^P!$= #M^  (XP#OR0:?]0" F $Q2@%\*0 \!C!]'G#^2C#>]P!X.
M"QCP>C6W'6*U"%U0'O] !S@@#FTP :M #LT0!$X6#S90 '[##S*0 F'B"GYA
M!_@(!%)S!XRTE&;P 5,5&=8P@CVA#P6 "?^ #@3@FL:@ *K0#QP@!#F#"FR
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MUQ '#R (I% #3S0.3_ !7O &#$ %?S(QT: &$U "OH!ZXE /<N"P9/8/UY
M71D/;4 !,Q #<\)H\, &$M !GA /W" '$O]0 H\P#F[@ #CP!C_ !,@P!Q1P
M!MH0!!=@".D ! /P!B_@ %0P"RR0 "SR#Y7@  6  G] #OD@ @J0!EK  $U0
MGU?(')Q@ 4M@"WI0 RVC#3/@ # P JF &7O0 C(3"Q&P $N@ M?P#3"  \^P
M#0L0!/6P"3[ !]K(#"$0)D7&'+A0 HD #+-P US #^/@#0XP!.> "AK !N9@
M"0  !&6@ Z\V>08X ^_S#]Z0 Q P!W[P UCP#\M0 KP@##-0)'-!!@NS#C1
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M'N)@"'\0!Y10C#PA S*\9M^0!5+ !;3@#G@0!WZ0#6N !F& #66  X20"%
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M^$B"^&>=<[#AA\V#%&$ E"_<82:8>$I Y* W7@"'HWI.H.6@,GZ;PX;RNUD
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M  ZH!4[H@C$ AV&  C'X!T_ *FG@ F\3AC'( S48M$@8@&UHA2#8@S2!A"=
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M%  66;B"<B@&"S#$3K&(>+B" Q "0EB #H 5/P" >8,$ -B#?["%#3B"*P"
M8J"&"-@#3P" 4/B')N@!_TVX@0,H@5CT AY(!B(  $4 AQYX 7Z(!/5P! B0
M!B'P .)+Q5#3L\61D*,@G'$ !V7ZS0?RM,8Q. QXA/F(!W[(@Q'@A]#K '9
MAA\HH$6X :+2@H,(@DCXAW=0@8*QAQ$8!F%P@&K4AP0 A'^P@4;MAQ)HL[O
MAD4XB'X@ PJHGT^]K U 37_H $BX@IY;"$3P@ FPU6R)B<E+!0'@A&%( ,#\
M!T"H@<GY!V80 )K2A$M9 9WRAP(HA5U8@&8XB#X8JG_0N*U9A+GDAQ+POTV
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M!66H P(F"B28@CPQ!![H!W. !@, '5P0@'X0A@AH@ES8!23 CX/VQ 'XI']
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M-^@'0>1 &&@AX9$EN/B#9X@EUWY2/M1 #M# %2# $=!,)RA %VS!%]S#$BB
MM#Q"!7@"/&! '_P#&D! .\R! I!,9&5$-AB BK93/G" ,.Z =I03'%;FM,1
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M>$$*L*H<0$ F^ ,[< $A9 ,,= $SK  /6/\!9[@+-Q"!!T"!$?  !^!#*/
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M2 ##-0,"T,$XY($-K$,^? ,'?&@5D, _\ ,")/]X.DA!SE !^U%#!]!,-BQ
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MDBG4>>2&C$ ![1_1HOGGA<[^08<?2V!0O$0/'6 EHR10K$.M?Q*1@+1_KA$
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ME6( @I"&!HD  EPD P\HP$8Z]L"&V6GB XNHQ0.(D Q/ " 2N0"" E2QEHR
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MZ"$#3.H?1( $<9+U#VDX !,9\80-H"..)T@ *1EQPAK^T8D-G"P?/,B'*31
M5[TH8@XAV,DM<) 1=+!S1^O@P:LR\HT)F"(CC+!!>!3R# GT@DAO<-$_=M"+
M9&! 7?_(_\/)IE2'!&3C5%';0R.\  (@U4('?%5 Y?XA!VD,(P>D604*S)'
M@,6&$/9C Q+^@803+/$?+9!#.F8P*0V2D,0D_J"0B%1B%1=)(:=X0RY8T0I@
MQ&84;6!527"AA[S\HQ5_H,-3_G&.,)3!#:\9HD*$,!1F^$$$0U.(.B31!U#T
M(@W/4(4?[*"-6;0A#U%C"3ADT8=/!&,.O/A&'WYXC9(HQ!YW\$(2;%$26>3
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M'-+!%?DI/GXQ/O$3/^M3"\?T3E?,/PT400%5'/9A'X B(<TP4 $520^T%9>
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M#N^ !P?  _"2@ <(FTQ2@&@4F]FA%.D0C5[F(O* ! /  3G@"NY !%P #MB
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MCO_0!*UR#1=@!\'E";2B#^UP)$;Y#\'@ +]0)4J 6.E0 SK7#".@#NX0!O^
M#2*0: 98FZFK%+.INMFA'6)&==[P"Q?##ZI "N'0#+S "SGJ"W4 %^^@#*#
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M:V" )A !%( '1 @ 4( $ '"58"  %("#(I  ,G&% _B"GLB1<A@!ZJN+3.@
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M@#G8D7#P(G"XA@6X #EY  BPFS)X@$;_0($/P 5V* $'P ,(4,=5< !"( ,
MH*D\ ( J,(0%>,AVL($(L($OD $*V 9]D( MH(>-C(=A6@@FH,.ZL(8'X (V
M0  8N(=7R  BV,A*6 !BF(IHD((?: 5]> 8.B --0"]Q>(<V (-J6($O<#R#
MX(,?\(=U6 =VH(&ZTP4NH(0Z@ !68)2^^X=S: (_4)X;&(=G"() @(08D 99
MD  @6 ($@+V/$(40^+@%R"536((>6(/JF8I[@ $[* 0&F+"Z"#T?RP$=\P;A
M\8(MZ(#S,(8G\(0P.(%<P!O9TPO:DPS;TXMRT $L"(1:. 4,< 0R>(Z/0(8Q
M:((&&(-_Z 4!_[@X,3B!?.DW0/"#(X !ANH")B@-%4"L7E" D:H+6T#/@S ^
MQ?D'(C@$W6F!2"B''.B#1WB$4O 9AAB?A2@"#D !1(B'&L@!&0B%@]@'!$B"
M?Y"$#,@E76" OCN'?]@$ R""8="'9!" 'MN##1# 3!  '"@\"6@P-L@ <AL?
MU=#(&<B#Z$ '!, #<RB##I %:IB5?]"&14B"" "D3@@ *,@KB^"&!BC"0@@
M(!# MW( +5".9,Q$<% !,X@'%, "+4"")W@&0:@!GFB&_T,/)J@_>9B!P6F&
M [ -@Y ''="$@\@'< @&"!BI?X &"[ &4E  2IH$#O@?*:"!0:0:=?\@ (=A
M@B$PQ!'  W?P@4?Y!VK8R"[(1!]S@&N0AP78J6\8 %!(AQ&0(T @@'*I"S-E
MA&2T %18A^[[AS80@9JX 385AP*@OG]@ B?K"V$X@%SZ!R_ E+FC!7IX@"V(
M B?( :<;B2( @H.0@?6(!0E0#C"H/W8@A7D0A12P#6^8@&SP&UQ@!C_P@,^!
M K0ROSWXAR^ U'28 3+QA13["2$@ 1F9!@/X''K@ :>*A@C@!7GP 2VHA#-(
M %?)B)4H!O#JF'\@A!TP 2:0!G.H 2)H,P- +%KX 'J#1PH% @BP@2.PA66
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M^ ,O^(=#L !(< ,(H(%\Z 4-* $K4 )ZR%@;( 2C3P,>2=,>&#Q[<(#*V08
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M5:\2XWM$(8+"%?_4K&+3Z]_B6NH5(7 "*@#<WOG:]:^9C*Z##DR.0JS@ 3O
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M.J@$0O*C0-(0@B1#&RA("3" T1D(*T3  Q0#,'W82TQ##7B%(@  $13(FRS
M >#"2Y#"!'!-: S!!G@)Q>&$)6  (WI''10 /L2'/"Q!#?!2Y "':@W;71B
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M  P#/93!#-#($^'#''B "51"'VA )C"#"A3 '!R!)A1"$#A#*!R 'KS#)@
MU)D#"7A")E" T<E#$^@L'0P Z$ "%P"#+SB -[Q#$'!!-H"! 2R+A=R#$/
M*[0#-E"!*&Q#"S2!:PS1,=B $TA#.FA#"CR!)#P &MV#"R"",!1!$#S'#_7#
M#$S!-"%$)KP ,AR" W!",!"! -!!(-3 %-0!((0 )+!#$CA $7R!""SD$-0
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M ^P0$JD!&[P$-"Q O.""#OR#)S  ( @"&2Q "?M$/XQ .UO*/B1 O/P#&"0
M.J@# K"")T9 ::R!"_Q#,G@ [<###"C!/XQ!;C!"#XS#.?  '%P*!TQ5(RQ
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M2,$&B,(^L, 'Y$8JYP,YD,$%9$,P1,$4"$,_1,$&4(XK" !/%,HSX( I[$(
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MYR2><,8\1H"/>-@ #O_HA81@" ,O\$$9.5@"*_;7 S?\PQ81,%@,YG 204Q
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MX0-M\,(3ZB&*#-!A&E*8@"SN\04QF,,<-,!=/,  @$J,PQQKR, AGO&,20B
M#$T"Q E:QBIQD,,, &"M-J8A@UB 0PH'8 8YR#$,*(P&#1AH!'.N4010D ,.
M;WCACY-A@4H@XPHE. 903P(.7GP@$N1 ARH(,(.SJ&( 2?B&)Z#0CF]$0!C.
MR$ BB($&$@1#,'@  /9,((/_U(P" +(H1A\: "N._0,:#)@"+38!A&7L)0AB
M.$D<6G<%*,7C!P7"!@'.P@L>J.H++P &/MZ @44T PQ_2(8"9 N/$) A'!=3
M!P,\(1$4R $<"*AF(5+ CACZZQ]*L!<^<H"G9_@@?N68@<#<L 1^#,,R:=B
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M ]9@''P! ;A@'^9!"0J  $" .2+_80&@8 L6H+1*KAPF 0*\8!\* 0* P!@
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M'[P!!0SI2MMA!HR"&23!%70@&8A _?2"LE;%"]9'QN]"%IZIP8&CKZM2%@Y
M)OYA$"H@_\CR+G3! QP;I1&,F=!RR=W$&4R:$F3N;M/<49VG'5K9%[[)"CIA
M=)^2'=+E.Q(F+!77Q!>8HOO\50V-*@\UA#68:!2@)[X<5+_R'!ZAOA08;#UU
M?=NAX,SA"M;[@LU2'LP@'VXJ;VRC!"Z@#4:M9\.!"0  3+*8'ZJ  FRA%P
M=]9@"#0/4;<[NV>=UB_U'Z@A ;I!HFK<&Y;@),SA!5R /M. ;UQAM?1A!3I
M!&[!'";!"9X@#9@#&*0 $!A@\OX!%/K@"2Q]@I;_@ G&X"Q.I BV@ =*R!M>
M3A'BZ22XX O ]E2Y8 IP@08P 1W2X1/<@*3&P1 F09+PE![2Z26\0 R(X1W4
M 'MX9M_>E#"R84^<(1!4X1?(X+_,X1O6($%<H '>0&!>< T803\( 0\L 0?B
MXF*(00#>]"2B0 8L0QO H!,T 1W&81H*@1X(P0YZ=!.88,?H  \:(B^T0(G?
M0^.,0ABB !-601[J0!+U@@HL_52& !G P1A$H1X$(1)4Q1VZ 1;^@1820 U4
M(7:4@0T,UB$.80ZD@ 7D^Y0RX0 6RQH^0+;^P1G<8 ^^*!U<(17JX0Q>H4SL
M!$^"H14*\>K2 0PD8!, _^\9=@'P#N\4D"$>^$%5RJ$56B%\LN$%5$ 5PF$2
M>$ ?JH'73\45 %1U@$$>IL&41FD;LL$<K $>2#8<ZH$N*HT<7($''&$ZDJ 2
MR.$4]OO/E0@<^F$(DD ?! ,;0$%93_44@($<S*$<S$%Y^<%X^>3U9X0=W!EL
M]2%>X8&1+:,>JO]4U($^3T(P'",>]*'&S-8=W#G858-_3Z(=@H$!#ITJS6$Z
M9L2;WV,<Y"$<@%0Q3! @_@D<*%"<0',%Q2E<^"^,'X%4J! T2+"B07A! +%S
M\F2;P&@C4C3[MY!BQ9,*!R(Q<.JD2T"'_IVZ(_ +)I(I7>K<R;.GSY\)&0(=
M2O^TZ,24E!+T(XGNE[A\T%(*HJ#LGSXE^03"0A H'2X>KN1%J["+78-7_X -
M ;: #<DEHOZ0D/>/F1-H_F*\^(<K135J,9B(NT=*W+Y]*2L].(?3HD O#^Z(
M,:#F'R  > 0.H0-.Z$![(YB1=%DR93$!MAIG.R(NC  7E>PHT$;OS8!?[?J(
M2 5/'8M2T&9(^8=(B:M & #A+/F/V((WH5!)X5%U60$_UD)\<H=% A%*7$K<
M^[<)R#\K34Z5.XF.QYK&Z&:$&?UOW$27$0MJ_J:."(,Z0T"0ATPRR.".(@@(
MD0D_@KQ1B@N3B"./$&UHXH,+[BS'4",';'/.-U7,T,W_/],LP,@;' #CS D\
MA%%% ;+\8XL"S? S0Q[SE"8./)\@H 8J_Q2"A2<B<+%4-S?, D<-5;2R3Q><
MC'&#/X*$< ,8_53"P1U,2*#+/_'$ <<?!'3S30U7] % +1J*P\@&6KC3R0QV
M_%,/&LI,LP,5]*21 PN5B',$&7LP<(4]] W4#QT$.$,(!SOD(8PN0F1A0B8N
MF:/'$4] X8X8,NS#CQ9 H/-/*%74L4(H_Y C"1Q9M+'>/5[XD40O_ZACQQPT
M4/+/(WWH 8,T_V#S1QA,N/%/,5IDH4D.K$0CA1PT3-/F/^E\$@2I_:!3!Q.-
M<-$"D/_X8T0<-$1 "TK_7%-$_Q]!:/./.V!<406NQ@0!1 RPO"-+$=G\(X\@
M:+2Q2BNA""(&*"]4 <\__(#1!1LQMKF(!TI$@L\23ISR@AKZ")2+)7[\HJ%
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M'(IX #LT(P;K->>5 MG'"B#@N'+L(0LXF(\Q"'!.5CB@*HF(0 )2%U2!B,(
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MMU4YQ V,<(.]/1FR"I"N<KUN.Y=LH0AX_<<[O,"82!! '=<UB.&WV]U_0*(
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M# +P,G]  P+S#[^0 P^@5O" !P, !\9)+,,P I]P!I8H:BNP9VT 5OS0G1U
M!)=G$/)P N#Y#T8@$5.X!_Q0 +X";$!57,S1!Q,PE +1"ZIP"1+@![5 C9J
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M'+ %_1 ( ( *YM ##J +[]A7R:  6N +_N "-" -H] "4T4%_N0'B) +;]<
M"< $*D *_S $/^ )S, &$9 /YE $,$ .XTH 1@ "MA /+, "U*@3<D6#T.
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M\ -XU0Z&8 B4X!%(91#H< A'L 23P%3G4 B%H OSL B5< S-< F(D#79T E
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M!(XC](%(J/C%/\ Q!=VYR34_VD4M_K$/$T@B;E@;S<9$.$(2M@LDRBA"#]I
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M'T; 03P2L@\$3((<+_#_02IP@8,>6&(+QC#")7@<@WA00@KYF(8 .E&-$?Q
M$8K(014PX<EJ_(,/=CA'+P9 "C$(0 2.:$,"[&$/)WB!&R/^!S]8\(=A@,$
MK_B'#*;P#"94H; CP,1&V\ &;,"! =U(APWL4(TMH$!X$$&'$&8Q 4<DQ Z_
MD$0/]-P' @3##DUXAR(0P ,AR* ?;D!#-T30 GE (P=:$,0".D&2<72A $YH
M0@HB6)/@?"$2_U###1R"AQ"0[J9& <8,>$H2:_# "T,PP!+:H8H"F, [I<C
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M0TB U1(%'!B'<#BUXX (.1 ">B*!,$B(?.@ 3@H)9?@!/6L&J8&R R &0UB
M(Z@"(XB! P0R"KBN@<B')P" -7B'4% !G<&$)/B'99 $>)B&&O"+;W@ Z_@'
M6:@%=9B$'G@'>4@ 3$B(%A 5)&BPA&""(_B';*@L(JF'(KB'<T"$"] @TK"
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M:(*UPK_O!,\5&0EF& '$ (<B@*P;&, "Y(78F8&72P@W&/^ %)BG,)# ?Z#
M?VB',3"#-O"!:?B'2U@ [X@%%3A+!R D6%N#%G '>"@ ,!0)$IBND."%'_"N
M9GB2?P"%$+@'+3"!=$ '?F")C&@$#?"$ 4D$#4"%W4S"?=2N@^J".SB!(>&%
M&+B2?R"'3]"")X"!<C"')H $\%J!>1*]A%"%"9@'2LA,B" $$)"$)0@"#G!$
MGU& 3<2#+4B)&ZB3T%-)?1 I5[C)>\@']IJ#+$B(*  $O% !57 %"3B%<^B'
MM6F''^@T8YB!9DF#-""2+""!A$@&!1"5=+"$)]@")] .'7@<1SB 1YB%5D &
M>1"",O2&$J <D$ '*@"'70B 70#_A#05 19@+UKH@B\0@=5* @CE@QGP&X>H
MAA^X&EP@ ;&PAP;PKT#"@*6L"7*H LO[AS(0N(1@ R.HJ8,;D'C<"63X@;TI
M@B;XAW5(@$#XAR.@.H)X!V5 A%3;C%?HTW_ A"BPJ2D=AA$@GX)(AU]@!"!@
M :IA B@Q!QAHSWDH3V9(@=7B0P/PAV= @2N)!0[8$A5PQ'=(@6U@GB200#)X
MA.C8 4+*!0G 'W0XAE P PZXAC1$'2[P 241A'" @2\PS!8P T;8!#!(A5,@
M "N< O89RW^ !1R@FF>8 =&XA1KX!T>(@4K !$F  X^I2P^@A%#PV3Z8 7:0
M!Q[PH-@Q_P -*LQ&6 #OTH<3*(91X($AJ (@8)99$(#[D)YI< 1\<(04.(7-
M>X&$B(,VX(<$D"'O2QB(, <=*",J (*$$((T,(<70--)F((B*,>!&(<J6,-[
M:( P, <46-%_X (32(@5( -PN $C  1(F((J^(<T*+Z'"<_*M5RB^ =F*($C
MB0<=@#,YHR<4Z+33VJA_F(5TZ ;"JX<S2(&UX8*W]8*PS<1\$E FT868C <5
M.%'IB80%X =RD $K< @<@!(*-4L,A1)>P,,VF '-,X4A&PEZ0($KT!F00(0/
M$)5>>)M_@ 1#984%\)XH(!=>Z &S00<FL()WT 844*1+5%-4]/^"'=B(<3 "
M+B@#_H&(=&@":%@'?@@'0#@ ^+R$&LB#*.B^?[B!V_D'.@B!&Y6&5D   $R(
M(<F#"0V"S $'&0@%=2@ QCL'7TB''OC:9QB!+<G3+BF#&CB98%  74B')Z""
M<O $A^G<._*$"X &A["&)S#<,T$!XX"(>J "=N '&L"!+6@'<B !$D@'<E@#
M'(B&8TA61MS#/2  "/N'9,@&:*#4?Z %&Q"+>W@ <DE#"7"%U#$)-S"O=TF!
M<E0"Q,&N=_P';MBI8RV!Z.,"COT'29"!49A<B+ &$H"$?@"!@Q6%%HT$)Q '
M%#!3G[E3Z5$%'"@%4VA1)@ M=T!4P9O_@7DX!@[HF61 @&5(ABZV!0?(ITB(
M 6N(!!1HC9P0!0L A"'PKG^Q@8-=6/Q1!RTH U-  >_)AF@$!0&@!"1PAVB(
M@.E"AQF8PX2H@Q,0'$NN$=-=*/=<GEG  7'@@B) H'^@O&QP"$QX@'KP/P@%
M!Q5(I\(L&G_L!Q0PAD4 @72(!\%I!!NTF$>0 C8(@3/>!%?\AS_P@W*H8T^K
M+(C Y,>Q*29\AQO0 \^\A': A^K-B'?X@<FUJ2=C 5%(B"YPF'*^@WC@ #Q8
MAX=.""V8 S:YW).VW(SHA@7(A?= QHI&!C,0@#M0AVTX  #]!RA C51H@';
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MAU> AE@X .AH"$Q( .]H 7JYA+?M9SHHAP8X6&Y&'XW Y+;5G70H@3UPAQ1
M@[_RQY$@!Q"HH#MK@W]0 ?/*SW(V@W3@ !5,B%5(!S6@ ^E!Z6W_SHP@X3+H
M B'PF'\XA1D @51@ D;P!M;[@V:AA"D0@B,0OW1 @AFXA"P@ FH A1)@@4WP
M@BF8A3NH@D00I5/]!S 8@4% /X<@!A!P@FAP!S-8 388@A</"6[8(6N( PA
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MZ %9D8<RH  <((%>*#L+T 5\V($.T+B,H <32 --8(%.>P0  ,.,2 <[T/\
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M)"ND\ F01/@P1Q!SS'/'";4<!P\((*"RAQ. /%.&$VS\<XT-!2CQ#6/C=$*
M"WM@$TX?)XBP1C'U>-%$&$%8\X\B)Y1@B#B3$+!#'S+040XH/B2 0S'&,$'
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M(!F#'^2!&DP#.RC"*,S"%QS"K'F#&[0!,@S$.GQ"'<!!/2P#">3 $91;7J$
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M"2A*%A" %>A"Q9P0(EB!(BR +\"##,! '@! )B"#%>#""RS!D$@!%01""D"
M-_"#%R0 ,&#" C0!'H3?0\Q" H0)/+P! @!!&.0##'C!&2" #.S1*G"!'P2L
M58S#*X!D.YR!*X@#&7B "T#>0&R##>3 .IY! NQ9.4@!%]3!#IQ!.( !#$#"
M(,  <O+!%53!"%2?(F1.,&0!#S0<&T! ![3 &\C JDR!$P!4#IF!#D! CY;F
M)(# %L2!+/0"/.#!#O]X0Q[DP4!DPAW,3B E QU@CSI\@Q"$VR641RT,@2X0
M!#+H01H80CM<0AF< 3]$@A'T0SSX@0\PP"2XP5Y-0L,UW@E(%('NKZ]5R2 L
M %S80P,D BWXP!<$ 12P@#"8@@&@SC^0@@+P@3,0G@S@'^EQ@";D@P<(4"@X
M .H8P0.8PCMP@\]T0HV> P=\03&40SKL@@08PCB$WB<00&SH@@)$(",\ #J\
M0PX$)S$HP#-^@0P,Q!5D 4V9 !0,1 W0P5$<P%Z%P0RD0S/T03/\P@G(W"U,
M #0TWB4(PC[  0D,"1%T@GEPBO%5A0JPP!NHP0*HP3<LP!.\P10X #=H @__
MS(*MI9$*_(&/0L!>J48!0!I%@( 1^YX-#,0-_$D+[, :=T#OG="LIA$<^$ :
MJ$$,Q(#OW<! R$ 9_ ,9X.@_J,(,D,,KS( M^$(?"( \9(,%."0\5$DO& !I
M,((&-%P9& L0^-L_U(#H_ ,5;,$_R ,/3*(*D0!OID,AG$!?<L$#S$,/R,$_
M8(,?B< 6_D,;I  ^3,$5B((B>  2[ (3#,0L\.8C4&A\-$(!C(@,Z"\G=,!G
M4,00A//H.$ E-4('P(,U)$ BV,(; $ R=(5:3EPQ>,##F$$*&$L3 "DD($ T
M\*H*\- W0 "6\H,+^)L[)$ A()4TX$!W8(' :(($_]0"-$@#"<B"/PP" 'C#
M-_P 7 2" 53#.$Q" Q@++R.5')S YOF# #Q,/?2 J ;# < "//A (_1#(E0
M:1!7/;"  ,B<..0"+HB")_3#,CQ #O2'#"3 ,("#$W1 /JP! %R". 3"!6"!
M"(R ZFB -_@"  Q@+ P $>1!$FP :2+" 30!*$B"!:#'$HQ 85($(H#!+@S
M%HK#)P0 %/!#$E# 'I2#"$# $4C0/VBN-^! "01.!_C")P  -+0" ! !)AQ
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M6,$_Z((%5-\B5( F_(,5-(#3\8$"O, U;,/ZW<$_K $&_UCX)0B "@0#'#C
MHHD"!F@@/G3 %MH"$ISD/WA"!TB#&TC %J9#"W@ H.E "HB:"13 $53#/31"
M!H3"*O@$/.2 %MQ##  I(D0 "D""#K2Q&5C (/P#)U1 *GR# 93;)#  "O0"
M$X3 ,/Q#%ES )'9%E?A!#:Q2JP$WW/>7<'. ]+0#!]1"*DS _2H"-,0"=$_$
MI47#$3P -]R G W$"S@"=_NW6JI+^%V##U#!*9W0&<R /.1#/.B#&6! *[Q)
M,31!":QO#HA:)B@ EL[P?1, X_3ZJM>!&UAPE<3#%12"("S"0'#" 2Q&)XR
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MT">4"=Y8)QP^BG'L%P>R<4^!5_XA0X:!F-AO#0H\^:>8)/#9*A0*JAE(#QK
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MIF!3QD$1FD /0*!7UJ %\, $1"#_#7; $AX #.CA!OA@"^J '&8!!")!%FJ
M!M9!%!J@!HY NR2"'OQ@"KPH$^P@#D8@.&2"'?J #5P $(P!!(X AU8@"LPA
M'W!@$U@@!,)@'%SA"IR (LZA#23A"+Q@4Q!!"+)@"^9!$!@ !\H 1Q#$"B"
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M _#@'AK0$6Y@(,Y@!L+A'E* _G;"TE:!!2BH ZZ@"JS@!49!"_A6' AA2Z)
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MOWXCM/W[!X7,OT<V_@63$.9@,4]<3!S\5\A=%$@'Q8G[9^]$L'^X,+@Z^$C
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M/\?8L 0=<>SWD2%-C?,":N(4 \4)LB"C1 F.S+*"#M^<LL$/(.!P!38/)J)
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M!W. !R)P@=&5!26P)TR9"2%P!ZMC /'8#UX0!UB@!?_ #4( !9A0 '4 "CO
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M!WZP#ID  'E #L&0 J-0#NE0"RD0#/*0##O "O#  BM@#K@P!?9P#0! ",R
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M\P^S,-B>X  TF :K2P6$?A&^8 %=O@-*33_OH )._QT$,&'MVWD*+B (8?
M_* ,6[UJ6O#5_X ,W+<0AWX#F\ :0>41XR %!U"LA<@'-: D1H#7__ 'IYH/
M9! $@C #B?8(AWX0S3 $E] )C"L3+(,"WO /-T"F!]$&+E .7Z QR!0&77 0
M*4T K>!5RM ##( '[J#1=O</=*#4K6V^K_T1[?"0__ ,(Q!^ND "&_CRZ4P.
M +1)/:#.%U-#3Y &Z: -Q7 /VR !;'(1_L #BF-E3.#N*1\#FI0$0%"6,3"A
MZQ %#D &8"1>UN !HM &ZO $5J (,"$7L* %;7  %Q@$Q/X/9' >C_8&:/
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M P<Z8.,ZE("!(U0!#>0H!040D0X:- $;;A!"-3: !%K4@ 2GD 8#"H$/.=P
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M&@"./QB ;N"%F?F',=B ++ &<T!*)6U3-WU3.(W3Q-2*)FVE7#  M_@'9C"
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M @3<+#,"-__ \D,\W>0@-AVKM0:-N+$5F-$M#Q!BR3_8'*"U0M7, PPR4QC
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M%9P!#B<401/O,) XR-$%%'C"#7L8QRM@< )6**,&,OB50BQ!@2 ,(5[N^,(
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M0H;@PJ/57SC4@@,TP@6:PRDP0%D$ PKDB1:*BZA](",(@"Q80Q+D@-W97SM
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M$Y3!"* !-"B!'%@!KO1"#63!)BA!"WR#,!0! J0!,K #$IP!$]A/IXF! KQ
M;M!#$9"!"=R LF7$(/P &L!! I0 ,PP#%X  /Z "":2!/(S!"HB!"DSK(@C!
M&;2 3;Q"#0S"$O3 U-B#$=2!&FA!MDS"'WP!%:R'(TA!'IB ML[&.QS*'42!
M.KC#)VP!*7A!#F!G@<2#&[31$:S#3PT!&A" $[%"$&R!#RQ2,+Q!&(P#' @
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M/23"&^!#&6#)201#"Q!%#8A#-(0 "!C"$?1 .*A# F1!,.Q &/R#"F^5.:A
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M*LP$!=D$.YQ ,97>GP1*) 2!1O#!$Q!" F G+*2  D0".# !#[W#1VY'*(#
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M@,82'O &=#@'%3D@@B2Z8()EG",(/?C"%VS B7I@@0=%Z $..J$*$]2 :6Y
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MR >6>](.9VRQ)_H(PCQV\HI2B#(>IJ"%-5@S#A^'8LV5[8DYKN$(6I";(*"
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M_^@!#:8@"6+I,BAA"2[X'X:A RX!$(S@%4CB&OJ@#N@ 07#%(U3@:GMB%Y;
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MX1T4H0)*P1T,003N 1S< (C_X, +4(,98$ >GH$%QB$:$" (>($.>, =^F$
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M).!@2(M: .CA$4* 1;1@08B%5&%@B37B/#FE)S!A->*!&1;A"WR &_I!!&#
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M)AT[-LS=_S]+'YHD^Z?O!S*F_]HA.(@0Q)%_6N @;+(H\+]$&6@))=.@6!-
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M3>@,QC")X  /KK9['D:$" $/5W@4YJ <FF86NV=MJCB,2KF43#DV1V$/1
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M.?B@"59PFZ;T!@@ !!D9B4TYG_19GVBX'@Y " A1!S/ ;EOA!A38:?EA#$D
M?KM'!Z% @9(V?@%Z'Z@  [A&?].W?1.J@=;X#ZD  O?1)<.'!XX4BQ4*@;PW
M#C5 $D?Q#20@#.ZP"AN@9;/@ 7/C"S-@;4=A"SB $)003Z: ">X@"A%0H#T1
M"AS  ]A!$Z)0 3]RHL34@N!P_PS(Y YC@$S')VG-, .)*7\H@0\I$$7D@ ._
M>7Y0$Z((L0DB@HCM%S6'  !4L#G9=@48H)]3*A_RQPY,L*1B0P]$X :B  %
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M!-=P W!@#D^@ %/  B5@!1T0!)/#"0DP"U8@ N1P" Q@!9^0!@?0"M, !34
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M#E[P(!CEH ,;_I$*/@3#&&,0$E)H08%A5&8<=A# *NPQCTU0(27F:$$<>)*
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M0?[X0DPTS=3A 3.D.'!,3/_$PT(6.=E0R3\\G%%0$XO<))>,NIQ7 C3_')*
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MOPM?0 N%S9[^])[5+.I1D[K4N +U4_ ,9TD7)!>V>$2@[LQJX*H:U6Y>-$]
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M0NPH-/Q A41LQ1A[X((HQA&K5SS!$AW6R2X"D8E U*(@J@B$(2H:Z'Q @1H
MQ'M!XF&*-US8T^9H11^,C PQ' ;LVM4T4B*%CE(X(J:JI[K"ESYU>X@B&A[7
M^%J(H2J9F,,;SCYZ0;C1H3:9 S\9K[!5[$[V^=-_Y9%JAQ8 \"]G,$ )KXH%
M#-"#H<47N=D:(D#(_[8] S(8R,-)'+]Y6C10P0J,G\E5($2, P9BX#\$PPH0
M@77U Q*P0$$@ B:$R37(!"XX@1Z!6@:V( :V0R!8@&]$!#FTP0H400>0 ##\
M S]XP1E$@Q(\@H% @PJ8@C=4P1K\0S\L !'HP >0WC@P @Z\P 9 @8]$2C"
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M@UH7/1! -O2/A_KK I1@I)B#'>2 %I@%!HH#/6 "#02C3+B#-^! *6Q/(QQ
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M 33D8:180PXH 2CL@P:- (6P@@Y "##<@AXT &,'=.Q*A#"0T#_H@3%<Y!X
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M,;1Z6JNR/G3!!12#+0A !><$+BB IHZ##)1!/)3 -/R#)"0 ?A=$,9 P*S@
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MO)[?S/Z@1DJ<*P]AY'M)ZO"&EKX;#?4D;Q^B4\@Z\NGMZFX ";  _Z3!]
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MU*++33)A!^++,L!A"\9*NK!,W@9-O]B$#+Y#T3:-TS).3N1-O9[ =&!C%$C
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M'^A! ,A@&58@#.!!"@[ !+R@";A  :" "1 !#7Z@&?) !>(!$WR  P8A$P0
M%;CA"G9@'L@A#.P 'M3@3=_#&49@$-@A'IP "NS!$R!@%IA"'-:@ WB $>(
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M0C1A#\9A'7: #<QA&1Y@&N2!%$: R=3 #R;"!L+@'UBA%Q5"#%C 0)C )#C
M0FGA!S[7 RRI!5*A2(_4=<V(#4( -6PA$<)!!![A'C(! !P!%W# +N*@@6!
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M3( ':,!IXP >_P$$:A@=<N!_(H$\9V$#D"$2(/_@MT* )E8! HAT=%@!#4Z
M!U3R'VX@M<6L0)X@<V=A ,):&\;Z@C/8\,Q!!A;P%=\ZU56]N (*#T; ")ZA
M'& @!<88(^;A"K[@'O: (_SA2/$['." !9(!&7Z 5X+@?QR[H2,;-D+A!3Y@
M#98DL\?*$3A )>M@!$);!1K:TCI@'3KA"R;B"U8[G.V" XYP(F8U#E1@N*[@
MC;WA"AYA&$I 58%!"RH@#=QA"YR02-[!,HJA".S@&()@KJ"!W$5!!18Y&YH
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M=*+D:GH@T(*U:S6]:G$D%R^TWK!N>XOH)<TZM/8Q;I-TFQ=9+[>W@#92.<)
MB&(OU]7,?;6T#XWM;&M[V]P^-JF_#>Y&TR01;EB#2L.-;G O.]WL;K>)X,&/
MYKB[W<G.RS;KC6]?SQO?]Z[WO/_M:'[_N_L?UJ@/P%O=[80K?.$,'^W!'\YH
M:D,<X.N>N,49'"1[7_S2 E=TQS>>F8^#W-TB1W=Q-][PE*M\Y2QG4K-G.^J1
MRQS7#X_YRP]N<^G,?.>BEOB\I31L*O4[V1$'^JIS#FF?8]S?/6^YTY\.]:AW
MVAWF>$<ZWD'U= @X'-KCN=<]R8V:*Z3HG?XY.3B-=+2[NN+5?FW2@^YVA+/Z
MZ*PNN]S7;?27J[;9&H^[E9C]ZU"W/>ZZCA'- 6UMJ2M^\8PO=(SR@(,=(*(;
M)C#!#E+QCV$(X0ZIT'>[TV[XC8/#%UMH GL'/A!3J"!,:@<]I@?"AP"U&AA3
M,,;<'?T/5]CA_PZ=1 PI^+"&2O=M%6>@@Z9J(HPSA,$O?5/%4RE'"E94(Q?
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MTU &1[ Q_Q '(( ,_T> ")GA#J5@*K;W#]<P!&Y0#37A#78@!K_ 1N*@#F3
M '9P84%0"=,P"&11$]*@"9SP#0V$#Z' #;W0"NCA")I@1O'@#<>0#)7 '*R
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MB; &D: #WR(=RZ 'F  #D?H**S )-\ #"LH,6R &5  $AU&E5YJEB"$/72
M;2 X=\ #S8 *=\D"M-H-_\3: YZ@##EP G30BD"2!G$P!7&0#_*@!TU@"%J0
M [9P47[ !SEPGO]P"WU !S( 6,MP!$6P ]\Z#5^@!7P@ 9GP#G;0!23 "."0
M#BOP"'.P &"[:O/P KX1(TP C(-7)L_P .= # )08R%9 '(:!RK @X^1#RO
MMJOJP \L=7US#0; "]"@!6EP!>*@!3RV#U! #_JP!5[@-S[ 8]20 ^K@#NU
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M(7 ")U ".: $&/T/=< #C/H/>E#L]C#J1&65_^ C(4X3VN %#F $IS-7-3
M<[$*9/(/%X\>7J &L8 ".,[G.CXT^S UL@"V0J "* \.E" !#P :9V#9TI$-
M(6 @U,0!QB ,)< YN6  0+WEK! /!+ 'DR#B:"#25;\$F# #KO /FV!FJ+
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,2J5<2J9LRFT+"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex10-13_img03.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-13_img03.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    , ,@!(<    :&AH;&QL-#0T" @(# P,='1T(" @7%Q<<'!P1$1$/#P\%
M!042$A(6%A80$! 5%14,# P?'Q\.#@X*"@H8&!@&!@83$Q,9&1D+"PL'!P<4
M%!0! 0$)"0D>'AX$! 0G)R<Y.3DF)B8U-34H*"@_/S\E)24]/3TR,C(W-S<A
M(2$D)"0M+2TT-#0P,# K*RL@(" Z.CHO+R\[.SLN+BXJ*BHX.#@I*2D^/CXQ
M,3$C(R,L+"PV-C8\/#PS,S,B(B)-34U24E)04%!;6UM!04%>7EY'1T=45%1
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M'\\H@0-*48_$L8$&R5"&%R"@"43<P!&J"\,6"E&$$L1C%C?_D$ =Z"&.#;J
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MX4 &L1M/=XHX!&&H__ .?O  'J )>2K![R &%HS!""%Y!P &JSNIE7JIA>@
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M P>1!@%P.':PAO+"#D\@"AC0O_\0"W;P":;LJK#*(J(P ,3(/Z[P +OD G&
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M XS@,). Z:F@"0+ G?_0##7P#O(@ BS\#V(Z#M,  8N@/^)@!7%@!W10!"0
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M5*3B$(;8F;5&@0<G)(*8XLC%(A(!B$I4HA/5L(40CA $(=!A%,^T3C@\(8A
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M 0L0 0E)H& 7D= !<_PQA K$ 1)E0,$M"O)H6/\#'&K80ATT$84\_(,<A1#
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M!F20$VYHAFX %]&[AV+ !^)3BF$PAORH!W1@SVC $ZNBAFL8JX)(AV/ #',
M!F=XAF1(!F$X$V[HAFX8A@_*QI6+![Q*"YQ[N6<"AY8".'H(AK.\$<(B"9W+
M.)T3EV9H$9?SMW&(E6$4PV8DQGNSE)]+Q5F\Q2PD"?XKQ]D;1R1M4G,A"'VX
M 06HD;7(@@^ CG5  24@AY C!%_XAQ,( G.0!@.( _\E*@<TP %E0"-I6()S
M&(=>8(!2^%)C>()?^0!6>(<S0  543=SL(<?L )RN <U2 "<B(<2.()WJ =V
M( -5P()JJ <<, -R@ 4F2!L'N(=P^ 0"^(2UL(<=R(9RH(,&@(5LR(90< 1T
MZ(4.T 15)04F< = >( I>(IQJ(47Z 8?) U16(!M& U\* (.2 59@0, H(-Z
M@ 86\ &>T(<CV !KH(=/4  -&8A2N(%OJ+E_:X8I^(%6D(8VH(#/@(E#,(+B
ML0404(5L.(406((2Q18ZB)"!((=0:  E2(MHB $S< 8T ( _D(9&Z((?D(7H
M2P<^(( >:!54LH$I@ =#8(#_._C6KVB!%I"&36"":ED+2:""M$B'4DB %2@>
M:RE6,; '9"B! ( #D-R!63@%$_  .""#+S !!X&'.]  -!@2(*" 2? '1^@
M+="$.N@!*D@*^RNF%J UFE@+4: "": #IUV+>&""+*"%7<""#< ;@A$&(8"
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MA&I@!4* !%L0AVV8!$J A&6X!$IPA%-@B=-R!$I(Q"AUTB2$4A4^E\!: @_
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MH@,W^<8$Z@B\G4@C-<9#2!9H0(U_ &,%1\B3*BB0#!?^:R>1: <V)C 44"P
MEX@;APR^MX\;].H?.+##_TZXP0G8_*,):EH?;&K1 2W90P!!4 L@!& 8A(R!
M&_IXP* 0X@E;S&4GVIC S$(:CRG@!:E;0$@>#NH*!K@E&@K8S3^2<!"'^$$&
M'JWH/XKQ "0\)1_JJ*E#Y) #AU1C5 AY!0#<@HT'"!,A\UA#/N*Q#U/] QO?
M.QD$4O$/>ABA(_]@QQ0HL!M=0$ ?"'%'$&1P%E,Y9 P5L$-GGG$!H^1$"$)8
M5F]/A!!F&& 4"'%"MXZP /4XPP1+_4<9XG"86PS.LPCI!@PX$:4I_*,?*$!
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MR"$98( 0 /\")\0 $BA#.@C"#W@!(!C"&+# +/R"!'B!4WS# N# <T!4.NC
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M(RR $FA#*]2  6Q"&R2 </T#+P1 G/N!&+B -FR!&LA! ." 'T@!(BP##'Q
M'N3<,ZA !CBS0SQ##9"!'ZQ &A@"%Z!"+-@ #=S".$B#$3P )_"#., &/)S
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M> *,3*(*U:%$()101#\@4(5_L()Y#Q'&!L8VPG^L8YR<H$(,M/&0=Z  "(=
M! [N]X\V4*$5+8R*Z,1BDEZ\81PY6.0_L/& :$WQ'Z[ @!K\8 <<R$0;)E"
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M11 B!XA\""0B 8<%A,45HA7(W=9P,Y.@X7?_&,0"UD">E%5#!3;@A3C.(3Q
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M")8@"J!A*KN@!!@+7WAA!EK@"L[@-%C!"J@@#C1!$X @$'SA"X@@#2#2%GP
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M$\(@#.K &4Z?$)2N$0(1'A A$@0A'-QAB5*AK2$!&0(A$.2E$!@!(M?3"5@
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M'. 4=1D$$D  TW\(0PHV>$5=^C"%'TC.()YP@.NL08%>_ ,8#AAH2ZXA.2]
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MD22@@!SMH($8+E$V3<4" GJ@P0I^.-W4ECD)!TG_!Q"&(8\0W.$MX!T3+!!
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M!QK2(@\75/T?*4C#4CUP2I:X8(#*D, '#_*&8B!D"D^X$RH0(@0"W-X@RMB
M("TB!',>A!0-\)/9-?7W"+AI'"Z@ T+: 0@+TO0@B)C V7*A %\%K!NG:,!"
M.[$!M-8%&!<X[3\H,0%;E<,)V<B'/-B1@T#\\9YC2D4#(DH^=I!" ?C_AQYN
M /\/=<$&-N,' ; &9V$#[>0*F: /]@ /:$!!_T +#L ,_Y $)] 8T_  A9 0
MK7!#71!W_Z +)Y NCC #!S$,*^!5*@(+''@0\_ #TO /_B #Z?,/VK #[M,2
M@Z!X3@%Y/PB$00B$DI=7^",48&!WAX "Z# 0'84#=/$/\V ##G *L' !2A"
M@E  >8 ,MA !0$ IL6 !;$ +F4 #W%$\1: !E% -7W $]& 0^S #L< 2[; )
M!2 &\,![ET=6_$ &!  (D9$)4? -RD *+D (*9<*&8 %RL -OH 'HY *'R '
MRB -=O  /E,/A, !C>"(N\ $SQ * + )>N$%*H *UR/_#ND "Q;0!\J0#&F
M 98P@YF 714T Q"P#0>A#S%P N4P)K9  :DP#_,P#7A #J,0 :EP#L.@!AM
M"E'!!Y)@#O?@ (+D#0M0"..@#U2PBW\W $94"1$04<U0 7&029NP )S0#=1@
M"V=@#^00 KN6<F.  ='@$_;@ ]CP#V=0!N/ "W,0@ .A#F'0 J]0"F3 164P
M!.+ "9,V$*C@ ?-0%W6  BWU#YC0"44HA!WID1]I2W>%<I0!%2<1'"&R#?3T
M#]%@"V-B#6K0!S?T#[[@!G"@"7WP"JC@#*LH#;E@#9+0!YD@.>"P"'Q@!G;@
M!M&XDF)0!VR@"'ZP!]8P)L* _R[_< UY0 9YX$+_, IYT >6  ZSX 9D  =>
M]0MP$ F%X"OY0 9UT F(@ A]@ CV4 AD$ :(  =L(#G_L UD0 :: )?;XPQ6
M  >9X#K)\ 9B\(W1P EA0 :(T EB$$>^L ><X"O14 =N0 CA( ]7, ,XX%/_
MX U!@ 1;T 0'QPC0P 54L 5*  ::L% ^(0M&0 1GDPCTX ]!4 (XT IDP *4
M<!#,T 2,Q0E,T -S0#"7L -  $FF8 ->8 6&X _EX 8A< :X8 Z)D (Q4 9?
MTQ*[T 9O4 ;0%@850%,&,0PH@ 0A@ (A0%;N  9E< 4EM%Q/$ )YT#*BJ00H
M< @'H?\'3,"1("F@ TJ@$B.2DW<1Z[%&ZX .Q-,0XX .U(&@G/$4$XH[*)(3
M\)$N14$>'7HB(]$03#@4X[$B(\D2YB /X9 .(LJ9YI .Z@ 9:Z0.X) .4%@<
MZ[ .ZE .%@$.\F .#0H.Y<"$A+$./]H.ZF .]2 0CL$.!S0.[( JXK .D<$2
M#!H.ZF GZ& Y+#$.9I *-#$.X0 .A6%5![&E P$.Y! .]4 =ZY"B>9(8 5J@
M<TJG=6HB!RJG'*&@+3$0X; /?[H/_B /:0$.$IJG-'*2\,$?'&(<3?$?ZN8A
M"Y*H%]H3.D*I'/H_)%J22"$:2;<'#I4;F\JIG.I)=FJJIXK_JN>!IQ0Z#N8
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M$$/P ,,@"JW0$JF0 !Y >'?@ %6 $(XP"AD:N)CZ$\LPD9?:S/_,N<_\@^6
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M !3E##>  +F]! Z@#?%0 S?0WTE\YM.^LFE>JI!G$.2@!6)R$#O,%'.N"/]
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M<8T;A, 0SX.//N(0!U/\HQAJ,,0_OI$'-N3V'\<0@R;,,(\Q7& -O/C'/OP
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M*()_$ 47\ 9B> $7Z(8JJ %<"(-GN!W2N(8-D 5UZ(<0L!MO4(!1<(E^F(%
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M%J0#+" '8H3#+?2"VW #.E1#DF!*+%!=2SQ#7HQ#DDP#,03&+J1"7J #,+S
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M@#A4@1S$0S^ W<'4PQMP0ACT0&$@ 4R\ PUHPSZ(0,>JP<4]R"J@0+M$PPV
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M+MA 2R#"XM7#,*!"$6R L*Z#*=MNC8#""C#"(4!"&(21#2SPP<@!$;0$/P@
M+9R# <3!(3@"#NPB-KS RP1!(;1$"J"</[P -YS#"GC!%&3!%_"!*TQ=",,<
MN9S $Z!0)W#=VW3 BPV""*R#.SS!92,X"EA*X@W>/^2 &X3#$C3!(,#O&%Q*
M,E0 &;1#,#P#/I! -/S#-[  U3U!G[4$"K27>]" (PQ"$:!Y*/2 \V(!..
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M,8HB. $CVH!"$> @#G>PH0QBX,5*?A$$1*1B$LFX=D/$T04+0O );3A%)/I
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MH!_R0:O*H1D00$*L  )FX1RB !K8(0IVH!_PH C@ 1R&P0#80!^T  G$(:!
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M9@$Q&X(4^" 71J -D.$&6N,6!F .V@(%BF &*J (T/\A'=[@%Q9! (3A#T
M#TK!'FA $C(A!\*,"&A $9B@ 6(A'X" !=0@&2I! >0S&F@@#,! !J)E%?3[
M'_C[T+A  N!$'FS #FH\'23! <KF$&[@#XH@ 9K@PFU\!W@ $>1A&VI $J)
M!B*L']1@$<1@!C*W(;C!#T @"!2A&JM $ZJ@"DZ\#G  #D" "C2A!2;A#%:
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MK$ HOI" /TCBB0ET8QXZH 9)*+B,?QR#! %]19>^@HT&7 $8PP"'&5X A2-
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M1 M"6,8&OEB2TAW$RD9:A & C(L%<(,;-0#R/&Y (AT/-=Q(O(4*+C )=;B
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M-Z X)#$$#\ O(!8%_S('#M/T#_9P P+S)7Q$$GU  G:2!5$0#CGP!.7R#F%
M*6;1#B]0#$/Q  R'"R;P#LKP AK6#C5 (MK  DX4"MDW$\$ #_9@!P)P#G@P
M S'Q#X'0#9F@*65E!V>@+"L0(:_" K5P<]NC<S3 2<YP P7A#300$\>Q!]+R
M#P+W*BE0,/AF \ER$$J1#_\0!GJP RC%13OV1#C&!)IB99+V!UT@#K&0 N4B
M! P54CAPD3$$0C!$$L%@0LC0!2N@)>&  E+W#\JP#3!0:/G@"]UP P\$"BC
M24;0%*"@  NI#MB0!4M0+OC@99F1!6Q@6R\04,%P X#0!B=S$)BG5)MG&O\
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M"C +ZW 0O2 !(ED6YA -_Q+ !_+0# + !^O0"H44I" Y!U&0"/WP!PAP#NE
M!2V@#HH0 4T@!E& 8F41#1A0!^%@#E] !>H0#DZ 2KP  :46"@@0&;5@ "P5
M"2-@+)V$:N>  /Y "A] !+RP"%] #H/  ]N@IV;Q!D80B9T  =NC"C; #OM@
M -3T#ZT  \80#/8@ 2SU"BO@'\<1!TQ $D 0(>!  ])I%O2P FI0$LD0!/%
M"F< #D/@ 02V#>6X8?'R#RT@%OS@ 884#S6P"?^@"S00B6(0!.= #?@V T_P
M*H>P#4@$"!2P"/&0#%IP#OIP!LY@"!Y03Y%P (J@#KL0!\H@ DN0#_-@!=M
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M#5#P H_P#XT0 %A@/C/Q#F-P 3+@"ONP $N K^@0!P-0 S+P".W@ N:D"@!
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M',Z-;_J-K]7=WMR-[KUA[\FM'-CMWN4.#HW ";.+[UL4W]O=[M<MWN:.[N+
M#JW@"490:/*-'.W.ZO7UVB5*\:B7Z[I>0-PP#3"L\:_^[;S>[2)?\LO.#ZV
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M G/ !Q8H!7 P 3Y8AV3 A7_@ Y[A JS1"7*0 :SYAU2@@&) AQ](#!QQ!06
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MAQKH!E:0@%;0AFE0AF,P@$\0"3PP  -@)OF( :J+F@40!@CLA"&H@-ZJ!Q(
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M8[$!5@"'?AC_ABSH@#-:@[,U B/5"7NH "4-!QF@!'FH 1"-"4]P@.D+!Q?
MBSD, 3+ H(](!A2H W)H@]K0"2<IT%W1AW#@ 1F9AQMPAEX0@$[\!VQ8 >MR
M*(K= B28UX\8T'#\AU@P 7HP!10X!5^X /88DAI(A8]!ASI0 FR(@[Z15**I
MU$O-U&Q3 !G!D%"=T"F8@4[:@QN0!\58U7^@A(7]AS5  W7  'S#B5R#,H4I
M!S98@=_$A-O,'8TH@A/0B!,0S4PME%S5A748 CWXA1U80C@@ 2C1@L']AW-
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M1 C64+  +7"&4\ !=X@%$)@.(3C!;R !9M"&D] ,%KB%05:!^1F$XQL-1S
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M?" $[4.N_&@+3."R((,8%*$+&M""/M-2?D9! 2H![H &C,E\*BB?AP1"$VK
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MQ!8-^,.:D?B.,@P %R''[#"(<(('T=K&..L#(GXPAQTQPPE(T((>$&&.7-C
M#2=/Z3OD0()AB/8?_MA!*4(.["_=HPY>6!0]F2&&*>#QL<)6X)?Z,8H\I$BN
M;VTS*^QQ]2LSN]EFG^>RS[[@N8HUC?%)Q@L<Q_;YX,&C8_U'(EY EF(D_!_Y
M*$&_[D&"97ZQB?\(A 9:\8]C*$ /&^1AX6&BAAF R(C6U2"YMK& ;?SC% ?@
M1 K]09HJE["H(/WB4&$B""20A103[8<VO$3$<OA %HQ>%^:+O XM["$M[RB"
M&MR.>C!18E'Z0('M42Q0#@Z_M:B7AR'_>F B:%&?JO^ @Q?*(HF'R(,(,:"&
M/=H@A'_THPF]KY*-6VM4,&D+'+F0 'Q4:"4^C$ND.;Y5/M3P #7/LQE6H$'5
M.=O8(5!'=(,2*$ \#6 $80, )%W949C:1:!:T8,X]-D#2F!!E8-+$<,H3)D[
M:,,[P,(RR8,G;()+08@H"$(=M  ]*(,](%PSZ(/L\4,H7 (_I$,E0  F,)"5
MA (D6(\X<,/_84-S-(0]7,$-((,Z5$,-Z$,^\ F$+,,P4 C@* (%K$8[D$ 2
M[,,SK$L^.(/<<1HYS!$U#,.$H8$-C$,W.$T##0,\@ LQ_ V$[$,Q3!N8;$,#
M*-X_>$'VB4,]_XQ#BOP#;SU$.L0AN# #:900A:S#W_Q#/+@##QG(CB0"ZSD#
M#SR"),H''GW%K:5 \FD(A.!#(D*(,XS#&I@!X*1!&6#1=;58B!F#"5B3./!
MTFU0!]V7 66B?HQ"#)P>Y%U90?T#%+3%B+B#!$0"6;"#%$ B'J#BXZW1&376
M/\P#"52#\#V>$.&BL%T5%L4'+R@ U*%0X4&C 65##OP%+II7-[I<0]&'/8@
M"3'6,UZC.-9C!1)#.EP>V6$@/[X5!5I@/R(0-4C!#V2"$Y@ #?!#+5 !">"!
M DB".U1!(11"!4Q4&!Q!'MP #Y##)XC ,J0#&^0 H%Q#%R3"$*" -O_H@0&L
M 2B B3P\P1Z4 0V@SR48 0N$P;B$20MT@2+P0S?<P!AD@0J8W#@L@B1$0@H\
M GG]@R)T /K,0P5@03:@P!W\ R[\@".40QV8 !^<0 ^(@R'$ 1CT -&I@0T@
M @L 07,(PQ<<SB'\PSJ8 1_<P1K A"3( 2>D0"@ CC<H0,_ @PE<P31TP1U<
M 0($@AED 5D0 Q3 P0C0PC^40Q]4 1.< 6DX1#TL0@IDPA&0P#6P @OP@#+$
M)1/X@S 4 1IL""4LP3_( 0)\ 2T\@QCTP#VP@A"8024$P!1H0V3R "Z(@RV,
MP,:$ R$,P1) P<W@@QDH01'8@&. 21F @27_1$$58,,^X($4#((YJ$,8E*9#
MY$,78  >;,,XQ, FL,$7=$*_@,,AL $>$$(^/H0[$((;D (:-$$QX$,<",$R
MZ$,:0 $\Z$,D\$$O' $>\ ,O),$;Z(@K>,$S.$$5F,FQC($9R,$RR(,KT,$L
M!($EQ$0XP($9#,$C1*8:T, 2  *@/ 0YM$ *A-8_V. _% $;9,,6.(*7I(,<
M" $6G,,X9$,FK (GP,$_- ,=-,$KC(4[P($57 *_=80S[, T8 (DP,<_8.@<
M+ *_%0,F<-HQC(([Z((AN!19S((@>((R1$.3BL,YQ,(^',,B^$*H! (IB,,N
M$$(VB(,\I((S\,(L_Y"%*A#"+XP%+=@ 1YK<0\P#(#!"N<4%)#1#AIC"(,""
M?,B"*WC""*"C."A#,OC#. Q#,T!B/^0#.[S"I,5'-1 "^C2$/_1#.82"+())
M.'B"*#"#.Q"#2[W#,;SA0TS#(5#I3SH#L%[1.$P#,0 )/B2#,[!#.C2#V$D(
M-%@C6=3#A@0B.6@#%>(,;P7*-#S(/]1#,$S9L06DN![0/Q;;N :(.7@##+!!
M/"@# N0!.N0! M1"-]Q#$]@!6< !#:B#)[@ 3#Q"#: #.8@ -"P>"-"#.91
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M&4(:?N#_"W(N=<_Q1 ZA @*A<?&'&Z[@!.B %,:!'QY!#<R %WX.?\BA#$*
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M?, .6F !Q*#_I Q!!_REH5JA >)"#% @![K@EC.%%$0@!^P@&>1A!.J@#6!
M8"GA#>P@!FJW&8$@GT,%'#*AT:A 'U8!!\8@$$" "5[C':Y ")2@ I2D.H @
M"7A &T2L"]   @"7(01A"[:@"[P!&(9@"4+!&4H M-#!#88 ">2@'%QA!,(
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M!GA(',JA#W;H'_1@838! X@ %N1  @SD$):@&UC! 4P"$M"@&C;A 4!A&B1
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M3(<:C> $"J2SC0;X(I<.>,8_>("&C\!# N7CPRXJ](Q?%(8(D(' *_YQB@9
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MH"\Z>*0>,G!O,VKP#FU,0'0H[40^*K")Z=C"'$ 3DS<5$+5YD$!C_0P'+!(
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MP!=PL08P_ ,,,\ NMA)Q #RP@@]6$,<HVA6(",RT#AQH@RZJX(E]3,"(DSA
M'6*!A$G\ Q<F,(<R6E"/?]3@%L,80!1^$8@T\,,%)RT"$Q-Y!!Y\I 67F,8P
MO) @%I!S3-1P +G^P0XJ8!GO, 66  WW(&O_(#L300-GDP@7( WKH D:4PP!
M=1F5L #"D \[4 +T8 XU8 E^9 +TX X>, 3A$ \^<!A'@ "-  M\P C_4 +R
MM#G9\ "\_V /]' #M?$--2 .T[  6P *S= %(S0FY[ !KU(1[V "3!$,&7!I
M_^ %97,,-6 .W; !?/ 1*3 Q<M !=7 .L% %X= '+M!'RO(/LI!*RH EET$/
M+H "Y# =:S !)L$#\@0,'@ )_J !HY$+#R W34!?Y<( ?,,%](4,#5 +4N,
MFH0"?S =^, "#B *F^,,"A +__ 'Y0976>(+#2 ,P! !0O0/,H! 8^('-X!=
MCR!BG(!S5: #4:,,6< ?8\(('M!?%:$*#L ,X^ #,?$/W: "M0$$Y9,'":!)
MP< "__ (&9")_X (TZ -(V .%?(/;1 "'Z$,&' *57 8N+ !9_\V*Q60 JF$
M#C9%"BI@=3!' W3P#[J0 =CP.;*$%.$P N5S63TW#D"'#B)08.- ".. +9.
MB],A#)^@!B602(# #DUP&%BG=5;W#YIP R9F /VU$O[P!QQW6VZ'=FOGD2'I
M=F/2#R20"Q-1#XEP!$= 3M/1 U[3=YY !$B0!*B "2' !9H@AV.2#2T0![[P
M!#.@!L_7 V8P#M; !3OP!? ").( #7B !$80!7A !SC0+NDP!CF  D+D"2?P
M!;T0"3T0!-R@#U%@ W)0!D,@CX%@ S(P!?JP"TMP JZ@+'4B""90 4"0#ZA
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M-F5P6!TID@5KL#54EW697=@B"%R@+]-Q%$C!"EV@+PFKL$DB#^H #O(@#^2
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M$ RI\ VLTPZJD @R>@_>\ TU=RG]  J9  FYB(:8$0:#H F@((< 6 B0P Z
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M9+ !"9 X-E(,5[ $<: )FL $6I"S;X  $R %]8 -6X %]M *1& &\7 //8
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M0SN,H0)[_*,(?O@'-P+PC'_408%=P44-I$2)&6S$!]YA10O$$8__&N0!&IH
M "J48@XDS.$?N/"!.KPA@RK$8Q<2F(<\4 "(?_A#!Z'LRCBD\(2-X $$\7!&
M CB*BP<@PT";$ <I8"",= 2B F/H!QEJH YUM""4HR@ )N31$SR\ 1SB6,,4
MQ+&.*/B ?PJ1!0O\@9@F@( 4V?! !J,0B'IT @"[&$C=[I:WET B!O?H1@*8
M  L?^. 6HE! +_[AB1!P@QXT"&4J>E",?/0 "L5 @0D6,006=D8>KMA!-M9Q
M#Q$\01MX*($Z@&$#)/S#&2]P!S1PL->7K,,%6/C'-A!P Y!< :3_(,,*VC&(
M'Y!#%P'@02&:((<=^  .1;A$ W91"P-4_^,;+]@ 'QCQ@R.8HQ<!T,0S>@(*
M)31C$@(8!RL0( 9&W  (YG"' +:PC1B$4J/M^P<1(I&G2AC@"D"8@!2<& <Z
M?*,(35@'3\91AS%\0PHTN <@'$!4%%S!'>$P@Q^^<8(G%$,)#6!"#<2P#",$
MH@P;, 8L I %F!#!$F?XPC^J\85$!&(%HQ!F%0*Q!01HM87E@(,&#J&-%H@
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MGGB$'Q"\1$"'6%  TN$%ZV*'.Q &<_@#O5NP_XW@@B X$4I  &/XAU^( $;
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MKAA(M' &$C@.T_R'@/P'1.B %F"R AD&!* $-UB'(/@",O".EU '0Y@#-#
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M #*@A!"0@5,8A@9P G+0A@,0@W2X!0"PA:9# 7]X!ANH1U,( $N  P'@@6V
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M,(,8L(%0P(+_!JB$86@!#[@$=0B!&/"#G7@)0C" 1>B$)["'-[@ 1FB&.X
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M= $A,($3E,67%,$8]  ER (5%,(_!$()8()9T,$3?$$:]!H4V$$EQ, 8)-Q
MR((4-((BI( G)4((#,(_9$(*J (X& (4Q,((;H,O ($1F/]*-K# -FC!#,2"
M1I##&*R!$9@"._!"$20"'@1!M/W#* "!$H3!KH1"";P '*1">G!"![!!KQ6#
M;@2#"Q3#&FQ!N_T#L23?P:F"(_3"%)17,;Q!%JA"9,C"(&2"( SB,4) *^D#
M&X1!-;1"'W#"-K #&5S"/ZC!'@3#&\!">Y0"&;C!G-6!!S0!*I###@Q#+.P!
M:6@$(7""(NR#.00#)!R#(O "ZO ,K\A!&.3#/\B#-BP#-_1!*0E$//!"/@1#
M/+9',K@!'#3D-(C %]1""TV#-V2#.0'#*8Q-,_1"*RS7/^A#&+!",<1#'53
M)"26-.P"8)$%*;0"&XQ -*$ )G7_!3*LPIQ1WRK40C7<2S7D L!E'"F0PSF\
M@S5X"3"%@UP(PRI<!\%UG2B2PM5%11HX 4*0@SJ4 SBP0SJ8QC_ @128U]K)
M9?*,0QH<PC^XP@-P@S+H@*Q=@PY00SO<0!;^ QYDE"6P0%C,@P)0PC]4015H
M1 [$X%,X@PC$8&&& #ID@P%45"240%Q4A1Z(@4:@0@+4PBN&P#_PP@Z<0C;
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M).# &D )!,Q!,A334VA"#>Q!&>0!'6##"!S+@[Q /,2#;P?##<P1,"Q#)/3
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MPC 40@H>-&%..5%')ZIP!$>P(QUMB($6H+",=+R!"EA88W#00 4Z%($QV_
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MM%$2]S#_$C ;*W*QGA'_1!$;[U'.]M$9W7$4,1$FH9$E9](%!5(G95(EP7$
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M%^]01 _S']X!$&9T#:'A"C!#)?(!"X3@0-+!%#8@GQK32 &0&9  "D3T-81
M"9C4'IH >5*-"GZA'[C@+Q1S,5>"&0IB&## &)SC&<C!'<Q  U[B#\O!&XA@
M "R!&M !%'I  3Z!'O_2SQPVH0'(P#D,ZP)F8D3; 5#@CR]J@P=2@!=-L1O
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M@/L?AN$%#*-BZ( *%*(4(B _L($%T+864$ A@ $#BJ<7)( >Z&$'%J$6,@$
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M\> ,QT$ 3?)!Z( $.9!-<T#_ O?2!(-CA09P!NJ@%(6 *-VP =;F GI0#E*
M .@#"6^P#1: <=70 (F %.XQ S!V$BA@)#O! &M0)8+@ ,= 'YY  5J 0)0P
M #7F'9H09%HT!;G8 P(G#C/P"/^P#MR@D>U1 O("!P+U#X4P MAU#N_P00^"
M#Q)08>VA!&KD#0I0)TH@!\[P $'V#]E@ /PP#'/T#Z^ 9%"W=F19EF8Y+_^0
M"\] #M!0#<> #\$ #,>@%/?P"'+&(OX0#/7%"_W0#,D0#-4@#, @#/AP#-P
M#3IQ#X7@"G/X#\2P"?)@#-C #L?@EF)7#=-0#N60",WR07TP X1@"$$C#N%
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MY[ &1^ &V# '6= @7MO%7KQ;=AO&8CS&9%S&9JP4RV #+'"=9]S&WC$,$3
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MTT+M&\@PMYU<U'U+N>,0#M^P"B7]Q]Q #]S "OKD&[:0'86LU- \T_T@"7+
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M\GD+\K63 .G:4O_ "EKU#^P@ U$ERTJ!74/^#R'P!6<$#1O@14AD!;7K6WA
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M! "!@9 &&X !,>@'*?\ @D6@@OSY!!WP@)BA#G HA!V(A#L@!'$8!C0P@"-
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M'C@YAGQ8A@IC"'!P!G@PAV6XAVBPAV:XAV9@AFKHAF8HAWLH!4!HC"1E"'Q
M4G'8!G?HD7VPA%T(!UTHAEZX!$B0FU#8A$J(!H<PA4UPAVW8A6I@A$2 !5
MA$?XGVFHA*8EDTV0@480!,86#4.X!GF(!7K@A3/G&'QH!$B@A'Q$&T;(!V/
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M<W'R^L\P8&#B%JVGZKHJD#L]NRN;TT[[#S]IH$ (.S%6@T$%_[GD:FV<6 #
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ME\BV.V@I!1C_,F!$F%[4(E;<(QR^, &QA/2)$^P"'/$HQ0:X]+E/P/!M\T@
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M,'"-10@B70X9ABY8<9<6[4,6I>A$"K8'CER$PA@0$88N<%$S<K3B': H13C
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M#U.(QQ\FP 0K2*$7/_@&(RK@#%.X@ 1]R 0$>'$.+8! %O[ @@6\\0]R_\
M$DH1A1[$,04;_/0=/K!$,'RP@CJ8 0%(J($3IO$%4^2B!G(8AR7(L HZH, 9
M@]C %=R0/3WHX0=W^ <[GG"(5G!A"]SX0@/08(8;.*$<M(!!CF^2"R#PP@S5
M90</F+ '%5A!'.=PP15,80) *%;53HZ;*02@A" (P MWH40>6F&%%J 3)/9H
M 1TND0 <E$/>KDC$"D;Q#U5DH11%B $RF." -:2!!4^(0Q%(,,7Y-6(2#E"I
M,+@0"3-<  TJ$00,>E $&#R ],:H02&NL(5_$*,+.>#&/_(!A$RL(0.0B T[
M[I" 9.B#"#+@!!= P*1IDR2(P!1(@B2TP!N(P_\GO, AH)JJL9JKT1H%5J %
M7J#TC$,*>-\_)((/8$48U, X& (,'$$5?$$2)!1(6-\DY((+?H$'1(8(%-$_
MS$,#D!Z3)0(//,0R-$ M$(,*!($09($/6,,QT(!;Q,T95- _4 %M9<,"2!TF
M8( [W(('* <_", G@ ,/G$$D1((2^!D1!%%>$(XQ[,!=S(,)[!4RB, Z0(,!
M@,$='$$#E()5? (#/$*QS(,B*  -$$L(F,)GK( @S@$@B(,EH, _Z(,#; )S
M@((;_(,U.(!]V8$0/ 051,(_< ()N,4[D( **<,<8,51%(&9A4('6,-#B,($
M2)005!<XN$ C/,X>H #_'\2!#.1 ,I  %/S!$&@ ;-2 (&8# B36)LC /_R"
M :@"*["!!DP#//Q *_P#+ZR .JB# 53830!""BR&("@4TLR" :1&#"A'%7A!
MZ379DX&$*2C 7HG" KC"/&  '+""(P# )U@%.#C!%3S$&>3 /T@"%^A"*/S
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M/$S""\B (]T$, 1 $[A")CS (,Q#S&8".23" YC "SC538A"#G1!*-B"$Y@
M+C"''6@ #ER!!/# /6A! J2!%?RD(!S $)27'ES '*A! I1 *\S "%3#*B0
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MT00.2NC9)0MC FWO'W=H@4,:;.Q1QQ1$Z%%I'$^\ 4D?6EY)*!]:LCFSJ'"
MV80:I(#A1TV#A$%D_YI <S)GF'9F)$>8<M@T:)P]QTD'''#^0><Q@<Q1)U@@
M USHG7XJ%-8B>P";T\@-6VKR60J%'3.E+B5,4U [EY*I%BV<P;6@7D(0)E+^
M_O%&!T4(X4$'0B9A89-&)JC%7?;LX0&)28+( !1]C+@@F8$!U X='_J ..)_
M>H&!"R@-FF2 0RR.6.2>  -&B0RV"7GDE0W:89%_QHG9VY'_886.,@80)="8
MX3G"@5(B!64#?-Q%J)\[D/!"EV=*H&*(8OZA!HH3?E$Y8IG'H;(_<P1Q816+
M#8(%ASK^V8:)+YY$"1U%;'#%:O'.H8,*8MY>N:!F^A@BGJ+KG@:,2.H&,/\=
M4"1Y)O Z"Z(FD'4.3X\<:4 9^&UT%?SGG1A(457,5&2 A\]R"SK%$X/.P,&@
M;>CXAP945IRQ/$UJ2.<?<*H ^AP2'J;R2S&Y75$F>8#=75*.&>D"S'^4 #FP
M(X]W?7F+H&\*C'/^244!2+7V':OG\Z-JS8I@648<TU+T$B5_1 CFGT$B1\D4
M;=1)QH6J:<+'E'68GP<%%62E1 -)./,&*YAC9G:KB,S^@0QY7<<;!MA%R/Y!
M#!4,X1_,B (."A(3=4SB 8YH7$7N(0D#I,IN6"M@3) A!1#LK3S\@ =YQI&*
M%<0A9"9,SS^XT84.^ )B-M01QW"! <,94#R_T '_&G;VF(%<AW)#08DB4H"L
MT,FB%_(P"#A\,(G/\4<<Z4"'08IP@H*8XQSD8$$PG"$*@A2$&:Z 1O;^H041
M ,,@MZA:-VXPCWQ8 R'WD 7U#.*.2;6E@OEXTIE\@8UW%/ ?Z4A'09RQ"G\$
MCQ2@B,<Z[-$.<*QC'N\ S#^<(0M>_>,04?A'.\IQ$". S"#X8 8[W+6/28;#
M'N[XXC^L2(^]'80<U.@'0M[QCTNZ:QR3@$$QQ,$+!2R#'+RR"#E>J;6CN$,?
M!EG'/MZ1$XN@@V@'>=*>#%(/<!XD:__HYC,%*;EQG*.<_VB% @"E.V#P()X\
MN$7S-->022"@&?]0QPZN_W"0." CGP4EDCB:< K)(60<+?B:[A2"!"P81!8Q
MR"!*R"$!0_!.>U1A0<H@Q-'FQ2RD!DG&"UAXE"'TPJ#B^4,;6H=/;3H/)=90
M0*@@*BR2]@XFXT!'/<:W//O$=%[_F$,(+EK.1>S)7.=JXKC.E(([J H24L!%
M"I!@Q7]L80H<XR)"PIB3=_B@#DR 0.K^\0DLI"$&BL#5/W;1 !G8(I6_[,8.
M(A$$ ;AA'%P[@1I.8(IX9&$$:A!!'.3!ATC8H0KT6,<5UM &)-1C9Y$P =E^
M404SI*!JF@@"'VQ #$2 H!;.L,(.HO$/0GRA#2?('"&4H D8V& 6!EFE01!Q
MA_](X"!41Z$%"#;ACCBLH!;8& (6(F&#&E3B2;T00AY:0(GJ$6$*GU "#^@H
M$U' H 9;V(<H!' ()^S ;?] !1C&4()'% T00@""%?CA"QF(P!?N@,(APK$.
M/URA!'(P!S+2T(9%Z( 8\3##$Y#0"G.\8@BUZ*(FC# '2?QC'XIX0@X<L4:9
M"$,*2]A";;/!!!B@X1,<FP<5,("&;(PC!I60Q!$N\8][&&(/P4P&&^J AGTH
M9!D7T*)1/3"/"$Z!D*NXF=OTL0A5C&((I4"$(0 QAWWX(@UH&)T\9D&&;.3A
M"M7XAQT:H 9?] 0;?I!$+-8QL5.DX@[+.!,\#O&$2O#_XTPG*()!7#&#BQ;D
M'!ZXQ#:&H-""D*(.<!BB>T[ABDW<X!K)^@4M2L$986""%JE=!RF>08Q$&,X:
MM-#'^/X!"DS<0JOC8 4M.(&"E(I#'I:0@!VT81!K7**V14,#'?;Q"D$6!!B4
MD,8_RJ$,?LP#J/U@!J_PH0IL2-.=#0A&/,[YCWDTXY=9DT<S7F60=HQ#'O8P
MCT'B0=)Y<..7!GD&->2QCF-;+A_!^P<]JI%*B^CQ"1C<&2!:,,I_^,-P;WWJ
M5_X!#Q$DPB!W-=PK>D#9?W "!$3[EE.:$E95O8,&?GB'+$30#G_0@!7GF 0
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MNY3A'T) "L*@!%H J(A@"'+A!OR@SN[L'_)LS_[A=IA #EJ@ 7@H$:S &J[
M!+RL)L3 "6RA"S#@&-3!"A+!&W"@#/[A&K: %!1! 'R!$!:@"=B@"T: $9;
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M%U" <2:!;\W@!9S@"*0@"T[! QY*#WJ !E7A!)*%!DJ%1!\@%K8(4G5"5&O
M@VRR PBW'/K@@7 7!^0M.PP"#$J 8])!!D)%&6Z@'J#S&S>!@F7"$30X,5W
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M"M:3&CS "ZY!%)J@&]!!!ERY"&2N&S"@&*   V3A&NY .&FB= 6F[KX&%B)
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MCXP)/ B$%CC_N""0\^ "@8 B OE%Y5K(<8-C7-+)"@3EEK],P !Z$$B/2("
MQ5$/"B)N$28T$PC<\^4-.AD<*1/E!W]WB)MT68)XB(82:8 *^0F:RTO(+P#/
M&-A!]T@4^?N')936E'V$@(R3'>$(U9$*>S0EE(?N=*(G&T5.CZ@><#"'6&\P
MX4IR$AV_J,&$-]T44KAU:C0-)5/N4(9_P(&I/5I$(032#2(;\Z;V $,+6,S>
M^#5C!\]P!0BX-MYG_B,3,H"ACDV,*75PX@!C"&0ZZF$.22S@$5P]LKF-G H/
M?.$6_VB$$>2A"URHHR/FN 4M3'$]3-E!!G2BA@"4<(M8]",?KH %_SG2X0MA
M.&,4PS(&)G"1EWGL(!BL,(4\<$,+3PB;%+1X1;?^<8U'Q**J]/#%.U:AC"3J
M0QICNH<V_A$*;_Q#'J&8;T>$$0]^\"(UP-B%1IR1"&-HI!FT:(,)E+;$IBS#
M%=3P5BL,0(94$206Q!A("' ACWOXXQSB4 <\](%$C;!C*:L DT"&A8^EO&--
M BD&+H[T#Y(UH[M9 H<T6'"+8?W#']7@T@'-$0@8G*(>[-@!-LIA#Q>ZHQEZ
MEW,UW"20)/!Q4XSO4CN<L8_+,D49)?3D/1K?#T6<@*/_(,(F_C'$.)LIQP(Q
M1Y7>9PZEW8@<*R0>!0/!ZV#4H/9J-M$R7/]-HF<8@4X?I)_QP0$#0YRV?QWY
M0RO"G&P.2K!]H#@V SOX#U.0X"10G#[VP?Q)#5XK'*ZWLXI6NL#E):'; V6$
M+/YA#A>L0=&J/K?]'?J-'53A^:Z  1C,( &<\ _K  :,0 HS, 10I&\R(!!Y
M0 &B$ D<< KP\ 83X'(JP )XH "Z< UI< LV$ +A@ \T( 9YH )^\ ^UX "?
M( DU$%IUL >L\ -U\ ^\( 6]T 11H Q"( !4D %<H(!-<0TR( /@@ P[$ *+
M$ 02D MT  (;8!Q@( ![< <P8 6OD 0>\ >I40EKX 8I< ?C@ YK\ 1IT!?Q
MD LW$ 5ZT@DG8 ;_*  )Z" '"7 $NI!]:U '7J )XV .-I *W= %)L ('<8"
M3%!5&H$)-( ':> !(D ,^9 $.! &)# %?D #MA$.:_ &6F #T( .8" #:; #
M1F _'<$.:H !0_!CL= "DI $8D BH& "(K 'PX ./- )9: #:* GO_ $F8 #
M@: M(P(/8. '2E '=&($DZ<+7M '+3!YK) &5P #MG(*92 ',7!>QL<.<= %
M)< '=!()+C ";'!Z!<0%@Q ).@ '_X -3A ).'$$F$ I<% %2C )XX )2A ,
M_, &:? *2H %S?4/JG &70 %W/ /R/ $0P &>?$+?5 &9% B_) '?: '_X+P
M#_  !VD "GI0!+ZS%H:P 43PD-#0 JB !6 @>][P!WHC8"2R#'?P!$"  A,6
M#69P!V&0#O"0 BHP",CP#\^0!U(0"=(U(O) "'K0!O:!%29@!1-1).Z "H%6
M!P:0!ZSP#]#0")L0"Y>%*<_P"9@0"O' "YN #_.0"+80#^X@"MZP"IQ #KU0
M#<4 "TP1"XT@;QU&"O(0"[H0)3,W"IOP!B<P)Z% ";KU#\K@"_40"L4@/Z)@
M!"SP#9J2#J,@",;Q#^!P#?R@#4*Y/?[0"+1 )<"0#_ 0#OS #9-B#Y_@#3DB
M8,"0$>(P#,!00NKP6)LI#,#@#SG2#,O0>0?4%/_M, P\U!%K%PZ^$C[40 U2
MT(Z8(@T[8"OKD .W4 [*F2/*,$2P='_=:4HID&O_L DJ #-]P("[8 *C( M#
M@ $\9%(Z$@!Y< <KT ?_< P*( K_, \B$ WBX <K, _.< TM(!>F0 7HP \F
M<#J%4 /EL M.L)$-H K_H .6X"&4L XR\ >>P 8   C$X &6< W18%+@<@DY
MH [I0 8!\')GL +?D X]P ?_( TUD ?L$ P5< CD4 H_P%TZ  O,$ @ @ V/
M$ +L\ ]U  /[  QQD +BL \!X!Y_P ,$$0#D9@\O4 K=  < ( SY( "E\%D3
MX N;^04AL1;-H 4(L K_S# ",[ /@@ !B- +HW **B =8# % C$%+5 /K&
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M!>( !G)P!SRP#]E0 VT0=V<P!G-P!%[B!X70!R%P.O^%A LGP <Q<#J?D .
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M,] $_TKT Y* 1N7@!D( ?S+P<L(J=)>@*7#2#R+@"?\@"_81 G88#S<0#.7
M!U_ #L[0#DF0!M.0#*O@ X%0"5%P /< "@*@6V%@ _\@!R4@$)N0K;ZP HH
M"#YX#Z_P -N@#X>"*61 ! (A!NY;@P-P#/#@ 760#ZP@0AVA#CB0!]7 "@#
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M02O4?Q"#)_!426R*4A@! '2K"LA 1RB%?V@'%%"@202)1?#6#8ZB*3!9VDQ
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MR#_^@##)/TSX@,X_-[QR&DJR_#/.)#.(D\X>(\ C#A%5A+,.":8M <<PN
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MH$$<.H(!;GQ!"\U(!C?<X;\:J.@TQC!!$*FQ FCPS%[7,<<8.M"%8?SC&20
MQC]\0:P^T.4@N@B!12(1N\/H8W3'$$(&V/"/0 0K'2 PHT&XP <W3.TI_XA$
M B[@(IE9)!V# ,,(F%4+%KS'>KUH !! T<;BW: 0]%A!__?^X0Z+5&$,';(!
MN"@W \LQ9F=U&()!H! &@YS@%\- @"8NL8E'D.)@JEPE*UOIRE?"\F#76$ V
M1.6'&9"#&S@@@DY\D N##"("HU#')6@SA#Z 4A?_N$ G_I&+%9!#%(3X!SPJ
ML Q.3( 5Z:"%F[I0O^I)X1X[P< _6-$#@W#B"/^ 0@O^,0P/= D4,BC6/43
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M,A!")5"1TS#")'S8/QA"$%##(<""[R2!/L%#(A!"<*6J(U&")9C"[&C#$T@
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M PE@ CF !/,@PP;(NIJA 2.(@PM@P4&D0A1,PP7*J2+8 3)0 44$@@WT B-
MP-#00PQ$0BW8@!*T@RIX@   !)\\"%S]$W?PW[\X.:Y]L?+O6XAOBQ#H,RCN
M7RH2!O3H<;!$7Y$).'(H:81AEQ__$/[^.:I2JTD)9T%>[+*'Q<*D?[%X_%)S
M89DP!)<:)0#USQ*-(2$4I#'WS\BA?\^ G,H%H\Y%C/6(1,G%XLV_6U)^_-&4
MY@4?8/Z8V#(%P]*J'3FT/,!D,.$O&5H@K=M&@DP:!SKGX5&4R8<NK1A!X4'4
MYD6R4RP:T(JE8->_4%PB*>GR+HP'*2EDB.MS9@\"5?QF=!DG#A&:/0VV_:N#
MA@P(08O_">-BZ,^,>_]<Q?!1R-=%S2ID'*$72\>A+#IBE:N3@-(_?E@.*4&2
M\"!"7!%._;O6@<\_<%NB_1MWZ<26'*O<_<DA1D8+1R,F\?"B[8LO9AC#G&QB
M: ,0#$K(_P<?(D1XH[WPS/&DAT[,(>2+1@H)@)'7POO'EB6@ *83)= H9I@N
M7GE'!4D608(1</ZAQPHYSC"CGW_V>2$;@PYAHXA"V.$MGC_>R,*;?Z9A I%#
M<&A&JV'*>.0?6,[X!1$B% M/G'!66<.654*0ZI]Z^MC"B6W .<6/5_R(XP\,
MXE@%/(P22B@>1Z0(PZ)G!/'FEC!*P<L;*Q#A;+%QN/&$F7&.D:6<312QY\XZ
MIR$$$63^\2>56YCAQ)9_VH%$$%W$4><25<+1ZA]\"%&D1U ,$>0><8(IA)A_
M@G$DD&[^6>>:9?Q9I,=F0IAB&W(^K)399IU]%MIHI9V6VFJMO?\6VVRUE18C
M0DR@)Z$]OOO'FQW>2>@9!S;!:]MHX\'BJ5 ,<"8A5T3(!\2G*@7""G2X060=
M$7Y)* \)^J&CBH3R@8"/<=38 9U_O!"BSH3N*.B5&_X!Q -F;.-'JW%:$0"5
M?U!I8!9[-KA$'GP080,B'?JIQH3AMK$AG$A(>,J9 !KY)X;L^*%!&E!.,,@$
M,?X1Y 9J_EED@&F@DHJ3' XQ1(8)GE$.GQR"^>>/(!+*I0&GAWEA53)8,,20
M$2X@YX\;XCEGG66#6"0A4 RHY1\_</B'#1R($::$!.I1+AT<-!E&&@B&@*@!
M/^209<81!AG&%0 >.8>%-,X!!9!QD2C_HAQ.>C H!%' UB:;&KXA)HH,/$;H
M'1\Z22@(*M3YAXXKZCS(X342$J2!6\2QPHEPH DAD']6B>$?<IA8AS=\8+#C
MGT%8:$%Y-1):1\Y_)HEA'5E$@^216#QPXA!8M)!"R0N4L:<)%589AH9!Q,GF
MA7S,X7)_,-A#.<8  2-@@Q 3^ :KZ%$%$H C'SJHPSA8<PYZ@$ *QC"$!%B"
M!2;4 Q@K*,(X_,&CC6'A';6@P.T^5(\M-.(=E<" +Z01 PE\P0A00L@L?I 5
M6OS !J-@@P'P%1YT,$(%(;#$&0Z0"(GA(!IX2 ([-+&! ^$ $S3 13.X5"EP
M'"$$PBC"%\J1_X<&N" 0<TB KP0!@EG\ @(Z^5 \AF"!2^R#"PG0Q")$H(=F
MB6("GH $"?;Q" F(H AMV( IR+$% .SA'^G(PAEDA!!]!$$7ES# *WRA@!><
M@UPK2(8HFL +.Y@ &K*H@!(6$005Y*,6(8@"(_BQK';=$I>YU.4N>;E+C(1!
M9@EI0A(24@L6G.L?S7" )]B%2P#^XQ)<(,0A.'&!,23$'E7 @!R$T2QA", $
M/]O%!7(%$06X8@:%N!,.F/ /--@@(5PXPN\2@HDY2"$$Y6@'$!K !GCPQA@L
M.%P[/ ")<S0@%'>ZAAI:L -Y[*(%=J)>'TAPKGL$P!/^\, L$C*D?_\0(PQQ
M^,$U#?&%A CE*$8@Q#^HT 5(3&(3NG!'%_=A"S1XX X)T84"CO$/_NWC'TR8
M B$F<8E2B",-(;#3LIIPNW_X0@81>\02_H$$*ESB$IY0A3\^5(T5=.(2C]C$
M*3"B" THS60@<$56+Y&,?]A@4% QA$'HT0X0Q0 C:#C (<0!#CR@X!&IPD2M
M$/*-%8#K'Z]X ##^88<B+ 8C:O#>Q@3P3SGL(!W_4,)<BZ& *BQC&>@ ($;,
M@(-^0$$4"-@&)%YAD''48A>JT((2$C("6"0$'Q7X1$*V<8Q9F($$[>F#%G"7
MB7]HXP7@ZN(X7&"&?_0C )>(Y M2P9MC8,#_&/\ PM]"H<YY&$ GPX# -IJ!
M@')^P@/M>,<+C(&.'N @"%FH 1 JB1%#_,"C)?B.'!Y+SW]8H0\)P8$E-J4#
M:[#J'T.(0T*P8(-UF,$;^'A#"<KQ#Q=(5Q[Y((%%QM%A#QT$'6_X1CCZ@ %\
MH<"/_<! *-XA@E$DQ B#X,U%*R$.:QB@-HR 'JM4\83GZF!@EUB!KZX /W?<
MP \&P<-P/L2)$$2"$R8 P3\PH0)?R4+&.<@#-DRA@2>8(PA3*$<Y3% 0,*#5
MEKU4\YK9W&8W1PLCD?@!R/XQA1",XQ_;D$%F_^$,!^S63L[\4#NF8(QD+*,9
M:*#!D-@A#TD@H 2[_[N3./)Q#"=H !':V  T$D*, /#"!W^XTPD>@@8>/(4+
MQ%6./*S A7F  @7I0 <_-.& & #U0]G8 ;C@X8%/W.,'Q3"(+)0 #534@!RH
M2 "^_L&.>X2!!(=C1@!&H8P)M!:;W.!!)-JQ SC\XQ!&Z.@-6O&/*$#B'S+
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M )I!'W[ 5^BA F[G&T  '99A L:@'N9A"I !VLJ!A#! %?XA!5H 9#+A$<
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M ;2@!# !'DJ !I83)Z% !L2@%>C@ K2!'I3 !*KA&%3@!:R ""(!P3*! :@
M#V(@%^ !!43O#P# $"3I +( "H( 'F#! LA@2'9! 4C@"F+@%]A!#B8 %8!!
M 6;!'Q[@%>"!!58 #8Q@#V N1DV@&[> %I+O"V* 'H!O#U+ $IKA$"B@&,2A
M#58@'>*!!<) '&Y!">3!'Q) V 1N"'I 1JX! C0%([SA #X!&91 !E8!&AP
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M&K1@!W*VB]Z!#4( "^Y"'#[!#_K %OJABXC!!R)!&Y* #V*A%HR ",2@#'H
M";3!'M1 &CW!X;@$SUJA=,EA#T QDO0@!33!$F)@$?[ !J3@&= A#FS@":K!
M'!;!!\Y@$[8@#GJA"Y!@%63A!)(@%>JA"F( &Y3#'#@A!I@ &C*A!(X &32A
M![2@BI<+"#@J'Y( -LMA$D* #O"!#'B@#MS!%V* #CH!#9X!'X!@ ZR '9J!
M"B  *P1.$$A #-(@$\PA%V[@TWC#%E8 !JZ!$!I@!+;!#1P #;@*(>C!!W:
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MQS]<$01Z2(,!AQA% I2PBTD$H!M32X8"9#$U<.'L'_R P2 $8@P%E$(@H5
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MA_@/#SBH)*2HO71SV$ ^5O 71-P<&A.8Q3]&\8![)$, 6R'"-IY! D]X PT
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M$471"QB #\QP 5*P$,I!#QZ0=]1S!P+1=UU!!VPE@Z(0#MZ #9L !.SX#0V
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M! < !N$@!!_YL45A!Y-Y#P@@6/^1 VF@F3,I$$SP!<%  C!V)X.((;+P PW
M".D0#FR  #*PGG9PF_]@!#\H V  #_; #_\P# L :EDP004!C*;$AVV!"_ X
M-:W0 )_1# Y05'V;#+902O-P#JD3$J5P VKT"S-0$)A0!86B7H>@! *1!D][
MCY< #!/@"<KP#/Y K 6!!N(H$)P0 '<VMZ#Q#\*0"6:  C%X"%%PN4^8 N7R
M#2Q0H8I@ IWT#UD0",P@ HU "Z]P"WADB )1!(3V#[6  <Q0#,"1!BF@"[2
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M?2'1#SN@',2 I?^ "V+,MPU@2H!;5*?0 ,N0"PO@(N;BBP41##L@/8H@;H&
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M<# #.DB"1@@'2R@"_UJH BJ0 1!(@FTPAB<H/$C@ 1$X 4$ !2BXP(3  SQ
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M&8#%%N '=@ "$?"'/X  6RB$.C.0#A@)()A/#U&%&? '?K" "3N#-? '0EB
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M(G8 (8!;";@%[/H':T  RO@'_TV  'S8AQ7PW>B@!A&@&6&P@GV  QUP BU
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M&)B":,@!!\""'Z!A]X7?\NXRA,B&%T@5+9@!I"$#'8"[?.G!X1*'&:!16&@
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M G, @3=0ACJW2Y+H@H%1!Q?(9DJ0TW^P@QK\ARJ8+W!( ?/CAQJPN1CP1%M
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M<$8#1*>*$ORC$#(PQS]<H*-FD.8?I\C1CJSS#V^LH!LQ\&#_GE06/8A@2O^
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M@.$, :#%/&J  UVLPPH(6 $)3/$/'U1A$C.0ZV:8(80&X*%9>ZB!(?R AG?
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MIW\FJ(,^*(1&*#7J@S$UZ*?$0@W8P A40>V$IH1^*(A:XT.<)FZ&J+99Z*D
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M-U1" O@#/(# ++C#%70 /M"" N0#.O" %= (%^A*68!"!BBS(1A RCW!C+S
M0=.""+!#*:" #=""'7R""73!*,A!+SP W G )2@#&P0 'A1#$+2 .60#"<Q"
M.R!)+B"!/N0#!:Q!.1B!)= #%%3 -HC! Y2!)K !'.# ,JR#-=0 7[0#(-R
M-YP#*IB >P(#$H#".[# 283 &H2#'E"!.7R#"'C"/F18*E##"9! HW8$.2Q0
M+'0#-[  *W2#(DS ,0@##ZP )U@!17#$$LR /@Q"",C#)G@ %]""'P2 ,M@#
M#]1  PU#" #//V#_PP;H@CC$P@,LPS(T002X 2ZL@'3<PQ*< CXDP0OT0RE,
MP! @@^J.@S!,@3#H0PQ\P3:L%!^$P"Q8@A T@QT  #!4UZQZPPP\0RC$@#H
M@Q<$@SZ@@!>(PRO\@"SX@@X8 <6V@Q-\@#:  @240#VH Q$$0C\LP"&@0@+H
M@C\D@0)  1+0  I@ !ZLP"-(;"W0 !NH@QDH0!8@P@S$ #M@@@P$02RT0Q.
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M\, (/ ,1N,%"& *<H-\*W-\AJ$ [L ,6F(,*RO^#._@ G]V##D##..B#&8C
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M%B@T:6>A><Z(X@I2Y$CBCG><:2*&*<Y;*)-=_NE'C]E(^@X:F3""_!]U]H
M#4I^:(21+Z8PYI\QC+ "FG]((4$$0>)HH18VEB@D&QL\"$,>(U* O*1QQ-C@
M!SVN_PR$!0E(H,4?)A H8D%H8&@B&U)8^(&78$Z0@(YY<KG!!6O*,4, %69X
M9ATB1"@CC17\2">+%1CY9Q,)# "!V)*J 0*#.:;Y!Y <&&&&1_Q#%S]@ 2\&
M(P\EU& .:="!)TRA@R]8 PT.<-Y"<C&$D51N# AH0A]T\(9L- $#COB&"W2P
MB73DH0(7@ $NT(&#(Q1E!3*0!CNR\  $I, ;M8A!#33R#U= X $><)@L9/""
M6LP" 6/0!!+@L0XL=" $*4!886+@!QF 0#.#^<<:G+ 9$#SD'Y^@P GD4 ,1
M[((.%K@$.(31@P>X8AS+\$ /ZM"%!R1B%!G(@C,<08 ]R/_#"C=8!"\$  A>
MS. >\,@ )+H624E.DI*5M.0E,8E),&U2'.#X&#AJ5I5IF4,='PN'.<:1R@@I
MQ!P?&T<Z9@/*!Y$$'..PFSR^5+EEE;(DXG#)/YCQCW0D)!SBB&4Z%L*/7I$#
M'Z\L%C^* 0S5Q*-QWRF(CQ+2G&/THT7(X 8RWK&09SRE&L08ACW.,8UJ7",>
MRAC&,1;T#V4(8Y@M@L9?>M6B8'SL8<502^7V 0UN:&,>%P'&-_X$S&$0HQJZ
M[,<TD!(-<C0C&<'(1S*J@0QU7*0..:N<0M!1C'R48Q;E. <TFD$,;@@C&?#Y
M!S(< 1]U%",:X#C',H[1JW'P8A/_]*E&,9:1C))HPQ#8N @QEB$,9\AC&8)P
MQ96*98M)Z".;T^A$*:*1#71\]!_"D-D_?!$/A8QC%Y; AS=DL0](N((8X? &
M(AAA"IMD@Q.@V(<@Y$&)2E@"&Y4 A"78<8Q./$,>D'"$(.PA3$\\(VJ9=.QC
M(1M9R4Z6LIK4966E!B8):99#G/4.@S#46!$](PQB:$)<1-NAU'X6M P2[6J7
MY2#/+NNRG,S0;#44-=ABEK>]]>UO@1M<X0+WHUR5[65#6USE%I="S)V0<5W[
MCULT0 1&]>QRK>E:[&Z7N]WU[G?!&][M#I>\Y37O>=&;7O4^%[NS1.Z%Q)O=
M54)WOO+]_](^R.&MX[9WO_'U[W\!'&#^KI? !3;P@1&<8!*-M[^[K:]XFTM?
M"$DXN^_-I7.U*V -;YC#W%7PAT$<8A&/>+@,SK"#)^S?"%O8O?8U,6V7V^(.
MSYC&&R;QC7&<8\Q*6,>2?7$N<ZMB]K*XP3+&,(R5:^0:+YG)W^WQDZ$<Y:VE
MDLJV/#&*I9QE+6^9RUWV<H*K/(YPE,,F%_[RF=&<9C6OF<V2#',YT%'+)+>9
MSG6V\YWQW.8PVRT<Z9 'Y>R;9T$/FM"%-O1YF3L.=,A#'<@<!SBP?&A)3YK2
ME;9TU:PICW.@8QS3NO2G01UJ48]ZQ0L9!SS^8C=2KYK5K7:UG?^Y2H]N#).?
MK[;UK7&=ZQ$7=QW*P,>/=!UL80^;V,2M7"VIP8W9%)O9S7;VLRDICGTT ZJ3
M_#&%ROPC6P;ZVM#V]K?!;6!Z<(.;T1ZPA:RL;19W.]SM=O>[>_L.9? CVY%D
M]RI1F4H>WQO>_?;WOR4I#V?,P].2Y/<L^\SI?1L7MP!W^,,ACB)U,",?Z# W
M9QLNH7 T.ML9SV9K(QYRD8]\0PM91S?N44^#E^09DVA$,.M=(:X& TF\IL4C
M$E&-R*4A#,@$+Y)M?.%(DYSH1;<S.9Y!<'-O!0<VR$ ,XIE<,"7!+L4U1R,>
M8 %5_*,4 (B :IS<#%(('<#_X$<PYFS_=+6O'<_NX :]EPZ(6_RC$@_HR6V_
M4XP$*,'BV0U2!7*V#C-D8E2KA) [O@ ("\EWM0UZ@B FS';)3U[-XJ!'->A1
MR>RB8P2JP7M)SN  #UBD).X 1!Y&X8(*X&(FQ-C+,[H2CVAL QOY50<@(K$-
M>30#"0JHPS;F<0UD& ,6D#A/,Z31K09A0Q3HNH<UKM&/=WCC2M Z "&Z88YZ
M^((4YZ'\]\&O97/@HQE!N7A"]O&'/0!;ZL 40@DJ *.%M"$#80"#" + >C],
MH#?64,$"3H$7$  #A$$<BN $/"$ MJ$2!$ $O. /M,$$)  &C$  4  0H@ !
M>N!*V.$,4@ )_[8@'J8!!#!@";9  $+@'"8! 4@ !;I@'IK@"3AA!> A_&SP
M!LLKS#2D'98!'L@,D\(!#@*@!OJ'Q_;K'\@ %FXA %2@?[I* %[C&4P \/ZA
M%10@"BX""!0 <E!  IRA&S: "NK!%33B""9 %XKE"S; #,9!"#9@#N A!"I
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M]5S1-5W5=5W9M5W=]5WA-5[E%=-J]4.,J<R\=+/,82%"2<RN5$/>].,BSSM
M2;14Z2)L:1,1MI9R2V'G]6'3[,CLAAU/)&'%3,QBZ;6V;1QJQI@@K6)K"1SB
MK$NQ!-*J#!S*(1W0(1W,H94T46'+P942XM'$(1UL*1S" 1TV"D/*01UL8F4^
M#\)2Q,* ]<&.K%47-;**UL>*MFG/#<F,#&(ARYK@U"8F=F@WKAS,83;,0>5D
M2QW806MQMA)C;D3LAE^UMD#,D22V31,Y-F?W=;__MM:3?D0>4"F4+G-B#Q:^
MA.Q$**Q>"35IC;:WEE9IG59PR6ZV_A9QI=;>+F)EJI:?RE9$Q '.+C7=&(2?
M3JDJ0(EB0T0<%FT3C0FVNI1C+Z(<[+0J..TB\JW6DK(>4K="5#9V^=:]&#6S
MB!9PRY2U.O7$"%=W'^MHH]94A7=Q>[=QN882Y*#<'B03"$1JTE8?2 $4\F$>
M<,GB'H0>B"$9Z $<WF$DO91?/W9$S"$?N $>D F9V*$;4$T?E$$9T(68N"$8
MZ@%S$P)U@Z$1BZ5FNX$?Z&%S,Z0<UH$>^*$>'#;"UF%:U$$>&B04)"'SOF,A
MTH$8L'?!<O=2X>LBJF$=_U1-8!=O\^:4LOYUY6Y+ZN TQ1HOA)&WDO# !U)-
MMIBB!=K =4ED6F;A@RZ!#L3@/+PV(91!?^(G% @@"X9I'9PA;%,I'#JM0$0W
MVQXM(5#6TQ3-'RS! $+@/&SI'B)A"HS@"3)!"(J@I%KV"0[ %.[T09AA!VZ@
MH+;6'2KA!*C (MC!EJ8E7ROQ8](69:DA#T* #F#N36W"?JOB%:9@"9[ %8I%
M$33!"VZ@!J.F'8( !I"B1#;)=H^W*J;A#$1@+]@@"VAWQ2XB%?2@"\Y@%";A
MJS+)&,1@#TPA%9H!'#RA"O;B=],!%^ @GQYD'*RA#BS"'R2AH")D'&YA=4@"
M'?^VH1"B;K_*81H H8(U$1:L884O;B$P80&^01Y!2QLR('Z MT+0@1I^8$O^
M 1=00.=^9-FVZA_T  #$8!RDP0OH("AL 0_P.)O^3&L531WZKA[(07-95QP8
M>*/.X0 ^8'6*J3Y"  ".0!RR008F(!$XZ@80AM/"01ZP%QBDH ?NH1SRZQ^
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M5 $!A/L?_( &1!=0<F!:N@$!_]2R)J'63"/D"RS!@_\!'Y @'@;6=B^B%3P
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MZ+#/+P3\\1,/!Q"#C05$0+.&!LM@HX$7'@. Q3^2 &#(/]MD@ (\G@"0@BG
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M01[R<8D#/*(?$O\P17PN< EV!"(N_] &!+[Q#W8<P1G+X,$@>B6 4OSC$14
MACQV4 =FU $ JS &#&13!Q^0:G&G2  =P/&*!$A!&X@PP3O4T00XU&,=8+A#
M.IY!IW)0)AX> ,,_]A %AS5"!.I !@1&\ LP.* 1>B!$(=3P#EY\@!7) ( Q
M_ $#2ZA#$AX81CF\,0-[](,'16B%"V0P!C?D@UT/:Z8SGPG-:$ISFOGR5R0R
M\(;\$",*6'@#!DHPD'\LK&',Y-<WA+4.12 ! )(0QQ 60(M_U&(")T '' #
M!O0!  K_D 4 B'"Y7]S@ "' !T'6X;-$5.$/#^C"$GM @%W,PP4(L,?_)@ P
MA7]0PP8*@,9_;@*B#(CA,?F8 3[-,04.C$(C5SA (."0C']\PP ZJ(<E !"'
M<.PC!QI01B@T8 1KK,(4]?!&!%( #E< 0 OHH ,'*A$C"^1@'OYX@@(X$ ET
M2 8<#J$,+3(0"H+800:#7,A8!](,!VRN%0LHQBAL4 ]RK ,>[*!,,!X0"X(8
MPP#<J ;L_F$$(MP$"900ZP*X@ V_O<!&\D3#%PS@Q5+0[E]3$ </1OH/0 2
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M+O /\% #CO$-,@"/-T 0-O 7L]  &2$.2) "-E(,8/ (:-()*V _"Q$,"C!
M<1"-^>  IC@.3V  $]<.>]!T<K<+Z( (*E .K- "!&$&1_ /[\ "RM5>G9 (
M#C#_0/X@9'[3 +Y $/*0 DXP!I(Q!4EV!B)@(_X  N6Q 1@T%I6P!6JG8S[@
M,.H@ UU&#0%06*" ==.69-.0 ;Q $*.P<_G1#3"@*)90!9'V!'8@![?S#Y3
M!01Q#!> :15I#+!@ HDU!_F4"2D##EYP902Q"N1@!]9C@ PHFJ-)FJ5I+_Z"
M#D;P N3P#^1@!2*0!M 7 J.P$%,@ @;U@?R""D\0"')0"&:08."P!0=!!B10
M$\^  S?P!\T@!RS0!<#@#T5  Y! #W$P!'6 !EJ5'Z$@ D/0"E%0*,'0!33
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MHI *#S )^@ (#F *-S$_.L .YQ,$%X (J[ )-5 *YD * [ )\? )#O ,@3
MB* )*D "TU )!# *E ,(%A #?X #V1 (-E -NJ #1N:2$V 'H7 "-; -O6 !
M8W 3OZ  .^ &7."-E.$(// .J0 #Y; +$S )C2 !,S ,\O #AD .C  #SD -
M") $OK ("] &_- +!: +E+$(#  ?PA4#8S .N_ !:: ,9@ !@. /(X  H1 *
M/5 ,B_ !EJ /=" "J:!5"Y$.)% &_]4 D, B$W!A21 &Q9 /2;!EKD60^3&'
MHH /5H#_!*0@,0N1"EY ":\0H)6P \$:#E&0 (U0"U(0"YG  ^BP#3O@!_+
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M)YY8X7)C8.^^DO/IR4&#2 U2]J@@N.8=O40D41X31OHOF )0=OI'E"]:D$?
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MXA]FL$$R_,$$$\2##%M AB4\L +;B* 7U^#'M'[P"D6]8 @224$:AJ4*'EC
M"WSZQS<6( =U2,(&_\C&!_BT!#)D-P!P.(4KUH ';ACC D] APQH4@1M"$@?
M(NC4-"[@AV1P 09V($,U+G4."UCB'VH(PF^C$0!,_&,7$' $.AIA >ST8@"A
M+$<7CF$,&>1!;A!X:"$NH UTA  2P;"#!;#QB@K<81A &'0S1!!D0)C@''3I
MQA4$L(]EI( $O4A%!;;UD6Y@@&%LZL<,)I&.5&1 $/FH @3Z\(WW5 (5.HC$
M,I  @3FL@@@4^(8S.("=&$RB'UC_@$ 5:B$$(_S#& ]H@D0B@0?]H@4?7V#
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M;GB!+P"&4C"%'-"&:N@""B"X8-.NY+"&&PA/([ "?)B%#4B&<UB!3W@&-^
M"D2+<#@!+L@&1@@ /OB':1 !?O@'3. !"PV"!& #1  %(FBF-4  <-B%!C $
M:-""C[R%#=BM"PC,$=@R/*@%:F"!;9 '.H@ 6RN==? !*S &6VB (7B'-VB
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M^X8&L,/ L /?>IL1, 9MF 9G8$L3$ %"J)X]0 $@(08(L 0E< )MN(9AV =
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M'6"<=:@">(B$7PT,:(@ Z?@'0;BR?["!(.*)-WA+B0@"+OB';7C?1YC%0]B
MJ,@"M!H&\64>$\B"(TD'/F &5K&$!J#9C]B$"<C>?QB#'1@',/C9P-@& ?\(
MS$CHQ%9Q A)X'7;0@5 :A@U(++B4@2]8$(D @W3M@A+H'6]0 &;@A0ZPPW\@
MA6]@AQ?85ATHASAX 2")AAIP'-/T ,8I@GXE@D9@$"Q8 9R:"%;@!62]UJ4:
M@7^(!!UV98GH H#MA18XDG%(@4V !01HWB+P @#;@3?M@8GP!!3 @UPPEC1
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M,!  =) &"A@#>-"% )B$ST$+^V6<)\#4*69(M @& \B!:% '=M@&/. '>#
M&/\2AR0(-DT(N7\8 C<_@<F=A<4;$!APASH(@'FH!AL@@G0H!AU E4?P@8G
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MPA1$@A/(@/P5 0[\ R"H !48PS^(@@>L E$ 0E?H@0X@0"6T0Q'(P!.(@!=
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M&QC"/#0!(?@##]R!."R#!ZR2-ZA +*Q" <S!/T2"!T!"(53B+P$#"2Q"+>!
MJYX"#+3 .&S#"R@ U0R#"J!"&1! (XP(#W#"-T2!JJ3#%JS"+!B )*"""#C
M',B! 42"P40!%O3"%R"!54$.&'C#' 04-'A $80! H#!/P##*">"!U!CX1YN
MXJH,(<C!*ZS )&B#"WA /<C"#]@ '30!#;@!&A#!","#+]0 _Q:(0R5XP!@0
M!!)@ C_,00*4@3?0 Q(( 1VPWS6X  _LP1>LP"+ZPQW8 1G0@-@U PYD@B5O
M0RO; #@0@PV 2CSP@2-\ 8_^PPS(PCG0@ #$W3^<01?\Y3H$@0*HP3FT@ !
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M!SP$)034*J"].8! (1 N#K\#IXM'.N2 W_/"SG&"#OA#.,R!"MA-#A3+/GA
M+'4!J(P#"1C(/R!!!%[# WS/,!C Q+P ([A#&"P F*[!#/Q#&' !_S(0 PEX
M0#L< <-+@;GX @V8%"&T2BL$@%+I03E\M\]]PP5TBJLHBX";@ EOP@!\CQFP
M,R!,0"N, R4@ 2TV0!CPPQ^H/F[,0PU@PSB$0P]H03"4 @P\ SAXP2:P R%P
M@)K/5X7#?[U42C!<P!Z>9/74P,.<PXA_MV=FC34 A Y@__[AZS:/1+1_XA@2
M! +D7SH9=OXY(]'LGR\6]?YIX?+/' ]<_^;=X*9LP2R"_]HU^?BO'HU:_Z*1
MZ/9/$!)0UVI4^\<#S3]5"^"M]/>OR EQ!#.Q()4EW,*&:'A$!;:AU#\6,Q?.
M>/4O!Y^%__($^4<U*L.E_[*P^7?, #:"N/\>3),*4M,"$Z#^T;GR3Y^'1,PF
M_%I)$$FC?^]8^)*Z]-R1 F7$$;LQ[]\:'O^>.?!$\(T70@B>$4RSYA^S ( (
M0KL ;4PH@G:*$"068P 3?4CI_-O296T9%O\@&2&X!G5#; ML$1QG9,B_%,G'
M51_W+Q8.0U^4_).DXZC:?]E>[/MWSL.A?\8:2$.E(!BXZX]IWJ#VK]>$:^/,
M$303?2UL)KB%('X\ ,2>#73YQQ\)#"$(F_+&^H>))PCJ9X=O_MD'BC^X,.,?
M2I  "84KFDFF&7+NRN6"9 B:9@)3V')+K:66@0$&18Y"CB C(/G'!5@.^X<,
M)@B"HH^[WM$A#(+_ O'@G,RJ6H@(,/ZY0J%_EKCD'Q+$(.B9&_KI@XMI@JE&
M'W$D6<&=*W'XYPLG".+E 6WNRL<%!"QIYY]M-OKGE1F6$F8/,%9PJR9G%J,!
M%?H. : )4.3Y9Q#PD!KQGQYDQ-!.+K2 Z0:W_D&"DG]::< ;D/3)I0H$* K%
M@7O^"4,$<JI@8I-//#%%FP#L_.<4!:;Q!H5U_@G$.&$0X.(;<L819P97"+IC
M.&)0HV\-+_ZQA@%7QBFBS6L6:.6?1C %1059,2F!H(;TN:&8?\H9@95_W"&A
M&F-@(",3/X2H5[PA!1Z8X((-/ACAA!5>F.&&Z6-F!22Z2<<2/"I2H30&_T50
MAL@,4DEGGS*V6>&,<,QIPQA\0,@GG8"%$(*@'-SX!QX0.+Z&!G#^@<*X?VPP
MK)\:[C&0B_MZ@<03#<A5YP:^J+G!'W%@^+*8'Z)TX8U_O($ C*AB^?(,=@D"
MQ@ !1JKQGS9LL$T%>_Z1P9J53F@N#1'4(>B(-OY1(X7K M:BR60&L(2@7V"@
M9RQR!OE'F"ZV^&</+#8,X!)T;H""H&PJ^8>*3?YAAX9ME'0LD0=*L8BC,T+X
M1YD-9/NG"39JH8 6@MH0ZYX $EG(G"-:4*,<@N@XXQ]02/DG% @^.V./?R:9
M($L]Y+0D"M/2N$L>%[)PKH>OIEO(NG]XJ8!C*_\^XN0'CL3+9@<5]9% /6A0
M_>: K_X9!N"EFKF!F7^X$4 .!-G'* 8!@?[\@Q&L^$$F"#*/%0BC&PKZ!SU
M0+Q_%.,%;5J+%$; CL_M8!C.8$$G_N$&U """@3IPDO^L8K2+*48$)#1!3?
MERS4X3'B4$<UE(&'!5AI#7\@R!<()X.L$805X7!"=/[QA"0U)!XK@ -!)N$!
M?)QE2B&Z 2;:L!8D<.D%=R!(,TC0#S80827\($<D+%4$=E$A"DM)10.,\1AY
M<$,-$3 ".HPA(5?,X!_-R$$DXL$"1)% 4>]@5 [C 0@6/" 7_^A$&T] D&AM
MZ 5VHL+VR%$#49'*5*C_^IP:UK )$ 30$P[ "!QD\ P2C.$PL!A J@)9 6MX
MPP=WFT3/LI&" \AA*9>\'P1ZX8?:H<T7#@B&(*  !%T4@B##2,#Q1$007\C
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M\!EQF ,-7 B'*U9P%!G8 AQ>B,,_[K$"*83#&3& !N104(]Q6,$*X1 /(P9
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M,(,;I@ "J" (:L /[F;'K@ "ML *:@!E4N %R, .'  6M/^A K[ &M9!#1P
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M%,1 #@8M$W @&.[!"6P %A)A"D A$N!@$U9A#-B@=F;!"V@@#'3F'Q2!"(Y
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M:( MT'6"4US" ;JXT#^(P04$'"$*"A "/]@0 !J\P #,T ,7!K$$+[1C# V
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MM84;\R0:OPB 0@A=#5M 0(#$-"9/M, $2>#B'[1P *K_\0QBB&*>G:C"/]1
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M1"/P-N>P @)D)OY0 T200&E0 [U2!?#I; H05E\% G6V +IH#CF@!^40 R
M"O3@"G+08KRX :D #QMP@4:@;$HD#B/ 8MP7 N6P!2+ 4JTP!^$ ,WQ3)>2P
M K0PB8K $YV@ '/S#UVP73, =G;0 _'@ M35$0'P#/MP [W"7:;X#R=@$YH
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M.F '&73$VA "5; )<7!]N8 ""2 )X?S.%7@"F  $7^,(_P.P!$^0 $K@#]H
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M^IZ?^JH?%Z</E/P !A;P"N:0^#Z1K,' UINB>(>_](M_F%AOXIF&#TTP D2
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M"3,81 (YPH\@K$$(86C_3D: ,80F$*$2R<!#"D8A!0_0HA(BV $I9%@&(L2
M#O(+QCS;\P)BH2,35ZB"%9CA#3R400T\0$;0V+&((LR"#SCPQ#\$T8-EC8$(
MR\!'(9P0BR!TH1FB0((4].:-"M"B""<0,!PW\0<AI.(?H"C"*\#0!HV=9!)&
MH (@Y.>*&* @$[[XVSYJ@ ) IDM^:C #*6P0B/W* PY=F ,PP%&+/9C"#VV8
ME!J"@ F#7$,-<W!$/[(F#C4TX J+:T(@FB$&6QQ$%I&0A"=)(@P$W,$@;X"
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MY>.(?8"!AO,#(S"'6I  /WB&<^"$%_ &;$B!W/N;7_"!_5*"I2F",S"(/-B
M8FB&%N "=AB&!L "<MB&")"T,[B!:0"&&9"!<DH 20@'7'" /& '7<  ?7 '
M%J $9" # )@&6D""@L@# ?B(=2 %&&@%=ZB#!X #?<B"'A '7-B 8Q@';\"
M.1.% Y"%O_D'.]"!?VB& #@ECLB#;0$%.E"&++B .@ &+," 1%"&+E""?W $
M"B@';A" 8_B'3-.;?>"T?]#_A""@!F1@ "D !0FH 408 DPLB'X0 P7X FM
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M @@XIXP@ PG@ S70@3M0!WYH@22@AE5P!R)XHD\H@3'A'';@@3/8!ELH@#S
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M/<Q-1G#P-=[?-*B":7@ B0$'>IZ!YB&):U" Q<E$ 5!3._A;DN '-3"-73@
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M($,K),Y:)&ZB&[39-8*L 0*G[AS1?#N&%:B 0S8PHO8):L]?BI!'E+]0&3V
MPJ'O\88*V/_#'8680,TGC)+9UWXGH7A 'Q3"#P^1W2&P,$$(/(UG"I=" 7YY
M>SB4X80-'(C"[PC'.;I@@1R%=QQF0(08% "**V"""S^(AYK9"':\PP74#]DA
MV#\4 Q3P@0-D7]T5@@X @=T%5CC P0O4G#BP&C>\@"WX'H*P0A402V#I'0F6
M(!*)PS3@AT($PPTXP\#@P@4@0R"!@QPI1'HI1"Y4@>(YV6KE4)J%0PW^ [3H
M@1G ECGD4;20P/!Y&6_$P@;XDI'%%G,AUT-4@>3MG0]RAPW0'HSAD+9]!R<@
M06UAD6P% 27TT!=FF'=DPA$8%X(X P@,WC<H@#< F7!IFT/@01'__L,8]!YN
MD>%FW>%VZ$$/X%863D@YS 9/'$$]_ ,<#MZ,I0%=)(,#>((:\MAK)0,)N,HH
MB,$)_,,S) )N'!Z"L(,?. 0XE((BZ19H49PAL:(7JI[$2<@X)$&$_8E8X9=#
M+$,,6&'UV14%Z8 O+ 2K4<,6Z$N-Z<,V.(0J5,%_C& )1J.ZI9 P6($3], F
M],T)[$ <P((KC( )H,$"V8(<# $6[,TY]($;!,$P)(,.U, >.(B$<,,9 $$[
M3(,>:,(C<,$3.$,G+$$9F ,_9$(:H((6>$$T3 (1'$$A_<,GB,$3G&.K^=49
MP$ 8B ,N.$$I_(,Y/ (>:$']Y (&L$ G__A%*T@!%YC!I.C"!B@#-(3!(B#)
MU-D$@E2#)1A#*^0!$84#+WS"-+A)-1A",BC$/&B"(12"@\##+[P"+R"!YCG$
M.1B!"T@"Q<2#)CB!(UA/"NT#)2Q"(12#)W0",*R#(P0"L?R#-;2!%8C"OFQA
M+QP!8*50,'BE-/#&)0S")-"%/\0"*N3#&&2C+^2!QD"%$$0#'(R"0IP#).C+
M,VR"/6Q#'@P.;!!")QB".H #'UQ $-A".O3")7#1+VC"(#"#'A5#/J1#(R "
M -X0)HC!*H1$'^!!/02"4SG$-M0!)<R#0@ #"1Q(*S1 '7X'*_0!*OB%/\#"
M/*!#,\!"-FD,//]TPJ8,PS0T@S@<@S9T@T-<P1Z(@RI@@!@8TSI8@S0X2*OM
M331@ ^(H1#.@ NFM RCX EW4PS<( SC$PS< 0QZ9@S5X@Q\5 0Z(PS $@S#H
M6C48PQ@I!#T$ W:< S1,@SZ$PS$<R#_80SGX0Q#D #^8 V_Z0S<,C@Z50R=@
MZ#@H P3DQ,G)!S3\1Q<E8$AP)"^0 #7@QD%RT;+YD629TC@H@LFAT"")FCG4
M&D<VXA>NT!/Q!A#&4+[)5I$NQ#N\P&L<WI)*GFH)P1=4V6VAH7>$PPM$ @N)
MV&DIQ!X,7+'!HK5)HYE*&E(@ 2;4 R0 @"CP@R[4P#V,@SLL @(<@SG_F (5
MV(,T#, 0H$,4Z((Y, $(Q$,AS, K[80P" $$S$,VG$ #>,(NK$ )J$(J0( V
M.(,3#( F7(,-R( A&(,,H(8K(,$Y@ ($(%\<A  ]3 ,&<$(X0,(#Y @J$  R
M7$,&] (^I $)@$(]B((/)$,RU, 6C,8&1 ,_8$$&Z LP;,!N2(@C3( -O,$9
M'( C.,,)/( 3X$ 6.$('? 4U>($B2(,4F  ^8,(/>$ 0> &),(0[A $-U,(^
MN(,4($(Q>$$*%%(,80$C((,') (V4( ?@ ,E-,#>)((-U((9=(!%+ $*+$(3
MY$!]/5@)> ,D+("^C $>2,,)I( ]X,(*F( <_Z@!!MS!'[!!1/S#$.0 N'3
M(HS#($R (JB#&3C $#B"$>0 //P#'H! +AS!%9@#(1C $/0"+_R "^#&)G0!
M*]3!#1##--C M,[!!;Q!VSF$)3 !(:0 )_Q#)J0 &1B! -3<)YC )CC!#*17
M-/3F/_QF'2H6)H !(9R &N ##EP ,&Q#"23 $"B!"DB"&N  #$!#*P#/.*0"
M"7A<$<A!."!" )S!+L"#%^!!'?Q -/@#$+P '6"!!.2!0@@"'D3""+#</I0
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M\) 2X($Y8,.FU  ;7,8-W(,YT  N_ ,\Q, RI@ ?_W"T!%B$A)3#%_2>/K3
M-JR"";B*/2# %1"%" R%$<R 0KC +SM!"/P''3SA/TQ!)V1@## !<4@ PP%!
M-D("2> #!-">&O# /T!# I G%_3 !2O -?Q#'-1 >NV$%0P<-*#&( B 7S3!
MP$W!P)U" TC0VOHF<%J10I3 $("B')B#-I  Q0R" VC#-$O ;*! CGA""N21
M$4B!0A2!5,P#!&A,-@@ '\? (:3#*%2 )8!#(;! .8"" +B"-90! W2#'<AS
M&4A /.B#" R>-4R ,?2# #R%'C3"/Q3!)XK#%MS &!G"7>P$*70 *8B#'?Q
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MA*2#"U0T&5  ,0P#%B@$-;#M'K" JT2#";A>*[A 5TM(+Z" JS0#!'0@*H!
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M@3\CKFA%#)8(=*.$=M:@HI!%+DDH&A+J-",%%Z.Y8<M54/"R,&R];.;24Q3
M1H_0["IL&Q&2H<<?>2;*YH5]$LH"AW^VF< 5=<GY)Y,@RCW$B(3>H0&5SA#
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M<(<N]" ?L?# %[#1CRTT0 <L $4WFE !3?1C(M%P ;S.=P<#9,(02\C&.Z9
M 4&4 QUHR( 9W(&/$Z0@$%80PSB0(0,'R.XNNE  $WBA#B!$@1=T*$,XZ.*/
M&^"A%U,(BR(4$ 0M7* )^ C%!"2 @C.$ Q(+$$(W(F$!-1RJ(*=(@ N(T 5Y
MF&,*.\"%);[0#F+_A( [U;B!#H0QB@YT 1Z?0$ E9-&#78B#%QA(P3*P@8$F
M^",6$9!#,Q(P@S $P0&C4$<+OA"&:N   ]H !QH$ (M=], 8^RB"!FSQ#"]
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MQ1)"\0]/B.!],USG/]9P@4 (8PZ=6$8#GC ,.=RLO-4 QMVD,1!] <!)B3B
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M!<[LT@ P__1C@":ZN$"3#T@5H<=,Q"C0RTRNE/ /-@;8]<\F%^S3#0S*P!6
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M)A&%:!2B \]XQAFV(8H 0*$<YII).3RQ@BQL0QQ)8,$CBH"!"S&B",^0@P=
M\9Y[#&$#5,C$%W; #VEL8 [B&(4% N&.*$# #G/801*JP D)A.$?J:B $+(
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M45 .QF "I2,3F<  KX"-/% P[^ !5L$TH. . M %P] -0U *[" !V# 3;;
MA! .^0 $L  !JT8++/ /H[ )_X , I /3% !MJ .HW 'LJ !<<(,#G (XE -
MI7 >W>1#GL !,$$..4 $>302"E IKA!6C<  EF .W2"2E0!X8. &;R$/$D!^
MDX  4&4#J/]CDZPC$UJ@ 8F0.NQ@ N,V#0N0"\J0 6KF=Z (?<[S##_ *H3
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MX 2*P#DBH )S-8\LL G2\ (BX K?8@)6_P '0N ,^W &"( 'UA $$( (OQ
M3> '0J #M> -"> %M8 .1^  *C "SH /6#!)[R 3VG #;'==HW #5+ -EC
M45 -E/  9K .A_  %X  <$ .;5  5H GS# #!V #+K )ZN %'B &0B  8_ )
M$* (=M $X3 ,.S  *#!@XP &!X '?P #*3 -D@  1(F6;^$/++ @+U0P6%$/
M84  G% -1_  KO .=\  -K #JG /7K !K< ,*; "E3)#)W #?C %#[ 'K9
M,< -@D !4M"*_W *.Z TUZ4.4K !;] &&% &X( &"W ':?  *@ +XQ!]M;4"
M2[ '-M  ;M DF_]P#2ZP"^9@ DJ@"-GP S.0#[WP $9 #;@0 5?0#Z9  360
M!";0"L2@ RF@#-)0MO@@"QB !S(I&ZC@ ''P#D)0!<2@!D"0CD62 SE@#__0
M#EPP $M !%M #JP0 4?@"%W00^-0 DGP>@[0">V0!@Z #.OP!360N^90!A2
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M!MS !L@P"UN P:T0!+_:;9)0 E8P,^% "$OP!X: !J"P4J. !)MJ#VBP!G3
M/S:Q#%B@!VL@7IS#!3CP!OTG$Z\@!%- "(W@!%;@"H:0!5+P#8#@!6VP"ERP
M!^@P#5_  K^M!A83"1@  I'@0]ZP!4V0"=_0 S?@"*?  S!@++*A#DK0 ]=
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M\BX9VW23I$IN ,$7?\R(@ 5?_HF'C@HVH?!*Z<P1:Z%_]%&""SMV8 &=:$;
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M I7-X@'",$C:!F@:@X2O(Q6<DK2HA*7I*&04/;!)F;Y L7&XP P]))1MN/4
M4A1$"CB8(2$8<4*A0$0.J0 B0N[0N^%1*0]8* @F6D:K('S!_V4R0P@2V)C&
MA/2'AGJ<(ZW^X05 /(0-U> 8$(&1AH*,(@9]%(VEDD(F'U+1(.C@@2R8AS8R
MX<X:'C $DQIBC5 4;3RY"P<F4*&;?:P!8^M!A@Y&@;SEQ;)A)XD"%>H7A@]
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MA!P7_(<\NG"MFK3#(0RLE5F.V,0J%@02FJ(5#FCA9EGFV4TXL80"@*&.(<Q
M"O_ A"(*0HT#L-@*8%!'+@P@B55@0@X>\,8@;H& 5L4A"^"HA >V_^",7SP
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MAQKHE7^X S-H!04(LK 4@'+(A3_]!RZH1:HX! _H"UAH &CP50-@AS\8@GV
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M1L@ +2@(*&  *U,(5HB $60#5J6'%^"A?]@#5OT':<B !1T#9<,'#R :9&@
M4@@'&'"$CXF"02P(&MB83P!+,KB!RJ2"[6R 6_@'9V6@6A@ !&8&4W &>;"&
M)!@!L3H(;KTL1[@!=7 #>?H'(=@66R6G>/"!02N(=X$"-DB(&3@>'Q >7:B
M>7B'_WU0ACN@@%B A@1@S#28(H$MB&W(@(,U E\<@2^8H5 P*JH !+!T@P>U
MAQM0XSA( U1X@&(HB$+P 7/@!1X0("+H)(TP! ^ KY/M"9)E!S'8@0IJA41L
M"'N  3DPB%JXH$4@@A7XAG\(10LMB%R8AQ<@J'\8@AZHB6"8AVY(VG1HAC10
M #QH!@'0!8/(AIEHB%O 9ENL ,D:!:_5"+ ]P'60@;,QVT#R!1:HAW"(AU8
M@@R 'JXH!!;H@610AQ;X >W4QA=H WH(@8WAZ)J  Q)8/'( @Q1HAAE-!WY
MU:UY <A]@;!1"W4P!!UH '(J@K/Y!R2X%DH8@5ZH!(@D7?_3?5BX ((D!@4'
M& 46&(,2H8IG, !+*HAV,(<3(-?_E 1S$ 09P(1)X('P 8*!50<44%YK4 %8
MX 82\ 5U2 "B,8@_V(%,1@)*&)E@N %\"(<<R,=_P $G()=(1%]7V,LZ& )S
M$ %3XXU_Z(0J*(@K.)M#4(*"4 /-,]O(]H8&.(5_\ 0'2$$>6.1_,(4$4(4$
MP 5YZ+&"R&K*^(<Q,($1 H<N8 1F6(!1:(=V( BD-<L[*()XZ(<I\P8:R%Y
M"  JM ,7*!(@T)1T$.E_D.V@H@%PX ,4J 54\ 9N> <2>)=_&(0F2 UQF '&
M_(=+:(#Q&0-N_H-!O.(L/G#/^ ?_?Y" X/N'2O@!"SN[#PB%6+B!()B'7E
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MWQNH'UE@ -]R@QNH&,8U.'9VAQ6XAG7X+GB6)W8(@AK6@W'17E/8AP6P,D!
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M\(4E?J"&5O1@%*IP@A"D00@M# $4K+@ #"1@@!I$@QR%\,%CWO&/51#!!'D
MPAZ T2-_W $+V3!."Z( A0*ZSA8_L$,I5$ "_NG@"[5(!QU($(!.=(H2(KC!
M'-90 Q/D0AY"$, ;[N %4=QA!48 Q1LD4 185.$'96"')%S0AR#T(53W\,($
M#. &=#C&"%YS72=@4((EB, +RH '$0:P@#68PQQ:0$ 8PD&'"B@ !*#(AA=
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M&^WH1_O9J/4UZ\'PF^$#&S#$; XTC7&L9PAS&LYI_C2I,0W44J-:S:..\S^
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MCG55Q50"%U2,$AA"5H(> Y:5"7Y$'[A"1.C!#"Q5YIWEB:48BLE96:68/-1
M!B*#/D#-)(SE/]@!%K!4.9@/ \)"!VC&/WA!"7Q$+I#*7/;86T:5,]#0UPW-
M+E!/ILD89))5#+J"#^Q?,6"#AR&&)$Q44X7" Z!A ;YB:SY:RFS""- "&BA
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M%;C"WO;M9(L5PAA" DQ-/ZP *.G##RS:/T#""JA#,3 N'A1S&,1 1.\ W@6
MV)Q""T2$(( E*$3 !ZN"I/2(*BR 9J2%:>L'-/ H6C #,3S"%50 HS;!%-1&
M#CQHY?3+-8Q!\*6G LAC*&S FXS!"HC#(,!V1#@!#XP#&)#B/^" 8*;_0PV,
M)C&L #Z, PG 0:>D0Q+80! $P0D4PC!@0#)$!!64AB^@P ,V@>U:PR940R6
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MTD"#E H CDB%<&#A :)"]/53'--0.P&C$\ P9P4_2E)''HC_B4;6DLA1K)0
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M( !0O"("3K!##4#0#%@$(#DI*$4Y+/& *=SC&3U0  ]T@-/+\8,%2/B##!!
MAWDLM!=AL()F_F "6,0B"=NPAQXZ  EN "$#J5#EPTZ0!#A(PP4@  8T3# #
M8HQ+ C/X 2;_!J:( :  "CV(AC=8$&0S , /[W@$!4C !Q*LHAM[EY(S0F
M/WAA$>%8!-[4X8%.M.,(;T#'%SJ@!BQXH9\F:04%.,$/7*"@7+28P"W6"!\C
M0.$5X"$+6@ ?X@$%@B >0J$ 9 $<O$ 3T@$/>"BG,$(=4. -,.(2*D"3_N$3
M.N 1>($'HH ;JD$ 4*'%!D$%\F&M)J .K.$,0* 5QD$)SJ,=2$#$IN -?,&X
M3"(?+D"^1 $&T@P3)L Q[D &_@$=5  1< ($@@09$$ 9> D&<,&ALF$0.D 6
MTH$-2* OT@"P_  "G"$??" 3RJ$04K 8QJ  T@ 9. $'Q.$4(B M_Q1##3*
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M&GB =E+81L=A&K;@ C!*>8DS"8S #9Y "X04:],!.PH!DK&6%8Z "IB@#;R
M ?L0&2; WI37))2!!9:)<W/8$ZS ![(@'2)A"%0 #%@T=;5W"))LE!\69E$A
M";! ,]) =[;W;E\,#L# .+WH5V!-RYX8BL_!$V8%FWG0%H(D'0C!/;X73EK7
MBLDB&]*A>K68G;<8:L758?]5)JQ 'MJTEC,W3J*@4+07@:<8(ZS 2?[A'0;U
M2[>"%OYW3_DUGO]!#VHK8)NTGW.*6*:'%6!$'*CA%/\B54[9@0;Z(AQ$81^J
M%#[ZP>7BY!-6JZ 'I@_#X0W:PA,@X'2"MP_EP0=,H!WTH0DVP,EL-(EEPAR"
M 09*!']%&CZ\]!4X8 S> 0X.8 GA(Q_(P))NPRX1MA_V@,%JN;1NXQ9&(!R@
MH0E:H07"(1M"(';[$$Y@P2 E[1_ZX.#(%F:](01&(*BD@*B:41G$^'*@@0MB
M(!:I&1Q*H*>\5QY4,,MNXQ<J0#BZ>306X0)\Z1P8H$3(628:Z<J":D[V00E@
MH*R)MYT[.T9)PQV,@1^.0188PAR8 17X817T 1RVP1T4 QUNX15N B>^01Y(
MH1@28Q_B@ 0280>U@190@;3_^E :5($7Z@$5<.$<P"$;VH&RJ8$60,&RN^ 2
MW.$60,(N_<$64J&OPZ$53,$+1"7"X$$=]"$>S*$<YN$=(-$>[.&\9R$!5$%P
MP$$E^&%#S$$?-(-H[D$]Q=%L@\H<.D$)]+M.1:0=ZOD?\ '"XD$?J.)7RT$Q
M)&$BG"$%$(L\*/ ?Z(%HZH$%3+"?XX'=0 @>DD$%3F,K*($(_@&'@B(;;>-F
M=PL$I.2EYZ$<#@@CTD&WJ,P<B  %0.(7/D 0(AHCP@<2M^(==*!'^CG$B6;)
M$W8K5H$"'.$I<J#(#W5) ]7)<1B'#R$O,"(,>  C/H5.XV07<*!Q4_I/N110
M2X(._\)ZS!$X'Y!@0ZA4Y?A:RY=8R!O5R@>F$:1<>N]9HNG\#] @SR>P2LV@
M"%KL&W(\T.-D#_ UH:5WS3>!8AP6'78!>XJ*G]/7LSL]BVX#'YI  )Q "52
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M/Z>(\,,=='A@QAQS&-!+0D+\(DD#D/S_D\T(B8P!01?B5&+ %/\X<\,>E9
MS2DSD*!&/MH(,<H=*#3D2@__(&)!"H9%XH(^E-%B !-_[.# (_^D(<$<-YS@
MB@J*8.1(%6_X\,:M"0 !Q ->WF1) D>8\D\T6_ AA!)S(;>-$&*T($8O)F3R
MCR P!(*1(5BL<<*";RA120@R**.9/EOH,<,9$[E3!!=&)& '.(H@D=87:Y3C
MS0]5B&-.)VAXP<0V/NBP!C*TM$"+&A LH@P7 F!BCH!\).&%+?/T\00L)X0
M##E25' %*2Y5]D\P*'QS116?_%/+%$/ YXD1MT":VOKLM^_^^^UWAH/>_Y1A
MPS^,2/#<D3<0__,/#[K "#\$0(EYD&!_R/$%"R9RA2[P1 \\>(Q)QK&' XCA
M&>D0QPQ<\0]_O  8MP@ UL+QEW]TH1+_Z,<-4A$?<>A#&)XH@@G.H8T*- ,C
M3/ "1FR@-W[48$'7>$$_TM&#%M3"'>@P1PMV@9$J/ $C* C%/PS(C&Z 0 I!
M>$():,&=,/SC'2L@PS\D486UP @JOP@!1C@A!8P,P5W#J,%@UL #(AE)'BSX
M!D8L88#!H $NV:D /M+! E34AP3W$(<-E*"%+'1A##I[5#M^J)E$M, KOE
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M'% )Y3 4Z[ #2= *=X  KD .48(+O> ".2!3K/8@9U#_"D*P K'0#.WX#RG
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M"=Y !"*@"JIP S3P"O60!080!YF  [KP"S(P K0@#IQ@ H=P#5S  GL0#GL
M 2]K!?$0#F3  EYP#&]P U-0#_;@!"(  F" #N-@"#D0!6?@ VOPI9;1!4-P
M!D[P%S<1!V #>O\ #2/P!9MP!S20";(P!2RPAGWP PK@!0TQ%/H@!R,P VP0
M2E !"1W !9H@ 7K@"T;  Y\ #N/ +@X  I30CS1P!,"@"2O !,PP!0$0!'N
M 9(@"3E !\HZ#NT@!0W0 $2 E$,Q"UXP 5SP>8@2 !X@5LQ@!1,@".8P"A=
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M#UBF#ZRP#"YA#^Z@#_'0#F6=#HVI%M!0#N7@#[/@/Q@Q#MK@#1_Z%-B@"ZV
M"\A@$M9 "JG0"^)P#IP)"TUQ#;)@W?\@#[,0"R<&(_40"[.P"LX0"[V "LV
M"[  "OA8#+$0VD11"KE0"N_0"[#0"Z7PA<!0"'Y@&#T3"8K@<?(P!ML$(Z
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MPI  ,-;Q@DSDH@X \(4J($"(7 0##4U@Q2,.\+N7<D,'N0"M".Q CAD(EQ8
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M(6]7M>T_) @ 1BA##R QASYXD 'DR,(">S!'.Y1AGAPQ]Y_H4A<Y:/"-SMW
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M+CR 2_U#-2A +&2#FIG(1 P#"*SD0C@#X R7"HR(/M0!'G@!=_!" \C*(1A
M/^ # D#"/S0" KS#-]S +)R"-& #/8P,,32 #&)# +@4&V1!AIA$%D35/V0#
M"[!%*,0 TBU!*Y""-ZQ5W06B>JXG>PY.1'3##P3<0A3! !C!0O" !\P2R1B
M%\!3) Y.;$3$,W ! +3@_S38  #D 3M$PPLH@#?0PR \ R040 P0@S!( SG<
MQB.T P:(P#90 0#\0CED@C,<0P3T@30X0CSP 0-, S!@@ G 0SW$P "XE"92
M)1P,0!1  S08@RL0 !T,@P%L@!7* 0!<0MD@002DPK.,P#@@0P9T03DT0P2L
M0#J(P@&, #O@@A(00CUH'D,(A#^D   0H3J(@R#8 3S\0 5DPSA @PI<P"W
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M#7Q '93#+BP #%!"-LS !T1".7@"#[#!%:3 *81#( #  IB")!  !G@#'P#
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M@C[@0 LL@R;<1R.\P#+(P$@YP1#\PQV@@+]-@"PLA!;$P3^00@=,03% 0A5
M@P) PO\[B$$-M,.:GH)+V<$F4P,,9,)".,%TX8$-+$0/(.O!F(,1$$%O[((*
M;H,+L$E*] ,+( $_L$,<; (X8$!!L#(PP (%^(,X6 $3C ,J*,"U6H(' )TA
M=$(PR,H_!$,#9,$YA ,8U(6>I@ B_L,MZ("4< +/LF$0.(XY#,,+N(8L;"TD
M3,!/B4,:1$,?DBU#-_2[T<0U6( B!(<]D(,\-$(@N(Q3X($($.I_MH4YH -)
MC(,]U,(U7.A5I,,V7,,Q> 4TJ((H+00[^((N+%8_6,,WM'3$D(,_@,*(X(,L
M>(+J&0,FI )Q3,,I#$,W=,,UH,(QR ,J^$(N= P^X,(HJ'/_*:3"/BB#+%R4
M-U1",^3#+V0#-+@&,0P")!@,./#"+^3"-_""*ZA",NP#(1B=2LS#)[ "P< "
M+MB"*;#%,R@"(HP4.NS"&*@"<!P#%EQ%V%9$+EB"*GS")P"")R0",'C")LB5
MI3T#&4A!*D0$+T1!'9P#':C".VR"%=S!-$1$*N"!$\@@Y8R#&+0!,71"%B14
M'CC!'<Q#/\!!% Q!,SP#%D!!&0!F.-!"%%2!<"W%/3C!&]!!+RR$/LQ!%Q1!
MO(@#(52!%TP"\&5!%>B"&*C!*ZS!$;P!T,G!;Z_!T8T,-.  "$1"']A +OC!
M$8R!,-!!%E2">11"*!+(*+" "$C+_S^L@A<8P S,QSY@ 0RH ",,9A*H@!^T
M0Q#0P!ZX00TT B#H@"9\@2ZTPPMPP1A$03.(P@C<0")@ Q"( !"(0B[D0 N,
M@CC4@0-<0 L<W1F0P!/4P0X0@CO@  U\@C:$@ ^TB#7X@!O801S40RH0@0BP
M BKD0 D JE8( PADP2<8P39TPQ0\ !P 79N< @*   V<@3J$ 04X@3*0P0>$
MP2PT@!3XP0A(@"68 0-P0C$(009L CO0P AX@1>L 7*\P@*H0 X<P:S2!"Q<
M !W,PA<\[35T@0&DPG[H*1TD@!T<@R8X0"[D Q9@0"^X@Q<H0!LHP6DTMD.?
M.JI;SDR$@_\;!,"E'DQ$?,, K(VIO\4XY(A!#,,N7,,IU$(VQ,(L:,,UD (J
MU((O;(,WB((W!#4J>$,V6(,N: ,QE (K^ (Q:,,JS((U^,(W$,,TP (L8,,U
M7,,VK(*Q&P,T^ (H],(P9$,I0,,W# ,RZ((Q7(,V8,,V;$,P3 ,I2,,S\+LW
M-,,QQ((V'$,QK#0I:,,R" ,R:$,P5(,P[#LV/,,S6,,PS$(,H$(VK/2X?T,O
M( ,PG ,P+(,Q",,S-(,P##$S<$,W1 ,RG(,RT$,W=$QVFLO@;(@\V?Q9?+2&
MR!?+&@Z'N*#03\3B&$3#+L5D!@<)AFEQ-,017.J B ,\W(,][,/_0XC#/?S%
M0LC<0K3#,^C#+,F#,XCI/SC',F0-..!#7PG$/%##.<RK,N##,YP#V.>#W\W*
M+)"CQS"#E,!#M[A#Q^P#,^3#,\1&/[!"3.<#,\Q#/E"#/3 #]!2(/V!"* "F
M/22"+ES#O<S05'S"?*2#)\C"*SA#*>B"+;!#+32",_!#*32#)_R"+?@"+<B"
M+GC:)JC"*.C!#"B5-6""*=#6R&A#&?S!8HE#*KB"+N@"N8Q,/?P!+E3#(Y@"
M*URV+82"S['!$=Q"@-IMJG>_]PMBY8S!%]R#= "&-WA!9>BI8CA$]D[ !;#<
M!5Q  C0 ":B   1 !P3 #R1  !Q !VP _T! \)# 080)&1A,,!"@P@,8%2 ,
MT# A0 (/ R@H@&B!P@$*%SXLB%!@P(4%"A0\<."@@@ ,!R9XP(!!0H . SPT
M&) AP04%&V(B@""@ X('-S X0(!A XP4&"!$A>  @@(#$BY<  'A @0#( *L
MJ"!!18 7*W*8X)/N'SAQ;]_^DSN7+ER[=^'2_6=W;]ZX>?O&[:N7[UZ]<@4/
M1@P8+]ZYA0,_9HQ8<MW&@L51/GSICA9"D2U;SKQXM&;3ITN?/OPXM.;4E5FO
M?@U8=6+8JW'GUO1EKCTK\0A?3FT[\-W<N(T?5[Z<>7/GSZ%'E]Y<>&/GU9-/
MUS[,WMMQW[__R_^EC#3QZW:%Z;K%"Q>N6Z5BQ2IE2U8I7*5N_8+5*Q6O6+]8
M82466&"YY;]2_).EO5)6844_6%B!19=0;'G%PE\F_(6^5U0)11530AE%%5H>
M\<053Q[!!)--'OE0%4]H<0436FB9\95'<*0E%%="\<0355*4115,?/0$$U=&
M6?$23!+YI))*$H$DD$ ((>200P(Y9!%&#-&EGG_&"8XV[<@4$[O7RDSSN.R6
MLZX3!#(I;DW(RD/33#NCJ^XP-M5L4[@Y_\'DABK.: ,*89334[K+%.O3T4<A
MC;3,,^E,E%(\)37-._#&&<VZ12O-5-11'17'''/N)/6Y2S%5%3H^YW3_;)WR
M8B4.UE335%0T\TC55;:XX,DE%5_4\9-14/]T5=EEF:WUS/,2*RW47N\*$\Q.
M:1MSU3'#"0<<3N?J]EM.JP4W-D[)957=ZM!M-UVXT'4.U;:LW;759I.=MMEM
M[[5W-GU),\Q>2[6=SM<Z\4T6.6WO/1C:8_>-6.)1D_OTX7,HD46<="SA!K1E
M\1IG'F7,L?8M=I()IV#J!%-E$'W$ 2<<=,(I!QUUAKD'''/ *<?GGX$&6BY^
M:F'FGW7(04?II94NI]NGH8Y::G"HKMIJJ;'..FJK98:::W32"3L=IL<N.6RY
MZKU5XGQ7GC@W<<)9[&%/(98M-LG:WK-?YBI%_S-OBO'FU5^  Z856<S^=EOQ
MQ5F.BQYRK#OG/+D.6<"(?YIY()6/E35N'"18((<U1"[PI]%7,U/'#3E0D&$?
M4^$*1X\-Z&C+'$K_.:>(+(*P(HT_OFQL'*Z)+YYJ=\$[5?GEF6^^>72=5Q[Z
MY8<?9Q@MHJBBB2'&V$9.5_-)091:*2.'B$LX9WRU>_8PPH]R!.;;TVOV&-]B
MW*C)),[@5#M,&41P4:J\B"(,AI@5<M:1BULT"Q_8D,==T'$,T?VJ;K^2"S%>
ME[BWY84<\""<^D (,C9)2R]K6$;\Y!(--5A0-',1 F_$ 8]U>.HVQ:&3;;)U
M-QR>HA69D<9GQ-&,5?_<#G'2LEA>7H&"?]S##>P TS]"<0QQ)(,$=KA681QC
MCQ3PP![_4(<C?L"/^ '&6L@+4[O$ 9XT=LJ,;73C&[]CESBFL33#D$ (JF&,
M%"1@&C9<UQ__$8\Y!,./COF'*,#Q#W9 P137PI;"ZO1'2?Y#'B7P12M@D(MT
MK.L?_FC'/TQ1 5D44D_$8$$5(HD.=RBJ$QE@PE[0)4F^I.(+L,# %>H$CG[\
M8Q<JP (I91DR\/RC&"FH0#$BDX\#, *8EXKE/_:A!@6\(GWL2I=<7M&"1*0O
MA-UD5F&<H8MNR&4?[5!'#.-1CG$(0@7?D,<_RI$/>OP#'TF0@C[D$@][N,/_
M,.5XB^D$=HY]?$$(:$ND%_^1#V0(;!_Y*!:MWK%/=(QF'L Q3#WL ;]UM..!
M['#'#-%V-+J4(PMPH$NGY/*.S(QFEWZ4BS_8,I=,4*$NT(Q!-?YA#A?4+C;L
M@%]DPJ$%'7QR+E]@Q5SVX9J<$H8N,9W-GFJ*L*CNBDQYB<<.DB"78D3@%RBL
M39[T=C>Q9@8;4-!+>*8J5J_ZS9!J_1YKOO&#+\DC#_-\:@O_40;O_2,$NL#;
MX.9RB"U M14!Q"%@2O!+M*%5;F/%H5RZ0$U@H,(QT;"$7.B@V+=B)I)&+ RY
MU'$-$A#2+O(HQ3Q8U=E8;HP7#?#KZ9KYS,Q0(P>-_^"F-W%+K;A 8@YS($&<
M,)&",HC#$#0@A#V4\(,_%.,<0] $$2+Q#17@X!#@H,42"M$%5_Q#$2=0 R=R
MT :VV,,)=(B# Q+QCC6X !O,R (8*E$" <!"+I>P B>$\(<]O#,NWK!")F0@
MB4#N 0Y&X$3<:)$%.A!A%MIP01! "8(__.,15?@#&%BP"3SL81QR<  0,'&.
M3'0AJ>H@@Q"4X%=U2,((>G!$P/IA!R_,X!/F6(<C>, #.!C#,/%H@P#.  UP
MY, ,MLC"(\($CTYDH0NVS<LY#%"[O'BCC]!X A>"\(U_"*,.?! $#^P@CS \
MP1/_T,8?6C$(&NQAGNT0 _\;WF"/<:QB#ZRH!!-R\8]+G.$-V?A'*IC@U[S@
M(PYP^,,P_F$/1CSB%EFPWUO2H8H\I $0XL!8'4"!!CK0HQ]IB$,AY $.0[1!
M<G'QQPNR*AX+&/8?N+ #'TJ!#G@&0@QI(,718*$(;,3!&KSD1!YH88H3FN(-
M<> Q,Q)QC6-<X:C@T,8D\O&/6M"'%[EHQ3^2P88SW)H8*^A!+.0QCUGP(S/1
MJ,,54"$7=[3B',A0PS-6HPY:[T(NY/A&-*CA">\91QRI4,6M_Y&.4SB#&ZQ@
M!V!\,8I;L.4;>AB!*6S1!Q (PF/_F 4M?)%"4(S#%^0^&24\D(IXA&,$HIB'
M+?C_F1EZ[,(4\$O.+;X1AH+^ QW=. >JED&$0N0C3/:X15)!TX,[Y"YN84*'
M,_ QEW=2 ][_F ?/#9,.F\NE'/=P08@1]@XM]&&>=IC#/_B1R-'L Y]S<2(]
M7%X8?!"5+N: 'UK?P8X:D#8Q]?(74^MB=[D XP)=[9_=%GN8)5#"K;DUO*3R
M4HH7?/(7&1C%/Y904'3H0 R8 X'D7O%*9- 4#F9UAP *\8]">.$?I8"!%YCA
MBP'PXA^\\^((/D$.2P0 %>=  P0D,0\K#.$?TT  (:%P@5#X<Z5(\,,_)A&'
M<11A#>?81 $8H8P0S.,?-WC!.#*1 Y6IH0FE_P$- .$'_U4@X0G_ ,8*Q. /
M9B!!!Z;C QW:<8D#^*(61B@'+%H@-W[80!#M0(0%+,$<]*$*EB ?#NXMS,$8
M3* 4V$$=9J %<&$0$" :QJ$)**$=#@$ 9F$P5B$##.%[WJ$'$,$=ZF #@B$4
M3$ " L$6=D +/,$/2, =("$!7L .\&  ]N ?FN %[*$(C, =_. ';. 1^& #
MAF$95@ %G(@75@"GXJ(?D  -GN$,!* 80 $%!$ /;("9X@(5)H 8=B$ GL$;
M6N "S( 0'L 1S $1 . 3Y$()F(#X,L,?6( (NB$62" )HNT? .$(A&$2#L -
MKV )JL$1)N 6[J$*%(#)PD 4$/]@&G9A 'P %48A +!!$T  'T9! DK #]*@
M"M7A#3:@&:KO$'+!#   $N#! QQA$SP@&KI!#V8@%>HA#"+@%/XA&TA $3P!
M!L9 'H9@ YS #6S@!"QJ+NZA!.R $D! P/P  W!@#X#  )PP+M@!#.+ $Y
M#,(A$1  "91@ ,CC+<+A$&3@R\Q@'#:!"US@#_X "FK "D !'?  #3;A!32!
M&FZ !K(   3!,);A"SP@#;1A'$Z #O3  ;[@DVHA"^K ";X 'B+#'H0 #^A@
M!8K _*B #I3@#,"!$6" "_X1&X @#[I #.+F+ZA "22A!8! C/!A",B "(:
M&N  "33_806HX!TT(0Z*P L(R1ZBP Z:X G<P1FZ8 =.8 O&$3 .H0):X ["
M00RN0!9<  B2;AP6(0BHP KZH1BR8 X<@06,P'3LHASJ  FH0!/^P1G$P \J
M@0AZ8!HRXQO00 N8  2((3# P12^8!GBP1'\(!O.( WPB2_D00S(X JVJQP
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M)" <8$&,\]@#9&T&!D$N5@$,JL #M*R(O?\H!RJA+3=X+KA !L1HR_A #P3
MI [A<H!3!K*A'RI@$\A)!1:!'#  ?=0A!_(L+DBN#.1"'E" #_[AE>6B"4)/
M,)P@2-MB!/#@'YP@#/X*'[[!#EI !DS'%68@,[+A!9**#VJ $\8@$A2!&G8!
MCR/C%2X 4<IA!&*ADVJ@&IP! ]:@2A !$R@#'B0 >__!$0R4'9KA$?9 !\B#
M![K*%A"@$ BA$@;A@5>J!\ @D';@&.;!!'CG";R %>1A!8Y!+HX@!XX >\9
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M>(!(LT!8[Z(<%D$)4,$6W/@?7"%=<_&Z[[3.Y?^B'G!A0.7$9?>R'.39Z6Z
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M(HQ&(8(!!, ._[#$!: PAA[P0!^@, $&;C"&=;"! EC0!A@H(/_&HL1C!47
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M7>I4K_K4K2[U?[PB 2D A3C&@76L " '[QPZUL/^CRX ( Y[/+O;5=4./(!
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MV8!D"4$$+)!1AT=XJR<B>;"0H6:$O?@/7V (S2$+#. )?7$+%. -4UD4D&
MB=%FA@ $V!1_[I& 1HB"R^*!08=XKU,+B9 098 &B)F%,MAGCA=: D@4[X *
M>=-XY4<.9)  ;(A+N(21,&B 6L 0IJ (>584]3 )O$1HKV.8A@:#KY 8__ (
M4P&;11&5HED4[6 #_]JP#FI@"1 !(ZRG#[GP#\30!4Z@DB@)DQLH(?G@'J6P
M G/TG*]H#DU@30N G+HX"0. F\$7#HPP 740DT67#B(@08VI"6]0 1OP!N=9
M$^9PDS1@!2H)DT^IGSSW.NHP"Y>0# ?U#ZO@";*03^]P":7 #W$X#K?P"<3I
M'O3@!"@P#>U@#C:0"\OP"X'E<H# ,3#2"@. $/\@!0(P1PFA325Q&[R@"X 4
M#\/@'N&@"M[0#O% ",J#4L?P"*>4$+&B#]XA#LU #6V'2M4P#UX0",U!"P?
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M6^ (Z^ )6% )<] &YU$$_TB0!<J #W60!7PA"DW !%D 0\6065H@6T4Q"%*
M"E9P!<Z0$-^ !D#P!_S@#&[ ";C0!<74!UD0!*H0A\Z@!U_@!89U#GMP T'0
M"3-4$^50"&^ ![I!"0W@ WHP20!#"V^@!LS1#I2 "-WP!'8@#_)0!E 0!NL@
M#F, !NRT#2D@ HYP#_8P!J\0.(.@#;;0!:U0#W10!5VK#H+P!(< 2#71#HR@
M!7T 5L[0!RLP")[P!@[P!W?I#H8 !960#O)P"[OP#95P#C6!#I&  $P@&7"
M!]Q "+<@H,OP"92P#/(7#@2#"^P KH  "+J7)[HP#\<@")ST#_) "XW "N]
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MX7 "@/ .FJ !,%04AR !G+ M_Q@D#24 #?"P U,@#",  7H0!)/P!G$0#Y<
M +_P#C;P"F:[ =8 #MW  H8H3.[A"!_P#+7 K,X0 T9@#:=X0W9)#2L05DH@
M &'@"2O !N(0"AQ0"+QT!WL0#C5!#6OP Z_@#ZRP &3P#YB0 %'@"$%  YH@
M!R<0!>/ #D6P6$Q !9:4$%" !-:0!4( #O"0!P&P":< "!B@"<FP#E  "-O
M GJP"SN  7?P GD-,*X@ &V@#?\@"3_P*A& "U,=!-^ "!@@6SIQ!FS@"@,P
M!O_0"OX<" 8@"/)0! JP!7$0 RFP#^$ !9*0"2K@#HC  )7 #%JP NSP"R2
M!&>0 _\AX E,0 -+T [:H 1;(@0J0 EEX (L0%*AH -YD (7:PDB  :88 RZ
M E;5P -Z< 4N$ S[T 4WL =3L %O"2/U, 5?0 <T< G_L MX( %O4*Q]<0EG
M@ @J\ D"O@J5\@,61PU=X 9:L 69I 1ET <UP'9I80Z64 )0, 0!T V6H 5:
M( 06!P]GL 4\$ =7D06V2M9-0 5GL#.D$ 1-L 77( Y\0 5', 3]T M>4.2T
M4 4K$ >RL M',*+2\ 958 33 @I"4 53T SN0 08H ?*-P4]$3A@4 =.L(C.
M4 =N  M-< >L"*W;#/"=EQ S4*S#-SGR@ ILD (\H Y[;0+_@C!#6V $EL (
M@>!B[N$*[3&2"E 0_D "564 D2 (EA (VP"B$X (HS  ,^$>:$ "@B (E! (
MSQ &(' 50? %"1$'CPD,'A #M> /X/ +/!"'>A "@! &39 %\? (\OP/W? #
M0D#M0' )NJ "*)4$X+C31$X*FI )<R  41H%4Y 0\N "$C0)'D /[2 !&/P/
MD8 <;> "3^ $1T"R87"Q1)@06< %-)$"NQL+*W KRN  @, (.7 ;4?"7;P!%
M8Z33RQ(%2;JG:I 075 )RA  W%L(2: *??$..U $A1 &0 #@_U $)L 0QD0"
M9U (G& $L< /%Y#C_W %<9 0O/ +_P,Z GN$!%TP#/AP#[-P XA0"&1 !4OG
M'I* ! F1!D0 JSB@"(.@!EW@#PB6$,=0-(60"5PP"Y1P%O\ #CP0JG!!$X+7
M"JS@#K\  ]?P#T8 /I.!#VQ0#L0P F)D"R9P*W3P_D>0\^]P!OX.$/\L&8CW
M[Q\3-@9+&/I'SP.O?\96D.-EX),K-1U^_1-G<,^W?Y] [/O'ZL*S?\,4B/I'
M2X0G6D\V/!.E8A^Y>N(ZJM/AR" G%/3^*:DCSP866I0D:#&G\U^C+P;/S*''
M@I%!,@B<Q4L1YQ\P!\?N-0#U[Y"_=!)\+KNQ#]T5&,O^X6B!CYR!0.$B78#U
MS\H*8O]F$/_ZA\?,/UL([/VSD>H?.$ 0GJ6S(<=@$QO^1E7(9"Y,BHXZS=VA
M8NY?IPW3_K5ZD(QC1W8D(/U;%.@?"EW__)DXYO<P* #9_D5!,J_5!F2OQ6VK
M$>-4)4HM0&$K >+=&3'C=@$@]2]+PFT#R*6M]:\+1#"ZOIDPUXX%L%LL^/Q+
M1TA -'3&7+CYUXV*,'-"X(*?#3CQ;@YP&G$!GW(\<<"5?X0101!Y/%G@%FE0
M4$$046!@2*>.#!)Q1!)+-/%$%%-4<4466W3QQ1:=FHL_@]JI9PPC>)'%A7?$
MV<>) Z3H9X<^1*S'G7$Z<F6&CHQIH*]Y;KA'$ 3<$7$?$%<;H!#_[T0@Z9\Y
M;!B1GFE^>&08'0 Q:(TU#/(F!PKN&*<4'L;Y)X8A2#1$"8-F6<"8$=^HH1R#
MDCA$N98TP$3$4Q2 YI\3H!!QCA3^(<0#>7SYTZ!!@A#G!LM$%,>.*Y0#,40M
MN/C''![0^,>3$D2,H8XT8@C1$1C2^:/.?Y"@Y#6#C#CTGS74*/239EZ@IQQ"
M@7UG!U#":;:C5@"HPZ!M)LB%68.*V< 4@X((@R.#Q)&%!T)]D6$!/\I1)0=V
MR@FG7*<*F<(@/-H8#@ASIJ5D"8-0 8$?;O]QXPD1GSAA51YD^6<<B)5,HQ 1
MDN-""WH[$@4-.'C XQ] O/"H"(.N62 ;_U\T0?00#\XQR(F$Q)GAE7_Z80%0
M8FX@1XP=KC%&F'S8R?(?5]HH@09__M%E V$B:@"B)U*8QIAE[E$GEA#L!-8?
M'3HQJ \K#()B$'PNB,089)31)\E5E3!6G(*6&2"6;AM0LP=PW6$!&7:VN, ,
ME\_QX-!L7B"I""0,ZN&,AG10.1 )VBDL5%__B6>82KZ0@)M_&C:(%@?.D9NE
M?U)I8)YJ7F ',5O)?4<' __)IP)/_H&E 4!!-,>.##BQAQUP/#_GAF:8>:&>
M?^0Q99U_2GCDGW588,DI<5R@PZ K2!@"BB&P0&:$8>BCA1_O$MJG%VTHT4&:
MX7Q8Y9YYK(' #/]Z:NGGGS=<_8>2 .XQ2(_#]"$)!@%%*=AABW. H@J2NH4-
MM%:"VL4A!R+"0180XX-"!8%>,.)@!SWX01"&,$4R<@(&4.*,-0!C *KX1WS^
M@8NKH*("J8"#"K!1LR>0KR.86%@XH-& 6>CF!?>(A@(.\P])# )8UHB $JF1
M ,;]HP\+0(5!T/"+<>SA#I(@W3_BX)54G (<F'" -T@AIG^400+*,(@@A(&)
MJ/P#'RL @T'Z@0A5(  8!HE")1 UB@-<@ERS:(!J@J J@TCA,)/P #F(L0!$
M&&014OB'%')0D']$8AYC*%6(-OB/*O#I'UUY50P,PHX;^"(2-TB'0>+_  1Q
MJ"$%=B+")H#U#R-,PI7&&LXFJM$ </WC&Y8@5SQ,0*-^>*T?19"#!+3Q#VA,
M8!$&X8<TE+$!AWG'!JT\33Q@$8)_A*,:X1#$ P*1BP%XPR#-N :P!G&O?V A
M(4J(E4%R88Y+$,$@OFC *@R"CU=H@@3(^X<6A+"J%&PD8O^81 _>\8^]_8,*
M& /6*E9P"DBE 614, BI1*2%+>QACUD:1!1$!#/%06@?+Q".,&I #CB(P#3_
M8$;X.B*/+8#!'8O00=*6UC0G060.&%RG/7B!+D1QS6O_8(,%O1,)?"B@$2(:
M!C@Z$HX6Y&F=J+C +0SB#A4(<@8J9>D_T%&(_PJTH!GN&!PT=Y"T(BP,4B13
MJEE:]H\B7*]7O]H&#51!B "@Q'.O<H ^A+& 71CD'""@!C%>D+0EA<9R*QB7
M07 @R-OESBGA,$,#UB<.'N#B'_JX 3> 48$;EJM74WT'#:KHE'7(P [!HJ2(
MSF&"IHWH._\H1R>2\ D7E,<8,<A %;KQ#TP\8 6-Z B;# *( ###('G]!Q?@
M*:)L "$,02#9+Y J,PCI(04SA<,.P)$*'IB&"T?XI C=^U[XQI>#64*&!W*P
MAAZ(HAT(.,(H6N" 0"3B M8 !@J6L0P(J" -/B",4VP1 $= 8A<,0$0_3)$!
M681C" S0PAFVH$.X$?^" T.PTB@X (9[4*,%"-"#$:P #FNLH ]B4,4-W6$$
M(]1C$2C@!SQV@(Q9&  ,HD#& $*0ARLT 1]^J "@S &%#K1A#TNXQ#PP0(1Y
M2*0(SLC2)C@@"')9(@/M]$4$%G4/%!0CDQ" ASBX( %OZ.,+(T!&*3X@!%'4
MX0OCP(.D_K&//]@B24X90P*"\8D$=&$9I7" :MZECF!,@ P-(8%C\$"#CL3@
M#ZKME2):@0\IZ.$?]<@!)-9!@P28@A<I:,5KRL&$ R!"%$EXA#C>4#L<C& ?
MY1 "!D8A"B?,XAPK_!P%BN"+/6C4%#^@QSBV(!<GH*$; 7#!-X2Q!'\Z)1/_
M6?O'%?*4"0VDP1F;B$HC*O4/>Y! ![)HQ11<88T#V)(R$#+'#D+Q,#N-XP55
M^,<N)- *<!C!"?9@1KUX\ ]EO. *Z=#%"A[JASQU!!L/J".B"M$"?X1/"K%+
M@</6\0(U2\,$XJA%!_JPCWT8(;$=V44'A$,'$Q3D=L?-Q@!J,8]/=& 0X>#'
M$KK1BW-G:1\)&)8F$/:/(8QA'#9X ><2,02KZL0/ V!)/H:0#!?DP2#?,(#+
M3@"N9U6#&7#XQST,H EV(,"/L0#!_<X@UQ(PKAXKB"0C#$ ^,!QQ":/XQPL,
M)(L-P.,?/NB%0491V'Q<@$L10<$ZAL&"U=E"KAU9_\<(X!F.'3AF%PUXE%/J
MH41@*&$+_VC!1N A@GGT P,T\@8QJ3!5=0076.FPGD&FL ."CF(:,*@L-ASC
MA&OE(0>FD0'._K$921!#&<.00@<@\@=>-B*Z4KD>'E[PT'^\PA<&*,4_$&%!
M7:!19BR\@@]"!(<!'E6]%)5O^]W__O:?ZA_)^ ,>U&F.45@!$LMX RORL08W
MH(/$^H=L^ ,L<!AQ8!MR& ,S$(9,,(,\^ 4_^ ,WZ(=X<(0KT -] )99B(-D
MLP5.F8-(<H8RP )%4(=_  4/8($=>($:.(5?*(,U (5IF(,K8(*-8(8EX 'A
M8 4O(($Y:(=52((UD 04G/^'/B"!'4@$@Q"%&>@!0\@"/> <@]"%+_ !)>"[
M!FH!)R@+2P@!,GB"(-H&+\@!.U@':EB"$<"")*NB2)"!%Y "8-B$$(B![F,&
M&3"!XW(*9>B!%)"$+]""8H"%"@@"39@"N?B'6+ !,4 #""F%&6@!0J"$$2B!
MW! 1-Y !1#"%'<"!4R"$&S "8L@&(J  '?B5+.D&*&@ %3@,2KB!X[(#$9""
M>/"')FB  (@$>9 #%#@"E[&U"LB (E ';1""'7B#9N !*@"#*N@.EX  $+ E
MI^B%&7"!6+B&*. !:6"'.9B !" ">V"%$?"!1T#!69"!";@ 13"(3)  1, #
M+F'_!S+P@2G8A:;0B4-X@"H8@Q H 7=(!/Z*!G))A07X@CQ( 1I@A2<X@$C
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MAWG U:_ AOL1D69 !NS[!Y?!ASU,UE5A!F+@<ZT!!DIF!S!P@B6%FQ YAV,
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MT$8,^F",<CA%'(T @2*>PP04A&$/$*#3-X P#5+\ #-U>@4$(, )I@A$&B(
M@Q\VT C0P$ 76< !.WA1 Q7_"&$"AKA&$" Q!A(T8QI1B$01O"#%TSBC!&2@
MPPID80XW!  ,//B!.X3SCV)X81!E,($HJ/&&&VC"&?7PP1KP, (@O.,?C8@"
M(9*0!7O@P019$($1>/4N1^AA$@GHBB7,L D4Q,$<SA "&YXP@FF(H0&IX$<9
M!! -;]A@"5J(0![.@ 1Q*,( )UC$,L!@@FRD2 IB( (8V!&/.0@A")DX2#"V
MH 4:].$?L3C!%#I1@3.,JQQQ:((1!-"%?T4D'VD @BKFT -#F.,3.> #%+:
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MD88",.,*<?@'/18@B3-;XA_L$,%ZT:"#0V "%(=( 9>I8(AQQ.,0#PA&.$J
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M 0J$,QB (^2!.8 #"I E:'B=L%3@!?*8GW @O Q99X'@/_1" /@?-63#-<B
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M%T@#*11 $51#*N" .SS#"FQISSY ;XW#&PQ (NR#)%Q!.1C"GEDJ#;B!J2!
M5V3##G@='?X#+T31/SA"%9S2!71!-^3##(RA 5"#.LQ!P9:*-BQ =/V#'=0L
MDV+"090#"O1".YB#%:1B%*B!FCE "1%#%M@*0>3@*X8#"^S!/V@##8P+)G3!
M/Z1$N\) <CA"X"P5"%!!D,G"'UA"C=I"YYA2/D  @'[#!C##.]R _Q7$.YC
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M9)8VN( #@ !FI$,=2$ "_^3 -IS#%T  &F3O+E#!0+3#$S2 "<2 /U## \2
M:?C$. "" -A *W3"!FR!+Z0! B!"M Z$-_QP* @#$HC +Y@#(E1  G@ $/9#
M#I# &G2! 72"F 25'*S (01"&^##.PC"#T3!9Z!&#R@!)*""#(A -!1# )A
M,B###5R $=" F"5,[HS !6@"('0!#3R#/EQ! X!"-U"!""3#%EQ;%3P )S"#
M%4  VQB%!K2 $.R ,ZR!!QP#*_# 8_:$*W@ +S0#$V2".(1"!TA":1D$(*C
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M/SC#'-A #* )+/! &=!!(RPW3R@"#"2!*[  '9C"%@2!+SP"%PQ!-#Q#%(C
M%AA!%?RM4P!$+@PAI'RI)*X2ER'$_OVCI$/,E$3_Q$7!P&=($7G_</E (,*1
MN3P7N/\,^Y<N"XU2X<3]DP.G84R9,VG6M'D39TZ=.WGV]/E37%"A0XF.,VJ4
M*-%_Y%H@,82H3R5U%!NV#$?F%,6D+;4FG5GTZ#BA#<-R#3H3W D>H8*!<G/K
M9TZS,;E6E7E69UVJ./72W'H7;]6M=?O*M4G8J%S">O_*3$PWL-:[7[F&O1ON
M$B*62GL6/ERX,5V^GB=#)BT::%_57GT2MAO3W,W3J/^%>SWWWSC!-<6F$Q?.
M-CB[X\K]0R<\]VYU4_W^H];N7[=TZ<:98[>Q7+J&U9AW/;N/A:UM\"BR^Y>=
MJSU?SF*6<)0-FMUUP9B=UY9,V[R6Y(K)'')MK[@$')#  @W_/-"[P80*2RP%
M6[)G$2[.B*6EK71S4$'*%BQK* 8SY*:/**;XPY@$,3P1Q10U3)'%%EU\L4,.
MQP(,1@]A3,K&H/JQ13 65[S1Q1];%!+(P7IL+#33CK3+R",CZTK)'J.DBK'2
MFML-LJ]HJVFUH?[9!H%GL!Q3)AXLF=*ONH#IY(XR7D,0SCCEG#,N'W_4C<@*
M4:3SI[+XY$D<!GOR$$$'._,34"_IY.Q/&ODT]$#6=K*ST=2:K+0S%3'EZY]D
MC-!!#W]Z$F0'%T#Q;K26;.D B'<V?1766#_;4T.RD#K12=-F>Q2QEL22]2M!
M>2(T4J^>Y O1216=D]%&FXT34@,E_\U+4V!ER]#:67'-5K!WNMG'&70 O4<?
M>^!Y=L5QX,&3VW;=+9!2)<L)]"A#EU.TG@:/Q90U>7[E-M"8V-7IL0#A718H
M@7>E<=]B8T6W4,X:3FU+Q;1<\EV&9USX83V50MC:B3G5=3:0,SX9Y52W!>R?
M1V)P)[=;+;RDA5:ZPL<-'_J;L6.SK$G##H.!#6H=.U+AV-9@Y#@SXK/"842-
M,O3IS)\ZIA&9LC?E#"H91Y#9%&*'A6H&&*P!/>\4:I#>ZYF-6/JGG7=,=I<U
M>M8&VTFS>,YV6L4NY7+NE 5/.=[=,%&B'GKUQ5&4'WKIJIU.2* '2EF_B\^4
M'880VO)__/^1X)+6$%)@#C@[1$..8#*(Q*=A&-"%\VO-B>=NGYA!XH!9P Y<
MV@K/XP&/V 6D1H\%<OGIFB2X<&(+1<R!0P=(*D>9YUZ$>&)P0]28#)$PIN<[
M;,#QXGTOLP<__]6]M9;,RI%M:N%XN[1A@1R#^[[VXA\;$L.-AC(Y@F4:BXQG
ML%8ERJU&8PT)P1W0I!I'B48>*@ 0,/*AOO6)XQ[H>!)HQD*)0; O;V8+C#C
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M:((),6"/-;80A!J\H1RW*($)J/ 'HP:J$B(H0A$\4(-I\ ,*+DB#"D+ !PS
M8HQ<: ()/ML)%F#!"PIPYW[F(  @A"X>0M "$NY@T+&4PPU0P((3J@'_AA(X
MPQA9^ (__E$+,$RA!;H0QS<08(@_Q( 32PH'%K"  RR(ZA9+.$(.-/$/7>#
M#K98@A;.\0]C6*$(7"B%*5  "77480:B4(<FY@ ++*0 &K^(01!$90DGR&(/
M/A!$-IQ A1*)@Q9'& (3T'$,'=Q@"\L@!1 0T1!E@.'2V_A'-.(@!V,8(0T'
MU)(Q8# "1-C#&!C 1!I*H#L;YZ$+?$BJ3(SA !Q@PSBC:$@5%'&+/SRB./R@
M!"+8\$E0*&(9G4@#..81R$[D%!VOB$0?6)&@+X4!#JBH9C(2,8U!+$(I[YA$
M)A0AJD208 :;^$<@A.",/DRR)?/@A!TF*0]<_T2#%X$(:TSV$09)3*,X[4@$
M'V#7$&+0H1']P(<HCC&.89PB&>) !RF(\8U'K'L>YIC$!<(0C7_88QE<$48O
M]/D/:(A"&FKCC#1V@<F&-$,=_ACDC/*A45 TM:C@B(<QS$./71"5+&*L1GRH
M HQ>!)0BYU"',:R1A#N\@QSAN!<ZT".4<#2.%5:M#3UX&;[1OMY2_Q@&!E@Q
MNS;@@ QU\,$-NA$# -F#!*<8Q0_J0 87+  ?V+@!I5/A +?'8A'_, (F_@$)
M"%30!ZRK!PVR\ ]I&  8Y1C!$<C0!@[TH7(A@%T];H#,,4  QH@8@#-@T8*&
M.&,#<+"''T; 'B8\0?\IUN$'#*$A."$'D@$<8J#&X, (M@$52" ';$,HP.$/
MCL ;1F$!@F#=$H ,\D#A_L$*OL ;9,$!E" ?2J %C"$6?L$&YN$?Z( %TLD$
MM.$?9N"#8J$,S($(,N$;$ $ 8&(LPJ$'C$ >C*$"?$$<<. *K$$1 " 2L$$"
MW( 6LD$.C@ 41F$"BN 99* 9*FT H@\;%.!4.J09FL  <*$;4$ (R&$3%  0
M5) 5&H!'.F$&8L,/$N >HL$$EL 3;*$=QH(?). 0.&P+6NT=6@ -+N0L<$$&
M*&(&R,$6+( &%P$"_,$?1B ^^&  X@$9(" -N $05J"IQD(<U  -*@T 3H'_
M'SR 1V!A !H!%&) !5AA&&! Y_! >A2A$,#A"]+@']C!!0:!'/(  N)@&J!
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MJ7: ==@!$&" #N@@"SI@&J2@"OS!'LIM+,9A!&JL919 3%I $O:A'[QD$&Y
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M=H!R7 '_+I.I^_;A!6@P&&I@:F0!@O_A%)[@#W(@BRG!>S-)!G 7"+)H?TP
M5-_U!8O 1,X"EP&V 52N%3R 'PI!"_3A'N!AZ6+B'42%'"9!!W8@F\CM=PC0
M(3*"!?8A'6@@5R^8"ECA%U@!%-*A&4! !2Y!$5LB&C @A9T! 1KA'U( SFA"
M#X*G(9) "L3!!8+F'PSA"QHB#?X@'5! #WY!%G8!0(; >VA"'>[@ OB /8K
M"4H!%W+!&')!!FQ#';1C&^B3DF; DL\@)IS >\4A!2KT'YR "_[A$@S@#M3
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M^N$<O!,=:.#_5/[A"11XHNQA'9C!##K@#S3H++BA B:BJ W 46T IF<B#5H
M.;C@" 1:C?]A$@(3/^V '!!@PQIB&=*!"6IL8&JC'M@  GS@'-;@6QO"'W[A
M!USP/. !&<S<%% :RPG]'[1@ILV!0AO"W/\!>F3";C+G 8YF+.2A!OYV62OA
M'U @.I6B15_4$3Q '?X@E@?A N[J%Q9 &8X!!%RP'W2 $#9AIF,"'1(AE]=!
M!@AZS[F@&4JG+^2:J+S@@/\A#G; T&J'KV'O+-0A#C1@#%Q%T1N "%2B1#.
M!HB #](A'K*  DJ !5QA'Z9@ &Z!J_! P?.A!D9 #*B@ ?R ':( _PA0H0YX
M@![(H1,X( SD@1<@0 64H EB?*:<( + @ DJ( 6F01 F8!&* 0GZ!QY<X N&
M019L@!FJP0DN !6H00DD@#W&HAU(X A^(1^4X 3NH1MR( KL814>H ;\@ @<
M02D$@0*.0!%N(!?802)*% #J8!S"@ &VP!%HP!+D 0>^H#B8004,P!&40 [
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M!&__5#UX!^L#&&K2@%2#R9@:C\5F%0S[!R02S!&;Q"T@].^1"7[_=EC\APD
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M;,*&>ECXX 8H+[3 S30>G,#,*1(8P,4+V[B&!Y20#R;!I!H0&,4W4A"-9Y
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M_(&QZ_CP'[K$Y";_@0Y:[@J2T9B';YC1$4;YZ1DP"<>FRE$/[(1C'*)\QI&
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M@9.6#FC  F@U3*J07(U2#4C 14/G#J;@ :"@>>DP!@MP"]C0"1UP""8H2G7
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M#8 P!OY #W @"7<$#JY0"&/06/60 Z5@"':P5"X#" $0*O"@ EVP2MP0!F,
M"57W#ZA0!YS@"Z@ #_W0"+:Y#'S@",=0#U   ZY %/P@"'&0"^*P#L10#,R0
M"<<@4G2P">@D#O58("Y@$1?B#0O0!XP1#1M@"HR1"G9P"P0H"SQPDHXR"+0@
M!6X )I)@"8L1#M!P#[-P".JP$>O@"]; #=S@"Z"P#.$@#1JA'6;@" (Q#:(
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ML8 !)1 $ J"J[, $'- (UX !,/ -X) ">? /GC "C? $+S ,UA  ,__Q"A?
MAUT*-?W0!6F "3M  F4*DB[@!F=0 U8PM"SP!H0@ =IP#B@P 97P#_$0 YS@
M#WM "X1@ *KP8TQP!%5@  (@"HF:!8> !4[Q#[?@!)8P F=0#WF0 '#@!CI@
M!>Q0+I4 !X?  F&@#%I@ FTP!"L0!O] !S_0!9L #2V@!>+0!S+  RJ*JN+T
M#5?P!E*0!+$!!REP!2B@ _(I#OL@!C/0#=S@!%W0#XH  GE0!\ [%=85!$]
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MRK>@ \MZ!NP #R+@?C&P%(4 !##! BI*TGV@!#!1" )0O@*3 (CP#Z6P N:
M"CZ '2XPB-4@ ;ZPJFCP#X[  [G "DB  (3]#TB<#^=P C$0#G_0!;E "1G0
M@#\P"+E !P#@"?X@ VL@#[O0 "[=$;6P Z&0"U,  -\@"P]0!^C@"""@&S1@
M)^^P!U?]#V?PO/\0##< #^/@!7; "XL  (1P"B^ ?ZJ  $'<IC\P6:"P N=0
M"B/@ MX #2HP!>' !DYP'RV@#Z:P D#@#*H  2':$8)0M\<P!(&Q R>9!LLQ
M#UW0B&F  ?* #1"P!^<P!TNP8F[P!/^ # " "^3_8 .64)D*  GMX 85P*%
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M!"(H1BTN< E5K" 9W," 'CXAF 8@@0>+Z,8)&G"X:,[N!#V0ASYTX(-.0&$
M3B!(4ZK1!P($ 1CBZ,8@&' '8;@C"4:X!BQF< ]XH $"K1"'$"K "3H$P 7)
M  4&7D %$Z B&";XPE^AO 89H,,<-7"-_T'D$(!?2*,'V_C')A0 ASM<@ K+
MR,4'PH .6V1@"K^(P@4X44MQH.,3&7A$. ;Q@&WDX0&7"(, IH#D?[CB ;;Z
M!RH@8 (Q>(&Y;)J"$O*!#1 0$Q 92$(A8J"+=4 A G=P P_L 0\)P"$<H5
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M+-@176@$2, .*$,&D#($Y#.(<0B$+R@#+&JT_S"0 F2HA%"@!UOX!%I *UX
M CG(QFQ A[N# D<0 V. @C* A7Y(@RP0!4K  I2;A^,8"61 @RXHJ37I!C=
M@SRHB7^PA2;(@H>BD$+H@CM AG6  RAX FB( R<  ]VSDF,  RXP W9PABN
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M2(4 N )G.,,X:(=FB($FD ,]^)I-$($C( 9#@($V< N#:(43" %M\(<[,(!
M@(=948,5D(4Y:(Y3F  6N(,<\ %MP(<9&( <P(%[J(4:J %MP 4%(((T%(=Q
MR(8HT( ]"+M6&  4T(5\R((.: $3$)(W\  EH +,! =6N( XX(<FT(%>B(0H
M (=#$( G: 9&4  )X $<J(9:@($FN(?96H()>((EJ -Q0 0+X(-1* $=*)S_
M@L '1M@ %,"&<8"'0\@ )L@'<= "&0"&:3@!;S '4SB ,$B'4L@ *>"%()@
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M9DJVV+FVXO"UL'LR:)B6Z(<&X/]#SNG:;C(^-AFQ)E]\^ 1\D-]W6(046#V
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M*Q\):9"L-T&"%-'6&P=S.@_T&[X'G?D%:L'S, ?6/,B>I4MG'9:.']";5+@
M_#-L%-8&"7#@<=AR/#<(6DB>466#$*=O*]&#-"B,54#H9VX3/^ <8I 60;YH
M<A[5,0"!=S"'7,CN-#:(8AB?;H;@=+"#MZIQ/CX&@[PG0<A98HX'<VF'(J@,
M$==M^5VF9&B!@&Q#;> !63GR9):$.*B&%VB.)G_R<G=D*S$%*T "="4%-%@#
M8O"'.8@$N7B$/F"#^5$&.2B%1[""==@'.? #-^B'?J $-PCQ_V;H TZ8 X_
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M4$,2]C0C0RA#?*<1*%DT040K]]B1QAT_(.+4/_N4T<6X!)&#"!94Z! #.;<
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M%@$8C0_DXD\QR" A9?#W/S[!@&TXZ@]OIL0%:O&/-;33$$0 QC/FX(#I- [
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MIH& /OQ#'+!1%&2=&231?]&!#*##/U1"5>)G&23$%^CC-B@ E'V"(_Y#&-P
M,?Z COP#(FB#"!#G/]1!=K #"5A'$##G/[2 ZFT!T\&#"@S9-=0=#CA'0E3"
M"S!!]?F3)'B!1KC#"F0#/C@ +3C_I0Y$ AZE0+EEP<!1P3'5F1_\6B5&TR+>
MP0T(Z#\L C]8VVTD0P/HXS^0PR_  P9 8B@T@"*%G@?L)4Z, Q;$P$_4 %)9
M"CW\@RG,VU#L CC4P@R,0+@$WS]<S+]-6A+N :JL@@*$*3.@0@ODP4>X CNX
M0,@Y"B<J#Q?\FCR0@,?Y$\@E1"'(#]SYX V HRSP@$9,@XO)@O&=P;4EQ#-T
M@RUTX7_]P@H0WPAL@S<<0-9MZ"EZFAYMPPZX1"E(W3C8PRH0P03\0L9I("\B
M!"10H3KD@"J0@P3LPD=<1!88X SL6!$L*E'LPPN$*2?P #B<08KP74IV(D9\
MR0_ P#&4_\,(&-TT>( P[,,0),$Q.,(+U0,-H * )4!=8*8_O<$,B ,\2  D
M*D0-&"I12.4AC-/JD=\6C,%+O-]ZOL!)1 '3S< H8$F*GH4-$)(2!$$WS.#-
M-$#:O,,='( -;(HSP&<Q3("SSH4.Z,,AZ$";?D*_$AD$Y$"C$(4=W  [),0G
M($"^&N7[;:9G#BW14@]1H(('(, (=-<R&,"5J ( 4,$Y&(,(J  /)  I$$,*
ME(!VY8,))  :Q&$_U,$$  (__$ >*$,6X($Y' $%;%80B ,F'$ 18 (-)(#?
M.44Y+,$41((H;($/W$,^T, )G ,W@$ 6N,,9H, ]>$(7]$-.U/\##!S3_,#
MJ_W#&%# )HR"#]R *_3"!P ".*3#(G3 *9B#(%9!*UP!!OR"/T0!$[##/K!
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M +J@"5LA"V0AZ<I.5LK$^R!A";KF/TC$4U*$Y;AJ40)D*)2!!Q"+$%WB&U8
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M'+1A!&A $LP  NK@"SJ !_*@&?B@!PQ!&:(   9@$(3A#VS@%<2!\:P "(3
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M(?RR87/R@A=.@0@6%AR^@11\Q27NX3;68=&@@0;-@A[*( ;PP1RT80?0@1J
M@T7:H1<HSR36@0Y:0!'981W>X>G>82A\KE2$9$KU4DW4@6I@B&E [4QYE D6
MH!1<@A<R( M4B $PXQ\0(0.^$T_E8^G@X0^0X0L 8 QXYA]H(0/@P!P, 0#_
MOJ!KLL [_P$: $  ZB$4 , +S&$0"D 5G*$2U&$3+  'IN*"FZ H&* ,BN$$
M,F :QD$.   8=N$#3 $=4   )D$:-  &0D\'(F 7XH%3>(H3#H &AH&)?6X<
M"@$ AN$6'N 3Q,&!L0 0H( 4&$$#SF ?Q$$/ * /QL$6'* '@J$<K@  %J$<
M#@$"KN$0 $ 5@ $ ]" <5J !HD$=%J$!DB 8^H$/=J ;/N$#8*'K M8EMH"J
M@*$%8$!8CL!VF<$$K& 8S* &E+4$7&$?P" !I,$/%D ,A $(M$! /N$ N.$;
M#* 9M&$)/, 2ML$ ' $<.@$ ',$E^C5M_@$4,B 8_[#! 7;A'VHA!7RA&V:
M"OX!$S( "L:!%!1@&\(A$1S@'-+A"[3!%Q @&"IA!43!'N*@ G0 $=Y@!:X
M$LH !.9A'*X@#)0!#%;@&LQ@ JK $JS@!O;A%$(@!&Z!,/^!'_B@ QY+$(
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M#^X<&8Z !X9A& )@JSAD#A1:-RH@#?:!#^[\&5C &_@!"PB *,W"%7H+)A>
MC:@A"H0!###@$&Y!"QY@'I:!!H0!'Y( !K(]-TX!!?)A',3  WA8!(A %=Q@
MJ&);MH4$"!Z@V_^!#39@"=)+3VQA E(YN#EE')3@"NJ@#WI B#-C"0#@%OYA
M%P!@"P3B# " 38V! [ ;%@# "/_4H1[J  $ @ S$X1$ P =2I1( X [&80T
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M\Q"QQ3BK4-!"*?$< H 1]>@!@"7-=   @H, ,(,B?Z "#PD W'),!!0<<X\
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M_K&,#3P(BBQ@AVQ&T8 G]D,%V\C$!'+%CBS<0S:"\ "JTB"=?QC!"G]YPWA
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MZ($,NB&-%^P@"U]0P23^@8,G?"<-#Y!"&PQ !WZ$( Y^.,(\_-&"+Y3"$ \
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MQ">XH0KLTR,>E?A*4/K_40E,".(>VK!$(RR!*I='"9C0"/5@$]I "8(P>,_
M")?0#"P <.BP!YK0#9JP"_[P"(\ ",E@"IA "3_Q#ZC0!GU #1;1#&50!+S
M"=C@-6VQ#4<0$>/@"D>P!F<T5.(P#KR !T=@"+D!3F  !)(A&ZTP!4Y "+$
M!5J@"I?@!%EP"K"P!7L@"FH !^- #4\ !*\@"610@I4@!%[P"LTB"T7 !(J
M"460!;=0"E( !B*G%\L@ U@@#6E@4:J@!TR0">.P"U20 %'P86T!##Z0!(-W
M#E 0;M"Q 53P!E-P5_\ "2!@ $  <$-5#GN0 I$ !;?P#X%  @36<9]H<9WS
M_P_L0 ["!XJGZ!\28@<L,!5L%R;-@ *$ "8HUQ^:=W;,, 5>$ ,QP&)=4 )4
MD 1!D 0E( 12, )>\ 4)X )M @)2D 1"  0^T (AT 5'D -<( 4^@ 0Q4 )
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MP_C!NXU:N4DZP<.+Q/#1L_! #9S6JH#;N_?[IL)0 Y3SN9XK(?[@ ]J@#EF
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MY; %QP=B2VD384!YWH ,1?FZS@P.3[ )M3 #%? 5\I$+N/ =0'!1_:P7B;
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M"LTP5*60 %! 4H7@&KD "GK!#J40"SGS'KG0 ,;P#\^  4R "J(@#^F0"KY
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MOO="@4X:JUC5Q 6S!6TK3&?5'CTCK0H?RG%ZH46:<1R*AQV(X"#AG:W&"26
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M+F0A)3X*!PK^0)L9..(?OF !@[PHCGKDZ!Y_>$ /Y.&.'R#B'\.X@"K^88Y
MG"$)3I@,"GSX#RR4H!6S  4TU&$("YP 9^+ %$0ZL0(<>B( ]!#&#G!HJG?L
M(!4HD<021J>&%OQ#"73812] (8S1;046$!!$+_[RCW@8KT\.6,HN6I"X67@
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M%7'$8PXX8(<Z1,"$<'"C M=8APN(Q@<AC*,>6UB"#1>$&G/(8!L^$P&#4+&
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M^(4#Z%&()Z $"BL-Q@W.D9)$D& "C!@'&5RP)$%$U1E2H,,M)% )N>C :K3
M-%*5:O\J2N9&"&FZE!7T8*9>L"!'_T ")5 B 0L!(@#MC 85#O"$A&FM&/-
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M E7YAU"P  _RRZN+ Z.Z"-4+AQH8,D-XJ&00 7\X!Q"8!V 1 Q< EM28 1'
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M,C5GSO?3<.&FFP9=[ X&'Z'$B6J"@<:F=!"I:3FPRFRH%5C6.I=M<4H)@['
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M"@05$,)T_E"%)W:Q*F&((AVEL 4Z]I&(6Y1#(>WPA"<<E YC2 ,?G\C5/(9
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M80Y:^!1![,$$-K1 $,08P1G^ 0M@DZ005\!#%8[)!"XX0@9)X,:']%&$(]A
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M*?C 9AD"$!1$+BC -!1$)%Q8+9B 87&"/IS"(J2#+5P N-2!_KC##B#!_QR
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M-.R!"B3#ARA1KO#" 0C",&" +HR#*4  ,!S##F  %>P )L2"%IS"'2" B=%
M$60""*1!1(F '9 ""02-+G1!*FQ!'K@=%-3"$Z3 ;A7@?>(G1RB$,%R ["A)
M #02'=R 436C ;@#,C3 -[S#"KR)![:!.@C (N1);V !?/;%,F"!)'0!^I )
M%;2=04Q" .0#.Q1,01@!]?S#*J" CW1"5;I= QA#00R"!&"5"UR.0;R"$/!!
M @2-&.  ..@#"?R"-EP#,=##1MC" YS )_R#)6! *ER#,41#.UR"#9B'/[Q
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M\A6$&/ 7"S !0Q2"/+2!LVQ$,YCE/SB"%@S0$*2 9.&"*3C #^7#(_9@$>:
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M/(A 862$,0P!21B!'I##"AR3-02 //S#%"R!\WK .Y0#'%! T+S#%+2#-OB
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M!K!!,F3$,$" (J1"$I1".,0 %W@",D! %MA!%&  *Z#"!:S!*YP##U  $-@
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M^5GSGI<D@*44ST!1B[2B5Z\L;<9C*]*-?%"VLN6%[W[YVU^^ZI>SK/PO-/#
M!370R;S_P,<A<+"%)Y@"_[S^!7 =-9&"+#S+O_F-*Y:LL8NZ_F,65KCOO/;A
MA/F$-K>;G7!\IYO9[KX8QC$NHUV3.^/QLGC#&=9Q7M6[WAQGV$?RHHB\;)M8
M%.\8R4G6[(I=/,J^AN,]Y3 '?.$3I@A+N,7S6J^2/5O;Q>Z#G/IZ!X!2_-T
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MR=YVMV=\CO*B1@5NX:"WWQWO%*]Y)I) #KOG'?"!5_C_O/J! WS46/")5WS
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JDU )EY )F] )GQ *HU *IY *J] *KQ +LU +MY +N] +OQ ,I3 @   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex10-13_img05.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-13_img05.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M<'!^?GYG9V=@8&!Y>7EB8F)F9F9W=W=K:VMC8V-H:&B4E)20D)"'AX>;FYN
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M@'@%LH0"R&(ODDC!0K'!A#I8U! &N 1&-Z&"=D!K#DU0!BM6,(=W# $4U3B
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M@B^Z<((9KB")<)!""DK8PTS5L8<DE$)J_P#$&/BBC2;@(!L"\0<E6' )4N0
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M,Q!&8 0$H0X^8(D%HP/6UX(G "F!8 !&L W_< \XM!+?X !&B4W\8 H,H H
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M#N!XYF $BIB'%  /;L$C)U(/X,D,$4 %7[D-Y@@M=X &%$0#2O!Q\(":>]
M6YB@ N$$R\47>E" _Z $H<F5KO(%T"D0\R "+F /D @%BB 0-* %_T */4 ]
MMC!P_[ )#;!+V?_  ;2Y#0+ DYJP2Y_0 *:R$L$ !,SQ"D6P P5H1U7P S>P
MC^X@!<!P5>R(68IE,,\@ =/X#^(0#>HE&?%31^X0H-"0  KX#Z+"!)HP$&A
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M!]*%T *!!-1@#C;@!5?P#KR0 (YW!3;0/T 2 G2PT8CZ#2<P!;S</>,0@-X
M B;\G8'[#\*@ 2F[$IK0 /C0!2:P$J9S*:$@ <B@"@S@")SU#_89H /!#9X^
ML'^P%Z)0 L+( >2YSAF FOO"%Q$ZH1(Y"UQ02&[0 ,^0FG48"DEM:PHPHNG@
M:= 2"@[@!9LPL5FPR">R"$00"(\@!@LP>]+> O_@"0)01BLA!GS-!C" V?\
M##6PQ:;VIY"]!)/C#"F@!$MP2/$[OYP-GO>P*/8@"1Q@":G6OW\ 9TH<"PW
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M%D2F0$O2?_C 8J!=9M!G('200.$>*H\0()5NC)A %'+V"> $5&!9@0:TGH$
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M  <D$ $R$89C(@0E>%!&D&5J.0<4R ,R085)\(H2@ QB/0%1LH@_>!8Y8 %
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MPP0\N 4X^K$#'[B"'=# P1!J(0Q,0  2X8@&#&(0#6S(8@B=H$8#? !38#@
M!-D@A][,T0D.$ (;@! ""I8ACU-@0 _8P$8NK  Z?LP" WW8Q\0T80.]$".3
MTK*!%(1!#6$@@@WD:$,$8"$,8;R""O;8Q!+&P9!\G$"D=I2'%,XB$618X _B
M>$41UB*%;)WC"@& !SG48 %CO ,<R$A &LA!#CPX@AT&V<<+%O$>+?2#ML[
M.SG8 0='U!VA WC$/]KA QM(_[P:;C@%."J!!_[BA!]7*(-.[O&"(-W#!;5
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M#/2!1)Q =DB$,E#-#F0'/JP $$1(3.B=+>B /X2#.'2;!$[1'30(,^S#,I2
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MCUO_Q-$) 0Y?"R_CSL7S0TW?#"SG:DG8\\_:$G7))( 95TC2R'4)/.5\I\D
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M&'FHP@*ZH80EK-B(%MB#&%Q@ 368 ;3^_$,9]05$ S3#U!(\P0PY_Z0*KF:
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M 1M\X0M&8#V0P040CB/4(0R43!B$X12 8!X*(0-BP<U/(0C$(14&8 R(H1K
M  T.ZR#$80]>P!O<J1R:3A[&81," *RK%AAJD1WZ@Q^< UKBP05"(!W8H1<\
MH!*$@1ID 0O6-Y0Q\),OD-0S,& >"SXXPEB"%H_JA8W>03;GH;0]1#3>@<L6
MYR#. 5ITG5Y;G85&CAS81[AYG7W_SB&R6(AQR$$<.F(>E&(>DITLS@$<B-T_
MQH$UQL&/QF$9-(*%/BD<H*$:MH$UTD$?TN$96'"2CF$;D($;XD$8K $:2OLK
MRB%HP\$=A $9E $:. (8I*$8EH&>PP$?R"$98(%=.4+?I\$:J($:JL&KJ$$9
MEH$_*'@>.$(9N $=-#T<:'8CZF$:!D-[_/0<DH$?[*$:(+YBV>&3FGV2YB&,
MP,'9:W<C %[@Z=D>EJ$8KN$;R&$9O,$:G&$=H$$9ZGT8O$$9IB$<QJ$:ID$:
MU!8G94$-<D$T[$$;&EX;L"$;DL$=J@$9H($;E$(=JF$8PL$?M('GUP&TJ6$:
MJ*&TQ2'@_X5!&K;!&:ZA'(8!&J[!'/IO'VK^*[@!XP<B2/I#&>;]Z)'!&K9!
M&*:!&YA910VA$3+!$RY!F-RA$@IA$R;A$:[AWQNA$R9A$P(A$72A/^ $&3BB
M'2+!1E/AD0,!$1ZA%,)!%$(A$ 3!2:N!%3XA$!J!<;[B&@Q!$2Q!BN A$3PA
M$YYB$6(A'P+!$P+A^7LF:OH!$4 ?$ 0!$QR9(V"!$C[A$LR[YD<BZ'.B'@8A
M$P!A%XXB%Q9A]X$A'(!!$";!W\,A&@*A^A&!$JB!>1-L_1?A&FBA^0&BT:9'
MBN#Q"N0I4Z-)R?[]:R>I4:]PY;;] Y4)T*!KCSPAVK3HE#N'^_^27'$8[I^F
M(5F*1(GRY=8U(%%<PLSED)47(U%P.?SI$-(0(V?J_4M9+TZ:/'6('0T'->6Q
M,56*O/J'KDX4(*;FR8DBY10U+TZ<O&22":C:M6S;NGT+-Z[#;_?^@0,G-Z_>
MO7P=@H-Z-V74E"@)#SZ\%NK:NW@7,Q9,^"=BH(KS1FU+.+#:RH791I8\&//E
MIY^?;BX].3'ERIQ1NFWM^33LV9OECG:]^C!JVY%W@^9M^'1GTJ!+2\;LV;C?
MN\.+TUZ=V#ALN*EEHY9N>+KOYK7[4OY^-*YB5Y&(LWV7G#KZX@[?L2M\F/F_
M=^' K:>_OK'W_?SWT[6K7W\"#J@68X'_Z89@@@K&9R"#CRT(8801&OB7A!9>
MB&&&&F[(H6[6=0ABB"+>!M^((5)8H8DJFAC=BBYV^,\WC_03FFHM]K8=::TI
M"-UQ/A((9) QUB6?D$8"-R&*#[[(9),G-NADE!M^""&%"QZ)999:;LEEEUY^
M^=IT8(Y)YH#_%5EFD"2"M]Q? *()WXVCD;@F=<+UR%Z+EE7GW&@&QF9C;C7J
MB"-K=7KX&I7*#<IH?16FF)V8:4Y*::667IHEHIANBNF9 7+*%U3D' -/,O4P
MLPXPZ(3##C# X!.8.],X^LXQP,"CS##E/*5.,O ,,PP^);):3U3,# ,/2N\X
MPTPQ^:BCS#3[_SBCC#KI(*-.,-. T\XWZ"#SWC_S6&--,2CI4\P]SMP35:_[
M?%-,LBBU TP^WR23###AJ /,/LB@XUP\W^0###."ID0.8[A)UAAGC1WCS#@E
MKE?B3_0!)@YI%.?ICC?*U%?/-^NL P]%Q^3CS#F3B:/,QI?)8[!IY7R#DGXI
M.@=JSCKOS'.9FO8,=):>!FW;/^/DL8 6_%32PA?&_*./'R0TA!<S7*0#("A!
MH+!('3MLXM K2MQ@21TG(*+C/X D\A,H?@2@2'NK](!'+E,8XD8+=112 C:<
MU #"*N'0XD(*DTA\"A-\2 +%&/[\<XP4/!@137ABPQ"$$4ML\<M(J_\4_H04
M4L2PBR\NP/ ''E*D0APU(>!PA!-A!,%Z:)M 8M<__?CQ!AM7R"'''_8@0L0:
M:JCQ!A;&5$+$%5 ,,84=])@F3QY%6$+<)T;LL6M*YJ#Q7DJ@:$&%'6)$ 8QI
MJQRQ!QEIP.&,)S[8\,@_JGS1PA_!$)=.)'TT(K'?K ('#\A"7?YA#2DP00T5
MDL8:QG".IVCC#FRK$]$NB,$,$NUG&NP@7X;F0>&0@P9_<$@?N$"8.' "0/^0
MA %,P4(WG, A:E! /AR"AA4XI! 6R(9IPL&%'TB,,$WH@"Q^0H5E)&,0_[B&
M!9KQCU5<XQ\NH,)/+I$#AT1# 4<TVA"(X)#_7&B@&\19!0.T\0YS+,("?D /
M)B2@#'*08QA\^ <F(+ .<50A #>\3"H8\ IW!(,0":B?8N:1 BV$9Q9SL <K
M'+ -?=0!%?;H00CL80])\J(>/1"!'%G1 QTXPS3ML$$#UA&>=)2  *$PS2PR
M (VGN*,.$U 5$V@@+UQ0 "<(5($/Q\ ">SBD$PE(UF72T8,U'/ [WPB!+ZI1
M R'\(QX_>,4XCE (A]0"!2? FD,J,0$]F">$Y"RG.;O$P7.JTR'MV!4Y-D;.
MRQ3B!=/#!@1@,4TA9"PE^9#"%*2I&#'HX#UW3-\_VO #AVR# []@82J*H(->
MA.<?>C@"!4KA$"_<_X(=[WF&!%3AD'F$(P=6= @GIN 0+!3!-<280#7^X0L)
M"(,XK9# %&DX@6G\@Q$(,&@\=L53<T%# T=4F#8DP(J?A&$!Z4N)*59P@Z9N
M Y7%\,'^@C&,?R"!"3]QASFT^H6?,,,!2$!/2N;1! K((3R-J$$/AOB/<U3A
M 2543" .L(]_B,( 9-S' NS@FE](XA]R&$$ /]$ @U6&#$#HTU^L<95_(*('
M_S %"_3Q#U>0((+_,$,)C*(8-%@Q0>LLK6E/B]K4OF4=PGJG.B^SC@CPXA^X
M $ V47$&TT""$=>P:7C*H -T-&,*5QC)/_Z0 G3L8PE0*):;W#",+ P!*/]"
MR$82$.##*R35(1X%*4IZ@ 1YB-<12GC( M"F&'GXP S_T(4$7GH9]\+W'\:X
M0"#^P0D$&$,>W, >?A' #75(H0;"4EAWPT.-#,3"(>0H@C90,(>)_F,8.#"H
M0YR@A'.<@QB"N'!8PP,'%8PD)?KP0B("8#!Q>($3,>A'>%K!!E[@-3R2H( ^
MP$&%&N05$!*P"&.\^@\R%"$=]3A'("*P/\4,0P%%H(0:^*$C^>#E$E (,A/>
MPPP8*,,A @5M2LQP$M*J=LQD+K.9>\;:?[CVG)<)AQ60X(XR_$$%G6U%>.K1
M!<R&H SA.0,,Z( !,. E)6%@01E@L(7W,*<:1OC_1RTFH(V?5&$:_D !#?2Q
MAZ2FY,""^4((' %J'30Z&PS0-&&4L%+Y$D?5*4G'#N[P#U((@ Z.R (>',*(
M!=S!!D PV)\X/6$"C,(AQB##/RRQ Q<KN<(3]4(+EK"$$VS!PZ[Y0PQ&#+4J
M%.,$AOA')M2PC62'AP_4^,<+[IN21U" ##G@ L#^08D'%+A(:D# $Z#]NB2G
MY!,!& 4V;" $<@SF3^(80N7J  >'! ,'6?U'ETF#AUN+^<P4K[C%+XZE-*_9
MG*'A!0].X8A]'. 49<!:2F ! TL4(@@I>)S#:5 //:! V?_80P@H6H-DN:D.
M)! $&!S0AY]$88K-&  :__2 T4U_-#PC+>D_',$%R#D@FXK9!P\ZS&K"F ("
M3DG)-Q00-T@H@&;^ !M^%5",K>+EUP.X2DJLD0&)UKP(H)"$!F:KF*HVU2%9
M  $ZT.&+.O[#"1].21]T@&U]&,$=>:A!.K+@#&*(^Q_Y@($F=-$")I##(8EX
MP2M48(6?%&(!ZGC33\X0!&:H QV*6("^_[&)(SAD$RQ0-F#DDP?_AN'6_W!&
M"ZS!91V ]A_NH,$>"&5!C"M_^<QO_C\T#L\0AD8?,=@!1H$@@4Y,= [14,<Z
MDK&#4SCD##I0LPF:ZY _C""N*H#"/!P"CS#P8QWY6 0.XL%W;F@S !28;S8D
M(/\*$]4#TS9,4?</2<!5/U$+ C!*,55N#C$-UE * F 1#F$("Y LF@ "0+$/
M[] +!  /\! !<7 4"M,-,%!Z#E$&")!5WK $N@ *J= &1C!H_W ++:!8?)>
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M$X354 Z!# /02BD!3C1#&$O0!#\A#=J7!1]&#UL0 .:B&.]@!!&D!PT 98T
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MU4 ,0!H.R= -]G ,M] 0#&8,UW -%R,,W( -R+ OS6 -V1#_F/,0#=P@#;
M"\VP#/2 #:&:#=WP;H/!#MAP#=I@I/)0J=@ #=&@#,10#4@9#OA #-;0#+!
M#=N@#>\7#]7P#'48K,^@;,M #<* #>& J-"0#2I3&=:@"G41#ND !Y4 (-.P
M#-Q #<8@+"DQ#5#T%,Z@#=)0#152#=J:#' J#>*0E#D*L $KL$:RHU&Y%^&
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MU4'#Y6Q&&%N0 RE!#!SPZ\' #L%@B>/P#8V!#J!@B83!"K?PL0ZA"J6P=OS
M!'1P#]\ !$Z0QQJ?"@&D#[%;"A-:&:S0#F:,#^_G#_U V?^ #ZG0C=B0 O&0
M#D)<(_N 61/%#_' !%CH$.?@O^$0#^:PZM!(__/_D HJP%GA0JCS$.4.H8;'
MX;?5< *H5"/T,'SA$?2$40_V4 =>0!SML ,-I[..\0_!\ #S"17B, 9CL'F/
M$ 20"E=04^>CD0,(?@[V4,D3A1Z<I1AQ>P\^\.T.@0][[Q#A4AGF8 PW8.M
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M !A.D,(\Z#"!$2#!"MSX@2Z0P0(AL$,+@\C&#@(SH7*8( W&*$(+[E$*%*0
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MARLHC7^8 HW" 7SZATUH ">+KEZ@@CAP #+Q@AX8.S]X!Q:(!):0!O<KL%@
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MEF &'WBE9I" Z&&&!C@RC^B#%8# /<BL1/\ MG_X@SX !R5(/):8A'V(&25
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MP_D'0'B"?N"&!?"'9(B 1YB%$KB!;2 &"!B"0X@",@"'2SA'=UB#%?# R(J
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M2$87]F""0?S#'2'0A!L.L 9Y\&L O/B'/>R0!B60(:18V<83]C""58!#%BO
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M@3G<@8Q<B.$ [?/T9"M;%TM@02*ED  W]D"$1"3B$I,81U#44(- )&(2A_^
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M#(("X($\; ,!K (Y[$,+.,(\Z$4DE, Q^ ,>H,$_/)P+.$(7M $W804U-$
M<,(G'$$^-$,0^(,X-, 3X$,QS( /\,(D)($]; (,[!/_.SR!!DQ"+2A!OGA!
M%^#F'GA8  CD&M##(RR ,)"##QA0.HR  1D#!0 #.3R!!52"*G!!E6$%,&C
M(MP#'>! ;%'# >2-,!# *& #*FA #C1#($Q!.B#""2@/<C0""2Q, \3". 2
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M8$,1%,"+X8,,#  .]((5  #_2@,&$((J"( L6(,1L$ *D$(Y,(/_"CQ!*MB
M%H2#*"S !(A!#0  )MA"X,T!#,S+=+MXG->S-2@4V$!S4\P"3>$#"^R \D!-
MR>CXA6#! U# *\""*? #"W!;)GA &4B$$$C 5]F!!Q@.(#! % !#*; *+Q!
M"HR1(QC BQ'!!,@0%S2 %<#"(S!#%"! 'X2#)W24G,NZ0]/Y/]CY,X-9#+!!
M(.0!#MR (82C<1-+H)M'$0B %*3',D@"(\@  D32/R#!!&B!MUI &82#-^
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M8PDSZ(=$P).,*7#A"4E PSQ,T0 QA.X?KXB#(BP@"ZV5AAMK2J/J=#.37W"
M$WHB!S:$@8Q(_>,3%M"&E&9""POP !DK^<<B=/$/_Z4<Q$TK&53Q>L*.,['G
M'S3JGC-B@0[SV$,=>LJ% J"!O_ $A3T@ T__S-$2H_W#'N0H1/IXE;Q3 ,"*
MC-#"^LJCE WA*!W.NE4L38F0Y:GD3?! A3*<0P8E."X\6CD/\19"C"#^ P])
M_(<P/($-%*CDAD,Z2!>.D! RF.!;W_K")GC8!((.QEP!,E(2JH @RCWT'S)@
M! ]?\P1)\#"@0DS2/U1AAH-4 @15^Q8:7F&Z?V"B%0<)0A3TTPZ6# 8PVO
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M*VM:PH\4D$#4=0" -[*1  J$\A_.L($(_KNDENS" C/XFSC 80=7_*,2&$B
M)=:P 6+70@(8.,,3(*",5XP@$&BH CP(<@50E. !E3B&"S; B'28P O.4((J
M#,& %=SA&?; 0Q%.$8)%L",+ )A"(!A A'C<(0J>*$'=<B$!.I0""Q7@PX6"
MX@YO@* #&?A"-M(TC"^$(1,/2"DF(L ))B@ &*D   N* 8@*Y( =T*#!!^X
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M$QP 'CBJ \K@(-8@&\KC%I( "WH@%^;A$7[@$.!@!]1 !#Z!!I@@&>[@"F2
M#MBA&8+_X X2H06F !^> 05H@ Q"Z2]R@0FB( 92(1T6@0E<80YR !0.0A[Z
M( V(( (\X6BJ@0)^X [\(1MBX!>RX N,[!]DX0R00 ^<94[> 0\&H!%PQ!0
M!@_&(!6:P U8(AN$8 N0H!CJP1;@X!>B@ 1IX0JVP QHK!N\H _>8(X PQF\
MX N*X&]JP05NX PJ 7,029%.9]M"HR5J(0&RZB!VP0N8(1 4  >FX2#$P04>
M8!M"I25( 0-@ !;%QPQVX1^J(0!. !V>@0.B@,=JH ,H81MN(1V>H ;T 1,
MP!8. 0"RY@O.C1RRX )801L 0 6NP1J<@1]:@ )R:18 P SB_R$$&N <8@$
M0* :KL$?: $ '.$<GB "^&$- & 9_N$/ ."/GJ.#_@$;C@ #!& &&&$>S
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M&4!A NQ@'2@@P_K@VF8"''Z %PZ"$4X &/:! NYM"O1.#J3H%6@@>0"C'G0
M;?[A"60 ':9! 6Z!'%(! B*)"EH($'8N-JI! '[A'^J@!;C@'Y*A"W#D'&S@
M#?[A#93 ':+!!M9 %@HA%!K #5A!%NK@ 8A( ::!'Z!@!&IA&EH@B.* "/+I
M(.A! N;@']+@"<[!$W@@"83!$F9 '^Q!"?)@'$)A EKH)OJ!#II 'GRP <I
M&'Y "#@J_9QA!0BM1_Y!&4*@ [ @&A!B#&8@%6@! :0A'%Y $,9!!PS!'N0
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MQTO3<*,YN>FE,%T(QAC*L)C&'*9RJ@B&$EB-A>B0PEN:R$(PFJ9"ZNC!!AR
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MFAC$*&;1"TX, A./C6PL9L':65CVLJMH;6M=X0K9VO:VN*UM;7'+V]NN@A'
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M&H2@ /G "C'P \.0"@NP!L9@"P@ #:C0 P?P"==0 CC@#[$  .C! K(0#%V
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MY# $=L *B@  C= .,\ 'Q< *A@<1\( #""(.,; &[[ . > -[\ $=\ *@U
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M"4? $&(@LO] #RV0"K7 SM/R#!(@(-\P!!. !>M *P&P &]0#^]  DL!#Q0
M&>EP"F'0!BW0<U- B<9] J>( _EP#RW@"NK0#@=314P@NO^P"BOP#X,P%O_0
M\A<2WPQQ#?\^< "'T&A3 #J78;KO( D[1P.-L@3@Z XC4-=>( ,."1&=,!;O
MH *1S1! ()$]E A1_0^Y0 ,5,@F+?P=WL*,,8 5QLU7;0 "S0 ;G( <DD F
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MZ,X>(MS$[8A'G_2AC$\U)<ZX?P;_1YM:>.&A&.0RX@+.]?YAW9_VM@JF#TL
MT2%B1'C@@1&<^R.^^.+M,]-XY9>';RLMQFC&'TH>B+B3%/Z)!@(C(.'##W$>
M=&>+"3 Y-)@PG'P$ U/^H28&9LCY HU_TKEADG^2::"5?PI1X9[*NJ!-#:;!
M.D_@8Q,Z.$=R2""/C"@C 70@G4ZRD8%N_*,*$S'#$M)A!.Y\X3)0"$(^/*$
M-]R#!ET(ARX.0 QPD*!HY%#!*;C2 O\!80"Q",8FQ@"IC 2!(__0 IP^ 0-Y
M%*,$0B!'/UI C(R082R(8-,2KA".61R@%OP8_T#1+I$"VRUA3/^@P?JB  1S
M."-=@ B!/X:QBPV4(B/@ZMD0_'&/;NA )XW@TC^\T(?*B L:+/")J@9'B@%
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M(A(-. +/^, "03BA3X.P !/&D (@7(,*"KC"&@X0"%W@  31V,0#I( ,7F0
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M!G7XAU.@C >!!;?X!W? ADF8#>_(B7/ !7\XAVKPAF'(!_0KAG50!FE8!WN
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M-. &B""")P"#.S,^61"42/"''KP$.&@$ I08'H !)("#./2# ;""/A!*7=
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MA%YH!S!@AE(@A%_P!T]8 0'PA68(!!G*"&(X SX805Q0@T@0 V7154Q @ .
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MP9D&': &?%B"'Q '0;  1VB'.S@!>Y@'$'"$R)" A4@#.&$&#S!P*. (7[@
M^<Z*3I  #P2+&YB#C+ "&J@&87  5PB'(MB-5[B 9SC1X#P# HB @<J(<OB"
M/A % " $X'  1B $#MB'2   (P"'6@" //@'/@" ,<@" %"%+@" 14"& (B
M). %-@  %-$',8B"1ZC_ $/P!@T0A&$(@,'>TUBX D&0 "_("'( "#H^!'&
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M.7@"+.A*1IR!!+0#/L@ $Y"#,F3 ?H""SJ@# 518,32 '-#CKBR!$X2#*61
M+(!#)6B!)^C"P;E!"L#9.23!"_2"-4!!+13"!K !-& "&*A#$3A=&?^ CFXT
M0@3\VAWL4"<,@#?]@PC44Q,, 3BX0V1$0@.8@SUXP1? F32TP#'H!C< @D20
M "&P0@?(03%( QI\@S@$0+;]PP_PP3_T@S),5F1P @&TP[C! "UXSLT- P%
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M XS $KS".R@!#)Q!L.(0/03 +Q0#!JS ZF1$-_" #)2!%,S *F " 70$'Q
MWN1! H  '9R 'Z $PYP! 0 !&93 $12#&#  "RQ !. !.F1!!&!"1'2##BC
M _ +/G2! O  "2!#/>! %JB!%.Q'1I0#'CR ,,!#%JR .H!#'9  +E""%O_4
MD1MD0!;$:$:P@@(@P3,$PPL0P2V4P5]%!C:\(BRX0"F, Q!@P 0@@"?\PRA4
M !V\@S($ !:XPQ@ P-]$!BE 0!_ @A40P3M\PP](@.7$P@ P@ 34P3^L@PDT
M !\H 0=8PC_H00)0@ CD0!S, RN\  -<@!., RH P!#,J;<]P028 >+L@3[T
M@@=4PCO@0!TT0Q%@)A@@P!VH@A&D@+*10R58 "B$PQ;80&QQ@<3<0@:TP1S
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M-B,:9[.W[]H62L_*LE$(M#'>%^Y;E16FA>Y1@9SOK1@*(J$3$V'&H'?G)+$
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MX8L9Z,,?4WC%-UR @O1"I!4I:,$X3O$ '%S"$Q*0T4&DT00X9&X3+&C$)A1
MBG_P @O#@ 4$OBX47TR %Z>P08$.L0-+0 $#>?B')<JP#2EXX1^ 6$,MP$
M65"" "<(1!%2_H\[\*$9"= #M\4@BTG,(#@+&48((#&("- !');%K"EF8CC_
M ?0K'738P!Q158<>5*XA\]A"#7@Q!/O4@0!)F$,22A"^A8A#"X\(A0O.D-L<
M8($7PK"%#X1@BWH\(@RAH,,4Y"&.+AR"$PF@A"QF<(5;P(,+/(@',U2  ?_P
M@P>XV$<6;-&'!W!+*/R(0O@[D(=\+"$3;8B!9.A@"!A!!G8 $4(!!9S''E2*
M"+C@&J)@ ?K &MP !LC@!8K &([ $(A #\9!$2C "C@A&IC@>OZ!%H"@#5!
M"_[A +' $)A@!Q)'P\ $PV002]YB$UX :/X!!#J!170 UP0! ]9 &6:)"D!
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MHH OBXT!1*H<< # 5H0-7@"2\&8%( 55R( "S&@DZN$)N(42S) ?4(#P]B$
MK&G_(33A!'[!%+"  VHF"0#A-)[1Z'S$%!P! #0!$J3L'ZC@Q+H R=RA%E(
MDI1! 0;%&BY/#[)@%C(A XP *LB!%@Z@$43!&Y#@#*[A$CK@$/8! 59F#Z8@
M'<+E*F,!!QAB"LX!%C*@9FYA 4@!&JR!"GH H18@?'[P']*!#*0,_5RE.37!
M&XJ@ 5#!'TB@Z&I02Y8!>23H05GC']! !3:#"WI0'VCG'S A @(@%;XM!][B
M&@8@%-* \-Z"?*RE"C( "LQ!#A:R(8@%(DYA !Q,/U" %OZA#,^P?/X!%T;
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M#3(@7R;E&@Z !]3A'\@  S+R+?A!!>!#%$C@/=DIP$X@3)' R?YA!U1$$:2
M(?!@VR0A"30C:2Z 1_^!&BB@'8#A3O4G2!O FIP /OZ40F+ARQA"$VZ@"W3I
M3UJA'<%) VKA'XH@UM[A!TR!''Q $S%A >R!B8_U'ZK !\1L_]9,X2,-(0,Z
MR2;&006R2!O281F<H ;086QYH06$X!_$X/*$D1Q?('\\)1$D80; 9AQTH/.:
M(@J:]A]Z8!3^P15^P&ST(05$(0[VDR&XX)NJE2&"8&\]EENOX('%@1[^  &Z
MR";0($_T99:NH8>L]0T.8!=EYAXR@0+4AQ@2H)@"#)>H@,O*H1^,80D@ !KZ
MH 1.!WN+5B@05F&CIPQNU28@EB$D@3 K-AT6 %*FC+6$ A=T(!7\P8,C!,YF
M;0"D(1ZN@0H\8!%JX0(,F*CH 4RQUP?L80YPER'6018@8'T9(A@6 AT<(! ,
M2P4^BQE\ &J;8@QX0'W^ 1XH '[>PO\-*""'1N(==.X8,H'8SD$%BA@8?&!I
MFF((3%AI(:D)]C9N/141"  5]VT)[(,A\($<LL!OM2%P&<(5%L ;]$ <TJ$%
MY@AW<F);%Y@?6*"(&?(<KB +F.$+NGB8/:8)!H O><$$4$6F&>(:FN 0>F$Y
M99<ET5 .=$ Q$.$%ZL$,HOH?C. ZBW=$A)=9MAHTWN(;;@ '5($3!  +_*$;
M(& 5WL$%KF < B$'WJ$-9H ;\ $)_O(!HL ?L($&Y*$5)@ ;W.$'3L$<1D !
MSL /I,!V# (<'.$!N,$>Q( )]0$/7N ;X$8H[. '=&$:/($'\H$=TF &OF$<
MAD &["$2F"#_':YA ?+5?H9@.&5! EYSA3L@#K"!#J39!>0X&!Y I,(!!8S@
M'E9A 2I!',Q@"E!E"<C@'P2A!ZA!&ACC'(X@!^;F#9PG%0Y <&V"#@; &J !
M!L[@':CA 20#$4:@(>#A -SX3[ A ZS#'+I@!>CA'#PS;G7!'1#@#=H!"!9
M%,3!!@"2$0H "JCA$:H@&DK@)+4 #FYB''8 '/OT'[KA +QA!98K#TR8#4:
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MHN$:<$ /%G@AVN'_"XJ #]3 '8S!"GC #>IG)*9!!'P@#OJ@!IKA#BC@\*8
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MXI*\\1;IL*X Y"XNPPR)E%8:9VG%=)@@6G/D;'F47)0[F"!12S8I4<Q0W7\
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M_D M1?$.D$ !N< O_\ -O' UCN(.+1@*]C .*% *5:8T1C$3^\ ,#_@PB$
MD 8.4S!M2R,$XE 4VF)C$_$0VO$/&L,J_U<>[,!A]/ $H59$_7 V)T8>=LAI
M1/$-%).%X<!AA-(.1=$,!W ,[F"'PY('![ ]N2!F\[ 4_T N2684P7 0DE(>
M\A")_..$.+2'DT(4=BA+D5 %G\0F*>=OY=$,27 G9N (!\=("588LCA)9P1R
MA3$">]!%S7 #H/1:_W %M4-SBZ1:7>0,"; _]E!1,^$/2$ 4T/]P P5#1DZD
M7/%V>[AW2-6"!* P!DE@#F4  \('#3,P!X_@ ] @#%- !+9@#MI0!:C "#/0
M#:&@((L0!3;P"&1 ! Z00J] !*J "#!P#8JP %G !E)@ \'@#$G@ YIP?G>A
M#FOP N-0### !?]@!@D !9$P!#X0#/^@#2(P"9N@ )!7#E= "HXP ]G0"R00
M R#0 1,R$_ 0!3AP!J;C!%=@!BW0 \ZR#4 0!E8 !^12'LX  P*@".<0#LX"
M#G&P!UZ@ J'P#[=P!6S@ FJ #%B0!?\@"C$"#F   VE@!3:@"%QP"/L ! _0
M!\+ "B,0!!3#"7U0!R80C+E0!&'@ JG_ERMGP NVT  ?<RX@\ =#T 7M4 8'
M( 1YQR?M$ 1;  5/8(>'@ 1U0 ((51CVD 4+\ ?9\ YYH 5W\ .F81_?( 5\
M22,_< 9WH .F1 Q)H 3\@@E;$ ?BE#?9> G_0 Y'$ "U@PL4AP]5T 9., ;N
M, L@P 9., .=@ 1B, 8MT Z#$ 55T ?D$ QU4 :08 0V0 S@H 44< >FD#>;
M$ 1?@ 65Z L6@@<_0$0S@0]B0 92\ O&( 2+\ ^X@ 12]P_1H =_L 3#M L1
ML E:L +RN2;-< %*,#?N$)/U0 *D$ 8S0$VO  5X8 29<@I)X E5P ;_L M+
M  )Y$"J8  16_P!Y<W('5: 'R  .O/ 'M. &.T *15$);D &)  ':S)=E1 +
M5; .Z: (>< 'X/,/M  &=D *LZ ,W& )N$ 4B' &0O +UV #)Y &^X )>: *
M2$ +XG &?+ '&@<&#> "C7 .GD &Z_(/B- 'U,4..&,&S- (2'!S_Z8.A) &
M<L OVQ 'KP (>A!B?'(,9< &E8 *\? &6Y ,_; (IH!RCI %:O =[D "S @/
MO=!JPN '*? )K' /NW"!X$$*7B!S,K,+O4"$]) '+[ (WZ /H2 ,$\$.K@ )
M,9$ON= .C;-Y_\8.J\ )5(H-;.  9N T=N(/1+ "C) .U; "Z] +T?^ 8N30
M#,<P$=/ ";W0#.?(8^FHCLN5$B_ +X;P#]:0 O-2"S6P<X-09G, 'E: !*9@
M"SL@*%%@ A3C T#P%3]@H$VP!Z8P"B]0!/;0 T9@% &0"?\@"4.@1?] #"?P
M$)\@*/+P QK;#R] (R 0C/\0!6[P#V7@ JN@"0.0 _KP!")0#MC@*7P"#2]P
M'/_@!$^0#_S0 K/P#TUP".A "P" "&R"#33@ 2)@K+Q0 \/@#"=0 ^8@ [B3
M!PWP#XR0 T11!ET0#J*@ U+ "J$0E7?P#^VPD=QC!3I #LQ0 JAP&P# #7"@
MKY% ":?U#4!X#C/ LB=5!6-0+ACP;3K@"WG_PPL!(!(+X W!0&S_X 6Q6AB@
MD''_T D^D%*!$ $V:!]L>QSU4 -T( ^_P +KD ^$< +U( \\@%!Z$ AY PY6
M, 40$P(L0+1>4&G_L @$$ [E0 "P4 TEH )N8 >NT --0 N$\ @=  W_\ "B
M  ]HX %K8 RG1@[3X .J@"KV00HL  SVT <U@ ^WX ,Y4 9OH _V80C@" ME
M\ ]Q( (0$06VU@XNX#15, %5.@%K, U!8 6IB"CO< D(, !DT&#U, )1$ IQ
M< #T\ T%$+M?L ;N8 D,< 68\ >9D ;]@ T,$*@F( ["H 1661@Q  ?C0 1X
M0 YBD  _0 MA$ #P__ /@? %P? ,$=!XY6$**-  >W $VJ 'B7 />4  ^= -
M!V ,RQ !.( *B7 !O<8+,E .CW"F:4 "FO<%$. '+H (=^ #ZP &(9 .VL %
M7C -T" "+? 0C7 $V\ *#$ (]  ' ^ %@V $,K X5O0-2B +R& %7T /F[
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MKIEHP1( (84TD"(&-+C%/R)A@Q  B1H[,($F]K $42SA!9?HAA%@8 EV7.$
MF7#M&[APB#T, QR-T($2EOBT2_#@#%JPSCV^H ([[ $*^7K$ V8 @G4@XPDW
ML,,OH@ #,YSC5O^LF((>^("%)_@#'7^ 01JZ08=6JP,*)C@#&PXPB$788 W[
MZ-D5*#"#"76#!WM  Q%">!5^C& !=" "! 9Q"A]T01IB8,$8['&*"3Q!#BI8
M 5JOPH@ S. 5X C'(Q(@@!ID:A8>^($,2D"&<\0" 22PQB<:\ DSC&$>OIC
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M/_ 4$\X^Q6@"PHZA0$!->NNUHL(_SQQ@22.-%***4^[$@!)Z[D!QWIP%_X$
M !KU'(GD-C[L,],#3E21Q1&J9-&'5IL$\8\6(BAR"!5-V-/(";WNHHPJ07@1
MV&!S'K*"F'C@\$\M-8B)WC]9Z/ ,/<J\HP(J_YS32S&J//'#/[0DH,P_=L0@
MR"%T'&$R>END (T]RI@2 "&6B-$#+G\HHA4IQP>1R%,UI/*/*Q,$PR\$S13=
MB%;D[/#,.2,XX1"&D,(<9B$ K>6"'HM3SS^F\0ES5&,'B_B'-%X@E3[]HQ"K
M(,PN'J N4PS ;HVPP3DX00$J7"$(##!%.QC0BG^< @+3(,PI.#03*VC%"'9P
M"CF 4(1">"$%*CB'.U+ #:TH(P/'&\,.\$ %$?_X0!E<D(HYK*"=&HAB*[X;
MPA:T0HT5_N,+H%$'JQ3R" 1X*ASX*$$6WP&",&D%#C!X#7KP4(A_=(("_!"'
M"@83C0-D"3W-@ $^_J&9/;@##S>PACN0X,%]W  ;[)B% Z"FB!Z XQQ<<,(_
M6L$">?QC& 2 Q#SZX()X_",%C(H5*UOIRD^E:E6M>B4M:QFJ.8'C"4?(PCQ$
MP0,N($4ASHB!&H)Q EG\PQ* 098+%&*/.R1N%3/[APMZ,:UJ70N.Z%'& &:A
M%7^P@%'8TN(_Y,&&#$#A')4X@L0<@@4<:@4?_  %"51U")(X11F7T,HX'F$!
MRPQ,*UX0 WN:0(A83,#_84N V3_*D 10P6,-$YB"]-!3#Q748F0E^P<8<* N
M)X0N!+A0W\P,$;I/R:A^2-*%##[1B1@<JPGN.X<*1/:/.M" &UWHSYQ$<80X
M",(%5YN")[3B"[T%XJ3CT$$HR*:5._SA'T]XPJ?"$8@BV((.6/A'*"0@F7\P
M@6!YZYH$>D8NI?Q "._P'1:D(B9W9/$?]K # _1W5O0((T__@(,)/B4.'\Q!
M*Y(@6 G0P(YC:24/.]**-) @B"1T\1^"(<P63-"J142 ';JHY[ZF<00"7,$?
M[*@IV+ PAR!<07X)V,8_\A"%H%R-,,,(P03&( XUL* <XU"5RRS3NR;(Y*(B
M_^,$&K6B"@E$XQ\RU4H\2H -?!"@$^- +#OV@ $F0(,P_^#"/E."!BD$($SL
M(,$G^O&#&N!##^H@#"Q@L%Y=2& 9_Y!$!.SAAA-4@QK0",8XFN$ ;?R#$00(
M)'HZH38QX$$K4( 9>LK1 C;D%QGH  <^4@#@?QA# %ET0AN$00UKW ,4-Q"'
M7TD;.5^] !!:F8<.#B:%]/V#55I!0@1F*%<V:H4+</S''B10#:>PPQ1ND,(+
M0J*"+*HCBDZIA S$] 86@$,(.RP(#LP1#PN',@7T^(<I:' U)G"R#;'3"A,2
M](<T:&4($[0EF]NLE5C&>)9NGC.LD"2("F#B'_J@P?\)^K,0(^#0'A&(F"*6
M^8]=*.L?V0! <BO1 ZWDP)KQ.$%V0X")>8@#/?(HP=D4M-$CD A)B1@I-11P
MC5[H[1]7@ .Q(/#C># !&:IPWC\$L4ST2&,%?@Y'!/8I"$C] P^![4&"H?&
M*DFA."<;0#>T\HAN(+."!$6/.%)PM'78@"5RP($]?O?0'"S6%<K*! /BMQUD
M[*(!+)D5!,*4C50_07_NJ,'Q1@8#&EAS3N9H 6A4$0.MR&!<@GCT),ITC 4(
MXQ]+P&<?/&<&'@##V;J8 ( 3D:!79, 86NF!&?[Q"MYI@P&!T$HK5'PD-+
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MZ,,48($X0($*N (;\  C. ,)^ $Y&$<+O( <Z$$5\(,+#/_".V !'?"0%+@
M+:R! $1"/(R! ,##."@!#8B#)Q3 ):@"'/# +T"##2P '_C!'O3#(6B -!#&
M-$! &#2#%^! -L #!=!!. "# _1"JX#! _#<G"0# D1!*E!!";1"/0P!$N##
M,<" M 1"#"2#/K3!'82#/+B "XQ#/"1!$IB#-[S "LC!%%@"*A3 )-S"%YB
M-0@#!)""/4S"#J##/)!"!G #.Q!!!BC"+OA S,U)+0B &*!#/$"#Z6D%+@3!
M-_Q##BS!/MC#*AP *QQ:%8#2G+P"!51)* Q $*!"(\@ ,/C! (A"/YC!!:""
M+UC &)1"(6 !.!#"#!!-+'S ,\#_0Q%@03&(PQ1TW)R$ @.<'SN(0--D @$2
M!CS, ("=@16$ PY\@C>L @2H0CN   N4@BP@@"CD@BYP0!"40B(D 4_]@S_<
M@'80 A.T0P"X@"Z@ A L@R-\P!G PAKL4!/B0R9$ "* 0RQ<@(W! @98RQ.$
M@3Y,EPUDPS\( 01@0C.,01J0PMF@0P+H@E. 51T$6PK,@S>H@"&0V#<L0.R\
M@01$'))L @_L S.(P@!(#R(< -MY0!;( S!\@39XPPW4PS^,0@*@ V$P@A)H
MA1D(@584 8,IQ#ML1"DD#Z_8 PX WC7P0'*: 0-D0CQL@Q8DPPHP 3WX@Q2X
MPC_H0"WT_T,YW$(P+$X;G("J^$,*2(4,N \XE-$_] ("1-P_O$,)P()6',&.
MX4&3388Y- #,-$(#! P6_<,^^(!**80L<,!7]<'8$8'G!-B(C<,)^"(W^( _
M/ 2M-0$2D-4Q:,4(R$08'$S1J-@)TBBI;(,[]&>-ZJBHO ,I$ U[X$^OX$,<
MC $PF((B)(,NX$(HO(,PQ (OP()"U((6H,(QN$$V] (<C($PA,(OV$(]]$,?
M=$,9H0<Q[,$;K.<\H (OC$+.?4HZK$(=%(*U_ ,G1$$VV,(B).<QT($3I-TT
MH,$>)((LH,$6?$*OC$P8Q,(<G($?5 DD_($?_,(KK,$:/(,UM/\@*P@!& S"
M'OR!]/P#,60!!61!/TR/$R@!'ZR#[]B$#2P!*G!!(FA#&=S!*JA"'_P!8B0"
M#D#!Q)!".#1#%?# $N"#-+#!'TS"L72%)*1 &GQ"",S"*/@!&U!#)_B!'10@
M+<P.JU8"%=S!+12!)<R#%!R!'@R!)FC@)P@ " P!&%S-*8S!&+R"*^S!'LB&
M,'Q! !B".XR#&:# (-0"%VC<+RA!$C@!-OQ#,LS!&DA"/-A7"@1!%D5.)WW!
M%#P!%$B>0IQ""W@#.* !'FP!$W !,O&(#A02>F@#"*# &DB/+=# #$R!?#&#
M$ZB %]S!"&S".<3!"]C $-!#,X" #B#_ACFL@3S&00R80B+<P!0TVYS, @GD
M 1LP0DF8P V(@9S%0Q/TP"%DP8^AS"+( Q/H0!],P@H<@CX4W:].@@[@@ D
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M'[1A ,SM%"B 4*(! F[A'/Q 5B+C(\Z/'?YA&R8 5% A V*+'UYAF]R@MA#
MR7 #',2  ^)@']Y!'0(@5])A!;0!'P( V8!!'ZP#,_[A![+%D\CA!0KG']A@
M"@1A"<P $<JA"O^LX"1P8 X*(@AH$!L2  JJ@5"(P?7\P0:XI+Z>01?,X 5H
MX0W'I[Y\8!CDX0#4<!L2 !3^(0>RI1]\ ))J@AWR 1D8X072X!\8 <OXP O
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MAL,?0($$$D8$MO(?X* ),-((_"(.@@ 5\F X\*\C](__K$ )TN\?T$ %*((
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M%TZ5;\2 "@KB$P@@:,JO%$@@T/ZA$%[ 5KFAQ'S 6=R3$) 3^U*@(_9A%P;
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M,M,.VL$.8J >FH$!\F#2 L 7, $#7"$>W. #>,%2#LX4_R$87B '^'<D1B$
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M'UB %?[!!+9R$>@K$V2 'XJ!;]B@:R0# HH &+[!"*ZA# 2 &,H!#V  4EE
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M%C@!!')@&7#A![Z %;HA"F+@#.YA$FK@"H#!'T!: L*(&9J?#\:@!7Q!:8$
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M"0;V%;LH!T-P4IX0!*/P!7L04/P !W7@!%CW#[A =_]P"'<W6U0 !JH0 H:
M$J< !5JP"Q&"#$Y@!(4P#^+0"XUP#4EP1RLC#WQ@!(: #_NB#R7P9-)P!UT0
M5(W1"K& "<) #<X%"XE "=OD#)N@#HQP"&,U#I[@!7+0 #+V>-3A>(+Y6/_
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M.\!&7R$.3V )V\ 5ZTD) _ *=A!4X\ %>0 -F   @* - 2 &M1 +ML $*:$
M?^ /=< %H>8"M<$$V9 ,*5 -R( $#""@@7$(,J 81, #P  .GC %\T!G<%4.
M.T + @($2K ,BLH/.2@#J(8#5B0%FT8U9A![Y2 " 9!6F1 (*:$+ (!,-V )
M^= % ^ '=  &6G !AC 'MM %04#_#HIP _X0F4E@#( P =I #E% !^#Y-$I@
M"33:"T9F YS "@T0AUI0J8WP H 1E/-!E'B'!BB "'O  93 =E7@#*+  (:
M#@=0?#30".U@!2W&!/TX'>D0 ED #3* 7JE!E@PF#5_ #=' CZ.E L?P"!-@
M MQP"V*P#9YP ,W !PE@!(00 BL04&&P!,O !P/P"85)+&E'2QMV#BK@"M(1
M#3-P"\+ #<%0&BZP"RE!"B*@$F7@!2D!##@0<F*@ _^@"2- =BI1"UK0!BO
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M# ^P#[=@ ^+%#PVP>%WK&(09T6$Q#CD0ABDA#=TP <B4$J<F A;Z7": <6)
MMPKE WBKMZN0 ;A8R--P"3V #,QP X3K [J%"QD0#2IQN0WB"0,0*/]0"A1
M#[.   +Z&O5P CK[#U\01:";$D;06_/P WR0#@N@""HA#_- !-/9.J(PN_^P
M!%CM#B20H4;V @( +K^;$H'0!)\U W%@$\C[#Y"  J41U2&E V!@#P[@1POW
M#T[0U2Y@H=\K-N+K!(6\ .L)$3^ !X#=U9IC#X> <9UP >@*!C@ (DNPBM5@
M!;,P##MP4E,0_YAX, *842"JP 4$X+!/HPT1+"&:T!+4!0]_0  R4 [IL -N
M"UK<L X\ )HI\01)D!+/X,+PE1*=X';_0 9TRPC:FA(A< AH$ (J<0D4X YS
MM['3'!;Z@,0<^P]>  ;]X "3R7=A,0L2,'6HD0D X 8I@0H9P)4I40\J$+I<
M,)G]DLC_L Y&P %_8 ] 4)0I@5Q?T0X(\,B<1:C)K<CT';I-<%W%+5L+'J4X
MD !R,!_[,@XT< 9T@ RY$ &74 >,$2&P  6'0 /7IPL2H"E#R0+1\0_E@ =C
MH 8ZT _VD (,NPT), O@_<M/8PT_D !I4"T33L/7L9&.< + $LW?_?\T7N#>
M(#H#R/ #I# ,WH .V*$.8X '/H"_DA  M>$Q]B (8? #6L :_T"6QG8$A# ,
MRM .( (%J4<.+9 +[. #IJ ,PP /XF /)2 OT^ #\F './ CP?#0%"W17YOH
MAID'%Z *\9 *=7 ,$: $P. /<]"/)& +*=$+!.!H_S 'U_=:#P!JH:ZWP2
M1$ /P9 &O] "^&L+,] /X_ "D7 .PP #-6 -YF (2[DRUA !L/D/FW"<KI
M"'%-2QCF(H *!0T+,A.A$%$"NN4$/. >SM %[G %L-DZV% "I ($[_4/)""?
MEF<.0_ %_W '=  1G2"\_U //["YR# !L4#_%2K0&$LP(N&P M,I CG@7,*@
M6UTP[#G XWA W=YF643@<4^ S."0 A>&!-VN.1;=TO]0 B-+"#@@,T@P52.0
MXPUP1TJ0O/^0"1;@4@*<#9I0&F#@FR0C##N '9#P#_WP!%# #5,Q#!Q8#A&
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M8!'[Z$$5\B '4_$"!#O0PN4X]X]Y@"$(<AB#%F,!!1&P 3=]9$<;7'")1O1
M#\N(@PG 4 L\A  3TQ@!%?!PAP4%$&+_2 <3++G&-?P#'-3*A@U20(@RO" 7
MBB!!'L;AC2R( !#N&$<='""$DEW"$2C0 C$$88(]T",3#Z@#/E#&$3R   E%
MB(8O#C #6APB R> A2-@4$P'\$$9)UC *J A Q:PSID+"00+WC '*#"CB4U@
M@ U^P QM$$ )8@B!"U2!!P+H;Y7)@,$(P%"%!;#.+>0@!06H\ UE@&  #_ !
M+/Y1!!ZT00] R,0_9'& " 1 _P;HD,4"]" -,"0@#ON(@@3F< 4(+ %Q7@-K
M6/^A-2:*U:PL0>%%E?625?:1C[3J"Q/;FC*YJA&N;X686MGZ-:_9-:[P(XF&
MO!-8JUV4<WKU2 @[0JTPJ;%.LP+'._[Z$7"LA"^]Z,$_3I:L?\CC' NI!SOF
M,=K(&78E=6+'.,:1CG.(]K/65*QI%U+:>;"CLNYP!Y<VM!)WV(,<]F '7]CQ
MV'&(@QUD"T<ZZ+%8,'&6KJ#%!SMB$@]QD$,>2USK/SYK#G;80Q_Z((<^X@%<
M>X##'<"H1EXE]X]U["4<]<#'M*[YC[RIZ23F($<_R%$/>[BC'Y(%1S8NLHUW
M2(,?Z?_X;GCG 0YJ2%:M[^ '*N#QCV\\(QK(0 8VNG&Y:.S#'=2XQSZZ@8UE
M?*,4S1"&7"/R"E4X^!_ZB$8S9/6/;81B'_U81CM@88QH!->MQU %,.@Q"5/=
MM!O$",50Z@$)210C)EL0 QC $ <9+.,?TZ $)/2I#6S<0AG-J$8M]#&/53P"
M%L1(AF3/NN:7D!6Q;(9S7N$W9SK[5<YUQG.>]3P2[US3SWH&=* %/6A"%YK.
M?#9TH@\[6 #*>59;@S0 #?O6=T@B DZ6]'-/95H[WVMK=/5, $,=ZNPZ=Y]E
M7:^F4Y9JF'S:T9QE-,SBVNHW[[.PDY[LJOG<DKGB=2&AB$'_<\F1AFRX-<['
M[IJ;[8QLLRK:U5]SMK,1K1(_7S/:U\9VM@4];6WG67+=QO.W5[*-+EBA#K(R
MM+@'K6YP>ULDV_YKM-G=[D!ONMOS+C2W%WUH8_@@!6<H0Q=^IFAF%YPCRC8X
MLK$=6'K7^]V=J79E&SYQB@-:WQ7?-\8S/JT,H23=\28TOC5^\3J+?-T@UWC)
M3?YQ4,O[X74--SY600E,G$S:"6<VPG$.9WA+&M4H5_FAGWEGH8>DS_,ENKM]
M?N^EN]RYB28YQ5<.;G:W/.1 =[C54_[SI!>]Z_G&^M:?W72G?_WJ1G^VQ<.>
M]9W#6>=M/VN]SR'C.3,\Z.&(AS4._PV-;*P$']EPK]*A36T_<H,<ZSY',$+8
M\'\82]LOAH>Q$J>.Q8,=[5N?.M.UOO"U"Y[L*8]ZW3O?<[.+O6KMSOR>7\YI
MT,,=SLCP>*U=?VLZ__D>5W@ X_)\^#I'W+(KL8,/*G\O31S@"?_0!@I0@-QP
M?_[3UJC"%!QL<6S X0XA& KJ<\$#2RX<%7J P@G*H8T]=&$$P'#^LF>_?O:W
MW_WOAW_\Y3]_9L-^[/2WNZZM:5EWB,('ZGBU,$&%@1NUF(D9:F&$58B);\@&
MB5LU<VB")?@'=N@$%)"\H7L+=?B$1ENZ?X@'1M"N1W !OA@LP'('*^ %=PB"
M5TB_=(N&,_\8EVO3K!XP!GA(@ER@ 6Y(!RA0FG#3!L;!OR 4PB$DPB(TPB,L
M0OOCNB.\%^GRHX5 .AKS 7^@%37["RM(+[ZP0I#@AQH(A%E[0HY8 B-8"%50
M@0M$"?4B!RW@%Q)LN7]P!"=8B%T( 3!\0W2P@<W:PF53JU[CJV_KHV4X 8Y(
MAA88EU,Y%2"X!R1DQ$9TQ$>$Q$A\1"64O2),"7_(!#'P VEXAB 0!'! A"!H
MA7^0AAM0A3MH E1X%#+8@BU !RN(@"FHA'_HA2M@ RQ(!G98A3;P!C$ @58X
MAR%( "!0A6,X!#J0KG9  C*(@@WZ!R,@PW_ 07!(A"/H IIIAB/_B(4P.8,,
M8 )&D*Q 6 ,M* 2;6XE*"( CP(1_V 4N\ 9;+(>5H <UH() :*:4V(8Y\ %+
MJ 3IZH5)6 1.Z0=2: 9LB 1+PH5'"(0)<Y=!.(6Y&0I[^(1 D(1Q&0=MP 5P
M,(=1$(5M< 1=D)9_6 9,8 18X :V>0M6 $AK8)4MN(%#8(5HV (;>(-<^(=D
M2 1) ,&%X(5'>(1AT <_>( WD 5)-,JC1,JD5,JEA E*5#\B7 DZT(-_@ ,^
M> ?P^P=[  $RH+$#J()$,((!@(9\4 %_V(81*(=G\(%>0 =N  !(2(<5L -Q
M((,$@(-:((,<< ==L %JF =6$ $:  =__[@!*6 '02"!MH#&A<@%%7"'8$ !
M%ZB38G"!"1LW&M"##5(#*%@';0B /T@6:" !*+ R5Z  .Q"$$Z 8?*@"32@&
M+@ !?>B.?>@%'_B%:B"'2" ";1B#W/N% &"!-0@ 5'"$-T &+5B^9."!4Y"&
M%F@ $ H"/= &)SB"=)"&%3"!?Y@$&XB!.W !"?B5:J" 5(B&!;"59/$$*E &
M-3B 8H %/, !5QB&6S "%K %9+B'(J"%5R  ,%"8)&@&/V  9T!'3/@JID30
M!%70!670]YN&Z3O*E=@#$]@&=RB<-WB9?T "_Q2&&1@*<[@!/D"'!*"#>%@&
M?>@''S@D9G"$>/^0AB.(@W\ !@I(KU10 8SP 03ZAU2( 7)P$GR !C=0@<]:
M3&E4 ;)Y!@F "$AH!,X: 4!QA@!(KW_(A 3 ";[H 3Q8B%-0 <E2 R#X!TNH
M@4_PA"V0@$'RBV_ @7SXAU^8@1ES 0RI@R^8!WD@!A80 T>  P10AEF8  #<
M@QFPBA58B'YP $.@Q1$,!T<(@;:0 3GX!T58 -E\ J[TBWKX@3X(!#'H -"\
MAA)0+$90@$6\!!?P!$$  11HAAU@26>0 G1HAQN(P25LT%JUU5O%U5R],@@U
MRI5H!Q&P@#.H$S"0PW]P @Z] 3;]!SW(@7<8! IH@5F$!Q\0AH7HAB[_4 ,9
M:!=A2(%%Q 6&<08<0+]_X 42D*Y@( (Y((,?(-)H;$S),X(A"(<ML,R58 <2
MP(5_8 0(^"IMN  TC8D<\(*%((4<6 AB_0<AP -O4 9@\ =I\0N)0+\QT $G
M5 0*$ <V2(.%  0!H(1..(7+(04&&(HVF()PT(+,6H@A&-A3&,%_ (,N6(@N
M0)9%( !Y^(<A$(-D(08$Z 58V(114(8$VH%#W(0&8)L:R )CV 5F,(=2.($+
M_(=K^+],T]6KQ=JLU5I(?%!3@\246 =YV(0'D)"8G=DW^ =JN &&+ (Q2 =[
M@ <A8 !3B <?V(9_> 4%(*(M@%1N]=;LG 8?_P#"6""!<. '&.#*94"!.BE2
M5#A#:XV ,#B$1KM71[D%"[ CPR& + Q8#-'7ES7;+7 !CF"&8W@+B?T'-S@!
MLLF)&'"'/I 0[20 V=0L:NB'+L@"3+@!T,D"&>"(.I!94@#=8CW6SEH",_@$
M*\B^E1 %#""BA=B@6RC:A3A:MEF!-N (=,B%"/@95CH&:UC;N]K:\27?\C7?
MMNO:2K3$?Q"##=*$$O@',\B!>\ &'Z"#?A"&!IBP?>"!;G &** 6%IB#>. !
M8T &-VB ?N"'$2B#<BB& !C:7+ !=OB&!6"*?Z #%/@'9.B 56"'.4 !)X,"
M*%@(7]!@CD"""^@^O_]@!QVHA&F8!A$@8:O@@K:P+!*X WC@!UH874+B@G](
M! PP!'IPABDH-K]H!QO@AW]0!0R(AH70 V09 ]@P' 3P WC !T0A!ST A%RX
M'))Q (_Z!Q5XA']P!8/]!T) @IE5@W_@ARP A%]YIGTX@2.8!GH8A#DPG!V(
M'$9P 'UR@PM(!7J8AB40!A^0@B6R@UEP!A: AW*8AU#8AJ<\WTJVY$O&Y(](
M7TH>PI7H@Q>0!"K8"+6] 309 6*0!RS0@D$0@DNXL@L@ DJ @GVHARFH@480
MAA.0*2<(@$$P@PQP@FV  PR@ W_X A2 !&@H@1K@A7Y0 ATP!#Z@@$70!1C_
MF %4\(8?4(!-J*Q_0(4JH!;OH ,6&)UL>  R8(0K.*2W, ,>R(-EB(((X 5N
MR $%@(1QR ()X($66!&5V(<Z2  ^4#P^H(%4((4D^ 914#Y.^8<ZT  *.  B
M^ =T.( H:(-EY"\F" %4  0@R =SH(,+H(5M( $>6(9J"( 0H$T.6((U*((W
MX+V5T 0&:( %, A^P ,+T(1SJ(8BD(!/B(=]"((+>( =V 4JO8 :^ +LA8<'
M<()>, <!L(),INJJMFI,=DJD#(9N>(5UIC!NN,GE6HAHR 4Q%H=J@(56.$1^
M:$",* 5R$ =AJ(=;J(9L* =LJ.MW@ >:08=2P(=Q_Q&'9Y!-L!:&:,B&;> '
M6,"&9N (.SCJP8J'9F@N=& Q<U0)<;@%>C '5L &:@ &6$#K<'@'5E@$G "@
M? B%90B%6QH%,S %LB&&9NB&9%B)<7B%.' %V52&)WB#*1N"HV&'1>"#4V@+
M;X@#.W %4Y #0Q &6\@#6BB':G@"-9BR)ZB4M\ &0L $,+$&-ZB$;DB'5W"#
M6\CL%PN$2-"BE:@%-^ .GBR$.B&%:.#DJZ;O^K9OH\QJII0M\7TZKJ'D=D $
M,Y "RZ:=C2,LJSOPH>.(>5B",F;,&#6VD)"'$7"6?UB$+U2Q=XOP_K:U^_;P
M#P?Q1LSOI,2XU%LK6R@ $?]8Q+*S-Z]K0?BP!RB(@"50@RI0A/AJOE7CARE@
M@3](@RSPA',PO1 G\B(W<OH;<:0L\=&#.7<X!L=C<9-+/;\X!U9XA$EP1L_S
M"W$PAD1H!"UZ<<T[\C$G\S*OO]B;;TNL.!//M3#W/"EG\EC;/#GGP#E?<S/'
M\SS7<ZY)\CWW\S\']$ 7=*_I\T$W]$-']$3'\T)7]$9W]$>']/-E]$BG]$JW
M]$M'RDG']$WG]$[W]/9[NT\7]5$G]5(WJU W]517]55G];%"\U:']5B7]4M'
M]5FW]5O'=3T7!EEQP%SW]5\'=A#?]?U+\V W]F-']@8=]EY/]F9W]F=GT&57
M7VC_I_9JMW;\D_9BO_9MY_9N1[9L]W:P>K-IYS5$=(FG%*QP5W<RU\'&FG4M
MO[_"^H=W8 =Z7[!P<(=T )/]$:N4> =W>(?Y^BWU$^UP\#'&"H=QJ"S> P=Q
MX+A_P*V%J/=^)[T6!RR0HWA:U3>1._<<GS\ZI_.,%[W+@[E:\_AFBW>2O_C[
M;G?+>G<Y/SV-9XEW4+-P((=SH/EY.(?:TO:0\+-X< =P2(?#FX?'0CO(XBW)
M"J%Y&(> KX?(@OIYERQV\#%QKWB.Q_BP"OF.+_F5+XDWAS^03_FN.7EU$[?0
MZWF[(W?G^_"6[_!5'_M2\YJB][0M)(=T8"RP(H>:)P?>_]M"MXCX>4^9@-][
MCJB3E; 'O@"'D/3:N(M[!7_[ .RKQW\XE2=!3A:UQI>_MS@LS;?Z$NPTL5]"
ME6.SK5\]KZ]OMT][2Q<24P $2M"#*ZA6PY\#H8I\JZD'<@"'>A '?P!X>Z"'
M?@"3R $KQ3J&8@"3Q2^)=X!8<_ 'SPIG:=$';UC$>S '<:#W:3B9MDC#N.,(
M:] &^.$,1-,_BQ?YM.<+<Y@Q!&\B<C\]B*?"G8L'=$<KGHNUT$^[L1]Y^Y=Y
MK8/\U >(=/_"#?QG\"#"A H7,FSH\"'$B!(G4JPX,1S!?VJ@F.LF@<&KA*IF
M<"IH<2&[?\SZH%'4I4B>0%WR"/],>3)A.&"&VAB90^_?/' 0W0T$1B7(KH'O
M")HJ04<>G"&7_OWRP88H.'KRR F]"<F)&C):V*BYD@G5@CH#,?Z#)>':PW>'
MBG0I=<W(%2'4_FWS@D74VHPW$69D>S-<OCHE:N$4'&T(%8O(X!3Q$PC1/UTC
M[ RVZ"V,D*X,D]6A ZY?I"WX$HH3A,=<YX7V8H6)%_@?KCWG'F(LW-B@X(6]
M"Z^;Y"DVP^$,Q\5:I] PQFBR#".O;OVZ0VD"P5''[OT[^/ 7"7:ZP.W?,AX1
M8!'^!\A"L^M"J\U(]2T$ #WJ.I'(]X]=1NR\PTY7Y) 3SCS_<)72..^\8Q [
MXOR3!P#_@/#AA#__U:/@/^ 09= [NQD4U#E5 ' &< #Z0D :\X@!@!/_F#)!
M%K8QT\5YY("H(X+AO//A<B*,8@\F !QB3RU%V .%&[=Y(TB&A0W7&SPNX&"/
M.(]4H A1[PRQ1U#@B#DEF66:^0\QWIATD)EMFC,) Z'@](\RPM#IA13 M9D0
M/BM@H8TJ-AB!I@IS!-8FHHDJ]PT-7^A)YC_(#$$#.>)XH8 Z"=T#QPO\'%IF
M8WNB0\4,_=S&!P@;*AI..M^ N@\ZJV+DCC/_/+/#%9_**NL_\:0SI4H#Q*)K
M./'\] \361"[*[/*B?=L0MIUV!VTU5I[K44$[</#&@95PP,/_[-X$L@Q!?DS
M0Q Z(N?./.RLDXE!40# QC_]2.(-.NR,\P\^^OXS#C#U@#/..>H(U \\T[Y3
MS#WUU)./$P#$ DZ&]@2S;SW]"/2/./T(M0XRJQE$H2?X, /4._Z4DLP_B!C@
M!SOT#"--./QT8<,Z[,Q#3CKDN+-//^'4HVY#Y\AB$"\<-&+0+>/X(49RP#W:
MVS^53&#G."N@ 1P<Y097T=<'P:%FV!!1-TP&<BK$!BX&46(%85]_C0H'VQBD
MC;+_^$$'FW+/V5[<SB*$B0QQMX=*#"DA@T.F"5ESP[%K_68V0L:<H ^;_[@C
M5'?4_@,)9I ^TLV:4U-]2B$C"]%W</^@ JZG0F7 I9 Z\W3^3R2^=!B,/&.R
M/CGKP#X:*K;/2LM=V<4KO_RU!#&R02+>O@!#$$4\$  H!IW#Q )J(F=@/^/(
M\V\1 *1AD#W[T '$*=2L8$DXOLQQA1%V'N-'%IHD D(>JYW"AQK2X PQ-, "
M)BC%/Y)!!RQH01GF $,1,/$+)B0"'+.8 Q66L R#F.$#>_B$",H0#WS@00ND
M (<ES$>/->AA%^@X@@52L(5>R"$*=+@'-(8 " 6%8QS)2P@N.! (DU#!#;X(
M@R?"P8Y?=$%-P7"#$/@PC$_]XQL(B(1!B@ #3UFC6P0IA2/D\(IPT",5KL!&
M'&X1"U6@H@S_QR"'(1RAB7B 8QJ%6$8O^' ,=HQ! &&XQ7-@$8<\G (HHKC$
M.A AA_$I2!.6 (,"U':0=Q B 2!@Q#\.@01YN($4!0$&)<"0"FIA P)7"$:'
M//F/*\A!&7+0G=!F(8="["L?I&C')@JYCT:4@3W_>$<@(J$-'TY)')]P RI0
MV8DD(*D:W/G'-.P ")'A@@0ID88/&H<0;>A 'MGH1H((HHQ<8$-J"'E'*6IQ
M"YFQ@AGO@$4W_",*%/0#&W8R"#" P99DY.(9'PI'+5Z1L%O ( _-0%YO=,$"
M-6"#(,M 17RH2 P<M $N=6C#/U31#I/<(A28$YXZWL$,YZ#G%9AC_UHRN+(*
M'F0C03I"ASU@QZ^31L,$UP"2F/YQ#GH0[2 2*H@^Y!$44(F#'J(IR$\]QSSD
M'$^I2WTJ5*\3CC]@ (O_^%8$4O&/0ER "R*J@P5469UQJ.L<Y3N?.QYT!@"8
M(! E<$0V/( ';6S@"_&(!QH P 56L   Q#B'#H;0CB[@ AE-L( =X"$.)1Q!
M&5-(0CW, ( 4O,$$;H#&!?3P# \PH1S_H ,$H.",, #@$>P@! "> (Y,Y.<?
M<P! %N8QB QPX17MP$0!1%"/8AB!/0UZ4$.H%L0AL@4-*QB$)2# "GV0P0/L
M$<(<U@$$3>@*'%40@8>4D %:_.,1Q_D'*_\DX M&)& ;M9A!!)P0@R>,  =:
MX($M]L $:N3@#?58PP6D,(DHY. <DVA!+];Q-6M<@!*I4( HN-$#!Q!!#C2H
MPCO H8<U&",,$)"D0<C!"1A P1;_2,0-$*$& I1D&7<P!B\FD+V$O$,,&'A!
M(WCTCS_\ !!T6(#=Y$ "43SA#QJ! '])P \I?&(5.I!#.O(PBE/@8!J'VNH5
M!A&"/7S.!W(@@@-Z82L'1*(/(#!5-5,BC&PJQ!@XZ,(3** %S)UB#+C@0A<V
MAA! ]$$3._#$+7 0!G"LP@&3^$<I5&")&2"@#^#PA0.Z]8]1P,$64#""/=XQ
M!TGP@06M<$0$K,#_BZ6PY1QH4$ 5=(<('63""EGXJ&$N88,?$,*U0)A$$$9P
M'GFT(1%7(,$&J98.-ZP R\K*!!R(H(1MB",-2! "$9QAA0>@H1J'L (@6H $
M4I2 %_^0!QO T(4QT!H!1"!&*DA0"8/ P@E@ (&626&%39C!!5LP52G0<(8:
M/(.*NB""&4# W4XHX0V*J,$84O+#J%9$&-MQ*L$3KG")Q$,$ M#R57FP $"N
M0@ X (9!V*"!0U@G)9O3:?GH58\$80(!)AC&-\2!#1\$(A<#B$"Y% $ ,'P6
M +/81PPDD(=U9(H-!EC%/U!1@"]( PD \(8O," #9)A#']) P1N>@8 9_V0J
M#@90"S(<,(-XZ ( >/@')0#0+9=M(:,(2(%M_,$$ 1@C&()0$#NXXA#A"E%R
M5-C:/URPM&A (!K_$$$5XM&.;.CJ'[Z00#)\00<G; $<0$#E/S01HWWX@!7_
MF 0+^&&[592 '$/KPC+<<840_*,= L#,*V; C'H$ )8)<484_D&/&31I&"R
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M,9Q 6DXFF26$-J2 9_V#$"#!)42 ;1C$KQ#&.5Q" $R *?S#'8R!021!:Y8
M;/P#$/QK&?PK)YP 0OA#"G"<4-2#..A <"H'/A#G/Q@"!8C,*<3 <F9$<QH$
M&.  YBQ!(# # S1B\!"$.OC >;!#"23H08##+:" ![0:,[BGK4B T29J+$##
M /B2_T$00W\:1,^:014<1!> P#_D@):50PH X3$D@094P3HJQQK0BT$$P:#\
M@6K^0Q!$SX:*Z$$4PX<"+N&6XB5X0/1<E0)8@'^J0844!!UDP-$@![#80P\
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M&,$B&,0;7,D_0,$DN(,*5,&&  /_&CP(U>S##8 R.8C %-A$(6"#,:2#(!#
M,=1" VS4,TB )!W!*>P# CBA :;", S  /^#%"B"1AQG%D&-"!02/J3 $D+#
MH5$ O42H"!R$$A!?&.SM$/AMX4*$X.)B.\?S4Q$$+'# ^?Q#-L@ '1C!(?3
M)7S(//3 "LA99R@',PS"#21 $H#";T(#%## $6S#@Y!"765"#US )CC#$K2
M%]A"%0@ &>P#$VP!( S!.40#"2Q &SA'+!P  6P!*'@#$N! 1!/$*GA $[B"
M%1R (9P#'Y  26]!&] #/SP!#@ !*OA! Q !-/3!!!3!/CC#%!  (5 B>.G
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M019  R$80CFPPRP P1(4@JGTJX$"<"$T01AH_2H\P1  TC_PPA#@PH$HAR9
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M#@BAAL A%=0@#$BA.[0!#/B@$O C%IZ  MH@T:0"%SJ@#=8L&#X!)M0!$,C
M$O@!)I[A#2P!&LX!#"2 $(;A''*A V'B%,Y #F;/';*A$?0A$N) 468E'K#
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M"'"A&D1 !MB!%YI@&=1@ )J!%G:@#*2A%EA@C<C!#;+@&>P  FJA'*+  <I
M$6  #(SE#"#A'V)@0W4A 1+B'VJ! BC!$G2 TO[A&0C ^9:B%$+ !%9A')JA
M!.9@"VQ #OX!$Q* NZ!A#%8!#99@50Z!!?#A']2@ HQI&+"@0> !!>A@$&"
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MI"$%^*P#/<&-@/^6S]YA&F" &<#!"O:)#1.I!DH!)@9! <JA&"*@Z/Y!#U;
M';B! @3$$$+@'RAA!NBS$X@Q*^IA!=@ )F0! P"S%4:@JA0"!C0@"L+E%'B
M#M@ !'@@&%9 V_3!!&3A'V@@?O]A$=Q(%!H@0_X!#TS '9:!!Q2K$P)X5D*A
M#F!B!*K)#"1@#1\!"_X!'G@@$H<A IK5/KJ ?&^!!:@A) )8'.Z@(#>AAA=A
M.ZY! E*!':@ "MQH$4CK276@&FL $N;A%/33&;A!%B(@%CA$"#SA'[KA ?@!
M'KZ "MP!&2Y@0_L@@F<%'QY &_[A#*" '8KA!%"R&E@@'^)A!S:T'W#_H.%
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M0D$:FD$! #DF:-MMS?_U<6] 4<"4'K!!!VKH$X);D? A\4X!$U!@#)S!#W
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MGN$$#,P)?'3K/YS&;3PKYO]!#(3 &PY!V>.A!%Y]LN-@!JKQ'YJ ND""'_:
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M2:'+[, :)X7&5AP[#_V#R 3#;#5"1\?P4.D_T3  "SC3C$.<4U)8\4\_R^C
M&B2_\J''/X- -(H#S$#%%#436/'B&1V$0M(:*40T0H"_F$"2-#O8\P\\$G3R
M3S4IL-:%&O\,DP M_VR!+SC%A<+!,?\X@L4_\^A04S(^V".*!I!$Q(0GWWW2
M 3_&^1&1%-J%,P(:P/[3C [\_E.,#^?^$TDFJ31#G03P]H) .__4L&8RK_QS
M"@2@?"?(3__@P<<X*?P1T3YG,/]S C+Q%:'$1>%<PLX(FOQCSPTX2G/#/O^
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M$_7:X8,O:",1#YB"-<I @3#THQ<*0, +(*(12YE@!:*(2"]FX( 5A.$?BGB
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M@1W[8 $4TE&M<R1" ,[X!SA$P0%,D*,9RI3$*1K2B@^TU! =&(X*Q+"*9<0
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M@_U@"[JPC\Y "BEVD$RIAX'8E.\XE+>(9:=@#@#I#)G (=03#N\P#-1&A?/
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M#_PP!CJ@KRI ![KP#HX0!ZI !3#@#.D0 FO "T$0 +JF$7&0 KSP!$, #MN
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M0!@4Y8^S*&,!A0C$.D( _X52\2$#M/#$ Z9PC5=DH!7S>$,#BF$)(SXC!L[
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M+_B%5D "/2 #,8#$4* #+[@$7\"#+J"8:T "(#@\4/ ")VB%4Q#_ CR !G]
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M3CR%2()#)O^ ,P\XY%S$B0/,:(/->?\00PHR O7S3CWR@/,//K9H\X\_?(B
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M$,D[:DQPQ!$Z*.+ $&E,,<0E?JB Q;<G*5$))RSD0:48!TBH$#D,"7-!'.O
M,T@<Y* S!@!R"#,")N18PX,CG#2AASG%H& %13(<0<D3/!A#3B$9R,(/%0'
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M[T3 82U!))Q'7YS!,MR#$X 6/MC E>2"#>C;)QQ ,/Q#&:2/=AS" L33)V#
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M#EPJ,^B .90# >12BI[ 43G##>@;4U25.:0 AE84#"R#_4W 1G1$/3 $-V3
M*3Z>'6P#,X!!+HC!$SS*->R *MC?#FR5&S0&.Y2 '0@$'7#!..@#$^2F&[P
MO;B#.TC$/3C"1LS+-[0 9%55);"I&^#$%;# 9?T#'?3#'00;5V' <=I1+&""
MB(%#$E@!0M! *K77!6S11:#" >Q+$ !@*N"72Y2##YQI#KC"/_3##@Q#/A"
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M_R3!"@2#."B!$V0#*"S!A,2" "P".\3"!!S",H0#.(A#/LA!%)1#>X1#,)!
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M(V!#&UQ!^+E1.D2""VR!(KA%+62!'Y"!,_S"%K3!(:!#)FP!&Q0#.&R"#=B
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M&7"@!0X-%2Z@%48G$E) #+*  R+A'P:L%;J!!,K@QURA!>P &4@A 4"@"QC
M%I1@#'2!!^Q '++  9R@#E8@!A2M"CR!%"A &T "!S#A&M(!#B@A%&;@#$#!
M!P*@"1Q@"E9@!;*@ [+A%.Z@%;0@!J;A';P@"C+A!&; 4QJ#%$[ 04Y!!^;@
M"@X "HJ/-"0!"=:  FQ"&8[@#J# !;A!'/# !BQ!"B1 $MSA$%I "@B! J#
MI4*A"MS@"*S 0A0A;VX@%:BA!'X@$9B!" B [_#!"=* "F: %MSA#V; #(#
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MP0C.0 9XZ!5"@ 6*X!#>0QM6X &(8!G(@00T(0]>P!*&!!C"0 I"@!*.@AV
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M"^ !&B  %_1A!^0@&&P! $[A&4*@/J @!OXA$QQD'O(  J+A'8J "@;"#PX
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M#.$(NL )-@  =$ .8, *_P ,,A #B5 "9B .Z0 S1@$/XO=NPA #$4 '8E
M6P *?5 !6S .Z\ $#E %E. #/= ,B8$$;# %+G ,Y& ('S "]5 -"E #F6 %
M#F +;  !25 &,_ #G% ''9 $5K@.0# $7( &Z4 -!T !?= &%H %SK +&' #
M<# '\V!;(<."+JAJ1Q &9( #38"!R?^P!8B@!5=@#Y$3"PS "ST3#/00#F^0
M!)+P!6GP#YB0 F8P"#X@!*E !"Q@<)B0 UJ !@00 E:8#$;0!R+P@ZF0!%C
M""^@ NU0#VF0!&_P76'@!11"%HQP!&50#F%@!&RP#Z+@ J#0#5_@!Q(1!CJ
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MD \[4 ##; D<L#S%\ ,!@ []H =R$ 878'"FT '8# \NH 'WH1")D &PUP8
M0 GS$*VP, Y<P &KD _)L _N< 4<D!J;J@KBD (=$ KB578<-,JKY@+670XI
MP WKP .IFXJBIP'D8S+S4 6W+!%G8 +A4 2BR0XD\!KJX ,\F@->(!&@D '*
M  QP0 B8X /*F C2_ ]W8!%CT@!LT<O?4P\Z@ O1H ,I@ QM$#7_8 0)^P\M
MBW>;T #M+#^'P *"XP1Q('9$4!1P$ +_$ 3[7%]&0 D240T9$!'7, #/T M<
M_Q0YT" %8- &24 U/VYI-R ,_Z -*7 .;4 #9%L,VR$+$A!P4/X/;$ %$J&A
MK"<&QOP/2P#8/AX*H0 !KP ,WW /\Q //I"SWI"&4FX1D6,28#Q.(U#DLY
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M P+ H\NP![B 60ID#!+0#7S2 _RA#SO@#?N0 &P@$<2P",CB#RA  U8C$>3
M!\B !S6 .'"PB$#@BN\P G[,#RF0NB*@!Q+1"S-@#T,@S>6P "@Q"3<>!O_,
M$'Q@ T)PUTE#!C'@!\HP!"/_$ E%L00K:^8NZPEJ[F=M+CA18 G_< 184!1
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M1JFN'S\ >&*=*@"(Y!@? -CD'T@@$. 0-S"A)PL \MBFA0I.$2<* .;@QQ
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MQ(@&,)Y1#5B\%QMI(G$X8-&*9$ D'ZQ8!BLRF+-\E&(<V"!&-[:!#6.PHGS
MB$8SB*55:92B&UD-QSR>80QLJ.(6UV %/GRRC4&,HQK:@$5(W*&+2:2&'ZJH
MAB@\&@Q$V()]]B#&(S[Q7A*38Q=Y2 5[Y 'N:""#MO_X11X"H8Q_;/]##I9
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MA'"X(D3(@A7P**;(ABE @#JH@4GXA3\VA0WPA'_8 S^@!D+( %VHA1EH@36
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M##CXAWMX $$Z!S_XX6&X /^L@63.!QP(0#+P 9^0@BDH8A)8(7A@@11E"EQ
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M(\\!QM #0R:D]+(+-_0<D(F$EFG918YH^:#,/]%T^0\=!!!B3SSKK"""*?J
MD\,6,-FSPA7_8)-".33:05,._=E" CLP]<#(/QH8 E-:C_SC R'_'$/ (%GZ
M-4\3%/!R3'?.:)-(#'G -$4G_XQ1 QQ4W-%&=S:-XT*M_XQS0R'_?'-;EN1T
MTPTE/_SQCR8(G*&.,_,PT4 KZYB#2 J'6!*'%_EXT@1,;D20"S[.4,A/ ,_
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M6,8+L,"/56!@"^@ 0@<4@8E$], 7"=C#)90 @4/$HP1%(,4Z1J #9YPC"3C
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M-&1 LVF" ]!#./B +R@#%*R .U@##W2!.?C" !R#V4@" &#";/7&"/R#*%R
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M'\C )'B#%' !)$A(%$R-O.'" _"!&8S*/UA>%YS"""A *;3""]B *-C#&%
M#X# ,!@##2B (+!#0OY#-0"!@U3('XA (;3!>#1#QPH".<!""[3 &' !%*A"
M$1! '=R""R" )9 #%=C &X@"!8P &#R!#O "$B1 '_B#7WR#"VB<ZRR" ZAJ
M"#1!.60#"R!  "3/.;A "NR"-"C!"Z"G'JB )+S!&(P#,32!#S1#+;3 %)1#
M'@" P/SH!"R!&O2 #[!8*>! <:$#">1 -^A!/$Z##%! *+S#&D# 'AP"!=A
MW=J$,;R )-S_ A.T@C@<@@=<@CC8)5]^+NB&[D%EANMX46.T0P1DE]V0D&-X
M[NB^;ALMQC+< $S"Q"),E=5EG;#U)60  @DY4U]NA3KJ;NN"T.XV!O%JQE8$
M3NPVACYT0<*X;O$:[V*\ A=4T3M8@1WE)6T]%F,D+U=T&U>XP\HM!I2T466X
M@^U@QE:<0]<)+Q2!0^*1@SM4T#P<2!\8#%BY@_C"1,G"1#V  SN K/]R5$D5
M5SBP0^#40^)1'<7$+CC80P71A#MDE31"6AN5P\J! SE8BJZX$XO- Y2, SG(
M&S\PTCC( SBX[SB< SNL,$S PN1\+TSL0R@D!$V0PS+00ST8 S70_T,^5(,P
MA,H_,(,TV,0Z:(,P;,/_*LP[W-=6 (,J*%@Q*?$V[-$WO,@WD(,X1,,V<,,W
M$ ,W2 ,XU$,T>$DRS 0^M(,Y1(,U1$/_HH(P)60X;$,T@$, V@0S= (+D@<@
MF$,Q:,,U< -,H,(9T,*!)(,V5,,Q(,,R8 ,^2(,(],)LY<(;3$,QG$()K\8M
M"%L_3$(DB-PS.((BL,HXR$(>J((M/$,#^P4T$ (E& P]4,(B%$)WB"XNY_)=
MTC$O]S(OZ\,:W  (?($13,(X^#(R(W-E_(,PC, .], 7[,$J)#,U5[,UK]>,
MT7$]<50U<[,V%\Y6N,XW%\YE@,,F6)<U(_\S;5W $BC"&[1!+_AR[71#&91#
MUH4S."-:S9@N/TNC.//1,A,68[C#&* S\!(6/O-S/BNT ?,N0]LEU:UOR%*O
M+$DO\LX"(7!!'P>O1$O&^CIT/WMNZ<(NUU&T8\A#F$K!^4QT\+8T\M*P8R3#
M'ZST2(=T37\T\AYT\^HR3_>T8J5S.O?()OP"(X$S4/.R95A+*"Q"*J3043\U
M4#\P5$\U50,U[0QO54\(.92"'2R!(X!-+U<&\]YS5D\UUB$S.:B&49<U6[>U
M6TN+#"P /Y%U+W]O-W/T6U\S.N  !.1*7JNS.QC"L?[U4?NT81_VZQ V7?\U
M[3!&'RDV5'LS9$__-EC13E[G=%CW46+A-64GY%G[<D5WMFB/MCP@L%W7-6>#
M=FJ/-H640SY(-F3K&VNK,V+7MFVW;F2O]6C/3F/_PV.S=%;#]FP/]S@+RE_K
M]H3H)6<+]UM?1CC\MKP1-U4CMW2+\TVK=FAC-W.+=G9S=W6/\VV'=VT_-4R@
MPS"H,TOCMO3VLCT<DC/U0V/R,DS<0^?*]VIOA3NT\C7?]W=3\VE72)A1]VP;
M-687]FG;MS=W=V8;=U4?.&HG>#WIFV]K-TQ#.-?IM("7KH$K^#\?+_A^\&I3
M-!WW]F43.'\#]3Z+MXKK\E.S R0$0-+9=WH7N.[*MR&P@'5L!2 \ "7+_QM,
M)$,6A$!"(+ADI\.N-5-0GWA_4[A?(,,:Q$ 4U-AWTSB%X,(9($$EE'!NG_@_
M/,,90($N &\XR(,F5$LU)Y9S-[B2V\0RB $:E)HXK\,NC(>6]$,OK ,R)\,Z
MM,,]Z$,Q[,,TB*0^3,,WM,Z,._B!PW8ZO$(W^'=-<G@X2,,QA,,XA,(TA(,]
MF,(U?#B%+'9R7P.>_\,T> -2UPX]Z'=9SPFJNVZJGX,\6/2*Q_HN6[>&1S0X
M.,,(" *!!T,LP3IF__ILA<(E<)#B[8 G')4]*%HYG,$/. B1&_4YD,(!X :*
MK_F2@W<;S0,7O (UJ( U9+AB4[E-/$,,J,,BX/\ ;VPYAXOZ#@C#%<1 JO@%
M6$(#"(3)F6=(FD^WDO]#*43!,(P 24V(.^C#.Y"" P0=A73#!D2O-H=#(L#
M#K!",8Q=%U!#.!P#'I1 )Q_Z<G-TA6AYR'X" JA,,EL+JVMS.L# &2A$!E R
M&71 OT5&AX=VA2C" 5@-(#A LOCX'O6##2P"N)>\/.# >V![<+^AK-2TK"^]
MUHVTZ\BV8UQ)HCO"H25V28/T3@>!0?L%+@S(,\6 A"N]/B_&/@@/0^^TS%^]
MQY_]C->X18O]8D##F$TO9+#O/>>T77NT0Y.!68X:AM<XUJ<XQ[S!!R'#._B%
M-W 2*8" 2]/\+6R,T^O_O4!W_.Y"P7OP0S%48;+\ Q4@#4T(,#-DF413R!^
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MMD$"2F$7-N$/_XY@'JH  \-A&K#!&"RA[_Z!%+@@(:C@T"PB&Y*A$GB \[3
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M6>T#$"C@#J*!#0C %8(!"5+5'K!@ V+@!][/7GYA LS@&K1 \M#A!>B &N3
M",:!$2I@%Y:A!I:A'6"  (P@!0IA'X(@ D;(4'J #J/! 80@>V. &%#A MJ
M'ERA  2!'9"  Y)@"OZ ';YA!R1@"$@@):RC"G1@&6ZA!Y:!'X+@ J"KS(H@
M!HRA%78 (E A 7C@"7Z@&U2! :0@'\(!'>P  FA!'M"A!D2 &R8!",A!%28@
M"EQ&%"0@"I+A%33@#/A!$0!@%61! ] @$E!@!; A$#I $N@!$1C %N:!"#[@
M"/]BH+2@@05L  APP.#V0A^D@QJZ00:JX1^@80=68!T0U<@@@ Q0 01@ !2N
M(1S=X1<&X!'V,PUP8!'W(AS^0 ",@1Z> "K3H0I(P!^\) QZX!& (1!X@!G
MX0\B0!ZN(0(0( [NP @^I'R P H^ 1HH 0.R(!.X !3D 0?V0$GN(07T@!R^
M@0#$@!U8X0,P@4P?*P=&A274X07T@!WR@0F4J1UL0'W*+ 3B0!7T 0@$YAQH
M@ K(H14ZX!;"(0ELX1_6X&755AH@@"C^00M&8#]QE 20 1,$0!/,H0]H("K$
MH05*ZQ^2( ;R@19X@!&&A2#_@6*P!P:.01V 00B,2R'_[H!V_\$+EL =K,$!
M.H$;I( $$(,&*@$8],%+?J$ A"4+>. K_V$(U  A3,"CP"$'+$$Y^H$'[N <
M$.$%1"$=NB -M@$G6&(5.H :^J$(L  <W"$%6@$A9" EMOD-@J <UL$= N .
MO>$%@,H4S$[E_L$.&  1F,$7]" 5<J\>7H *]X+J0 ,9<$#@=.$'HL0;@$ 5
MNF%,$&$"*$@<4E0;),!VHT 2^$$ O.KD#.'.W+>\TPT<T#N]U1M^PRD<[$$8
M")&"CO<3;ND?[B$1#&DMA $;VN%QNT'@+,4<>D&J_J$<#&$0*.C_J*01( (2
MG/<?BJ&:60(?- $,QNH?K $;_Z@!&QHD%R(!&$:!&+ D(<0A$X3!'B*!%:@A
M&(P!$%*B'CC!$6I!2;QD&2SA$OQI):0A$A8A$*3*&@Z!$A3A9HU,$N+ <Z/A
M$ XAM1-B%Y91,5"!"5P!&=K &RKA$BC!&@#A$23A'L0!$9X@$0P%F,! 9P^H
M'Q A"^Q &[V!$ JA:_\/"OP@$R)AP^[E$.3@"C-A$2S!J9[A$!(A$M1"'<A@
M"!Y!']Q!$PK!$K3CRB5!%S#A$3*A&Q(A$1#A'BKA"%K!&13!&SIA$1)!&0+A
M$B;!'<SA$>P@%@QE&_8@"N)6.?1!$9H@"BQV'B"A$!;!%<9W13)!"3P!&Z0
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M^.&0-A*4#1'6\#CBA2,>)E.1Z1V6HY /LC??44:J=Q."6NH'D3DQE$*0(;R
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M@@PDN.5AY!&&*^S!#I#)!A[2\ -EA(,1;;B"$=AA##;TH2*9N$,5O$"/)QP
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M*@]AA A?,!!]H(*R4 ,>Y0)=\ ]PL /(8 TO4 MUYP #$0#9  Y"4 ;_P H
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M['$0JB !??0/N0 %@7 "2_@/0X!)8#"=X80#,R0*._"H!@8$B1 "&+@,)#
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M2 ,Q0V[@!01!N/56G_] #E/P"&7Q#%P@ 9SP-]60 [:0#B)@.K]PAY& !>%
M YPW/-7[-^'0N/]@#IV;4Q0 9QYA!R] 9_!  9CTLZ&@"A'0&-I4.Q !!O$+
M#II0 ZE0#??[#VB0 RB@!@0AL7W$NNDF!CHP#^00!C)0#5,P!R=!$/4  W-
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M%^!C_U %=XH/$> \1T$.+O"9Q4  B0 .R#  "H@/, !)DG$-9T 3,# +[A
MIA .:3 #\5 +&:"+SL %_" -)] 0G" #'S-_^5 .4B !SH,+\=L':T 04-#*
M_[ ":\P/$6 Z5S 027"G' (%6_!@$5"6O5#LA?"M81 !3"L,+?!06N("PSH/
M*3"T@4 !FQT1A-#_ @W1#Q306?^0D-\P 0],"5(N&7.0HO?0 #\4#3AP&UNP
M"-K  &%TWQ! ;Y70 +UQ!BN@$(CP!X7 "@D##EH0 Q<Q#SY0HK?  D@F&>5
M *HC"RT0=JGPMO\@"-_Z-Z-0#O8P!Q"P#H" I/\@!)Q'!@D04^* !NEP!6_@
MT[_)(4B@=/_  I+0#P2@L:WP"/A  /7S#V4@.["@ ?[9M"U@#^5P \K>#"5
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ML"/>[!C!%HHLCSD0H*?CGKR>7Q]=YUNLB1@&*6 !U?&^B> '!0"$C*&'+3@
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M18F(!R$@@"H8SW_(!$=P@_%\B7C@!4CX!C-P W7(*D' A4I0@W=(!T%X@SR
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M 2N8+84X!T]H@5,87#NX@FEXA & QH60AAQX ";0@@/(@7MH! B(@2@P 6;
M CO8!B>8 7A !138@U?0ASG@A&38JF_@!A.H!2/FA&4X@23 A0^EAB*8@5LX
M!U<0#$ X 3U(VB60!6;H@1ZH*W60 @(P@B'@ C:8@-/1AA>HA&L(@ A8A6,(
M@"[8A"@8 7=0A14@@V1@AR) !&,0@3W5"4Z8 FBPA03(@W?(!1$X@FGHARM+
MATQH@5% AY!1@D#0@PA AG\XA#$ !C^8 3%>"%S  $=H!V9HAUE(@)*-ARX
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M#%R(<J"!-6"'<_B#$! '>5 !(!"'1$  &=B#4YB$,5B'7 " 1J@''&CR*Z
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M(A$76 4Y/)&&=\2@#_.8QU/,X -YO.,;+1"G''SP#TILP WF(,8/.N218T@
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M P30U%R#0R8@@&3ZA!&4%/66[%,T@VG50QJ(DW-W^%::@MXZ,#L@@K.%1R[
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MRN 9_N$1"$!/Y@X>E('0>._0B(Z"E 40&H"8'"U9O,$'].$4("#8K@'D5"P
M=H\@9 $#,NL-7J#L_F$-GN ?S,D?JF$  @,(L. ?2, (!/]#%\ZA!W"OBOY!
M#G)MJQ"@F_:! @CP'T+@]6B@%OX!?1+D%G1 ?EY$&TX@.'8! 5CC"'!/%R@@
M#PB@M@B""OKL'Y2@$Q(B ! J&TB $O!@OHQB&F(@#WY,!/Z!'GQ@%QPD!5J,
M*19 $"#'*()!!>J@'FR!W)H !Q-"&\J!$@K.]H9K"@HN]'S)$ J."M+$*/9
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M!\SA2)@!'!:ASWI I(3#!^1F&V8 17"AX?[!$02J'!:@$>Q!',"@([:! K(
MOAR!$DA!769C!M1&J6R@<-"!![0*PR( !531**B!0OV*$-YM#]EJONA ?LP
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M8 @.^>6/__,, +)HZA$W':!B.6B^EFYZACNU@4$=_B"Y(%;>K/)/.ET88(=
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M6&80D_B!$O_ !YCI""0@$+'  #ST$MEP E7@#[4@ 5?P#V*@!0(Q!)$P@@Y
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M$*20*RP0.-S@ \32"B4@(-Q@EMGYE?\@#"E@#N:0 G5@"9& !8F@"0C@">*
M#3RUH+*[H$*A# O  J!U!0R@::N0!]T5%J11H^DP#C\  'P@:/#@ AS "@)1
M/&L  )E@)?^0#1#P O9@"@  !>" " ;0!N+P$"X1##D !=.0 C: 87$  -BY
M!QX "?4@  #076D  '8D$N)P#FXB#E_  6F@'N^@#BI  *RZ3,I0 A: # \!
M#G,  '*PE@!P"OO  @^P1O]G8 !A.@L 8 7N$ @?L 7L@ VA:@P2H';[$
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M"T(7<4*1"@N0#/PP"1SPNTF @4*Q#0N0!?>@#T+P*HXP"M5  ,R+"!5@!O7
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MAHS4!V[P2)Q4V?7H!APPI$_H@7^H!A7P@5?(A0B(@G^P!-[\ Q:@AV> @21
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M-V7'*=B$T6F&%)@#8B ',5@$:  "&%B&+I  +BB!'X@"!P #-> !+XB$/G"
MU"$$#:"#>;B#"="#-PB"'Y@'<> "*&C_A0!@A&!P@A(P WB@!R!@!$!X #
M)2 9@4)8A!G8A'O  @0P@CXX@<?8$TQ0@"BPE3R0@3<P@1=00&0H@D06@6/(
MQ24 O'^HAQV8 PD1@$I@!!CP T[XATU0 4=  00P6OD0!AKX SW@@G@ !1@
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M804;6<1O_I&%.NRT 46\!@2&88H"0(H-0OC'*'[P#W%< 0$B<08(@H$O<N1
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M&-&.@RKX [IN0S:X:S[T@C&XQCRL@SGX@SF(PSW80S[$0PZ5PSW(0]N>+#+
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M')R!'/Q!(*""*$0!7I/"$N G =B!22R#% Q!$*2'.Y# %.6..?" (VR$$2A
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MX8=SR!CBG'MH*,*OH8)I(0AM)-$ D_]YUG@ GW]4H>&>!]^1H09]_OG#E8B
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M8!7\>$<S+OF/;^!@&/_01S4<L8(C_,,;,UC'/T!!@G]X@@L8&4<P_]R1A1I
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MI!Q*X EE:,0NXC$$!_0!&DL@P#JFD0 HD,,?)?#!$Y9P"VL,8 Z+14$\A-$
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M2,$8_*"/1[" #G)H$3@,@85$^&"PG=@H1OYP!\>TH@V/@($;_L$)!.0&##C
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M"4;4;?)WV<4$0C"47DC^'_T( ;8QLHX4[$![56B!.3S!@=9Y P<+6$DXK("
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M;B!;NH #^N 37&"!)F(<0N#_!Y!&#F1F$R!@V:Y! ):*&7K $#*!&W;H'4*
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M( -H(1!([!N8X02"@!]((0/>#Q6D2DKP00 LX1\VX0#.X?\=?" .8#$TT($
M_,YW2*\YI>\?2B$Z_\$)2JP/(D 8&*@,5",[9^L?)H$$0H%0,((7)L0$@E(Y
M0203(B!HR> /1@'X^H$"O'(^[W-[N7<)A^(9J. (^(#!J,$.[. -C$$R:N$,
MSB 6]"$.Q"<'E:$,L$ +8.(?;H$&^D ;]* 6Y*$,0, 36.$(>"$1P$ 1A,$2
MS( 0SD$>T,",;M89HB &?P8P(&$(K$ .K*<53$ $G"#BF$0-:N 6-"$$IL 5
M",$%<B ;\@$.4& 'U (PK $*V@ ,ZD >C $)>@ ,ZL$?LN 'J( >@,$!%(
MW*<9,*&&7F$5<B +L.$-2* -ON'_#@3@#.R@ 7X!$YC !;#B/>[A"-Q)#L)R
M(A"! D@@$$C@"E:A!WI @AZ!"[C@FKR!!@Y #0HA2JE@!.(V"G* $=BA"7B
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M$Q<@40<;(XQP2D'.I>0/-6A2M]P7Q*3!P#3_**,%!B%TLW&U6MY&'Y+*K<*
M*P=G]TX=!J#RSRL  ,*KA^:$@XH"?P0;#CZIZ"!#(90(@H(N4=')CP9G3*D0
M0I( 0$M.",U3R10G=%'($D<0DM%YX/0X'SGV1#'!K7&FA,@G__BBASW_B+.(
M'WZ0X<@5)]BR+[D#>7.%U"Z_1,P8;:SA!16/J+7X/_JXH0A;,8'#"1Y^:('&
M.-V@H$PL=A1<>;\6_LMZZSB^R!F=(N+9(.W=>;WJ/X.8,9 D//13;F;_E#*
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M""I,H0[V.H@^;I"$@?C#J]+(_X()NC:'+=P#%U]H1!D$4(5^V-<%A7"'):J
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M %3Y#\(  3-8!CR&&<TP (E@%A\ !_G 96H@ 8MP#_KP#B2@@/!  0\(#ZK
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M&&!-8?"R".$* _!!?E!XZA !C6NARR *&8!Q_T "D)02F: !C# 0;) ,I-
MWB(&.O /BI  K50-$' +_[ .-Q!+??#/1$ ]-VH&IE )9$9,+J"K V$"L>"B
MG'D,"-PFS-  2?8/?\!Y_( #FO /-5"8]C 'XQ</.Y40C, SG4 )2C %'E$.
M+Y"9_Q ).E /_;"]_[ --_!/\5 #-,0)"Z /\V #B&B %* /W@ !3/T/R'
MWZ -^*N_G8%5B_H/D/_@ :,0#T=P!?_@!C%@P$)-!^H[$*L0LJ-!""T *1;\
M03K+#H:P (L:#17=%A_Q!!F U]A#8SV6 "1 0?#0 B:P"G'T#_U0 S=@B^ @
M!3! R0-A#R.  \E #_XP"A1P ;DP#0(@!;Q@BU/###C0 @,[$*'@ "'0"W^[
M#SC AO3# *DP#R1P -00#DI  .O@"1TP"/1@ S$ *=Y1#@$PI4%CQ^\-WZ^Q
M##QP U"  A\T"2_ "JK !=H@#R3C"_(0!0P "O!  BJP#;,$!>O@"P/P!_XP
M"!Y0".*P"P1P U)@!>WP"@*@!?G0"0  !O5@!P4P D' !>; ##W0 -R@#B'_
MT #9L \FT /6  P10 1Z< >?,"XIL0P1< 6PH@7LL P-  +\T P9< 7U@,M#
M< G6@ 02D SFH 1\Z@PW\ *2H =AH"SAD Z7@ &C  S<4 8!P =[@P)?\ QB
MD%C^( -YH G(8 0:4 >*, (>DQ)D, #<  YHP'_U  0@(&VC<0H=< GSD AZ
M4 ^J@ /R\ 2?\ YS8'EB@ .<H 4#$ 70( ,]P E$  .[H XF$ 3D4 X+$ :/
M#JR40 *W@ \A$ &*L <A@%+_X H>X FN@ !?4 W5X $%U H=4 KVP ,N  N5
MH !$,#0#A ()( 1#(*29, "C5*7A@ T2D 3=( 8<_T *5IL QJ,"D/@.3>"S
MH.  DK *H$"5HS$*&K!9KO %YM /#5#FUZ !2982ZQ !0E -^; %XMD.%W"7
MI(<$NV %"9P2^E!K9(8-3! /J)!ZQ) !3A /Y@ #<# F,M"X\J  U=<,#?!6
M_"  ;  -5< #Q# .)8 'HF .C0!\_V $)Y"PGV %8]@!&#<(&> MG0$%"#!*
MY3 )'B $X# -&( (\: $)( .TW !O7 -C,  3( +B0#QIC +[Y,2EX  W+ /
MOB !L40)// /T: RH@ +4#!*M9,*"O "'G,/LY "I_ +@U '6@ !FQ +K> #
M/0"E?R!1"5"8[B #!X +Z/^ "Z(@C220"8'0/[C0 ;,@#1SP0NUP""P5V0(
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M9H8<9LEC@$_HB0("1MR))((&;OCEJ9>DBZB5'2B8(0HD=)# "E VN.&;;0Y
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M UXPES^&,8Y[S:,>?2T6'$I0!!?8@ E%@($GP&" 4Q2W5N<P PGH_S '(<0
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M<;@D C4=O,O$:#&:'F #"@*@4%R &4B$7R@""F@"]TN&&5""?T@#!<@'-'"
M9(B%QF ##+B'6N@ 8@ '&5  '=""&RB%1=@ (P '>\@!=' % / ":Y" &!@'
M82@!!: $=,"'&L#"9("!&F &1;@ 6[A# #B!4B " )@$<-BKI3$$ +B$8E"
M+(B'9YB! F@$>Q"'_FB9>O0"D"-*+ "&=]@# %B"5# " " //@  )S@'.<
M_R^ !G50@2.0!S[(-(D)03<21(M\BFV( #\P!CU( :V1@4THAT, @+V("'=
M@3&0PG"@@RA0!U9H@#/X!T2X@"=XAD58 #: !#ZH 7,8A1: @41P@PYHA']X
M A7(21"8!U!(@1J8A$Q@ %,0!RP@@#:L!QUX!9+HASOP@&\ AA,P@G,@ARD0
MA5"P 1;P);0<NGFH ;;\F$DP4UB( &7H!RJ R!:M%#G(@&L0A .(3DGPRW\
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MS>B#-E0#  CI.P  2D@* !""?U@$ %!2]W& "P !:S"87:J41C;6!& Z78"
M8X"$!C@&J^&:2H%8$%!):6F% < &C(2 1=V!&IP&!)!@58  OV,"J/T'7#@!
M=E '.$ #*-B!R7&";!.!JYP#'Q@'(? [#>H"O'V"""@%16C!\<4!:4[+6QB
M6=,@4@ "/<"!%R??7X,$(L"# _ U<W[9 7")C]D#$L":;:CQEY4 ;O@':+B!
MP*"%=<8"$)"%5@B%%\^%#/ !M=.@(]C>?SB#$D"%5F %;>B'59@ $MB%<) &
M&+"%5JB%_V:XAV/P@21[B4& @7GXA>BX R!HA51@A6H0GXAP%#_0 3@8C!1X
M]$BW!TS8@:8Y@C3\F$]0@ D8\9<P@CL0=E'@AFO@ 43(A5=X!F<8AQ(P<J*K
MPM.1A3XP 77]AUO(@,21Z7\HAU%8@Q+ XG.X ;7^AR\ T=E9A39H@304@PCU
M" AH.Q)(/CV @3*H S,0!$_\&&MX@"70!G0(!Q=8A9>X!P6@./)]!!B0A$N@
M!#= ALQV&WQX 448=2?\F&JE.%!(@'5X"4=X 798AQ>HT(])A"!X"53 @>A!
MA*"_ AE8A$6(A#=PBB,<;J/) 26-B'6@ BJX>2;]I5(8OKRA O\':(&RV04(
MB(&"& =^4(9I> ()0()TB $"<,2!,0()B/F(H(870 #.^P=A@ $\^(8 ,(%P
MX(<=0(##&X<IOH9*  "Q9866^P=2 (!K-0, >'ER8!E\F($$  L2 (!F  <4
MX #>>YD7^8<U ( UR+A_:(4H8!E%./ R  "HC=9K=81!_@=S4 =?B  ,6(5X
M@ 3\^<-*,4$4C AH2(!/\04)  92R(#T^8=A^.F(. 0-$-_F8018L("9^P=E
M< !M>(<=H$IG:/(LE@"@: )Y_0=*^ %^*($O1@0>:)\N4&N.!U9FP $YT(."
MJ!574 %)B(4%  * &*/OWS\P.,S]XX3_8-J_9Q)4_0LG,9PE!;#(L8!4T G!
MB?_.]+C7#<*U?Y(HP/MG2P="CVU(@/O'+<&L?[HD5/LGS8>Z?[]&_$,2@N _
M8,KL28NB85#$< 2_</P7Q@8Y@N64B5,&9<.J8P> $;56#,>WB/_H/2!%Y]B_
M,4J(QJ,G\9\X(DZ2V>&(+X6V?\)\V"MS8QS!*9Z:.O7T@$D,902A>"'ZSQ2$
M;43IZ2L!BV"F$RV=1C*138X/A.],V)F%Z)^\*U".)5KR+YX/,$\YKI,B1=F0
M1__$;"'(;P&C?R3N_,LR1;*[CA.=/J.1@=*\$(H(PCM@:.._*R8D_TNEHA[!
M2#.X>;'W_%\]_Q6U_FU*4/9?* +)0 EPAMAIHB8$4Y%052)6_+.#&.#-!9Z"
M"S+8H(,/0ABAA!-26*&%%TZXWC43B&*6*@44 !&&#H;CCE/@N+/+ !-D$DX[
M-PQ00CG2S(" &+YLL<T=I_CC T=]9)!#-F+@ @X( [3R#SC@.+6&!JP0!(<'
M<G3B@ ['R*.#!)-@TT\, D##C -8_!/'![J8!( 0[)0!P![C,/D/.7$@F8P
M/_CSC0T&O!(..>28^$\E ."0S3S<Z-')/^FT 0 9X: !0!S@* ) &.", @ <
MVU03!#>YO+#*,QTH8!F"'MG!03=F(9,!+O^TPH SWU# @BK/3/%+4___!)/"
M#- 0!(P?M]B3@A%.%2*%G#CXPBL$J_Q3"@/4_-,$(02!D(DY WCBCA\VW/./
M"-?^\T,L1-WQ09+/.>7/#3?T<TH!B9BEA@WL_+.*!.O\0\T%J\[ES@Z199.
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M1B IR7I(" U6" A>H U*G@;RX 9RH =>THC (((0(7B0@PZ4S0>&(-SL8/V
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M>)2?@(-^*2&[+,DZXF$[NN,[3L0\/(($Y, VA,,ZEF$[_H,Q8( $A((RP6-
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M+*A $#P;&;3!%0P!.=0#](&!$D")1_A#%_C!$<!!/Y0#(:" "( !F#I%)KR
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M4]@#$QS"/70"  P".*Q! SQ#%G07,<" +.S#&GP -P2" Q!"+@ #'43&-@
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M0.&??A2 Q*1H!J#&)&IN"4:2!2"=Y B3D%CC'TVXD YEI(I1P(M\LOD&'1^
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M>$$!C.$=6F$%XB$8 D /P($>1B 6PD$(\" <ZB$%XH#X/D(09  6_[;!%0@
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M%B3 =[8=KJ[@#&#A ?H&*?A!'.J!#R  ^S["#XX@PQ7)&DJ@ A9A'C1A 1I
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MKK1@3EG_2(*".__8,H L_R S0"@,-KC("^S\@\X+;J0SR SXZ/\#!!C_:'-
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M!@(M-/./*@S3_X/ >/]@10:P00\<> -2-CM.SO1@&2"\ 6A"(]H_C(8T=?A
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M00_,X _ ( Y7=X>,*'+RL SC]X@MYQ.IT MI 8BU]A/\P T@YP[0((\8)T5
M,?\.\:!RYC /U(A^]_: -V6'_\ ,QC)QC?AQ[LAV4>B/]QAT@2B)E4@J0&$'
M $!)PP !6,!_X$<-*64!C; +3$ #D) .12=R@",7<= ";< /"#B+#@8.U> Y
M5QAT#?(.I] $#[$)OG(.@1 !"' &^L -6(  *@ )_$ .IJ ".:**9F<.PA 7
MZ @=?E "7. )#2(*>D #8/ N5B>./P=TDD  !P>1-@@4\H 'EE %-[!/_YAT
M?G #4-(@[" '". & /=1?S,(*P BJQ@),V <$OD9-.<.84 $N$ATE5 &2D %
M1A:60O>6-!B)#PES^% )2R YE?ERI< (G* -^N ,"SG_D139(&\  5+P#^7P
M D# D5"B"Q-  <EB"QR0 *] <12'"@40 CT1?H!(@9.Y;ACW-_% !;N0(3UW
M&9 5#RXP ]K@!Z3P#SWA##D  '#0$[O@  !@'!Z$!PL%AOV6=.)9<?]@"EZ
M2S6YF0WR#!V )I>X!S:9@WXHA//Y$_C0#%U"=*73/478(*.P O\P#4) %I()
M%)4@!EK8#C/@GC@(#JI@ W1 -.!0"RRP5Y5YEN=P#@Z6!43PA?O7"B/P#YE
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M6U -LQ $K< (0M (TX &8& /U1 '16 $Y*,.8+ $B; +7##_!_Z@#B-  "5
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M!D5 !5@S#%^@""10!]50 S< ! )C!E4P!RF@".30"C'@!%(P (7K! /!""$
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M\ '8, L L#-=8 "G\ \YL &MTP,:X*2OBS4P<0/Y< XA, #)H \)P .8]*H
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M/;^S!3G@%$M@!:;? ,/@#ROP)XK@ .' "%Q O2N O;+0 :CP#5&  IJP"^H
M!77_#Y\ GV=_ P"Q+QPL%LC^:=I ZU\XAO_<.'GW+]@+.\ZPN "7;$4V?U(4
MT%OX[]\0&_<6-A1)J4HZ8A,BZ>-#( VU+S4.E6*!B%\; D0J,4'@;1J 7/-2
M0)(G!L&<6R/JA+/%89+()W; H1295>M6KEV]_WX%&U;L6+)ES9Y%FW8K0W!K
M-G0+]X3"#69:PZDURT@ #F%J #!1]H\=F0II8GT:U(]1A37_VI5(H"X4 !#V
M_HV*0L?!DG>U $ 19WG<D@I\!CDB92X- $;L:'"HABY&@F'3&D"H9$M3*7U:
M ,2BUT! LW,C+@A[]PX<N'^J,* HQT\% U;(,M@X]F\>.W#NR(5+Q^4 $37C
M?/&@0*1=UD%4QLQH\^^<E0Z70CX"(.)<UEMWPI1P89A_# $ CW_ND$"-?R0!
M0 CM\O"@ SWZN>NDM>ZZY0)"+,QGPW^,L.^?7U HY@5%1)('!E#(24&8?[CQ
M09V3[H(F 5S^T8<',_^.<0:>>D"I(:)WS@GG!TLXX<05;/[1!0=SXGF!DI0H
M<,<4$MB9\1]?(!#PGVTNL.4?+W*XBZ&[.-%A%$96T<6D6!HHAQL^[MJ#A'\X
MB0 >''VP),<V&&'DEU+^ 4)*<$Q A9L?YA&IG@.M&"467E"IQ\Q_UO$AF850
M4".657B)YA]S1 '#ADC^P64#)XQQ1Q0"BA'I&0:(8<<'@Q3A 9]WRCEECP5&
M^6>/,$1JQ8-8_E$A%Y'L8$&<6Z[(DIPB)E#$&7_^R:::1)0@(9QU</!&I#3V
M^*><%6+H1E<Q<Q"IG&TPJ8*"8DCI]A]Q1/GGDRG^ >>(^/XA)P0#^3!0I&W_
M#E!6#VNRO*4$R_900J1Y2N@C2S&V$ D8'(+Y1Q08WHGC!#6@8.(.?4+Z)PD;
M]IGQKF020"6E!,H!Q@9^_F%$!Y%D(.(?65I8YQ]F%G@CGSSNN86$1/ZI!H9^
M_D&$W7_\<.&=>+*X%BN\MN:Z:Z^_!MOKN]AQ 8%0N7E@!7S@"6.1_<+>RAWF
M.@%  &?J*0$ /\KYYPT Y!#)'G$ZJ2".<E>PH)UN#)C"'&AV&*,9"8(0IY0.
M:,@.QS8 R$0D<.JY X!9W $!@V;0>6" ;] Y 8);1'J''M(PF<<'"4+Q1X4,
MLCDIHEH04"$?=6C(P)AC7E"@+H#=D1M+-1J@0)5___)1HH,TK@(GFQ0\\<4"
M+; < H!>_AGGGU@,J$(<YN0I(HAFQ(-5$P.0^ <. ,X8T  QY(.'D <Z:,0_
MZ&&9"F6E(?1X01XL) N,_6,)AA!)*4I0(BF)9 2V<$<*M/$/8<0H2]M(P"S^
M$0\2]$PDQU@%#.0ADG/P@P2!R,HW_J&-%)A#'RPXA$@4<8 JD< =66I& EXA
M$FH,0%EC*E-#>L&#>'A.1O[  2 L,:A@V2D3"%B//GP0"7E( !-9288[I)!#
M=I" %;7( #=$(@YUA,%!GM.'I30FH'KL !19$0<^HO ';F#!<.!(!0H@0(I<
M2,!%3!M -.+A Q<=@@7QN/]'$NQ0"P5\\0YW$ DS&M *9"GK'_LX0"S<D JN
MV$,,/+B!&CW!!5GT007A: <.NG1)D3CC!P,@@SC6=1=B0"$1L?"!,SR1@K<)
MQA/[>L<.*B82( SA'V7P LJ$8(1E4"$B6A'%#LPQDB1D90_QL908HOF/.?Y#
M@NS00L3N 1)^-:0,!]"3I?X1C0MX,A824 <W3@"27HA )#F(IBM,D!40%.$?
MH4#")4P00%&4X&3Z$HDR)" +5( A2W##:$8UNE&.<L5,90! )_X!B@\HD \
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MPQ/_4$</L, * D#C'W-8@6,V=MYAF2),G\  +_ZAAQ[\ Q\LP!\[8+".4F
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M2@ %4Y"%7)"%5JB%5%"%5F@%77"%73#65/\8!4T !6GU!4B0A5?PA5@X!5.
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M[\4  =  !;#?")@ #=  #B" UQJ "K  "/  #[@ "KB !I  "$" "8B ]&6
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M@SZFDHY$$" *S1#$#,@@BSGL0!SGP(''BG$ :<B##E/XAC@ 88%+L(HHJP!
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M[,(&5($V1,08:( 45,MQ5$4E@EH;F$!!,($0?)D@F$(JB((0-0,1_@,PX,"
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M#T!",B1 +G1#.PC "D(# B""-%S!P_$#!9# ,LB"$91#)*R ,I08%U3:(V0
M GW##3"/"\BC/02 %7+&'QQ L*0"#>##/+  !X&..O34/Q # TC6*4A :^1
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MH)=BG (+D((I!,$2]$(M0,$2I (X&,(-P$ 8U(,R^ $4X '_*!!8!@!".:1
M!#BR8M1"":3 %DR!#-!9'1P !51!\5C 'Q@"$J #.#3!"&Q"'AS $23@.^C!
M!$A!&+R )S)"! 1 "NB=-K# $\ "(1P "%Q#/<#!"3R"$(SC)\P "OR"(%"
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M2"%68HG*#'%SQB$'D.T?AD"!QO^@WFA!!U2@=GS@LQA! HSA'TI! ,A"':Z
M-:S %R(1!\X!$1Y &[K'%Q3 &?Z!&M9 1R)!!&)B&"P@$_Y!'@X CJ)$">K@
M'V3A >RA'X" !.YK!F9A3]!A!48A'(2!!Y* 'EY! J+A'Y+@#"S)"_YA$V0@
M&>#!!2B@& @A D!!'OS@!$*A'T3 $-#A$0+ $."A$&! '+1A^&+B!_X@)NH@
M :0B&+H@?R8D#'1@E0Z %:4 #KK0 PB!%_X@ 1:A$%)A#-[ '$8! !:!&4K
M&/@!"QK &BZ! C2A'8: !TPA'FA@^<B "."!&R2 "J@!"@*@%?(!!V+A']0
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MN,0AX"$+/@ 5DF$*)" ,>.$'F.U#<L$ >,$9%" 7A"$$(  .2$$'RF!/J($
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M$'4U;)8A ZCM'Z# /&4 "<B@#/)@1+A!INY" OP,6+'@'R@!-[Z@#EX!#.9
MR2KA")9B'DR V?@@5QS"'G1 -&/""(:@F9I@B>R"'ZAA$8R@!HH""I8O'$R
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M"T#L0<#!$^[2/WBA 63A"DB,C72@%R=D#F3 '=QA"AX!/)!L!SCA%5:@*)9
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MPF %'B+'*>0+K)$/>F%/2,$%8H()ZM,=1N!>)DF4G7Q?K$$"PO<?EH 2&#$
M /L;8*T8;J!/9$$"=G(<N& &_.X?NB "=HP?-&@7M-4_V"$(;"!_(00.>#PF
MFD"+T*$!M/JP"< \M>$$8@(*V@X<1N">+&0$/O^('W#@^:[!FZF! :S\'^H
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MB#6^P  *>*$Q:5! $/B0 F_\PQ4+Z,$<<G"$;E#B!".0QAM:H(0[CB,-&)C
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M Y<WB?4 !3+P) )Q"U^ 6Z/'BW.'=Z1(BECW<O2I?AHF Z? $^2 6Y;'%*B
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MS( ^X"@(.-9!"I0=Y!8$\ 8_<."-?X !!_I "!=VQ8*%[.,!I/A&$OB C1*
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M@3#0!I_(AR1(@2Y@A1Q @48PA1LH@>WYA!= @DEH@DS0AVB@@3Q8!S6X T.
MAS4H@2\HAD[8 2=(A"/8@WD !12XA&U@ KPZ!WSX R7H _(K!B6H 2P(!3UH
M@T[PIR&H@Y2B 1WPA"ZX@F. !@IH C-H@@QCA83[ U0XKR_ @4]0!1/( >#8
MBFYX 3P8@S^0!W+0@AU( SY0@4_PA!@P 5YPAS)8@2. _Q=RH(0;P($KH =?
MF (2\ 4R0 $NB 9E. (;>((8&(&J:H0#8  4Z(9IT((2N /0\@EIL $8R(,Y
M" !.8(,;L(-E@((2( 1PL(,%2($[(($J8,<NLP0%2  GH(=Y\ (3^ ,2RP1
M6 $\D(8WV($ZJ =<F($,>(!=^(=Q2 ,+R  E4(9MV $6P(5]@ ,'4 1O>($>
M  ,I4 !=4 <;,()0Z(0)^()I (<\$(%16(,7^04;< !0F(4$ (&5VXIY^(,9
M8(0W: -W@ <]8( P&(:$(8, \(-?^ (8( 9B@($<\(964( JV <Z2(!3((0N
M<!PEHP<;B*\Y>*.MT(0! "X1*/^!9I"" ]"%?X"%((" 2G@';Z" 'W"#*FB
M-W #"TB#;W"$##"$LO. /W"&!E@!CV01.^ !-1"&-E@ ;  &+D@!:XB& TB
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MSS].R%%1#E[T]M473GSEB@E?";+$/V@DT4@BGXQ"#A_ ^KA )(\T4@DT8/0
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M4)#.R"67),X-*>LJ$_] !<R"=)()3<-F/@H "D90CG3U 2SNF$?1CO8/242
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M@S'TP@B\4 8#T@")(W@G(EX@@@+F,(] 9* %-B#F)@!P,W#QXPP)V(4UAD
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M]  NC8/ 32(.L@-T0<(/% $+2 (.X= XO,$,L$ 0V,HM% $K_F#6_0(^O @
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M5(S9' 1!*_ #(63!(JQ '42!# "#':S $R@#,X3 ('C#'93'AKY!'YC!@?^
M@A# 010(IQ-) QU$0BR8 !$ 0SWTPAHTPQ#8D3,,P1IT0?&L0@R @3<4AAC4
M@BI00;C^@S'<P1"H  _X:#*< 1,8 ?+\ RMD@1!L00SD:9FN A%,P3W%PR:\
M 33\ 1,@ SL<@A@\ D-.PAQ(45AL@R/X@B[@P2SPA"L4@1] [ST$ 0^4 34,
M@QS40L""P2&H06R:@B6XP2]873(PRR9XQ# L0AWL0DC^@S+D@1VLPC-LPQK<
MFB^T@9[10RG$PIE @C?00A[D(26L@2* 9C"(@2/@00GXK%A40AOP 8R-0S<
M@C/( ?6"BSA$PS.L@R X L8N*ATOBC>L@C7X0C'_#$,TI$,JE$PR.((>R=4R
MZ(,\:,$#,((N]($*!&2DH((MY,U%^ ,HY(+]II ]Y((RA ,R4(,=AL,RL,,W
MZ )BM0,OD((/\#!&@,)!18HSR$A$-J0I4  N! 8(] (YU 18  /+E<(SQ,-!
M>JTT9@$'3 H4), ?^ Z>W$$K0((!!( Z&((KL (', "DLL)^X<,*$$"H$0(
M; X= ( AL,,C (#7) ,#&( FZ,('K( \I,('Q($[&,$'  *O?@54P ,0 , R
M# , $,$Y-$,#)$ IZ!W0^<85+ ,RK$ #A( W9$$ZL$,09$ Q, ,$_,$\9$("
M)$$RO,,;>$ <_$,A?, S_X""7+[#"9S0'"  /)1! Q0#+#2.W4TONEBO.S2"
M %0!,!P"#@0&A_Y#/M# **##& " .B0"1M="'X@##A3''KRI$[&#$3@".SJ
M&?2#)-P .HQ#/L  '@"#)+! /3##"H1".2!! SA#'$S $FR!*PB" L@#,*1
M&(06%G0J"<Q/,!P /_B#"^ #+'#!.C"##H! S)3$,_2  [A!)A! $IC#)0B
M%NA!'G"#"Z0".^1! D1#/$3! E!K,00!/#3" !0/->Q *^Q#'PB ,+"##/R"
M/$P"!*Q#,;Q +:##%>Q %5>A-V  *JC##(Q".?Q!!O1!)?R $;!#*4C &7S%
M%O]H@1B"Q2Z\P ]L0AY(0'NL @Q 0S;PP",L:@N$ CU,@@1HACQ<AS/P !8L
M5!1,Y #X$O:X0R%,  DXP1? 0A!TPS/@ "!APQ28PBI8@&ECP0DE0PQ442_8
M0!#$-0(LP1@@P#6@@2*D @@D 3@D@PAL0B>D  F\\E>PPQAXP2Z0@0X@PS+D
M0 -< 0X$]N^H@ -@ 1Q$@ S,*QEP0BK00!U\ Q,<P!; @ M,0024@1^T@!MH
M 11$@)ZM@0!( RCY0"6, A3@0" D0SS P2=@.2+\@S30@"+, 0:8)O;0 Q$0
M #((0PZ@03B\P0+(01D\ !K@4"JH !RHP L 2#?XP1W_<$$=,(,0E, 83$ $
MR4PY4,$"X &D#@891$ 7_,,U' $4S* C9$$?A "VLBP$EH0\) (;W,$-((":
MS1R>P($LH$,+;( B\(%E50 "]$@[D $9V$($.(!W9$),_T,> ( 8G%,'* $[
MJ$,$-, WY ,&V( ]J $ %%L45$!+S ,.004V:, )[0,+[+4P$$ +S!,8>H47
M0,HO*  /<&XXO ($6 %)]H -Q ,H,( 0? 4?:$ D]+<-4&LBP$(V"( 2C((1
M%( L$ (#I( F^$/T@H6SZ_(_F$(5E8,- $@TI$"A.'8A2(L@"$(9^,,G=( D
M],,]S$,0Q$ SE -#.M$SM !H_[)(.4Q#"CR].L! C5###<S#)P1 %4!!$H
M.Q!#SWZ%-43 A+3!"; #K'T%&^S!$P7 &IB#,>@#&BC!)5Q!$N0 +CF1(8
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M&:C,/Z9@-GW8\UWQ&L82!J"%'MU$;QG5_^A&.=K1VP1''+ZP0A>2<1!WR*
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M@U#PT0*L" <F+D",8U" "ZS@1A):(88+H (<E'A!,.SQB&(<\Q^&\ $XCA&
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M)T-&'G[#&=9A&LK!&=3A&.Z#'I+!F.+!&]3A&PJG_R;LP?@"J'#0X1B"81_
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M'&I@?/:A)#9Z.SA8<L,9Q0:Y2\U9&;,8W+Y9-D@:I5\:IF.:BI]A !!D6([
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MU!Q.[!^V81_T@1=BVUM&0;2$FJWS6_^_]YN_^YMY@Z,,2L"8.F)=4$&-U"$
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M+EC@$9P,U*+A  +!&'"!2U3F%&@@9.Y!"OH@'*J! KJ 'VXA 0Z(V/]!&CY
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MH-THEL"%$Y ")8&PP,CYRX<)?(%V_E["/L[1!BD 80@I2,(U^(&'*! "&#5
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M]E-MH0]&_\ .V'  "\ %Z% %\$ .6* !JA /.^ "VE4YG-< =% (,,!P;<
M). $+W &K@  <= *!K!GX. '#^ ,4@  W% &"& $U6 /G_ !28 <%K &_2 #
M"$ -[S %&< %OD #$G -ZX  )Q ,,>  TI%^ZW= [?=^0K$$6;$)%M "OQ &
M'Z 4G? !5G .=.  )+ ,[6 #4A .0/ ("TA>Z_ 2N\ !8/ /OX &_^ /+M (
MZ3 (%[!J7=$.4/ #R_ -6Z  1L %C" $5A /6/ %X8 /33 )UB "C$$%0E -
M^+ ) _ )X*$"KT -(= #^G *$5 #NS +%B +_W "4F .0Y"$__^ A.1U'1"
M!P;W#V1P VIP" + "96A :7@"P$ #)@P R] "%5!"7T #&G0 ,%0"U!0#(\@
M EXQ" "P"?$@!A7 "_\0!E@P#YW@ <N5AWOX#S$A9_]P!2F@!3V0 4[1#$/
M#;1PGC53+LQ@!"U@#O] !YF #0$ ">_P!:SP"3.@#(@  +G0#UJ@ 8N2!F?P
M"4! !.<0#T,0!Y=P JG8%=N0 B/P#[S  CJ@!R,0 8MR0/# !&F@!@30"__P
M"DIP"5NP -T@#U_@ 'C@!0_@!.^0"0>@!&RP SR <=9 !(/ !SL ,7L0!85
M 8?@#47  Y&0#&P  ;QU#G 0!HN  LK_<0D+D 5^, 4HD R8@P]1( &ET HL
MP /1H XHT ;0( 4[T ^C, ,SX ?C( E,4 DN< (*>$#K( 5!T 11, _;8 4B
M@ DWD +;H Y.T /X50Y!D'9=\0MZ0 1#8 WH8 0A$ GX( -FP!*2D =P@ 3T
M0*J48 <C( _<@ 9S  6^8 ^*0 1%M@Y@, <F4![+$ 9VD 6$X"*$ITHEV7G_
M< TOL)+_L 6CMT1P 9-XD@F@-P1K< [)P (L$!Q&, #4>4"<=P!PH <O@(=T
M0 !3\ [E< ZZ@ .5D D)\![0X  _@*11T(P:D"">.0!5D!D78 L'R@&+\ ]/
M( %R\ \UD " _V /4W $IU "!S ;>AEB?0E_]0"8GID!(1L(&I &'UL$_W *
M!& "H=D"$; &V9 ,LC1=Z" %F,$& / +SY @G% "&H<&<N<5>E!T_\ -,Z!O
MAD -^Z ',\ .B*"=M+ &X= _$Z$$^ 4$838- S"(-* 8[T #(%8(U@ ,?N "
M*,&=",1J?<  +S +!"$&*4 036"9F^ (_T -+Z" CI #5N4-+2 'FV '#&(*
M*,!HJZ [7'$$5G<+'$ +_Q 'M_ /\Z #4N&@?"BA1: '!)$&*1 /6@ ":N"Y
M1'M MW "T=4$,K8+JT .*V ,XGD,WR !IJ >$P ,TL @V' ( " -8/_P'O\P
M"%T[79W@ L.3 R!@#_T0 *'A.6/ &RAK!O.@ H-X8S8@#]N  X$0#JI  ?G
M#U5@!/Z #@O0($4 )J+P E' "CF 4V?@GX$0! 2!#3A >WGP!03Q"AJ@"\P
M C'0#NG0 JU[0,S@ .D2!R]0#^2@!<?@#ZX  X.!!VV6>"\@"N?0 S]7.:3@
M ?;P#S; "_L@!Q&P"LR0!*!9"Q60"P2Q!&G6$=^  MI@#EE  .IP"PD@!*6P
M!7@R"%"@#M'  %'0"BZP G6B#"/ "N#0!#@@#WG  [6B!XT H890#R:P"_P0
MHQJ8KJFTKB?I;SF  *V[!0.P=>\SDFD!DXK_@P8", %*80L"\*+_, 00\+P$
M:P(3D G_@ 320!!L, &+-Q&W( 0C\ !$:PP*,*0$,0GJ)X$@^P])( ':L0<2
MX 7_4 02< ;C4 ,$8!KMH 1'@ (\@&<WRU]E, %,H#OREA6X, !$>PD8T&;%
M3+3<L  _\!VK$ $0H 3ZUG73]0YR(%K], 0!P @@M@DC$'2FH ,+ACN:(+C@
M<0*B]0_XX'U9H +GX <AVQ%H0*8$,04/80.MX1$@L&=Z )J+?++O< 9A< =*
M,+C:N3WZA@HI( '+)08Z<!Q)4'W_H M(< <M@!Y@T 4$T0L24 O.  ST4 _J
M, 030 <K-UV@P (I_S$ 5V .=? H^G #DBN[$-J'70$%5O8/I8  JT #5\ (
MG. *TA .:N4J!  +_Q +&D "F& .X" &%_ 'WA .U2 !NO /LY  Z  (#= )
ML> *J: /7(!?IJ4"JD@8NP"^_R %849]M=0$XN&15SH :58- [!<)U#)UG #
M6;$%?. :G- /+7 ( L,+US '5T 0\_ =AV $F^<#Z>("XO$/XQ #[M8$')T.
M.Z"X!S0/2A!<AO !K5 -RD%G/C 8?@ %CV()0$ 095=,_5 -T# '+* BOG"D
M+<' _P '$M$-6\<5B8 "A7 (A+ %U%(++< $<P<%2Q )A4 '=!"O9T 0@?\0
M@?^ #-H!#"^P*'N@ +D@#^NP#"U@"8=@"'A @SNFKEM1#R$0<(2Q!AI0"_^@
M!QV0U:U0 XO@*>M=%I>3#M=)$/;0!1?07IK+ E("!1< ;N?T*/80 @D0*ZRP
M510Q 4-P.])  6-0"Q @==SP "T CH6! 0!M"Z=L!1!@87^@ ?ME!\@RRP0
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MA0"J/5L=CV !1+#4EP\>"2 #U. -6M /V, !H* ,".  RR 6EW,%M?(HT8
MBO^Q#0E !@01!E= NA=2"&PM#3,@6NT  4(3!C;P#;*@ 4;P#:4 !?=0!BC
M#]B"S_\P"1(P;<6  ](A!2T, KWP#0!AH-8\-E/\_2-$Y-]"AN'^K4&UL)X/
M3O_.Z%BXI,J_$FO^40M [)^:+ OA\6@"+-^:4[1(_=M&8!K#A>$<Y@$P*9P(
M'/ 6@L-!:.$42 NWN/GGD.8_*%\6(@IRKLL!5?]0H:EITR$U"-'^\5EXI\HV
M.?_N\?A4[H"M?Y8$K,-V80V[?VY@Z>%1[M\O%>Z6.G358R&A+@N1"-6JE(X#
M;?^&Z0EF@\U";@Z"O=LA[1^R&_3^P9FS\,BI?R9JM/O_URX.IPND]2%9E^E
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M+'"'?7B! 36!0VB&4?B 0^"'ARF'96"$!="%;G ""'B'-]B!Z) "(SB'69@
M20B'6EB =C@'%/!%XJ!G*("#9X@%# ""=.@!+6"&7(B?__USB/^D!'+(!0=@
M@WGH!@+@3IAM1'YH Q\XAWY8 34H!4,  %T0!PKPBFUX@";Q#F38 :_0A@%H
MA"0A@3LP.%GX@#;: 4S8!CJH6&?H 23X!VD8@-#XAS=PA*7ZATCH37$P@PL@
M@U7 !#GX@7^H!1P !V@@@3 "@=?UA!Q %3-@ %^T Q!8B# X@'8@A0@P@FFX
MA01X!G"@@/XH!!'XAW%PT@Z) D#XAZ_Z!SL@ $98AQI@R#0H@71J@&# AAT(
M EB8A%(@@6(PAS#P &RH 5_L@]#P#E08@$DB AN(#B<0B4A8 $PH!ASP5)0A
MC6[0@6((!QV0 :E^ %!PAA/HCO_$8(<_: !ST(<(0 IE^ %?\8%Y,@4"2(5Q
M\ %9" =I6(#ZJ(8!0"=;Z(%BV(<O.('\=8AG" %K2 <C\(%D4(<:0 2]Z((8
M\ 502(!<^(=,8 )@6 8'.(1JR $;B 0X8 0:J()P& 0-,(1PN 4A>,L$ (M&
M, %YR 2%F 4D0(9@:( Q$)(?,88'6(-.* $8F 9TF();X(<>@(*F7 A_D6MN
M$ %@" 4=8(<RP(-VN((@N(<A2 %P\(8%2%W6*.4#@*DWF $A  ($* HKU@M<
M<(-B^(4(("DTFX==B $O("9+H %!F(,,,)1@.()<@(82R&_O* ,).!HR^X8=
M> -CH('_*3"'7:" +P #)G@ /QB#.I@!=.B$!T@!/:@""& 66V  5.B%[:Z%
M%+B!.(B"O*07"WB)<W@"/,#DDM(#,V"$%*@/)C !0I!N8LJ$%@ $%W#)?T@$
M5?X'-M !5_X'9SB"&$B#%'" T!"%$C #(_ #^]X!:?D'3U" 9_Z11O "/CB!
M5 B'52@!2R@!-7@:/- "*]B"?Q"$&2CU %"7BI1F:7;.5/@'>+@!9YB&&3@%
M5[ %4S!/+L"$A?""+."%63"%6B '-] !WC "(_B':H" D6T''%"'7+ !$06"
M1X '!S #5^"%5*@:)1@$<BU9 -V,"?"%7$P!KXB/F-UK&/@'_U] @"NX@S 8
M V4XAQ-H#&GP =+UCDAX !&% JX&!Q+8 X3+AVC@!DBX@4 H]QT0DDV0Z[P.
M 'S AR7(4XV:!$O/!@A0HF" !5U8 Q(8"258"&CHAG]8A63=# AH!<R03WAH
M@$_X!Q8(4&20@/QINEF @O6@:\REB3%  %Z(!Y\0@]PL J% !F$HA3Y0 )7Z
M @SYAS!H 450!#MH@V@8@P.8!7D !HTBAQC(@W_(@PQ(AGUH@X60 R P#+#X
MAQX@32\@QG_@AI'-!1KPC]Y$+V6(@,:X ;&&A*+@@Q!@""40_!^HBGNX@:/!
MAA8 AGI( >#X!W/-WR3A@BJ%) 0PD/\14#RF$.!_& %;>(<<  $L<((:&(-_
MN ,M8(A!:(%XF(<#X$I%>!!P2 $X080#J!I52(<:D())> 0E, +:^!%M@ $M
M@H8$\ 1.T(%&2 0@:((BH@DXD&MJB(!\EX5SD((F2(9[\(1_&(,80(\O.*Q1
MP U5>(&> @@R6/[]^Y/BW+(4\NJ90"(F3((B!,-1K$@PB"6"D2C<^X>DQS\Y
M-\Z40>&#W3^+?R9<2VGQWYXE!.$I*/2/B,Q_,9"$JV=C6<@<X_[5B4 /4)-_
M^P*H^B=IA;Q_5?S\H\?BT;]Z:<RY#/=/W %&_VQA^\=%2;UX+(C].W)J;(ES
M_Q(E_2=&AUS_@BG%&5J@BQZ? <S$A/C'K<$Q<$A^U/OW*%%7K[:^]/N78\L\
M%H?^1?KR;Q27?_"2%G+@Z]V2+5WULF[M^C7LV+)GTZYM^S;NW.Y(X/JGSD<R
M9P'4Z07W;THG@E>HZB5W=R@4(_^B26@*#,>^20_P$902J%T&4\7!(7<YL:)7
MUA3_^=(@Z-^V!+/^E4NA+3+!)9O_@<'Q#Y<$Z^@U#C\I&/./-#X0A]X_=K3
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M,*&7+A%$8WK!QPLR\H\\+.X?7I"!6:*@EVF<@T':8,!F,D>,?:S@2^&X0AO
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M9$!+D.T\C,$@5 %>K 8>P( <6K39=C,VZ(!GT'#W#O Q"($%<-0JF\,8@$$
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MP, D(,,[3($0] $(W("F5$(?Y$(;W(!)\4H?/$ ;B, +4$ SW(,)W, 3 /_
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M'8CYIPTB1%KBD$'-H> V?FP [9\U5(A'N']L$4$D=D* 8Z<%K"E'ATQ>":2
MFP@$Q@<]^@%&AR3J^80"35 99@1/1))B"G(8V6'-05!8\PA)_CD'!U_^<<0*
MD?]NN..?*NXC\!]WO.A"I#MH<'(48<=#!(A_N('B'SIP.&?A(_Y9!02L:*CB
MGT-NV 89'Y#+"1RL!A'V'48N8&.46*PHJ18=YG'F!WC^40*$?_C0(9QW8'$
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MH0FR: 4LB#&-!^Q")&\@P3^<@0-@_",7*JB'UV3!!QJP[A^R&@\\*,"N9^#
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M!-)@"J-I5FN5'5BA +A)'1S@#U A"QX@&H+!!QY@#HH #, A$UI $E*!&#J
M$-@!%S"@$_1A$I@@'>2!!9Q@'(S! Q1A'G1"'(2@!/K!'WK@"<8!&%B@#]CA
M%F)M$U( !;8!''!-'\RA7GSA'2B! &X$#U;@&,IA"31M'W1 #R+%!H" '&(!
M IJ@$)K@#.JA!UY %40A!9P@GVX, 6[!'53A!:IA*<J  HC0O1(A!8BA';AA
M E A'' ! ;S!255@$>S@"[I,)\H !!Q" ^:@'> @ D"A\V;+'4Q@OGZ/#$"
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M(?6XGD[Q@5$3U<,;/QT(.YSQS8\P X\KF0<P9#&!+1Z$'WI8 SM65@P(.J1
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MD(Q%),"+R;!"+[00@W^@@PBC>,0-2I&4?X B!72 @P"&.0XM/.(4#Z@L#%!
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MPS:XT8,[0$$:X3C%%!K_T8X<M" -PTC'"F8Q!C" ">_08% P"SS !?S025U
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M)B 0(X!-K= "E4 *0[ !0(00F' #M:$.$?"$_R "*[02Y4"4I  & * XK4
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MB?\P!''P#]O@ PY3#CA@8QH6<!AQ"/]C"@SP<'*@ N;@#U%0N@CQ!WT@$,,
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M WB$!)[9Y#+ >@1P8.ZP V&$ ^BJ#@0 V2U1!A=@"NYP#4)P#L  !<$0!B6
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M?$/'68836"_L(X-_((<22(5^P $@_T""*A" Y=&)9%@ (B UG2@&") @AK"
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87,S-7,W=7,[M7,_]7- -7=$=W;8*"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex10-13_img07.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-13_img07.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M(1^G@, 4(BN.:JB@#]4@10%J4(E*!$(%V"B%#4P0!"LX803Z8Q8YZA#N1(R
M"^_@!@@B\ HL^T,*," &*T[@@DI<X0:^0 @[!IF$(G!A'IK_$,$+(K&J7J#
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M!5Z0$+?0"^/8?__ #Y?0 )$ .?1@ H7P#_M0 '/P#V/0 SCC"W" $$F@CE;
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MD0@[P _"H 27  /6Q0])H DYL#?$@ AA_]"!_[ ,=+ &.O /UD  GP09J*
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MX0<XH 9]T = L&$YPPC?2 -GBQ#94 ,/T 0H__0/\8 "01 (:! "I<4LW(
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MR,SB!:> !C" LO^ ![8P!@D01'G M <Q#RJ !X/SH070!O_0"P2 "M#@!<(
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M57@\_STL!1@@@T08 3;X!WF@@Q3H P 5!T)X@2G8AIC[AU< @BL(@B< U'_
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MF$(V",$!1CP=$EQ01R= L ^9Z$')HG-') 18D'-D80*"J(86G!"/>MQ @M?
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M#!A!/8"#R9Q!MVW!:*F##@C!.(!##6B"!Y&!X*2#"VC!EIA#)QP7#6T%,OA
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M3@P" 5":?= "%.R '*1)-QQ!"?1!/#1#$I! #T0#*YQ "Q""/6S_@7:)P1&
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M&<PHH>*%3V#;QP@W&JCM'SIT.?\'HD!RR&^==L+2Q0??7,D@JUA[T"D>A."
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M ,<]1D  /R )B)XPP.X(0@PO$#<0)F@&/.Y!"-],(P%SAD@T! "\P_A#!$&
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M(4&(ASU^,(6K7L*>A*# .T)A"5I 'F0!##"#%?C@'Q"! :;D'^X!!E9@!$A
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M"HB@#9 $*<"A%9  "_X@)1QA!,: $92 "H(@M*/@%#R!&?G ?OCA$J2@"MB
M$?  "))A$)[ %0A&'L  "J3@%6\!!F) "LK IT1!"8A@#.; "X" 6C4A"L;
M#8P 5O]!'OA G5Q!%:[@"!"7(%ZA5 G"&MZ@"8Q FF1!"ZH@#"0U$7X #+P
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M@ [VP<)X 0@BH F2P1,"H \XX0> )QLB8 LR(0EL8#3^(198X F\J \$HAM
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M#OXP##/0!G>B!%70(NS070B2#/\ !ES0%^I@ F P/O] #UY #OCP BY0!__
M"#, #UWQ!GJP"ZQP"BZ "5WQ"09@#_=@ D/0%:MP 8B (,/@'L?4%T6 !8DB
M!R#0%8!P _%8%Q\2#F8005UA!W#W#VO0! P6 F!P)]2@ IPQ,6MHDB>)DK[7
MAOT"#N,P/A03(HD5+>(0!C: /9'  +#Q(;& !40B#EF@ N^ #C:@1__ "1C
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M!RH@!$7P!\%P#VR0!5G@">L0"5?@IT_T#YZ@!&Q@!/P #D\0 )]9$(?@ "(
M C(0!,2!"#KP!8/0%H&P R@ "@4Q#2.P!(E@C%E !/69G^-*KN7J+OO9*-])
M#_6P#E*Y#N<P#JM7+^;2)1URG.9P#@3AG_7P-N#0#D02#NN@E.+0#KP)#NGP
M.(W1(<$U#O"P#@1;CCQ"$/6@'>V #N! #VR!#NUP#F]C#C+1%>@P#+AE$.9
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M $@ UY:   T@"EU1#"Z@Z5 2##/P XRCO(#M,)0\#G&@ 61 ).8P!;^@U>I
M!T'X#ZW@#OH@"BHP;ZSR#_<0"RXZ!PAPVA,A#ITP")S2#I:@ ;&PW#*P ZXF
M#S^P"W4^V*!PSUCN*LI0Y=N"(-, !2;0[& N$>%0!GD ?D=7+=,P!5:PYD"=
M'D#P @UQ+>0 !P9 Y^Y^!TUPY11B"S/0 D+KYW!]WT1L#RXP W74%>EP S,
M2(WNN__ #C60  -*$.&0#_E@C/-@C-M5O.A .NAP#_>@'?-0O/E@#Z)@ "C
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M^JM'U!/'?WB"Y7H((8H$ [ X@!FQN=N#%S"=?X@$%;@'<^"^#KH'7_J';)"
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MLY@#@,V$&9@'(Z"!<AB'5T "\BB)<0B"&)"+:H "<]"$)SLN3H '!)"C7CB
M3@2"8CN''ZB28!@"6! %?/@- 7 #DZ@%5H"#:?T':MC)?YBQ7:D&$UB"8"@%
M!#"#LIB%!; X.<BGXWJ$,_F$'?""I3J$!BC/,9 %&N!(6*"!A_ &$=E.4L-.
MQ%W<)Z2'3# "&W"!)YB%AY KA@ "RI6&%R "<W0F<[B$'$@#_ZJ&*%"!&P"!
M7Q@"F. $(N !*W"$$$"!-JB'9!""!&B $+ %:P "%] !1F""&QB!8\ '(B"
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M1'T0A56 !?0^BWYPA67HAU;X!5-PAE)8!5D0!5I@!>MF!5$P\( K"6Z AI(
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M: @"RA[2BA?AM9Y-UG^(1'="ZK0);4""H9;X9H%XZ)]^L?]!0>O7?&7J!1R
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MQ2:EC @JG.PC(P-L O5_,,T3,F1UA:."%5GF1-D_7?T;TRLVY)!/ER]-RPH
MWWP;3C15. "B3>4B^B \Z8BC'S@4ME)"%$#[]P4.)%8X9$SV%!#$3+[&Y.O1
M6U>.^3^E-/'( '94*O(3;O54#!&E(*@H..1(@8/"0?L]1A!WW&%&%]#0"_&:
M,7ES1PG5Z)G,$)^$P4,_48'R!H5EGKV("(4(2G9,J80 1!28@,.*#D!L,<DZ
M;6)# QAR_:-/'0:X8NS/S/8LY="70T8,..$$"G^K,S7RA%P4DIK4*C]@RTSD
M8YZ>0B43)W@B=6X*U2,< ;7VR:L;Q6#_5> 2]"!%7*-8<*O,)5YPC]#]Y1[*
MH! ]E("/?YQ" -M8H&,L!@9V%(@7>Y ))YA@P&A)I2;%V(:66%8GGQC#:X\X
MA4Q$D< >HHQ28!H3$G.$LG^,0A*-"Y$XIO"(?Q"B$B6"Q@E6@:K _6,9-?#&
M5_X1B'V$PQDQ %X9K_0/;KB "B<TQR$(( P-]J^-=O%8OBPH+R0.L"?N6 4+
M@N$3=%RA%. @A0KT(9<>Q6(,_*N+*YAA-Q]8(C[1:@<K(. % K7C%00@ ^6J
M9 \E?($NYP@&#T0AJ"7JSGZRG*4UYE>_6?I,)MJ 1!^:(!-Z $XFK_ %/]0D
M#VY\\!^@6,$X_^+!CP>U(Q>O8!P\R&B,[YG#%-=(T#E(40L8QB0=N$ &$SY1
MQG-DHV(RL=D[9/:28[P@#NJ0"3%0 4.9N(T=WY-)/QSYCW[PSR<?K,<)@46,
MCHD#%06 A=NP8C(5V<,?G[B!VUY2#V?.@QW]Z <YP&&/=WP+'.VX1 3VD@H!
M>&,>%<5G,1HJCW[,SQ\P/(<?4. -DL5D'UL8P@D-H3]U?*\RL9F1A3Z8#Y#*
MA!SB,$?'+.:W:%3M'P0"ISC0H0Y]U.,>[WC'.MH1CXZM QSIV&=7O&$"4/QC
M'C4@1(G"L8Q[2E4F)]P1.8AQF,K$PVLY0FI,[O&>$HEC&30A%CV:>O^/+ 1"
M@>5H*E98P%;RF8,)5*"),S7T#TLT(1QU,84-8-@/'@"C@,>CHAMP\$$Y*4$9
M,EE'Q=H7)IG8@W&O%6 L^?B/>JC@CC3)@Q!DX@P5,)9/4F!#@?I!@EW(A J)
M59"H_K&/"*AA)N38 2<>^ ],*"$I4\B%CFJ+R^_:JI;T ^]B8H(.,^ A#!$8
MPC]R\0)&G T0?QC#"&"X""R<807<Y:P@JK"#7_S#&DS0@A2(L(Y5M* *?K"
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M 4#"/RA"%D1# =:@2^R#'"2 '!@#&FC +CA#"\" )DR"*3P!<1D#"BA,(!#
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M00%0 TW40@.P43>8 !+, 1<8P##(Q#$( "_\Q#ULP@W$ AEI@0]@ A&0P'O
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ME$ ZU($-H,T3/ $ZT( <.)<!)! :H( [1 4XA, ?R$3_)-C0/^@ &9C#"HS
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M@P2DVC_0 "G4 PKH !A\00&4P3_4@"OUC6L5Y]H>"#1HEG<%IS0@ !']PR%
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MP,'% 0ITC!7TEI?&PC_$@PJ0W3?< #CPP@$@5R%XP;M P JIP0Z,[C^(0BS
M0'9-* IT15T@@P@,P2;8P@T,P0?&HOGRIR"#[[P1P@[4@R#,@(/.@>2<P!P
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M!7B!'@!!)8S#%N3 +K#"#"B!9TI5%_2 .8Q#%D2"F\< 5<7$.ZC (XR",Z2
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MC'1B>>$ $C8!<"!<F&C!C#[2P&?2'? H(XY_6'$!AEX,B6 &8\Z0X(MR%($
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M?8 .[PY'R#WPKKP/*W#A,)'0W?_NOE3*<MC!'19VEZ\CCS3,@ ([^,\_MD&
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M:\4&CDQT0!QRX0I6\)\@@0O"@1&4X*M , 2W(02>0!M#4!BR_R#\],X</($
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M%B2 !C9KF>*!!V:@H$;,*& N##[ "[ZF"@!@#DQQ'OP #)I@&,0!'B8A#XQ
M#'1'AZI #32A!A9 %XJA"XS@&NQ!#YA@#Q;!"ZY@&) -$ZR@#L(@#SAA' 8!
M#2ZA"]C!.I03(<H@ G(((?JA!F*A#H2 %Q!B&OX #I0 'E^B":2@%*) #KZ*
M$\* "A)!)0C!#<K $&*''A[!,')@"/Z!%[2 $\*A$^#@%<8 "[IA(+X!./3
M$Q A'(;!#^#_H MPQ3+J 17NH!_*@1+\8!>8X!+FXFK<80TB  N\)0SD0!N
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MP 2HX0QX@!Y<@0):8 ]&P!B:P!2@(0:VH&(%@AT4P0!JP1O\H08TH1K&@ "
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MQ.$)M/*]GH8, " +:$$2%N$'&$ 0P($;9N %F@$./L 9:J$'3($1,* ,&@(
M)%(?M@  U,8(4!<5O/ ?9@$#D@ <I@ #GJ$>5/]@!^C!%B9  4J!&,X!'13I
MN0:T0/=%'WB@09TA!^#!$';@"XH "EY 91?)"*KR'WZ $>KA!J*@"+Y@!O3@
M& J!'F!! F#A'0H CWI(K&N #U0S!G[K%5" 'MX! 3+A'Q*!!+03!]R '+!A
MXR;$'U"@A48!!4P1"FYZ0O"A !H!;8A@*DO0!_!H$1J@E$2.>:@A 3Z!'\"
M$7: '.2 (OYA'O! C?K BN&A!-#@<UZ[+;>"+GLA![IC$4( (=X@17\A :YV
M@=# $\:A%E!@<[3 #=YF$GR@$R*!"'8@52=D%Q)@XRSA!EJ8!R32#ZH2'I1O
M($QA![;A'U1A 5+!'Q+_H)1*G):G@ ZJ2!]B(!?^81](0 ^^ 0?\)PNXP!UH
M0 O^P1:RX1M8@!($X0T^@!0.005>KC4G9!@BH!P0 @1V]A_:( UX-A].@ _
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M",*\8>=@#;A !NB!'UA ,X:O!IKCV^D@#&Q ;0P!"!""#?::% @ BN0&$_K
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MRX8M#QRX?^#$S=[-N[?OW\!G!\:)*T$6>KC_X8KA2ENJ-?GT\:F4.GCKVVD
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MSAV?\ $,5I"+:N2""SRX B_"<8H>?. .G4 ''QHP!T_LX D^C 4#GG )%^0
M$\8 @@GV0 PRF& )OF@#"YKP#EIH  E>8((;J($,%/A!#T^4Q0!J("[L$:T>
ME. !!=( #''PHPP0X$,WC-" -83#$05@P0L.2J%.L( %K/!$ 51@BG(\ 0(1
MJ (X(K&#(\SA!B.PABPDH((BV, %KGA$ ;C0BB% X K=R$(#_&"/&<S@!R=
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MD5.7.*QAD=F3/3[5-[X ")X0"HOP"8@ ":*P") 0"8S "#/Q";+@"*U0"XC
M!H^P"(<0"920"ZY0")^0$(X@"HT@"9L@"9WP"9*0"*T "Y$0!")P!H^0!@G
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MLK>1#%* !G?  ]U #GU@ F=@ TP@H'TH!6_ !D(0#_(P!2^0!=J %G&P!@5
M!NOT"VL "55P!^3P!S@ !C,0 4P@ :U@"@C  [70#DG@ ]2P!EW0JZ*0!(&
M $B,#?]XH @N< =]_ _UH =/4 <AX#2,L (_< 2E@ 8NH -5H OT8 EET 5:
MT(')  ;.U0G58  RH GSHAN9( !'4 CHH A&X DS  0\@0Z3H 1.L 49732U
ML 1ML @X\ 3<0 8)H 7(L0]KH 4]D 3\  Z60 1'P 3;  ]L  .9@$R.\ _=
MT =0@ Z^4 974 DJH -#@0Y^@ 1Y4 9&B"+U\ 9/  0NH O_, LW< )[  CK
MTHE<D 4J0 OCL E.< EI0 !L8"Q+H 1O-@Q<X$KBD E<0 EM( %9T _5\ 5
M< D-P GDH 12( 1#X [>X 7_#;I]@ FE  2HH0YE$ 13X G_[V &1, 6]: &
M7; $9; /]$ )5+ )>3 %:+"DNO$*3D %,F!&\1 $.> %=>!#<IT%$F %>.0&
M=U I0< .(5X%9F0/9" '3X! 3JK#-9!KJS !$$8/5]"!2'(%=? $4(((5) )
M1( $HH $A( %=+ ,=) '7J )]? *5E (ED #;8 .S) "(F %D8W"*CWG=%[G
M/\72<IZO^G #J/$/5- #]E +!' (V# +. $.5\ P_T $,%!W-U!VS6 "8H .
MGR "]$ ,+L#8@+ !IF ,+* &AG *T" !I? /C. #!4$'HP /EA #W"$#Q3((
MN[ A@; -8_ !,*0;V8 !"S4$.94(_^Y4$&K0WN(0!EIP#:R@ 6M #DP 0V\
M >F !%$PQC@1#EU@![<1"")@"\I  (7P#Y@ !/N #S]0 ^M$5)#@ D 0ISR0
M!,K0"Q+@0U[@"/?P"P!P!M^P 7 1 FK0#W^0 &, #7F@ O. #5K@ ^+0"R6@
M J?@#"FPP;*  'FB C6 *#@A!D! #^U0!390*HY@ N^@C.*PUQW4 ^%P" 30
M!-AP" Q #.- !"C '<[0!//@)Z'P C+ #)XP &2@#U90 +AP!LHP!$, K3Y
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M#IP28,6]3:9XKXPM%E*P"(?^\<,*AAS!IP&Y1L-PH3_^0 B*0_Y9IX9C?FG
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M1O]0AQ'0@"%H#=L=#66X "0@!R)(@&)HABT  !;-A#$0!T!(@%[PA0;(!7'
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M:&@'*.B"7+"_((D -VB#&.@#X4"$RK?W=9 '(+ $5!"!2S"9;B@ $] '.[B
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M!&XH* 8:Z-F,P'&'#PSB'^801SQJ\(!@0,, $E@&/'B0 O]J_,,/'R#$/_"
M 9;]@P]$V$,:[D$3<X2C)7%(@-5L,@1C[*(!K="% Y[R/!\D(!'UH $$NBD.
M:7A"'4_[!S6< I5_2**#X>A"GO8A E$] QVZ6 $7:N*TY2"@!>\0!Q 6$ B=
ME1.::F#$WO!ADR)HPB:(<(%A1&")G/;M']E0@4X=@X]RQ(,- >C$.'KP"&^N
MX!3^$ '+%M&$R<DD$'1)32"H8)-[F$ 40]"B]KS5'G@LX1&H:$-OAK "S%6R
M"C89A030@--H"$ P-FF$.+ @"9VI00XV84(M\&& 6M@$'J@8@P:/HP)V.JT]
M@_!!.VPB#6]$@!4VL04$O&$/'FC_,GSM2$8[2*&"%M1#%37 7 6;\;X0U 00
M1?#=5&PBCUM(P#ZA6$*(:A*+%_2,"8V)!0Q:$H@CID$%]?B'-230F*4 PX)P
MJL%S"='!#[K#,L"UR33\,8L1J%0.5H'6#GH!#.0I!@%<M(DPK.&";?SC$10(
MH3>G080CIH@&O5E*&)H(!2X.\A2.64<:GK /4:QP"5_]!S0000%YO/$8)T!#
M6'K@B'/@X&UIE!RT5. -=R0A"=50PQX@C +9IN\?E;A!9FT2C1(X(BSF0$<5
MIR")4LQA!;.X([-.D&),:K+ _VA&#FS!RB6;"Q[@ ,>\F"SE*8]2*>%PAQ0<
M$(40VD(!_S#8!CR20(9SH$,'%IB"S4H)#G2<(Q 9"$-*].$# /@!'+U8@"/J
M$046H,94$(!#2]8"@!.,(A"?,$<3 % (SH5#'PQX@#2BX8 %[(,<$?A +\1!
M!P"T(1Q+6!DX7*$&;>@#.^'H9SAZ0P8$U(#"].B$"L(!!P6$H@T)F((FZYD
M389A $K^QQ4  ,7I08, 8-@H(SR*@CS\ Q@&\*0<,B(+%Z@T1/_(APV&8)-,
M%$!'-;D& :;1#!H4P1^9,$"O_F&%//UC#SIH!RX20#=)&,!;</#!WR+@"V=@
MIR;.B$)W9R")<"!@L/^@@2]X80%:X*,+0@C&/\* [Y8%<"F:X/]"+5U@#SLX
M0 _>@ 45GMN>:NB %\=X%0(#0,D1&+P=59# !>MQA!2((AMS&(,3<5H3*>C!
M)EM T11>\(MH]$$2IJA F;QA EZ<0Q2H2,TN+' &;K"B"^X@ EIS 4A0ZN@2
M,?@'$LI4C?N^@@;S((8Z<H":?Y B =3P!Q:,L(Y&6" 3Q1@&%("!!16T)@P@
MN >4;:($0<WC!JX QRI<(!- -' 1%?B$F1K0B)6T!T?Z*- /6I*)%_7B!NZP
MAR8",(M_5 ,&\* %I*(92UNX@![%$( JHF@% _3L%EWP!PJ.<8]<', *\%C'
M&B"!"1+(%A8\N/Q2R("9?V1A$?\ QP__E-R>8UC DX< $2,4H.1LI.$8!L!P
M.XR #3:\:1PJ %L.IBH.-_!-%1+H1RX@$(Y_)*$.1U;!JWSAQU]P /+M0 (H
M& $*[!$\7(%.+04A4, =W(,7G, N1=$/]!PQH( _E(X,Q%X\%$ D4!D'7@L]
MV$S@=: (CN"U4!<;?,$0%,$>)(,Z#($+B  <&!PX1 (.A$*4C=(XK,,YX,(7
MK,$A.((7@$$PE,XF'$$8N($OB$,Z;(D9Q-[\E<,:2, 6$((^0,,63,$0E$/-
M>,(-O, E#,()R, HC$(-L, G1$,4B( 5H,(4K  5O,,98, 6]$ 3_ $RB 4E
M\( -\  47,$1_Y3 %(##)!A $5""#YQ [/T#*_Q :]S"$W17=C3  :F+,QP!
M"SR!+\A$*J" "MQ"+>3 "BC"%:0 $*C#(.P &H !-,E+3>0!Y/T#,T#!_-6$
M.G !"O@!&8B )E0!#LS!.*Q""[# +<#)#G"!(X" $F##$Y  )NQ"",P )YR#
M$J! (OP7'AF %UQ"%33#K@C!*%@""@B!-BR!"> !&N! )MB"#\3 )_@"$$2
M)21(>_3"#_ !(&0!.^%#$13 #/R X$R? !0 !40 $22#.9B!"%P"'\P!CM4$
M)Q"!SNS#% 0  I3!.G2"#:# *_S#(O! #QC#+,2 $'@#--2  A1 'O^(0SB\
M@0((@18@0!-  PQH 'TEQ3CL 0$P@ \(0UVP0!F<018\PS,<@0%H@C%000K4
M AD40!V4 16@0S>DP!!$@AGL@!QTES>\P RXP104 "'<@QHH@ "P@"BM0@[
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M!"]0P1^(0AP(PSAT0A700B\HP3? 0B>XPC64P2=\PCKD@Q]X 2) 8C"X01'
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M#NR "82 "JC #_" #.  #:! "J! #?A "_# "-1  >! #,0 !$3 #=S #DB
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M)@09Y&A'CAN>:34+'3KYAY<FVGCC!'Z0N2.-*52$ZR-TT'A!$&=^\&$2=Y0
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ME ! &M;Q&GG<(!/(<,,"G &/0D1A'W8)@PN <8]:&$$=Q&! $NJ!!#WHXQ
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M(@XRH @8\#6: 0':J#=0P/K6#E(L"X^4X F*:O 8@!MXH026P!WNP!MJSN=
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MCH$+,,$/LN0?2($ J($A6H$&XN" _D$85. IZDP9=V '3V$$&D$-OJ<\](
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MH1R6(Q848"[AP09"8!R]@00>914"@- .P4#"H0CHP!BJ80</XQ@:8 I4@1>
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M"/CE-?R!#.+ "+#@"5#A(SKA.V"J#NI@!GZA'8S !YAA24D !ZQ@2EYC$7X
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M)B$>BL !SL <5D$"2, &_NT=1" $.$$6%N 2,D$&%N8UWF$,;Z$+PA8;A"
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M ,08KH:)"G)#!#!X!V4&THL:@*53N:NA#6^(PQRVI1Y5J,T__ "N@=QA"?\
M0Q+<(1 R@* -F.#'/[C!@%;\@Q R.$<D<I"/?Z"B ,?XARI> (U[4","P@#&
M#U3P#W, X0^JJL,-JI%%=Z C+6I(T#\RL;45;- </>!#./XQC1K\ 0Z=^,<P
M&."*90QD'0O\QR\HT(Q_V."!_W $#MX!M%6$(QH[Z/_&/S21 ^K@@P)D&@<5
M8" +5CA!&9HPY#] <0&< 4@<G%B#D6:GPUSJ<I>\[*5"N,$#7X0E"T#(!SV
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MC>YFCL36:02AC>,P#AF5CN>X;N#8$B A#N$P#O<P1_((;_1841YQC^/0#O:
M./S8;OYHC^$@COIHC)]GD..&D!]QC^: #NU #N8P#@[YD.$6D0#9C/10#^Q
M#^/PCQMI;O'X$>"0#OSP/']DDN>&D@"Y#OS@1"7YDN,6DQXQD\=SDS I5"&Q
M#OWP8SU9;CEY$?7P#O+@DD0)D?1($A:F#DO)E!SIE".Q#O/ #AHYE=G6D?98
M#_S@4EJYE=;6E1\1#NL0#RHEE6/);67I$>;0#NI@#OC(EN!&4>]HE#:V:O.
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)S_WLS^\7$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex10-13_img09.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-13_img09.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    , ,@!(<    4%!0='1T1$1$'!P<8&!@(" @?'Q\>'AX7%Q</#P\)"0D:
M&AH<'!P2$A(9&1D0$! ;&QL5%14&!@8*"@H6%A83$Q,-#0T! 0$+"PL,# P#
M P,%!04$! 0" @(.#@XO+R\M+2TF)B8Q,3$[.SLH*"@E)24R,C(\/#PU-34S
M,S,^/CXY.3D]/3TP,# D)"0A(2$@(" K*RLT-#0_/S\G)R<L+"PI*2DX.#@Z
M.CHC(R,B(B(J*BHN+BXW-S<V-C9>7EY+2TM75U=45%1965E65E95555)24E/
M3T];6UM*2DI-34U:6EI<7%Q145%=75U?7U]24E)'1T=,3$Q(2$A%14534U-8
M6%A$1$1!04%.3DY 0$!&1D904%!#0T-"0D)^?GYZ>GIF9F9H:&AL;&QW=W=P
M<'!V=G9\?'QK:VMX>'AQ<7%C8V-G9V=B8F)I:6EA86%_?W]O;V]E965M;6U@
M8&!T='1Y>7E]?7UJ:FIR<G)N;FYD9&1[>WMU=75S<W.:FIJ"@H* @("$A(2,
MC(R.CHZ4E)22DI*0D)"5E96/CX^+BXN-C8V(B(B1D9&'AX>)B8F;FYN7EY>6
MEI:8F)B9F9F*BHJ3DY.%A86=G9V?GY^>GIZ!@8&&AH:<G)R#@X.LK*R\O+RR
MLK*PL+"ZNKJ_O[^^OKZGIZ>OKZ^KJZNDI*2NKJZIJ:F@H*"XN+B]O;VAH:&T
MM+2BHJ*FIJ:HJ*BQL;&UM;6WM[>[N[NMK:VJJJJEI:6SL[.CHZ.YN;FVMK;?
MW]_5U=79V=G'Q\?2TM+8V-C%Q<7(R,C)R<G>WM[<W-S,S,S7U]?!P<'#P\/*
MRLK$Q,3/S\_-S<W0T-#1T='3T]/=W=W;V]O.SL[6UM;4U-3+R\O:VMK P,#&
MQL;"PL+^_O[]_?WT]/3V]O;Z^OKIZ>GN[N[U]?7BXN+HZ.CS\_/Y^?GAX>'C
MX^/\_/SFYN;GY^?DY.3[^_OEY>7@X.#W]_?X^/CQ\?'R\O+M[>WP\/#KZ^OJ
MZNKO[^_L[.S___\(_P#_"?P';J#!@P@3*ES(L*'#AQ C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LJ3)DRA3D@P7KJ#*ES!CRIQ)LZ;-FSASZMS)LZ=.<>/(N?1)
MM*C1HTB3*EW*M*G3IP;+F3L7#JK5JUBS:MW*M:O7KNC2J:OZM:S9LVC3JEW+
M=BDZ=.L(MIU+MZ[=NWCS?D7'CIQ<O8 #"QY,N+!AB'S]#CW,N+'CQY C&TW\
M5[+ERY@S:][<D/)BSJ!#BQY-.FT[8.Y:?B[-NK7KU[!IGF8);G7LV[ASZ]Z]
M<+9JWL"#"Q\>VG=MXLB3*U^>U[AMYM"C2Y^N]!VZU&2I:]_.O;M,>/'DA?]S
MY[V\^?/H+X(73SZ]^_?PT:\?'[^^_?O+Y[?'S[^_?]?S7,?2?P06:.!E[=!#
MVX$,-N@@8 DN^."$%%985H0M6:CAAAPRA>%S'88HXH@O?4CBB2BF.))S*K;H
MXHL2L0CCC#32*&.-..9(XHTZ]N@CA>@ 4UN&']$GUW.UQ<71<3\VZ:1@P  C
MD'@@R:-D5>[81DXXXX!3ST;@A$/E.-D]:>:9:$4Y99D;B?D/D>#8L]] [04#
MRCUMXB///U2BZ>>?7*G))YL:N1.74.>(\X\Z0MD6"ACP: 0..>ZH(XRB@&:J
MZ5."]MF1.UN*-PPQ_]3CCJ?_"!5./L7XE=%Q[P#_8LRFM-9Z5*>$9C3>>..(
M<LR;DY;ICCN*@CA12_8@(XRMS#:;4S+L8#F2._JDHQJ3SF:KK5G02CN2E035
M9NRVY):[5+?_S"F2N-B:Z^Z[2:&K;D=A%L3NN/#FJ^],\HH4CCWRW(OOO@07
M7)(R[X S[$CM[M1P0B!BN]J]!MG;[L7L#B3PQN)JS"1+$G*\V,/A8@LR;2Z)
MW''%*K<L[LDHNQSFR3)S?%#-..<\,\@Z]_R9RC#[+/300]),]-%"WXRTP$HO
M[?33#5/<M,YS(:SPO&L=-^F4 LV9Y4"Y*I3QFWL*Q*109N\G=9E2FYU0F0-Z
MW+9 85=F$,@7/?PS0SO7_^WVW2&OK+'8$(W,I. LB[UVW"4[Q'1#>\M-$,P5
M)\[WU$DO1/G@'K-\N,2(0_RXR))[#C7F4*>>N=QZ^UQUP@O?%888@0 QAB!!
MC+*,$$.0L0\S8PA!!"FE%&%$&?S\,T@09)313-/_[&/&&&>@08@I CF3AAIB
MF)'//\L4$<0IC0-R1"'/&'((-(V3@D@B^PB$"AE(K!%-]$ DD<IQIRC!QC E
M.PX[QK $,"B"',M0@A"8T 0B.&$,[4E%&YPP!%44A"RH<(,3 K&(8DB#$8!
M1#F$<8A&H$)IJG $(!YQB&3\ QF0B 0CI@$.:A!"$I/ X0H-(:4W504?JRC$
M(O^J,0QK&((2B&#%/UI1B$I8@A[UJD<HLG2<?EPB$*YX13BD@8E,,"(2PT"&
M,CZ3#D9(0A/[D 8T#G$-<"CC$(KP1[CTX0RYK&,2>!P$*_HA$'+ (A/4&,8S
M^$@Q;/AC9L&(1CO"Q8]A9&,9[<"&-+3AP6WL0V#G> 8S@O$,OU0#&NG0QSE^
MIJ2'Q2UEKI(3.-;1DG.,(QWI&(<L!?(ENVT,8C>3!WGL4<N_+(A+9E.2/5HB
MS+&):QUE.V:Z_L:ZT'5NF<R,)D;&QKD #DR:$J&FXTBF-.@I#G)S4XO58E<7
M<KS!&N<  1S&$8LWN ,-'RB%>*@1@##8@QQC$( RY!'_AR=@8QM+D$4WCQ$"
M*,0#'[,0 ?E(,0))J(,=92 !-]R1B@$$P5[_:$<)3,"-?"2" %' Z#A.4 !4
MK,,=<D!!-[ !B!1LXA_,>((!:$$0>)Q!!7+,&#]6< :62@$<B& "-M(@@%(,
M8PK(^ <96% +;-BB!7,(V#C:4(*FJD( AYA'$#Y B7%DPP! 6,;-_E$*%QR@
M$71X 2KF40<#K &*\& $#&PQ#"H@ !)OB$$@[%$0:("@":281!5DP Y*)& &
MLUH%#1*0B'Z$Z1_4> $[Y-*/*KBA$4,( 3FD000%$*$0E+ #">QQD'2\80%,
M:(<A&( ":OR#&"9@0D[_T0P9_R3O'^M@1 -2  DKI. 6_["')1@@!4I<X02@
M:-P_BE )N9RB!B+8AD"$(0<;3,(,6" ""4)P!2DTP6SBZL<=;C #0_P#$5EH
MA!%P< V$@ ,22P@"(JJR""UP @R_^D<WKA"%+'0B'&'00A3.$*E86*$)SO#$
M%JH0B$"@H0C1& 02C. $,<0!%^#MV#T*40A'-"(1BZQ%)SS<7F8(00MW0,,0
MAB ^(&CC3?^ Q1 XL80V_$,26D!"'-2QQ"DX(1-NFP7V"A(+(VC!M02QA!+F
MD HK#,$(1BB"$YCPI8[9@PEV4-\E'%&(<0@D&'10@AARH1!V?((3C3 $)@0A
M"68LXO\0G^ &/B"A"$N,8A2<4#,G.(&&7SF3K%59F2X$<0E,0((>]N P(O P
M"7H()!^=4(0B]HP&6=1C%YBXQ" X$8=$R&,7C]@&%0MB#D=\8ABI"$0N0L$)
M1O-C&Y1P;4%X08MM%*,:W3!&-8[1#63@(VJU.4?\!#(/:' C7/7PQC2\T8QH
M$&,8WR@&ZUYW-;M,JKWNR$$>!,(^0^A@V.78P2$$(H@0*(H+8Q#(,.PPUGID
MP0H&R44J[@&#2QAD"NE.!P@$@#V!<,(!0A#(-G;0@%+(I1</H$%<*J&#<@R$
M$ R8QS\ $0 1&/P?FZA"A@LR#0&T]Q^8,(<S(F6)&O#X%=7_"(4#GC&0:$!
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M,:!$_^ /F/]P 'E "3U@ D/ !%B !*_@>6VA#/!0;74Q%.2@;7^A"#NP?O^
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M N!J#U!0"R9 N7*@ X9 "V 0</\@"X+ "Q)@7GHP"[8ZN0YA!,X@!U*@)-<
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MB@?0;TSS"3;@9<<!#&8Z$(C !@(1!DVGP5_ 1]]P =<N$(E0#N10 QU9$)]
MD +A!LY0#^. #SX S[6 H?_  W*'#L[-G%&9.,!0 C+P#OK  @S /A<DK[)$
M#SK_, @"(0: +*B&]P_Y4 *&MPT# )<"$0EQ( [^H YLL (",0TG+!#_B008
M508J4&6/,P5F'*#\Y[4((0]:H 6DQ<;_(+(\( ^O@&2P4 &#F 8).A!Q\-R:
M/1#C\"42:Q!,  )ZNS)QZS::P  N5!6A8 1^@0@P0 [?D &6P&VC(!"D8 &Y
M*\/6_0^+L-\9A0)]$ :!$ 6]/*U6P&/D, <W, 2YW>*W;#/OL+0%(0@'H+)D
MT0)"4#89]@\[;NZ:/A!>@/55>Y?0L'Y,DP@@$ 5#0 4/</BVR'=>-P+@^HY,
M0 XDT *6ZUT"H0[=(!!YF_0"\0B1P \"8 AID SM<.=O_V"X N$+ B$+\$P.
M1' #@G#XA7[G"S$'43 &5I  AOSH5K GLO !9= $> +2!>$(#R!MG.X5 *$,
M'CAW[OX=1)A0X4*&#1T^A!A18L)R@V[\6!7N7[,J,=3TZZ<F1A5OI5;LP'3.
M2@M"G:I4:FA.B0@TCZ!8JO>OG!8QC2!YL?1OVI4;Q_[9T?//EHL"LI3U<>'K
MGQ\H_ZH%J4"KG[LU*'(-*Z-BVC]M2X@P W>0C*!_X-RZM5H!C[=.2HH=/,9%
M@J)\<$_Q<'1LD Y8!Z]E$?#I&Q@BU*(M^4!I'#H$#, L"_?6+;$N,+#)@_N/
MC@!8V!"5Z/;OFI((J8T%J$+,'?\C"9VPF7+S2=VH D7:D8T2X58_.RG6'31G
M)0(T83MZ81L%X]6X2 H"8<,&S8HVA:&#=#FX9L5!</H&&4'X+D<,:^5"./'W
M3]&$0_NX'>!B[M\C YC\D4( &818R:"2>DC)PIZ#_#EBB[3 ":>.&_KI#JYV
M>DCBH!Z6.6@%.1IB88B#YB#FH%QT^">3,Q *(99_3EE@EH.><6&L?[  [R!A
M+OE'"RL04B0!&35+ZY\AHB OK6D"  2A-.(XZ) #U/E'$ M8^<<;(@Y:9P=-
M_H%% ZG^>4>%4 [ZY!&$EDE E'_LF2*?@_KYP83XTI)%@/@JA*N?&"1IZY]B
M=" $H5W_ D"%SW]$24"90(V1 !N$O.#CH%H:18@4;]IZZZ DM'%'GGJ.0$\?
M%[Y(*(4/_Z'B1VH:<..X?X+($"&V*H&!PH-:^0<20)]0P(U_Z(G@E(/V0"&A
M1.X99<5_T,'A Q?3LB:"73@E,BUVIBB'&&\2.8"9?Y0Q0J-_]E  "W'^:44
M>@["1P4@'BQR(GOOQ3=?A@0BR"!]_P4XX(C4.:888J;)C!ELA#GFGGN0X68:
M89BAIAADQ&EF&4,PR>:A>EKIY!$. _VGFT$22>:@:# Y))5_SKDGG%T<D:22
M8RY!)!-PYGG7%44J482=@[I1Y)),TCEH%40*L250?9[)%AQX_UX9Y9!!J G4
M%T( @<2:T+;Q=9%AR/NGGD2T($(1?EYT!!!$RKEFDDDZ4<4>(@=90H@\UH;+
MGD2B<**-L<*!A(H]9*$0EBS&6+<7)89X(M%WKKAB"4S^^:,+(?CXQH@E2#GH
MER4^V20:,/Z(PHI$OPF""28HUP*-A3H5A==_1E$SK56J&**:@R+IHH@_RA"B
MBZ#<(6.),\X@H@M%_EE'#2K.@&,)1]KB!PTKA A$CB@TJ2>M<MHXYQ]R\HBB
M"4ST0P@N<Z: (028<"@BBB[F0%HA> IAH09CG3C!+'AQ D3\0Q8)2 ,G7#<.
MG=1!!E) PA%XA(\_B, '1L @"6I!B?\;I( 3G( # F2!+<T,XP8XD$9FW.*.
M.,2@#)RX A?>E8DL\* 3_! '%1  "&R\X ^!* (9[&8/,\" #&!8P1E <PD&
M0,(=X+!')RQ0@UM$H@)6,$=:A/$%H?V#%%)P0!SVH:ATZ"$#0Q!:6I!1@T9X
MXQ O*&"%_M$.,2R@$5DL1QD,T(=\V.,7)N ".]2QA@LHPAO>N,05**29?I3A
M!.6 UQL<, M[0*,&1=!4+BJ "7"XH@)>T(\A-D $:V1#!%PX9"F8 (9V""$"
MM3@D'>!@#1MP@ARF<( QR*$+"N !'^_H#"\..8@ZG(,,30C?/ZQ1@B&MXQ4:
MZ 1HHE8/.G#_ B'1L$ 8_@&/*E#I34P8@3W<D8<87,,=P<"""X"!+8&UTYWX
MXE=!WCE/>NHK-/545'<24J1ZZ9-D[9M=/SM%PH'N\YY).BA"9P<1(O&IGTGR
MYS\=\M"#A",S$#%71!%:)(O*8QV:.8@[+(J0</CKHA4UUTA#&M*.^HL<![%'
M9C32#W*4]!II(8>_$#H.9@!#&,D 1S[400W?2?0?ZEB&-92!EF%X0Q*)2!0X
MF+&,6Q!B&,<IDC)Z88Q[P+0:R;"&-L1:#'',8AFK* 0C<(&.C::E'WQ@A"9.
M$;[0A((1C#C%2\%!BV, 0QH4RH<PB*$/>F#C$KAX$%X0P8AMD"<;_]P0!CF@
MJ I -",8GMA$(N8!EVGTY1_?.$0O$I&_]L&%&X[HA2&BP:E_4.,113B#HP+Z
MCV$80K3<^(<K[I!:LO)!"(,PA2^*X 8F-*$)2C 62+>A!DI$(RW'( (0GA"/
M?[#C#$.X0AIZ ;,W ($)D8!>&+I@AC4\P0W&O0(3\.&(*+#A"4U(0A>$88@N
MU$%2O$(&'Z! A%U$X@IU*&X2HI",6UB!":[XAT96,:9CM $(=4!PMOX!B!Z4
M04[@^$,)>! '-9A #NI("SV&0 Y%P& &6NB"%<;P+I#BT\7SC*=.7SSC>D:M
MQ:6U\4-LO&,>]]C'/P9RD$,CY((2])X%1?_RD0_:SXM"""Y%3BA #:H9E1;4
MHB>5XT(L2J^V;)DA;AFIDR>:T(=&>9\+S6=I\97C*5.4S&-V<[U4RA 50A3.
M92XRV::LT8E(F*09U;-&*;IF*>LX22JM<TAM? \*/3&HZ(A'-I@1#WK461SR
M:$<[YF$-83"0H#0&];]B'&I2M[/'#O5S0XB\:E:WVM6OAC6KK[SE5J-ZUBI\
MRZV%?&M=[[C7>18RJF,];",/N\>_!O.L3]WF4]^XK3Q6J+"I?&5^)EF@@R[T
MF=O*T'WVFMG6_G*G!IWJ4I?;(:,V=[IU/&1C__C9[89WO.4-;V2W6]JK#NB\
M85UO???;W__^-[__H?UM7RL;X,0F>)[5O?"$H)OA#S=JH'$\4"@ON:%\QK%#
M[:GPB-_9S&;.%[;[3&8_7YG9]^*XG=.L\CY'FYWK=C9K^VQP=T\TWP=/;+$!
MBG.>VUC@.[YWU'[><R '7>00+[?#D:YN<)RC%XLP@R<<L5I@)$(6E-"%W8AD
M#ZFXQ1^4, 1WW%(-2E3"%@U]AR:>( 90'(0;5M>$)R)1B&V\A1R[P+K6P9R*
M2? B&I/HQ24<X8BW9<.VERB$,302&F%4 A"7,(8WP &-2<CB$(,_1#!& 0C+
M,^),V4*%) +/"%!T%1RO,(0J$C%X1^S#'I5P1")P00QI7,,<V@!&,L:A_XUD
M%&,@[;A&,*3!#'I,@QK!"$8_JF$*=E1#&M(@1CZ 40UX<,H<V+#&-,81-7R8
MX\K[((8R0-PI?A1#&?/(!CNFT7UJL$,8V"#&->3!*79DHQAR,B@]B._\:O -
MBE_5OH,H!VG8AGP(!UUYB'YX"W<HAI3AE)?Z!WF8OPC4*2)9!]ER-'^1E01K
MB%ESN8U""!G3-D&+N9N[N#T[N9M3M154M:,S01?\M)7C0'MY,Q)4"%PCN93+
MMRQ#P35K*!U<.E)3NB L-X(HA1?@@F:0@P.(A7LHA R @VC P;0P!158)'40
M!1<H =P"AWA@ Q+ FD[AAAV0 V- A2W@@W4PA_]&6  P: 9<< ([X!1W< 8:
MT !G8*U2N( CB 9VL ().(- " 0GT(-W^,,RB(,90 )(2@M/" %#:(9#P $J
M$)0L0  \$$0L4 1L\ ($$ 0UV(%&(*%_<(8?>( SX 0I\ '<@@8LL( V$$0D
MT -1^ %.6(("N -"^ )G& TFR <TT $6X)!40  FN 0KJ(%.R!P?P -M(((=
MV(-+N 0M4(-?(($;$)!Q,0,9L(3R:2@R^(0$DRHD8( [8"UUR((:Z 5DR((=
M:(-YN 8@T $O* 0YV $Z0(A8H($>*)$S^P4?>($VN 0C< %C@)<_,($XT(],
M"($XL 0BR($1>HAR$ +_3ZL'."B!,O"7;8 #)A $/$@")D"#.]""-;B+3H$'
M)] "(4"P?_ %)V"#;X #(X"#85 $LV@"RCF"54BPS,"'5;"[3% $6@ I9T"Q
M5[@$)T@"RBF>:3B$(EA**V"#4CB(=!B\$ND4?]"&:4B&9;B&:5 $7>".8@.'
M>H %0S $6$BF?R"$0N #)Q &=JJ&/'"")W"$, A#@J %13 $;B"&14B$7^A"
MN9&$20 :7W '5;@$2O"$8# $0'"$;D@+?S"$0Y $9&@&93B$2F"$\X,$0"B$
MKANH9+@$3G@%94 '8]@%;C@&?F@Q9E $2QB9(B$%2L &90 'X1.&9U@& C0'
M_WY8!K\DP*[JN&O@RW6:HV,0E[:0!VRHAF6@AQ_,A4\P2';B!UA(A&FH!W/0
MAVB0AFIXOV50!G-9!V08AK$$AVS0AF)8!FHPEZ"R!N@9A^TS'W^),XH#.2(,
MM2'4SU K$EHY"!=P C)A %WXM CY@$T@&43(@"CP)D4HE$[IARUH X3@!QBX
M'&5(@%&HJ&F!BS*@@#=HGRCX $@X"$F @74YB$'X!UQ9EU0@  6]'1B !H3@
M!CXPB#"8 83HAS/1T8-0A :@+I"ZA!0]JA50@K0H!!/P-' HA$XP"F>P &GX
MAUX@!G#H 7S\AR4(@HIJ =_IA028A[9XAT+X!UVH /_D+ <S#88&H(%W.(A\
MT()M*P<$F (P^X=D> $78*NT0 4+F(*#@ 0$@"35J !*4(L+R(1 00-&F"TQ
M (&<"(8'>('EM 8E. A=8("6A(<EX)&'.(4+J 5."0= ,( T0 A8Z()S4 <N
M\ %\Z =<X((:" ;KM $?\#1Q^($SN00.J 1R. )2&(82R )L2 4HP--6D &]
M<@=;*($$.,FVN (-* 1Y>(<9X +LP(8T\(5[P(%LQ09 $ $B2 9U8$,MF+^T
MD <D:(#L'(,(@()%$(0<P (J%3IDL $;0(8Z$X8C@ %2.(=.L84"* -LD 9!
MH("Q>0MH" $94(=D& $)P,/_<8B#$3B&52@ '.".99B!"(B%<OB$"1@PI> !
M,7"&6] "',B'2:  /O '? B2&3"*@>($'@"#1^ #Z7@&+!" /6B'@;*#*;"$
M,LB".Z"2<: #*F $*L"!=8B%(Q !3&"#(L"",Q &+!@)(K""+8 "!U0(/$ !
M3L #'##1;V "!-"F?W '6@B!)4 &D#*&+F""1D@Q_4B+7$B!)B"$-?B!2P %
M$"""%>"!(E@"+CB.;: 43*"!.9B_,N !&Q@"(C@"3'BI5&@!)+ #0>P"7G"&
M)W""(M ".#"%-ON'>0"",8+!_L0G_E3=&2L2*6@"G3 !(?@';HB PD@VC? &
M-T@#_RE8O'\8A#\( 2OHJD8(BH28!0L0ER+Q@Q&HAVQ( %X@$] !*3U  A&@
MTG^XA2   2B1CQT@SF9X*44 WW_8A0O $G'P@4[HLH,8(\Q) 80XDZ/8T5X)
M@/@$*?(ESB)@@;3HA!+(B8TXP)<*A0K 0WE0$#^8 7SX!Q1-&6R @I>"A0CX
MC7_ !OV88.KZ!W[0#WI  1B0@N-HARCPQH%ZA" 0 5P(E'=H@08017"0!SAX
M@27PWQ(@SGDX )CXASC@@03HA8,( P6-FG\P!!+0B&@@@10X @JI!MH]AQE(
MBD!Y!E78P7. GR(@FU_H@00 K]P2T7](@B-(#QG8$H5PA/\'**IA( ,3*8!L
M"(=?,)\08(M_J 6[.2HJD("V@PL_H(!5^8=70( 7&!DEB-TXK;XCJ)5_@(8/
M (-_" 88>(!;"!10L( ?8.!Y8(!)$,"9X,*+LX(?8:=+Z%+6R@<;V(.$. -)
M[A1#$ &DP84$D.1_X 09S0(Q0(@GH,1_6(8 ^&%]D($\0 A]. )ZR <&P)(W
MJ8%%6(A%* #I-9\Y,(-_H(4$Z-,BB0,5@--_R <1*(-_\ 0'&%-^B (Y\80(
M6)L$TR9C&( ?_@=3V $C4!"X" <T& 'DU(80<-1_B((%D)V#((++J3-I0( H
M)H<FD +]X 48<)&#^ ,P2 70>03_$]"'?R@#>V &! @$Y)"")U 0-! !"KF%
M _B#@T # 4 '>7"'7&"$<#B#&'B&:3@"'F!$D!H'(="!F2[!UJTGUM5I?"J2
M):""6* "&#B38KA=4ATI/_@%HXZP?P@#77@%!Z@#MA3%A)@#!+@&UEJ%"K@&
M:] !(;"#+%B#4<P#5Y "/4B+-M"%%<"#@T $&% %6V"%(: 21(@!70 %&2B"
M^=L&"TB4S#"&5X"&U;H#+[&%-$""@S@#&[ %2. !1I"F3GEK6I %(JB!T=V/
M%S@%6S@%(5"0@\ % TZ(4JB U" # N 5.Y!166@ 3[ %6DB"KLH33;"%42""
MM=&&.NB&_P3P YU8U5'T!R\@!B\  H10!CB "CGY!39X@R_P7Q'(!GVX!V)
M $3]AS70A3%@ -^Y@R898DO(@9=J!CYXAP/0 G)0!A&Y!0A09;C8P(P#A#&P
MA0-8K;3H!3" !05PF5BPY7\@@EQ.BSTX *]U.P;(9SM(E']@A0+ FH/0AQ!H
M:XABA36@ S$.%#T8 AUXAH.H@S%X 3QD%=H5!V/082HHXX-H@A#H!VE @1%@
M Y@: BY0@;5)!QUPU+1X!@=XX8OK@ASI%$7 5-92A0"H5;B@!W0 *69X@$6]
MA@08:WSH@B'=@CFX92DX"&>H (.\A >(RY%2!6I !V,^B'HH ?_V30A^> %M
M@@M@ *\)/LFT8(8&2*ZT^(0#R(<_-99_V(3JHP0$..=V*!]T$ ")5/ ,P!*X
M:/(O@0LT. "D@8,LJ( $KX.FT0PR" &#T AN"(#KH8%5T8AV (1S>*E'J($Q
M8@=W$(,L()MO@(#1A80:F&@P9H&#P(,0".!Z6"<\L(&<$(4!P$J0B@,J( &<
M!L*>%AB>-O9Y^FDOH(59B$]!.>J!*H8ON 9ET($Q")0P *]!6(!6R(1"20@V
M.(!.-E\)N(9DB $]Z(4R4/-.$0-OV 0&@)LGP <7B'"[I@1:B 0G6!='B $@
M$  B,!=/4("_/KT?> &#=%Q8H(5">(+_M+@#$0 "" C'3[-K0%"%*!" 2# (
M2&@ 2Z"%-3CO0 EM/(0+<0"!,#B'.7@"(7"'+NBB/&D",2@"(E"07F" *1 #
M(,"!,=(&+$8$ Q"$?1B"$H:+3'AQ1H@ W!H7(%!R'A&#8S"#+$B+1M"!,"B>
M*4" +B8#4M@'$+B!9'@$F!CB.0CO?\@&5.4%#8 $=J#=0?@ 2@>Y7$L";@@'
M <AH/#%')H !>O &*O=O /\'3;" 35$(,_ !>\"'*7C?!0_#?WCPMNZ4=3""
M>:B&!FBLM$B#54"!:*8&*#"%!P#Q*' !02 "&7 6$R>; VJ'8?B#6&" 6B4%
M.G"$$EB;<G@!_QY)BW-( 2=(UQ;K<86ZA" ODB=  0;"3[APARA0]5$8"7GH
MAJIH"RY0 E2P?BQ8@BN7 #,=@BI *7-AAAWX@US(A5;0@:I&B%\( $E.-#")
M@#<WWPHH\K3X!078!75H@0"H@PTWB$I @$H B%RJBNC[!RV!K'_@_J$[8$GA
MPE,5L$'\9RM LW] GB61@.M?G5(5[ZD8HS#<OWHS[K K,.E?N)C_R/VKV:D&
MOYKL8NRIN;"<CD?_'HF8U@[4C4$UP<BXQD\9IYIX0L@3UT3&/(C@%OJ:@^Q$
M.:U;%]8L:_8LVK1JU[)MZ[:M,GC@W+E[:_<NWKQYR4IY4G9AL0BPM/_B^X>&
MS:)';$H$JQD&T#]Y>@H(:7664H)B"FNFZ2&.60)1-;F-W?I/C*E^,"R9B?4O
M!)Z:BG84_G>,IB(=[BKM&%;SF(67X19:B5+S3XJRPH[_^!>FA.;2"V<7!D=&
M@K9_-^O5Y+5P(:X*SK0.S=(K$301F-"4A14!74U-X_[!>L"M9JUS_ZH9J=E(
MP2!/S#?6/^Y$040G<T@0VS_*& $.'"@T$\0_?&2Q4"<EF&,./](@0$E-=*3R
MCS R.&'&)F(1F$<.-,5SQE(#Z,&&10ZL0EY:IGFC0QY/')!".C7)HL<_^X2
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M0B\  CZB@R< PBX<J5:80R00PBFP0S5(@S+< S%8@S40@U!E SU4 RMNA3Q
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M($ +> -'4\$N#(,/P/_ "H9#/'!!'QA"$7C#&$3 +[Q"%6C#*!0 %C2#+X2
M#33#(#1 )]QU*?B ")!:(*! +JQ!$_#""LA *.S"%KR#'7  "03)/1C! \3"
MIOZ#-." (.2!#OB!(K@ ,@""]"%".,3"%NS 'C3/0ER#"M3-0M!!%P3""?!
M(/P!$YPCR"[#%@R!+FS"%3" *T3"#?0 J7$""^0"+92 "10")]0 %=<#%=!!
M(*C %%P"&WQ"1;2""]WJ&8@ #3@"(XR $GP5+M  %;R=B^)! ]@ -\P" H@
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MY2.&X0'*3B&J(0K_<,$6?$$,6* >MN90K&0*!L#.!"O#)F_#*"X3$.4?^D
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M%G*@ =Z '\*A"$S@#R(!!VR@"0SS!#9A%FZ@!I81'("!#AJ !@S3$8-!!4S
MF^:A"B0 "-K!'>X  :R "9# O%*A!T3 " PS!SS!' 1@"BX!#53@4^).(:"A
M"B( $^8A$&K@$<H!_++ K^*N'QRA!%8 %8JG%D) !A"A'Q2"#0K@$Q !#HQ"
MW?(!$2I@! [A$!0A!S2!&&:@#$Y)"GV O<"!&8S  6+!+^W!$S* "+"A&0[
M!;K&%Q9 "DA!&G+ !:0!&Z0A#,8@[Z(!!60 &Q(F'IB D,PI@1##'4Y! UB!
M;\3A!+K T?   I !'"Z!"<^K 4K!+LYA"@!N._]2#670@ /0(!NBH0\&X1R
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M"?Q@&;2 "<#G'YQA")2 ">(A'!#!"8[@#+1I9@EB$ZQ "^K $^2$#?XG"HS
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MZA,"'M5UP0*$8+BQA)ZI]&%&%@>-O>U!UCQPE4L6D9-#'E'B8<-XX?_HJ4H
MT$3TN3W^M'3A/XKL, ]$Y_RP1-I4+'%0ZO/LH+)U>:!@'2$B\/,/*PD,(\\Z
MEP#_7"H5+/-/+Q]0MTH?I#6"1QM(]/M/,CH\@5 -1HPL!??'2&#&<[RT<8F8
MLJF!2!$V,*-S$M;=GCM$;_ .D>_FV$.#%5KR8X(X_(,2"&B710C8KG^((@/C
MZD0)-$(.3.C)@0;JPP>0E;P+,$(VM[B )60#"3%\H1,1N= W*G IZSA0(_]
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MH'('<80A\* "/UTB#GF@@A>1P(PU>&%D^G#!'LPA"PNH2ATG*.-SY"&/=YA
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M>LI#K_8D@GR0 PD_/T@P_PH ;Y*6-Q^>P'$M%M!<, /+7DZ] 80<0(HHL:(
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M.1 "HV$*8V =RR  <*(GXW-N%G$MG_(/M0 /CE "GS(.5. %EV81B4!"O5
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M#N^ #AU8E5R<R;$LR[-L:I9LQSL,R$LCP[3,R[WL'^S (<N[PI9C2.=@#NJ
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MF,6D@AKE&][@3][BT4OD^SV](SS'C?Z,8SR\U3OIM-S18QSHZVP1]@#_"RO
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M1RB+''@,60!% ^F$M>P'$1B$@5B!6U.U% "P?_ $$X"%!N"%<S 'NP$11HB
M8,B'TOF'%2B R_@'** !<\B'XE '&=@L@?\0!]G[!VNP :.R@_VCA0*0AGQ
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ML2_[L@_KL4=[LX_VL%;[M0>'<[B%_/SUX"'VMV_1U0 &(W  1'!J [$M.\
M$1 IKN?VH;9W%E$(BU#\HN=I&_03E&/VV.DTQ=_V5>R/?.=IR+>0T%DO9N=\
M=Z?V8V\/X+ /B= -WGB%18"$S?WZT*]VB^'Z<B"%5$""Z.SZO=IZW,?IR2]Z
MO+][NP=^X'?[[ /[X3_]X#_^/-1\9R_^YK_[$$F&5? %6_\8APNYTGC@!0_G
MD>LW_K?W?;-O^_5(>^___5PD_^=/?O47>^(7?O=W?F GD#X  "78CO6'_[H_
M>TD   GPBL+??8#X)W @P8(&_UD3]R\<N(,.'T*,*'$BQ8H5P6%L^# CQH(<
M/X(4R-%CR(PB0:),J7&@RI $6\*\./(ES)H=:9K$F9*DS8\\>?K4R?*FQ:$[
M=?8D:K0FT)4'8R(-NM3I/ZA3I9X\>K5ETZ1>DT+\R#!=-W)59V[5FM7KOWR"
M?ITM*G<N7;H)%U*MJW=OW:]$_:95&1AK7K^&K9Y%F]BFP<,Y%SMFNC8RRLF4
M\_+-K'DSY\Z>/X,>RC(TW<>D3^O_O<L0->NY7P6BTR3&'V28TPSA^WHMSJ+:
M(=\%^J+JWSPR6AP=LG:9\C]_AR!]BUN5G+)@]L#"@P4)G;=BDE.&P\<+W='E
M&,\56]?1Y/)_][@Q-(^Y-?WZ]N_CC^@R?U/^_@>J-M]_K+$5CSS(M%%#.;[M
MI$L,\#!862T/B!%A1_@H 0HC!7SC!"5^2 #!+1;*MQ,_0YRB1P3M5.7>/\[(
M\ ,_)':D#Q>Z'+&# HB0:%E#Z=3QP2R^T0C6,@;4,M!J>$7V3S$H9&&6? -2
M6:655^J'U7]:8HE:@%VVII1##643A4#5]##C21XUILZ8. U$PQN0T?2/+S?(
M\V(B+0AD_PT[YRAE6J"*#4IH0Y2,(- OXS14#2$+A6'F6E/]8\@1_\1CB";O
MK"?2:,$ 4IM WDC 2HMK2N*+=$6Z5,XF$/ZSR#T"G>*.="[!I \A.4AI'IB_
M AOL:?L-R*6PG26CT)+'>J:1,[4T PXYN'0S#CZQ> -.,33,P,LXR)R@CS?0
MG+H,*-@,%,P^_#3SSSG:@!,.,J*XDH\X;OZS#2CQM+B.*:*H0,9B_[CC"B_[
M5.7/&S=4@T\X:'@!3Y[Q"81,*?;TBXLS U6CSSCUC$0/*,6T> XN^Y#CDSSP
MJ!F./FRP@+)(ZAA!AYN0F GRJ?+HLQ8Y;<#1LT#A"+0.P0.9(_]0/4" 0><_
M_4CS@*D$YS-0,0?@PE(_DS9F4)X$I<+G/X5805 XMA;TM6(#U8)#G2_!/::8
MS-)=M]V-&9M?WG?758R; O(]%SEY1"')#HRXPX<%U=R3Q@OJ[%)"%[.(LXP+
M9[C! "T"02+$(SA@\D\E)2#AA 6=&)'%/]4@T 0=2=@PBCAQE+%'#K'\$XP6
M<%CQP!J)_;//$W L$<(Q_WB"10AVN%*+$CC@88H=(T0G3AY\$/'#QMDT8;L>
M]7QR0QL_""%2.*F04,<,F?Q#SQYS5*$(\,D@4<8<7; #CADNC"!<5>Z@X0 ^
MJ,,X""&$6X3 "O,0B":@0 4Y++ AX$#_PPA\< 1;; ('L[A'()PP"1\PXAI0
M6((8F*&) 3A!$VMJ!A"F0 ($I.(?MCB"%[H C'(8H0%P4)4JKL %,/!+(XIH
MPRB 008_5.(?DEB#,%31"&.@@!&C:((_ML&#&4!"$#90@2#0\0]0 .$*@7 '
M,<# BES\H SU !XHSJ"&3F L;,0X QE(MI!/J"$-61.%&-: NVRD(73(N(,9
M"H&/504ND8I<)",5J8U#-G(O_I"!+OZQ!B;\ QX\D,8_J-&#!3TA$ (YQ@&&
MHX<E_(,6-DA:,RXP"WY4P0OLZ 8S#$&#?S!#E/90@1/",8@7L (4".C!.7[H
M+AD(K"/D<$(>_ZH"A1>P:!$UF-4_-%&%?Y!C$0-0%2:0X*X(C $<*V@$/'0!
M@$.X @&"X(4*&X(/$S0M#EOXQQZ:V8VFU6@%DW#/"80P#G&X@07S$$='XF$#
M/R3-$0*0!"].@(9_Q"((\4B&"*X@CXSL@PY-V$<_(F&!2. C$!( @B RP81!
MU,,)F=#'$?0 #Y-$0P2U\ <>'#"*?T0@"?X8 A3(D8L0/,,<J0 !,>(1 2A0
M+!07D$0]^$ !59VA"/Y(@@7@X 8^? (&[S"'&W!@C78(8@GQ< <MN) ,9$B@
M#Z, 00,:H0@'E"(NO@  );;! $?\@Q<"($$>KDB/<(QA#LOX1 .0@?\.-Q @
M:^FP 26H485A.*,$0,@3X")IV<MB-K.@"08D-7N1?[PC%9_(0C/GT0-T>0,$
M,R("'D;E C?1@@3_* (1BI:%L@6A"0/9Q0I6PH<25$T+4?"#'? @"6/ 8!H"
M28,;XE(-"Z!"(-L(@ H[40,U50(+ EF&!$I!#A_([Q_(*(8Q$! &0A#B#KWX
MQPR&L99K2.,262C"/V 1 3\D@Q\F"84#GB$02JSH'V3(P9K4$8(X<.X+ A&#
M'OX1!2I8 A).B,(XXH(Y@90# 9+X!S8"\ J!($$*Q% &NIZ 8).(P0D"T48%
M-@<(9U3##5-X$0AFE002, (22[#"(35RA23__ ,8#X#%/]K@WV;<8$'_X$8(
MO#A@@33"3.- P1(6P0@G>#,,]/U'%.,BC$'T0QLC ,(_1@&#XY7B Y0HA0ZH
M.05OY@,&,7Q%;=4P C*0P0<,(%EE/>OG/P,ZT+GKK*#?M @4&.,/;/A'.WI
MC7\\0[7_8.VH0+"@7LP3"T 6R!A8\(\@U%8@LNBM0 !1 &\(A J"($@D*G"-
MA0"!#W'!A@2B&SP8/.(?UL6N=O_Q#0E XQX,2,2I9F$!81#D'BHPQ<!H(05
MV*$+_ZV "T@1EUL$ -6=E($7\\"KN.@C!*W]!R:&(! X^.$?2N!$/_)AM)'8
M 0X"208"*/&B"H1B_U0U"( ?UDCI"ZE@$ (A1@-X$>0IY,$)1O@'-"J0M2Y
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M-2@"?9'!G/P#%Q";1A!!_PW4 SNX@!O4PRF<@$#L P]D0S4H@/XQ@1H,S1-
M@"A4A1X,@".(PS9T 3I0@R90G NZY$O")&C H*>L(#BXPR%002$L Q!LC#$H
M02<\ QV\@CL$PQ!X@C0T 1,\@BT0P14,AS8 P1VH@7) 0A,0 9'-@A$4@2/D
MPA+\01@0P1!\6"M000U\@M&80QX@P2?<02!(8T>$0Q\ 01\@CNC4P1/X@3^<
M D\) C<( A.(P:L=P@[XP'"XAQR\P SH@CKT01*, 3 DAC[<P1)  BVX #+H
M@A98 11$ETD40QU@0100FSMX0A+  2#<@TF<@@D@0BB0P M$@BFP0 F<@CG
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M2@2*W!3&O")28MPKQ7"KM"KL_\+&*+6R8(E ;,2:![Y2K,0N!\7BZ\1BK):
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M(09@89-8W,!CH'#LD:8'"7Y01AYP[%FFA I^N$:>?] H8(=-E/F&#"+JP<6
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MD!AWD(.C:RW.+-/)C#Q\@1/8&,@Z:*E8RR'6M*D]5$'L 88>1.(HZR#'/)(
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M@>_5_ONT!5_^IAG$'M\  R:6<90^@S>LL=!"-S[CXFEK%K\&O(031#M15Q2
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M[."R3H,4&L";>L@A-3(AINV<WL@H3/^!#E3@";X!@:9HQ^+)PHQBI_X!&49
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M6,4+A/$/+,3!W#BP>*-J\0%*O'LQM3)9.41@B'I,(0 Z[GID'*,/*4BC'C-
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M+_^0"#$ '/HP B+0#?R0!XEP"XCP#\%0 8FD D<U!27P<G=0 _*P"!K0"?+
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M.\ $?"$!#+,%G, *;"$';+L+_, 0[!H-S+\17,$6G!G_V;"_%[S!'(P:&2S
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M8(=_+,,$Y8 K.$C@B$&@(O\/B'A$*0IRAA6( Q8'R"\+FE (/<#C$3_(:S0
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2TS5ETS9UTS<E'1554C@*"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex10-13_img11.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-13_img11.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MP$&.>Q2==DCYJ$4(@IE3I\_QH(845W9 1&<OX( /XF!Y$P%E\3" 0O> %E&
M\Y: "B@1H?<.AP6!&B@2$NA^WX<1<T(.[K2!)-@1'6AT'W@1XD .\, .#EB"
M,(@0)VA@WO=I$B$.]B /9Q&#/&@1QY!=%3%5Y8<1W#<._8 G/9B$$O&#%B&$
M+_A8XM /FZ>$5.@03!B$5?*$!T$/ZS!&5?B%"7&%%.&$&]$.^? J  B&&E@/
M0#B&6*(1X( .YN 2::B&#ZA\G(>"TW<1Y: /V96 =@B&> A9'KB'%B$._G!8
MS!>(5#B( /\H?148$>$09?;$B(VH=(^8@A8A@);XA?R B85(;QL1B9U(@L@
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M3- "&5!0O.!ANO^@#?_ #2U@ :?P#_&0"5DA$'LP 2N@#.  "_0@"N8@ @6
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M=F $ J$*!7  8H44;$  +!!]35  =( '%V "LG W5. '[> #'D $0^ .HF
MG.NYM .ZVX<0[V %BG )A# #!X & V$%9?H/DI !3/ /0,".L  #$[";ULHK
MB[ !1>!!_W /(7   "8.+B * D$,!VH& L$*J+D,,E  "WL/U7M+_U ./W
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M#5L $1#H"3#G$^"S-XNS./][ 'R^Z'MN 17PZ'+; I(NZ3)0Z2UP R*0Z2(
M IS>Z9I^ B>@Z9M^ RU@Z2L@ZIO>Z2"0Z3X0 B0 ZJ#N SPPZSQ0 BAPZ[?^
M [K^ RC@!%W@!$7@!%EP!%DP!DC(UD''WG@,$^( #Z$0"J6P"])^W]3."ZL
M"]@^J*J@"K@0"9G0"> N"(XP[N-^".9N[N3N"(0@">S.[H+P[N_>0O*>[H3P
M"&# 7XAP0F&P[VDP!OX^!F+@VF7@!WUP!P9_!W'0!@JO\'%P\'=0!G_PD'X@
M\ .O!G.P\!V&=5BW!AS/\6#G=6\0\B%?!21/\E1P\B?/!U(P!9SP2\53QVX=
M/$W_-]S( 2:BB.PQWSM6WN40P7_]%]1 '_1"/_1!WW^8$?3JD/1)/QC'^$ #
M2$ GX5B4B//*OGWS,!JVF/7LXW2E-WI>__5=7GE*O_1B__6B-_9H3U5$_R5H
M;_1N__.D2#LP7_7$0XNT"'1G/_9OO_=\W_9\__<_O_9NG_:$O_2 7_A4!?AK
M+_0P@?=CKCG.P&_@?#F +R,&M$#H8UQ%;_1!?RF"L?>U.")V/_HWSSS94&FE
MF/HG<?HVJ/JNSQ&L/_FO/_NQ/_NVWQ'%T.6M?_N\#Q&Y_VB]'_P4\?N[+_S&
M?Q#$+_O'KX;)O_S.KQ#-__S27Y:H'QQ:OS_&=?V9G_U0_W]!!G0_"H']#-$^
MXC\[Y4\3^&,8Q5#]P)'^K]B,VF\^3L^*WK]IX#__R&C_E]]Y^V\3Z5\8 %%,
MW+AQ_PP>1)A0X4*&#1T^A!A1XD2*!PD67$CP(#B+&!5ZC*BQH\B+( U>K'C2
MY$.1#%N&3"GQ94R:-6W>Q)E3YTZ>/7W^+/F39DFB15<*1<I3X,RD39WVU%BM
MS"5&AL20273P%!PI?SJ5^S=.$YA&:=1$:A;6H;I,82XA.F9PUYD^O<(6S"?K
M[C]3C:IY.\6.8+A*?D3]0A;6&[1HHMXVJA6&TBEB3 ]2DU9-6J_$8<5=@U;M
MFBQ9H;")S-=+5*]T_=#)HH:M%/_I4,O^<2LE^E0I;-&2&0R7+%FU8Z*P):-]
MC1X_6=6VR>J5]NETZM6M7\>>/2-*[0F#GD3XO?MXA$N/DD??]**[/AKB./,$
MQT!B22\H(=N5Y4B[?\:.8* CD2LX\.6A<%2Q (,]WBFH&!5.X&:O,IP(YRYH
ML.  !UOH(0B<64!PP(]O_@&'%">R8 63$A0H)!)-WO@!K(9XF8$ )HA H8MA
M_E%'%1@.6((**HB0@1J#<'D!#5;X4*&)>RHAP0,EA#QB!'ABR6(#*5BA0@$:
M;#%(G#D@&,,9.@A004@J:""$F28B*&%(')AP)3T[[\0S3STA>L:-353R3KR$
MLC&$E9S_C"*H'6=0"4><?#Q!YZ[S]FS*/$HOQ0DE?A( TR \JCDE 6@.0J<"
M/PIZ9(%H_H%'A",B\H0"2M3ZQX@1-3K'APB(V2L:"AA1J2 \ MA1HSGF,$B*
M"NXY*(QX/D*)$0JD^0<:!Y)@QZ ^-LCFH#0B^><3 5(Y"!4;SODGDP/2.4B*
M B7!H)9_SN$!!?!V86&>?_8YH(J#@F'BGV<48,.@>)2@@!9,%V:X88=3PL@1
M!90(MB1P+KZX*(,&42"(BA$UB2B,,]:HEQ)F^*>9$E: 1U*B'O;)4IAGWJX@
M;1)0^!]2PB$G!RW ^^</!Y[Y!Y$+2C$(AR18FM>&)/3]YY2?__=BQ0@2\-CK
ME L0<?F?/!2(4",V]# ("1/B^D<;8#@,5".C0TDV@<Y(X6":@_99IQX#D  Z
MB (3,0#M?:R1YQ]%$(#%H$H6T*L@,69->X(I3@*FF'&>(4".@^9)XH5]: 8]
M=-')$TD(BH-%")Q)"_H#"XO"&ZEMBS!^O1,O>.3%!G]H[7ITFV3V'6:4M#'@
M$69$20&<?"88 E!;(*BD: EH6><0# QAJ2!'&*CSGSGJU$B<+(Q1PX!UU-*:
MZZ"^#KN@.B IVP1@_GFGBG=XK[CH!Z[Y9YH)@+"'07[! 6LH[A6&>X I)/6/
M?K!+$@;HAT&FH$##(<X@Y"#!Z?S!A/_[1<Y?_\A'% R2#0*@ 3R8:$ K@K="
M%K8P4QCIPA30P0QT%:0=J5A%A?ZA#WKT(QH<$88S]&&0,VSA'_48HCWRL0]S
MC ,=Q\@'=SI"HF$\BR/_B$<P#A*)V_U#&C[8W3_XT;(%NI BP#/CI89G CVT
MX0<L  <_3,"WO: " IPHV@&\$ ,5[*(<D]J+.VCPJG0 @3\:$84)GQ$!/!8D
M?5UCWU[6H N#!,$$>$"$'6!PR+85!!$$$ (2>H &8:C%$@:X@A2D0 !5_*,.
M#KB5%!-Q@"-(00D&X%\%$V>0-%S &_^H!-EL]H(>J#(',U#'/[(1@4"<$ *&
M2F,TI2E-D5S_@05FT,$,S,% *:1!"4)0!AA\,(0?'  >8; #&$I0(#!<(0\3
MJ$$RM/&""5SB']_P0!X*$C(&FD$(3,A#.,!Q"3-< 0D[@D0730'&?TPB"5O8
M K,L,\V$H)&B=QI> E:Q0SZHXQ@3D *@:,$ 5$AO%^_\'"!%$@<'U ,3BUC@
M'FQP"4#$( 7X,,@CN<,&L.W%#=TSFS/P$0\S##%D*$$$!RQQ!0(H8R]UB( G
MHA&-/4C"E0[@E7@@80!>1$,:2<B%00Z7N((,@P-EH,<1J&6S"EAAJI-( 5BR
MX0!2[(42&)C$1?6Z5YJ)1 LE6 <S$J")<%A!"L,(!9E"08 K_ (7_Z]8@2^>
M@0,%P*,0*O"%+VZ0A7FL0@*4A <,G#J3@FSB"?](Q@G^D0@47$,4&P#"/[AH
MD(6VPQTW<,8\H$"TB>[5HGP=#TJ8$0'(9<L?)5@:K=AP@'P4[0+0. <,6%!#
M02T0&Q+8!!J*L9=@?$$1EQB$&A(0UJAM;2_-F(<@%%! C=0!%_&KAT&"00_\
M=0T1#R!&/2J@!7&HY6NVV5=:!K& 690QF0\LW#^0X51=DF@<X0@""5#A.K40
MSX3_"$<J.#+7 V)D#!+8!>K" S(2 ]?$)SX4#(WP#WJ(( WO\( >)!&)3D #
M'Q-0A$',T(1)L($+6(!'((A@$$ULP#9)H/_"/UKAAS)NY!^"H$ ?ZD&-=B0!
M!U(P A;(A@F%^J =\(B!$9S!C'L@RL2_1?%U4 (,!6QTG__PA0 Z]0]A% "F
M_P#$ Y!6"@2X(7\C+H@XEK !..SE'V#HQ$'8 8+F_>,:#WC$0>B!!G+( @)S
MOD<. "P%$YR/MIF ED88\0"]N (".39('#A0C8.H8Q/3*, 7DGF00/!J$N8[
MR#- S0D&U/5B_X % 7Q 28T$8P))/@@FBI$/NAXD'S7X00 !!6@2&R7-U\9V
M2##2!->1(P:+@$<$#FB0>9PC!_94QPCX@)!PB(&.O-C B'3!@67P8552-(CJ
M_L&(!$P %.900/3_+))0VOK@?M]HP08 X;+J7A3-V7[*1;;1!@P@P1@+7$0$
M")$+3)R@#W(I0@,Z$2E'#& *T @'OKMV"PGP=ASJT,4!.J%O>V1A 9A(!R<Z
M((5<W"(7;WC##EUP USD8A0X4 .&ZX$""<A"&: @!0\*U$E\U $"KRB('3@@
M"73I00*F( <ZUO$&KFD" 4C@!CF"X08XC(,>;'" -\A!CF2H@!7M* ,$-*&.
M7^.C!SI()D'FP8T((&'NY#!%%M[QZ$/,_1HV>,$V^)("_AVUVM:&>.8U7SJ^
MV2,&C$"'!?A0H6$@(APP*$18O@8W<9!!'XA8\3]480)W8#@)()A#RE6N_[I9
M/$,;1C#!,G 0A2O^01R3..T_2F&#=IBC&O(HPP7P^+$S#P20F@<*04)!BUO0
MHAO?288?AE"& H=%#%-81"U**5LE;$)?I$6)/201^'^DXPUVV 1._]&--=1A
M#8M0@SQ8 SL@P"'H!H-XAS^8 CO8 D< "W] A#68@S\8 SZ8@CZ8M1$+"S9P
MFC0@FG7(@1J@ C]P 1T @B58@BZP@?7[A2P@ 2;8@DD8!W*H@A)( 2= P1#0
M G;P@Q#0 1;8J%^3A$C3"%#( 1W  11< AIPA%)P@A[(@25@ B!H@VU*%PN(
M OKJI,MK..SS0K[2"&&@@2ZH!V<X #FPAS88@/\CH ,2P(5U>( ^T!=9<( =
MP(,G"*D^2 %V0 8;(,)_H 0!N+?=\YJ?X08*T 9+^  ]\ 4[T)Q,& &#Z 49
ML(=Z$ +Z H$X<(<\&,3>BJ:'^T*?4+F7@1;OD!UJ\XA1O+YI,\6&L+QQ@ =W
M2"::\X=TV =_((=[B(==K*&#<(=TT"%UD =<=(==O >.@(=WR,5V&!D'NXAV
MT =R\ =]H$9W$ =RT =\>(=X2 >HT8A0(((,W A/G Y2' G,H[905,=0TYBP
MN")39 =#N(,Q> 1&\ ,XL 9Z" 082 %*&(<\0 ,_()I_P(0LJ $YB)1N2 (B
M0()&H)5W, +ZJBZ.L(3_%Y "*,@$<&B'/B !$0@"=%B%*!B!25B&(8"!,S"&
M'+""*8@">8 & -"""E$YA[.^==Q"<T0*G*R)=CQ'GOP8G>3"ENC"4V3%C^BD
M/Y,)C7"&*X ;D!B'>>@O>#@&>J#*JK1*@<(8BQ&9D0G*572(H;3)L/Q*::,(
M>NBO>7D=$M$_C(@'<DB(2@"UKWS*=HB&]3,(=D 75O$'=B!&>]"'=BB'8CB%
M"A&'5'@"B21',P)%+RPQ]0!+BO!)A@-*D+G)KK3,R\3,D5$=$M.&N)B)<*B0
M4QB"*4"#TC1-TS2#U$Q-/6!-/;"#-KB#.)#-V8R#//@#1EB$W-1-W?R$WNS-
M_T< SGH,A.$<3D8P3N,,3N!D!-_LS>-<SMU<!.>4SND$A$NP3D PA$/0SNWD
M3NY4A$X ST[(!$(@3T=0!$G@A/14S_24!$WPA/?T!$A83TB@3TB0A$3 S_R,
MA/V,!/E<S_64A$H04 &%S_?4A ,]T +U!$I@4$KP!%2P!5S !54@A5^(A0OM
M!5/0T WET%WP4 ^%!FH0T1$=46[ AA/%AFI0T17]AA6UAF9XAAA]!F>@T1JU
MT1N5T1@M!F+@46+(!AM=!F=8AB$%TF?@AWK@AW;00I? /)(0#RDJB'BH@BC
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M/F@'E*B'+M !_W%8A0QPG4K@@74U 2"(%' 0 RWP @O0@NQE!"Q(@B78AUI
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M-10!#@!".!P"?@)!,JX#$R@ $W"!#0@4FDR" /R (9P '5"#'90 &82"$O0
M(]B#&T1 "!B!#U#!.@###U#  <3!.^2   #!*[*$,K1 "OC>!C3!-5R! KQ!
M[AS  M3 OJT$/B0! 3"!&Q@ (K1#%,1 &GR7!S2&!_Q &>A !FP#.F0!!X#
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MQU3K1UI?AU:<-7Y0T%?O[=ZLM7H\2-:Q1SE@ 3<-A",<"GMXV$"$@U2"ZT#
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M1IS#&^# -R#"#SR!+YQ!#B1!7'"!"O  FT 25E=UU![Z58,KHS<Z1H3"#Y
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M>?->LYY7OYX]T[!SV\>OBJ_NT,D%H39;<<_^?:>/ZS.FAG3LPTB+(M3Y1Y8
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MFWDDF0"=442X(1%7/&!!$5T,./_D'VI,,&*3)!((Y9\H]KCG$@=0&<2!'.
MPAW\;@DA&698,**=>N+( )9FDD+&@#O^@46 $LB9APMM_H&G B*@N0$,<K!0
M@"Y@H05OR  *N. "1W"@%IF@@3QZ!X(XW"$!W:A&#E* B6"D!14)B( 8+C>9
M,DP@"'<X0"+^@0L#I.(,'E"&)1+  A<P8!J.>$,LIA #821C"VG@PA+D H8>
MI $'/6 '.Y9PA3"0@ G^($4$,N"A5S @%L]0PB'6L -J#&("2[ "!9@!"#T4
M@@53&(<[@*"$/LB@!"I+!A!V< 9E1,,#<#!"!.* $4?P81 \^ 0RGB ")C2
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M<  !$E3L'V2PP&ZN((1_&*(+_T"&";XACC>@ !O,,$4$Z. (.@ @#&Q@PC_
MX0;)3>:N0N)%"^9!B!"(XQ_.X, F_J&(%_#G%&GXQQ*$D(DS0$ )[.@!$]*1
MBR5)8Q8S , TX* #C/SA!C/Z!R=HP#!22* 3XPA#".;Q"Q/D8AER $ L8'$
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M@8\$?.P?HP@ -@J"@DK\XQTBF!)"#J"E?SRB!=](@16(@ 8B(.+"*QB'+R[
MY=L^@#8C$,,_!@$!:L@#"O1 +'"888)XR8(#\9+$##"RAHA/X@D%_TE"Q/\!
MC @P'4I3MOO=\?[0*+LN[U2)1-O_H88J_",5">C()79 GRJ(^1\NR'(\9/ (
MDF; '!B) B-6X8#/Q<,7YC  >"]RC *XFQT^4,4_!$WHI&3C!3Z@!*PY  2O
MXR@':\"'%K#P#WR0(-P8F8&5QA&("HS"&!$@!9C5@)$GE/K4!!D+.>2@Y%UP
M(,^G]OH5@*@(&&@B'3X@"0JR_ \TY'8H_!%%%QIP!O\0@0>2<[@S3I"'H<R@
MO?^H@PY,D=1=+"!G>)F'U3&""9* *(XA R3O'SXAWM)B$2PLISB &R;O'/I@
MO(;"'DK!!PPJ$3C@IW2F'[:,2M#@<&:@#?]HP;,2@A1*8 ,D@1PR0!&& AS<
M000((;Y63ALVP!*4Z@8&01\BX/4<$ +'X0=HP<Q$8$<0P@)0Z!\R001:P0&\
M(2FH*7X<H.'^81LDP-'"  ;HP0YH !$2@>E8[#&: 03BXA0XX D/ 0@P@@UT
M!1*\P.%(8 Y00@A JB >I^_P, _U<$[V;@^O0A%6SOYR#QL"@!;J00AV0!K"
M80J:K?'*[!QV(!"&S@$HI1I>0!A$3P>VX1B^0!7FH0 \X2["P0A(@&%NX00(
M0A,* &V4@@L,H![^P1<0 (4FPQ8&8(-&P C^ 4.ZP=E.(!7(RP/:X!^@(0 P
MX1_TH#K^X0>L9 W_0B <R&$LSJ$'-"4Z:& 2/D0%)N,+<H\&/$D9:J#A9L .
M, (7,.#J_F$-=.$2\"<3#N X)D,5$& &Q6$.3$$-;D#)8$ 9EZ$%<J 7\\$"
MI"!!4B$$=< 7,&(3)  ;_V$(4J$+<D!R&F$'^&8R'N$-GTYW\"T#RB$-$F 7
MUE 4FL$&6"4:.,#E,N$/SB$&V(<=:H 3,$(7,B '-N@B7.$>SH&"?J$$E@ H
M^L$,]D$%!.HQZB %=*\'Z$WW9( 2[B$"GN,?="$ 2.(?9D#3[N$$$ PA/("M
M"N$%3B$#="5_JB,,8D#B(* 6,*(;$L!6L"$#ML 6*"$&I  6.><NGN$%_XZ#
M&@( P0A!KM)10R !\%( "89""*:M[OPP,15S,:^B#QD3*D*!"4: $DS!"UR
M$L*A#1Q@"!;! _"@$SS@!30!$"J@!GBA$!P@!*Z!&'CR$9I % H"$B8@ EY
M#-2A#38@"O+A+IA!!90 %:  +4<A!QR@##:H/AJA"28#'FP YR:C&PR !>@@
M"TR %_K@ N1@']CA$P2 "X"!'I3  +9@#F+@!#AA!%)@&A1! +3@& 1! ?2
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M!<A "I+A'-[@!Z[ +]!A"(!@%-B !:1@%>@@!ZC@1@["$IJ #(Y #%A%'M:
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M@7)&&R/<>A[*(:T1:[I9I1)> !%.  W&&!S$ 1Y^X/3$P>M$A*[!P8:1N#(
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M$/B#&"YA$&YA$M* &=[A$A#A6X"B&A A$'!N@H<;&"0A#%SA'-!!$&0@ _9
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M.?\.:_  BG! AC<N[; $M?,/JE !!H &_] +#I %X;8"!%!NRY(:8X!ES$(
M#34(\+9JIE50_R +.!  ='4&"&!F1B  8K(+*B &4A  F. 5=B47_Z (%X &
M_8 .1,$+-T  (. 4!DB$);%Q18B$QE%AY3 -28 %PP .[I(,/S -]"!!1@ &
M > !I_ -+] !GH +&Z !J4 ) . !N< O%@  1A 'MZ .ZC AR- %?. *![ &
M]18  ' )"[)JYE "7% /$U(-7L  != ,BH "WX &10 .>6 &SR "?] .*
M5& /N$ "K/ +HJ -__ ,.=,(V< !'^ +\\ ' * #?R#_!L9@#RP  %/@!X!0
M#^-@==Z5A"6A$HS6!QZ1#B\0 $$0#KW  24P#5]E LM@#0D@ LLP!@)V"O:
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M 6X0#1[  (Y #1)0 VH  @2  N[P"1+P OCT#\TP @] !7BP!\9P -$ "A%
MI>EI>(;IK,ZJ9/%@"MM0#*6P"[L@"]+@#=Y@"M3P#=G0#>ID#<3P#,S@#-/@
M#,J@#<\P#,&P#,70#,B@#<%@#,WP#,0P#-F0#<C@#,.@#,BP#,QP#,?0#-HP
M#,/ #-8@#,ZP#,&@3LAP#/V@#,H #/60#N;P#.9@#MK0#\?P#/% #O 0#Y8
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M2YCS,!8L</\ %E  __N_!G   TS  EP L#; !OR_!#Q0 C8!.(JC!YS  T4
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M<>"PL^\@#[,D#_NP#OMP#_JP#_O0#_8 #R[K#O%P#NA #O$0#_H T/Y@#_'
M#O00#^^P$O;@#@"M#^1@#^4 #_<0#N2@#^_@#N] #^^0-># #CI+#^U #N)
M#OQ,#O@0:?B0%ZM&#^=0#N?P#N6@3TV,<?<KTTA(%/H0"KUP"[G T[DP"JD
MU*3@"K2 "D5MU$:-"9"0"$L="4W=U) 0_\M1'=62T F.8-57C=59;;M;7<NH
M? F@_ B $ AA  9E?09O@ 9G(-9DD =QT >;D =T(-=Y4 =U7==\@ 9YC093
M0 5\H,5HD UE4],>$0]/U@0[7 2)W0194 1"/ -/ -E.X (AP .570(Z@-DZ
MD (K' *=7=F?30(V(-JC3=JE/=HD< (F3 .KS=JK70.O_=HR(-NS3=NU3=L[
MT +XAF\ML .SO0.M70.U_0+#/=RP_=H9,%(3\, 0C*/*_< 90-PUT (*0-T*
MX   C-T [-S*+0,U\  %H#%(. Y$(0D>8 ,Q8$4KH-XQH-XT< (J$-JCK0*C
M[0/U[0..$]\V0/\"^[W?G>W?E,W9G5T"*PP#,% "!U[@)= #!EX"!0X#(Y#9
M.E#$*/##/R#$*@ '3SO8VT73&VYX'&'.]1L.9FN+U&:S+B/3EBI>]L#B+4X/
M[$ ._H .^$#CYQ#CZ(#C_G /.[[C[^ //P[D0'X/_DSD16[D17X/1<8/2\[D
M3)X/3_[D%2OE4T[ERD!]U!>PVJ#E"+L,7;X,_YJPP] ,7D[F7OX-U8#FV& -
MQ<#FQ6 -;P[G;5X,Q( -:%X-V(#G=<X-U\#G?>[G?PX-UQ *U[".2*B_T/ (
MCK#5B[[57[UVC0S6D2[ID_X(BR"DEX[IF=X'>> &<^#I;@#JH1[J<U#_!WI@
MZJ9N!ZEN!U6@!W<P!9!P@QXN61TNZQDW#^108'!88;L>)+U^7K\.[,*TZ\,^
M=+T>),/N2$>B[,IN[,WN[,1^,A[1#NT0A1-!;8'!TAQ1XM'J2-:Q[4:R$LXN
M[N-N[+4N'>2 ND18#A46K4?"[N1BM.:N2+0N[^#%$1A1>,N>&B2A[_O.[_T.
M\/K>[,K.[N$^>"@>'.Z^$6+1$4$KZ^,]$T<2) !O["!.[A>/\14?\!O/\1R!
M[*IQ)" ?[AD_[L2N\1VO$MTN#M^.<>JP\"MC\1F/'.6>M$Q4[XE$[S>O\SO/
M\SWO\S\/]$28\T%/]$5O]$>/]$F/]$.O]$WO__1/#_51+_4<OO(L/_57C_59
MK_5;S_4?P?1=#_9A+_9C3_;X^_5EC_9IK_9KS_:<<_9M#_=Q+_=S3_<>\?9U
MC_=YK_=[__1WS_=_#_B!+_B#[?>#;_B'C_B);[]5K_B-[_B/#_DXS_B13_F5
M;_F7CQR%C_F;S_F='_B:[_FA+_JCK_:@3_JGC_JI+_4M8_6J[_JO#_M)S_JQ
M3_NU;_M$/_NWK_N[S_N$;ZF]#_S!+_Q)F/O#;_S'C_R*] P,<DC)[_S/#_W4
M,10A'_W5;_W7GQG3[^_8S_W=C_W:W_S>+_[C?_S@W_KDC_[I[_K+\/OJ[_[O
M3_O%#__S3_^B+__UC___^4_Y]Z___>__A@\0V<3]&_?/X$&$"14N9-C0X4.(
M$25.I%C1XD6,&35NY-C1XT>0(46.)%G2Y$F4*56N)"F0($N8,67.I%G3YDV<
M.77NY-G3YTZ7!7\.)5K4Z%&D294N9=K4:<*@3Z5.I5K5ZE6L6;5FC;K5ZU>P
M8<6.)5M6:5>S:=6N9=O6[5NMSL*-HRL4[EV\>?7NY=L78K.Y=?T.)ES8\&'$
M1P'7M9O8\6/(D25/;KA8,&7,F35OYDS6,MW.H46/)EU:Y^?&IE6O9MW:]4/4
MKV7/IET[<VS;N77OYNT6=V_@P84/=_J;^''DR97'-+[<^7/HT2D."PS:*^/_
MU-*U;^?^E#KCK]B[CR=?GNCWRUO%FV??WCU,]-;5@W]?W_[]CO&S7UV/W_]_
M !FBCJ#]K@+GP ,#5'!!_P:4;RL$$V1P0@K+<[! JR($IT(..XSN0K T]'!$
M$HD#\2L12U1Q1=NT"8= %F.4<<:,7(211AQSU!$A&Q_<\4<@2>P1PR"+--*_
M(8]4<DG_@!DGG!>9E')*\XYY,DHJL]02.BNAW/)+,(_K$LLPRS2SMC'/5'/-
MUM)D\TTX.W,S3CKKA&Q.._/4TR\\]_3S3[?Z!'100L42M%!$$[7J4$4;=50I
M1A^5=-*>(J7T4DQGLC133CLUJ9YQ)/1T5%)+ E74_U)3576C4S=<]558*6HU
M5EIK96A66W.U-9]07=7UUU?W.3 ]8(OU5%APB#5VV4N15999:!UUUL=HJT5T
MG6&3M7;;1-,!+1Q?N1773V\+ G=<=/<L]Y]STW67SG7;?7?>->4)E=UPZ=47
MS'O&44?;?0/FUU^ !3:8RG[_)?)@AG=,N."&(P[RX84E7NK>EPX2*L%\+3[,
M7G,KM@H[DDLV^62417XK9?HR T>=>>R92YV!P!$G''K:&8>>C/KS6"R0V569
MJI818OEHNT@V#.FA#0NG''7\I:><#=MIAUUQFD[(YY_!"GHNLAACYVIUR#D'
MRY,-2OF?<HHY1^G"LO-1Z__!GOQ'')X/VK"@<>S!V"*NN_;J:[J=$LR4*8I
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M!A-"S2#70 $ C( Z;!R GF_ P=68X(=_'*,';<0&"4RACEH(8QM$,$(XM)&
M7@"O"&6X&PK^\ ]MG. :_[@'"?! B4Q(X0]Y(]-D>3+*K%F6*>#QGR,.@H\B
MW. =WB  *?XAAW6.MH!9" $^#/*-:W0!"T=UP#.42A&N,4W#*-O:ADWF-R.>
MXU]4$PH1NF@0/DSX'_LH0!>1%C=\G*,:^!@'.L[ Q7]\ P3?^,<D6 "-8?
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M8 4*T$(Q%N$!020C#R)(A#O,0'="/.$6Y%##%&Q!#VEP 2"8!!VX@V*( Q(
M WX !W@H P,8@3X0ED$P@7K OAR"$@S,P)I[L\ 1OL>C/($#0<?3/%7SP*.I
MC72XF1?Q/*0 /I8YB'(P&WJP!QJ$I7FXP7F (AU4!Q[D01V$HA[D01:$B1H:
MAVTX@V,0AW*XF:.I+\H AW-H!YR!!WR0NG&8M7+ AT$ !(-0!UFH@W,X!W<H
M!WN8AW-@!W9PAQR*AYQ1AW?0AW P&WD(0W]H!W;P!W:8AU>#I'Z8!WP(AW:(
M!W+PAWS@AWW_6(=^2,1$E =&9$1]>,1'? =TF$1*K$1+O,1*Q =-W$1.Q"2K
M^410#$50M(=R*,6I^4':"4+9R#?62$$O&<*]F,%WH(0UB(,^N,5;] -=)"DZ
MB -?C(,\"$9A',9AI -B)$8Z2$9E7$8RV 1$>$9$" -IG,8TJ$9KM,8QR$9M
MU,8S (- ^$9P_$9$ (1$@ 1SM 1:\(1!V 53Z <A? AQV!!:.P5!,$=(2 1,
MR,=*X(1$P(5.2 3(>8P$ 1MXB(,>V 1%"(1*L :AX!M\HXMA 1OW039MZ1B[
MB$=7.04N\+XUD ,]^$B0!,D]8 .29(,U< .43$F57,F57 .7/,DY_XA)F9S)
M.6!)FV3)-OA%G?Q%8ER#.OA)[RM)-IB#-BC*HB3*-I@#/!"#/VA*,;C&/R #
M.)A*,L #J\0#,C@#K3R#,6@$0R@$L%0$01A+0?A*L"P$1U $M52$0SA+MWQ+
MN 1+1YC+N20$N[Q+O,1+1[ $3(@$O_S+2, $2,B$3BC,3K $Q$S,Q.P$P<0$
M?K"'7GH-5US!T>!!>MB'9LC,S!R&9\@&SUR&8J@&T13-:2A-TSS-T\0&;]B%
M4FA-UVQ-4S@%V9Q-VOP%V_R%6!@%W;R%48"%5?C-57@%X1Q.XK0%XS1.6F@%
MY5Q.Y40%2JB$29@$Z+0%06@$9"C%)82(<_]YF5A@A$/XSD)H!/%LA$MP!$@H
M!$,0!<J R'1PA378 TO8!\D[P<!)FWM@!M*K!W-01/Y,Q'W@!P#=AWHX!@(M
M4 ,]T ,%!@4%!F5@!@=]4 A]!F>84 JM4 NU4,_TS- <S6HP36S@AM<,T5(0
MA5XHT5[PA5M(4=[43=T$A5IX45!P!59@3DJHT1J-3AR53ARE!%;H45;(T4GP
M!!NE!$W 44V !$?(2R6]R[54R_ <3RB-4O$<!"JM4BIM!$9( VIL2B[M4C$8
MA#+H V:02-F83%/;#'" )8)@1;&0F]29!S*M,X*@A]IALW>2/'8@P1/4TU")
M3 R["-^S#U]AASK_+5,5/%/->!F:(4,<;%0<Q$Y(C51)]:05#+Z&T!#LT) ,
MW-39^4$U*YD+Q,!Q4$(GHILKP<!/?9*LR2$V79J" (=299=Y*-3H\;#Y1!DT
M'(=)Q<X@[%5?_55@#58?1$5B+59Q<")Z2-:IV=4=8HP4T9M-U1!-Y50,3(A0
MI59LY=16Q8Y-W4")B,=CI8=6+0TSA46]V!N:2562R59V!1<[0T5,=<%,S1HS
M]+Q>B9!7+37)>!G:N<#BRQD^O3,3U)98VAEE/=ADA51QQ;Z4F=9LE5:(E=;:
M8M>(A=A.+=9H/3B'P%2CP5<3M-1:99F*A1B&!0UU: =]G0UYB$?*%(VA_[&S
MHP!56 R^OXF,!Y$7R/L)F U8G?"WR#L)@3VUW5C9'$)4^SK:^B#:ED5:IK4/
MI37:IHW:[GA:<Y5:J[6-=Q@(G+U:KM4.=-#:<>U:L26.K\67L3W;YRC;K45;
MMA4.?P#;MHW;X:#389%;N^T-VHG3N]U;VN!!O>5;P&T-OZW:P"U<PAA<PTU<
MU8"2^5%<QPT-CGU<R749CYU<R]W7RKU<S4V,R-U<SRT,QJV\SQW=M^#!L"5=
MU&4+TTU=UM6+U6U=V"W=?XE=VE7=V:W=#-F;8]59FX.\[.L)E($2'529>YT?
M90F'&\P-Q,5=HAG5<@A!HO"\9_TW<+'8(%1!#/]$Q4W5WFQ%175 6(2%U(*M
M"PU)19AAV785WA_L7I3-02GLVQXB7.:-"9N)1W+(AGK(W_PM/?[MWT($4 !%
M1$5,!P(FX/T<X'N(!P76AP(F8$A\1 6.X'N88 JNX'MP!PR^!W1 0P[N8 ]N
MAU[=U5)\"/(U#'O0&_DUC.6=WZ=PM0,QAD6P@S>8X3?8 QN^81P62C:0 SOH
M83M@ S=P23=X SXP S/@@SI0@SNX S6(@Y<\R9U<8BG. Z-,RIEL V&D@SFH
M@R>^23>H SD(XS#VX1[FXI>D295<@SR0XC@H T0  S (@TU@A$^H8SNV8T;(
MXSR^XT_0XSWFXSL&!"O_%<^X#$] ..1#SDNZ7&2Z)(0D7=*\5 3#+$RR%(1,
MN$=S3 15J(1;@ =Z<$+66&$6?@I[. =Z@. (3F557N5TX$]^T-]ZX(=UF.5U
M$%!8OF5<AF5EV.5=%@9?]F5E6-!C:(9J( 9C)@9K2&9E5F9BX 9G?F9HW@9I
MEN9K"-%=N.81S05?V&90( 5O]F97"&=7\$W@7 5Q#N=R-N=S3N=TAH5U5@5<
MB&=YCF=58$Y6\ 1-R.<B-5),2 1_CH2R_$Z!'NB!?F2[=(2S-(1!8$JF'(-,
M^(3P(]G6@**_'>6DH)F:/9.LV</9Z%R+_FBI\&B0'NFE$&F2/FFC,&F47FF?
M_U!IEG[IG'A=F)[IGI!IFKYIG+!IG-[IF=!IGO[IE?!IH!YJD^A HC[JCS!J
MI%YJVPE4IGYJC%!JJ)[JB)!JJKYJII;7/</J^=V\DC4XKF9>^#&:?_ ;K4[A
ML+9;7' #.( $9N@#Z(N%?VB&,JB#(4L#%"A4%TQKYMT'%WB 9"@'3(" $UB'
MWHJ$%)#/5/B#@5"&4X 1-[.?#^1KVBV(7Y" W!J')="!&J*#ZTN(-CBQ^=P:
MTB9K8:/LU"V(<R"!(:@=,$B Y%$')3 '2$J%5"@',;@ ,S@%?[ $0E"&0H %
M=BB(?!B$*5"%/%6'1=@#0?"R?NB$3$"%4CN$15@>U/\F7:'  P(P;".@ /_2
M!9P2+0+H 7L@!!DH@V;@A )H >=3@$Z8ZRC@A5SP "(HASV @U%8 3\XAR(H
MTA) ("6 @5J];NPNB%T(@%?HAR# @A^8!S*0AC7=@Q$HB!1@A;MY@1\XX28X
M@G_X@Q$@A+%R &,H@4#X!UF(A'K@@%KX!URH0'<(!JLF<,6]'QPP TF(!%K@
M %TP@W)X"388@7] A@2@!(/8@20PB":0@G'( 2U0!$)(A%X AT.X !P !4F\
M@@;8@]!I2*>6<<D5C$'8 2%X!V"@@1OH@S7]!PD/\B$O\B9XD28P@G$@ =[Z
M!W> !W"0!2%H /]R!T0X 0/_D 7*PQKEB;.3N5ADB[/TK59\JVB0V-[UC9!N
M=8BG YS[89IX!>M_XUY116LOWYV"R 8%<*=P6((,2)\$<8,4^ =@B(!42#,9
M./)_$ (C^(<[X(!30 =H^ %F4 .#(((L^ 9!8"\/6+9AR ;!T$.]$59'=52:
MV<%FQ\%G-U9BY<%2G-4>=%CU7=_NI?9>]5YA_4%A'?=PS]Y%Q\!>W51GO]X?
M;%2.MKQ#CY!/MUG0  <=(/)_  06>$AOL($=@ 9P ((0N -?,  0Z(9ON $2
M6(9E  $'H $#T(1_H $E4 4G* -EH(!#((80@)PL*('H218,Q/8>!/=@%?=P
MI_9B_X49DA]68_55E4_W;E=YFJ]Y\W5Y(+S>[)58I(G6X:/VZD40R9X=3Y_W
M^0"-7C#L?S &4.B5<?B&7C"%-BJ&.0B&8H &6> &4H@^/JJ'/]B$<@L'18@#
M-Q"$=G"',RB#0*@&@Y#1R"&(YU6.XAU9GJ\+5,S4D>URHU>-]; .>3\]2B]M
M0P_9N\FA9B %:$C\Q*<&QF?\;GA\R(]\U"S-9T9-;.!0S,_\;4@&;/@&:Z@&
M; A];,@&9V#X96@&;4A];4 &7M[E!570 270>J#E6=X'V[?]!DZ'>*C@>WH'
MWX^D2?0'LPE#XB]^41Q%&J3!4$S^Y%=6J4/8:+_!'M) O/]'E7[#M[U_#,F^
M],ANF<L@%N.Q#F<="'H0A3Y0 S)(?SQ0 _9G_ZE\?_B' R5F8YVD8J-<@QK&
M8?W7?R!N RU.28"88X9*E2I4ZL2A0R=/'#QJ'N*)B(=,G#46U[A1N#!.GXX=
M)49,J#!.&S=SYKB)0R8BF3EZY,C1,\=/F3)^R)@\.2</3YX:-?;,@](-T38]
MV^"A61,.F:9-X4"%6G/JGZI5_6#%*F;KUC-COHY)(U;L)D:?SGY:I';1)T!N
MW5Z*>VE0HT?4Q(T;]V\OW[Y^_P(.+'@PX<*&#R-.K'@QX\:.'T..+'DRY<J6
M+V/.K'EQ.'5[Z9U3-V_T/'NF3Z/_;J=Z->MS^,[!=HUO-NW:MF_C(Z=[-SET
MOGV_@_=NN+OBQH^[BZ=<>;KFS?M!AWYL.O7JPI!A1\9,&W=FSZR!!_]M_'AB
MYHE]BZ9>/;7V[=>OIQ;?/35HWNY[*V5J/__^LOX#&& OOQ#8RRRD($@*+PLR
MV" O"2*8BH2IN%)AA;"\DF&&B73"33C_Z+69B".26**))Z*8HHHKLMBBBX2-
M TY?>=%8HXTQ@I.CCCON^**//P))3XA $EFDD4<BF:222S(I&3CBB /.C37R
M6.6.X8@3CI;BJ--EEU""&::88Y)9IIED:IFFF#QZ^:68;8Z9II9MJO,FG&>&
M26>=>/(9_V6-?MTXHY4ZVOB/CNK(V*2BBS+:J*./0LKH..',4PZ=<H8S:(Z8
M8IDFG?/H&:JHHY):JIU>GHDIEZC*N:J7Y< **VFSTDK:GE!^&FLYH)8J*JV9
M:AHLIW).J5>4D2*;K+++,MMLLS'RA2.AQ5*;UUXTPE@MM8U-*J>P<B96;6-8
MEBDEMMSN6.B,ZEXK;K0?@NBLO//26Z^]]^*;K[[[\MNOO_\"'+#  Q-<L,$'
M(YRPP@LSW+###T,<L<034URQQ1=CG+'&&W/<L<<?@QRRR".37++))Z.<LLHK
ML]RRRR_#'+/,,]-<L\TWXYRSSCOSW+///P,=M-!#$UVTT4<CG?^TTDLSW;33
M3T,=M=134UVUU5=CG;766W/=M==?@QVVV&.37;;99Z.=MMIKL]VVVV_#';?<
M<]-=M]UWXYVWWGOSW;???P,>N."#$UZXX8<CGKCBBS/>N../0QZYY)-37KGE
MEV.>N>:;<]ZYYY^#'KKHHY->NNFGHYZZZJNSWKKKK\,>N^RSTUZ[[;?CGKON
MN_/>N^^_ Q^\\,,37[SQQR.?O/++,]^\\\]#'[WTTU-?O?778Y^]]MMSW[WW
MWX,?OOCCDU^^^>>CG[[ZZ[/?OOOOPQ^__//37[_]]^.?O_[[\]^___\#,( "
M'" !"VC  R(P@0I<( ,;Z, '0C""$IS_( 4K:,$+8C"#&N1:M7(TI V"$$C5
MJA2\0FC"%XV0'HCZX E;>")M@4,=]&B'.%QH0Q.Y2QSL\(>08L3"&P*Q1.$
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*#XK,W;U:0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex10-15_img01.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-15_img01.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M$$,;?)J82(Q!#6^P@R.J< N!$&,.2'#"&N[1V$4H(0QIL(,;G* +7)PA#6&
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M8'>( KSL( F!/"$& ^D$K GF" .T ]<.\(1 QIV-+YXA /S_8.8_2C!K:+R
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M<@$/9AS"!/;HA]X_X0LDX.#4[5 &"( (ON +@C 'YX (%A '!>@*5  /HZ
M1M 6?7$./N  K? .W( !2^ +M+ +7- -O1  -<!=X> ,1( )LG 'M' &"6 )
MLX %)5<P2;!SB&$,<) !%!4._= &+2 *HC #&A +J) $+Q &M(08^; (&: $
MF[ #?V .W> #$^ ).=8P6N (S"0,0^  ?" 0^& (!Q )^7 DD& #D; )6_ $
M320,)D "8= &>C #,X@4<T84\% /_R /!A ).1169_ #;Z$)$F Y[Y #C/ /
MWL  EB 0LO]P1 .A!5, -0*1".Y@!4&04**0 -?P#T7@ D)0)9G ;L\@$'\
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M )=PE40@#"DP!P.1"1;@ [Q $%7P ]P0#*&@? V3!5+0%T>P 7ZC!QWE&7O
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M>O@/CO .?* "_U -9@ .(D!11  $7[L$4O /O[!LT[  8S .FD"!!$,++=
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M"<RD"E)@!^MD"@7 !W,@ I^ *I)0 &(P"75@ FI[ %$P"8! !99C#&@P#1@
M9:. !Z. N)N% T=PSCF@C?\ !]+@"15@D67PPX=;BM;L#)^I!9<K$/Y ?B+_
MH +@X W+]@]+0 9?1 <TL&V?JP)@@ Q58 ",8[JHZQGP, 3H4 5,,!#RX 3[
M, 4[P%U<,,%]D6L6V2G8T '#Y@8\P NG4 5PF10K.D1 <;PP^D5RH -4(@YA
M( '( P23Y@YZ@0PVT '%\$5$*LVQ40X:8*1],0\?H&E;P [>@ #>H ?7  T&
M\*KNZP[0D*V)X WFP .JR@D2P%P"T04UX+\Q30@>D AB,!D' P^8D !* "P.
M3*>KX "OZAD>:@Q:D(D^&ZB;@ <'@+1*4@TR0 O.\&O_4 XD\ DJUP2I- P,
M$ J]8 !V^0_!0  +^C&?"@OU< W-@ &E*A!10 61_Q &$[!.GL$,YFF4_] $
M!5E$_-98]" #B? (M" &64 *@O!%DF "@  &&_ % ^$%4  ,,C!L4%,"@+ -
M'<!OG0(.(8 'D= $#P"E_U /Q/0/?/  N- '2<:0@\S(\5:!F_ !&P"E!%/(
M?;$/9* !!P#A_Z +/P  U@8/+5#-Y"($8=4)&% +S4 -;Y!RIMP7]@ !J>P9
MJW "A* (G/D/M.  T\!,ZL %>H@+FSH'!N V#2<(&: !H:0+$R!M?=$.3-!$
MRZ<#O_ *&J 'S 0&QFT) ( )D#!IT\RS('S-=+H($S"4W;P OM(PXMP7J,
MF1,,EY !49L$4B ,P1 +E/\5S__0!TQ@"Y*P !8)#R?0DHCA#G#@ +O4"13
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MNO" 3LCC$AB@@BD,<8D8T$(8,I@#/B+BC0*@@B"5JH K<"J;7_1@$H8!QQ\
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MT09%G*- FN##&AY1B3X$@C?_D <IP($),LQ!$W^8A# R72 U^*$/I8C0)L#
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M8(<D8 '[0B]O\ !\I0=,2 #_/@6"*("-7E"%.' R"G"$?ZB%I[""'>"-07@
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M#L"!7DR#"0@76%"!V.B67YB!%1,!'6B0/ " -9"(9Y"  [".?T@!@HD(1;B
M4:AID?"7K?V,OQZ.0'  ?HD(6A 5V]N"0%D$#<@Y)BT?#MB%B" ' P";0Q@!
M9PD%!+BLB!#C?Z"&#^#4=Y" *S*\7N  J;.(,[B2"9@UD6"$&]"U?X #&  '
M8S@ #?L'_S/@A7\HA@3H[8CH;6  [HC !R<H@&W6/'TP $R C6F8@)72!@G0
M@&_^!R#PTMY8!@PPDHAXA0E@T4+ @$-KNSF(!JGV! W J5OPAFN @'F."%G8
M@&[X!VD@@>S"@Q$(I-\.[D+^AV1(@(P !@<XCM-+C0V( 06CC6/H@G1@!Q&
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M#  (D/\"*V3!"(R'.-0 %QC94\C#&C1 (JQ@)&2!/#S"!50A*>A"%\B#/.3
M!CR"*U3"&81%/T4$&>@ J]@""5A4.*2#&@! ))S#.;S" I@!.<##$G" ,H1#
M-IP "; "+N@"%+@".>@!  S".^##('B %O!#/Z7#%8R (I!"'PQ!,KB#(@!
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M#1Q<4PR# 1"8.= #**Q #]P9.28!(Y#"$US#+@@ )US#(50.POUY$5Q#*@1
M&_S#.% #!K#!-5P#+]A ,R # U"!(>0!#!##/"0" ,Q!JY8%+5! BC0%-N2
M'B3#,G@" ?@"/RR!#%!#+EP"%<C".""!'5S#(A# YT"$/<0! (3!-2B" @S_
M 5"\ RL$@"B<0TY0 PA@0"MT PMTPA]$0!L8@A"P0A/N@2$T0?^H131@P0:@
MDBD4 21XPQ)L@"HTA#V@@1%, @R8PAQP0")T@A"D@C'\P T,0SR4@0#402>8
M  L@KSU4@@+T@2&8 B,H 2P8@2&T003\02?D "QT0@*H7T.T0@-P@CLTQ1AH
M@2E000<L@B<$03P(0@04P3V$0RA\  PT S@8%!JX643L@PQH B4\@!6P@A5H
M3E-8PPZH@2%P0@P003LT0@*@JA9\@12TPQQD@!&PP0L<P=HH PVP 15,P"%8
MP@[$M7#G@-R9PRJ$ 'QT0@J80*>%PS. P0&D4$0\_P,7+, =R ,>*  6E \S
MO  6$.8_1$,.T"?BAP %4$(;9$ ?F(,XN (+?  ;(($.X$)N+(&W_0,F2, /
M')P_I$$'; (?L, =A( !5,$5@ "=>0,2*  ?Y$,PY$ C4,(!*%([),$8Z((9
MA  XU((,;  A^,\W,$$.1(,D0, .W,$=5($(),,D9, --$$5U( 4.%IL1$,*
M8( 31($7($$^QP) 0%B@Y]Z_8#T&2/L7[M\S%@VTD L7+A,!0+M2F+"SK,:3
M)A2^. *B:R'#,) 6_@/69(6CD@SU\(@D3Y".+8X<K?F2S4\)+W_4V+BC[1^O
M*RUFE?Q';HJ-2::,A'CBR/_(%6M*_V7-NNA'B#GPM'(-8889UD4@W("1 P==
MRD(NN&"I026'FJSQPCB1TJ54UHG_XNDYY*C/(4U]L$&JLR?4N$]KZ#QRIH;.
M'$&"YF#2NIES9\^?08<6/1K8.*RC4:=6O9KA.1J!LH)XDY4:'J7Q9D!(EI(8
MAU3_V'%@E+5:@E__['$ ]/+?' "/_IG+NLJ#%WI9\X"R1NQ?L0FDHC>;R%#<
M#CI9K]C(>HX''ZW)]H7C(>;?.1E+_GU+4.USF@JP&1HG"",VPX25?Q#!0JM\
MX-M F:S$*(2Y;@+@)BLH '!OH3'P86Z-%_[)1I;N$H %,%Y682"?A<R0QT,0
MLUK_A[]I$#" J'^\>0,8"^4909]_A(GFGSM2R&J;$D-,8+A_N"$ &:V$X<9"
M6!(HYI]I7OFG%@9VR6H2NU(RIY!U_A%CA*Q$*8>="431J@@"HT,. @G*^H>8
MI.C1P!/ 0%'*GQXTHRV)AA)(*BM:SOGGAUC^J8<&.?Y!AJ1O" CFGU6<24D,
M#UI1J@\1LM*& 1BL_(>?+?QBB!P#!,DJBT&S8@,8I=:HH-._/LV*#PR@R2J-
M'_YY)P8>5OP+&0\B4<J8#$:X,1TNFGOFGS].D(Z1Z_Y:982VA,#O'US*^(<0
M#JXCYXMV_@$B"+_^Z22,K,#H0JM6+-1AB*S2.42!$<?[_X>5#/SY9QTKO"!S
M& HXR:J>&E1A#IL.H&/H'BW([$6!>HAAXQ]T/M#DGVH,22F?'N!D"!L*1.B0
MH68"N*'7?V: 0BM&^%/!VV*FZ(&=?WZYP EU_F(% $C_280 "Z$90P$ /6OB
M!W68 V,";%X*)Y(;GC2'DAC 28F.6N:YXH=YDBGB''9PJ(,?>TKY !&ED"%"
M&UD ,$6?.$:!Y@,A[/EG'RQ&R(8>8SH 1)]ZNGFBSM48;]SQK$H[[?')*>_L
MKS%\@/H(#98INA.EPKC$B$-2JN:!3JU18)2LI$G FW].\>#MOZ[1@@\2T)6.
M%$E<8"*=?]YP1:MA,D!%JW[?$?_!CG_<X0$.?$?0D)=:_H$G^H5P>.*?5AY0
MJ+-OT A#AW>R&J:#6R6>-1 08LP%L!Y N J:J_I%!H85_PG##07:1*>.?9A3
MAQV\@R$?XX"A>$8 *+@(%&#IEP"U8HNL[&()2+ ! $%1!*TP8P3-V$P3?, 0
MT_6I2:O[1^N>] ]G_"@KL^  ?]A%!PCT0Q]2 .!X"O@/,HP ++1ADU:L((6L
M2 <3>&!!JW)X#P,,(E5_ <,*$E5 5IP#'R]815;8<0^&Q* 760D"$\(Q#M/
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MF4</S,D0Z;SC"\_ @AY2XH\HB*$%UV$&''2A ZB%HP99:$8S-'$K'U!5*T#
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M#0M)P@XX,0DKN&$A(:!JG-N% :CF+PRA ]1@$I"@ U8' '%A XQ [>YJ(:Z
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M S81"8.@S/)H$*: 788D!M@HCZB0[0QB CY!*:XA "+QFKKPOVH "J8A.I%
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MJ1]. +(.\Q\.802@+ADRX*/^X4VR(AKN\DXYX%:0PP F011E(0(812L^81R
M80+H%!VNP@>,1Q<6P'L8PA8>H)W^81S2@!].R1\^ /Z*<@?:PAF<0"O0  #
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M';A!!5Y!'!CB%F:@MO@V!B9@%H"&''0! !H!'1BB&SA $OB!%%1@HR:B'[9
M U;!%WPA$-( 'N@ "?J!(>Q!!S;AG)QU$+#.'$X!!DZ@&^A!#01@$LCD""
M%=CA$@3 $4X7%[C@0=*!$P! %R1B/,ZA$ 3@#.CA,/_#@1E2H .<82+HP14L
MX!#0R1ADX 7D(1Y"X+FR(A@4  04[1Q^00'>(!\.TQ$( !/T 1D<P1#  10N
MP!'X(1Z@80APX1XRX!"D0PLHH!4^>!U& 0"D#APV8?[TLP9<Z50@0-%: 03(
M9V.Z0 >(K%\^3V;^P1%<()GH01"8 $?5H09&H!A.Y0-0<1H20 O\H1R"X 2N
M0Q(4@%%$V$3_(180X#><H3<1L@I8H&L$Q@H*0*IP*!VJ@*9BH C8(1TT@4
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M%5PA%)YZ#@ZA'_H!$CZA#OA @OKE%[0@#?8@'B!A".) T;*"%?KAOPJA"L;
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MZ3"R8I[=5K[E*\ER+.?R7CZ'8#[G+9+E>7XT"NCF<?YXB)X.'^?F>W[=CG[
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MN18@3&$A5!!!CP;1B[4X8A(L@(19JO$ _A&#  #\QR]6T*-J$" 6:^%&%\Z
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M"B83>WB#"X40"L,6#K9P"W]@!W( !W"@>=SP!'=P"&@0!6R +,3P!$.@!$Z
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M5'S"*_R^_!L.2<N], RY3#$C]D +N4 0MN +JX +P! ,N0"(H7#_"JU "[8
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MA8 /]_ &*I &@H &.# #32 ((  #AY IHQ $8"X'T> $.2 (0L "*$#_!EE
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MB!R"8?7H&2'^D8H":$ ;CT  "N9!D'740 '&^\<?($ "!FQB5%O@!YPB@HL
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MTTLR:( !B G%%0$@01HF,0D@4(">X; G/O^A"AE@(  C\*"*A"((QZT#$(D
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M60B #;@")("+TI,F,'"!(<C$6TN #P@"I(D(!/N -7@"'<#$/^@ %J@!"LB
M/K"/?C !#2@^FD,^$2,(:I""'N2 @0NK#8"!->@ #AQ!H)BQ'L""(B@"(3@!
M"=BQ1R@ $>@"".B1.;.!#P@!-B"!#2"$VU-+(Q "'GBF?R"%#2B  !$*I1D!
MW &##O@!,UB 2<O$ SP $I"#BOL""'A @LB#8:B& ) !K1 *:B"! ?"%?+@"
MD$"_ ^ "')B"U=NS [B!*,"#"=@!DFE!%K@!$)"!)=@**]  $RB"!S /H-B"
M>M"'$=@ &P"%GUQ"Z>R7(A0'))Q.[+1,NO^:QRB\QQ$X&3*8)Z^AM7OB#1R,
MABG@@+Q2*Z$PAR@P@ 2(A'_81@:@ Y- A"FHA# P @G0@(2[J %XA7J0@ +X
MH8@ *1\P!S@8 !PH#(6XA1XX@BWX 0D0 7C$A$.J!QW8  .H+TO4*<OTGRVP
M@2.8 ADH /5B+<CY!S'H@/<CN!6@)#?H@/_CEZP* %K,JJUBJJ^*O@G(@G_0
M!0^"AW/XLEG0&7V8@PT8@ ^KJV=*@GX8AV?PA0#H -,!27 P@@V(@;D"'"&P
M&%&HTE'P!F-BKG&4K.*JK'+\AW3DS0PHA'\H@M4*AFWPA7\XAT[P@0=8SR]3
MK7] A7<P!U$0 O#_BP=18")G>(,DLM.U4P<N"+!_N(09L(,JR#_Y=,@7_8<H
M(  8V(=PZ#N34 5^>(<<F !,^(<W\ E/C3&9F0"L' <[*,D5"  TV(IXF $,
M((.MX(,.>"=4E06"F ,&,  32#N%TZ\;F(=J4)]VX(>(H(<VF ,8>C.C3+!H
M& <M&)(3BC B:(<IZ  N8$%U^((!$ +_B3&MM A2R =P0 4LZ( 9^! YX"=X
MZ 2(,0=T2,*&88!6N;4<D\L>0P5=%0=S&#(-H )5@  -(!R"4+*?^0)X4H=Z
M4,1.*"XRP( 9J"$P0( \,(<WD!OP.4!2(JY_@ 0R2[M]P )?H 1CFCNA_]B"
M@BJ$6/B)(<L ,;"&*3@9?2W!)[($#8  ,=RL#F $6J@H@@"$ EB!:5 "TTE.
MK2 %"8  'T"C[*S:S0@'Z]17JQTUO0@%L&L5H9@%#. !>/J'\#0+@LB;O+H&
MUH0S#S!0]ER1"7"!?+A3'Z" 4(P(=.@"%B2;'>@ ^P21%A@ TP$$7?NX?XB$
M/B(;$QB (G@(</@";F '=B"&Q'JL0%BJB( %"#  7'([^H&*D(T(6GB#>/"'
M>& W%?@0<H #$5P'((B CTG(NBG;+KB />@7;OB  "@1H=C=#;BI?]B$ 7@!
MG1P##@C.?#@I/:@AZ.J$7=JC!6 04J#1PFB94O\ A,!)@#$X#F. BCV8@!)H
M36>0 EBB!0HH &Z!@@Z0 3TB7N,MKB+8@/@M&.>IJ'R8GL]XA7[0ARC(!L @
MB&0H )>%+O&IF'\H ^.X4R\P@'YH Y#]AS98@ LK@P= 6QH! L@]@DDPA5Y@
M@PY0@;J=C0GHWG_0 PHX %]RKA(!BB:X!G4HU8%K!7^@!T9DU7^H PZ038*@
MAR X(9[!@(JEH#-8@!FA*BY(@#> "CSXL(U:@@)0 6I*IX/3H71H%4>XO'!X
M@HJ]@@"@@89$L  PCE (!V$PG$/@@ E#' <BB$[( !E@CJV8JVM(OM40PPJA
M@ANXB7D= 7_0!O/PA!W_.XYX6"?H:P4\&B8>RP%UT =N^81M" <;* "$=(0.
M"( +:Y@!D*%>\ =U.(1UN(('<$:@*((%X"8_4("\,@89"EDP,X"!.+23+1DA
M@ ,TL$M%>BA1T  #< +[B @Z6ZI438>S)$%2BF4CX("?W*QE&@JRV:(P2%IZ
M^(7+.P6&V0*M^ =4Z@"RVMKLK,[K]&8ES(MX:(0%B  R: >6B <PB( )Z 5U
MV <E2)+"< <?0  Y*P<,. -H& =,Z  /C=OXF $!*IP<&)ATT (-(#UXL((%
M4(!+>(='>  /$(1S6(>.89EQ0(,'D &9((0'<  W> ==D $$N=,:&  2Z 9X
M_S"#.D!"HO& J$F(?'"""G@!=7;E>WB!5OX:"G@ ,EB'?3B!2C23%)BR0""
M#[@&<F@$9AGA?8D&#)@ /# )J9X Y(P$![B!DQD" M !:K(',T@!D( N4E
M5(@(/XB!#[F$!QB GS$'7F@!U1@&'*@ 0?"'<G@&33 #TN6  ="%?2B&&-@[
M5.  7?H'9FB!"4"!PQJ$K2X,_^$"!N#JGP@'+E  ;Y(('G" 7=J&+5"$<^B
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M@;YE!RF )QMX  HY!VHT >9P!Q'(@%Y[*?N<A0R  ";Z!U!P'%_ZASW@ !!
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M96""#]  *2 %== +?8""&6B$1OB!+) )> "##7"!@1 E'?^8NJT8AU#0 0J
M "!H@BW@)&V @@<@@E TA9^=)T.H Y+3@29H A/@@&SH!3,,@"C@AGF( 0Z
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M,,\?E]!%/^1!#WB$PA"CF$4JF$&,6L!C&I=HQCY*Q)MU\,,>R]A'/)9A#WO
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ML(,Y7(,10$(XM,(-&( !-)HG!D$Z3(<XQ (!)  MR ,@$, *#$,X],,3($
M>$,Z>(,+0.(_S(,1)"0]T ,OJ, "),,Y&$)8 ,([P$,*-,$[^ ,:B, _, (6
M: ,K$, #^ (WF, CN ,;.$ "[,(\[!H7@ ,QD  !I, ]Z$(&9 #/D8,8(  !
MT($MI"-IE$,(+( 0V (C8  1).=PV$,4>,8G<$0PY( =U,,H], #?(!4Z,,?
MD$ TW(,>., $2((E\$  $,)E6<,0*$  F (LA $"T,'_/]'  B !+ C"#?
M8Z)8&_[&&JXIFP;2/Y0#=Y; ?_V#,U!  7A=<6 #,RI! A3!5@"! R1%.N3
M!C !;)CE/G1$%TR %G3$+@3 #>A8-O3  .3C/W1!!QB!.DB#(ZQ#/H8#$S#
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MP )TH@,*;  T_@,>/, 11!@K%, &^,(_H ,SH !'I&P:=,0C1  2[-EPR,(
MM(!R_4,4?&<2=  $N$!R L/>(@,%0(!4, ,-3 #YIO *N-<_A$+[_L,5/( (
M_\,:+, 1D!B<-H^;.O'K7,<AR&L'%$9'',($V  Y) XZ"-7_"G0 ,Q;'$##
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M/&B#"70 $"B#%2"/-G/S*@U'-4@ !/!!(Q@ "M"<DZ/SC;M" ?! +["""YS
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M(S,LX(-,,IN *26<A%ZA8(!)XKN)EQO:.**##Z;XZ9]5\OJGD  TV*&K?[2
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M"=;UCV<$0 ^JJL,"CB .DC!! <'[QQ"\01(S)( (\/$$ U10TW]H(I@)P44
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MH[3_*X!',MP("NIJR8U*&, .XGE&-9Y8C66L%(I9C,9P($,"9'"'0THQ@06
M8(/:( (!P) ,8! B"&<21Q,6X(A[U&,)'!A%491Q@QM+(A%20,8_VM&)!Q @
M!-UX!AX<D !"V&,8$(B ":0A#!40H "K*(8HI/ ">DQC!1XP0C=,T0,40*LS
M[>@%!1[ B5CJA1(7< ,Z\)&&""Q9'-@(@@=& "U79* !36C'389Q@ 9DH1_T
MD(,2]N&96%!@&WH9QQ%D@#_/7*,'!#B$-NY!"QF$HAT(J(/L.+&!9G@%%!AX
M@"#,\1!TP"$.XY#*$CAB" 9P(!<<:00!.H":=(QB!-EH_X<+4E$4?^P >479
MQ ,2T B OK8#$X#$S<;!B E0(!;,H$4*0CV./SQ  Z?XQS%Z@( QK,,=.G@
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M !+@#*I!"1R  .Z $@9!!SY@'W:!!PA@!2+!#VX@#=CO)L2!#CC@!A@!$%S
M$D#+$AY@$/(!(L3A"7S@'_3!#12  #+!%T)@!22A)*AA"10@ SI!&$@!!&#@
M'$H! A2@!#0P$A @ N(@["C01!=%Q4SL1%?TC%04C,"K9\#H&7A  <[/\-9(
M1=<HC<20(RK_93U(BR/(@4=F9D 693W$H3)P]$=O-#[4 1\>8AS  1Q\M#+
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M_Z$-/""%Y($6;0$71" &'$4<O !"E8,6=F $_  ,\N #3" ;;L %P* %,L
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M P@0!B_!!Q@0 A?(*&6!"EO@#I*  22@'H'V#ZUP!?&T 2VQ;>CP [@@#R#
M ,?S#]NP'6O  #4@!<9 #CNP 0JV#"90 (X !H!P>NXC##0@ 1\  K9!1AU
M49 3  7P4&TD :QP!>H176MP?F3A2 7@!RXV!AQP-A:A?,AW8QO0!*9@"I5
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M+/_ #0'@ ##@#.%@#U"  $Z0"MM "$+0PX93##H0 3 @#8]3L,TY!QRP!LU
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M]##>3_")5M  6M ,V^ )8:#7[( "%2 (GU,'!  NXL -!4  @.!WB\$'"&
MK+H8:>  )* -YH .5+  1N ?WI "C) .#Z $<M(/*U '\A8/+ !=%X$)!- !
MURH&$< #W*.B/C"'./@!"R"FKX5'#3 ]+   0( .V_8+ 6 #]/*F%F FRT "
MJ#* 920$MB%#_Z ';58E^H $,)H&%$46ZF #)_ 6Y3 "#?8/Q4 #)]"YDO
M)J!>_Y *:?(/)3 !<8H,M)28+H8.22#*_Q $";!$,LR/YND$''#>9.$,Z$&M
M>[C-6I7-M,[-9#$+B3 ,PX ,(H,._YB "<00#,KP#)10";\0#,;0#97 T(F@
M!G\@!A"20-/@#M9P"(?PDZ70"L30"GP [96 ?XVD"60 "$R]0L/0"&HP!P%T
M$;&@"9, ")6 #?\0#8W "(H0"9$P"8S ""L5#7^P[XE@"F01#8X0[)KP"JL@
M"). "940"6+@""UV#,>P"8G ";H0YV51#6HP"(8P$K/0")/P")O@'__ "VR
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M;#;_:40%T@ 7<-2@OG0H@!NXAG_H TSX!SMX "KHB#*PA"#[GT;P@*K[!TJ
M/T68@!P D$5XA'_ AR;P #-8#W18 EVX/0P8 73YAS/@!8+8@ODC""A8@"4@
MB& P@ [0A'_0A%CXAVK0  W@AG^0AA3X!V'HP6 @B$_( !9@N7_0A4/X!TP
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M S" @;"'QO@&ZQR(?X $!E!"9MB$?0!.-2" *Z@Z?6C  G(%X>S-@?F& 3
M)Q@A.>#_@"P0D$[ @#"T*B<0!V"@@!/H!<UHA-2$0^C8055X/18PC'?:A'_
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M#G2!2>B%$C  '(CA!0U31_,!!0 "?F3HH*"&<""&O02%?U["NDF',2H%)SB
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M$]MY0C\=;S9?@N ##O@ DK#//=6%ZL,'^?V.<>@%FNP%$%AF?I #!I@"*9K
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M ;C,] \B"2!@1L((M9+ U/_@@X,>A163@!3#G-/(!,+(HP$ B/A7+3BE;("
M'^H<!,XF!$P0"SKHO*' #=N$ X\-"&#A3C\,\(1MH(,:&_C$^3CTCWT$0! *
M:<(/UF&0=[!A)PF1QP@XH(-KP.,.!"A *OX1#0U$H GG2,8-'L"$'(TA 1/@
M!3V^_R &A2B# @08@SNR 8-AC ,AY<!!$E:BCE1@  &2<!]+(+(.-NC!07W(
MBCA.D;);C ,?-F"$0G+A  0\(BY<0X4#&%"F7T5$'%@H$4+T 0$D)*0;*9@
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M(^7#S$8VN"F]$&0FQ(OD-@BY TEN<(##0=W^=KC%?3:9A&-Y]PJD1\[M/H6
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MH,,S9(,Z+.DY-)P[_RR/.M!#O37'.)S#&X;#.0Q3+")C,1ZCH@;C/VB#"$P
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M !/<0SC( Q4\P >( C6 @@&\ CAT0@=$ !E,PQ<X0!#PY=C]PROL0 =X0C
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M/T0! 5P*<!@ .]+$"!! -*8!!_ ).*S#+9#! K5 5UQ2%B  &R2,ZRW#"#S
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MJ/R#G,O*-(S!.RR%*6  #:3#-KS!.H@Y9$_ =__#&#R %R2$- C'-_R#/_
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M:0.%:E*CCDPX[$: 7?B2"+@SCMN'#; 0AM/[#Y:& (*L65$WTE6'$<DV[LD
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M""- :D#7,]0'09@60*4MA"4TX4I P1-E2,4<1GC '*02#DE1JF8%P,L_9#&
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MZ(4M=$!!M/VC&"&000"*\H]WH& #1A!-LQ)RE [H0A5W.,A&BC.#9L!#6?\
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MLO:RCBU 00Q1D$$!XO_PUHT\H@ 4F%&%TH>C?[1A3L@(QV\+\ L*MV,CTSC
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M#F 13B$/#* /SH8;J, !'* .KN$<@B ",* 7+BIRZL$1'B !B&"Q]&(9PH
MRNT4>J$-&@ 1EJ$.'  !A. 43&$)!& 6ID$'$@ #4,$28, '=(O]-$ 7D $4
M9L#_ >1 Q;X  1[ $[YA%'8@!MP!%'3  T+@%.8@ *:@ S<! #A X"H$&MR
M Q!@#*3!&]R@ )2!&I* !K!&';S  18 #P:G$&@@ _X &79A#+(@'NKA,1&
M#4[A&\Z@ KK!'[)  3K $,AD-\S!&K!  0[@%.J31NIA#K23#_IA6=!A"Q2@
M!Q"!%+8 \<9!%3Z  %R@N";! 11 $^9!!H! %?;A$&X 7OX!$P@ L(Z!$_*
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M%." "JQ $2CH'?)@"_+ 4_2A#*"@"KH@#,[@"M: R/Z!%MX$'3CA"ZI@".#
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M'C!X=5)/'V"02S%W"/ $//\DDT<# <S22@T1Y$$U2N!4(04UH##Q IED(*#
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M!PTPT(>=_:,<, C $NKR#VV(RAQ>F,"'_K&&9/P#"1P 0T72@( @\ 0=)2!
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M/!3C_\()_.$?X A" "B@A6" (QY5B?"$S;%4:1A  \&(X@TX<,;/(((',O@
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MX$(4X<<,,D ?E!1B&=BHR!8F\#N+H*-JB9@ #CA,$51T@ =W@P0#5""C9]"
M 8&L&B$>,()%[!$52\UU # GM!_28@ G( ;PM*$&N>Z  ?8"T08,@ O&1J6%
M.C" !(A'D3R'(!WZY, 4_H$,(1*Q"@]PPC]:L8$/5"-HKNC "+1(#0A@0!7
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MP/-K%'"%6C !@O6?&;!8N9 -XJ (58,/-F [_U +-- #VGFPW$$*F2<(0#@
M-="N5>$$N,D3[4 %7+5N'90"'8 $GJ2:ZWMO:%L5:AMPYF $'+!#FZ!FG?]
M"X951->2:H]F!U&0"9. !AI  QVW#"?PE&(JIEG H9IH0@YP)E71"0S  W'D
M<C,PO@$0 "ST:)&0B<Q@!0[ P1\0 *]0%9AP(:;  "30#/"L= .P"=&5=B]V
M'''@ TOP"#Y  4@PB=X8MY^A#$)D;9\1O$@*#!-6O(G  2>@& ]$$7N0!7\
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M6 H'# BA6_=(PXA$I.0(.=6T'B(#"7Z4 G?PX--_S9(0P&3K#04^!ZTE05#
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M D4P #4@ABKH@ [X@E)@A1W8  K(@V+XAWFX @2@ TTP !O@!28KA!>PTC;
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M!2U8 0UPSP;_!^\=@ Y8 1(A+4H9 PK@ 8V BG[X 0KX@G_@A@\X@$ZH!UV
M !IPD>0ZB"B8 %3> !) !3!0<53BQEFN9;?(Y0T(@VW8AEE 65\68A*(!3I0
MW]W:(F1>@6G@AAO@ '#-90KP!'V ! C @?[J@@"(@2>!BFZX@0!PV6$8@0
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M039>)0,,M,\M<D" G5#2A A<A ZZP,@\KA" ;2#+!N:H!V4( 0UT00LCH@B
M!)CA)=5, P(!Z%940&& '@#C&2=@P!M0DHHE!"(0G( ! WJ!$6=$[Q^*8( !
MR&>'AORC'U! P"!" H$;&.-)[\#(-Q(VC7]HXA^J(!]F7K(*"F"M,G_TF#/^
MX8<.D. >X-.-:=A "4H(XHN66$T8.. %D#QP-1^2 -+^$80'M$%G*\" )?L
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M)(('D %&9 (%N, J^((K;,&1$% \)($'B( QB(,YH,,PA/\  N  ,WA#+[Q
M$[@#)Q"  LR!-M@! 91!FI6'.6P!$:#$-'! Y10$/N!!!!C -)A#.(@#+C!
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MP!J(7#ED@5A7P27Y@ &, C?K!#-\ 4E-02G($A9( "&0P0%HP WTDC^P 08
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MF!LQYD"84( C=&,5.Y" 3_]1, WT@B:ML"9-M"D!;C*! EQ01 OT.I! 8.
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M^$(-;SB!E9$/ S=XH0TG$\U%-M!#+]%2 TQP P_4? HV9V\F<,X7XY"Y@2-
M80(;H$40JRD!:MQ%T![F+@KMT#9 "/#@ ZR!)F)A!@*  GI O+:E.\:@&M3!
M! : 4<(!%#J@ ,QJI$B*I$XN1<+!""9 M@0"&'[/ITC"!*X@,:J@K6R-XC#
M!<S   :@X#3"CS9@",:@ )+B'VJA  H@J^A!&8HA&YRA.IQ-(R0A! *@ &"
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M-\JP)M 0&60(B 1B'6K ;1(J#O^A'G" ^3Q0E02. ?" DD)! PY@3-(@ &9
M%70  _#E#FDB$AC@!.+G2X*  4B,$FN"%"Z1#_1 &>*@ #Z@*D4P.H#A',@!
MLT*1LU"@'/1 9U#1!N E"QA@"3(B.D#P'^Y@%-Z!"SJ@!-SA+FY1((SN'^0@
M Y  1F!$&B"@ _)F&A[G']Z@ 'A !_YO&JDQ[*+QZX342#5"'&K@ 2:H&F0
M [1 (.SA!1@@2];A'V+A@ !! /)@(VK!XDY"&81QA(0!"U"H431@K 3"&@Q
M _!1(#0AB<B$,G2 7O\2!M".9@P&( 223".L)T,%@AH A8;&P0HN(.9(IP<.
M8,;.(0F S!ZFX '^!_8THAQH@ $*82/(@)[^H1((82/6@P>J:!U2@ /(LFY
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M;^LN=LLN-B$!<*"]8$@#(.#_@N$*- (=CF  #H -_X_T2(DT2)4WNII!!A!
M"IC&#Q0@ C*!'TZ! B*@#_CA&3Z! &;!*M$  13!'MI!$QI@9=QA$P@  9H@
M'[)A 8J@&_A!%R"@7\.!?0E@ >P@O\)A'YK  TZ &C2P SR "\KA%FZ@&XY&
M'.I@ 12@#]8A'&2J!2H #B@X',9A%3A  21!((0A!A@ 8NBA"2[@4 ;%0OF"
M!/!SXL8!#SP@!X;!'2R!O31"#BI6JXH@ XB#EPA@#=SA& Q@!D;G'X:A!S)
M#=)A')SA!P9GM$; +F0! SC@P7)5(\:  &*@;C5B"!+@WO[!&@*  6(!8!Z@
M!_YO=XP@)J:2&B+ #J,$ ?\FY2TE1R/L80\J5AMRH '"0//(X1*2P"MBP0$@
M(!;>P1[&8 \$PAU"@ .&X#)X& :,JQ3>(D<ZH@PR@ (4$),S8 /ZU283 )*!
MP@TL!0<D=1UD( >'4B#*X6@W(@@R 'V"<*%852D^8=GZE -6N40(PASFX (J
MUBI=8 !."FDLSBXP(2.O#NL@(0%V8"^J( ,.@)MX]KDT @Q6JA] 8 %,\A]0
MH %R\ HR "W3X0-\5ATD0 THB @R8"1G2P(PX"%1H0,PP%318&0T@A$:\4%F
M@@DVT0SU9P F!H >  5BAA $( >O85IAI!$  #U)1!YL( %\X65)M4]&M !6
M8#[_X@ #2,!>L2X.+, ,-N(6)F '1J;%$. V_V$)Y/4?/,%,- (0J$4CD. !
M'NQ#T/(<0F "!D$C%($#8B"5W*$CX+0&8*0>2& ":G$C+.$D.(%K_T$=3E0(
MCD8@Y&%4-*<C;J<%8N(>8H  +%HC_* "JB"$.<R36."3H<MYQ8YYW]H9\X$/
MQB .X. 0W*$=[& ,VL 1U@ /],"O_4 +[@ (;0<*A$ +]( .N$$<>&$,\D /
MSJ 0MJ$1)($.Q" /IJ$F(#L/\J -2F$@*.$,VB -RF!=%@$-WN 0\@ -_(!>
MH*$,\" /J@!B?J$.:#L.:$$@1"$$S" -[" :8 0>#N$+__B #8:@?R"$"%Z@
M"##L'W#A*4N63-S@!U  "8# 2_ A$7  !XCN'_!!":Z!&(;@!UR@!IB@"AA!
MT_YA%:8 !W0@!ZB "GY@![:!$%3 !7Y@"\ E#EI@!]IUU-0A$E+@!U@@#Y*"
M&>8@!GX@! Y!%I2 !69 "%8A%J: !7!@"P1!"T9@6J?2J]  #RKA"("Z&<9@
M!D) !=9 #)!@ W)!(_1A#TX@!-8 "#0A]?YA'=2@UUP "?A (+(!"DQ !T+
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M/Y;Q@00 ^!(F" I."$$ :_0)'%C 2!X6@(1_^(,*VV-!!HR0$6;$(#]/ 04
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MBADAAA*0!GH  D&1$9T0  =0 $E@D[/!A4,@+0WR!H6P 1)@#*55"J3G:G+
M!11 9W* A?B0!@.P 1#P!MTQ-*9XEWB9E[N'BL7%>TR)$_U 6O\0BZRD!0/
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M$6 #SK8$#' #QC /\_"SFD<'#[ "V\,/:@ ";UIF A &T $+')!S;+$-!_
M?O<47< (&H$,&I  %C<;74  A(R4\/ "#-!D9M$$=%!:B4 !A_&#*T!%N= !
M&8"+I\ #4PL+!J  :V9]:N 'T\,)"D "W@ /]] %HY 1AC  $Z"EH+ !"5!I
M@D9H,#(V54  ,>!/__ .*H  %I=G'$"V2<H$DL ,!+ )&:$,#' <90$%#E #
M5/0/H[ "_4 /*4!$[YL (^!LL\$&#V#_:/_@#!)@!WU""APP7?] "AZ0#,N
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M00<7&$1&?C& !X B(U$ 0!5T,Y^9!,, #DC%[)P0@AU@@!7_H$49$F0)!+0
M&QHA!S[6$(J@L-"8QU36"6^#3&8V4SV@:8G2RC'#163$5MWH0 5N&8Y7 )&
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M<,@#!!B#,/]J,7E[  3PHV4@@C2;B6)8 208BG+8 @_H V=8AWWXA#9@AED
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M)15[2(=\< ?AF,I)%=?PB-1Q-=>WD(R?*(J%>+UV?;UUG8C7> UX;=15:5>
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M>( G@D&-(A A+DRA! _, QAXT;"&-KPA#G.HPQTZYB[SZ$$=&D*%"<3A'_J
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M30,$=(!"?9]!( (#G(#_TB@$/B#! ^R!LG#!X3R#"A@ !VP9)AR"01C" !R
M!C03B<7 /T1"&3#2.CP!!DC!2\AB/!U##Q0 ^5W$NSW4'&1 "8S*B:U?PGS"
M@Y7"#4  !&3#HER$( Q " "!., #"DB "*3714!< ?[$ 1:)Q64 )1B$-6A
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M\%<"[-<_'((Q_D0:+ !OA@'_!_Q 2JS".*I#$PC %\2#07 #$R3,10C#!V2
M-#%%(8"G/[1$(G@ 2PT0%2  *1A$*:R!5/C! (CG8;R! @0#:"0 NAG$*F3
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M@BYX@B\8;3EX0B'<@B500H)LQ4^DPB1\@B34PT&X@B>8@BE,@L.]!3E\0B%
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M0 BPJBM$ 3M6028XP0@X5+FT0Q\4  A<P14$ 0K\ B:TP&XX AR\P!4\:CV
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M>G #7_VC",/BQ@T@@ ,N6$I\'6@"(4  #I&6!0X3^ )2VZ&"#$0BGQ_ 1!Y
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MC0 8H!IFL4)-Z*&',*ZC!@KPEXE&T %1)&41:KMR41 1MWP\PT9ZJ(<]0C
MB&/Z 2NX?%F*,($JE"44!=# ?B)1"6F<@A5O/,P_0I$&8I'"/ZWZ1R\P0 -X
M6(,"#)#,<386 >+16]_-=_[SH?]6<60" 0Y(!#G@X8H'8$(<8?!  &AAHA6L
ML"CD /^!"L01#G[\H %L((<YJG&"07CO%R2&7STDP((ZXWX"#D D;HN"'Z@@
M O1@'\!!'QQ!#K+%!A! !2 )# K#%,+!'T2  .NK&:0 *7J! ": %,A!$1!
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MIH LAN$)7*E5@?\T4FV5'=K%0LQA#@  %8_C"+C,>6'-4_\!'T  #TS!!AX
M.["W?_TW7Y.! 6AQ8#Z@',K"#I+I']:!C,H">+Q3L6A)'1A8GK)%R-QA"=S
M4GMA!PK $LQ""Q2M+,Z!20#M'%AWL8BA"T7F $SF?UWXA1]5<%"@OBZA D"-
M'+[ 1L$!%)8 "[K@&<"!$:1@$EJ@"L*@"@)A!I3!&*[ "Y*@%<#A$HP@$?A
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M/P45046'8PAACE<%T0)#,HC=B&...N[(8X\^_@ADD$(.B:-BC#$TB "EI&'
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MMA 'N'K8$FHAD6P(N&3,UA;/)A@:6!<QLW\?"((A.'K;L O'D K5\'/_T V
MT"$U00^)0!/*!@V L#V-D0ZX< K2( H*$0[?  J^  T_)PZ%4 P>V("KAVS2
MH H#Q1#R0 H$(X#5X!3$ICSX\ YPEA%6^ [85Q3L0"[_)X)A*(9C2(8[P@U
MP $^\ H(*&V$T '_K<8/$<$,OP* _\ *$G %S-8/E$ "'2 &_A 1O- #18 -
M1(</$ !<;P8/"7B![_ %$!  6* ,$X,$?_ %LR \FD ":"9MP0 #(B !;? /
M[/ #(H #,] "DL [GD "G@2&90B+L2B+LT@7P>  J0%MX9 /!.,Q>H W,;9Z
M$2$&>8AL1K #YL$0<W ,T': R< >_R '*?-LT_@/D, $R\ +&; _YY "5@0,
M,E --5$,&O ##X%Z>U $>S &W! .8A $H> +KZ #$E,,@G "92 \M*B/^\B/
ML:@8N-@R\% /QB8@UZ #2V C_]!D$=$/U%!F$4$&2X"!X> #4,!^$1$(_RDS
M#OSP#\R@,06Q#CHQ"!3P"D45#MV0#>R@#N$0#<YP@:D@9F<  __P"P, :^O0
M F%0$/#@!(W@ B;)$/4P Z]@%.,P"47U#]I0 @)2$"]0!_G8CU$IE5.9>XKQ
M"^KP!R$@",EU"_\@#%(@D8*0 4;P">DP!B]P-ZP@!6'  EU)4!()&Q2I!1@(
M"<T0#T@  H\  B(P#.W0!C!P#,2P B2  K3P#F] !UK0 ^UR E10@=M4$7+@
M5I,  U,6!93S#W70"\X  T 9$8R   20!(&5;03UE!'Q#CMPFDA(E:WIFJ_9
M:XH!"N(0"QJ0!OJ 0O00#WD  N2A D^$#I2P ?^P]@&BN"$0"9<,(9<8. G#
M  ^<( &\0 \Y@ ?XP LRD KB@ @#T SA  L'4!!>L(RDD!H/>( B,0Y8, K_
MX 1)8!1CL /_L NB* TP(""L!0W6$ D0T 'M<ECKX 4VA)JJ"96P:: 'BJ#B
MI"_E< **Y0TTH&26D )OY0*T\0_QP -2\0W=L A<4 /(.9$EL#^P 0DV! K=
M\P])0 0%,0.TD"<V^0_<4 !/, W)$$S.=IX5<0N0] ]+@$0%\08ED U3H#&@
MT)E49A3?$ "TP1#>8 0(,:!?\XH)2J55:J6AHR_:, +C80M'&@@U0![$HZ52
MX0U.( N-8 ,@&I=>P +_CE,40Y ROH #TL0%7!!-.. +_W ) Y"0J@ #"[ &
MS\=:Y_E)<N X1D4_0;$%<V (") ",? #-+ #TU"'_R &*)!LX*%%#)&:>U"@
M5PJJH2JJ[P)$6;$,/( -__ -.T /_U (4D >)C &!5$//+ ,[G  6Y(+F*H:
M3N!L_Q &#. W!<$/+J BL, ""$$%CBD.+, 8B\  !#,,V9 .C/  AN!_!_@/
MTE &$;$.V+ -'1 ,&7$#GU /AH"N;M "F< .;:$&GE01^" VL($... *GSJJ
M^:JO^WH8H]  .C,,%) *>;(!BD0&,.!!(- $I( -UA  V[ -"[ 'P: %/# -
M_^>@!$\J/,5  5V0#?/ #4*@" 4A"0?P#.$@!;"J#P:@".$P"Q-0"KRP"TA@
M'C.@,V3@,!!1$=(P I+P!VW@!<GS!5\S"D* #VDQ#2=0$*P@!S9:!M+0#[8
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M@Z- "J7 #;TP"K) "[C@=[+ #J5 "K2P"Y=0B 71#:;0"YWP"\ @N]QP"89
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MX E!@RG<(8<=%!@X:K 1-I!#FQA>66@J"I#YQQ(,2%@KH7:&L&(#$?S!:ZP
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M']O(PC_LP#,V!,,>*Q!F.O&E$%488 /38LXRF[F*5?P#'D<(  E"D(]U3"$
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M4<B%.!"!)2&"0?B',W@O9CB ^-R\(IB' )C-:.#)?* !(HP'"0!*7XBW8$"
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M .S,AQN8 T;0'Z-42FB-UJ34$F0H 038@%O(AW @!UW0@ 1P 6?P!SUX  [
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M0_" 2D '*1 !=PB&!T@!.*  'J@$8,"#"T"&=7B!#?BE?PB##D "SS+*:="
M:T &-HBHHM$' F@9<[B"%\ ;3 "!JU4 '\G3;/, 1?J'+(BW7E#_ %;8AW?X
M@$9 L @8!70X! YPAF+H@!=(!6Y @\8PB4Q5B'9@@14 A6=@@E"PA0NX@WMH
MA2KHAQ0X@%GP!R6HCB<P@H4@@PAHXG\X!@90 F+ !CCHAB+X 0*2@QS>!U'
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MD (#.D@""4QQ@TPH P*U6(8-$  %2GQ@#O\+P";8@8P2.(,11@AT0<YA"QX
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M$^B C(S#/KS(.B0! ]#!+P& %'E#WG@9 _! /3B# X@ /*"##@! -"1#![C
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M , !/X@"!HC!+[B '/P#-[2 *<B#3)3#$9R!-IA#(W!!,IQ" /1!;MQ#%V1
M"$!"$$S -$## Y1!.-0" \1#+WS " """*Q"'=A!-\#! -A#.8Q #5 "$:C4
M+U# *>B"! Q2$7Q#*@0 ,:!#%^@"-'S!+FH$+U3!#'@"+=B -,J )(2"#?@"
M)$# +UP#"'  $&#"#!Q!&_0!!*S!H9[DSJ)5-F2 G.K"!UR1#U3!1&0#'IA!
M"_0":W$ )0F"2KV"#"22/ZA  ?PJ?:C##^C1+4S A)&"#+0#I? B.KQ#/_A
M M1$&0" (OS#-MQ #]P#-2A #O3#-%B "[A#>/]>P#8T@P/ @&E\""FL  =8
M0D&, R_:9I$!QQ5X0!0L0@9T0">$ Z\8$X%(!&$Z0S%(P .T@2>80R0   T0
M635$@ 10I@+(0#[P P0H0##T PDPP#*<0L_] R<  "N8 R[T@2"80 3H43$P
M  S<0S$X@ HPTN,H[C_T006$P ?MAR\DP /(0B*4U<FH0PY<I4340!+\0Q[
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M $[@!C   RB  CH@ SJ@ R10 @.@ ""@!39 E3J  C2@ R   SI@!FZ@ PA
ME5:@ "9  V1@! ^@  B !U8  @:  EZ@!PC@!RB  7: !S"@ 'H !BKP TC@
M!8K0 "A !%I !$A !0(  TA  %+@"+[ ! @@!&(@!R1@!V9 !6Q@!QX'"UR
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M)!:A !SIB!B@!RA #O[!&CQ@ C: !RC@%OX!&Y:  5"!+1C!=DJ4<ZK!"#K
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MI5.Y]I7) V)8H!;^H19XH3>:H1%XI*$(%RJPP03H@.]\8P*:#E7/S[B8@ G
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MUN$4D&$>&*(3X@ 7&-@=%"$.?.$=QJ$88H$>4.$01J\A7J$-5H'_";HW.[B
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MN,"1""$&F"$3XL 45* +_(US+IP8TD'ZHZ  M*$;?L %C'L#*H$<EH"%T2
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MU" ]X*.+(>B8DD$NR>T SC^)P-#//X/(4,X_59SBH$KI\$ '9M@40,H_FHQ
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M4@Y.:.$$5/B'-6# ,U=,0!^+T$ ^U'4 3?"'"T=("B;.(ZUV_6,;$Z"%.)Z
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M"_^P=<Z0%+9  6= 1)>Q#/I0"SH0 !8909Y7E5:)7YLG(.( #OJ@#9(S7^Z
M CC0"['  S[ #9:@ 4!0#]+  @5P F% DIA!#V"@ 4OP!TN@!MM!#E2  X_P
M!F#P,#-@ L@@"C+P LX@"1O@!-D !Q 0"6H !*5Q!Q_0!6Z0 D? "TYP )3P
M#2#P 8/@9&5P?E3Y$O6P!AS@ J'P#IAA!7AT4FST#YA3"*[ !3UU(.[P"1B@
M :*P#@J6 1"P"N%0"   !'!  A\@"X-P 6P@#VY  )/0#T[P 'Y@!PP@!:&
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ME4KMTR#%13 (UJ4)U:9G8^*P#E"@+TT]%KS6UC;VMK;0 CGWGTFA/5FK$M4
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M;=]H7D%Q_1]UE _=@"OT%>!I3A:V@ JL8 T6'I*K3>)KON$@_N=S_B3T'>A
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M"H&H_UV_?EWM@)[$L%'_ _1EW[]]T_X5*Q"G]FF%FKR%*]4GW4!8!4#@NJ+
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MF6AXF:,6\\*QI!90V GGFEV8"<<B\+")> RD"35X1REX,0]WU$(5\!"(*NQ
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M5+B""1 )KQ"$'AB5[2@ >$&'&5B"?X@'#$ $<< ".=@%0@" \GB8D9B''"@
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MR[F#!'@">. ""- '>-@!%@@'48@  %$&"*"!:5@'<M"!$L@&+M@"=-@'&AB
M-KB'?9@8@7B& 'B:BKB'5  #*E !#C4 7]0)>4B%0<@"#. %:K2%!%@F+-""
M7O@ 36B$1+"#:@ &#L"ZVDB*WZB"!("!I$$#'1@((FBD>N %1Q""'N@(%R#,
M?]@$&HB$1A@$/SBXC-B#_Q80B$X8@'9(!!Z0DW^XA@&0A67( -'Y!V%8AS!
M 45H!$?X@P[R"EW8@:'I! Q(FB6@S'TA P@X@%(HAPXX0G*  9_CB5'8T']P
MA2<H!W9X@A@XIAH0A7A@O=$"@S&P!WR@@9^).AWP@HC@@Q%X"4L8 "/Y@QL8
MASZ@@4=PA"@0@J)2BG\(@PD @D2H TD@JU)  ##XASI0 (CR!@-X@4@0 WD
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MG#R&#PB ;Q '$Q@!=M '"F""?_"&!C@$<Q "LOP'0FB 2LE"*V $(!H(0P@
M OC:$;W= L@$:K0$'+ $7GB!<]B'%VVH:#""38"%#""7BH"%!Z!3(M "1#B
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MN_TVW&*U]59Z<8O%7TAQ>6GW:B'-I7?>7>*]VN 4;Y6,',>$?% UA$L[>.&
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M4Z6J(CE+4!N>5I%#':U'TRK=Z9)E07F 0 ^"T (<I *G:_E'+!;0A\\:)!@
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M$<A A,!"#*!"(B1 )HP$ .P",%C!!G!",F#" LS8-:# (G2"#L !.-C!!*3
M(20!!8S:&CC"*N2 (Q3*)?2 %I@!!(1L/ !!+H3""Y1!-/1 "?1!!,!")KP!
M+-Q!#:0#&'A 9"$!!Y3!&D@ %(2#.X2 $J "#>@"DRQ!#KC"*EB!#JP".=0#
M$)C")P2 +!0"!TR!#HS K1D$*1P #A1!$"Q &Y##$G! $I0 HN!!%Y""%%"!
M//R"#+3 >U7#"+#"'&! ]9&#$;R!)'Q #Q0#/C1!(\1"#Y#!.)##$6C!(VA
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M/;#!#&P)'&0 ,.Q#"X !.:C#(+3 9.[# )R8+\A #[\R,9Q =_0!"AQ$)C!
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MY,(#D$P:(( 30&]<D(,AL,$()$'"<4!WH4(&0$,J8+&[&8 F%$H1@ '%+$,
M1/(R#$ N=,,#:%L]\( _#,,"=%<X4,&)50,'_+<AY(#F<,,$%-NB>Z0*5$'-
MR;D/$,HG5  32$-._0,E5&X9>/$2F $L\,(W\/].%5R@(A@1+*@"-Z@&".37
M.[P HS7#"2"</1!"&9! C]>!%_]#('R;.+! (\!"*TR#M:% "R*2':B> DZ
M/NN &OT#$^SR/]R!#HC#._  K2L!+.P6#Q##.JS V_U#+C! ,K"!"O@!&#@"
M(R3##"AV*W!W\WF%@?^#-W  HUW* W0/WH" /F=A"!R$$8R!/,A '$2"(AR"
MTM;&/?# '$3"(/Q!1ZY#%JSR0;C##KP')73 (0S!$O@ X<H PIW"")Q#/O!
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M 0ST& <;9 "'/O!@#.F0! G*X(8_3.^%C/B'/KR@@ S<X2"\@$ $>!"4>(2
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M&6]#.5A/ERZ1DSZ'3B;$88=.4T+NH04J L+Z 0@X+)2!@0-0@A@R !?&X07
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MX$ NH0%$][8^P7GB@0ER0!A&.1\L@11&V3VM]]4RHR.P81U\0!?RC8+NYY3
M&Q?X05-9FJ=!WM,X 0OJ02,,Q!L>( QZ@0\(HPJ*H!ZLH0'4H!^DP :2X18"
M 6[( 0(:81Q2(0& B MB(Q4ZP1Y>P!?B@1'PRAANX'\R@0'8VMX X0,X+!8L
M:AY\H0.PX1D80!'L@0X(P!\/9!@VP H,@0Z*8 D*8">*80?_?(0;'.!@&+LB
M(($%TL$=IN %QB$4O& >WL$ LF >D( "#"$-R%TFZF$$YB@/]D)%W.$.%" .
MP( 2CD$!'"(7 H >H $#KJ 9BB$ \N 5\. #Y($<I& +E%L'.,8.1D\A+.$"
M?&03#( >C,$%9& 6,!]L$$$%[D$>3$!?!@$(X$$:&D 6FN$&6J 3GF Q$P(=
M@N$ _( ?KH$'CB 5$"$ 7,00!& KVJ#(3 $D)B00(N 8S@$$-$"E42&620$
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MT _X8"RQ\'#WT '0H T*0/\+_Y +"> /:2 "Y+ ,&[ &[[ ,F;@.-U!OW4$
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M347_4RH@%]H  3%U!Y-359#S#T5 +.+P FH$!W'@1\O  _E0BU4@%\DP ND
M# -P.;<P +E7(T!@=O^P#RB0 N@@"0^09EHP.9P@!%\! UE E-&@!.$@#N*@
M>O?D# ]PBEZ!#0-@"/^@#B]P.=A  ^QP#B/V"P$P-T'D>Z$IFJ-9);Y0!$R
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M8M -3##_),<@ B%P#7\!!.:H!AD0"6)0 "D #&#P Y&@#;+@ )F #K&@ ;K
M#$_ ">*P"  0"/U !@* "XKY$.,P#1+@ K[@"Y:  R@0@XL0 91 "1!P!/KP
M"1( ",;@"0 @!6T  U54 S<$FK1D#WD  (608?\P#1< ".*P"HPG#K-  -\
M#BT@#>-0 _\TN:3)NJW;>_!%<S0')8A1+'@8NWB(A[HG%^QP!D39+E B1O,U
M#G?(/"X1O'X4#N/@#O%P#N#@%?@ #.#$,_ZP#_?P:N/@#^N #BAHEU5A+O[
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MI WSPV[TLPX1L<#_ 2MP#_L@!!>0""=+#T@P!1S,Z/AT4$CX"49P&?D0#^A
M"!?@)B*?O)+0".>@"G6P(/. !<'W"MJ0 P/  W<C#1AP!$J7\'*1!0" "Z(
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MT<&O>C<$0O@'(&A@ACZD8 8C3 8;( &'*1 #*G$E?.$-_Y",3,,!NUC#+[0
M F* +"/Z2,4GL#"#=?3C (H0B#<2P!&F?F,26>B C9R !('\  W_B$4&NNH1
M*SA6(-)X@(V>40!+K.0!TJ"'#&R0A24@ ;WK"0<2-+ '.RQ#!1^X A^&)049
MD.,;#J 3_S!H\ $Z1((?MJ" ""I1"'<$H0?D"(8"]C!V$AS %+U P/*\,0&B
M#%XEZ:CO7A2?(C\ H!;@* (Z[O&)9G"%%6B"?VB#$: %>@B6)TD")O@'59@
M38"'XWB$#="%==BL0@BP<?B!/$"'%?"!(K " PB#5" !2-&'6ND@3]" C<D#
M<?D'*< LJ) $(Q"(:= %>IB!WOJ';G@ 6_@%#M@V3J"V[YD GM $":@,+2B!
M?T@&&:@,/#"!1JG!*)H-71B S3(''.@R.Y ]?/@ -_B'+["7?V"!7F"->3
MH0H&#VB$?W@##GJ%!S@,(]B*?VB%%LB5(%"WP4.")2B*&1 (*?\X@W>@@3I
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M?#"!$ "'W22U26B 7UB'%C  *YJS &*]"E"$</ !!L@-1?  ]44""EA*1:B
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M!' &9N@ '7@%6["#2]MA@6B"!D!@&/0 2YJ% '"!/O"" $@#=G@$!PB$.L@
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M(-"!)\2 H]S-.'P!#_Q(K_P#,XC#/&#!&(P!"BC#..!!"YB!':Q '$C#%IS
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M  S9TD"0P0A$W$"\0PB$@,6A%@C40->@6_OX A4PP1-PR=M<P@  C((\P0B
MQL&80!RT1B0(XC_4PAG, 1S< S]TP1:T0B\( 10@0_/!P3CXPAB @1SH2"6\
M@2@$02:8PR?X 1K0 7)TCC_P #6@ RD\@3>D@R'H@2W,@1 0PS8D01'4VC:$
MP2"$ QMD0 BL@;) @AU<@2>TACL,PA=D00]L"!\]0P $PC\,@R/PQ3]<PA&P
M@2\\QA(D@BT8@2ZH1C%\0O]5A4,,&,(_9$,@# ,_I, '",(V],(BK() Y,(B
M,%%@A$(FZ,)]8$,D9$*3\8,A, ,M-,+@74(F@$8_@((P! ,G'"DZY((B&,)X
MD8,T\$,Y0,*&R$,S8(.0@,,SM$PK<BH4=4$5- 0K",#I=,,*,-&X8 ,,E$<K
M>($[P((!*(,]$(,+C $AJ $ \,$P/$!5I<,(+$(X ,,(;,,_.,((#) XW (!
M?$(X((,"@,$Z_($,P((P4,,+;$)#P,$)4,\-<)@[:$$ZX$,(>)LP%,"&Y ,)
M@)T7R$$R*$,'0,$\&$ NW!X$0!U@6,8PT #UX((! $PW/,!W=8XHN$!## ,&
MI,'_.PA""X1#,ZS *S0#&@" L=#-/HR $"@;9J3!%31$%*B .\Q" %0!.=!"
M C#"/#!"#[0#-^! "TQ#*4R XZW <UK"#KP#*V# &?"#*V  E^#!!]Q#I0%!
M/HC#/I@#"RB$':A)YS2"X\V"QJ+!"SP&""3!/[3" -B!,?1!!( ="1@+'DR#
M/FA!#^3#.&3!%8S#.K! %(1#*GS -/S#$NC7-"  -1!#"8@ +'A"-5S!#ZA&
M+B17(H$#&GP :,"""]0*!S3".D3#"M D&_" WU' X,V"&,S" N2*+Z !*$R
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M,QA" %"G[?:%&^@NMGDG>$+&>)9G7V0#\?I.J9T#*0"#*,1 6,LG?3X*&G3
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M5E;U:PB9 K2P)@HW_NFGCP56:<<A_?X9IPT IDCA#'K2>$"6=?XA9 $9N(#
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M1 %8]& # E: A+2)Y!QUX  5B+&&!0"A'F>( !R,<00%E*$8*B" )ZR!@1:
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M  #A+/V!&QIB'\+6$0.X/<F3C(72&^63/EGQ."DQVC"A &+)#&_7D>+#&=P
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MKOE!X^C9GO'Y"?Z!$7C@"/  "U9@I,Z  DZ!'[B@!^Q 0P@A"BB!!7[Q&:0
M#(;  33<.;V OI>A!HR -'K!!!Q!!TP!',3@!=K@#4Y@"[XC$B"8#QS #SSJ
M(<2!"Y2@WYJ@#JJB&%HA4M-!&7A[WBC!IBNC"*JA'_2 !/Q@"#J C.2A"UR
M'@;A $0 "<KO#OI@">" -);!"_3 !B9 7^,IJNF;&GIKY'+!"^) "H9!'=S@
M!72!"2B $,*!'0+@4\( !6S!KH5%'>8@ &9@#O:A')K@"FH@"HIT'/X@#<[
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M8P79.Q]"Y/"#I'FA(O\HQ0@6$ =P?,4@?VA "V"A4! <A P\$,<3[.2562!
M&E)IPQ7TH0UH\$,=JF ! _80'$PL0 :;^$<50N"5-71A'#08S#_,P48:$+&>
M@H""&PH0BW\PUK%="(<)YM!%L5RVB$] PPVR9HP><. -\/C')1+P <C\8Q8<
MH,X5I/ /=O]LX!7_"(OD]M""<10#!@[00F(U5H<=O".^%"A)'52@#Q&@P12&
MN,7%;.*UAIAC"0CP!%GX,0,63.,'2L@'/7+ @%%H P,O^08!\O"/+\B0'R_@
M 2QR4 9Q^ ,&!I@$.]115WX8X)$,WJ2.=\SC'D/+##K !S;/NP ;T(,KA$#8
M.W9PBG5@0@'D,!@:_L$/%OZC$P!(W3_80(%ZM)  4>%&%8R1 >N-PP:!K>LD
M.C 68B1-C?_( A(.8@L9V.,@@4A $-SA(X24)G,5K2LX8O!"A'R"Q/](@\>F
M !ASL."90Q5:'B!PC8-$@A44,-D_NG"(O_T#"4Y R"4 L(ER>*#_%_]XA0L.
MLC28B. 8_\A$$4K!@)#^QQ\4P+%-V-"'(:LQ%@KP#T* D+EA##84'"#6[/+Q
M([6^8P57,(@\&%$( L 7'#P83,Z@$8">'@06 M#%+SC /R6,S! #J#1HP;$/
M W1"%QQH:;7@T8.91&,!H3A(-0; #'2 H B9 (Q7;<"V+KF##38XB"-.^H\F
M)#P.-(CB/QJ1C"44.M#AL(()X$"/.5!@#!/[1Q*R5HT'A"0>A65F"^:BV+LT
MUIZA%D<\Z-$( C35:\\ !S)2 (%V=")V8N#!&%D09?Z  @)-'<8K#G&#8-8B
M&.L01R4>, ETK$,84T  ,?K @Z+/(0OF_^A;0>!Q#F^@P " ;L@ZQE""?K1C
M KEP[LN]4(1PX* *!RE$ "3W%5,,8!K_($$B#L(/,63@"_\EQA4\0$GT$O$8
M'U@%'-9@V;!,M;__C<=+I1!E_NX '?$-P.5-H XA>+*(S,ZQ:&R2C1N<@&4'
MB88M&("$6\#W'ZG(P.\J40%!ZB$"JF@&!ICP#TDXH MXH!HN$L!+S?T#Y1)5
MO8^G3_WJ;_(2 9A4RQN"#A/,Q";E,((!?#$.\4'B%04 0AEF0 -<5*(#LDA'
M.TP@#',@0P4+T$4ZOM$# AQA!()4!0K "';  "P@(@QA#@6G!#$ #M70 &Z@
M6!LE ='@#"[ )?\&$0\WX&W&X@ZA0 "+8#[-8@@$P ?=4 ^>X ,]M ].< #E
ML PC  3H, P;4 GX, T8, FQ@ P0\ &5P 9W@ Y.D "8H L[$ (]A#'JD P[
MP 3^P ZB  $ZD [=X !K, I!P .T, XZX#CV  &;8 YZ8 +G@ 8+< O_-17T
M, -I4!#F$ [X@ 5?0&/2=UWST )2P#++$ =E<!"L4 &[8 Z'H'7_< @8(#1/
M  .XD R5< %;  <V  KE4  MP V]X !H@ XYDPP34 ;^X _&8 (GT Z6< &S
M$ T=< ?&L @*T$-SL 'DD \8H D&DP!(](92<0XZ, 3?P XV, 7AE0;_%\0*
M/^ )B  +4S4)%8 $HP '?A .7? #SL ,C!  /6(%JU8+"Q #H< ')!8$<X8L
MJ6 !E/ /R*  K) 0($!=T[  B& -T( !S ,*!B T+6<[7/0/*+ %U/ +A_,/
M)8!/4S$'E.0,&+ ,MY  SB -*7 #]- ) G %LV &2H .45  BG +*3 ,OZ
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M#BV "MHS&J5@,S81#9@ "CYQ"FT04Z2P!]E0#9Y0#6T !IJP*=1@#OA0"6#
M!VXP%LW !W@0+N1 "'< "ZS@"N10$PKX%CQP0MV0!U)@68/I#Y\P!WS0";AX
M$T5U+,T !F[0!W[5++7P!%@P!4.P'Y'E!WWP"[E@!V0 #'4@!&M@#.: !TE
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M[D '"# )G]8!(B #,H"P9X  OP -+/ !]7 )*P );U &$Z,QI( !0E +9(
ML' .2; !V: /,=   0 "EB*8JY=J.Y  ![ $23  _SV #]0P 0?P!3DP".#P
M PQ0#N0  1P@!_VP!P"@!$.P #N0"Z4P ="&!:^0#CM   0Q%:.!;+U2A[(9
MN9)+?87@ V798!953>]1I [%N)Y[60EX$(QP>H#P!Q((N?; #(' 3<S"N<?R
M#D)625(Q4%]1<+3K%:"7F@MA#N< #NH NP63NY9%#NN #N= #N!P#NVP#N#P
M#N( #NCP9O]"#BE@"04Q#NFP#NK@#F+['Q9%#O:0N^&0O.) #N*@#NO@#NI
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MA%_<>7(A?11QI80J"+H'$UW<^4<9&89P9B%M.%D$+X*^2>04%DBI,J0^SOA
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M,T@P;9"!3# $0[B%;I@#>&,_'7 9=7D#7'@'&3"#<R""?I &- .)8$ %)=
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M6A=F2 4;Z(!L."4\N000^ =#6(%@>@)1"P9B_ =7<('1B+VT"8<D&()_((;
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M#_B +PP),KU+%XA8/Z@1 F I1AA(8I"  4"&_L6 ;#0$!#"5N^R$()"G9!H
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M!R&(@(CD GS(A@.0 "O8@4.0!RY0#'\H 1:H!V' @#Z@AT8  !3X@A5@!F]
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M%MB 3, $'9@'1 " .("&,N  2="'*E"#BET+.$@"6@B&1@B!EK "*_B'0+"
M+T"%,XB"<T")<<@"$@B6?[B# D@W-N@!G4J%%""KK/%>#E "<5 &GU@& X"!
M5!"&+> &>.@!7;0L!H@'>2@!-.B'9NB![;($B)V#"V!10C@!8:B;@D"#)_ '
M?K@%#* I/%@4.VB 02B'6;@"NPJ)14" +1,'$=!='-@%70&"@?R''SBG&#"
M4B@'5_!%&E#;1H;D1X?T$ET+/D""4T@%A?O_!U1LAH'AB6^0AF (AWE !EOP
M!63Y!V!(NG3@AG!8AVDXA7& !V. AE:PAF/0AU^H!E58AVW@ZK1IAT?PLW@0
M@S0I47&X!$H AV-0!F2X!D XA6_ DU9P@U08C6[[AV)X!$WX TW ]%^@ VDX
M!DY@!G$PA3+@A6%P!&KX@T-@!%W)!C?0A&<8A45 A77WA4XX!#<H!7'P!#[
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M;#P@A2^SVFF^-HT?V,<2'1@<_^)74IV.IS28( 1%XR!2\OWQ$:(RQ@," T@
M\N(!U7!+/]Q(,0S^U!PPP,0_XF'%DOZTJ6Z9Q@MFA ]VN,46^Y3-)J[P%CJ
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MQ36\0 8T S^D0 =H$2I41@T< #/$@@Z\ "9@PR480!4DP0,X0G 8 Q/PP!0
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M.,Q#"S#"M)6#):2 6[1##]C!/Z2 #\(#!8C!/\1 $>2#.@Q%<?P!#_P#*_#
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M3U#!.;I%(C3 "@S%'D#!6Q1!#?Q#"6QC/O1 )?S#-)S  0B"%!5'&="</=B
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M8A["O>98 DA#/@2 !Q)%9/& <YC'/*S #ES#!I. 2OS#_S)('.RZ(#,(';R
MMLTW#R2C/A@ %QR()W#",+B'(@2 .WS# \R8.JQ +O0" G!<&M2H$.#(+D!"
M.7! B@5',YR N)C! KN%#BQ"<$A"!M!5#K]?)_2P*CB (FB'*7PH2U3UC!%#
M!L2['.@ 1GA!GT(!#A0Q."2"SK(L;<]!$)C#/AQ )'2'&9! '=$#'KQ#'KB
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MB0F;2AS19Y18L@&$$6^<8221<M0IQ)'-C4F$#UK*RT4,1JKUQHTB&H%&OG^
M8054K"L40L#_PRPXAY WC$$9GF!$*9Z1B41(XQ_>0,,3KO.2?TQC$(H !"0@
M(09)K.L9<"A!(?X!C4<( A3-: 0CIO&/;U2!"+>P@RC4\0])8*$*]_B'+QKA
MB79P+B:J\(5-CE&*EOB#$HF Q3^L880P4&,3B3@%-C#Q"&.4IQV>2$0,S1,)
M&RPA&_\@AAVX\(93_ ,6 0#!&+;@OW]08P@Y" ,Z_O$.3?C@"\)HB2QR (@<
MQN0<?E ![Y"1@C9,0G$:;(<5CM"*1DA!#/N(@Q<F8<8DU, )")O5.=8@!49T
MQ@MON 8<4O *;G !"%N\!1)\4 F;:+ <;*C"'A#QN#L8H0ST*,T__S;AA10H
MXA^Y8((72&&3;+ A!%KX&S@ X8,V%&((WX#'&VH0GU[D(!'B*,\U#. -F\RC
M""" Q2=2, =YI*$&9%IE"-  #J'$9!I": $5CL (/F6#"4NH1SEHP(=VR",(
M(-C&'5+P#7I080PZ8080N,"+/$@A%/^X Q#R\8XJ2*$F@?!!&G*X" $0JS31
M($(*3O8,)H#@"$[8AS (, $'&& .ZQ#'#T+@RW_ XPH:N,$2CO$/2Q3  "C
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M3* A!H$&UN@%2^,><(#_?@9PZ18.$<Z@T?J,#,#@_!QP#!U0$.K@'/J!!.J
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M0,'_O&<+/* @\V .N($$2F7_5K!A"8SA#V[ '@Z! +)!'H3  &)G![:@"%Z
M HXA&5#@!XKH#+C!$AZ@%XZD#&"! <Z &9I !3XAR_Z!%W3 "5;!'$X!!%8!
M$ B 7EQ"'%!!!+Z %L(A"': #XI@ C:G%:9 %P:! 5#H)8!!#S1@#V)A'=8
M" C!"F@@1YJ!->'!-><H!3@A$%C@$,1!$   $=A!!RS -R)!!9)A#BY@%N;!
M"A)@#,S@ YR@T?A ![P!#F" #?H1)>I@ +"@"40@ F2!&EA@!\*  T3A%U*
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MP,C&9Q_)IX5^\>CT$8;W::#/ZO'-K;:>-%;0X$'"*T1#Q<L!-[Q0B.#<U$"
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MCW]H8P14;/"#TR*/5'@7&I9P!C7PH&C&+,,.;.#%/_:!"0FT(1K7X,0'&"'
M<6!""YF8H+;G< =W-R(#:^#&._]1B 0481;@>,,:ZI&'2QPD'K=(]R7J0(I[
M&"<6'-C&/_CQ@>S^8Q5J*$PMH@")>(2#'Z]@QBPJ\0Q67",6@5 )&\A #<MV
M(QC[" .>_=$$&2!"F$C!1AT,H0IQS*,%SL!%'Q;YCWCD8A6IN*>WE=M4NJ1
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MD O@T <_H ==H '*X Y]@ !&-0EF_T *0E!KB]&%J>4,#/ #!L$&S/0/EF
MIC &4D /88  *8 $!G & : $6T $LG  ID '),!%!L #87 %'7 ,_I &)Q (
MRY 4]Q $O6 '!= .Z6 "3Y &._ %YG .,6 &J'  )7=U[9=U<L$$3C %!K !
ME\<-5S +:A  ;K06S  $O8 )-& ,W\ "%H ,@:  Q_ /O& %N3 %*X -C)
M1- #)_ .9+ %FW  3K8%$S!5MT %BB $NQ .FX ";. "B#!(*[8%'C $]\0+
MD_</UM %8^ %<<!6:O$.>^ #4> #%U(*6I '/^"3:X$/:? "S: --G #=2!$
M;1$.== #0_\ #N0 !SY #K]0!',0 \8C#&- !R) "+A0 !]0!>C@#450F=Z5
M%,#@!&B0 VP6#I! !$D@!F>4+0S6B<@''W"0 $.0#760$.(P!!@P"(NP 28@
M#32P 5QP"@#V!1PP!@DA!PAP8<&P 3E0$PD !/]@ R(@#N(  Z)4?ZF3!#1
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M$ _]P .F\ _20 +[@ Y2L$AO( 7'T8DB_PDC_X $3Y /*!@$_] $7X +IA
M.3!\"#$$5$ *IJ !C\6K=* (4^4/)X!Q?P  AV /(9 'L. -JP #D,8',K /
MVW #,&4#CO /IR +X!  QN,(V<H-&U '^C *#I (_[ ))C .[8 #HW /A@
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M#D90/O\P"E]0!2) K2V 9XMA"#& $,@  VJE"YD% FL "KQP"OI -6MA!PY
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M:(0->(=LT 3-@KG_\XM "9Q "BR_W: '-W  %."%?PB&$3@$2 B"9P '-4B
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M+R5)K3B'+\"-,YG!:*  .^&'#6"=YSJ 4E@('\ &=0"$^!$$#GBA0(BG9D@
MM[ B(#B"HGJ$XU)%E- ";R@V4D2"(UG%A<@"'?V'.7B#MUHJ0F4(-[(]1E4K
M9F" *[6(?5.(1X"%.LL & 0%#9B0:.B ?Q(1<CB"9  ';."!+E"= H@G:O@
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M, 41R#-SF(86@ (:784?^ ;_6#" .MC)7+B!#-B",V  +.B'1=" =,@'/V@
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M+1@Z..WG_ZSZAWQ( =P !R\X@Z?Q@KG]AW0 9PJY[NP&Q[;1!Q[8 !C$! 9
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M-%3)@\(,U=R2@C[+V)#!-=GT@$4R+>&1P" @//,/.2ZP$$8(PUYC P_89'/
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MJ_\EYCC QF)3#BBT^XXI/^0C\V"3N,P!)O]H0@?\(8X7P+<@TDE,/#2006U
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M#.3!/PA#!HR"+QA !@5!*ZA" *C".#1!(M2#&7Q M$3$. @!#A@#$V"!$16
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M&$'SQ 054 $Y#/]#"PC:$5P%D0 P09@"!K#-#\0( L_+ C<P#Y#9H:S"#/
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M^+8.B!AV0 ,)F,"=O?^#<%8/+4""+EQ"2"3 +Z2"=?P&1(@#%Z!V/XR YO&
MN;.WN24&,"QR;@B ,-3" @3U(RC#+-" 4XY#"[P".HQ WE!"!=#)/\!!,K!"
M %#3'KR $GF"?73P0/]##%3",W" $J3%+; %"G &<.C</PS"I2O# )!9.FR
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M,RG^-5\U8884%/X^2?@&*T8\8A.6?%+\[]@'3-;:T/D7C4&1=+@BU,$'5EN
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M?#;G"Q! -3K_K-#?'?H^34'@O=JYFG7UU:,'0Q").K)1@C-4_!^IH$)E4-&
MQ%>"!R-Q Q&JI ]:W&!ABR&',TKP!YB_'_[Q#V)R)D$!\+$" &UH3AE"IA8F
M-&$)?.$??B$)&&$-9@ 2MF 3NB )TF$1X& )UB <] $, N$7F, 'K*$86. #
MWL ;Q"$2E$ /'@&+QL$1 @ +*"$<T$$30  +$B&6NH$,- $7?F *BJ$?PD -
MQ $8]B"95 $-!,$-;* =[D$3DB +>.$?9H$" J$-]$#"U@$2D@ $=*&*5B$)
MED /EN$?DJ$,I& )0H95HH$-O" )R,T6P. 4/$$+0 5R2F$(:J /_P2(&]B
M"%J@!M+.'O+@"$*@!YJ!'#HA#[K!&T@ !]3 &U1!"S#L'X3A";@@#&Q&&N)@
M$GC!##@A;,B!$]P #U:A.<[@^EBE9?X!%4X 'PRA )*A.8H@"-(*'9C@!/:!
M$Y;@<;B$#/S@C;C$&I  WQCC&0* $KY#&Y)@');!$E#!&-!@$<)!'(P!#(9!
M&GY@!>3@'DA%#-X <))#&OB@#!CA'X!!!+CA$?0@ST"!#'PP(OAA!0I-'7Z
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M!D" )*H %\   VSA#SA !?Q "$K #:+ !YZ@.8X !N3 !A3 &YU!"$A!%PP
M$J+A!&Z #0I %[*('0H!!,)L@FH@$) RK9QA (YA'&2 $)JC&P8@+?Z$ S)E
M2Y: #+P26J,U_LS!"[H 'ZC %S2@%7H!$,#"%9)!&-S !"IC"5"T.4R@5O_!
M&3"A'%B!!S L%B;@]<1  DAB D#M&P; $](A%!XG(M1A!FPR&3H@%9J#$!R
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MP6@*^D$%P@ 71B$#[B 70@!; N$*VL$%\@ 7(N$"VD =;F ,NE !*N$?>&$
M"C<(:F"-E$ "^@$-:@ 70H$%5N ?YN %WF$9V@&"+B$'!L .GHI7">X?\D /
M_@$>:K8YAF$"^(<4,R!AF\-9ITY:1YB$ZRH3-D -U$ ==* (^H!9%Z<)TB 1
M9B#MCH#QU@X'E+ Y/*$+/N$%"O82!D 5R6 $_B$7/#AHQR "1"!DM@4?<$
M-X$!G.<4%  6OB,.[J Y[J$ /B%BY>$?#*%K_\$',/(?AD!2NT04."![*@$]
M__\!%-*@##! /$T! U9@X"+!"^!A'NY'E."A#<P@"XB@.6+ *>5A!1HU.8KA
M#OR@!;S#!-*@.0R! :X!:7B+!PH-&59@:<1X)-I1%,2!!T8,;3%V"=SO'U!
M;<.A%T20!Q(C;B'''J# &IIC$&Y =N2@!M(J'. @+8Z !,!G@J[A V)F@M"!
M%7])&S! ]!A#'[@ +MR 2/^A"S;S'V*@<N3@!^""&6A@ R;AT$:"'H8  ;I
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M8, 3NOM8B;LY@H$>V*$2*( %QD$4MOD[X*$''*$YQ$$%^$<$VJP90#R+X.
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MP E6(;%N]&!M(.%%_Q6DP(1)4,<60\#"'EA[J6P(H!"8>F8JAY$"#8PRG,Q
M 0::@8\G)(#$*!V'CC>)*7B0 0E>*%@,'1$#+6!8D_]H!A @,$!(<B,'*EB#
MI<P!#F>\00UQE-@L2C"#)V#K0]'HPAEZX2%YB"(*\S"+/_2@@BA<V9+4#;2@
M!PW,-54# 820S1@",+Y;?>$<<03T$S6*WW_DX1B17E,M=L'&A%9ZIM4-M5EH
MD0 -PG&+J XH-$^M1$2DH-+[H(%HSE$+QH9C#N(*1S7RD>J%GK$*8Y!8(ZC@
M"D9$@ W_$$<2[E"=%@ 6).Y0@2C^<0P)E,4$@QC%"UK0K@^EPP8&D#)(MO^1
M@#[@5QHA>(<,/X(.62 +'&IP!VTQA8Y2C$ ;1XP;.#R1@6&$HQLC*"&3_ZF(
MG075N$( 0"1>MPT*:.#-IH1'*" @/$A*HP2?. ,  N$1=ISA 7)(,TB2<8)#
M.*( +&B8,3Z@BGJLP([A*,0/"D"M6V$!"U60P DH"VA"^_SG0%?AFM2A@BU\
MB!4*@-L_$"&)T3"CV__ QSC>P=AT#*=AX8 &7C%%LW8T[!^FV  H!#S@<IQC
M3?6P@2[D495Q+&/K9%1W.YBWCGCLC![W\.T_!,Q9V:A#&^K^QRX>T UW,*]>
M_MB56?CA#YI]Z!W:R/6ESL$,JW\('+T#(1GW0:__&^YC12"@=SV(P0/;9.H3
M,8C'<=<CFW9$#+74H=T-[Y'G#[WA#!(+! CQ<-]N#$!EYHA!)5X7#P/ #1@?
M2-<I9!,("KSK0X.8@PKNA/8 3 4D]<A"[S#U=4U- @<1C2$(87>"=%7Z'_*6
M#2GZC7X8")R*FC)\FD%$A-[)$J*8&L('0H!UIXQ@!:MS*OG  QTA3?^ "OT3
M#CH0;,RE R%72O^@"ZX@&ZQ  +_P#U2@![(A!C^P6_]0" 7P#+*!"W@@&Z]
M +)P1T&W@BS8@JIR*9-  8!U"P"0!BA1!=3S#]'@&C^ 9ICP GC !#>0!S'@
M!B40!/30!6@P!%LP#]< _P15X M!( +*  PT( $V( S]D =_0 2.8!;C, 8%
MD -T$ [M< 5C4 1,\&P?T@I>H =B( ,O4 WV$ 0H@ _ ( 5;\ ^Q4 -KP 4&
ML S#T 1E$ (D-@L4$ E'( )Q\@YOL 1<X 16YPM5  4XT!2@( =%,1-,%0ZT
M$ 1K4 *\<( HL B,< -DH Z7,@I<H 57D&?FD E"\ 8:L(?_D HV\ 8H\ '
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M D;@#+B0 =[S(=X  +;P#S.@"!%X OHP#DV CNQP G3U"1A0#.R@"2<P#^[
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MID"@_[ '3? /ZX<MH%  ;Q /UD!<ZH #K_ /IQ  -5<("=!E_^ '0" ;JX
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M#!Q ">8 "N, #!*P-KS0 N"0#9% #M\@ Q.(DO&U#BHP@6LR#1#0$97P#?E
M WM0"8=@ YL0"@Q "^"P&J+P TWU#_0  SCV#[Y  +8A IRC#1+P8[*Q!,_@
M"Q$ "RE1#IW@J]%@1Z#0 <)Q""3@5OK  P7##D10#.U  H@#"B?0HA\A$>(0
M"%?P 5S 7.#PK>NT#B$PLI?  4WQ#]*0 ".+)+ZJ1&Q@(A-%KSB<P]&50X'
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M"07 P0=H!?+ *YF0.SWGZ.9__KWT(;I@(O]@#US0K?] #FV  V%@"C]P"X)
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M")Z HU"2R@<5 N EL/XC&"@8@.F><(%<*!%33KP4/@0!_P(=3 %VEH74.LK
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MJ, 1?_I'.^(@A3K,)QSG:,473N,1?%2"!"50!#F,J<S%,K:Q,/L*,#A@B92
M(0#0L.,6S&:U&E*G#:_BF3O_P0I<++&6;*,:U*:#BQ^(@Y>N_1L-3SM T+XS
M);VP@73008-L@6,V-(H#:OCQCMJBQCTNW- 8SL O/?C!'J^8P!-B5 (M$N,
M$P.)/#[0I'G0_\!@+YB%-&I @GC\ Q"24(8=)L 7H)1C IG8T#*(-AWW@*,;
M[_C'/H;P'[I1+QLG,%A!B#N664Q@8</@P"QN&#3.EC8EXVB#.P :MIV5D!@9
M.(TY\/"9N.7L*XVP16EC1F'0@ ,7,/ 6VFY8%W",@0^BH$$!?M4.%C1")2
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M !74&8<FYH,/$"A7%AW ES\TX*&4U&#@!6DNAVS@A"K3O>Y4]M$E!O K3P"
M#?]0!Q1V[H<75((%:1B''C)@!+.:X01M\((.KE&#/:3A!_A010N\<(@O:, 4
MRR@"!>H0#&TT(1-(V - Q_&)&YSA-+,P B":@(,^%B03/^C"&%2P 5TXHPLT
M(,<W3D"$?SQB!5!( 0;B@8L:5 (&C @'+3#0!"=,(!?_($8*Q' $&_ ;#V"
MPP^\-0HH*,+Q%0^')'X@\],(0@-MZ((*0!#AKZ#C"D.@@PV^>(XF:,$- \CL
M/WR"%##"#!A ,K3#_Q?, #[@ @2TP!(X0QXP0"BD1!_  2.<0"2(PR$<0!0\
M7 C,QBFPP!K(@".DQ!DHEPR!A1'\0R7T0%C]0Q=@P8:( QID@"'  6E9BS@
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M CB#,&"!#BQ#=AG"/V2!W^U""_#;"58/2,X +_R#(TC /*3$$GSC5ZQ## !
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M)@9!"BB!MVR3);2 +93"#BC1$:BKHC(J61A!)33##$!I(-1 2M1!$_R#*>B
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M0!?80SA$PP140FM=P0$$@AHPP!IHPQA P#;$PQ.H@#_@ @<L C6L00E  R_
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MY3"^#W2Q./!!%JB!; *%'_P ([3!(: ))<R )/3"$\#"'*0 &3A#2@@#%)A
M"38#%I3 'X""#\3 )S0#"D#!+%0!'F0#_T"0B3)F#;Y_V9288&/OGSESX>"Y
M04%&E ])E4!@\5:F!A-__\+]DV<EA:Q -K2%$X3BC1\HL/[%*G$$T1)+RXZD
MZ"(O'I<ZSZKX4%+NGR(0<=JP"[>G1LE!1&H,"Z3B"2HNBT+E0#(+Y+]E7J"6
MR"&DW;]V?O:,"092R8%4_W81X<-%UC]N/W@$"?-1'92Q58:!##<XI+I*(=I4
MR6+MW[]!-;[4^I,B"BP\-8K(ZP9"B;\Z.:!\^27XWR83<<YTBG>DQII22$
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MQ0Z@(():@$05 ;! !W;1&'2< 0 7 ,/G*,$"'HB #:XJQ Q:8(5Y?/$?U "
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M?, X_N$,$&VFBB %_D$,/F!8+"10S@$):& 8XD 1)"</(H]*4H$-.HM-GB$
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M!?Z!%33 !"2A#$J!!9!A''Q  L8A%1X@#)JA!,@M# C@'XQ![+I! ^P!'JP
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M'N3)#6[ "9* "%K@&X2C$YX!%IC@,$L $?[!'F1 FMA$&RRA'#J!!R1A'%Z
MYOY!$_BR"H"@,>[A!*Z#&&C :E#!3&GI 6IA''A $QH#&Q3 $YQ+&__!!2XO
M$;A!&]*@!:S&+^F&$*Z@,<@@7!O#,!&G&(;@" Z@WQZ"&Q)A!S#@.L(!&C8A
M"RZ YMQ$,TGC&8X@5&K@#;*%!J0I&WC@(ZJ 6K$@!;(!'OJ-32!! [H+%<8A
M&4B H=: !L2A%0!!'%*! NK"./^A"H.,HV1@;/*@&N+A!O@ $.S@!A#!%3Z
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M&&MK$U0]F<*2L?,H74SZ(0]./HYXT,!!*)9!!P6LXA^[($&;OI 'S/[C$P/
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MJV $Q, .64  Q/ $!8 +\V #+V +_9 ":O /<+ #_] ,&< E<< !S7 -1?
MIK /4L %__ +)3 $_^'@"U*@ LA@"P_ 7FPP5JIP 6:P#"C4"SF0#_L0 &\H
M#0G 7D."# 2@ 3X7%>.0"#P  8/V#Y.@FKR  \]X$&M@B(5!"P&W"!K !M1
M!Q  #^Q@!CF )3E ".0@#QNP<WH09 >A"*.%"&O9?L@0# 9 C#;@!?^P"0.P
M++)H*;58&,4  ;7U#W' "^P@ K; #$X0 /8 !YOP#W:P!OV  EU0#K#C#E,
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M_^ &)O8/5N!@.D(/LE '$S ' 4*0DQ=+N% "MV,'(U LM(@!91.G;Y((33
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M"2+0 Z8@# ,@")5Q"ASP Y7 !&J@#I%P /N@#B#@ ^[@ D$@#7$P +X "B[
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ITYOF=*<]_6E0AUK4HR9UJ4U]:E2G6M6K9G6K7?UJ6,=:UK.N7D   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex10-15_img02.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-15_img02.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MM1S;;*#TB(>LFAU/><L[8_(\9Q9D?-)86=+:/Z@! B"D(0AC4(,0YA$+ H1
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M!P*T$L3@!NM0#0Q007H 8((0 _$P6&T@!5LV%ZF !_1 "@@@"//P"8_P#UV
M D*A#H/  +EF#0DP"?,P#]Z0!*1P.W+0 CBU$IF0 [2@#NR0"S@ #?Q@"!+0
M#*U5 ?KS#[N0 93PC*1 !>! # N0"/- #\4@!N. #1/ 8V#X#^_P @/0#>%@
M# ;0!O-(#W,P#]&0 #605_\P#S> #$<@CV6@ -/ #4V *9ZS#PV0@V-B#%U@
M :YP)?@@"45 #;*@ 4SP#;G@!@V0:V)R#IAP 7H0""7P!^H #4/_L "9T _C
M(@9C>"7(H <%\(%7P@HQ( D\&26ZX .($ N)D *%9P]CL &$P NO< *<H%=-
M$7?#<Q1RH0Z)EPUY)Q#LE ,4^ ]DP (FU0T&< GL P%QD'NAP$!SL0X@4 71
MDP^U0 \",(QS<0L:$ S_8 528 *\%&!LD .]T)! L 4G$%3@D 9CL (R-0)&
M$#WS< #UAPI<$ 0@$%*EX(110@T-  9;I@SN0#GLPP.@=B5D0 *Y6'HUT 3F
M( )/$#W@4&_3, ';  I,4 ^"\P^<$ # Z0H,4 WOX "Q,%! L#[*4 "@ (8H
M8 4" 04Q<$5.0@C6H X_D <#L0)$$#W?__ $(L ' Q$+$% ) K$(/Y0)#K /
M E$,_  NX1 $62 00- ##K4*8P"&0O$,7H $9$!/X>"!U9D"*V$.-Q"!X7 #
M/[D2\+ ".E %0_(/NH #!D ( F$+=? J8+@"E,:/X/(,$P!@EU  I2 0FD /
MP(,.*3!YQL !];97L_ /5* %490/?O</5\!O<^$&D#<%]RD0^)!704!G O$+
M#%!O48(//* _T8 !I_ /5<"#<Q$&4?@/7C $ G$&.1!%6&!]_[ -84"&!H!^
M G$'5K<2]^ %$] ([U0))2 #M?</>< -[A!2KY #M>@-Y!0.^E"+RC !%;0.
M^; ,%%!!*]$.*O_P"41C#2QJ#0H@"O^@#M+P#T\P!0.!CP3W#TB I/^0#*OD
M.<.@ QSP9"L1#0J 5KKV9('  ;7GB@ 6JA* "P.1#.$0#1(0@0+1#^, ##P0
M &AZ"#U@ ZM$#CN "0,Q#+Q48U? 2^P@!.R0#5&D"0'P0\K@4)[3" RP!15*
M"P=  NOS#Z'0A_T0 *(H$&GP ,D /,]0 ( D"Q@0A6N0 FOCI"]0BRU1!Q<@
M" -A!XI::PY0> +A"@9PJ:V  , @$/7P"E+%%%R)547!'K!P .U*I"0 !M&P
ML6S  VO9EJ*""0M0 OX*//3P .I9+K%0 ,$U%\-P ,,873WPA>M@!*[_D "+
M20]5< P<,*7+$ :V< /_P T%L)QS(0X@P 7_8 MM0 T(,'G9P*1S$0YI   X
MH L%X0RL.1!3( 1 5 5=@ P'X A,A0T!  1+D(KCT@@$L S<< ,XP [0X "B
MB9_KIPP*< G6X 8%@+7)\ "\]R<J,2;Y, -A8 W64 PQ$)[TM :C, L#T)KG
ML (84 7?,!"=( "B$ W?H 0<&"65( #<0(P($%QW$(5.4@>ZP DD$%17 @)7
M8 R#0 !N:7,Q0 G0H 0_H#]ST0B0L H($(#_$ MYH L8X*^@T(<#X01DVSHD
M"F#4< ,"8 F@-KAUZ0-V@'E%0 %IX _A$%27_] !3E"C6Z:E&CH7=Y!<_Y $
M]WD/F="I6$"V+;$$2=!4]/ #H_L($1"262 &[_0&M2 00Z %XQ , X '0B$(
M%, $[3IB;.F6+;$%H;(2J< 'K)M[*Y$'L% $,> /-BI  M$)*Q!5@UI! K$%
M/L!+3@($() Q[)$,=$L06:"I E$*$X!H_^ $)1L+*7H03^ )1[ % X$&/G!%
ME"$4EV  'OP&"F!*P2 !BVD.FA!%3XRDBH!HV? 'AI#"_&@$A) #M8</.Z"A
M_[ * ?P/@A *$& &(50$'AQYM)<0]L %OI #O#N*;M %-F!2LL"%\A  6;D2
M]1  FP \K<"R_Y +%/] >G;@ T%%+8KP!"9 <2T!!THP 5GY#P!,-. @!S 0
MAP(Q FGP#ZE0 /J##\NP/Q![55@!+L7P PN[$O@P U? ";8\!";PL;7[#[Z@
M Q>0!^ R#PE0?^#"" Z@KRNA#S+@KUS@#V=0 >S@"X@0#U!L;%[P#T<PAF%P
M#*YP ENE /+;$E>P!!;:A_(Z"=6 ?E$2#K @ A'P!G>TFJWY#U'@M0/U!$(0
M#!/ H.6"#3(0 "L G.^B"090!$M !+ U#!+0"<QYMPF !DN0 \^&#1N !O[Y
M)P*1#W#+!1R] VY@0E> #L>P (% 3_6 !A,P 8NP$IUP &? "870 AX,+O#_
M, "U  USL 1OP Y5,)]",0]?@ [?\  .>R5), 5;< &F0$_IX 0KL ()()AB
MX@2ET X]X+\K$0N3!P8=< O+T(<M$;_!^;P"L0])@ $^H+;7F[U!) 494 )%
M;0Z"8  4P(4"X07GNQ+I*\ GD =H, .A\@]BW1)5@ 1-)0\_  9E\ *&(!59
M4 ;_>\9'( )$X !E<)CE8 8+T "4^@\//%!0T(GAT ?M2@!+O1)\X OQH  !
MC0=3E]4TX#O@4L(#$01?$!0KL04'P+M1 L-U^P];P ) ,-Q14 '$]P]%X 1Y
MD <X,*L%P0U>BPH*()CZX /D+!#4, =,P&^*P %'_] %,L"1PA4 3>#7(7!%
MP1  0[#<(S"-V> 'TJ !A4<)G+ (<8P/,% $RVT#R_D/E@ .N2  D6 .6C#3
MPAG'6 ((&88%&<;2:O .![ $XA *.?C'@1Q"/-"?4=(*"@ +HD "(,!+C?S(
M48(.0* /DH #KOL/2M ,9' ! ;S)<Y$.*? '<E<'/& .H.  :J (1Y"RV5,4
M5A7D7ADEW5 "L?P/^) #B# 0@*?+_V ,F$0.>[ !(3D7Y_ ">=T2K2  *3H7
MU>  :,8%\. -!Z (;. /QE#-]'#-K?  C#!YM7 "X( .-P $T>,..V )2ZN\
M:J  1M#9 P$/J]0.98  #/^]$EH[ST_PF/<L!>>@ OTI=__P# > "U9@ RPZ
M+L,9#_+6#03PVU6 :,\Y#=)@ .KY#_L0 .9Y+NY0 GM@#N:0#BT@Q (1"2U@
M"&W0 U3 )/T@%-N0!1-00N[9?<P0A^#R!%I0"*Z@""F0"(4\%X*0!(9@"#-
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M 2%D $ #^4$ 'UHM""@0!W.R48!K,&<-*< )(O AC 8-A!0<R,9 YI A$*%
M S8T"R@>(+O@"2 7_UC%!%@B*TYVTI,#896K/CE*4OYI0*X(PQS\P$5QD$$)
M=VB-(*H@!TXT PYWD ,KDC&)/=#!#_4Y'3G*P(0UH$%!_Z#&&Z!@!3LX"QYY
M^ ,;I#&.E4W_HP]WZ,,R#L&$-JS#'1#+Q1<&D0O=Z6(+6; #]O[ABBHT 6*=
M:PU.YD&$.DB"""LCDQOD\ ;B+<@1<V@"$ 9QCXK0HPDW\ (;(#8*-]P!#<>
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M"!G0 AC H(4Y%*,*$Z"!CN6@!7N0(0>X /]'*AY;BA[(X!'4D(0 0J#C+;P
M&8V0 .,@ @TO '>=,RC (-0A('"000#7^D<[OO !,=AB"SA@T4"N<(MS'&(#
M6K %+*(P O%NAAY^N( @\O&28@Q! 8#0A2[&((=WU. 3,OR', 9@ F%X#A+I
M@,@Q"F"@#Y$A!=F !RM&8,)\; ( C6#'@$JYZE*&TBRLAK6LI!H@G"Q(50ET
MT*O[H4/+1,?6I?IUKTU9:U7/*MBO_D<]_L><- /UUZ$C-K)E]NIP=(,VT*9U
MML^QCT)%9QS=UE1P?=V-\@G;E&,J!Z;#88XQ%QO9O@9VKHO]#T@SVR7@-L>8
MV#&/>L1C'6OD!S+_NE&HS8BC&/B8QSG"@8]XO,(7['B(.][!"D<<0]S&R,0L
M(!X.=13C'/8PAC'.]8]B0 ,7Q\B%;N46#AK5 QH$>_4[XN$-@I?#&_BPASP@
M(HYXQ,,=\L %(%@1W'? (A._ &XXI-$)7E##)>_@=S>, 0]HA!@BZ6CW._91
M#VOD:DSB\$8_O.&/5VO#$]<Q]S_T88U^Q&/0YH &/.!!C7%DPQEBST<WJO&*
M6 !B%5RUE"IXL0O.A2,;N3 %*@HUCE)D(A:K"$DR1.&+6;0G':F Q2U.88M>
MQ"(6G=AU+&11"\\#0A_HB(4VO%&U-2XC%L* ACQZ,0O2QR(3,#K%*7PA_PYH
MG\/JKIC]*7B_F7&DXA7;< DY3$&+7KSB%+?0QH#H,0]Y9((6M7A%)[:Q1@%%
M Q:T,$4W[@V).?!A#G>8 Q3BL8HG[(&K_]B$7N-@"#R(M"*XX**K;)$&2?0!
M>)[R@S?P@XP(ME@SP%1QM7D[P 5\E7>#MP!1M01R0'&3FUCYD#'QM0610 ><
MM7/KI'D3)7D[E0G\0'<KI0@\P0(<00GTP 8,05)10&8;-EC!P&A3P!M400C,
M0&*[M6.KP7/SP1\,MR$$MA $P0(\-E+20%F+P"!$MAC405,10AF4PARDM@X<
MDAUDP"TLE03,02[DP@UT0C'$-1N<PA7<P PD0_\<G$ L1,,UE#<.?$%/(D,Z
MG$,U9$,H+,(US$,^],,_!,1 %,1!+$,@),1#1,1$3"!P8$1&5,1'A,1(A,1&
M=,0[!$,&],)+U$1#Q,)#Q,,SK,(T-$,Q_,0XU$,8]$-3',-5J\,2)$$S+$47
M3,51E,1:M$5;_,1;U,5:I,1IV\5?!$9%[$4WW,0#S,1BU$1B1!4W5$$DI,$O
MM$ EI,$HA,!31$5KY*08A,9EQ,:5N\9G- M1>L4'I,5@A$.:*,1R_,,_6;DQ
M%$=;$\4:-)U:K,9!_)-AO$ X-,=]W$5\'$=D7+5C!,@#7(<\JL!]6(9OV(=I
MB(9KR(9L8 9R> =2D(;_9B@%\6(V80B%:\@?<%"&:@@&9\B&9QB5:[@&<F@'
MW2D5=\B&:-@&9IB&0?F'?F"&BB0%4F &\1(&4MB&:'"&4C@&<UB&8]"&? "&
M:JB&$+L';8@&?&@&:7#(D;0'<7B&8*@&9<"';)B'=L"&31H(:5"&:%BC>-,,
M<[B'>0S'=;B'/.J1=,@'1F0'=B@WEQB'5%L'<',0<R@?=> '@QP(<&@'</BW
M!?F&4H XLN,D<9C+<"@'I>2'0KD'?EBV"AP(W@.'X1N',4N'N_R'01D'?I A
M=AB4=S2'?("T>:.+>VB5=&!-]FH5O61'&S0V4N1!/$2(R?3%ER@'1F3-T\S&
M_]LT%;PLP\9$B'*H-ZDRAZJAP-B411;LM6<[PAHLMW]HQ&?,0B)DSMF,QU:D
M1AE\1U'\)+P<R"T4R/%DQ7^8ACJ@@4L:$'1 @0"(A6-@@@,( B  @BGX V3X
M PE(@S:H 3<8S8BP@CX0A#EP E,(AT?(@1=(%)>*AD\@ "?(@S6(@JHZ-WM0
M @%0 D50 AM 4'I  P6H T50A"=P V+@@4EX@PD  TW @5+PA /P@7/0! C0
M ?'JAAXH@FH @@2HSRJ(@BMPASW(@11H CI@ B0 A2V  +\:"$>H "T0$UQ#
M! F!"&^  Q2PDP4Y@Q:@@VN  R30@E;(!S*0@BG(!?]=Z((CV+#7$8,@L(.9
M2$)D^((@J(,\Z ,L<(6!0(='& (E&)5F.((ML *5\HL5S H)&8A;B((BL(:!
ML <QZ((VR ,MH (ZR ,@Z(,,D:I*0($@@(4N@H,3:(5%& (:@ 10 ($\>((I
M*(,ZF)(!088SZ+9UB(0NJ (R^@=L0 $H:(9** (JX (NT (0D(93 ($EZ (J
MD -,0)%[B 0RH(3R&9!C( ,R( 9=((-)* 1.B - X#Y340= * 1#8 2"$BY$
M, 1+.%=Q\P4CD (E* ,TL*CHH(03 (%2( 4=8(-.^,Q&4 /7^@0]4 5U$ 1"
M4(-=H(<]P(0\0+!_4 4_D(+_.XB%2QB&,K $36@[D!H$/X$W>GC5C/H$9B@%
M&I "3AB&#RD&,AA60R HB,B$*[B#,6"27""$3\ $3N"$,ZB&93"$3S $;Z4$
M%'%.89 $*+"#6!@(74 #07C9<;@$/1"$+W&596@#*B@"$Z/.@1B%/> $3!B#
M60 &,^#626@$2:@$A%"%,P ",T"[:5B#3Y@$A+6X?R %/2 1G>799<#;,C@#
M7QC-((386:#,+*2&/6"$ (6&,]!:B# '8> <1OP984!78",'50B%:;@&5A@%
M;W@'5- &59"'?%@%92"%9-@'5+B&5=BP=0@%;' ';S!/8VR5?YQ="X2(60"
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M-#."%A"#KY2 2U([WA,&"0 ><2  -1@(%(@-G-#:,#B2@3B'06D#'UBC1:
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MW**&24"81-"&*+"!"?X$0C#N?Z@"4L "VX&(=Z@$2V"!D*"&)M@#'@B);C"
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M&84.%J$($B#!<%>@1S,F0(TSU.(=)8@'0?Q0 W_H0Q5H^D>A#L409VR@64
M1B4DT(Y*B&(=/P#=I1K4BP7, C.> E7]N$"JEJP#!5(@EK."$@T)R&(/K<"!
M*1IQMW30  ZN$,,:4O %7RF#' -@ A2KP0)3H$(5IB" AE:U"PJ0J7[4LM9Z
M&F& WK0$$@=8WS]\,0(/8((@>G@!+5"!"SE0#B$*80@R!" *>:4#!TJH24LP
M$0!WX&,(-<'" *I1!7C(RQTEN ,F&3(&$W"C 97_8)A=@J(3GOR#'CF8&$Z,
ML((-#< 7J(!$ Z[@G6<X@!.H< 4<!H(-"5CB!#B(T5;.X0)?>",+=>B'V083
M2S4(XA_ *,$^?L8'H1$MED=+FF4:I*:@P.(!2. "%X9  #4P1FL-68(%3F"C
MM/$S;66S8S\#&IJ6P (LE7B!$*[Q#R6L@4D#6$9/X.$/:D@ (G78P6'*88->
M]40+3#F##_S"I'^,P0?_T(8 9M*E?TQC H$C2 ]BAHH)-*,GQ= &0TXA 6 ,
M"1\FL($K_M$% ^R.(5.\VS_TX8Q_N( (6V'%/RK!I7^0P@ -X(:,&/(-(S2#
M&=O@@PVJ!(V";4,&67#$_S\0XAUZ)$!Y_YA#&PCBC!7510L%N&0Z&4*+"2C4
M'$+H34XTP()]^&, 2@@*.VBA-@:2K0K;(,4RB) $R@&#H^4PP@*F<*A!!. =
M/5D"%@IHOJTP(P=ND!9#S'&">K6$$$((BCF(4 MF,(,6 UCJ/ZZ U18D@4?)
MZ $*87@#G."C'.G @Z%Z$@D%&,-YVF@'"RP!A'/@HP3J 1^F<%*& %PK50TZ
MXGK8D8XD?&(]Z@@#"=JQ'G2H8U4,&4<2;E '<=2!!G^0X#ANT">"",$]_VC%
M!/:3!52M!QK\"$8/EC22!B!Q+_-X0!Z(Y)VCB.X?]] %!'*QGCTDP!_*P @Y
MXO\0@,.(H03F( @IP>'(C(!" )EC8#C8\(,JX40++D"'/;Q0)6OXP 5#Z >#
MQL$$'<3H#EXX!PEJM1YQE(,AL^Q)%H(0%'7$H'DZ*> _0K$ D6@*&TR2"BFX
MVPP-),)^/?'$!&S  A9PH)!$ZDDL76$)@@!C +TK1Q B_(^AT<6<!H#&>MS;
MDDW\H,*+<, PS&&.?I1@,0;\Q[7 P8L7K" I KUT:/XY6DQSNC(MZ40?PM&.
M%ZQ('$=PTC]6X8!CI,,<_N@#-;Z1@4Z,1 =!,$DM!$ 'A?PC!!R=@PW:88YQ
M9 ,._[@##*0""0O$HF4H&8<N(I )?G1#"0]8!CARX0'_7O"#'\GP0DW'H0@/
M>.PS:QB >A$!@>8R9!D:N(6BQ?&&7_PC!E50]#AN,:@U*)0@D2B ><XGE"W4
ME""^N, D_:%2(^S .W3800&!Q(@RI<#81ADC0_3A HN!@Q(0/1]#;+& ZW:!
M0N,0@@2X5(@(:()R]8!#+\ !BV<P*(59L<\"%&L,Q!&D'2FXP8G+D ![_,,>
M:.! X !*D'& X ?JQ8D)W+">3U@L(\U@"D&\D 1T_(,+S54$ (1DC0?LYQ]N
M(#)!RB&)<*!A)01Y1@/&R2CU;((!<L('"WCZ#T-PH">FF("&]-$[&(^$ )3H
M23< 40X"-(L@QW!$-#3P!]A!_\,,"@;YDRXP.U9D8!(920<,A,1?+J2H ,;A
M108T')<LZ,,:+* E.2IP>)?1H0 >(X@B%D%5%F"$(&DX!A5>2Y!YR, 0_PB#
MG/Y!C@!$ WP_H!Q!#G&/3_S <,8@01.\RY"6*I8@Q'A(4J^ $VM4P ;>8:PL
M MP391@@%/\@ P4<1Y!BM$%O_]@$Q#/""PN0HB> *$#S(<(.<-W+"( N_,,V
M(("7$40E>)@-2$7X#$-EV$,T#(,P!,$=/$T4U<4_+$-<_8,WJ ,(H-4]S,#'
M24,/I)A4,((!'(;+$ LG/%%&Q((#',8_B$,)8$TD! #1T4%9_,,U!$ X=1H1
M5H:FO?]@$6(:0SP##7Q!4'7"?KP!"Z@ +'A#&SQ!&AR!%XP &DB#"_A 'O2.
M-@@!&C1?*&!!$'#"%G#!-H1#DNB %W!!$:R ,CS"#\R 'BP)%$A &)1/2W2#
M'1@!'N0!'#R!<3A#&!C!&^1!'MS!&C!$*+#!$YB!"[:$*K3-/S0#$W@&V1S!
M"[P3%V#!$=1#&,S #<#3$.A /$#""RR!!!*$)5S77NR! H@!1N1#'^2 #QP"
M&,P J?"")#S)"I  (3 #%>Q $'P#^+Q #?P",FR!#5Q">QG%L$0# (  E@7%
M*FA!#D!!*"0"#_3!*_8#%RBC.@C@$Y !$/3).I# 8C#0.&S_P@$(PGM)P@"T
M "? @0T8@@0I@Q68 R#,0 _(P1Y0@1](8#9EA"8X%4/<0R'TP G<@E2\ A+\
MP"=@A#" 0 R(CBM000+, 2>@0!^\0S[,P3T<@QS( !-H R"(0 _X01S$@0M(
M@C:<0 ",P1K,@0S0 3N4@R[\0!FP S*<@#AX@QY<P!M PS;4@ #$P1K4P0\@
MPD$ 0+FAA#HXP@9,04RN 0@PPR] P CL0BL,P@E U24TP JLP5/6E*#]@S$,
MP&&L PM 53CD QUX0!\ 0SB@P@[HP#?X0QA<P"' PSB4@0(802\<@A!P0SQD
M@07H03W4 QY@@!?\X%[PPQ$8@!*<_T$8J,$]4$,2:  1Q,$>2$'N[$,7N($J
M=(()= \8;$ LA,(<9$$Y3 ,2"  L:$(;-$$;),,10( @@((9X  3 !F,,<0B
ME$ CH$(NX, =E,,Z. (!M$(Z, 0OS,"V$!XGV, IH (O], K*9\7(( DA,(A
M:$%]9.(2;( BK(-$C$,<W$ GH$(@_("&%0,0:( GM((A'$ 5A ,W$$$$?$(K
MM (?  $WR,$%Z($ZF ,2O  D>(=E,$'0O ,*%$)E,,,.N$$>] &$S,(4M ,F
M@,! C(,ON)A=V,4G4(#P_$,N  &081XY# $+8!5#,$($J )!G,,+= \F( !6
M04$:<)TLP/\ +24ADAXADB:A1)"#,:1#D[&$/\3#/M@#[( (-12#.N@#-RA$
ME"X=2U"#-$P5.% #/<Q#,12#,5R+F=*#,9S8.G2#/*22'8E%.$"?F=UI3U3G
MLZ&#1( #C84#.U"#/71#FAK#.I@#,LP#/1PJ*4%#/!@#.9B/2*E-/+AI=99#
M,;Q#/$1#,D3JG=Y#.!B#G')#H]H#-6 3-<S#/EC#/1C#/D##.,02/X1#.;R"
M$ZB7VM #-]@#8QK#/ ##I#*$.H@#3KR#,0C#DE"$//@I/!9#/'3#GT*#/'B#
M-)@J,#CK/[##.'3#/B"K-- 28X%<.U2B. S#/'B#,=0$U<P#,E3_ISX80SP8
M:SB<JC%(0SP@@T)(13T,@Z_60S'$*B0X@B-DPCJP0B?T@B=4@BI0R#J( BQD
M CF @^DH@R*< B0$PRK PBDP0B7H0G>%@S?\ 1HPR,/V BPP B-<PBFPPRWT
MPB]D0J[P O3% R DPBL$:E:% SHP0Y.! S;D@T2< R"<0B!D@SF8@BB(0BD,
M0R"< B#H'3.P 1YDPK8$ R,8[3S,0]9F CVX%T&@PB54PCY5@R+4 B2H+"5,
MU3_40A40@HXNA#9D B7T 2P4T"YT@BED@B)XK#4P0RR8 B   BPDS7'BA#:4
M@16L <U!VB+$0BZT0TNXPK40'K7L@16(_\$^,40Z[ (4P $@D))$T$(F] (@
M^(/Y:(,=' $AZ%TU+,+>=H(CL$(!66PMB$(G=$(E6*LB],(B !DT> (CT 7(
M,4V8Z$,=?(_-D$$5&,$7%,%3_ ,F+($=^(S_O,$6T$&MAD,RI $1<$(![0K1
M85XO,$$3D '1T0(2R '!M8,5^$ -] (VG  0;$(]D($0_,$8" %N+6D2*JG_
M=MJF.<Q8:(;Y*-VF%;#:+);201-?)/"X'G "9P9U-+"9;: "(R$&>Q>*G<$N
M9)722# (:]]H6?"T//"X+O )OQD+3W!0:+ !>YH!2X0W[ '-I3!H0+ .VZFJ
M@&TZ/3!FM*6,Y/\5"@/Q0!WN"PKQ\"3Q!"-P$R,A#"NPI]7/G:Z"'O"%X0C<
M/Y!21&0Q18 #GM9$6Z P=7B&/I#2.+@#.,C#.<B#/K@#A8 #1IP#,A!@ !=A
M,E"."]\QDR(Q#I-P0N[L<0JR'P]R\>[Q% ?R(1<R(5LN PO:.Z1G"!\N!1>R
M)0O:)4?Q)&>R(C]R(V?R/YB"[3#R(G.R*9]R0OZQ'S?R$B\Q*A/>*\/R()^R
M*\?R)?^#/%C"(ZER"=>I+P/R /NP$4LQ'V-:'E]P,2,I)Y.Q(><5)9?R,B_R
M$7<R,#=S->^P#I,&$E>R+6.S)8N-+0=Q*L?R-3MQ-Y_S*DLS-)LS.K?_LSN_
M,SQ_<SG',STC<C*?S3';\ST+5"]+,!,7\0SK\PH/] _G\!]/\B$[LYT"-$.3
M!A0%\3JWA#!KL0-3<PSSLC4S,R;7LS=S-#FK\R-CM$>/-$F7M$F?M$7O<]CD
MLR:KM&C 3CF<V#_,:C@<2I-1L424 ^6 PT!$A$X/!@OSA3GTM$^GUC^HPT"D
M Y9-!#H,1#ED(\\ZM;$.ADP;3CB(5#EDL4:S!'M1M0QS8%TT"$Z PU1W\<V,
MQEA7AE;CA$QO,%_@*1$'-6;<] L+M-) D<L<-%IO\D./< XG-$&[L.4"E$#;
M=12W=");, 07KU]KLS^#M&@$LSYO\\X2,C,[_S,KN[1F]P1+;S8_X<(41($I
M;$,71($9Z$TF@$ W900N[ =#N$(5=$$?P$$5C )!R (3>,$5# $10-5>)(.;
MP88<@$!P:(X6% $@/(%3#@$:D $2" ]#-(,?%$$;[ $7=()4/$,?4'<>&$$0
M' (TU,$07$$1^ $I38(0> $:4,A>=(+NU<\D'($:I $?H"\:1($57,$5=$$5
M<)TO2$$1I,$8+"M#!$(4%($2Z,$2X,$0BH,?@  ?Z.HXY,$24$$FW$,8+($5
M>$$</((0*%: 3@$F5((D^T\0:(%^"\$2V (O@, @]+0^-($4( (9+(%^ZS<6
MY((P+$$4Q$$\_ (G#/_"($A"+AS*/*3!)GR!$%S!$B@!/\A!%UB!$ R!%GP!
M/;A!$GB!5/Y#(]! %;Q#2[P"#5P!%P!!)!!"+PS#)T0")M #/'!"(SB"+/X#
M)(030R1#$BRY%RA!)' "1C0(0&K!$52"+4C#,5C"(WR"&JB!&/3".6!")!R"
M&"S"^/)#(^C!)U0"(9#!)/RYY@@&0VB#)6A"D!\"(G17.V@"(A0"Z)A#)V "
M)[S#-!@"(MBV/CR"&A@'3NS" 14#(3P"(91!)$BH+$C"(Q@"+6"5O" #7;QV
M')3=/_ #)FP"V5I"'E#[(^C! >*$+'Q"(PB"/J3#(GP"N5-(-A@")Q@"-HC_
MPR0(PB=\<#IX B8<@C-L@S \%BDP@S7PPS,( S&0 BDT0T^;SRWHP2P _#18
M6BH\@C0LPY)L@RTT@S1,!#Q@@S0H YASKS+@JS-( RG,@S&00K\O@\A+;DL4
M Z!)1#\P S$89TO0 S$H@S\\0S#\.\!SPSI@PS?8O#+*[39\@WM.!#@@P\]_
M@S)\PS.0@C) WW'> S8$@S9@0WN%@SE<@S940S9,O?D,0ROPU/:VA#JTPYEV
M&Y%8 RH0+P.! SI(;CFTPT#<PXFQPU 7D#BHPSV,PSBT0SNP V)[-F9T!C+[
M?637=!PD0#V$PR)\P-T@ Q6<WP3)S9_.0@34@CO$_\$$> PX] (#Q,(PM($$
M2$9+-,(!$)U$R(,(%$!64(0:<$(RW($X- ,&X$(ZZ(&.MH0M8$ IJ$,<6$#<
MU@(&(&TQ;,/:H0("\,(P5($(Q$,Y9 $+Z /A@0,6H!I.@($/!(,YM$,A/!\U
M&, >  ,P! ,;*@,/8,,P#,(/?,U$Y$,=", VE(,I+ #/_4,QW, NI%(\6$$#
M[ ,P+($V_ (%& ) 5(M4B!P/,,-LD7CV+UQ#<YH*\ (&;%66>H(8S$'WSQPQ
M)Z%,, -V(PDP4W;&'?I *)VV!%FJT6$PB..V W4F9IL22\ZW4A4814L3B]B/
M%_7^_9-%X-DX<.'&U1$%[/^+E6JGA/ 39.%2NW*T+)1!U_ ?NQZB&/Y[-0=8
M(0BTM/TIQC#</W%,HE2+YJM'H7.3+M31I*G,$G:!(&B)5*2!K'^H0D2J0\%.
M)"FYTK*;T>K?TWEC .RIEJE D7'_RF5C(>:<PU0"3K1+1J("LG_HP/3PEID%
M+[KNSF PHRF*D]W)J"R@(XB'H71TZ\YID_3?,R("UH#[=^\3!$AHJF@*D>-:
MI"FGZR:K,:"4.C%(5,4*X.S?-!Z 5#D 8^Z7!!W1.%KD 3:0:6,"(Q11! XL
MX-'C "H4J62%&%R![I]2:C!!$4^H&.&;?U)Q  %)V@F'FQ1BP"8M:KPH((9X
MDE+_Y8$Q@I'B #..02&/1PA \(A)Z/HGCCF2"J<>.@K H\A_QI&B #+FF:2!
M)1(48P9@ B& 2C56P*+"4:+0 )0@JSG@!E5<N>$%0SB1HH5;TJ(N*7<^"2 %
M1]9I:!U'6&"AD#S)0J:*.1#!@PE*@BS$BSR2,($..-XHYQ]YB&C"BB#B*+*N
M?_IX0HTNB,@C"E@6&6(*/-XYA@D0FFBF$BJ$4",/.X*P1\Y;<<U5UUUY[=77
M?Y!!;]-?B2W66%_)*J8".->Q@8ZZ.FDDR%E^X&&>M)R9 )7M% #RL0*V^:<?
M!"H)LI\3)F D3CQ*X "8I'!AY1ZDKIF EG_2J:>ANE29_X"^?@1 ]!]:)B"&
MNG?^L4:%:OY)AH%,_L'C!NWV)4L7%GH8)BU6-F!%SC#.^:>(<I."YIU+ H#Q
M'S6ZL5"-'L3Y!QX?'DC#G*3D4,5"-F+XAQJ#MRE Q7R6D8:!79)29!4+V>%!
M&^J:$4>=$S P)"ETKBB&LW^F8"(I97S>(1@F4S@CJ2Z02$J=$M2@KAA7N/D'
MGQ)LBT?%;SAX)*DV3F'HJ7+"_<<,$9(*Y9]@>. G*7L,\"3(13*(0M)_B-GM
M%P6@^2>>=_;]QY *^J%.&"W^&:8 PY-BY;D3?/DG'QBD^(<9SD)!P#9M8DD+
M$ #\\/N?>EAX6F0/]* ." #)^O\GCQ[<^:>6!(Q)RI![R5KD C>6;*4 V_;9
MX(ZD9IF@Y3(>")FL9!  0=)-IP  $.KDH&:2=83T(:E;U(GSCA"22N&2I"ZQ
MB7_HH0B%&T-2I% %.4&!8>:PP;V2)H]_V  .<Z+" 336.4I$(2GFF,)Y+E2
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M!Y9*>]Y%0$+7%'2+'$Q@".3V%\B 3\?A$@A 99Z@]*K# J:O+OA@0CM7#D"
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M&P8@"M0:<1>8 LBJ(<IA$AA@&M*!3Y5A ^S@OO]A'D1 >9-B'@P "/@A&T[
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MP2[^H0Y" , 4Y?A+.XKP F=4@Q$I:$$QP#$,!_A!&]JHQAMHP8X6I* :J8!
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M4/\!U@ 9_W!U"+$&+Z HU" %:P &>Y "=8 791<8]M43RF .X& *O(80BH
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M$JTP>M.@ #XP9I)0 B%$#1*&$/<@ QCS#U(@8>1@ G* $+(  8( ?7JP4#&
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ME/ +S[ )C%"4,_4(E5 )B8 RC- 4OF (KX 0U_ )FN ( N+_#Y&0H;@0#JE
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MH ]"-KN_"[S!*[Q&4KMV$J"*E[M0H0[S$ ]0-+S/"[W1*[UQ4;RM\A>XRR:
M 0_((%6..[W?"[[AF[75RRZ2LBCN, S&YKWBR[[MZ[X#2[Z>XKNJH;36X(+O
MB[_YJ[\&&_^_V3N_E3$.Z% ,M+2_!6S !PR1_8LH="L^ DS " S!$2S!1Z;
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M"Q*P A Z"<.@#B)0 9RX# 9  Y6($-] YB#]!1+P ()8!A,P!)R "/[V#VQ
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M&XB#ECB$ /"'ULBZX3H,)A"F?T ! D2'&7@/)G ";SB'53 9>C" 2?@H-""
M>=C(AE@#86"'01B!K4 "0L *<>@!POF'5^B)9B !([L$ S"O,!B!?Z"'']!)
MDG$"+[B*'"!&:!  YP$L=-B#)%@()OB"JS""<]"BA^@& ]"??XB!%="'(-"#
M3 "$%W #2O*$'=B"2E@#"' T3(A,6%B(0M"!7X %*BB!?QB$$TBK9N@!'9J&
M/UB(&' J1] !?4B'3= G,*"#+$@ ):@%%M"A;MB!8U",+[ "\]B" > '>QB
M,?B'=L@"T &2&#BP'S.L?^ "/ L#)'"$2O^H 0>PMZE0A@H @3Q0@SQ @P<@
MP%@H 4)DAP:@ XC0@700!Q] A(6@ CRK@R6X!$T@@"D0!RU@@W0P!MI3#&>
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MF 4\F+SIX(0 J(T_P($8_($>M)L6<%5\R(%#V#8)Z"YS*(,UJ (N6 AE_T"
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M4=?:DFV=HFY=E:FH!01X#V53@#?#@_AZB$/8@77]C';=NG]X C4*!Q<P@G_
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MA>B'9>"!P8P%&L!>[369+_@"5RA909!@AE@'< B_!7"#]BV!4ZJ!.D ,;"B
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M@;G4A@ X!7-P! (@1#BX@9': 6^P!VG"[[E;AQR@SV*8@&>XA@\P6#B8RX=
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M"(3Q@PZ7LN %_U/HS&="4XG1G"8UJVG-3&(! $<8YC6[Z<UO?O,?^"B! .Z
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M<)W/.M4<*(ZIG'UC@CRD-[7HJ(,%))'8?UQB!\(E8R!]4P@.;#.KAFG%%W#
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MB&A"#<" %! "&4@!'=@ %OR#)CS!'H" T7$9'.3!#B1",#"!#5@"N@&" =
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M[,(3N$$PJ,,RF$$I] $/"<,<=,%1KD,HY$$[6$,G/,(P: $<*&,_2((6;,'
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M#WSF/C0!%^1<$?B ,,3##W"!--A# - -''P!,)""!D!=6%B#!I D8ZH#(#@
M&)P#),P ./"##Y"D/.3 _OD$./#"": #.V1" :2!+>2"*=Q ^1W" %@#,_3
M%U@#+$@ % ##*1! *&'A%J2!_SC<PR](0"VX@R%H@!C( Q'T "00@Q2<P=,D
MP3O< Q?D "RB0RW,0#R80S;8@#" PR!,P,$\Q.W]P#R,0RQP@!1J0@)H 2E
M@@-P 2N0P0MHJAP@ C\< @"L N507AJH@RQP "JD@Q],P3_<@Q? 0#@ @@K,
MP%/N0A7$P#]D A8( "+4 @)0VBB\0#'L0P+4@,LZA#64@"WP41'H@"[L@@.$
MI1BXP3NT@@>,GHA@PP$(P25<@A5\SSI\ @!LP^"VVQ[,P3G 0@>8PAY00!/
MP1MH0PU<0S]PP!]\0Q>, #C@@PT0 ])5@S_$P#:T Q-4P +Z4Q#P #PD0Q+H
M #6\0_\5.,,[8 $2*,,0*, 83,$9;,(".,,_J(()=$(V8 $(O%,:N$$VT($
MP T64@$*D& 8Y  VC $-C$,_> $S- ('N-RL)$$2-,(<L$ H18(<',,G'( S
M/"\36($81(,4M$(U\$ AU(,;O, ]V(((!$ >Y($!?,\<-, R"(((M ,\8 ('
M*$(.\8 I ,-(9 (R\, 1!(,+P$#XF%!8G (-K,+.^B(H5$&_20 C=,,@<  G
M$,,L;("?;<($1($:<$%P_@,<Z($PI($.Y /N*D(J^$ (O-,_8$+(4DXX2$$1
M:,$-&$ NB ,48,#!I(,+J %PI(,@L, =O,(_<,(,C,$;4,#_=>B#%7A"*?S
M&:34&H#!+LQ )RB# 6R3+$R 'JR#'"1 $]R #VA! #R!*"J#%80")P3 *$3"
M ^" #'/ M6 #"W1"(P2A!?H!)^3C*?C"#LR $.2 _?W#*+B *&SQ,J #(M3
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M0#HL@PJ0@26H010X N740@!<B4))VR'$,QO@0&],@27^0RV@P$\4 A7XQA!
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M<%A#^( RO#,,Q(H5''4D_  G> (6\(!WN=@/^)DJ8,(_.)MON '_&H2#-#1
M+MQ#MVQ *) #]V9!(WR" [0!.$@!$J S"V"".63S9K/!/\3!"#R"(#S #:C#
M%@C!/=##7/Y8#<3;*<Z O5R!)=J($4C!KQ  W;1!%)P,#]3"/P#!'_P#,VSL
MC93#"2@&H<H DC.!^@T!"/Q#*^1 /RS##C!!-CC")," '$1"+VA""2 @'T(#
M&KR *>C#%*1!.-C""+A#GQZA.N^(.1L&.B/[&&XE GPX(7C!9J\T%K!-/MA
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M 1R((($X=., 8J!$%&R6E%YPP K<>(4!@@"/6!B  RK8_X(Z+ &!([2CGE%
MP ]:0(QZ]&$#>'C%%0C@BF<D0 ?+@$(.YG ' GS"'E#0@!^$00\>I  2ZC@#
M G;@@U<<8PD%"(3)KM((!6B!#S[ 9#U (($?Q& >WG"#!L[@C5'(0 ?($(4"
ME""/1VQ@#^H8A 0J\ (Y_",7!XA"(VPP@$2T)0Y=@547N! +1B3!&3@:Q@N.
MH6!QT" %9R#%%"J@C'-@H0'1X(8/"L"$%:QL*>50016B\82[,&(#6> ##FP0
MBEED@!#W$(<: ."(RHB" C+@P@BX80P6B( >RYC %?K1!@:H(1 L($ HGB$
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M!6!(;/>U+=;!!Z062:0A"K  '-Z!"&8@T40U5K1D6 MB'!3A 8)%3"=!#80
M!]2W8UFW6=?!$NR@!""(5)-!"7!@'XC3.5?A 7J.2\=A$NH@#>K@#NX "LI@
M.$HF')HA"F3F*M#_@08P(1[@P 6>XBIX00H,M17^  [P8!#LU&/U5L&0U&2,
MP1$X 8CRX1G6H(1K]U#;H1GBX%]LMS=IMVC!&#Z;P,;TTU4#=!J8YA\DX9MF
M-D+=,SG7@APVD@Q4-1Q,H*,<UAODH"U*80;"!G),V(195CHC])"=LQ-0@ 11
M[Q]@(:% U-+800W"RM(VH0"ZP8'1P$KD,SX=&8C<@1E ]Y/5<BW&8 /Z$%'U
M$W8/=$N05I+[<RE>P2D#=!.-<QS. 00:08Z=DQP\:&/?CP0SX6#4(0]4&8C$
M@0QV)!U@@05"T$D]@<!(D)J1)!AT(1SL(0J"Q90)=1AD8!_0 0P,UI1Q_X1A
M-E9#L7,INH$5D40-FL433FI0D[ ?H$$37L!FV%,8VN =G+08NJ !<D$7; $6
M;.!?6C<<A $$[N(JU*$,2L$>)"$!8N(J<L$/"D(<EJ$$^0$6+B +K*]^ 95*
MO0$E_S5'%*!1)N(;OF "(IE)<X.4KF !5)6,;U.,:WI V>$2$N 2\$Q#E.&+
M!9$8=F(MD.$;*L,?IL /;$8,C(!,_NLRHN$;6I0<:/15*,(:K*$;\"$:O*$8
MQL$:AB$$9?0?6H$$? $?T,$&]J!1)50?WB $!(H5?* <]H'62B08L!4SQJ$:
M2AA'VJ$:#/8R2,H;/'1:DL)@^R'_"@(6=B0INO_!*??A!+:!-X5U2P0J%D#
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M!8O@!8SP#UR@!+E #V"P!*#D!5<@#J>0 5H "%,P".Y@ VIP,R2V"@#@:F-
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M$ @28 G4< D/L 7OP 0!L#L]X :L\ 4)T O]T"&'H [_&)$+*/ O^Z0.D$
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M75?DTD)E?SQA$/  "AH5#N2 #NAP#^R TNW@#NG #N9P"TC@#:[ >?Q@U.U
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MX(4@C#05%1##"F;0"B^E @I%:$$E<8$%,L0!"5.A23(&\(8JN$ -X)@&"+H
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M#",%(=#%&# >6AD,812'R$ DTH&'#-3/'4A $ZP27@Y /(!U!4G'%SBQ#C]
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M!AKXO%O(@1T0 T&0@5I("#IH@&3 A!1HAUS(@14X!#50 ,K"B'O @2?@AB4
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M.8B$+D@#^]*B&]*!=_.$+LJ#%\"XN/B'A?V':'@Y?EF V,.(N"I:N$4#?C
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M(GB ;$"U,F &!J@D<%CO?Y #'# =%-B"?T@!:?,'$J@2;+"!UN,@$[@682B
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M'%NVP39:_UBV<&XY3%T@5SG+,P8M(,W,Y#.SN<T*=K.&=9S>&\NYSF-S9-8
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M(_2-+Q@"(ZQ#,:P #]#!UP%&*>1!(?3;/^S"$?A &T!<3K!"#NB *JQ#,/B
M,4B&>_S#.VB"))S@X(A!#SS..03 %N!1.[1#':V#.EQ#*-P#C/U#-%C"*V"4
M/_! -&Q#)+A#3K##*<0!*> &,'P"*;Q#X,@#-/TB8-B!#RS/.20 $/P#-/A#
M.X30.72#UW #*A"#^JU#+%3"57A/,O2#.#R#-?Q#/9#""S&2-8 #-_\TPP#]
M Q9X@CG@0@4T M;)0S'DA#_@0SXT0TW^0S[8  O>)&0] RN@'4^RPC8@P>_!
MS1=\ CDXPVV 4#5X0SBTPS(, \QX Q300 F!P@FL@S/$C]=, RJD#D?JPSD\
MP]8DPS;P SA<@S;X(%8L V!P@S;D1#=PP"+6)=D@TM2TFM>@4366 S\, 1G\
M"F#L@P&0H#W$04YX08]$@PG]@S^@ E'B@SGTPTH. RD<&S%4@PG!C"4< 0*A
M8DX40RC@1$Y89DH,$#"094X$PVTAX3B,B#3<!NND!#L8C]O8%#S$YC]X <\,
M"-D &MGPP_) C3@89DZD SCXP0G@H3K,DSC_U%?4U)?7\,/GQ%0^9 8XS$WP
MD,TX/(XP<0%)>0U>Y(3Z>8WZ10366-\"!F$EQB=Z 5LY"*=\PA<M^,    $5
M<( 3U,,A&( +<$$%1$,:],$S ,$.8-THY( BU$(-Q( X#$(!),,Z $$ 9(@D
MR$$I=$$0=$,?^  B+!Y@J(((X$(O*, :@,,H$$$*%((VA@,JT, 5, (Y  ,+
M;$$A.,"G&,,0H,(I&( GR D9/ !Z),(%I$(V5, NW ,F.( Q3(,*\( 60  O
MV,(2-$(0!($XZ(,.& $1P, 2Y$X7+ $BL$ F_(.Z14(0T,$_ (,6, (AI$!=
M&H8=6. _] (&*,(M_P0 %3Q!#J!!"CQ!3B1"% B""JS!/Y #%$R")?0 -P$&
M.NA! E0!'4R!#@0"%*Q ".0#+93 %^3I G >2RX"/U3!#MC!-3Q##@!!.!#"
M#T !$U0  7!33Y)".=!! -S(.=2!(Q0"#W3$,MQ (1C! CQ"1C76$1@ #SP#
M/:0  NS"/_0#"S0";H@" 80 ()1#*YA '% ! >RC._A!)4S"#)R3I*I! Q@!
M'.Q %8"#*6@ (J2#)1R +\"#$0"!(E3! >Q!)8#KC73# .P!&DS $VR--[3!
M%L2 $/##*BP!&;#!"70BS-2"%?"')H0#/<0!#&A!'@#6/["#$R@ )MQ&,?\
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M#<A#.=@ %\!#/^3 &ZG!$.3$$]A!3F!!PZB##>QM/:2!$* O%<3 -T!#$KQ
M/HB##;!".'C#"=S(':P -J#"#@P!.J2 )6S/#1Q"1FW!$$1#,:" %'@P!###
M/] #$,Q/8Y+G/[C" W#,$5@A)>  ,Y0"#^A?2HS#-JC $<A#,Q" D3Q!&N0$
M"#B". 3" CBP&&0 (=P#&:2 QKY %SA#*DA V](!GUQ#!I3!/-# "DR#).P#
M;CA##MS6+F0 LH[#%'Q"-Q$#"'S #3QA3C2!#(!",N3 *IC# S F'QQS+A"
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M@0(.&(<ZZ, 4GH 9Y(01: '4@($(#(,*Q,_A[%XQ_$!EH (,2-\*=!J:G,"
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M/UP!#CSZ'ZPOS+1##O0(, C =NAY)S<,*13 -?P#)'# H[0"/=,#!XBM&:1
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MD 0M*&,<3[&"+C!!A2TXPPT$L,0B?*"*-@2!"$51!R)(P (SF ,?70 "$/1
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M(*GX@0@.80UL8 5*H1AFX!*@( $VX1[JX/\'G, -[D$2V$ 0NH ;<*(<)D$
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M(/Y#"#P: PMVX<?K;*$&Y]B&-+^&T9[DQ"X9[:A'D_:0==@ #^"P"R<"4!9
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M!$2B"B-0 $>@*PX!#8(P!'4@#!61"%HP!U9T#2O0!7W@)N=P!D5@J?: ! 9
M!$A@K&HG P1@!NB "EZ0!0@8:$$@!%< "X[Y$.!0"$/0!$-0!7B #>%@#FQ0
M 7I "%,@"\?0 C;@,D7@"W00!10J#G^P Y\@*XG0"U'@"_$P!C0+-C/P"1GX
M<3<:)MR  CR "'(0 [4P! 20!\)P! EP,[80 #10!R,@!NX0)JTP "N0"W%@
M (30#W/0'F^B @+@ \WP(>'@#$9  "# */1 !RJ0 HLP#I[ B'G C>#P"CLP
M!/)@#TZ0 WC0!#" "^%@" ]  "<P#/5@!0?_($O]\0]*\ !H8 A80 WI0 ,^
MP 9;( ! <!2!,Q5!<@!\8 A94!8/P0J9BPKL0 4A( I0\!1AT@P(( 31:0&J
MD ]<L '98 Z20 $%\ #4V1#F8 L/@ +,T MBT 6"\@H"( $X  +Y@ H?H ?B
M,"^(, Z&< %W( D[  /!X \@0 $M( +7$ \G, -+^*!?TZ#GJ[X@%2:*$ +2
M!%9><7]# &DYB#2S]A+I"Q/Q6Z$Q\3'[RQ/\"U8#/&L"+!,?8\#_\$+WRQ'R
M^[\.\<#[]0_DH 0:9A"JH&+1\4)&%A,+S, (H50OI!45L3#611* H\!VH5^T
M=@[Z, YO50XDXB5V_]$.VN%XZB##UE,./'L/('(/WV!=YB ?0O4/[  X"W,0
M]#!9,IP.&\51W+!*C@=6^P#$\IL.%"$.4*8.^0$/JP0B36P0QF 7@S02Z5 .
M7QP.Z8#"_L$&D#4R^6"%ZM -Z9 ,T( ,YQ -W< -8RP-^?!6$>D-<RP-T) ,
MY  ,A#S&QO!=$ 1!\_ -^X ,E]$/VM -U" -(P$/Q/!-_S .PV -PP ^]P ,
M]% .?_P/T& ,4K,>T% ,2,,$(2 ,Q  7^! -=J0+4H,[;P 7ZU ,L1 +Z0K!
MSY *'Y,+B=!:4FP+M0 /L: (JF /@= :;><(2U$7[0 )BP (BN (D2 (X?]'
M,HX ";HR"HH "?- "HH ".!C"IOP#*60"]($#Y^P!:2&#9Z@"&*\ODRCO_G,
MSSY!:X] !.?@Q.$P#7U@-1DUT FMT$BST EM-E6A$QSU4B\5$Q MT1<=T0-L
MT1H]?QB=OPS\$!M-T551#!R !LP0"J; !RQ7T277T2/=P/LKP!9].?LLTS5-
MT?+[T3A=TS?MTB\=OPHMTS-=P#O!4>*P"6>0!),TT$8]TSDM$T'-R/^KT_F[
MTY?CTU4=D?\ !/['N"_1#*1@!XGPU2]MU1\-U2V-UOQ[UE@=P&T=T_TLUW.]
MT+=6#2GU$N"P# O3T&P=P'U]7%/MUP]JTS-1V$;_4]<:]<$/00I%0 (T0 >^
M,=158=A"/=>5G=:'O:#Z:]/]( (/T+J 76N<_<'^7-J+-0(S0'-2C%X L 8E
ME=:X1MGVZ]"7;=NWC=E-+6L1#<!27-M  =B!S<B#[:":/=G$732)_==0_5+]
M(,-//=L5;=FXC=/1;=P[2-JQ[24SXMN_7=RGO=S1O5BTH MO!-3A4 W4!]ZY
MC=P0.MW4#=^7S=#MK<^+G=C:+13INU'(%1WTC8/7[=;BS;X9+>"Y+=T;?=PV
M06OK3=>E'=+^W8/VC=\=W=T3/MH,KN 8OM8CK>$;SH/*'=\ASL]A4@_O8!?\
M8-ZQEMTCXQ#OT,0%GN%A_Y(.PD [^TT2]B#!(][A68V^06WA0QW5[\W:N%;=
M(J[=!-S/*Q[C;;WC#/KC,0[A:RWEBOWD/:Z#42[B6>[D0?("?Z(-)A!Q*B[A
M$]T1$H!Y,"[;/5*C'# X.C$.F7 #*X7ENXWF,?$*5M!['O6[O7 %3%WG.^T*
M2(#7%3[;%VW4S! & U76,D$*G\ (S! ,N!P4R3 )WP;<!G$/KR 'JVT0I/ '
MW"T3^* )CN )_? +D< (^?4/I] (G* ]2\/;:^T/NR '%''@Z; *=B ,X. ,
MC3 ,.4$/IM!UF^T0ZJ (-AS QT )]=#D\!#.#QX-KR"Q<][D/$$-V #J!TY?
M)/\!EUH.Z]6.VQQ.#D"0?OKJ!#P>ZPWJQ!Y>W0]!#IT6#OSP"36NT=M^WGGY
M#VX @6C ''9A#-D0#M?@ ORW[A5.X88^Y,'='^.@. 2^[G?[5T)MV1/MQ.:0
M#20 2 4OVH&NJ,$=)M5 $0X?)OU0&LPP MY'Z#E1#&[ D]@@#AY/:[K0 !D/
M\QP%#^E0#V!  .<5)II0 1>4T.1P!AX@ NO@"S]P 90 (MKP G3@F37?U^N
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MXQ^C&$$XW+ $A<2A!.&HPEW_T0:RR(, 4B0& JJ9!3$4!!(+2 (KTH$3;(
M[?H'+SB94H !1G&$W3&$ . %6U"%;%B<A)@&_S0 @1<0%1W@C7TH 7K A@&8
MAX(0@B4C"'A0 5T9%@C A7\@@B[XASWP@%PXAC,HB&+0O92K@8Q)A"GXAU*8
M ,QY@AVLBUZ0 &'XAR<@KX+X@N]9B'I0@4FA R2L D,@!Q:X GD2@T3(F"S#
M$@)A!!F8A#V(@S@ )!H A7^8AQ*(AV'0 +KXARO +R1X CMH S& E$T0@LD#
MB5-HB7^HAA^PAW^8!3[4A "HAW/H 1C(!&]@#YSX!T(@@&XP V,8 %A@!$_
MB&ZX!D$H@A;\AQN0A8*@AQ)X%F.PA4'  L/[AQ.H/7\H@6_X!QJ(!0*A!Q@
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M E"QPOP_B" &'! $?G""1N"^]W(L [@W72B_+;A,B0F^(T _%XR_ ( P99B
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M! 5X$ <HX#+H+C#H+O$R%GV8@6M@3 DP"IRPA&0Y"@*0!4TP *Q]&^V"B&6
M  OZ!VE8(W^H@D0@@)E+!@>HKW\HADOJ@OWY!S"H "Z]A (> 3.4A74@AAJ(
M@7F8@93P+4Q@@A$8$'@H ?-XBFXP 33HA%'@@3  Q'^HA1C(&$L0U%S@0TS
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MAS= @<UJ@!PXA#& @BIQCB3( $/H!1?8A7J(@F\\ @[8!G'X @P8@UUP@E>
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M_N %1#BC$YV*XO 0F"!KM&$+0)"')BN'CE;<X16MI%P_/,$$9<P2C,K @Q,
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M7@HGIH8E] 0>7DI'#>[0DWC\ +=T@,)[LQ>C!PVA#.ZY1P_&,&#6C&$W_F@
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M8 TQ?G$-8\LC'JKZ!RAZ,?AUG"(:1Y</*5BPZWSHPQW\\$<[_)&.>X2>'ST
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M$S@"(6Y#&EB +G #%Q1!)I5"$<#!#/"!.L2#"E1!%G" $'3*3$@" ;1!'0@
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M*Y# +<R"&7B *^S# 51"/E0#D,A#!;1"3U !$LA< "A#/<0#?DC!B/Z#'_A
M>;E &:T!%\Q"+L2G8!B!LR+1/YP!$_1$+5! *[B#%-B!!CX =YE" 4 #.]P
MNO[#"B!!.0P!ICJ"#8!#/9S C0W# 3S%)!Q I+0"&SS./_2" K"2*.  ]@B#
M!&3".I@!FP9#,@!' VB)'" #/ @ /,[""/R#-0R ;_0" D1#/<B $=3#*7#
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M_(,L   M$,, ?$:)/MX31 (]C( I3(PC6,!2FD,S\$ !U ,<;$$_U$0S<("
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M..Q"'X  %G@)$H"A.*1 4I4##10;'@A8O62" SP<#>!!8!0!%9CK%A@)V+[
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M"$3#+)R EV !IF:Q>5PT#^A"$Z@#?Y0,J_]#"_A!8&B!()L!$7Q(C;P#%#"
M8"*# ,"P+$" ,2B""HP)GNR# 5R"G<P 2==$.9S 94%;QK4 L]>#2W=T"5C)
M*9R WS0Q3@/Q%#2!X;XM(Z=#N:M(-A! OWU% 33U4^L+.WS"%[\"!7"74_>$
M%R#I+'2!*40""AB% XRH.\@ D@I&,(S !>P!.A1%/L0U:XP#"E@"*>"!#: "
M&XQ)%N,V,/Q /^C!#GQQ3TP##YR#!@9 BDPR,X3_LC$(!CF,O'R00P.H>;&'
MP3CX &XS2(GB$B<$ #O8@0^0SB HLPY(,X.H Q;<@3TXM#/TH#G 'U-,@ PL
MG2.<\3B8P-VF0XUH0\SW1!;<'SC$@(/)1R!8P1Z0P &KP@\D "9\<DU\0P.H
M4RS^0R7,]SKX 'RC?4\P_#]<@QS$ 0S(4BH<X#_0@@Q4P"'@74T0@K:;48T8
M @ D55%P@\5'>.IC32M<P"BL Q$DP3H$P@5@0C^(PI(:PA6P@S^8 P]($QMP
M0*2T@PE8DQ/D:3J0@%S71#<\0+&%X1O\@R^P@-0Q0I37!""T #K PS#T0"SR
MP@G\PRI<@!FT S"$@'%/_Y\)6/0_*$$<[$,&+,4GT$ FK4 APX)/Y8.0AX +
M> DP)$#& 40M%/_^A3/XKY.+<O6X%1CUSY< ?:8P% IG#X2S@N'^.:. J>"_
M805 _;.U(!O!.5O^Y2K@+=T)$ 0'T4!XP1+!/MOTE?"WD6,\!Y$(>K+R[YN*
MGP8Y)I. *]V_/WT(2C'R[XN*8TBA@ LYC\6(> 3_0?N3KLD)@NIZ7/M'A=*_
M=CU"_7NE8-X_'+$(VN$S3P.M?XQ$$ RRZ-\X'RD3.^$@JR \9$ Y\E( [=^:
M%_P(.GF3^0[E?Z1*E@J@B-X$7/]F%9CGS((B@KTR\4O@Z-^T":4V%KP!&5Z/
M8?__:!#YQZ^!H'_">L"#6/C?IBO_1A5P^R^$(6,""A%,1%2$+Z#_HFU _ \2
MB7[_XH0.!\ZK.!S;UAYXE%D.02&5X&G(95*M;A3X)3$@8F#G'W'<J"44<P!Y
MH)J0W-E!DMX*P<$/>:BP 1:"UDGAF7^0*>&>4BCX;[1=ONF!,WE^:.8?8B9@
MIAH-/B&HF$+*Z:$,RM1QH@JR:$CE'Q!%HV4"MQH)0)Q9$ B&H$*\",>',PAB
MBB-:8.#COV@4T(2@8W[11I]JO(CA'T60(.B$(.XA:)9I%*B%H"HJ_"<?&\:P
MD =\_M$A1&CN060#V3C:)X'[_C''%$H"< X<$^SXYY+_) B*([],7J#/B0YK
M28$?</+9APX$[!CG(#5R..<?K\;QPX40.&I*@D#(NA777'7=E==>??T5V&"%
M'998@KZ1(0 [W!"@EW3,H."%%8SY9Y$$[$!F$ GVL,<>+5KP!(U;[+J!AU)V
M^:&(:'K[I8$^T)C#'V!0R"$0>X9@0;:05CF@#F;6R& -:OP@01!U]-!@AA0(
M/&B=%D@P)8\BZD$GB0'@J,*!/&KA0 1O_BDF "T$.X@8%9A8!8A-_@EF"P@
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MZI&)4]RB%+\PQ2+NH8Y<!&(55S*(,SQ1BT[L(AS'8,0I,@$9=B3B"VJPA](
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M_!RF8!&P(068H!E@@ 2"X 6 FRF&X0NB0!7"(1M$@!=^(0!Z!$OZP0QRH!*
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MS*@&/,CQ@D3TSRL.2,8_UJ&#5OQ#<O;@1 -LP8QM# ,=2_&'#-X (W\$8##
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M@D'\XPU7 $9P-,('8OY##>E%P13$X0H%$*(<RGA!OW!P@W;<XPA2$--2Q/"
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M[A ( ?  GI /O7  :^ +=Q#_#.* "!9P!]V "A40 GP0  G ".Y0!!M@ C9
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MKZ!*[- +LW +&F0-OQ +N: *M2'_#K8 "\<%#*)P"JQ@J>% #[^P5BVQ!V3
M-)8J#K+ "^Z0"KE@"LO@"[[ "S-$"F\@!JFZ%.% "'. !GYP!W?0!&V0-^_P
M"$ 0/=\ !7U0":! !'< ,\$PLJ- !J,@,;VP!6,@#^K !VP@!S')2CX"!:'P
M#8\P#)4@JM/P";=0"^QP#Y/ !+A0";K@:Z7 !X8P0[C@"Z)@#):J#IR0!\:
M"[NP"\Q@"K-P"OC0#Y< !+"#7"VA!W; !V:0#>/ $J!@!)HP#640#>NP!T"
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M"! P[?V>9NW@)=;.J39P33T<V>*0"4"#ZVA6#XT@ 9>R$O4@!B^PIC8,#%9
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M\; 37MB!9I%=RH'&DE=X\8*B4PJPPI=PSED##T#D8>FG/^+@@XMO&,EEG&<
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M0Q\S,,)"W" #/*0! E7@VS^8L((];:08!)"$*A*PB7JPH0#W H$+UH$* ?R
M'/]810"HL19;?. 7CE" -';Q@P T80POH,,_\D$%,:#""U=3BB86  HZ#* P
MPX((]XYED54@8!N_@, UCH$# : A$0.8 QK:\()F>,H)OL"%"APACCU<0!CZ
M  ('Z@$(!8Q@#W*H03^ T84G!.L*9TB%#-2WD0B^HA,5R((USI" ?DA#!#H(
M1SH, 8MK2"$$M-J(/6" !5^00!#V"$(.\( &&X1!()8X 2_0P  C;80?<%!
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MAA_0+C/@@;4!A F(DXU(PMK0,S-H'@.@A']0P5]:A@2H@$;@!Y;@!H/@AS>
M -H)@41 !W%0"$?@ 7ZXB$R@ 86HF5E(!P*H(X$0@2:0"340"!?0D5-9ARX
M!(%(!@7XA878 O\B!Q; !8'@!0E !J7P!SP8@A>@'7Z  >8(AAZ B'I@ =?(
M@MO;B&KH@RH8@%'X!T8@LG\P R)(,_SY!V4(BE,Q!2#(@ATH'?ESM^90AB:
M AE0.CMHKW\8 B[X!W3P@37@!P[(HG]8!@C(!E>0@&#X!T+8@5W_88*L"@8!
M<)\M@)X4<0 JP+N-$ 8)N#B.(S+L,8@M<(%K1()K:(9JL 9U.)5T<(0QV*I_
M8 8?R!-/B(%T((0<2*-_N +\(0LAF)9_>(0=$(=RR(0U& (2R(IH4(">8 +L
MJ(=3B(,B*()&P8%L^X<W>$?L<0=RF($U.(1-J 14$)H&2"Y_( ":L 4$" 9@
M@(+FL ,?< KK RM7T(%_B ,?8(1+N 2&V8APX((22*Y3,88#$!E^+ !BX(8"
MB!)L:(!'<X8>$(=[" !-$ @S4(%UD(9L6 0G8(+H*0$4@08%H#=V*(&0.(4W
M(HLER*)KV( 8^X=:0 !M.+Z_!,S ; M._\@ D:P%2/B'7#"#/:@!I^ $"!"Q
MO82%.XNL?&"!\^N'<U.%&B U9L&% XB$."" H]BD*&Q#"(A 15B!/IF")\B(
M:@B?/IN!>GJBPJB%&!".;"B'05" A?2)OFL [& "!C@UA2 & 4C$9T@!X2B!
M. &_%*# ,$B!)3$!#>3 ]_&Z2RBSYN $*A (:ZB 99"P;OB';; !I_""G^L'
M=J@&.=@ 4.@&!$BK=N@!;2@'+, "<2 &J)L">AO"BQL"3"BP?["&YOR'13B
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M\ <;$ &6VPA&.( [Z ,MP!)V@((%>(,U^ %#"#,;_^@)9R"!+7@#)2@,09"
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M@EQP G7="$J8@"/P QE( %_P!OK@ R?(@45@!R"@ "QP@38H!XM A06X@C5
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M%84(HIP%(7#YDF+T !3@*$8-!B',9'*UJU[]*E@_!0YMF( 2K4%$$?YAC'P
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MN.BX!12R('%VS*(,Q_T'-L9@A1% 03_H< 8:;#&.:?!A%6'H0L-C@H\F__!
M"XI0Q"6:D8Y?2((6_[B'#@K\#RG8*,$./CO:TZYV3O'#!*,HBA!T4 U]R""8
M:]"",8Y1 21[Y1,-$,0E A\"%6 6#"@0XQ8"  UPQ/@:)+BS+!# BG"TH!#2
M@,0'TN", 5@A%)X(:E&@<(.BB* )Y,A$ )30C4WLP!WLF($@S&$,%L 1#%Q8
MAB@^8(=LJ& (G_"$.>28#C1 @1_C@ 4"SB"/*'#A'\$P03;6X84!./8?O[#
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M/QC!0B)!%WQ#-20#.=B" >35/[S!?GJ%'3P@(C; 0S #$53!#C3<CN;#,@A
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M(^0" JB!.L@#".R#&+2 1;"O7=4+&4# 4X;"%R"#"EQ!C^ OO2XI(,0 .YR
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MX,04\ #H(^CA"ZWXAQVD4 = (8)3Q<##&(:@6NW$ @G#&$(6&/V/3/C!"&!
M)COH4(0K/.,>L?"#,93@A1/MYAMZZ(5 :"&$./PB'.G(Q",0P8QK%*(6X:@%
M)T"!%VX0X@NK@ \K./&(&J2M0=8( 0'$@*UJ'&(3A2IH4(^REWO,0&1!M $I
MF&F%:S!4 *+XR&&F"I]=-$ :___8 Q7PE@!,](@"@-).-(1P 1K4 JT-.#,N
M?C .>9Q '/^0 Q3  8L-^*(?_3@"'*01B@4(01@0@!<=PG<7= B!78)@02ZA
M4 Y \$ @A?A'*6S0P$'HDQ@'Z-02)%:("CQC'4-X *!8"XH?8$,:;&"J:CZQ
MTW]LP0[H\$4.!!$.5EB@$O+@@-7$,0,XC$,3#E"M%>Q,$$/\0""9@, K_N&&
M)_Q##3DX1C!:8(#A[$4>,0"$-" !@$_\XQ<3X(06NE6-'=A"&(0  #,J\0!*
M1&,>B7#6/1JP!'1 H@3DX <)%'$V2NBC!+60QAL  "^">*("0%3$!G3Q#W[F
M[B[(</] )KZ8@BN\ Q4/Z$8[(E$ >&$A3H*(TV4L@0!AW",* ?C#/PHA3OX!
M$"1 (%Y@%:QA"GQ@&EYA&H@ !UC!%#*A !RJ!&2A'^@@ 7J!'&(@#,(A%FA
M=Z0 PRJ!$?X!#WP &>R!!-I$K_Y!$VZ SNPLY0BB&W9@#8(!$2Q@$<+A!'KA
M'CP! &YA2DP@?'B! Z)A'*A@%_AA$ "@%KJA!H[A'E9@!(0A"P3@#+[A"0B
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M+VAA HCA'_A@:OYA')S@"'+D"13F'VA@P5#A&+B!)@&EL-B!'ZC@')@A )[
M"KK  !:L+V!!!\;A'YIA 4"A#4S@"8  !OQ &!(@#QAA#0Y %N9!!3H%$&J
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M:= /_$ @H&$+CB 41B#\'&%>CTV*0%!+AXH-(( &?N17_P$+,.P;K, 3# &
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M"0:@&N!!!"C@OXK@'APA @+N'SPA XP@$+ @\40A /9!'S8 <NJ ">AA!QX
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M"P50AE6P!.@0#SL F:YP ]1 #RS@ M!P!!N "6W@7!0"#HMP I;G"Q5 "O]
M!@J #+G  BW@"+!P1JJ4!6AP#IT  *)P#RX0 /!P!($0)DX "?JP!@> #&;
M 5X0!:<P"6\0E P0#PD"!_^@"$\0#V@P!?^ "6;0#:\P 5UZ(<8P 9P0#"0
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M@8Y/($$+Q)#E,K@@ !5D8AQ(V$$]T'$>20Q3!0N8P3*X 0()Q"$HI)#! 7H
M"\$\  ?$$,4#$L$$0_P#&S X  O D Y2 * -S>*% +#P!BT0X!2&F  AC*$$
M!RQB'4]8P!OJ@( 0U.-A\LB!$PA!" L<(1Z!B( 2V!$)#=@@"E(85P(=_& (
M1[@Z&W2.FS[R')1BN%$$I/"V0.;@1QIPPV6)!S+_$,&(N9R3%C108(M%<TX7
MBX8]ROFD5S],G1*%^,40>Q.,9?SA8Y)6PQR\:(HAXD)P@ ,C_U"'.OZQ#GZ
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MH 9ST(8^^HAN"(5C@YAE&((K^)840P=6( 5N8(=L" 9S<(=G0(9)^P=X4"(
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M'OBD>2 !8]"&%]B$2B!H7Q@#*4@$2A""&T"2&@B*<#DF+1"@+* !2J#_A"[
M@6/P@7+^ASD@\(^X@S6X3JSZ!U]8 $U*@C( AW> MW^@!/LDAQ)H6S[^!V$E
MUG] !QT8G':(@:R@@P6U JD9!Q20A'F0AT9(@(*Y!0NP!5;(@2(# 2U(GJ28
M!5HPA@&(@S*X@PA8!"HX@^!H<++PA@K89UMH -XVAQ-0"+(HAQ@(+E_XG7V8
M@>-X B%-F_\,!S_0AUS@@#-0 RRP #[D""? @G/(ARZ0 7SXA!Y !6>@@@U(
M!BZ0JF)(@&P0!1MX"'IP $= !C5@@:*0@QC@#>/^AR9H@FQ !1( @85XB6I
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M((5*X %QJ(<K0(5ZX/^"!FA% ;5NSU>^EV@#%9#/; MOJ#" JV0%$L U:B@
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M23E'I#7."7B$PP<(*):@CSW^9%/$"_84$45(HW03"7X5AN.//\>$D$ Q\/P
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M7:3 ,-A#$K!"3*0"/[2#(RR 7,R&*-!!:'ZI.BB"!5"!.LR#"RQ *4R,//Q
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M>,$,_()=N(4WM, ,F($W"(,$T (CZ($-UL,I[&,\2((A6$):'2(F'$ 6OL,
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M9ATZZ.0_-J'0,V2&:",@ CBV,0-PO&$&K_L',\@!AQH(S@5'50$B QJ+8HA
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M[0!+$J+G%_C@.4P NWKJ?0)@\TB! @J!4%0! (!'#!H 46R@&9XCT-K,%2Y
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M+%P<H;\0K_%"4B1'DHL2(ARHH D(!1=&@ ?XX FJ(+3TP082[/-.(Q &  <
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M#>3A$CP@#MIA$R8@%K:A"AXA'%K! *P@'[C!!P*@"$K \T[C%##@#8CA$]!
M'$QA PB!'1Q$'7*! <" '%RA(LE!$19@$!K+?ZS !K+!%1[G'EX@!%)A"V3@
M$)XA![K@_,K!!/X@$%JA -2 _S;F84XWH0LX(!#. 0FDD1X&P [&80D&P!=X
MP0"NX'R^0E5381P<X0"^ 1SX  7H(RJ @0+ 0!N@@ >"@1UJ8 _^01]V(&T2
MHA(L@!EF2P\TX!.400E$#RYJP 8F3!SF0$>7X0Y6HPN Z1]L@'(J 06D@6E(
M4E_WE5_CY#1"P0#RB%GNH4/:[#D48<9JLB/V(1B"@1P0@A^T@1ND(8_TX1D$
MR4&\01BFP=T2@AR:P1D*37"^81IDCAN"X?BD 1B"@1L>I!^TH1C^01:ZH<24
M81I&[$'$X09^01'23AJ^81B$@5F0(1*B(1P 838&*1,Z]AXZX1C*06*) :#>
M(19>9/_RM,$>SL$5LJ,<8@$3FN<?@.$;ON%=%J431,5NW$$;\@@9V.$<E,$8
MF@%1<F&][N898(&,BB$8I $9^@<L&($?XB$8CF$?DB$:@B%FX:$3<$%D'^1K
M!D'6\&$3>B$<K*$2!$'8Q.$6)L$YAF$3+@%P$^(;-J$3C&07(D$39$$<%&$2
M! %3= <2,"$4F*6GF&$2-$'6EA(3&&$0UNA,S $6:N$=!L$1(*$9-($1/$$7
M!J$1=J$?& $1-,%K_#8<O*&3$L(7SN$TM($0W(L1HB$0**$1SJ$=!B$1$H$^
MJL$2W.L2ND$4*B$2@,$3SK<<BL$09.@T5($3.*$99$$3*N'_&VZA$AI!'DPT
M$\P$&H;F']HA$2[!$[#!$QA!$-QM%80 #<)E'3Q!?"6%&L;@]!KWU[)@"+0&
M'P:!$B(!'ARD'1C!$1R!&""A$@)!&RKA$CC!&BQ&"*K #JJ ^<)A&ZX@#82A
M#@PA%1*!$X !(6+A"(0A&)( "<0F'1H!!.# &8B@%1Y!"[J@%C:!"Z@ &(P!
M#:9@$-A@#]8H*N !#X8 #I1!#KH@#W;A";P@;: "'2PA",R@$TA $1Y!")2@
M&;)@!9H@$/^A&IP ,'I*'-+@ 7(@#;(C(1J!$PA%'JJ  &:@#-;A$52 !V2!
M$G8 !X0A%'* "3"K7TO9E/OU02)A_PG>(1P@JC[&X1F48/44UG\\B$U,M.@0
MSV+*R?$<]Y8=UP>LUK]L^4P0#QQ<69>+64U ,IF+60YOF9>C^;EVV?&<^9G1
MI)E[69FUV9JI^638B'H%QV)\^4U LIS)N9?E4)S-V5^Q^9J7&9W3V<TD[SQ<
M&9[/)!4B*5.@^6[@&2%<.3NV\;70.2II"1V2P>Z>8Q(&%)>[H7/NXG(LQAN2
MUAJHP1CD@1NL 1F&B1["[90_&J0;SW%C@1'"\8S7("IKN8K"F:5;VJ5?&J9-
M-!_\8 '\0'MCNI6/6:=W&J=[VJ=_&JB#6JB'VIN)VJB/^JAGRV^GV7%9FJF%
M^A_>(61>A_^G_0N7M\R;RNH\AAF;MWJVW.2=U\08I* )F& VJ+>;GZOHP)J=
M0]JM23*HK:ABTAFIP_E.G)J6<[IB[N$4?$$46'E.\)JNKSJDWUFPWWJP'62G
M[3G PKJ;"=N?53I1<!I/[%I. *$.^N!E'#N7]8$^Y.2P)_N=I4$'1"#EXCFO
M$5NU]36N[20J)/NI77JQ*=NU+?N*%%NGNQJT;3NR(?NC#9NW5_NQ<3NW"8RS
M8QNVW=F;[SJF*QNM77NWV]JYE_JVPUH<:/>X5QJUA9N[&YN*R%F=F7NYG]E_
MGOF8'TJPE]M??3FY:QLDCSF["ZR6MUNMN]NQG[N[<]F66_FA&!O_P+*[J=5[
MF]N;3@(\P*?[M0F\MZ-;P>6;J?.:F9_ZO^D[ORN\NMMA$?S!?]+A&#+AICL"
M&%[!O]=[O"U&%[PA(=*!E4^#'+:AA\(!%71)J<-A'+QA$;I!P,_Y//AA%HJA
MP7?[.8*A$5J!GTQ:NJLY'53A4'/\F\TA&,HV'Q [P7?I8=?YQ]VZ(_3!'1)B
M'3Y.*.3AO(V;PD\#'5*8R:WZR*,[E\?YR,$[S97[RJ<YL-'\S$F<G=G[S:TH
MSBV<ST'['[Q! H3K'\@!'<B!"PI &!,"$A# W=[$'<[OL>4[*CC!#.KA'V#!
M!CJ(4&RA!?0@"UX$&)# 6Y9:'T3QY?;<_YV1*APP00/T*L_AY)\IH0KZ   B
MR,@+?!ZD@ =>7,$3 AT>P0N\@ GXP U 0<J)N6-F;\W[7'"F@ FD H3D1\JX
MVKL;/"I0X0368)_99 R,X-5U_!CD8%N^61+ "ZSK(QKLH G.[]NU&M8I7$V8
M80^LX!GB6TV>5PV0N2/NX1D\X3B>2QHNH67! 15D3HO"X1T"X1I0O<\;?IGK
MHQR\P9G^ 0\<8AY( !EGQ1VLP30D77#L +!TV9Q[ZA(X,!Q^(9#K@QH,(!,*
MCP4L?1YJ(!>^.J!&(.WXV>/_ 1>\91UP0%8D::VW>=L3HAQZ8'5^ 1,^;;Y5
M>JG!H1'2H1TNH?\$HC*SRLH=HF &7@8<5*$"^$>_T1SHO_Z;USGHW5UP"B'D
MOZ(3^@,UOI7-R7O 35+L3\/*OWOI=_F[_8L.Y*48EG0<WD&^Y#SLR]O*Y_Y!
MR$'8\/XKH,$+ML#(ZSXJ)H$/WAZY%3\JOB$)0,"6+0'*Z%[E;*$<G$$)7L",
MZ[JNEQ()Z@$,1.!U@#I*)  'GJ*G]A/G["8<PL "*,<=?B ZD/H?W,$//.!H
MVMWA+;P<VB$=+@<=RJ&QT($?"HT<V$$<-.$'DB$=[&$ >,$<6C^:$T(<'+DC
MRH$75@ ?M,P:V+[3I W\HX(<4B"4HH(03 8?A_ ?[J$$2.0?#('0,DO_RVW^
M.<0!(/29^P<.G3EVZ<*A0Z?N7SY^Z<"%F_C/6PME_\R=(/.OW+]_X3XR_$@R
M(TE^'T/^8S<.Y+]X 4A][%/-Y3^4)4E.W$DQ4Y"/RQ#(3*E2'%&*F!8$*RG(
M#TEU+7/:E/IQ(,5_ZZBF+*D2Y-5_1C]ND_'.Z]=_YTA@D\KSK%:J;N%VW<IU
MY]N<(=_@2/=/T)"C<Z?2Q4NX+L5+;08#_K>&1U2O>.U^! >.J]:N;K^>6G%4
MIUR*K$1\C-:CGL[ /.5:OILY]>HZ74#*:WNV=5=#>\U>+?;#FF"0-]" ?*>O
MKN?.QY&#PQ+I]]WGT*-+GTZ]NO7KY.;8R"5-_P0*7O_86(E&9L:P;"-8@"E6
M+T4C*#<XLAJRY5\O*7XN47%2##*R)2_@40HZ99BA11?2+#,%$XD$X8),=CFB
M@E$4B9$%25=$(5(*?'Q$B@'$F/4/,%^8044%K?Q32Q=CQ. ,.%><H$19=OC
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MZ(<YG#" 70#" <?:1!*4L0L+,&(5!(A!)XI@"BI PAMUZ $_PL""<SAB!_+
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M>$)$8\A!';ZP >%\HPO9$(4";@&97N2@!2]S0B .@8-QX&(.OX!"%J#A A.
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MDR #,4!KU0 %%P &X> &)U 9/?H/<#!8(J$, ^ E_\ (7:D2(E1F]?$/7I!
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M ;9@#"Z@!<+0$MW_P '%0S4A4!DD4+44,0\!0 O,4 \QH"WU8  BN@04H G
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M$-T )?8O2S"@$?#L'SVLD !:A4.C^;-&%_SP@4W49AA60,(44&"&?W"" VP
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M@6SZAUI@I3:0@U.P 4R0F'[  R38 E)(AUQH@DCH RKXAV(002T(HVZX@B:
M@Z_[!VX( A@H ^C*!BB8@B,HLD8I!TEX T?8AC! @UL !T(@@W\(A"*8ACNP
M@W<(!U2( UV8BU$@ BXHE7\( DVXA"WPA+%Z@P=0 EJ)@D%(!3FHA*-:A/\]
ML -:* ?$((0=,#AHP8E_*(4Q@(-(\,!_\ ,_ (E:\,@!4*QJ( 0P6(1RB(=
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M@W8X@PUX)RC !&L* #O@A1W0 W,  PHH!/4"@6-8!0 H2"UX 4:PA ;8!Z$
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M%"P0 HF( 1+TH&#X@@R0 7#]!SLP@I<) $U@XFF(ASRX@;D(@7^,@QG8A$/
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MBE1\"1#[T$(.JK ,7)3@!7[)! \:@ -F_,,0')B"(7# !7W0X05G&$<S5A"
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M>N,G4J(:NN$X;B(RBB,X)N,U#O\B;F$C'U(A.BXC(SI*+X#!ME5C%K+#"J1
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M/R3!;[V(5?A'/WRK3_A.=1J;3U0JL V;3TQ"B00;MTZIR[XLS,9LE)X#%D
M,?C"!NB -[1# Z!!,A2! @##,^  #O!!/YR#"=1!&C3 &?"K3F1#"7 "&JS
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M-#3 /)!"$I  +GP#!P ".,@" _B"1S0!NK2$'/C T*R %?##*>S %'P#)!#
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M%RP[*L! J?Y#)$C!/]A!#TB;1\A#[XX"#)P$%DA%*FA -HQ#L1U((^B[.+Q
M&?C$$J@+'JSP@5B#')C!&/Q @]B![FK!LC\# A!#&72$H_Q!C?_#%.A'.\
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M(#)P [&A WDO!/^A'-8@ "1@UBJ! MA@!1'@"EYP#-"A!@[@2Z1@ F9!W*Y
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M(!QAA?]A$G( +)A01YL7E+0!#"3J('BA9?Z)]0Z"'4Y@0MKA&JZT18U5'90
M"XZ-'DR@:$)JSNX) >',G>:)HASA!8:A'61! DH!')9! 4XBDJ>4G-97F*]X
MG?^458*8*!@>H!$&RF5T@ C^01TP87.9-140!SB!07D%"L#:0 +ZLO0^ 6CB
M:1]J,9[T=GV#51K@5J8TM!R0  ;NZ-#<H ML( R0Y"">8 .8X9(KPR&#009R
M@!+RX1]J 17:816DH1N4(1>*(2)(P0)$0![BX1N.@1^@X0D^(!$BQA]> 13
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M   %]*$6#D &E&$3#B  8D 3__"!"O) #+P 'YH8HX+!".3 "'H *)@A!0(
M"-R@ ;X 29B!!Z[ $F8@ HY[GX#D$@! !3;V']0  &*@&"+! HA '^1  5A
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MQ?Z(H04/#*,0+/^PQC6\\;)7B7&,9"RC&<^(QC3:BP(T"P<X;J&"-JS! 4E
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ME1L.@,4_[I&"QVAC)EX(F3P"H!9SQ$ )WBB&-UK%C 9PH!+NH,P_JO&%/(@
M$0R$ 8/FD8 \0*,8\Q"'/_4A! PHX:N+<( U50$#?J"C!9S]EPE^88!IA4,$
M1-@GJ/XAC0H$@QF]&FB*/C$"J_X#";_P'2RB_S&,=["C"T[Y!SQX\#A\\I,E
M+?C%/VB! .QAP7V^(!Q+!M$ >%SI(UM@ 1QR& 4AF$0&EOA'-'0J10X<(A:B
MN$4V_G&.7I3A!U;X1RD\>\T1_"(6IG@%/G:Q@I:$48T4KK"%+XSA"V-C E]
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M\0YT   20 O"8 <-8 ;P4 Z;\ $$, R&8PMNIDOTT&;UI0>'- T]0$_LL D
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M.GH !5!@G/,@"4OV#Z3@!ESP!N/@#VE0!&3P!G\P"?V0#X1@>H$S"5LP!YX
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M>"QQ"-C3U$7-UH_RU[O,V(WMV'#]8FWPPOX$#H=0;V\M1N<P!T4@!<ZLT4?
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M!/Q0#3-L(!GG6$$UV%&% KAC#VZH&P!, 8T)[$)D<F%% NB*B0W( AS9&("
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MM" %P7"# (X@ AA,80&Z:@8.,-$&"0"%?[ $-X $*5B!1HF(,;B 2[@'('B
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M%WEX #5 !U\P!UQ  9[[!RO(#4M(@<R@!Q)8LH&PHH&P!":0"";8LLX(!03
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M&BBE4SB!L5D'&[B%,K"!B4B';KBA4$P. 9@EB5B"-OB'5CC"BK '0YB(3:
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M DSX!QI(2'G8FA$9P8$0 P15T!%)A0E8+VF0 .=JTUC(@09(!' X!0D I']
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M!QFHIW^PA@ 8AF.8 !'NA(^MU1\0V1YPBW](BGDP@'JZ! ]Q69B568FXA@8
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M0X" 7B@'.Y@#<Q@& S %<&B&!Y"42S@ 8-"''<B"<; &&W"%<B  ,F %)^
M4>A2_[D&!= %NA2#%X#6WM "'?@&:Y"%!*@%<R $$L!&."" =F@"V%V$ X@#
M=R"$$F@4<.@#"%B#10B!9A@$'1@;&9@0N>"'$@ ""OGA9.  298+1U  6'$%
M$_]0AT4(X6KP 2; AWLP@3TX- #8!'%H! <(A/26BTJ8@7Z!@YS12\[IC%W
M@+CEQ@ZH UY8 C&X!A!@CQVX!E!HY519<VG0 "GHA4F@@7-H@P6H!%%8 EJ
MA@UXA$(>"%2@ ,4PXH$-A0W 9)ZP@PP !*#QAC$PG#^ @;'1! \D!@2(6U$0
M $,E Q;()170E7UH %E8A0N8ER'H@N=@ ?_9A]PS"3E8@&98C$!@@<Q),AN
MG!6@A-#A@6\8!0"XAG5@ A*0!G3(@2\", V0 V18ABL8AB[ 9$"0 7Z0A5G(
M&[F8AP=@A&A0!W25""&(WB@H %B(AS<XJ]Y@ Q]P#W[_L('5^84*&-A92 &)
M2 4&@ )Q((8@((=4D !#-03JJP)TBX8"D 5Q.'1^\(%*@ 0$,!QY" *WD MV
MR(%-Z(B* 84"P!B?#P5P0 $7H)EFL 1<R("9_8<W@,;>H )[#X<:L$5Y*(&)
M/6NV;_M2* -*P@8U((/5W(4S (5C" 1D2 4RT(-1H(4RH -L@(4\B(-A  =?
M6 -)F$RWO00[N!-Y$ -#T*G%F(8QP(1%R Q5* -,* .ZFHAVD(5M6 ,S0(2Q
M&00UT -L> 4R* -K* 4SN 1N< -6, 5)T ,)OH8VN(%2$@=!F(,Z<(2=D@M_
MB ,KD(2X!04_((,%>XL'M01F_RB"01BB@?@&+@"!3'B#.! &(D@",A"-?X #
M5'$%$*C.X+*"%;"$.0 #;Q@'24"!&.@23TA<7-@$)Y "6S"'38@!+HB#*D@$
M@,@7+MP_946<8&IV)82@6"ZFU/HWD."]2RZ&="G33>*_0D[.@.$GCPD(.:.4
M.(%"3,N*-/-\C*#3)-,X<X5TF-&%!!8A)UJ(@0$A!-J_?[_L2)Q8%-.F+%VP
M,/K7+ F-3:&B@'"$RDD23VB,E%J"!!/!=7\X] #T[Y2)*T8FI1LH$1,2*=J8
MU<A"1).ZI/\<-9CSI8NQ?\QFY+#39\:R-SZ$($.'1X80/#W.X./(:B&O5%VF
M9&J5)/\**H[(ZCA1,N\?.S8$#A IE\J$%2V3PM5R@.7(%VL2/<T0$$+5OWY&
M-!B ],\<F!B+DA*\I.-(EJC!FF!1@@TZZT\E8C1I$K&X%2Z#JB2#-\3!G&U!
M%'RRE<+ (GPP?G":0N<?O"@_T#QQP"">&.""*V)(X$4\1?&R0E$3$13("%%D
M804*TZP3AP-18%.(!'((LX0)6\A1 2*"<-#"-44Y4D #)'CRSQ0O."+$)O>,
M, $W?JF3A0V/8$/# ;Z$4H(,RP"C P0#&$%.4NET<H(!>T"CE!T:/-''!$_H
MLD(%CX"33A@6U-"#(N14,8$IQ"!1 "V#4("''0Y,00\+:C3_(T(H]8S 0 @V
M1#61-Y=<< 0PXX0#CCN8 + ).N@( L >Z?32P0E#\. ,.EI0\%07ZT!7S0Y5
M^,., &54D\H$E]Q#4%&OPAJKK+/26JNMM^*:JZZ[\MIKK*[Z"JM<M$*HE+"\
M KOKL,D*"V%1XCPXSJO%,ON@L># :LZTP YDCCGAJ.-J.;)B6]0ZXXR3CCCA
MF /M/^!(NVTXZ88CCCKEA%-..N"T6^RKZ:1C;5'I\#,P.O^@ W XZ92C;3KO
M!-#(/0>_JNT_]_RSKCGE'!SPNTHL YVQ^9:K<#H)AUF4Q0.'L\ZPUCCY[C_<
M^":RR^: &@XQQ5A+4"->Y$-*/QS!_Q/-/^,0)4T[Y;A;##+_4-/S/>'>PX\Y
MX/##3ICH3)0.J.A\6Y0U-2-JS#%%F>+ *].,ZZH_P#Q85#7R</1/P,[^HT\I
M_CP+[3JMXMU/-M?$ZVHVSA!$3C;'4)//-=](0\TRU2 ##PR\E&)T4>UDP\X_
MWZCSN#+"C+Z,NWLD(O) ]O1C#S/,Z(-P-L$T TTUP6#S]S.K"9..,M\X4V51
MPRBSCT347%,*,46=\X8RW.DSC3G[-*.-T]<HLZ ]@*S2LSG.7"-,*?,HY<\A
MS/ #B3_T-'.,,MB.<XHEP_RS3R3?5%,*)I/< DXFB.C#%H&XAR<D\0E0%&4>
MCU #*[@SBO]":&(2GBA8.*@QB4@<HA_].$0C$.&/<(CB"G8(1E'(\0DGD*$>
M?A&'(A!1"&*(XD2#&$0D,,&S8.$PASK<(0][J#IJ^<N'0NS9L.151&+AS5=R
M.2*NEB7$:NDP64FLFZVX48 \2,M85)25,E" @S1 48E-#&.NY%*)'O3%+[TB
M"!-GU<8VQNH4&ZA9$K4XQ%_9D8RO@D8 :J;&6W4#$WK @CUD52T]UHJ)S!H'
M+[:0,SNZL5F0G*(A$5E&9E%2(N6Z)![A:,@[@C*4HAPE$$MIR5'>*HA&1*0J
MUYA)6[4RA[&4I2EG"2M^2,((=7B&Z@"I!32,JX>QM*6N"**-)#3_  [Y^*,K
M*3E,9Q)D&%T8 !\\5TM/1O&:T/S',)HP #><8XN]A-4U%) #!&+2E)W49BWO
MT8O,L#.>\IQGL<!A3WO2DYX__&$\4>G/?P+TDOT,:#,5^4I)8C.5!T4B)'%(
M3"4.=(P/%:<PH=E0986C'M1X!S?PE5!8/G.2%B6',>3A#7"P$Y3S["0YD&$/
M;JPKG0U]1SN8R4^1YE.5.=TI3R%T3WSV-*@K)2A1BXI*G7+KHT9MEAL72L13
M-O6BB70J1J4:K%H*3*!.=6)%<:K4J7;2H2$5YUA7Z2^KTC*B/</C.L/H56JU
M5:ARG:LV?XI2NN(5KDO=*U^S*9=O0,(;_T6A!B2(\M58C:-@1\7'0";65EN1
M8Z*PS&HQJ5I98[DKA^PH95$.!E4@*A2MR+(H5!D*VJMNZU?3>BQ"KZG:.^K4
MB%$E8UDKF4?6QA6I^C1K7DN)SZ?F]*F\U6M*^VK<XPKT'[50@A<XX(UFR&$*
M"<@&17'%"!*H4)2C6($7BC(%-ZRS5L9X0A;6&JQQK $3U35K:GE8+%X4(16F
M#6,HZC"&?1JC#""(VBJ $#-9D6,+1O/7-HZP$8.B5:\,C:1$ZA&(.L #HIP-
M%CB<P89.D'488K!$)>/66G7Z0P]?B(1 KKJ,/"ABMN'@1B2VPXY;5 F2N:@&
MA,2A##V<K;6=]/\&(';1UGNL8A=Q::LT3I&P9/2B'M=TAR_XL5-IU")<P.VM
M3PGRC1CS-&]Q,98^7.;:<O2CN,@=,W)'1A!Z_$ :Z=@"-G2PHB_(E[C&C+-2
MB"$(:+%QRBGUUW5<0)!,J&6?JE"AO^9A!23HN9_C8$(A;CH1NQ)D&5O&JT00
MH8!<\!/20'Q%#^H G7N&HQI+D,#9-I$$"OJK'BY8D;]LX8-WO.NN^;2KK*_)
M#"]/9!Q1T\80#N ;*L\S'9M8P'WAR@L"1 &XZ1!(/O_1#BE XA$88(:C:SF.
M2CC@#8XNBB(D8(KZ+> 5^PR'#K80-WR8(0*BJ+:_RG&)"7PBO*\PP S_,,;9
M>6"A ?F(1PLVH(UMKP( I& W7%TQ@Q?$+*; ABMZ'2 +@JM3'SV 1=W($889
M;..F1?&?#_) <#*#W+A0K$8)X@4*!43XD[(Z0E2X4TR0OK8HH!!!4F5E#413
MM!,@B/E%W8I)<MGS'\C0@H?9JW*7PTH$WW[J)FU%!RC *NA%844!2,C@8V$]
MUEG_<*R:3L1CP6,%=Y,+-/0@-A(0Q;S"W7H>I7C(5_'@#./\QQ&F\,E%K/N(
M"HY;*SB L62$"XXUCQ4;_L#;5Z'@V^7@AL>*'@[6&4L> N@%%=]81"\T>NOI
M0(,/0$59B8R#&3P(9S1><+96AL,=VBAQW;BU_]H'J6,,/W#'/ZH1HR+B5%Y,
MK;P3A4$"=.[T'_RX0\;_D0M_N",3"<@X:+T1"G!L8P3%=FW(J[_4=4"B"%6P
MA53@P ,U/,,:3QA '#!-#$)P(A$>,P48F" +<X1A TIXQ=CS\0J)%6,1BPB%
M$.@PCE>T 2Z\"S8\0C$@0ADD S[H@248SS^X0QX 01[4#"E(@B!401"$ S1T
MPG@X R%\0B#\0S=@ 0O$@?%,PR<0 G'\!1;\PRY\PB$\S3.0@2X\R368@CEL
MPB44##OL0C.T0B74 RO(5U&X AUH@I.D@PW.PR!80Z*$0S*L0 O<VC^LPRN,
MP7:(S#\4PR30PCZX _\S/,T\D,*!:>$D0((*E0,.C((QY$$R9.$_B (C!$,]
M;$,UK,,Y/(,P0 L8O $Y2$+&88LZ[$(9R $!! ,XS(,P@ ,R*(,R5 DT8$,R
MD,,Q;-8XK (#T<,_V,,JR 4UB($BA),#P@TI)(*]*04_B,(>4%N^' ,\4 ,Q
MX)KPQ<(G^ 8W6$$*K(([R 4\6,$-A (_<$,/S(,V?$/==$,H%"-W@ //",."
MH ,I*(.V$(0\J,+3O(HPH((U_@,^^ ,_1 .V\ ,IE$()9$(6DD,I; ,6@$$"
MD8(S:,LQ\( 8),,THL(R8(NS@$,VE$)V>4,:!( I6*-<R ,J;(,\)$,VV$/_
MJ"U#F,D-*F3&/\!!&OA.%CD+.DR#,YC >+"#.'BCW>3+.(R+.>AB661#VO!"
M4< #*M!-44A+.01D44A#/5Q!YL%*/E0#2OV#&:3 N^29\%',/VS#Z/%'#U3#
M&^;#D,W*)@43.KA+.?0%093!#_"#.A1!'N!D.'B.K$BCJZ21JVS,@UB,.JP,
M%8U##3S<ZWW>UKT*-YC T-P#QJW2/^R!(Q3%':RCVJ6E]>FE/_'!&>R#("Q
M*KP#(/# *,P#.>1! N"",6R#$Y3",-B '_Q%%!"#'@" +IA""I"!FLF%*LB
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M.$3!$:R#)"B %S0#&#RQ/\2 *1R#%:A .^3"% C#-Y0 %*1#)5C -Z0#'W"
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M1(,Q(, T_ /_-+Q /"R##,3./UP!APV+'#2 +MQ#)MH!(U,"HD5#*"3#)N1
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MFP*(^0>0!]19A0(PUI&'"F&NF(&??ZQ889Q_0%BP"1(6NJ$*<&@9 1Q[BA@
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MHQ@(N-LJ-N"-94C "\IX1@N2\0<5^.,?M<C)-"8PBV%H007# ,2"X'$ TOA
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M&1SL$GQA!R3@$'Z! WI %_AA"PK #<"@!#IA&T0@ 19N$E[ FU; !^J@"7*
M%\3@ +[ %:K@ >Z@'?B) %Y ,N)A":9@$++ ,-9A" K "+2 !,2@%@P #\J@
M"LZ!$P+@">)!)X3A!TCC6S*#$VR@6*A@+L(A'\@@ \Q@'41)#A1A$C  [O#@
M LJ +-X$!-"K%0@@".)A%Q# !>S!% K@ :9@!A (UIX1&J-1CMAH(:@13JP1
M&]D(;%@-&]\H'%:M&L6"';[!&;C_0#].\1]Z 03FA!J[44ZH$1RK<1N!PAK#
M\4[PA0?K41_K!%]VS-60 AQ6K5AX4![Q44X"TI[@9(WH,3O0D3;V42S8:"IV
M0G'*01LCLA_Q)!OQ<2+#81S>(AW,81L%BB#I1*#"H1R*91P>;<>H\2/,07'^
M82J0XB/"0<G^ 1JB)B*1(:C&X2/*81U \BW\H3TH"4GZ81ILHAZJP1[$(1Z"
M!1W^P1A,AA[T81RN@1_2 9O^ 2;E<1ZD81G@S!VT(1F&P1V&81C@81^B81CF
M@2B%X6W*X1O"81W@S!N. 1B,02>D 5'J@1C6P1RV ABXX1L(DQJ(@>2Z(1CZ
MXDV.X1F8_X@A H$?V&'ZV"$:*$$4T&T;DN$:0.T?KB$B&E(G^L$P_J$9>BH<
M^F$0+F$3\"$<("$6\B$1+H$2AF$V*:$CPZ$4/J$>F($3.&$;9F$0$($WLH$3
M*&$K_%$:EY,YFU,T3Q$ZHU,ZIY,ZJ],ZKW,Z$3(@H?,?&@$ .$"FH',?[. !
M;$$DL=/0E',GM#,AT[,?6[(@Z1$]D>0AWS,CI;,@N7,ZXQ,CDP(AT:8Z[3$S
MOO$_WZ0>O20]Y5,;\7$>E=,@$S0B&3(?_1$_Y?$YVQ$^$50]G[,AW]%!KW%!
MXT0?Y[$D1?0>VU%/W-$>2Y0=,;(_\Z0<3D$-A(#=.-1+-O1$4_\41YV31WN4
M&[$32(-42(>T.MDS.J%A$<R%X7 !#&[A%]B!2$ET/;4S2JO42J\T2"^40 N4
M2(U42K$43,-43+.4':E32\$41*^43@*T3(>4'^=30;DS8SI@-M)42-?T2\W4
M1_>43^-H3/\44$_12QTR/Q]432-R4 -541?54+\E487T4<^442>54J,33_>S
M/\743JOT4BO40]VT4]DT3KDS&LY-1(DT5"552ON455LU5$ET(Z^S4"OU.@,R
M4SG5/46U&MOSJ[CS1BL46&EU&ZU42VWU']IS2%=M._-45,-T5H45/ZUS5E^5
M4/D33555/S'50W,53W,50%<56WUU5,7_=41!]5/54U==55W7]5G?Q!8J8<C^
M014<82ZMTYX"<AW>H5?#%5?/-3/8 1)F01WT=%S+(AWT]5#Q86 M-1URY!_0
MP2+QD^2BTQP>"4CY%5P!<U'1K1^08F+O]!_\P5)OU5+-@1J^M5HWM6"AM4$)
M=F-)UEPOUD*]M5!7EF!9M%U7E67M$U!M]D#9%6CW=#K#( WV8 .0 1'0( P
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MWL"$#.Q!#!(,(A[W<((@\/$$ 0SC'U+01#DRT0&+_*,-4"C'X3#$PQ[Z\(=
M#.(_LD$"9. #'_<0DS.6ES$'%.,?)N@#.<[1L&_LX&^E&88#,E&54YP ,?]
M01/"485R>.,%J(C'.=IA%"^H+ATG@(,X!D"&>IPC'^/X!R;_(("":04C!!0@
M0L,8= 0DE,80,GB6%PBQ$@8!8P0(V,."')&P?XBA!..P B-W: H15.437OA9
M2V!1@!PH@AS_ ,$3JK(%._QC&"60T3_^ () <" >58'#'_[A#0-<HBJB2( X
MF.$S2_Z '>5HPP:D4#&'G>"5+]#6/X[!@6/0@P74H)8.UD&L>@2@$54IQPC\
MH(X=Q*N1M!&&!'KQCU1,H#.1"( ]_E&')22F!'\#!0[4I(FOF2$*NZB%+H(Q
M# 7,YDPVI,&]_G$--AR! /?R@Q_^L0\9A $7N!@%W3Q127!DYA]64(;AQ*2/
M7J3!!'WZQR4,T T=Z6 <^&!!?G8Q_PI$_",6*RA-R\QQ@U-490B>&X<(1C$-
M 3QB%[1P134B)B8ZE$ <_Z#& \*PBUFXHAM0L$@XTI&.:PA I.DIP#:448(%
MD0-759G%%XFEC 2@1U=-^,<XEM&&("P/'39 Q3\:T8->[&(5H\!'R]SPS*IT
MZ!_XX$$S/B<Y#:0!& W+@E9I "X>/*,JW&">'];VCRYPXG.V.$ V_U&%)/VC
M!>#:*PG0X8TLJ(0-SV2& H3Q*#. 8PI:.,0AUE (R4VA<FX8!PWHY8P>,(]!
MMG :!"& "T[4X!"8*$0;OF<:>2A@$9P:E!9L2 @;E*8%0_A'&C#V#T(D(!DI
MZ%?R+% -;__( (N <$)I:D I-]"@*OE@ 1_^800Z_4,'IO@')5"!#TOL@'DI
MR$;R>- (1/"!!\Z (3C_(0<G@$,<64#1#H7(X0Y[^,,2<H8&-E6I "^#B?_H
MA .L\8\:A+(JFC#% :95J5/$0P)<]--:_P$)%7PB$O^PA@,8415S3,N-_X C
M'] 1 *I5!176B,<UCE" ;- #'X-PP!R,0ILZ\$!5_]##,?_!A4TRR!_D2(0!
MHG P0R;E!^"  INK0@IWT HQA'AQQ,!!CF#T00,T(8*C_G$'5P[C!RR>914R
MX<*JA&&BW?!E5>"1 TV8 4C&S(<YTN&+$4! %,Y,S '4\@]XD*#_&O$H04MM
ML4UB]>,'^UW)#9RS@TUNN"K!6&<[)R!23@1 1DU0W*&AX5)N-N)K=@AO5<Y!
M"P'(":$K4>@_;G$#7Q2# Y'[ Y.@(0#U[@L<'"T-)#B@"#SDL67^.(((A($'
M)JF4I2[]ASPJP*:JV ,<C)#O2/]1CA/X%&",[+<J4*&!:)1&'4SUTPQ0>0H,
ML+,J_<B"%4J3#E 40*\0;$ Q2)$"54FC ("H2B[62K9:"."M9R!". *A UN$
MH@3^P*M>&W$#TXBC97.X 9<+0;ES0'BD JG$ PY "R4YV073>L$OQ:2.?_@!
M#P$"9\LLD8"X_4.RT5YH,0R0"DC0^ _/_]3$QE@I!G(\P!.F"0<D$C8.)XG#
M 'GYQS903!M6<S-WMY#$%B*4# <L% XIZ"R(_L&&%)AI#.'% ]3_H8@=O,(
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MK) .(/"$T3 !X.0-#0 N?) 2G[E+?? "[@ 4AC0-_PW HXXP ]QP#'(38(#
M *$@5R=@ADR@;R-P"^E0 )8@8#N #S7C"L7@"QMP!<- "D70&4F0E&+""@R
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M\%Q&>R1/N2<N]'7N\QHO2I%.VIA]YD=?^86?])SO^#8_#TR@ $7']B\>#T
M ?WH[9,(!"#  FF #N @"&O@! + 8NP>]F?OV_/P! T )+"  +8/]O30!WY
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M:U3!0X;^P:8Y),0S-SF(/K"9I%-%BE8  V<XQ2F2:\0@ 4UH@BJTT(AX8 (
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MH E'O$ -[< #!(B !AM0X1!5R,$=)*<"+?CA!15P!C^HD %%U ,)$LB"'WX
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M Q+(!$;@ 1# !W/X@1LSA@8H!F#@ A98!$FX!B>8AG]X@@9PF 4HA&Y8@28
M/0[X!UTX@'H0AAV0!VU@.EZP@6EPA@,8@N0R"#;H 6X@AA5X 'GHA0-@ 3A
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MAV0P!RBH@2^X A#( @$S"#1P "<(@2LPT']0 CE B!"HDT^@@H-8A4) !RQ
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M;77C-T:(/A!5HV6! 8 %;$@"61@$#  $=<@$"&@$<]B"&DB&6R  (["&0?
M.T"&,E #>PB %$@%;0B!4E@$#QB$<*#_A )XA7NPA5@P7;6 PE(\"$F8 6AA
M!Q/0@I)(@V]L!>>D!Q<X-G0H 5PHAFEP6QG0!6;8 ..D @U&!@+0IT'HX3>X
M2CHX@.W0!02HT5-0@&LQA!*H$2/H.W[P@T\@!0 J$7_0@1.XI(UY@W%H P=
M-'5@ =J1@I@)!Q, %WE@ > Q@R,XB%PP 'I(@B @$PY8EDL(@".!@W(M$ XP
M 6WZ"%I0@3BZAJ'S50&.!P58A6@ @![Z!!IPI!AXTG]0! I0@W^8AR+@A6[]
M!QPP3(-HO<!(!0C8#BZ0UG] ! V@A'*(!B^0"*<P! VX,6TX GA8D1J1AAU
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MH+C:/ID#/YU0'>Z#QCP(5I &$_C8>?Z4@U@"["5*C0E:-H;C$T=QA%@$%6B
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M%)XF&!<WF,,R2 +'R<(@ (,=T($Y2,,?- 4UK$$KJ ,TF (I($0F., ^D$(
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M0B@L@0WL*#V80"&TP # @52@ 0T@0S[@ 16T A/( "2HA"0,P1, 03U$0@#
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M#05^.&J8(S*PPJ2&:H% QW^$26";?^!PX4&4_N%F" RJ,,<5_QW6*6X*PI[
MJ)Q[EJGNGRW,]/ 4']+!"I\2XB"(&PD6^4<'7?Z!IH28Q/@!'7]ZD%$O&<3Q
MIP3,G#G+P>*T**2'SX8([I]V;&CFG D (8B='MKX1XI'_A%G!%NP0M/%77GM
MU==?@0U6V&&)+=;88PDZ1P0"]-!#!V_2P>. EM;18P9\PBFD RM2@8(.?58@
MX)=+>-C'FP1D.08<#['1X)9_=ME@S$D,:,F-'MHQ)P8KP&F'A#<:Y>"6<4)
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M\(][1$,%+3G%6F+'!4F 8QV-V$$[X">)?]  !P/A16,:TH\9^( LK+##WPJ
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M( $X"$&'T'2+"0Q !#?(!CS,< %#G*,;?=! +/+1C1% H 4^4 ,X]'"!%.!
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M W E&@R@DG52DK&B%%* -7?RG&U95YQ !PC"$#Q@<0T3+WM9*%EA,/XA#/X
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MUVC&X\ C=;6!Q"FGW( #*C)$4U<+FLR:B1-UN4'7<1J FI\I"*PJ# >?D)+
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M+G0@*T?B#STP'>KB#P1091P'54O55.1F9@\(@1$H9NG  T6@#LC  KWP#Y)
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M=@D6@ )^D -S0 H.\ 2)@ 3QP!TF, BK__  /3 -N7 !13 V%Q "_A + ^
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M(<Q3!") "*/P!5' #_XP W"@#AQX!6,  UE"%.!0# &0@JO  <$ #E(0!*@
M!A/P!N\@"SF0,8\P 7SW QGE *SP#ZN@ O'0#RGP Z* "T&@#/OP  "Z0IU
M 346#RV #&\Y !4C,OGIP1^,G^@"#5'13?W0,;/"#SUP!N\0#W5A#O;_< [P
M, [HT@_& 'U!T C0D#'=9 W<>#3>4 _S8'0UXX[T  _OH"/_P _(0';X\ [P
M4 ]I(P_W()CN& _W04]'P@_O("O@L _X0 \]%1%KIZCRX _T, _VX _R0 ]K
M/!CC8 NM]L7S$ _H8@RI *%Q]2;:$)CU0 J*D,?"P L[_ _Q$ O3@ P@\P_8
M0 WUJ238 +SU8 S:,0[>0 ^U( RGD JGH"/#P MOH@ZUL NRL ^GX NV0+#Y
MP0R_X [U@ WO( JI8 O0T NT0%%U800+Z8;)  OMX ^M4$[UT NZ< [84!=9
MD#=$00M7$PK\< ^I< N H&D[5@OMT RGP O7_] ,N& *[Z *LW +84$/N& +
M B'*N$ -N) *O9 /Y" *%;I#N[ +M_ -U_ *8= )OBD0P? +M, +Z/(-?& (
M]7)W8" &^( $-//,MX /!E0.OK +I[ ,N9 *HM#(_T .L1 &;Z+$E) &S@ (
MV5!'Z((.OD +]P'+L2"S*R0-G0 +%&8NJ/ +NA" =9$,_9P*I& *OJ +JH +
MIZ -]7 +H[ .B- <Y: (<+ ,H" -B-(*O5 +]X$NX) *NX +^[ *OF *UX +
MOG +_7 NJ] $QG ,O8 +Q+ *N] +"UD,=D $K(<ND= $:""L(U8)7_ -G> )
M\? )?= '!6)C;B 'JO^I"W7@!Y60"G+@!HW0#6@@!Z7P"GY #XA !&NP"8C"
M#XB0!84PLODQ#V'@:68 V/. !FS !L9@#IA0!WV IZ  !5^ 4?] #9( !'(0
M%HJ0!#J4'\[0 ITP"FY0!ZK "ZL-,IC  C'0(ODA#GW@ TN@"E?0 TR0#J#P
M S7 "$*+"J7+!J/0!3X0!Z: !28P">B !E% "%)@"G41#"*@ G4C#D\P R#
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MOD+U$ <@4 05D^6F[NJO#NLW3GLYD-Q"7N*QKN4'CNN>3N2FWNM+[NM0;@8
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M@,,8#):*V=W1=CO1 Q-^T84^O.L?V B#&\R0I)3<XQ-P4$(MP#&- ^3B#%M
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M @6VX>E*X ,%O=!--A@@1%@(P 3W8 <6H'&0+Z3 &V? 03W&4( 0A,$)8T@
M#=Z0A49L8!NHD$ U1$&  7SB%1LPA3SL$(!;M",EH;A!.VSQ G/08P=@0 4-
M $@+ *#B&!,@'5#'],?;'>00"O!#' (0A/]U((,&URB% Z! $ISP@0W&>,,%
MZD&,"D1!%%T@E2X@( M5#" 9K;#!"R9Q&$[\ QD# $0\9C  2,C##:YHAA-,
ML(YCJ& 3MAB!#_)JDV1,00N@T$<U5# (6C2@">QXR#1&\ 3M.D(&:AB# E*T
MC"B4HA<&,,,X<"(-$0@@"6)( 1K6H8D/S*(>6[! ,@(A Q;\P0XD4 (1W/"
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M@%U0!]I*"4I0 .=@!@T(A7]8@CY,"5]X@20Q2(1T@5AXRC$9!1)X@#P0S93
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M(;")/RBN;S  XEB#!LAEA!"'&0 #9"@'+1L(%@ =."@ 2R %(,@[G.B'&0B
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M/NT_T($)&D#B']SP 3;FQI ]-*&@Z>A$"XJDCR-T0K6X7*0A %$.)8")#9G
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M) S -^3#'.Q =#B""9@!#ZC</_A!%L8*(!# "&P! H9!%^P!#^ "5GW" -3
M':B#(5S!+ZP $E@#O*S!'/#!#9R"K5"#$TP!)F !#$A#/%R!#=B#,NC #?"#
M*[  'YB"#F#!09" &_0*$"2!&!B #H0<.;!!&T !%DB#+8C_P!9PP00$X$C4
M Q?\01=DP3VD@QV00 HXP>=HU,H0P Y<PD+(3#STP!G\P0Z0P7100@Q4P1(<
MPS@80@W$ 0X403G<0A5(018 AB\8 10<@?'D13VH00@ QCQ< 7U>@B<*P1<
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M$C!$:0I+.FP!&FCB#U2*(3A ^L0*.&3!'N *(>0 +;1##93!/P@"#&0/"OP
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M  *$6#(HP"_\PS,4P#2DPRXDPR*T ">1 PM@S NWP"=80AU\@3<X00M<@S<
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MHHX> ,(MX&@$$QXAC#Y\XPU_J$,NSN"&.T C2*9X@B:&L85:.$()?<B%&=S
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M-T@,X$X["G1I1!7C+.+ (O:HDL(UYX3 0SOR&! (.W=X (I"2"@"3D7H,!(
M#VH0,D$?\/ ! 15O_ ')!&?\PTT,BTC#! GQV *#"E8@P0I@[_A1Q#;YN%(#
M-MOHT,4]OQ7C C'*$%"**QYD<@\F+_QE1A_!("&#.N>4($<E.A2AVX7U[)!&
M-#5 (JP+E+BR@Q/_D*&!(RE"P(H[9&P0CSLAC"*)$_W\H8(8TH"AP!!WL,!%
M)47X0(5%G3SAB!$N#'/' 7)4$0 ;Z0C_$@ 0OIAYX3HB)#%'#@H@B@($B?S#
M3@IUE&/12$@GK?323#?M]--01RWUU%0_/>0X-YCUSR<[M"/("_HH!,T/Q>3S
MPBP*I5-#)/^<,,A(%^;S@QC_H"*#/PJM D$S2>-S@@-E )..,@H419 ]@B#X
MSSW]_*--#WC/,D(YX85S3BATI+#7'U\H1$T)UOQSA@_H_"-%(_^LHX-6C$P@
M!C2Z;6&'0H\TT#@>,2@DQ1'AN"!"$UO(@<8XA)3P$Q A_+,,#"+9'-0_702=
MC@Z!QO,#-VUC)D\ ^%F&V3LR[/1/-C/DPQ,2"CT#P:I>$*+0'DW\4\8.2@2/
M!CRT*J2)#N9?_]B[$0J)A .2\0\CY,X58 C//_#!@V5<! 6]^ <Y>O"-8 Q@
M"TVH0Q5V,B10., 0@ "$//XA-[IQ8U/_&(,/%,*-!HSP'K_ ASPXX"]E(& 4
MX$ %-FZQ B7(#W#D$$8YL#"'0DA"#F6P4%"ZP0(L& $*L5#(.5X@# OQ@&Y+
M>,0_P&$*9VRC F>PA"&R, T%TF$O_SA"$O_1I\K5@0:?L$08C##"$]1"(=TH
MR#_4, )"6$(,;E@%#][QCW:(@AR?VT?EC'($A4 !#0JA@73\\8)G_",205#(
M'1+R#RPLPA@.0(,=M* "4 QB!0J9A0"^\0].Y$ ?ZL!$/+(AA"O\@_\9!;C&
M/]A  B8T:P#$Z(<!I&,9./R#& #\C6KZH!!#+& 8XA@ ,Q2R$KH)(7F%#$ "
MCY!))09%#4SXASA2P)Y_8(,!+;E0-@J@B'_\PA[O0*$J3 ".;Z! '%Y10CG@
M08)LF),$>+O0//Z@CW5,02Q5\.$_'H&#<?S#"0A+1PH"19!^8&,"VOB'(?Y1
MC!+X9A\Y<,,_CK$ 0?Q#%P2 1S0J$(AE< ( GM ,'?[!BQ>@0QT$D([S++(.
M' RA'O#HP@SXL8\$W#$=<Z#)T:K&U*8Z]:E0C2K<+E2.$RCG'[?XP3H0L0-\
M*(0@WO#& <2BD"%<Y01H,Q,)YT;3#:!"(:G_F  QD@:.;KQ! CZPQTM<\8]Y
ME, >C?B!^22HCV"4@"FG. 'E+B2.-40A&&7@PC_@8)Q_(.,'H;,#Z4RGB7^8
MHP9:^4<F9""#5<E.(9P(P C_< *')J$*X2A!.:DIAA^TXQ]92,(_KI$ 9US$
MFT'!66=5IQ6"8.\R_]A>]Y [CQX$0R&H@,%MM5 A<?H@%:IQWS_L0(0T$FPD
ME,R#0C;!@WK\)APMH$Q^(##75B#@&V-XZY#.P0.^A8,&4:0O,D3Q@'.,Y%5#
MPL0$AH&T$OXC&0[8B6;_PH@'Q&,DXX"& 2[!H D4I158($06MJ 0/6@@!6_5
M02Z0IM9N<*"=2+-&_PD(2,(2)#$(J!M))R;@F*E>R X<5@TF_E'54_RF'# (
M0]+4<0(?_X,@!$Z#$)!&C '4^!_C  9F%RF&+"@D"V2X" U^\8]ZS,"WA)#L
M/[80K$Z^(A@(R 8ZO&$^%(CT'[V0P',)L0/_2@,(?*B"E54Q@3)*H0OVB,<[
MV!$.;TQ8(:\0@#P.$<$A544ZM]Q -NI1@AKGP\7_B(*8Q_$$$_Q#"%H KD6J
M[!(#F/0?_2C![,QD"0S4@*\GW(DM=/"/2S@(:?$HP7.7P0/_#ND>EB""#03A
M#@+<(I6M[23"\F&#MTJ9'OK PE@)68W#;F0'E(F&!)1#"PAPHQ,/8,0K3/^1
M"VG(XP?=8! ,Q($/[E7N9C8@ZR(4 (TQK_ 6&WV>5/?-[W[[.VI#*@<.3*&0
M/G1N$R_PC4M^P)0NX$ W['C!'6.0SB&Y8P>% (<W"+#1?Z0B!?A$VBG (XP&
M[,0&6D'% .I!# 8$8CE"D$8\>M X6N3N-[[P ('58,L](" UR%"!?\&PV2!<
MQ1L[L&09P-$.*LR@'',@JR8"8 ^4W%P*5?C'$F8PPG_XP1^?T.H_F% A96Q@
M58M;I%@] 64<K*JY)S&!,?-1 0IC;4%^)? M-TL(W7)4!KK40E=2Z,,Q)& ;
M"D$$+&* &;<,P9L/](5"8K$#=VQQ"#^ PD^&Y(__$E1#(2V(H#YF, QH"&#P
MS<#/D-X@@(P&Y>*2^ <])$!P,Z2@=*R P.!I0>P$4/BBUU &!/AZ""N_HAVE
M6 (/Y$$#*RLD$XL-2CP,P':@_&,?*U9(.S =A>^FXQ&B0 !?_T$-Q ^I#0H=
M0E?2<8,17V@<5*"!;OX1B-")X*K>* 'V),&!T.4'%@&@7J'@"?3P X2D5GJ0
M3$R@!Z G"B0$ [[U"6*F!+/S#TGP"\D  9V@$/'@"E"  C_A"P)@$'0F#L0@
M $E$"0CB"@B >$=  T=C"\'@#X?V#^B  D" !XWC:%*@1?]0"@=@#?"0?2V6
M1$D0!2.A!$!P$(^W2'2P_X3H8 )ID#8ZP$$5 0_GH I34 "L( \2X("L4 -P
M)@!S95G20&F?YPR]]AO1, -L( Y*8 CND /EE HG  [*1D(V4$8=!0W@X ]E
M< !'P [28&WXL /N$PP2$$%Q90V:$C8*X0YY1&#1Q6[N9F/!Y0,5Z E!^ _5
M4 &R  ?/I6__5HJF>(I.-23I  (ID U%\@WG\ 4:P%?MH 8EU0_+4 %*  QB
M  3EH T)8 4382;FX 4F0 CO  L#\ K3H 5!DS2O$ &]@ PXL I540-JP 4/
MH 3S  03P 0H  7J  D6$ GZ\ 5I\1O9H %^  LTL .N\ XO@ .04 0+L ;X
M$/\'FY4%*J )3# !3> /2^ '("(%X] $5Q (W: &$D -[/ $ V -Y' "2X .
MF8 !,: $20 &Z& 7*A$%,: .PH  :S -P_ #AZ! T; !*3D,!N!CKB  V"4'
M/" *<" !5X ,Z% "2S@/#] (D- /N\ !U0 .9]  I5 .8^1904 $YB .-/ $
MX+ ,"K #BS &2Y /A;  F2 ,2S!,XN _-> %_" /(8 Z%A$*&Z <:M4/*F (
MHP //D 'X8 , 6 +Y3 %%( &L0 #K5 Y2L  SU(1Q2@"NB '$[ %T/ &.Q V
MZI $$% (B] %\5 ,&@ >I& !K. *#* +PA #5^ /1Y#_DM)  .]0!A&0!J>
M!G=@$1<"#"RI1/EQ %5D@RP@%IN  89P"D P"?R@ SL "Z]P T4Q)'7 !7A8
M!$T0#NCP QXQ)+^P $" "V9P _EP#@$@/M)@ ,KP#\Z@ 2" "X,@!= P! 8
M"Y" !<G0#:;B$+\!!B=@/DL@9$ 6-,UP (@W!MCD!6W1#S/@@$O@ **0#4D
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M#L% .7SQ"<]%#J3P#=> #+QP#,TPS@KA"X9@#/5@"E2Q#6+0E:[@&R#@@_A
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MQ#WU%&1/. 7Q(X.(!/4+< 4$VVN(&1/NP=#!"/7(XB!7OG HQ 0A3'$[B<+
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M,8-*E&,$=OB'/TAQ!PTT AL:N,9!TJ&T]7$ 0"E"M-]BW0Q\**"H#8G'+2:
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M"/"R?S@%14@N";@179B T&N$ , 9Z  "%D"0?VB"9N@' S@]=K !4OB'3%B
MUL@),G"# 8C#?R #?0""!J$.4Y  8?^0&A[0N5V@@65+)EJ8Q7]HA ;X$5H
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M63^( DZ8A0'@@BVAA1Y8 "P %7GX@@>(@BQP 5V@A!4X EGH!A$@@3:0@Q_
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M$.-H@PE(\80/7*-/*L"'-";P!63TP #=* <39C",26"B&SYXPC"JX MO_
MN-@'%Q9 !6H,HX7$, <18* +&$@ 'IL  "#R\ &FA((%,IB$,78!@ 3XHQ@Q
M4($RU.  4*AC#0 802^L0(%?Q*T<[5E).-3!+5Y\@ 2E^ (8)/]C#2A(  JN
MJ(<H'( +,   =0;RU@1648\Z($ .:KA!$FI#(G4PH0BJ0((/RN$(#/BB$#E
M&Q=@X8H1D*(<0&B#,H20@L+PIQI8H,$HRI$-&1QA#3O@PS_><053;*,&3VB&
M#U[ AA=D@PY;4 8B<@",#/TC&B+(A"YX0(1_( ,$B\@%!C#Q#TP\H15WX  W
M!"&!?<"C#S_@QR XT (EK  67& &&XH0%6,(H!"[D  VKL&#";"!#@0X1#KZ
M   ZC",<0_C#ZWJBC1-(P HX2 ,R[, ,,53@1V]0 BA\T(+<J>T?XCD#)1H
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M4]"@'__PPA#^D001Q(,>%1C%/UI0AW_T8@;A6(4$[O".6>R '^LP@1W^\0@
M6*(=4S"$,B@!@$<TY1^+P((_U/&& 5"C'* 0P"K8H2%U/(,$WS!'.W!P U58
ME2U$2 ,_8 '$W)ZVZ$8_.M(AU!/5LO9*#O#_ =I>3MO$W+8-1.>*H1 1@2C,
MXP@ Z .MYC&"!E@B%I60A2HN< )V@.,VS#!  JKU#") (0 R0'@E?   $T##
M'&2@  #*$ YRN   +RD# '3=CR!X(!BHX*YARI$.=C0"#&^XP!O&K((-$&/
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M$41A0EA#.QR"%R0$+E# ,J0.-4"% &9<8K@ )4B!221$* S" XP.+9("-)1
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M#$L3Z,(4K,TZL( T_$,(>(0X\ ,,? ,XA( 6I.8/( /_H 8#C4W :+98+R!
MY_V#$EB)$$P"Z:P$&3Q T[)#QO$!M^G##E1"/VP (*2B#B1$%VC"/TS#!(3"
M@'5!).R!I] "!?#M/T@#*!J$.FR30KC P:JBA3X%,)3 HK5##QA),CA +@Q#
M ?!"0A0#Z.IHBI:NZ9ZNBOR#-CC 7D+""H !"#R!#MQ"3WC#"X" 79#N5<!#
M)[C #/B )H!&%TA #6"#.S !!)3 'S1#.H3"#61 #,P*(TQ  C2#EO8 ,Q5
MI#+!$ """Y0".6"!&>0!%=3#*R2 !!A",1P!IE@#*00 ! 37+E2  M2 &IS#
M&2Q %C#"#N3 *8P#&F1 %;C"_R440 ,,Z A^0A+<@3K@ Q,PP W( @ADP!=
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M$1QL0S#)*!P !#@  1"  7! !1C  P0 !QQ !4R  QA !20 !$R  %#I 3C
M 2B  CS !!R !$A  G"  P@ !$B  Q0 !"  !W!  4S \E._ G2_!B" !!S
M Q2  W" !#"  "3 #K# ^@]  !P _3L _T HF"#!@0 %#60<H+# P8,'!"I4
M(,#AP8$))%@$J. @@0*(#@@Z%*E P@$#$R48-)   H,"7O+]DSF39DV;-V^&
MT[F39[B:/7OBE!GT)\^B0'4>1;ITJ5*@3H_*] )@BKM_/FDRU?K4*=&97H=N
M%8M4Z%6N6(42W5GTZ]6;D#) ZA9M$B=U:(UF16NV;-B^>]?V%3R8<&'#AQ$G
M5KPX,5C&BI..^P8.J;MX89,^_C>NGBYGV[15NZ:LVK)GP:Y-F_;LVK=KV;:-
M4N7,&2ELS9HY>_9,6>UFR[(Q0\4,6ZE2SVY/FWUL6K9LND>%(I4-FRIERUBA
M>O:M6BE6S4*U6O^F+5NK5M.,8\.V#;BJ4=-ZYW;6;/6S4,JB72?&O-EK;-=Q
MPRV;YIR;1CA46,FFE%&<N08<S?[2JJN\<'+,K,"^8FK"L;C*L"F],,3,)U8>
MJ8<O$#G\$,4.1=SKPA3'*DM"&35<4<-W/FD!!B(":3'$%UFTR;&M("S2R".1
M3%))"Y5,*[,/@U1,G'&.=+')*Y=\$$LB;:0P)R];W# S#V$DJ\L?AZ00S3+-
M/'/,,-UD$TPQK:233J+*Z8;,-%7\<LT:L0Q4T$&%E--0%O$2ZTXP8Y0)G$<?
MG>G10[T,9U*=M,2,,DM;!"<=3-NR%*MPQAG'TD=-S6LM3$VE["HM(<7_]%2C
M7+4I4I[ :56G<2#M%==,*3,GTT(I-=3'1H$L5EE%CX5QSR Q++999>-\<MD4
MIV4VV6N7)=3;;Z]T=MM1RRQGE$],3"6-<\9EE,-%_S%F$'XXI4R<1*(15=I_
M:I'CEKM6+8<:3?QI-RBLAND%F'_,^91;8ZN]UBQSWLF''7GDN2?;AWL2IA@Y
MU1'&88Y)3BH>7KXQF$AUE/&'RPQE N8>2O_9YYV29?*FE&EE2J><DFM$YRR<
M-R[31G"13EHS;*UQARQJV#':GR<2N"P1 I)1V45L(_['$0J$D6G*?ZZY())_
M-J5TG$/0N 0!7?A"YQ]G?-C &:W7<@8).>ZH_P,*),(&FNMG!?_''35<0(&,
M,7S@)%7!GPJ'!R'P'O6?3B[(&G)N_U%F"R(XH*7RO*SYP@%4#/[I'VBL2,&>
M;3<&!Y$&9!D=VTZ.L.&)=I*5J1Q+6KC&=IIG">&7"V42 Y#A.61&C%689VJ=
M4/+@!TBEL<^^L*W;HBD+/5T$IPX3 ;-R3&M^H,=1M]BJ<.OR!7-1'6MDVJ</
MWY.Y:]AH$?6)F@ NPPIJN*4><?A'.7XA@&6(Z%G_:$8.$C$314C@&.Q#'OL2
MY1-RC0E-,+/@4#QT-,RHSB\C_(<7'O"Z,WC $1=TH5'(1:80;I 1N/C@B?BR
M#5+(1!AJL)ZUDK)!L/^LBG!"Q*!:?#(.*7CB'Y1 A.@X&$03 J(;Z.!% 9X1
MI@ZZXQ,\P,<1?;(+?2 /*."0Q0Z@-S0Y_>,9/=#',*3PNJ#D(A[E> 4![K:Y
MM3!#!8RX8!7R$#T)C<,2"X"#()^B#2SD@!S7T]XC(7D371Q"=/^@AC'J 8YH
M6(,?_4!##ES12'400QKXR(<?2H -ZXDC&,(8XS_6\;IA[(-]QX %*6"@/G78
MXT'YT$<XPL.^;GS#1%F1B3&" 8V[_ ,>VC &3801C9CLHQCM4 <PO&&]?WS1
M&S*)B3O@< -QB.T>6II+.=Q"CV+ R1K1>)!.?D$ :&A))^7@@Q8>I(L"#(/_
M';S#BCNBP4!O#* .(/P''%@Q$VYHK";B>.4\UE$AF?#CF3.)R3]>EZDGV02@
M!I4)N_(2C1_^ QWFZ)Y9J)07+B!!;OI(0!O81R6##NM+AL%+6F:"CA;4@H0T
M[<I@HD2L.G5C K"0B1%.@4'W^:08.YC'/T*!@&UX\*0U048/V&43:4PAI4J1
M20W@5L*JWO!-;MG#"5;TCWG$X(OWF,%4Q>K1!AJS?3)9 B5>-%;84=6%,S$!
M& B7$[[*A!0S:&1>(YE82 (B"'%P 1_2X0H2_ $<C2# (*0A!!*( 1GPP(,@
ME% %:8"@!):@AS9J\(8^V* ;UJ#!$O(0!1GP]!^3_[B!&6Y@@WSXH@9!"$<V
M3+ $.X"  [9 &QF P(D87&$-*;64([80AQ]4XQ^G^,,E8H"'=-1##GQ0@@F0
M$0@(."(?1%! *^(!!"2X 0%G: ,-TG$)&\P@#O+@Q ]<<95#>"$(6* N-H9P
M!#G(XX*2*((+AL -!TYA!V HQ$A?P8$6%&(<NJ@ (; P@AW^XQ)56,(5%KB6
M3F0 =6OY!OU*YX4N;.(?W6##%G(1A1,@0Q,-H$([N($&.-3""E0(Q54R400O
M0,$>\5A#%WB1!17X AUFZ$(8K'>)(:@O,X\H0A"T0 Q^"8$03; !2'V"C2L4
M8073^,<C@A"(-"2A$O_HQ?\2@/#,6CAAAYGQPA)DD@@/3.(JYM $'8A@AW':
MHPIF, (3Y:$&/<2"!I?X1R#"\(8X#((4X, $$:I !G ,@Q"(\$44XH .<&!C
M#ZKXQS>6\(0F;*$+P0@''-S0A,O(80)?8$8_&$'A?Z0C#W#HP_+L,0@^%(,/
M5^AF7CXA!R:<(1_K6$0=CC&)%?0(AHB PQ8LD8YT0-H50_C$A=#QB- N#QA1
M> $2GB"% VBA%_^(!QC88(51X",0A<"%%!XQDVW<H %AL 8S#H"+.%@!KO,@
MPQ ,0>6UU",-0G""#KZH#3MX81+\D(</!E"&NPE#$E=XA,;6LHX1Z((7A<"&
M6YC_(0<E[,P8F3C&(F81+TT\XA81_<<R&L&)4: M$"[0 2+,;)-SH&  >;!&
M.V" C4Y@0G@R:<4@-*'@;GB"'KQ Q%/S$HM-B"*B^)!F*0JA#+<<XQ&5L $D
M7L0.9^2K'ZK0!S<B\8[K^:,9U4 G+)5Q#;G[9!W.4 8[_G$/&XBA'<?PIU&@
ML0UAK$,?Q S',(21#ZQTPQG%9(4-\D2^LBJ6\]^BQ0_D#HT"+,\%1OB'.&0@
MB7\DXP<QN<4+9#*&?UCB!SYY! 2HI()3D,,0''A%.("0A7^@8@ !!<0+X $-
M2]P@'?) @P9V\8\O#.$?MB@ ,OXQAPHL+"GLD$$N_A&)_V;H P:P&,88 !"-
M/5@A\!)8PS^P8 E8]L 7Y,B#!.P0B5E<8@;Y, <BG  =^,$7" !Z/&$%\ $>
M"  +_&$&S,P,IBHSZ" )U($?M* $YL$<L($$@&$=T@8=XF ((HH6)@ /JB$+
MBN ?4F$%H,$=7$ &Q@@KV" !Z"<OX($& &$<6L$"(B$8I@ "+($8I$ %,D$9
M5" 1D@$*$* /6"$$$D :H@$ P,\&-B$>ZN  F& 9H. &_F$8L% F,,$/TN8?
M<($%H"$=YD &\$$5'L %-*$*"L8GR,$ _. ?\& $V*$1&H &2H$1<N =]"$$
M?F"<2B$+ "\SF* "Z$ 25( />/_G'SZA"MP!%31 #\0!!-Q 'T;A 'HA&89
M *Z-$DQ!!<ZA&@2 !68A$ #@&K ! E)A%TP@!PSABBY!'1C! 6+A'W*!#[2!
M%C@ !. A"VX ']B ^J;A!SX!&I)A"E;@']3!"/S@'$!A 3Q!&+Q  ,: %48
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MQD$+CDTGS&$(WD FWL$ Y*\'R,!#TO]A%8IA&Z!@ .#A'TI #VJ&! :(&12
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MBH#]1,$592(:!" 1K($:GNH23L"D_N$,>/_ 0'- ??X!$UZ =W  IOY!%_H
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M@T("31R! ![;R#""&%_LT HW/5"1"3TK((#^;+"#TW0=[\0R01/DW+(! ^0
M!? HA.,T-0\73&  .\C%/V0A TTLHPBO^,<R8I" 5)0C"O\?N %@L#(, CSA
M%[Y8@!7FP8D+S$$<F&  ":2PA'ID@@-VT(<G$,")<F!%&@9P0B564(!)M ("
M85I$!]H@CCYL( Z2>( -J(65:.R !MY@!@3JT ]8:( 7Z6!>&S0 A"R\0!AH
M<( K&O$ -P0#$QD@PB-B( MQR" ,X)"&&<%A%B2$X1^=:$ Y=B&!2WR"!R-
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ML$0>:(D559@A%LE0PS0\00A)S*(1GRB#,=I1B32((A:D@.PD8:&&3YC"$X;
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M(0 )\) $-7 'I_</__CP#4?1"H2!F<4)B>N@"8?0"SHT#KB@!YS0#D?A#9;
M",. 2OQP"WM@E[!D"@\P!LH #F9P O;P"+.@#EM)"7J0&-;4"Q(@#0:!!3HI
M)*^P!ZY0&?E "9>@*>A@#JW0A?\P#8; #.?0#4[0 MDP.NV0"). 4NJ #.5
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M#;'@!$M@)?^ "W^P!E:@JARW""X@!4D0#^VP!BRP GF@!RG@ W0@#^A "$K
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M(F 0(E 0[K #:O /M<  +F *=B6VT'0#>_ +MU +6M8"W^L&*? *:P\*SO
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M(9AW(*$/W; "8<WAC"DP@!#E:,<:!'""$ITH1?="X#\D]P])"'<C]^A'(E"
MBER,X!_[<  I%[:X!6R#,A!H1CU ]P]4('>1JWQA@QW\8 AOR1L^0, 0?&"*
M>[P@"8V@0@$*00D&S/\"%3J01S1R@  NV. ,D-G(%&+ "6Y((0#26%$)HA&,
M'QC "RS()DG,H0TO=( ,1VU%!(0P#6^T@ )7$($<GE2!/\Q!$KH8!S8D8 9\
MY"$&R!!$#\@AB!*4@12PFL$17I +B;QAN-JH  ?$X 4SE ,/%/#$*E;0@%@8
M*ASC\ 8/8C"/=!*# R$0QSB(4(%OF*,).4(& =00CEMTP _$, ,%_A"/*TA
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M0T$'"SG_+75(!F#XAGJPAF@0!J)BA%_@59J(!G08AVM !GP=!F#0AW=0!G)
MA['HE(TXAW?5*G3(%'Y8*%@-AX7UALQP"O\P0G$H!S?5*F-PAWO(C76XA_"P
MU'@8%KC;B&B EA1AAVS0AHVHAVH8AF^0!F$0!F30AV.8AD9)$6^0V7H0B&I
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M!UGHTHTP!PN1!O>>X7RP!6A(IUY0@&(PAI_;B&*@!=!-$2+0\G_ A%JADG3
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MS3_V %&'%*;\L\L0DW@1!95-; '%//_T L0<9_2#D3)^)#%$*O]8,XD9M/3
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M03MLX$"H0@/( ">0@P<* 2 -1"5XCR8TP&V9%BD4 "H,1#)(P"E\0P^ZT2"
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MGD%8% CB.JQ@A-';X'Q#']R;'9 -1,P!#GQ+.(1 OS #HB6,*0"E$&(*+4R
M-<1" 72.+$R#IOT#$>#?/^# %V3*"5C0)QS!/9P '?R&$Q#$":C)/WR!#2P@
M*D2#,?1#&U271(!!"8S7>C6C)@2 F-VA!LC"0!3# 3B#LWT+B,&9./_H0#:4
MP@:$PD"XPR[PP]\Q4C@@0S_<@@JX #*\P(4-!"HT0@-XS3\P@SQ@ PPL4B8
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M%"3 !S-$,+A #J0!*23! #Q"*N@ "YPF2"!" ,S -?S"#MR *HR#()A !<1
M/4J##U3 'J!!#&3H162"Z\#!%)%"#.P )?1#&[W##03!+.!! U0!*3 ! 1""
M.HQ"#51 "XR3$_[#&$R!'!0!"GB6+HR "A1"+/R ">S"&#3 $8P!"9!!(I"
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M*%S";-J"(C "HE?+/? ")<1#*PA"-T!"+/@"*0"^^P##'^@!(/B",33AEP_
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M5'$AP+@&.\BGCFU Z1_^,,4I?K9&58B#&=8PB3WTH )*)(,@K.#% CUBBU.
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M"'P@&*PA ;Y&!)XF#GQ '$R! !I!%W1!$+P &H3A 8X@&%A@B_K@KPHB'G1
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M1D$']&G_"(P'&HQ #'RA!)*N7@F"'DI 7P66()A@<4/ 7JVI8(<G'%R 19O
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M+;R4/E#I=871,1[^_@U E1>O-Q)]_HF[$>O?F!SD&F\,]T\0AFG_6+6HURY
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MDLX_U.C!Q23FI(I7.H7<(0<KEVQA!&.A;+'%+/]$,H<2N^ 531A<%((.7HI
MH<<D=_5BA!MQP)/A/]VPX$0><*SRCRM&;"%(N@^I46$D2NR1RC_>N#''&?V,
M&$X_:O0AS3_&L'%&&L%XB0\L8H!1R+S9F(N-'J>@LTX;1^"QSCAJR'%&-7',
MT48\&1)WR !2E()7/TS$ (0CX"ASQQV,S/)V+O_/=!'$':#\ PX=/7R"R!*K
MS")''YE$<L<?VS0B!QB\T 'W,V'(,0@M?6RARC8U>#%*$VV8XPP/=IR3Q\+
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M#!LP"/S  @"R#BV !>$ "1 PU(60 N2C*2B (<>P!_]P!>_U#W/@!_]@!T^
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M<(4QOO" ;/!! 6-@PPN\P)T1BL"'_Q % @A0 A1@!2G1,&\MY, %<*@#"!$
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MZ 0*J(9P" %L )0SF)4VX(5GV($ >(5(6 )XF 4.")5QP ,&T 10$()<R 8
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M@S8HKDJHA52H!D*0!%SX!G[)AUM@ TH0%CQH S$X!C- @Y/2!2+XAE+P S-
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M_RP$$D !-)""-OB@?^B'0HB"%A #?+ '($B!). %<WB&%W@#1*@"=V '2S"
M&3B&?) "!%""/PB .Z &0TB !"B!3- '.5B /_ '?GF&%$@ 7L &'2 !9G"$
M AB".CB!$4 &7I  +["#&G@!7C@?06355G75-%$D[-&A->DQBWR2ZZE5BZQ5
M- $F,ME5^%"$"6#%=X"#[JHB;_%5^. @9"T37%436V76.$G6YEA#98565BD3
M?F&3[+DX;?66:K56,E$D;,U6;TT36[W6<"W7984/:-";;YW6=?5#=%76*C+7
MYH"3=!5$"R('NT 3</55.4F'>W '7K(@7FH@"TJ+_W]0!Y=J!W-@AW5 1(X
MAW98AW6HAW3H"'7@4X)@AP:JAB) %&!@@GW@!XD-!W3(!Z8YBC2E"X(H!Y?*
MAR8D"&# BJ&@AE#IEJ-(!WLX67M !WZP!7]@!WOH%G^8!5?HB')0!5(8A>"X
M!U8@!7$@!O'Y!VA8A>+"!UN8!EV(22@YAE$HA6F0AE90!6( S%8 AV@PI'\
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M8(XTH& T69"#-X"P 2B\P1)Y4,,_VF '<*1!"M0) A_^@0@+T,,; <A&*US
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M 8\26+B3U*4."5KW#VT@P'*=E()0T.&#)$/C!\#XQQJ>T* IN-(.)D@)%X3
M_P\3%&$+2MB"_5S DS#?PQ;? (0-,%$.&"0B)6S  8.08$1=Z. >N_7H,2H
MAWH<&QD]:(\X>L",?U"C *>;10W"L0@6%,*B1Y %.E0@#&WV((]"R*[V,F:
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M("K 0(4\8,1U@P&XXC_$P0_\P^FEA.O]P_Q]0TK4PQ)D0!=8&"&4W#^ 'TM
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M#8! GQ0#&Z1" 5C9/X2!@/V#$&S"/QB" Z0#,\48,91 A82! NS;(\*#,TS
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M+T# %%Q""BR".<3L+OA" KC *)R#"-S .PP"!02")\P %4@#,#0 )?B"-AA
M!1@"$/2!.? " _@"#O[#- @ 3C*-'?A -Y##"637*0A S?AN0I7#+&2 *:2#
M(U@2+FA ()B#?+[1#3Q!(&C#"DB!.G1#!2@!.\3!!12!(5 1-2P &F0((%A
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M !/T0RX@P *J@Q>TWR_ @,>6@#6X@@TPP3D@P1*,@RD<0"R 0R*@W@FPP3_
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M@B0L 36D QN(@&T& 7IB0;F9PQP\0!S8 0V,@C:<P!? @2&L@S]H@12D@B&
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M_J$==@ 3<O @M*5&JNX[UH$ A+!0_H$9.J"GK$532"(?E& "&@%36FTP?"$
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M-PH#%% !')Y! <Y 3422/[BA&^X$5DY%#N'M'\K  D !+"+!!6@ ! BG=!;
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MVK$?@<XG)X<JP$$*'N 9=O "8F$1.J %0*,8=N &R($= R31U"$=Z*$*W
MDN!92(<5:B $,B$&%B ,PN$9<@ !5($?PN #D( >AH ![N ?GN$%&F$23& =
MGF #"B ,=B$6$* '".$(&, .8F$$)F 62")ZXF &!D$=], "2J 04& #(J$?
MI, #9H /^#+\7*(-,( &[$'?>$V$M@$%W$ (__X@'5C! %Z $V:@ ! A "3
M"A"!%50@3%.!!R; !GCA&Q[ !%KA'Q8A!)I@ /A '4YA!<! !T) ;?#@ A2@
M#U"!'J"@"(# !:P!WPSB'F! "5Q"#!@ %1RJ"5P1">A@#4K@"%3$']Q@#XC
M#^!A%4( #Q#A!IP )74#&9#@#5P C3HA!O[@#&Q "-AA%'(@!7#A'Z(!!^YP
M)8 A".K@#E"@/,6A"JH # 9 7R5!!XA!&D" !L@A%'R '._!#?3@"])@&6C
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M^@$'5("="F'X!B()<  :7.$!B 0/H* 8F"$"FN ;_VC !IS!'AK@<!ZC'%I
M"/XA%AQ 'K)A!E  %+ZA (!J$QS 2=#A#T3H,1PA 4HB &[A']* !C0C"IX
M1P; 7RE! *R!G%G@'W[!!UX"#O[!%T8@&!G! ,;@'.)@ ABA'FA 7R_!!88!
M&'* ";KA"62 &9+!FBG78*^T%7)@**^ *0&!"(Z#&I:@!.) #T@A"%"!'?K@
M KHA$') 'L3!"H#8%C8 %<+!%@[ &\C!$C!@&N3A#QC ##CA%-8 #?(!&SI
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M"G6C$J3@'\I!!^8<= Q@#5;$(UVB$0Q@&5H@"SZA$+J@DW7##CZR",; )7Q
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MDL(&WLC3P _XJ#,/! [(<\T'.(!#RP=3_#.*!QW^@TTWPTP0P#V^>! $.JD
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M<N" <_^P A[(P0,GW 42>."J8:+Q (G] Q)."$=<@@&[W>EUKQ&BB&&ZR-?
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MIIA=;WF6"^*4O7B7!;*7!Q*7\D</@;!'!X$#)2&7VN>4%!*6N\B8$Y)X$5&
MM=B7L@.,E;F8?GD0L: +Y4(,EZ"$E&DUIG %:Y '8Q &5,8'8< &J\D&8> '
M5U '>S &:" &99 &1M $2D $NWD'O=F;=> &P>D&=S '=U '?4 $3\ $RPD$
M5>"<S@D%T0D%1O $U5F=RXF=V<D$4- $W>F=W0D%2N &=4"><T $<^ &?N '
M?<">?> &NPF?P"F<36 $]6G_!$Q@G?GY!%D0GO!)!%L H$0 !?II!4U0!$I
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M"TWX#]H@"(L0@/[W,W:0H))@ /]@"JTP=-"@#,\M"*!@(@I*!@<P#0?Q"Z0
MJ[=P"3IQ$-U "<\$#TN@ \_0#^+0#,X@&; @"+EPBJQ@#/ P"*!XIN7W#U#@
M!^A,%/M@!#;0#.N0##UP#JZ "SIW$--0"1X<(*?  "5A&/XP+;VB"+Z0@1(6
M#O.0H-M!K@>C#TE(%/Y0#1OV#_QP*\EP+^1 #?M #34:K=CZ'^Y #!G("470
M:19&$>CP#<* _ZWR4 +]D0X%8<Q]T0TZ<X/CT \6%M':<"\_-R?Q8!/WX,$4
M00X6U@UE= HS$#G_< 4*4=%N"<ZZ\#K*!@DNT,O_40L4]0^D  %$]LXN#>U%
M40[D4 P;3-,(P@PM\ "28 LV  5<P@'T8 Z !@ZQ8 ,!< BY4 ).4 BV$ "!
ML#,/\ 9Y@ ,$( WJ0 1Y@ ]QD$EG@ !<< =N$-9 :P#9  U9\ *$MPL\X C+
M0+$480YY4  -8 D@W@TO< 6^H <-4 _BP )-\ Y=H 7FL 83,)!V< U>L W,
M< !DH,[60 LJT.K_(0PF8 FA4 ,[= @2T -MT "_)A'E0 @<P C[,/\.3F #
M=- $,I 2L; &RK &$N"]5I/:!\$'&K *O  !PK /=4  [  (,I #49 !N: *
M6' *8" !69$$(* &1O  CO0)*A +2A "X< -6+ *;- 4P5 $IG ).T T '((
M#,"*IG !C< (!- #25 !0H #6' 0;! $J1!HZH -($ +B?  G+85TK ""9#:
M.\ #R$ +!7 &Z0! KV +.U"3%_ +<Q (AQ  [I )$! ,]_ '%4 .YR %69 )
M#: +[^ % O %;) "%:,))* $LZ"KG08$!! &PW$+4[ '*U #=[$5Y2 (!O %
MO? /*BX'6(  8/,+!# 'VR$%9" $]RP?LZ#_  E@!O?2$M10!Y@ !R\ *;70
M!650 W  $,F\Z"!T;%*!-__"B;E"YX<1=(L$?#FCXD2^?QD5ALN(3A</8!LU
M9N08"@6,3_ZLE2@SQ "B?^,^V1&C(M-(A7!RR-L8#MR\?^3NP"&20UF]+ TF
MU=DQB9>4'+'6L8E!R(H*)"%-Z<C30I"Z22?PF$FA Y\K%0T:_<-G0\@]G,.8
MZ%GAZ%^E&*^0I CV3]X2/W*.U/M'KT2U?^E._.G)L527/H@(J"BE[I".,BR6
M_$O%)4V/6/],A3B$R< ?65(:&/IW:<:6-AQ V'MF@P4:9/^\;!+*14VZ>UO*
MX*17B BN.ERHF=)"_P3?/V]P\!PQ]<\>(B/G.$]0UOB?(ADH&-T+5PE(%%@X
M,U(:8$-3N5$FI+'!(X^C/#5%U+Q3W]__?P #%'!  OL+YT $$Q00G''"$:<;
M:]#YQYP"<5*0DP;:^<<3'/X9I@1Z_O'EA'+^V02$C.1H(J,@*/E'EQ[T^8>;
M!PKB  @FI"B@%W\06(4D!/]A)X4T,IKG +O6X>$8((/\!Q4://#AFW^Z,< N
M8A!@!1TBLIF'CQ?R4:<$5S+:HHM.$E$ABFI(T.6?6/S!"1PFGLCH& UJ^4<.
M*OZ)AQ\%H7F!F\1B8.*?=G;89IX!].CD$ '(\.Z?)E3 I D27'2G!VW^D?^F
MAW/,(:*&>Z#YYH1KA)3BEW] & *<?T30XY\WP/C'%1B^>R&>N\)!HX5*!JD@
MB"8YFF2"+<CPX0E]REGAB@?#N02+?["9P9Y_'B$U#!H&$60'%RA$<!QK=ACD
MGV\4@&-/6^EQ()-QT-#AFF26>0"5?P#)AQ]./>6!'6!XT"X((L !18";%"%
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MA@3(Z!L5X'@\9,!Q%U*#!=Q=V0QJ_ #U72-BJNC -<PA!Q5 (Q\_Z,L_TH"
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M@(,0OH$;=>C@7>& !B P42%'^ !E!H$'&+( !GB8)!TQ8 ,L0)"<>4"B$+#
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M$*(=0C!G&7!P!8; 00G;*,(#SI!;A(Q##I. ! FX80L(F"(<L"A -?X1#20
M@A ;P,4_J&"%272A!"1Z2"L2H DUJ  8U$-!' J1 R;\8Q$;@ ,X'($ 1>C#
M#A-0Q3CH$ =+D* 3O,@!%W+Q#">8X U)&$ AV(""'=0I&U=PA!D:P(Q<Y* %
M9M"! [Y1C260X!/_T* ,%Y8@$&L@P0';@ <7<G"O$>]@7HGQQ !.P 9TD (&
M,>3!+/YQ#SM\(0HKT-%#\)&#6?WC"B5(Q17:$ Y(2$$,X<!$%S*A!1R(HQ-R
MX$(2NBZ$)23B!R/ Y#R8< 4JW"8<H)A#'*@0FF<H(0U2  KEINO__T,7NS@
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MG$#-" (F*@$8' 0-# (XX(,^[(#?1(, J$HO^, _= ,$($DJ^,!5) 8Y! #
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M0R] @#Q$P@[\UC]8PP_$PS&P@#;L SW40\U$Z;0L!/Y<0!0(EB6@J9<.014
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M+N!A-Q1 ,6P"%;"#,%3 V-:"#,P#.-B ++Q#,Q@ $WC#/"C!,I@#"Z#V,91
MMR@"#?Q#)G0 'MC#-U@!-73#"[P'*00B/2#@/3Q57=2##-2!6_S >7P#"TC,
MG.81WW3T#>!0$NR *OA#+L"!=)P DD "!MS+%_S@)T  *(P#+GR!/LQ &:@#
M*K3@/^@ _XT8Y(\_C0<@@C\80Q8P ]VZ:!88P3^L @(0@SMD@1,XA1P(K3FD
MP#NN0P[8#C?\&;$ ,"+8 2@0R4.\P]B" PJ4U0BHP:_NP#?D"PY4S"P,2!*
M;#FD0)\\1!74  'Q "ZL0P!,^2" J#KTP(#00RWF)P349QK\PXQ! 3BDWCBD
MPRL)Q!P(+5F6U G@0,!TQC^,0=-&WR:2P0ZPPRS_5I?D@$IB;0%T"#240'J-
M6 DXFV4<P?'6W [HPS\H095J00Q<!3K@P<$D!C^\ ":(AAP \!3@'3OX0#8(
MQ!"@0%*(@QZ@@Q4*1!B\03C, :S0 P*,0CH@0SEH@@8D@B6P0/_-F$5CV/3
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M,+1-A"^E#ZYL>8"%W:T%)+K4\!:LP1U\J"#P\3?RGYT-A-Q,J(+O$H4FE9)
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GWWK7OQ[VL9?][&E?>]O?'O>YU_WN>=][W_\>^,$7_O")+]F    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex10-15_img03.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-15_img03.gif
M1TE&.#=A, ,@!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MT":CL(($0FB%0 8QA#00P1!M$H0:$F&L8!2A!(K H5&8880UG*$(SY#'$8*
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M(1#@% *A1!">\0]^(.$*XCB') H0!B?U0@E^.T@X0F"'?^P#"[P 1A_488L
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MT( .<%@# 57(1SJH0 %J  ,8:2!UFD,-"*!,CE,,-' 'P) /JM "LE .JB
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M!\)0#0L@> (A"P[ :H;P #B@3/_0#D)0 Y?T#W/  $] 0\B0 CE05JV0 -N
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MT? /XR,0QI !KO^ $&,P 8TE$V+  _FP!4(@C?Q0#N\  V6@"DV@@AQ##!K
MI)DP -ZX!4-06I>02.<@ V'J#2\@<.3@!$"0)4:1#_+0#C% !@A1 D,Y0+5P
M!ZH0 ="I#RGP (;@#^(0*]EP >?W#Z<0G+IR"A$@#/$$ >3X"\5F%*50!F$@
M X%R$)#  ^$0#E5@ _US#C:@!O_@#B80C0,T#U40"A]P7?^@#D0 " #@FO8P
M!?> $*AJ+IN( U*G#R*0 [  #O3@HT4Q#E00IOH  RN0L.D 5XL@ 6'06'!E
MGUM06JG I/^0!%T@$-!0C/\0L'*" B@@40?!#PL@"?^P#0&0=/:4HB7_*G#_
M@ 272I$XT":<< "2D"6V]0].BA!68&&(>@6*, '%,$"SP 19D &DI0UW66L<
MX A/)!!X$ .)VJJ!^@_^\  762&.P &X.8T-()8"004"6+;1) Z70#3_0 Q$
M4 <N8#[_8 D!P)M.@D/;P "NN0T:@)]SJP&D(!"Y8*W@, +J^0_*8%3A0 1>
M8*>ZV @_('CV8 *4(!#!D$BZ. <-L+G_P =J*!#,T *LV!!O( 8O@'$'(:]T
M8 'KV*\H-P0=BQ"6YI)&@08=^@]B< ']\ XMT&LF,P=L8 %+)E-/P 4+ %_W
M< 04=Q#U< -K8#JL0 'K6 1F&;/H\"[$DT1,_W$N1=M&$1 (EW )FO "HTFT
M16H,+$  7$!KGF$$(Z!+M[H _B@313 "OAL+B6 "BY(%V0 %R4B1W/ $51"S
M;O -#0!?)P"O,G$$>9H+:/ /6=!^Q; $4-0-35  .8"/1K&HC2H01U ##/L/
MN\  Q> $$KD\[E "+6 !Q;@NQ/ !;% )'X &VX.R!\$)3'H.6  "5I #8H!#
MY_ #U7LN]2 #() %3IP#;9 05F"M.8"U!R$-24  )K"^V9 #35 '9' $L:(K
MYJ"<_^ '%R!P?M"H,K$$RU .#>":!\$(#8 '2G $ _:D(8 $D! "0V!41N$)
M9O /+/"K7_4$XJ &%_]P#$3[KP+!P[K"#@1KGCT@ %>0O!;S P)X"C?0 5=P
MJ$]Z!P5P UXE$+9;6G) CO^@!%A@"$/P F]YLJF*$(3  #/<LC-@!MA !*/W
M#U80 C8;"SAK:8LP!SJPB.YP!@.0!"#+OE+,"@-T"305 GTP0+^@!O90 CF
M#\2@P0+!#U<K/ >QM8F:#!'@C'TA!!;Z:&6;<__0Q4=POH]  ]873Q?0!%F
M A?)$'W@"NWP 8?[#UK0 S@DG'Z@!7W0#M+P ',@"#+P!AT$:0\ !$]\75Z
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M!ADZ< ;<2*( ?+!%& CPAGVNP0O+X$0"MB#)2:# %J^XP2;&<0L1B",83JA
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MIA>1A3(H UQHA6+ @T0(@VH8AX(,A$BH-?9#!U,XA$Q@!6PXAT$XA'<DS+K
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M<)U_C.%J&^%$ _;QCW6X0 \3V8 GJK(+])9@PAO)@A,V6PL"I*$JF,A)']I
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M ,A!*^A"$1S".W3##HB +Q@*R8W#')3 -Z3#-XC D;##"H"!.D2#$GB9,X!
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M!#DM)38E)-4&!@'#,PM, \PGI=(,!U/B%22@V*R"%X"PXG#1;U@@"WIA-J7
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M"_+!#Q@6'7; "_"&$B@ $*:A&@KA#.)!'T@ !/2A'=2A$\Z@&QI %-X!'9!
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M$@["$8C"#J2@#/2 "OY #^K #HQ@@HAA#ZK:S:RB'O+@"JR !>EB'$2!#J[
M$ +&&NB@"ZA &\+!$); #R[A$EP $+SG'U1A")K@19CA#JR@"Q@,X-+ !+P
M">!@A(,@!D1 "J1 ";S K6*@!X9*'7Z@!MP@'*3!#V8 !0RV"V8 #[1%'KA@
M!EC $*[  D:@&#S! HY F/XA$'JP+HRZ,<YA" R&(]K "_\66%\ (0NH(!8,
M80B( -V&P0*@H!"&H :J8%!$X0*:(!!:@ CZ01AI8 <^ 1%N( DV_!\ 85!Z
M+@2,X ]$U"K@(0^Z( N,(1A$@ Z$P E(#!S8P BXP G,@'__81^N0"R00!$\
MYA1PP 6V0 J$X <:X1AT8 C&H [.8 Z.?". H0JJH ^8H ^*0!2J!M5:P D<
M 1W2-1N!NP"!8 =$8*SDH1)8P ? D[LY8 D _1\*H05R0!0"008&P1R*048X
MP05N@ GH00Y<  3@&PEL@!CN@ =$X B&8 G"@-Z,00AD8$H<P48FP01RP!%N
M80160 F0H CHP%H< 0"B3B56(0G_7B .'.$/7  1B $%DMT1X( $ $4R>."Q
MZ<!8 "X1<$ $7B&)-D(0/#(-DN 0MG0NGN$/DF>"VD$1#$ $@F%&*& &="$?
M[J "IL ,S" .4& B%OJAV<:A 9X*K68=<H+>-*+Z?/-*36:4%XOAU2/B%ROA
M5\(O!J,T+8,EI'#7)%PX'?X>5"98&W[7,'[C [WD,;''G,VO6%[C[X+D=\TO
MDDUHYS:'B+?B:[ <2(.DX%CEU^X^A2'S@DD=X"$:HL$;W $<ND$=L@$>-@(?
MI $>QF&@YD$:\'H<X$$=U$$CQH$?^ $>@B$:JEX>G $>I&%Q :.#16T,W0&.
MR:&=JJ+Z_SIH(\(!B5:G&X*A&^8A&>P^'X"A&/*A&UH.'-1A'P(_ZI<A'<@&
M[>W!JV4^)^0>'-C!>X!AL@%#&KR:;. A&83^'J2!'H($&#K-'7 5YG."'7@J
M'D!IL>8A&I)(YDWF'\QASR6_&^@A&OKAO(3!&?"!'/H%]/-AS^_!\.MA']K!
M]^6"'[)!Z_F;Z(U^&5+QZY<!5S/"HIS!&V!M')9A'ZBK&[*!'KK!&_:L*L0!
M$" C)[I![Y-A&+RAT_ !&/9^&(0A&BS^'^)A&90!G&]''(0A'[)!&@!BG,!_
M_^8A,N6/(+B%#.EMF^<-'SAWIE9Y0@9.EZI5L9)Q>K4I4J1%O/_^,01',*7*
ME2Q;NGP),V;*;>1.RKR),Z=.EBA-]CRY4.!"G4-7,FQI$RE0E45=]E38E"G,
MHU"?,K7JDZK"E#:7<HVJM6I8KE^'AM5J-2I/L$G%MO5I5&G:IV_7(KU*%F]5
MF52QFBV*5NW7NW;E0C7JU21BOV<%X\3J]BIDP&H9EU6J.&_<Q5(SOQR*K<NP
MK$3];BX+EN_ISW5WNG[]DF9KV+1KRP4:5*#0UKCK]OZ]^'=BM\)Q!R^./+GR
MY<R;.W\./3KRX]*K Y=L/;OV[<FI+U_+/7QV9>FR:O<N?.IYV^QARQ[;/C[L
MXKIWPR^.OG=^_=B;[Q</8( "#LC<?P3_3M??@0HN:.!U"2X((7'6-0C?@]#)
MA^%-[SF688<QI:62;GN!Q]-F;$$V%6(J2N943L:!E]1L.PV76(P5RJ@9<0^R
MB%IDYDE'(82^"4GD@$$.)V&12E9WI'K9>0CE2ANB&&64[Q"3S#;A;+,-,?.
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MX% "2_,/?.Q #/\81Q.JD)(BM (N?#! /C)# SG\HQ\K&$)*KF '@O1 ">N
MBRX L(C,8,(#(6 '05Z!AW2$@2 Z^,4_K$&)?X1A"RE)!06\\0]XX. 2*:&#
M#,K#C0 8@S2Z>  ]"#(*#;P!)6\804JJ08O_?U@A!";IP@W*<Q17'" 7)CD%
M ZJ L#=500%12^(.\Q&!2=CQ'T8,!D'PH3U3)& ;/Z-&#IX@K*$\(P,T.!-*
M;E$ -&SE'T3 @!^'0HD/W.X.$K &0?;P@6L0A!]0\!4)K*"82R@@'J1)A@A&
M<9=YC$ ;TA!"$D;8@V_\@PEE, DQ2B#)A9BC%0\X@_\>B,QD*G.9S&RF,P^X
MP 92Z9F8^0<;5- M62A E/5X@SL4 P\BK(!W*&$'#D3XCR.<("5O0&<4<M /
MQ:S#"D1( ;90@H@IT& .*+$$&,3Q37'(X!7T$U8B,$@06!A@-$R PE:*40%3
M_(,6&: &:6IA@W.D_X00$5C&/XJP3H*H@R!6* %!"L& >Y#&&AK014I 48''
MH80;.KB!(TQRCG;\PQD7T",X_K0+ R#Q'V?Z1RP,X"N"B$( I( ++GI @T^D
M! TZ< -<B+&%$>1!9(W@0$)\L8$I-D,#MH"+*Z;Q#QOTCR"8N$ VX'(.%.Q0
M*?9(ZB>P\(]9J*"%IP@!I_ZQAF#V! 1]."8U#XO8Q"IVL8S]7S0=N-BCM"(!
M&[P%  #QCUN8 2YA&(4J5G"[?[#C!WN8QR,F\ B?%*&TET" )>#"C3[0@P*Q
M4(PB- &- K#A'Z"(0TH$2M"4),()\"CN(Q2P#7G$@'.*D8<-BC#1BI+&%O\F
ML"%*JH&!5/S##S"(!2P*(<E_4($$_)A%"_;0PJ,8(P/M0\D^)N!;@O!A%H!@
MP9U2DHT+I#8EH\A *HP1"=[](ZC$4$P^'D!.E/P"#H:X@;!\P08RU&PH8]#(
M ASYCTQPX!J\^$(36LB(!<3S).0X!PF* (]]P$,0'WCK4&IA #Y(80IH9<I?
M.<6()OQ##%G@E#-4,-0][ &N,A#L-!N+Y"0K><E,9N9CCZS8HX2C!'<XQQW\
M@()ST&&**&G'%\R!C@N @B#L( $2FG" ,:.D'"! P1X80-"B6*$6_W@"$N[;
MB$-D> .E<,4=% -<N!@"!H H-!,6T UI(*"PF4'_PA&B:]&C4->Z_R!&!D+Q
M#SK<@ ]\0 (1"/('&(PA +LUSS_6VUZ";&$*!+'&IX.A@:8.);^I'<HH%. &
M,1B!T026)PTV.SPUZ.,#@_B'$)11!U2BA!Y&^(<]=B )VUI@#QA@0DH*\0!V
M4>4<)T !(!(!""#LP,4HB40-L+$/$TA!HUP1$3J<@-8\^($@^;A!4H5,9",W
M>=_\[K>__RV?/(%C'%!VT7<\5HD8D"(1TEA *.[PILSZH YA>$"S1>L#,O!C
M!WI(B3UB4 =WO& .6]F'#^P0""TDH!H$:40="$*(!O1AAR@)]% "@5 ^:J 8
MX[#!O!4SVC5 .F&_J*YB_TKA@%)\-*3C<.E'OQ .+K @D>IEKV+P48-$$,0,
M-*""$320A:W0&BY!]>@_5$&06QB@P"@9!@4( 1=;_.$?;T !-ZP #CDH^Q^%
M ('T?(""^?W#$36H!Q]LP*Y_"*(!5]RV#4A.D$&X%2Z#N.4_/,$#;/V((''
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M#L7EK.J@#^SP$Y,DK-5Z0."@#A%GK=O*K=V*6.E0K#/*$LCZ,_;@#_J@#_B
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M007EJ 4/OE"&1.AC/F3X0E:HL !G/$,#L1@'/7;0!6!(@@/U$ <4#K&,1W2
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MPXMTH &[*@@9 (D\> #5J8<ZB 4*&+M_J 5D$PMTN(%#N(D5(+%M_QL_9,"
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M@ $IZ(00N,ET^((/P(,J: )S@(4,X 9V2(0%6!*Q8 <:2 )?"(0LZ0<<_T
M3\@%'=@":Y@&# B<49" 01B$!_@!:U %&?"'8&  9GBL6."%;K" 0R"':&B
M02"'6:  5K"'+Y@ .(@#+-#0 :"$<%B% Q@P%$ #3^@OL1B$#HB$4="!*?B&
M:3B 0 @'5_  1OJ"'; %5&@ *M@&-%,"+1@+<O@;78!;#PB<:[B /' 'M+.+
M>0D')>B"5^@&.Z"!>#B')7""=TB%"C"!3?"#.ZC6?;" 0J!"&9"&<" $!.!3
M*Z@P<C"!H: $# @%=7 /=Q0+?9@!*U@&,0@ /; '+; !BY$!$4T$ = $>LB"
M<'V'A-F"LD$60N@&2$B! C*+=4B!?OL;@>$%&/]0CA"@@V-H@PNH!'8H! 7
M#3> @9M@@%O0ABC*#T6( +LBAA,XLFVX ,W"BV'8 6,H!W28@R]X!V4,.'ZP
M@&KP!0( !6?X@AEH!F5 MX)PA V8@U98@T.XAAQ L1+8*Z4HA  005\ @G9P
MAQ<P3;Q@A 50G5L )F*0 $M(!7#5$V0X@%-@!Q'(@#B( RG8AE:H 11;&'J8
M@ELQ@4G(A@\0@5#0!"S AT,  #F@A2K8A'\( BZ@A2XP@#JHASSP3BY-IVI#
M@UD8AARF!W*@ PR !%;  ET A208F@D8C),5 A!0CD80@7-0APRH'L+3A!;
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M<]C.=,#]==C[=E!Z/=:;>"@'?4"KQO>'?9@FN\0C[GQ[ O]RAQPAL7K@^GL
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MY"23=*""&%-PVS]LMH]H] ,<W7#&.Q)R#V)T QWE.(,*A'$0@\##(#5\VD&
MH0R$_6-WV:#:/TK! 4?80V_?FR4M:VG+YX3O=!83CBLJ4(M_4*,"3UA+'WIQ
M$%B8P XG$,,__QJ1@R9@80%/< $:7N %9:# #U8 03VH@0(HP,$+"^"%,5!
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M!:[(*H <,;R -P!/Z]GA'>*AF[S>L7'/.F!! B##/_B" S"!8@##!\C'*XS
M083 +1R$/[@ U)$#$&A>.'R )OQ#(I#9/V3!N>B!^@F'..B,/V!!(5:!(1P$
M"?#"-CB \4'"^/G!&!P$$&!-8&2"",B$/RQ ,*!" FC;/[ ! 26$(E0 *1R$
M(S#%(C2"(/S BI!!!I#0/]C!-MA""!S$/.Q "5X#XL =.R@#+)S<!>B"(C1
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M&^P!)Z"(%O1 &O0#->P!& C"O> #(^" %! 0-W@!&VQ"D6F!&U"".]S#'XS
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M&E"Q&B08Q3=<P 6>.5<@;)#!-?\(X0!3_$,03)C&U+_QB0FH( 90 ,U*K-$
M2_"B =B;11&P0>]K_ ,%]5+"%:Z!"0[0H!*58( O_E$+'.2B%32P S@: 0!*
M\*,'#?#&/YSP!G$0XP;=^$<JA ",9D3 $>#H@A&6D88+##\0*U &(QP@@V&8
M0@O#4$4"J&&,$&3#$@OHAU/6(?M)Q.,?6F!!)^Y  62,8PE J 86[+".,$0
M%1:DQU;!!>0@99[ !@H!$A8@&,KA#@@ $_[!#EY,!\H 8@#! /Z"$@B #?[!
M&8K@--[A"YH %'Z #-"A#30 "G#@!T8  ?I !@[A$V[@&LJ !.1A$G+ !<(
M#AB@&(+_X0F@ !88 R[LX0>8P!<XP$_NP "H( Y60 I.@PQ"8!/R(  B$"&
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MLF$<SF#]KL$%[N$<0B (W& -:H (JO_! IPC&UX@<W9@#=#H B8A'%@ "=8
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M8AVP@ 'Z1S]RXXI^H #"0"/881OR0!]2!0 4 1R&$9@6 0*(4R!&80"2(!=
M@1/B@10DH!'0X0: P!WPP04(@!K  0\*8  "P1SR(0(R !K^ 1 \X JX010B
MP1E<00*ZP#P400#Z0!80P1'VP0<JX/0TP0/^8!UB@QRN0=5"@0H"( .4(1$$
MH Y<01$&01EF@ 0D@V>L00-4P!]F80-0H$V&P .JZQ\2 0#LX!]B 0"PX)\
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M_$ @J@"(\& (ZG,EP,$4ZD (EN ?Y $'FO\A>V) 'Q;!!2QC'R[@0!.B$[#
M@' @.3"A*=_ "6K!%EH!&]8#(2;D'[@!"R# #L:A'U9@6(9! TKI''8A#V8
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MH2(G S+G-,Y!!1Y9&FZ@'+8! XA '\KA"AYO*"@A E1M)?0@!W0$$U<B&WQ
M80'A"9*5 (;''5K %.;A HB BC(A DE R#"B#_;(&QA $LQ!!FB0'=1@>+[
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M(" .SF$3,N %<" .\N<U4N$%,& ,^"%9L: #^L 9U/]!!*C@%Y[ 6:8!!&[
M&-JA""B #=@  4+ &UXA 7: !+8@'6@! ;[ .1K"$0[@#ZS@!GS@&GSA C@
M!OR '5!A 4A &LY  . @%V* ZKB! 73 &JP!!X; %>@@HE9"$4C /: @9 (F
M$R[@$.KA&G"  G @!XZ!'.@@ (J "C) "OBA#AI@"I0@!!@A'$+A Q) !)S
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MPQL__Z= 4\\V'/8V3SOIV")*//^@]P\SI= 37RFRL)-2.[DH4TXQT/ ##S;
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M@ PPH)40,*8&'K ##00@   8P  F8(!/-B "%KAD [R)@$]FX)H.F, /(H"
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M[DK%N\7LDC>F(J7.=#VZ79JJ5[SM/2__=H$*NIV6E[[XS:_GJ+A>,D('/>0
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M0T?O/Q9Q*I'.F+K<,@,5%H +<\U#$9*H$7KX808FU&%"_SA');Z0A6'$1!=
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M#HAP"*"@ YE #H3@!%L0"RG1#5W0!'3@ @JH%:Z !IV0*'YP"N00"GE "H(
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M"_X !QQ@E;IA#UVP!;A" FL0#I&  240"VZP ^7B!U- #Z>  68@OG! RQ3
M"I9  5+0F2'Z$.%P#!] "?Y@#B,  Z80" U@(H# !_K@"06@"C&T#3K@ $]P
M,RF!"4_@:0Z ">90 JE #P\@ _*0!37P#O[0 TX@#U1P $-0!'J4 )$@#K?
M +%@#XCP 4 ,#RA0"L/@ B%@#TC "/QP!*5P<[E@!?_ !BJPD</2!(X0#"D
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M&=#51(#CN9L'<V@([/ -.A"$^9 #\,$--V .Z= "AA=%C0 "1DF3O+ )4M(
MXNH,"T" H$"**7 % 7<$4V"_6M$(*: >;+!P2T"Y_] /%_#B7I!W450).# A
MT* !O; **U (@) '/< +4, &@$ )(2# .Q!^TJ !KQ!#E& !X($..O '@) &
M-B (VB !(?<("@"1V'A[#< 3QU .__W@ GTR"#L "8 P!S:P#^KP C22#C&0
M!X!0!BSP")50W/^0##?0DBA1"5.0$G]0</F@ !2(#0%@#,/@=*(H!^;  F
M"(F0 E++ ^$':KOQW]C+#C@0!\FR *E@#RK@!Z$N Y-04_P@!AF0 7@0#O6
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M0:)NDNDGD I.X><&>OZC0!EY>$A5FQ7>^:<*8,D!X95_KB #Q:$X84":RBR
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M$718(!+B.$$#=J&,,#3B&17@ U:?4(Y23" ?V6C!%-9QC0 @2"(H^,,_<G&
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MQ!<2H1GQDF"H $]H4 ?=DF/H R/X \T2F0=]1 8B$B+Q$0B-T!&]$DR0%(G
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M%; 44YSJB1A,"]+_Y '"ECJX (:6WHFP! 70LI?V%'90 <\LDI@:U'OVAWG
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M]2\2!E3G1&CZ-PD -G\]AOV3Q( 848?X;C#2:@9'R$D,/LT;HN3?(!3KRD5
M,Y7A.*,AR1W]U>#"%GHAXRE9 \I#FG^%#*0B0X!>+ !"QO4"8.2?+0Q2_ #P
M_P4* !!V;C)@T7;MPX-]_QIQR/4&@K<B >*5:I*ZJ$-W=)[MJ8 H9#(80V0!
M&!-M18M=P!P:-2JDRE(.O=,"%?]4@<(_H4SPA36P/-#-/V9D40\Q$R02F4.U
M -!,/@YXA<H"[02#P0BV!"+!'7P(L@D7Z62CP"/XA'#,.4YX,<X9D_R32&5%
ME?.'!&F4X@44X,CC!"?VI'+!+/4$$00][!0E#S418.(/,#TT4PXA.2R3%#A[
M^').'KJ0(X4C[^B! ##_#+%%2'5<P!"8#I62P F8V.% )_]8HH W_["!1CJ-
M1/"-.%CT<8\;!D#SSR,MR#-+ %)XXT@3_M""@2>1*?]5Q!7IG,( +^1DD@!%
M4WAR#A^R^$/"$_UH\T$)JAB1S1\+V&,/#B)LHLD!<H##2 ODA*/#%.*0PL I
M^F 3!3[T[(#'.'4ZQ,@;_;!B "7_W//D/.E(TP(;41X"B3NW(/"-'1GT8<4:
M(36D3QHY%.,//RG,4HX8+61CC0HCW#&",T1M)<,K]M !BC,;O.*/!6H\U (>
M_W"21#G:4- I4@W]$\\)2LS#S04D@-%#*1RDD<\'F?1S1 )YW(+"".+D$X(^
MU-RP32M3I%!,--Q@D4TO'S3CB@-*T'%".9ZFD04_H-30Y!0QLR"'I_1 <0DQ
M77!@#2\J5'$*/G[<<,@G#>C_\<\P6-@R2PZ\I%)!"DA\\,D%6ORS"P,DL-8%
M-;-( ,8_N+B1RQ!9_/.,%*%0@L,V&&8U.>562455Y9EK'B XY)SB3"<N</&/
M,0E@\P\H!L#S3QTYD"/'#U=(,3LYE_00$B5'_+,(#2'!$P$IP4P@QR%S]) +
M&4V$1(H!D'F<SP2*:,4&#NQ >H$__\!!@SA38 %)(%)<T0Y1XYC_3VI)*?*!
M ?&.P\0,XU2B0"G$9&#'/Y_D,8X@&T3RSQDD (M_M((#/  #(^KA" =DXA^=
M($"WCA$! -%" I]0AP'^, XI4"!>K<"00\QQ!"KLXPD9>,4_Y!&$'(BC'46(
MAC1J_P"%HZ G)%4@@3V4PA!R#*(:K)!!%$)" D[\0QTY" 8]/O"-K>0 $B"4
M1B.R@0D)>,4*( @)$ JD,86< PM:8$,6&B")1>2 #E;4 3FR ()FK&,9-1S$
M!++GAA_XB01'&0*"JJ [R15# Z/X1Q[T@CX:K"TI*!""-=JACFI,H M6: (%
M:N$F.+%N3JJ1ET.2*+U_2 $&J%- /K*Q@"-880D2& 0O9E"/G^S@&%\I OI6
M<(A_0 $%5'C#!-S@*:10XP(0.L</;/&Q%@2*!%((ACU6YX7CB$,%9SB*(&:P
M*QX$(B1@L, Y2B$#U@!A" 1, #+^884=,($).!C!.NKTC_]HS, 8(='# E9W
MA#W*HP5A*&(,GF %(AA@$>Y8@"3/4<-$\  =_W"#%T+RCAJ,P4U\^,<YSN.0
M?4R "^K AS?N@89X/,,$0IA8&,B1!"*(PA(O",(Y.D8G3@I2!V_X!SGX\81I
M1*,%$MN%!KY$B!FL@Q\MV,0_KC&/@]H@)$&@ B@\P0$KI(,#%VJ:QZ+!@S;]
MHPTX& <F&. ,=LR#*I 0P5% H#<0//0?2["!]4CP4C7(@"<U0($]3, %=P@C
M'-N[AX%(  YZW"$<XG!!Q0YQ@G#\ Q;N0 $;NL$,#11HEYM[+.4NYS'(4I9R
M#1&%%"P!!"G\0QL9D,4_-J& 9/S_ P\M.,<0K/"/<(!C'>?X@PQ2FKN#_D <
M(E$ *:9Q WJX(YWEZ $=0K*+YGF*'PMPQ/2J=[UL"(H$WEA )LS1-'><!CT>
M*X1V_A&(!L"@'K+( !+*0(1 %2$"I W).*J @&P(8P$PP.LA*H &A9Y@ :2E
M@J-*>P!8C ,+"]!#$0KQ#N18@ &8 &%(^B "+2 A!BM@;BH<<*&C-(( GP#A
M2HW0@"^ITQE]$$09G"#$5.S- /G81 U6V0\>.+&&K]""(&B "DC%(![PJ,$J
M_O'=9OQC&QFPA#2H,8QW'.$$U\#&,>+Q#VK@8 -Y*$<-'<$!V:!!!KH)8DCX
M0,<J")(J_\QX@3/$L8(Z' 4%HZ.ACBU @4J (Q(P0 8VOE&,IKTI3I949S8N
M\+\(N>"3]""& 211#60HPQZ$V",W&N#.-M@Q'0CPA3X^0(9J8,,:\<#<43!A
M@"^90P?"E$8,BO&/7W!  Y(@[!:\68X8%/(?D.#!-+OU#T$\8!UAV.8_4OT/
M6F1 &_]P@AF^@8UGT..2!NN$ 0KV#U94@!;_F((@[4&Q?P3C!;JH1C6&T8Y]
MN(##-7SU4)X0ASO281T\J PFZ20)!3P@$2 AQA#X (.*E:,%D$#' L+ #6Y,
M8Q_5HN%*H?V/=?@ ?R$)AAWL$ /\B390>(B!/,YA!0=,(1@AJ?_R/Y;! $CL
M6QG+ ,8$^B2Y25A 'R$9!07VT8D'*-E3X1"!Q$(B!23\@P3S_<<5$DH.&:CA
M'3]XPB'T8(A3V,,%9 Y)*PZ "VE$(0?=Z,3_I%TQ7F3@!ZH@!SY<((9%#,(1
MPL1T9</N%*D83.QFAXI#J&$ A7#AHYX%[9](6X88#$L#S B)(M*AAAX05A"Z
MN\,.5JD.!;@B&!(H1$BT(0HWA, AKM! H#QFW$5HY0Z>7.X_P*"#=)0@"O\V
M@T%7BN9_A, O_T@'#2PPCT$X8!#\^!@YGC"#=(2$'<NPP!6*(0,%Y &B0E
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M:,6K[<H,H)L@_[R .#":47D3KX53$IS9=M#>"HY" C#&/_3" DC#/QQ!M+5
M'@:# GA%$87"/,0 18")J_' 4'3!"!P%'##!.\Q BZ&'/)B#,+P! 'P"-,3
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M@@,0P2C0@@6D0!FD@@6<P#2$ @I,PQ"XPC_XP0J$7D,XP@C(0T@0PP/DP.J
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MZ(#R[,Y'_1K-$<0+_\#!Z=G  L0"-GB!,LQ"!G!8Q_P#('" 9[X"./T#.^A
M+HS# P "@A&#.T;!'L3!"V3< ;6#.>P &8B3 32",=Q!'8C#(FCH9#F!%.A#
M-OP UOR#(02 .M1##:S!.MR" A1,';3 /WB"CK## W0*&MB166V&,2C"+;##
M!1!1#2'G)A&":@T"!UB@L4E" (C:/V !'<+ ,_T#$234/_2 +K%! ER".;#"
M&:P##<P2G23"!LP2)P! 'OZ#.1C=/V1"T]A!#N1##_A ,(3#++RD8V6DV5FD
ML2'LV3F$,X2 #3!"%YC *7Q"%KR"/  "$?""/<C!'TS#/R#""32 ')2#/_^$
M@180 S^< 1HLT2[@@ [  1)89C0\P02,P!*)0R+, !90 0KD&%40@@L05H^%
M !=<PQI8 3) PPCX 45 0@N\P"%8#UAJQ29 P16$ !* 0!O(!C]400VP@!V
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M5 .LA$$<=(,XK((/?$$U__3#*?A $$ &-[3 !DP *( #&'  '*134B #%ZS
M+J##.13!#ZQ!'] A*^Q $;P>5>S##1C!&C1!,N2"!D3!&<0 !]""-.  '\A#
M.G ! 4C &YQ#+@" #LC&9*G!!_Q!)\@ %TBB,=2 "$""#[Q +I2! $R".RR!
M V##*VC )R#"$:A#*_# #>B".WP#"1# !J#!.&R" .CJ:^9"#A#")$Q!/I0#
M$U2 )!F;.,P!":B"(RR!.VSO!- !+H1 #'A#/#P %CB#-_C !M" #"2#,T3
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M'6#6.TQ081)%*,,_8O^1AR3T(5_M8$0C(!&)35SC&GNP1$$D,88V4*(;-D"
M%ZXABS',8@F3D <DSL"$_/5! D3(Q3UR 0:8K8(/3(!%AKAQ"&*8P0^O7>A4
M$HK/D__D'\Z8 7C@<0%$_*,8/."-'OKP#V/T@1Y1J,$SW-&$&HSC$SHH2"\Z
M0(M6<.!/TKP$#B(A"A@LX#($Z<8.#N..%<P!)E.H1*/^L8\8I*\>/M!"/: 1
M 66@@Q L:+D!I/&/,4S9(O* 01'^(8D4Y* 8Z>B"X/Z1!"'\@Q<O>,<T0F #
M;41"%C10PC16,8L<% 0&8I#')B[ AW94@@;@T$<.Z&>16BS@R[EP@"6ZP0+_
M$VA#$>I 2!TN4! &> (=DG@ *M+1!"#\XQXY^$-!WG YB^R#"@3( 2 TJ(4;
M3 ,=.QCI$5+P#VP\P!_!2($,<(&,8L@@%,L8 P"N(81QAX%.!^,%"-1 1Q^
M^0[_H,/O-?$P-\CR'T$@Q#\2\8=EM&("6PB'$E0H'FX@GH#B"O#N'TB@"*1A
M#C3 #YJA#1P &=+!!S9%&3* $:(!#!K@$K3A"XQ@*]IA$BI@%\(!%&0 H/2@
M"OX!%Y8@(<[!"\R &2A! +2A')" ![SA":H!'-X!"!SA&L   %)A$1"@",(
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MJ$#_!0OB";S@'Z(@:A)B'9:A% YA K[.&E9 AD"A!R!G!<HA'KK@FXPB%$!
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M00]H$P@2 1*,8 DZ[2:Z00/>@PN"@!(@80D0\0]$H"!.(&H,]!\Z(0*NB1/
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M90MB3O]A%$#@8Z  #>Y !WSR$PR@'" !!@1'$99&(XCA0__A%63@/ XA DI
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M@0;:KQI,H""" %LRM05(\Q_"@ :LP_\*V 487  >_F$6W,X97L!X+*(.9D"
M_H$(>#<))',IR.&TNOAAH$$%!&@5\K4@#H$'O*"8C+9,"J(=&N 4_L$(=@\<
M>F -WL$"X"<:8N ^WF ,OA0#W/<1(N$;:$X%^$ AW*!>>,$8UN$.,, 8)"L9
MH$ %[X!.E4 3,)E.)=E.>:$@BJ"0@2(+?KD$_&!Y1;0@>F 54"$"'.,?&,$&
MS@$76.!/-&%["4(9\GAY%?0?FD$>AH$%R!8A:.$ GFL6Z,0:_N *5F!B-,$
M@-061,$97,#U^H$'Z'0>&.$?SD X]X$8W$$1(H 9PH '(-H3FE(CRB &9H>E
M8Z0'=%8CV.'_!RSJ']ZZO%) #-H! 4S%6/)@=FZ"'+K@EUO@.$C I%?! OCA
MJFMA &7A #9!7S_!'&B@'J=A!=ZA$AK & I"$V9A!5!$U.S .GY1!IZ@(,*!
M!NH+'ER@-35"#82[(.)A!7;1#C_@F0TB&#Z@OD0A;L2A2_]!&EJ [GK""FA
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M/N$>D$ (VJ$?@H#_#/YA"V;Y#_B@'EB  B(!%I+ &M"A!C:%&29@&;Q! 6[
M%BI!!.QA#0A #6AA"1[F3F(M "8C&I*@F+X! 23+(D3A =)(]TV5'*P !;S'
M($IA ')A&;S "X*I,//[ W!'(T[! 4* %B;A!)J%MX(U!SXN&E[ !%Z!%4)
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M8'4'MA ,>@B%?] &:) #5LD#11 )+:$EZ) %3; &-> SA+ $8T "QO_8%>X
M!S/ !Q)G"EH !B=0!9/$$?8PKFP "^<  EY@!2^  NY0#FN  ;-E"5P0!BP
M<3ET#B30!0PQ!0F #%7!25#D!43@!B7@#]A@ RB !A00!$G@!48@ 9Z0"".
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M#"D  3_0DNQ@ V" #Z]  ^7 # Z@'4X !^(@"@RP"0(9!8'@#:\  &S0"A;
M$&P 2JTC FXR!B,@#J7  4;@#KY@ 2NT QV3#CO_$+!:X@U!< +%\ K?0 .J
M( R0  #6P T'H"Y?< +^H"9A\#,V0 [L, 7V(<7O, @4  F]D I6( 4&]P!-
MO0"#\)U9T +KH XYH"#O4 )!X ^IP -MD ^1, ,;]1Z=\ .W(PH+L W7X ,G
MT N3T+(<T0DL<#ME, 'H( \\X#/(4 /[  X3@'65  0-T09,T(4E,-[C( LJ
MT _CH P_4-#0( /) 04V\ \N0+5I4'3!X +%0 [>@ 5RH)4C@ E2P@"4@ Z%
M$ %I8 QTX 4)QQ&8< /7L XL,I.[8 "\H);GHPD@H _GH T*T 7:P-C_@ LK
M8 7] @7Q4 PP8"%"G#I _PR$,#[$T8 #'&#34K("&RH-A* %/+ +_X &,K \
M4* 'MP )DJ =4X $K@,#J>D,#6 )P) !@Y +B: )P#0"MX#'*I"P6S $@"4.
M,O *K@F#2\,#M_,&7"P$=*P+&; ,AF "CL (FC )^G +"K!,MP(.*2 *#%$$
MM$,7^- ">< (AO )N0!ZK?,-5^  6, .GC !A, (BO )MN #*4P/+7$$D. Z
M9+Z<*\"$UM  LS4)M+,..! 5<@ #F/ (D? (\X (&$ 'Q] .8)4))4 -U*"O
MML(.+K!]TE /X0#J,Y4/IQ '#Y 9;$  9B ,&O,5?#G"=%"P#&$$*%!!W1 #
MCO_!#CX !ZXY 6ZB#1D@T(Z@ 6< #++X%<B0 +]0!IV !R*@#E, 7.9P#ZVP
M!PT@RXB0!%W!ZETQ#\% ""X@R_/@J#]# <DH!)YN48!P EU!!3_P#Y$0R(#E
M"@V !LC00-"P \[G"R;P#YB [5HI&NK0E^88 QI3U0R!#I*P Q$@&HAY;_3P
M L$@#M+0#)7@ IZ^#2V@/</P 77P").@":S@#"Z !-3@GBX3#]/0" YM#NP0
MV_]@#"L@#J[  [%3 B-H46;@!PQA"08 "6>H"?.P"A*P3&70VO_0!6+P#]&
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M031&]H-1V.$ <@#&#S30AB/(81V $  ISM$M<-C@"I)8!@I4X __>] @!/(
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M4?J\3RO=TOK44BY-49%(I@+]4O>L4I(0TS&M3S0-3C)-SS5M4SB-TRG=AC"
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M"758\7 (!W!"!8S^AVTPAD^B$6&X!F_(/F]X:[(8AV=@!C*Q!F HAW<8AFZ
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M#5 "7K !.?""+/".I 7QDFB%)B@$*3 ">5 '*S !*^ GZV.%(2 $&@ %16
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MH21&\(&#Z P8&S2UKB3Q]2]8G$1 ^XDQP__ETC]]A. DRY)E'NG^_O\#&*"
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M.3&4\@XA&7#BS32#9!"=$XNH38H%O/SC!A?6S.* ':,8VHX;+@,V5%&)_R
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M!4P\&C#UX=1]>32PV!6:-!I?4" Z0'D'KKW'[]'L@P%%R=8/^/ /Q2?,"A.
MKSU:,%\H')LW&@ 70O !"3XP3DNV,(%DW?F]*41A-&EX 3BX4 F@0 -5[?B6
M66C0N9X"!@\FO(4,P@$40TQ '*X@@?4A<809@[]!S@ '.1 4_O,S2!4>V TX
ME, !_WH,1P@UZ- %K*8)#G3N'W^ U#^P(8!>08(5_4,(,(P\T "XG( IG(,X
M($0P9  H (4JR-(RW "&)<HYR 4X2$$;N,,#3 DK7, PR,,.-,'>F<'QK8 8
M_(,S*( I)$@0> ]0;(%4><(%N)$;K,$_< $( $6N40%O70,%6-H_R$(><$(P
M_,,J!,!,( 0KM,#X& (7R8!4^8.H/0,$V-4_=($*1L$-%,,_A,,3\(,GM%JB
M $, N* B_ !01 %%D0,+9 A0(($&I!I"@(,,_(0[W !2)0$YC0*WL 2PN,,+
M%-T@!-^GV$DIM!!0B($MO !%#(/>]9,8_8,1I)0V&  QH/_#!RR!./S#-UQ/
MHJ#"!LP$4*3#")S1V'!*+XQ&$P !8+1#184 !-I"![C'/X#"** !#>R9,WB<
M*P1  Y&/+W1# B@//N! 2F6#!*C'+7!(:=B" _@%X.% .( <A?6'*]2($[3
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MA$(/)(,[1 ( 3,(X@($ *($5T$"U)$HZ; $.L (_-(,($ )@\/]" \ )"LP
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MN I[",0*RK .,S @"X# )=G^] P+C,$,,0!&*U*P@SCD(0*3^(<^H+ $0)B
M)X422#JD</\'0'SA!?V(! .0X8\]U.!I9V !(-HF*AD(!Q,52,0_6C&'MNVB
M$1501%VL<(=#K& Z?3A!(EY !G.@@0=A6,8O7A '@9AB"Y X @G\<8TM!&H+
M&JC%L 12!Q$DX@=J ,<8&L"%*#1 &H1H1"56<!/G:&(&0^A#"4J@CW]T0PF'
MB,,*F"&,$I @$^"E%"]B$(4Y4( 8LZ #(IQ0!'3\0PXA>$0(:. /1F0@$O)
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M&]RA!^[@'Z+A JKA6O[!$GQ (%S@%,(!$2Z */8@O<9@! 2"%%Y@BQ0"#XY
M(!IA GJ"!FAA1'9@)%)@$/ZA$EJ0'.+H']YA"WSD'XY!!0"I!.9,$Z9 ((9
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MJ/!!WH #_M,?1L<!^@X52( D8^ >X$(->A<; N"-#6%A)H'Y_F$.U$!EZ,$
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M$2H!!Z;A#1:@#OZ  _+@'?Z8$8[A#"A %.0A!]Z@$]!'&KK  #!!'Q;A /(
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M!7 8 *YP"C-@ VS0!1R0#;B  CA0"/Z03]7 !RN@!ZD0#FM@!-SP!UC@#[3
M Q;P!@WP"L-S$\G0 P= !,<%$]RP V9@!@N0!O\P#0O@")*  ,M@##J@ B50
M <<P"'V@#4XP OW0"G_0#%H "&\)$_9P!P3@EKP0!9*P!&;&!V?0"#CP#+W
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MRY&IE/ />" #^J /,N #_] &*? /WD !<3 /<O &\< /$? 'O- #(= *U]
M0N$&2  ._: "7<"KPOHNT4 ZF8PXYH #M_F)%# CT9 .[  .*0!Z_[ +!E"#
M#SN-_[ )"I ,, $&-/ /D0"_D;$)6N '*^ /Z^ #!/R0U  ,V6 /;?8/7G!L
MC/,#678$:14S@J"Z,,$)#) .90#+LOPB9) #X> ',* *HK *#HL&/6 W^40.
M/>"6HV  *@,-*X /ZS ''4 %G,<-&7#_)LYP =?U#_8@S/5[ 0"Y!7( $U$P
MPNN@ ZS0#@_P!Z:@"J0P5$X,$R5@"?^ !C*P7%^5NK=A!"AP$WW0 O^0"I$&
MM3#Q7KX@ AD %KV  ][4"1_]#]U0"4L0 ;4+"4\ $[&P JL@"K>@"_I #!P@
M J.@#E^ESFY)#0@@Q^A #GJP 7[P#.R2 O;%B89@#S=P![>P"K#P#:J  "RW
M#C# !M@ER[3<"BI@#NC  2/\#V3  .BP ^Q'#!+P"^-  PZK#"Y09>)B!62-
MIP^@+G1@ _\P!"DP"JM "KJPE<$"#S?0"*MP"[! ##WQ"@6P& $< 8"P"J]P
M"M> #1D@/.  _P/BZ;8P@0GP*PY$@ %OX+"98 ,]/0JV8#OV= -M+0\K0-:3
MH,MM]K&T\@] \ F9H@,9X@PMX"64D !O  T6U6;OP )YX N', L&  U4,%0-
M@P^[P 8S(*2S\PPP$0@[('_L< QB$ 4P<!M+\,3_4 *(\ ]^G6TPH0H$, 3(
MX!&/H+C_8 ;8N@[&@ =6X (O,<5X6L4:8P5Y !.\D "PT 4D0 =4D F_L [=
M, UET .*NPTML#B<5 _PB0DWH,HUPXFUNP5/0 F48 =U\ ]?D-/_\ /<( XY
M@"N4L 9B -\K_@\C, K2D $*3 CV]EF=["Z;?(M##B_FH .P+!V_0/\!D0<.
MF$ .(R PJVP [,<&VCS+,,$&.$"$#)"(_[ -W^ &)3 /\. "P.P#U+<("G![
M^L"M *0$NTH2./#,F]9GBJ  KMP)&9 .  X3B*#E>- "X6 %);T5TJ &&2WD
M,!$.ZUSE-7@,*] /XE .G& !*I .QY#/_[#/CV"9:OX/G=  1KT"I/L/3I )
MFVH"N- .#<"[,%$-Y[ $>/ 1*? 8&+TU&_W+_Y %P083>L "X& &(\ ^^<0(
M#@L;(F!ON* "8+/;WTH#FP /.5#'D!#DH_ !W@03SG .T6 $ = '#A4LXB #
M;BD=4@ !=G .XG +-G !]D75_U /.: (]"#_ <(-$_'0" H D.R  V2--?_@
M"0I0:,V@ NO@#QS@"#!!"1E0#R_PV]"  ;]P#BL@N<S0 GP=+/%=X"E"",@;
M!+$H&?50,/G  8S&'CVA"@S@!!F1"P$P83"Q?9R^SZL)$\Z%VIEB#HKP #.@
M#I/PZ_]@#OQ0,/3  7QY-SB N="^9ZO^VZG^]#(= \4P#N>P" _  2F6/?\0
M!CEP!-MP#SM  FI %,D@!6'@#2% !?_@"AE@## !"3B\+I?0 Z?0"RIP&T-0
MZZC\&!W?,Y80 Q7@,4W/!E0 #J8@ [' #2N & 2>IU9L!04]*1> "#:@OC!1
M#IIP!:,P!O!+#!J__V<]\0Y\, 7(D *1-^(\4+LH$+>C)@@MT ^I8 '%@ X-
M\.DXL?>V?@K8@ '@_0^)$.08=>3C\JO!2OSPTA-I< !WD@I-X PDX /,0 ]>
MH>/]# H)( Q780<IK,(:D"!VT.7$D %+L _0, 7<T "4B0H[ ,PN0 O@D IS
MB0_IL 3(8&=EX+M#OP.C\ ]"P @ \0\<N'\%"Q*\U@%1P4-"SMUI<^X=+ /9
M_AV*\8_0!DCGVBWI-H;$P8$$#?X;!^/7OU,:HOUKMN(?+#G_U'U I2R -GOJ
M)BS\5\\%K7]E/O#[!\-,0263!)K(-4[&#F3_=@WY1^10P1"C_OD1,:Y?R?^3
M!:VM:/?O4@5<!?V(^6<%!<F!9=6D,7AD[C<?Z_XAVO)O"Y1_Z28D^F?H2<%O
M%.;@^]<&5B)F_QP%2":P;$$2NOXU(J:6PS0R!;\@^2>BYK8%AL1!X6'MW[<L
MIQ)H*N@#CL"29%%IR'QH13A_"W#_XY.E'8\^!9G5R!=.Q;1_VUQ -EFVR])_
MBSCH^S<*Q+\U&8B:TW)M\[]X+[:D^\=MS+]C:JB]"&/3PA>DE\ILRX :@9I8
M )I_6-GCKR3B ^,??W PQ)4"&OGGG"=\60\<(E80!R46U-N$,,U.(HB='[@I
M*(I/!&*!E7_H:2$?<FKRYP0@",J.I'^$0:"+@HC_Z,"S<?[AA(."0*#C'U\2
MD.T?1G)PYQ]^,J"P&1>BS$*/@DKP*@NXS*FK+#O><2>-C$!9\!\SY@@G DK^
M,>8&^'09KSL.XN%MLR[F4W('=82PP9E_^N'#%@<P!"6$'5?H9T2#3(HCHW]2
M@&6SNM+) 9!_3B ARL3<R<:&.,S AKT9LBB('3'.(:*T?T)P11D,5"FH$BGH
MRG$]77?EM5=?U^,'''+(&2?77X]%-EE="?)'B IL$*&8\!Z( ($BS+&D!A6^
M^6>9'6S(I1D9:&AFF"@N" .88TS@H19R[,"@ 0L^ 4>("ZRH(H(RPNF"@S',
M,<, &DQ K*RZRDGA!$6T_Z@CG%5>^$(81TDBAY$88ADE"8L(F:$.9)BH )9E
MIE@ &7^JV("$'RJA)X4&JN$MS(+<06. *X0!HP!#A)$A U)2<:"15%IHQAT?
ML&#$E ZH@*P=&V[0XHP&UOBE@2_4T<:"*=2Q!((AYJGE @Y2"&(>;2: (1M7
M#N##'D\L0&,EF0NBQX\.'E%''BQ^J.82).Y)QH8):HDY5SL"T$,1-F+819Y
M"'C$'S\>".80#,30XP,32-$B!FG!"62 'TJH(IP_1FA&CQ*B-+89!>Y IXH8
MONEDBWMBH(28$PKY)PX-CJ#B@Q^^X4:#&KP  9MSOD! $4@R"&*9WLC*YX,D
MS/^0@0$SU%G!B6DNR0&8?RJA !5K_( $'%(D*$2?00*XY1QC_U$#AS"&B2.
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M[=,_A6.^X/N_YFM WML[ 7R^PML]!+S JG/ []M X ._"AP_#KQ @Z"'D>O
M"+R_GP.]<_\ N18D.A"L0+\;P,D+._=#O0P\P+JKP:S#N_$S..[3P6PC/1E$
MP@!,PB5DPB9TPB>$0J>#N"A\0GT !QAT/"HLOK!#AU&0'L0#OI+P!VQ0.GO
M!6( !W:H!6T(.Y300;$K"6A B@G\!WGHA%]XAQ\T.G:@AR",O8)(!DP0GW_H
M!E78AQ4LPJ[3PD6,.D9TQ$>$Q$AL00>41**S0BRLQ!&4NGBP@@$PA15<O.\C
M"#.H 8%JIWK8@PJ0A(NH #X Q<-[0[\SAS% @//ZOQ>A C#(@)K0PS#I Q;
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MC,OB*XAPR,G+*XAJ4(&+BP8>@ R#4,NE_RP(<VB"3W1(F%2]E%3,QG3,QTQ
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M7OC"NL"$+' "E__CA39P@3! A6=@@AT8 Z$<!C'P@BY8M7_0!C10@DR0AS#
M@#_X!"8[0LE4TB5ETB9UTHJC3"[*PDHD"#(P GT0A#(XAS:H@G]H!R6P@1MZ
M@"OP!"HX@%RHAQN(AGU  7^8AA8X!7RX!@#84!DH W;0 P-H U[0@A$(AUYH
M@5Z8!VQ@ 18 3P"@A''P@BS*AWF!SF>:A0%0I7\H C/@R32$A17@A7+8!R@
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M:!!:M2 !25"$/> !7I""YP2'&_V'$7C7Q+S8WO7=WP7>D\Q8B<7&?]"'*""
M)O +,?"1N!"!&QK'@F@#'0B/"*B!2@ '&*F,?Z@&(*B$+ZB#?V"&%<"35Y"!
M?_"&&.A1-) !@=J'*X"$(UB#D;P J&4'K'RY!V %77@FLJB&%=C.)0@!DY "
M*\@39H@1!UD!]4#@=I@%&@ &>%"'ZR0E)WC.5L" MO@':*  4I@&'- N>$"
M0E"'?>B'G%R"+_@'?/^H@5(0!PX0A() AQ5X)BI0E$FA%7V@@:I8@A3X!W/X
M  JIBV;0 %B AWQHAR'I!16P)I-2WW_H R(HX7L(!Q/!6X-( 5$PR>#EXB[V
MXB]>PG(8"(UER8$0!G90A1F8 G:H@ZF-"S7X!V4P *_XAR<(I&T !C4(@%4H
MAQ8PI%N8@%CX!RHH#69P@9QZA9%(AA@XQ']@7W" !@MH2SEHVFRHWZ@M610@
M HZ$Q_^%C"4X 8-0 U2I"P3.*7]8 9AIX%Z@ &)*!UYXMR!X3EP( ,:]H0_8
M!F-@XD%1@=,MB)@%!A\(@RL8 W'0!PX(W\Z%@4^T@AO.8@6&F6X( 4K  R+_
ML(<\008*(,>"*)56V.5_2(866#4W\ &3R&40L .#^(9S& $MCDHPAN=XEN=Y
M5A;(D!_BA42"Z .7$X4.Z(='D(!I( 864 )@L(8.> 4?;8!KV(; ^(<<P(-V
MR %>N 8P: !0,0$W@(=DF(%S=045 (=EX %B2"HW,-1&D(!XB <4L )IB(<(
MN 2!4 %>%%\-6(+(:X86F(=HL(0$L,4?T&*L55]C,(<84 ]AV(%WD(8(.(%I
MB(8V2.@P"0%RZ@<:.(*<S 0LF T7J"$F< !'< 93R )Q@(44F 04&X<E>($H
M@88<$!0J*($C>5=YN 'JX(4G^(17R,NZ, <1H %?_Y"&-<B/:F@!%4R%!N@G
M31@ -G &9L"":O ##+"$;* S<B"!5]"'<S"&^*3GSO;LSY9G>TY2*OV'.Z@!
M2N"",OB'?)"!%E@#%' !1/ '+@@"0 @!I]@&"_ #,NB"=$ '&+"!2_"%!S@!
M.Z"#&=@$,.B19L@" Q #<4@"'RB$5M"!&N"$;;@!$;B#(8B 2""#"P"":9B$
M!["!6"N()(BU=E*&&X""6R '+G#8/D@$CR,(;]@!&7B$3+@ -!"&-;B ,2B'
M2:@! YB!-*#O=@"$!]@"5["*"6@"0$ #;UB&+OB 0[AF:< ""4  '0A9+9"
M%]B!$"B#=K &&NB"1#@#PO_1A17 @5KHA!F0@F\(A ]@ G[0! >(@1K0@34
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MPP DXMJF82-\H',-#Q+<8HXC;9#S<6\^GEF..3NMTU,X N<:CI#CB"///Y$
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M)MR!!R4$@1/_(,8=.I$+$:2A';5   @JX52"X(,.0]C#,<91"CB4XA-6H*@
MQ5"%%#0@#0T)10Z4 (EZ#(('M(C#'8SYCTUH 0MEZ$=#V@&#')R",*00"!7,
M, H8I %$ZGC#%ZH #7$,]Q-=,,(_K-$')+B!P<)H A?@@.;P](,-2MA#:B<1
M!6Z<8 BFE$<BD-#_!,7]XQ56988+(L40<8  $8*@ 44)TXE#Y $6<VU''11F
MB5[P 17@0 4?=M@*'?#"#72XQC_V 8DP@,\==2!$')HA$&& 00^!<,<H9K"%
M1XR4,.NP0P:.@ B!2$(/>5#<0E3! "4P@AUZ^$$S]B &CSZC#F) 1#H10@Y>
M4 (:AL #I^H0!T. [QZ$,$,HU)$&!#2!&/F(Q#-6(8=]C&(2 B''+=)@AGS8
M8PL+4 0PZ+$)4 D$$U9@!)KUX0MA(,,.J=#0/T0AAE,8U3_<&,4I<CJ.9""C
M'+O AF(=V]C'\MPLS_C %D:J! /PX:HWB$ K!%**#'"!DC0!$E&'H0$ _ZB"
MH_I0 @"N0(D3\.(25(?% :R RC,   C"^ (!5E$.'<A 'HX !#ZL ( \I(,<
M1L"!/01Q 6#T0@(9B$,5IB ,+$@@'U?H@"[^P0H,\  9I<  %O#!"@!<H!W;
M8+P_KD& &>C#&2HP@"7X@8P+2( ;_X!$##%&G@$76"2GN( @= &#,/P#%@F0
MJR="< Y39$&.G#B +_X1!@DLX1_/.(- NA$ /;1C"WY0QQ(4(/$U\,$!1>!#
M&08A@7Z8@@' .$82%@"(3AQ $_B0PQ?R$2>,;.$$\>@#$,XQW1%P(A ,@# 3
MOL"/4EQ@#'7#AQ&@P3Z$PR)H@!F\P@_0P3_@ O\*\(,SK  7K!]@N,(+'( 2
MX)Q [$$)I((G&( M_(,, ($[A $4N,,F/  0)$(?*(,7' ,Z2($-C(,5C$(Y
M_($Q)$T@[ $[4$(7_(,GW( GD,(-;(LE#  P<$,$L$*G?=H-=$-#G ,4R( G
MU $#-,(_*$(:\ ,B$(!7,80G<($YB (0H$,7N, [^$,/0$%974 4*$(4\, V
MS((+Y(#DJ!L_I$$'4$,\0$$J1,,$_$$\< $3T .'&,0XY(,3Q,$\Q$T39,,F
M5, E) TVB, <P,,X],(.A($G+$ B+& (!$,R[$#1C<4YJ,$!I$ 6;($T*,$F
M6 ,,/ $Z_ $N:,,+I(+_*R2@-VP" MC 'K" )X@ $@@$]3V#%]S /E3""B!"
M/JP" A3!3MQ!'[S"$/@ /\ " I0 '"A! DS#/Y"!R>% +N!')TQ!+ @!#,Q#
M-9@ #:S!$C3 MO7<0.P</,[C3Y2"!FP!CRB!!L3!/_3##S# ( A$+R@ %C"4
M8+A0-O   '38C,R!!\P!.)0#.<#"%X2")PC %^@$(0" E?T! / ;% # '$R#
M.MB#&0" &:B-M!T#&U =,&0 !53#.;2#.X !%S2## B *?Q#+0P "/P%# !
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M0S@D722,@$#<@1;\ S)<PCOXP@R(PA*>"3$8P"XTA#C(0-7]@Q:(0#RP0!$
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M*V0 - Q$)W !&+Q "$&"$#AF'?Q#)CC!0Y3#'= !$)R =V!!'94##DS#+3"
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M#.B5-#!#-:A 4DU!68Z!\@J$(JCA&'CM/PA!\+B#+O3 ,S7$&NQ /_U#(G#
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M&?S $7A"(IB "80"*JQ++)Q#)2S $/2"=_A#": M.UQ#"[@ A%V$,.S!#9
MV?Y#*8P #MS",9P #IC"(]3 $4B#)5@ '' !&Q1B0Q!!?GZ#".A5H.7 #2U!
M#G@"$LQ 'HB#_S-(00W$Y3_H>[+S@!N@ @W@0"O 0@P<032<@@)X 9L21#>X
MP 60N09,0B3$ !T,PR&\0)DK@@;H !/P  J$$$-H@@,L03/H.R) PQ?0@"[H
M@Q!0@ 9@0<P3A#Y$P1&\01[X0(&M @PH03*HP@[0@30( 0[T 1_L0""LP0-(
M00^;0Q]<@ :4P#2L@PH8@1@LP3$TA!#< !PL 2A\PQ:P0"@T PF8@#($0@#T
M0!BPP!'DPA7LP"#T0QL\ "4@:L7X0:.? 1EX!S>80 3H !N@%4'\@0O8P1(
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MSE&,E*'C';^H1CS.T8G/ V/UKLB^])T/>((TY"$1646'F.,=6?Q.\69&CG$
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M8V\8,1!$AMP!\3"^XQ@W6#>[N?B.3UR@&O*^]V4B%2J67U^EX] %!T !FW9
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M:B /2($7T/]@$N* !CQ!#D[N'XCA#YQ ")*!%F+ !A)!'W:A"*CK'UZ!#YS
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MGD ,)!4 =$$8HD %D,L&$, 36($!(H'D_F$;4  "1$!"*Z4!XBX>'@#6+,$
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M'*AAOIZH"5) 'OQ %![@&4YA3<WA$@[\"NS7'%Q <_^!!4C!(1#!%]"A$VX
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MP0QX.8@#:*$/,^C!-CP!@4/,PPP$$$4YG$"#2=PA 5*HQR P\ ,?0"$>KL"
M(=RAV^'*_S>_;=W\[^\;O+2C0B49QVODX3#OD"&R,0Z>\S(E00Y ] _QT!_C
M4$<O\QKH &+!Q18/. [\1P[J$ _D$ [SD#BKPPX@!A+"T 0,13KDX _2H Y9
MD0Y?\AH/Z!KXX SXL \B6 [;,"?QP _W  ]XP0_C8 [.H _J0 _\T _.$ X)
MH0_.T _Y@ [P #KHL0[\P%!/Z _SX'^,0@\B> _JX _J@ _S$ _Y  ]?Z##Z
M$'_GT%7WD UA- [_.!$/((9"3+$/WK Z4T$&)9$.0E41YT /*7(0[P /BZ80
M_D 6(-$.R; /$<)H0N4,\Z ._4 /\5"#:L,*BY(L]I -2_@.O2$+V  2[^ /
MR' *)&.(_P /7=@/X+ /\S")(#$-#W40XI *RP .TM /\$ /(&$+H+"+X) -
M\4 /\[ /1X@.]L ,HE A!_,/Q! )>O(/[1 -H*,. Y(.TD .K( (PJ05KZ!G
M41,++@,.[V +]6 /\- /TM ?]; )I5 3H$.#D.@/W2 .I/.&_< ..-$)(7"'
M3_@/R3 M_U %RS,.R& #UG!-\9 .X;")K;@/^K /_#",\, .]_ *LJ" _T4'
M#N6P0./ #$F(%_Z@"ROA"^C #_[@A.<@A/L@#X$V"M;D"\M0#:/P"L"0#?ZP
M#Q6""TJD/]&0"A7B"_%0"_F@@<7H#.SB#9OP#=O@#-<T#[>0#^T0"N? #;MP
M"\2@#+=P"\G@&O< "J< "^X0#JZ0"J8@#<Y0!+<0"Y9P!%=0"ZD0"\20"J>
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M#C51(>9 *O& $^RP#/Q7POI0Q#D1#?$@ M9;,MSX#RWI#O"G/^60#'A%#O3
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M>2&=8(#((91/;/$C!S/(: 8*399AA !?*-&@D'[<(.$<=&A8I<8(HLOCBFA
M 6 16BPXHHQ/_R22J!X8-OEGFP;^"&<=+=; )YS3PBG%!GO (68!*Z*!PX1_
MEN'!DV6L<(#&TR3* @3G=%@@)"UDB0D2"-P)AX-FA!&!AU$,0:6)%<J 1!0)
MFOEG!$;HH0.#-;I!(PIPMFGA&G).^V>=+Z[K)8-2_OD$#'":R0&6<TQAX)AP
MS@EA"GYT84 9G928PBX.]!'I'5M4B &57#BXXAXU,*"DDU[H:.,?=X!HPAY
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MP0T(U*%E\/B',1(P"X]1(!NH6(!?_H&("/ #& 8 GPVJL(A/" (0V/E'-RQ
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M)V\@I3AL 8]+W  .-7I _WJA G"H(P;),(U$+,&#>OBC >-S@S5B0@*PO,(
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MC17X110ID(@ZDG  .O#V>ME3P7]BX@YP[($*,;F'$?K #1W XA]6"(%$II&
M4VPF?B<8+T[$P=@5/0(!W?@'&W"PH"D\2R>IM(8@A$ "6<0A)K\+WBX,H(Y&
M+& >,2'%0J5A + \0! YB95$HI$#T/Z#%A1 AC[_0,H31W#@:6B00>V2D,.P
M%",&.JNI"L*Q"1Q,@@];O4<+0GQ-WL)05IM0 #?+$(-W^(,#N/E''5:P#!4X
MZA_6D$ HSK$"HC*C!?N4E35D@($SM",>+F 6,E;@CW]HX0@2Z6]](\& ?<:$
M' Y&(21XL(X_Y'%4IZ!&!8B*$W>8P"*VG ,,[FN7"^R3"G;-GRQD<%]B0.<?
MKFA+)T[ 9OQ*A!\6<(,:RA$)%Z0!I2LR0Q,8L0-J_&,*2!/,Y<#Q#C(<@1$I
M2(//9O!03<  '/LXL2WA\0%:<"(%*2"&FOYQ#AF,D,[ME(%D\C%'VNSC"F9(
M!0VXS&8L7"(FI9" -T!Q_X$7V@(#53U3 DA1#1L0Y1]1H((<KJ 3Z%JP&R?N
M[0?XL0040I$+<0B'.4C"9AWTX+[F8 $I8W*[0\(P!:+X1S]6\(T?#N$?N9!
M-=YQGG^ @:/_R$8#&D$;>_"!"&R  9HUT0$:J (<YVA7";3Q#RWOLQ <2(<X
M%N"(?Q3# LA\1*+!@8/+9>,"DZA1!J#AB@Q88QWH\ 8Y9$2)?T0:L59@M*RL
MH&=DH^$?_.  2L_1@U?0QLY^<? 2*6$!<_R!"<>H!C&Z =/8QITIKC6=W.T.
M%'/@8%SZ> $#]= "<_Q#& B@0TP0T9D5M0,'N2!)%Y#[#STT@"15,,0_H*&"
M8/^NH@13)JHI)$"+?R@B"A_R 0J":0TB ,@/,9D#"V+"@E_\PP@GB,DS:L#
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M)E@ 94B',YB-23@ [<L)>3 #"=@&<K "3S(''7@"X%N1;7@ DKD&$6@'5?"
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MAPO8 UF8@P@00"AR@B*H'10(A']8A"_\AW X A8 OC#X Q$S@/AJ!1_H!VE
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M@E)8 QI8 U98 A](@W<P!BC( 1U8V?R1"&E  K@C@U&3"%6X@1,HA"D0@E,
M AW0VDN0 1JH"V-@@1,0!#= @E#@ A^  UF @A\PW#<  ?NTI73(@OX!A3'
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MBV0TBR/W<7_X;<:""&Z@(6'0AW"HAUI(M>SQ!UC(K7.8!P<GAT;0@V:@!EP
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MK,,'97C',I@*&DVX@D$S$<<74'!.M42"J/E01D\)8@YU_ ,>/*3J0_M"H'W
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M!:B!.VQ"!>P"_V2*"70"N[D40Q ""_#%+!P +L1/#$@A.,! _;A#&K@0/+P
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M#/P#)IP 0;C!'!!$$'32-]" ?J%##31".$B#+AS""GCK-L2 >*6"#>B7+6C
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MQ![\0%-]  .2 Q)D+!:0")#RP+LR0PO E2MD@#$<A#\LP.,2A C,G_*M#4:
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M*QQ!]C'P/\0"(!L%%+3!+*!IJ.CO3+!#"G@,7'A"#>05'*! :!S!N_[#+XC
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M3( '_^L!P)R#%T"=(7" -'$$+%0 XN)!#6#1'Y1K%3PA2\Q# WBP-F"K.KP
M\F%#!E@Q-EB $]P-2_0"#BC4/Y  )J!" Z@4(*@N(_  /A [$#Q$#]#".MQ
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MDL .1  $U($8E& % H$9K$ !1# ==$ )['-%7Q1X@[<9J<Q%P<$)S" S(D$
M7&$<3( )_D$?/H KPM'WKF$"K*49U*"C(($'*L<3.B 8;H$#)O,("$ 9Z(0%
M?&\<C@ *UF$V6&!K@* 2P($;,. H-_<?>($#@N$?U""BO*#_"V[S"1;!# 2@
M"-A!!=Q &+*!&"9 #8:A'S*A!1QA<Q? &TS _/ZA!"90)YXA!^(R%18@9*0
M!=;)'9+ CNXA F#A'BY@2O[A=,/A%0P@%S#I!*@*!CY7&!9 &I:! T9A&" !
M &XE"C)C#DK@'SJAB$_Q!5#-<S)C%B@ %]C!"T0@'\YA!TZA/-0@!M[D @#A
M'US!CM@A",K@'X"A!>S&'VY@#M;!& + 0:;'$V8@,UI 1J:G&WY@"NJ!'RS@
M"<YA#"*@%[#!&)R AL A"%A 'P3A EY!'/+@ 'YI ;9!; *@$NJ!"W)@&G#!
M&9+ _,)A&'9@&N)S '<D Y[A%Q1 _P[" 10R(!K@(0&F) M$T&=S\Q^&P NH
MJA,4H!.T@1JFH$)P(0' 01B\@ 7VP1HTX!?.@0>F+PT:X1]H(0&NX1]R805:
MP1JN0 "XP1 F8!5<H5P*I!DF $7L 0:*H$"<0%2["!YN@*G^@0U\ !V\(0-,
MX1^JP V(X18 ($@XAP:PH-&RP0R:H J@V0OXL!Y:8!;>H042X1]8@0>6LP:L
M0!E@81!R(#,60!7F00U<%1\6( 4G 0@R@Q\F0 XR PEV)QF%EZ5;F@N)MT6#
M 0'41RDL@/9PP'VRH0%$E1HHX$G^P0U*. Y^H3Q8-3.<80(& 0Q"@!LY@10$
M[Q_8P01J^/\?ID (. ,>]. /<& 0A*@%;J03L. ?N@$&$  3YJ% MF (OH(#
MGGD0/(%_=  ;EX$!+FL<4* *)*$1+N$4+*$%+C0(/+ B]J$%;(,;<""A\  *
MUBD><J"PD#,<&.$'*F,1&D >> %!_F$1G( W3,#W"'L>(J$&(N$2$ $1MF$*
MX 8<W,%N'(&SQ\0'T@0&;/ ?S.$&X. ?O*"KUX$%TL,K9J$!@*$=:N +Q@$,
M4#(+\. ?F*$%\N$?^D$@_J$8-,#\O*(;(L$*%@"02JD''.0?( $!]*$1<H Y
MJL$ DB$S8@$#ML$64B SBB$!6($,2( SFH $P"$/Z#LS1,">KX7_ Y(A>F/A
MJ"-@$O1! [0X%RC !>F!%USV$G^VE(Q@"S(#&U0@H9Z;&2B!"C#Z'Z1 $'*B
M!UX!'.;@ NI@&<J)%C*@._D@!C[A$BAA#>I!%<3:W0I$$D2 ,^#@!;C("3BX
M &- &#(##?@@)[!@$O:A <;@$C9A$VIA>NS!!$H@H>C#'G  !_X7)]ZAM^,&
M%]) "&"@'M:!!RJ!4*(A%-P@ FA($)X@,XQ@"C/AM?^A$CC 'YA!"WHM1EU:
MS_>\\V":1:/A QZ!,TX@B'#@]++A @2=%SZ FK_" AZA#[C(*_# %:'7 AKA
M"J: ,\H!QBI"JJEZ"C0=.8.@#=(!"7""_Q5@@(LF8;'1X@X<X _<1*VO11PY
MHQ_<8:HS(QD4 %+J80?<1Z/6@ ?\(3.\ )JM.P9LHQ=4H*I$H82!PQ]>(%4S
M(ZM?P.(: 0':@15T8$[@O+9SO1MB(!X 80*D*AM/X XX(Q[P8;.W4P6PH1QX
MX*0MY ;<I\>CV@1\>WK8P08.(1;"0 =V00T::PB4F[F=NQ]X !+^@1@,X$KP
M& LZY0=J>'K$009(\A]V80+0H1!X((90(0'XEWHD !M.800RPQU\(!?B )\R
MHQ F8!W60 8:+07VYA]4(0.R(1DJX$KB9@$T01T</HPSX!K,80VRH!7>@,AK
M>9.&8,+_8=FKBO^]:CX5Z/@?CF#A+7X4,H,/)" %GD86,D ;_N$+CJ!.)N'9
MQ>P?)J$'+DD7Z)3ID9V2_V$/EM!G+V'G4=)"*&(<VL  SK= V $$0. 0G< E
MSV'+.^$+$"$75* >[$'A,V,84& /OB$'Q 02S/X?F.#TO#TSRN$&/L$1B!K#
M^-ST3U_^_%P:R0$+0B SU($#3!$&D+>%1><;=H#8,X,.-B"(DL(,JB SA&$&
MX.$3.F!ORN$*5'I,:, 7"N4)I" S\N !,F-HJ><Q_@$1D!@07B&,#< 4O2 +
M:KMUP<H5;E9*,J,;&& 5<@(-&("#^@$-$*$"#"$SH( /O2(>6H!7JL'_!PXQ
M$)X>(,#]PW<C2KM_J>I<&W#JW[] *?[QPL'NWZ H_\#IZ/5/70MTM#K$<2C(
MDYH&P?[58^)O$<9P[WP@^\?DA\-P,4;]B_+I'SD6',$)%6AH@9]S70YL<OBO
MRZ%_SV+8^X>.!Z!_PC2$RNA0BP^','!E%"C.QBN':IK\8Y2CW+]]$P@Y;/4
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M@QVRV*#"7[<<X 8C(N@PBB  9%)/'A!P0\@$V+B2PCS<Y"!#,>140L *0I#
MS"X!^"$/.;5TL,94R/"P !$CF.).$!J$T=<*I8QE3R .[(+.&1I4%H)V7(%S
MR  I+ %%-./$@8,UN?_L4$L_B0B0"CI]*,#*,PTPP8\K!P12SA4$"+&%#>)
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M Y,C#P'X<74  %CP&9&P 1( !TO0 5J "B>P ;31"BV@ %D0"#-P ML #J"
M XJ0 R% #/7@!@/@!/_@"0?@ Z@  Q[ "G&@ 4D "3@0 Y$ "1/P GDD#GE
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M P]@#L*P 5<@#QSX#_+@#J:%"    T(Y#1"0 -IP#!K  \0 "P40 NW #DL
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MV0(!"3F064P@ O_P!#C0!G2P!Y#0L*)] TKPFZ:0 =G@$(V0 ?QP"\GQ#X?
M R)(!"CP#\1  QJ[#HXY#MC "F.@ HH>#3&@+K1@ A5!#SEP%68 LM %!6?P
M#YH  +] #^SY#\X0 W_QW;>:J]!' NS9#R[@#<#@ )BQ2A@ #-'0 BFV9!JR
M"0K01^?@ FX %1. #.# !,Z>- "/"D+  6TF VIPIAR@D]-  :R #!&P!'2@
M!FV@#,82K)>@ /H0"CM ?\/9&ZSQ#YP !0[1 V=P#B5P G30!F?0Y6U0J%]0
M&FQ $8HAFU8P DSQ!SUP#O[_P '$"5WA_0J%\0^"D/1H  6 0 EVL ;WP%89
M@0*[C@P&(!<9 0-CX!!3LQ2#80/_@ I X!#^\ OGL \ <0'3/R$E*"6",R??
MDA:HI/D#%S'BOTTT_EV\,\'?OR%X_H&[&+(?CTX7OV'X]NX")XPTPOWC$N4?
M/&[" %DP]L]1#7?__I"XB*+(OVSX_K79 >R?+E[!U#3P]J]'J(NC&,!39Z#6
M15$)^#E+ .M?L@70/DK\]RU#M8ML>)@+16%92+IU[=[%FU?O7K[C_/H%R5?P
M8,*%#1_>B[;NG!KQ_O4SA]APN'E-LD4FE0% H'^B $AY;.%"MG/OWET$-RX1
M@1#S__X1>\#!63,&/,J9@K#%'K@K $3]RU7!QDPHB>8 N/1O%P EXH#54, L
M))X!9M[Q 6#GGQ$ E;8#4.3/&3IQAR 8^<<&P*1_9SR J:L8+TAV.-B<_0>)
M1[]_5D[\.\&*D,Z11R*0WHG"!'G. JF=3AB0YB)N$B@&%2PN@J.$=3C:(JT5
M-OI'BR3^:00$5HJ0XQ]A8NCF'UM,8.>B0EKPQHIZ&$0KDQ74 >.*.1A)Y:(5
M6[1'A5XNVF((U- Z1P8T_E&'QF@R"/*?6.1:IH5\0AHG,+HV42"9?\3YP8U_
MSCG!B%:(6-) 7XY@9(P%HOG'R7_XX<"1?XS)@)I>Y J)'/]9^OQ'D@;J$6.'
M<BYR(I-_>E$!G7\FN9 <&?(PIX%%Z"*'BOO^P8(]-G#H";# AOCOHD L,$>?
M/'$,+,F+7I%!G/RX  >&3R^RE2Z0?C'A$$  $>*%??ZI[]-M&-CD(C1DT*F'
M<P9TYH*2?%BCKFV2V. (UPQ,CX5>!>'@'HX\\O*B93+PY*)Z5*@&GPL>N8@6
M UR1AX8Z_DDG$"$*J4&3_/;K+X2+0A#PHD\@L.4B?,@@X@@>Z)3AE8O I&<:
M"7*Y2)H(5)GREW_F64$Z<!^YZJ)9#F &EA>^E2QFF?7Z"["9;\8Y9\0D.D</
M-N#!\ UP2,FAB05UOFL<>MPHYR7_<C(!8(X]$5#AM0ZV$$><==)]!  =C/(F
M 0;B48:"&MY9+H1ZR.$" )8X 6 /?9)  !TV#H#DGU$*"($<?RPPH)@S_Q'$
M@WW! "!;(RI8Y1]  !!Z*7DB$> ^.P!P= \  !FS#"*"P2^OP&"  S]&>$CG
MGS?^\R,'8C[Z W1P1?%@H)!*6249#5"Y*!0?_K%DQ'_&T.*B)8#X!QD:CNZA
M$U<R<$;U-,9R@9]_2K%AG(OR42$&4V"=*!H7B+ $F0^ 2/T?\:.7QP=L+@)B
MB38#Z^&,D5UP!AX*!/Z'E 7Z$88+TA>9=%T$$0IHT3MBX)U_G((#+& %K)!U
M S4TT "N_ZG?/^+!@4;\XQH9T,8Q.O")BT2"%,S(P/MR40-[B,(!N[A($$B(
M"Q\L"A%0N$@/UA .$D!!'_\PQQK,00<S7"0)R7$##+1GJHN(80&.^8<;G# .
M?W!0@O^ 0A8NXHH>D,-Q5>A/#K)QD3&(R2Y_:-A%MI$ @;T#!BGZ1S$RP+OV
M]. ?IAA +"X"B5;4XP+M"@$(8C0\7#0N%!<H(KA&(0&S_",1/UC0$L+PD;KH
M8P>3_$<]9J -=%R /> XAQJZH(8U=,D-+KB1%?7S0RL8[!\(NX@O($!">^0C
M":#1A0&V9 .J4$0!_/ &!:J4#PM<8QL9<,4_Z.$"DZ&E%AIXW_\_>!$!>H@"
M>91$6C8)4[,N:=.;W[S91,RA P#\(!&%,,*QQC  !0P#G!=91RQ ,(IU>+$=
M5VC"M"C!@5 L8@:6^$B77A*.;/2F :2H!RHVT(%9P,T"UE $ %Y #W%PH0!Y
MR 4)6H ,8K0  &0X @"B((W+X4 =I   !6YQ$7D0@3G2^ , B@"/$P#@#^XH
MQ@@\4 4B!$(>?@# %;Q!!0AHX1R2   4J-$,!0  H!,1W3B:\0$DX(,<X&C'
M'"(@#7L$ 0?MZ(4$7# ()]S'0" AAQP,\ AA#,,4>?CA%&ADCR1H8AUZX,$^
MS.&'!:A#'$"PP3NNH2EV@.('Z)B$!%#_ 8L80 $:T]# *<"!"@0\XZK_,,,'
MU &^P+"A >WHAP(F.8YPY)(9X,C' C(!#G/88 L; E<^7C"$<0@C J( 1Q]B
MX(US[*%TSVA )U[1B1\<XRZ7@  NY $)%X"('$Y P?Q XHX=".$;?\A (_SA
M@B&08XUB.(<L(&"*<QQ! VE@! WVX8H!G((<OF! ,-9A@A8<(Q0+&($W<M'7
M<9Q!!^PHQPVZ.P@/?.$14. $.:H0!'/D@P=Z((<C7A *D75I(LZ8P!S>80T<
M1+ 8"<##5<'UCR $@1/&2,0-T$$.-H3@';/8  @B000_%' <H"A!C$"2C0FP
M@!_HJ $37N*/_QPP@A3](,(-RM$/$>Q@$' P03V*$0!(C ,5& A")/[0!V4\
M0!O_4,+TP 6/!Q@!'.^8PD#>L84S:,\N8LB!N381A7)D P,=3-X/9G&-?1BE
M!"(HARL8((=V&,("DC)""BZ2 @%MXP9^N @9#*&#.(3##0CPQ7P;$95;9&!+
M4RC!:43QGV)(H!3_D,8,MH&C?[2C!72XB".X #P[8O.=M[X(-PN(:U[WFD$>
M! ,6NN"*#?U#'WVXA9O!F8]('$(5,?(B/&81DD@\(0QL\16R7"&&0L A$O@8
MA1[T4(M.U($2L7B$(,S CW,( 0*,J 01N/&/<6B"#KTH11LPP0]/L/_A$\+X
M!1XHL8C39 ,-8^!$+1*AB$;DHA!I<(0]5)0'(7A"'NH00QD.,8M%Z $2[+ '
M'HR0BWK880C6@VI>I'&$*7@!#JFK1A"\H(E+.,$+ *T%$E! B7: [R*=F,(1
MA#")E_P#'W%HPAV2\XLH?$$1M@""$R:A"B4 01O"J$$0P. '88SL"DG81":\
M0 LY .$/T'C#%MJ0OD,,A;,@B86>_L&(G(!CJ$"X@S\(X84IJ.,248@"(GX-
M#C%XH0K&"(,3N."/<Z#!#V8X1(SF<84O?,,2+?"(7?;AAB7D(0]*"0G$?7X.
M1F#A#*&H B(4$04AF"(,02#"+/@0!2,L QW_>2 !$H0!#R)$X0R[\(,3U/ .
M8G@A"F'0@B&N00<G,.(43HC"+B01!260XA^82$(*% $.0U0!!;90Q!>",(UX
M>$$-_4@-N+AQ!#FX 1>M!D,4FI <5ONB!(YX11"B4(A+-,$+S0(%)PB!.-B2
MNJ &(+@Y:E."(' #.#@")$BF?Q #&!"%6)B"(. <9=B"%#@":U@'-0B"*D"&
MZPN!%,B"8Z&#+\B".TB=LTJ>JK."11@'<X"$(VB"2C@:3@$#$.B",; '=Q #
M):"#J)B0&*"!&^ !8O@%'AB"3X"")& %(+@ 0M@%))B!3O"G&XB%0\" )UB"
M)K  6Y"#!> #O#*"_W:H@QH A&10@@98@W)(!AOH@DSP@VWHAS] @"7X!BV(
M@#/0!Q>TA0^@ T8X@WXH!B]0@#)XAUWS-:1QP4;$M4?,IK,:,5]A1)T!EW[H
M!G5P!FG(AWF8!WW0!U#T!WS@AWBP!WSP!W_HAW1PQ73 AWJ0AW; AU9L!UI,
MAWI(AWFX!W3 AWE(ABE( %TPAW*0!W1(!W2PAV4L!WM(QF;D15>,AV1,!WL
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M0N &=0")9H"#1J '<W@##MB$S;(&_SF A1D'%WV8A#CH5A-&!G[ A5-(W,?
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M\D\2O?RSQQ?@R(/#FL1,$$R.*K 3CR?_L.,#&O_(0L0_TE#0"912_F/-"\Z
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MZQ^FT$" N/H/5!B 5,P0*UG-"@D>V*,5%+!&1X*1 6V\U!BDX<"T**P37J"
M &@X!RUTH I4,,#H@@W##(#3$7,@90HH&,U<?@"<R$8H'(;H02_$$-!W-*,+
M!%C#: :1@P3H@A,7^'9'Q+&*!?AQ','P @3:H.8GZ>,%MAJ'6_XQA ?Q+!U%
M>$+_,,@0(W^LH!K!N>\_[E"%4Z!I+<#@@#8ZT@L)*..ZV64'IW7Q@7L$@@=
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M>,,#?$ 4L( F^$,1+$!,K4,)T("^_/_(.?Q! ."!(,P "'!#*R3 $]2#)M0
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M% 9C(## *D#_@Q_\82\8 !EL@B=4@";4@QX,@"V(@[LJ00@$@3U\@@;<@DL
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MR4>\Q6-\2-Q! /@ +[E\H6,<Q"M\D@OZRGO$Q8-=,,9\SZ^%R9/P.0C!"NB
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MK 0?H%&0?B"#'H\@1CZN(8U:[.,?H5##+ :"CF:\ Q>YH(LJ%- ';5BD%R;
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M$NS!'0Z"'1R! OAJ%#K $GCA T"A%-P  )CA%Q8@'[+A>6"@4^KA =3G'^3
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M FS('5Z $6[!!DK!%F1!&^0!%4QQ(-P!!\AJ%"* <_YA%B2 &$(A ER'.EA
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MSDFJ'2 .%X$%YB8*D%@Z4.!Y___A%)+:$)X BEP@*S4A_1YA!L#(/X:A 5
M.LKP%&!B$1)@(&+@14!! 3@*E:,/;#?@E./@!_Y!'UH @; !!Z"W 9)W'/@!
M122"%7P .M#! L3O!S#X$33 ==*@X2I#(%(! ;Z@'O:  TY2CD=@(.K@:]^
M5B6B##A ,$@ %F;15:&X'Q0 $/XA&V+@L9C@GP&!"S(G7D[\S ?B!+:/LL.F
M&*Y9&#" ;_ZA%>H %IZ!'0(A [;9+[<@3<:!!!YX% Q@"1&"$I3@$ SAL1)!
M R;P$$K &68@CE>H 7 A"'!:&EK@G 2Z86H#-PQZ8=Q!!,! %49@3N1  S(
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MP\XM1'@2CC2:=!(+./,,L@DGM_Q'RR*?@)C,(Y9@PLZEGJC2S"2=V&)+))]
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M0D01!A-WM1,'#UV484(=%]$'P  *<'9%&^!ZXE-  [Y'/K,[(-'*0[B,,)"
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M:B,S#[:@#L?P"@*&$;0P"K_P0AA1"K< E!P1#+<0"E0Y#ZM "M7@E[>0"L7
M$<6@"M=X#NF #M; #?=@#_<P#N&0#OWP#H0##M0P"A<%#_$@#\&P:+Y7:(3S
M#OP0#>VE1>8P#"H0"_N0#1E@!N# !2)P#M1  U'P#J>@ *K <T\0 J&0"0L
M#(3R#1Z ".4P K!W!V;P#G+@!O_@!+9@#E40"\/@!"CP#\7@ O>@#%]0;CM
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M4)'M(0]2@ +6< )=0 YAP #U>/\"/ !S99 "K_ ("P!XQ$$,0+  ]0 ()?
M8M &#" )XU$*-# %M? /EI #!<,!@? /PA %J! +%V '_R$6Z0 (%P 'S, *
M&Z (EW !K("-/? /B1 !JJ /C'  8L .?* !0* ')\ "^%4&+) ,?7  01!Z
M&<$/(% 'L2 %+[ -]X (*L (HW"D15,*#G *JM  &DF0!HF0(Q,,(A ,F_ #
MXB (&0 /^4 $-W!S?5 %K\ %&G /O["HBP #K2HO72 #H; %9_ /\L %D! +
M.? &^T '(G *\* &#M +_X -(" *F' !H8,'#" ">: $/!!U3+$,"G (BJ
MH? /3##_!J2  S=;-/+0!QC@!V!  D*@!W_@ E;6HV) H=;@#3>0 ;KP#\[
M )Y .'Q@ D0 !1)P"<QQ!+O0"1:P"L2!#U*@ 2. !BHP!<-5"'_ "D^P!?+
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M8+W%L,*^8 /.E0D3W Y&L %K<+\C@PYPH 4V  /V8 \\D-;#H &_\ P9L,U
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MM&KW!4UV#BX : (.DNUA#10@6\8U Y/6X(22#28P!NXP"MQ)YE:\UH\4#_$
M"1+P!^- !'OMT./P DR-$3=[!I-Z#BC@807$XK#, >UU#\-@#)V-$:.>8[D
MO?^0"0C-#O$@" ^  C?\#^UP!%0@#Y7  ^VPY%],# ;@"]4@ <^T!6@__S+&
M@.7_H.T<4095?B%@CA&3 !!0_OV[,V<=AS4#_Q'3!T[A/V@97/VC1H/3N!"B
M_J7"T6;!MX'V6N#YETS!IG^R,E#;6&/1%3_K'@YT ^/<0#-*_K7#P>T?.*!
M_RUZT>I?"%7_7&4P]H]9"W4_@X)CAVZ3B0G2G+6@]Z^5B7^F,@@;J*[;*0/$
M_H69$DXJ4'I$MNA+%>*?DRD*O]$;Y"2DCVKZ%&0:*([&)707'OTS9\+66X?7
M<!RJAR03.'G8A"BH!?E?OA;3_E5;T>^?J!%>?X3!MZ+,0&((!FF).M6A%3 #
MDRW()<.1PFSGII8\F3)#L5$&3 ^49B&,0GFW O]L4VCOGS N";S<^\=JQ(8[
M_[#IN+3*1SU[/"#]_,=.A2%"@SSO4R!IX+D??/X)H21UYG\  Q1P0 (+-/#
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M@,A#Y8.V86M(V)('[A_#A@X9+H3$H]^_A<ER0+$CPLFY?Y30-'L"(]^_<>#
M%5NS0I4R>UZ:_,)"19RF!C>2!-!5)E"L!5;($=OQBM0+'+?0G:!CR08;<MIT
M3,"G2P6--D8B8/HG[\T;6"%<B('(L-&3.RUT_=/2ILX+%<7^J=*AAD4=AFQP
ML/N7R<G#OG[_ @XL>##APH)/(DZ\L.))PX[_W8M$KQ:(+?^244#[3L:2?UC"
M_CO4P/^?NAOZ_K5S\8IAL@Q9<T!BR&3&/SDZ&A);T2^<*&G&GC3YURH!LG]%
M2B0"Q(2+.<8,6?SZUR\'MG_48M1S'NS#-8:#*,QS1B'Z."!O&&YR,2Y-#$>
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M&8U@*X;8XP=!\O]& F+Z#W[4P&^#!(</.O,/86"'$@V %XRNH8P,7*Q78FA
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M0,WDZ ,"X&N+%^BC'3LXJ3B2( E_*Y<AQ\B!D01 #7Q$H0KR8 4&?)&.11
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M(ZS %% #&+B &:2#6$3B$JB!&JA#/ES! O !111#G7A!%7P '+3#'V0 ![!
ML)@  C0.8!D $,SC'=@ (H !',A@+ 0 $9B"%SQ#.-R!!BB!B8V#'7S (!1!
M&A">$;A $9R#*3R  MS TJP#'U1 #/C OET/$E 20\!##FP!*OP6%B1#(1S
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M=VSSM8FO-CD80REX;56O.(*3.(G/]XV7N(V7=WR[^(ZS^)#[=8^/.#S@PBS
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M8Q$8Z($\_*$$+_W#"R7 QQFP4 X[9" $<^ "$S*@ QFL01,_N <>7,#D'*R
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M!*9%'W( $OXA$*H ,$Z@"/^!$M(3%4GN!^S3(!CA+A("%13 "@.2!/Z!'Q9
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M(04V! = X1]>_\ 49B$0)$ 9K.$'T& =G.$!(H46<B!N*P %<($1FF =*@$
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M-AB!!=8E!MIU#WRM$1C@+OI@/A."#53 ((ZF'1P! @Y!&Q(!!LE !P1'"+Z
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M""+/..K!#OP,)1E-*8HRY($><.BC'@U<1S_LT8]Z@(,=\T@'.A;T&@O^@QO
MZ%)(S-&,=830..Q AW^$9 YBB$.(4.3AQ/YAC;=A3(K/H9'K^"(@R96M)^=
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MBQXQ!2K$8AW0&(-_QQ$(+ZS!%R(1"5(P!9? 0B%1#UJ  %1P7520!LT@!9\
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ME4 ,'. )YC $$  %<H #R$ + I !HY ( $ #J0 & O 'X/ - P  W& .50
M0I *+S  U% //=  Q" "&V ,]U '#+ %M6 /_W4  %KP#ZI0 (F0#300 O60
M#S8  '8P"0& D.#P1/_R#Z7'AO_0# UP!K^P!#:P95!@"?!P!@G@#4(A#5:@
M 2?P!6&@"!( "_]@#!?0"?6  @F@"/-@ B9P"VQ@ ,O@#%7 !-60/Q\A#5R
M!,\ #K_0 \T #3W0!0H6$NVP MX( B50#K@0 'S@#@UP">1 "EA0#+,0 68@
M#"PP V 0!,S "%GP#'S0 ?M@"10 !_\ "R6P#'5@!/\ "$RP#(@  #CU$>9
M"A=0!BS"!RZP":*@ :=P#W^P 0W!!'J@#TG "68$!@^ #_J& 87P#XK 3O\
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M)& (X: '5! (#>!L\2@H&U$"#3 -_W ($0 #.KDW-7% P@ "'C (R?$/QZ
M)' ,>M !J- /-9  J> .V_ /8> !=/ /:@  54H% %!RY1,.YX ,5Y )NA
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M$)L(_X "!" 6_. '=@ "&_")JZ"5)L4& ! &T4 #'&"_(>MK2   QE .,>
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M< 3L0 MH@ N&8Q/V\P_JP (=0*3O1@ WL ]5F [>D ,2$ Q?-0Z>   I>P8
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MU_8/P\ +YS#62LX/@) #/V ,-]!C(B$6=5$,&C#719#<6+"%>EV]^9 ,A(
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M<>Q@ N+4#2CN:HZ\%"2Q57*@ 3C (CFNX[&( "_<"!U0O3A0 #:P:[Y!6KC
M  "@!RZE#JUN!Z40!KBP#0M0 =<1$G*0M?]0DFKP#T?@ 7=05B)A!Q$;ZB0P
M2FU>!.+@Z1][" "0">I ! "@!/? .W6C!0#0 O-PYYYP "+ "K>0!O<P!  !
MH,Z_</]J#7B 3Q> $^P, ?A";MZ$ O_(_B$! $F<C0W5B@'P<4S$@$3R2 &
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MHP8>A%#&&2QH:$*8=]R!I 82,#%C!R5&^<,"+J"AIH<;8 %&B1S>$"6)%<0
MI@D#(/DC@B[F@4<(#"CYAHD=D+"&G3*XH,,$4_[AY8<?!.'DA1M<Z86#!Y8I
MK%1P^"%D!@3XZ.<?>JK(H U<GDA@#'$BF>"!%QQ!;A\C NBCGGKX,,"&?.3A
M(088;D AF$X,@*(7,RBH(I]/'C"BF\(40?^@"F7@,>$*1.B(!+FBXIA@A@]
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M&(0B-/$)0:3A$'8XA"<FD0A"@"'5B6@$(,H0"5,T8A&+T$0A B&)1QCB$)7
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ML[_H4]>_ !3  >2Z /2_GW._K@-  M2_ RQ !E1 _@LR$:"!$MB"+J"%]X/
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M!QOP5"I0C>]9#VG @QJPT:&L2Y'8@ID4#I4$TGUMM',HIZ%PHF'IJ6P8,Z.
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M!3?H!2W@@F".!S=  B! @!1.#F]H@BJH \<Q@B.P!!VP@^C@!S90@BU(UG]
M QEP(D<@W/K A0G@X58=YF(VAUG0 D^(@R@8!338!$88@4UPACE(@5,0&SWH
M@W=0!CT0 Q7Q@_*:!S[P RY A'6@@@RP@MBAAT-0@ICVE9;\AV.P92N8LF3
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M@'GP!1M(,!@H]&R@!.Q=AN28A0%XA6B8 %W(!RK  "X8!!UH W/J4V$0! R
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M*QGDZ\@#\?P#2@__<!%%/.K0L_@F$2SS#QXMD'/%NPWUDD$NZN2#SSF;3\)
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M*NP ' A"%_3#-FR!!HB!5R+ (Y!#1I #'7" '(0"#?" +8C" ^! *]"#7>:
M%\S#88P"#[  $GR "<Q")3" $=B!#OS /%@"!RQ!-W@#"&1 #I2 8V9$+M#
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MI',RGTP\5[-!?;, .3.P_=.N);,PG_,Z0VT\_[,X'X8["W0Y ]0]IW%"@W-
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M1E4G0QGL%Z]UPRT$\46[@C_9-T:H0R88A=E$ SSL0SRT S#,@S3L SBT@S?
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M856(0 (:$B&):(PA!@$PQ#<.T0=_'(042IA"+DI)"3(T8QYQ:,-]DK() X1
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M1DYE-"E $@X"%,;A4&B! G[Q(!ZA TJP%P) $/#! J(@'-@A"@P $PX"# A
M%MB!!6Y@'M*!!G!@FK(@ 9 !'7R !^"A'4"  ^X!'G)@!Z#!%S9@T<(BT$P
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M;N &[A954 \4*, 'KH0<VD #2 D-$J ;6N$  D$<^.$&?D!.S$$$6. ?&"$
MTJ(4 H"JO($'H" =:($!8(\6.H#_"<(!%BH =L"  LI",?1  JC@()3! B+@
M%6313ZY  B*A5!U /\Z@5J*S,G0U)#KA!=@H"6+6%83U'QR! ^1!#A+S'[+A
M 79&+Z; 1^\ !RHCD-"!#'+ (;SARPRB6S]"0W]A#=!P-MS!#A#Y((BA7?^!
M!RC7'G!@$$1@:A@X7_DUE57Y9)9A!ZZ@'91!!6QA'/!A"[; .#2"'+!! 5 !
M'%) #<C!#91 '1X $<R!YOYA#3Y@$,2  TZ &$@ "+YA"!( $.+!!*9 '*2!
M ?X+#SS "(S+&^)!!"*@#MJ@"J#B*&)! 7#A',B@"-9A' *! J A*8A! Q(A
M%OB!!L9@_QS0X04XX1R.@ 'TP!!&($#T,!YJ8&K2(01*81U"( 3N!!PNH0&$
M91-&8! DH1FVQAQD  7 @1XNX F#H0(NX1D&8!*F(0APH!C P0>:X$SF1=,,
MX2#DX 7DQ" <P0%F 1MH( ERP1H: !L. A4B($*"P0'(0!BT8 <DP1FPX+S<
M80>>< U"@!7LDY J@"GX(&O)!AQ* ":T( 3 @0UPX!JR$@_*!P+ X!)\ !&H
M80/FH!L0(0&2S#< 00<, @U@R(H2( T$Y"A0H0#>\A.K( O&81@H(!*<81<8
MH!6"P06B8![\ 0@\91,*H(?< 0=*X"#$8 "&H!GDH ^TP0&T(/\:<.%=W^4H
M.H$"9.09;D!I62 MXH\I-L(6S$H/'(!@I.$!#K(8-$ -Z($-#, 5P,%]3:$#
MHD 4TL *P$$5?. ^Q"!_,U0'IN89.& :RH$*X/,HZ"$)LF 4,$$-CM,12@ <
M@.$!CB$J&($"E/8H..$ MC(I^B$'A**4+D /M,$?ON"+Y8$#LE8,"( (/&$*
MT F &\)4;: <S $7VD '4($/ D$/M$ "UL 1H.$$?N ?M&$#Q@ 8#4 -FH$:
M,& AWLT&9$ ..( #^B 5($$"PL 46OL(-B$5-H"KGH & N8-#N 7V.$';D /
MNN,H^D$$&""OJ&$'., QGH$!AL ,&N#_!LA@'Y9  >K@%_(@ &PA' "AIL4B
M)*S !<:A7O*J%## .P?A \ZA$R0@:%YA G)!,8# "]#!'=+ 8OZA$R*@'5*6
M#HA!&;C@2HYB%S3 /*@A 9*A#C"@$YR!&J@@'/#@#7^CN/\!!4H@0ZSA ?:A
M#VZ@,BKA TYQE45]U%O#(/:!",Z #=@E'3C2"0[A20S"'YC "9I '<@ !=A@
M#M+!'(; "=! #1;+&(( !49!#/0 'E#A!-  %JI %5;!"X[@%P@A"(Z@%<YA
M#$J@!% W']  1![K*##A"<;@#.ZC%Z(@"OS@D PB'/K ";XA$E#@":A!$YS
M")8!';1@ D@K_TRHY!]HX0NB@ E:!Q/./8VW(0NV8 [$(1(JX (08 )BX!HN
M(0B0X!0 (0BNP!<.80J,H!G88 'F(!9,P!5"00BB /+F!1RRX!L.XA3,RB"D
M 0E .1%@(!?@P GFP!VNH0NVH W0P1SPP *$0!-Z ! 6 0F:P!4^X0B68!J&
M(0>FX-#J80V<@ [RP1-&@ NN8//48 N:0 B<"AH>0 8J(02$(!CJ@0HFP*EG
MD@-4@ U8P VVYBB,H0FD@ BL0/ .P@NL-"]*Z0MDY"@ @0,,0!'>P0M: !:B
M(09V@!#@@ 9$00HL@-CBP0S P1J"@/'MH!S.P0X:X **H#((@0-^8/\*;F )
M N0HV"$-=, ,A*!$UH '5" 4V. "G,![)+ %'D 1W"$;N(H:9* &:& 0WB$.
M,. (G&@, "$'7H RQV'P,< +_&$67* !KOP%>BXLF$$&@D@HU&$&<F ]&F(,
M$D",1> $HG,<RF *2("!)@H$HJ 2=G,6G@ )V "2&Z(-"/<<(($#PH 9 .+'
M"F"V</ I=\Y-!@F&_CE\""[B/WE[=EB, N1#A3NN"@!A)RS&!4.U.+@P\X40
MN7]K+EAQ]VJ J'_@QHTQ$$=0A"K[%AEH0LQ6ABWYWF5)D69*MW_P;M"H5P\&
MCU?C)%[K\>#%CS=3U QS.(\% CA>+-QI]X3_ 9%XEA \*!'G'<V(X!X^M*4@
MR9@0+V*U85!+G1$$N,Q=,8!DR 4_ZV@Z)$0!2ZXB/(S-\[+@F#@F%3(\N#6W
M[BL-?V#)./3/WQ$!"FI@PX<B [)_Y$8)."3N&P<FI=JX^G?M10E",BC LHL\
MN?+ES)L[?PX]NO3IU.U*_&?.8=US#L71K0M^)7:'XQS*=?R\[K]QW,%QMZX>
MXG>'Y-AI/U=77+CY#\/1/,<=.?[]XTQCXQQ(US_B(*-/=]V!$\Y*X<CC!RGT
M\#./&&P,:,Y[YHA#FT/1..3/> I^EV _Y$3$3CWSG2.-0PUR%\XXZ_@'H$/2
M@-C/>@Z98V!C^X!(_Q=[_YP#XCC7R.-8.\^45U<V)3IC5S<-/K3/,O_<HUV"
M_Q CC'8.M4+%2BC.U^!WT@13##RI+?4//]NLQX\YSP@SS7O_V --,L)8,V T
M<SX433;@Q!B:>L-4HPY-; [#CS+)$",/7?184\PTXOV#SS7>!$.,>\0T"H\X
MGRH3CWK.%$.B-=LDXXPRPI2#(J?-9.-8,EZ42)<_Q6SCC7CJ*:/E7/OP@]V*
MX-R3SC_K>#>?,@^$Z5 PX[@S##'I $-/./Z-$PPPRGT7SC#!>./--*X64\\X
MPS3V3SY+I1$ )L@T^M^@Z02SCD3N)/,/.\.4)\\P[?SS3C#V.'3.-<QH9_^/
M,MU$M ^B=-WS#+K*>!-?7?O,.8\W#F6C3#D.68/(H+5:%XXWS_P3S2S]3+.-
M,_=<4\R([_RR"SVLM/>=)9024PPP_C"S#:[GM)+)-8G^,PH"8Y#T4#J?+,+J
M-8XHT@LX\G@R""?N_"--)I7XXI@RD'3""R+\Q%==W'+/37?==M^-=]YT=^SE
M=-MDP(@RS/CBU=TK7Z=WXHK;14D//&B3Z)EP+PY?<XA3GE[<]K"QR-/I3;[<
MF5"C(*[E<(L^W77L@(!!+UUVG+F875H7.G_)V0Y1[M*!'OKMN(\+7X*I:+"/
M?+3KCGQHMV/.?//./P\]\Y+_;KI[J'B1@PUY+#7_/>_,=>]]].(CQ\<"FD0N
M>?.HU][WZY?GO3)TO3:#_N_QCSN]0[;@T>_DX-_OG/GXXPTK6 $;LM,]Y/PO
M@0IDH'P6N#[V07""%*2+.0@! 5S4KX+_&Y\'/PC"$%*N@]'I&ST.ML'W!="!
M(OS@.M#AOOQ)#X -;%_D%D?#[UV'A ]48?#R)XZJ^&^"N_O..J3D#WC@AX4I
MY&$/(]A$\*V0@U248C_T\(911+&*U&NA%[\(QA:F;RY%[-L"4V=&'X;1>?/9
M81?U!L4:OB^'=I.(&O%'Q!^&;X/*LR$%R_@^(<KPB7^4(Q2Y.$4N*A)WBX3@
M&A\)R4AB;GUW_-P9RZA _TD^SW:(>R/\8*?#\-D0;SO$)![GZ$GT$7*(I21C
M=<YTH%A2TI!T5.$L]6C)1#9RE[QTHB9_"4P)[G$YQ'"",M2WPV.<@1&J3(X[
M$'$)4RQ"$8UX6 IG5\1_",,.2]!#OY:Q"%& ;1YL3*7OVM>.5>RA1VBLBS0T
M 8;LD*((,!REXL@QC3JD8HH%RX8WF '08K!CD,AA1A6*)3]PX&$0[83',)RQ
MC6M,HQA \Z$]Y5,>1PDB##&LX3]ZP25UI",BQT#&/J+!#&MX(QOG6>5W8HD@
M%/7#&1Q\QS"DX0Q@M$EV>@2'.X#Q#E9&Y!S]*-12S@$,?"R#%]@,92^?"M6+
M!O]SJG.+JN1@*D@B?@,%,;*JZ.B!C7^88@9+H E6)2>/6,2  6ZH QA8@()J
MU.\?Y4!&%>F* EK8 @/38,HA*-""4;C(JR^%:07/2A=UT&$#LMAB8:O2"X'8
MQQ$)<),L">LL?)QC$!*0@V/;L8L9>&$1DE!$"FPQ%\36ZA42"-,"Y6$R<(!
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MRE !=# V$N$-+W #:- &G? 5R7 #3X /)% "]Y - %D(B. /1! !QT .3A
M[8@%#; ,M#  CV ..Q"2S40$.K P=/2\;>W6X8 %5? 0\M *#<!1#O$$4ID"
M,^$/*R!7S- "C8(&,O_ '9!P! Z!!N8;!15F%U@,87U@#@N @;-,#KH@SO]
M"4#@'WM@ N-@#T!@!]7@ _"\'28 P?\ ! TA Z$0)QS@"&34#QKL$'A0M?\P
M!!R% I6@9?LA$2E<%_80 UL@#LE  H)0Q??P#C7\#XK  %>",!(A#C9P/O^P
M#PT@"46\UDB,<_^0#5>0 %P@+MPP @3 !N. "X/\#YV 7.CP!TF #%? 4<1@
M ,$9SMUP"2VP, Y1# W0.0^Q1)S2!G=@"SO 4:J**VP  ^#P!.;W#U6\UC1!
M @VA9?U,5S% "?J0 ;6&PI^HJOD #L*8#1?P"/\ "A_ #*V@ "F78*,@ =/_
M-PT4T O4<-F.P %]5Q=(NR<K  I/IP"I0 P4( ON4 [E,%(1FP-&\!#2P X'
MHP\SL +4@L!?$0X]\,T(3 P*UP1U40^90 *20 )O ,Z7#0XA<)Y,  (/80<Y
ML YK( ,KL059,#LXKAY9L /XD Y50 >'< '\7+6S0 '!,"!&]C3G@- .,01;
M0!LRX ;KP .!(.3B8 ]25 L-$ /%HPS-\ XF\P^%  &X"\X:$ )FP 8 ,PT<
MH /X@!TF0 +P\@_:@ !*4!ZOH  8 (E+H !ZD 67(&F(D %.@!QU4 %YT 9E
M8!^;$ !P_@_T$ -G?@P-  +KT TU4 *4Q@'UT L._Y!E8T0%"D!SYN36W_Z@
M@7  53@%Q( $)5!L+Z!%):!%\D #3I<,+@!#;M#.AI"^S&J^=[  D&,/Y@P*
M]ML&_S %+8 LQ. %X= *">!TBV !#>(&/? /X: '=\ (/49&X7 "[;HG/ !B
M) !B_< !I+TEKOT8S-P%9HH"+ "!^= %<7JF,& 7:P !OQ .*[ &_] -,7 C
M.8 :U9  =VT+;KL=!.L0]# !8:4',3#4$C$./V &_[ ,K,T-$> *W^ TD? !
M_8 -+V ?@N"BBZ !J&X$9AH,!K!/_^L,J3  HJ:MN- $)M C]; $SLT%(> 0
M,6"FD7 !N&(',/\'*H#JVO_@ T1"$]CC=/.@!N= M<#6 H=@#C[@P6F  RO!
M":OZR3B7#Q,PXL&@!*^@"NWX:":' !A(# ^@#[20 >*5"1QP>Q*1# P@ANS0
M F8:#1% "L"0 !"L#0PE$1;<H+.M07BP"EMP MEQ"P90+"S !U!C %<>!AY\
M"P+P,"<@S:=  307 M*<!Q;@=4)@SGS0YO\0!(PM$?N@ &+H$-J  6D@_N;7
M#!@@+E!05M\@ 3WZ#]7 IY)V#C8P!PYA!(@.$/](K%DW@\Z_?\K,( 37T"$X
MA)0H2$'X#]^?;/_6H8E@Y%^Z21L,D?LW;]RF#G40\F* !6$Z=HXV#,)W"QR9
M&3K_U(%@00^A-X<(NU 0PQ!AE@;(?HY[(\$5PEP!\H2[U*$H(P^7V/'((@_*
MA%_V'@;]1\0&NXID*ZYEV];M6[AQY<ZE6]?N7;QY]>[E2S<;C@116"#ZIRM#
MG6N$]IS3UJ!//E(2$O%3)$$4LA$(FO$[\J)8-QDUN@&S\$%P(WI%.!P#AL5$
M/&H+:#AA,0M='@&KX/4YT Q8CQK9G'%XLF3-I'9!>V5@1.\3'W+=<HQ95XW"
M&'$-_[GKP:50,2Y UM$S(:4=+ ,@#I'8]*]AN'E>/M1B1LH(@D+_]"TXH>O,
MA$.R,<&/1I(Q8@,JY"!!&/<:XD0#1<S9Q(US\*'B@F[&_W%(G&H:\ (?85:8
M9AT:JG'E 6"4R2&=83)0PPP3;K#ED !$,86')'SA9@- S.%D@%GJ0:&!-++0
MXA]4!$#!D1(4<0\A%"RHY9$$3OBF$@FD^4>+'<YI9@ _KF%"@5DTA,BP%Y30
M811R0$#B'W44N.,?,SS0HQ44>+#FGS4H4*>=#^;XAYD-&J'3A4\Z>827?\8Q
M\PT,S0FCB']>&:":?Q))("/MMJ$@D5J"66"4?ZJ!@)-_VA#@CT1 >*;!?XK1
MX(EUUNGG$2384<.-3 $0XYQ8*$ $G&=^N.8?52"8YI\S=' 'R0U>644!+F0)
M!0-.2AE'!R[(4>:#-\0AAH9OR/^I@@9P],F!(EA!Z: ,?_;Y9 (ZPOD'A12T
M&4*!,[Z)(HE<BFD# B'* *$;4EBX!=9S<'C"EF2\&.$?>V9X YP]')!"$!08
M'<LA<J3100(OIH%&CPCX,&6+*$BI H$^ K&D@RN.P8,*<:X8X!2$@)F!@TU(
MZ2.>)@PHHA0C?/E'A";8P>*"6W)1HI8&P<$%@0,&"4>[?XP( )!FEL#$'1Y<
MT <A,22PX9=: !C%G@B>,.>>'$1(HP86YFBEZJ#"\>*-?T)Y AU8^S+\<,03
M5WQQQAMW"R)AQ@CBEXJ@H:*)1NQ=91%%6A%E$$FHB>0131[Y1)-8GG%$$5FX
M<60076+_#<.(7?ZAII!!+'EED4R.^<>8*Z1HYI]N"ID$%%PT^8047Q09Q!=I
M3#CB""5H8*3J?YJ9 @U'QODG$R2DJ.6.*K(HYLE_1"DAE5V"J$(;4X+PPI9_
M6)$BB=JU2\<,(8QXX@DC3"(?"#G'(+Z0!VKT(0SO6 44+/$/>.0!"E=0!O;^
MP0DOB.$3]KK$$:[ !V \Z1E$:$(5[&",+FC!#9+X!S:@L <TT"\<> B!(7:!
M!FMD8PY>V(4DGM"+.#R!";Z@@Q3BL(YY9.$$=I!'HW:Q!!$(@B$0<444I* +
M,*#!%7^80BFF\80J4,X32L@"(X;0"S-!Y!91^ )AJ/$$*V1C_Q)*^$,^^D$%
M)#P!"6YXAC2,((1?;"(*;N ')((@AG$DP@=><,((.-"+1GD/'V!( 1'8@(][
MW"$*FY#'&#8YQ7?8H0664(02XD /,@1!#^M@1QYFD()95 T?99!"$>I0!SF4
MP!7!*($9WK'&*/C"%A&0PA*\@(M_Q",,7GB%,(R@A%(D4PH+@(0<1. +=MP!
M"*=(QA660(P6_F *"/P'+J1PA6&DP@M4T!)"JF&$*S2!#7\@0BP@\@]?.*$+
MERB!%H"!"B?\01_FF ,0D+"W791 ">VH&BJ"4 E0/*$+RU!%%-HP#WD((@DG
M4-K'M$.,/U2A"TNXPA6BX 56K"$!H?\HC MDX(UT:&$"-JB#.]K1A2*DXTFF
M< $-^K",?[ A!X.HQQ>L0 8U^"06+IA!%>BGG5[X@0M#^(-2H)J"!7AA$A0S
M ALJ,HD:A*$<['C#%> @!X:*PP\M\(4??K (<GCT'_?X /TJT0!_%,YQ>^5K
M7_WZ5\!.<2U<&ZSA[BF7PZ(O+G, 1$6H 0<+-LHHCZ,+82<;E\16UBWGN*RC
MU")9A)"D+9F%"VE'.]K/LH4<G/V':-GRD+:(5ARB]5Y;6'L.T8;#>^# QQ/.
MAY QJ(0LW9@'0G3;VK@V"K;@*&YMLQ-)A,S#7@\)A[W^4=U[[K:V3F2 ,(!!
M.'#@]KKB("#_1-CAC$8U<2VLU= _Y.$-AK!6'-9E[3_>D9;!)E:GF/V',\Y@
M#M+><[[&?6UF'=)>M]1#'17IQSHJLHQR7#8H\<BK>\X1CW^(PQ[GV(91_)$1
MQ=:WM;"5!S#N>6+M\&,MR_#)D\I!N'XPE&]<RT06-/0.9[@VL#OF<8]][&.R
MC&6*ILVO1S_&MP*CV,A<.X(/P "&/,R!04*.;'Y+:^4J)YFP)QYR6@S<92^G
MMK!AGBS7N(S:,!_VR(I]7&+EJE<LXS<NWW# &+8!#RR"$[9>EO.,+QOG-1?X
MS[&HP++@'&?!LGG+1$9LD"6LYG\<@PD5_#*:P4SFMR@YT8FF<N$,_[SHTN[9
M@FJQK*.'#-MJ. $>;/YQJUW]:ECK9<F!SO2LEZQE6S^$'I<@@A$J<;9<&QFU
MP<9UL(5=Y%P7V]BTGO&RF>UL:%MVR.]H! E(4((N:"G:VSYVFF%[CC#P  ^G
MYC:T&QWM>/3CT,[&M;++'6UWO]O8_Y@&'= K[5CG6]_[=O6RSVUN9/L[WLD>
M>*?)7>Z"B_K@W$[XO ,N[S<7V;CZ4'>S(<[NASLD'/>P!SXN#F_,;OO2"[]U
MP!O^\8B3'.6SEL=N\<UOF,=<YHL3>*A![FV,RWO8!,<YPS/>;94#O.<B_SG*
M=^[FE=]<Y45/NL';K'.F/UOA%F]ZR8=>]?\U3WWF6^=ZU[W^=;"'7>QC)WO9
MS7YVM*==[6MG>]O=_G:XQUWN<Z=[W>U^=[SG7>][YWO?_?YWP =>\(,G?.$-
M?WC$)U[QBV=\XQW_>,A'7O*3IWSE+7]YS&=>\YOG?.<]_WG0AU[THR=]Z4U_
M>M2G7O6K9WWK7?]ZV,=>]K.G?>UM?WO<YU[WN^=][WW_>^ '7_C#)W[QC7]\
MY">_QQCGJZV7;_6^:,A[YV@'.>[;6D>YI[K5=8=U*R)]<)##^N08A_CM4O.G
M$]OKLTZ<S_O._GX3'>>(HS6S!QYRH"O?KUKW<U^=SV/X,QQQ6(=S" =Q& =Q
MP*WL. ?6>@<&- ?_<R OMA@'=G '>=@:<E@'1DN__ZLU(W,4$-S ?0M PY(_
MOB-!('L($/0LZ&LVQ%E!!#LX_$NYHW,Z_6L^[5B'8<B&<_"&8M@'&P0L,=L_
M47LYO9 '\O*>=M# Z[LN<P@'!RRM[1J'=XC"\S/"NDBY[!)!?MLRFNLS%/P[
M_DM!,]LN&GRT%]Q"0)M!3// />/"&Z0_B B'/I@ '(B"&+@ 2LFRQEF&9E &
M9?@&;6"&ZX/#+WR2=/@$?&"UO7 'B$ &;LBKAO ';%"'>_C!<=@';(@'9VA"
MA/"><0@&;F@'!/P'M+A"<%B&:L &8B &;-"&$(J&2X@PFR,+>&B%5PD'_W:(
M0:Y+!V4@B7E@!@?3AU4XF\,!AW# !6;0"&CPF#<$AWS8!D.$NW)(!6!S".]Z
MM8=XAVW@+'FPAG=8,V6HA[9(ANR8QKCPGFSP!U[<P@T,BGU !HC 0A<<L3C\
M*^UP!QC0@ A(@!UH@$= LK[B!B!X@!E @BQH@1)X!!';L7;8DYP! #U@1+T@
M!WLXA"D  A8H!HO,!S-0 1D  V3P13^XID5<"Y)P!S5( %1YATN\"XB0AAK
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M_WQ(!GL8!WKH!O2B!T*P $: AT&UAFM(!^N[KNU:BWC),"60 7/8#FD@AA6
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M@SG(4VI0@%0H@R)@*=M96H1X!#N@@T<@5SY;AT/(@RQ@VD/0@B)8F R3@5=
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M1E48 EM0@QU IH]6'#_P@C(K4[R@A06(@3W @0; @74% PK@ T^P@070ABU
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MSCG_0 ) ("("<,8Y>@"@E#CDL/^/-RI48)B*E.@QCCU9"!#+.# $8 PY2GC
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M<6D- >BG)CK !4(TX 'C,\(&%F$+:90@ Z=8!PAHD(Y0." .X?@% 7C@C%@
M@ '" (E"8%"%=81! _H" P#:L YR: 8<]M@# (3@#73(H@JBNH>//*&/& "
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M3#$.4+C '?\PPT7*X !/_X@C%P_0QCM6\P4MZ ,'2"A'/5P@@F948PNHZ,0
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M!VB &$@#$DC "$3%/.R!!NC@7#^*,:?U/T@#%U# GAIL-<! $'0!#3Q!2 0
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M<( ^KM&!7-@+7_KBUU,:D8$PN,("+9#'):3@CWUH8 KG>(HL3+ #=]SC"_Z
M1Q#@<8P8S(,;0C '&A#0#WM@@07V L KEA$!=$5B G](PP2)%H0I*&T)B/!'
M$6(0&YND0PZ"D\8(M.",%F1@"V/P 0^^H28IT*(1!K!$,G0P@2&8 0<P!=MD
M*5M9RU[_%K-:NXD;".,-"]" $_D 1S LT -9X*@5*F@*)^KVCFHPH@@W**PB
M'H .>]G@'WAX*T[4D0X7:&$1BVC$),SAE' ,XQ9M:$ 8_F%1'(U!!>O @AY.
MT@S5>B83/(",/QZ B7WDH!*+>$0F4.&O(YS$#38XAW4: ,PS/$,?'/##(CYA
MB%GHCQ)4DD4"MO&.)_C#,_?9PC_((0/>L<,%P3"*#]@@BQG8]A^!0,"1</L/
M0$3!?3>)Q 6<X9(;',(Z#$!%/V[@!2Y480F@F-H;># $+ES!"!5+Q0=D@"/I
MLD (=W@1.0"1@Y.\8G/_Z$<LQF&/!SB"<P[8@SJ"(8T< ($+_T;P0B8\DX;=
M_D,)4/C'-#)@B_$\(P._.,D4&%$3&T ('2U 8A!FL(IYS..)^?B (5@!!T4P
M(!IQ&"DXVK&*8H!B!'#XQSYXX(V3U,)-)RF%,7*!AK'\(PDF.<<*!/&/(YPW
M1T])1@.:,(UCS",9+M!2*&3P#T< X23;8-(-D%4-&MBV7_]8AR%JT $\@*/
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M&Q1 #='-!WS!,\0@!O8B&RX XMC!!&ZJ&UK T'K!!\[!#_)P'<*P7]#A"##
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M@(3^00?>QA0T(!E.P@0.@1<ZH#/^X19<@!QL@02F1!#^\2DDH0%PI!R([Q^
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M'PS ).[4!43N*72!!NIE&Y?H'%C@OJ2A!9:0&G"@N1B 3L!B[Y[B&\BA%G
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M%D1 !^3T$VC@!9H@$&\B%Q:@"?3!OX" $/[ @:KP'X+!!9# &NS !X+@&^S
MR*<!#FC@"J8!"%S ,F]!!F[@!^CZ KO !W[U%XI!"6[ $'@!!5R $U)!!: @
M$4*@"K!A#E2 $*0!#50 #"Y7TDO@"-3@"<2C'HJ  3) "%98JDN !59!'VP@
M"$0$'H*'"/R "=8!'EZ@!KJ BD)!%PQ@!<! "#X@%[9!!H@ #9Q "%&! W;
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M6087AJ",25ED%PWH@C?^$88@E,T8TL'&-2P2C$9\XQXW*48$#"$0(>C ANA
M FN0HHM(\$,@\F@&.T+1CG<<PQVGH,<_GH&):"@F:.2PABY(]0L+E"$;S:.>
M)C?)R4YZ\I,RD487:+ &;?RC"4D@@Q8, (U_M*(*U% $ VS1'6Y (?\5DLB
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M1648D(]_I& ,ZS"# 6"A"VH@8@:EL,8]2.")?_SA!.> Q0? ((Y!O. ?]6B
M\3*IV#*;^<QH3O-M>J$">P@$"(] R@\8T0X>&*$2AN#$/*ZS!2I4HA*?",51
M<$$ L8)9!ETP!*!'\8](E$ @C)B"0,@AJ'^,@+>BR$ )=/$.9F"O$H7XA##
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MC%  2OPC&C>H "L\PC8K>&0<FBB#&PH0!'*0HP@ J(0Y@-"!E/8! ))P2 @
M0 -$Z"Z&/)4)+##0C/2DH@\.N< E&F(&'22C!>CY!S(HT(IVN" 8_X &#?Q1
ML6K08$#TX( ;?J$+5M"##R#@J0F:,%]:2.,?N%!!/?XQ_P5I_<,3,?C'*E)
MF=0=1!4)..\_4M$" 1^AB0'E @AR\0M9I/,?1@A<&O[8#QXDXA\ET$)#S-.-
M331 %+_P1376T8DD-$0.=!#'#0K!SW_4(@&+2 4T]OG3KS7D%SC(!SWNT1%P
MI*((<=B!-?[!"0* H!3_.,)6&D*''X C"ULAAPRN6Y\A%,$'_GA'"]SVCT$@
MH!W-R  U&J*'&9B#$(BXVC@$<8 A@)<;?;A#"^0\A93]HQTX$!8N+E"#0>R3
M'QRH7%(2T041U'@$S[SL/YQPE59(0,[H-0 KE)&!5GB$SN?8!".TMH<]N-8
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MF -0: ACJ (F.(8U4(14Z((J$ 5.6 (A<&-UN(+P:6(H!O  [U^"S>@JMN*
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MS#_ZK'%")'[*5Y>IU)+3"0=LP/</,FHL,XX.1!Q675&^W%""L&?&),H;:@3
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MPAWL$8Y0L&$6A_ !O,@0@20XXH]4F<<;H( $V<ZB"*K(Q P(@9E_-"(*7YB
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M#VRE*2A JU#F/]Q##(0?=_W#-E@"/PS"!"A+%H2!0BB#"Z!#.W# ??T#+AS
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M7$"YL,%A/@&FO ,1\0,'>-LYR("CVDY-7(("W-0_S,'_'92# FA"6%#%("B
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M2QS<  6U@C"(@@QPRPA@TP_(MT(<@LON@0S,T!;<MV0O<D18@F+K027[ PU
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M(RR ,UP#.SS 0'F#!- "/&2 $/ "+_C 5IJ!IOX#(T1!.@QH1$A"!]2Y./Q
MD'K!PV?%-F2 '_S#9D/"(U% +%S#(^0!,P3S/]1 +]A"!A2#&[' 5OX#,'S
M+[P#(>S /.#"!LS!.@##$^R#O,KB/X  _T#$^E?F KU__T;4^>>&Q$$O70ZR
M*\'D8,5_FV;4^_<'HK\8K0X.X>/. J.#U%J0:\8"W+]/2BS&E#F39DV;-W'F
MU+F39\^8X,X-PN*%R*Q_TX@PV6.KI<59/"C-(A%#C"X56%#](\6"PY=M_\"%
M!4=.S L6G/[U@G&&SJA_^VY$D=/'G:\92)1\&J?H !^P8O^%VL'(F)<6><B
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MN, %QA,PPB$.QB )[L 92@ 'LN$96/]@0/7 !JY "5X '69!">1@"V2!%7)
M!8B@&E*@!B0A$V7@"ER'R;B "/Z!&:# !4J@"&RS)5HA"KX #A( %OK!#ZI@
M!++#'X1 "J @#<+'%)# "T0 =Y[!")P !?A@'8Z!"Y! %UA !0J1'YK #Z;
M#.1(#XY #QY@"^8*'%)@%^JA!VI # 0)"); ,W=A!-:@"1Z 'K:A#:0 !#JA
M)43!"Z*@"=8 '9B !Y1!'8# !!J0"+[ '$JA"H2 #1*@%?BA"Y[ !"#!AEX!
M"LB !&H *B^!![BR)8Z!8 U6"(P $'H "TX%59Q!"/:@!!+A'T8!"#[!$'X
M"<"2R:I@#(+_H#<MP08$H0XLX ZF85(F(7R  07Z8 OHP!RPH0C@ !Q<80@<
M 1P&80M0 0YXP!#(@1 N8 LD80G5X0Z.8!-V8'<H00FVX T0<A&P  N X$SK
M00V28 J,8AW,8 BP0 O*(1P,80LVP0P^H!#FYQ"@( 2,8 @SX04RX0= H)?^
M 1*J !P(80G0H'].00F^@4MPX0VX0 J. 1Q.X0^>H N6H1V\X .2H!2J@0AR
M,!S(@ VLH 3AP 9Z@ NT01X(80_>X!1L2!PRX0R(@!C0009X@ MZ"1J8H GD
M('R$(0U"(1'XX!) 05S!H10^81M0A1=V8 1,X46VX1$Z(12>##7!_Q>\P($,
M?L#O)$$!G"$=7H 3?,$* & 2;A/I^@$(RH\=3& J_V$)7*$<;@ 1I&$2 " 1
ME@$'CD :7J$=0F )PD<,\ U5W.$+ID,>0@ %Y.@3@J#Z .$%,K$!6"$?V" &
MN $?3.#]0*,:4( XN $(5$ 8AB$"C(@.4,!YD$ +_B$7'H :E$$$:B ;Q$ #
M"J$>_  !0@$?6H 0[D$4'L -\($18H 5YR %C#(/N/ ?;H$"-&4=HN"B4 4;
M)"!^&N 0_@$3-* <2&(%>L$4&F (?D$1:,$'6&$;L@ #T"$,0J 8<B$#C. :
MKD(8A.$"CL 8N"$#0"()"*$;7J$#Q. ;4O\@"J(!&2H@%5032GUD#7X@"R-A
M [RW#TR <JH C 0$)\O "7I$%A! $? A"X  K4S!!H)I#;2B C0%$%C '7J!
M!X3@%QX!&4R %+P!"2I@'SX!"'H$%S( %PXB""I7+/;A#;R@-^Y!!4H!1<&A
M&(Z@ 2PA$UKA"N#@&O   'QA$&[@'UIA Z[!'7( )-R@%L1A D#A'8;! " A
M&GXS$[!!!J92#R1@.2Z@$"FA!D;A%!9@"AXH!42A2S# >__!"H:M):"A!V @
M#!B!&KY %Z[!"RJ 'T(!!ZZ'18,I!US!EQ; &[J!"V[ '8@!!1[@%@R!&J
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M$YKY((# " +#U'WD$5+Y'PC0F'G%#5CY'Z"AYK#<"WPA&*B!&MR  7"!'6)
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MP1@&#); J(/L8P'Y&\?A;A%.<-"A+_]8!A!P0 5WT.(%:@A&%UQ@!V1X 0:
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ME98*"_$/Z%"9_> /_^A@#Y%6#@#S#M R#NK #PPA#O? EFY9"DR DO^PD_7
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MYJ $-)!6,SLNR% $0% )'&E,%D$.D  7BQJH>QJQ.MLM*GM,4DNI*-L8EU
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M%=9P"9FSLI;[#LT0"0##PL*;#Y< )M)@"9@ O9]Z#XXPD^#V#H/P![Z%J^"
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M#%DGG?B@#\Y@,HAP 5]\1U-B#@\##/$0)MF !4JP#>!@"B(0#L5@X] B#<9
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M485M$(0)'_B',A* #%+(0 2B&(0@5( #1+ !$Q6 QC]<L(MBO" 'FK!&$K0
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MAR\2\#&>^<P;P^C(#%QF@EP09!! P,H,D%>\_PS8@QDJV(@B2K U'WC-1.;
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M8P_WPO<>^.7$ V3'AOH9. ;YF$8 7-2="]1,!J_HC@L<8R)_/,!6_W@'"^*
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ML<B%#"">:WL%!("-1. !?:&"M[*&'4"J6^BI?T"!7_J'7QBJ#RRP&?B]9N
MY,$!+=PD".0%"HBU?_B$;CH&'[@Y3\A @AB#%6"6:\D6-VJ A4L#%^A$?YB
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M(@)]VYMSB)>$"$X$D*8L6(%U"/^'-]@"DSP@(!""79B&-B#2<#B")' ':H@
M*-B%+M@#FKR*7<" )M@%)3"%7A@ 1F@&%+ !;? #Q#(&!N '2"@ +M@%)@"#
MAL.&#+B#%]$!RD"$#8BU:_,$!^ 2,T" D'L"$PB'9%" /= %*-@.MQN#7'"'
M6.@ 7 "';]B 6GL )@B&(C" 29 ''< #4<@'1Z"!?A '*/@!:2"'.9 =3+
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M^O>^P96P[ZQ_<+QGM??.^_$XH,&W$^#X4;R_^J['$VVP F+9>SM)@QV(_W#
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M'++((X?)CR++@$/.*92$<0I#IE1"AC??B '-/Z@< @Q#V02"ATSJ@I,.+:2
M,X\G^+""!ZL/*>+$/^94P\M-Y-2"!R;G%/.*SJWD @](PL @0BWIY,+ ,:T,
M4D]#H=@Q2D71Y*+.),3\<P\E@4ASF3"4F")/W;7(X 8UN<X4SR*:Q$/3.-9
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M;>Q_L,,$M>!--M1P@"^D8QW$X ($W ".,MS@OT\0, D"RY!V6,8U)M93.6*
M!PA'0!44_@<;</"/362 'GK6!RA*P! R5++$@7@"0_RQ@E@1H\5W4 %(PM$+
M%12Y&PP0)T/080D-8/).,2BR%(Y,,5YXP1"K: %6GVP%-C $"ZN81@5D FH(
M-^ 9>AB"$S@1V+/ (@=+((-B16"$O*7,$SU(12M44 ][\,"#L>O!*Q@RC"?H
MP1LRB 6&0RQ1TKV"TB6FA01TP9!@:$#24:]T<O_]#V9L^A^G>,$*L. W=[1
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M02V( R\PP!#PPS@X@0PXCT=QGB;8P07_9,$VH,<X> ,+;$$]3,,#O$$YF,$
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M)$@!'22"0M1!$BC!&A19#DJ!%^P!,"S!%K!!*DP!%#S"-7@!"2S"/_^  A!
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M%FP! DC9\=Z#JWV!D/Y"$:2"(KR &HC#+,2 "K1>-ZQ 'BQO.&"""(P"'-Q
M(MUF%J#!%X0H*4R "3A".1@"",06.)"!'ZSA^- #&_1!$OB":["#*%Q!((R
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M73 ",EX C900@8*"F$)*_/#(?Z0!A>10_T$#_W&%)"2"$EIX@S4>,+5_G(&
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MK@  +>L!  TY P#"4$2>[*,)S5F&#A)0AW],H@,D9 4&:GL%#:P7# YH!#M
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M45("'NIA##;"VEA"Y%("&Z1,_E(N#.1M'L1  Y)@]VX.&(-1&*D',\P!%G2
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MOJ#_#:[!$90 "4H!%X@ "0P!%8P@"A+!'4H@ 43 !G* #?HA[E("W&C0";)
M,6>""+P #^XA):0O)4Y!"5K@#_1!)0P!#Y$A"9Q@!"AA@X8A"$R 0U1 !_ &
M'=  !UQ@#\[*&)1@!J) "-=@!]@@"^ !&%0@"B K)3!C&J" !*9@"HH &+0"
M"6*@"Z8A"FY #KYA"W" EFR!!7+ "P!,"G"@36O!'U3@"N3 #6*.5*0!!>(
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MX 660%E;805Z(-?FPAMRX 'RH AD@!ID@02<@!'DP >R8!^TP@PT( %.("1
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MAC\NU4.N^,(X(Q@75_SE5\_ZUKO^];"/O>QG3_O:V_[VN,^][G?/^][[_O?
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M'"_ZHO^ #$H ;WA!?^:@ Q;PF*%@ %#P#_#@ CNP.IC)A1HA!C:P*F;P/$4
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M!)FK#'J@!X2@#ZW  R#P"?B@"W4 9XA !GJP"$;(#'HP#9TPLK7!#.[6#X^
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M^0 %JA -=& "_* (+U #=9 )%; +_P #)W /6G"J_\"ZA($/)T  (&# Q-P
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MDG_^@&$=BN"HXA\J*OUG"RW6$>&.?UZ!3.D<ZB'Y 6@0>V(O73(PYD8I]EX
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M/L:Q!!NX"?],E_C3/\!0!(HHH1*@2\0   $,5[BA'ST  D7X%KH:".,?@K!
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M\(TR?  ,YLC&#X(@"B_<@AR#P  6X$$) G2A'(E$ 7&V,8.Y^"@$$J!*'FX
M"5>H  ;*2(4$0O^ (+><00-V*$($_O ,*'P &]:X@0\B]0]XO* DZXG**A+
M RC$X!K6B !IP " 2M2#$@?X00E"L(U>;, -R)F&"VIPAA@,HAYBN, PZ*$
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M;=$63@754!75 1553ZU1#"U2 %5,4QW52V75(&W56)75!.S060W5?Y"''P"
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M%(@%#H"" -9="K&> AB9KM5=<<"# F"7D-V%&E@!UX#:L1VX%9@!*_X'<>
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M@RE8ADQP@4AH!S-0@:BB:7ZX C*0 B-8P33P@14X@Y* C5TX@3?0@9 H!!:
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MF,L-(CQ3"P:X@)/&!_S\4TP(FN5%3CHA2'D-$Q%,LL@L/2SQSR,Q_',*!\6
MH\$;[7"!A3OI'!* +_],0H(_;'T@#2D_L-"++0EH0TX."ZEQQ$I^W)'F/Q[^
M0X8C)"W0RC ++/(/'R3\HPL#Q7#C@PIYE%$+"]AT4\4"P)APS#]@:)/F+@*
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M?"5W()BL&Y$/#:RB'.B #3G&8:0U&$ XKITM SBQ$G:H\!].:),Y=!!P:<1
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M7\R#"*P /Z##$9S .3A##/R!.13).]3!!EP#.:B" *C1(!Q $21""716%X"
M-B3"!-C!/(C-.J" $\@#.BR!QYQ#&_0 /?1'+12 (]#"%(  /93# [3!4QT
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M[X=>[]]?:[NZ,S@=JGL;I7N^7]2_XWO! ]BT[_6W+ZFV#SS"_SMN\ON%T3O
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MM" *+D,BEL$.$( #DE 6$B"!BJ$&N@$<7F$;_R8!!X2*&%2UOWP@!*Z "*(
M$'P%$0Z 1E(F 4CU#GC@'TZA59\E9)#*1@[@&5Q!^]K$!D)!6S/ &5AA <H@
M$,9@"UR(!XCL60 A DS!'IZ!WF2 *NQ 67"!%OPA(8$/#3KJ'V+A @@!#H+
M J!$*-:A!^) (()! A;A'[2 #[(F'6B $=@A%IPA$F;@#_S "2[@&(" ,,E!
M"FC!'B8 TTR %!&!!=;2%W[ '/XA"!IU7 Q 4YI!#<[R9VUE*L#!'^Z(+I#A
M R!+(,C!$!Y ,.XR+P/A^_[!#^[@'_8!"M*@&'X J<KN,&- -.3@!M#G'SAA
M :)(*?* \R83?29!H/]D@ X00H,P @UDP%"4(0-H5 5FXQ^X#2:JH!)$X0*B
MR!YB0/,RX?G^X0R$#0D,5"#"X3>#LT(: %K_@1PX"DB4DT+PH0DH8 G0P1Q4
MH#B$H07T 1M>((_X9UWJQ #Z5"F&X#S75B!\(04BP0U4@!RZH&KUAFZ#)@16
MX1]X( P& @N4A0HF,1D48*\.XG %8@ZL0"B<0!,DLP+)5D*3Y!^.("^G%WV&
MP$"/@0)ZP1U$]!QD8 W,X0$T;R!T(0"4)Q$P9B"\(7D%P@U^P% :80&RX0YP
M"2,FTT.RX0(:E1HRX!E^00.6J9^J806NQQ]H+19^;_MD &4@06H; A)X((7_
M/F$$A.(0I,P=J. (*@$'?@<-,%8@JB '&J Z_@$1&."4! (>,O<ZC. (I&$(
ME.L;H. 1XH +(E%1L6!,V $&D*$?#, 2O.(?]" '!.,?%H$ R4$&3N4@JN$!
MQD,T>< 9K($&7D@4M"\3'@";&F(8)F1Y+"""<2$#L*84:@"R-D$("L$$#.%"
MM?@?X $!,"UK&*$#T@84-*"*9\$%@H]<#P(>7J W+Y0"D.$44N#7/G5U\T$1
MS/8=(L,\6L 9LB8>FJ #G&"9'H'SP*!@SN$0IH -&H!&BV ,! (0.& >\&$:
M+,X=6@ .E/8$I"P.T&!7-J$">. 4_D$,HJ 8K*$8_^AA&F9@&1!"&@#X']9!
M!VSA']IV('+!!&S6";A%():@N\Z %)$.:+GY+<@A,M(!'J!C+J#! 0I6%BX!
M$3" 7=#! O*2$"(S",@ >UGE$N<E'UP 3PXB&FY@?U!! M[Q']* AXM&#G23
M'+0!!PR%$^#E#V8 3\;!")P'(_J 6[WA \0%!U[T"2+S'V3 $TI! KHP!D)*
M$,[S#X1M#R( 2OY!#M#!#ZC)5\QA"QK7!& P$&L5(Y;!2DLA \I@'&Z %)<A
M!\IA+'-V%VZA&S) X6+! %125XS 0)$!!T2'&1K %_XA$;ZN#ZA8("@A'?9
M3/_!'7[@=[5@! 9"!L;D/___ 1@40#<.0A.R[A_VH&K_ 0F$K1=6P% "P4#!
MH&"G0*CXR@>*Z H0EQHB8!_* 0/'H0?F !R>@ =>J.MFX0&$2R_+%"&2P0"L
M]!_>( 0BPQY@  7BN"%ZP0=0QADN8$RT(0.N818.X/+299X/PAI6P$/H@ ,$
M0P1.!19Z0$ H(;,;@A(N^!^* /7^80FH8!R H+OLX0;T8@]\5B"<@ KJX )V
M)Q@20#63YA/PX6N; A=B0 M0 Q@:( W^01*6B ID^1]0 ,?X(0>(P1QVH&#=
M(0_R21,:(.3&($;_@03.]2#*63?XZ@'Z@1A4P#5, ?4D(0!^XQ\>@4F% A36
M8"#_%"$!R@$;,D!G%J$!TH$5+D TAJ 2,D,%G+8%^D"%.@LC?B$ OJ9.*N 8
M!.(7;L!@T9I.Z $!&/0[-, ;8($ *Q<$:&07#$ =1H$"'AP7IH$>6N!W&@(8
MSD$6<.#Y+%,@_GH<AD &] $?#(!&C%<@'($!C/D?K $GV<$'/D\@4$"HLL -
MEN(>^($9D" !C,$0<F"R@Z$77F!-E!D7U$$!+N\<?@"K(T'N2E$'E,L)KD\@
ML $!)J$/!J>;)3TNK$(>I($?\&=F4.(=\* "G* /?N 8\N$%#$ 1#F$!H-42
M*N /U" &<* 7C( '4$$+*N 0IJ,"(J%S,"(;." -/,$<_Y( !+;A&;[@-P["
M$DS $4YA%0Z %*1D!^#A&Q;@!M0 "6@;(]Q [-0A#6[Y&AC@$WZD%RJ@$])A
M$E"@'MY!!E2@%#"A 4[ &5)! SH!$G) !9IA&QX !R[A#=!@'-X@NO;GIC"@
M$<#A%T0 &*!' G)!>S B&EI &\0!!A)A'&3@"UYA"0Q@#.)!"C8 $!XA"/*!
M&RH -3@A4^A$'Z" !<(A',J  Y8)%AS@$FK!!FK &GJ! GZ %-Y #<8A#5H
M%IKA&BK $QHT 6 !'#S0']0!!]8 '*X! P84(\;@'L&A#6P@'\(A"5@%&3"
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M>!\'6W#@!O1P!6(@@<-A::I" SLT;^PP"17 -9L4#?HD=_=E#RJ0.77V#[K
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M NU !4-@!C1 "]"0 BK01)7P!F)P ;?0$6]0"5%@!)QE0F4P WJ  GAU#T$
M!W$@ MKZ&)%@ GHP!1H ,]^K/5BP#6,0 V&0"^$@"7J@!SF0"<]@ USR 58
M!%50"3)0 YY@!3"P OM0#WV0 -H #U*P &O !0Q@!@X1!GI+ ]73#T\ !W)@
M &@@0[V  @]@#Z2  T@P!R;P E_E&.;0!VY R$Y0/:)P F$0!2C0$/!P BX8
M X,Y#F9@_P64  (ZL,#DP F%G GZ0 DR$ 8^T CCH @?8 A1$P.'L _XX )*
M0 4S$+\Z$@@@< <XH "_( ]; ('D\ Y?L >@: LW  *.8 ^/L !D< 4UH O7
M$L2'$ .<\*P@0 +I$ [%@ )"L$#I, 1\H 8PP!'"( -D( 5<4 ^[T )5H 4)
MX S6L 5@T 0*,,<.8@YT0+0@8"2;0 (Q< :*(+S_0 OUJAN9$ #:4 H], CB
MD @A@ =>P /U( M=( 1>,)CZH 5"4 *.  Y_P !.<!/.\ 9/( )U, [60 54
MH D6< S$P 9I4 7-^!QDH 9&P#WKX 8M  ->\'I(E['31A;D8/]&Z5 .@59P
MWB0.<.0,TL!/1?%-"88--_@/0+ &_Y -M$ .$Y JT("[($ 5Z> "N8H$]$$$
M)H L"" 3[H %*[! 6  S15 "FR ),X %,F0)*+ 2:5 $-ID#/",-"* &_=
MTOD/6M "ZZ +#P D:3 %,D0,,P 'CM ' #!]J;  E< '310*%E (BQ $ - ,
MK9  C2 ,ZG %=N!V*\ (Y' (1[!1-$!2JGT*/H -TZ % " 8%+@#/P$-$6 ,
M[: "=+ (2P  >/ ,&E (^. ,:B #C2 )-' #^[ "8?H/2_ "CB0*7U!"C:
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MI0.KH1DE>!3S)(,@W/DGDP3^<NB>?2Z8C!T8Z$#_J9Q_6E%ANW7"P."%8=C
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M#7A\X HC7L II*&")>AC&A,8PRIZT0$PL.,4'B!$ZDE2A@4<(QI0.$U"@H$
MWU*/"CD8!#/$4 %F:(<CF(%L6(86V $T0 $_<!-VF(87N %B6 98  $=N"-&
MJ(!:((<X4)@22(%C( 0-, -O<((M:(IYL($:P(96>( M"(8#R04' (5Q6(4?
M> U22( IH9Y=(( \@(=\V 03P(([HH<9X EW6 %*2 AN2  ?& 5# (%NL((&
MR(11 ()<"(<<P(1:B <9"*Y_Z +F" 012(AY^(([NH+9.8@2:P%I^0<TD +%
M,((I4L,?JT,[K$-PT#%$H9X[_(=N_\B%9L@%>0"&5XB#7T"(;^B$,CB&@TB'
M3$"%=E"$8AB':8@#9+B'0,B'8AH$-(B$_C '6>"%6=@,>""#-; &O?D'5YB#
M:, &7;"'>? !.G #3"B9A*"&.U"$9#D&-H #4N#%,>"OC5D'3E@#1^ B1K #
M?&"'2H #0  '<U %/J"5:# #/0@#>G (:+@#.^B09K@#,ZA%0!"#0*@9?P@$
M-WBRC3$'0R@#2N &0-"#,>B06,@#/. '?\ #/4@#$OF'8K #->@4A]@%. @$
MOOJ'70"#,,"##*J'%S :ZID'.*"$1# .7QB#4C(%,3 #4)@650@!8C@%/*B#
M6!B$.K #^/] A#B @Q:BGGLXA!$P!$88!'S@AC@@@V@0!%4(AU!H@XGA!S'
M@16[CV7X RV !#.A!S$( SB R*] !#9P _C0!#?PAJ\1 S;P!W$ !"S@@V0(
M!T@@@S'(KG_@A27P AYA!C#  TW !T@P@B0 !&B)AS%@ 37X"T7@ -TXD%U@
M T& ABLP!7TP@RSP VRBGFU@ B"(A4  !0+:!" 8 G,A!TF0 JM4AS4( 4(@
M(3P0@W3)!3/ @T[8!#Q(@UP8A#0H UK(A#(X!&L@A#(H!&L@@S2 $7J @Q*
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M"(B'!2*F53@ R&&$'6@'=F@!6O&'&4"#<*"#;W@',S@G<-"!T[B&"1@65%"
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MC,=T:P7TC.]XCU=ODK $4?]0A3'^>),_>9 'AT&X40F8 D1">9B/^;-&AR8
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5HTZM>C7KUJY?PXXM>S;MV@4# @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex10-15_img04.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-15_img04.gif
M1TE&.#EA, ,@!'< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     +      P R $AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
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MN_?OX,.+_W^Y?;SY\^'+HU_/OKGZ]O#CRY]/O[[G]_;SZ]_/O[]_L?C])^"
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ME#VZ"5O XV2WEV2$1D[FB8<"IV(3]$Y>"$N_YT^8](@)T4LM2$-[QFX2DF
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M 2BN9#$49T^"/P,(@OCSRD2E5P($&'A%_^-$JAIE)F4A%2J+B5(E A48M62
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MRPBX!H\*P+/.V!NMR1JS2^J\OGXZ#:O.2L+)/1OKXE%*)IF,[*+<9).)Q;R
MHTA(F>+T"S2E&A*)*[N6TQ(VXE)LJ,*WD(2,K:?(#+0A NE,;+3AS%J-(B:]
MTM,O/+<C*,>^AFIH,+6@^C#4K\KKC$)#M:1KJ$BA&BXYKLXC<+[(U'33*H22
M4Y0S,:&;*<RXW$QR-49?C;6IN%+4CD7'2/1JO@$)-&BK\U"LE$#.##-+10ZY
M70B_;L$-%R2V[BKH,0YG--"Q\H#=:C:ULG4V3W=7,C(NIL ;J*W-" /_4J_;
M/K3KMK<X<Y8D.*VTLL) _3/HT/4TVNX\R>@\*B_%E&TRV=/H2^J@A1E%;Z:$
M/78XKZ2"@\V@:$V-R6.6":M-4"G_!2QFYCS]+=J'3)N8YI@'HJA1CPT+RK04
M)[0S,Y6[=+CHD<"J,%HW YYJIK[<2Z[&%&,R#>NN^=HT3NUR?G(AKW_+E##-
MJIJIPLYL'9G+2O>JLV*BP8(MO63W2@M*HGVU."/0* I1W&Z_/5SQ#7'RT-N_
M%!.M0WKUBHI:J(6>]ETX7]SN7+KZ%>Y&0HM#UJ&O%N21K[PZ?4MMGK>CFDF5
M]3Q2VFOY7-E9T77+B[FF*_O:X2C!I(AEVV;+_WQ!OR9L;ODX]0U:/X_96COF
M$I/T2_"2)]29\R Q"^K127W]2_N,#%3>T8-*SEZ^/XU'KNN.Z[1>9;4.U-A*
MKB>S./+9SN(=JRG$/4H27=$,8Q"<:>Q?&-D9[@I"(MIQ1G49V5*##@4= P&'
M1WF:W_5 N+/%92AQ(S0AM_#E'.;M2$3(^M&;,I*7<XUE4D$#$KY<E,(3N:TI
M4*J<YR"%*=W8*R9[2PW"A!8UK""0(\BBW&2F4C3N_(MM03L+HKP%GK!8+5#G
M"\WY3!9![:SD;/'AWPJY]IJ@^*QW'.SB4?C%P(MPCUUM1)KVDM>VRNDG<_W3
M2]W\B)@F?1$V@Z&: O^-=S4LJLD^>SNDK CGM*N9!%(*,=S&#H6^\+DJD&-Q
MH SUZ$G!T0I,KU%*R027D*KY)CH+&\SQ3AA+6<Z2)F_"'U 80T"QB"@WD+J,
M5>*H*0/-B&Y T4]7LD(CL: .==<93O[,-:U8>65&5#$=W :3+MB=CDHM4\RF
M?'@IX/QLBQ[*WL(.I:=EV>EFF!'.F1))J&>1KW'Q)!=S G:>(::22)7K8=O2
M5Z?IA*E5B[D/KBHUK]?8*'D<HU6.7I0^(;[(4(LJI0.E5+?9R8AZ_@I+*M,3
M)H*)1W_-8LT>@\;)=A)G,)<,'A.#U%"*V<9MU"(@V_;H1F)A<6-3@TS)RE/_
MQB JJ7X@^QXM;X)4I1J%0>L1$(3V4\*<-!6JZK&=A;CS2ZA2U:E.Y:H^5S4M
M!:I&-;%!SS$)J*YPJ@8^PW*KL8R8FOZ8C)H"2X]EXF2;4M55H0G2UIOV6BK;
MQ(A-X5F98WIWR:YTBH/LJ9E0()<K@HTT.!83&#5=^"]C6LQY-=*.8+/&5UT>
MBZ.;==VV+'N5SQ8G*Y])74)%RY0W509%!'//9OLE62&E")>:@9%AHZ0<(;E(
M29?%$RYM)##H.0I@A=D5*]N2)"[]=BJ1>AVC@"0L:Q6N7$NUB52]&U[Q1DAR
MY3V(>=%;HO2N][SM!6"OL.)>^4K.1^P=WD[<\A#\_RR/O_J=KRJS6%_Y#L^\
M ;X(SPZ4'0!OI+_I%? ?Z5NQ#UTDJ (N[W  5&")_)&,"HR<CSB\80=C&$H7
M#M!OH*E/!*%82PE^YA]5K)Z5I/B9C7OFQ&XLJJ<0T(CXW(]WI(-BIT H3,19
MS758(SZGX(<_)OD=>7XW(/".U\!4MK*5D[FJJ$1E*UWN5*> $F8O@WG,6@[K
MEW%)YC./Z,MM=O.;X;S;*\_YN\ 2R92Y=6<Z7WE_>_;SGP$=:$&C!#K+*?2A
M#9UH1"]:T<-2=*,9'>E'2_K0@[8T?6K471/B^=+@\B6G.QUJ08-:U*4V]:E1
MG6I5TS+&JW9UH$G]ZG#ME_^I*'F>>A=,ZRHSV+^[!O&!IZJ36,^ZU^,J=E)/
MHFM@+]N[P_Z(LCU][ 7?U]B^+A&UL3UM;?_ZV=+F]K;][.P_DUK<+DE<N66=
M;G6OF]WM=O>[%1<FE "L6V4I2H^2W9CZH'LCP+2JH:%)'\=ZM\(K"R>&-)V0
M@]NDA\]IF D7#I%S8[@GZ&%J@L'-D\-D&]X=IS*_QVN<H_IDY!@RGGYZQVER
M#16KWB8TG@BG)6Q)_))(W5GR$EYM!J/RB!=:C53Z%'%/\WSG!R>4QFF*]*LD
M4>@T6=V_7N=QJ4^]6^B,.LW1+=5#PJ1[A/:=SKXE86L;A$0.H3=JP[<X4N]-
M9>;_C@FO+0+MC"LI0$(#KW]THW60)-#:X;3C2SXR*+S;>JRG(1'?/U24NV,E
M)DTC/-4AS[A43]961QK/FI[#=D,!F>)'QO1EBH-RWZ044(#I+G$/5)BG0EW(
M#X?C,*F)&2"1RT$,:;R0(Q?4%S-H>:V?>( /E$*6-*S@T(1/U .NREMW6^(F
MZQW* YZ_K?/SVW&'^]SI@S!F;[_M/.F91WG6](=TWW^1-__YD8Y-QER&FB*$
M(D7Q.1\5L0DY& P3A2JE.\/XQHD#XMQ7CB17AJQML*DX<&6P#(_\Z(U0S(-F
MB(4O_$)*NF(R3DE97$=(+"J<S&E),(NC0BIL;(]/WF*=_YBB7)AC74(C*]*F
M5R;CLMK*WZ2%.69K0&"D/6;%,2)F 7&I>S*E.&ZC1M B3VCC: 0&8SRH(7#+
MZK*G"%.C1U1+3$I/.])#RKP&+;X)8YQL]!Y#1F30G4SC,QK$\:!C2M##4 8.
M_="PEE2M8M2D0I:L51#);%2&2O+&BF1,*&P/C.J%(7SK4O2DQ+J"Q1KJCEJJ
MAS(K6OAE^MQ(=_K&18)G+'"*?P[#E:I(,58CA7I.$@-(D[9H8U[I2U+)<#0*
M;[(%[+IH!#,)>#*E3:AGC3)GF@S*2M3&ZM[EM;9D9GKH#0M+DUID4]A$B58H
M5#X05[)%=$Z/HUCD*00E.1(Q__\<)4F((YVP"8V@IVZ0+$&XJV[@D%[B*@V]
MT=Q.C1;[1S9:;8!22W"VQFUP*P_M1FV21'9FIL9H;F[4!0YQI]!0CC>0A9S8
M,9HB0X- Z#I*QA=79#]4Q.J<I> 6 BQ:Q)+.@L>>A)&J!QX'9R&S12':YVJB
MI'X@J2*+R[/0R$J 4#9ZAAIMYHR.[K$F<CO 0F'@"8Y$2<( )V:@HU<^[&/6
MR $IZ?V>:6?F9A$=J5G$B4'NZ$4,8T&^;Q 5**/8[XK& CB6[QNETN5"C0W[
M2(2PT3FJ9%% ,D+$*IK,A7?6Q)*2!BM7)GVJHB43R@[[[ #S4!%!"*74YJ48
M:5@,Q@__6[%RIHQ/6.DM@V(.*S!*4NI\W*]_TL0T1J/"HF4.WRD9'8;H#HE2
M[H*1&**>/#(N_2B3Q*>;&LK]VM D?G)AE$3.^$DR \8MZX0] +/\Z*0M-R8L
M>I![XB?[VBJ;:,1:IC(W.PY0*#*=BM)N:$8T5:2V-E$H;LHD5P@>OZD^;.=H
MW)"[A.EZCF[CQDF,G*2,I$5.[N1Z/B6QVJE_VE!N9.C:HBD'01-J(-(H 6DE
M!_&2D&QZCHDWF@:6WG--QO.01/)GMJ3Q%)$]>*/[9-(QH],E@>8HKC"0NJE
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G2(55:(57B(59J(5;R(5=Z(5?"(9A*(9C2(9E:(9GB(9I&&8! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex10-15_img05.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-15_img05.gif
M1TE&.#EA, ,@!'< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     +      P R $AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
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MA81O7G44'AL%PL4$Z@5D3.0BNL)X.BF%K9&V:I*^TK?'S:4L?;S+&.=.E[(
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M./==B=0[EN;%V#7)3#L]E\=>J6,D5H?)["O!Y?:L\A7#Q8M,G+FB^I9%_N>
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MS[&OT#$<D[$=NQ@>Y[&(G3$??_$>_[$@#_* !3(A'S(B*UDB+S(C%[$A-W*
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MY37O1\9[7O6NE[WI9>][X1M?^<Z7OO55BWOMFU_]_^(6O_OU[W]EVU\ #YC
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M,"<](E(D#Q:I4!J_+R0XQ/F*T.9 [R)&+X+.,C8LT/+8LBT39BMAL2KE4NS
M<BXI BY]A67J[#(NZ;(O[](M 3,P!7,P";,P#?,P$3,Q%7,Q&;,Q'?,Q(3,R
M)7,R*;,R+?,R,3,S-7,S.;,S/?,S03,T17,T2;,T3?,T43,U57,U6;,U7?,U
K83,V97,V:;,V;?,V<3,W=7,W>;,W??,W@3,XA7,XB;,XC?,XD5/E @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ex10-15_img06.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-15_img06.gif
M1TE&.#EA, ,@!'< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     +      P R $AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
M_YDS )DS,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF9
M9IF9F9F9S)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G_
M_\P  ,P ,\P 9LP F<P S,P _\PS ,PS,\PS9LPSF<PSS,PS_\QF ,QF,\QF
M9LQFF<QFS,QF_\R9 ,R9,\R99LR9F<R9S,R9_\S, ,S,,\S,9LS,F<S,S,S,
M_\S_ ,S_,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\S /\S,_\S
M9O\SF?\SS/\S__]F /]F,_]F9O]FF?]FS/]F__^9 /^9,_^99O^9F?^9S/^9
M___, /_,,__,9O_,F?_,S/_,____ /__,___9O__F?__S/___P$" P$" P$"
M P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$"
M P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$" P$"
M P$" P$" P$" P$" P$" P$" PC_ +$)'$BPH,&#"!,J7,BPH<.'$"-*G$BQ
MHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7,&/*G$FSILV;.'/JW,FS
MI\^?0(,*'4JT*,E61I,J7<JTJ=.G4*-*G4JUJM6K6+-JW<JUJ]>O8,.*'4L6
M(=*R:-.J7<NV+=JS;N/*G4NWKEV9<._JW<NWK]^_K?+^'4RXL.'#4P4C7LRX
ML>/'+<\JADRYLN7+F M.SLRYL^?/>C>#'DVZM&FLHD^K7LVZ=<_4KF/+GDU[
M).S:N'/KWJWP-N_?P(.K]BV\N/'CE"4C7\Z\^6+BSJ-+G_Z6NO7KV,5"S\Z]
MNW>AV[^+_Q]//F;X\NC3JP]Y?KW[]_ =MH]/OSY]Y?;SZ]^/;3[__P!2YU^
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M%<6HV:!6.:?]K(<<_*%"]V>SK:6+GWI*(/3.LDWM3<U_+ATH7 C8T<4MKJ4
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MI75"A:?ALVY"E!Y6U8U0!L6( T6Y;*F\[@O>(TM1G[B(HA/LF%E04IJW#/2
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0>,='^W&."_K2F-YR0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>txmd10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd10k001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" $Y DH# 2(  A$! Q$!_\0
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MM:B@#)_X3W0_^@UI/_@7'_C1_P )[H?_ $&M)_\  N/_ !K6HH R?^$]T/\
MZ#6D_P#@7'_C1_PGNA_]!K2?_ N/_&M:B@#)_P"$]T/_ *#6D_\ @7'_ (T?
M\)[H?_0:TG_P+C_QK6HH R?^$]T/_H-:3_X%Q_XT?\)[H?\ T&M)_P# N/\
MQK6HH R?^$]T/_H-:3_X%Q_XT?\ ">Z'_P!!K2?_  +C_P :UJ* ,G_A/=#_
M .@UI/\ X%Q_XT?\)[H?_0:TG_P+C_QK6HH R?\ A/=#_P"@UI/_ (%Q_P"-
M'_">Z'_T&M)_\"X_\:UJ* ,G_A/=#_Z#6D_^!<?^-'_">Z'_ -!K2?\ P+C_
M ,:UJ* ,G_A/=#_Z#6D_^!<?^-'_  GNA_\ 0:TG_P "X_\ &M:B@#)_X3W0
M_P#H-:3_ .!<?^-'_">Z'_T&M)_\"X_\:UJ* ,G_ (3W0_\ H-:3_P"!<?\
MC1_PGNA_]!K2?_ N/_&M:B@#)_X3W0_^@UI/_@7'_C1_PGNA_P#0:TG_ ,"X
M_P#&M:B@#)_X3W0_^@UI/_@7'_C1_P )[H?_ $&M)_\  N/_ !K6HH R?^$]
MT/\ Z#6D_P#@7'_C1_PGNA_]!K2?_ N/_&M:B@#)_P"$]T/_ *#6D_\ @7'_
M (T?\)[H?_0:TG_P+C_QK6HH R?^$]T/_H-:3_X%Q_XT?\)[H?\ T&M)_P#
MN/\ QK6HH R?^$]T/_H-:3_X%Q_XT?\ ">Z'_P!!K2?_  +C_P :UJ* ,G_A
M/=#_ .@UI/\ X%Q_XT?\)[H?_0:TG_P+C_QK6HH R?\ A/=#_P"@UI/_ (%Q
M_P"-'_">Z'_T&M)_\"X_\:UJ* ,G_A/=#_Z#6D_^!<?^-'_">Z'_ -!G2?\
MP+C_ ,:UJP?BE_R3+Q%_V"[G_P!%-0!O4444 %9/C3_D#P_]?]G_ .E,5:U9
M/C3_ ) \/_7_ &?_ *4Q4 :U%%% !1110 4444 %%%% !1110 4444 %%%%
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M_9O*N);.(2R^3JVGZF,D=-SZ=%&<?PG/517T_0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6#\4O^29>(O^P7<_\ HIJW
MJP?BE_R3+Q%_V"[G_P!%-0!O4444 %9/C3_D#P_]?]G_ .E,5:U9/C3_ ) \
M/_7_ &?_ *4Q4 :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!\R_&G]AKQ1\6/C%K_CN+QX=/U>:X@L
M=&L!:@:?;Z0-/N+22&X>,1WC2F34-2N 8;F(;FMAP8A)7+^$/^"=_C+19?!_
MG>)?#D": ]Q%F#3X&:PM99B[PQ@6R([NK./.A6SD!8&1KD#:?L*B@#XO\!_\
M$Q]>N?$&HZIXXU;PMKD]SJ>BW-M MO-/%:P6,7A^"X0&7O<Q:/<!@ !MO3&=
MR[R^9_PZO\7P7]^S>-K/4K62&Q^R03#R1;16UI8VW]F@B%V-H6M&N%65I;<2
MS'?9RX8R?<=% 'RO\9?V,[SXI_##X%>"=7\7>&_[6^'6K6NI:C$UNMNNM6\5
MG<6LD,,$>T*K+*1PH7"M\JCY1SUK_P $R=7TKXD7VLV^K>''MVNM7328FMW1
MO#UG>7<-Q$EMA2%\N.WCM]B;%\MS@X0(W<_M.?LT>)/BQ\5/$MSI6A>&[B/Q
M+X=T72;'7[ZY"W/ABYL[_4+A[N)/*9VD074,D6UES)$ S(/FKS;X'?L?_'SP
M7-X>D\8>-]9\5-:1HVI1KX]U*VBFU8-:DZDNU-S6I$=R#8MBW;S4Q F&:@#J
M/V1/V#/&OP*_: /C/Q+XIT+58#I#63VNGVI@$MV^P37> B\R^6C'S#+-C:KS
MS%!(<*S_ ."9.J:<-4NM/\4:+:^+'\;ZGXLM]22&3SK>WGT^9+&T?!#&*+4?
ML]V8\A&,!.-W-8?@K]A;]H!](OX_%7Q5\37]]_8EWY<UCXUU&UAN-=)@\N]5
M(]K16[E7/V;<8(\!5A4,YDC\6?L%_&^U\7>+K_PAXPO-(U;4[.33]%UZ[\<Z
MI,UI:1W>MO!#<V[*XNI/LU]8QI/,TDD)C=U.Z)1* 5M"_P""27C+PWX3DL)/
M&^G>(]0%U>7TVIZE%$)M;N+R:6=Y;E#:R1R-#),WEBZ%XH3*Q+:DJR==KW_!
M.I/&^KZ?=7NN>#;MAXE74WFBM=G]JR'5="O;[,8)"RRP:5?6K+N?,=QAFVM(
ME=A^RK^S+\0_AAXL\4ZKXT\0^(/%%C<^&K?2]$TC4?%M[?PPR_;-3FN1*LA*
M%Y(Y;%!/)YLJK&4#[%PWEVE?L!^.M4T6QO;CPKX'T;6+^\6>]L;2]$5AX;DC
MNM$DBETU4A)PMKI2PC=L=Y88Y&VK*PB &)_P3$U>^U"V@N/'FA7VC'6M.EBC
M.U3';6<EL)-&3;'YK6YCMI'$9G\I9'/^C[E$H]0^#7[!>J?"KX>?&?0(-8TB
MRN/B9;7=MIVL6,#I<Z3'(+N*UA*C:3':P2P+'MD&-K*H0*I/FNA?L"^-=4T.
MUN9_!W@3PSJVH)=VUQ8V5\!IWAEI'T46=SIZI!EFM+?2BH=@DDLQ5_W2/LA^
MYZ /E_X6?L"3>#_&?Q%\0W,'@6RG\=^&YM MM(M-,:?3-#BD9S]F4'RVEM68
MB62,>4'DEEP$!&*/@G_@G[KFI_ WPSX>\6ZUIYU32+F_C6ZB>34+G3=/NM"N
M],-I%>S@3SXFN?M&Z7IQ'R(T-?5U% 'R=%^PAXSUCXA:_K^IZWX5@/CW6?#.
MJ:_!:03.-.70;BRGMULV;&XS_97#[POE>:A4R>5^\^L:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'XI?\DR
M\1?]@NY_]%-6]6#\4O\ DF7B+_L%W/\ Z*:@#>HHHH *R?&G_('A_P"O^S_]
M*8JUJR?&G_('A_Z_[/\ ]*8J -:BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K!^*7_),O$7_ &"[G_T4U;U8/Q2_Y)EX
MB_[!=S_Z*:@#>HHHH *R?&G_ "!X?^O^S_\ 2F*M:LGQI_R!X?\ K_L__2F*
M@#Y/^,G[+/B;Q-^U+_PDL'@;4=7\#S2SMXNT-]5LI(_&/!%B\/F2QM*(F=9'
MBO2J0_9T2VRI<23_ +%O[.WQ1^!>I^'Y_&5E?:UXHM_#<NC^)O$T.IP77_"1
M74KZ8+.<F65994L8H;Q&,J*WSL8ED,SBOK^B@#X&T#]B[XFV5IIZIX:N+&&+
M1UM+.W_MFW8Z/XF\O30_B4L)CD,T%V2REKA][EHO])EK[5^+_B:^\$_##7];
MTXVGVK1M/N+]4N8FDCE\J)GV$*RD9VXSGCT-=)7'?M$?\F_^.?\ L7K_ /\
M2:2@"EIEO\3)K")YM3\"M(ZAB4TNZ4<\]#<'^=3_ &/XC_\ 01\$_P#@MNO_
M (_78:9_R#;?_KDO\A4] '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^
M"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]%
M '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\
M]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."V
MZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__
M $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^
M"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]%
M '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\
M]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."V
MZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__
M $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^
M"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]%
M '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\
M]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."V
MZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__
M $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^
M"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]%
M '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\
M]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."V
MZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__
M $$?!/\ X+;K_P"/UV]% '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^
M"VZ_^/UV]% '$?8_B/\ ]!'P3_X+;K_X_1]C^(__ $$?!/\ X+;K_P"/UV]%
M '$?8_B/_P!!'P3_ ."VZ_\ C]'V/XC_ /01\$_^"VZ_^/UV]% '$?8_B/\
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M1_X&R?\ QJM>B@#(^U:]_P ^6D?^!LG_ ,:H^U:]_P ^6D?^!LG_ ,:K7HH
MR/M6O?\ /EI'_@;)_P#&J/M6O?\ /EI'_@;)_P#&JUZ* ,C[5KW_ #Y:1_X&
MR?\ QJC[5KW_ #Y:1_X&R?\ QJM>B@#(^U:]_P ^6D?^!LG_ ,:H^U:]_P ^
M6D?^!LG_ ,:K7HH R/M6O?\ /EI'_@;)_P#&J/M6O?\ /EI'_@;)_P#&JUZ*
M ,C[5KW_ #Y:1_X&R?\ QJC[5KW_ #Y:1_X&R?\ QJM>B@#(^U:]_P ^6D?^
M!LG_ ,:H^U:]_P ^6D?^!LG_ ,:K7HH R/M6O?\ /EI'_@;)_P#&J/M6O?\
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MO?\ /EI'_@;)_P#&JUZ* ,C[5KW_ #Y:1_X&R?\ QJC[5KW_ #Y:1_X&R?\
MQJM>B@#(^U:]_P ^6D?^!LG_ ,:H^U:]_P ^6D?^!LG_ ,:K7HH R/M6O?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#H&:/_ .#.3_XQ1]MU_P#Z!FC_ /@SD_\ C%;%% &/]MU__H&:/_X,Y/\
MXQ1]MU__ *!FC_\ @SD_^,5L44 8_P!MU_\ Z!FC_P#@SD_^,4?;=?\ ^@9H
M_P#X,Y/_ (Q6Q10!C_;=?_Z!FC_^#.3_ .,4?;=?_P"@9H__ (,Y/_C%;%%
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M*G2E[1WE/^9[_P"27DDD6HI:]3'^VZ__ - S1_\ P9R?_&*/MNO_ /0,T?\
M\&<G_P 8K8HKL*,?[;K_ /T#-'_\&<G_ ,8H^VZ__P! S1__  9R?_&*V**
M,?[;K_\ T#-'_P#!G)_\8H^VZ_\ ] S1_P#P9R?_ !BMBB@#'^VZ_P#] S1_
M_!G)_P#&*/MNO_\ 0,T?_P &<G_QBMBB@#'^VZ__ - S1_\ P9R?_&*/MNO_
M /0,T?\ \&<G_P 8K8HH Q_MNO\ _0,T?_P9R?\ QBC[;K__ $#-'_\ !G)_
M\8K8HH \\^.]YKC? _QD)-.TI8_[#O=S+J,C$#[.^2!Y R?Q%=+\4O\ DF7B
M+_L%W/\ Z*:J'Q]_Y(3XU_[ -]_Z3R5?^*7_ "3+Q%_V"[G_ -%-0!O4444
M%9/C3_D#P_\ 7_9_^E,5:U9/C3_D#P_]?]G_ .E,5 &M1110 5QW[1'_ ";_
M ..?^Q>O_P#TFDKL:X[]HC_DW_QS_P!B]?\ _I-)0!U6F?\ (-M_^N2_R%3U
M!IG_ "#;?_KDO\A4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "0GQK_V ;[_ -)Y*O\ Q2_Y)EXB_P"P7<_^BFH WJ*** "LGQI_R!X?^O\
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M>K6HH R?^$CO/^@#JW_?RV_^/4?\)'>?] '5O^_EM_\ 'JUJ* ,G_A([S_H
MZM_W\MO_ (]1_P )'>?] '5O^_EM_P#'JUJ* ,G_ (2.\_Z .K?]_+;_ ./4
M?\)'>?\ 0!U;_OY;?_'JUJ* ,G_A([S_ * .K?\ ?RV_^/4?\)'>?] '5O\
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MLY.O^J\?_$B(]O\ B<+(/_'XS79]9Q?_ #Y_\F15Y=CL_P#A([S_ * .K?\
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MD=Y_T =6_P"_EM_\>H_X2.\_Z .K?]_+;_X]6M10!D_\)'>?] '5O^_EM_\
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M]I(Z;OW@PV2IV\<=ZZ_3_P#@G)\(8;A9]0\-7'B*Y!R9=;U:\U'=]5EE9/\
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MXXYYQZ5C]8K^UY?9OE[W7^9Z/]DY6L#[9XR/M;VY5&=K=_A3_ ^G?^$CO/\
MH ZM_P!_+;_X]1_PD=Y_T =6_P"_EM_\>KR@?LAZ]']SXX?%_/\ M76GL/\
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M+ZPEO%_=_D7_ &1)_!5IO_M]+_TJQ[#_ ,)'>?\ 0!U;_OY;?_'J/^$CO/\
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M* "BBB@ HHHH **** "BBB@ HHHH **** .2^/O_ "0GQK_V ;[_ -)Y*O\
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M_)%=!10!S_\ PF6H_P#0I^(/^_UC_P#)%'_"9:C_ -"GX@_[_6/_ ,D5T%%
M''^)9T\::2]AK'@#4-6L9?OVUXNG3Q/]5:<@_E7C/CG]AKP#X@T_4&T#X=>)
M/ NM7<+1PZGX<U"WT][9R.&\N*[6-@#_  LN",].M?2U%;4L15I?PY-%1G*.
MS/AC]C_]@SXE?LZ>!]3MO^$P\>Z!J-Y?O+';Z+_95QIWEK\JR/%<NV9'4 G;
MMP,*=V,UZI+X _: M6_T7XDZI.OI?>#=&=C_ ,"CO8Q_X[7TG1715S&M4FZD
M[-O^[']47*M*3N_R1\U_\(Y^T>O_ #-^GGW/A*QS_P"G&D'@O]HFZ/[SX@FV
M'?R/!>F,?_'M1/\ *OI6BH^N3[1_\!C_ )"]H_+[D?.4'PI^,E[QJ7Q.^(+)
MW73] \/6GY%I)#^M61^SOKMT/].\8?M WA/W@NOZ5: _3R"A'YU]"44OKE7I
M9>B2_)"]I(^=KC]D#PWK(_XG>C?&+Q'ZC4O'$L@/X+?J*CM/V%OA):3>8?@E
M=74G=[N\@NF/U,EXQ-?1M%'UW$;*;^]A[2?<\/L/V5_AAIH'E_ 31&Q_SUTK
M29?_ $*8UJ1? KP% N$^!FAH/1=%T8?^U:]<HK-XFL]Y/[V+GEW/!_B%^R;\
M-OB3X4O=)O/@G:6:WL1C^U:?8:5:7=N>S1RI,&5@<'T/0@@D5Q_P]_X)S?"G
MP3X$L='N_A-JVO7-LN9M3O;FT%W<R'DL62Z7;[*N ![Y)^J**TCCL3&/)&;2
M]6/VLTK)GSK:_L>>&/#_ /R+N@_%SPH?^H1XT>)?^^6OF7\,8]J+OX*?$C1%
MSX8^(?Q;LF_N:U#H6LQ?^/NDF/\ @>?>OHJBCZY6^T[^MG^=P]I+J?-<.L_M
M.^$6Q%IW@GQG;IR?MMLND7,OT:*[EC!_X#BM?3OVJOB;H-L)/%G[/_C"S0<,
M^@ZQ8:T3CN$61&_#&:]]HI_68OXX)_>OR:7X!SKJCP.^_P""C/@70KI8-:TS
MQGX9F(&Y==T9M+5">Q>X9$S]&-=OX)_:8T+XE*I\.HNN[AD#3]7TNY/Y)=&O
M0Y8UFC9'4,C JRL,@@]C7F/CO]BOX3_$J=IM7^'_ (7FN7.YKB"R6UN&/J9(
MMKY_&E?#2W37W/\ R_,/<9V'_"9:C_T*?B#_ +_6/_R11_PF6H_]"GX@_P"_
MUC_\D5Y9-^PY;>'<?\(9\1?B?X+CC_U5G;ZZ]_8Q_P#;&[$OZ,*GLOAS\=O!
M:_Z%\2?!WC!.@C\0>&6LY /^NMI,HS[^7^%'L*3^"HOFFO\ -?B'+'HSTS_A
M,M1_Z%/Q!_W^L?\ Y(H_X3+4?^A3\0?]_K'_ .2*\QO?BW\;_![;=0^$>A>)
MT'+7'AWQ6B<>T5W%$?\ QXUYK^TA_P %1KS]GWP/'<ZA\)/'6DZU=3K#;)K,
M<4.GR]WQ<Q/("P4'"[<G.>@-73R^M4DHT[-OLU_F4J,I.R/IC_A,M1_Z%/Q!
M_P!_K'_Y(H_X3+4?^A3\0?\ ?ZQ_^2*\J\$?\%'?A-XJ\+:9J-_XD'AF;4+=
M)C:ZS:S6C0%@#MWN@C;K]Y6*GJ#7?>'?VE_ASXNV_P!E^/?!FH%NBV^M6TC?
MD'S64\)7A\4&OD0X26Z-?_A,M1_Z%/Q!_P!_K'_Y(H_X3+4?^A3\0?\ ?ZQ_
M^2*VK'4(-3MQ+;3PW$3='B<.I_$5-7.2<_\ \)EJ/_0I^(/^_P!8_P#R11_P
MF6H_]"GX@_[_ %C_ /)%=!10!S__  F6H_\ 0I^(/^_UC_\ )%'_  F6H_\
M0I^(/^_UC_\ )%=!10!S_P#PF6H_]"GX@_[_ %C_ /)%'_"9:C_T*?B#_O\
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M /)%'_"9:C_T*?B#_O\ 6/\ \D5T%% '/_\ "9:C_P!"GX@_[_6/_P D4?\
M"9:C_P!"GX@_[_6/_P D5T%% '/_ /"9:C_T*?B#_O\ 6/\ \D4?\)EJ/_0I
M^(/^_P!8_P#R17044 >:_'7Q=J$_P1\8HWA?785?0[U3(\MEM0&!^3BX)P/8
M$^U=9\4O^29>(O\ L%W/_HIJH?'W_DA/C7_L WW_ *3R5?\ BE_R3+Q%_P!@
MNY_]%-0!O4444 %9/C3_ ) \/_7_ &?_ *4Q5K5D^-/^0/#_ -?]G_Z4Q4 :
MU%%% !7'?M$?\F_^.?\ L7K_ /\ 2:2NQKCOVB/^3?\ QS_V+U__ .DTE '5
M:9_R#;?_ *Y+_(5/4&F?\@VW_P"N2_R%3T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)?<_Z41LYFY/[P_-R>>:ZR@#@-+_ &A-"_LZ '3O'2D(%(;P5K((('O:U/\
M\-":#_SX>./_  B]8_\ D6NXHH X?_AH30?^?#QQ_P"$7K'_ ,BT?\-":#_S
MX>./_"+UC_Y%KN** .'_ .&A-!_Y\/''_A%ZQ_\ (M00?M&:-+>3QMI/CE(X
MMNR0^#=8(ER,GC[+QCI7&?M+_MBW7[-_C'3M.G\*1ZK;ZTKQ:<8]8CCO;R=8
M7?=]G",4M%E^S6[W#NNR6\A&Q@P)Q?$O[>>I>'M*'D_#/Q#K6J#3/$T_V?2[
MI+I+K4-%FF@;3[8*OVB:2=X<HWD* LB9&XE  >J?\-":#_SX>./_  B]8_\
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M\-":#_SX>./_  B]8_\ D6C_ (:$T'_GP\<?^$7K'_R+7D'@G_@HU!XN\;^
M]'G\&WVDMXRBMVN!<7P>329+BYU"VBC=HXVMRWF:=(#OGCWEP(?M#*RCZ7H
MX?\ X:$T'_GP\<?^$7K'_P BT?\ #0F@_P#/AXX_\(O6/_D6NXHH X?_ (:$
MT'_GP\<?^$7K'_R+1_PT)H/_ #X>./\ PB]8_P#D6NXHH X?_AH30?\ GP\<
M?^$7K'_R+1_PT)H/_/AXX_\ "+UC_P"1:[BB@#A_^&A-!_Y\/''_ (1>L?\
MR+1_PT)H/_/AXX_\(O6/_D6NXKE/C1\0;SX7?#V]URTL-/OA8 2W+ZCJB:98
MV%NOS37-Q<,KE(HXPS$JCMP/EQD@ S+[]HO1;:$-%I7CF=C(B%1X-U@85G 9
MO^/7^$$G\*F_X:$T'_GP\<?^$7K'_P BUXGX:_X*3W/B'X:ZCXG/PP\1V\,/
MAG4/$%GI<M[%%JLTNGQV)O+2>&4(ENT<E]L#&1B?LTQ*J=BOV7P^_;>TGQQ^
MTS/\-7M+&RU(0RR0(-466_S%;6=R6FM0@,,+I=_NI2Y$GDOPO&0#NO\ AH30
M?^?#QQ_X1>L?_(M'_#0F@_\ /AXX_P#"+UC_ .1:[BB@#A_^&A-!_P"?#QQ_
MX1>L?_(M'_#0F@_\^'CC_P (O6/_ )%KN** .'_X:$T'_GP\<?\ A%ZQ_P#(
MM'_#0F@_\^'CC_PB]8_^1:[BB@#A_P#AH30?^?#QQ_X1>L?_ "+1_P -":#_
M ,^'CC_PB]8_^1:[BB@#A_\ AH30?^?#QQ_X1>L?_(M<7K6N_#G6?C=H_C&Y
M\$^*KGQ)IMA/;V^M-X+UCS+5=R 1X^S8)(>3#$94!P"-YST'[3/Q[U+]GSPO
M;ZQ:^%G\166[%R5U&.VD,C2110VEM&59[B\N))0L,0549D8/+&2F_P MUO\
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M'_"S/#W_ $&]+_\  E/\: -RBL/_ (69X>_Z#>E_^!*?XT?\+,\/?]!O2_\
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M&,JM;S*2/*E6OL#_ (0W4?\ H;/$'_?FQ_\ D>C_ (0W4?\ H;/$'_?FQ_\
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MLV=Y83RO9/>Z/'>2VR6^HBX6,QPRE8+>Q6= +CYOM#_A#=1_Z&SQ!_WYL?\
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M@NY_]%-0!O4444 %4/$_A]/%.AS6,D]S;+-M(FMGV2Q%6#!E;!P00.<5?HH
MX3_A1?\ U./CO_P;?_84?\*+_P"IQ\=_^#;_ .PKNZ* .$_X47_U./CO_P &
MW_V%'_"B_P#J<?'?_@V_^PKNZ* .$_X47_U./CO_ ,&W_P!A1_PHO_J<?'?_
M (-O_L*[NB@#A/\ A1?_ %./CO\ \&W_ -A1_P *+_ZG'QW_ .#;_P"PKNZ*
M .$_X47_ -3CX[_\&W_V%'_"B_\ J<?'?_@V_P#L*[NB@#A/^%%_]3CX[_\
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MG'QW_P"#;_["N[HH X3_ (47_P!3CX[_ /!M_P#84?\ "B_^IQ\=_P#@V_\
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FWP'CF4I-XJ\:7,+#;)#-J8>.53U5E*8*D<$=P:[RB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>txmd10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd10k002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %& FH# 2(  A$! Q$!_\0
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MBB@ HK*USQKIGAR[6"\N?)E9!(%\MVRI)&> ?0U3_P"%J:#_ ,__ /Y D_\
MB: .AHKGO^%J:#_S_P#_ ) D_P#B:/\ A:F@_P#/_P#^0)/_ (F@#H:*Y[_A
M:F@_\_\ _P"0)/\ XFC_ (6IH/\ S_\ _D"3_P")H Z&BN>_X6IH/_/_ /\
MD"3_ .)H_P"%J:#_ ,__ /Y D_\ B: .AHKGO^%J:#_S_P#_ ) D_P#B:/\
MA:F@_P#/_P#^0)/_ (F@#H:*Y[_A:F@_\_\ _P"0)/\ XFC_ (6IH/\ S_\
M_D"3_P")H Z&BN>_X6IH/_/_ /\ D"3_ .)H_P"%J:#_ ,__ /Y D_\ B: .
MAHKGO^%J:#_S_P#_ ) D_P#B:/\ A:F@_P#/_P#^0)/_ (F@#H:*Y[_A:F@_
M\_\ _P"0)/\ XFC_ (6IH/\ S_\ _D"3_P")H Z&BN>_X6IH/_/_ /\ D"3_
M .)H_P"%J:#_ ,__ /Y D_\ B: .AHKGO^%J:#_S_P#_ ) D_P#B:/\ A:F@
M_P#/_P#^0)/_ (F@#H:*Y[_A:F@_\_\ _P"0)/\ XFC_ (6IH/\ S_\ _D"3
M_P")H Z&BN>_X6IH/_/_ /\ D"3_ .)H_P"%J:#_ ,__ /Y D_\ B: .AHKG
MO^%J:#_S_P#_ ) D_P#B:/\ A:F@_P#/_P#^0)/_ (F@#H:*Y[_A:F@_\_\
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M_P#_ ) D_P#B:/\ A:F@_P#/_P#^0)/_ (F@#H:*Y[_A:F@_\_\ _P"0)/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU >$UA:.RECL+:TOYX([N&VN)H[>VB_>10WDD8V%$;9$SJ[IOKW>B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#A_C9]_P (_P#8R6?_ +/7<5P_QL^_X1_[&2S_ /9Z[B@
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M]XBU;4+JTDOD-BEN8Q"C1HSDR3(?O2*,8SUXQS3_ /A:=_\ ]"1XP_[YL_\
MY(K)U#_D[;2?^Q1O?_2RTKT:@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0
MD>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/
M_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B
M@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:
M=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1X
MP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\
MY(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?
M_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/
M^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2
M*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_
M /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\
M]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[Y
ML_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_
MX6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0
MD>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/
M_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B
M@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:
M=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1X
MP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\
MY(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?
M_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/
M^^;/_P"2*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2
M*["B@#C_ /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_
M /A:=_\ ]"1XP_[YL_\ Y(H_X6G?_P#0D>,/^^;/_P"2*["B@#C_ /A:=_\
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M ,CWJ/\ UX6G_HRYK7K(L_\ D>]1_P"O"T_]&7-:] !1110!YSJ'_)VVD_\
M8HWO_I9:5Z-7G.H?\G;:3_V*-[_Z66E>C4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG7B8;%8G%UX8G#M?5[/>]Y=I+396LKVOJ^QDI2D^9;'1_&S[_A'_ +&2S_\
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M - 33/\ P:-_\9K>HH P?[6\1_\ 0$TS_P &C?\ QFC^UO$?_0$TS_P:-_\
M&:WJ* ,'^UO$?_0$TS_P:-_\9H_M;Q'_ - 33/\ P:-_\9K>HH P?[6\1_\
M0$TS_P &C?\ QFC^UO$?_0$TS_P:-_\ &:WJ* ,'^UO$?_0$TS_P:-_\9H_M
M;Q'_ - 33/\ P:-_\9K>HH P?[6\1_\ 0$TS_P &C?\ QFC^UO$?_0$TS_P:
M-_\ &:WJ* ,'^UO$?_0$TS_P:-_\9H_M;Q'_ - 33/\ P:-_\9K>HH P?[6\
M1_\ 0$TS_P &C?\ QFC^UO$?_0$TS_P:-_\ &:WJ* ,'^UO$?_0$TS_P:-_\
M9H_M;Q'_ - 33/\ P:-_\9K>HH P?[6\1_\ 0$TS_P &C?\ QFC^UO$?_0$T
MS_P:-_\ &:WJ* ,'^UO$?_0$TS_P:-_\9H_M;Q'_ - 33/\ P:-_\9K>HH P
M?[6\1_\ 0$TS_P &C?\ QFC^UO$?_0$TS_P:-_\ &:WJ* ,'^UO$?_0$TS_P
M:-_\9H_M;Q'_ - 33/\ P:-_\9K>HH P?[6\1_\ 0$TS_P &C?\ QFC^UO$?
M_0$TS_P:-_\ &:WJ* ,'^UO$?_0$TS_P:-_\9H_M;Q'_ - 33/\ P:-_\9K>
MHH P?[6\1_\ 0$TS_P &C?\ QFC^UO$?_0$TS_P:-_\ &:WJ* ,'^UO$?_0$
MTS_P:-_\9H_M;Q'_ - 33/\ P:-_\9K>HH P?[6\1_\ 0$TS_P &C?\ QFC^
MUO$?_0$TS_P:-_\ &:WJ* ,'^UO$?_0$TS_P:-_\9H_M;Q'_ - 33/\ P:-_
M\9K>HH P?[6\1_\ 0$TS_P &C?\ QFC^UO$?_0$TS_P:-_\ &:WJ* ,'^UO$
M?_0$TS_P:-_\9H_M;Q'_ - 33/\ P:-_\9K>HH P?[6\1_\ 0$TS_P &C?\
MQFC^UO$?_0$TS_P:-_\ &:WJ* ,'^UO$?_0$TS_P:-_\9H_M;Q'_ - 33/\
MP:-_\9K>HH P?[6\1_\ 0$TS_P &C?\ QFC^UO$?_0$TS_P:-_\ &:WJ* ,'
M^UO$?_0$TS_P:-_\9H_M;Q'_ - 33/\ P:-_\9K>JKK6N6?AS39+R_NH+.UB
M^_+,X1%SP.3[TFU%7>P'BW[6?QN\4?#KP'#9:?IT=KK6NR&&TDL[E[F:-4PT
MC!?+7M@9SQNSCCCJ/@[\<M1^+OA9;NSTFP6\MML5_:S7[PS6LN,D,AB) /4<
MG([]:C^"VG7/Q%\3WGQ#U2*6);^,VF@6LH_X]+#.?-QV>8@,?]G:,XKGOVRH
MD^'_ (6_X3'19[S2_%P9=/@FLDR;V-\[HY5QA@JAF5B,JRC'6OEYXG$TO:9L
MY7I6^#^ZOM)_S/5I6U32T9AS-7J=#U+^UO$?_0$TS_P:-_\ &:\T_:-N]<^(
M>GV'@!=,M8;OQ1())7@U%F^SVD+J\KM^Z& ?E49R"6Z&J/PE_;2TJZ^&EM=^
M++75](N[.+R)[N2R=K:\F1 2$=00'88.UL<M@9KI_P!GD2_$"[U;XA7@93XD
M80:5#)@M9Z?$2$7C(#.^YV /4CTK>>8X;,J<<-AY7]HO>[J'6ZZ7^%>MUL/G
MC-<L>HOPC^$+? ^UO8?#_AZVMXM0='F27799064$ @-%P<'G'7 ]*7XFW^KW
M/B_X>K>Z;9VL/_"2@[XKTS-G[#>8&TQK_.O3JX7XR_\ (R?#W_L9U_\ 2&\K
MW*&'I4*:I48J,5LEHC5))60[XV??\(_]C)9_^SUW%</\;/O^$?\ L9+/_P!G
MKN*V&%%%% !1110 4444 9%G_P CWJ/_ %X6G_HRYK7K(L_^1[U'_KPM/_1E
MS6O0 4444 ><ZA_R=MI/_8HWO_I9:5Z-7G.H?\G;:3_V*-[_ .EEI7HU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+XG_ .?_ $'_ , )?_CU'V7Q/_S_ .@_^ $O_P >K>HH P?LOB?_ )_]!_\
M "7_ ./4?9?$_P#S_P"@_P#@!+_\>K>HH P?LOB?_G_T'_P E_\ CU'V7Q/_
M ,_^@_\ @!+_ /'JWJ* ,'[+XG_Y_P#0?_ "7_X]1]E\3_\ /_H/_@!+_P#'
MJWJ* ,'[+XG_ .?_ $'_ , )?_CU'V7Q/_S_ .@_^ $O_P >K>HH P?LOB?_
M )_]!_\  "7_ ./4?9?$_P#S_P"@_P#@!+_\>K>HH P?LOB?_G_T'_P E_\
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M_P#@!+_\>K>HH P?LOB?_G_T'_P E_\ CU'V7Q/_ ,_^@_\ @!+_ /'JWJ*
M,'[+XG_Y_P#0?_ "7_X]1]E\3_\ /_H/_@!+_P#'JM^(/&>D^%-%GU'4M1L[
M.QMBRRS2RA54CJO^]QC'7->%>"OVK]?^/'CO7O#G@Q-$M?*=IK+4M1+Y%JH1
M"PA R[ER6&2  PR#BO,QN;X;"SA2J.\Y[16K?R_5Z$2J1B[,]=36=7>>]C&N
M>%_,TTJMVOV63-L64,N_]]\N5(/-<GX6^/$OC+XL7_A+3M:\-7=U8V:78N(;
M9Y(9B3AXU(FP60%">?XC_=->?_#+]C#Q"OQ6N]<\?W/A_P 4V>I;Y+N+S9LM
M-_!($V*AQRN#P QP.!78Q_L/>$]$U1]4T*ZUK0M:5FEM;NVN>+:0YZ)C:5YP
M5Z$9%>7#'9Q74:D*"@E)W4G[SCY:63?KNNQGS5'JD>D?9?$__/\ Z#_X 2__
M !ZC[+XG_P"?_0?_   E_P#CU>:_";]IF\U;XS7/P]\20Z:NLV$!07ME+NAO
M9TRS  _=)C*G;V9''ICVBO;P./HXNFZE%[-I]TUNGYHUC-25T<KK.KZQX<MO
M.U#7/"]E%M9M\]K)&,*I9CS-V4$GV%?/OQ2\"_$+]J_4])UBQL]''AO1YF:P
M6\+VRZJ-P)F,1WMY;@!1N/*Y.!NJW^T#X1\5_M'_ !M,/AZTTR^T3P#/%#)'
M>38M[NY<+)*AX^; "HP[?C7T[:+MM(AY:PX0#RUZ)QT'TKPJL7G$ZN%JJ4:,
M7NOMM/O:UHR3T6^C]<G^\;B]OS.>TW3O$MKIT$:W'AVU6.-5$,=A+LBP/NC$
MH&!TZ5/]E\3_ //_ *#_ . $O_QZMZBOJ$K*QN8/V7Q/_P _^@_^ $O_ ,>H
M^R^)_P#G_P!!_P# "7_X]6]13 P?LOB?_G_T'_P E_\ CU'V7Q/_ ,_^@_\
M@!+_ /'JWJ* ,'[+XG_Y_P#0?_ "7_X]7'_$V#6H_%_P]-_=:7-!_P )*/EM
M[62-\_8;S'+2,,?A7IU<+\9?^1D^'O\ V,Z_^D-Y0 [XV??\(_\ 8R6?_L]=
MQ7#_ !L^_P"$?^QDL_\ V>NXH **** "BBB@ HHHH R+/_D>]1_Z\+3_ -&7
M-:]9%G_R/>H_]>%I_P"C+FM>@ HHHH \YU#_ ).VTG_L4;W_ -++2O1J\YU#
M_D[;2?\ L4;W_P!++2O1J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_:?D3P9+I1MDMOB69?[+CT9^=UV=JB9?6##B0,>J@^AKV6OFGXA_"#XD:O\
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M.[C''Q5H7=XM^_\ RJVEO-7?9'VGXA^#?A_7-::75=4AN]1DVJSW=AIDDS<
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MGQ=^/O\ P4"TCQ7H.M>,K+P[X?MDAM]3NUT6$7DL$ZS*\,"&,+EE0@R$Y3C
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MGCC"A<MGZ4J,76IP;HX23Y/Q?KZ=/Z9G4DE[M/8*\^\+?LH_#7P1XLDUW2?
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M?$3PMX<?2=/\/:-%#JT$ILO#.I2S7J2A@8I+B25$0PHW)"Y7NP(&1=_:X_:
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MG_"MO#O_ $ =&_\  */_ .)H_P"%;>'?^@#HW_@%'_\ $UMT4 8G_"MO#O\
MT =&_P# */\ ^)H_X5MX=_Z .C?^ 4?_ ,36W10!B?\ "MO#O_0!T;_P"C_^
M)H_X5MX=_P"@#HW_ (!1_P#Q-;=% &)_PK;P[_T =&_\ H__ (F@_#3PX3_R
M -%X_P"G*/\ ^)K;HH Q/^%;>'?^@#HW_@%'_P#$T-\-/#C#!T#1<?\ 7E'_
M /$UMT4 8C?#3PXRX.@:+@_].4?_ ,31_P *V\._] '1O_ */_XFMNB@#$_X
M5MX=_P"@#HW_ (!1_P#Q-5/$'P9\*>)]"O--O/#VD26E_ ]O.BVJ(61U*L R
M@$<$\@@BNFHH3:U0'Q-X+_X)CWW['NH:CXQ^'NK6GBS48S,)=!\062?9KZQ)
M5A LJAFCN%VDB7&UC@%5&<\O\/\ ]N:+]MGQ]_PK?P%X*TOP/J&JY:37;VUA
MNI=/M4B#3M'$L>WSMVY4+,%^Z3@G%?H"1FN5\%?!#PE\.?%FMZ[H?A_3-,U?
MQ'()=2NK> ))=,.Y/;)Y(& 6)8Y))KU5F,:BE/%1YI_9?^:V?](W]LG=S5V>
M:_L__P#!.WX8_L[:[>ZII.C'4=1OX(H7N-587;1;5 =DW#Y#(V6?'4G PH"C
MU8?"SPR+@R_\([H?FE0I?[#%N('(&=O3D_G6]17GU:U2K+GJ.[,I2<G=F)_P
MK;P[_P! '1O_  "C_P#B:\O^(W_!/;X3_%/XG0>*]7\*64E_%:O:R0Q9@M[K
M=@+)(B8S(@R%8$$;N<E4*^UT4J5:I3?-3;3\A1DXZH_.O]K#_@F-\1+WXG^'
MM+^'6K7=S\/[N8I]FO\ 4&?^P,KB7S&8^9- 5!"C+$9*8YRWWAHOPE\.:1I%
MM:C0-  MXEC BTZ*.,8 'RK@[1Z#)Q7245T8G'5*\(0G;W?QOW+G5<DD^AB?
M\*V\._\ 0!T;_P  H_\ XFC_ (5MX=_Z .C?^ 4?_P 36W17&9GSK^W'_P $
M]] _:T^']M::?]C\->(-)D,MA>0VP$3[L!HYE4 LIQP>JD9'!8'SWXA?\$B-
M+E_9_G\.>&O&OC*+6(;(1PK>:FS:;=RK\VV2#!"(S#^$_+D'YL8/V917=2S+
M$4X1IPEI%W2-8UII))['S5^Q_P#\$X/"/P*^#T>F^*])T7Q=XDU&$KJ5Y>6B
M7"Q*P -M 77<L2X]BQ); R /:_#'P/\ !W@S0+72]+\+Z%9V%E&(H(4LH\(H
M]R,D^I/)/)KJJ*PKXJK6DY5'>^I$IRD[LQ/^%;>'?^@#HW_@%'_\35;6O@[X
M4\1:/=6%[X;T*XM+R)H9HGL8RLB,,$'CN#7245@FT[HD\+_9I_X)Z?#K]F&Z
MUJXTG3%U2[UBX=Q/J2).]G;ELI;1DCA%P,D_,Q ))P,>L_\ "MO#O_0!T;_P
M"C_^)K;HK6M6J59\]1W8Y2<G=F(WPU\.D?\ (!T;_P  H_\ XFOC?2?^"1,R
M_M;^(_%,_B_5K'P?J0DNX%TRX^R:BTTS$O S*H58D/((&2-HP,$U]QT5KAL9
M5H*2I.W,K,J%24+\O4^$O%'_  27U7X>?'5_B%X%U]-9?2S#?6FC>(9II'U*
M=3B6&:Y5@=C*,J6!!8[7&T'/?:C^WS\(= 5=(U3PE=Z=X_(-N?"DF@@WPO24
M6.V#!/+8R-("CAMK+\V1TKZOKY[^(7_!-GX>?$G]IZQ^)NH6TAN80);S3%XM
M=1NEQY<\G?( Y4<.57/\0;MAC:>(=L?=\JT:W]'Y?CYFJJ*?\7H<Y\/_ /@G
M7H_Q+\567Q!^+&FZ?>>,7NEO%T>Q"KI.FP*K"*S* 8F"%@[.?O.,<KD-]$-\
M*_##F+/AW0SY)W1YL(OD.,9'R\<$C\:W@-HI:\^MB:E5KG>BV71+LC&4W+<^
M.OV\?^"6EM^T;XDT/6_!,^D^$]0CGC@U:*.V6&&YAW'_ $D"-06GC#'&[[PP
M-RXY\[_::^-/Q,_X)\>#?#^BZMX4\$>-M/:6*"S\5R6#K+=Q1'+P74;;@MPZ
M#APY!&X@%@=OZ$U4U?0K+Q!;+#?6EM>1)(DRI/$LBJZ,&1@"#\RL 0>H(!%=
MM',Y6A3Q$5.$>C_SW-8UGHIJZ1P?P*U#PE\=?A#X>\76/AO2+:WU^R2[6![:
M"1H">J%D!7*D$'OQR <@=9_PK;P[_P! '1O_  "C_P#B:^/OV]G\7?L%:9<^
M./A$EQ8:+XCE:'7=.^SK/I6F7#%2E['%G]S+(<HQ"F-CC< Q7/8:1_P5'T;P
M3\%;?6?B7X5\5^"_$S60FCTZ?2+A;?5I-N5%K.R[/F&#AV!7)SG&2I9;4G%5
ML.N:,GHNJ\FOU^>@.BVN:&J9](_\*V\._P#0!T;_ , H_P#XFC_A6WAW_H Z
M-_X!1_\ Q-<[^SM^T?X9_::^%5IXM\.78>QERES%+\LMA,H!>&4=F7(]B"""
M00:P_P!K3]K70?V6O@]<>)+E[;5+Z9%&E:9'=HDVJ2,0%V<Y*#<&9E#84$X-
M<:PU5U?8J/O7M;S,N27-R]3O7^'/AR-<MH6B@#DDV4?'Z5F>#=-\"_$30(M5
MT&T\,:OIL[.D=U:00RQ.58JP# 8X8$'Z5\B_ OXN_%7_ (*D? _5M%N5TGX?
M^&]PLM5URSBN)+G526+F&U4NJQ@*$64L[YW\##$"Y\$?@%XV_P""57@35M=-
MQ:_$/P?<C[7XAM+61K.YT=8B_P#I-LDC^5*#&5WJ=CDJH!(%=TLM4%*G.:55
M/2/?Y[7_ *ZFOL;7BW[W8^PO^%;>'?\ H Z-_P" 4?\ \31_PK;P[_T =&_\
M H__ (FO$?V?/^"GGPJ^/<>JYUVS\*3Z==&&*'7KJ&R:]BS\DT99L$''*YW*
M>HY!/6?!K]N3X;?'?QYX@\.^'O$-M/J'A^78QD81QWR87,MNQ.)$#$J2.XSC
M:RL>2>"Q$+J4&K;Z&;IS6Z/0O^%;>'?^@#HW_@%'_P#$T?\ "MO#O_0!T;_P
M"C_^)KGOAS^TSX'^+/Q!\0>%O#_B"RU+7/##A+^VC/*= 2IZ.JL=K%2=K<'!
MQ74VWC32;SQ7<Z%%J5C)K-G;I=SV*SJ;B*%R521DSN"DJ0#CM6$J<XNTE8EI
MK<K_ /"MO#O_ $ =&_\  */_ .)H_P"%;>'?^@#HW_@%'_\ $UMT5 C$_P"%
M;>'?^@#HW_@%'_\ $T?\*V\._P#0!T;_ , H_P#XFMNB@#$_X5MX=_Z .C?^
M 4?_ ,31_P *V\._] '1O_ */_XFMNC- &)_PK;P[_T =&_\ H__ (FC_A6W
MAW_H Z-_X!1__$UMT4 8G_"MO#O_ $ =&_\  */_ .)H_P"%;>'?^@#HW_@%
M'_\ $UMT4 8G_"MO#O\ T =&_P# */\ ^)KC?BCX/TG0_%WP^FLM+T^SE_X2
M0+O@MDC;'V&\XR!GL*]-KA/C+_R,WP]_[&4?^D-[0 [XW??\(?\ 8RV?_L]=
MS7#?&[[_ (0_[&6S_P#9Z[F@ HHHH **** "BBB@#(L_^1\U'_KPM?\ T9<U
MKUD6?_(^:C_UX6O_ *,N:S/CA\35^#/PB\1>*FM&O_["L9;M;59/+-RZK\L>
M_!VAFP"V#M!S@XH ZJBO%)/VI=;G\+:3':^%=,D\7ZIXJO?"?]GR:VZ:?%<6
MMO=W32?:Q;%RC06C%?W&=\BJ0 "PP?V1?V_K7]K+6M#^R>&YM(T;Q=I6KZMH
M-S+>B6XGCTN_M]/O%N(1&! ?/N8_+VR2;T#$["-I /0K_P#Y.VTG_L4K[_TL
MM*]'KQCQY\5_#'@#]K71VUWQ#HFC(WA:]A#WU]%;KYANK1@F78?,5YQUP,UU
MG_#4?PT_Z*%X(_\ !Y;?_%T =W17"?\ #4?PT_Z*%X(_\'EM_P#%U7OOVLOA
MI926X_X3WP=+Y\HBS'K5L1'P3N;Y^!QU]Q0!Z'17"?\ #4?PT_Z*%X(_\'EM
M_P#%T?\ #4?PT_Z*%X(_\'EM_P#%T =W17GNI?M7_#33M/GN/^$]\&S>1&TG
MEQ:U;,[X&<*-_)/:I_\ AJ/X:?\ 10O!'_@\MO\ XN@#NZ*X3_AJ/X:?]%"\
M$?\ @\MO_BZ/^&H_AI_T4+P1_P"#RV_^+H [NBO/;#]J_P"&E] 7_P"$]\&Q
M8D>/;)K=L"=K%<_?Z'&1[$5/_P -1_#3_HH7@C_P>6W_ ,70!W=%<)_PU'\-
M/^BA>"/_  >6W_Q=06G[5_PTNIKA/^$]\&Q_9Y!'E]:M@)/D5LK\_(^;'U!]
M* /0J*X3_AJ/X:?]%"\$?^#RV_\ BZ/^&H_AI_T4+P1_X/+;_P"+H [NBO/6
M_:O^&BZ@EO\ \)[X-.^-I/,&M6VQ<%1@G?U.[CZ&I_\ AJ/X:?\ 10O!'_@\
MMO\ XN@#NZ*X3_AJ/X:?]%"\$?\ @\MO_BZ@O_VK_AI80!_^$]\&RYD2/;'K
M5L2-S!<_?Z#.3[ T >A45P@_:C^&F/\ DH7@C_P>6W_Q='_#4?PT_P"BA>"/
M_!Y;?_%T =W17!G]J/X: ?\ )0O!'_@\MO\ XNJ^C?M:?#/6-(M;O_A//!]O
M]JA2;RI]:MEEBW*#M8;^&&<$>M 'HE%<)_PU'\-/^BA>"/\ P>6W_P 71_PU
M'\-/^BA>"/\ P>6W_P 70!W=%>>VG[6'PTNY[E/^$]\'1_9I1%N?6K8"3Y%;
M*_/R/FQ]0?2I_P#AJ/X:?]%"\$?^#RV_^+H [NBN$_X:C^&G_10O!'_@\MO_
M (NJ\?[6/PTDU.6V_P"$\\'#RHTD\TZU;>6^XN, [^HV<^FY?6@#T.BN$_X:
MC^&G_10O!'_@\MO_ (NC_AJ/X:?]%"\$?^#RV_\ BZ .[HKSRZ_:R^&EK=VT
M7_">^#G^TN4WIK5L5CPI;+'?P.,?4BK'_#4?PT_Z*%X(_P#!Y;?_ != '=T5
MPG_#4?PT_P"BA>"/_!Y;?_%U!?\ [5_PTL8 _P#PGW@V7,B1[8];MB1N8+G[
M_09R?8&@#T*BN$_X:C^&G_10O!'_ (/+;_XNC_AJ/X:?]%"\$?\ @\MO_BZ
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M"L]3TR\M=1TW48$NK2ZMI5EAN8G4,DB.I*LC*00P)!!!%6\5YW^R_P#!"?\
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M<OVDO#_P'TXOJ":AJFH;?-_LS2XEGO1$(KB9IBA90(UBM;E]Q(W>257<Y5&
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M_L]=S7#?&[[_ (0_[&6S_P#9Z[F@ HHHH **** "BBB@#(L_^1\U'_KPM?\
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MFT^-%@\):E"L0VH$^QKL'3 Q-QQ7G6N_LR>"?$FM7^H7OP]UR:[U-+^.Y?\
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M9(XFN2D$DL=I;[WA5&<Q!B2V6/L__"+?]1'5?_ C_P"M1_PBW_41U7_P(_\
MK51B>*ZM^Q?X UUM4^U^"O'<Z:M'*DD3^+;DPVSRR)+--;Q_;]EM/))&KO-"
M$D9B[%B7<L6G[%/PSBL?$$5W\,];UR7Q38OI^J7FMZO_ &M?743JRL3<W-W)
M,KE&">8KA]D4"[ML,03VK_A%O^HCJO\ X$?_ %J/^$6_ZB.J_P#@1_\ 6H \
MAT7]DSP-X<^,-AXZL/ WBVU\0:7<W-Y;;-?<V,,]RDJW$JV9O#;!Y//F=G$8
M9GFD<G=(Y;KO^%>:/_PB)T+_ (0O6_[+;6CXA,/VR'F^.H_VGYN[[3N_X^_W
MFW.W^'&WY:[#_A%O^HCJO_@1_P#6H_X1;_J(ZK_X$?\ UJ /!;G]@'X477Q,
M?Q>WPR\2C79-8D\0/*OB"589+^0RE[@P"]\HL?-<<I@ @#   WO$W[)O@#QA
MHNJZ=J7PYUNYLM;!6]B.J!1.#<7UR1D78(_>ZE>-P1_KL=$0+ZY_PBW_ %$=
M5_\  C_ZU'_"+?\ 41U7_P "/_K4 >$^'/V#?A;X6NY9K;X;>)Y6NE*7JW?B
M&6ZCU1?+,:)=I+>LMRD89C&LP=8F=V0*S,3/=?L2?#S4CI!O?!7C[4FT6ZAN
MX'OO&%W=-,\%Q!<P+.9+]C<)'-;0ND<V]$*D@#<V?;_^$6_ZB.J_^!'_ -:C
M_A%O^HCJO_@1_P#6H \5L/V+/AUIM[93P_#_ ,6+)9BU5O\ BHY<7JVT-K#;
MK=#[;BZ6-;.W*B<.%9&<?,[LUOX#_LC> OV:=>&I^#O 'B?3[Y;:6S$USKK7
MY$,BV:.@^T7DF!ML+0#T$(QC<V?7_P#A%O\ J(ZK_P"!'_UJ/^$6_P"HCJO_
M ($?_6H \2L_V(_AKIGA?1](M/AUXGL;7P]G^S'M=?D@N;!B+0;XYTO1*KXL
M;8;@V<1GGYWW,T+]ASX:>'-)?3K;X>>+#I$UM:VEQID_B.:?3[M+86RQF:VD
MO6BE8K9VZR.ZLTJHRR%P[AO</^$6_P"HCJO_ ($?_6H_X1;_ *B.J_\ @1_]
M:@#$\"VB_#CP9I6@:5X:\1IIFC6L=E:+<7T-U*L4:A4#2RW#2.0 /F=BQ[DU
MK?\ "4WO_0N:U_W\M/\ X_4O_"+?]1'5?_ C_P"M1_PBW_41U7_P(_\ K4 1
M?\)3>_\ 0N:U_P!_+3_X_1_PE-[_ -"YK7_?RT_^/U+_ ,(M_P!1'5?_  (_
M^M1_PBW_ %$=5_\  C_ZU $+>)[QUP?#>LD'J#):?_'ZY/XG?#;1?C%;6D/B
M'P5K=[%8LSPHE[# %9@ 21'<KD\<9SCG'4UV7_"+?]1'5?\ P(_^M1_PBW_4
M1U7_ ,"/_K5E7H4JT'3K14HOHU=?<Q-)JS,KP^1X7T2TT^R\*ZS':V42P0JT
MUK(R(H 4;FG+'  Y)S7DT'[#?PJ@\1^"-5/PFO9KWX=Z/;Z!H;3WJ3)#96\,
MD,$,J-=%+@1I*^TSARK'<#N 8>W?\(M_U$=5_P# C_ZU'_"+?]1'5?\ P(_^
MM5QBHKEBK(9XSI/[&GPZT#Q!9:A8_#SQ-:"QO5U&.PAUYX]+DN$NGNX99+(7
MGV:5H9GW0EXV\GRXA'M6*,)0^'7["'PO^&2:"MG\-_%&I)X7@AM-(37?$,NM
MIIL$-O+;Q0PK>7LH2)8II%"* OS9QN"D>Z_\(M_U$=5_\"/_ *U'_"+?]1'5
M?_ C_P"M5 >#ZU^P7\,=<L-)M&^'WC"VL]#E@GL[6S\336UJKP.[P%X4OA'+
MY6]D02*P6(+$!Y:J@[3Q5\#?#GC3XG6_B[4/!_BR35K>2VF:.+7##874MLV^
MWEGLTO!;3RQ-ADDEC9E*1D$>6FWT3_A%O^HCJO\ X$?_ %J/^$6_ZB.J_P#@
M1_\ 6H \.7]ASX;)8V=L/ 'C(6^G16R6<0\47 2TEMHHX;>ZC'V["7<44,4:
M72XG5(U42!1BNC^''[./@_X3>-5\1Z#X$\16FN;'22]?5Q/-<A[>VMW\UI+M
MC+N2SMB=^[+Q^8?G+,?3O^$6_P"HCJO_ ($?_6H_X1;_ *B.J_\ @1_]:@#Q
M+Q#^P_\ "[Q7-J<E_P#"[5YY-9CEBO&&J!#,LIU R<K=C!;^U+T$C!(DC&<0
MQ;(/#_["'PL\.:?J]K'\,=?N[?7_ +*-134-;:_%X+:2>2$/Y]X^0&N9B1T;
M?@@@ #W3_A%O^HCJO_@1_P#6H_X1;_J(ZK_X$?\ UJ /&H/V/O T#Y_X0[QZ
MX\VRN=DGBVY>,7%G+:S0W.PWY7S_ #+.W9YL>9*5?>S^9)ON^.OV<='^(_C;
M5=7U30_&B+JCV=X(].UA=+GLKZVBGMQ=P7-K=QSQR26TY@D ?:T:*,8+;O6/
M^$6_ZB.J_P#@1_\ 6H_X1;_J(ZK_ .!'_P!:@#R?PO\ LL>"/!7BW2-8TKP)
MXJL9M#2 6=I'KS_V<KP6PM(IWL_MGV>2=8 L8F>-I,(GS952#X@_LK^!_BGX
MCU34]>\!>)[Y]:W/?6G]N-%87,S6WV7[0UJEX(/M @PBS[/-78A# HI'K'_"
M+?\ 41U7_P "/_K4?\(M_P!1'5?_  (_^M0!Y)H'[*'@3PWJ-K>V_@#Q+)?V
MMPMV+RZULW5S/,JZ@@EEEEO&>5]NJ7HW2%B1*/\ GG'MXKPU_P $XOAKI'A\
MZ=?>#/&VJ1P:A/>Z<S^)9HCHZR7!F$=KLOAY&,1J[1;3+Y2F3<>:^D/^$6_Z
MB.J_^!'_ -:C_A%O^HCJO_@1_P#6H \1TC]AWX7:)\.]#\)P_"[5V\.^'+-M
M/L+&?5!-'';L]H[1OONR9%+6-KG>6R(R.C,&NV/[)/@O3]4T&_\ ^$0\=:A>
M^&+H7VG2:KXKN=2"W"_ZJ259[]Q.8R,Q^;N\LY*;22:]A_X1;_J(ZK_X$?\
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D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>logo_img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? 0X# 2(  A$! Q$!_\0
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M^['*K'\@:FFGAMX]\\J1)G&YV"C]:\-\0:1\/8M)FO?"^N+::K:KYL.VX?\
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;RK_<'.%_4_Y%=/1142DY.[.FE25*"A'H?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>txmd-10k_123120_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:txmd="http://therapeuticsmd.com/20201231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txmd-20201231.xsd" xlink:type="simple"/>
    <context id="From2020-01-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-08</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_VitaminsImvexxyAndBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsImvexxyAndBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_BijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_KnightLicenseAgreementMember_custom_BijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:KnightLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-04</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-03</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-06</instant>
        </period>
    </context>
    <context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-05</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-05</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="From2019-05-062019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-06</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_PerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_PerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_PerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MultipleTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_MultipleTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUSPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ForeignPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ForeignPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticPatentsNonApprovedBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUSPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUSUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUSDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ForeignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ForeignUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ForeignDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTopicalCreamCandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ForeignUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUtilityPatentTx009HRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ForeignPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_DomesticUtilityPatentOperaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">txmd:RepaymentPeriodEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementAmendment8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-27</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period3Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period4Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period5Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period6Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period7Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period7Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period8Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period8Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period9Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period10Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period10Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period11Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period11Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period12Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period12Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period13Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment8Period13Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="AsOf2020-08-05_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-05</instant>
        </period>
    </context>
    <context id="AsOf2021-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2020-11-08_custom_LenderWarrantsMember_custom_FinancingAgreementAmendment6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-08</instant>
        </period>
    </context>
    <context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-01</instant>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-11-092020-11-13_custom_UnderwritingAgreementCantorFitzgeraldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-13</endDate>
        </period>
    </context>
    <context id="AsOf2020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-10</instant>
        </period>
    </context>
    <context id="From2020-11-092020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="From2020-11-092020-11-20_custom_UnderwritingAgreementCantorFitzgeraldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-20</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="From2020-11-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-02-28_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-24</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-05</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember75219000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_WarrantMember75219203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_WarrantMember75219203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_Plan2019Member_custom_PerformanceStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-18</instant>
        </period>
    </context>
    <context id="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-17</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriodIndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_AmericanInternationalGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:AmericanInternationalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SupplierOneConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SupplierOneConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_SupplierOneConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2013-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2013-07-01</instant>
        </period>
    </context>
    <context id="AsOf2018-10-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="AsOf2019-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="AsOf2019-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-01</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CatalentMember75224546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_KnightLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:KnightLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-02-08_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment7Period1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementAmendment7Period2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementCantorFitzgeraldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="N">
        <measure>txmd:Number</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-12-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-12-31">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0038">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_us-gaap_LicenseMember"
      id="xdx2ixbrl0170"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:IncreaseDecreaseInSecurityDeposit
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:WarrantGrantedInRelationToFinancingAgreement
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:WarrantGrantedInRelationToFinancingAgreement
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember"
      id="xdx2ixbrl0588">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember"
      id="xdx2ixbrl0590">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_custom_BijuvaMember"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_custom_AnnoveraMember"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_us-gaap_LicenseMember"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_custom_PerformanceStockUnitsMember"
      id="xdx2ixbrl0748"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31_custom_PerformanceStockUnitsMember"
      id="xdx2ixbrl0750"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0794"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      id="xdx2ixbrl1028"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2020-12-31" id="xdx2ixbrl1634">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="AsOf2019-12-31" id="xdx2ixbrl1635">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="From2020-01-01to2020-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2020-01-01to2020-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-01-01to2020-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-12-31">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-12-31">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-01-01to2020-12-31">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-01-01to2020-12-31">951 Yamato Rd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-01-01to2020-12-31">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-01-01to2020-12-31">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-01-01to2020-12-31">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-01-01to2020-12-31">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-01-01to2020-12-31">(561)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-01-01to2020-12-31">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-01-01to2020-12-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-01-01to2020-12-31">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-01-01to2020-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2020-01-01to2020-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2020-01-01to2020-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityShellCompany>
    <txmd:EntityCommonStockHeldByNonaffiliates contextRef="AsOf2020-06-30" decimals="INF" unitRef="Shares">246062968</txmd:EntityCommonStockHeldByNonaffiliates>
    <dei:EntityPublicFloat contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">307578710</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-03-01" decimals="INF" unitRef="Shares">387825545</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">80485784</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1117854</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">904040</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">32381701</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">24395958</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7993087</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7543397</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">128403969</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">208416180</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1942224</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:LicenseRights contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">36196916</txmd:LicenseRights>
    <txmd:LicenseRights contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">39221308</txmd:LicenseRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5247723</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">9565700</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">253121</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">473009</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">51263460</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">55061682</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">181609653</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">21068327</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">19181212</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">38169869</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">59238196</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">53004825</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">237697531</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8675477</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">246373008</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">203779692</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">305611204</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">256784517</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">299765396</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">299765396</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">299765</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">271177</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">754644100</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">704351222</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-878945416</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-695421279</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-124001551</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">181609653</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">62872280</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">34140537</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">16099460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">64872280</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">49646937</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">16099460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">15974977</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">6334585</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">2737652</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">48897303</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">43312352</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">13361808</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">192963967</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">174112612</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">115988954</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">10431907</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">19792212</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">27299138</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1042170</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">612786</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">293886</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">204438044</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">194517610</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">143581978</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-155540741</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-151205258</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-130220170</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">597647</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">2500106</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">2280844</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">28581043</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">17382215</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">4677834</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-27983396</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-24939741</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-2396990</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-183524137</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-183524137</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.59</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="Shares">275648552</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="Shares">246353318</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="Shares">225026300</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">216429642</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">216430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">516351405</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-386659120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">129908715</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18578430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18578</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">89889219</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">89907797</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5454367</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5455</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1660753</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1666208</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8658561</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">8658561</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">240463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">616559938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-519276280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">29900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">29900</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">77001358</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">77031258</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">814637</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">814</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">107842</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">108656</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10682084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">10682084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">271177</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">704351222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-695421279</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">26953125</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">26953</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">31675682</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">31702635</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1182195</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1182</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">270496</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">271678</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">453000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">453</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-453</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7668161</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">7668161</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10678992</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">10678992</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-183524137</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-183524137</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">299765396</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">299765</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">754644100</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-878945416</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-124001551</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-183524137</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">772624</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">415193</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">181412</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">269546</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">197593</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">112474</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1131776</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">275379</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1405443</txmd:NoncashOperatingLeaseExpense>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">1062318</txmd:NoncashOperatingLeaseExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">213814</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">307438</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">216022</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">136832</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:InventoryWriteDown
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">7204818</us-gaap:InventoryWriteDown>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">10678992</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">10693662</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">8661967</us-gaap:ShareBasedCompensation>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">3024391</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">778692</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">2256429</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">856302</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">269859</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">8199558</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">13639575</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">6951041</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">3337189</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">8593046</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1782312</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-3429443</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">1880048</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">2657190</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1887115</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-3562629</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">18646241</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">2903947</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">13675008</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">9107947</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-159470335</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-165697595</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-106811781</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">20000000</txmd:PaymentsToAcquireIntellectualPropertyLicense>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">20000000</txmd:PaymentsToAcquireIntellectualPropertyLicense>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1390834</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">1441989</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1105407</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">207073</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">2450285</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">217040</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <txmd:IncreaseDecreaseInSecurityDeposit
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-20420</txmd:IncreaseDecreaseInSecurityDeposit>
    <txmd:IncreaseDecreaseInSecurityDeposit
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-175410</txmd:IncreaseDecreaseInSecurityDeposit>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-1597907</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-23912694</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-21497857</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">271678</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">108656</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1666208</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">31702635</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">77031258</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">89907797</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">200000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">75000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1250000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">6652270</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">3786918</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">81660719</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">80724313</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">188826925</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">162787087</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-80343929</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-783364</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">34477449</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">127135628</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">80485784</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">25849236</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">17787903</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1890166</us-gaap:InterestPaidNet>
    <txmd:WarrantGrantedInRelationToFinancingAgreement
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">7668161</txmd:WarrantGrantedInRelationToFinancingAgreement>
    <us-gaap:NatureOfOperations contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80B_eus-gaap--NatureOfOperations_zTDSbu1RScr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;NOTE 1 &#x2013; &lt;span id="xdx_826_z2TojvhJBQk9"&gt;THE COMPANY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;TherapeuticsMD, Inc., a Nevada corporation,
or TherapeuticsMD or the Company, has &lt;span id="xdx_90A_ecustom--NumberOfSubsidiaries_iI_dc_uN_c20201231_zQUiSrPNfplb" title="Number of subsidiaries"&gt;three&lt;/span&gt; wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or
vitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation,
or VitaCare. Unless the context otherwise requires, TherapeuticsMD, vitaMed, BocaGreen, and VitaCare collectively are sometimes
referred to as &#x201c;our company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us.&#x201d; TherapeuticsMD&lt;sup&gt;&#xae;&lt;/sup&gt;,
vitaMedMD&lt;sup&gt;&#xae;&lt;/sup&gt;, BocaGreenMD&lt;sup&gt;&#xae;&lt;/sup&gt;, IMVEXXY&lt;sup&gt;&#xae;&lt;/sup&gt;, BIJUVA&lt;sup&gt;&#xae;&lt;/sup&gt; and ANNOVERA&lt;sup&gt;&#xae;&lt;/sup&gt;
are registered trademarks of our company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Nature of Business&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;We are a women&#x2019;s
healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy
prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership
to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled,
long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also manufacture and distribute branded and
generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. Our portfolio of products focused on women&#x2019;s
health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. During 2018, the
U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products has transitioned our company from predominately
focused on conducting research and development to one focused on commercializing our pharmaceutical products. In July 2018, we
launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal
pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched
our FDA-approved product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#xdf;-estradiol
and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our FDA-approved
product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free,
reversible prescription contraceptive option for women. Although we expected to commence the full commercial launch of ANNOVERA
in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch
of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as the pandemic began to negatively affect our
revenue growth. We resumed the commercial launch of ANNOVERA on July 1, 2020. On July 30, 2018, we entered into an exclusive license
agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize
ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement,
with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and
BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply agreement, or the Theramex License
Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada
and Israel, or the Theramex Territory.&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <txmd:NumberOfSubsidiaries contextRef="AsOf2020-12-31" decimals="INF" unitRef="N">3</txmd:NumberOfSubsidiaries>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zItv4Oy2b268" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 2 &#x2013; &lt;span id="xdx_829_zMY7YMirPiNd"&gt;SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zbWuVh9adzo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zCCnWITYyUYi"&gt;Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial
statements include the accounts of our company and our wholly owned subsidiaries, vitaMed, BocaGreen and VitaCare. All intercompany
balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxel2fnrUmS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zdZGAt846502"&gt;Risks and Uncertainties&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We continue to be subject to risks and
uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues
to be highly uncertain and difficult to predict. We continue to provide an uninterrupted supply of our portfolio of products for
patients. We have sufficient inventory of finished product to meet anticipated demand in the near future. Additionally, we currently
do not foresee any interruption in our ability to continue to manufacture additional product to be used beyond this period and
have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products. During the year ended
December 31, 2020, we recorded an inventory charge of $&lt;span id="xdx_90F_eus-gaap--InventoryWriteDown_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_z3beEO1Oq3Rb"&gt;7,204,818&lt;/span&gt;&#160;which was primarily related to BIJUVA and resulted from the
impact of the COVID-19 pandemic on our business, which decreased demand for our products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Since the early phase of the COVID-19 pandemic,
we have been using substantial virtual options to ensure business continuity. Our VitaCare Prescription Services patient model
assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice,
including via home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple
third-party online pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time
access to both diagnosis and treatment. We continue to support prescribers&#x2019; needs with samples and product materials through
our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for live virtual e-detailing of our products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of our response to the COVID-19
pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented cost saving measures, which included
negotiating lower fees or suspending services from third party vendors; implementing a company-wide hiring restriction; delaying
or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event
expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The full impact of the COVID-19 pandemic
continues to evolve. However, we remain committed to the execution of our corporate goals, despite the ongoing COVID-19 pandemic,
as demonstrated in part by the increase in product revenue throughout 2020. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity,
or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our operations by monitoring
the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic
has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression
that has occurred or may occur in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;While we currently believe that our COVID-19
contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of
the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity
of the pandemic, the duration of &#x201c;social distancing&#x201d; orders, the ability of our sales force to access healthcare providers
to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients,
thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are uncertain.
Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable
amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs
that we may undertake to address financial and operations challenges that we may face.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--LiquidityPolicyTextBlock_zBQndKwXmNy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zvBKo3cmFt66"&gt;&lt;span style="text-decoration: underline"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the filing date of this Annual
Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement (as defined in Note 8 -
Debt). On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement, or Amendment No.
6, with the Administrative Agent (as defined in Note 8 - Debt) and the lenders party thereto, pursuant to which we
temporarily lowered the minimum required cash balance from $&lt;span id="xdx_907_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z6zi29hmeiHl"&gt;60&lt;/span&gt;
million to $&lt;span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z8O7p4TL3t4e"&gt;45&lt;/span&gt; million through December 31, 2020. After December 31, 2020, the minimum cash balance reverted to $&lt;span id="xdx_908_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201231_zHQCHcqSC1ej"&gt;60&lt;/span&gt;
million. Based on our current projections, and recent equity financings, we anticipate that we will remain in compliance with
the minimum cash balance covenant for the next twelve months from the issuance of these financial statements. In addition, we
have reviewed numerous potential scenarios in connection with the impact of COVID-19 pandemic on our business and we believe
that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary course of business for the next
twelve months from the issuance of these financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However, if we are unsuccessful with the
commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if commercialization is delayed, or if the continued impact of the COVID-19
pandemic on our business is worse than we anticipate, our existing cash reserves may be insufficient to maintain compliance with
the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY,
BIJUVA, and ANNOVERA. The Financing Agreement also requires us to maintain certain minimum quarterly product net revenue requirements
and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA were revised. See Note 8 &#x2013; Debt &#x2013; for a description
of these covenants. These and other terms in the Financing Agreement have to be monitored closely for compliance
and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.
If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements,
or otherwise comply with the covenants of the Financing Agreement, all or a portion of our obligations under the Financing Agreement
may be declared immediately due and payable, which would have a material adverse effect on our business, results of operations
and financial condition.&lt;/p&gt;

&lt;p id="xdx_858_zLVm9OdIocal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQduWR076XSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z0kdb43Ciy2g"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We maintain cash at financial institutions
that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20201231_zQ3AOk9yMPC4" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per bank. We have never
experienced any losses related to these funds.&lt;/p&gt;

&lt;p id="xdx_85B_zuuw5lOMJAxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_84A_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z0PXW0Wks4q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zoeKDk3UUjUg"&gt;Trade Accounts Receivable and Allowance
for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are customer
obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks
and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection
information, reasonable supportable forecasts, and existing economic conditions and we record an allowance that presents the net
amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent receivables against
our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances
of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful
accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves
may be required. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws,
coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption
associated with the current COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced
significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying
amount of trade receivables in the future. At December 31, 2020, four different customers represented &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeMcWBPAkK27" title="Concentration risk percentage"&gt;25&lt;/span&gt;%, &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zFblFmC1C4tf"&gt;19&lt;/span&gt;%, &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJYlkjf6rLea"&gt;17&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zrz7FpodhDjb"&gt;11&lt;/span&gt;% of
our gross accounts receivable. At December 31, 2019, four different customers represented &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zQd80LlYI9Lb"&gt;36&lt;/span&gt;%, &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zTuZYhyAeing"&gt;21&lt;/span&gt;%,&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zUl1Y7LTCLuh"&gt;16&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zwAnBdJ6IQNc"&gt;11&lt;/span&gt;% of our gross accounts
receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zr4gbPw0pdZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for Doubtful Accounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 33%"&gt;Balance - January 1, 2020&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20200101__20201231_zkKUwDVtxyf2" style="width: 12%; text-align: right" title="Balance at beginning"&gt;904,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Increase in allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--IncreaseInAllowanceForDoubtfulAccountsReceivable_c20200101__20201231_z2ElkvKerBU5" style="text-align: right" title="Increase in allowance"&gt;422,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Recoveries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_iN_di_c20200101__20201231_zqIFO0vWPGR5" style="text-align: right" title="Recoveries"&gt;(181,514&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Write-offs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20200101__20201231_zo2AETyNBur8" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs"&gt;(26,809&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance - December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20200101__20201231_z98bXEewnbJ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;1,117,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zU3AskfXE1Nd" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zA9T6GNGbCQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zNPe8jcvuR3d"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories represent pharmaceutical products,
packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products
are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for
excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value.
Obsolescence may occur due to product expiring, product improvements rendering previous versions obsolete, or decreases in demand
for our products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Pre-Launch Inventory&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pre-launch inventory costs associated with
product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial
use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined,
then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during
the period the costs are incurred. We have not capitalized any pre-launch inventory to date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Inventory Write-Off&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We evaluate inventory quarterly for short
dated and excess inventory. During the years ended December 31, 2020 and December 31, 2019, we recorded an inventory charge of
$&lt;span id="xdx_902_eus-gaap--InventoryWriteDown_c20200101__20201231_zfLrLmKKSFud" title="Inventory charge"&gt;7,204,818&lt;/span&gt;&#160;and $&lt;span id="xdx_905_eus-gaap--InventoryWriteDown_c20190101__20191231_znwcXFB4i4a4" title="Inventory charge"&gt;0&lt;/span&gt;, respectively. The charge recorded during the year ended December 31, 2020 was primarily related to BIJUVA
and resulted from the impact of the COVID-19 pandemic on our business, which decreased demand for our products.&lt;/p&gt;

&lt;p id="xdx_856_zfohqwWieDZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zLEBTqL1leIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zODjpnlN2nFa"&gt;Cost of Sales&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of sales includes the cost of inventory,
manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. The Population Council License
Agreement requires payment of royalties based on the sale of future products. Such royalties are recorded as a component of cost
of sales. Additionally, the amortization of license fees or milestone payments related to licensed products are classified as components
of cost of sales to the extent such payments become due in the future.&lt;/p&gt;

&lt;p id="xdx_850_zBo09VWnaBog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxr4m9jKAlg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zqMgBOxm7Gkd"&gt;Fixed Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We state fixed assets at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives
of the related assets, which range from &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zwStNlSSdvcc" title="Useful life of assets::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zQYPap4IV4Hh"&gt;seven years&lt;/span&gt;. Leasehold improvements are depreciated over the shorter of their
useful life or the term of the lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We capitalize software and software development
costs incurred to create and acquire computer software for internal use, principally related to software coding and application
development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable
that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized
in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into
service over the estimated useful life, generally &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zz4odzWls18g" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0590"&gt;five&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zXJarThY0hD4"&gt;seven years&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zCOuXAwCqboi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zHNQkewR0Dw8"&gt;Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have adopted the provisions of Financial
Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, &lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;, or
ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications.
In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent
using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December
31, 2020, we had &lt;span id="xdx_908_ecustom--NumberOfIssuedPatentsDomestic_iI_uN_c20201231_zUgBdjjhjVOi" title="Number of issued patents domestic."&gt;38&lt;/span&gt; issued domestic, or U.S., patents and &lt;span id="xdx_90A_ecustom--NumberOfIssuedPatentsForeign_iI_uN_c20201231_zaGjxEbi1Ww2" title="Number of issued patents foreign"&gt;39&lt;/span&gt; issued foreign patents (See Note 6). We capitalize external costs,
consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review
intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1pD2jkvUF3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_z9aHXGYIYrjg"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We review the carrying values of fixed
assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate
that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant declines in an asset&#x2019;s market price;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant deterioration in an asset&#x2019;s physical condition;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant changes in the nature or extent of an asset&#x2019;s use or operation;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant adverse changes in the business climate that could impact an asset&#x2019;s value, including
adverse actions or assessments by regulators;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset&#x2019;s use; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If impairment indicators are present, we
determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value
for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are
largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate
the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate
to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise
of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held
and used. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019;
fair value and respective carrying values. We determine the fair value of the assets using an &#x201c;income approach&#x201d; based
upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We perform impairment tests for intangible
assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change
that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for
assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also evaluate the remaining useful life
of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment
or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#x2019;s remaining useful life is changed,
we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of indefinite-lived assets
is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment
test. During the years ended December 31, 2020 and 2019, we &lt;span style="color: #212529"&gt;wrote off $&lt;span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20200101__20201231_zXt7gpxpg4Qa" title="Write off of patent and trademark cost"&gt;1,131,776&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20190101__20191231_zWv3D9gcdwq8"&gt;78,864&lt;/span&gt;, respectively,&#160;in
costs related to trademarks and patents. &lt;/span&gt;There was no impairment of intangible assets during the year ended December 31,
2018.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z38d8DPCPpkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zlLEgNREqtec"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of December 31, 2020 and
2019 (as disclosed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair Value
Measurements, &lt;/i&gt;or ASC 820&lt;i&gt;. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for
identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 1in; text-align: left"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;unadjusted quoted prices in active markets for identical
assets or liabilities;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 1in; text-align: left"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 1in; text-align: left"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;unobservable inputs for the assets or liabilities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At December 31, 2020 and 2019, we had no assets or liabilities
that were valued at fair value on a recurring basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zBlBozfK2Pa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zjtSmTJjiblk"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recognize both interest and penalties
related to uncertain tax positions as part of the income tax provision. At December 31, 2020 and 2019, we had no tax positions
relating to open tax returns that were considered to be uncertain.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our U.S. federal and state tax returns
since 2011, which was the first year we generated net operating losses, remain open to examination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_ziINyPlLXYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zk32UZu6u9Sh"&gt;Share-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, to value
options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our stock-based
awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January 1, 2020, the average
expected life of options was based on the contractual terms of the stock option using the simplified method. We utilize a dividend
yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. In
addition, the terms of the Financing Agreement (See Note 8) preclude us from paying dividends, and any future debt agreements may
also preclude us from paying dividends. The assumptions used in calculating the fair value of stock-based awards represent our
best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.
We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance
with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We grant restricted stock units and performance-based
stock units for shares of common stock, par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20201231_z2GxITWehrV5"&gt;0.001&lt;/span&gt; per share, or Common Stock, to employees. We value our restricted stock
units and our performance-based stock units by reference to our stock price on the date of grant. We recognize compensation expense
for restricted stock units based on a straight-line basis over the requisite service period of the entire award. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the performance restricted stock vests. The number
of target shares that vest are determined based on the level of attainment of the targets. If a minimum level of performance is
attained for the awards, restricted stock is issued based on the level of attainment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgShP7jOATyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zQ2ipGElfXOj"&gt;Revenue Recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 606,&#160;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;, or ASC 606, revenue is recognized when a customer obtains control of promised goods or services.
The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these
goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the
transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for
those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify
the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance
obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription Products&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="color: #212529"&gt;As of December
31, 2020, &lt;/span&gt;our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began
selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we
began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed
the commercial launch of ANNOVERA on July 1, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We sell our name brand and generic prescription
products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription
products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations
related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service
for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription
product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or
service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the
customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on
our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional.
We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services
sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The transaction price of a contract is
the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will
not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that
supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and
the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ
from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would
affect net product revenue and earnings in the period such changes in estimates become known.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of six months prior to and up to &lt;span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z3ySKQtvDA47" title="Return period of unsalable prescription products"&gt;12&lt;/span&gt;
months following product expiration. ANNOVERA cannot be returned before the expiration date and expired ANNOVERA can be
returned up to &lt;span id="xdx_909_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zmR0T8rgRole"&gt;12&lt;/span&gt;
months past the expiration date. Our prescription vitamins, IMVEXXY and BIJUVA currently have a shelf life of &lt;span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--VitaminsImvexxyAndBijuvaMember_zT2KiZyFAJs3" title="Shelf life of prescription products"&gt;24&lt;/span&gt;
months from the date of manufacture and ANNOVERA currently has a shelf life of &lt;span id="xdx_908_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zzAsj5sOc8Ha"&gt;18&lt;/span&gt;
months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of product revenue in the period the related product revenue is recognized. Where historical rates of return exist,
we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched
products, for which the right of return exists but for which we currently do not have history of product returns, we estimate
returns based on available industry data, our own sales information and our visibility into the inventory remaining in the
distribution channel. At the end of each reporting period, we may decide to constrain product revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the
expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic
products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the
customer&#x2019;s consideration. Since our returns primarily consist of expired and short dated products that will not be
resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the
initial sale (when recognition of product revenue is deferred due to the anticipated return). Return estimates are recorded
in other current liabilities on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We offer various rebate and discount programs in an effort to maintain
a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates
and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on
a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenue at the time the product
revenue is recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor
fees are recorded in other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units
sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors
fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates
relating to invoice discounts and chargebacks are deducted from gross product revenue at the time the product revenue is recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of commercial launches for our
FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket
costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with
our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. The variable consideration
is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average
assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time
up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription
products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain
variable consideration for our prescription products to an amount that will not result in a significant product revenue reversal
in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates
of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by
insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently
available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIeQdb0LePU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zIUJyq1Gpgyb" style="width: 12%; text-align: right" title="Net revenue"&gt;9,767,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zm4kXwTPfFzb" style="width: 12%; text-align: right" title="Net revenue"&gt;9,885,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zRSEpLOd3G4l" style="width: 12%; text-align: right" title="Net revenue"&gt;15,041,259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zJfE6V5ja3Mc" style="text-align: right" title="Net revenue"&gt;27,139,387&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zVZkVbCvPFNg" style="text-align: right" title="Net revenue"&gt;16,252,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zvBbyNZlnXLl" style="text-align: right" title="Net revenue"&gt;1,058,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGYUHrnBZE1" style="text-align: right" title="Net revenue"&gt;6,353,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zLSGvlHRufNg" style="text-align: right" title="Net revenue"&gt;1,836,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--BijuvaMember_z1JXyWuYn72d" style="text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayMzasE8eb6" style="text-align: right" title="Net revenue"&gt;19,611,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zYvSCX7ojjG8" style="text-align: right" title="Net revenue"&gt;6,166,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zjpw8uaRoM46" style="text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zydUwtLaPfM1" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zEuVRJerfvu7" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSl8MRsNl7Jf" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_zQyorgOoNb95" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;64,872,280&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_z2VgHc6SD9Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;49,646,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z9pXHF47yUB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;16,099,460&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zf7LBTNOj0Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front
fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the right to use functional intellectual property is transferred to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with the Population
Council&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 30, 2018, we entered into the Population
Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a &#x201c;test and learn&#x201d; market
introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. &lt;span style="color: #212529"&gt;We
resumed the commercial launch of ANNOVERA on July 1, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the terms of the Population Council
License Agreement, we paid the Population Council a milestone payment of $&lt;span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNmM0XbdrIkf" title="Milestone payment upon FDA Approval"&gt;20,000,000&lt;/span&gt;&#160;within 30 days following the approval
by the FDA of the new drug application, or NDA, for ANNOVERA and $&lt;span id="xdx_902_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRlIviFCHJSa" title="Milestone payments (payment after release of first commercial batch)"&gt;20,000,000&lt;/span&gt;&#160;within 30 days following the first commercial
batch release of ANNOVERA. Both milestone payments of $&lt;span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zHvxx9ISU3ic" title="License rights acquired"&gt;20,000,000&#160;&lt;/span&gt;were recorded as license rights in the consolidated balance
sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became commercially available for use.
The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our
cash flows, which is estimated to be the remaining patent life of the product, which expires as early as December 2032. The cost
is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the years
ended December 31, 2020 and 2019 we recorded $&lt;span id="xdx_908_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20201231_zU0ennHdqNG" title="Amortization of intellectual property license fee"&gt;3,024,391&lt;/span&gt;&#160;and $&lt;span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20191231_zoFDDXXJ6XF8" title="Amortization of intellectual property license fee"&gt;778,692&lt;/span&gt;, respectively, in amortization expense related to the
license fee which was recorded as a component of cost of sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Population Council is also eligible
to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible for marketing expenses related
to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based
royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as
follows: (i) if annual net sales are less than or equal to $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zB1xl9STslZj" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zHDWWmUGwgea" title="Royalty (percent)"&gt;5&lt;/span&gt;% of net sales; (ii) for annual net
sales greater than $&lt;span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zT2XmmFVoWge" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;&#160;and less than or equal to $&lt;span id="xdx_90E_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zTAI4ux2XhT6" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zC6XNUaPEozh" title="Royalty (percent)"&gt;10&lt;/span&gt;% of such net sales; and (iii)
for net sales greater than $&lt;span id="xdx_90A_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zt1yVxYQsZOk"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90A_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zBs9xrl0NxU4" title="Royalty (percent)"&gt;15&lt;/span&gt;% of such net sales. The annual royalty rate will be reduced to&#160;&lt;span id="xdx_90D_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zQetXhTVEaka" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"&gt;50&lt;/span&gt;%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent
of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to&#160;&lt;span id="xdx_908_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zXp9UntycC9i" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"&gt;20&lt;/span&gt;%
of the initial rate. We are required to pay the Population Council milestone payments of $&lt;span id="xdx_902_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRb6ERjPJGr9" title="Milestone payments upon specified levels of cumulative net sales"&gt;40&lt;/span&gt;&#160;million&#160;upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $&lt;span id="xdx_904_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z0nEr1VekSOf" title="Specified level one of cumulative net sales for milestone payments"&gt;200&lt;/span&gt;&#160;million, $&lt;span id="xdx_906_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zTUERTX9tZt7" title="Specified level two of cumulative net sales for milestone payments"&gt;400&lt;/span&gt;&#160;million&#160;and
$&lt;span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zUELoe4agUhi" title="Specified level three of cumulative net sales for milestone payments"&gt;1&lt;/span&gt;&#160;billion. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval
studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such
post-approval study exceed $&lt;span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z4kNf57Lbi3k" title="Maximum costs and expenses for post approval"&gt;20,000,000&lt;/span&gt;, half of such excess will be offset against royalties or other payments owed by us to the
Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a joint product
committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible for all
aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired
clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.
The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational
vaginal contraceptive systems in development by the Population Council.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Unless earlier terminated, the Population
Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#x2019;s
U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during
which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may
also be terminated for certain breach and bankruptcy-related events and by us on 180 days&#x2019; prior notice to the Population
Council.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with Knight Therapeutics
Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2018, we entered into the Knight
License Agreement pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.
Pursuant to the terms of the Knight License Agreement, Knight paid us $&lt;span id="xdx_90D_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zUD7dpRngPs2"&gt;2,000,000&lt;/span&gt; in milestone fees upon the first regulatory approval
in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is required to pay us sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory
applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in
Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain
specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement,
Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with Theramex&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="color: #212529"&gt;On June
6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR &lt;span id="xdx_900_ecustom--CashUpfrontPaymentReceived_pn6n6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zJCFLkOukmJf" title="Cash upfront payment received"&gt;14&lt;/span&gt;
million, or $&lt;span id="xdx_902_ecustom--CashUpfrontPaymentReceived_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z92lh37so5V4" title="Cash upfront payment received"&gt;15,506,400&lt;/span&gt;,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR &lt;span id="xdx_909_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_z7IqI8sc6G2c" title="Regulatory milestone payments"&gt;2
million&lt;/span&gt; in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR &lt;span id="xdx_900_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zoyAeZAvCZb8" title="Sales milestone payment"&gt;27.5
million&lt;/span&gt; in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory
ranging from EUR &lt;span id="xdx_909_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zcUhRqEMr4S6" title="Sales milestone"&gt;25&lt;/span&gt;
million to EUR &lt;span id="xdx_904_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zAacOzdvIPjd" title="Sales milestone"&gt;100&lt;/span&gt;
million. We are also entitled to receive quarterly royalty payments at a rate of &lt;span id="xdx_909_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_uPure_c20190506__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zq6e23cqcAxe" title="Quarterly royalty payments percentage"&gt;5&lt;/span&gt;%
on net sales of BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory. Theramex is responsible for
all regulatory and commercial activities for BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory.
Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all
regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA
and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex
challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party
that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zenh362Wo67i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zv3nAQnaW9M8"&gt;Segment Reporting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single executive leadership team that is led by the Chief Executive Officer of our Company, who oversees all operations. We do
not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information
with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business
as one reportable operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zxpqbr2bmcbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zmyttqWPgYYk"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We expense all shipping and handling costs
as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--AdvertisingCostsPolicyTextBlock_zdhmPYMiEK52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zyINHvbwxSv4"&gt;Advertising Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We expense advertising costs when incurred.
Advertising costs were $&lt;span id="xdx_90F_eus-gaap--AdvertisingExpense_c20200101__20201231_zJaZR6tmsl89" title="Advertising expense"&gt;35,799,313&lt;/span&gt;, $&lt;span id="xdx_907_eus-gaap--AdvertisingExpense_c20190101__20191231_z2WkwD8JFvA" title="Advertising expense"&gt;9,045,571&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AdvertisingExpense_c20180101__20181231_zTk92CW5pAXb" title="Advertising expense"&gt;1,682,746&lt;/span&gt; during the years ended December 31, 2020, 2019, and 2018, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbIx9lxZUof7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zs115znl8Fgd"&gt;Research and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development, or R&amp;amp;D, expenses
include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity expenses include laboratory
supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory
experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken
by our regulatory consultants that were classified as R&amp;amp;D expenses include assisting, consulting with, and advising our in-house
staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking
work for our clinical trials and investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations
as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.
We expense nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity
has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses
and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion
stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion.
We charge revisions to expenses in the period in which the facts that give rise to the revision become known.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGxe5iUgOs2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zY8NoTbthJw6"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We calculate earnings per share, or EPS,
in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic
and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period.
We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options,
warrants and restricted stock units and were excluded from the calculation of diluted earnings per share because their effect would
have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could
affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zxZw0sPuvJN4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.5in" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuoTVoVLv1X4" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;23,781,930&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA3iPFU4QS93" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zln2FQ1cG1xg" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;20,872,824&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6a7Q8G2kyz" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,534,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAcN8G1ZGnC" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrW6K1PYpl3j" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,007,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Performance stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zw7hkCKqtWXe" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,403,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zeOF1BJWYdDj" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuGGGXBHxbSc" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCzVK1LkrEla" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;7,061,024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziCDxmGKrzz3" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,240,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7UbyYPGZJCl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,040,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231_zJ9z974o0Fec" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;39,781,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231_zEaiLOIhKlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;28,102,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231_ziJUIS60zymh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;24,920,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zZpXowcWtFb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z2CF8RaRZ6B4"&gt;Concentration of Credit Risk and other
Risks and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially
expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial
institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not
experienced any historical losses on our deposits of cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concentration of credit risk with respect
to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors.
Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zSN8ER4xhn9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z9q28YO8Zn8d"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znmqU4R9pzrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zhOmlAltG07g"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;In March 2020, the FASB
issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference
Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting
impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank
Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally,
contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment
of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022.
Our debt agreements currently include the use of alternate rates when LIBOR is not available. We do not expect the change from
LIBOR to an alternate rate will have a material impact to our financial statements and, to the extent we enter into modifications
of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;In August 2018, the FASB
issued ASU 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public
entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting
Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness
of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information
to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December
15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or
only the provisions that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not
have a material effect on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;In June 2016, the FASB
issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments.
The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be
presented at the net amount expected to be collected based on historical experience, current conditions, and reasonable supportable
forecasts. The amendments in this update are effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the first quarter of 2019.
A modified retrospective approach is required for all investments, except debt securities for which an other-than-temporary impairment
had been recognized prior to the effective date, which will require a prospective transition approach and should be applied either
prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13 requires expanded quantitative
and qualitative disclosures about the Company&#x2019;s expected credit losses. Effective January 1, 2020, we adopted ASU 2016-13
under a modified retrospective approach for all financial assets measured at amortized cost. There was no adjustment recorded for
the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;Other recent accounting
pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants
and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.&lt;/p&gt;

&lt;p id="xdx_854_zxqwplGFy472" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zbWuVh9adzo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zCCnWITYyUYi"&gt;Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial
statements include the accounts of our company and our wholly owned subsidiaries, vitaMed, BocaGreen and VitaCare. All intercompany
balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <txmd:RisksAndUncertaintiesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_848_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxel2fnrUmS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zdZGAt846502"&gt;Risks and Uncertainties&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We continue to be subject to risks and
uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues
to be highly uncertain and difficult to predict. We continue to provide an uninterrupted supply of our portfolio of products for
patients. We have sufficient inventory of finished product to meet anticipated demand in the near future. Additionally, we currently
do not foresee any interruption in our ability to continue to manufacture additional product to be used beyond this period and
have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products. During the year ended
December 31, 2020, we recorded an inventory charge of $&lt;span id="xdx_90F_eus-gaap--InventoryWriteDown_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_z3beEO1Oq3Rb"&gt;7,204,818&lt;/span&gt;&#160;which was primarily related to BIJUVA and resulted from the
impact of the COVID-19 pandemic on our business, which decreased demand for our products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Since the early phase of the COVID-19 pandemic,
we have been using substantial virtual options to ensure business continuity. Our VitaCare Prescription Services patient model
assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice,
including via home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple
third-party online pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time
access to both diagnosis and treatment. We continue to support prescribers&#x2019; needs with samples and product materials through
our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for live virtual e-detailing of our products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of our response to the COVID-19
pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented cost saving measures, which included
negotiating lower fees or suspending services from third party vendors; implementing a company-wide hiring restriction; delaying
or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event
expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The full impact of the COVID-19 pandemic
continues to evolve. However, we remain committed to the execution of our corporate goals, despite the ongoing COVID-19 pandemic,
as demonstrated in part by the increase in product revenue throughout 2020. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity,
or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our operations by monitoring
the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic
has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression
that has occurred or may occur in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;While we currently believe that our COVID-19
contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of
the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity
of the pandemic, the duration of &#x201c;social distancing&#x201d; orders, the ability of our sales force to access healthcare providers
to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients,
thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are uncertain.
Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable
amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs
that we may undertake to address financial and operations challenges that we may face.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</txmd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="From2020-01-012020-12-31_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">7204818</us-gaap:InventoryWriteDown>
    <txmd:LiquidityPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_ecustom--LiquidityPolicyTextBlock_zBQndKwXmNy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zvBKo3cmFt66"&gt;&lt;span style="text-decoration: underline"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the filing date of this Annual
Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement (as defined in Note 8 -
Debt). On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement, or Amendment No.
6, with the Administrative Agent (as defined in Note 8 - Debt) and the lenders party thereto, pursuant to which we
temporarily lowered the minimum required cash balance from $&lt;span id="xdx_907_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z6zi29hmeiHl"&gt;60&lt;/span&gt;
million to $&lt;span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z8O7p4TL3t4e"&gt;45&lt;/span&gt; million through December 31, 2020. After December 31, 2020, the minimum cash balance reverted to $&lt;span id="xdx_908_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201231_zHQCHcqSC1ej"&gt;60&lt;/span&gt;
million. Based on our current projections, and recent equity financings, we anticipate that we will remain in compliance with
the minimum cash balance covenant for the next twelve months from the issuance of these financial statements. In addition, we
have reviewed numerous potential scenarios in connection with the impact of COVID-19 pandemic on our business and we believe
that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary course of business for the next
twelve months from the issuance of these financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However, if we are unsuccessful with the
commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if commercialization is delayed, or if the continued impact of the COVID-19
pandemic on our business is worse than we anticipate, our existing cash reserves may be insufficient to maintain compliance with
the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY,
BIJUVA, and ANNOVERA. The Financing Agreement also requires us to maintain certain minimum quarterly product net revenue requirements
and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA were revised. See Note 8 &#x2013; Debt &#x2013; for a description
of these covenants. These and other terms in the Financing Agreement have to be monitored closely for compliance
and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.
If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements,
or otherwise comply with the covenants of the Financing Agreement, all or a portion of our obligations under the Financing Agreement
may be declared immediately due and payable, which would have a material adverse effect on our business, results of operations
and financial condition.&lt;/p&gt;

</txmd:LiquidityPolicyTextBlock>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member"
      decimals="-6"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member"
      decimals="-6"
      unitRef="USD">45000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement contextRef="AsOf2020-12-31" decimals="-6" unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQduWR076XSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z0kdb43Ciy2g"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We maintain cash at financial institutions
that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20201231_zQ3AOk9yMPC4" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per bank. We have never
experienced any losses related to these funds.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84A_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z0PXW0Wks4q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zoeKDk3UUjUg"&gt;Trade Accounts Receivable and Allowance
for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are customer
obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks
and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection
information, reasonable supportable forecasts, and existing economic conditions and we record an allowance that presents the net
amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent receivables against
our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances
of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful
accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves
may be required. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws,
coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption
associated with the current COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced
significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying
amount of trade receivables in the future. At December 31, 2020, four different customers represented &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeMcWBPAkK27" title="Concentration risk percentage"&gt;25&lt;/span&gt;%, &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zFblFmC1C4tf"&gt;19&lt;/span&gt;%, &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJYlkjf6rLea"&gt;17&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zrz7FpodhDjb"&gt;11&lt;/span&gt;% of
our gross accounts receivable. At December 31, 2019, four different customers represented &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zQd80LlYI9Lb"&gt;36&lt;/span&gt;%, &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zTuZYhyAeing"&gt;21&lt;/span&gt;%,&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zUl1Y7LTCLuh"&gt;16&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zwAnBdJ6IQNc"&gt;11&lt;/span&gt;% of our gross accounts
receivable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zr4gbPw0pdZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for Doubtful Accounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 33%"&gt;Balance - January 1, 2020&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20200101__20201231_zkKUwDVtxyf2" style="width: 12%; text-align: right" title="Balance at beginning"&gt;904,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Increase in allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--IncreaseInAllowanceForDoubtfulAccountsReceivable_c20200101__20201231_z2ElkvKerBU5" style="text-align: right" title="Increase in allowance"&gt;422,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Recoveries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_iN_di_c20200101__20201231_zqIFO0vWPGR5" style="text-align: right" title="Recoveries"&gt;(181,514&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Write-offs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20200101__20201231_zo2AETyNBur8" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs"&gt;(26,809&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance - December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20200101__20201231_z98bXEewnbJ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;1,117,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zU3AskfXE1Nd" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zr4gbPw0pdZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for Doubtful Accounts&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 33%"&gt;Balance - January 1, 2020&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20200101__20201231_zkKUwDVtxyf2" style="width: 12%; text-align: right" title="Balance at beginning"&gt;904,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Increase in allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--IncreaseInAllowanceForDoubtfulAccountsReceivable_c20200101__20201231_z2ElkvKerBU5" style="text-align: right" title="Increase in allowance"&gt;422,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Recoveries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_iN_di_c20200101__20201231_zqIFO0vWPGR5" style="text-align: right" title="Recoveries"&gt;(181,514&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Write-offs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20200101__20201231_zo2AETyNBur8" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs"&gt;(26,809&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance - December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20200101__20201231_z98bXEewnbJ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;1,117,854&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">904040</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <txmd:IncreaseInAllowanceForDoubtfulAccountsReceivable
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">422137</txmd:IncreaseInAllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">181514</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">26809</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1117854</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zA9T6GNGbCQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zNPe8jcvuR3d"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories represent pharmaceutical products,
packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products
are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for
excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value.
Obsolescence may occur due to product expiring, product improvements rendering previous versions obsolete, or decreases in demand
for our products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Pre-Launch Inventory&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pre-launch inventory costs associated with
product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial
use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined,
then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during
the period the costs are incurred. We have not capitalized any pre-launch inventory to date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Inventory Write-Off&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We evaluate inventory quarterly for short
dated and excess inventory. During the years ended December 31, 2020 and December 31, 2019, we recorded an inventory charge of
$&lt;span id="xdx_902_eus-gaap--InventoryWriteDown_c20200101__20201231_zfLrLmKKSFud" title="Inventory charge"&gt;7,204,818&lt;/span&gt;&#160;and $&lt;span id="xdx_905_eus-gaap--InventoryWriteDown_c20190101__20191231_znwcXFB4i4a4" title="Inventory charge"&gt;0&lt;/span&gt;, respectively. The charge recorded during the year ended December 31, 2020 was primarily related to BIJUVA
and resulted from the impact of the COVID-19 pandemic on our business, which decreased demand for our products.&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">7204818</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zLEBTqL1leIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zODjpnlN2nFa"&gt;Cost of Sales&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of sales includes the cost of inventory,
manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. The Population Council License
Agreement requires payment of royalties based on the sale of future products. Such royalties are recorded as a component of cost
of sales. Additionally, the amortization of license fees or milestone payments related to licensed products are classified as components
of cost of sales to the extent such payments become due in the future.&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxr4m9jKAlg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zqMgBOxm7Gkd"&gt;Fixed Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We state fixed assets at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives
of the related assets, which range from &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zwStNlSSdvcc" title="Useful life of assets::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zQYPap4IV4Hh"&gt;seven years&lt;/span&gt;. Leasehold improvements are depreciated over the shorter of their
useful life or the term of the lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We capitalize software and software development
costs incurred to create and acquire computer software for internal use, principally related to software coding and application
development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable
that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized
in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into
service over the estimated useful life, generally &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zz4odzWls18g" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0590"&gt;five&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zXJarThY0hD4"&gt;seven years&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zCOuXAwCqboi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zHNQkewR0Dw8"&gt;Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have adopted the provisions of Financial
Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, &lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;, or
ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications.
In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent
using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December
31, 2020, we had &lt;span id="xdx_908_ecustom--NumberOfIssuedPatentsDomestic_iI_uN_c20201231_zUgBdjjhjVOi" title="Number of issued patents domestic."&gt;38&lt;/span&gt; issued domestic, or U.S., patents and &lt;span id="xdx_90A_ecustom--NumberOfIssuedPatentsForeign_iI_uN_c20201231_zaGjxEbi1Ww2" title="Number of issued patents foreign"&gt;39&lt;/span&gt; issued foreign patents (See Note 6). We capitalize external costs,
consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review
intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <txmd:NumberOfIssuedPatentsDomestic contextRef="AsOf2020-12-31" decimals="INF" unitRef="N">38</txmd:NumberOfIssuedPatentsDomestic>
    <txmd:NumberOfIssuedPatentsForeign contextRef="AsOf2020-12-31" decimals="INF" unitRef="N">39</txmd:NumberOfIssuedPatentsForeign>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1pD2jkvUF3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_z9aHXGYIYrjg"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We review the carrying values of fixed
assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate
that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant declines in an asset&#x2019;s market price;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant deterioration in an asset&#x2019;s physical condition;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant changes in the nature or extent of an asset&#x2019;s use or operation;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant adverse changes in the business climate that could impact an asset&#x2019;s value, including
adverse actions or assessments by regulators;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset&#x2019;s use; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If impairment indicators are present, we
determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value
for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are
largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate
the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate
to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise
of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held
and used. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019;
fair value and respective carrying values. We determine the fair value of the assets using an &#x201c;income approach&#x201d; based
upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We perform impairment tests for intangible
assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change
that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for
assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also evaluate the remaining useful life
of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment
or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#x2019;s remaining useful life is changed,
we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of indefinite-lived assets
is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment
test. During the years ended December 31, 2020 and 2019, we &lt;span style="color: #212529"&gt;wrote off $&lt;span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20200101__20201231_zXt7gpxpg4Qa" title="Write off of patent and trademark cost"&gt;1,131,776&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20190101__20191231_zWv3D9gcdwq8"&gt;78,864&lt;/span&gt;, respectively,&#160;in
costs related to trademarks and patents. &lt;/span&gt;There was no impairment of intangible assets during the year ended December 31,
2018.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1131776</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z38d8DPCPpkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zlLEgNREqtec"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of December 31, 2020 and
2019 (as disclosed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair Value
Measurements, &lt;/i&gt;or ASC 820&lt;i&gt;. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for
identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 1in; text-align: left"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;unadjusted quoted prices in active markets for identical
assets or liabilities;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 1in; text-align: left"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 1in; text-align: left"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;unobservable inputs for the assets or liabilities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At December 31, 2020 and 2019, we had no assets or liabilities
that were valued at fair value on a recurring basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zBlBozfK2Pa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zjtSmTJjiblk"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recognize both interest and penalties
related to uncertain tax positions as part of the income tax provision. At December 31, 2020 and 2019, we had no tax positions
relating to open tax returns that were considered to be uncertain.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our U.S. federal and state tax returns
since 2011, which was the first year we generated net operating losses, remain open to examination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_ziINyPlLXYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zk32UZu6u9Sh"&gt;Share-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, to value
options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our stock-based
awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January 1, 2020, the average
expected life of options was based on the contractual terms of the stock option using the simplified method. We utilize a dividend
yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. In
addition, the terms of the Financing Agreement (See Note 8) preclude us from paying dividends, and any future debt agreements may
also preclude us from paying dividends. The assumptions used in calculating the fair value of stock-based awards represent our
best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.
We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance
with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We grant restricted stock units and performance-based
stock units for shares of common stock, par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20201231_z2GxITWehrV5"&gt;0.001&lt;/span&gt; per share, or Common Stock, to employees. We value our restricted stock
units and our performance-based stock units by reference to our stock price on the date of grant. We recognize compensation expense
for restricted stock units based on a straight-line basis over the requisite service period of the entire award. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the performance restricted stock vests. The number
of target shares that vest are determined based on the level of attainment of the targets. If a minimum level of performance is
attained for the awards, restricted stock is issued based on the level of attainment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgShP7jOATyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zQ2ipGElfXOj"&gt;Revenue Recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 606,&#160;&lt;i&gt;Revenue
from Contracts with Customers&lt;/i&gt;, or ASC 606, revenue is recognized when a customer obtains control of promised goods or services.
The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these
goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the
transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for
those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify
the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance
obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription Products&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="color: #212529"&gt;As of December
31, 2020, &lt;/span&gt;our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began
selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we
began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed
the commercial launch of ANNOVERA on July 1, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We sell our name brand and generic prescription
products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription
products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations
related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service
for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription
product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or
service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the
customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on
our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional.
We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services
sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The transaction price of a contract is
the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will
not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that
supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and
the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ
from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would
affect net product revenue and earnings in the period such changes in estimates become known.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of six months prior to and up to &lt;span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z3ySKQtvDA47" title="Return period of unsalable prescription products"&gt;12&lt;/span&gt;
months following product expiration. ANNOVERA cannot be returned before the expiration date and expired ANNOVERA can be
returned up to &lt;span id="xdx_909_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zmR0T8rgRole"&gt;12&lt;/span&gt;
months past the expiration date. Our prescription vitamins, IMVEXXY and BIJUVA currently have a shelf life of &lt;span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--VitaminsImvexxyAndBijuvaMember_zT2KiZyFAJs3" title="Shelf life of prescription products"&gt;24&lt;/span&gt;
months from the date of manufacture and ANNOVERA currently has a shelf life of &lt;span id="xdx_908_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zzAsj5sOc8Ha"&gt;18&lt;/span&gt;
months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of product revenue in the period the related product revenue is recognized. Where historical rates of return exist,
we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched
products, for which the right of return exists but for which we currently do not have history of product returns, we estimate
returns based on available industry data, our own sales information and our visibility into the inventory remaining in the
distribution channel. At the end of each reporting period, we may decide to constrain product revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the
expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic
products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the
customer&#x2019;s consideration. Since our returns primarily consist of expired and short dated products that will not be
resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the
initial sale (when recognition of product revenue is deferred due to the anticipated return). Return estimates are recorded
in other current liabilities on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We offer various rebate and discount programs in an effort to maintain
a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates
and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on
a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenue at the time the product
revenue is recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor
fees are recorded in other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units
sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors
fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates
relating to invoice discounts and chargebacks are deducted from gross product revenue at the time the product revenue is recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of commercial launches for our
FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket
costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with
our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. The variable consideration
is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average
assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time
up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription
products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain
variable consideration for our prescription products to an amount that will not result in a significant product revenue reversal
in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates
of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by
insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently
available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIeQdb0LePU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zIUJyq1Gpgyb" style="width: 12%; text-align: right" title="Net revenue"&gt;9,767,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zm4kXwTPfFzb" style="width: 12%; text-align: right" title="Net revenue"&gt;9,885,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zRSEpLOd3G4l" style="width: 12%; text-align: right" title="Net revenue"&gt;15,041,259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zJfE6V5ja3Mc" style="text-align: right" title="Net revenue"&gt;27,139,387&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zVZkVbCvPFNg" style="text-align: right" title="Net revenue"&gt;16,252,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zvBbyNZlnXLl" style="text-align: right" title="Net revenue"&gt;1,058,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGYUHrnBZE1" style="text-align: right" title="Net revenue"&gt;6,353,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zLSGvlHRufNg" style="text-align: right" title="Net revenue"&gt;1,836,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--BijuvaMember_z1JXyWuYn72d" style="text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayMzasE8eb6" style="text-align: right" title="Net revenue"&gt;19,611,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zYvSCX7ojjG8" style="text-align: right" title="Net revenue"&gt;6,166,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zjpw8uaRoM46" style="text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zydUwtLaPfM1" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zEuVRJerfvu7" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSl8MRsNl7Jf" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_zQyorgOoNb95" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;64,872,280&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_z2VgHc6SD9Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;49,646,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z9pXHF47yUB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;16,099,460&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zf7LBTNOj0Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front
fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the right to use functional intellectual property is transferred to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with the Population
Council&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 30, 2018, we entered into the Population
Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a &#x201c;test and learn&#x201d; market
introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. &lt;span style="color: #212529"&gt;We
resumed the commercial launch of ANNOVERA on July 1, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the terms of the Population Council
License Agreement, we paid the Population Council a milestone payment of $&lt;span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNmM0XbdrIkf" title="Milestone payment upon FDA Approval"&gt;20,000,000&lt;/span&gt;&#160;within 30 days following the approval
by the FDA of the new drug application, or NDA, for ANNOVERA and $&lt;span id="xdx_902_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRlIviFCHJSa" title="Milestone payments (payment after release of first commercial batch)"&gt;20,000,000&lt;/span&gt;&#160;within 30 days following the first commercial
batch release of ANNOVERA. Both milestone payments of $&lt;span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zHvxx9ISU3ic" title="License rights acquired"&gt;20,000,000&#160;&lt;/span&gt;were recorded as license rights in the consolidated balance
sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became commercially available for use.
The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our
cash flows, which is estimated to be the remaining patent life of the product, which expires as early as December 2032. The cost
is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the years
ended December 31, 2020 and 2019 we recorded $&lt;span id="xdx_908_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20201231_zU0ennHdqNG" title="Amortization of intellectual property license fee"&gt;3,024,391&lt;/span&gt;&#160;and $&lt;span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20191231_zoFDDXXJ6XF8" title="Amortization of intellectual property license fee"&gt;778,692&lt;/span&gt;, respectively, in amortization expense related to the
license fee which was recorded as a component of cost of sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Population Council is also eligible
to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible for marketing expenses related
to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based
royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as
follows: (i) if annual net sales are less than or equal to $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zB1xl9STslZj" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zHDWWmUGwgea" title="Royalty (percent)"&gt;5&lt;/span&gt;% of net sales; (ii) for annual net
sales greater than $&lt;span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zT2XmmFVoWge" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;&#160;and less than or equal to $&lt;span id="xdx_90E_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zTAI4ux2XhT6" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zC6XNUaPEozh" title="Royalty (percent)"&gt;10&lt;/span&gt;% of such net sales; and (iii)
for net sales greater than $&lt;span id="xdx_90A_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zt1yVxYQsZOk"&gt;150,000,000&lt;/span&gt;, a royalty of&#160;&lt;span id="xdx_90A_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zBs9xrl0NxU4" title="Royalty (percent)"&gt;15&lt;/span&gt;% of such net sales. The annual royalty rate will be reduced to&#160;&lt;span id="xdx_90D_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zQetXhTVEaka" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"&gt;50&lt;/span&gt;%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent
of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to&#160;&lt;span id="xdx_908_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zXp9UntycC9i" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"&gt;20&lt;/span&gt;%
of the initial rate. We are required to pay the Population Council milestone payments of $&lt;span id="xdx_902_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRb6ERjPJGr9" title="Milestone payments upon specified levels of cumulative net sales"&gt;40&lt;/span&gt;&#160;million&#160;upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $&lt;span id="xdx_904_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z0nEr1VekSOf" title="Specified level one of cumulative net sales for milestone payments"&gt;200&lt;/span&gt;&#160;million, $&lt;span id="xdx_906_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zTUERTX9tZt7" title="Specified level two of cumulative net sales for milestone payments"&gt;400&lt;/span&gt;&#160;million&#160;and
$&lt;span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zUELoe4agUhi" title="Specified level three of cumulative net sales for milestone payments"&gt;1&lt;/span&gt;&#160;billion. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval
studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such
post-approval study exceed $&lt;span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z4kNf57Lbi3k" title="Maximum costs and expenses for post approval"&gt;20,000,000&lt;/span&gt;, half of such excess will be offset against royalties or other payments owed by us to the
Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a joint product
committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible for all
aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired
clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.
The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational
vaginal contraceptive systems in development by the Population Council.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Unless earlier terminated, the Population
Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#x2019;s
U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during
which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may
also be terminated for certain breach and bankruptcy-related events and by us on 180 days&#x2019; prior notice to the Population
Council.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with Knight Therapeutics
Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2018, we entered into the Knight
License Agreement pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.
Pursuant to the terms of the Knight License Agreement, Knight paid us $&lt;span id="xdx_90D_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zUD7dpRngPs2"&gt;2,000,000&lt;/span&gt; in milestone fees upon the first regulatory approval
in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is required to pay us sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory
applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in
Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain
specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement,
Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with Theramex&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="color: #212529"&gt;On June
6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR &lt;span id="xdx_900_ecustom--CashUpfrontPaymentReceived_pn6n6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zJCFLkOukmJf" title="Cash upfront payment received"&gt;14&lt;/span&gt;
million, or $&lt;span id="xdx_902_ecustom--CashUpfrontPaymentReceived_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z92lh37so5V4" title="Cash upfront payment received"&gt;15,506,400&lt;/span&gt;,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR &lt;span id="xdx_909_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_z7IqI8sc6G2c" title="Regulatory milestone payments"&gt;2
million&lt;/span&gt; in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR &lt;span id="xdx_900_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zoyAeZAvCZb8" title="Sales milestone payment"&gt;27.5
million&lt;/span&gt; in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory
ranging from EUR &lt;span id="xdx_909_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zcUhRqEMr4S6" title="Sales milestone"&gt;25&lt;/span&gt;
million to EUR &lt;span id="xdx_904_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zAacOzdvIPjd" title="Sales milestone"&gt;100&lt;/span&gt;
million. We are also entitled to receive quarterly royalty payments at a rate of &lt;span id="xdx_909_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_uPure_c20190506__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zq6e23cqcAxe" title="Quarterly royalty payments percentage"&gt;5&lt;/span&gt;%
on net sales of BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory. Theramex is responsible for
all regulatory and commercial activities for BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory.
Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the &lt;/span&gt;Theramex &lt;span style="color: #212529"&gt;Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all
regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA
and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex
challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party
that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2020-01-012020-12-31_srt_MaximumMember">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2020-01-012020-12-31_custom_AnnoveraMember">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2020-01-012020-12-31_custom_VitaminsImvexxyAndBijuvaMember">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2020-01-012020-12-31_custom_BijuvaAndAnnoveraMember">P18M</txmd:ShelfLifeOfPrescriptionProducts>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIeQdb0LePU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zIUJyq1Gpgyb" style="width: 12%; text-align: right" title="Net revenue"&gt;9,767,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zm4kXwTPfFzb" style="width: 12%; text-align: right" title="Net revenue"&gt;9,885,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zRSEpLOd3G4l" style="width: 12%; text-align: right" title="Net revenue"&gt;15,041,259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zJfE6V5ja3Mc" style="text-align: right" title="Net revenue"&gt;27,139,387&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zVZkVbCvPFNg" style="text-align: right" title="Net revenue"&gt;16,252,045&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zvBbyNZlnXLl" style="text-align: right" title="Net revenue"&gt;1,058,201&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGYUHrnBZE1" style="text-align: right" title="Net revenue"&gt;6,353,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zLSGvlHRufNg" style="text-align: right" title="Net revenue"&gt;1,836,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--BijuvaMember_z1JXyWuYn72d" style="text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayMzasE8eb6" style="text-align: right" title="Net revenue"&gt;19,611,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zYvSCX7ojjG8" style="text-align: right" title="Net revenue"&gt;6,166,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zjpw8uaRoM46" style="text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0648"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zydUwtLaPfM1" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;2,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zEuVRJerfvu7" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;15,506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSl8MRsNl7Jf" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_zQyorgOoNb95" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;64,872,280&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_z2VgHc6SD9Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;49,646,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z9pXHF47yUB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;16,099,460&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">9767644</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">9885493</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">15041259</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">27139387</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">16252045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">1058201</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">6353963</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">1836443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">19611286</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">6166556</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">64872280</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">49646937</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">16099460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <txmd:MilestonePaymentUponFDAApproval
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentUponFDAApproval>
    <txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">3024391</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:AmortizationOfIntellectualPropertyLicenseFee
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">778692</txmd:AmortizationOfIntellectualPropertyLicenseFee>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember"
      decimals="0"
      unitRef="USD">500000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep1Member"
      decimals="INF"
      unitRef="Pure">0.05</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">500000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember"
      decimals="0"
      unitRef="USD">1500000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep2Member"
      decimals="INF"
      unitRef="Pure">0.10</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">1500000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementStep3Member"
      decimals="INF"
      unitRef="Pure">0.15</txmd:RoyaltyPercent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.20</txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember"
      decimals="-6"
      unitRef="USD">40000000</txmd:MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales>
    <txmd:SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember"
      decimals="-6"
      unitRef="USD">200000000</txmd:SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments>
    <txmd:SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember"
      decimals="-6"
      unitRef="USD">400000000</txmd:SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments>
    <txmd:SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember_custom_AnnoveraMember"
      decimals="-9"
      unitRef="USD">1000000000</txmd:SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments>
    <txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid
      contextRef="From2020-01-012020-12-31_custom_CouncilLicenseAgreementMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid>
    <txmd:MilestonePaymentReceivedUponRegulatoryApproval
      contextRef="From2020-01-012020-12-31_custom_KnightLicenseAgreementMember_custom_BijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">2000000</txmd:MilestonePaymentReceivedUponRegulatoryApproval>
    <txmd:CashUpfrontPaymentReceived
      contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember"
      decimals="-6"
      unitRef="EUR">14000000</txmd:CashUpfrontPaymentReceived>
    <txmd:CashUpfrontPaymentReceived
      contextRef="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember"
      decimals="0"
      unitRef="USD">15506400</txmd:CashUpfrontPaymentReceived>
    <txmd:RegulatoryMilestoneAdditionalPayment
      contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">2000000</txmd:RegulatoryMilestoneAdditionalPayment>
    <txmd:SalesMilestonePaymentsInTranches
      contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">27500000</txmd:SalesMilestonePaymentsInTranches>
    <txmd:AnnualNetSalesMilestone
      contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember"
      decimals="-6"
      unitRef="EUR">25000000</txmd:AnnualNetSalesMilestone>
    <txmd:AnnualNetSalesMilestone
      contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="-6"
      unitRef="EUR">100000000</txmd:AnnualNetSalesMilestone>
    <txmd:QuarterlyRoyaltyPaymentsPercentage
      contextRef="From2019-05-062019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember"
      decimals="INF"
      unitRef="Pure">0.05</txmd:QuarterlyRoyaltyPaymentsPercentage>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zenh362Wo67i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zv3nAQnaW9M8"&gt;Segment Reporting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single executive leadership team that is led by the Chief Executive Officer of our Company, who oversees all operations. We do
not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information
with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business
as one reportable operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <txmd:ShippingAndHandlingCostsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zxpqbr2bmcbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zmyttqWPgYYk"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We expense all shipping and handling costs
as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</txmd:ShippingAndHandlingCostsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84E_eus-gaap--AdvertisingCostsPolicyTextBlock_zdhmPYMiEK52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zyINHvbwxSv4"&gt;Advertising Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We expense advertising costs when incurred.
Advertising costs were $&lt;span id="xdx_90F_eus-gaap--AdvertisingExpense_c20200101__20201231_zJaZR6tmsl89" title="Advertising expense"&gt;35,799,313&lt;/span&gt;, $&lt;span id="xdx_907_eus-gaap--AdvertisingExpense_c20190101__20191231_z2WkwD8JFvA" title="Advertising expense"&gt;9,045,571&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AdvertisingExpense_c20180101__20181231_zTk92CW5pAXb" title="Advertising expense"&gt;1,682,746&lt;/span&gt; during the years ended December 31, 2020, 2019, and 2018, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">35799313</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">9045571</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1682746</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbIx9lxZUof7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zs115znl8Fgd"&gt;Research and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development, or R&amp;amp;D, expenses
include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity expenses include laboratory
supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory
experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken
by our regulatory consultants that were classified as R&amp;amp;D expenses include assisting, consulting with, and advising our in-house
staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking
work for our clinical trials and investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations
as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.
We expense nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity
has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses
and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion
stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion.
We charge revisions to expenses in the period in which the facts that give rise to the revision become known.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGxe5iUgOs2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zY8NoTbthJw6"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We calculate earnings per share, or EPS,
in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic
and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period.
We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options,
warrants and restricted stock units and were excluded from the calculation of diluted earnings per share because their effect would
have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could
affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zxZw0sPuvJN4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.5in" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuoTVoVLv1X4" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;23,781,930&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA3iPFU4QS93" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zln2FQ1cG1xg" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;20,872,824&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6a7Q8G2kyz" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,534,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAcN8G1ZGnC" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrW6K1PYpl3j" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,007,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Performance stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zw7hkCKqtWXe" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,403,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zeOF1BJWYdDj" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuGGGXBHxbSc" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCzVK1LkrEla" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;7,061,024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziCDxmGKrzz3" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,240,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7UbyYPGZJCl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,040,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231_zJ9z974o0Fec" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;39,781,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231_zEaiLOIhKlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;28,102,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231_ziJUIS60zymh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;24,920,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zxZw0sPuvJN4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.5in" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuoTVoVLv1X4" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;23,781,930&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA3iPFU4QS93" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zln2FQ1cG1xg" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;20,872,824&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6a7Q8G2kyz" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,534,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAcN8G1ZGnC" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrW6K1PYpl3j" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,007,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Performance stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zw7hkCKqtWXe" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;2,403,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zeOF1BJWYdDj" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuGGGXBHxbSc" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCzVK1LkrEla" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;7,061,024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziCDxmGKrzz3" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,240,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7UbyYPGZJCl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,040,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231_zJ9z974o0Fec" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;39,781,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231_zEaiLOIhKlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;28,102,805&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231_ziJUIS60zymh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;24,920,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">23781930</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">25030234</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">20872824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">6534687</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3007571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_custom_PerformanceStockUnitsMember"
      decimals="INF"
      unitRef="Shares">2403951</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">7061024</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1040000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">39781592</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">28102805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Shares">24920395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zZpXowcWtFb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_z2CF8RaRZ6B4"&gt;Concentration of Credit Risk and other
Risks and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially
expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial
institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not
experienced any historical losses on our deposits of cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concentration of credit risk with respect
to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors.
Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zSN8ER4xhn9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z9q28YO8Zn8d"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znmqU4R9pzrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zhOmlAltG07g"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;In March 2020, the FASB
issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference
Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting
impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank
Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally,
contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment
of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022.
Our debt agreements currently include the use of alternate rates when LIBOR is not available. We do not expect the change from
LIBOR to an alternate rate will have a material impact to our financial statements and, to the extent we enter into modifications
of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;In August 2018, the FASB
issued ASU 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public
entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting
Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness
of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information
to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December
15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or
only the provisions that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not
have a material effect on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;In June 2016, the FASB
issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments.
The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be
presented at the net amount expected to be collected based on historical experience, current conditions, and reasonable supportable
forecasts. The amendments in this update are effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the first quarter of 2019.
A modified retrospective approach is required for all investments, except debt securities for which an other-than-temporary impairment
had been recognized prior to the effective date, which will require a prospective transition approach and should be applied either
prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13 requires expanded quantitative
and qualitative disclosures about the Company&#x2019;s expected credit losses. Effective January 1, 2020, we adopted ASU 2016-13
under a modified retrospective approach for all financial assets measured at amortized cost. There was no adjustment recorded for
the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"&gt;Other recent accounting
pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants
and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zajTsxMknFXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 3 &#x2013; &lt;span id="xdx_825_zwwj3ViuRwyj"&gt;INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z4VIWKaJ1hnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B8_zGhhd5wdffZa"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zmsSAMGBKAy9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zIAXW9h947I8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzQbM_maINzicc_zTwzl9zMR9lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Finished products&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,350,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,976,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzQbM_maINzicc_z6ccfz20W1y2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzQbM_maINzicc_zxy3xVRWrBDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Raw materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,422,589&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,701,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryNet_iTI_uUSD_mtINzQbM_mtINzicc_zj3NQdbZOL56" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,993,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,860,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_zBhj3909m1Ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z4VIWKaJ1hnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B8_zGhhd5wdffZa"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zmsSAMGBKAy9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zIAXW9h947I8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzQbM_maINzicc_zTwzl9zMR9lg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Finished products&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,350,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,976,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzQbM_maINzicc_z6ccfz20W1y2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219,918&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzQbM_maINzicc_zxy3xVRWrBDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Raw materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,422,589&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,701,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryNet_iTI_uUSD_mtINzQbM_mtINzicc_zj3NQdbZOL56" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,993,087&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,860,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3350580</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4976910</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">219918</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1182059</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4422589</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5701747</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7993087</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_804_eus-gaap--OtherCurrentAssetsTextBlock_zsdeEMek8hk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 4 &#x2013; &lt;span id="xdx_82E_zj6xO6iAAHJ6"&gt;OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zyDotqxUZZjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B8_z3E7SUgITetf"&gt;Other current assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zWlfmIhVR7h5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20191231_zaPuNRXP6zbe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zTX1UGrHOIDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,583,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_maPEAOAzRrD_zWdzxiUe5Nw1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Debt financing fees on undrawn tranches (Note 8)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0794"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;550,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_maPEAOAzRrD_zV5AAuUETA53" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,568,269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,812,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_maPEAOAzRrD_zPdNfb7f2uod" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,331,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,595,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zbM6X4J7YOFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,639,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,787,482&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_mtPEAOAzRrD_zWmZJ6fH1651" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,543,397&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,329,793&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_zwVTX4gg8gGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zyDotqxUZZjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B8_z3E7SUgITetf"&gt;Other current assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zWlfmIhVR7h5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20191231_zaPuNRXP6zbe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zTX1UGrHOIDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,583,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_maPEAOAzRrD_zWdzxiUe5Nw1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Debt financing fees on undrawn tranches (Note 8)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0794"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;550,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_maPEAOAzRrD_zV5AAuUETA53" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,568,269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,812,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_maPEAOAzRrD_zPdNfb7f2uod" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,331,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,595,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zbM6X4J7YOFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,639,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,787,482&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_mtPEAOAzRrD_zWmZJ6fH1651" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,543,397&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,329,793&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4308</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1583698</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">550757</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:PrepaidInsurance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2568269</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1812135</us-gaap:PrepaidInsurance>
    <txmd:PrepaidManufacturing contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1331100</txmd:PrepaidManufacturing>
    <txmd:PrepaidManufacturing contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2595721</txmd:PrepaidManufacturing>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3639720</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4787482</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7543397</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEdVbqz1aUZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 5 &#x2013; &lt;span id="xdx_828_zus5oAUiLXD7"&gt;FIXED ASSETS, NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwalxkNjwlpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B3_zpzb2OwFhoZ4"&gt;Fixed assets, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20201231_zJIfVFMJGDmk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zpgoHHfaLpb7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zXVawOStxG4d" style="width: 12%; text-align: right"&gt;411,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zm9EPO4CUHbk" style="width: 12%; text-align: right"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_znRbalwMXMfg" style="text-align: right"&gt;1,704,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zPIVpZNZNZac" style="text-align: right"&gt;1,619,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zwDDCVnUTvF7" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmrLBXnu01Rb" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zFRX5JHfIGq5" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zBAJ6spUyCOd" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zvn7rxfAzVGc" style="border-bottom: Black 1pt solid; text-align: right"&gt;80,121&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zebvqVsbkxsi" style="border-bottom: Black 1pt solid; text-align: right"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_zHwmcCITGIVc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,683,671&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,476,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20201231_zaTLGDdVBvm2" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation"&gt;(1,741,447&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_zHp8qjyh7OHj" style="border-bottom: Black 1pt solid; text-align: right"&gt;(968,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_zlvcHLtLDnNg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,942,224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,507,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zM3luYgKygP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Depreciation expense for the years ended December 31, 2020,
2019, and 2018 was $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20200101__20201231_zS1VPS1vozdg"&gt;772,624&lt;/span&gt;, $&lt;span id="xdx_909_eus-gaap--Depreciation_c20190101__20191231_zRbjcLOUYLJ1"&gt;415,193&lt;/span&gt;, and $&lt;span id="xdx_903_eus-gaap--Depreciation_c20180101__20181231_zF184FoseAS6"&gt;181,412&lt;/span&gt;, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwalxkNjwlpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B3_zpzb2OwFhoZ4"&gt;Fixed assets, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20201231_zJIfVFMJGDmk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20191231_zpgoHHfaLpb7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zXVawOStxG4d" style="width: 12%; text-align: right"&gt;411,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zm9EPO4CUHbk" style="width: 12%; text-align: right"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_znRbalwMXMfg" style="text-align: right"&gt;1,704,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zPIVpZNZNZac" style="text-align: right"&gt;1,619,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zwDDCVnUTvF7" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmrLBXnu01Rb" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zFRX5JHfIGq5" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zBAJ6spUyCOd" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zvn7rxfAzVGc" style="border-bottom: Black 1pt solid; text-align: right"&gt;80,121&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zebvqVsbkxsi" style="border-bottom: Black 1pt solid; text-align: right"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_zHwmcCITGIVc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,683,671&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,476,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20201231_zaTLGDdVBvm2" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation"&gt;(1,741,447&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_zHp8qjyh7OHj" style="border-bottom: Black 1pt solid; text-align: right"&gt;(968,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_zlvcHLtLDnNg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,942,224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,507,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">411550</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1704931</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1619646</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1406858</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1406858</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">80121</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">68788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3683671</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3476599</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1741447</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">968824</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1942224</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">772624</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">415193</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">181412</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_801_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zKVHVcTGWZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 6 &#x2013; &lt;span id="xdx_82D_zJtKxGSrqsl1"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z4clAvQB88J8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B4_z8NdkXyYT5Xc"&gt;The following table sets forth the gross carrying amount, accumulated
amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross&lt;br/&gt;
Carrying&lt;br/&gt;
Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated&lt;br/&gt;
Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;br/&gt;
Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted-&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;br/&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Period (yrs.)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zSYuKPdQIVDd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;4,044,552&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zALv2sZjcEfe" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(748,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHAO8XCZRci2" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;3,295,925&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlsvJLAC4KM7" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z8bRYnrmuxok" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;1,628,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zc3zWfX2t3Qb" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;1,628,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zdVboSaMaXWj" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;323,341&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zqphpEFgOJJa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;323,341&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zDv0mJvaJSk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;5,996,350&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231_zR3YedimwWm7" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(748,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zP2E2mjJ1Due" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;5,247,723&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross&lt;br/&gt;
Carrying&lt;br/&gt;
Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated&lt;br/&gt;
Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;br/&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted-&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;br/&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Period (yrs.)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zKnJASx50b3l" style="width: 12%; text-align: right"&gt;3,463,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxvVB9iunx1f" style="width: 12%; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zReVzPUfDAE5" style="width: 12%; text-align: right"&gt;2,984,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z7kwhX16V0ng"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zk3uT2fprYog" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z6mTdKWmF8Rj" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zR8Me2QAcuwk" style="border-bottom: Black 1pt solid; text-align: right"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zwrOWh3L3gqk" style="border-bottom: Black 1pt solid; text-align: right"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zVTewfUNILE3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,737,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zraYe4cYgmJf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_z3ErTi9gGA5e" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,258,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_z7k1K2akQEU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We capitalize external costs, consisting
primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone
therapy drug candidate patents using the straight-line method over the estimated useful life of approximately &lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zr99z1YZYDPe"&gt;20&lt;/span&gt; years, which is
the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time.
Trademarks are perpetual and are not amortized. During the years ended December 31, 2020 and 2019, we &lt;span style="color: #212529"&gt;wrote
off $&lt;span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0i_c20200101__20201231_zwHJkluFg3Uj"&gt;1,131,776&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0i_c20190101__20191231_zp3BudRUttAi"&gt;78,864&lt;/span&gt;, respectively,&#160;in costs related to trademarks and patents. &lt;/span&gt;There was no impairment of intangible
assets during the year ended December 31, 2018.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2020, we had &lt;span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zb84hNxk4FZj" title="Number of issued patents"&gt;38&lt;/span&gt; issued
domestic patents and &lt;span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zQ3GEY3Tbpy4" title="Number of issued patents"&gt;39&lt;/span&gt; issued foreign patents, including:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zE7TGDHXeao2" title="Number of issued patents"&gt;15&lt;/span&gt; domestic patents and &lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zyesTFzuOuTd" title="Number of issued patents"&gt;nine&lt;/span&gt; foreign patents that relate to BIJUVA as well as &lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zcvIvUiInO1k"&gt;three&lt;/span&gt; domestic patents
that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation
and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel,
Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zVwtAja4g67f" title="Number of issued patents"&gt;12&lt;/span&gt; domestic patents (&lt;span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zGVAz1QFsWyg" title="Number of issued patents"&gt;ten&lt;/span&gt; utility and &lt;span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zbnT7XnsLmH7" title="Number of issued patents"&gt;two&lt;/span&gt; design) and &lt;span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zIWLh9HLxNVe"&gt;18&lt;/span&gt; foreign patents (&lt;span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zqPNDL7iLvYi" title="Number of issued patents"&gt;eight&lt;/span&gt; utility and &lt;span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z6jnUS6IcUPh" title="Number of issued patents"&gt;ten&lt;/span&gt;
design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned
by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign
design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection
through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil,
Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_zk4t8lH5kPj" title="Number of issued patents"&gt;One&lt;/span&gt; domestic utility patent that relates to our topical-cream candidates, which is owned by us.
The domestic patent will expire in 2035;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zmitEfPyOK3f" title="Number of issued patents"&gt;One&lt;/span&gt; domestic utility patent and &lt;span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zrGKH3tQ6Is" title="Number of issued patents"&gt;eight&lt;/span&gt; foreign patents that relate to our transdermal-patch candidates,
which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We
have a pending patent application with respect to our transdermal-patch candidates in Brazil;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zf050oudVsD3" title="Number of issued patents"&gt;Three&lt;/span&gt; domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate,
which are owned by us and will expire in 2037;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zCmiPjTgtIq8" title="Number of issued patents"&gt;Two&lt;/span&gt; domestic and &lt;span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zySWeuiKXGy" title="Number of issued patents"&gt;four&lt;/span&gt; foreign patents that relate to formulations containing progesterone, which
are owned by us. The domestic patents will expire between 2032 and 2036. The foreign patents will expire no earlier than 2033.
In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Australia, Canada,
Europe, and Mexico; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zPGQ1AFmuwK3" title="Number of issued patents"&gt;One&lt;/span&gt; domestic utility patent that relates to our OPERA information-technology platform, which is
owned by us and will expire in 2031.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Amortization
expense was $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20201231_zD2ORwFbcPEa"&gt;269,546&lt;/span&gt;, $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20190101__20191231_z1SPBGHDSzl5"&gt;197,593&lt;/span&gt;, and $&lt;span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20180101__20181231_zkaSaHWfOPJg"&gt;112,474&lt;/span&gt; for the years ended December 31, 2020, 2019, and 2018, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z33kdLUjHoci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span&gt;Estimated amortization
expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20201231_z1JUp7oWRApk" style="border-bottom: Black 1pt solid; text-align: center"&gt;Estimated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zZyWjdNjBbcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: right"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zj5ls5NSbUHl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zozl23CkGf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zXrb5arYeYK8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zY4MKUsYBGvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_zA8ImBbyKVl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z4clAvQB88J8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B4_z8NdkXyYT5Xc"&gt;The following table sets forth the gross carrying amount, accumulated
amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross&lt;br/&gt;
Carrying&lt;br/&gt;
Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated&lt;br/&gt;
Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;br/&gt;
Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted-&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;br/&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Period (yrs.)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zSYuKPdQIVDd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;4,044,552&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zALv2sZjcEfe" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(748,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHAO8XCZRci2" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;3,295,925&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlsvJLAC4KM7" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z8bRYnrmuxok" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;1,628,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zc3zWfX2t3Qb" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;1,628,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zdVboSaMaXWj" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;323,341&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zqphpEFgOJJa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;323,341&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zDv0mJvaJSk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;5,996,350&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231_zR3YedimwWm7" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(748,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zP2E2mjJ1Due" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"&gt;5,247,723&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross&lt;br/&gt;
Carrying&lt;br/&gt;
Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated&lt;br/&gt;
Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;br/&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted-&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;br/&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortization&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Period (yrs.)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left; padding-left: 0.25in; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zKnJASx50b3l" style="width: 12%; text-align: right"&gt;3,463,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxvVB9iunx1f" style="width: 12%; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zReVzPUfDAE5" style="width: 12%; text-align: right"&gt;2,984,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z7kwhX16V0ng"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zk3uT2fprYog" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z6mTdKWmF8Rj" style="text-align: right"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&#160;&#160;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zR8Me2QAcuwk" style="border-bottom: Black 1pt solid; text-align: right"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zwrOWh3L3gqk" style="border-bottom: Black 1pt solid; text-align: right"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zVTewfUNILE3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,737,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zraYe4cYgmJf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(478,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_z3ErTi9gGA5e" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,258,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">4044552</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">748627</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3295925</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2020-01-012020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1628457</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1628457</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2020-12-31_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">323341</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2020-12-31_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">323341</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5996350</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">748627</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5247723</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3463082</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2984099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5737194</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1131776</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUSPatentsMember"
      decimals="INF"
      unitRef="N">38</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_ForeignPatentsMember"
      decimals="INF"
      unitRef="N">39</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticPatentsBijuvaMember"
      decimals="INF"
      unitRef="N">15</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_ForeignPatentsBijuvaMember"
      decimals="INF"
      unitRef="N">9</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticPatentsNonApprovedBijuvaMember"
      decimals="INF"
      unitRef="N">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUSPatentsImvexxyMember"
      decimals="INF"
      unitRef="N">12</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUSUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="N">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUSDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="N">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_ForeignPatentsImvexxyMember"
      decimals="INF"
      unitRef="N">18</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_ForeignUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="N">8</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_ForeignDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="N">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember"
      decimals="INF"
      unitRef="N">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="N">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_ForeignUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="N">8</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentTx009HRMember"
      decimals="INF"
      unitRef="N">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticPatentsProgesteroneFormulationsMember"
      decimals="INF"
      unitRef="N">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_ForeignPatentsProgesteroneFormulationsMember"
      decimals="INF"
      unitRef="N">4</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-12-31_custom_DomesticUtilityPatentOperaMember"
      decimals="INF"
      unitRef="N">1</txmd:NumberOfIssuedPatents>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">269546</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">197593</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">112474</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z33kdLUjHoci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span&gt;Estimated amortization
expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20201231_z1JUp7oWRApk" style="border-bottom: Black 1pt solid; text-align: center"&gt;Estimated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zZyWjdNjBbcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: right"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zj5ls5NSbUHl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zozl23CkGf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zXrb5arYeYK8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zY4MKUsYBGvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;274,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">274669</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">274669</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">274669</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">274669</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">274669</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zWTtJcOhdnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 7&#x2013; &lt;span id="xdx_82B_zlEeOlBd5rY2"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zWFG7m1cBZL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B0_z0igxA9SVRpb"&gt;Other current liabilities&lt;/span&gt; consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_z1xo8tvfSIge" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20191231_zWIqwsQfSZPe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zaTCBg7RazSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,758,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,040,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zeyV3oadnasd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,770,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,316,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zNcBXHLzhL6b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,285,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zhYdjdiDEsF5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued compensated absences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,353,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,463,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_zQ7aXpeBqyMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,632,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zMwLBfP5Q63d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;422,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zIPy0XfuYiHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;925,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zBo2rNF1j4zj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,253,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--AccruedRebates_iI_maOLCz3D1_z9a5LrouC4Vl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued rebates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,010,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,916,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zZe36SEC1cHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,339,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,480,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_mtOLCzij0_z5oEs5EK70W1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38,169,869&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,823,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zaOWz2G0v393" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zWFG7m1cBZL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8B0_z0igxA9SVRpb"&gt;Other current liabilities&lt;/span&gt; consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_z1xo8tvfSIge" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20191231_zWIqwsQfSZPe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zaTCBg7RazSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,758,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,040,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zeyV3oadnasd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,770,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,316,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zNcBXHLzhL6b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,285,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zhYdjdiDEsF5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued compensated absences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,353,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,463,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_zQ7aXpeBqyMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,632,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zMwLBfP5Q63d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;898,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;422,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zIPy0XfuYiHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;925,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zBo2rNF1j4zj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,253,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--AccruedRebates_iI_maOLCz3D1_z9a5LrouC4Vl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued rebates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,010,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,916,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zZe36SEC1cHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,339,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,480,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_mtOLCzij0_z5oEs5EK70W1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;38,169,869&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,823,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8758073</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">8040278</us-gaap:AccruedSalariesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6770206</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10316298</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">227500</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3285662</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2353996</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1463878</us-gaap:AccruedVacationCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2632432</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2347122</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">898568</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">422336</us-gaap:AccruedProfessionalFeesCurrent>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">925314</txmd:AccruedResearchAndDevelopment>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1049603</txmd:AccruedResearchAndDevelopment>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2253994</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <txmd:AccruedRebates contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">11010588</txmd:AccruedRebates>
    <txmd:AccruedRebates contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3916672</txmd:AccruedRebates>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2339198</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1480225</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">38169869</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_809_eus-gaap--LongTermDebtTextBlock_z0Lc13j7mEA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
8 &#x2013; &lt;span id="xdx_828_z7KQ3ZogzQ47"&gt;DEBT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 24, 2019, we entered into a
Financing Agreement, as amended, or the Financing Agreement, with Sixth Street Specialty Lending, Inc., as administrative
agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party
thereto from time to time as guarantors, which provided us with up to a $&lt;span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zT0AXzKGg7Vi"&gt;300,000,000&lt;/span&gt;&#160;first
lien secured term loan credit facility, or the Facility. The Facility provided for availability to us in three tranches: (i)
$&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zpthIp6Cwi0b"&gt;200,000,000&lt;/span&gt;&#160;was
drawn upon entering into the Financing Agreement; (ii) $&lt;span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zsyWnBAMTlqi"&gt;50,000,000&lt;/span&gt;&#160;was
drawn on February 18, 2020 following our achievement of more than $&lt;span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0i_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zdKLAwDNebQf" title="Revenues"&gt;11,000,000&lt;/span&gt;&#160;in
net revenues from IMVEXXY, BIJUVA, and ANNOVERA for the fourth quarter of 2019 and (iii) &lt;span id="xdx_90E_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zhlT40GNMH74"&gt;$50,000,000&lt;/span&gt;&#160;was
previously available to us in the Administrative Agent&#x2019;s sole and absolute discretion either contemporaneously with the
delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as the Administrative Agent
may have consented to. Subsequent to the pause in the successful full launch of ANNOVERA caused by the COVID-19 pandemic, the
undrawn $&lt;span id="xdx_90E_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zXcnPtbRWxn"&gt;50,000,000 &lt;/span&gt;tranche
under the Financing Agreement is no longer available. Borrowings under the Facility accrue interest at either (i)&#160;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zPVeV0wuGvT2"&gt;3-month
LIBOR&lt;/span&gt;&#160;plus&#160;&lt;span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3dms8Czlin3"&gt;7.75&lt;/span&gt;%,
subject to a LIBOR floor of&#160;&lt;span id="xdx_90E_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zMjzo8Midjnf"&gt;2.70&lt;/span&gt;%
or (ii) the&#160;&lt;span id="xdx_906_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zHBzFBbDJ7y2"&gt;prime
rate&lt;/span&gt;&#160;plus&#160;&lt;span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zxSSBmgdEwab"&gt;6.75&lt;/span&gt;%,
subject to a prime rate floor of&#160;&lt;span id="xdx_907_ecustom--PrimeRateFloor_iI_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zAS0ri0fVuc1"&gt;5.2&lt;/span&gt;%
as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. Prior to entering into Amendment No.
8, the outstanding principal amount of the Facility was payable in&#160;&lt;span id="xdx_907_ecustom--NumberOfInstallmentPayments_iI_dc_uN_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zxNsII45QZWi"&gt;four&lt;/span&gt;&#160;equal
quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. In connection with Amendment
No. 8 we, among other things, (i) repaid $&lt;span id="xdx_905_eus-gaap--RepaymentsOfLinesOfCredit_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDXzbY67F1Eh"&gt;15&lt;/span&gt;.0
million in principal under the Financing Agreement on such date, plus a &lt;span id="xdx_909_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0MgY7Uekn96"&gt;5.0&lt;/span&gt;%
prepayment fee, (ii) agreed to repay an additional $&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodOneMember_zMKCEXLiRjDd" title="Principal repayment"&gt;35&lt;/span&gt;.0
million in principal by no later than March 31, 2021, plus a &lt;span id="xdx_90C_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodOneMember_zGuOlDVYVIxc"&gt;5.0&lt;/span&gt;%
prepayment fee, and (iii) agreed to make additional principal repayments as follows: (x) $&lt;span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodTwoMember_z25NpNlTyoCj"&gt;5&lt;/span&gt;.0
million on each of March 31, 2022, June 30, 2022 and September 30, 2022; (y) $&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodThreeMember_zB8ECcvYo9je"&gt;10&lt;/span&gt;.0
million on each of December 31, 2022 and March 31, 2023; and (z) $&lt;span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn4n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodFourMember_zBNRx6eCQbCh"&gt;41.25&lt;/span&gt;
million on each of June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, plus the prepayment fees
described in the following sentence. We have the right to prepay borrowings under the Facility in whole or in part at any
time, subject to a prepayment fee on the principal amount being prepaid, which was revised in connection with Amendment No.
8, of (i) &lt;span id="xdx_908_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodFiveMember_zrqBEU9y1o61"&gt;30.0&lt;/span&gt;%
of the principal amount being repaid through March 31, 2022 (excluding the scheduled $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSixMember_zR8lTtRCB5Ik"&gt;5&lt;/span&gt;.0
million principal repayment on such date, which is subject to a &lt;span id="xdx_908_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSixMember_z54PxhVRbOhc"&gt;5.0&lt;/span&gt;%
prepayment fee); (ii) &lt;span id="xdx_900_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSevenMember_zwTMAbnLn6wk"&gt;5.0&lt;/span&gt;%
of the principal amount being repaid from April 1, 2022 through March 31, 2023; (iii) &lt;span id="xdx_90F_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodEightMember_zAyMpw7mPmJk"&gt;3.0&lt;/span&gt;%
of the principal amount being repaid from April 1, 2023 through March 31, 2024; and (iv) thereafter, none, in each case
subject to certain limited exceptions, including with respect to a repayment in full of the obligations under the Financing
Agreement. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility
fee equal to&#160;&lt;span id="xdx_900_ecustom--FacilityFeePaidPercent_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z21h4l8uOn5i"&gt;2.5&lt;/span&gt;%
of the initial amount borrowed and were required to pay such a facility fee in connection with subsequent borrowings under
the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition
to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants
applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a
minimum unrestricted cash balance of $&lt;span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z1AjjsD6Du04"&gt;60,000,000&lt;/span&gt;,
and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and
ANNOVERA products beginning with the fiscal quarter ended December 31, 2020. Pursuant to Amendment No. 8, the minimum
consolidated net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised to (i)
$&lt;span id="xdx_90C_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period1Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zFPcOQ5sNoQ2"&gt;17&lt;/span&gt;.0
million, $&lt;span id="xdx_906_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period2Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zzw9yTflbxr6"&gt;20&lt;/span&gt;.0
million, $&lt;span id="xdx_906_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period3Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zGYPtvUkiZwe"&gt;23&lt;/span&gt;.0
million, and $&lt;span id="xdx_908_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period4Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_z4Ku9yQcdFw2"&gt;26.5&lt;/span&gt;
million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $&lt;span id="xdx_900_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period5Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zgtcrDt0j6F7"&gt;30&lt;/span&gt;.0
million, $&lt;span id="xdx_90B_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period6Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zQLwyBo9FNV6"&gt;35&lt;/span&gt;.0
million, $&lt;span id="xdx_90A_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period7Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_z3x0ztv50Mfb"&gt;40&lt;/span&gt;.0
million and $&lt;span id="xdx_905_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period8Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zDk7k2am9BRb"&gt;45&lt;/span&gt;.0
million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $&lt;span id="xdx_90B_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period9Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zNtl5cfKYZPa"&gt;50&lt;/span&gt;.0
million, $&lt;span id="xdx_909_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period10Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zeCtuhVGyR99"&gt;55&lt;/span&gt;.0
million, $&lt;span id="xdx_90E_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period11Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zakn57nHjtud"&gt;60&lt;/span&gt;.0
million and $&lt;span id="xdx_902_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period12Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zg5BaqQj9XUg"&gt;65.5&lt;/span&gt;
million for the first, second, third, and fourth quarters of 2023, respectively, and (iv) $&lt;span id="xdx_90C_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period13Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zXpp1CJAd8r4"&gt;70&lt;/span&gt;.0
million for the first quarter of 2024. Pursuant to Amendment No. 6 (as defined below), the minimum required cash balance was
lowered to $&lt;span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_znJdXV3fEqu2"&gt;45&lt;/span&gt;
million from November 8, 2020 through December 31, 2020. As of December 31, 2020, we were in compliance with all covenants
under the Financing Agreement. The Financing Agreement also includes other representations, warranties, indemnities,
restrictions on the payment of dividends, and events of default that are customary for financings of this type, including an
event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent
and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and
payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and
its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon
exceptions, by a first priority perfected security interest in all existing and after acquired assets of our company and its
subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect
subsidiaries, subject to certain exceptions. Also pursuant to Amendment No. 8, the Administrative Agent consented to a
framework for our potential disposition of our vitaCare prescription services business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 5, 2020, we entered into
Amendment No. 5 to the Financing Agreement, or Amendment No. 5. Amendment No. 5 adjusted the covenant in the Financing
Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our IMVEXXY,
BIJUVA, and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant was effective beginning with
the fiscal quarter ending December 31, 2020. In connection with Amendment No. 5 and in lieu of a cash amendment fee, we
issued to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zI61F8GEjRN2" title="Number of warrants issued"&gt;4,752,116&lt;/span&gt;
shares of Common Stock with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z5GIH5eJwp6j" title="Warrants exercise price"&gt;1.58&lt;/span&gt;
per share and a ten-year term, or the Lender Warrants. The Lender Warrants were issued pursuant to an exemption from
registration under the Securities Act of 1933, as amended, and no registration rights were issued. The Company concluded that
the modification accounting model is applicable to this transaction and recognized the fair value of the warrants as a debt
discount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 8, 2020, in connection with
entering into Amendment No. 6 to the Financing Agreement, or Amendment No. 6, we amended the Lender Warrants to provide for an
adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted
average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise
price. Pursuant to Amendment No. 6, the issuance of Common Stock by the Company in the underwritten public offering at a price
per share equal to $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20211108_zEgMmvRCIOY4"&gt;1.1856&lt;/span&gt; triggered the automatic reduction in the exercise price of the Lender Warrants from $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zt920nnHIO94"&gt;1.58&lt;/span&gt; to $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201108__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zJUrhQg1Hbf6"&gt;1.1856&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 1, 2018, we entered into a
Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as
lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as
amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $&lt;span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zVPDmAPSJpG3" title="Line of Credit Facility, Maximum Borrowing Capacity"&gt;200,000,000&lt;/span&gt;,
or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in&#160;&lt;span id="xdx_903_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uN_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zbWTZ2h6yAjl" title="Number of tranches under term loan facility"&gt;three&lt;/span&gt;&#160;separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts
borrowed under the Term Loan bore interest at a rate equal to the sum of (i)&#160;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zbB61kc3itwg" title="Debt Instrument, Description of Variable Rate Basis"&gt;one-month LIBOR&lt;/span&gt;
&#160;(subject to a LIBOR floor of&#160;&lt;span id="xdx_904_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zD5trAgIz9Nl" title="LIBOR floor rate"&gt;1.50&lt;/span&gt;%)
plus (ii)&#160;&lt;span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zfzZnx0M4x9b" title="Debt Instrument, Basis Spread on Variable Rate"&gt;7.7&lt;/span&gt;5%
per annum.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 24, 2019, we terminated the Credit
Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $&lt;span id="xdx_90B_ecustom--RepaymentOfDebtWithNewCreditFacility_pp0i_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zS0oG7kt7oUj"&gt;81,661,000&lt;/span&gt;&#160;was
used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of&#160;&lt;span id="xdx_903_ecustom--PrepaymentFeePercentage_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zq5316yBeWVb"&gt;4&lt;/span&gt;%, a repayment fee of&#160;&lt;span id="xdx_906_ecustom--RepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zW8j96OpNqrh"&gt;4&lt;/span&gt;%&#160;and
other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement,
we recorded $&lt;span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0i_dxL_c20190101__20191231_zx1FLKRkKzI6" title="::XDX::-10057632"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1028"&gt;10,057,632&lt;/span&gt;&lt;/span&gt;&#160;in loss on extinguishment of debt in the second quarter of 2019. Interest expense for the years ended
December 31, 2019 and 2018 related to the Credit Agreement was $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0i_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z1Q40lF5lODh"&gt;1,816,747&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestExpenseDebt_pp0i_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zt9DarYAfUi1"&gt;4,407,975&lt;/span&gt;, respectively. During the year ended December
31, 2019, and prior to the repayment of the Credit Agreement, we amortized $&lt;span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zMGagYlPtuma" title="Amortization of deferred financing costs"&gt;120,146&lt;/span&gt;&#160;of deferred financing fees as interest
expense in the accompanying consolidated financial statements. During the year ended December 31, 2018, we amortized $&lt;span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zBfbp3pfViZ1" title="Amortization of deferred financing costs"&gt;269,859&lt;/span&gt;&#160;of
deferred financing fees as interest expense in the accompanying consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As
of December 31, 2020, we &lt;/span&gt;had $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0i_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z5ejBrpNZnYj"&gt;250,000,000&lt;/span&gt;&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated
financial statements. Since the inception of the Financing Agreement, we have incurred $&lt;span id="xdx_90C_eus-gaap--DeferredFinanceCostsGross_iI_pp0i_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zCSFoFqVSN05"&gt;7,902,270&lt;/span&gt;&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
were allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to the two
tranches of borrowings that we received of $&lt;span id="xdx_90B_eus-gaap--DeferredFinanceCostsGross_iI_pp0i_c20201231__custom--DebtTrancheAxis__custom--TrancheTwoMember_zgxjvZuF7T9i"&gt;7,626,891&lt;/span&gt;&#160;have
been reflected as debt discount upon each draw and are amortized to interest expense using the effective interest method. In
addition, during the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of
$&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0i_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zZ4SOZlWM6pc" title="Fair value of warrants"&gt;7,428,178&lt;/span&gt;
as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the
Financing Agreement. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value to the debt discount
of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0i_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zGkmiNugi5nk" title="Debt discount"&gt;239,983&lt;/span&gt;,
which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement.
The public offering in November 2020 triggered the down round provision underlying the warrants
granted in August 2020, as modified in November 2020, which was immaterial.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the third quarter of 2020, we concluded
that the undrawn $&lt;span id="xdx_90B_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zbKv5T4ySVBg"&gt;50,000,000&lt;/span&gt;&#160;tranche under the Financing Agreement is no longer available to us. As such, we wrote off $&lt;span id="xdx_90C_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pp0i_c20200101__20201231_zTTCFlRoUJ0g" title="Write off of deferred financing fees"&gt;275,379&lt;/span&gt;
of deferred financing fees associated with the unfunded tranche, which were previously deferred as assets until such tranche had
been drawn.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2020
and 2019, we amortized $&lt;span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zauQQjdQEBi2" title="Amortization of deferred financing costs"&gt;2,256,428&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zhgLPwwxNhH4" title="Amortization of deferred financing costs"&gt;736,156&lt;/span&gt;, respectively, of deferred financing fees related to the Financing Agreement as
interest expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement
is due and payable quarterly in arrears. Interest expense for the years ended December 31, 2020 and 2019 was $&lt;span id="xdx_90F_eus-gaap--InterestExpenseBorrowings_pp0i_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zE095bRo9O8e"&gt;26,049,236&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InterestExpenseBorrowings_pp0i_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zsb7QUeW8Pf2"&gt;14,709,166&lt;/span&gt;,
respectively. The overall effective interest rate under the Financing Agreement was approximately &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7YiWUjSjGK5"&gt;12.5&lt;/span&gt;% as of December 31, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zPwkD1Td4woa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z2o13kQ2qy38"&gt;As of December 31, 2020 and 2019, the carrying
value of our debt consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Financing Agreement&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zwMTUNoEabB4" title="Long-term Debt, Gross"&gt;250,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7jLOiHi86Hh" title="Long-term Debt, Gross"&gt;200,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Debt discount and financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20201231_zJZIcl9hA7Q3" style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,302,469&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zwN3DhrO3tLa" style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,365,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LongTermDebtNoncurrent_iI_c20201231_zBq3vAz9k4rj" title="TOTAL LONG-TERM DEBT"&gt;237,697,531&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LongTermDebtNoncurrent_iI_c20191231_z7cAUqfBdSZ1" title="TOTAL LONG-TERM DEBT"&gt;194,634,643&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_z9QIONfH9CBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zxHfodBnKX38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zxEhXGMEwQB"&gt;The following table reflects our aggregate future principal payments
under the Financing Agreement for the next five years, as amended by Amendment No. 8:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_z3X51nIyMpud" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_iI_d0_zYdZnuq1q9g6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_iI_d0_zAXeX7sTPnMe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_iI_zcu09OXQhgR7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;133,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_iI_zE0O6fqRfQ1c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_iI_d0_zy2jDUsGPtmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zh4LGFfHc1Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable>
    <txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember">3-month
LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0270</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">prime
rate</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:PrimeRateFloor
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.052</txmd:PrimeRateFloor>
    <txmd:NumberOfInstallmentPayments
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="N">4</txmd:NumberOfInstallmentPayments>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">15000000</us-gaap:RepaymentsOfLinesOfCredit>
    <txmd:PrepaymentFeePercentage
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodOneMember"
      decimals="-5"
      unitRef="USD">35000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <txmd:PrepaymentFeePercentage
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodOneMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodTwoMember"
      decimals="-5"
      unitRef="USD">5000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodThreeMember"
      decimals="-5"
      unitRef="USD">10000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFourMember"
      decimals="-4"
      unitRef="USD">41250000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <txmd:PrepaymentFeePercentage
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodFiveMember"
      decimals="INF"
      unitRef="Pure">0.300</txmd:PrepaymentFeePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSixMember"
      decimals="-5"
      unitRef="USD">5000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <txmd:PrepaymentFeePercentage
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSixMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeePercentage>
    <txmd:PrepaymentFeePercentage
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodSevenMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeePercentage>
    <txmd:PrepaymentFeePercentage
      contextRef="From2021-02-272021-03-01_custom_FinancingAgreementAmendment8Member_us-gaap_SubsequentEventMember_custom_RepaymentPeriodEightMember"
      decimals="INF"
      unitRef="Pure">0.030</txmd:PrepaymentFeePercentage>
    <txmd:FacilityFeePaidPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.025</txmd:FacilityFeePaidPercent>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">17000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period3Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">23000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period4Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">26500000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period5Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">30000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period6Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">35000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period7Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">40000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period8Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">45000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period9Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">50000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period10Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">55000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period11Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period12Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">65500000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-03-01_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment8Period13Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">70000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member"
      decimals="-6"
      unitRef="USD">45000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-08-05_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">4752116</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-05_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-11-08"
      decimals="INF"
      unitRef="USDPShares">1.1856</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-05_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-11-08_custom_LenderWarrantsMember_custom_FinancingAgreementAmendment6Member"
      decimals="INF"
      unitRef="USDPShares">1.1856</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:NumberOfTranchesUnderTermLoanFacility
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="N">3</txmd:NumberOfTranchesUnderTermLoanFacility>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">one-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <txmd:LiborFloorRate
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Pure">0.0150</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Pure">0.077</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:RepaymentOfDebtWithNewCreditFacility
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">81661000</txmd:RepaymentOfDebtWithNewCreditFacility>
    <txmd:PrepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:PrepaymentFeePercentage>
    <txmd:RepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:RepaymentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">1816747</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2018-01-012018-12-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">4407975</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">120146</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2018-01-012018-12-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">269859</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2020-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2020-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">7902270</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2020-12-31_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">7626891</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2020-08-05_custom_LenderWarrantsMember"
      decimals="0"
      unitRef="USD">7428178</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member"
      decimals="0"
      unitRef="USD">239983</us-gaap:DebtInstrumentUnamortizedDiscount>
    <txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable
      contextRef="AsOf2020-09-30_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</txmd:LineOfCreditFacilityUndrawnTrancheNoLongerAvailable>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">275379</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-012020-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">2256428</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">736156</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2020-01-012020-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">26049236</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2019-01-012019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">14709166</us-gaap:InterestExpenseBorrowings>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2020-12-31_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zPwkD1Td4woa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z2o13kQ2qy38"&gt;As of December 31, 2020 and 2019, the carrying
value of our debt consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Financing Agreement&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zwMTUNoEabB4" title="Long-term Debt, Gross"&gt;250,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7jLOiHi86Hh" title="Long-term Debt, Gross"&gt;200,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Debt discount and financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20201231_zJZIcl9hA7Q3" style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,302,469&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zwN3DhrO3tLa" style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,365,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--LongTermDebtNoncurrent_iI_c20201231_zBq3vAz9k4rj" title="TOTAL LONG-TERM DEBT"&gt;237,697,531&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--LongTermDebtNoncurrent_iI_c20191231_z7cAUqfBdSZ1" title="TOTAL LONG-TERM DEBT"&gt;194,634,643&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2020-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">12302469</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5365357</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">237697531</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zxHfodBnKX38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zxEhXGMEwQB"&gt;The following table reflects our aggregate future principal payments
under the Financing Agreement for the next five years, as amended by Amendment No. 8:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_z3X51nIyMpud" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_iI_d0_zYdZnuq1q9g6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_iI_d0_zAXeX7sTPnMe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_iI_zcu09OXQhgR7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;133,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_iI_zE0O6fqRfQ1c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_iI_d0_zy2jDUsGPtmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">50000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">133750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">41250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zevvxjX5Eo33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 9 &#x2013; &lt;span id="xdx_826_z9KCoir0Pphh"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2020, we had &lt;span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zadL1y9Kiw6b" title="Preferred Stock, Shares Authorized"&gt;10,000,000&lt;/span&gt;
shares of preferred stock, par value $&lt;span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zL5auj1mcSdd" title="Preferred Stock, Par or Stated Value Per Share"&gt;0.001&lt;/span&gt; per share, or Preferred Stock, authorized for issuance, of which &lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20201231_zMdkPuF07txb" title="Preferred Stock, Shares Issued"&gt;&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20201231_z4ktvPaYuNxd" title="Preferred Stock, Shares Outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares of Preferred
Stock were issued or outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2020, we had &lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zETZF7pENal" title="Common Stock, Shares Authorized"&gt;600,000,000&lt;/span&gt;
shares of Common Stock authorized for issuance, of which &lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20201231_zPgGFQklb5Ac" title="Common Stock, Shares, Issued"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zdycJgL6WmRk" title="Common Stock, Shares, Outstanding"&gt;299,765,396&lt;/span&gt;&lt;/span&gt; shares of Common Stock were issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances During 2020&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2020,
stock options to purchase an aggregate of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWL7lnRBYlMi" title="Shares issued for exercise of options, net (in shares)"&gt;1,182,195&lt;/span&gt; shares of Common Stock were exercised for $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDzhsgKiugrc" title="Shares issued for exercise of options, net"&gt;271,678&lt;/span&gt; in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On November 10, 2020, we entered into an underwriting agreement
with Cantor Fitzgerald &amp;amp; Co., or Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201109__20201113__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zqGbZGoDAHMb" title="Shares issued in offerings, net of cost (in shares)"&gt;23,437,500&lt;/span&gt;
shares of Common Stock at a public offering price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zCzbiIckQG02" title="Shares Issued, Price Per Share"&gt;1.1856&lt;/span&gt; per share. We granted to the underwriter an option, exercisable for
a period of &lt;span id="xdx_909_ecustom--PeriodExercisableUnderwritersOption_dt_c20201109__20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zk0suB4XaUz5" title="Period exercisable underwriters option"&gt;30 days&lt;/span&gt;, to purchase up to &lt;span id="xdx_906_ecustom--UnderwritersOptionGrantedInPeriodShares_c20201109__20201120__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zanMzhITS889" title="Underwriters option granted in period shares"&gt;3,515,625&lt;/span&gt; additional shares of Common Stock, which was exercised in full. The net proceeds
the offering were approximately $&lt;span id="xdx_90E_ecustom--ProceedsFromIssuancePublicOffering_c20201109__20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_z4NSlubpzt65" title="Proceeds from issuance public offering"&gt;31,703,000&lt;/span&gt;, after deducting the underwriting discounts and commissions and estimated offering
expenses payable by us. The offering of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201109__20201113__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zDzDIsb2ctVc"&gt;23,437,500&lt;/span&gt; shares closed on November 13, 2020 and the offering of &lt;span id="xdx_906_ecustom--UnderwritersOptionGrantedInPeriodShares_c20201109__20201120__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zFcL6LKPQKF3"&gt;3,515,625&lt;/span&gt; shares closed on November 20, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2020, we entered into a
Controlled Equity Offering&lt;sup&gt;SM&lt;/sup&gt; Sales Agreement, or sales agreement, with Cantor Fitzgerald relating to shares of our
Common Stock. In accordance with the terms of the sales agreement, we were permitted to offer and sell shares of our Common
Stock having an aggregate offering price of up to $&lt;span id="xdx_905_ecustom--MaximumCommonStockOfferingPrice_dm_c20200101__20201130__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zH0MJ3E4LRni"&gt;50 million&lt;/span&gt;
from time to time through or to Cantor Fitzgerald, acting as sales agent. Cantor Fitzgerald was entitled to
compensation at a fixed commission rate of &lt;span id="xdx_907_ecustom--FixedCommissionRate_dp_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zhUMSLPVsvdj"&gt;3.0&lt;/span&gt;%
of the aggregate gross sales price per share sold. No shares of Common Stock were sold under the sales agreement during the year ended December 31, 2020. As
further described in Note 16 - Subsequent Events, on February 8, 2021, our &#x201c;at the market&#x201d; offering with Cantor Fitzgerald
terminated following the sale of the maximum $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_c20210101__20210228__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zbwaDJBp2gCf"&gt;50 million&lt;/span&gt; of shares of Common Stock in January 2021 and February 2021 pursuant to
the sales agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances During 2019&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 24, 2019, we entered into an
underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters, relating to an underwritten public
offering of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z2h9oFSnHer5" title="Shares issued in offerings, net of cost (in shares)"&gt;26,000,000&lt;/span&gt; shares of our Common Stock at a public offering price of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zMNfU5hFd5c7" title="Shares Issued, Price Per Share"&gt;2.75&lt;/span&gt; per share. We granted the underwriters an
option, exercisable for a period of &lt;span id="xdx_903_ecustom--PeriodExercisableUnderwritersOption_dt_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zrY70L9cq1Hi" title="Period exercisable underwriters option"&gt;30 days&lt;/span&gt;, to purchase up to &lt;span id="xdx_903_ecustom--UnderwritersOptionGrantedInPeriodShares_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zsItt7AIR0J4" title="Underwriters option granted in period shares"&gt;3,900,000&lt;/span&gt; additional shares of Common Stock, which was exercised
in full. The net proceeds to us from the offering were approximately $&lt;span id="xdx_905_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zsecvHzmeRng" title="xdx_907_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zSAbRt90BdY"&gt;77,031,000&lt;/span&gt;, after deducting the underwriting discount and
offering expenses payable by us. The offering closed on October 29, 2019.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2019,
certain individuals exercised stock options to purchase an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwLg2siMkLFc" title="Shares issued for exercise of options, net (in shares)"&gt;331,619&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMS273NxSAG4" title="Shares issued for exercise of options, net"&gt;108,656&lt;/span&gt; in cash. Also,
during the year ended December 31, 2019, stock options to purchase an aggregate of &lt;span id="xdx_900_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20191231_zduc4iYxQJSe" title="Number of stock options exercised in cashless exercise (in shares)"&gt;12,097&lt;/span&gt; shares of Common Stock were exercised
pursuant to the options&#x2019; cashless exercise provisions, which resulted in &lt;span id="xdx_905_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20191231_zO0sMCeCS4zg" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"&gt;11,834&lt;/span&gt; shares of Common Stock being issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances During 2018&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 1, 2018, we entered into an underwriting
agreement with Goldman Sachs &amp;amp; Co. LLC, as representative of the underwriters, relating to an underwritten public offering
of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zmq2OsvdXGFj" title="Shares issued in offerings, net of cost (in shares)"&gt;12,745,098&lt;/span&gt; shares of our Common Stock at a price of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zT0g1eBP9hU7" title="Shares Issued, Price Per Share"&gt;5.10&lt;/span&gt; per share. We granted the underwriters an option, exercisable for
a period of &lt;span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dt_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zdsxWOgxQfIf" title="Period exercisable underwriters option"&gt;30 days&lt;/span&gt;, to purchase up to &lt;span id="xdx_901_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zMLZnLxOtWjb" title="Underwriters option granted in period shares"&gt;1,911,764&lt;/span&gt; additional shares of Common Stock. On August 2, 2018, the underwriters exercised
the option in full. The net proceeds to us from the offering, including the exercise of the option to purchase additional shares,
were approximately $&lt;span id="xdx_901_ecustom--ProceedsFromIssuancePublicOffering_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zRqydcYEtCy5" title="Proceeds from issuance public offering"&gt;69,908,000&lt;/span&gt;, after deducting the underwriting discount and offering expenses payable by us. The offering closed
on August 6, 2018. In connection with the Knight License Agreement, on August 6, 2018, Knight entered into a subscription agreement
with us, pursuant to which Knight purchased &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zbJWmNdIxBQd" title="Shares issued in offerings, net of cost (in shares)"&gt;3,921,568&lt;/span&gt; of shares of our Common Stock concurrently with the closing of the underwritten
public offering of Common Stock at a price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zDjJWk4XjBGd" title="Shares Issued, Price Per Share"&gt;5.10&lt;/span&gt;, for proceeds to us of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zXhW1Xh38PNa" title="Shares issued in offerings, net of cost"&gt;20,000,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2018,
certain individuals exercised stock options to purchase an aggregate of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxzVFySqaZB1" title="Shares issued for exercise of options, net (in shares)"&gt;5,444,526&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQFrePRJZdI3" title="Shares issued for exercise of options, net"&gt;1,666,208&lt;/span&gt; in cash.
Also, during the year ended December 31, 2018, stock options to purchase an aggregate of &lt;span id="xdx_901_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20181231_zkDhw48ZgHMj" title="Number of stock options exercised in cashless exercise (in shares)"&gt;10,000&lt;/span&gt; shares of Common Stock were exercised
pursuant to the options&#x2019; cashless exercise provisions, wherein &lt;span id="xdx_901_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20181231_zc4Sui8Vqqvc" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"&gt;9,841&lt;/span&gt; shares of Common Stock were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Warrants to Purchase Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2020, we had warrants
outstanding to purchase an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231_zG6yWauvexhh" title="Warrants outstanding"&gt;6,534,687&lt;/span&gt; shares of Common Stock with a weighted-average contractual remaining life of
approximately &lt;span id="xdx_90C_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20201231_zQF75OpByNNi" title="Weighted-average contractual remaining life"&gt;7.25&lt;/span&gt; years, and exercise prices ranging from $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zuOiOyQJYNCc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;0.24&lt;/span&gt; to $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zToPRD7Gv3T6" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;8.20&lt;/span&gt; per share, resulting in a weighted average exercise price
of $&lt;span id="xdx_90F_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYD8KlOza87c" title="Weighted average exercise price of warrants (in dollars per share)"&gt;1.55&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,
including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with Amendment No. 5 and
in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders under the Financing Agreement the Lender
Warrants. The fair value for the Lender Warrants was determined by using the Black-Scholes Model on the date of the grant using
a term of &lt;span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zFq1ZymDuLh8"&gt;ten years&lt;/span&gt;, volatility of &lt;span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z25U0CWNsN0b" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"&gt;68.8&lt;/span&gt;%, risk-free interest rate of &lt;span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zoTOEUcWjUJ3" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate"&gt;0.34&lt;/span&gt;% and dividend yield of &lt;span id="xdx_901_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zRsf6BxHzLX5" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"&gt;0&lt;/span&gt;%. The grant date fair value
of the warrants was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zFA7i4iPEnWh" title="Weighted average grant date fair value, granted"&gt;1.56&lt;/span&gt; per share. The warrants vested upon issuance. We concluded that the modification accounting model is
applicable to this warrant issuance and recognized the fair value of the warrants as a debt discount. As a result, the fair value
of the Lender Warrants is being amortized to interest expense over the term of the Financing Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 8, 2020, in connection with
entering into Amendment No. 6, we amended the Lender Warrants to provide for an adjustment to the exercise price if we conducted
certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen
trading days ending December 31, 2020 was lower than the then-current exercise price. Pursuant to Amendment No. 6, the issuance
of the shares of Common Stock in the November 2020 underwritten public offering triggered the automatic reduction in the exercise
price of the Warrants from $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zSSM7TXC0RUl"&gt;1.58&lt;/span&gt; to $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201108__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zNIemvC7rTHc"&gt;1.1856&lt;/span&gt;. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value
to the debt discount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zv62SeJgagZ9" title="Debt Discount"&gt;239,983&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2019,
we granted warrants to purchase an aggregate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zETZ3fmKAQpd" title="Number of shares under warrants granted"&gt;75,000&lt;/span&gt; shares of Common Stock to outside consultants which vest ratably over a
&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z6KPq0u7PX4l" title="Warrants vesting period"&gt;12&lt;/span&gt;-month period and have an expiration date of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zGptuM3Xzy1f" title="Warrants expiration date"&gt;February 13, 2024&lt;/span&gt;. During the year ended December 31, 2018, we granted warrants
to purchase an aggregate of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zivTQmjh9yl8" title="Number of shares under warrants granted"&gt;175,000&lt;/span&gt; shares of Common Stock to outside consultants which vest ratably over a &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zy7SCWdnFgk3" title="Award vesting period"&gt;12&lt;/span&gt;-month period and
have an expiration date of &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zrd4iPyErWB3" title="Warrants expiration date"&gt;March 15, 2023&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recorded share-based compensation expense
related to warrants previously issued of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgQNHXusCNkc" title="Share-based Payment Arrangement, Noncash Expense"&gt;26,446&lt;/span&gt;, $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXXQ3RiS3qW8" title="Share-based Payment Arrangement, Noncash Expense"&gt;254,970&lt;/span&gt;, and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2PY20UsVsXe" title="Share-based Payment Arrangement, Noncash Expense"&gt;494,136&lt;/span&gt; for the years ended December 31, 2020, 2019 and 2018,
respectively, in the accompanying consolidated financial statements. At December 31, 2020, there was no unrecognized compensation
expense remaining related to unvested warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zQIEBlKA5QB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Summary of our Warrant activity during the year ended December
31, 2020:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares Under&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life in Years&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Intrinsic&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRRfJbOqoFuf" style="width: 12%; text-align: right" title="Number of shares under warrants outstanding beginning"&gt;1,832,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zV0mPa5GYoF6" style="width: 12%; text-align: right" title="Weighted average exercise price warrants outstanding beginning"&gt;2.62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxLMoeHGv0sh" style="width: 12%; text-align: right" title="Weighted average remaining contractual life, warrants outstanding"&gt;1.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zI9HnHhuALE2" style="width: 12%; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning"&gt;2,447,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyYJ8fQEKFIb" style="text-align: right" title="Number of shares under warrants granted"&gt;4,752,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9MnAk7PDqsa" style="text-align: right" title="Weighted average exercise price warrants granted"&gt;1.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhpZv6rBSF6f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Forfeited"&gt;(50,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh9SXiF0REug" style="text-align: right" title="Weighted average exercise price warrants cancelled/forfeited"&gt;6.35&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRmnrBa1Ixka" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under warrants outstanding ending"&gt;6,534,687&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYMBmVblsfE3" style="text-align: right" title="Weighted average exercise price warrants outstanding ending"&gt;1.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHkKR2Z3kSue" style="text-align: right" title="Weighted average remaining contractual life, warrants outstanding"&gt;7.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB7D2SbhQIng" style="text-align: right" title="Aggregate intrinsic value, warrants outstanding ending"&gt;1,041,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested and Exercisable at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zToiBI49G18d" style="text-align: right" title="Number of shares under warrants vested and exercisable ending"&gt;6,534,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHtFFJEiNjzk" style="text-align: right" title="Weighted average exercise price warrants unvested ending"&gt;1.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOhy3RAC7XNl" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable ending"&gt;7.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLUCFsclWND7" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;1,041,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zQsBOyx2o9ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zD2LR7eyNHaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted average fair value per share
of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018
are set forth in the table below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzzohakCd7ib" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdGcFn7jkUsb" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zfDz6mG7bx2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--WeightedAverageExercisePriceOtherThanOptions_pii_uUSDPShares_zfh5i8004uWb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5.63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_z2wJm8856j8j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_z5fuJJ2oCdj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.36&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_zt1cBcLV5i3e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62.12&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zDTGR0r3w2kl" style="text-align: right" title="Term (in years)"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrntf4TgaIXi" style="text-align: right" title="Term (in years)"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjrWxfC1bd4j" style="text-align: right" title="Term (in years)"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_zqNSt6wazfbg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_zdc3kPZnDLWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrant exercises&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2020,
&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE9Ev2PWsAr6" title="Warrants exercised"&gt;no&lt;/span&gt; warrants were exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2019,
warrants to purchase an aggregate of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zNcbcQhbK0Rd" title="Warrants exercised"&gt;1,250,000&lt;/span&gt; shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise
provisions, which resulted in &lt;span id="xdx_90B_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlzOamFaa91c" title="Number of stock issued in cashless exercise of warrants"&gt;471,184&lt;/span&gt; shares of Common Stock being issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2018,
&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbV1UI0mn4P7" title="Warrants exercised"&gt;no&lt;/span&gt; warrants were exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration: underline"&gt;Options to Purchase Common Stock of the Company&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In 2009, we adopted the 2009 Long-Term
Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants
of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock
options and other stock and cash incentives, or the Awards. As of December 31, 2020, there were non-qualified stock options to
purchase an aggregate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zCN6cUIpt71c" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;13,285,205&lt;/span&gt; shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009
Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In 2012, we adopted the 2012 Stock Incentive
Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive
for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
As of December 31, 2020, there were non-qualified stock options to purchase an aggregate of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zdfGIErC8jUf" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;6,305,974&lt;/span&gt; shares of Common Stock outstanding
and an aggregate of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOVaX8pE4ZDe" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"&gt;890,000&lt;/span&gt; restricted stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan, no future
awards may be made under the 2012 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 20, 2019, we adopted the 2019 Plan
to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and
advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted
stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan.
Generally, the options vest annually over &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dt_c20200101__20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zsk1eY9FOX24"&gt;four years&lt;/span&gt; or as determined by our board of directors, upon each option grant. Options
may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified
expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20200101__20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zhdZtjjsJZm3" title="Award expiration period"&gt;ten years&lt;/span&gt; from the
date the option is issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2020, there were &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_znGkjdUJ2LJ4" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"&gt;2,583,565&lt;/span&gt;
shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) new shares, (ii) unallocated shares previously
available for issuance under the 2012 Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2012
Plan), and (iii) unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding
&#x201c;Awards&#x201d; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#x201c;Awards&#x201d;
under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the
underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of
the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction
of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration,
termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of
December 31, 2020, there were non-qualified stock options to purchase &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zc4sTBvUvO6" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;4,190,751&lt;/span&gt; shares of Common Stock outstanding under the 2019
Plan and an aggregate of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhB3nGTXUDuk" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"&gt;6,171,024&lt;/span&gt; restricted stock units and &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zTkUUzrcTerl" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"&gt;2,403,951&lt;/span&gt; performance stock units outstanding under the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zK73YAIvjLQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. &lt;span id="xdx_8B3_zFjG7qlKfWp9"&gt;The ranges of
assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdRKOCY194Fb" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;1.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm1q20xQpHlc" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;3.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU0RGQJ0eQP4" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;5.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zidH9LoM7wI8" style="text-align: right" title="Weighted average grant date fair value"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsks95RV0Fla" style="text-align: right" title="Weighted average grant date fair value"&gt;1.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3zmIglYQXQd" style="text-align: right" title="Weighted average grant date fair value"&gt;3.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd5Gy8sGeof8" title="Risk-free interest rate - minimum"&gt;0.34&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJwEaTnpPMOa" title="Risk-free interest rate - maximum"&gt;1.68&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEeyhRC6N5vb" title="Risk-free interest rate - minimum"&gt;1.64&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNDhpRN2P563" title="Risk-free interest rate - maximum"&gt;2.54&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9AZUWqOxlb4" title="Risk-free interest rate - minimum"&gt;2.38&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyc3vOPXLIJc" title="Risk-free interest rate - maximum"&gt;2.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z54cPeUNn1fc" title="Volatility - minimum"&gt;63.53&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4QToulRpY67" title="Volatility - maximum"&gt;67.92&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z136BI8h4gZk" title="Volatility - minimum"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX63SVikg5oj" title="Volatility - maximum"&gt;64.49&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEXhJmbtOxaj" title="Volatility - minimum"&gt;59.45&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKWp9HvkneX1" title="Volatility - maximum"&gt;64.04&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zfErmA5yB31f" title="Term"&gt;6&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zjHnM7guZ3Td" title="Term"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zEwpZpbrrsA" title="Term"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zr8jstVV9iL7" title="Term"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjogRE4kyEX5" title="Term"&gt;5.1&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zS49ZdephDu4" title="Term"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUS3Mu5ASo8f" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zma4MpsEpOE1" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVWNjv8rptFg" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zzknt228Iyx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTUGf9YtZhZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of activity under the 2009, 2012
and 2019 Plans and related information during the year ended December 31, 2020 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares Under&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life in Years&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Intrinsic&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zOWxDl2OmMV" style="width: 12%; text-align: right" title="Number of shares under options, beginning"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFZbBzcvewna" style="width: 12%; text-align: right" title="Weighted average exercise price, beginning"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zHq1IWLmGAm2" style="width: 12%; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231_zUcEtCZBuQpj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;3,668,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zGMx6F3D6ZKh" style="text-align: right" title="Number of shares under options, granted"&gt;736,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zvSF7LkOHy4g" style="text-align: right" title="Weighted average exercise price, granted"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200101__20201231_zPI1pUWgipxb" style="text-align: right" title="Number of shares under options, exercised"&gt;(1,182,195&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zDu6VR4Q0aC6" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20201231_zuosgxVLzVWl" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;1,738,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20201231_zdi9BU3pwUO5" style="text-align: right" title="Number of shares under options, expired"&gt;(386,609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zD9L6LV7Wfme" style="text-align: right" title="Weighted average exercise price, expired"&gt;3.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zejaUJeR5ZR" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(416,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_z8yQlXeRfJ45" style="text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;3.80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20201231_ziOsw50js328" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending"&gt;23,781,930&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zmkwoS8XeKLb" style="text-align: right" title="Weighted average exercise price, ending"&gt;4.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20200101__20201231_zOHq9IcPTqY5" style="text-align: right" title="Weighted average remaining contractual life"&gt;5.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20200101__20201231_zYyeO6L5dF0h" style="text-align: right" title="Aggregate intrinsic value, ending"&gt;152,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested and Exercisable at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20200101__20201231_zKXVf5SnUPX8" style="text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;19,862,681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zZveoHdWBtgj" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;5.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zgoGIzgv0bdg" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20200101__20201231_zrblXPQD82Pg" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;117,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20200101__20201231_zOpLSxrBy8Si" style="text-align: right" title="Number of shares under options, unvested ending"&gt;3,919,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zAcpuOCuOwCa" style="text-align: right" title="Weighted average exercise price, unvested ending"&gt;3.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zrd64DCGRALe" style="text-align: right" title="Weighted average remaining contractual life, unvested"&gt;8.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20200101__20201231_zq2yZIhCwPhi" style="text-align: right" title="Aggregate intrinsic value, unvested ending"&gt;34,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zCYrATHIvmp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2020, our outstanding options
had exercise prices ranging from $&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20201231__srt--RangeAxis__srt--MinimumMember_zoxuNelaib64" title="Range - exercise price of options"&gt;0.38&lt;/span&gt; to $&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20201231__srt--RangeAxis__srt--MaximumMember_zePcthb9sHvi" title="Range - exercise price of options"&gt;8.92&lt;/span&gt; per share. Share-based compensation expense related to options recognized in our
results of operations for the years ended December 31, 2020, 2019, and 2018 was approximately $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_z5eLMzIWM6Ke" title="Share-based Payment Arrangement, Expense"&gt;5,235,585&lt;/span&gt;, $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_zDurT9OhxWUh" title="Share-based Payment Arrangement, Expense"&gt;8,798,707&lt;/span&gt;, and $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20181231_z13vmzA2ilGd" title="Share-based Payment Arrangement, Expense"&gt;8,091,294&lt;/span&gt;,
respectively, and it is based on awards vested. At December 31, 2020, total unrecognized estimated compensation expense related
to unvested options was approximately $&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20201231_zMJtixXviPte" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"&gt;5,238,000&lt;/span&gt;, which may be adjusted for future changes in forfeitures. This cost is expected
to be recognized over a weighted-average period of &lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc8lTcI89ZJf" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"&gt;1.9&lt;/span&gt; years. No tax benefit was realized due to a continued pattern of operating
losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Restricted Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Restricted stock units granted under our
2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common
Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares
vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Performance stock units will vest if certain
performance targets are achieved. If minimum performance thresholds are achieved, each award will convert into Common Stock at
a defined ratio depending on the degree of achievement of the performance target designated by each individual award. If minimum
performance thresholds are not achieved, then no shares will be issued. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at its grant date and through the date the restricted stock vests. The expected levels of achievement are reassessed over the requisite
service periods and, to the extent that the expected levels of achievement change, stock-based compensation is adjusted and recorded
on the consolidated statements of income and the remaining unrecognized stock-based compensation is recognized over the remaining
requisite service period.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2020,
2019 and 2018 we recorded $&lt;span id="xdx_908_eus-gaap--RestrictedStockExpense_c20200101__20201231_zVYrOOwEv5Zf" title="Restricted Stock or Unit Expense"&gt;5,399,472&lt;/span&gt;, $&lt;span id="xdx_900_eus-gaap--RestrictedStockExpense_c20190101__20191231_zXpFpaBNf6Oa" title="Restricted Stock or Unit Expense"&gt;1,628,407&lt;/span&gt;&#160;and $&lt;span id="xdx_908_eus-gaap--RestrictedStockExpense_c20180101__20181231_zGK8BUbXaM41" title="Restricted Stock or Unit Expense"&gt;73,132&lt;/span&gt;, respectively, in share-based compensation expense related to
restricted stock units and performance stock units. As of December 31, 2020, we recognized performance-based compensation expense
using our assessment of the most likely probability of attaining quarterly EBITDA break-even which would result in vesting 1.5
times the base number of performance stock units. At December 31, 2020, total unrecognized estimated compensation expense related
to unvested&#160;restricted stock units and performance stock units&#160;was approximately $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20201231_zPACtXFqzIGl" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"&gt;9,989,000&lt;/span&gt;, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of&#160;&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNPihaeACL2j" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"&gt;1.6&lt;/span&gt;&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zIPEnR0HqOs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Schedule of restricted stock units and
performance stock units&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;
                                                                                                       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;
                                                                                                       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpell54xGhm4" style="width: 12%; text-align: right" title="Beginning balance, number of shares"&gt;1,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEI5qekRZA2" style="width: 12%; text-align: right" title="Beginning balance, weighted average grant date fair value"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znrSniegE5g4" style="text-align: right" title="Granted, number of shares"&gt;6,152,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLTIusfAgI23" style="text-align: right" title="Granted, weighted average grant date fair value"&gt;1.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDUff6ykhbVl" style="text-align: right"&gt;2,585,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zl46URc21r1j" style="text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Vested/Released&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrr6E2e496V4" style="text-align: right" title="Vested/Released, number of shares"&gt;(301,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFn9vJyGoWp7" style="text-align: right" title="Vested/Released, weighted average grant date fair value"&gt;1.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zE4tbr4OSqu9" style="text-align: right"&gt;(151,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeCG9cEPaTsa" style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQSChyti9sO5" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited, number of shares"&gt;(30,294&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoOzrrMk41L8" style="text-align: right" title="Forfeited, weighted average grant date fair value"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJm02Iv3Hx3g" style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,294&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znKJMmPU6OO4" style="text-align: right"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJAZPd398kKk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, number of shares"&gt;7,061,024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxuh3DzApZT2" style="text-align: right" title="Ending balance, weighted average grant date fair value"&gt;1.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____zKNcfa9MpK0g" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,403,951&lt;/td&gt;&lt;td id="xdx_F22_zJX5trdtnZEi" style="padding-bottom: 2.5pt; text-align: left"&gt;*&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjEJORWN5x1i" style="text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F06_zr1lKch6hv28" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td id="xdx_F12_zfnzvpgq2c4h" style="text-align: justify"&gt;The number of performance stock units (PSUs) represents the base number of PSUs that
may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the
Company&#x2019;s achievement of break-even quarterly EBITDA.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A7_z0vsJ8mm2Gn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Employee Stock Purchase Plan &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 18, 2020, our stockholders approved
the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan, or the ESPP, which reserved &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_z3J4010UkTAb" title="Common Stock, Capital Shares Reserved for Future Issuance"&gt;5,400,000&lt;/span&gt; shares of Common Stock for purchase.
The ESPP permits eligible employee participants to purchase Common Stock at a price per share which is equal to &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zCffGAHUkuyd" title="Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"&gt;85&lt;/span&gt;% of the lesser
of (a) the fair market value of the shares on the offering date of the offering period or (b) the fair market value of the shares
on the purchase date. During the year ended December 31, 2020, no shares were issued under the ESPP. We recorded $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zd2BdH7smUMi" title="Non cash compensation expense"&gt;17,489&lt;/span&gt; of non-cash
compensation expense related to the ESPP during the year ended December 31, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">299765396</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">299765396</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1182195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">271678</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-11-092020-11-13_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="INF"
      unitRef="Shares">23437500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="INF"
      unitRef="USDPShares">1.1856</us-gaap:SharesIssuedPricePerShare>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2020-11-092020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2020-11-092020-11-20_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="INF"
      unitRef="Shares">3515625</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2020-11-092020-11-10_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="0"
      unitRef="USD">31703000</txmd:ProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-11-092020-11-13_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="INF"
      unitRef="Shares">23437500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2020-11-092020-11-20_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="INF"
      unitRef="Shares">3515625</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:MaximumCommonStockOfferingPrice
      contextRef="From2020-01-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="0"
      unitRef="USD">50000000</txmd:MaximumCommonStockOfferingPrice>
    <txmd:FixedCommissionRate
      contextRef="From2020-11-012020-11-30_custom_UnderwritingAgreementCantorFitzgeraldMember"
      decimals="INF"
      unitRef="Pure">0.030</txmd:FixedCommissionRate>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-02-28_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">26000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="USDPShares">2.75</us-gaap:SharesIssuedPricePerShare>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">3900000</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="0"
      unitRef="USD">77031000</txmd:ProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">331619</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">108656</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">12097</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">11834</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="Shares">12745098</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:SharesIssuedPricePerShare>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="Shares">1911764</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="0"
      unitRef="USD">69908000</txmd:ProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="INF"
      unitRef="Shares">3921568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">5444526</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1666208</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Shares">10000</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Shares">9841</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">6534687</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2020-01-01to2020-12-31">P7Y3M</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.55</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember">P10Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Pure">0.688</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Pure">0.0034</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-05_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-11-08_custom_LenderWarrantsMember_custom_FinancingAgreementAmendment6Member"
      decimals="INF"
      unitRef="USDPShares">1.1856</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2020-11-08_custom_FinancingAgreementAmendment6Member"
      decimals="0"
      unitRef="USD">239983</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-01-012019-12-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-01-012019-12-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2019-12-31_custom_OutsideConsultant2Member">2024-02-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2018-12-31_custom_OutsideConsultant2Member">2023-03-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">26446</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">254970</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-01-012018-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">494136</us-gaap:ShareBasedCompensation>
    <txmd:ScheduleOfWarrantRollForwardTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zQIEBlKA5QB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Summary of our Warrant activity during the year ended December
31, 2020:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares Under&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life in Years&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Intrinsic&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRRfJbOqoFuf" style="width: 12%; text-align: right" title="Number of shares under warrants outstanding beginning"&gt;1,832,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zV0mPa5GYoF6" style="width: 12%; text-align: right" title="Weighted average exercise price warrants outstanding beginning"&gt;2.62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxLMoeHGv0sh" style="width: 12%; text-align: right" title="Weighted average remaining contractual life, warrants outstanding"&gt;1.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zI9HnHhuALE2" style="width: 12%; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning"&gt;2,447,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyYJ8fQEKFIb" style="text-align: right" title="Number of shares under warrants granted"&gt;4,752,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9MnAk7PDqsa" style="text-align: right" title="Weighted average exercise price warrants granted"&gt;1.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhpZv6rBSF6f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Forfeited"&gt;(50,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh9SXiF0REug" style="text-align: right" title="Weighted average exercise price warrants cancelled/forfeited"&gt;6.35&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRmnrBa1Ixka" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under warrants outstanding ending"&gt;6,534,687&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYMBmVblsfE3" style="text-align: right" title="Weighted average exercise price warrants outstanding ending"&gt;1.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHkKR2Z3kSue" style="text-align: right" title="Weighted average remaining contractual life, warrants outstanding"&gt;7.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB7D2SbhQIng" style="text-align: right" title="Aggregate intrinsic value, warrants outstanding ending"&gt;1,041,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested and Exercisable at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zToiBI49G18d" style="text-align: right" title="Number of shares under warrants vested and exercisable ending"&gt;6,534,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHtFFJEiNjzk" style="text-align: right" title="Weighted average exercise price warrants unvested ending"&gt;1.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOhy3RAC7XNl" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable ending"&gt;7.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLUCFsclWND7" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;1,041,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</txmd:ScheduleOfWarrantRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1832571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.62</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000">P1Y11M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">2447929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="Shares">4752116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <txmd:WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="USDPShares">1.19</txmd:WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <txmd:WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="USDPShares">6.35</txmd:WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">6534687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.55</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000">P7Y3M</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">1041219</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="Shares">6534687</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <txmd:WarrantsUnvestedWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="USDPShares">1.55</txmd:WarrantsUnvestedWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000">P7Y3M</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="0"
      unitRef="USD">1041219</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue>
    <txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_896_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zD2LR7eyNHaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted average fair value per share
of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018
are set forth in the table below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzzohakCd7ib" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdGcFn7jkUsb" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zfDz6mG7bx2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--WeightedAverageExercisePriceOtherThanOptions_pii_uUSDPShares_zfh5i8004uWb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5.63&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_z2wJm8856j8j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_z5fuJJ2oCdj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.36&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_zt1cBcLV5i3e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62.12&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zDTGR0r3w2kl" style="text-align: right" title="Term (in years)"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrntf4TgaIXi" style="text-align: right" title="Term (in years)"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjrWxfC1bd4j" style="text-align: right" title="Term (in years)"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_zqNSt6wazfbg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>
    <txmd:WeightedAverageExercisePriceOtherThanOptions
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="USDPShares">1.19</txmd:WeightedAverageExercisePriceOtherThanOptions>
    <txmd:WeightedAverageExercisePriceOtherThanOptions
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="USDPShares">5.63</txmd:WeightedAverageExercisePriceOtherThanOptions>
    <txmd:WeightedAverageExercisePriceOtherThanOptions
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="USDPShares">5.16</txmd:WeightedAverageExercisePriceOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="USDPShares">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="USDPShares">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="Pure">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Pure">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Pure">0.0236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="Pure">0.688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Pure">0.608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Pure">0.6212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember75219000"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Shares">471184</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember75219203"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">13285205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">6305974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2020-01-012020-12-31_custom_Plan2019Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2020-01-012020-12-31_custom_Plan2019Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-12-31_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">2583565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">4190751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">6171024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_Plan2019Member_custom_PerformanceStockUnitsMember"
      decimals="INF"
      unitRef="Shares">2403951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zK73YAIvjLQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. &lt;span id="xdx_8B3_zFjG7qlKfWp9"&gt;The ranges of
assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdRKOCY194Fb" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;1.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm1q20xQpHlc" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;3.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU0RGQJ0eQP4" style="width: 12%; text-align: right" title="Weighted average exercise price"&gt;5.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zidH9LoM7wI8" style="text-align: right" title="Weighted average grant date fair value"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsks95RV0Fla" style="text-align: right" title="Weighted average grant date fair value"&gt;1.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3zmIglYQXQd" style="text-align: right" title="Weighted average grant date fair value"&gt;3.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd5Gy8sGeof8" title="Risk-free interest rate - minimum"&gt;0.34&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJwEaTnpPMOa" title="Risk-free interest rate - maximum"&gt;1.68&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEeyhRC6N5vb" title="Risk-free interest rate - minimum"&gt;1.64&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNDhpRN2P563" title="Risk-free interest rate - maximum"&gt;2.54&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9AZUWqOxlb4" title="Risk-free interest rate - minimum"&gt;2.38&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyc3vOPXLIJc" title="Risk-free interest rate - maximum"&gt;2.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z54cPeUNn1fc" title="Volatility - minimum"&gt;63.53&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4QToulRpY67" title="Volatility - maximum"&gt;67.92&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z136BI8h4gZk" title="Volatility - minimum"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX63SVikg5oj" title="Volatility - maximum"&gt;64.49&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEXhJmbtOxaj" title="Volatility - minimum"&gt;59.45&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKWp9HvkneX1" title="Volatility - maximum"&gt;64.04&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zfErmA5yB31f" title="Term"&gt;6&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zjHnM7guZ3Td" title="Term"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zEwpZpbrrsA" title="Term"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zr8jstVV9iL7" title="Term"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjogRE4kyEX5" title="Term"&gt;5.1&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zS49ZdephDu4" title="Term"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUS3Mu5ASo8f" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zma4MpsEpOE1" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVWNjv8rptFg" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.5945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTUGf9YtZhZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of activity under the 2009, 2012
and 2019 Plans and related information during the year ended December 31, 2020 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number of&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Shares Under&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life in Years&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Intrinsic&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zOWxDl2OmMV" style="width: 12%; text-align: right" title="Number of shares under options, beginning"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFZbBzcvewna" style="width: 12%; text-align: right" title="Weighted average exercise price, beginning"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zHq1IWLmGAm2" style="width: 12%; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231_zUcEtCZBuQpj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;3,668,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zGMx6F3D6ZKh" style="text-align: right" title="Number of shares under options, granted"&gt;736,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zvSF7LkOHy4g" style="text-align: right" title="Weighted average exercise price, granted"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200101__20201231_zPI1pUWgipxb" style="text-align: right" title="Number of shares under options, exercised"&gt;(1,182,195&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zDu6VR4Q0aC6" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20201231_zuosgxVLzVWl" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;1,738,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20201231_zdi9BU3pwUO5" style="text-align: right" title="Number of shares under options, expired"&gt;(386,609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zD9L6LV7Wfme" style="text-align: right" title="Weighted average exercise price, expired"&gt;3.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zejaUJeR5ZR" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(416,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_z8yQlXeRfJ45" style="text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;3.80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20201231_ziOsw50js328" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending"&gt;23,781,930&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zmkwoS8XeKLb" style="text-align: right" title="Weighted average exercise price, ending"&gt;4.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20200101__20201231_zOHq9IcPTqY5" style="text-align: right" title="Weighted average remaining contractual life"&gt;5.20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20200101__20201231_zYyeO6L5dF0h" style="text-align: right" title="Aggregate intrinsic value, ending"&gt;152,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested and Exercisable at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20200101__20201231_zKXVf5SnUPX8" style="text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;19,862,681&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zZveoHdWBtgj" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;5.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zgoGIzgv0bdg" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20200101__20201231_zrblXPQD82Pg" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;117,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20200101__20201231_zOpLSxrBy8Si" style="text-align: right" title="Number of shares under options, unvested ending"&gt;3,919,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zAcpuOCuOwCa" style="text-align: right" title="Weighted average exercise price, unvested ending"&gt;3.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zrd64DCGRALe" style="text-align: right" title="Weighted average remaining contractual life, unvested"&gt;8.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20200101__20201231_zq2yZIhCwPhi" style="text-align: right" title="Aggregate intrinsic value, unvested ending"&gt;34,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">25030234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-12-31">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3668171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">736500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">1.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">1182195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1738740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">386609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">3.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">416000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">3.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">23781930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="From2020-01-01to2020-12-31">P5Y2M12D</txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">152253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">19862681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31">P4Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">117443</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">3919249</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">3.53</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2020-01-01to2020-12-31">P8Y3M14D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">34810</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2020-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.38</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2020-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.92</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">5235585</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">8798707</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">8091294</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5238000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestrictedStockExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">5399472</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">1628407</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">73132</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">9989000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zIPEnR0HqOs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Schedule of restricted stock units and
performance stock units&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;
                                                                                                       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Number of&lt;/p&gt;
                                                                                                       &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Shares&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Average&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-size: 10pt"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpell54xGhm4" style="width: 12%; text-align: right" title="Beginning balance, number of shares"&gt;1,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEI5qekRZA2" style="width: 12%; text-align: right" title="Beginning balance, weighted average grant date fair value"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znrSniegE5g4" style="text-align: right" title="Granted, number of shares"&gt;6,152,818&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLTIusfAgI23" style="text-align: right" title="Granted, weighted average grant date fair value"&gt;1.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDUff6ykhbVl" style="text-align: right"&gt;2,585,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zl46URc21r1j" style="text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Vested/Released&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrr6E2e496V4" style="text-align: right" title="Vested/Released, number of shares"&gt;(301,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFn9vJyGoWp7" style="text-align: right" title="Vested/Released, weighted average grant date fair value"&gt;1.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zE4tbr4OSqu9" style="text-align: right"&gt;(151,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeCG9cEPaTsa" style="text-align: right"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQSChyti9sO5" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited, number of shares"&gt;(30,294&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoOzrrMk41L8" style="text-align: right" title="Forfeited, weighted average grant date fair value"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJm02Iv3Hx3g" style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,294&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znKJMmPU6OO4" style="text-align: right"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJAZPd398kKk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, number of shares"&gt;7,061,024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxuh3DzApZT2" style="text-align: right" title="Ending balance, weighted average grant date fair value"&gt;1.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____zKNcfa9MpK0g" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,403,951&lt;/td&gt;&lt;td id="xdx_F22_zJX5trdtnZEi" style="padding-bottom: 2.5pt; text-align: left"&gt;*&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjEJORWN5x1i" style="text-align: right"&gt;1.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F06_zr1lKch6hv28" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td id="xdx_F12_zfnzvpgq2c4h" style="text-align: justify"&gt;The number of performance stock units (PSUs) represents the base number of PSUs that
may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the
Company&#x2019;s achievement of break-even quarterly EBITDA.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">6152818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">2585745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">301500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">151500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">30294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">30294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">7061024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2020-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="Fact001446"
      unitRef="Shares">2403951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2020-12-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-06-18_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">5400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-06-172020-06-18_custom_EmployeeStockPurchasePlanMember"
      decimals="0"
      unitRef="USD">17489</us-gaap:ShareBasedCompensation>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_802_eus-gaap--DefinedContributionPlanTextBlock_zFSunyPavn81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 10 &#x2013; &lt;span id="xdx_822_zV4M5n5r0Z5k"&gt;EMPLOYEE BENEFIT
PLAN&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains a voluntary defined
contribution 401(k) plan covering all eligible employees as defined in the plan documents. The plan provides for discretionary
matching contribution, which is equal to up to &lt;span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pip2_dcp_c20200101__20201231_z4ZnpvC3Wxph" title="Matching contribution percentage"&gt;four&lt;/span&gt; percent of each eligible contributing participant&#x2019;s elective deferral
not to exceed $&lt;span id="xdx_90E_ecustom--DefinedContributionPlanMaximumEmployerMatchingContribution_c20200101__20201231_z35XromJ4aFd" title="Maximum matching contribution per year"&gt;2,000&lt;/span&gt; per year. Employees who elect to participate in the plan are generally fully vested in any existing matching
contribution after &lt;span id="xdx_90E_ecustom--DefinedContributionPlanVestingServicePeriod_dt_c20200101__20201231_zE31kIc8aJjg" title="Defined contribution plan vesting service period"&gt;five years&lt;/span&gt; of service with the Company. Contributions by the Company under the plan amounted to approximately
$&lt;span id="xdx_900_eus-gaap--DefinedContributionPlanCostRecognized_c20200101__20201231_zq9ueVwtyqA5" title="Contributions under plan"&gt;487,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DefinedContributionPlanCostRecognized_c20190101__20191231_zlQ9Y8g2va2b" title="Contributions under plan"&gt;403,000&lt;/span&gt; for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <txmd:DefinedContributionPlanMaximumEmployerMatchingContribution
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">2000</txmd:DefinedContributionPlanMaximumEmployerMatchingContribution>
    <txmd:DefinedContributionPlanVestingServicePeriod contextRef="From2020-01-01to2020-12-31">P5Y</txmd:DefinedContributionPlanVestingServicePeriod>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">487000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">403000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zgkAzeD7GxXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 11 &#x2013; &lt;span id="xdx_820_zfvddJ7t15mc"&gt;INCOME TAXES &lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYaE2QoEmhYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For financial reporting purposes, (loss)
income before taxes includes the following components:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-bottom: 1pt"&gt;United States&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zguCFyRPD1ik" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;(183,524,137&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zC3C21UWS0Xc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;(176,144,999&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_z7ehvKbVq99j" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;(132,617,160&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231_zjsoXl7n8sM7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(183,524,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zoHfrzFGf7Il" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(177,144,999&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zC7zcbxEydWh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(132,617,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zOSqzGVVKmM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;For
the years ended December 31, 2020, 2019, and 2018, there was no provision for income taxes, current or deferred. &lt;/span&gt;At December
31, 2020, we had a federal net operating loss carry forward of approximately $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_zq31T0Xo72di" title="Net operating loss carryforward"&gt;761,701,546&lt;/span&gt; available to offset future taxable income
through 2038. Approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zIgTBYApSvne" title="Net operating loss carryforward"&gt;338,775,332&lt;/span&gt; of the federal net operating loss carry forward can be carried forward for &lt;span id="xdx_90B_ecustom--NolCarryForwardPeriod_dtY_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zPEimXBmSl9l" title="NOL carryforward period"&gt;20&lt;/span&gt; years and
will begin to expire in &lt;span id="xdx_909_ecustom--OperatingLossCarryforwardsExpirationYear_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zaNAPu9Qd669" title="NOL carryforward expiration year"&gt;2031&lt;/span&gt;.&#160;The remaining $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriodIndefiniteMember_zIxqWuvl0Mle" title="Net operating loss carry forward"&gt;422,926,214&lt;/span&gt; can be carried forward indefinitely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjRPx5ggl1H3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A reconciliation between taxes computed at the federal statutory
rate and the consolidated effective tax rate is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20200101__20201231_zNMMJonDbVr4" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20190101__20191231_zdl9tOiJ8FOd" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20180101__20181231_zX2FXwBwhHO3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_maIT_zak6HihgVW0c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPure_maIT_z8NNHPmmKKP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_maIT_zBQUuhjCjVE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pii_dp_uPure_maIT_zz1X9yLFzn27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Excess stock benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp0_uPure_maIT_zIdMSs7oCQN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal income tax rate change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPure_maIT_zABe7zYzkFvl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(0.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_uPure_mtIT_znjLm1h5T7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zlBVXbMJQjDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income taxes result from temporary
differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYnj1A9WQn2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of the net deferred income
tax asset as of December 31, 2020, 2019, and 2018 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_ziSVdkEpnGI8" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20191231_zSgCwboagMPk" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20181231_zUg3mP0nvgG5" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhQAL6kZqtHd" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Deferred Income Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzcsC_zzDrXcGjVRfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-left: 0.125in"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;195,008,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;157,555,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;126,419,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGzcsC_zEiqUd5lJmid" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Share based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,251,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,913,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,640,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetInterestCarryforward_i01I_maDTAGzcsC_z6p6IREdlPh8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Interest expense limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,991,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,389,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,173,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcsC_zxB7OY1bHfb6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Other, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,818,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,662,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,658,573&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGzzfO_maDTAGzcsC_zgclBwHpui5b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;R&amp;amp;D credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzcsC_maDTANzEH4_zfcLcbgF6Ze3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,257,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,707,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,078,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzEH4_zZkjhxFogA86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(230,257,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(180,707,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(141,078,111&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzEH4_zj2p6EyLBNkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred income tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_zi1rz11aMPyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We believe that it is more likely than not that we will not
generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and
as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The change in valuation allowance was $&lt;span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zLmxywPf2218" title="Change in valuation allowance"&gt;49,549,973&lt;/span&gt;,
&lt;span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20190101__20191231_zt72pgKfIapd"&gt;$39,628,945&lt;/span&gt;, and &lt;span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20180101__20181231_zttrJOfIoFXc"&gt;$41,295,443&lt;/span&gt; for the years ended December 31, 2020, 2019, and 2018, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Unrecognized Tax Benefits&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2020 and 2019,
we have no unrecognized tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYaE2QoEmhYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For financial reporting purposes, (loss)
income before taxes includes the following components:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-bottom: 1pt"&gt;United States&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zguCFyRPD1ik" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;(183,524,137&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zC3C21UWS0Xc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;(176,144,999&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_z7ehvKbVq99j" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;(132,617,160&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231_zjsoXl7n8sM7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(183,524,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zoHfrzFGf7Il" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(177,144,999&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zC7zcbxEydWh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;(132,617,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2020-01-012020-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-183524137</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2019-01-012019-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2018-01-012018-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">-183524137</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">-177144999</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="0"
      unitRef="USD">761701546</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember"
      decimals="0"
      unitRef="USD">338775332</us-gaap:OperatingLossCarryforwards>
    <txmd:NolCarryForwardPeriod contextRef="From2020-01-012020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">P20Y</txmd:NolCarryForwardPeriod>
    <txmd:OperatingLossCarryforwardsExpirationYear contextRef="From2020-01-012020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">2031</txmd:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember"
      decimals="0"
      unitRef="USD">422926214</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjRPx5ggl1H3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A reconciliation between taxes computed at the federal statutory
rate and the consolidated effective tax rate is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20200101__20201231_zNMMJonDbVr4" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20190101__20191231_zdl9tOiJ8FOd" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20180101__20181231_zX2FXwBwhHO3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_maIT_zak6HihgVW0c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPure_maIT_z8NNHPmmKKP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_maIT_zBQUuhjCjVE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pii_dp_uPure_maIT_zz1X9yLFzn27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Excess stock benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp0_uPure_maIT_zIdMSs7oCQN9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal income tax rate change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPure_maIT_zABe7zYzkFvl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2.7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(0.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_uPure_mtIT_znjLm1h5T7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Provision (benefit) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Pure">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">-0.270</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Pure">-0.225</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">-0.312</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">-0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYnj1A9WQn2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of the net deferred income
tax asset as of December 31, 2020, 2019, and 2018 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20201231_ziSVdkEpnGI8" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20191231_zSgCwboagMPk" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20181231_zUg3mP0nvgG5" style="border-bottom: Black 1pt solid; text-align: center"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhQAL6kZqtHd" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Deferred Income Tax Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzcsC_zzDrXcGjVRfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left; padding-left: 0.125in"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;195,008,131&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;157,555,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;126,419,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGzcsC_zEiqUd5lJmid" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Share based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,251,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,913,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,640,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetInterestCarryforward_i01I_maDTAGzcsC_z6p6IREdlPh8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Interest expense limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,991,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,389,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,173,614&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcsC_zxB7OY1bHfb6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Other, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,818,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,662,037&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,658,573&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGzzfO_maDTAGzcsC_zgclBwHpui5b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;R&amp;amp;D credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,347&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzcsC_maDTANzEH4_zfcLcbgF6Ze3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Total deferred income tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,257,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,707,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,078,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzEH4_zZkjhxFogA86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(230,257,029&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(180,707,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(141,078,111&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzEH4_zj2p6EyLBNkk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred income tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">195008131</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">157555975</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">126419113</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">17251900</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">13913568</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">11640464</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">12991716</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5389129</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1173614</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4818935</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3662037</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1658573</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">230257029</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">180707056</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">141078111</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">230257029</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">180707056</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">141078111</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">49549973</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">39628945</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">41295443</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5CamXjNc75e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 12 &#x2013; &lt;span id="xdx_820_zo07iBxRMRQg"&gt;RELATED PARTIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2015, J. Martin Carroll, a director
of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with
Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by
independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During
the years ended December 31, 2020, 2019 and 2018, we were billed by Catalent approximately $&lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zVm6hPfLoVV5" title="Amount billed"&gt;3,036,000&lt;/span&gt;, $&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zg6gFtOrBz3d" title="Amount billed"&gt;6,101,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_z2ZNfZ7eAiNe" title="Amount billed"&gt;4,111,000&lt;/span&gt;,
respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation
testing. As of December 31, 2020 and 2019, there were amounts due to Catalent of approximately $&lt;span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zbqpkgTDXzKl" title="Amounts due to related party"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zdKHYABU1L82" title="Amounts due to related party"&gt;35,000&lt;/span&gt;, respectively. In
addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 14, Commitments and Contingencies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2020, Karen L. Ling, Executive
Vice President and Chief Human Resources Officer of American International Group, Inc., or AIG, was appointed to our board of directors.
From time to time, we have entered into agreements with AIG in the normal course of business. Agreements with AIG have been reviewed
by independent directors of our Company, or a committee consisting of independent directors of our Company, since April 2020. During
the year ended December 31, 2020, we were billed by AIG approximately $&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zzyCrYe9ReK5"&gt;209,000&lt;/span&gt; for various insurance coverage for our Company.&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2020-01-012020-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">3036000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2019-01-012019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">6101000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2018-01-012018-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">4111000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2020-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">35000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2020-01-012020-12-31_custom_AmericanInternationalGroupMember"
      decimals="0"
      unitRef="USD">209000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zuDcSZ4RlZ68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 13 - &lt;span id="xdx_826_z35jNAzObWC2"&gt;BUSINESS CONCENTRATIONS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We purchase our prescription products from
several suppliers with approximately &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zeEinaQ0hK1j"&gt;36&lt;/span&gt;%, &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_za4bwRzBEWz8"&gt;30&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zLH0VN68v2Ue"&gt;25&lt;/span&gt;% of our purchases supplied by three vendors each, respectively, during the
year ended December 31, 2020, &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zBVb9Z4VrFTc"&gt;24&lt;/span&gt;%, &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zEsyU2IWwZ"&gt;27&lt;/span&gt;% and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zlmj09UzW6ih"&gt;35&lt;/span&gt;% of our purchases supplied by three vendors each, respectively, during the year ended
December 31, 2019, and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_z9SVCfUYyj59"&gt;43&lt;/span&gt;%, &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zgJB6p6poND6"&gt;33&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zIa2Opf9NUh7"&gt;24&lt;/span&gt;% of our purchases supplied by &lt;span id="xdx_90C_ecustom--NumberOfVendors_dc_c20180101__20181231_zoqdVHpUOswi" title="Number of vendors - suppliers"&gt;three&lt;/span&gt; vendors each, respectively, during the year ended December
31, 2018.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We sell our prescription products to wholesale
distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies,
hospitals, and other institutional customers. During the year ended December 31, 2020, &lt;span id="xdx_90F_ecustom--NumberOfCustomers_dc_uN_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNYx6Nf73YJ2"&gt;three&lt;/span&gt; customers each accounted for more
than &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc7eOy3RzJrf"&gt;10&lt;/span&gt;% of our total product revenue. During each of the years ended December 31, 2019 and 2018, &lt;span id="xdx_90A_ecustom--NumberOfCustomers_pii_dc_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlBpaKn0s3Fa" title="Number of customers - revenue"&gt;&lt;span id="xdx_908_ecustom--NumberOfCustomers_pii_dc_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zG9xZsjDqgi2"&gt;four&lt;/span&gt;&lt;/span&gt; customers each accounted
for more than &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziq6KhIb9My6"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkPdSXcgA7Qc"&gt;10&lt;/span&gt;&lt;/span&gt;% of our total product revenue. Product revenue from the &lt;span id="xdx_90A_ecustom--NumberOfCustomers_dc_uN_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zfGBxDZHe9Il"&gt;three&lt;/span&gt; customers combined accounted for approximately
&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zSzTHiudfEo1"&gt;63&lt;/span&gt;% of our product revenue for the year ended December 31, 2020. Product revenue from the &lt;span id="xdx_905_ecustom--NumberOfCustomers_dc_uN_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zs3KhhmU7X93"&gt;&lt;span id="xdx_90F_ecustom--NumberOfCustomers_dc_uN_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zf0k5M0OFwo"&gt;four&lt;/span&gt;&lt;/span&gt; customers combined accounted for
approximately &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4QgXcOXV1n7"&gt;73&lt;/span&gt;% and &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJmCIM6Ax7c1"&gt;76&lt;/span&gt;% of our product revenue for the years ended December 31, 2019 and 2018, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2020,
Cardinal Health accounted for approximately $&lt;span id="xdx_908_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvduzlursID4"&gt;17,489,000&lt;/span&gt; of our product revenue, Pillpack, Inc. accounted for approximately $&lt;span id="xdx_90E_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYpMsmVD0Rk6"&gt;13,228,000&lt;/span&gt;
of our product revenue, and McKesson Corporation accounted for approximately $&lt;span id="xdx_908_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJHNKFHoTVEb"&gt;9,862,000&lt;/span&gt; of our product revenue. During the year
ended December 31, 2019, Pillpack, Inc. accounted for approximately $&lt;span id="xdx_90E_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgruKxhYV437"&gt;12,676,000&lt;/span&gt; of our product revenue, Cardinal Health accounted
for approximately $&lt;span id="xdx_904_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLDsfaP4ydAj"&gt;4,551,000&lt;/span&gt; of our product revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_900_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zN8XF7vDrkPf"&gt;3,927,000&lt;/span&gt; of our product revenue
and McKesson Corporation accounted for approximately $&lt;span id="xdx_905_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYrhcixy4rQf"&gt;3,911,000&lt;/span&gt; of our product revenue. During the year ended December 31, 2018,
Pillpack, Inc. accounted for approximately $&lt;span id="xdx_905_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkpyx6JbhKed"&gt;5,075,000&lt;/span&gt; of our product revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_903_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYyVDJDrVbcj"&gt;3,246,000&lt;/span&gt;
of our product revenue and Cardinal Health accounted for approximately $&lt;span id="xdx_902_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6j8c0vpq6o6"&gt;2,308,000&lt;/span&gt; of our product revenue, and McKesson Corporation
accounted for approximately $&lt;span id="xdx_90D_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1ZBlyidCPC"&gt;1,610,000&lt;/span&gt; of our product revenue.&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_SupplierOneConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_SupplierTwoConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_SupplierThreeConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_SupplierOneConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_custom_SupplierOneConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember"
      decimals="4"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfVendors
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="N">3</txmd:NumberOfVendors>
    <txmd:NumberOfCustomers
      contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="N">3</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="N">4</txmd:NumberOfCustomers>
    <txmd:NumberOfCustomers
      contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="N">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="N">3</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.63</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="N">4</txmd:NumberOfCustomers>
    <txmd:NumberOfCustomers
      contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="N">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="4"
      unitRef="Pure">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">17489000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">13228000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">9862000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">12676000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">4551000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">3927000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">3911000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationPillPackRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">5075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationAmerisourceBergenRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">3246000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationCardinalHealthRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">2308000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_custom_CustomerConcentrationMcKessonCorporationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="0"
      unitRef="USD">1610000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXO01roVpH79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 14 &#x2013; &lt;span id="xdx_82C_zPpozXAS9B3c"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We adopted ASC 842, Leases, effective January
1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office
space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease liability for all leases that
have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The
lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured
at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any
lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the
present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying
lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments
based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in
effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our
portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of
the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in
the initial lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We lease administrative office space in
Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a&#160;&lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20130701_z0WXKmWBbBPc" title="Operating lease term"&gt;63&lt;/span&gt;-month
term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space
in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with
the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May
1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement
with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease.
This addendum became effective beginning November 1, 2016.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2018, we entered into a lease
for new corporate offices in Boca Raton, Florida. The lease includes&#160;&lt;span id="xdx_906_ecustom--NetRentableAreaLease_iI_uSqft_c20181002_zFnEgLSZDql9"&gt;56,212&lt;/span&gt;&#160;rentable square feet, or the full premises,
of which the lease on&#160;&lt;span id="xdx_90E_ecustom--RentedAreaLease_iI_pip0_uSqft_c20181002_zfGSxuLSVrj5" title="Rented area lease"&gt;7,561&lt;/span&gt;&#160;square feet commenced in 2018 and the lease on the remaining&#160;&lt;span id="xdx_906_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSqft_c20190801_zjpwDKA9I8f3"&gt;&lt;span id="xdx_90B_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSqft_c20190801_zog8N3qcuDWa"&gt;48,651&lt;/span&gt;&lt;/span&gt;&#160;square feet
commenced in August 2019, or the full premises commencement date. The lease will expire&#160;&lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_zViRcxSFO2g3" title="Operating lease term"&gt;11 years&lt;/span&gt;&#160;after the full premises
commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of
the lease for&#160;&lt;span id="xdx_906_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20201231_zaEY7Lw5PSwk"&gt;two&lt;/span&gt;&#160;additional consecutive periods of&#160;&lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dt_c20201231_zXhfcFQyY4S2" title="Lease renewal term"&gt;five years&lt;/span&gt;. The extension option is not included in the determination
of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent
periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses.
In June 2019, we entered into an agreement with the same lessors to lease additional&#160;&lt;span id="xdx_904_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_uSqft_c20190601_z1xbIP2gkEXj"&gt;6,536&lt;/span&gt;&#160;square feet of administrative
office space in the same location,&#160;&lt;span style="color: #212529"&gt;pursuant to an addendum to such lease, which commenced in
May 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z0qHaQXgGYsf" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Supplemental
lease information as of:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_zvsQK6mhd6H6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20191231_zwCekJDFreEk" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zgSJwi8HN9p8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,565,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,109,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zRmUVpY5KQNh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short-term operating lease liability (included in &lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20201231_z7Yt0tyMkr3g" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20191231_zPu4jiwRNLTl" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1635"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,253,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zmGRt1AS3nWj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,675,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,145,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average remaining term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zQrO6eP9Cye5"&gt;8.9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zkuU70CWQ0Ne"&gt;9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zUT9oLVC6zUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Supplemental cash flow information&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;for the year ended:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20200101__20201231_z4Kvyri66KD7" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190101__20191231_zjEikObZOm47" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_zoHM3doKuPbk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,617,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,164,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_z5mz9Do3uNtb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;998,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,171,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSRjabTl3LOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table reconciles the undiscounted
cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_znBA6Qv3YUQh"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zNaAzI5TOiV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 26%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,334,582&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_z9806I5Zru21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zDS4sf6wjyhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,443,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zhk5xpIRSuR6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,476,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1WK_zuFZz9rMrOi3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,513,458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zQhlQPsjm8p2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,434,412&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zVDcOeTVXDne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,615,418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWCSU7W9F8H9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,685,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z9oRF49fzBAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,929,471&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_z8ieqkvdIXni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2020,
operating lease expense related to our real estate leases was $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20201231_z5xfuW4RwL2d"&gt;2,325,844&lt;/span&gt;, and variable lease expense was $&lt;span id="xdx_904_eus-gaap--VariableLeasePayment_uUSD_c20200101__20201231_zcGqvKe2xly6" title="Variable lease payment"&gt;423,578&lt;/span&gt;. During the year
ended December 31, 2019, operating lease expense related to our real estate leases was $&lt;span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20190101__20191231_zxvkbCxhX6M7"&gt;1,558,794&lt;/span&gt;, and variable lease expense was
insignificant. The rental expense during the year ended December 31, 2018 was $&lt;span id="xdx_900_eus-gaap--OperatingLeasesRentExpenseNet_uUSD_c20180101__20181231_zwfEDtYwxmm2" title="Rental expense"&gt;1,068,275&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Intellectual Property Licenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Population Council License Agreement
provides for future milestone payments to be paid by us for access to certain technologies. In addition, we pay royalties as a
percent of revenue as described in Note 2, Summary of Significant Accounting Policies to these consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Purchase Commitments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have manufacturing and supply agreements
whereby we are required to purchase from Catalent a minimum number of softgels during the first contract year and a higher number
of softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to
pay Catalent &lt;span id="xdx_908_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_uPure_c20201231_zHlmLgK99v5e"&gt;50&lt;/span&gt;% of the difference between the total amount we would have paid to Catalent if the minimum requirement had been
fulfilled and the sum of all purchases of our products from Catalent during the contract year. The minimum purchase commitments
for Catalent for the next five years are as follows: 2021 - $&lt;span id="xdx_90B_eus-gaap--PurchaseObligationDueInNextTwelveMonths_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zyEGNj5aMty6" title="Minimum purchase commitment, 2021"&gt;3,458,000&lt;/span&gt;, 2022 - $&lt;span id="xdx_90F_eus-gaap--PurchaseObligationDueInSecondYear_iI_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zEEMNRZaUOnj" title="Minimum purchase commitment, 2022"&gt;2,150,000&lt;/span&gt;, 2023 - $&lt;span id="xdx_904_eus-gaap--PurchaseObligationDueInThirdYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zCgZbR9fhbO8" title="Minimum purchase commitment, 2023"&gt;2,991,000&lt;/span&gt;, 2024 - $&lt;span id="xdx_90E_eus-gaap--PurchaseObligationDueInFourthYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_z1TeeOZUex04" title="Minimum purchase commitment, 2024"&gt;3,347,000&lt;/span&gt;,
and 2025 - $&lt;span id="xdx_902_eus-gaap--PurchaseObligationDueInFifthYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zvF6Tplc5KH4" title="Minimum purchase commitment, 2025"&gt;3,786,000&lt;/span&gt;. In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum
number of units of ANNOVERA during a contract year. The minimum purchase commitment for ANNOVERA for 2021 is approximately $&lt;span id="xdx_90E_eus-gaap--PurchaseObligationDueInNextTwelveMonths_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--AnnoveraMember_zFZp6NjwV9J1"&gt;1,526,000&lt;/span&gt;.
As of December 31, 2020, we have met our minimum purchase commitments with our manufacturers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, we are involved in litigation
and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would
have a material effect on our consolidated financial condition, results of operations, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Off-Balance Sheet Arrangements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2020, 2019, and 2018,
we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to investors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Employment Agreements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have entered into employment agreements
with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including
a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the
term of the employment agreement.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2013-07-01">P63M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <txmd:NetRentableAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="Sqft">56212</txmd:NetRentableAreaLease>
    <txmd:RentedAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="Sqft">7561</txmd:RentedAreaLease>
    <txmd:AdditionalAreaOfLeaseOccupied contextRef="AsOf2019-08-01" decimals="INF" unitRef="Sqft">48651</txmd:AdditionalAreaOfLeaseOccupied>
    <txmd:AdditionalAreaOfLeaseOccupied contextRef="AsOf2019-08-01" decimals="INF" unitRef="Sqft">48651</txmd:AdditionalAreaOfLeaseOccupied>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2019-08-01">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Pure">2</txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2020-12-31">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea contextRef="AsOf2019-06-01" decimals="INF" unitRef="Sqft">6536</txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea>
    <txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z0qHaQXgGYsf" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Supplemental
lease information as of:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_zvsQK6mhd6H6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20191231_zwCekJDFreEk" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zgSJwi8HN9p8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,565,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,109,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zRmUVpY5KQNh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Short-term operating lease liability (included in &lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20201231_z7Yt0tyMkr3g" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20191231_zPu4jiwRNLTl" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1635"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,253,994&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zmGRt1AS3nWj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,675,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,145,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average remaining term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zQrO6eP9Cye5"&gt;8.9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zkuU70CWQ0Ne"&gt;9&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zUT9oLVC6zUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Supplemental cash flow information&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;for the year ended:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20200101__20201231_z4Kvyri66KD7" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190101__20191231_zjEikObZOm47" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                               &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OperatingLeasePayments_zoHM3doKuPbk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,617,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,164,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_z5mz9Do3uNtb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;998,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,171,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">9565700</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2253994</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8675477</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-12-31">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-12-31">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-12-31" decimals="INF" unitRef="Pure">0.0830</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">1617645</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">1164234</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">998821</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">11171471</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSRjabTl3LOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table reconciles the undiscounted
cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_znBA6Qv3YUQh"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zNaAzI5TOiV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 26%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,334,582&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_z9806I5Zru21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zDS4sf6wjyhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,443,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zhk5xpIRSuR6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,476,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1WK_zuFZz9rMrOi3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,513,458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zQhlQPsjm8p2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,434,412&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zVDcOeTVXDne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,615,418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWCSU7W9F8H9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,685,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z9oRF49fzBAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,929,471&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2334582</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1413289</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1443143</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1476534</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1513458</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7434412</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15615418</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4685947</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">10929471</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">2325844</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeasePayment
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      unitRef="USD">423578</us-gaap:VariableLeasePayment>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-01-012019-12-31"
      decimals="0"
      unitRef="USD">1558794</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1068275</us-gaap:OperatingLeasesRentExpenseNet>
    <txmd:SignificantSupplyCommitmentPercentagePayable contextRef="AsOf2020-12-31" decimals="INF" unitRef="Pure">0.50</txmd:SignificantSupplyCommitmentPercentagePayable>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="AsOf2020-12-31_custom_CatalentMember75224546"
      decimals="0"
      unitRef="USD">3458000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="AsOf2020-12-31_custom_CatalentMember75224546"
      decimals="0"
      unitRef="USD">2150000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="AsOf2020-12-31_custom_CatalentMember75224546"
      decimals="0"
      unitRef="USD">2991000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear
      contextRef="AsOf2020-12-31_custom_CatalentMember75224546"
      decimals="0"
      unitRef="USD">3347000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear
      contextRef="AsOf2020-12-31_custom_CatalentMember75224546"
      decimals="0"
      unitRef="USD">3786000</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="AsOf2020-12-31_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">1526000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_806_eus-gaap--QuarterlyFinancialInformationTextBlock_zQazNNsFg25" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 15 &#x2013; &lt;span id="xdx_829_zc0nkY9To9kd"&gt;SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zfXZTA46Uurc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BC_zWmViDIqFdz5"&gt;Summarized quarterly financial data for fiscal years 2020 and
2019 is as follows&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20200101__20200331_z6rrFh6OByEd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20200401__20200630_zZCpBW64XMCh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200701__20200930_z1pUNMwR3iT9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20201001__20201231_zqnyUQTcCaf6" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;First &lt;br/&gt;Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Second&lt;br/&gt;
Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Third&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Quarter&lt;br/&gt;
&lt;sup id="xdx_F5E_zJhND2Sl5J81"&gt;(1)(2)(3)(4)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fourth&lt;br/&gt;
Quarter &lt;sup id="xdx_F52_zdpoaQjMzzkj"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zTaRWi9Bojzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;12,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zTmPSvKBesW2" style="width: 12%; text-align: right"&gt;19,343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20201001__20201231_fKDUp_zhou96xStL1h" style="width: 12%; text-align: right"&gt;22,577&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--GrossProfit_pn3n3_uUSD_z8GEljnynhu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GrossProfit_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zs1jjBIXEGlf" style="text-align: right"&gt;16,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20201001__20201231_fKDUp_zyYD68qP7L1d" style="text-align: right"&gt;16,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_uUSD_zRDlTSpwFoXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,849&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,976&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zLc9X0tXDuF8" style="text-align: right"&gt;(32,611&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NetIncomeLoss_pn3n3_c20201001__20201231_fKDUp_zhBCouQ7SyT6" style="text-align: right"&gt;(42,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zvJ1IxwcGY59" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.21&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.19&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20200701__20200930_fKDEpKDIpKDMpKDQp_z2VZ6BcRKMdj" style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20201001__20201231_fKDUp_zXBzDesZKu5k" style="text-align: right"&gt;(0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20190101__20190331_zLItBRipd1b6" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190401__20190630_z7lyNgKXa7a3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20190701__20190930_zzkGCPzdaGPd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20191001__20191231_zdHCdsnhGRia" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;First &lt;br/&gt;Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Second&lt;br/&gt;
Quarter &lt;sup id="xdx_F56_zuZyx7yGIx28"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Third&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Quarter &lt;sup id="xdx_F5A_zgkjBnBWNqJg"&gt;(7)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fourth&lt;br/&gt;
Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zQUf9wuYvpl9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630_fKDYp_zhoa6OAP7HIa" style="width: 12%; text-align: right"&gt;6,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930_fKDcp_zl2c2NZrJHA8" style="width: 12%; text-align: right"&gt;23,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;15,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--GrossProfit_pn3n3_uUSD_zPfRErpHlX4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20190401__20190630_fKDYp_zUm7MmC9lhve" style="text-align: right"&gt;4,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20190701__20190930_fKDcp_zT6E6UN8L0Rh" style="text-align: right"&gt;22,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_pn3n3_uUSD_z6k5bp7JoxL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,506&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20190401__20190630_fKDYp_zGWN8WPLUUE8" style="text-align: right"&gt;(55,237&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NetIncomeLoss_pn3n3_c20190701__20190930_fKDcp_zgG2QV0213Pc" style="text-align: right"&gt;(31,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zjxeUGUvBbe4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190401__20190630_fKDYp_zX8xMvGJPwJ8" style="text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190701__20190930_fKDcp_z8zBgJdMGhQ3" style="text-align: right"&gt;(0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.19&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td&gt;During the third quarter of 2020, we recorded $&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_znlN4bjOneM9"&gt;2 million&lt;/span&gt; in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(2)&lt;/td&gt;&lt;td&gt;During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3p0_dm_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zzstULDejUfg" title="Fair value of warrants"&gt;7.4 million&lt;/span&gt; as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;During the third quarter of 2020, we wrote off approximately $&lt;span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20200701__20200930_zbp5nfI78fAa" title="Write off of patent and trademark cost"&gt;0.6 million&lt;/span&gt; in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(4)&lt;/td&gt;&lt;td&gt;During the third quarter of 2020, we recorded approximately $&lt;span id="xdx_902_eus-gaap--InventoryWriteDown_pn3p0_dm_c20200701__20200930_zzpUeya085Mh" title="Inventory charge"&gt;5.7 million&lt;/span&gt; in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(5)&lt;/td&gt;&lt;td&gt;During the fourth quarter of 2020, we wrote off approximately $&lt;span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20201001__20201231_zzyk86lmPAse"&gt;0.5 million&lt;/span&gt; in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(6)&lt;/td&gt;&lt;td&gt;During the second quarter of 2019, we recorded approximately $&lt;span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_z3r1bzKRWu15" title="Loss on extinguishment of debt"&gt;10.1 million&lt;/span&gt; in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(7)&lt;/td&gt;&lt;td&gt;During the third quarter of 2019, we recorded approximately $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zT1eC19R11qi"&gt;15.
                                                                 5 million&lt;/span&gt; in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of
                                                                 Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F0A_zfLFhuE5BfRf" style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td id="xdx_F17_zPuPm7yI0if8"&gt;During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F0D_z9vclAeXaBF" style="width: 0.25in"&gt;(2)&lt;/td&gt;&lt;td id="xdx_F1C_zTsLEb9IsUs1"&gt;During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F03_zF1DY0Wx71Nf" style="width: 0.25in"&gt;(3)&lt;/td&gt;&lt;td id="xdx_F1B_zkzvmv0xaEa8" style="text-align: justify"&gt;During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F02_zwANq9PitIP1" style="width: 0.25in"&gt;(4)&lt;/td&gt;&lt;td id="xdx_F10_zMH9wMYnGo54"&gt;During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F04_zNdRKYs8T8h6" style="width: 0.25in"&gt;(5)&lt;/td&gt;&lt;td id="xdx_F17_zi3pMoIBCvwb"&gt;During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F00_zxjQ2fGLDGwc" style="width: 0.25in"&gt;(6)&lt;/td&gt;&lt;td id="xdx_F1E_ziFSieJPBL67"&gt;During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F04_zC6OWyYFKqnf" style="width: 0.25in"&gt;(7)&lt;/td&gt;&lt;td id="xdx_F18_z8We1Rc08aQk"&gt;During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p id="xdx_8AD_zcP7mDJijidd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zfXZTA46Uurc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BC_zWmViDIqFdz5"&gt;Summarized quarterly financial data for fiscal years 2020 and
2019 is as follows&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20200101__20200331_z6rrFh6OByEd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20200401__20200630_zZCpBW64XMCh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200701__20200930_z1pUNMwR3iT9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20201001__20201231_zqnyUQTcCaf6" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;First &lt;br/&gt;Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Second&lt;br/&gt;
Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Third&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Quarter&lt;br/&gt;
&lt;sup id="xdx_F5E_zJhND2Sl5J81"&gt;(1)(2)(3)(4)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Fourth&lt;br/&gt;
Quarter &lt;sup id="xdx_F52_zdpoaQjMzzkj"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zTaRWi9Bojzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;12,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zTmPSvKBesW2" style="width: 12%; text-align: right"&gt;19,343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20201001__20201231_fKDUp_zhou96xStL1h" style="width: 12%; text-align: right"&gt;22,577&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--GrossProfit_pn3n3_uUSD_z8GEljnynhu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GrossProfit_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zs1jjBIXEGlf" style="text-align: right"&gt;16,064&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20201001__20201231_fKDUp_zyYD68qP7L1d" style="text-align: right"&gt;16,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_uUSD_zRDlTSpwFoXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,849&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,976&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zLc9X0tXDuF8" style="text-align: right"&gt;(32,611&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NetIncomeLoss_pn3n3_c20201001__20201231_fKDUp_zhBCouQ7SyT6" style="text-align: right"&gt;(42,088&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zvJ1IxwcGY59" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.21&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.19&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20200701__20200930_fKDEpKDIpKDMpKDQp_z2VZ6BcRKMdj" style="text-align: right"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20201001__20201231_fKDUp_zXBzDesZKu5k" style="text-align: right"&gt;(0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20190101__20190331_zLItBRipd1b6" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190401__20190630_z7lyNgKXa7a3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20190701__20190930_zzkGCPzdaGPd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20191001__20191231_zdHCdsnhGRia" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-style: italic"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;First &lt;br/&gt;Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Second&lt;br/&gt;
Quarter &lt;sup id="xdx_F56_zuZyx7yGIx28"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Third&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Quarter &lt;sup id="xdx_F5A_zgkjBnBWNqJg"&gt;(7)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Fourth&lt;br/&gt;
Quarter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zQUf9wuYvpl9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;3,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630_fKDYp_zhoa6OAP7HIa" style="width: 12%; text-align: right"&gt;6,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930_fKDcp_zl2c2NZrJHA8" style="width: 12%; text-align: right"&gt;23,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;15,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--GrossProfit_pn3n3_uUSD_zPfRErpHlX4e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20190401__20190630_fKDYp_zUm7MmC9lhve" style="text-align: right"&gt;4,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20190701__20190930_fKDcp_zT6E6UN8L0Rh" style="text-align: right"&gt;22,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_pn3n3_uUSD_z6k5bp7JoxL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,506&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20190401__20190630_fKDYp_zGWN8WPLUUE8" style="text-align: right"&gt;(55,237&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NetIncomeLoss_pn3n3_c20190701__20190930_fKDcp_zgG2QV0213Pc" style="text-align: right"&gt;(31,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(49,435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zjxeUGUvBbe4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190401__20190630_fKDYp_zX8xMvGJPwJ8" style="text-align: right"&gt;(0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190701__20190930_fKDcp_z8zBgJdMGhQ3" style="text-align: right"&gt;(0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.19&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td&gt;During the third quarter of 2020, we recorded $&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_znlN4bjOneM9"&gt;2 million&lt;/span&gt; in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(2)&lt;/td&gt;&lt;td&gt;During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3p0_dm_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zzstULDejUfg" title="Fair value of warrants"&gt;7.4 million&lt;/span&gt; as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(3)&lt;/td&gt;&lt;td style="text-align: justify"&gt;During the third quarter of 2020, we wrote off approximately $&lt;span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20200701__20200930_zbp5nfI78fAa" title="Write off of patent and trademark cost"&gt;0.6 million&lt;/span&gt; in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(4)&lt;/td&gt;&lt;td&gt;During the third quarter of 2020, we recorded approximately $&lt;span id="xdx_902_eus-gaap--InventoryWriteDown_pn3p0_dm_c20200701__20200930_zzpUeya085Mh" title="Inventory charge"&gt;5.7 million&lt;/span&gt; in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(5)&lt;/td&gt;&lt;td&gt;During the fourth quarter of 2020, we wrote off approximately $&lt;span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20201001__20201231_zzyk86lmPAse"&gt;0.5 million&lt;/span&gt; in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(6)&lt;/td&gt;&lt;td&gt;During the second quarter of 2019, we recorded approximately $&lt;span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_z3r1bzKRWu15" title="Loss on extinguishment of debt"&gt;10.1 million&lt;/span&gt; in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(7)&lt;/td&gt;&lt;td&gt;During the third quarter of 2019, we recorded approximately $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zT1eC19R11qi"&gt;15.
                                                                 5 million&lt;/span&gt; in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of
                                                                 Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F0A_zfLFhuE5BfRf" style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td id="xdx_F17_zPuPm7yI0if8"&gt;During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F0D_z9vclAeXaBF" style="width: 0.25in"&gt;(2)&lt;/td&gt;&lt;td id="xdx_F1C_zTsLEb9IsUs1"&gt;During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F03_zF1DY0Wx71Nf" style="width: 0.25in"&gt;(3)&lt;/td&gt;&lt;td id="xdx_F1B_zkzvmv0xaEa8" style="text-align: justify"&gt;During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F02_zwANq9PitIP1" style="width: 0.25in"&gt;(4)&lt;/td&gt;&lt;td id="xdx_F10_zMH9wMYnGo54"&gt;During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F04_zNdRKYs8T8h6" style="width: 0.25in"&gt;(5)&lt;/td&gt;&lt;td id="xdx_F17_zi3pMoIBCvwb"&gt;During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F00_zxjQ2fGLDGwc" style="width: 0.25in"&gt;(6)&lt;/td&gt;&lt;td id="xdx_F1E_ziFSieJPBL67"&gt;During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td id="xdx_F04_zC6OWyYFKqnf" style="width: 0.25in"&gt;(7)&lt;/td&gt;&lt;td id="xdx_F18_z8We1Rc08aQk"&gt;During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-03-31"
      decimals="-3"
      unitRef="USD">12251000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">10701000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      unitRef="USD">19343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      id="Fact001698"
      unitRef="USD">19343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-10-012020-12-31"
      decimals="-3"
      unitRef="USD">22577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-10-012020-12-31"
      decimals="-3"
      id="Fact001699"
      unitRef="USD">22577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="From2020-01-012020-03-31"
      decimals="-3"
      unitRef="USD">9536000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">6301000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      unitRef="USD">16064000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      id="Fact001705"
      unitRef="USD">16064000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-10-012020-12-31"
      decimals="-3"
      unitRef="USD">16996000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-10-012020-12-31"
      decimals="-3"
      id="Fact001706"
      unitRef="USD">16996000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31"
      decimals="-3"
      unitRef="USD">-56849000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">-51976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      unitRef="USD">-32611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      id="Fact001712"
      unitRef="USD">-32611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31"
      decimals="-3"
      unitRef="USD">-42088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31"
      decimals="-3"
      id="Fact001713"
      unitRef="USD">-42088000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-012020-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      id="Fact001719"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      id="Fact001720"
      unitRef="USDPShares">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-03-31"
      decimals="-3"
      unitRef="USD">3947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">6079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      id="Fact001726"
      unitRef="USD">6079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      unitRef="USD">23719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      id="Fact001727"
      unitRef="USD">23719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-10-012019-12-31"
      decimals="-3"
      unitRef="USD">15902000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-03-31"
      decimals="-3"
      unitRef="USD">3184000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">4830000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      id="Fact001733"
      unitRef="USD">4830000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      unitRef="USD">22275000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      id="Fact001734"
      unitRef="USD">22275000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-10-012019-12-31"
      decimals="-3"
      unitRef="USD">13023000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="-3"
      unitRef="USD">-39506000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">-55237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      id="Fact001740"
      unitRef="USD">-55237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      unitRef="USD">-31967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      id="Fact001741"
      unitRef="USD">-31967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31"
      decimals="-3"
      unitRef="USD">-49435000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-012019-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-04-012019-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-04-012019-06-30"
      decimals="INF"
      id="Fact001747"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-07-012019-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-07-012019-09-30"
      decimals="INF"
      id="Fact001748"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-10-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30_custom_KnightLicenseAgreementMember"
      decimals="-3"
      unitRef="USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2020-09-30_custom_LenderWarrantsMember"
      decimals="-3"
      unitRef="USD">7400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      unitRef="USD">600000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:InventoryWriteDown
      contextRef="From2020-07-012020-09-30"
      decimals="-3"
      unitRef="USD">5700000</us-gaap:InventoryWriteDown>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2020-10-012020-12-31"
      decimals="-3"
      unitRef="USD">500000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">-10100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember"
      decimals="-3"
      unitRef="USD">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_z8Co9uv6xHPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 16 &#x2013; &lt;span id="xdx_829_z8OTVS4HZLaf"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the period from January 1,
2021 through February 8, 2021 in accordance with the terms of the sales agreement described in Note 9- Stockholders&#x2019;
Equity, we sold &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20210101__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrwrgLMhjjF" title="Shares issued in offerings, net of cost (in shares)"&gt;28,600,689 &lt;/span&gt;shares
of Common Stock for net proceeds of approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_uUSD_c20210101__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfDdQ7PzRq98" title="Proceeds from sale of common stock, net of costs"&gt;47.3
million&lt;/span&gt; through Cantor Fitzgerald who acted as our sales agent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On January 13, 2021, we entered into Amendment No. 7 to the
Financing Agreement, or Amendment No. 7, pursuant to which, among other amendments, the minimum consolidated net revenue
requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA for the fiscal quarters ending March 31, 2021
and June 30, 2021 were reduced to $&lt;span id="xdx_90E_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment7Period1Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zDLs5c4qRHb2"&gt;18&lt;/span&gt;.0
million and $&lt;span id="xdx_904_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment7Period2Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zSriJ7OOLta5"&gt;22&lt;/span&gt;.0
million, respectively. On January 13, 2021, in connection with entering into Amendment No. 7 to the Financing Agreement, the
Lender Warrants were further amended to provide for an additional adjustment to the exercise price if we conduct certain
dilutive issuances prior to March 31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 1, 2021, we entered into Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA. See Note 8 &#x2013; Debt for information regarding Amendment No. 8.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 11, 2021, we entered into
an underwriting agreement with Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zY3ih7pRKQT3"&gt;59,459,460&lt;/span&gt;
shares of Common Stock. Pursuant to the underwriting agreement, we granted to the underwriter an option, exercisable for a
period of &lt;span id="xdx_909_ecustom--PeriodExercisableUnderwritersOption_dt_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7BB1HF48HNh" title="Period exercisable underwriters option"&gt;30
days&lt;/span&gt;, to purchase up to &lt;span id="xdx_90A_ecustom--UnderwritersOptionGrantedInPeriodShares_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgnNBDHFfuv3" title="Underwriters option granted in period shares"&gt;8,918,919&lt;/span&gt;
additional shares of Common Stock. The net proceeds to us from the offering, excluding any proceeds that may be received from
the exercise of the underwriter&#x2019;s option to purchase additional shares, are expected to be approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztrhJARpXUs6"&gt;97.1
million&lt;/span&gt;, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The
offering closed on February 16, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-02-08_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">28600689</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-02-08_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">47300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">18000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <txmd:MinimumRevenueRequirementUnderCreditAgreement
      contextRef="AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period2Member_custom_ImvexxyBijuvaAndAnnoveraMember"
      decimals="0"
      unitRef="USD">22000000</txmd:MinimumRevenueRequirementUnderCreditAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">59459460</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">8918919</txmd:UnderwritersOptionGrantedInPeriodShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-02-112021-02-16_custom_UnderwritingAgreementCantorFitzgeraldMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">97100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001446"
          xlink:label="Fact001446"
          xlink:type="locator"/>
        <link:footnote id="Footnote001448" xlink:label="Footnote001448" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The number of performance stock units (PSUs) represents the base number of PSUs that
may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the
Company&#x2019;s achievement of break-even quarterly EBITDA.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001446"
          xlink:to="Footnote001448"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001698"
          xlink:label="Fact001698"
          xlink:type="locator"/>
        <link:footnote id="Footnote001760" xlink:label="Footnote001760" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</link:footnote>
        <link:footnote id="Footnote001761" xlink:label="Footnote001761" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</link:footnote>
        <link:footnote id="Footnote001762" xlink:label="Footnote001762" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</link:footnote>
        <link:footnote id="Footnote001763" xlink:label="Footnote001763" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001698"
          xlink:to="Footnote001761"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001698"
          xlink:to="Footnote001760"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001698"
          xlink:to="Footnote001763"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001698"
          xlink:to="Footnote001762"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001705"
          xlink:label="Fact001705"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001705"
          xlink:to="Footnote001761"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001705"
          xlink:to="Footnote001760"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001705"
          xlink:to="Footnote001763"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001705"
          xlink:to="Footnote001762"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001712"
          xlink:label="Fact001712"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001712"
          xlink:to="Footnote001761"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001712"
          xlink:to="Footnote001760"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001712"
          xlink:to="Footnote001763"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001712"
          xlink:to="Footnote001762"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001719"
          xlink:label="Fact001719"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001719"
          xlink:to="Footnote001761"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001719"
          xlink:to="Footnote001760"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001719"
          xlink:to="Footnote001763"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001719"
          xlink:to="Footnote001762"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001699"
          xlink:label="Fact001699"
          xlink:type="locator"/>
        <link:footnote id="Footnote001764" xlink:label="Footnote001764" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001699"
          xlink:to="Footnote001764"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001706"
          xlink:label="Fact001706"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001706"
          xlink:to="Footnote001764"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001713"
          xlink:label="Fact001713"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001713"
          xlink:to="Footnote001764"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001720"
          xlink:label="Fact001720"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001720"
          xlink:to="Footnote001764"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001726"
          xlink:label="Fact001726"
          xlink:type="locator"/>
        <link:footnote id="Footnote001765" xlink:label="Footnote001765" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001726"
          xlink:to="Footnote001765"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001733"
          xlink:label="Fact001733"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001733"
          xlink:to="Footnote001765"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001740"
          xlink:label="Fact001740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001740"
          xlink:to="Footnote001765"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001747"
          xlink:label="Fact001747"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001747"
          xlink:to="Footnote001765"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001727"
          xlink:label="Fact001727"
          xlink:type="locator"/>
        <link:footnote id="Footnote001766" xlink:label="Footnote001766" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001727"
          xlink:to="Footnote001766"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001734"
          xlink:label="Fact001734"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001734"
          xlink:to="Footnote001766"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001741"
          xlink:label="Fact001741"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001741"
          xlink:to="Footnote001766"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001748"
          xlink:label="Fact001748"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001748"
          xlink:to="Footnote001766"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447819190600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Rd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307,578,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,825,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EntityCommonStockHeldByNonaffiliates', window );">Entity Common Stock Held by Non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,062,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EntityCommonStockHeldByNonaffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EntityCommonStockHeldByNonaffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447819161768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 80,485,784<span></span>
</td>
<td class="nump">$ 160,829,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $1,117,854 and $904,040, respectively</a></td>
<td class="nump">32,381,701<span></span>
</td>
<td class="nump">24,395,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,993,087<span></span>
</td>
<td class="nump">11,860,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,543,397<span></span>
</td>
<td class="nump">11,329,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">128,403,969<span></span>
</td>
<td class="nump">208,416,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">1,942,224<span></span>
</td>
<td class="nump">2,507,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseRights', window );">License rights, net</a></td>
<td class="nump">36,196,916<span></span>
</td>
<td class="nump">39,221,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,247,723<span></span>
</td>
<td class="nump">5,258,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">9,565,700<span></span>
</td>
<td class="nump">10,109,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other assets</a></td>
<td class="nump">253,121<span></span>
</td>
<td class="nump">473,009<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">51,263,460<span></span>
</td>
<td class="nump">55,061,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">181,609,653<span></span>
</td>
<td class="nump">265,985,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">21,068,327<span></span>
</td>
<td class="nump">19,181,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">38,169,869<span></span>
</td>
<td class="nump">33,823,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">59,238,196<span></span>
</td>
<td class="nump">53,004,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">237,697,531<span></span>
</td>
<td class="nump">194,634,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">8,675,477<span></span>
</td>
<td class="nump">9,145,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">246,373,008<span></span>
</td>
<td class="nump">203,779,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">305,611,204<span></span>
</td>
<td class="nump">256,784,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; (Deficit) Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 600,000,000 and 350,000,000 shares authorized: 299,765,396 and 271,177,076 issued and outstanding, respectively</a></td>
<td class="nump">299,765<span></span>
</td>
<td class="nump">271,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">754,644,100<span></span>
</td>
<td class="nump">704,351,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(878,945,416)<span></span>
</td>
<td class="num">(695,421,279)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; (deficit) equity</a></td>
<td class="num">(124,001,551)<span></span>
</td>
<td class="nump">9,201,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; (deficit) equity</a></td>
<td class="nump">$ 181,609,653<span></span>
</td>
<td class="nump">$ 265,985,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447811425784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 1,117,854<span></span>
</td>
<td class="nump">$ 904,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">299,765,396<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">299,765,396<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447822132264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 64,872,280<span></span>
</td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">15,974,977<span></span>
</td>
<td class="nump">6,334,585<span></span>
</td>
<td class="nump">2,737,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">48,897,303<span></span>
</td>
<td class="nump">43,312,352<span></span>
</td>
<td class="nump">13,361,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">192,963,967<span></span>
</td>
<td class="nump">174,112,612<span></span>
</td>
<td class="nump">115,988,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,431,907<span></span>
</td>
<td class="nump">19,792,212<span></span>
</td>
<td class="nump">27,299,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,042,170<span></span>
</td>
<td class="nump">612,786<span></span>
</td>
<td class="nump">293,886<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">204,438,044<span></span>
</td>
<td class="nump">194,517,610<span></span>
</td>
<td class="nump">143,581,978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(155,540,741)<span></span>
</td>
<td class="num">(151,205,258)<span></span>
</td>
<td class="num">(130,220,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">597,647<span></span>
</td>
<td class="nump">2,500,106<span></span>
</td>
<td class="nump">2,280,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(28,581,043)<span></span>
</td>
<td class="num">(17,382,215)<span></span>
</td>
<td class="num">(4,677,834)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(27,983,396)<span></span>
</td>
<td class="num">(24,939,741)<span></span>
</td>
<td class="num">(2,396,990)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(183,524,137)<span></span>
</td>
<td class="num">(176,144,999)<span></span>
</td>
<td class="num">(132,617,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (183,524,137)<span></span>
</td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">275,648,552<span></span>
</td>
<td class="nump">246,353,318<span></span>
</td>
<td class="nump">225,026,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 62,872,280<span></span>
</td>
<td class="nump">$ 34,140,537<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447819191720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2017</a></td>
<td class="nump">$ 216,430<span></span>
</td>
<td class="nump">$ 516,351,405<span></span>
</td>
<td class="num">$ (386,659,120)<span></span>
</td>
<td class="nump">$ 129,908,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2017</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 18,578<span></span>
</td>
<td class="nump">89,889,219<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">89,907,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">18,578,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 5,455<span></span>
</td>
<td class="nump">1,660,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,666,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">5,454,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,658,561<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,658,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(132,617,160)<span></span>
</td>
<td class="num">(132,617,160)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
<td class="nump">97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="nump">77,001,358<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">77,031,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">29,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">107,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">108,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">814,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,682,084<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,682,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(176,144,999)<span></span>
</td>
<td class="num">(176,144,999)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 271,177<span></span>
</td>
<td class="nump">704,351,222<span></span>
</td>
<td class="num">(695,421,279)<span></span>
</td>
<td class="nump">$ 9,201,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2019</a></td>
<td class="nump">271,177,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 26,953<span></span>
</td>
<td class="nump">31,675,682<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 31,702,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">26,953,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 1,182<span></span>
</td>
<td class="nump">270,496<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">271,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">1,182,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock (in shares)</a></td>
<td class="nump">453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock</a></td>
<td class="nump">$ 453<span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant granted in relation to Financing Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,668,161<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,668,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,678,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,678,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(183,524,137)<span></span>
</td>
<td class="num">(183,524,137)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 299,765<span></span>
</td>
<td class="nump">$ 754,644,100<span></span>
</td>
<td class="num">$ (878,945,416)<span></span>
</td>
<td class="num">$ (124,001,551)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2020</a></td>
<td class="nump">299,765,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,765,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447835102248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (183,524,137)<span></span>
</td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">772,624<span></span>
</td>
<td class="nump">415,193<span></span>
</td>
<td class="nump">181,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">269,546<span></span>
</td>
<td class="nump">197,593<span></span>
</td>
<td class="nump">112,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write off of patent and trademark cost</a></td>
<td class="nump">1,131,776<span></span>
</td>
<td class="nump">78,864<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred financing fees</a></td>
<td class="nump">275,379<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,405,443<span></span>
</td>
<td class="nump">1,062,318<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">213,814<span></span>
</td>
<td class="nump">307,438<span></span>
</td>
<td class="nump">216,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease impairment</a></td>
<td class="nump">136,832<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">7,204,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss of extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,057,632<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10,678,992<span></span>
</td>
<td class="nump">10,693,662<span></span>
</td>
<td class="nump">8,661,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmortizationOfIntellectualPropertyLicenseFee', window );">Amortization of intellectual property license fee</a></td>
<td class="nump">3,024,391<span></span>
</td>
<td class="nump">778,692<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">2,256,429<span></span>
</td>
<td class="nump">856,302<span></span>
</td>
<td class="nump">269,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">&#160;Accounts receivable</a></td>
<td class="num">(8,199,558)<span></span>
</td>
<td class="num">(13,639,575)<span></span>
</td>
<td class="num">(6,951,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">&#160;Inventory</a></td>
<td class="num">(3,337,189)<span></span>
</td>
<td class="num">(8,593,046)<span></span>
</td>
<td class="num">(1,782,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">&#160;Other assets</a></td>
<td class="nump">3,429,443<span></span>
</td>
<td class="num">(1,880,048)<span></span>
</td>
<td class="num">(2,657,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,887,115<span></span>
</td>
<td class="num">(3,562,629)<span></span>
</td>
<td class="nump">18,646,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,903,947<span></span>
</td>
<td class="nump">13,675,008<span></span>
</td>
<td class="nump">9,107,947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(159,470,335)<span></span>
</td>
<td class="num">(165,697,595)<span></span>
</td>
<td class="num">(106,811,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PaymentsToAcquireIntellectualPropertyLicense', window );">Payment for intellectual property license</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(1,390,834)<span></span>
</td>
<td class="num">(1,441,989)<span></span>
</td>
<td class="num">(1,105,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(207,073)<span></span>
</td>
<td class="num">(2,450,285)<span></span>
</td>
<td class="num">(217,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IncreaseDecreaseInSecurityDeposit', window );">Payment of security deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20,420)<span></span>
</td>
<td class="num">(175,410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,597,907)<span></span>
</td>
<td class="num">(23,912,694)<span></span>
</td>
<td class="num">(21,497,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options and warrants</a></td>
<td class="nump">271,678<span></span>
</td>
<td class="nump">108,656<span></span>
</td>
<td class="nump">1,666,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">31,702,635<span></span>
</td>
<td class="nump">77,031,258<span></span>
</td>
<td class="nump">89,907,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Financing Agreement</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from Credit Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="num">(1,250,000)<span></span>
</td>
<td class="num">(6,652,270)<span></span>
</td>
<td class="num">(3,786,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of Credit Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(81,660,719)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">80,724,313<span></span>
</td>
<td class="nump">188,826,925<span></span>
</td>
<td class="nump">162,787,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(Decrease) increase in cash</a></td>
<td class="num">(80,343,929)<span></span>
</td>
<td class="num">(783,364)<span></span>
</td>
<td class="nump">34,477,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">160,829,713<span></span>
</td>
<td class="nump">161,613,077<span></span>
</td>
<td class="nump">127,135,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">80,485,784<span></span>
</td>
<td class="nump">160,829,713<span></span>
</td>
<td class="nump">161,613,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">25,849,236<span></span>
</td>
<td class="nump">17,787,903<span></span>
</td>
<td class="nump">1,890,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantGrantedInRelationToFinancingAgreement', window );">Warrant granted in relation to Financing Agreement</a></td>
<td class="nump">$ 7,668,161<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmortizationOfIntellectualPropertyLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents amortization of intellectual property license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AmortizationOfIntellectualPropertyLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IncreaseDecreaseInSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represent increase decrease in security deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IncreaseDecreaseInSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PaymentsToAcquireIntellectualPropertyLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outlow for payments to acquire intellectual property license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PaymentsToAcquireIntellectualPropertyLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantGrantedInRelationToFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a warrant granted in relation to financing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantGrantedInRelationToFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813672248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">THE COMPANY</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--NatureOfOperations_zTDSbu1RScr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline"><span>NOTE 1 &#8211; <span id="xdx_826_z2TojvhJBQk9">THE COMPANY</span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TherapeuticsMD, Inc., a Nevada corporation,
or TherapeuticsMD or the Company, has <span id="xdx_90A_ecustom--NumberOfSubsidiaries_iI_dc_uN_c20201231_zQUiSrPNfplb" title="Number of subsidiaries">three</span> wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or
vitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation,
or VitaCare. Unless the context otherwise requires, TherapeuticsMD, vitaMed, BocaGreen, and VitaCare collectively are sometimes
referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221; TherapeuticsMD<sup>&#174;</sup>,
vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>, BIJUVA<sup>&#174;</sup> and ANNOVERA<sup>&#174;</sup>
are registered trademarks of our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Nature of Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">We are a women&#8217;s
healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy
prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership
to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled,
long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also manufacture and distribute branded and
generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. Our portfolio of products focused on women&#8217;s
health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. During 2018, the
U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products has transitioned our company from predominately
focused on conducting research and development to one focused on commercializing our pharmaceutical products. In July 2018, we
launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal
pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched
our FDA-approved product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol
and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our FDA-approved
product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free,
reversible prescription contraceptive option for women. Although we expected to commence the full commercial launch of ANNOVERA
in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch
of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as the pandemic began to negatively affect our
revenue growth. We resumed the commercial launch of ANNOVERA on July 1, 2020. On July 30, 2018, we entered into an exclusive license
agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize
ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement,
with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and
BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply agreement, or the Theramex License
Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada
and Israel, or the Theramex Territory.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447827274968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zItv4Oy2b268" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 2 &#8211; <span id="xdx_829_zMY7YMirPiNd">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zbWuVh9adzo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zCCnWITYyUYi">Principles of Consolidation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of our company and our wholly owned subsidiaries, vitaMed, BocaGreen and VitaCare. All intercompany
balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_848_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxel2fnrUmS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zdZGAt846502">Risks and Uncertainties</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to be subject to risks and
uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues
to be highly uncertain and difficult to predict. We continue to provide an uninterrupted supply of our portfolio of products for
patients. We have sufficient inventory of finished product to meet anticipated demand in the near future. Additionally, we currently
do not foresee any interruption in our ability to continue to manufacture additional product to be used beyond this period and
have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products. During the year ended
December 31, 2020, we recorded an inventory charge of $<span id="xdx_90F_eus-gaap--InventoryWriteDown_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_z3beEO1Oq3Rb">7,204,818</span>&#160;which was primarily related to BIJUVA and resulted from the
impact of the COVID-19 pandemic on our business, which decreased demand for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the early phase of the COVID-19 pandemic,
we have been using substantial virtual options to ensure business continuity. Our VitaCare Prescription Services patient model
assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice,
including via home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple
third-party online pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time
access to both diagnosis and treatment. We continue to support prescribers&#8217; needs with samples and product materials through
our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for live virtual e-detailing of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of our response to the COVID-19
pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented cost saving measures, which included
negotiating lower fees or suspending services from third party vendors; implementing a company-wide hiring restriction; delaying
or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full impact of the COVID-19 pandemic
continues to evolve. However, we remain committed to the execution of our corporate goals, despite the ongoing COVID-19 pandemic,
as demonstrated in part by the increase in product revenue throughout 2020. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity,
or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our operations by monitoring
the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic
has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression
that has occurred or may occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we currently believe that our COVID-19
contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of
the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity
of the pandemic, the duration of &#8220;social distancing&#8221; orders, the ability of our sales force to access healthcare providers
to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients,
thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are uncertain.
Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable
amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs
that we may undertake to address financial and operations challenges that we may face.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_ecustom--LiquidityPolicyTextBlock_zBQndKwXmNy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zvBKo3cmFt66"><span style="text-decoration: underline">Liquidity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the filing date of this Annual
Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement (as defined in Note 8 -
Debt). On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement, or Amendment No.
6, with the Administrative Agent (as defined in Note 8 - Debt) and the lenders party thereto, pursuant to which we
temporarily lowered the minimum required cash balance from $<span id="xdx_907_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z6zi29hmeiHl">60</span>
million to $<span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z8O7p4TL3t4e">45</span> million through December 31, 2020. After December 31, 2020, the minimum cash balance reverted to $<span id="xdx_908_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201231_zHQCHcqSC1ej">60</span>
million. Based on our current projections, and recent equity financings, we anticipate that we will remain in compliance with
the minimum cash balance covenant for the next twelve months from the issuance of these financial statements. In addition, we
have reviewed numerous potential scenarios in connection with the impact of COVID-19 pandemic on our business and we believe
that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary course of business for the next
twelve months from the issuance of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, if we are unsuccessful with the
commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if commercialization is delayed, or if the continued impact of the COVID-19
pandemic on our business is worse than we anticipate, our existing cash reserves may be insufficient to maintain compliance with
the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY,
BIJUVA, and ANNOVERA. The Financing Agreement also requires us to maintain certain minimum quarterly product net revenue requirements
and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA were revised. See Note 8 &#8211; Debt &#8211; for a description
of these covenants. These and other terms in the Financing Agreement have to be monitored closely for compliance
and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.
If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements,
or otherwise comply with the covenants of the Financing Agreement, all or a portion of our obligations under the Financing Agreement
may be declared immediately due and payable, which would have a material adverse effect on our business, results of operations
and financial condition.</p>

<p id="xdx_858_zLVm9OdIocal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQduWR076XSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_z0kdb43Ciy2g">Cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain cash at financial institutions
that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20201231_zQ3AOk9yMPC4" title="Cash FDIC insured amount">250,000</span> per bank. We have never
experienced any losses related to these funds.</p>

<p id="xdx_85B_zuuw5lOMJAxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p id="xdx_84A_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z0PXW0Wks4q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zoeKDk3UUjUg">Trade Accounts Receivable and Allowance
for Doubtful Accounts</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are customer
obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks
and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection
information, reasonable supportable forecasts, and existing economic conditions and we record an allowance that presents the net
amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent receivables against
our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances
of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful
accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves
may be required. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws,
coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption
associated with the current COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced
significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying
amount of trade receivables in the future. At December 31, 2020, four different customers represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeMcWBPAkK27" title="Concentration risk percentage">25</span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zFblFmC1C4tf">19</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJYlkjf6rLea">17</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zrz7FpodhDjb">11</span>% of
our gross accounts receivable. At December 31, 2019, four different customers represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zQd80LlYI9Lb">36</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zTuZYhyAeing">21</span>%,<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zUl1Y7LTCLuh">16</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zwAnBdJ6IQNc">11</span>% of our gross accounts
receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zr4gbPw0pdZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Allowance for Doubtful Accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%">Balance - January 1, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20200101__20201231_zkKUwDVtxyf2" style="width: 12%; text-align: right" title="Balance at beginning">904,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase in allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IncreaseInAllowanceForDoubtfulAccountsReceivable_c20200101__20201231_z2ElkvKerBU5" style="text-align: right" title="Increase in allowance">422,137</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Recoveries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_iN_di_c20200101__20201231_zqIFO0vWPGR5" style="text-align: right" title="Recoveries">(181,514</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Write-offs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20200101__20201231_zo2AETyNBur8" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs">(26,809</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance - December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20200101__20201231_z98bXEewnbJ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">1,117,854</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zU3AskfXE1Nd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zA9T6GNGbCQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_866_zNPe8jcvuR3d">Inventories</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories represent pharmaceutical products,
packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products
are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for
excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value.
Obsolescence may occur due to product expiring, product improvements rendering previous versions obsolete, or decreases in demand
for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Pre-Launch Inventory</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-launch inventory costs associated with
product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial
use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined,
then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during
the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Inventory Write-Off</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate inventory quarterly for short
dated and excess inventory. During the years ended December 31, 2020 and December 31, 2019, we recorded an inventory charge of
$<span id="xdx_902_eus-gaap--InventoryWriteDown_c20200101__20201231_zfLrLmKKSFud" title="Inventory charge">7,204,818</span>&#160;and $<span id="xdx_905_eus-gaap--InventoryWriteDown_c20190101__20191231_znwcXFB4i4a4" title="Inventory charge">0</span>, respectively. The charge recorded during the year ended December 31, 2020 was primarily related to BIJUVA
and resulted from the impact of the COVID-19 pandemic on our business, which decreased demand for our products.</p>

<p id="xdx_856_zfohqwWieDZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zLEBTqL1leIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zODjpnlN2nFa">Cost of Sales</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of sales includes the cost of inventory,
manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. The Population Council License
Agreement requires payment of royalties based on the sale of future products. Such royalties are recorded as a component of cost
of sales. Additionally, the amortization of license fees or milestone payments related to licensed products are classified as components
of cost of sales to the extent such payments become due in the future.</p>

<p id="xdx_850_zBo09VWnaBog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxr4m9jKAlg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_861_zqMgBOxm7Gkd">Fixed Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We state fixed assets at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives
of the related assets, which range from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zwStNlSSdvcc" title="Useful life of assets::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0588">three</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zQYPap4IV4Hh">seven years</span>. Leasehold improvements are depreciated over the shorter of their
useful life or the term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We capitalize software and software development
costs incurred to create and acquire computer software for internal use, principally related to software coding and application
development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable
that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized
in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into
service over the estimated useful life, generally <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zz4odzWls18g" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0590">five</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zXJarThY0hD4">seven years</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zCOuXAwCqboi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zHNQkewR0Dw8">Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted the provisions of Financial
Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, <i>Intangibles - Goodwill and Other</i>, or
ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications.
In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent
using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December
31, 2020, we had <span id="xdx_908_ecustom--NumberOfIssuedPatentsDomestic_iI_uN_c20201231_zUgBdjjhjVOi" title="Number of issued patents domestic.">38</span> issued domestic, or U.S., patents and <span id="xdx_90A_ecustom--NumberOfIssuedPatentsForeign_iI_uN_c20201231_zaGjxEbi1Ww2" title="Number of issued patents foreign">39</span> issued foreign patents (See Note 6). We capitalize external costs,
consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review
intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1pD2jkvUF3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_z9aHXGYIYrjg">Impairment of Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review the carrying values of fixed
assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate
that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant declines in an asset&#8217;s market price;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant deterioration in an asset&#8217;s physical condition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant changes in the nature or extent of an asset&#8217;s use or operation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant adverse changes in the business climate that could impact an asset&#8217;s value, including
adverse actions or assessments by regulators;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset&#8217;s use; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If impairment indicators are present, we
determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#8217;s carrying value
for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are
largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate
the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate
to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise
of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held
and used. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#8217;
fair value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based
upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform impairment tests for intangible
assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change
that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for
assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also evaluate the remaining useful life
of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment
or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining useful life is changed,
we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of indefinite-lived assets
is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment
test. During the years ended December 31, 2020 and 2019, we <span style="color: #212529">wrote off $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20200101__20201231_zXt7gpxpg4Qa" title="Write off of patent and trademark cost">1,131,776</span> and $<span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20190101__20191231_zWv3D9gcdwq8">78,864</span>, respectively,&#160;in
costs related to trademarks and patents. </span>There was no impairment of intangible assets during the year ended December 31,
2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z38d8DPCPpkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86F_zlLEgNREqtec">Fair Value of Financial Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of December 31, 2020 and
2019 (as disclosed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value
Measurements, </i>or ASC 820<i>. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for
identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 1in; text-align: left"><b>Level 1</b></td><td style="text-align: justify">unadjusted quoted prices in active markets for identical
assets or liabilities;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 1in; text-align: left"><b>Level 2</b></td><td style="text-align: justify">quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 1in; text-align: left"><b>Level 3</b></td><td style="text-align: justify">unobservable inputs for the assets or liabilities.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2020 and 2019, we had no assets or liabilities
that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zBlBozfK2Pa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zjtSmTJjiblk">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize both interest and penalties
related to uncertain tax positions as part of the income tax provision. At December 31, 2020 and 2019, we had no tax positions
relating to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our U.S. federal and state tax returns
since 2011, which was the first year we generated net operating losses, remain open to examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_ziINyPlLXYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_zk32UZu6u9Sh">Share-Based Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, <i>Compensation-Stock Compensation</i>, to value
options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our stock-based
awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January 1, 2020, the average
expected life of options was based on the contractual terms of the stock option using the simplified method. We utilize a dividend
yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. In
addition, the terms of the Financing Agreement (See Note 8) preclude us from paying dividends, and any future debt agreements may
also preclude us from paying dividends. The assumptions used in calculating the fair value of stock-based awards represent our
best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.
We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance
with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We grant restricted stock units and performance-based
stock units for shares of common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20201231_z2GxITWehrV5">0.001</span> per share, or Common Stock, to employees. We value our restricted stock
units and our performance-based stock units by reference to our stock price on the date of grant. We recognize compensation expense
for restricted stock units based on a straight-line basis over the requisite service period of the entire award. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the performance restricted stock vests. The number
of target shares that vest are determined based on the level of attainment of the targets. If a minimum level of performance is
attained for the awards, restricted stock is issued based on the level of attainment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgShP7jOATyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_860_zQ2ipGElfXOj">Revenue Recognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 606,&#160;<i>Revenue
from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer obtains control of promised goods or services.
The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these
goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the
transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for
those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify
the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance
obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Prescription Products</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: #212529">As of December
31, 2020, </span>our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began
selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we
began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed
the commercial launch of ANNOVERA on July 1, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our name brand and generic prescription
products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription
products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations
related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service
for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription
product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or
service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the
customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on
our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional.
We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services
sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price of a contract is
the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will
not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that
supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and
the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ
from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would
affect net product revenue and earnings in the period such changes in estimates become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of six months prior to and up to <span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z3ySKQtvDA47" title="Return period of unsalable prescription products">12</span>
months following product expiration. ANNOVERA cannot be returned before the expiration date and expired ANNOVERA can be
returned up to <span id="xdx_909_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zmR0T8rgRole">12</span>
months past the expiration date. Our prescription vitamins, IMVEXXY and BIJUVA currently have a shelf life of <span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--VitaminsImvexxyAndBijuvaMember_zT2KiZyFAJs3" title="Shelf life of prescription products">24</span>
months from the date of manufacture and ANNOVERA currently has a shelf life of <span id="xdx_908_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zzAsj5sOc8Ha">18</span>
months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of product revenue in the period the related product revenue is recognized. Where historical rates of return exist,
we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched
products, for which the right of return exists but for which we currently do not have history of product returns, we estimate
returns based on available industry data, our own sales information and our visibility into the inventory remaining in the
distribution channel. At the end of each reporting period, we may decide to constrain product revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the
expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic
products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the
customer&#8217;s consideration. Since our returns primarily consist of expired and short dated products that will not be
resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the
initial sale (when recognition of product revenue is deferred due to the anticipated return). Return estimates are recorded
in other current liabilities on the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We offer various rebate and discount programs in an effort to maintain
a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates
and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on
a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenue at the time the product
revenue is recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor
fees are recorded in other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units
sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors
fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates
relating to invoice discounts and chargebacks are deducted from gross product revenue at the time the product revenue is recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of commercial launches for our
FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket
costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with
our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. The variable consideration
is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average
assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time
up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription
products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain
variable consideration for our prescription products to an amount that will not result in a significant product revenue reversal
in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates
of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by
insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently
available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIeQdb0LePU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Prescription vitamins</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zIUJyq1Gpgyb" style="width: 12%; text-align: right" title="Net revenue">9,767,644</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zm4kXwTPfFzb" style="width: 12%; text-align: right" title="Net revenue">9,885,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zRSEpLOd3G4l" style="width: 12%; text-align: right" title="Net revenue">15,041,259</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zJfE6V5ja3Mc" style="text-align: right" title="Net revenue">27,139,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zVZkVbCvPFNg" style="text-align: right" title="Net revenue">16,252,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zvBbyNZlnXLl" style="text-align: right" title="Net revenue">1,058,201</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGYUHrnBZE1" style="text-align: right" title="Net revenue">6,353,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zLSGvlHRufNg" style="text-align: right" title="Net revenue">1,836,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--BijuvaMember_z1JXyWuYn72d" style="text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayMzasE8eb6" style="text-align: right" title="Net revenue">19,611,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zYvSCX7ojjG8" style="text-align: right" title="Net revenue">6,166,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zjpw8uaRoM46" style="text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zydUwtLaPfM1" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zEuVRJerfvu7" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSl8MRsNl7Jf" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_zQyorgOoNb95" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">64,872,280</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_z2VgHc6SD9Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">49,646,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z9pXHF47yUB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">16,099,460</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_zf7LBTNOj0Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><i><span style="text-decoration: underline">License Revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front
fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the right to use functional intellectual property is transferred to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">License Agreement with the Population
Council</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2018, we entered into the Population
Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a &#8220;test and learn&#8221; market
introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. <span style="color: #212529">We
resumed the commercial launch of ANNOVERA on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Population Council
License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNmM0XbdrIkf" title="Milestone payment upon FDA Approval">20,000,000</span>&#160;within 30 days following the approval
by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_902_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRlIviFCHJSa" title="Milestone payments (payment after release of first commercial batch)">20,000,000</span>&#160;within 30 days following the first commercial
batch release of ANNOVERA. Both milestone payments of $<span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zHvxx9ISU3ic" title="License rights acquired">20,000,000&#160;</span>were recorded as license rights in the consolidated balance
sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became commercially available for use.
The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our
cash flows, which is estimated to be the remaining patent life of the product, which expires as early as December 2032. The cost
is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the years
ended December 31, 2020 and 2019 we recorded $<span id="xdx_908_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20201231_zU0ennHdqNG" title="Amortization of intellectual property license fee">3,024,391</span>&#160;and $<span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20191231_zoFDDXXJ6XF8" title="Amortization of intellectual property license fee">778,692</span>, respectively, in amortization expense related to the
license fee which was recorded as a component of cost of sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Population Council is also eligible
to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible for marketing expenses related
to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based
royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as
follows: (i) if annual net sales are less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zB1xl9STslZj" title="Net sales amount per step-based royalty">50,000,000</span>, a royalty of&#160;<span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zHDWWmUGwgea" title="Royalty (percent)">5</span>% of net sales; (ii) for annual net
sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zT2XmmFVoWge" title="Net sales amount per step-based royalty">50,000,000</span>&#160;and less than or equal to $<span id="xdx_90E_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zTAI4ux2XhT6" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of&#160;<span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zC6XNUaPEozh" title="Royalty (percent)">10</span>% of such net sales; and (iii)
for net sales greater than $<span id="xdx_90A_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zt1yVxYQsZOk">150,000,000</span>, a royalty of&#160;<span id="xdx_90A_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zBs9xrl0NxU4" title="Royalty (percent)">15</span>% of such net sales. The annual royalty rate will be reduced to&#160;<span id="xdx_90D_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zQetXhTVEaka" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent">50</span>%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent
of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to&#160;<span id="xdx_908_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zXp9UntycC9i" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent">20</span>%
of the initial rate. We are required to pay the Population Council milestone payments of $<span id="xdx_902_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRb6ERjPJGr9" title="Milestone payments upon specified levels of cumulative net sales">40</span>&#160;million&#160;upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $<span id="xdx_904_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z0nEr1VekSOf" title="Specified level one of cumulative net sales for milestone payments">200</span>&#160;million, $<span id="xdx_906_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zTUERTX9tZt7" title="Specified level two of cumulative net sales for milestone payments">400</span>&#160;million&#160;and
$<span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zUELoe4agUhi" title="Specified level three of cumulative net sales for milestone payments">1</span>&#160;billion. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval
studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such
post-approval study exceed $<span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z4kNf57Lbi3k" title="Maximum costs and expenses for post approval">20,000,000</span>, half of such excess will be offset against royalties or other payments owed by us to the
Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a joint product
committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible for all
aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired
clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.
The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational
vaginal contraceptive systems in development by the Population Council.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless earlier terminated, the Population
Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#8217;s
U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during
which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may
also be terminated for certain breach and bankruptcy-related events and by us on 180 days&#8217; prior notice to the Population
Council.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="text-decoration: underline">License Agreement with Knight Therapeutics
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2018, we entered into the Knight
License Agreement pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.
Pursuant to the terms of the Knight License Agreement, Knight paid us $<span id="xdx_90D_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zUD7dpRngPs2">2,000,000</span> in milestone fees upon the first regulatory approval
in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is required to pay us sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory
applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in
Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain
specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement,
Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="text-decoration: underline">License Agreement with Theramex</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: #212529">On June
6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR <span id="xdx_900_ecustom--CashUpfrontPaymentReceived_pn6n6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zJCFLkOukmJf" title="Cash upfront payment received">14</span>
million, or $<span id="xdx_902_ecustom--CashUpfrontPaymentReceived_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z92lh37so5V4" title="Cash upfront payment received">15,506,400</span>,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_909_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_z7IqI8sc6G2c" title="Regulatory milestone payments">2
million</span> in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR <span id="xdx_900_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zoyAeZAvCZb8" title="Sales milestone payment">27.5
million</span> in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory
ranging from EUR <span id="xdx_909_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zcUhRqEMr4S6" title="Sales milestone">25</span>
million to EUR <span id="xdx_904_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zAacOzdvIPjd" title="Sales milestone">100</span>
million. We are also entitled to receive quarterly royalty payments at a rate of <span id="xdx_909_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_uPure_c20190506__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zq6e23cqcAxe" title="Quarterly royalty payments percentage">5</span>%
on net sales of BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory. Theramex is responsible for
all regulatory and commercial activities for BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all
regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA
and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex
challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party
that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zenh362Wo67i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zv3nAQnaW9M8">Segment Reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single executive leadership team that is led by the Chief Executive Officer of our Company, who oversees all operations. We do
not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information
with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business
as one reportable operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zxpqbr2bmcbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86B_zmyttqWPgYYk">Shipping and Handling Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--AdvertisingCostsPolicyTextBlock_zdhmPYMiEK52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zyINHvbwxSv4">Advertising Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $<span id="xdx_90F_eus-gaap--AdvertisingExpense_c20200101__20201231_zJaZR6tmsl89" title="Advertising expense">35,799,313</span>, $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20190101__20191231_z2WkwD8JFvA" title="Advertising expense">9,045,571</span> and $<span id="xdx_904_eus-gaap--AdvertisingExpense_c20180101__20181231_zTk92CW5pAXb" title="Advertising expense">1,682,746</span> during the years ended December 31, 2020, 2019, and 2018, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbIx9lxZUof7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zs115znl8Fgd">Research and Development Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development, or R&amp;D, expenses
include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory
supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory
experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken
by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house
staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking
work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations
as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.
We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity
has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses
and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion
stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion.
We charge revisions to expenses in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGxe5iUgOs2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86C_zY8NoTbthJw6">Earnings Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We calculate earnings per share, or EPS,
in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic
and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period.
We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options,
warrants and restricted stock units and were excluded from the calculation of diluted earnings per share because their effect would
have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could
affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zxZw0sPuvJN4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.5in" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Stock options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuoTVoVLv1X4" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">23,781,930</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA3iPFU4QS93" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zln2FQ1cG1xg" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">20,872,824</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6a7Q8G2kyz" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,534,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAcN8G1ZGnC" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,832,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrW6K1PYpl3j" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,007,571</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zw7hkCKqtWXe" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,403,951</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zeOF1BJWYdDj" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuGGGXBHxbSc" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0750">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCzVK1LkrEla" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">7,061,024</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziCDxmGKrzz3" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,240,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7UbyYPGZJCl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,040,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231_zJ9z974o0Fec" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">39,781,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231_zEaiLOIhKlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">28,102,805</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231_ziJUIS60zymh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">24,920,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zZpXowcWtFb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_z2CF8RaRZ6B4">Concentration of Credit Risk and other
Risks and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially
expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial
institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not
experienced any historical losses on our deposits of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of credit risk with respect
to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors.
Credit is extended to our customers based on an evaluation of a customer&#8217;s financial condition, and collateral is not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--UseOfEstimates_zSN8ER4xhn9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_z9q28YO8Zn8d">Use of Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znmqU4R9pzrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zhOmlAltG07g">Recently Issued Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In March 2020, the FASB
issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference
Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting
impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank
Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally,
contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment
of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022.
Our debt agreements currently include the use of alternate rates when LIBOR is not available. We do not expect the change from
LIBOR to an alternate rate will have a material impact to our financial statements and, to the extent we enter into modifications
of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In August 2018, the FASB
issued ASU 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public
entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting
Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness
of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information
to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December
15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or
only the provisions that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not
have a material effect on our disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In June 2016, the FASB
issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments.
The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be
presented at the net amount expected to be collected based on historical experience, current conditions, and reasonable supportable
forecasts. The amendments in this update are effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the first quarter of 2019.
A modified retrospective approach is required for all investments, except debt securities for which an other-than-temporary impairment
had been recognized prior to the effective date, which will require a prospective transition approach and should be applied either
prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13 requires expanded quantitative
and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January 1, 2020, we adopted ASU 2016-13
under a modified retrospective approach for all financial assets measured at amortized cost. There was no adjustment recorded for
the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">Other recent accounting
pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants
and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</p>

<p id="xdx_854_zxqwplGFy472" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447825941800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zajTsxMknFXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 3 &#8211; <span id="xdx_825_zwwj3ViuRwyj">INVENTORY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z4VIWKaJ1hnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zGhhd5wdffZa">Inventory consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zmsSAMGBKAy9" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20191231_zIAXW9h947I8" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzQbM_maINzicc_zTwzl9zMR9lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Finished products</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,350,580</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,976,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzQbM_maINzicc_z6ccfz20W1y2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182,059</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzQbM_maINzicc_zxy3xVRWrBDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,422,589</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,701,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryNet_iTI_uUSD_mtINzQbM_mtINzicc_zj3NQdbZOL56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,993,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,860,716</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AF_zBhj3909m1Ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447814907592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--OtherCurrentAssetsTextBlock_zsdeEMek8hk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 4 &#8211; <span id="xdx_82E_zj6xO6iAAHJ6">OTHER CURRENT ASSETS</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zyDotqxUZZjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_z3E7SUgITetf">Other current assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zWlfmIhVR7h5" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20191231_zaPuNRXP6zbe" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_405_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zTX1UGrHOIDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Prepaid sales and marketing costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,583,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_maPEAOAzRrD_zWdzxiUe5Nw1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt financing fees on undrawn tranches (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,757</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_maPEAOAzRrD_zV5AAuUETA53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,568,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,812,135</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_maPEAOAzRrD_zPdNfb7f2uod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,331,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,595,721</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zbM6X4J7YOFk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,639,720</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,787,482</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_mtPEAOAzRrD_zWmZJ6fH1651" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,543,397</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,329,793</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AF_zwVTX4gg8gGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813308440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS, NET</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEdVbqz1aUZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 5 &#8211; <span id="xdx_828_zus5oAUiLXD7">FIXED ASSETS, NET</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwalxkNjwlpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B3_zpzb2OwFhoZ4">Fixed assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20201231_zJIfVFMJGDmk" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20191231_zpgoHHfaLpb7" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Accounting system</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zXVawOStxG4d" style="width: 12%; text-align: right">411,550</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zm9EPO4CUHbk" style="width: 12%; text-align: right">301,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_znRbalwMXMfg" style="text-align: right">1,704,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zPIVpZNZNZac" style="text-align: right">1,619,646</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zwDDCVnUTvF7" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmrLBXnu01Rb" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zFRX5JHfIGq5" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zBAJ6spUyCOd" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zvn7rxfAzVGc" style="border-bottom: Black 1pt solid; text-align: right">80,121</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zebvqVsbkxsi" style="border-bottom: Black 1pt solid; text-align: right">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_zHwmcCITGIVc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,683,671</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,476,599</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20201231_zaTLGDdVBvm2" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(1,741,447</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_zHp8qjyh7OHj" style="border-bottom: Black 1pt solid; text-align: right">(968,824</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_zlvcHLtLDnNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,942,224</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,507,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A9_zM3luYgKygP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense for the years ended December 31, 2020,
2019, and 2018 was $<span id="xdx_90D_eus-gaap--Depreciation_c20200101__20201231_zS1VPS1vozdg">772,624</span>, $<span id="xdx_909_eus-gaap--Depreciation_c20190101__20191231_zRbjcLOUYLJ1">415,193</span>, and $<span id="xdx_903_eus-gaap--Depreciation_c20180101__20181231_zF184FoseAS6">181,412</span>, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815390904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_801_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zKVHVcTGWZ79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 6 &#8211; <span id="xdx_82D_zJtKxGSrqsl1">INTANGIBLE ASSETS, NET</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z4clAvQB88J8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B4_z8NdkXyYT5Xc">The following table sets forth the gross carrying amount, accumulated
amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross<br/>
Carrying<br/>
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated<br/>
Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net<br/>
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted-</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average<br/>Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Amortization</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Period (yrs.)</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Approved hormone therapy drug candidate patents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zSYuKPdQIVDd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross">4,044,552</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zALv2sZjcEfe" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(748,627</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHAO8XCZRci2" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net">3,295,925</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlsvJLAC4KM7" title="Finite-Lived Intangible Assets, Remaining Amortization Period">12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z8bRYnrmuxok" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">1,628,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zc3zWfX2t3Qb" style="text-align: right" title="Finite-Lived Intangible Assets, Net">1,628,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zdVboSaMaXWj" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">323,341</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zqphpEFgOJJa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">323,341</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zDv0mJvaJSk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">5,996,350</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231_zR3YedimwWm7" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(748,627</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zP2E2mjJ1Due" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">5,247,723</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross<br/>
Carrying<br/>
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated<br/>
Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net<br/>Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted-</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average<br/>Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Amortization</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Period (yrs.)</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zKnJASx50b3l" style="width: 12%; text-align: right">3,463,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxvVB9iunx1f" style="width: 12%; text-align: right">(478,983</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zReVzPUfDAE5" style="width: 12%; text-align: right">2,984,099</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z7kwhX16V0ng">13</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zk3uT2fprYog" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z6mTdKWmF8Rj" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zR8Me2QAcuwk" style="border-bottom: Black 1pt solid; text-align: right">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zwrOWh3L3gqk" style="border-bottom: Black 1pt solid; text-align: right">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zVTewfUNILE3" style="border-bottom: Black 2.5pt double; text-align: right">5,737,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zraYe4cYgmJf" style="border-bottom: Black 2.5pt double; text-align: right">(478,983</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_z3ErTi9gGA5e" style="border-bottom: Black 2.5pt double; text-align: right">5,258,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_z7k1K2akQEU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We capitalize external costs, consisting
primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone
therapy drug candidate patents using the straight-line method over the estimated useful life of approximately <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zr99z1YZYDPe">20</span> years, which is
the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time.
Trademarks are perpetual and are not amortized. During the years ended December 31, 2020 and 2019, we <span style="color: #212529">wrote
off $<span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0i_c20200101__20201231_zwHJkluFg3Uj">1,131,776</span> and $<span id="xdx_903_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0i_c20190101__20191231_zp3BudRUttAi">78,864</span>, respectively,&#160;in costs related to trademarks and patents. </span>There was no impairment of intangible
assets during the year ended December 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, we had <span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zb84hNxk4FZj" title="Number of issued patents">38</span> issued
domestic patents and <span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zQ3GEY3Tbpy4" title="Number of issued patents">39</span> issued foreign patents, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zE7TGDHXeao2" title="Number of issued patents">15</span> domestic patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zyesTFzuOuTd" title="Number of issued patents">nine</span> foreign patents that relate to BIJUVA as well as <span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zcvIvUiInO1k">three</span> domestic patents
that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation
and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel,
Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zVwtAja4g67f" title="Number of issued patents">12</span> domestic patents (<span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zGVAz1QFsWyg" title="Number of issued patents">ten</span> utility and <span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zbnT7XnsLmH7" title="Number of issued patents">two</span> design) and <span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zIWLh9HLxNVe">18</span> foreign patents (<span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zqPNDL7iLvYi" title="Number of issued patents">eight</span> utility and <span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z6jnUS6IcUPh" title="Number of issued patents">ten</span>
design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned
by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign
design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection
through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil,
Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_zk4t8lH5kPj" title="Number of issued patents">One</span> domestic utility patent that relates to our topical-cream candidates, which is owned by us.
The domestic patent will expire in 2035;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zmitEfPyOK3f" title="Number of issued patents">One</span> domestic utility patent and <span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zrGKH3tQ6Is" title="Number of issued patents">eight</span> foreign patents that relate to our transdermal-patch candidates,
which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We
have a pending patent application with respect to our transdermal-patch candidates in Brazil;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zf050oudVsD3" title="Number of issued patents">Three</span> domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate,
which are owned by us and will expire in 2037;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zCmiPjTgtIq8" title="Number of issued patents">Two</span> domestic and <span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zySWeuiKXGy" title="Number of issued patents">four</span> foreign patents that relate to formulations containing progesterone, which
are owned by us. The domestic patents will expire between 2032 and 2036. The foreign patents will expire no earlier than 2033.
In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Australia, Canada,
Europe, and Mexico; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uN_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zPGQ1AFmuwK3" title="Number of issued patents">One</span> domestic utility patent that relates to our OPERA information-technology platform, which is
owned by us and will expire in 2031.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Amortization
expense was $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20201231_zD2ORwFbcPEa">269,546</span>, $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20190101__20191231_z1SPBGHDSzl5">197,593</span>, and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20180101__20181231_zkaSaHWfOPJg">112,474</span> for the years ended December 31, 2020, 2019, and 2018, respectively.</span></p>

<p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z33kdLUjHoci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span>Estimated amortization
expense, based on current patent cost being amortized, for the next five years is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20201231_z1JUp7oWRApk" style="border-bottom: Black 1pt solid; text-align: center">Estimated Amortization</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zZyWjdNjBbcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: right">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">274,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zj5ls5NSbUHl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zozl23CkGf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zXrb5arYeYK8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zY4MKUsYBGvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A3_zA8ImBbyKVl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813673512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zWTtJcOhdnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 7&#8211; <span id="xdx_82B_zlEeOlBd5rY2">OTHER CURRENT LIABILITIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_89A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zWFG7m1cBZL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B0_z0igxA9SVRpb">Other current liabilities</span> consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_z1xo8tvfSIge" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20191231_zWIqwsQfSZPe" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zaTCBg7RazSi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Accrued payroll, bonuses and commission costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,758,073</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,040,278</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zeyV3oadnasd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,770,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,316,298</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zNcBXHLzhL6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,285,662</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zhYdjdiDEsF5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,353,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,463,878</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_zQ7aXpeBqyMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,632,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,347,122</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zMwLBfP5Q63d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">898,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">422,336</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zIPy0XfuYiHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">925,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,049,603</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zBo2rNF1j4zj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,253,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--AccruedRebates_iI_maOLCz3D1_z9a5LrouC4Vl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,010,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,916,672</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zZe36SEC1cHe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,339,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,480,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_mtOLCzij0_z5oEs5EK70W1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,169,869</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,823,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_zaOWz2G0v393" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813673512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_809_eus-gaap--LongTermDebtTextBlock_z0Lc13j7mEA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE
8 &#8211; <span id="xdx_828_z7KQ3ZogzQ47">DEBT</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2019, we entered into a
Financing Agreement, as amended, or the Financing Agreement, with Sixth Street Specialty Lending, Inc., as administrative
agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party
thereto from time to time as guarantors, which provided us with up to a $<span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zT0AXzKGg7Vi">300,000,000</span>&#160;first
lien secured term loan credit facility, or the Facility. The Facility provided for availability to us in three tranches: (i)
$<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zpthIp6Cwi0b">200,000,000</span>&#160;was
drawn upon entering into the Financing Agreement; (ii) $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zsyWnBAMTlqi">50,000,000</span>&#160;was
drawn on February 18, 2020 following our achievement of more than $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0i_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zdKLAwDNebQf" title="Revenues">11,000,000</span>&#160;in
net revenues from IMVEXXY, BIJUVA, and ANNOVERA for the fourth quarter of 2019 and (iii) <span id="xdx_90E_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zhlT40GNMH74">$50,000,000</span>&#160;was
previously available to us in the Administrative Agent&#8217;s sole and absolute discretion either contemporaneously with the
delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as the Administrative Agent
may have consented to. Subsequent to the pause in the successful full launch of ANNOVERA caused by the COVID-19 pandemic, the
undrawn $<span id="xdx_90E_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zXcnPtbRWxn">50,000,000 </span>tranche
under the Financing Agreement is no longer available. Borrowings under the Facility accrue interest at either (i)&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zPVeV0wuGvT2">3-month
LIBOR</span>&#160;plus&#160;<span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3dms8Czlin3">7.75</span>%,
subject to a LIBOR floor of&#160;<span id="xdx_90E_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zMjzo8Midjnf">2.70</span>%
or (ii) the&#160;<span id="xdx_906_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zHBzFBbDJ7y2">prime
rate</span>&#160;plus&#160;<span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zxSSBmgdEwab">6.75</span>%,
subject to a prime rate floor of&#160;<span id="xdx_907_ecustom--PrimeRateFloor_iI_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zAS0ri0fVuc1">5.2</span>%
as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. Prior to entering into Amendment No.
8, the outstanding principal amount of the Facility was payable in&#160;<span id="xdx_907_ecustom--NumberOfInstallmentPayments_iI_dc_uN_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zxNsII45QZWi">four</span>&#160;equal
quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. In connection with Amendment
No. 8 we, among other things, (i) repaid $<span id="xdx_905_eus-gaap--RepaymentsOfLinesOfCredit_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDXzbY67F1Eh">15</span>.0
million in principal under the Financing Agreement on such date, plus a <span id="xdx_909_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0MgY7Uekn96">5.0</span>%
prepayment fee, (ii) agreed to repay an additional $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodOneMember_zMKCEXLiRjDd" title="Principal repayment">35</span>.0
million in principal by no later than March 31, 2021, plus a <span id="xdx_90C_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodOneMember_zGuOlDVYVIxc">5.0</span>%
prepayment fee, and (iii) agreed to make additional principal repayments as follows: (x) $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodTwoMember_z25NpNlTyoCj">5</span>.0
million on each of March 31, 2022, June 30, 2022 and September 30, 2022; (y) $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodThreeMember_zB8ECcvYo9je">10</span>.0
million on each of December 31, 2022 and March 31, 2023; and (z) $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn4n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodFourMember_zBNRx6eCQbCh">41.25</span>
million on each of June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, plus the prepayment fees
described in the following sentence. We have the right to prepay borrowings under the Facility in whole or in part at any
time, subject to a prepayment fee on the principal amount being prepaid, which was revised in connection with Amendment No.
8, of (i) <span id="xdx_908_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodFiveMember_zrqBEU9y1o61">30.0</span>%
of the principal amount being repaid through March 31, 2022 (excluding the scheduled $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn5n6_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSixMember_zR8lTtRCB5Ik">5</span>.0
million principal repayment on such date, which is subject to a <span id="xdx_908_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSixMember_z54PxhVRbOhc">5.0</span>%
prepayment fee); (ii) <span id="xdx_900_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodSevenMember_zwTMAbnLn6wk">5.0</span>%
of the principal amount being repaid from April 1, 2022 through March 31, 2023; (iii) <span id="xdx_90F_ecustom--PrepaymentFeePercentage_dp_uPure_c20210227__20210301__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementAmendment8Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentRedemptionPeriodAxis__custom--RepaymentPeriodEightMember_zAyMpw7mPmJk">3.0</span>%
of the principal amount being repaid from April 1, 2023 through March 31, 2024; and (iv) thereafter, none, in each case
subject to certain limited exceptions, including with respect to a repayment in full of the obligations under the Financing
Agreement. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility
fee equal to&#160;<span id="xdx_900_ecustom--FacilityFeePaidPercent_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z21h4l8uOn5i">2.5</span>%
of the initial amount borrowed and were required to pay such a facility fee in connection with subsequent borrowings under
the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition
to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants
applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a
minimum unrestricted cash balance of $<span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0i_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z1AjjsD6Du04">60,000,000</span>,
and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and
ANNOVERA products beginning with the fiscal quarter ended December 31, 2020. Pursuant to Amendment No. 8, the minimum
consolidated net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised to (i)
$<span id="xdx_90C_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period1Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zFPcOQ5sNoQ2">17</span>.0
million, $<span id="xdx_906_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period2Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zzw9yTflbxr6">20</span>.0
million, $<span id="xdx_906_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period3Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zGYPtvUkiZwe">23</span>.0
million, and $<span id="xdx_908_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period4Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_z4Ku9yQcdFw2">26.5</span>
million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $<span id="xdx_900_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period5Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zgtcrDt0j6F7">30</span>.0
million, $<span id="xdx_90B_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period6Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zQLwyBo9FNV6">35</span>.0
million, $<span id="xdx_90A_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period7Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_z3x0ztv50Mfb">40</span>.0
million and $<span id="xdx_905_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period8Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zDk7k2am9BRb">45</span>.0
million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $<span id="xdx_90B_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period9Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zNtl5cfKYZPa">50</span>.0
million, $<span id="xdx_909_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period10Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zeCtuhVGyR99">55</span>.0
million, $<span id="xdx_90E_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period11Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zakn57nHjtud">60</span>.0
million and $<span id="xdx_902_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period12Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zg5BaqQj9XUg">65.5</span>
million for the first, second, third, and fourth quarters of 2023, respectively, and (iv) $<span id="xdx_90C_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment8Period13Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zXpp1CJAd8r4">70</span>.0
million for the first quarter of 2024. Pursuant to Amendment No. 6 (as defined below), the minimum required cash balance was
lowered to $<span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_znJdXV3fEqu2">45</span>
million from November 8, 2020 through December 31, 2020. As of December 31, 2020, we were in compliance with all covenants
under the Financing Agreement. The Financing Agreement also includes other representations, warranties, indemnities,
restrictions on the payment of dividends, and events of default that are customary for financings of this type, including an
event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent
and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and
payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and
its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon
exceptions, by a first priority perfected security interest in all existing and after acquired assets of our company and its
subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect
subsidiaries, subject to certain exceptions. Also pursuant to Amendment No. 8, the Administrative Agent consented to a
framework for our potential disposition of our vitaCare prescription services business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2020, we entered into
Amendment No. 5 to the Financing Agreement, or Amendment No. 5. Amendment No. 5 adjusted the covenant in the Financing
Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our IMVEXXY,
BIJUVA, and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant was effective beginning with
the fiscal quarter ending December 31, 2020. In connection with Amendment No. 5 and in lieu of a cash amendment fee, we
issued to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zI61F8GEjRN2" title="Number of warrants issued">4,752,116</span>
shares of Common Stock with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z5GIH5eJwp6j" title="Warrants exercise price">1.58</span>
per share and a ten-year term, or the Lender Warrants. The Lender Warrants were issued pursuant to an exemption from
registration under the Securities Act of 1933, as amended, and no registration rights were issued. The Company concluded that
the modification accounting model is applicable to this transaction and recognized the fair value of the warrants as a debt
discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 8, 2020, in connection with
entering into Amendment No. 6 to the Financing Agreement, or Amendment No. 6, we amended the Lender Warrants to provide for an
adjustment to the exercise price if we conduct certain dilutive issuances prior to December 31, 2020, or if the volume-weighted
average price of our Common Stock for the fifteen trading days ending December 31, 2020 is lower than the then-current exercise
price. Pursuant to Amendment No. 6, the issuance of Common Stock by the Company in the underwritten public offering at a price
per share equal to $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20211108_zEgMmvRCIOY4">1.1856</span> triggered the automatic reduction in the exercise price of the Lender Warrants from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zt920nnHIO94">1.58</span> to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201108__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zJUrhQg1Hbf6">1.1856</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2018, we entered into a
Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as
lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as
amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0i_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zVPDmAPSJpG3" title="Line of Credit Facility, Maximum Borrowing Capacity">200,000,000</span>,
or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in&#160;<span id="xdx_903_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uN_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zbWTZ2h6yAjl" title="Number of tranches under term loan facility">three</span>&#160;separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts
borrowed under the Term Loan bore interest at a rate equal to the sum of (i)&#160;<span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zbB61kc3itwg" title="Debt Instrument, Description of Variable Rate Basis">one-month LIBOR</span>
&#160;(subject to a LIBOR floor of&#160;<span id="xdx_904_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zD5trAgIz9Nl" title="LIBOR floor rate">1.50</span>%)
plus (ii)&#160;<span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zfzZnx0M4x9b" title="Debt Instrument, Basis Spread on Variable Rate">7.7</span>5%
per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2019, we terminated the Credit
Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $<span id="xdx_90B_ecustom--RepaymentOfDebtWithNewCreditFacility_pp0i_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zS0oG7kt7oUj">81,661,000</span>&#160;was
used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of&#160;<span id="xdx_903_ecustom--PrepaymentFeePercentage_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zq5316yBeWVb">4</span>%, a repayment fee of&#160;<span id="xdx_906_ecustom--RepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zW8j96OpNqrh">4</span>%&#160;and
other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement,
we recorded $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0i_dxL_c20190101__20191231_zx1FLKRkKzI6" title="::XDX::-10057632"><span style="-sec-ix-hidden: xdx2ixbrl1028">10,057,632</span></span>&#160;in loss on extinguishment of debt in the second quarter of 2019. Interest expense for the years ended
December 31, 2019 and 2018 related to the Credit Agreement was $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0i_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z1Q40lF5lODh">1,816,747</span> and $<span id="xdx_907_eus-gaap--InterestExpenseDebt_pp0i_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zt9DarYAfUi1">4,407,975</span>, respectively. During the year ended December
31, 2019, and prior to the repayment of the Credit Agreement, we amortized $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zMGagYlPtuma" title="Amortization of deferred financing costs">120,146</span>&#160;of deferred financing fees as interest
expense in the accompanying consolidated financial statements. During the year ended December 31, 2018, we amortized $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zBfbp3pfViZ1" title="Amortization of deferred financing costs">269,859</span>&#160;of
deferred financing fees as interest expense in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As
of December 31, 2020, we </span>had $<span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0i_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z5ejBrpNZnYj">250,000,000</span>&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated
financial statements. Since the inception of the Financing Agreement, we have incurred $<span id="xdx_90C_eus-gaap--DeferredFinanceCostsGross_iI_pp0i_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zCSFoFqVSN05">7,902,270</span>&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
were allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to the two
tranches of borrowings that we received of $<span id="xdx_90B_eus-gaap--DeferredFinanceCostsGross_iI_pp0i_c20201231__custom--DebtTrancheAxis__custom--TrancheTwoMember_zgxjvZuF7T9i">7,626,891</span>&#160;have
been reflected as debt discount upon each draw and are amortized to interest expense using the effective interest method. In
addition, during the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of
$<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0i_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zZ4SOZlWM6pc" title="Fair value of warrants">7,428,178</span>
as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the
Financing Agreement. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value to the debt discount
of $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0i_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zGkmiNugi5nk" title="Debt discount">239,983</span>,
which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement.
The public offering in November 2020 triggered the down round provision underlying the warrants
granted in August 2020, as modified in November 2020, which was immaterial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the third quarter of 2020, we concluded
that the undrawn $<span id="xdx_90B_ecustom--LineOfCreditFacilityUndrawnTrancheNoLongerAvailable_iI_pp0i_c20200930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zbKv5T4ySVBg">50,000,000</span>&#160;tranche under the Financing Agreement is no longer available to us. As such, we wrote off $<span id="xdx_90C_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pp0i_c20200101__20201231_zTTCFlRoUJ0g" title="Write off of deferred financing fees">275,379</span>
of deferred financing fees associated with the unfunded tranche, which were previously deferred as assets until such tranche had
been drawn.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2020
and 2019, we amortized $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zauQQjdQEBi2" title="Amortization of deferred financing costs">2,256,428</span> and $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_pp0i_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zhgLPwwxNhH4" title="Amortization of deferred financing costs">736,156</span>, respectively, of deferred financing fees related to the Financing Agreement as
interest expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement
is due and payable quarterly in arrears. Interest expense for the years ended December 31, 2020 and 2019 was $<span id="xdx_90F_eus-gaap--InterestExpenseBorrowings_pp0i_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zE095bRo9O8e">26,049,236</span> and $<span id="xdx_903_eus-gaap--InterestExpenseBorrowings_pp0i_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zsb7QUeW8Pf2">14,709,166</span>,
respectively. The overall effective interest rate under the Financing Agreement was approximately <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7YiWUjSjGK5">12.5</span>% as of December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zPwkD1Td4woa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B6_z2o13kQ2qy38">As of December 31, 2020 and 2019, the carrying
value of our debt consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Financing Agreement</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zwMTUNoEabB4" title="Long-term Debt, Gross">250,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7jLOiHi86Hh" title="Long-term Debt, Gross">200,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20201231_zJZIcl9hA7Q3" style="border-bottom: Black 1pt solid; text-align: right">(12,302,469</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zwN3DhrO3tLa" style="border-bottom: Black 1pt solid; text-align: right">(5,365,357</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--LongTermDebtNoncurrent_iI_c20201231_zBq3vAz9k4rj" title="TOTAL LONG-TERM DEBT">237,697,531</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--LongTermDebtNoncurrent_iI_c20191231_z7cAUqfBdSZ1" title="TOTAL LONG-TERM DEBT">194,634,643</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AF_z9QIONfH9CBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zxHfodBnKX38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zxEhXGMEwQB">The following table reflects our aggregate future principal payments
under the Financing Agreement for the next five years, as amended by Amendment No. 8:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_z3X51nIyMpud" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_iI_d0_zYdZnuq1q9g6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">50,000,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_iI_d0_zAXeX7sTPnMe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_iI_zcu09OXQhgR7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: right">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">133,750,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_iI_zE0O6fqRfQ1c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,250,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_iI_d0_zy2jDUsGPtmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zh4LGFfHc1Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813314968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zevvxjX5Eo33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 9 &#8211; <span id="xdx_826_z9KCoir0Pphh">STOCKHOLDERS&#8217; EQUITY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, we had <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zadL1y9Kiw6b" title="Preferred Stock, Shares Authorized">10,000,000</span>
shares of preferred stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zL5auj1mcSdd" title="Preferred Stock, Par or Stated Value Per Share">0.001</span> per share, or Preferred Stock, authorized for issuance, of which <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_do_c20201231_zMdkPuF07txb" title="Preferred Stock, Shares Issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20201231_z4ktvPaYuNxd" title="Preferred Stock, Shares Outstanding">no</span></span> shares of Preferred
Stock were issued or outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, we had <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zETZF7pENal" title="Common Stock, Shares Authorized">600,000,000</span>
shares of Common Stock authorized for issuance, of which <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20201231_zPgGFQklb5Ac" title="Common Stock, Shares, Issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zdycJgL6WmRk" title="Common Stock, Shares, Outstanding">299,765,396</span></span> shares of Common Stock were issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During 2020</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWL7lnRBYlMi" title="Shares issued for exercise of options, net (in shares)">1,182,195</span> shares of Common Stock were exercised for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zDzhsgKiugrc" title="Shares issued for exercise of options, net">271,678</span> in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 10, 2020, we entered into an underwriting agreement
with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201109__20201113__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zqGbZGoDAHMb" title="Shares issued in offerings, net of cost (in shares)">23,437,500</span>
shares of Common Stock at a public offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zCzbiIckQG02" title="Shares Issued, Price Per Share">1.1856</span> per share. We granted to the underwriter an option, exercisable for
a period of <span id="xdx_909_ecustom--PeriodExercisableUnderwritersOption_dt_c20201109__20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zk0suB4XaUz5" title="Period exercisable underwriters option">30 days</span>, to purchase up to <span id="xdx_906_ecustom--UnderwritersOptionGrantedInPeriodShares_c20201109__20201120__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zanMzhITS889" title="Underwriters option granted in period shares">3,515,625</span> additional shares of Common Stock, which was exercised in full. The net proceeds
the offering were approximately $<span id="xdx_90E_ecustom--ProceedsFromIssuancePublicOffering_c20201109__20201110__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_z4NSlubpzt65" title="Proceeds from issuance public offering">31,703,000</span>, after deducting the underwriting discounts and commissions and estimated offering
expenses payable by us. The offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201109__20201113__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zDzDIsb2ctVc">23,437,500</span> shares closed on November 13, 2020 and the offering of <span id="xdx_906_ecustom--UnderwritersOptionGrantedInPeriodShares_c20201109__20201120__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zFcL6LKPQKF3">3,515,625</span> shares closed on November 20, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2020, we entered into a
Controlled Equity Offering<sup>SM</sup> Sales Agreement, or sales agreement, with Cantor Fitzgerald relating to shares of our
Common Stock. In accordance with the terms of the sales agreement, we were permitted to offer and sell shares of our Common
Stock having an aggregate offering price of up to $<span id="xdx_905_ecustom--MaximumCommonStockOfferingPrice_dm_c20200101__20201130__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zH0MJ3E4LRni">50 million</span>
from time to time through or to Cantor Fitzgerald, acting as sales agent. Cantor Fitzgerald was entitled to
compensation at a fixed commission rate of <span id="xdx_907_ecustom--FixedCommissionRate_dp_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember_zhUMSLPVsvdj">3.0</span>%
of the aggregate gross sales price per share sold. No shares of Common Stock were sold under the sales agreement during the year ended December 31, 2020. As
further described in Note 16 - Subsequent Events, on February 8, 2021, our &#8220;at the market&#8221; offering with Cantor Fitzgerald
terminated following the sale of the maximum $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_c20210101__20210228__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zbwaDJBp2gCf">50 million</span> of shares of Common Stock in January 2021 and February 2021 pursuant to
the sales agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During 2019</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2019, we entered into an
underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters, relating to an underwritten public
offering of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z2h9oFSnHer5" title="Shares issued in offerings, net of cost (in shares)">26,000,000</span> shares of our Common Stock at a public offering price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zMNfU5hFd5c7" title="Shares Issued, Price Per Share">2.75</span> per share. We granted the underwriters an
option, exercisable for a period of <span id="xdx_903_ecustom--PeriodExercisableUnderwritersOption_dt_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zrY70L9cq1Hi" title="Period exercisable underwriters option">30 days</span>, to purchase up to <span id="xdx_903_ecustom--UnderwritersOptionGrantedInPeriodShares_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zsItt7AIR0J4" title="Underwriters option granted in period shares">3,900,000</span> additional shares of Common Stock, which was exercised
in full. The net proceeds to us from the offering were approximately $<span id="xdx_905_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zsecvHzmeRng" title="xdx_907_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zSAbRt90BdY">77,031,000</span>, after deducting the underwriting discount and
offering expenses payable by us. The offering closed on October 29, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019,
certain individuals exercised stock options to purchase an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwLg2siMkLFc" title="Shares issued for exercise of options, net (in shares)">331,619</span> shares of Common Stock for $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMS273NxSAG4" title="Shares issued for exercise of options, net">108,656</span> in cash. Also,
during the year ended December 31, 2019, stock options to purchase an aggregate of <span id="xdx_900_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20191231_zduc4iYxQJSe" title="Number of stock options exercised in cashless exercise (in shares)">12,097</span> shares of Common Stock were exercised
pursuant to the options&#8217; cashless exercise provisions, which resulted in <span id="xdx_905_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20191231_zO0sMCeCS4zg" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)">11,834</span> shares of Common Stock being issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During 2018</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2018, we entered into an underwriting
agreement with Goldman Sachs &amp; Co. LLC, as representative of the underwriters, relating to an underwritten public offering
of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zmq2OsvdXGFj" title="Shares issued in offerings, net of cost (in shares)">12,745,098</span> shares of our Common Stock at a price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zT0g1eBP9hU7" title="Shares Issued, Price Per Share">5.10</span> per share. We granted the underwriters an option, exercisable for
a period of <span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dt_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zdsxWOgxQfIf" title="Period exercisable underwriters option">30 days</span>, to purchase up to <span id="xdx_901_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zMLZnLxOtWjb" title="Underwriters option granted in period shares">1,911,764</span> additional shares of Common Stock. On August 2, 2018, the underwriters exercised
the option in full. The net proceeds to us from the offering, including the exercise of the option to purchase additional shares,
were approximately $<span id="xdx_901_ecustom--ProceedsFromIssuancePublicOffering_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zRqydcYEtCy5" title="Proceeds from issuance public offering">69,908,000</span>, after deducting the underwriting discount and offering expenses payable by us. The offering closed
on August 6, 2018. In connection with the Knight License Agreement, on August 6, 2018, Knight entered into a subscription agreement
with us, pursuant to which Knight purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zbJWmNdIxBQd" title="Shares issued in offerings, net of cost (in shares)">3,921,568</span> of shares of our Common Stock concurrently with the closing of the underwritten
public offering of Common Stock at a price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zDjJWk4XjBGd" title="Shares Issued, Price Per Share">5.10</span>, for proceeds to us of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zXhW1Xh38PNa" title="Shares issued in offerings, net of cost">20,000,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2018,
certain individuals exercised stock options to purchase an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxzVFySqaZB1" title="Shares issued for exercise of options, net (in shares)">5,444,526</span> shares of Common Stock for $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQFrePRJZdI3" title="Shares issued for exercise of options, net">1,666,208</span> in cash.
Also, during the year ended December 31, 2018, stock options to purchase an aggregate of <span id="xdx_901_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20181231_zkDhw48ZgHMj" title="Number of stock options exercised in cashless exercise (in shares)">10,000</span> shares of Common Stock were exercised
pursuant to the options&#8217; cashless exercise provisions, wherein <span id="xdx_901_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20181231_zc4Sui8Vqqvc" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)">9,841</span> shares of Common Stock were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Warrants to Purchase Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, we had warrants
outstanding to purchase an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231_zG6yWauvexhh" title="Warrants outstanding">6,534,687</span> shares of Common Stock with a weighted-average contractual remaining life of
approximately <span id="xdx_90C_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20201231_zQF75OpByNNi" title="Weighted-average contractual remaining life">7.25</span> years, and exercise prices ranging from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zuOiOyQJYNCc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.24</span> to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zToPRD7Gv3T6" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">8.20</span> per share, resulting in a weighted average exercise price
of $<span id="xdx_90F_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYD8KlOza87c" title="Weighted average exercise price of warrants (in dollars per share)">1.55</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,
including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with Amendment No. 5 and
in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders under the Financing Agreement the Lender
Warrants. The fair value for the Lender Warrants was determined by using the Black-Scholes Model on the date of the grant using
a term of <span id="xdx_90F_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zFq1ZymDuLh8">ten years</span>, volatility of <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_z25U0CWNsN0b" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate">68.8</span>%, risk-free interest rate of <span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zoTOEUcWjUJ3" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate">0.34</span>% and dividend yield of <span id="xdx_901_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zRsf6BxHzLX5" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate">0</span>%. The grant date fair value
of the warrants was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zFA7i4iPEnWh" title="Weighted average grant date fair value, granted">1.56</span> per share. The warrants vested upon issuance. We concluded that the modification accounting model is
applicable to this warrant issuance and recognized the fair value of the warrants as a debt discount. As a result, the fair value
of the Lender Warrants is being amortized to interest expense over the term of the Financing Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 8, 2020, in connection with
entering into Amendment No. 6, we amended the Lender Warrants to provide for an adjustment to the exercise price if we conducted
certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen
trading days ending December 31, 2020 was lower than the then-current exercise price. Pursuant to Amendment No. 6, the issuance
of the shares of Common Stock in the November 2020 underwritten public offering triggered the automatic reduction in the exercise
price of the Warrants from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20200805__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zSSM7TXC0RUl">1.58</span> to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201108__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zNIemvC7rTHc">1.1856</span>. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value
to the debt discount of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_zv62SeJgagZ9" title="Debt Discount">239,983</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019,
we granted warrants to purchase an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zETZ3fmKAQpd" title="Number of shares under warrants granted">75,000</span> shares of Common Stock to outside consultants which vest ratably over a
<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z6KPq0u7PX4l" title="Warrants vesting period">12</span>-month period and have an expiration date of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zGptuM3Xzy1f" title="Warrants expiration date">February 13, 2024</span>. During the year ended December 31, 2018, we granted warrants
to purchase an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zivTQmjh9yl8" title="Number of shares under warrants granted">175,000</span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zy7SCWdnFgk3" title="Award vesting period">12</span>-month period and
have an expiration date of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zrd4iPyErWB3" title="Warrants expiration date">March 15, 2023</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded share-based compensation expense
related to warrants previously issued of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zgQNHXusCNkc" title="Share-based Payment Arrangement, Noncash Expense">26,446</span>, $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zXXQ3RiS3qW8" title="Share-based Payment Arrangement, Noncash Expense">254,970</span>, and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z2PY20UsVsXe" title="Share-based Payment Arrangement, Noncash Expense">494,136</span> for the years ended December 31, 2020, 2019 and 2018,
respectively, in the accompanying consolidated financial statements. At December 31, 2020, there was no unrecognized compensation
expense remaining related to unvested warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89A_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zQIEBlKA5QB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Summary of our Warrant activity during the year ended December
31, 2020:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Shares Under</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Warrants</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Life in Years</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Balance at December 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRRfJbOqoFuf" style="width: 12%; text-align: right" title="Number of shares under warrants outstanding beginning">1,832,571</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zV0mPa5GYoF6" style="width: 12%; text-align: right" title="Weighted average exercise price warrants outstanding beginning">2.62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxLMoeHGv0sh" style="width: 12%; text-align: right" title="Weighted average remaining contractual life, warrants outstanding">1.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zI9HnHhuALE2" style="width: 12%; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning">2,447,929</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyYJ8fQEKFIb" style="text-align: right" title="Number of shares under warrants granted">4,752,116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9MnAk7PDqsa" style="text-align: right" title="Weighted average exercise price warrants granted">1.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhpZv6rBSF6f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Forfeited">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh9SXiF0REug" style="text-align: right" title="Weighted average exercise price warrants cancelled/forfeited">6.35</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRmnrBa1Ixka" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under warrants outstanding ending">6,534,687</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYMBmVblsfE3" style="text-align: right" title="Weighted average exercise price warrants outstanding ending">1.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHkKR2Z3kSue" style="text-align: right" title="Weighted average remaining contractual life, warrants outstanding">7.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB7D2SbhQIng" style="text-align: right" title="Aggregate intrinsic value, warrants outstanding ending">1,041,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zToiBI49G18d" style="text-align: right" title="Number of shares under warrants vested and exercisable ending">6,534,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHtFFJEiNjzk" style="text-align: right" title="Weighted average exercise price warrants unvested ending">1.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOhy3RAC7XNl" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable ending">7.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLUCFsclWND7" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">1,041,219</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AE_zQsBOyx2o9ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_896_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zD2LR7eyNHaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average fair value per share
of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018
are set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzzohakCd7ib" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdGcFn7jkUsb" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zfDz6mG7bx2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_407_ecustom--WeightedAverageExercisePriceOtherThanOptions_pii_uUSDPShares_zfh5i8004uWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Weighted average exercise price</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5.16</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_z2wJm8856j8j" style="vertical-align: bottom; background-color: White">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.79</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_z5fuJJ2oCdj6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.52</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.36</td><td style="text-align: left">%</td></tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_zt1cBcLV5i3e" style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62.12</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zDTGR0r3w2kl" style="text-align: right" title="Term (in years)">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrntf4TgaIXi" style="text-align: right" title="Term (in years)">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjrWxfC1bd4j" style="text-align: right" title="Term (in years)">5</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_zqNSt6wazfbg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
</table>

<p id="xdx_8AF_zdc3kPZnDLWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Warrant exercises</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE9Ev2PWsAr6" title="Warrants exercised">no</span> warrants were exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019,
warrants to purchase an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zNcbcQhbK0Rd" title="Warrants exercised">1,250,000</span> shares of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise
provisions, which resulted in <span id="xdx_90B_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlzOamFaa91c" title="Number of stock issued in cashless exercise of warrants">471,184</span> shares of Common Stock being issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2018,
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbV1UI0mn4P7" title="Warrants exercised">no</span> warrants were exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Options to Purchase Common Stock of the Company</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2009, we adopted the 2009 Long-Term
Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants
of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock
options and other stock and cash incentives, or the Awards. As of December 31, 2020, there were non-qualified stock options to
purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zCN6cUIpt71c" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">13,285,205</span> shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2012, we adopted the 2012 Stock Incentive
Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive
for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
As of December 31, 2020, there were non-qualified stock options to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zdfGIErC8jUf" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">6,305,974</span> shares of Common Stock outstanding
and an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOVaX8pE4ZDe" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number">890,000</span> restricted stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan, no future
awards may be made under the 2012 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 20, 2019, we adopted the 2019 Plan
to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and
advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted
stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan.
Generally, the options vest annually over <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dt_c20200101__20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zsk1eY9FOX24">four years</span> or as determined by our board of directors, upon each option grant. Options
may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified
expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20200101__20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zhdZtjjsJZm3" title="Award expiration period">ten years</span> from the
date the option is issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_znGkjdUJ2LJ4" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized">2,583,565</span>
shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) new shares, (ii) unallocated shares previously
available for issuance under the 2012 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012
Plan), and (iii) unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding
&#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221;
under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the
underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of
the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction
of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration,
termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of
December 31, 2020, there were non-qualified stock options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member_zc4sTBvUvO6" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">4,190,751</span> shares of Common Stock outstanding under the 2019
Plan and an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zhB3nGTXUDuk" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number">6,171,024</span> restricted stock units and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20201231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zTkUUzrcTerl" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number">2,403,951</span> performance stock units outstanding under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zK73YAIvjLQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. <span id="xdx_8B3_zFjG7qlKfWp9">The ranges of
assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Weighted average exercise price</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdRKOCY194Fb" style="width: 12%; text-align: right" title="Weighted average exercise price">1.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm1q20xQpHlc" style="width: 12%; text-align: right" title="Weighted average exercise price">3.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU0RGQJ0eQP4" style="width: 12%; text-align: right" title="Weighted average exercise price">5.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zidH9LoM7wI8" style="text-align: right" title="Weighted average grant date fair value">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsks95RV0Fla" style="text-align: right" title="Weighted average grant date fair value">1.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3zmIglYQXQd" style="text-align: right" title="Weighted average grant date fair value">3.24</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd5Gy8sGeof8" title="Risk-free interest rate - minimum">0.34</span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJwEaTnpPMOa" title="Risk-free interest rate - maximum">1.68</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEeyhRC6N5vb" title="Risk-free interest rate - minimum">1.64</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNDhpRN2P563" title="Risk-free interest rate - maximum">2.54</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9AZUWqOxlb4" title="Risk-free interest rate - minimum">2.38</span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyc3vOPXLIJc" title="Risk-free interest rate - maximum">2.89</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z54cPeUNn1fc" title="Volatility - minimum">63.53</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4QToulRpY67" title="Volatility - maximum">67.92</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z136BI8h4gZk" title="Volatility - minimum">61.25</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX63SVikg5oj" title="Volatility - maximum">64.49</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEXhJmbtOxaj" title="Volatility - minimum">59.45</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKWp9HvkneX1" title="Volatility - maximum">64.04</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zfErmA5yB31f" title="Term">6</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zjHnM7guZ3Td" title="Term">6.8</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zEwpZpbrrsA" title="Term">5.5</span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zr8jstVV9iL7" title="Term">6.5</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjogRE4kyEX5" title="Term">5.1</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zS49ZdephDu4" title="Term">6.25</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUS3Mu5ASo8f" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zma4MpsEpOE1" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVWNjv8rptFg" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td></tr>
</table>

<p id="xdx_8A5_zzknt228Iyx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTUGf9YtZhZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of activity under the 2009, 2012
and 2019 Plans and related information during the year ended December 31, 2020 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Shares Under</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Options</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Life in Years</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Balance at December 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zOWxDl2OmMV" style="width: 12%; text-align: right" title="Number of shares under options, beginning">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFZbBzcvewna" style="width: 12%; text-align: right" title="Weighted average exercise price, beginning">4.65</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zHq1IWLmGAm2" style="width: 12%; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231_zUcEtCZBuQpj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning">3,668,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zGMx6F3D6ZKh" style="text-align: right" title="Number of shares under options, granted">736,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zvSF7LkOHy4g" style="text-align: right" title="Weighted average exercise price, granted">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200101__20201231_zPI1pUWgipxb" style="text-align: right" title="Number of shares under options, exercised">(1,182,195</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zDu6VR4Q0aC6" style="text-align: right" title="Weighted average exercise price, exercised">0.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20201231_zuosgxVLzVWl" style="text-align: right" title="Aggregate intrinsic value, exercised">1,738,740</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20201231_zdi9BU3pwUO5" style="text-align: right" title="Number of shares under options, expired">(386,609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zD9L6LV7Wfme" style="text-align: right" title="Weighted average exercise price, expired">3.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zejaUJeR5ZR" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited">(416,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_z8yQlXeRfJ45" style="text-align: right" title="Weighted average exercise price, cancelled forfeited">3.80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20201231_ziOsw50js328" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending">23,781,930</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zmkwoS8XeKLb" style="text-align: right" title="Weighted average exercise price, ending">4.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20200101__20201231_zOHq9IcPTqY5" style="text-align: right" title="Weighted average remaining contractual life">5.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20200101__20201231_zYyeO6L5dF0h" style="text-align: right" title="Aggregate intrinsic value, ending">152,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20200101__20201231_zKXVf5SnUPX8" style="text-align: right" title="Number of shares under options, vested and exercisable ending">19,862,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zZveoHdWBtgj" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending">5.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zgoGIzgv0bdg" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable">4.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20200101__20201231_zrblXPQD82Pg" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">117,443</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20200101__20201231_zOpLSxrBy8Si" style="text-align: right" title="Number of shares under options, unvested ending">3,919,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zAcpuOCuOwCa" style="text-align: right" title="Weighted average exercise price, unvested ending">3.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zrd64DCGRALe" style="text-align: right" title="Weighted average remaining contractual life, unvested">8.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20200101__20201231_zq2yZIhCwPhi" style="text-align: right" title="Aggregate intrinsic value, unvested ending">34,810</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_zCYrATHIvmp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, our outstanding options
had exercise prices ranging from $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20201231__srt--RangeAxis__srt--MinimumMember_zoxuNelaib64" title="Range - exercise price of options">0.38</span> to $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20201231__srt--RangeAxis__srt--MaximumMember_zePcthb9sHvi" title="Range - exercise price of options">8.92</span> per share. Share-based compensation expense related to options recognized in our
results of operations for the years ended December 31, 2020, 2019, and 2018 was approximately $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_z5eLMzIWM6Ke" title="Share-based Payment Arrangement, Expense">5,235,585</span>, $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_zDurT9OhxWUh" title="Share-based Payment Arrangement, Expense">8,798,707</span>, and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20181231_z13vmzA2ilGd" title="Share-based Payment Arrangement, Expense">8,091,294</span>,
respectively, and it is based on awards vested. At December 31, 2020, total unrecognized estimated compensation expense related
to unvested options was approximately $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20201231_zMJtixXviPte" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount">5,238,000</span>, which may be adjusted for future changes in forfeitures. This cost is expected
to be recognized over a weighted-average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc8lTcI89ZJf" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition">1.9</span> years. No tax benefit was realized due to a continued pattern of operating
losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Restricted Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted stock units granted under our
2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common
Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares
vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Performance stock units will vest if certain
performance targets are achieved. If minimum performance thresholds are achieved, each award will convert into Common Stock at
a defined ratio depending on the degree of achievement of the performance target designated by each individual award. If minimum
performance thresholds are not achieved, then no shares will be issued. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at its grant date and through the date the restricted stock vests. The expected levels of achievement are reassessed over the requisite
service periods and, to the extent that the expected levels of achievement change, stock-based compensation is adjusted and recorded
on the consolidated statements of income and the remaining unrecognized stock-based compensation is recognized over the remaining
requisite service period.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2020,
2019 and 2018 we recorded $<span id="xdx_908_eus-gaap--RestrictedStockExpense_c20200101__20201231_zVYrOOwEv5Zf" title="Restricted Stock or Unit Expense">5,399,472</span>, $<span id="xdx_900_eus-gaap--RestrictedStockExpense_c20190101__20191231_zXpFpaBNf6Oa" title="Restricted Stock or Unit Expense">1,628,407</span>&#160;and $<span id="xdx_908_eus-gaap--RestrictedStockExpense_c20180101__20181231_zGK8BUbXaM41" title="Restricted Stock or Unit Expense">73,132</span>, respectively, in share-based compensation expense related to
restricted stock units and performance stock units. As of December 31, 2020, we recognized performance-based compensation expense
using our assessment of the most likely probability of attaining quarterly EBITDA break-even which would result in vesting 1.5
times the base number of performance stock units. At December 31, 2020, total unrecognized estimated compensation expense related
to unvested&#160;restricted stock units and performance stock units&#160;was approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20201231_zPACtXFqzIGl" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount">9,989,000</span>, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of&#160;<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNPihaeACL2j" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition">1.6</span>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zIPEnR0HqOs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule of restricted stock units and
performance stock units</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Restricted Stock Units</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Performance Stock Units</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number of</p>
                                                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shares</p>

</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Weighted</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Average</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Grant Date</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Fair Value</span></p></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number of</p>
                                                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shares</p>

</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Weighted</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Average</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Grant Date</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Fair Value</span></p></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Balance at December 31, 2019</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpell54xGhm4" style="width: 12%; text-align: right" title="Beginning balance, number of shares">1,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEI5qekRZA2" style="width: 12%; text-align: right" title="Beginning balance, weighted average grant date fair value">3.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znrSniegE5g4" style="text-align: right" title="Granted, number of shares">6,152,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLTIusfAgI23" style="text-align: right" title="Granted, weighted average grant date fair value">1.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDUff6ykhbVl" style="text-align: right">2,585,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zl46URc21r1j" style="text-align: right">1.08</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Vested/Released</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrr6E2e496V4" style="text-align: right" title="Vested/Released, number of shares">(301,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFn9vJyGoWp7" style="text-align: right" title="Vested/Released, weighted average grant date fair value">1.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zE4tbr4OSqu9" style="text-align: right">(151,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeCG9cEPaTsa" style="text-align: right">1.14</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQSChyti9sO5" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited, number of shares">(30,294</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoOzrrMk41L8" style="text-align: right" title="Forfeited, weighted average grant date fair value">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJm02Iv3Hx3g" style="border-bottom: Black 1pt solid; text-align: right">(30,294</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znKJMmPU6OO4" style="text-align: right">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Balance at December 31, 2020</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJAZPd398kKk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, number of shares">7,061,024</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxuh3DzApZT2" style="text-align: right" title="Ending balance, weighted average grant date fair value">1.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____zKNcfa9MpK0g" style="border-bottom: Black 2.5pt double; text-align: right">2,403,951</td><td id="xdx_F22_zJX5trdtnZEi" style="padding-bottom: 2.5pt; text-align: left">*</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjEJORWN5x1i" style="text-align: right">1.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F06_zr1lKch6hv28" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"/><td id="xdx_F12_zfnzvpgq2c4h" style="text-align: justify">The number of performance stock units (PSUs) represents the base number of PSUs that
may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the
Company&#8217;s achievement of break-even quarterly EBITDA.</td>
</tr></table>

<p id="xdx_8A7_z0vsJ8mm2Gn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Employee Stock Purchase Plan </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 18, 2020, our stockholders approved
the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan, or the ESPP, which reserved <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_z3J4010UkTAb" title="Common Stock, Capital Shares Reserved for Future Issuance">5,400,000</span> shares of Common Stock for purchase.
The ESPP permits eligible employee participants to purchase Common Stock at a price per share which is equal to <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dp_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zCffGAHUkuyd" title="Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent">85</span>% of the lesser
of (a) the fair market value of the shares on the offering date of the offering period or (b) the fair market value of the shares
on the purchase date. During the year ended December 31, 2020, no shares were issued under the ESPP. We recorded $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20200617__20200618__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_zd2BdH7smUMi" title="Non cash compensation expense">17,489</span> of non-cash
compensation expense related to the ESPP during the year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447814436952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DefinedContributionPlanTextBlock_zFSunyPavn81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 10 &#8211; <span id="xdx_822_zV4M5n5r0Z5k">EMPLOYEE BENEFIT
PLAN</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a voluntary defined
contribution 401(k) plan covering all eligible employees as defined in the plan documents. The plan provides for discretionary
matching contribution, which is equal to up to <span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pip2_dcp_c20200101__20201231_z4ZnpvC3Wxph" title="Matching contribution percentage">four</span> percent of each eligible contributing participant&#8217;s elective deferral
not to exceed $<span id="xdx_90E_ecustom--DefinedContributionPlanMaximumEmployerMatchingContribution_c20200101__20201231_z35XromJ4aFd" title="Maximum matching contribution per year">2,000</span> per year. Employees who elect to participate in the plan are generally fully vested in any existing matching
contribution after <span id="xdx_90E_ecustom--DefinedContributionPlanVestingServicePeriod_dt_c20200101__20201231_zE31kIc8aJjg" title="Defined contribution plan vesting service period">five years</span> of service with the Company. Contributions by the Company under the plan amounted to approximately
$<span id="xdx_900_eus-gaap--DefinedContributionPlanCostRecognized_c20200101__20201231_zq9ueVwtyqA5" title="Contributions under plan">487,000</span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanCostRecognized_c20190101__20191231_zlQ9Y8g2va2b" title="Contributions under plan">403,000</span> for the years ended December 31, 2020 and 2019, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447818272136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zgkAzeD7GxXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 11 &#8211; <span id="xdx_820_zfvddJ7t15mc">INCOME TAXES </span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_898_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYaE2QoEmhYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, (loss)
income before taxes includes the following components:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-bottom: 1pt">United States</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zguCFyRPD1ik" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(183,524,137</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zC3C21UWS0Xc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(176,144,999</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_z7ehvKbVq99j" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(132,617,160</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231_zjsoXl7n8sM7" style="border-bottom: Black 2.5pt double; text-align: right">(183,524,137</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zoHfrzFGf7Il" style="border-bottom: Black 2.5pt double; text-align: right">(177,144,999</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zC7zcbxEydWh" style="border-bottom: Black 2.5pt double; text-align: right">(132,617,160</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<p id="xdx_8AB_zOSqzGVVKmM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For
the years ended December 31, 2020, 2019, and 2018, there was no provision for income taxes, current or deferred. </span>At December
31, 2020, we had a federal net operating loss carry forward of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_zq31T0Xo72di" title="Net operating loss carryforward">761,701,546</span> available to offset future taxable income
through 2038. Approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zIgTBYApSvne" title="Net operating loss carryforward">338,775,332</span> of the federal net operating loss carry forward can be carried forward for <span id="xdx_90B_ecustom--NolCarryForwardPeriod_dtY_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zPEimXBmSl9l" title="NOL carryforward period">20</span> years and
will begin to expire in <span id="xdx_909_ecustom--OperatingLossCarryforwardsExpirationYear_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zaNAPu9Qd669" title="NOL carryforward expiration year">2031</span>.&#160;The remaining $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_uUSD_c20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriodIndefiniteMember_zIxqWuvl0Mle" title="Net operating loss carry forward">422,926,214</span> can be carried forward indefinitely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjRPx5ggl1H3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation between taxes computed at the federal statutory
rate and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20201231_zNMMJonDbVr4" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20190101__20191231_zdl9tOiJ8FOd" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20180101__20181231_zX2FXwBwhHO3" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_maIT_zak6HihgVW0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left">Federal statutory tax rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPure_maIT_z8NNHPmmKKP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.2</td><td style="text-align: left">%</td></tr>
<tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_maIT_zBQUuhjCjVE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31.2</td><td style="text-align: left">)%</td></tr>
<tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pii_dp_uPure_maIT_zz1X9yLFzn27" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Excess stock benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">%</td></tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp0_uPure_maIT_zIdMSs7oCQN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal income tax rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td></tr>
<tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPure_maIT_zABe7zYzkFvl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Permanent and other differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.8</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.7</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.3</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_uPure_mtIT_znjLm1h5T7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_zlBVXbMJQjDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes result from temporary
differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYnj1A9WQn2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of the net deferred income
tax asset as of December 31, 2020, 2019, and 2018 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_ziSVdkEpnGI8" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20191231_zSgCwboagMPk" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20181231_zUg3mP0nvgG5" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhQAL6kZqtHd" style="vertical-align: bottom">
    <td style="text-align: left">Deferred Income Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzcsC_zzDrXcGjVRfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 0.125in">Net operating losses</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">195,008,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">157,555,975</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">126,419,113</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGzcsC_zEiqUd5lJmid" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,251,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,913,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,464</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetInterestCarryforward_i01I_maDTAGzcsC_z6p6IREdlPh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Interest expense limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,991,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,389,129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,173,614</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcsC_zxB7OY1bHfb6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Other, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,818,935</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,662,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,658,573</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGzzfO_maDTAGzcsC_zgclBwHpui5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">R&amp;D credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzcsC_maDTANzEH4_zfcLcbgF6Ze3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Total deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,257,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,707,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,078,111</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzEH4_zZkjhxFogA86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(230,257,029</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(180,707,056</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(141,078,111</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzEH4_zj2p6EyLBNkk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred income tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AD_zi1rz11aMPyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that it is more likely than not that we will not
generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and
as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The change in valuation allowance was $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zLmxywPf2218" title="Change in valuation allowance">49,549,973</span>,
<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20190101__20191231_zt72pgKfIapd">$39,628,945</span>, and <span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20180101__20181231_zttrJOfIoFXc">$41,295,443</span> for the years ended December 31, 2020, 2019, and 2018, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Unrecognized Tax Benefits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020 and 2019,
we have no unrecognized tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447814219256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5CamXjNc75e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 12 &#8211; <span id="xdx_820_zo07iBxRMRQg">RELATED PARTIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2015, J. Martin Carroll, a director
of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with
Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by
independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During
the years ended December 31, 2020, 2019 and 2018, we were billed by Catalent approximately $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zVm6hPfLoVV5" title="Amount billed">3,036,000</span>, $<span id="xdx_901_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zg6gFtOrBz3d" title="Amount billed">6,101,000</span> and $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_z2ZNfZ7eAiNe" title="Amount billed">4,111,000</span>,
respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation
testing. As of December 31, 2020 and 2019, there were amounts due to Catalent of approximately $<span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zbqpkgTDXzKl" title="Amounts due to related party">0</span> and $<span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CatalentMember_zdKHYABU1L82" title="Amounts due to related party">35,000</span>, respectively. In
addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 14, Commitments and Contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2020, Karen L. Ling, Executive
Vice President and Chief Human Resources Officer of American International Group, Inc., or AIG, was appointed to our board of directors.
From time to time, we have entered into agreements with AIG in the normal course of business. Agreements with AIG have been reviewed
by independent directors of our Company, or a committee consisting of independent directors of our Company, since April 2020. During
the year ended December 31, 2020, we were billed by AIG approximately $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AmericanInternationalGroupMember_zzyCrYe9ReK5">209,000</span> for various insurance coverage for our Company.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447818103800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--ConcentrationRiskDisclosureTextBlock_zuDcSZ4RlZ68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 13 - <span id="xdx_826_z35jNAzObWC2">BUSINESS CONCENTRATIONS</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We purchase our prescription products from
several suppliers with approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zeEinaQ0hK1j">36</span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_za4bwRzBEWz8">30</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zLH0VN68v2Ue">25</span>% of our purchases supplied by three vendors each, respectively, during the
year ended December 31, 2020, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zBVb9Z4VrFTc">24</span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zEsyU2IWwZ">27</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zlmj09UzW6ih">35</span>% of our purchases supplied by three vendors each, respectively, during the year ended
December 31, 2019, and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_z9SVCfUYyj59">43</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zgJB6p6poND6">33</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pp4p2_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zIa2Opf9NUh7">24</span>% of our purchases supplied by <span id="xdx_90C_ecustom--NumberOfVendors_dc_c20180101__20181231_zoqdVHpUOswi" title="Number of vendors - suppliers">three</span> vendors each, respectively, during the year ended December
31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our prescription products to wholesale
distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies,
hospitals, and other institutional customers. During the year ended December 31, 2020, <span id="xdx_90F_ecustom--NumberOfCustomers_dc_uN_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNYx6Nf73YJ2">three</span> customers each accounted for more
than <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc7eOy3RzJrf">10</span>% of our total product revenue. During each of the years ended December 31, 2019 and 2018, <span id="xdx_90A_ecustom--NumberOfCustomers_pii_dc_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlBpaKn0s3Fa" title="Number of customers - revenue"><span id="xdx_908_ecustom--NumberOfCustomers_pii_dc_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zG9xZsjDqgi2">four</span></span> customers each accounted
for more than <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziq6KhIb9My6"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkPdSXcgA7Qc">10</span></span>% of our total product revenue. Product revenue from the <span id="xdx_90A_ecustom--NumberOfCustomers_dc_uN_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zfGBxDZHe9Il">three</span> customers combined accounted for approximately
<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zSzTHiudfEo1">63</span>% of our product revenue for the year ended December 31, 2020. Product revenue from the <span id="xdx_905_ecustom--NumberOfCustomers_dc_uN_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zs3KhhmU7X93"><span id="xdx_90F_ecustom--NumberOfCustomers_dc_uN_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zf0k5M0OFwo">four</span></span> customers combined accounted for
approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pii_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z4QgXcOXV1n7">73</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pp4p2_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJmCIM6Ax7c1">76</span>% of our product revenue for the years ended December 31, 2019 and 2018, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
Cardinal Health accounted for approximately $<span id="xdx_908_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvduzlursID4">17,489,000</span> of our product revenue, Pillpack, Inc. accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYpMsmVD0Rk6">13,228,000</span>
of our product revenue, and McKesson Corporation accounted for approximately $<span id="xdx_908_eus-gaap--Revenues_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJHNKFHoTVEb">9,862,000</span> of our product revenue. During the year
ended December 31, 2019, Pillpack, Inc. accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zgruKxhYV437">12,676,000</span> of our product revenue, Cardinal Health accounted
for approximately $<span id="xdx_904_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zLDsfaP4ydAj">4,551,000</span> of our product revenue, AmerisourceBergen accounted for approximately $<span id="xdx_900_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zN8XF7vDrkPf">3,927,000</span> of our product revenue
and McKesson Corporation accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYrhcixy4rQf">3,911,000</span> of our product revenue. During the year ended December 31, 2018,
Pillpack, Inc. accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkpyx6JbhKed">5,075,000</span> of our product revenue, AmerisourceBergen accounted for approximately $<span id="xdx_903_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYyVDJDrVbcj">3,246,000</span>
of our product revenue and Cardinal Health accounted for approximately $<span id="xdx_902_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6j8c0vpq6o6">2,308,000</span> of our product revenue, and McKesson Corporation
accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1ZBlyidCPC">1,610,000</span> of our product revenue.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813287656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXO01roVpH79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 14 &#8211; <span id="xdx_82C_zPpozXAS9B3c">COMMITMENTS AND CONTINGENCIES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Operating Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 842, Leases, effective January
1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office
space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease liability for all leases that
have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The
lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured
at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any
lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the
present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying
lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments
based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in
effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our
portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of
the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in
the initial lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We lease administrative office space in
Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a&#160;<span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20130701_z0WXKmWBbBPc" title="Operating lease term">63</span>-month
term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space
in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with
the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May
1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement
with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease.
This addendum became effective beginning November 1, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2018, we entered into a lease
for new corporate offices in Boca Raton, Florida. The lease includes&#160;<span id="xdx_906_ecustom--NetRentableAreaLease_iI_uSqft_c20181002_zFnEgLSZDql9">56,212</span>&#160;rentable square feet, or the full premises,
of which the lease on&#160;<span id="xdx_90E_ecustom--RentedAreaLease_iI_pip0_uSqft_c20181002_zfGSxuLSVrj5" title="Rented area lease">7,561</span>&#160;square feet commenced in 2018 and the lease on the remaining&#160;<span id="xdx_906_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSqft_c20190801_zjpwDKA9I8f3"><span id="xdx_90B_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSqft_c20190801_zog8N3qcuDWa">48,651</span></span>&#160;square feet
commenced in August 2019, or the full premises commencement date. The lease will expire&#160;<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_zViRcxSFO2g3" title="Operating lease term">11 years</span>&#160;after the full premises
commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of
the lease for&#160;<span id="xdx_906_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20201231_zaEY7Lw5PSwk">two</span>&#160;additional consecutive periods of&#160;<span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dt_c20201231_zXhfcFQyY4S2" title="Lease renewal term">five years</span>. The extension option is not included in the determination
of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent
periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses.
In June 2019, we entered into an agreement with the same lessors to lease additional&#160;<span id="xdx_904_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_uSqft_c20190601_z1xbIP2gkEXj">6,536</span>&#160;square feet of administrative
office space in the same location,&#160;<span style="color: #212529">pursuant to an addendum to such lease, which commenced in
May 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z0qHaQXgGYsf" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Supplemental
lease information as of:</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_zvsQK6mhd6H6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2020</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20191231_zwCekJDFreEk" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2019</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zgSJwi8HN9p8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Right-of-use asset</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,565,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,109,154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zRmUVpY5KQNh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term operating lease liability (included in <span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20201231_z7Yt0tyMkr3g" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"><span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20191231_zPu4jiwRNLTl" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1634"><span style="-sec-ix-hidden: xdx2ixbrl1635">Other current liabilities</span></span></span></span>)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,253,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zmGRt1AS3nWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,675,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,145,049</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zQrO6eP9Cye5">8.9</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zkuU70CWQ0Ne">9</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zUT9oLVC6zUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.30</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">%</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Supplemental cash flow information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>for the year ended:</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20201231_z4Kvyri66KD7" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190101__20191231_zjEikObZOm47" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2019</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeasePayments_zoHM3doKuPbk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,617,645</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,164,234</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_z5mz9Do3uNtb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">998,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,171,471</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSRjabTl3LOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the undiscounted
cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Years Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_znBA6Qv3YUQh">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zNaAzI5TOiV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,334,582</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_z9806I5Zru21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,413,289</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zDS4sf6wjyhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,443,143</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zhk5xpIRSuR6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,476,534</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1WK_zuFZz9rMrOi3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,513,458</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zQhlQPsjm8p2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,434,412</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zVDcOeTVXDne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Total undiscounted lease payments</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,615,418</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWCSU7W9F8H9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Less: imputed interest</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,685,947</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z9oRF49fzBAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Present value of lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,929,471</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_z8ieqkvdIXni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020,
operating lease expense related to our real estate leases was $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20201231_z5xfuW4RwL2d">2,325,844</span>, and variable lease expense was $<span id="xdx_904_eus-gaap--VariableLeasePayment_uUSD_c20200101__20201231_zcGqvKe2xly6" title="Variable lease payment">423,578</span>. During the year
ended December 31, 2019, operating lease expense related to our real estate leases was $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20190101__20191231_zxvkbCxhX6M7">1,558,794</span>, and variable lease expense was
insignificant. The rental expense during the year ended December 31, 2018 was $<span id="xdx_900_eus-gaap--OperatingLeasesRentExpenseNet_uUSD_c20180101__20181231_zwfEDtYwxmm2" title="Rental expense">1,068,275</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Intellectual Property Licenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Population Council License Agreement
provides for future milestone payments to be paid by us for access to certain technologies. In addition, we pay royalties as a
percent of revenue as described in Note 2, Summary of Significant Accounting Policies to these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Purchase Commitments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have manufacturing and supply agreements
whereby we are required to purchase from Catalent a minimum number of softgels during the first contract year and a higher number
of softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to
pay Catalent <span id="xdx_908_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_uPure_c20201231_zHlmLgK99v5e">50</span>% of the difference between the total amount we would have paid to Catalent if the minimum requirement had been
fulfilled and the sum of all purchases of our products from Catalent during the contract year. The minimum purchase commitments
for Catalent for the next five years are as follows: 2021 - $<span id="xdx_90B_eus-gaap--PurchaseObligationDueInNextTwelveMonths_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zyEGNj5aMty6" title="Minimum purchase commitment, 2021">3,458,000</span>, 2022 - $<span id="xdx_90F_eus-gaap--PurchaseObligationDueInSecondYear_iI_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zEEMNRZaUOnj" title="Minimum purchase commitment, 2022">2,150,000</span>, 2023 - $<span id="xdx_904_eus-gaap--PurchaseObligationDueInThirdYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zCgZbR9fhbO8" title="Minimum purchase commitment, 2023">2,991,000</span>, 2024 - $<span id="xdx_90E_eus-gaap--PurchaseObligationDueInFourthYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_z1TeeOZUex04" title="Minimum purchase commitment, 2024">3,347,000</span>,
and 2025 - $<span id="xdx_902_eus-gaap--PurchaseObligationDueInFifthYear_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zvF6Tplc5KH4" title="Minimum purchase commitment, 2025">3,786,000</span>. In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum
number of units of ANNOVERA during a contract year. The minimum purchase commitment for ANNOVERA for 2021 is approximately $<span id="xdx_90E_eus-gaap--PurchaseObligationDueInNextTwelveMonths_iI_uUSD_c20201231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--AnnoveraMember_zFZp6NjwV9J1">1,526,000</span>.
As of December 31, 2020, we have met our minimum purchase commitments with our manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Legal Proceedings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we are involved in litigation
and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would
have a material effect on our consolidated financial condition, results of operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Off-Balance Sheet Arrangements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, 2019, and 2018,
we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Employment Agreements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into employment agreements
with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including
a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the
term of the employment agreement.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447822063832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
<td class="text"><p id="xdx_806_eus-gaap--QuarterlyFinancialInformationTextBlock_zQazNNsFg25" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 15 &#8211; <span id="xdx_829_zc0nkY9To9kd">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_89B_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zfXZTA46Uurc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BC_zWmViDIqFdz5">Summarized quarterly financial data for fiscal years 2020 and
2019 is as follows</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20200101__20200331_z6rrFh6OByEd" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20200401__20200630_zZCpBW64XMCh" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200701__20200930_z1pUNMwR3iT9" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20201001__20201231_zqnyUQTcCaf6" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands, except per share)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">First <br/>Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Second<br/>
Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Third</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Quarter<br/>
<sup id="xdx_F5E_zJhND2Sl5J81">(1)(2)(3)(4)</sup></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Fourth<br/>
Quarter <sup id="xdx_F52_zdpoaQjMzzkj">(5)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zTaRWi9Bojzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Revenues</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zTmPSvKBesW2" style="width: 12%; text-align: right">19,343</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20201001__20201231_fKDUp_zhou96xStL1h" style="width: 12%; text-align: right">22,577</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--GrossProfit_pn3n3_uUSD_z8GEljnynhu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--GrossProfit_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zs1jjBIXEGlf" style="text-align: right">16,064</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20201001__20201231_fKDUp_zyYD68qP7L1d" style="text-align: right">16,996</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_uUSD_zRDlTSpwFoXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(56,849</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(51,976</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zLc9X0tXDuF8" style="text-align: right">(32,611</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--NetIncomeLoss_pn3n3_c20201001__20201231_fKDUp_zhBCouQ7SyT6" style="text-align: right">(42,088</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zvJ1IxwcGY59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20200701__20200930_fKDEpKDIpKDMpKDQp_z2VZ6BcRKMdj" style="text-align: right">(0.12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20201001__20201231_fKDUp_zXBzDesZKu5k" style="text-align: right">(0.15</td><td style="text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20190101__20190331_zLItBRipd1b6" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190401__20190630_z7lyNgKXa7a3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20190701__20190930_zzkGCPzdaGPd" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20191001__20191231_zdHCdsnhGRia" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands, except per share)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">First <br/>Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Second<br/>
Quarter <sup id="xdx_F56_zuZyx7yGIx28">(6)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Third</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Quarter <sup id="xdx_F5A_zgkjBnBWNqJg">(7)</sup></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fourth<br/>
Quarter</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zQUf9wuYvpl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Revenues</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630_fKDYp_zhoa6OAP7HIa" style="width: 12%; text-align: right">6,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930_fKDcp_zl2c2NZrJHA8" style="width: 12%; text-align: right">23,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">15,902</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--GrossProfit_pn3n3_uUSD_zPfRErpHlX4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20190401__20190630_fKDYp_zUm7MmC9lhve" style="text-align: right">4,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20190701__20190930_fKDcp_zT6E6UN8L0Rh" style="text-align: right">22,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,023</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_pn3n3_uUSD_z6k5bp7JoxL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(39,506</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20190401__20190630_fKDYp_zGWN8WPLUUE8" style="text-align: right">(55,237</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_pn3n3_c20190701__20190930_fKDcp_zgG2QV0213Pc" style="text-align: right">(31,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(49,435</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zjxeUGUvBbe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.16</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190401__20190630_fKDYp_zX8xMvGJPwJ8" style="text-align: right">(0.23</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190701__20190930_fKDcp_z8zBgJdMGhQ3" style="text-align: right">(0.13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(1)</td><td>During the third quarter of 2020, we recorded $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_znlN4bjOneM9">2 million</span> in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(2)</td><td>During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3p0_dm_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zzstULDejUfg" title="Fair value of warrants">7.4 million</span> as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">During the third quarter of 2020, we wrote off approximately $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20200701__20200930_zbp5nfI78fAa" title="Write off of patent and trademark cost">0.6 million</span> in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(4)</td><td>During the third quarter of 2020, we recorded approximately $<span id="xdx_902_eus-gaap--InventoryWriteDown_pn3p0_dm_c20200701__20200930_zzpUeya085Mh" title="Inventory charge">5.7 million</span> in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(5)</td><td>During the fourth quarter of 2020, we wrote off approximately $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20201001__20201231_zzyk86lmPAse">0.5 million</span> in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(6)</td><td>During the second quarter of 2019, we recorded approximately $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_z3r1bzKRWu15" title="Loss on extinguishment of debt">10.1 million</span> in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(7)</td><td>During the third quarter of 2019, we recorded approximately $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zT1eC19R11qi">15.
                                                                 5 million</span> in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of
                                                                 Significant Accounting Policies.</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F0A_zfLFhuE5BfRf" style="width: 0.25in">(1)</td><td id="xdx_F17_zPuPm7yI0if8">During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F0D_z9vclAeXaBF" style="width: 0.25in">(2)</td><td id="xdx_F1C_zTsLEb9IsUs1">During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F03_zF1DY0Wx71Nf" style="width: 0.25in">(3)</td><td id="xdx_F1B_zkzvmv0xaEa8" style="text-align: justify">During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F02_zwANq9PitIP1" style="width: 0.25in">(4)</td><td id="xdx_F10_zMH9wMYnGo54">During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F04_zNdRKYs8T8h6" style="width: 0.25in">(5)</td><td id="xdx_F17_zi3pMoIBCvwb">During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F00_zxjQ2fGLDGwc" style="width: 0.25in">(6)</td><td id="xdx_F1E_ziFSieJPBL67">During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F04_zC6OWyYFKqnf" style="width: 0.25in">(7)</td><td id="xdx_F18_z8We1Rc08aQk">During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>
<p id="xdx_8AD_zcP7mDJijidd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815437304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_z8Co9uv6xHPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">NOTE 16 &#8211; <span id="xdx_829_z8OTVS4HZLaf">SUBSEQUENT EVENTS</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period from January 1,
2021 through February 8, 2021 in accordance with the terms of the sales agreement described in Note 9- Stockholders&#8217;
Equity, we sold <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20210101__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrwrgLMhjjF" title="Shares issued in offerings, net of cost (in shares)">28,600,689 </span>shares
of Common Stock for net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_uUSD_c20210101__20210208__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfDdQ7PzRq98" title="Proceeds from sale of common stock, net of costs">47.3
million</span> through Cantor Fitzgerald who acted as our sales agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 13, 2021, we entered into Amendment No. 7 to the
Financing Agreement, or Amendment No. 7, pursuant to which, among other amendments, the minimum consolidated net revenue
requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA for the fiscal quarters ending March 31, 2021
and June 30, 2021 were reduced to $<span id="xdx_90E_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment7Period1Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zDLs5c4qRHb2">18</span>.0
million and $<span id="xdx_904_ecustom--MinimumRevenueRequirementUnderCreditAgreement_iI_pin6_c20210113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment7Period2Member__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember_zSriJ7OOLta5">22</span>.0
million, respectively. On January 13, 2021, in connection with entering into Amendment No. 7 to the Financing Agreement, the
Lender Warrants were further amended to provide for an additional adjustment to the exercise price if we conduct certain
dilutive issuances prior to March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2021, we entered into Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA. See Note 8 &#8211; Debt for information regarding Amendment No. 8.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2021, we entered into
an underwriting agreement with Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zY3ih7pRKQT3">59,459,460</span>
shares of Common Stock. Pursuant to the underwriting agreement, we granted to the underwriter an option, exercisable for a
period of <span id="xdx_909_ecustom--PeriodExercisableUnderwritersOption_dt_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7BB1HF48HNh" title="Period exercisable underwriters option">30
days</span>, to purchase up to <span id="xdx_90A_ecustom--UnderwritersOptionGrantedInPeriodShares_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgnNBDHFfuv3" title="Underwriters option granted in period shares">8,918,919</span>
additional shares of Common Stock. The net proceeds to us from the offering, excluding any proceeds that may be received from
the exercise of the underwriter&#8217;s option to purchase additional shares, are expected to be approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_dm_c20210211__20210216__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementCantorFitzgeraldMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztrhJARpXUs6">97.1
million</span>, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The
offering closed on February 16, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813732328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zbWuVh9adzo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zCCnWITYyUYi">Principles of Consolidation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of our company and our wholly owned subsidiaries, vitaMed, BocaGreen and VitaCare. All intercompany
balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_848_ecustom--RisksAndUncertaintiesPolicyTextBlock_zxel2fnrUmS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zdZGAt846502">Risks and Uncertainties</span> </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to be subject to risks and
uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues
to be highly uncertain and difficult to predict. We continue to provide an uninterrupted supply of our portfolio of products for
patients. We have sufficient inventory of finished product to meet anticipated demand in the near future. Additionally, we currently
do not foresee any interruption in our ability to continue to manufacture additional product to be used beyond this period and
have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products. During the year ended
December 31, 2020, we recorded an inventory charge of $<span id="xdx_90F_eus-gaap--InventoryWriteDown_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_z3beEO1Oq3Rb">7,204,818</span>&#160;which was primarily related to BIJUVA and resulted from the
impact of the COVID-19 pandemic on our business, which decreased demand for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the early phase of the COVID-19 pandemic,
we have been using substantial virtual options to ensure business continuity. Our VitaCare Prescription Services patient model
assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice,
including via home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple
third-party online pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time
access to both diagnosis and treatment. We continue to support prescribers&#8217; needs with samples and product materials through
our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for live virtual e-detailing of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of our response to the COVID-19
pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented cost saving measures, which included
negotiating lower fees or suspending services from third party vendors; implementing a company-wide hiring restriction; delaying
or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full impact of the COVID-19 pandemic
continues to evolve. However, we remain committed to the execution of our corporate goals, despite the ongoing COVID-19 pandemic,
as demonstrated in part by the increase in product revenue throughout 2020. As of the date of issuance of these consolidated financial
statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity,
or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our operations by monitoring
the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic
has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression
that has occurred or may occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we currently believe that our COVID-19
contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of
the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity
of the pandemic, the duration of &#8220;social distancing&#8221; orders, the ability of our sales force to access healthcare providers
to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients,
thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are uncertain.
Our future results of operations and liquidity could be materially adversely affected by delays in payments of outstanding receivable
amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs
that we may undertake to address financial and operations challenges that we may face.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_849_ecustom--LiquidityPolicyTextBlock_zBQndKwXmNy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zvBKo3cmFt66"><span style="text-decoration: underline">Liquidity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the filing date of this Annual
Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement (as defined in Note 8 -
Debt). On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement, or Amendment No.
6, with the Administrative Agent (as defined in Note 8 - Debt) and the lenders party thereto, pursuant to which we
temporarily lowered the minimum required cash balance from $<span id="xdx_907_ecustom--MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z6zi29hmeiHl">60</span>
million to $<span id="xdx_90A_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201108__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementAmendment6Member_z8O7p4TL3t4e">45</span> million through December 31, 2020. After December 31, 2020, the minimum cash balance reverted to $<span id="xdx_908_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pn6n6_c20201231_zHQCHcqSC1ej">60</span>
million. Based on our current projections, and recent equity financings, we anticipate that we will remain in compliance with
the minimum cash balance covenant for the next twelve months from the issuance of these financial statements. In addition, we
have reviewed numerous potential scenarios in connection with the impact of COVID-19 pandemic on our business and we believe
that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary course of business for the next
twelve months from the issuance of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, if we are unsuccessful with the
commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if commercialization is delayed, or if the continued impact of the COVID-19
pandemic on our business is worse than we anticipate, our existing cash reserves may be insufficient to maintain compliance with
the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY,
BIJUVA, and ANNOVERA. The Financing Agreement also requires us to maintain certain minimum quarterly product net revenue requirements
and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment
No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial
sales of IMVEXXY, BIJUVA, and ANNOVERA were revised. See Note 8 &#8211; Debt &#8211; for a description
of these covenants. These and other terms in the Financing Agreement have to be monitored closely for compliance
and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.
If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements,
or otherwise comply with the covenants of the Financing Agreement, all or a portion of our obligations under the Financing Agreement
may be declared immediately due and payable, which would have a material adverse effect on our business, results of operations
and financial condition.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQduWR076XSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_z0kdb43Ciy2g">Cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain cash at financial institutions
that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20201231_zQ3AOk9yMPC4" title="Cash FDIC insured amount">250,000</span> per bank. We have never
experienced any losses related to these funds.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z0PXW0Wks4q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zoeKDk3UUjUg">Trade Accounts Receivable and Allowance
for Doubtful Accounts</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are customer
obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks
and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection
information, reasonable supportable forecasts, and existing economic conditions and we record an allowance that presents the net
amount expected to be collected. We evaluate trade accounts receivable for delinquency. We write off delinquent receivables against
our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances
of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful
accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves
may be required. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws,
coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption
associated with the current COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced
significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying
amount of trade receivables in the future. At December 31, 2020, four different customers represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zeMcWBPAkK27" title="Concentration risk percentage">25</span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zFblFmC1C4tf">19</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJYlkjf6rLea">17</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zrz7FpodhDjb">11</span>% of
our gross accounts receivable. At December 31, 2019, four different customers represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zQd80LlYI9Lb">36</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zTuZYhyAeing">21</span>%,<span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zUl1Y7LTCLuh">16</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zwAnBdJ6IQNc">11</span>% of our gross accounts
receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zr4gbPw0pdZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Allowance for Doubtful Accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%">Balance - January 1, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20200101__20201231_zkKUwDVtxyf2" style="width: 12%; text-align: right" title="Balance at beginning">904,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase in allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IncreaseInAllowanceForDoubtfulAccountsReceivable_c20200101__20201231_z2ElkvKerBU5" style="text-align: right" title="Increase in allowance">422,137</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Recoveries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_iN_di_c20200101__20201231_zqIFO0vWPGR5" style="text-align: right" title="Recoveries">(181,514</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Write-offs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20200101__20201231_zo2AETyNBur8" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs">(26,809</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance - December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20200101__20201231_z98bXEewnbJ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">1,117,854</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zU3AskfXE1Nd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--InventoryPolicyTextBlock_zA9T6GNGbCQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_866_zNPe8jcvuR3d">Inventories</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories represent pharmaceutical products,
packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products
are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for
excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value.
Obsolescence may occur due to product expiring, product improvements rendering previous versions obsolete, or decreases in demand
for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Pre-Launch Inventory</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-launch inventory costs associated with
product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial
use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined,
then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during
the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Inventory Write-Off</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate inventory quarterly for short
dated and excess inventory. During the years ended December 31, 2020 and December 31, 2019, we recorded an inventory charge of
$<span id="xdx_902_eus-gaap--InventoryWriteDown_c20200101__20201231_zfLrLmKKSFud" title="Inventory charge">7,204,818</span>&#160;and $<span id="xdx_905_eus-gaap--InventoryWriteDown_c20190101__20191231_znwcXFB4i4a4" title="Inventory charge">0</span>, respectively. The charge recorded during the year ended December 31, 2020 was primarily related to BIJUVA
and resulted from the impact of the COVID-19 pandemic on our business, which decreased demand for our products.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CostOfSalesPolicyTextBlock_zLEBTqL1leIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_866_zODjpnlN2nFa">Cost of Sales</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of sales includes the cost of inventory,
manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. The Population Council License
Agreement requires payment of royalties based on the sale of future products. Such royalties are recorded as a component of cost
of sales. Additionally, the amortization of license fees or milestone payments related to licensed products are classified as components
of cost of sales to the extent such payments become due in the future.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zxr4m9jKAlg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_861_zqMgBOxm7Gkd">Fixed Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We state fixed assets at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives
of the related assets, which range from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zwStNlSSdvcc" title="Useful life of assets::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0588">three</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zQYPap4IV4Hh">seven years</span>. Leasehold improvements are depreciated over the shorter of their
useful life or the term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We capitalize software and software development
costs incurred to create and acquire computer software for internal use, principally related to software coding and application
development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable
that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized
in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into
service over the estimated useful life, generally <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zz4odzWls18g" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0590">five</span></span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zXJarThY0hD4">seven years</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zCOuXAwCqboi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86D_zHNQkewR0Dw8">Intangible Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted the provisions of Financial
Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, <i>Intangibles - Goodwill and Other</i>, or
ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications.
In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent
using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December
31, 2020, we had <span id="xdx_908_ecustom--NumberOfIssuedPatentsDomestic_iI_uN_c20201231_zUgBdjjhjVOi" title="Number of issued patents domestic.">38</span> issued domestic, or U.S., patents and <span id="xdx_90A_ecustom--NumberOfIssuedPatentsForeign_iI_uN_c20201231_zaGjxEbi1Ww2" title="Number of issued patents foreign">39</span> issued foreign patents (See Note 6). We capitalize external costs,
consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review
intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1pD2jkvUF3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_863_z9aHXGYIYrjg">Impairment of Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review the carrying values of fixed
assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate
that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant declines in an asset&#8217;s market price;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant deterioration in an asset&#8217;s physical condition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant changes in the nature or extent of an asset&#8217;s use or operation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">significant adverse changes in the business climate that could impact an asset&#8217;s value, including
adverse actions or assessments by regulators;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">accumulation of costs significantly in excess of original expectations related to the acquisition
or construction of an asset;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">current-period operating or cash flow losses combined with a history of such losses or a forecast
that demonstrates continuing losses associated with an asset&#8217;s use; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">expectations that it is more likely than not that an asset will be sold or otherwise disposed of
significantly before the end of its previously estimated useful life.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If impairment indicators are present, we
determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#8217;s carrying value
for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are
largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate
the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate
to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise
of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held
and used. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#8217;
fair value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based
upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant
estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount
rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information
about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and
changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform impairment tests for intangible
assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change
that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for
assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying
amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also evaluate the remaining useful life
of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment
or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining useful life is changed,
we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of indefinite-lived assets
is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment
test. During the years ended December 31, 2020 and 2019, we <span style="color: #212529">wrote off $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20200101__20201231_zXt7gpxpg4Qa" title="Write off of patent and trademark cost">1,131,776</span> and $<span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20190101__20191231_zWv3D9gcdwq8">78,864</span>, respectively,&#160;in
costs related to trademarks and patents. </span>There was no impairment of intangible assets during the year ended December 31,
2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z38d8DPCPpkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86F_zlLEgNREqtec">Fair Value of Financial Instruments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of December 31, 2020 and
2019 (as disclosed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We categorize our assets and liabilities
that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value
Measurements, </i>or ASC 820<i>. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for
identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 1in; text-align: left"><b>Level 1</b></td><td style="text-align: justify">unadjusted quoted prices in active markets for identical
assets or liabilities;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 1in; text-align: left"><b>Level 2</b></td><td style="text-align: justify">quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 1in; text-align: left"><b>Level 3</b></td><td style="text-align: justify">unobservable inputs for the assets or liabilities.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2020 and 2019, we had no assets or liabilities
that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zBlBozfK2Pa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_zjtSmTJjiblk">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize both interest and penalties
related to uncertain tax positions as part of the income tax provision. At December 31, 2020 and 2019, we had no tax positions
relating to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our U.S. federal and state tax returns
since 2011, which was the first year we generated net operating losses, remain open to examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_ziINyPlLXYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86C_zk32UZu6u9Sh">Share-Based Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, <i>Compensation-Stock Compensation</i>, to value
options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our stock-based
awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January 1, 2020, the average
expected life of options was based on the contractual terms of the stock option using the simplified method. We utilize a dividend
yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. In
addition, the terms of the Financing Agreement (See Note 8) preclude us from paying dividends, and any future debt agreements may
also preclude us from paying dividends. The assumptions used in calculating the fair value of stock-based awards represent our
best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.
We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance
with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service
period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which
simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We grant restricted stock units and performance-based
stock units for shares of common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20201231_z2GxITWehrV5">0.001</span> per share, or Common Stock, to employees. We value our restricted stock
units and our performance-based stock units by reference to our stock price on the date of grant. We recognize compensation expense
for restricted stock units based on a straight-line basis over the requisite service period of the entire award. We recognize performance-based
restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over
the requisite service period beginning at its grant date and through the date the performance restricted stock vests. The number
of target shares that vest are determined based on the level of attainment of the targets. If a minimum level of performance is
attained for the awards, restricted stock is issued based on the level of attainment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zgShP7jOATyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_860_zQ2ipGElfXOj">Revenue Recognition</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 606,&#160;<i>Revenue
from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer obtains control of promised goods or services.
The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these
goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the
transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for
those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify
the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance
obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Prescription Products</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: #212529">As of December
31, 2020, </span>our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began
selling during the third quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we
began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed
the commercial launch of ANNOVERA on July 1, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our name brand and generic prescription
products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription
products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations
related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service
for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription
product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or
service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the
customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on
our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional.
We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services
sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price of a contract is
the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will
not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that
supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and
the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ
from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would
affect net product revenue and earnings in the period such changes in estimates become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of six months prior to and up to <span id="xdx_905_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_z3ySKQtvDA47" title="Return period of unsalable prescription products">12</span>
months following product expiration. ANNOVERA cannot be returned before the expiration date and expired ANNOVERA can be
returned up to <span id="xdx_909_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zmR0T8rgRole">12</span>
months past the expiration date. Our prescription vitamins, IMVEXXY and BIJUVA currently have a shelf life of <span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--VitaminsImvexxyAndBijuvaMember_zT2KiZyFAJs3" title="Shelf life of prescription products">24</span>
months from the date of manufacture and ANNOVERA currently has a shelf life of <span id="xdx_908_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zzAsj5sOc8Ha">18</span>
months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of product revenue in the period the related product revenue is recognized. Where historical rates of return exist,
we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched
products, for which the right of return exists but for which we currently do not have history of product returns, we estimate
returns based on available industry data, our own sales information and our visibility into the inventory remaining in the
distribution channel. At the end of each reporting period, we may decide to constrain product revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the
expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic
products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the
customer&#8217;s consideration. Since our returns primarily consist of expired and short dated products that will not be
resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the
initial sale (when recognition of product revenue is deferred due to the anticipated return). Return estimates are recorded
in other current liabilities on the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We offer various rebate and discount programs in an effort to maintain
a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates
and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on
a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenue at the time the product
revenue is recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor
fees are recorded in other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units
sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors
fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates
relating to invoice discounts and chargebacks are deducted from gross product revenue at the time the product revenue is recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of commercial launches for our
FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket
costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with
our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. The variable consideration
is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average
assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time
up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription
products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain
variable consideration for our prescription products to an amount that will not result in a significant product revenue reversal
in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates
of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by
insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently
available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIeQdb0LePU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Prescription vitamins</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zIUJyq1Gpgyb" style="width: 12%; text-align: right" title="Net revenue">9,767,644</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zm4kXwTPfFzb" style="width: 12%; text-align: right" title="Net revenue">9,885,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zRSEpLOd3G4l" style="width: 12%; text-align: right" title="Net revenue">15,041,259</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zJfE6V5ja3Mc" style="text-align: right" title="Net revenue">27,139,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zVZkVbCvPFNg" style="text-align: right" title="Net revenue">16,252,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zvBbyNZlnXLl" style="text-align: right" title="Net revenue">1,058,201</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGYUHrnBZE1" style="text-align: right" title="Net revenue">6,353,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zLSGvlHRufNg" style="text-align: right" title="Net revenue">1,836,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--BijuvaMember_z1JXyWuYn72d" style="text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayMzasE8eb6" style="text-align: right" title="Net revenue">19,611,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zYvSCX7ojjG8" style="text-align: right" title="Net revenue">6,166,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zjpw8uaRoM46" style="text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zydUwtLaPfM1" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zEuVRJerfvu7" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSl8MRsNl7Jf" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_zQyorgOoNb95" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">64,872,280</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_z2VgHc6SD9Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">49,646,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z9pXHF47yUB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">16,099,460</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_zf7LBTNOj0Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529"><i><span style="text-decoration: underline">License Revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front
fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the right to use functional intellectual property is transferred to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">License Agreement with the Population
Council</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2018, we entered into the Population
Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a &#8220;test and learn&#8221; market
introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial
launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. <span style="color: #212529">We
resumed the commercial launch of ANNOVERA on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Population Council
License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNmM0XbdrIkf" title="Milestone payment upon FDA Approval">20,000,000</span>&#160;within 30 days following the approval
by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_902_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRlIviFCHJSa" title="Milestone payments (payment after release of first commercial batch)">20,000,000</span>&#160;within 30 days following the first commercial
batch release of ANNOVERA. Both milestone payments of $<span id="xdx_909_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zHvxx9ISU3ic" title="License rights acquired">20,000,000&#160;</span>were recorded as license rights in the consolidated balance
sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became commercially available for use.
The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our
cash flows, which is estimated to be the remaining patent life of the product, which expires as early as December 2032. The cost
is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the years
ended December 31, 2020 and 2019 we recorded $<span id="xdx_908_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20200101__20201231_zU0ennHdqNG" title="Amortization of intellectual property license fee">3,024,391</span>&#160;and $<span id="xdx_90C_ecustom--AmortizationOfIntellectualPropertyLicenseFee_pp0p0_c20190101__20191231_zoFDDXXJ6XF8" title="Amortization of intellectual property license fee">778,692</span>, respectively, in amortization expense related to the
license fee which was recorded as a component of cost of sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Population Council is also eligible
to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible for marketing expenses related
to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based
royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as
follows: (i) if annual net sales are less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zB1xl9STslZj" title="Net sales amount per step-based royalty">50,000,000</span>, a royalty of&#160;<span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zHDWWmUGwgea" title="Royalty (percent)">5</span>% of net sales; (ii) for annual net
sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zT2XmmFVoWge" title="Net sales amount per step-based royalty">50,000,000</span>&#160;and less than or equal to $<span id="xdx_90E_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zTAI4ux2XhT6" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of&#160;<span id="xdx_90E_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zC6XNUaPEozh" title="Royalty (percent)">10</span>% of such net sales; and (iii)
for net sales greater than $<span id="xdx_90A_ecustom--NetSalesAmountPerStepbasedRoyalty_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zt1yVxYQsZOk">150,000,000</span>, a royalty of&#160;<span id="xdx_90A_ecustom--RoyaltyPercent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zBs9xrl0NxU4" title="Royalty (percent)">15</span>% of such net sales. The annual royalty rate will be reduced to&#160;<span id="xdx_90D_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zQetXhTVEaka" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent">50</span>%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent
of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to&#160;<span id="xdx_908_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_zXp9UntycC9i" title="Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent">20</span>%
of the initial rate. We are required to pay the Population Council milestone payments of $<span id="xdx_902_ecustom--MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zRb6ERjPJGr9" title="Milestone payments upon specified levels of cumulative net sales">40</span>&#160;million&#160;upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $<span id="xdx_904_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_z0nEr1VekSOf" title="Specified level one of cumulative net sales for milestone payments">200</span>&#160;million, $<span id="xdx_906_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zTUERTX9tZt7" title="Specified level two of cumulative net sales for milestone payments">400</span>&#160;million&#160;and
$<span id="xdx_90F_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments_pn9n9_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember__srt--ProductOrServiceAxis__custom--AnnoveraMember_zUELoe4agUhi" title="Specified level three of cumulative net sales for milestone payments">1</span>&#160;billion. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval
studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such
post-approval study exceed $<span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementMember_z4kNf57Lbi3k" title="Maximum costs and expenses for post approval">20,000,000</span>, half of such excess will be offset against royalties or other payments owed by us to the
Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a joint product
committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible for all
aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired
clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.
The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational
vaginal contraceptive systems in development by the Population Council.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless earlier terminated, the Population
Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#8217;s
U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during
which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may
also be terminated for certain breach and bankruptcy-related events and by us on 180 days&#8217; prior notice to the Population
Council.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="text-decoration: underline">License Agreement with Knight Therapeutics
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2018, we entered into the Knight
License Agreement pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.
Pursuant to the terms of the Knight License Agreement, Knight paid us $<span id="xdx_90D_ecustom--MilestonePaymentReceivedUponRegulatoryApproval_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zUD7dpRngPs2">2,000,000</span> in milestone fees upon the first regulatory approval
in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is required to pay us sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory
applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in
Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents.
Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain
specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement,
Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><span style="text-decoration: underline">License Agreement with Theramex</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: #212529">On June
6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR <span id="xdx_900_ecustom--CashUpfrontPaymentReceived_pn6n6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zJCFLkOukmJf" title="Cash upfront payment received">14</span>
million, or $<span id="xdx_902_ecustom--CashUpfrontPaymentReceived_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z92lh37so5V4" title="Cash upfront payment received">15,506,400</span>,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_909_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_z7IqI8sc6G2c" title="Regulatory milestone payments">2
million</span> in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR <span id="xdx_900_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zoyAeZAvCZb8" title="Sales milestone payment">27.5
million</span> in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory
ranging from EUR <span id="xdx_909_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zcUhRqEMr4S6" title="Sales milestone">25</span>
million to EUR <span id="xdx_904_ecustom--AnnualNetSalesMilestone_pn6n6_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zAacOzdvIPjd" title="Sales milestone">100</span>
million. We are also entitled to receive quarterly royalty payments at a rate of <span id="xdx_909_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_uPure_c20190506__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zq6e23cqcAxe" title="Quarterly royalty payments percentage">5</span>%
on net sales of BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory. Theramex is responsible for
all regulatory and commercial activities for BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory.
Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the </span>Theramex <span style="color: #212529">Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all
regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA
and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex
challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party
that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zenh362Wo67i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_862_zv3nAQnaW9M8">Segment Reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single executive leadership team that is led by the Chief Executive Officer of our Company, who oversees all operations. We do
not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information
with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business
as one reportable operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShippingAndHandlingCostsPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p id="xdx_841_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zxpqbr2bmcbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86B_zmyttqWPgYYk">Shipping and Handling Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--AdvertisingCostsPolicyTextBlock_zdhmPYMiEK52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zyINHvbwxSv4">Advertising Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $<span id="xdx_90F_eus-gaap--AdvertisingExpense_c20200101__20201231_zJaZR6tmsl89" title="Advertising expense">35,799,313</span>, $<span id="xdx_907_eus-gaap--AdvertisingExpense_c20190101__20191231_z2WkwD8JFvA" title="Advertising expense">9,045,571</span> and $<span id="xdx_904_eus-gaap--AdvertisingExpense_c20180101__20181231_zTk92CW5pAXb" title="Advertising expense">1,682,746</span> during the years ended December 31, 2020, 2019, and 2018, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbIx9lxZUof7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_869_zs115znl8Fgd">Research and Development Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development, or R&amp;D, expenses
include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory
supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory
experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken
by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house
staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing
protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking
work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations
as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date.
We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity
has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses
and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion
stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion.
We charge revisions to expenses in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zGxe5iUgOs2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline"><span id="xdx_86C_zY8NoTbthJw6">Earnings Per Share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We calculate earnings per share, or EPS,
in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic
and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period.
We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options,
warrants and restricted stock units and were excluded from the calculation of diluted earnings per share because their effect would
have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could
affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zxZw0sPuvJN4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.5in" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Stock options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuoTVoVLv1X4" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">23,781,930</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA3iPFU4QS93" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zln2FQ1cG1xg" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">20,872,824</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6a7Q8G2kyz" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,534,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAcN8G1ZGnC" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,832,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrW6K1PYpl3j" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,007,571</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zw7hkCKqtWXe" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,403,951</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zeOF1BJWYdDj" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuGGGXBHxbSc" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0750">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCzVK1LkrEla" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">7,061,024</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziCDxmGKrzz3" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,240,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7UbyYPGZJCl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,040,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231_zJ9z974o0Fec" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">39,781,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231_zEaiLOIhKlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">28,102,805</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231_ziJUIS60zymh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">24,920,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and other Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zZpXowcWtFb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_867_z2CF8RaRZ6B4">Concentration of Credit Risk and other
Risks and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially
expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial
institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not
experienced any historical losses on our deposits of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of credit risk with respect
to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors.
Credit is extended to our customers based on an evaluation of a customer&#8217;s financial condition, and collateral is not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_845_eus-gaap--UseOfEstimates_zSN8ER4xhn9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86B_z9q28YO8Zn8d">Use of Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znmqU4R9pzrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><span id="xdx_86A_zhOmlAltG07g">Recently Issued Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In March 2020, the FASB
issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference
Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting
impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank
Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally,
contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment
of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022.
Our debt agreements currently include the use of alternate rates when LIBOR is not available. We do not expect the change from
LIBOR to an alternate rate will have a material impact to our financial statements and, to the extent we enter into modifications
of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In August 2018, the FASB
issued ASU 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public
entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting
Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness
of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information
to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December
15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or
only the provisions that eliminate or modify requirements. We adopted this standard on January 1, 2020, and the adoption did not
have a material effect on our disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">In June 2016, the FASB
issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments.
The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be
presented at the net amount expected to be collected based on historical experience, current conditions, and reasonable supportable
forecasts. The amendments in this update are effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the first quarter of 2019.
A modified retrospective approach is required for all investments, except debt securities for which an other-than-temporary impairment
had been recognized prior to the effective date, which will require a prospective transition approach and should be applied either
prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13 requires expanded quantitative
and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January 1, 2020, we adopted ASU 2016-13
under a modified retrospective approach for all financial assets measured at amortized cost. There was no adjustment recorded for
the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our credit losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">Other recent accounting
pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants
and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShippingAndHandlingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for shipping and handling costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShippingAndHandlingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447812532808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zr4gbPw0pdZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The opening balance of the allowance for doubtful accounts is
reconciled to the closing balance for expected credit losses as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Allowance for Doubtful Accounts</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%">Balance - January 1, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20200101__20201231_zkKUwDVtxyf2" style="width: 12%; text-align: right" title="Balance at beginning">904,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase in allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IncreaseInAllowanceForDoubtfulAccountsReceivable_c20200101__20201231_z2ElkvKerBU5" style="text-align: right" title="Increase in allowance">422,137</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Recoveries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllowanceForDoubtfulAccountsReceivableRecoveries_iN_di_c20200101__20201231_zqIFO0vWPGR5" style="text-align: right" title="Recoveries">(181,514</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Write-offs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20200101__20201231_zo2AETyNBur8" style="border-bottom: Black 1pt solid; text-align: right" title="Write-offs">(26,809</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance - December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20200101__20201231_z98bXEewnbJ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">1,117,854</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIeQdb0LePU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information
about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Prescription vitamins</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zIUJyq1Gpgyb" style="width: 12%; text-align: right" title="Net revenue">9,767,644</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zm4kXwTPfFzb" style="width: 12%; text-align: right" title="Net revenue">9,885,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zRSEpLOd3G4l" style="width: 12%; text-align: right" title="Net revenue">15,041,259</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zJfE6V5ja3Mc" style="text-align: right" title="Net revenue">27,139,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zVZkVbCvPFNg" style="text-align: right" title="Net revenue">16,252,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zvBbyNZlnXLl" style="text-align: right" title="Net revenue">1,058,201</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--BijuvaMember_zUGYUHrnBZE1" style="text-align: right" title="Net revenue">6,353,963</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zLSGvlHRufNg" style="text-align: right" title="Net revenue">1,836,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--BijuvaMember_z1JXyWuYn72d" style="text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayMzasE8eb6" style="text-align: right" title="Net revenue">19,611,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zYvSCX7ojjG8" style="text-align: right" title="Net revenue">6,166,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zjpw8uaRoM46" style="text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zydUwtLaPfM1" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">2,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zEuVRJerfvu7" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">15,506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zSl8MRsNl7Jf" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231_zQyorgOoNb95" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">64,872,280</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_z2VgHc6SD9Wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">49,646,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z9pXHF47yUB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">16,099,460</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of calculation of diluted net loss per share allocable to common stockholders</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zxZw0sPuvJN4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 1.5in" summary="xdx: Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: justify">Stock options</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuoTVoVLv1X4" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">23,781,930</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zA3iPFU4QS93" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zln2FQ1cG1xg" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">20,872,824</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6a7Q8G2kyz" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,534,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAcN8G1ZGnC" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,832,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrW6K1PYpl3j" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,007,571</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zw7hkCKqtWXe" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">2,403,951</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zeOF1BJWYdDj" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0748">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zuGGGXBHxbSc" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0750">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCzVK1LkrEla" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">7,061,024</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ziCDxmGKrzz3" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,240,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7UbyYPGZJCl" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,040,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20200101__20201231_zJ9z974o0Fec" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">39,781,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20191231_zEaiLOIhKlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">28,102,805</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20181231_ziJUIS60zymh" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">24,920,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447814226216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists of the following:</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z4VIWKaJ1hnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zGhhd5wdffZa">Inventory consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zmsSAMGBKAy9" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20191231_zIAXW9h947I8" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_uUSD_maINzQbM_maINzicc_zTwzl9zMR9lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Finished products</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,350,580</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,976,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--InventoryWorkInProcess_iI_uUSD_maINzQbM_maINzicc_z6ccfz20W1y2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182,059</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InventoryRawMaterialsAndSupplies_iI_uUSD_maINzQbM_maINzicc_zxy3xVRWrBDl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,422,589</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,701,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryNet_iTI_uUSD_mtINzQbM_mtINzicc_zj3NQdbZOL56" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,993,087</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,860,716</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813856168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other current assets consist of the following:</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zyDotqxUZZjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_z3E7SUgITetf">Other current assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_zWlfmIhVR7h5" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20191231_zaPuNRXP6zbe" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_405_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zTX1UGrHOIDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Prepaid sales and marketing costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,583,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzmtR_maPEAOAzRrD_zWdzxiUe5Nw1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt financing fees on undrawn tranches (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,757</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzmtR_maPEAOAzRrD_zV5AAuUETA53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,568,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,812,135</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--PrepaidManufacturing_iI_maPEAOAzmtR_maPEAOAzRrD_zPdNfb7f2uod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,331,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,595,721</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzmtR_maPEAOAzRrD_zbM6X4J7YOFk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,639,720</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,787,482</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzmtR_mtPEAOAzRrD_zWmZJ6fH1651" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,543,397</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,329,793</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813682984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Fixed assets, net consist of the following:</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zwalxkNjwlpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B3_zpzb2OwFhoZ4">Fixed assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20201231_zJIfVFMJGDmk" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20191231_zpgoHHfaLpb7" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Accounting system</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zXVawOStxG4d" style="width: 12%; text-align: right">411,550</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zm9EPO4CUHbk" style="width: 12%; text-align: right">301,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_znRbalwMXMfg" style="text-align: right">1,704,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zPIVpZNZNZac" style="text-align: right">1,619,646</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zwDDCVnUTvF7" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zmrLBXnu01Rb" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zFRX5JHfIGq5" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zBAJ6spUyCOd" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zvn7rxfAzVGc" style="border-bottom: Black 1pt solid; text-align: right">80,121</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zebvqVsbkxsi" style="border-bottom: Black 1pt solid; text-align: right">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_zHwmcCITGIVc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,683,671</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,476,599</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20201231_zaTLGDdVBvm2" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated depreciation">(1,741,447</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_zHp8qjyh7OHj" style="border-bottom: Black 1pt solid; text-align: right">(968,824</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_zlvcHLtLDnNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,942,224</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,507,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813341256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z4clAvQB88J8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B4_z8NdkXyYT5Xc">The following table sets forth the gross carrying amount, accumulated
amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross<br/>
Carrying<br/>
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated<br/>
Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net<br/>
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted-</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average<br/>Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Amortization</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Period (yrs.)</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Approved hormone therapy drug candidate patents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zSYuKPdQIVDd" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Gross">4,044,552</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zALv2sZjcEfe" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(748,627</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHAO8XCZRci2" style="width: 10%; text-align: right" title="Finite-Lived Intangible Assets, Net">3,295,925</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlsvJLAC4KM7" title="Finite-Lived Intangible Assets, Remaining Amortization Period">12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z8bRYnrmuxok" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">1,628,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zc3zWfX2t3Qb" style="text-align: right" title="Finite-Lived Intangible Assets, Net">1,628,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zdVboSaMaXWj" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">323,341</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zqphpEFgOJJa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">323,341</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zDv0mJvaJSk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">5,996,350</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20201231_zR3YedimwWm7" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(748,627</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20201231_zP2E2mjJ1Due" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">5,247,723</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross<br/>
Carrying<br/>
Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated<br/>
Amortization</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Net<br/>Amount</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted-</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average<br/>Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Amortization</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Period (yrs.)</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zKnJASx50b3l" style="width: 12%; text-align: right">3,463,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxvVB9iunx1f" style="width: 12%; text-align: right">(478,983</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zReVzPUfDAE5" style="width: 12%; text-align: right">2,984,099</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z7kwhX16V0ng">13</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zk3uT2fprYog" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_uUSD_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z6mTdKWmF8Rj" style="text-align: right">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;&#160;&#160;Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IndefiniteLivedTrademarks_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zR8Me2QAcuwk" style="border-bottom: Black 1pt solid; text-align: right">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pp0p0_uUSD_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksMember_zwrOWh3L3gqk" style="border-bottom: Black 1pt solid; text-align: right">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pp0p0_uUSD_c20191231_zVTewfUNILE3" style="border-bottom: Black 2.5pt double; text-align: right">5,737,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_uUSD_c20191231_zraYe4cYgmJf" style="border-bottom: Black 2.5pt double; text-align: right">(478,983</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_uUSD_c20191231_z3ErTi9gGA5e" style="border-bottom: Black 2.5pt double; text-align: right">5,258,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z33kdLUjHoci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span>Estimated amortization
expense, based on current patent cost being amortized, for the next five years is as follows:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20201231_z1JUp7oWRApk" style="border-bottom: Black 1pt solid; text-align: center">Estimated Amortization</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zZyWjdNjBbcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: right">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">274,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zj5ls5NSbUHl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zozl23CkGf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zXrb5arYeYK8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zY4MKUsYBGvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">274,669</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447817872296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other current liabilities</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zWFG7m1cBZL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B0_z0igxA9SVRpb">Other current liabilities</span> consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_z1xo8tvfSIge" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20191231_zWIqwsQfSZPe" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccruedSalariesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zaTCBg7RazSi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Accrued payroll, bonuses and commission costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,758,073</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,040,278</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCz3D1_zeyV3oadnasd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,770,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,316,298</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zNcBXHLzhL6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,285,662</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AccruedVacationCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zhYdjdiDEsF5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,353,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,463,878</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCz3D1_zQ7aXpeBqyMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,632,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,347,122</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zMwLBfP5Q63d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">898,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">422,336</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--AccruedResearchAndDevelopment_iI_maOLCz3D1_zIPy0XfuYiHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">925,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,049,603</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zBo2rNF1j4zj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,253,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--AccruedRebates_iI_maOLCz3D1_z9a5LrouC4Vl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,010,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,916,672</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCz3D1_maOLCzk7K_maOLCzij0_zZe36SEC1cHe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,339,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,480,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCz3D1_mtOLCzij0_z5oEs5EK70W1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,169,869</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,823,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813511384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following:</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_zPwkD1Td4woa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B6_z2o13kQ2qy38">As of December 31, 2020 and 2019, the carrying
value of our debt consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: justify">Financing Agreement</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20201231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zwMTUNoEabB4" title="Long-term Debt, Gross">250,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z7jLOiHi86Hh" title="Long-term Debt, Gross">200,000,000</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20201231_zJZIcl9hA7Q3" style="border-bottom: Black 1pt solid; text-align: right">(12,302,469</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_c20191231_zwN3DhrO3tLa" style="border-bottom: Black 1pt solid; text-align: right">(5,365,357</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--LongTermDebtNoncurrent_iI_c20201231_zBq3vAz9k4rj" title="TOTAL LONG-TERM DEBT">237,697,531</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--LongTermDebtNoncurrent_iI_c20191231_z7cAUqfBdSZ1" title="TOTAL LONG-TERM DEBT">194,634,643</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zxHfodBnKX38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zxEhXGMEwQB">The following table reflects our aggregate future principal payments
under the Financing Agreement for the next five years, as amended by Amendment No. 8:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Year Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_z3X51nIyMpud" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_iI_d0_zYdZnuq1q9g6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">50,000,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_iI_d0_zAXeX7sTPnMe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,000,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_iI_zcu09OXQhgR7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: right">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">133,750,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_iI_zE0O6fqRfQ1c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,250,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_iI_d0_zy2jDUsGPtmc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813663928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock', window );">Summary of our Warrant activity during the year ended December 31, 2020:</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zQIEBlKA5QB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Summary of our Warrant activity during the year ended December
31, 2020:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Shares Under</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Warrants</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Life in Years</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Balance at December 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRRfJbOqoFuf" style="width: 12%; text-align: right" title="Number of shares under warrants outstanding beginning">1,832,571</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zV0mPa5GYoF6" style="width: 12%; text-align: right" title="Weighted average exercise price warrants outstanding beginning">2.62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxLMoeHGv0sh" style="width: 12%; text-align: right" title="Weighted average remaining contractual life, warrants outstanding">1.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zI9HnHhuALE2" style="width: 12%; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning">2,447,929</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyYJ8fQEKFIb" style="text-align: right" title="Number of shares under warrants granted">4,752,116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9MnAk7PDqsa" style="text-align: right" title="Weighted average exercise price warrants granted">1.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zhpZv6rBSF6f" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Forfeited">(50,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zh9SXiF0REug" style="text-align: right" title="Weighted average exercise price warrants cancelled/forfeited">6.35</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zRmnrBa1Ixka" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under warrants outstanding ending">6,534,687</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYMBmVblsfE3" style="text-align: right" title="Weighted average exercise price warrants outstanding ending">1.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHkKR2Z3kSue" style="text-align: right" title="Weighted average remaining contractual life, warrants outstanding">7.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB7D2SbhQIng" style="text-align: right" title="Aggregate intrinsic value, warrants outstanding ending">1,041,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zToiBI49G18d" style="text-align: right" title="Number of shares under warrants vested and exercisable ending">6,534,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHtFFJEiNjzk" style="text-align: right" title="Weighted average exercise price warrants unvested ending">1.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOhy3RAC7XNl" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable ending">7.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLUCFsclWND7" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">1,041,219</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below.</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zD2LR7eyNHaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average fair value per share
of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018
are set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzzohakCd7ib" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdGcFn7jkUsb" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zfDz6mG7bx2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_407_ecustom--WeightedAverageExercisePriceOtherThanOptions_pii_uUSDPShares_zfh5i8004uWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Weighted average exercise price</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5.16</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_z2wJm8856j8j" style="vertical-align: bottom; background-color: White">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.79</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_z5fuJJ2oCdj6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.52</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.36</td><td style="text-align: left">%</td></tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_zt1cBcLV5i3e" style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62.12</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zDTGR0r3w2kl" style="text-align: right" title="Term (in years)">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zrntf4TgaIXi" style="text-align: right" title="Term (in years)">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjrWxfC1bd4j" style="text-align: right" title="Term (in years)">5</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_zqNSt6wazfbg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below.</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zK73YAIvjLQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. <span id="xdx_8B3_zFjG7qlKfWp9">The ranges of
assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Weighted average exercise price</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdRKOCY194Fb" style="width: 12%; text-align: right" title="Weighted average exercise price">1.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm1q20xQpHlc" style="width: 12%; text-align: right" title="Weighted average exercise price">3.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU0RGQJ0eQP4" style="width: 12%; text-align: right" title="Weighted average exercise price">5.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zidH9LoM7wI8" style="text-align: right" title="Weighted average grant date fair value">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsks95RV0Fla" style="text-align: right" title="Weighted average grant date fair value">1.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3zmIglYQXQd" style="text-align: right" title="Weighted average grant date fair value">3.24</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd5Gy8sGeof8" title="Risk-free interest rate - minimum">0.34</span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJwEaTnpPMOa" title="Risk-free interest rate - maximum">1.68</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEeyhRC6N5vb" title="Risk-free interest rate - minimum">1.64</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNDhpRN2P563" title="Risk-free interest rate - maximum">2.54</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9AZUWqOxlb4" title="Risk-free interest rate - minimum">2.38</span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyc3vOPXLIJc" title="Risk-free interest rate - maximum">2.89</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z54cPeUNn1fc" title="Volatility - minimum">63.53</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4QToulRpY67" title="Volatility - maximum">67.92</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z136BI8h4gZk" title="Volatility - minimum">61.25</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX63SVikg5oj" title="Volatility - maximum">64.49</span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEXhJmbtOxaj" title="Volatility - minimum">59.45</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKWp9HvkneX1" title="Volatility - maximum">64.04</span>%</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zfErmA5yB31f" title="Term">6</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zjHnM7guZ3Td" title="Term">6.8</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zEwpZpbrrsA" title="Term">5.5</span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zr8jstVV9iL7" title="Term">6.5</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjogRE4kyEX5" title="Term">5.1</span>-<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zS49ZdephDu4" title="Term">6.25</span></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUS3Mu5ASo8f" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zma4MpsEpOE1" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVWNjv8rptFg" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zTUGf9YtZhZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of activity under the 2009, 2012
and 2019 Plans and related information during the year ended December 31, 2020 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Shares Under</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Options</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Life in Years</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Balance at December 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zOWxDl2OmMV" style="width: 12%; text-align: right" title="Number of shares under options, beginning">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20201231_zFZbBzcvewna" style="width: 12%; text-align: right" title="Weighted average exercise price, beginning">4.65</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zHq1IWLmGAm2" style="width: 12%; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20200101__20201231_zUcEtCZBuQpj" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning">3,668,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zGMx6F3D6ZKh" style="text-align: right" title="Number of shares under options, granted">736,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zvSF7LkOHy4g" style="text-align: right" title="Weighted average exercise price, granted">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20200101__20201231_zPI1pUWgipxb" style="text-align: right" title="Number of shares under options, exercised">(1,182,195</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zDu6VR4Q0aC6" style="text-align: right" title="Weighted average exercise price, exercised">0.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20200101__20201231_zuosgxVLzVWl" style="text-align: right" title="Aggregate intrinsic value, exercised">1,738,740</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20200101__20201231_zdi9BU3pwUO5" style="text-align: right" title="Number of shares under options, expired">(386,609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_zD9L6LV7Wfme" style="text-align: right" title="Weighted average exercise price, expired">3.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zejaUJeR5ZR" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited">(416,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20200101__20201231_z8yQlXeRfJ45" style="text-align: right" title="Weighted average exercise price, cancelled forfeited">3.80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200101__20201231_ziOsw50js328" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending">23,781,930</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zmkwoS8XeKLb" style="text-align: right" title="Weighted average exercise price, ending">4.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20200101__20201231_zOHq9IcPTqY5" style="text-align: right" title="Weighted average remaining contractual life">5.20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20200101__20201231_zYyeO6L5dF0h" style="text-align: right" title="Aggregate intrinsic value, ending">152,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20200101__20201231_zKXVf5SnUPX8" style="text-align: right" title="Number of shares under options, vested and exercisable ending">19,862,681</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zZveoHdWBtgj" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending">5.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zgoGIzgv0bdg" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable">4.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20200101__20201231_zrblXPQD82Pg" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">117,443</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20200101__20201231_zOpLSxrBy8Si" style="text-align: right" title="Number of shares under options, unvested ending">3,919,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20201231_zAcpuOCuOwCa" style="text-align: right" title="Weighted average exercise price, unvested ending">3.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20201231_zrd64DCGRALe" style="text-align: right" title="Weighted average remaining contractual life, unvested">8.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20200101__20201231_zq2yZIhCwPhi" style="text-align: right" title="Aggregate intrinsic value, unvested ending">34,810</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of restricted stock units and performance stock units</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zIPEnR0HqOs1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule of restricted stock units and
performance stock units</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Restricted Stock Units</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Performance Stock Units</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number of</p>
                                                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shares</p>

</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Weighted</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Average</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Grant Date</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Fair Value</span></p></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number of</p>
                                                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shares</p>

</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Weighted</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Average</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Grant Date</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Fair Value</span></p></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Balance at December 31, 2019</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpell54xGhm4" style="width: 12%; text-align: right" title="Beginning balance, number of shares">1,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEI5qekRZA2" style="width: 12%; text-align: right" title="Beginning balance, weighted average grant date fair value">3.56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znrSniegE5g4" style="text-align: right" title="Granted, number of shares">6,152,818</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLTIusfAgI23" style="text-align: right" title="Granted, weighted average grant date fair value">1.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zDUff6ykhbVl" style="text-align: right">2,585,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zl46URc21r1j" style="text-align: right">1.08</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Vested/Released</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrr6E2e496V4" style="text-align: right" title="Vested/Released, number of shares">(301,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFn9vJyGoWp7" style="text-align: right" title="Vested/Released, weighted average grant date fair value">1.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zE4tbr4OSqu9" style="text-align: right">(151,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zeCG9cEPaTsa" style="text-align: right">1.14</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQSChyti9sO5" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited, number of shares">(30,294</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoOzrrMk41L8" style="text-align: right" title="Forfeited, weighted average grant date fair value">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zJm02Iv3Hx3g" style="border-bottom: Black 1pt solid; text-align: right">(30,294</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_znKJMmPU6OO4" style="text-align: right">1.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Balance at December 31, 2020</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJAZPd398kKk" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, number of shares">7,061,024</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxuh3DzApZT2" style="text-align: right" title="Ending balance, weighted average grant date fair value">1.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKg_____zKNcfa9MpK0g" style="border-bottom: Black 2.5pt double; text-align: right">2,403,951</td><td id="xdx_F22_zJX5trdtnZEi" style="padding-bottom: 2.5pt; text-align: left">*</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zjEJORWN5x1i" style="text-align: right">1.08</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F06_zr1lKch6hv28" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"/><td id="xdx_F12_zfnzvpgq2c4h" style="text-align: justify">The number of performance stock units (PSUs) represents the base number of PSUs that
may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the
Company&#8217;s achievement of break-even quarterly EBITDA.</td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfWarrantRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447822028696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">For financial reporting purposes, (loss) income before taxes includes the following components:</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYaE2QoEmhYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, (loss)
income before taxes includes the following components:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-bottom: 1pt">United States</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zguCFyRPD1ik" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(183,524,137</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_zC3C21UWS0Xc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(176,144,999</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--DomesticCountryMember_z7ehvKbVq99j" style="border-bottom: Black 1pt solid; width: 12%; text-align: right">(132,617,160</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20200101__20201231_zjsoXl7n8sM7" style="border-bottom: Black 2.5pt double; text-align: right">(183,524,137</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zoHfrzFGf7Il" style="border-bottom: Black 2.5pt double; text-align: right">(177,144,999</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zC7zcbxEydWh" style="border-bottom: Black 2.5pt double; text-align: right">(132,617,160</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjRPx5ggl1H3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation between taxes computed at the federal statutory
rate and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20201231_zNMMJonDbVr4" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20190101__20191231_zdl9tOiJ8FOd" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20180101__20181231_zX2FXwBwhHO3" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_maIT_zak6HihgVW0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left">Federal statutory tax rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPure_maIT_z8NNHPmmKKP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.2</td><td style="text-align: left">%</td></tr>
<tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_maIT_zBQUuhjCjVE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31.2</td><td style="text-align: left">)%</td></tr>
<tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pii_dp_uPure_maIT_zz1X9yLFzn27" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Excess stock benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">%</td></tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp0_uPure_maIT_zIdMSs7oCQN9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal income tax rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td><td>&#160;</td></tr>
<tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPure_maIT_zABe7zYzkFvl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Permanent and other differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.8</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.7</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.3</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_uPure_mtIT_znjLm1h5T7ok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision (benefit) for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows:</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYnj1A9WQn2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of the net deferred income
tax asset as of December 31, 2020, 2019, and 2018 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20201231_ziSVdkEpnGI8" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20191231_zSgCwboagMPk" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20181231_zUg3mP0nvgG5" style="border-bottom: Black 1pt solid; text-align: center">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zhQAL6kZqtHd" style="vertical-align: bottom">
    <td style="text-align: left">Deferred Income Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzcsC_zzDrXcGjVRfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left; padding-left: 0.125in">Net operating losses</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">195,008,131</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">157,555,975</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">126,419,113</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_maDTAGzcsC_zEiqUd5lJmid" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,251,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,913,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,464</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetInterestCarryforward_i01I_maDTAGzcsC_z6p6IREdlPh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Interest expense limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,991,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,389,129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,173,614</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_i01I_maDTAGzcsC_zxB7OY1bHfb6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Other, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,818,935</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,662,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,658,573</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGzzfO_maDTAGzcsC_zgclBwHpui5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">R&amp;D credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzcsC_maDTANzEH4_zfcLcbgF6Ze3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Total deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,257,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,707,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,078,111</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzEH4_zZkjhxFogA86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(230,257,029</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(180,707,056</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(141,078,111</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzEH4_zj2p6EyLBNkk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred income tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447817872824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock', window );">Supplemental lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z0qHaQXgGYsf" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Supplemental
lease information as of:</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_zvsQK6mhd6H6" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2020</p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20191231_zwCekJDFreEk" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2019</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zgSJwi8HN9p8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Right-of-use asset</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,565,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,109,154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zRmUVpY5KQNh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term operating lease liability (included in <span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20201231_z7Yt0tyMkr3g" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"><span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_iI_dxL_c20191231_zPu4jiwRNLTl" title="::XDX::us-gaap%3AOtherLiabilitiesCurrent"><span style="-sec-ix-hidden: xdx2ixbrl1634"><span style="-sec-ix-hidden: xdx2ixbrl1635">Other current liabilities</span></span></span></span>)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,253,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zmGRt1AS3nWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,675,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,145,049</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zQrO6eP9Cye5">8.9</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zkuU70CWQ0Ne">9</span> years</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_zUT9oLVC6zUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.30</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">%</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Supplemental cash flow information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>for the year ended:</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200101__20201231_z4Kvyri66KD7" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/>
2020</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190101__20191231_zjEikObZOm47" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">2019</p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeasePayments_zoHM3doKuPbk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,617,645</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,164,234</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_z5mz9Do3uNtb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">998,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,171,471</td><td style="text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zSRjabTl3LOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the undiscounted
cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Years Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20201231_znBA6Qv3YUQh">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz1WK_zNaAzI5TOiV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%; text-align: left">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,334,582</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz1WK_z9806I5Zru21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,413,289</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz1WK_zDS4sf6wjyhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,443,143</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz1WK_zhk5xpIRSuR6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,476,534</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPz1WK_zuFZz9rMrOi3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,513,458</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz1WK_zQhlQPsjm8p2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,434,412</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPz1WK_zVDcOeTVXDne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Total undiscounted lease payments</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,615,418</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWCSU7W9F8H9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Less: imputed interest</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,685,947</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iI_z9oRF49fzBAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Present value of lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,929,471</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplementary lease and cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447814865656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zfXZTA46Uurc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BC_zWmViDIqFdz5">Summarized quarterly financial data for fiscal years 2020 and
2019 is as follows</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20200101__20200331_z6rrFh6OByEd" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20200401__20200630_zZCpBW64XMCh" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20200701__20200930_z1pUNMwR3iT9" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20201001__20201231_zqnyUQTcCaf6" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands, except per share)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">First <br/>Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Second<br/>
Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Third</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Quarter<br/>
<sup id="xdx_F5E_zJhND2Sl5J81">(1)(2)(3)(4)</sup></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Fourth<br/>
Quarter <sup id="xdx_F52_zdpoaQjMzzkj">(5)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zTaRWi9Bojzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Revenues</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zTmPSvKBesW2" style="width: 12%; text-align: right">19,343</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20201001__20201231_fKDUp_zhou96xStL1h" style="width: 12%; text-align: right">22,577</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--GrossProfit_pn3n3_uUSD_z8GEljnynhu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--GrossProfit_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zs1jjBIXEGlf" style="text-align: right">16,064</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20201001__20201231_fKDUp_zyYD68qP7L1d" style="text-align: right">16,996</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_uUSD_zRDlTSpwFoXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(56,849</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(51,976</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20200701__20200930_fKDEpKDIpKDMpKDQp_zLc9X0tXDuF8" style="text-align: right">(32,611</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--NetIncomeLoss_pn3n3_c20201001__20201231_fKDUp_zhBCouQ7SyT6" style="text-align: right">(42,088</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zvJ1IxwcGY59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.21</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20200701__20200930_fKDEpKDIpKDMpKDQp_z2VZ6BcRKMdj" style="text-align: right">(0.12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20201001__20201231_fKDUp_zXBzDesZKu5k" style="text-align: right">(0.15</td><td style="text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="font-style: italic">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20190101__20190331_zLItBRipd1b6" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20190401__20190630_z7lyNgKXa7a3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20190701__20190930_zzkGCPzdaGPd" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20191001__20191231_zdHCdsnhGRia" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">2019</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands, except per share)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">First <br/>Quarter</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Second<br/>
Quarter <sup id="xdx_F56_zuZyx7yGIx28">(6)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Third</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Quarter <sup id="xdx_F5A_zgkjBnBWNqJg">(7)</sup></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fourth<br/>
Quarter</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_uUSD_zQUf9wuYvpl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%">Revenues</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190401__20190630_fKDYp_zhoa6OAP7HIa" style="width: 12%; text-align: right">6,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930_fKDcp_zl2c2NZrJHA8" style="width: 12%; text-align: right">23,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">15,902</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--GrossProfit_pn3n3_uUSD_zPfRErpHlX4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20190401__20190630_fKDYp_zUm7MmC9lhve" style="text-align: right">4,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20190701__20190930_fKDcp_zT6E6UN8L0Rh" style="text-align: right">22,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,023</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_pn3n3_uUSD_z6k5bp7JoxL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(39,506</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20190401__20190630_fKDYp_zGWN8WPLUUE8" style="text-align: right">(55,237</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_pn3n3_c20190701__20190930_fKDcp_zgG2QV0213Pc" style="text-align: right">(31,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(49,435</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_uUSDPShares_zjxeUGUvBbe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.16</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190401__20190630_fKDYp_zX8xMvGJPwJ8" style="text-align: right">(0.23</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--EarningsPerShareBasicAndDiluted_pip0_c20190701__20190930_fKDcp_z8zBgJdMGhQ3" style="text-align: right">(0.13</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(1)</td><td>During the third quarter of 2020, we recorded $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--KnightLicenseAgreementMember_znlN4bjOneM9">2 million</span> in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(2)</td><td>During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3p0_dm_c20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderWarrantsMember_zzstULDejUfg" title="Fair value of warrants">7.4 million</span> as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">During the third quarter of 2020, we wrote off approximately $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20200701__20200930_zbp5nfI78fAa" title="Write off of patent and trademark cost">0.6 million</span> in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(4)</td><td>During the third quarter of 2020, we recorded approximately $<span id="xdx_902_eus-gaap--InventoryWriteDown_pn3p0_dm_c20200701__20200930_zzpUeya085Mh" title="Inventory charge">5.7 million</span> in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(5)</td><td>During the fourth quarter of 2020, we wrote off approximately $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3p0_dm_c20201001__20201231_zzyk86lmPAse">0.5 million</span> in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(6)</td><td>During the second quarter of 2019, we recorded approximately $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_z3r1bzKRWu15" title="Loss on extinguishment of debt">10.1 million</span> in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(7)</td><td>During the third quarter of 2019, we recorded approximately $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zT1eC19R11qi">15.
                                                                 5 million</span> in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of
                                                                 Significant Accounting Policies.</td></tr></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F0A_zfLFhuE5BfRf" style="width: 0.25in">(1)</td><td id="xdx_F17_zPuPm7yI0if8">During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F0D_z9vclAeXaBF" style="width: 0.25in">(2)</td><td id="xdx_F1C_zTsLEb9IsUs1">During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F03_zF1DY0Wx71Nf" style="width: 0.25in">(3)</td><td id="xdx_F1B_zkzvmv0xaEa8" style="text-align: justify">During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F02_zwANq9PitIP1" style="width: 0.25in">(4)</td><td id="xdx_F10_zMH9wMYnGo54">During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F04_zNdRKYs8T8h6" style="width: 0.25in">(5)</td><td id="xdx_F17_zi3pMoIBCvwb">During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F00_zxjQ2fGLDGwc" style="width: 0.25in">(6)</td><td id="xdx_F1E_ziFSieJPBL67">During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"/>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; display: none"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td id="xdx_F04_zC6OWyYFKqnf" style="width: 0.25in">(7)</td><td id="xdx_F18_z8We1Rc08aQk">During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td></tr></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447814982344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>THE COMPANY (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Number</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSubsidiaries', window );">Number of subsidiaries</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiaires for period reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447811336616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning</a></td>
<td class="nump">$ 904,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable', window );">Increase in allowance</a></td>
<td class="nump">422,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="num">(181,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="num">(26,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 1,117,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable before recoveries and write-offs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447823322936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><sup>[2],[3],[4],[5]</sup></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><sup>[6]</sup></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><sup>[7]</sup></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td colspan="2" class="nump">$ 22,577,000<span></span>
</td>
<td colspan="2" class="nump">$ 19,343,000<span></span>
</td>
<td class="nump">$ 10,701,000<span></span>
</td>
<td class="nump">$ 12,251,000<span></span>
</td>
<td class="nump">$ 15,902,000<span></span>
</td>
<td colspan="2" class="nump">$ 23,719,000<span></span>
</td>
<td colspan="2" class="nump">$ 6,079,000<span></span>
</td>
<td class="nump">$ 3,947,000<span></span>
</td>
<td class="nump">$ 64,872,280<span></span>
</td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember', window );">Prescription Vitamins [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,767,644<span></span>
</td>
<td class="nump">9,885,493<span></span>
</td>
<td class="nump">15,041,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember', window );">Imvexxy [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,139,387<span></span>
</td>
<td class="nump">16,252,045<span></span>
</td>
<td class="nump">1,058,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaMember', window );">BIJUVA [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,353,963<span></span>
</td>
<td class="nump">1,836,443<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,611,286<span></span>
</td>
<td class="nump">6,166,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815427960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of calculation of diluted net loss per share allocable to common stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">39,781,592<span></span>
</td>
<td class="nump">28,102,805<span></span>
</td>
<td class="nump">24,920,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">23,781,930<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,534,687<span></span>
</td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">2,403,951<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">7,061,024<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447731460072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 06, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 06, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Number </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Number </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 08, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">$ 7,204,818<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatentsDomestic', window );">Number of issued patents domestic. | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatentsForeign', window );">Number of issued patents foreign | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write off of patent and trademark cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,131,776<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmortizationOfIntellectualPropertyLicenseFee', window );">Amortization of intellectual property license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,024,391<span></span>
</td>
<td class="nump">$ 778,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,799,313<span></span>
</td>
<td class="nump">$ 9,045,571<span></span>
</td>
<td class="nump">$ 1,682,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember', window );">Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid', window );">Maximum costs and expenses for post approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member', window );">Council License Agreement Step 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member', window );">Council License Agreement Step 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember', window );">License Agreement Theramex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CashUpfrontPaymentReceived', window );">Cash upfront payment received</a></td>
<td class="nump">&#8364; 14,000,000<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Council License Agreement Step 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | License Agreement Theramex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestone', window );">Sales milestone | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Council License Agreement Step 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | License Agreement Theramex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RegulatoryMilestoneAdditionalPayment', window );">Regulatory milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">&#8364; 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesMilestonePaymentsInTranches', window );">Sales milestone payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="nump">&#8364; 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestone', window );">Sales milestone | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Land and Building [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Land and Building [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember', window );">Customer A [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember', window );">Customer B [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember', window );">Customer C [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember', window );">Customer D [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member', window );">Financing Agreement Amendment No. 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment', window );">Minimum cash balance requirement under credit agreement before adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaMember', window );">BIJUVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,204,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member] | Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentUponFDAApproval', window );">Milestone payment upon FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch', window );">Milestone payments (payment after release of first commercial batch)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">License rights acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales', window );">Milestone payments upon specified levels of cumulative net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments', window );">Specified level one of cumulative net sales for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments', window );">Specified level two of cumulative net sales for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments', window );">Specified level three of cumulative net sales for milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_VitaminsImvexxyAndBijuvaMember', window );">Vitamins, IMVEXXY and BIJUVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member] | Knight License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentReceivedUponRegulatoryApproval', window );">Milestone payment received upon regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member] | License Agreement Theramex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_QuarterlyRoyaltyPaymentsPercentage', window );">Quarterly royalty payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmortizationOfIntellectualPropertyLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents amortization of intellectual property license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AmortizationOfIntellectualPropertyLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual net sale milestones in the Territory per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CashUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CashUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentReceivedUponRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment received upon regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentReceivedUponRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments upon FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable after release of first commercial batch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments due upon specified levels of cumulative net sales for under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetSalesAmountPerStepbasedRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net sales amount as defined in license agreement for step-based royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetSalesAmountPerStepbasedRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatentsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents domestic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatentsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatentsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents foreign.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatentsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_QuarterlyRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of quarterly royalty payments on net sales which the company is entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_QuarterlyRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RegulatoryMilestoneAdditionalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RegulatoryMilestoneAdditionalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of the net sales to be paid as royalty per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesMilestonePaymentsInTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales milestone payments per licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesMilestonePaymentsInTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents specified level one of cumulative net sales for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents specified level three of cumulative net sales for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents specified level two of cumulative net sales for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_VitaminsImvexxyAndBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_VitaminsImvexxyAndBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447811051016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory consists of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">$ 3,350,580<span></span>
</td>
<td class="nump">$ 4,976,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">219,918<span></span>
</td>
<td class="nump">1,182,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">4,422,589<span></span>
</td>
<td class="nump">5,701,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 7,993,087<span></span>
</td>
<td class="nump">$ 11,860,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447811268872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidSalesAndMarketingCostsCurrent', window );">Prepaid sales and marketing costs</a></td>
<td class="nump">$ 4,308<span></span>
</td>
<td class="nump">$ 1,583,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing fees on undrawn tranches (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">550,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">2,568,269<span></span>
</td>
<td class="nump">1,812,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturing', window );">Prepaid manufacturing</a></td>
<td class="nump">1,331,100<span></span>
</td>
<td class="nump">2,595,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">3,639,720<span></span>
</td>
<td class="nump">4,787,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 7,543,397<span></span>
</td>
<td class="nump">$ 11,329,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidSalesAndMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid sales and marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidSalesAndMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447818025608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed assets, net consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 3,683,671<span></span>
</td>
<td class="nump">$ 3,476,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,741,447)<span></span>
</td>
<td class="num">(968,824)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS, NET</a></td>
<td class="nump">1,942,224<span></span>
</td>
<td class="nump">2,507,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">411,550<span></span>
</td>
<td class="nump">301,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,704,931<span></span>
</td>
<td class="nump">1,619,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,406,858<span></span>
</td>
<td class="nump">1,406,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">80,211<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 80,121<span></span>
</td>
<td class="nump">$ 68,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447823335384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 772,624<span></span>
</td>
<td class="nump">$ 415,193<span></span>
</td>
<td class="nump">$ 181,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447817993576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">$ (748,627)<span></span>
</td>
<td class="num">$ (478,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="nump">5,996,350<span></span>
</td>
<td class="nump">5,737,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,247,723<span></span>
</td>
<td class="nump">5,258,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTrademarks', window );">Indefinite-Lived Trademarks</a></td>
<td class="nump">323,341<span></span>
</td>
<td class="nump">294,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">323,341<span></span>
</td>
<td class="nump">294,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">4,044,552<span></span>
</td>
<td class="nump">3,463,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(748,627)<span></span>
</td>
<td class="num">(478,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 3,295,925<span></span>
</td>
<td class="nump">$ 2,984,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 1,628,457<span></span>
</td>
<td class="nump">$ 1,979,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 1,628,457<span></span>
</td>
<td class="nump">$ 1,979,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447812591928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 274,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">274,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">274,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">274,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">$ 274,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447821702680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill) | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,131,776<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,546<span></span>
</td>
<td class="nump">$ 197,593<span></span>
</td>
<td class="nump">$ 112,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember', window );">Domestic US Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember', window );">Foreign Patents Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember', window );">Domestic Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember', window );">Foreign Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember', window );">Domestic Patents Non-Approved Bijuva [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember', window );">Domestic US Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember', window );">Domestic US Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember', window );">Domestic US Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember', window );">Foreign Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember', window );">Foreign Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember', window );">Foreign Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember', window );">Domestic Utility Patent Topical Cream Candidates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember', window );">Domestic Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember', window );">Foreign Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember', window );">Domestic Utility Patent TX009HR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember', window );">Domestic Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember', window );">Foreign Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember', window );">Domestic Utility Patent Opera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815625496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">$ 8,758,073<span></span>
</td>
<td class="nump">$ 8,040,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">6,770,206<span></span>
</td>
<td class="nump">10,316,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">227,500<span></span>
</td>
<td class="nump">3,285,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">2,353,996<span></span>
</td>
<td class="nump">1,463,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">2,632,432<span></span>
</td>
<td class="nump">2,347,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">898,568<span></span>
</td>
<td class="nump">422,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">925,314<span></span>
</td>
<td class="nump">1,049,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,253,994<span></span>
</td>
<td class="nump">1,501,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">11,010,588<span></span>
</td>
<td class="nump">3,916,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">2,339,198<span></span>
</td>
<td class="nump">1,480,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 38,169,869<span></span>
</td>
<td class="nump">$ 33,823,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815399432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="num">$ (12,302,469)<span></span>
</td>
<td class="num">$ (5,365,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">TOTAL LONG-TERM DEBT</a></td>
<td class="nump">237,697,531<span></span>
</td>
<td class="nump">194,634,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447814996872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths', window );">2021</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">2022</a></td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">2023</a></td>
<td class="nump">133,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">2024</a></td>
<td class="nump">41,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive', window );">2025</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447725109592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2019 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[6]</sup></th>
<th class="th" colspan="2">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 08, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 08, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 05, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,577,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 19,343,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4],[5]</sup></td>
<td class="nump">$ 10,701,000<span></span>
</td>
<td class="nump">$ 12,251,000<span></span>
</td>
<td class="nump">$ 15,902,000<span></span>
</td>
<td colspan="2" class="nump">$ 23,719,000<span></span>
</td>
<td class="nump">$ 6,079,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 3,947,000<span></span>
</td>
<td class="nump">$ 64,872,280<span></span>
</td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">81,660,719<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,534,687<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,534,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">$ (10,100,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,429<span></span>
</td>
<td class="nump">856,302<span></span>
</td>
<td class="nump">269,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,379<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember', window );">Lender Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,752,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,428,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member', window );">Financing Agreement Amendment No. 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member', window );">Financing Agreement Amendment No. 6 [Member] | Lender Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,428<span></span>
</td>
<td class="nump">736,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,902,270<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,902,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense, Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,049,236<span></span>
</td>
<td class="nump">14,709,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Second quarter of 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Third quarter of 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Fourth quarter of 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Second quarter of 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Third quarter of 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Fourth quarter of 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Second quarter of 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Third quarter of 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - Fourth quarter of 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">65,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Subsequent Event [Member] | Financing Agreement Amendment No. 8 - First quarter of 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtTrancheAxis=txmd_TrancheTwoMember', window );">Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt Issuance Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,626,891<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,626,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3-month
LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfInstallmentPayments', window );">Number of quarterly principal installment payments | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FacilityFeePaidPercent', window );">Facility fee paid (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">prime
rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrimeRateFloor', window );">Prime rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable', window );">Line Of Credit Facility Undrawn Tranche No Longer Available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayment by March 31, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal repayment</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments on March 31, 2022, June 30, 2022 and September 30, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal repayment</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments on December 31, 2022 and March 31, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal repayment</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal repayment</a></td>
<td class="nump">$ 41,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments through March 31, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayment on March 31, 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal repayment</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments from April 1, 2022 through March 31, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member', window );">Financing Agreement Amendment No 8 [Member] | Subsequent Event [Member] | Repayments from April 1, 2023 through March 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentOfDebtWithNewCreditFacility', window );">Repayment of debt with new credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentFeePercentage', window );">Repayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,816,747<span></span>
</td>
<td class="nump">4,407,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,146<span></span>
</td>
<td class="nump">$ 269,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfTranchesUnderTermLoanFacility', window );">Number of tranches under term loan facility | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="22"></td></tr>
<tr><td colspan="22"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FacilityFeePaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FacilityFeePaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiborFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents libor floor rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiborFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an undrawn tranche under a financing agreement that is no longer available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumRevenueRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum consolidated net revenue requirements attributable to commercial sales under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumRevenueRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of principal installment payments under credit and security agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfTranchesUnderTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seperate tranches under terms of the Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfTranchesUnderTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee, expressed as a percentage of the tranche funding being repaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrimeRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prime rate floor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrimeRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The repayment fee, expressed as a percentage of the tranche funding being repaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentOfDebtWithNewCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentOfDebtWithNewCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period11Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period11Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period13Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment8Period13Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementAmendment8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=txmd_RepaymentPeriodEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447827275640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of our Warrant activity during the year ended December 31, 2020: (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares under warrants outstanding beginning | shares</a></td>
<td class="nump">1,832,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants outstanding beginning | $ / shares</a></td>
<td class="nump">$ 2.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, warrants outstanding</a></td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, warrants outstanding beginning | $</a></td>
<td class="nump">$ 2,447,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares under warrants granted | shares</a></td>
<td class="nump">4,752,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants granted | $ / shares</a></td>
<td class="nump">$ 1.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Cancelled/Forfeited | shares</a></td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants cancelled/forfeited | $ / shares</a></td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares under warrants outstanding ending | shares</a></td>
<td class="nump">6,534,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants outstanding ending | $ / shares</a></td>
<td class="nump">$ 1.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne', window );">Weighted average remaining contractual life, warrants outstanding</a></td>
<td class="text">7 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, warrants outstanding ending | $</a></td>
<td class="nump">$ 1,041,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of shares under warrants vested and exercisable ending | shares</a></td>
<td class="nump">6,534,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsUnvestedWeightedAverageExercisePrice', window );">Weighted average exercise price warrants unvested ending | $ / shares</a></td>
<td class="nump">$ 1.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, vested and exercisable ending</a></td>
<td class="text">7 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue', window );">Aggregate intrinsic value, vested and exercisable ending | $</a></td>
<td class="nump">$ 1,041,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsUnvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which warrant holders can acquire the shares reserved for issuance on warrants outstanding and unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsUnvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447812747480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceOtherThanOptions', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">68.80%<span></span>
</td>
<td class="nump">60.80%<span></span>
</td>
<td class="nump">62.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815745784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 5.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - minimum</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - maximum</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility - minimum</a></td>
<td class="nump">63.53%<span></span>
</td>
<td class="nump">61.25%<span></span>
</td>
<td class="nump">59.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility - maximum</a></td>
<td class="nump">67.92%<span></span>
</td>
<td class="nump">64.49%<span></span>
</td>
<td class="nump">64.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815661656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, beginning | shares</a></td>
<td class="nump">25,030,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning | $ / shares</a></td>
<td class="nump">$ 4.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning | $</a></td>
<td class="nump">$ 3,668,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares under options, granted | shares</a></td>
<td class="nump">736,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 1.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares under options, exercised | shares</a></td>
<td class="num">(1,182,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">$ 0.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised | $</a></td>
<td class="nump">$ 1,738,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares under options, expired | shares</a></td>
<td class="num">(386,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired | $ / shares</a></td>
<td class="nump">$ 3.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares under options, cancelled forfeited | shares</a></td>
<td class="num">(416,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled forfeited | $ / shares</a></td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, ending | shares</a></td>
<td class="nump">23,781,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending | $ / shares</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending | $</a></td>
<td class="nump">$ 152,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares under options, vested and exercisable ending | shares</a></td>
<td class="nump">19,862,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and exercisable ending | $ / shares</a></td>
<td class="nump">$ 5.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, vested and exercisable</a></td>
<td class="text">4 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, vested and exercisable ending | $</a></td>
<td class="nump">$ 117,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares under options, unvested ending | shares</a></td>
<td class="nump">3,919,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, unvested ending | $ / shares</a></td>
<td class="nump">$ 3.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, unvested</a></td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, unvested ending | $</a></td>
<td class="nump">$ 34,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447818321672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of restricted stock units and performance stock units (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, number of shares | shares</a></td>
<td class="nump">1,240,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, number of shares | shares</a></td>
<td class="nump">6,152,818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested/Released, number of shares | shares</a></td>
<td class="num">(301,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested/Released, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, number of shares | shares</a></td>
<td class="num">(30,294)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, number of shares | shares</a></td>
<td class="nump">7,061,024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, number of shares | shares</a></td>
<td class="nump">2,585,745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested/Released, number of shares | shares</a></td>
<td class="num">(151,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested/Released, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, number of shares | shares</a></td>
<td class="num">(30,294)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, number of shares | shares</a></td>
<td class="nump">2,403,951<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The number of performance stock units (PSUs) represents the base number of PSUs that
may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the
Company&#8217;s achievement of break-even quarterly EBITDA.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447726191592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Nov. 20, 2020</div></th>
<th class="th"><div>Nov. 13, 2020</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Jun. 18, 2020</div></th>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
<th class="th"><div>Feb. 08, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Nov. 08, 2020</div></th>
<th class="th"><div>Aug. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,765,396<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,765,396<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,702,635<span></span>
</td>
<td class="nump">$ 77,031,258<span></span>
</td>
<td class="nump">$ 89,907,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,097<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="nump">9,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,702,635<span></span>
</td>
<td class="nump">$ 77,031,258<span></span>
</td>
<td class="nump">$ 89,907,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,534,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,678,992<span></span>
</td>
<td class="nump">$ 10,693,662<span></span>
</td>
<td class="nump">8,661,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,781,930<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,235,585<span></span>
</td>
<td class="nump">$ 8,798,707<span></span>
</td>
<td class="nump">8,091,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock or Unit Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,399,472<span></span>
</td>
<td class="nump">$ 1,628,407<span></span>
</td>
<td class="nump">$ 73,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,285,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,305,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,190,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,583,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member', window );">Financing Agreement Amendment No. 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares under warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,752,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants', window );">Number of stock issued in cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,534,687<span></span>
</td>
<td class="nump">1,832,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember', window );">Lender Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,752,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember', window );">Lender Warrants [Member] | Financing Agreement Amendment No. 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares under warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 13,  2024<span></span>
</td>
<td class="text">Mar. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non cash compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,446<span></span>
</td>
<td class="nump">$ 254,970<span></span>
</td>
<td class="nump">$ 494,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember', window );">Underwriting Agreement Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,515,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MaximumCommonStockOfferingPrice', window );">Maximum Common Stock Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FixedCommissionRate', window );">Fixed Commission Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember', window );">Underwriting Agreement Cantor Fitzgerald [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">59,459,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="nump">8,918,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 97,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember', window );">Underwriting Agreement Cantor Fitzgerald [Member] | Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember', window );">Underwriting Agreement JP Morgan Chase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember', window );">Underwriting Agreement Goldman Sachs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,745,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,911,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember', window );">Subscription Agreement Knight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,921,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,182,195<span></span>
</td>
<td class="nump">331,619<span></span>
</td>
<td class="nump">5,444,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,678<span></span>
</td>
<td class="nump">$ 108,656<span></span>
</td>
<td class="nump">$ 1,666,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,061,024<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | 2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,171,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,403,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FixedCommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fixed commission rate of the aggregate gross sales price per share sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FixedCommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MaximumCommonStockOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price of common stock shares permitted to offer and sell under sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MaximumCommonStockOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PeriodExercisableUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period the option is exercisable per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PeriodExercisableUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital by public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnderwritersOptionGrantedInPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares available to be purchased per underwriter's option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_UnderwritersOptionGrantedInPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=txmd_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447812725176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contribution percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DefinedContributionPlanMaximumEmployerMatchingContribution', window );">Maximum matching contribution per year</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DefinedContributionPlanVestingServicePeriod', window );">Defined contribution plan vesting service period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions under plan</a></td>
<td class="nump">$ 487,000<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DefinedContributionPlanMaximumEmployerMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount employer matches of the employee's contribution per year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DefinedContributionPlanMaximumEmployerMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DefinedContributionPlanVestingServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The service period after which matching contributions vest in the defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DefinedContributionPlanVestingServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813271176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>For financial reporting purposes, (loss) income before taxes includes the following components: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="num">$ (183,524,137)<span></span>
</td>
<td class="num">$ (177,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="num">$ (183,524,137)<span></span>
</td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447812747480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="num">(22.50%)<span></span>
</td>
<td class="num">(31.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Excess stock benefits</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Federal income tax rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other differences</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447818147208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Income Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 195,008,131<span></span>
</td>
<td class="nump">$ 157,555,975<span></span>
</td>
<td class="nump">$ 126,419,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share based compensation</a></td>
<td class="nump">17,251,900<span></span>
</td>
<td class="nump">13,913,568<span></span>
</td>
<td class="nump">11,640,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest expense limitation</a></td>
<td class="nump">12,991,716<span></span>
</td>
<td class="nump">5,389,129<span></span>
</td>
<td class="nump">1,173,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">4,818,935<span></span>
</td>
<td class="nump">3,662,037<span></span>
</td>
<td class="nump">1,658,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D credit</a></td>
<td class="nump">186,347<span></span>
</td>
<td class="nump">186,347<span></span>
</td>
<td class="nump">186,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax asset</a></td>
<td class="nump">230,257,029<span></span>
</td>
<td class="nump">180,707,056<span></span>
</td>
<td class="nump">141,078,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(230,257,029)<span></span>
</td>
<td class="num">(180,707,056)<span></span>
</td>
<td class="num">(141,078,111)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred income tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813732328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 49,549,973<span></span>
</td>
<td class="nump">$ 39,628,945<span></span>
</td>
<td class="nump">$ 41,295,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">761,701,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Expiration Period 20 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 338,775,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NolCarryForwardPeriod', window );">NOL carryforward period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OperatingLossCarryforwardsExpirationYear', window );">NOL carryforward expiration year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Expiration Period Indefinite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 422,926,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NolCarryForwardPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period of operating loss carryforward included in operating loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NolCarryForwardPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration year of operating loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriod20YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=txmd_ExpirationPeriod20YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriodIndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=txmd_ExpirationPeriodIndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447822387304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_CatalentMember', window );">Catalent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Amount billed</a></td>
<td class="nump">$ 3,036,000<span></span>
</td>
<td class="nump">$ 6,101,000<span></span>
</td>
<td class="nump">$ 4,111,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Amounts due to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_AmericanInternationalGroupMember', window );">American International Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Amount billed</a></td>
<td class="nump">$ 209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_CatalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_CatalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_AmericanInternationalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=txmd_AmericanInternationalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447827292408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfVendors', window );">Number of vendors - suppliers | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember', window );">Supplier One Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember', window );">Supplier 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember', window );">Supplier 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCustomers', window );">Number of customers - revenue | Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCustomers', window );">Number of customers - revenue | Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember', window );">Cardinal Health - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 17,489,000<span></span>
</td>
<td class="nump">$ 4,551,000<span></span>
</td>
<td class="nump">$ 2,308,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember', window );">PillPack - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">13,228,000<span></span>
</td>
<td class="nump">12,676,000<span></span>
</td>
<td class="nump">5,075,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember', window );">McKesson Corporation - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 9,862,000<span></span>
</td>
<td class="nump">3,911,000<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember', window );">AmerisourceBergen - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,927,000<span></span>
</td>
<td class="nump">$ 3,246,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of vendors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815661688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental lease information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 9,565,700<span></span>
</td>
<td class="nump">$ 10,109,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability (included in Other current liabilities)</a></td>
<td class="nump">$ 2,253,994<span></span>
</td>
<td class="nump">$ 1,501,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">$ 8,675,477<span></span>
</td>
<td class="nump">$ 9,145,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities for operating lease</a></td>
<td class="nump">$ 1,617,645<span></span>
</td>
<td class="nump">$ 1,164,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">$ 998,821<span></span>
</td>
<td class="nump">$ 11,171,471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447811417592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,334,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,413,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,443,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,476,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">1,513,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">7,434,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">15,615,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4,685,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 10,929,471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447813777512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 02, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jul. 01, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetRentableAreaLease', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RentedAreaLease', window );">Rented area lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalAreaOfLeaseOccupied', window );">Additional rented area occupied under the lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber', window );">Number of options to extend lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea', window );">Lease not yet commenced (area) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 2,325,844<span></span>
</td>
<td class="nump">$ 1,558,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable lease payment</a></td>
<td class="nump">$ 423,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,068,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SignificantSupplyCommitmentPercentagePayable', window );">Significant supply commitment percentage payable</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember', window );">Catalent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Minimum purchase commitment, 2021</a></td>
<td class="nump">$ 3,458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Minimum purchase commitment, 2022</a></td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Minimum purchase commitment, 2023</a></td>
<td class="nump">2,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">Minimum purchase commitment, 2024</a></td>
<td class="nump">3,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">Minimum purchase commitment, 2025</a></td>
<td class="nump">3,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Minimum purchase commitment, 2021</a></td>
<td class="nump">$ 1,526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalAreaOfLeaseOccupied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional rented area occupied under the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalAreaOfLeaseOccupied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future rented area to be occupied for administrative office space as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetRentableAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetRentableAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RentedAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rented area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RentedAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SignificantSupplyCommitmentPercentagePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SignificantSupplyCommitmentPercentagePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447815332424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 22,577,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 19,343,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4],[5]</sup></td>
<td class="nump">$ 10,701,000<span></span>
</td>
<td class="nump">$ 12,251,000<span></span>
</td>
<td class="nump">$ 15,902,000<span></span>
</td>
<td class="nump">$ 23,719,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 6,079,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 3,947,000<span></span>
</td>
<td class="nump">$ 64,872,280<span></span>
</td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">16,996,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,064,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4],[5]</sup></td>
<td class="nump">6,301,000<span></span>
</td>
<td class="nump">9,536,000<span></span>
</td>
<td class="nump">13,023,000<span></span>
</td>
<td class="nump">22,275,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">4,830,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">3,184,000<span></span>
</td>
<td class="nump">48,897,303<span></span>
</td>
<td class="nump">43,312,352<span></span>
</td>
<td class="nump">13,361,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (42,088,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (32,611,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4],[5]</sup></td>
<td class="num">$ (51,976,000)<span></span>
</td>
<td class="num">$ (56,849,000)<span></span>
</td>
<td class="num">$ (49,435,000)<span></span>
</td>
<td class="num">$ (31,967,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">$ (55,237,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="num">$ (39,506,000)<span></span>
</td>
<td class="num">$ (183,524,137)<span></span>
</td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share, basic and diluted</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4],[5]</sup></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write off of patent and trademark cost</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,131,776<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,204,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,057,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember', window );">Lender Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,428,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember', window );">Knight License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember', window );">License Agreement Theramex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer
to discussion in Note 6-Intangible Assets, Net.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer
to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related
to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately
$7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term
of the Financing Agreement. Refer to discussion in Note 8-Debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks
and patents. Refer to discussion in Note 6-Intangible Assets, Net.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License
Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the
repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140447731431304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Nov. 20, 2020</div></th>
<th class="th"><div>Nov. 13, 2020</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Feb. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,702,635<span></span>
</td>
<td class="nump">$ 77,031,258<span></span>
</td>
<td class="nump">$ 89,907,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Financing Agreement Amendment No. 7 - Fiscal Quarter Ending March 31, 2021 [Member] | IMVEXXY, BIJUVA and ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Financing Agreement Amendment No. 7 - Fiscal Quarter Ending June 30, 2021 [Member] | IMVEXXY, BIJUVA and ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumRevenueRequirementUnderCreditAgreement', window );">Minimum revenue requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember', window );">Underwriting Agreement Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,515,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember', window );">Underwriting Agreement Cantor Fitzgerald [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">59,459,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">$ 97,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="nump">8,918,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumRevenueRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum consolidated net revenue requirements attributable to commercial sales under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumRevenueRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PeriodExercisableUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period the option is exercisable per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PeriodExercisableUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnderwritersOptionGrantedInPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares available to be purchased per underwriter's option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_UnderwritersOptionGrantedInPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment7Period1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment7Period1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment7Period2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementAmendment7Period2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementCantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M\SI>!R,TIN_B;ET00EL(">::PYV1A8:A0(0D(Y%"4B&W(K W.:Y^_P.#-*7
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MNI+<;]_O3[38YAO:2Z&UB//##6<!E]D-<'TEA#Z<9 \HOT09_ =02P,$%
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M[QY6WDK*CJ!+?;#/J)#7!-U,Y4T.,64@Y^>4BH^.NBO4=\/A/U!+ P04
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MX.@X<JU"P7:)\D7HX3;'>Z\OPUO!A!W:"B:L?2N05IL0Q]KFJKT.'1RI=5C
MN]XB5$E4R\HDW6H1VQ0Y:44"L8N$][A9AS(%M?$;'))W/O4TN1GF=WN:&>;R
M@2BV8H$0*[UOU5&. ,6Z S&T$BC?9@M@"BT=<BN#1*LX0]??:J6!,O3]4P-
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MO]_D>?7C0GXN?OA/B_F_4$L#!!0    (  2>8U)<I!W37@D  " I   8
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M87GT&!,D$>,FC1PXAW^1/X%_CPQ0+_Y;73YF#:4#1AG,R\U]O=CD$#!GY:;
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MK^.U7^IRW5Q0NR_KNEPU'Y<JG2MM!.#OB[*L7[Z8"7:7(L__#U!+ P04
M"  $GF-2J[%/TW0'   >$0  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;)U8:W/;MA+]SE^!46<ZS8PL6;+3I(WM&?F1QNWUX\:)VTZG'R!R26(" @P
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M+>,<S@9XGEL;^A]\P/ OD8/_ 5!+ P04    "  $GF-20'%ZU-,M  !1A0
M&    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;+5]:X_;1M+N=_X*PF^P2 #.
M>#1WYP:,Q_:N]TUBPY/+NS@X'RBQ)7%-D0HO,];^^E/U5%5W4Z*<Y!P<8#<>
M2>Q;=7754Y<N?OO4M!^[M7-]^FE3U=UWS]9]O_WZ^?-NL7:;O#MMMJZF7Y9-
MN\E[^MBNGG?;UN4%&FVJY^=G9]?/-WE9/_O^6WSWOOW^VV;HJ[)V[]NT&S:;
MO-V]=%7S]-VSV3/[XD.Y6O?\Q?/OO]WF*_?@^E^V[UOZ]-SW4I0;5W=E4Z>M
M6W[W[&[V]<M+?AX/_%JZIR[Z.^65S)OF(W]X6WSW[(PGY"JWZ+F'G/YY=/>N
MJK@CFL;OVN<S/R0WC/^VWM]@[;26>=ZY^Z;ZK2SZ]7?/;I^EA5OF0]5_:)[^
MX70]5]S?HJDZ_#=]DF<O+YZEBZ'KFXTVIAELREK^S3\I':(&MV='&IQK@W/,
M6P;"+%_E??[]MVWSE+;\-/7&?V"I:$V3*VO>E(>^I5]+:M=___#+CS_>??A7
M^NY-^O#V[S^]??/V_NZGG].[^_MWO_ST\]N?_IZ^?_?#V_NWKQ^^?=[3>-SJ
M^4+[?BE]GQ_I>W:>_MC4_;I+7]>%*\8=/*>)^MF>VVQ?GG^VQU=N<9I>S++T
M_.S\[#/]7?C57Z"_BR/]W2T6S5#W9;U*WS=5N2A=E_ZONWG7M\0M__LS USZ
M 2XQP.7_%_)^ON^?WOW\.CU/__9?M^>SV3?I]%#)Q%#I^[:L%^6VHM4VR_2^
MJ3M:?)'CF/R\=G14%LUFF]<[)LS"_^R*=%G6.37-JZ3KZ0LZG7V74F?54+BT
MUZ8#?TD=-T.;:D=I7A?X_+1NJFJ7-D\U]=8-\ZXLRKPENF?I8]GG/[HB2U\V
MB_SOK7,U6OU*7]_GK3M-[ZJ*QNI=JYTF\[RBV= J^#G:L[K+<=:[=)T_NG3.
M7;BJI&.#R9=UM!AZ[#3]4'8?I?4OU$_;DQ#KF0=^<_PD\<5 JVJH(Y[JOTF0
M\*?6&B7#J%%._R,YU9$\X-4S->[?_?KVU<GL14K3+=RF).YE^KI//1'.'EH.
M_="ZM*0U+8ZW3&EOF(#SH2,^Z#H_P2Z1&:Y)_A!E_9RPK*)<+LL%SX@>(JE=
ME(O^=']YV[9Y+&G_\II:@\#ML.VQ/]LM;Y9LY;9I^R41K^$OJ$TQ+&B?22\D
M6R(G<P)Z!NF[@<?E+XGJC_1/TZ(?XI^2A%5A[7GX#>N>G*9#+(E]HO7RW&D)
M3(G:Y:W2B%B@*$K>NIR8*$N?:!U#VU+WU2XIFK1N>IZ/ZQPO9I?ZM3!CET*_
M?%Y69;_C@6,:T(C#DNC/.Y'[0>)I$HF'CF8W=[N&V6U==NG6M653@!?VERWJ
M)MVN<](="S?0\G)FWQ5O HX-S6G-ZZ098Z$VG6(T&2.^TOLT?36T?"RYQ8Y)
MXUBV)B09W6;N6B\=09W6+9J6?N:M#?NPH#FMT/,7Z4UV?G:9W<YNTP<ZQG*&
MJ5?:=9IYYXZR8Y8\N>B4,5.N<)Y[WDE:Z6/9]@/]VVSE1!(%297SBO8YF';C
M-'U':[233O+)=8NVE'U[<.UCR8=<N2S=-(6KDKSKRJ[WWW;8WSDS/L_$Y9W(
M'!J#EJT[LN!1:2*THI))&D8!'P>FSGL<9>JMLAW<*2FHX6+=T(2R1.0>#_=8
MYNFZV3ABW8IVG6A\T%B&"2<DKSHZ>7G;UXXX@K1^OZ8E%&[+^TFS)1FWH=/8
M[ZR/4N7<ADXSR^Z$.+ M3K@+ZA[:8?_1GL#/AL\\?I-3WA(%UCF?$T(7S(.\
M"Z3NG%";J$!"O=GFQ.O1GGDJ8^Z$_JJ3GK!9$F@Z;V@!),M7=4,;HQ+9Y3VK
MB .)PX*%I(EM ?%M!S5V\PT==U=T0HXNWT!'<5]V$ F'T9DCXM$JVF98K1,^
M'5W.S]$6+DA&O%W:5M,\:("^):''>L4XEK!JQ;MFK$F<LZV( G82.Q>&P=2Q
M5\+LA[R;4-M:)EG6RS:G\08YNKY?$)Q$5O,D?,8\X@^(.RG *YC1_F&_Z\ C
M]@.M9DLS=LK$_E@F_ECR(DLF&].=10F=!)H+MHCX;%CPVMJ/#IC'?2)NZX1R
M$!IAM7$?BZ;KB<2/W,3ZHX'6Y6)MNK](:K=JZ."C7UHH2:*E8WS!!D#'3 T!
M86=YV3:;% R<"@/3(2V:MOLF#,S/YX8?3IY80='S_*WM*6W>-WSB<L8I"8VT
M8#10@9)U4Y\09YG4%>N%&;QWBW7=5,UJQV1FG4Z#\N894+#6M,M.1!D=CT=7
M92E3 ZJ5IY=!;]'#F;1FX9H8047-+P<&+)]7ZXE7XSAMCTWU2"S\#R(@B1&5
MX6Q;01Z4/6^'[KW[Y!:#G%F#6BT=*F+<=-70'F9$FFY;]B+3FWK5\,HF!#GA
M%OJ+V*IO#2:!Y^8[M*0=IG/<"3OK*6QYN7R4Y0R2L:?L<]?92ADO\M]EUPV\
M+?I]Y_X84&8Q+%*L1(L6AIL&1YM\MZ?.Y?R2'K,-( KYP?A9T?$9'<;?!P*A
M_2YC%A+\)O"5M'LN$D+VH O@2@Y*ZZ4:-')#$+"#..3M62Z!%S^'Y:(1B-BT
M!27I9^9E;B5&-@"ZM8=0I9\>"3$W)+T-[<:'%;AF,\]E:#]BM%/\/9G*57&:
MOGYDD+TD6AWA3L( BM)5@.X3FCF>X#MO<%X0RW8&9,'/(\"ZAX\9H!$\J1N>
M'@$5>D05$"G!5CXED)P\B68!I%= 0=$<\-D@HJ'#W]9EY4:HD-!)51*SB@CF
MZ7B1*:M8T=1W+*9K# ,3)B!$.G'E*M<CI#OZ9P&Z<'''YYA[TV9>'"1_#N4_
ME21#!!7P;WE:#X!YC*6I(Q*96>IQ2$;M>J!@EF7"#3*-8A!& PO9G!*=4U >
MHT?I5U;*YV??= T.35$RNB,PL<+W9',RN&QUI48VE4:12L;)$(V\)N30KQ=\
M<CP>2<0$V30L,"+MEWG1 Q4]U([8O-F)\!5A0+9F59A>"UB$9259B3QG&9#:
MD]:"&&)5AU$4T62T$7240# ^Q=M\YUB6$HGR5?2XGY0=PK%@W]_ 5=60=6H6
M%"'NDD0-R2-^7N;.- CR)&$ K")O6@;QN%Y6Z<KG+I9T>@#Y+[ J&RL[49 "
M<O*=&.S8HIXWLQ!]NG#E8SXG3)EOQ'I7(Z=FM5E90]*=[88H$"^*F4(M+/HE
M&)]BPTU12PRS$ECA41 "$7?5YIM.CKM*F8$(2GU]%/8I"A8)D02'0R%0AR93
M58Z.L\);[83.",F%'SS9@GY:"N(R-05S[JZN"9$E'QS *>TD._[2V=G)?V>B
M8?-NG:K3(7UB>39O'D4XM(Z&8/ED/ZOV?",3II'NR/*#D$Z_A,:EI8BR_8D9
M_S8](1MNWG]%IA!_]2C6W&UDS)D+)?::""9!/T2E.^J^P! _-:?IM2&%B3ED
M3/;1X\EU)JB;6]P5&S;4&1 P5+U;?6;:*:;M-[IB^Z7M%-;1-V0)D1#:#BWC
M@$B1/Y$%0R>:$$M;$C<!,SKI@P??#)M U!'A@1V_2*_/TLLK_J\'2^429,*Y
MZ@9( X)@?E5)$ OE?[R(>_OCKZ__YW_^E:4OW_[SEU_OA# __?3NU]<?[M#E
M8:NRDT/%*I&>+I=[YOLTY$N.RGCJC_1Q!R55RTZ;,T3XSGVBO8 OCNG _HV6
M3PXS^-Q!MGFW [ /,8-"QFU5"K,2#9)C_,C"CK[M!:W3&KOE#N,&<:,[(>*#
M/::5D9K%AIAT1G 6#1'-G"=Q8B1F7C$:"U2>FA;L$!V8!NW&:U,Y8ZSR^T#\
MYN"W4(Q:NX!3X^DG7@6R=X(9-!@4CRX0 P?QQ[PE5A67R@RG\#,'[O9/'[@$
MCT^<"J(-P<"5SBNWYU7%VF)'"/K8.M.\IT41(+ ="IN2B'*>XOYX:U(^D=QW
MV3D"BP_.V:$WGS,???^!567.1H<Y59((\GNB_HPO(,NP1N@4 W)3; "[6_QO
MBI!9(%0-%!V/&=@\$8^/8 +9TGV?WXH=^*/3U[2RI[*C(R^R:1(#D4^F=.>N
M=GSBV#@<H]S3Y&TDA8STGFWC71SJX)P823C:A<4: [*N5#'2-SV-9FV/;3IL
M&!#VJ03=-ZRIO5R/3OKR.*<"IO!>LAJ,#,QF7C$:!FF@G8]UD:AD*MRBRG%8
M-NR&(G:ER12#;#^!"B:/03FAK;C&/*CQ-H5A[WV(/0F5P 83MMYI>L]4_LU%
M8H2_8&^8?YJD:5_V@W0DCALZGN5&Y:W[M'"JI=ZX C+D%<&%KNS3MQYCWJLE
M#OM2O;MO7KV]SP2'ND+@9B<NV/.KL^SL["S]N<T+TK460/G@49D<2G8?@<F9
MYU\UP[QGY>8?E]8^_-)&K=E,1231M4F\A[P3LH^*\WKT@1,) Y>/OGN:[)0G
M06BOJ1!>Q3#V% XA>[E)L^1MH>[F>;[X*#L3A1MR6Q3Z*VQ1UI5W,G6(O!;I
ML(4-I/,Z"F.I(<$YMJ47V/]*8\!)Y ABWLF[1HZH^B-M98[8PJ"^U[W>5O7\
M)$OU;O;Q@L Z;,="%DL@HU=\#:MYH=;ZW-D,6<@2U=UC7@TP.H]N*:A%0JG^
M?6#[%<V>VA)0=AE^Z6.:I/F*?1@]'*9_0'@E-Z(F14F[Q8Y*W5.=G@!^@;[^
M# 92\XDEBBH1.UINN63:E>UBV,",=!WK!V-,8S@0DO]A$U5TE)_4EO>]&3J6
M:"W[PFHL]VGM:ETH1SHZ"78$IQ6,T\GU)M8UJ25SJL';1)HUYXU5)SAQT6*H
MU _ TH@X@D44':&&_L,&=\[^"!%PK5LR$8B&',J:@P;%OVF=HI8%(W3.XSB3
MEH9V)1A"+-+ ]<[C"^5)YW4JAL+ZU/=G9!1,-FD(TCF$?40DB<SP*G\BK6'V
MKFQ7Z\K-G*")Z@//^7#+P)LLIU^#GSOV>[&+H+= 1M7PP6N\&7SHYV'WI+<<
MD_WVT%7BPYGP6*:FX_RR3SR#J5.$@\7]FCU>WNL?) +1A;<LN*Z*I"M7-;=G
M+#:B-HGLGN4/;48',8=S#;,FV. 3"DMM -@JVZ973W+,!ZJ!:1-:^*]5-/#7
M./?QT=WS<]WUZ42\;\F,P %?![H%EFB=RB$B[_E52J2<W:2S67IQG9[/TMDU
M_\T@G#-]6-*9H:4S_"-9478)'UA2GU7P3C- B_OBIE[JC?DY9S<1@B-?)W>C
ML0ZT7/)2NSM)_YF3K=[N%)N?D1Y]<7:9G5V>)6^CLQ_F?GE^GLTN;LBX][+E
MR]GM++N:7:9?);^Q\#PA:4+?GE]GMV<OZ,LPV &U:;A9-IO=9+=7EZ3X);+*
M?<9_>[KO1X&],XELPL5'.G8%DA\VI:J4-G^* EW!7<22ET6<^' ER@*IV_5\
M)@04PDYE3L73(DR.C)]$G4H$=UFV'8?L]0]V%V\<':3">Q_"1/?;@E=$C)Q@
M2M(R1A(-?+86A^;4 <93 L*;.=DTKG?1 U"OV)FB>:K#$R.,.]02T,*:0UOB
M0T98)JJ+:>HD[]!GMX '.SB6"Y\9 5N2.!>AI\Q_0^>[92>-$\W,* K>0U51
M*4L!0 2;=":>[<BA*2ZR9-_#>,KA[Y,?<I*O:\]..WQ9R9=1)+_A$/B>]$QL
MC@L&1@7TE/K120RRY-NY/BC,UJU8MX'>6UX4RRF6;OF6MIH-^$(]*\&7SM*/
MA6)+TAUX1!R7D84YJ)%G41Q3 &(Y]8C2PF^*+KSG^*"C] \ZXD7RDJ _%<^Q
MSY-!+'NJV+WK.'#U9ZG'CHQU.D'"',$HQ/> ,OAHPSN /!NB2]5L8;#ZJ&HQ
M^&".)HJ(#891$1^6F$9("N"5Q'1G^V]RZL2;/*O3B$%$A+TC0!1CR- D>$B8
MX[HUH;-$/ @"<R5B;H\?Y)ETDF@R(0JY^=ZWLQ=_)OTDB=-/SLAJZJ#^'N"<
ML$_BJM P<^<IB-"B=9DE(6,&IW3T,65YO^98&J!H[+S&7F2C!(-N76ZWB#W7
M!?)S*DF"Z]1YD;YOMGQ>&./>DU(BK9?^4"YXQY/@M/!N*W.=TW3;9D>HBQ6#
M1]>($-$"(]8/8N"!&3$TRMN8H)W&QIM:>^<9)D:O_40IB.8-6_/!\5G)I'V8
M?D/JFQ #9XI8G*!U5:Y6BCY=1#DR?$XK3L-9EC(C/Q]!]J,-[$?X6LZ8#3.G
M57'NS.#V@<Z;\A-U?4<PH4=2'F+$I)L^84!\F_<8*8-\%VMAV "L%PD"B7RV
M8?QS#HJP'LQ_=H0LG+& *%G-(8O08+63.<O9)6'$<*22P,72S!^&->P[E"D9
MAM[F99O(:6<GD;@GXJR+O!N+ *;?T+LTGG:D6]D=SSG&)TCU4;7,O"V4]8HN
MGF3B)RD[:3.4Y;9L$%@N!K$NW**U'O??8A60=LVR?X)MP6?(/D1B3U=J"U*S
MA;>+6^0+G =;8ANZ8&&$/+U:A#VK6&2G J=''.A;+)K"SB<I+&),$"J)Y@)J
MSMV*N:F97$4LKV7BL"*1Q"1J2=-!6I\FPLRW@MJ#5\V9Y%3[0%5A8O9!& LA
M7,L>Q)[W$*7LC@JB/EI>%^74-K5R(.A3$ T7-F/Q8VM"#2$[]), 6&!Q$'UM
ME!1W0/S/S@";+3+#:>QYS($DQ4JE&]*<Q">>Z)0^RYE+VN85*? 6F[SDLQ.S
MWMNZ)\Z$N17.OK@&BP:9J0H='DL%64MS0Q+TB)*Z']@WE+=%E[YLZ!]@L#=W
M#R^S=/*A>^*LI?*3..P?[K/TXHJ,JS"ECNR!OS=-@6WE/7@'4_3B-KUXD;[=
M\*DWB?]#4Z].?@#*"NM0*!S;?@)&.TF0)=F6F&SCD"_W4:&/,I!%']#,7U<)
M*X+#<*#"-'A_.-@A&4J0])$C8.2/@;.'5A^8F),=]^;(&-D#+G$;T(146T5C
MC#I6EP5S]"C"8:D^,/]HD*^3O_W7B^N;%]_$(AAN9/;WPJ"K9>V:+MAI-AL+
MC87[YDASMJ34'SO9QW:]Z]15J*Z]Z9XBPL&AETN&;ALE=!_TS?BUB5)]IGLV
MM\'>""'=L,(1$APO?@?U,!P,B'V*DD(2Z]NB&NS:1YZ2:M]=, &Z,#NO1Q4N
MB% 8:T::I=EO2^JV)('+SAZ8^3YSR@MPN1Y >J K)3K4(I"%=$D=Q!83IJ%>
MH!,%T$&+-AJ.7Q+GF">!$Y\0G@:0S]7E \,"B$,?0VS#W+S"ZU$"7,CM1":C
MNBC&-L+4+B.+T,][1 0,(7J"!"I9[N5'=LXAW,MG2<(,VJ?7%V0W%F-3MRB[
M;0/HN$S&.S%WO!X1MS62QLJQPW12",,*BV2%GO]&W8CJO6 HGWB+B@6*!"?K
MN"D3BHT*]8BQ:*#Y_4<\C[T3%SHX0%2V%V+&CCV'YH:MI^A8[L!*]O(&YB*C
M<2(H]QW@=B0M1R(2?8]=)]2L8D4)@:EQ!LZ\)J)B=IZ[0(RD8N0(G@\YVMZ%
MYY_D<R#4B21X*3/&)1=D6"DM_=E2-&:+^/=0K#R,L8V#&3G0!G507,Y;Q-'H
M>V$%T;!X5"">\]8T!/4@.5W$4GGEG7UAWDB];57FA&DT^ZAW7T-P(GZ+Z& 3
M#'%V(> ,[C]M9HU7)-C5(* "633IM5W046!<:V2"2,?SQF-*F4'N+ZAU]V\A
M#895 K'3YC$FSQ^1)>C;Q/2M]V2,%[;7L)0H0;10L$(=1X_D#-EM$'/D<BJ1
MZY_XDD7H3T])LJ3CI^.)S7%L4\!*83- I-!V/%>Q..AX:_8?:1(VS^ <RA=K
MR_V#$9MH1,ZD*>A-XDOV2KGQD&?95HO/UX3[WRY<R:0(7_ <=*(0HI$ 3$)
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M)%4>5.PH*,1O/7X+YQVC)S%W[\:9#8HZF"6=A#[R3T<.A2=)<,<84J<V+'V
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MF!$BS!?F'LK&P=TBP+\(X6F[H)9_E+P;*=FFO W /+%J?RET4J$<[*T ]OB
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M5>-%M<14PK*51LW[AM\^C];C47WJ:+0JOW@0:%S(<"^3RP^2:6)):6_9M*V
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MGFATHW8&]%XJ2O)P< [&/X/EOU!+ P04    "  $GF-2?_YO#R,#  !4!@
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MD^:T';!VQ]LQ]2/72R$-%4U!HL.C-.F#;D>_EK"J]N/67%D:WOQR1=,R:G>
M]@M%2;@AW 7=_#WY&U!+ P04    "  $GF-28:\8"FP#   !!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6RM5<%NXS80O?LK"'71$Q%)I"1+J6W
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M=?H"YWI2AU<I:?P_.0VQG >D.AJKVG,R*FB;;GB*E[,/[Q+RZ(,$=DY@7O=
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M*'BO(OE,\[U9HG""@;,Y@]R,@FDV;1OZ!3FG"D+/*JDXI>45KUK"4-5X5\K
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M0K>\ /,K:_VAPQL,/UC._P=02P,$%     @ !)YC4J.,::>C P  HP@  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULM59-<]LV$+WK5^RPF9XXXH=D
MUTDES<BRDBAU&HWL)H=,#R"Y$C$! 18 +>O?=P%*M&S'.G@F%Q(@=M_NOGT
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M$!@47)/<E>ZI-:A&0ZZJFLE="%MF@-6UXM)18178$B%33!= I@<WXR8STI%
M:4,*2)UXKU4%EC:B]Z(W@2&4[ Z!C% 3'($J8!N-2-O5&I*P+7M/8)@D.UIC
MZS47G!IB0E#Z*!@5XG*2;J\)2KS1!ETZ66.()V/Z,'T<H?-MD\D0W3%Q1_N6
M4LIV/4YZI+.K<!:/"G3$S [$4 [,T51Q:Q%I1.>-(58WSO(D1,<MY9?C0VOZ
M<-5H NBY<G;(R,-!%$#"QBI#W8G;/9.WGAH:7'ABM\0H9%P(7\1#C=0\K>XY
MG4-(<=[ ((P'YV$<QW >)G'B1\,P2=I1#(,S/R#-3&O-Q3[>7TP32]=]N*8$
M0YC?8]ZX8['WE5,)2XV&^V)=2K.2XQH^-A63L$)#)>=HX OU+Z<:B(1IA9KG
MM+IP.I#,[2EJW0>MFKKMNJ=WNOCP$_TY!I_KK]][I=Q<E%=(R'D]5T^/B/_5
MZID]5L]#DY[)YV7U/)>+J^>I4M+XK9/"STZXZ.CBH&9N_/5H''/2MG=(][6[
M@:?MQ?-@WE[?=!9M.!VI M?D&O?_. M MU=B.[&J]M=0IBQ=:GY8TE\$:F=
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ME-(!$8T?/69P".D<C^4]^D>?.^6RY@872GX5A2VGP3B  C>\E?9>[3YAG\_
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MLJK+>K%E,+-,ITGY\$R3L;?IE'-A940>#WF9Q P-B%9>7@*Y10\G\C8SU\@
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M>[UI61XT[,>LL-W'95[I1CE*U4J@RCL<X5@8W6]D0Y-0-X<H/(6DEZ1\L!K
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M4/8.H660&#XYB%:OBR^TO!M2M\:]%8=?'W=7A&,RR2/W@N3V%P "WZ8=()!
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M?ZVKQ=&O4+(/0/G@B'N@?'B:P. */1QB\K22PD]2(C(IP4DI/$:),0I_A/J
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MN*:67%L>XR 'PG?D&%N)Z,QF?@AILE([:H))!A/"C9S6 UQO,E=[!X9^>8:
M5I\H/&P0HD7 F TO>*1H+TC=B (7N:_PY;6B!$2,<]^H1+1I(S ?L/L/^%-O
M;)E>.RQPGJL<0T[$Y*ND^JJ&MFORW1I8?_MT?'<<S[5\!4%>9#T$@T4M>B#1
M:B:N,$B; DA.(QHN/89^2V1'.)>_Y1UKSPY9+#=)2,V9>IAA^FKDR>&:XCOV
M!AV]@*9R2ZH%*7-[.]@='FJ<>>X;/PYX@Z0R!;]) (850KPM[K?>$S -%YKY
MV,LB6K#->(1ZZ!V784B^%L7?QQ!;;ZF)B1M))IT>I[00R!TIJED4-$&SR/]Q
M?.=W$>_?A4LHL!KXH*RN[>K9YR0:?L-=UEB)4@<0DZE.DSYR1#H1 $)!=?DJ
M#2<(6%V+[D*?6V](AV.?'CH1B>/ 3%_6S0=GL-+ZG *U^$EHVCII8,D&ZJ]R
MSA->'R9 =05]\Z),9Y^/[F9+SH0]>DOTQAX&Z27%NAN[4-"PRY6$]=Z(W\IO
M*7A6OA89B!=$HQOA8Y.KI(>31W< ZA!-@5$[IR&P5_XV '\4/B&)CFF3:W',
M:D7#RH$RIU,$_2X^.3XYF1PD:E_<-SE<I_=!2RH_",;OI>>#H^QI=+@[]#XY
M<7%RD<3Z?(2XPZUT"#,SY]85)_3ZM+VWQ+J;GD46^2('3C3+N;J3F'&5DGBX
M;V"3LK.;&:I6J;@"7I>JYVQKIWL_ GLX\Y";DD![0DP0_"+LO%;D0<\U) ?Z
M4P]*2L,H\/@:$.L\/'U0\F:UO"37T=L$+J-%S:0$@\P*/+1!QF.]9UT]V3N^
MEIW])D'6?U=_'S^=/-N[&)[]Z?29XWZV+F, D?-INRJ9>2Y1!'1W"])-.:.3
MS)PY*2DKUP 1U?LIK"DH*WBJS=D4[L)]#A2UL2-P%<=(W7K4T)0U#-@#/L1V
M=>^-=!3K04!T1>%UO8,A9<4><)E71;NK8[C!.3)D.J&#HB;*BPHA$ \F=$ED
M$M!OZO)8:*WF2,L<K?I$"[0!G1,TJ"G7W#6+G=9SP2D9>6"*:@.:OC]4L^&E
M*5OBHOS'\0L5T)%$@90)2(NYZH%[( :%2C4@S[4(>T["-XN4,RNX@07K;D#6
M=5UPK8MF&Q=HM65AF;2$36).G%YU%1C4K,^@_*(,TR031)(]S7*2;J2J/YBR
M>1R_UR4PX@]/C!1$ICS"J0W\^=UVK35IV<8'04]%I[TXB3-NO"/MM22+O58T
M:K591H@LXO$*.@"([\,B&[)#+MC29&CS "I&"ANSYB9J'"F2LLNETP(OR8@1
M>P4F:D@= ^X0['Q '5&/]?=RJ@$B%)=_ 4T8IPP2:S0Z2</_<7.;!!477B>4
M!B"MIDT%'?$ZZT80[8*J:-$:35,W-)_%%8!FELKL+7+/6J#_)V&],VMR]Q+N
MF]4<(Y6R1U\H';F]2:]#ZR[1CU'VM%PSTLF,J,10U2+B,BU6_C'C^9)Z#AFY
MDZP.TU%$1%AG&Q0:/]76,(HKA?<$#S#OF>0;6<S5^SX.CI!JDQUX1"/A[GY(
MF*$C21;=&(Y+:Q.+__3QVQUH']$U389KR'/73LU1B3KP)'G7XAO.7Z#N+(Z(
M<HJ-V-(ZH[A[$FVYAC0NM37 7W9C86*</KBT$[<&3KI+B1C'-Z"-H!TF?G7#
MA3,U7&?D'3A&$(W]4H4@L\N57(D_M!=68N':M'!'#@[ DNP>\G@HB8-X)OLF
M(G9%2"S9B<)#E<;\^_[=LN1RL6KB-MP94[P;ADT#MY<-%?6' L\3&ZVH E;J
M9.DX.C:(^@DC&DV."+K(Y*P[6>. 2!L2M'B5([M%E[HR!DT90DJ51%F'0'5M
M7L+X[>A965M=;-:26J)]B#J$OLO)1SP"4F;W?!4I.*B.$D^6MF@3;EX@*ZU[
M@,I'3!'9+RG;&+"*3=DP[)H+\OD!Y$TX<-B]P]A#NM<,.4[!X?;/E),O5E:Q
MK[6(G,$K+D*Q6M"ZREBQ=@7&J-;SH%>KP]BSC=V+/E74)WVXL#+B'?QNR.Q[
MG60BS1NI)([< RH,>.+_!$^W!LT=E?0SGY_B)8F6&'VNZD?M/0IKV7G!"$(;
M0F)DW43K4=G\#08,$*,0-S^/:^MBET[QA1L@\<T1:TY5!E9R@MF:_YI,^7_3
MLWARQ8NK^11<EU(1H[U<)-?Q3_,@I.%$V*LHDFR.G!07<![5SPQ@$GN1[LJP
MH'P+22\TG1I>H@AMV\M6%"[7*UEG'-N(V@[!;PV=UF$W)C$DX8D>J"L#UE!4
M&<W/E;%2UQR:AY)AGVM_1!= (^JHT&2!<#%AQ3L-*B\UWO+*X43H%NVT*\6]
M2S&S=4M5#J. I1$N&DY'V4%+$:C<\\?J+/CWR'[OI:^$#3\"!)):/ <4(U_H
MW'8_A"CJQ_$'CQ6RU+B?(A<,&\WSH>^<G:N==)'H*RWH.U*9)/9]RJR7 6YH
MZ2-"H//YM?LVJW 'B>*?^60)*\I-/TL6F+0X5=R&PCRR:U<(/RI0=LY6%/:0
M0 &)7<74_!Y@!3CPG7CWI:2<J9EOIHC79[61F#>=M!_^:NVLLF!]/9?\[F X
MU "J_X\X&._!P: Y>I"C*/7.&H"C/46O7]X<274Z-/X1WJ@F;8>/K(S1>$>T
MZU@N&0#B*,>29AADU2)3**\:[IJ3^?[XQ%A;J*6X)*.>$9>*?-V7Q'LD(B:1
MG)0Y7P8-2"T=R2Z69O%N6-]!-X2+7E/@DB!1L@K> \:*:C)4]0>]XPN;"MJ3
M9LPJ/6OGF/ : 8EB%JUGW29"PNL'M'N[*+7C*AWG.WEUU]&94Y<MC;4?,B7:
MF!$ 4KFNPH/#A<.T/D\)OG]F6C<L[#<*SS(MLN%,2(YH>V79)FP<!<)T)?%<
MY:7K..H8$,+VN!DEO%;"8I+W6W=+BMUTX'H2P^G -(?FVF*:NP;$NB[?Z6%,
MMHMXE$0U[N6Q2.43'"R< (;+&D16!Q062#2X;*1YIAP(@AZZ!J>MHSDR"(]5
ME4137[MQK\5PN=Z7"NV^Q943OG]G3_,9;#]T:;+)5^AU2$4U+Q%$=^U.Y;H
M+-&:C<L],5(\0XK%'HOC,("A[<0[P5A)?T5'<ZA-H9:^3YF.1K*!W_7;1/9T
ME''X'EZN>BJQ84GIZ6G#5KUL^X$/@HDBN(MF'_]S.HS+AQD44.TA!#<\44*
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M&C] O\]K4K;T T_ >AR6]_/_ E!+ P04    "  $GF-2BF_]P[<$  #O"@
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M"LWF<\7GS*93\4?>M)Q @QU_^F(5R[8PV%N>71IM/5XX4QJX?:L_1F._@YP
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M<+UX-8]TI]TT-U@-,=_$5Z/@!5-S^W@J/D-5?R_%=J)6X]5J8^32C313:7!
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M2X.D6QYI<J-V!G1?*DKRL'$.QO^"Y6]02P,$%     @ !)YC4HK5>9?V @
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M=6.^D8:6AA,KVM*HK &];Z4T3XH-<-S[L[]02P,$%     @ !)YC4H%(-EP
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MC*]NII.;RZNSCQ<PN;N[F-X%<',QA:,IG55,'P]#@T[LT;#8 )ZU@.0-P(C
MM11FJ>%"E*Q\#A!B=%V(9!OB&3F(>,Z*$XBC $B/] [@Q5W*L<.+W\"[E+)<
M\ZH"*DJX$H:*!<=D8:(U,QK.N2XJJ5>*P>^3F38*/YP_#KA-.K>)<YN\X7:Z
M9#"7%=X"+A9@;'W!.<2;999@<'NAI-904*4>[1E:RY4P 7ZYQ:I>5=2PTNJ4
MX7_1]I/&! 1>W!<6(.<@5PKX4VZTS8UJNX<%9?6,J:ZH#HCTHOQT7[\/IF5)
MXU0WM& C'UE!,W7/_/\F5^\;Y^J]VO,N75"3G7K?H,O/[FJS\AU,[IE"JH+)
M;F2W3'%9PM&CTB?'WG;+1O(JJ%-OTC1*WB/P$CE%"F9KH6CS"*5:+3 Y4?(2
M'4.#/P*S^!Z2H)<D09H27!]ER2#HDPR.48@#DJ=!3E*(B/?AZ^".D,Q+K-XQ
M1(@S")(T@Q^^&Y"(_+BC$2'U;J1X1P_G<HW,QQM4X!TI\:W =P1B$@=Q$G6@
M6YDC&<RYX(9YTY^GDX\8/\:>]X,X[;U,+ U(D@49B5]V*,K_EQV*@Z0?![V!
MZU"2#8)\$+M$"*ZP?7D.4?Q/.I1G.?8XW^G05O,O.D3R)!A$<0>ZE?=V*(NS
M(,J3EXEAA])!0*((#A!CVA%C>I 8+[3A]6MR8P]8"<T"]^B6@)IBI136:%,J
M**0V,&,;+K"&K PLPSA^$>S!P!Q??'AD5&G@CA%:4M)[>>Y@E/MY;G_HWC<-
MW?L-E?9QM=;/+LA3-+M?OX?,%MF/,4N"?C^W(GDNQL_%Y+F8/HE[NQWN#!\U
M4PLW8B&S6W9NYY!.VTUQDW9X>3K>CH#75"VXT%"Q.9KV3C)LB6K'JE8PLG&C
MS$P:'(S<<HF3*%/V .[/I31;P3KH9MOQWU!+ P04    "  $GF-2"IA9]&0#
M  #B!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q]54UOXS80O?M7
M$,(>6H"().K#4F ;L+,IUD"V"1SO[J'H@9+&EA!*5$DZ3OY]AY2M==%U#K;X
M,?/FS:/X-#M*]:)K $/>6M'IN5<;T]_ZOBYK:+F^D3UTN+.3JN4&IVKOZUX!
MKUQ2*WP6!*G?\J;S%C.W]J06,WDPHNG@21%]:%NNWE<@Y''NA=YY8=/L:V,7
M_,6LYWMX!O.M?U(X\T>4JFFATXWLB(+=W%N&MZO8QKN [PT<]<68V$X**5_L
M9%W-O< 2 @&EL0@<'Z]P!T)8(*3QSPG3&TO:Q,OQ&?T/USOV4G -=U+\:"I3
MS[W,(Q7L^$&8C3Q^@5,_B<4KI=#NGQR'V"CQ2'G01K:G9&30-MWPY&\G'2X2
MLN!* CLE,,=[*.18?N:&+V9*'HFRT8AF!ZY5EXWDFLX>RK-1N-M@GED\;K_<
M;\C=M\WF_L\M>5@O5^N']79]_TQ^V_)"@/Y]YANL8Z/]\H2Y&C#9%<R0D:^R
M,[4F]UT%U7\!?"0XLF1GEBOV(>)G*&](%%+" A9\@!>-74<.+[J"]\3?77.$
M=Q59EJ4Z<*')7\M"&X7OR=\?E(C'$K$K$5\3UM2@\ 25@LX0T?"B$8UI0/]*
MSP^A[+V\U3TO8>[AQ=.@7L&[CC]!L: M<!,%FUC!4+4PG[@VH2(]?U=2"$H*
MV1WT28-2MFVCW4TKI3::?"(9G289#::1&P=Q0-DTFRP%7F/>E4#0$##VT,MN
M@%!@#@K'*9U.,39(21C0*$PIR[.QN.9GU=$"7L TW?Y4D+$I38* 1)1E"4U3
M-N8@-[0@S0V.>:$!BV,XC9*(YCE6H7$:T>Q_W(ZUQ%I8CU0-'FM3' RN[L E
MIQ&C<<0L3#RE(?M93<">"\>0E]A>YRC"FV4 ),LSFJ09B1DF1NF89$^%J[)V
M>16\HM?UK3V7G"6H08PD@SBG:1!-'GM0W($*0#<93^X=N3#7DHU. OQ%^46!
M OO7)$0@E#7),A0J1W'3*9L,KP(_A9ZX.HFBG(9Y9B7*\$A8,MD^;I</Y/JE
M_T2BC(9I3K,TMQ,4ED4T#2/RJROA7_A."VKOW%43)]M@0>/J:.#+P;=^A@_N
M_Y6K?8-OCX =I@8W4_1+-3CJ,#&R=RY62(.>Z(8U?H1 V0#<WTEISA-;8/RL
M+?X%4$L#!!0    (  2>8U)LN0DZ, ,  .$'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;+55;6_;-A#^[E]Q4(<A ;3HS;*3S#9@-\E:(&F#U.TP
M#/M 2R=9J"1J)!7'_[YWM*VXG6.T0/=!$N]X]^@YW@M'*ZD^ZR6B@:>JK/78
M61K37'J>3I98"7TF&ZQI)Y.J$H9$E7NZ42A2ZU257NC[ Z\21>U,1E9WKR8C
MV9JRJ/%>@6ZK2JCU#$NY&CN!LU,\%/G2L,*;C!J1XP<T'YM[19+7H:1%A;4N
M9 T*L[$S#2YG,=M;@T\%KO3>&CB2A92?67B;CAV?"6&)B6$$09]'?(UER4!$
MX]\MIM/]DAWWUSOT&QL[Q;(0&E_+\L\B-<NQ<^Y BIEH2_,@5V]P&X\EF,A2
MVS>LMK:^ TFKC:RVSL2@*NK-5SQMS^%[',*M0VAY;WYD65X)(R8C)5>@V)K0
M>&%#M=Y$KJ@Y*1^,HMV"_,SDZGHVAY.Y6)2H3T>>(4C>\)*M^VSC'K[@'H1P
M)VNSU'!=IYA^#> 1EXY0N",T"X\B7F%R!E'@0NB'_A&\J LPLGC1BW@+ U>%
M3DJI6X7P]W2AC:)B^.<(>+\#[UOP_@O@4PTR Z*,U0)51QM$G=(BN'#!+!$2
MH=2ZJ'-X%&6+["%;1:5#Q!))Y:T-IJQEVTR6U"=D?'DH&4?9</]>ZD8D.':H
M036J1W1^D&+OARCV_@O>L^ ,W+LI:E$G'/<T5XC4R09^@3#V7=^W#TM^)_5L
MIE+*E&S)DOEE'4*&J.$D"-W(#]W^X ).X21VHP$]\1!.>_/W\^DMW+Y_]\=O
M\^N'.[!E3?#1T!U<#-TX"D@*+OKN(**G'\&1Y,==\N.CR9_OGP48;B$>4SQO
MM#T^D5/<N3!DUAJNO485%$XC2FC$FL]#0TMMH^RQ'CHN&KIVK\8G$FA\P1J%
MTBX(#8(LJ.5@L88I+ZW#.WD&YP=+YV@LATOG9P38^U\"[/U%5CQR&.W;\N-4
M/Q<9:T);=_N:B,LABMQAW*GZI.H';OBLB4GSZZOS, A_/U@OWM[8K5#E]G+1
M8.MW,X$[;7=_33=C^]E\<_G="947M882,W+USX:4+K6Y4#:"D8T=X@MIZ$JP
MRR7=P:C8@/8S*<U.X!]TM_KD"U!+ P04    "  $GF-2$^^ZRPD'  !+%0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6S-6&USVS82_LY?L:-+;NP.
M0Y'@>VI[QF^]9JYM?'Y)IG-S'R!Q)7',%P4$K?A^?7=!BE%B2<ZEO6D_2  !
M[&(7>)[% D>K6MTW"T0-'\NB:HY'"ZV7K\?C9KK 4C9.O<2*>F:U*J6F3S4?
M-TN%,C-"93$6KAN-2YE7HY,CTW:E3H[J5A=YA5<*FK8LI7H\PZ)>'8^\T;KA
M.I\O-#>,3XZ6<HXWJ.^65XJ^QH.6+"^Q:O*Z H6SX]&I]_HLX?%FP+L<5\U&
M'=B325W?\\>;['CDLD%8X%2S!DG% YYC4; B,N-#KW,T3,F"F_6U]A^,[^3+
M1#9X7A?O\TPOCD?)"#*<R;;0U_7J1^S]"5G?M"X:\P^K?JP[@FG;Z+KLA<F"
M,J^Z4G[LU^%K!$0O((S=W43&R@NIY<F1JE>@>#1IXXIQU4B3<7G%FW*C%?7F
M)*=/;F[?GO_SQ[<_75Q>W_S];XGPXN_A\E]W;VY_A8-;.2FP.3P::YJ(AX^G
MO=*S3JG8H=03\'-=Z44#EU6&V><*QF3A8*98FWDF]FJ\P*D#OF>#<(6[1Y\_
MN.T;??X.?9<?VEP_PK]/)XU6A(S_[-$9##H#HS/8M90=KJ&>0=TJ>"^5DI7N
M<,>39:W*JSGH!<(C2@7(:P/D&9835(-WK[>M]]Z9F;BOFZ6<XO&(F-F@>L#1
M[S3'&LRQ?FF-?:3G9B%)/=S1R$%A ^\-\DGV] $5$1DN/Z*:Y@W"E<JG^+3_
M&CE:\.3GA!)>_E86\%,^0\@K^)6,:>!T/E<XEQKA#0W)*0A,X9TL6K3.9"$K
M4BOUEVOGI>#9B2_L,/;@!0@G$N Y:<AU.PAB.Q6I]0\VFHP)[#@4MN=%U.LY
M7FJMK<[ \$!\_V5)(Y:Y>MIOG;,]18'9F +%#'-6?Q"ZMNNZ<$CJ(\</]Y@M
M7(CLT _L*(F-,6$(L2/8;,]V \\69-T[;%BMK++U\C(YOU7;7?70Z]LFO\/_
MH=S#E7#@2KB7*[>$NM4:%[+'Q4SF"AYXDV%)]C2,-H;=:HVTO&G:?A$8MI(^
MRR4']P9:WCA"#[>?%7)Z_^IFNJ@I?%$DRK#X$NW-+O9U.++-'%1+@&UHZ'"D
M\T\OUC-HL_@3/M*<;73]@YRW_F3GK6>=MPQ@#/6,P/LOW<)U+%B:6-!QC8K0
MB7Q3>-%3H;F)5!FS?V-9#)B9KKY#Q&)^QZEUG3?WKV8*.71HI.BD0;&<Z_@!
MO*0QH3"%'\%+ZUU=2)T7'/VBQ$FH(W*[0CAT9KVT;E&5<$!^FF4Z!,^%$$+K
M@B)F1FL&CSD6&>FF^5]^7NSA1#1P(GH6%N3XG+:-]OVO"^[GO>#]DB;I*E$O
MZJPNZOECYX6N*6>BC:)4!BV>;6.#R6O*=Z;W4/=^Y\TNEQVXW;$6"NEHYU.*
M)6E*LY90#6?8QKI:>34MVHR7[N$3,F@,BW:6&-3:ID%M1YH],!(_+BG5)!\+
M/LD^4],[U%D][+'U)^^Q]>T<#A/#0\\U' ["K^>PVQW(GI,(HT($^SGL.5'"
M?P%SF?_\A/Z2]#,R^T[H0Q0[J8#(X\,N"IP@A3 ET[CN!D^H'=&QG)#MU$\_
MBD-4BM]+]7B@>KR7)*?K2Y!!Y#HC:TU>Q=M#5ZK4;*18[V,*5Y0_-.93(7EN
MT-)=RIAH7YE<,J5D0U@H:.>;K:GF7LNWIYI?[X[U?W5G5ZKZMN?87RE3%:'M
M^JXM".(O(' BQF#"==^.HL3V8F](56.?,CISY#'Q-A+5 \_V$DIBB5&'AEK"
M-VE>["=V'+A#PGK@)Y$=N:D9Y3MQM#UE#;QHR%E])W'WYZS"M^/$LU/?-0XD
M=%0ZPAA)>;4(_?\I9:6(E42"<E;/!!0W(HTAYPF>%U/J[C^3L?IV2AI$D!K+
M*18DCC#UP$XH1NUA;#(P-ME_N9LN,&L+$]<Y0A%>V)HNO+=5KCLL4^IF0,RK
MMM&WC6=_Q'S6COFLZT\B-Z;YSHA<;0S?:'_*FR=,,%B$"X;Y#QS.#<+A&^6>
MN\.)H+L\F<V,AGO'B^'&M69&9#/8$B\QW/")57:8A(3][HAQDQZ$XVLL4!K*
M^*YGR'1H1L0)D2C<;/$":X,2S- TZ+O<^$G#?HK$MAO1I4L$W5P17T-=PFKH
MP7=K [\S.<&G_&3'CL+!U<T='5L*3=CE"P$'1WZ0VA#F,=0NM57*1V#&="E'
M'[BV#(157A1F9%>;<.:G5X@5_!=5W24WJQIT7N+N*3-<4H3F.%F;_,(ZK\NE
MK![[%R7"ZG21XP.69#@+313*^U?44,&'5BHZ](M'N#Q[<WMQZFPCZWCC@:M$
M-3?/> U,Z[;2W5O7T#J\%)YV#V2?AG?/C#]+-:<@#07.2-1U8KJKJ>[IKOO0
M]=(\ETUJK>O25!<HZ1CA =0_JVN]_N )AO?3D]\ 4$L#!!0    (  2>8U)
MA]YBN 0  -0+   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;*U6;6_;
M-A#^KE]!>&T1 YPMZMUI$L!I4JP?V@9)V@T8]H&6SC97B51).D[__8Z4K+AM
MXA7K/MCBRSUWSQWOCCS9*OW)K $LN6]J:4Y':VO;X^G4E&MHN)FH%B3N+)5N
MN,6I7DU-JX%7'M34TR@,LVG#A1R=G?BU*WUVHC:V%A*N-#&;IN'ZRSG4:GLZ
M8J/=PK58K:U;F)Z=M'P%-V _M%<:9]-!2R4:D$8H230L3T=S=GR>.7DO\%'
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MVZ'(S![0=,MQIM#4(@B+.#K+X,"I-5:";-$_I.-X* [@ _Y$*7QP7F4S9[J
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MG VQCE1WN^@V1C;VB[Z2!N\'=EG@A8PK.H#O-U*:YPT1]%>\V=]02P,$%
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M'\8=D,VUL'G08FFO8K="T\7.FCG=I%$:!WH_%Y12^V ";.[F1_\ 4$L#!!0
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M8^TV$HP/</>5UG@R_)1,.Y[] 5!+ P04    "  $GF-2])DDP[("  "A!@
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MF'_;&V#RP/9"3![97HS)?<?K.YA_QQM@\L#Q0DP>.5Z,R7W7Z[N8?]<;8/+
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M J^IG+/F&W3YA)HO8U28)VK:V#"V4+86DE4=6#FH2-V^\7-7ARV &[P#\#J
M]U& WP%\DVCKS*0UPQ*G8\X:Q'6T8M,#4QN#5MF06I_BK>1JERB<3"_K#=22
M\1>4,74T0@K$"B1+0 6CZHA)O3Q%1S.0F%!QC+Z@^]L9.OIT/+:E4M<<=M8I
MG;=*WCM*,\A.D.]^1I[C.0/PZ8?A;O(6;JN<^\2]/G'/\/G_37Q&1$:96'-
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M<!V@[B\9D\\;?6)NOI F_P-02P,$%     @ !)YC4M%]Y;%9 @  H 4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULC53;3N,P$/T5*]H'D%C<7+@J
MC=22HN4!5%'876FU#VXR;2P<.]A3"G^_MI-FRZ6(E]@S/N?,C)V9=*WT@ZD
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MA%[@[N"WR$5>!!/?CC]L\(>GXL<U?G4!;4##?0#(CR+D[0"UR04Q@M .-&J
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M+_?R=$#^2A1GB)%OB&**/>Z3D]U)_M$]A$"[:&D7+75Z;$#OCK_RN83@>+U
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M2T%#[V]X^XE5&W=)FBL+5RXW7,.M6.C& -XOE;)OD^;>U=VSQ_\#4$L#!!0
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MF&"V)+ :QLM@&-FY*YU+0P/"+6N:R*AL /FW4II7PTZ):<9G_P%02P,$%
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M4^1I-">7K'O9-!J(-UNX)LU$^B"VWEH4<<[M>-J  O#051"NC/SY#5: <9?
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M8<67?LOIF:<]'_<5W_F];&?XVAG.+L]6M:=^1R(;I/%T\;S\.DKCZ&8DBH>
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M^'$HHEN1R@+X^5V2Y(M?9 /+;QE^^_]02P,$%     @ !)YC4B(W9^7K P
M+ \  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULM5?;;MLX$/T50NA#
M"[26*%F6'3@&<MG%%F@608-N'HH^T-)8)BJ)7I*R$V _?GF1)161Z!B;S8-U
M(^><.3R<"9<'QG^*+8!$3V51B4MO*^7NPO=%NH62B G;0:6^;!@OB52///?%
MC@/)S*2R\,,@F/DEH96W6IIW]WRU9+4L: 7W'(FZ+ E_OH:"'2X][!U??*7Y
M5NH7_FJY(SD\@/RVN^?JR6^C9+2$2E!6(0Z;2^\*7USCA9Y@1OQ%X2!Z]TBG
MLF;LIW[XG%UZ@68$!:12AR#JLH<;* H=2?'XNPGJM9AZ8O_^&/UWD[Q*9DT$
MW+#BD69R>^G-/93!AM2%_,H.?T"34*SCI:P0YA<=FK&!A]):2%8VDQ6#DE;V
M2IX:(7H3HF1D0MA," UO"V18WA))5DO.#HCKT2J:OC&IFMF*'*WTJCQ(KKY2
M-4^N'NQJ(+9!K.;HD7!.*FG%HO(9936G58[D%M S$(Z@RB!#MY!"N0:.(OP1
MA4$87*#WMR )+<0']*F-\OW.C/JQ]*6BJ@']M*%U;6F%([1PB.Y8);<"_:8!
M?PW@JQS;1,-CHM>A,Z*B/&GI?GNX1>_??7B'?"2VA(.POPZ8J-4S,C#1",Q-
M0830:AXU8!P9JZ/O7]10]%E"*7XX@*8MT-0 34> _JS- B@DRQW52BB.#A96
M4:BED*3*].JM(:=5I>_^04.96OTLWLS@Z<V\7^%Y%,8)7OK[ :)Q2S1V$GTT
M&T.9ANR!JXV.X EX2@6@':<IG&;<K=(0:PL^[[$.)[-PF/*LI3P[CS('7> T
MG52YDJO=49,"%70#'P?Y#Q%U0V*[O3!&I?6]V@$9>799,FFS29RAK_*<0TXD
M(*JX4U504[0G13W"_5?MAS*Q<'%?\NDT682+8=7G+<_Y?W)TKB]J45P>GK_P
M\#2)0XQGP]06+;7%VWBXX^AV[>*%:_$$C^B'@ZZ6!TZ:-Z1*57^#S%<=:P/T
ME%I-N+Y<G^) _8T0Z345_#9ZI2WC38^Q6[L&NR_>;!+%(YS#CG/X9@45[,6I
M;?A"VUD<36?S9(1HUV%P]/8%M65\0MMHP)CQF+9=K\+N9O6_%-03F(FIJ )%
M345U5%+<]3+L;F;GUM).]L$,XA>5% =3'(Y6@JZ!87<[.67F/0BS'%5V= ]9
M%_ J7\_.]'77IK"[3[W:UW75T'^MJ9-S3-VU*^SN5V>9VBGX(&DW^#GN[KH<
M=K<YA[M/&6;8WXM7^MOO'6!*X+DYIJGNP.I*VK-,^[8]"E[9 U WW)XC[PA7
M_[X(5,!&30TFB4+G]FAF'R3;F>/0FDEUN#*W6W6<!:X'J.\;QN3Q00.T!^35
MOU!+ P04    "  $GF-20*E3Q7\#   N"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6R=5EMOVDP0_2LCJY5:J?$-3* "I!)_GUJID:*D;1ZJ/BSV
M@%=9>^GN LF_[^P:7*#&2?L">YES9L_9BV>\E>I!%X@&'DM1Z8E7&+-Z'P0Z
M*[!DVI<KK&AF(57)#'75,M KA2QWH%($<1@.@I+QRIN.W=B-FH[EV@A>X8T"
MO2Y+IIYF*.1VXD7>?N"6+PMC!X+I>,66>(?FZ^I&42]H6')>8J6YK$#A8N)]
MB-ZG(QOO KYQW.J#-E@E<RD?;.=3/O%"NR 4F!G+P.AO@U<HA"6B9?S<<7I-
M2@L\;._9_W?:2<N<:;R2XI[GIIAX0P]R7+"U,+=R^Q%W>A++ETFAW2]L=[&A
M!]E:&UGNP+2"DE?U/WO<^7  B 9G /$.$)\"^F< O1V@]U) ?P?H.V=J*<Z'
ME!DV'2NY!66CB<TVG)D.3?)Y9;?]SBB:Y80STR\%PM:9@SFP#2K::U@PKF##
MQ!IAA71&"J80Y *V3"E6&0U<Z[6-KW(P1,"H6Z[L/FI8:YK@E1N?"98]7-QE
MA12HX5KF*"!?*UXMW?03,J4!JYP0*698SBE9+WH'<1B']C<:O7,YJ#4$NP9-
M]X".NBGV&0R;"X2Y/;T^O$G1,"[T6[B ^WJI\/W:T?Z@H5<0U%+T.#!DG34@
MR'8VS6J;XC,V13$MOS*%AO_L<H\) O*\,3[>&S^+.QE)L-^(;5G0U8OAT:@%
MGKX</NQ0TVN.4<_Q]<[P70DZ _:(['V7"MP3 M\_4RA\,ECJ'QV)^DVBODO4
M/Y/H_O2LXB.JC&LZJ8IGV+:S->'0$=I7<#.-?.O9YM#M/X,2?] [#DK;@J)!
M$W0D*&D$)7\G:.G\RYDYO(=MNI(67<G@1%<=E!P$G8KZDR;V+T?MH@:-J$&G
MJ%NN'RX6"I'NJ4&Z<084"6I3T4T4^KW^Z[;;T0V+_21N@Z7/P7J#UQV']+*1
M?]G)\TT*9KC@YJE-<3=V,/2'8:OD9W#A&5SZ#"[VHU.OCD0/&]'#3J(OJ$IX
M0^^R>];?MBGO)HC"&MJFO1N9G 6F_P \4C]JU(\ZF5*^X3E]RN")H\C;Q'?C
M0S]LW_5_@Z5_#:M5!P>51(EJZ2HR#9E<5Z;^MC6C3='WP=4Z)^,S*@;KVNTW
M35U)7C.UY%0H"%P09>A?T@.DZNJL[ABY<O7*7!JJ?ERSH((6E0V@^8649M^Q
M"9H2>?H+4$L#!!0    (  2>8U(KLM_?.00  %X0   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4S+GAM;,U876_B.!3]*U=H1]J5VGP2"B.*U)9=[4B#MFIG
M9QY&\V"2"UA-8M8V4/[]7CMIH!!<.D_S4O)QS['/N=>.;X<;(9_4 E'#<Y&7
MZKJST'KYT?=5NL""*4\LL:0W,R$+INE6SGVUE,@R"RIR/PJ"GE\P7G9&0_OL
M7HZ&8J5S7N*]!+4J"B:WMYB+S74G[+P\>.#SA38/_-%PR>;XB/K?Y;VD.[]A
MR7B!I>*B!(FSZ\Y-^'$<]@S 1GSEN%%[UV"D3(5X,C>?LNM.8&:$.:;:4##Z
M6>,=YKEAHGG\5Y-VFC$-</_ZA?TO*Y[$3)G".Y%_XYE>7'?Z'<APQE:Y?A";
MO[$6E!B^5.3*_H5-'1MT(%TI+8H:3#,H>%G]LN?:B#U E)P 1#4@.@"$5R<
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MH30!]'XFA'ZY,0,T_U(8_0]02P,$%     @ !)YC4FDGV?K'!   CQ0  !D
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MKT^_ZH9DN^K$:<6D9'EUNP6JI*Y?4/^O&9/'AD[0GD$N_P-02P,$%     @
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MWX%$ZR$K5$P1GRL@2QY(LN/A%I!LL22J"*?C]DN$G;;;K6;;R]GV&MG^JIF
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MTJ\$>%P@#J0C"9P<R5 I_RKH/S.QGM] N8]@C^R-PHKB5&WQZP!'LEL/TIV
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M"XT]S@X3_ J!-!OP^48(?9B8 /5W+7P!4$L#!!0    (  2>8U*W'M3*VP(
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M$T1&A$Z)Y*#$5>)E3"$+T3A^BQ*<X)X#73\;'E_TP-/GP^<>:\:=7\>.;SS
M]Y$;UP'Z8I1/J<J84+4$]&.]45J:N_;3L\6DVV+BMI@,;/'^22P<_-SG3C]7
M$H<8O^E3_96X].6X1R),.Q&F7J);;>/Z8/A;Q$VJ%D5W3^S$!C@45/>)XN>>
MAG&_)G[89$B24[LE7D7..T7.O3SK_)=)6^9IT(AR=$]8W2068B\]X1FH/B7\
MG*-D9HWJRQ/7IY!)..U'IB>0X]@J<N:19-9),O-2O7LP5BMS441V=PB'7A7\
M-'@H'D[!GCBVL=\/FX9C;SS,.^/GSTH3M,E(W5N0E81O>U.%GP\/98K7P5(_
M;(1[ N^1#A>=#A=>IALP90JWU\*^EL(\EQ+EU+R1$H8NA9\0A_-^(?RP41+.
M!B[$"2"V$>&3(L;_J@[L%T.*>^IJQU%['\Y,62"/@J1?D1.T@['Q2ESZ<EPC
M2'14D54@MZZRM>54S753DG2C7?6\=C7C?^-7MJIVE=X_FJ8D_T3DEG*%&!2&
M$H<SD]YE4^4V'2UVKN[;"&VJ2-<LS9<!2+O S!="Z$/';M!]:ZS^ E!+ P04
M    "  $GF-2\BMN+6X#   ,"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6R-EF^/FS@0QK^*A:I3*VT7&S!_]I)(;5#5?7%WJ]UM[[673!)4@U/;
MV6R__=G <EDP-(J4V/ \X_D-9N+%2<@?:@^@T4O%:[7T]EH?;GQ?%7NHF+H6
M!ZC-G:V0%=-F*G>^.DA@F\94<3_ ./8K5M;>:M%<NY.KA3AJ7M9P)Y$Z5A63
MOSX#%Z>E1[S7"_?E;J_M!7^U.+ =/(#^=KB39N;W439E!;4J18TD;)?>)W*3
M$VP-C>)["2=U-D86Y4F('W9RNUEZV&8$' IM0S#S\PQKX-Q&,GG\[()Z_9K6
M>#Y^C?ZE@3<P3TS!6O!_RXW>+[W40QO8LB/7]^+T%3H@:N,5@JOF&YTZ+?90
M<51:5)W99%"5=?O+7KI"G!E(-&$(.D-PJ2'L#.&EAJ@S1$UE6I2F#CG3;+60
MXH2D59MH=M 4LW$;_+*VS_U!2W.W-#Z]>MP#*D1U$#746B&Q1=I<J<V&,\4#
M*6&#RMH( &GV@IA2Y@YK=#D44#V!1"&Y0@$.L/TFV15B]<:.4L0D6.U6<+.[
MU UZGX-F)5<?T$?T[2%'[]]]6/C:0-A4_*)+^'.;<#"1L%GVNE_285]?;">9
MPYY?;D_?VGU3^;[\05_^H(D73L;KBGS;%OG1%/F3+;*ZF8D>]M'#)GHT$?UO
M\[!,AY!,E_4.<6$"*U?%VRBTB6(;Q?.*9!3CE(1DX3^?%]>AI FE-$OH6V7N
M4 9Q1#)"PE[Y!BKJH:)9J(>]W5?V7=\T.]?T(&9;B NLC12?)Y$$E&08#[@<
MPC C(8W3 99#2.((1W'DIJ(]%9VENJTU2% :P8LE L3+JM238'2<1I!E)"'Q
M &PLI&&:&?& RQ&0)&%,)K#B'BN>Q?K'=!-Y9?N)BR(>+1JE),W"P5Y:CW5A
M' <X3 808QV):4J3B1V7]!#)+,3]'ZPZ_)FCPKRHI1,D&2^<QF$TR&]]F2S_
MK>P-1=I3I+,4CT(S/MW575CI*)$@Q %-\'#[K,=*DN+$?.A@0^8.941PDA)"
MW'Q9SY?-\GUG_,C:LX3]OV%U 2ZF;+3^QRDHAW2*RB6=QR+X_W]H/ N63STR
M-?EB=1'/N^^PX_U>DL]*6AC_[.1ASXE_,;DK:X4X;(T'7R?&+-NC5SO1XM <
M1IZ$-D>;9K@WQU605F#N;X70KQ-[OND/P*O_ %!+ P04    "  $GF-2"ECJ
MP5,#  !H"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6RU5MMNXS80
M_15"Z$,"M)%(76PM; .)G:(&<D/<[06+/C#2V"96(E62MA.@'U^24F0G*PMN
ML7F12(KGS)D9<C2CG9!?U1I H^>RX&KLK;6N/OF^RM904G4A*N#FRU+(DFHS
ME2M?51)H[D!EX9,@2/R2,NY-1F[M04Y&8J,+QN%!(K4I2RI?KJ 0N[&'O=>%
M1[9::[O@3T857<$"].?J09J9W[+DK 2NF.!(PG+L7>)/,QQ;@-OQ&X.=.A@C
MZ\J3$%_M9)Z/O< J@@(R;2FH>6UA"D5AF8R.OQM2K[5I@8?C5_:?G?/&F2>J
M8"J*WUFNUV-OZ*$<EG13Z$>Q^P4:AYS 3!3*/=&NV1MX*-LH+<H&;!24C-=O
M^MP$X@" DR, T@#(>T!T!! V@/!40-0 (A>9VA47AQG5=#*28H>DW6W8[, %
MTZ&-^XS;O"^T-%^9P>G)_&YZ?WN-?KW\XWJ!SF:@*2L4NJ-24IN0<_03^KR8
MH;,?SD>^-O8LRL\:[JN:FQSAQ@3="J[7"EWS'/*W!+X1VJHEKVJO2"_C#+(+
M%.(?$0E(T"%H>C(<IQWPV>GP88\W81O[T/&%1_CN*[!1YBMT(Y1"4Q/T%W.3
M=U3F"GVY,;O17$.I_NJQ%;6V(F<K.F)KNJ9\!8AQM*7%AM9WKC"WGO(,NE);
MT\6.SA:/[21*XRA-!^'(WQZ&_-N-89J081K%;S?..A@Q,9S1GO&-:W'K6MSK
MVIQKD)P6Z!&VP#> %B"W+ -T-G]<G*,OMU ^@>P+8M):2CX\88/6UJ#7JSM3
M\T5KK[#V,FL/-0:[<E8S)@<1'B1X$. X2KI#/&S%#+]'B-$_Z/JY8K(^7@\@
MF<C-94%_ I7JE$2DK9[TPQ.!@WV)#+Y[*AK*-]<B' X&<1B2[ES@@Y*-^_7<
MW]0"&ONH<I'NE-'/9'+S8G/3%R:RET7^FRS8GP5KI5-?/R4)0MRG;5]I<?AA
M!WAN?EY+QIF&4XXPWE=D''W\(=X72=Q?)?_7(8Z_+=F$I"0A.'IWB/V#%J0$
MN7*MG#$A-ES7__=VM6T7+UV3]&[]RK:1KK79T]0]Z"V5*\85*F!I*(.+@=$E
MZ[:NGFA1N4;G26C3-KGAVK3"(.T&\WTIA'Z=6 -M<SWY%U!+ P04    "  $
MGF-2+;P!G;D"  #C!P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6RU
M56UOVC 0_BM6M ^MM#6OI%!!)"!L0VHG!.WVH=H'DQPDJF-GME/:?S_;"1F%
MPI"F?2%^N>>YY^[,77_#^)/( "1Z*0@5 RN3LKRQ;9%D4&!QQ4J@ZF;%>(&E
MVO*U+4H..#6@@MB>XX1V@7-J17US-N-1GU62Y!1F'(FJ*#!_'0%AFX'E6MN#
M>;[.I#ZPHWZ)U[  ^5#.N-K9+4N:%T!%SBCBL!I80_<F[FE[8_ ]AXW862,=
MR9*Q)[V9I@/+T8* 0"(U U:?9Q@#(9I(R?C5<%JM2PW<76_9/YO852Q++&#,
MR(\\E=G ZEHHA16NB)RSS5=HXNEHOH0187[1IK8-0@LEE9"L:,!*09'3^HM?
MFCSL -QC *\!>/N X C ;P#^N8"@ 00F,W4H)@\QECCJ<[9!7%LK-KTPR31H
M%7Y.==D7DJO;7.%D-)_<#N\G,9H-Y_?3R0)=Q"!Q3@3ZACG'NB:7Z!-Z6,3H
MXL-EWY;*I0;:24,_JNF](_2NA^X8E9E $YI"^I; 5EI;P=Y6\,@[R1A#<H5\
M]R/R',]Y1]#X;+C;>P<>GP_OGHC&;]/O&[[@"-]8U8P E>CQ#HHE\)\G.(.6
M,S"<_K&2 L$24C3#7+ZB>XZIP/6?[/%6F:*IA$*<<M1I'75.BA\6K%+2ESDA
M^Z6M*UG#.P:N^\]SY#M^Z#BJ;L^[)3NT"UW'/;"+#^T"UWUC]R:.L(TC/",.
M@=(*D&2JF=7Y*W7^W@NK9@MW9.P'%!X&WCDJ\[J5>?T7F<#S!%,TI1(XQ;JD
MF* OG%7E.>^GV_KI_M_WTVL=]?[M_?0.TN@YO<,\VCOM3^5H;<:(0(EFKQM+
M>]I.JJ%IT'OG(S7!ZH'SAZ8>?W>8KW,J$(&5HG2NKI4H7H^4>B-9:9KLDDG5
MLLTR4U,8N#90]RO&Y':C';1S/?H-4$L#!!0    (  2>8U(PGL]NA00  .,6
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;+58[V_J-A3]5RRT2>])
M;TUL)P$JBE1(IU>]E2)XW3Y,^^ &4[(F,;-->9/VQ\].TIB4Q" $7R _[CGV
MO<>Y)_%@R_BK6%$JP8\TR<1-9R7E^MIQ1+2B*1%7;$TS=6?)>$JD.N4OCEAS
M2A8Y*$T<Y+J!DY(XZPP'^;4I'P[81B9Q1J<<B$V:$O[OB"9L>].!G?<+L_AE
M)?4%9SA8DQ<ZI_)I/>7JS*E8%G%*,Q&S#'"ZO.G<PNL08PW((WZ/Z5;L' .=
MRC-CK_KD?G'3<?6,:$(CJ2F(^GNC8YHDFDG-XY^2M%.-J8&[Q^_LO^;)JV2>
MB:!CEOP1+^3JIM/K@ 5=DDTB9VS[E98)^9HO8HG(?\&VB VZ'1!MA&1I"58S
M2..L^"<_RD+L % ; )4 ="P EP!\+, K 5Y>F2*5O XAD60XX&P+N(Y6;/H@
M+V:.5NG'F=9]+KFZ&RN<'(Z>YO>3N_D<C!\GX[O)]]GM]_O'R1Q\"JDD<2+
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M @=CIJP GJ^D-/N%-=".VM/_ %!+ P04    "  $GF-25'KBE  #   O"
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M.[G_"%U"F8U72*'=+]EW8Z. %*TVLN[$Z*#FS>')'KM"' EB>D(0=X+8^3Z
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M_!Z(BERPI J6! E-RV_\4A5B+P#!C@!4!:!3 YPJP#DUP*T"W \!,.@(\*H
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M88[2.#"KY&6+HWC&8R;[L(&8.=\B'L]YS/K8=TSL;A!*&D$J>[19O-]CI&%
M/2^.XT;F8Z0Z3T*ZK]*'Z]P/K0Y?584>&JAQF>=E0>0L$?Q07[:DXZK5FJ39
M0J$'H^%2<K1ME=.G?F-=V/7O61>XZ$9!>-TBNGU-X&H:Z+]%J1AMK(5.LD8X
M5:,D7K8XAJ\!W,R&Z*L6T7C^XU8'C=Q'J8)FVJ-48;/6HU1^C"=[M$[VR.K=
M9Y$J3LKI%/[(/%&KXX02R83GB?@&JT"B#4]D+$!=XYJK_]PD"Q"R&Y.,4I>&
M80/0]R9=&$6!UX#*ZK.^63Z2\V3,3WISP247C[QW2BSGH7@-9FP%<U3 >4B5
MXIF,H68\<&P9Q\:.[8<8("9=R!POHE$#$)-N3_FCSN92RFDO@%#X^'>5%@^+
M5,ZJ4R4DR(3?8[GPKA:X>TJBF%MVU9U"L_0;5>GX8> VU\TO4+D+Y-;M'K4#
MR8L)[".?$WTV5Y)\N>;Y/1>VHS=E&^'L-[D.H)L;"NI:'7Z3I((\)ME"EQ3R
M5/N-+8-:T$Y^>TC"?*@)=U:\QR(:[NEPZ>;R@MJ/KN\*_8J$7*5C7DA \$'P
M)5Y=PK0Y-E+_=PG3IKFG]I;.<F]S3LW&BCF[@=G5NFFK:$M?90#]%SB<Y/Q[
M)\0W.QJ-?A?$-QL#M>\,%L1'->ONA9 %<:8+^>[(IB(Q>T7">\MA"]?Y0L!&
M $!Q,BT70LU6;ROT*M>WFX?DB9,G4=:M1#*?B_)[FD,[D3V3%]"ED#S-,OW:
M,RVJAD(2P3.8AD:CW/0:LHK0L@N1??*13[DX ())*L<+*6O^&ZTF>#DJ% 0R
MO<\@QE)R)0\)G%K[MK<-F]K*6%N?C,)DY]J"2<U2,4%1$GQ<B@DX_H)M@Y+5
MBT,L$V4''I"WKU;906(OER^8GK4%=^E#D4[3,51D<C8>EXM"[^[DM@35*9=6
MX#8; +-O '"X0(&S<_T8<(WL\OOA-I!IHP<[)'.1ZI=L0%N#JM$:CBX__7U6
MPT?^8_@V6Q)KN4WU</CL7#\&7[6*=_9I/=)L5?2G!1/=!)Y!FDVJ:GE3]HFO
MZ7<"</ B['OK "2PA*LNL<)3@P3*9^EXIM]3WG-M9I*70E6O/ 'UM  [N530
M:\ZKS%[(E2M\.N75-Q(;HIRK60E6/595&[SE(C^H'7BS?&L*S,W%L2>ZT<MS
ML-,:M\TFSUKN!=&S]+"%JU/<+%4UZ%A5#\RJN@>3GZJJF[:#_<Q%U;"%RXX2
MC:W%@?J[>T]+F5TW)'6A/>B82[^L4FR:*?8SMQ+#%JXM+"4@5OP@F$Z?[H!I
M/2<VL#T0?)X\KPBT!:\$GZ3J%RS7P=8'&#F'FJ^_JI*D0KYNU=?#ZT^WSJH/
M6!KC0WIT39'Q&WITBXT/V=$K3,XY.WJ-C8_8T24V_HX=76'C9\PY^L <5+/^
M^@RWB<$,ZAUS8<9%9SR8\= 9'V9\=": F0"="5=?Q@TV\5A^5W<->W):2)+Q
M*<3&Z8=0(L7R4[7E@RKGU?<R]Z5295[]G'&H9$(3P/RTA&RH'[2"]0>#I_\'
M4$L#!!0    (  2>8U*Z*_!@;@0  .T1   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;,58?V_B-AC^*A;:'SVI(W%"?ITH$A384:VL5T9WTW1_F,2
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M(S5:+:#ZEXS)_8,^F!9?>'K_ E!+ P04    "  $GF-26);*/%\"  ""#
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M@U_/3W"**JKF73"$O?T5)Z1B-]VL!U.(=E9O?S&/Y\V:A/U71_074$L#!!0
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M&^IM!'K;:+.;0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U
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M<F]P<R]A<' N>&UL4$L! A0#%     @ !)YC4MTY:;#O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ !)YC
M4IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  $GF-2@[=.#O(%  !0&0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ !)YC
M4AU0(#4O!@  51<  !@              ("!-@X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    (  2>8U+9BD_=#P,  "<*   8
M      " @9L4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  $GF-237N-L^P%   @%P  &               @('@%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ !)YC4F+4.R^4!@  =2$  !@
M             ("! AX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    (  2>8U)<I!W37@D  " I   8              " @<PD  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  $GF-2J[%/TW0'   >
M$0  &               @(%@+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ !)YC4D!Q>M33+0  484  !@              ("!"C8
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  2>8U+J\E;W
MD0(  #0%   8              " @1-D  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  $GF-2IFR5" $#   8!@  &0
M@(':9@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  2>
M8U)__F\/(P,  %0&   9              " @1)J  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ !)YC4I0C3.[9!   BPL  !D
M         ("!;&T  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  $GF-28:\8"FP#   !!P  &0              @(%\<@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  2>8U+U)@DIIP<  "\1
M   9              " @1]V  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ !)YC4IX=3QD/#P  ZBH  !D              ("!_7T
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  $GF-2.<)&
M%:8"  "#!0  &0              @(%#C0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    (  2>8U)3_*D]V 4  +P,   9
M  " @2"0  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M!)YC4J.,::>C P  HP@  !D              ("!+Y8  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  $GF-2#&Y1 2T#  #<!@  &0
M            @($)F@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    (  2>8U*6FVCQ( H  !X8   9              " @6V=  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ !)YC4BJ (2B&!0
MSP\  !D              ("!Q*<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  $GF-2^DD"_]L#  !O"   &0              @(&!
MK0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  2>8U(_
M<UM4V#8  /FH   9              " @9.Q  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ !)YC4HIO_<.W!   [PH  !D
M     ("!HN@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M"  $GF-2XVL^\8T"   _!0  &0              @(&0[0  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  2>8U*^H2?? 0,  !<&   9
M              " @53P  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ !)YC4HK5>9?V @   P8  !D              ("!C/,  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  $GF-2@4@V7  $
M  #G"@  &0              @(&Y]@  >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    (  2>8U(*F%GT9 ,  .(&   9              "
M@?#Z  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ !)YC
M4FRY"3HP P  X0<  !D              ("!B_X  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  $GF-2$^^ZRPD'  !+%0  &0
M        @('R 0$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   (  2>8U) A]YBN 0  -0+   9              " @3() 0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ !)YC4B:XJ20S!   [@D
M !D              ("!(0X! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  $GF-2ZP)SXVH%  "G#P  &0              @(&+$@$
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  2>8U*)8P"N
M_@$  .\#   9              " @2P8 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ !)YC4O29),.R @  H08  !D
M ("!81H! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  $
MGF-2,ZH=I80(  !Z)0  &0              @(%*'0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  2>8U*S;A4_PP,  )4.   9
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M970T,BYX;6Q02P$"% ,4    "  $GF-2T7WEL5D"  "@!0  &0
M    @($</P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M  2>8U)JJL.;- 0   ,0   9              " @:Q! 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ !)YC4F,GLZE: @  WP4  !D
M             ("!%T8! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    "  $GF-2;CG4MCT&  ":)   &0              @(&H2 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  2>8U)&4U4IO ,
M ',+   9              " @1Q/ 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ !)YC4O\UY4S' @  \P8  !D              ("!
M#U,! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  $GF-2
M3^#",FH"  #O!0  &0              @($-5@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    (  2>8U(LITJ;/1,  '%X   9
M      " @:Y8 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ !)YC4B(W9^7K P  + \  !D              ("!(FP! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  $GF-20*E3Q7\#   N"P
M&0              @(%$< $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    (  2>8U(KLM_?.00  %X0   9              " @?IS 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ !)YC4FDGV?K'
M!   CQ0  !D              ("!:G@! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    "  $GF-24JWG#Y$$   @$P  &0
M@(%H?0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (  2>
M8U+QC9@+I \  $QA   9              " @3"" 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ !)YC4J(KZ+>I @  XP8  !D
M         ("!"Y(! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    "  $GF-2MQ[4RML"   #"   &0              @('KE $ >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  2>8U(U;9ZI=0,  '<,
M   9              " @?V7 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ !)YC4O(K;BUN P  # L  !D              ("!J9L!
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  $GF-2"ECJ
MP5,#  !H"P  &0              @(%.GP$ >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    (  2>8U(MO &=N0(  .,'   9
M  " @=BB 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M!)YC4C">SVZ%!   XQ8  !D              ("!R*4! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    "  $GF-2RA2(#=4#  !V"P  &0
M            @(&$J@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    (  2>8U)4>N*4  ,  "\(   9              " @9"N 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ !)YC4JQ=6OFV!
M51(  !D              ("!Q[$! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    "  $GF-2SV3)OI\(   \*   &0              @(&T
MM@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (  2>8U*Z
M*_!@;@0  .T1   9              " @8J_ 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ !)YC4EB6RCQ? @  @@P   T
M     ( !+\0! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  $GF-2EXJ[',
M   3 @  "P              @ &YQ@$ 7W)E;',O+G)E;'-02P$"% ,4
M"  $GF-2^A?BZ"\&  #-+   #P              @ &BQP$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ !)YC4A;=:Q0F @  8R@  !H
M ( !_LT! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M!)YC4N'L7A'T 0  HB<  !,              ( !7- ! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     $P 3 #+%   @=(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>289</ContextCount>
  <ElementCount>486</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>122</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNet</Role>
      <ShortName>FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNet</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - EMPLOYEE BENEFIT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/EmployeeBenefitPlan</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetTables</Role>
      <ShortName>FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - THE COMPANY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CompanyDetailsNarrative</Role>
      <ShortName>THE COMPANY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Company</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails</Role>
      <ShortName>The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details</Role>
      <ShortName>The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails</Role>
      <ShortName>Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Inventory consists of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails</Role>
      <ShortName>Inventory consists of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Other current assets consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails</Role>
      <ShortName>Other current assets consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Fixed assets, net consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails</Role>
      <ShortName>Fixed assets, net consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative</Role>
      <ShortName>FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details</Role>
      <ShortName>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails</Role>
      <ShortName>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails</Role>
      <ShortName>As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details</Role>
      <ShortName>The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/DebtTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2020: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details</Role>
      <ShortName>Summary of our Warrant activity during the year ended December 31, 2020: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details</Role>
      <ShortName>The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details</Role>
      <ShortName>The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails</Role>
      <ShortName>A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Schedule of restricted stock units and performance stock units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails</Role>
      <ShortName>Schedule of restricted stock units and performance stock units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - EMPLOYEE BENEFIT PLAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - For financial reporting purposes, (loss) income before taxes includes the following components: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails</Role>
      <ShortName>For financial reporting purposes, (loss) income before taxes includes the following components: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails</Role>
      <ShortName>A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails</Role>
      <ShortName>The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Supplemental lease information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails</Role>
      <ShortName>Supplemental lease information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails</Role>
      <ShortName>The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails</Role>
      <ShortName>Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="txmd-10k_123120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="txmd-10k_123120.htm">txmd-10k_123120.htm</File>
    <File>ex10-12.htm</File>
    <File>ex10-13.htm</File>
    <File>ex10-14.htm</File>
    <File>ex10-15.htm</File>
    <File>ex10-16.htm</File>
    <File>ex10-24.htm</File>
    <File>ex10-25.htm</File>
    <File>ex10-41.htm</File>
    <File>ex10-42.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>txmd-20201231.xsd</File>
    <File>txmd-20201231_cal.xml</File>
    <File>txmd-20201231_def.xml</File>
    <File>txmd-20201231_lab.xml</File>
    <File>txmd-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo_img001.jpg</File>
    <File>txmd10k001.jpg</File>
    <File>txmd10k002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "txmd-10k_123120.htm": {
   "axisCustom": 1,
   "axisStandard": 21,
   "contextCount": 289,
   "dts": {
    "calculationLink": {
     "local": [
      "txmd-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "txmd-10k_123120.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 677,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 53,
    "http://therapeuticsmd.com/20201231": 6,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 65
   },
   "keyCustom": 90,
   "keyStandard": 396,
   "memberCustom": 90,
   "memberStandard": 28,
   "nsprefix": "txmd",
   "nsuri": "http://therapeuticsmd.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://therapeuticsmd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - OTHER CURRENT ASSETS",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssets",
     "shortName": "OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - FIXED ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNet",
     "shortName": "FIXED ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - INTANGIBLE ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsNet",
     "shortName": "INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - OTHER CURRENT LIABILITIES",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilities",
     "shortName": "OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - DEBT",
     "role": "http://therapeuticsmd.com/role/Debt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://therapeuticsmd.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - EMPLOYEE BENEFIT PLAN",
     "role": "http://therapeuticsmd.com/role/EmployeeBenefitPlan",
     "shortName": "EMPLOYEE BENEFIT PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - INCOME TAXES",
     "role": "http://therapeuticsmd.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - RELATED PARTIES",
     "role": "http://therapeuticsmd.com/role/RelatedParties",
     "shortName": "RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - BUSINESS CONCENTRATIONS",
     "role": "http://therapeuticsmd.com/role/BusinessConcentrations",
     "shortName": "BUSINESS CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "role": "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://therapeuticsmd.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - INVENTORY (Tables)",
     "role": "http://therapeuticsmd.com/role/InventoryTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsTables",
     "shortName": "OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - FIXED ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetTables",
     "shortName": "FIXED ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - INTANGIBLE ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsNetTables",
     "shortName": "INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - DEBT (Tables)",
     "role": "http://therapeuticsmd.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://therapeuticsmd.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "role": "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "N",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - THE COMPANY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/CompanyDetailsNarrative",
     "shortName": "THE COMPANY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "N",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails",
     "shortName": "The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "txmd:IncreaseInAllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
     "shortName": "The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_custom_PrescriptionVitaminsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)",
     "role": "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
     "shortName": "Schedule of calculation of diluted net loss per share allocable to common stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Inventory consists of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails",
     "shortName": "Inventory consists of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Other current assets consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails",
     "shortName": "Other current assets consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Fixed assets, net consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
     "shortName": "Fixed assets, net consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - FIXED ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative",
     "shortName": "FIXED ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details",
     "shortName": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails",
     "shortName": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Other current liabilities (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails",
     "shortName": "Other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
     "shortName": "As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details",
     "shortName": "The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2017-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2017-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - DEBT (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/DebtDetailsNarrative",
     "shortName": "DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_custom_FinancingAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2020: (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details",
     "shortName": "Summary of our Warrant activity during the year ended December 31, 2020: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_WarrantMember75219000",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_WarrantMember75219000",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:WeightedAverageExercisePriceOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)",
     "role": "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
     "shortName": "The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_WarrantMember75219000",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:WeightedAverageExercisePriceOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)",
     "role": "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
     "shortName": "The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails",
     "shortName": "A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Schedule of restricted stock units and performance stock units (Details)",
     "role": "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
     "shortName": "Schedule of restricted stock units and performance stock units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2019-01-012019-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "txmd:NumberOfStockOptionsExercisedInCashlessExercise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - EMPLOYEE BENEFIT PLAN (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative",
     "shortName": "EMPLOYEE BENEFIT PLAN (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - For financial reporting purposes, (loss) income before taxes includes the following components: (Details)",
     "role": "http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails",
     "shortName": "For financial reporting purposes, (loss) income before taxes includes the following components: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails",
     "shortName": "A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "txmd:NoncashOperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails",
     "shortName": "The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - INCOME TAXES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_custom_CatalentMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - RELATED PARTIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative",
     "shortName": "RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-012020-12-31_custom_CatalentMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2018-01-012018-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "N",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
     "shortName": "BUSINESS CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2018-01-012018-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "N",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - Supplemental lease information (Details)",
     "role": "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails",
     "shortName": "Supplemental lease information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails",
     "shortName": "The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-08-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2019-08-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)",
     "role": "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
     "shortName": "Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "AsOf2021-01-13_us-gaap_SubsequentEventMember_custom_FinancingAgreementAmendment7Period1Member_custom_ImvexxyBijuvaAndAnnoveraMember",
      "decimals": "0",
      "lang": null,
      "name": "txmd:MinimumRevenueRequirementUnderCreditAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - THE COMPANY",
     "role": "http://therapeuticsmd.com/role/Company",
     "shortName": "THE COMPANY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - INVENTORY",
     "role": "http://therapeuticsmd.com/role/Inventory",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123120.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 122,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r452",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r452",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r156",
      "r235",
      "r236",
      "r389",
      "r426",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r156",
      "r235",
      "r236",
      "r389",
      "r426",
      "r428"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r244",
      "r245",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r244",
      "r245",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r427",
      "r429"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AdditionalAreaOfLeaseOccupied": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional rented area occupied under the lease.",
        "label": "Additional rented area occupied under the lease"
       }
      }
     },
     "localname": "AdditionalAreaOfLeaseOccupied",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_AllowanceForWholesaleDistributorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Allowance for wholesale distributor fees"
       }
      }
     },
     "localname": "AllowanceForWholesaleDistributorFeesCurrent",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AmericanInternationalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American International Group",
        "label": "American International Group [Member]"
       }
      }
     },
     "localname": "AmericanInternationalGroupMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AmortizationOfIntellectualPropertyLicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents amortization of intellectual property license fee.",
        "label": "Amortization of intellectual property license fee"
       }
      }
     },
     "localname": "AmortizationOfIntellectualPropertyLicenseFee",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ANNOVERA",
        "label": "ANNOVERA [Member]"
       }
      }
     },
     "localname": "AnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AnnualNetSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual net sale milestones in the Territory per license agreement.",
        "label": "Sales milestone"
       }
      }
     },
     "localname": "AnnualNetSalesMilestone",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent.",
        "label": "Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Approved Hormone Therapy Drug Candidate Patents [Member]"
       }
      }
     },
     "localname": "ApprovedHormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIJUVA and ANNOVERA",
        "label": "BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "BijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIJUVA [Member]",
        "label": "BIJUVA [Member]"
       }
      }
     },
     "localname": "BijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CashUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from license agreement.",
        "label": "Cash upfront payment received"
       }
      }
     },
     "localname": "CashUpfrontPaymentReceived",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_CatalentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Catalent",
        "label": "Catalent [Member]"
       }
      }
     },
     "localname": "CatalentMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent council license agreement.",
        "label": "Council License Agreement [Member]"
       }
      }
     },
     "localname": "CouncilLicenseAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Council License Agreement Step 1",
        "label": "Council License Agreement Step 1"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep1Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Council License Agreement Step 2",
        "label": "Council License Agreement Step 2"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep2Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Council License Agreement Step 3",
        "label": "Council License Agreement Step 3"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep3Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A",
        "label": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C",
        "label": "Customer C [Member]"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationAmerisourceBergenRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Custome rConcentration AmerisourceBergen Risk Member",
        "label": "AmerisourceBergen - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationAmerisourceBergenRiskMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationCardinalHealthRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Concentration Cardinal Health Risk Member",
        "label": "Cardinal Health - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationCardinalHealthRiskMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationMcKessonCorporationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation - Major Customer",
        "label": "McKesson Corporation - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationMcKessonCorporationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPillPackRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major customers in concentration of sales.",
        "label": "PillPack - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPillPackRiskMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer D",
        "label": "Customer D [Member]"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DebtTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portions of the Credit and Security Agreement to draw funds.",
        "label": "Debt Tranche [Axis]"
       }
      }
     },
     "localname": "DebtTrancheAxis",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_DebtTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DebtTrancheDomain"
       }
      }
     },
     "localname": "DebtTrancheDomain",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DefinedContributionPlanMaximumEmployerMatchingContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount employer matches of the employee's contribution per year.",
        "label": "Maximum matching contribution per year"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumEmployerMatchingContribution",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_DefinedContributionPlanVestingServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The service period after which matching contributions vest in the defined contribution plan.",
        "label": "Defined contribution plan vesting service period"
       }
      }
     },
     "localname": "DefinedContributionPlanVestingServicePeriod",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_DomesticPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Patents Bijuva",
        "label": "Domestic Patents BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsNonApprovedBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Patents Non-Approved Bijuva [Member]",
        "label": "Domestic Patents Non-Approved Bijuva [Member]"
       }
      }
     },
     "localname": "DomesticPatentsNonApprovedBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Patents Progesterone Formulations",
        "label": "Domestic Patents Progesterone Formulations"
       }
      }
     },
     "localname": "DomesticPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic US Design Patents IMVEXXY",
        "label": "Domestic US Design Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic US Patents IMVEXXY",
        "label": "Domestic US Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic US Patents",
        "label": "Domestic US Patents"
       }
      }
     },
     "localname": "DomesticUSPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic US Utility Patents IMVEXXY",
        "label": "Domestic US Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentOperaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Utility Patent Opera",
        "label": "Domestic Utility Patent Opera"
       }
      }
     },
     "localname": "DomesticUtilityPatentOperaMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTopicalCreamCandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent domestic utility patent topical cream candidates.",
        "label": "Domestic Utility Patent Topical Cream Candidates [Member]"
       }
      }
     },
     "localname": "DomesticUtilityPatentTopicalCreamCandidatesMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Utility Patent Transdermal Patch",
        "label": "Domestic Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "DomesticUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTx009HRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Utility Patent TX009HR",
        "label": "Domestic Utility Patent TX009HR"
       }
      }
     },
     "localname": "DomesticUtilityPatentTx009HRMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_EntityCommonStockHeldByNonaffiliates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.",
        "label": "Entity Common Stock Held by Non-affiliates"
       }
      }
     },
     "localname": "EntityCommonStockHeldByNonaffiliates",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_ExpirationPeriod20YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Period 20 Years",
        "label": "Expiration Period 20 Years [Member]"
       }
      }
     },
     "localname": "ExpirationPeriod20YearsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ExpirationPeriodIndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Period Indefinite",
        "label": "Expiration Period Indefinite [Member]"
       }
      }
     },
     "localname": "ExpirationPeriodIndefiniteMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FacilityFeePaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.",
        "label": "Facility fee paid (percent)"
       }
      }
     },
     "localname": "FacilityFeePaidPercent",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_FinancingAgreementAmendment6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 6",
        "label": "Financing Agreement Amendment No. 6 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment6Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment7Period1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 7 - Fiscal Quarter Ending March 31, 2021",
        "label": "Financing Agreement Amendment No. 7 - Fiscal Quarter Ending March 31, 2021 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment7Period1Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment7Period2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 7 - Fiscal Quarter Ending June 30, 2021",
        "label": "Financing Agreement Amendment No. 7 - Fiscal Quarter Ending June 30, 2021 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment7Period2Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No 8",
        "label": "Financing Agreement Amendment No 8 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period10Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Second quarter of 2023.",
        "label": "Financing Agreement Amendment No. 8 - Second quarter of 2023 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period10Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period11Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Third quarter of 2023.",
        "label": "Financing Agreement Amendment No. 8 - Third quarter of 2023 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period11Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period12Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Fourth quarter of 2023.",
        "label": "Financing Agreement Amendment No. 8 - Fourth quarter of 2023 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period12Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period13Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - First quarter of 2024.",
        "label": "Financing Agreement Amendment No. 8 - First quarter of 2024 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period13Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - First quarter of 2021.",
        "label": "Financing Agreement Amendment No. 8 - First quarter of 2021 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period1Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Second quarter of 2021.",
        "label": "Financing Agreement Amendment No. 8 - Second quarter of 2021 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period2Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Third quarter of 2021.",
        "label": "Financing Agreement Amendment No. 8 - Third quarter of 2021 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period3Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Fourth quarter of 2021.",
        "label": "Financing Agreement Amendment No. 8 - Fourth quarter of 2021 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period4Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - First quarter of 2022.",
        "label": "Financing Agreement Amendment No. 8 - First quarter of 2022 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period5Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Second quarter of 2022.",
        "label": "Financing Agreement Amendment No. 8 - Second quarter of 2022 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period6Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Third quarter of 2022.",
        "label": "Financing Agreement Amendment No. 8 - Third quarter of 2022 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period7Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period8Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - Fourth quarter of 2022.",
        "label": "Financing Agreement Amendment No. 8 - Fourth quarter of 2022 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period8Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementAmendment8Period9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Agreement Amendment No. 8 - First quarter of 2023.",
        "label": "Financing Agreement Amendment No. 8 - First quarter of 2023 [Member]"
       }
      }
     },
     "localname": "FinancingAgreementAmendment8Period9Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member of financing agreement.",
        "label": "Financing Agreement [Member]"
       }
      }
     },
     "localname": "FinancingAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FixedCommissionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fixed commission rate of the aggregate gross sales price per share sold.",
        "label": "Fixed Commission Rate"
       }
      }
     },
     "localname": "FixedCommissionRate",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ForeignDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Design Patents IMVEXXY",
        "label": "Foreign Design Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Patents BIJUVA",
        "label": "Foreign Patents BIJUVA"
       }
      }
     },
     "localname": "ForeignPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Patents IMVEXXY",
        "label": "Foreign Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Patents Member",
        "label": "Foreign Patents Member"
       }
      }
     },
     "localname": "ForeignPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Patents Progesterone Formulations",
        "label": "Foreign Patents Progesterone Formulations"
       }
      }
     },
     "localname": "ForeignPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Utility Patent Transdermal Patch",
        "label": "Foreign Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "ForeignUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Utility Patents IMVEXXY",
        "label": "Foreign Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_HormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Hormone Therapy Drug Candidate Patents - (Pending) [Member]"
       }
      }
     },
     "localname": "HormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyBijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMVEXXY, BIJUVA and ANNOVERA",
        "label": "IMVEXXY, BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "ImvexxyBijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about ImvexxyTm.",
        "label": "Imvexxy [Member]"
       }
      }
     },
     "localname": "ImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_IncreaseDecreaseInSecurityDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represent increase decrease in security deposit.",
        "label": "Payment of security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposit",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_IncreaseInAllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable before recoveries and write-offs.",
        "label": "Increase in allowance"
       }
      }
     },
     "localname": "IncreaseInAllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_KnightLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Knight License Agreement",
        "label": "Knight License Agreement [Member]"
       }
      }
     },
     "localname": "KnightLicenseAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LenderWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lender Warrants",
        "label": "Lender Warrants [Member]"
       }
      }
     },
     "localname": "LenderWarrantsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Number of options to extend lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtendNumber",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future rented area to be occupied for administrative office space as defined in lease.",
        "label": "Lease not yet commenced (area)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedArea",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_LiborFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents libor floor rate.",
        "label": "LIBOR floor rate"
       }
      }
     },
     "localname": "LiborFloorRate",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LicenseAgreementTheramexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Theramex",
        "label": "License Agreement Theramex [Member]"
       }
      }
     },
     "localname": "LicenseAgreementTheramexMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of license rights.",
        "label": "License rights, net"
       }
      }
     },
     "localname": "LicenseRights",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LineOfCreditFacilityUndrawnTrancheNoLongerAvailable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an undrawn tranche under a financing agreement that is no longer available.",
        "label": "Line Of Credit Facility Undrawn Tranche No Longer Available"
       }
      }
     },
     "localname": "LineOfCreditFacilityUndrawnTrancheNoLongerAvailable",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity.",
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_LongTermIncentiveCompensationPlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Incentive Compensation Plan 2009 Member.",
        "label": "2009 Long Term Incentive Compensation Plan [Member]"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2009Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MaximumCommonStockOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum aggregate offering price of common stock shares permitted to offer and sell under sales agreement.",
        "label": "Maximum Common Stock Offering Price"
       }
      }
     },
     "localname": "MaximumCommonStockOfferingPrice",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.",
        "label": "Maximum costs and expenses for post approval"
       }
      }
     },
     "localname": "MaximumCostsAndExpensesForPostApprovalStudyToBePaid",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MidCapAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member of Mid Cap agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "MidCapAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MilestonePaymentReceivedUponRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment received upon regulatory approval.",
        "label": "Milestone payment received upon regulatory approval"
       }
      }
     },
     "localname": "MilestonePaymentReceivedUponRegulatoryApproval",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentUponFDAApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments upon FDA approval.",
        "label": "Milestone payment upon FDA Approval"
       }
      }
     },
     "localname": "MilestonePaymentUponFDAApproval",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments payable after release of first commercial batch.",
        "label": "Milestone payments (payment after release of first commercial batch)"
       }
      }
     },
     "localname": "MilestonePaymentsAfterReleaseOfFirstCommercialBatch",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments due upon specified levels of cumulative net sales for under agreement.",
        "label": "Milestone payments upon specified levels of cumulative net sales"
       }
      }
     },
     "localname": "MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.",
        "label": "Minimum cash balance requirement under credit agreement"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreement",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement before adjustment.",
        "label": "Minimum cash balance requirement under credit agreement before adjustment"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreementBeforeAdjustment",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumRevenueRequirementUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum consolidated net revenue requirements attributable to commercial sales under the credit and secuirty agreement.",
        "label": "Minimum revenue requirement under credit agreement"
       }
      }
     },
     "localname": "MinimumRevenueRequirementUnderCreditAgreement",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MultipleTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiple Trademarks",
        "label": "Multiple Trademarks [Member]"
       }
      }
     },
     "localname": "MultipleTrademarksMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NetRentableAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area as defined in lease.",
        "label": "Net rentable area"
       }
      }
     },
     "localname": "NetRentableAreaLease",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_NetSalesAmountPerStepbasedRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net sales amount as defined in license agreement for step-based royalty payments.",
        "label": "Net sales amount per step-based royalty"
       }
      }
     },
     "localname": "NetSalesAmountPerStepbasedRoyalty",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NolCarryForwardPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of operating loss carryforward included in operating loss carryforward.",
        "label": "NOL carryforward period"
       }
      }
     },
     "localname": "NolCarryForwardPeriod",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_NonQualified2012StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Qualified 2012 Stock Incentive Plan Member.",
        "label": "2012 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "NonQualified2012StockIncentivePlanMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to operating lease costs.",
        "label": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to stock options exercised in cashless transaction.",
        "label": "Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number of customers - revenue"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of principal installment payments under credit and security agreement.",
        "label": "Number of quarterly principal installment payments"
       }
      }
     },
     "localname": "NumberOfInstallmentPayments",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of issued patents.",
        "label": "Number of issued patents"
       }
      }
     },
     "localname": "NumberOfIssuedPatents",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatentsDomestic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of issued patents domestic.",
        "label": "Number of issued patents domestic."
       }
      }
     },
     "localname": "NumberOfIssuedPatentsDomestic",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatentsForeign": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of issued patents foreign.",
        "label": "Number of issued patents foreign"
       }
      }
     },
     "localname": "NumberOfIssuedPatentsForeign",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to warrants exercised in cashless transaction.",
        "label": "Number of stock issued in cashless exercise of warrants"
       }
      }
     },
     "localname": "NumberOfStockIssuedInCashlessExerciseOfWarrants",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfStockOptionsExercisedInCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options exercised in the cashless transaction.",
        "label": "Number of stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfStockOptionsExercisedInCashlessExercise",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of subsidiaires for period reported.",
        "label": "Number of subsidiaries"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CompanyDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfTranchesUnderTermLoanFacility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of seperate tranches under terms of the Credit Agreement.",
        "label": "Number of tranches under term loan facility"
       }
      }
     },
     "localname": "NumberOfTranchesUnderTermLoanFacility",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfVendors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vendors.",
        "label": "Number of vendors - suppliers"
       }
      }
     },
     "localname": "NumberOfVendors",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration year of operating loss carryforward.",
        "label": "NOL carryforward expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "gYearItemType"
    },
    "txmd_OutsideConsultant2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A person who provides consutling services to the Company.",
        "label": "Outside Consultants Warrants [Member]"
       }
      }
     },
     "localname": "OutsideConsultant2Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PaymentsToAcquireIntellectualPropertyLicense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outlow for payments to acquire intellectual property license.",
        "label": "Payments To Acquire Intellectual Property License",
        "negatedLabel": "Payment for intellectual property license"
       }
      }
     },
     "localname": "PaymentsToAcquireIntellectualPropertyLicense",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent performance stock units.",
        "label": "Performance Stock Units [Member]"
       }
      }
     },
     "localname": "PerformanceStockUnitsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PeriodExercisableUnderwritersOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period the option is exercisable per agreement.",
        "label": "Period exercisable underwriters option"
       }
      }
     },
     "localname": "PeriodExercisableUnderwritersOption",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New 2019 Plan.",
        "label": "Plan 2019 [Member]"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PrepaidManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid manufacturing costs.",
        "label": "Prepaid manufacturing"
       }
      }
     },
     "localname": "PrepaidManufacturing",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaidSalesAndMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It refers to the amount of prepaid sales and marketing costs incurred.",
        "label": "Prepaid sales and marketing costs"
       }
      }
     },
     "localname": "PrepaidSalesAndMarketingCostsCurrent",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment fee, expressed as a percentage of the tranche funding being repaid.",
        "label": "Prepayment fee percentage"
       }
      }
     },
     "localname": "PrepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrescriptionVitaminsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about Prescription Vitamins.",
        "label": "Prescription Vitamins [Member]"
       }
      }
     },
     "localname": "PrescriptionVitaminsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PrimeRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prime rate floor.",
        "label": "Prime rate floor"
       }
      }
     },
     "localname": "PrimeRateFloor",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital by public offering.",
        "label": "Proceeds from issuance public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuancePublicOffering",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_QuarterlyRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of quarterly royalty payments on net sales which the company is entitled to receive.",
        "label": "Quarterly royalty payments percentage"
       }
      }
     },
     "localname": "QuarterlyRoyaltyPaymentsPercentage",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RegulatoryMilestoneAdditionalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.",
        "label": "Regulatory milestone payments"
       }
      }
     },
     "localname": "RegulatoryMilestoneAdditionalPayment",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RentedAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rented area as defined in lease.",
        "label": "Rented area lease"
       }
      }
     },
     "localname": "RentedAreaLease",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_RepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The repayment fee, expressed as a percentage of the tranche funding being repaid.",
        "label": "Repayment fee percentage"
       }
      }
     },
     "localname": "RepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RepaymentOfDebtWithNewCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.",
        "label": "Repayment of debt with new credit facility"
       }
      }
     },
     "localname": "RepaymentOfDebtWithNewCreditFacility",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RepaymentPeriodEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments from April 1, 2023 through March 31, 2024.",
        "label": "Repayments from April 1, 2023 through March 31, 2024 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodEightMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_RepaymentPeriodFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments through March 31, 2022.",
        "label": "Repayments through March 31, 2022 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodFiveMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_RepaymentPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024.",
        "label": "Repayments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodFourMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_RepaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment by March 31, 2021.",
        "label": "Repayment by March 31, 2021 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodOneMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_RepaymentPeriodSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments from April 1, 2022 through March 31, 2023.",
        "label": "Repayments from April 1, 2022 through March 31, 2023 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodSevenMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_RepaymentPeriodSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment on March 31, 2022.",
        "label": "Repayment on March 31, 2022 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodSixMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_RepaymentPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments on December 31, 2022 and March 31, 2023.",
        "label": "Repayments on December 31, 2022 and March 31, 2023 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodThreeMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_RepaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments on March 31, 2022, June 30, 2022 and September 30, 2022.",
        "label": "Repayments on March 31, 2022, June 30, 2022 and September 30, 2022 [Member]"
       }
      }
     },
     "localname": "RepaymentPeriodTwoMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ReturnPeriodOfUnsalablePrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the company accepts returns of unsalable prescription products from customers following product expiration.",
        "label": "Return period of unsalable prescription products"
       }
      }
     },
     "localname": "ReturnPeriodOfUnsalablePrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for risks and uncertainties.",
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_RoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of the net sales to be paid as royalty per license agreement.",
        "label": "Royalty (percent)"
       }
      }
     },
     "localname": "RoyaltyPercent",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SalesDiscountsReturnsAndAllowancesGoods1": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.",
        "label": "Allowance for coupons and returns"
       }
      }
     },
     "localname": "SalesDiscountsReturnsAndAllowancesGoods1",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SalesMilestonePaymentsInTranches": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales milestone payments per licensing agreement.",
        "label": "Sales milestone payment"
       }
      }
     },
     "localname": "SalesMilestonePaymentsInTranches",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below."
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of supplementary lease and cash flow information.",
        "label": "Supplemental lease information"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ScheduleOfWarrantRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.",
        "label": "Summary of our Warrant activity during the year ended December 31, 2020:"
       }
      }
     },
     "localname": "ScheduleOfWarrantRollForwardTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Weighted average remaining contractual life, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms One",
        "verboseLabel": "Weighted average remaining contractual life, warrants outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Weighted average remaining contractual life, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of shares under warrants vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.",
        "label": "Aggregate intrinsic value, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.",
        "label": "Range - exercise price of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire unvested shares reserved for issuance.",
        "label": "Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.",
        "label": "Outstanding Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 3",
        "verboseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShelfLifeOfPrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period shelf life of prescription products from date of manufacture.",
        "label": "Shelf life of prescription products"
       }
      }
     },
     "localname": "ShelfLifeOfPrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShippingAndHandlingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for shipping and handling costs.",
        "label": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostsPolicyTextBlock",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_SignificantSupplyCommitmentPercentagePayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.",
        "label": "Significant supply commitment percentage payable"
       }
      }
     },
     "localname": "SignificantSupplyCommitmentPercentagePayable",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents specified level one of cumulative net sales for milestone payments.",
        "label": "Specified level one of cumulative net sales for milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents specified level three of cumulative net sales for milestone payments.",
        "label": "Specified level three of cumulative net sales for milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents specified level two of cumulative net sales for milestone payments.",
        "label": "Specified level two of cumulative net sales for milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SubscriptionAgreementKnightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Agreement Knight",
        "label": "Subscription Agreement Knight [Member]"
       }
      }
     },
     "localname": "SubscriptionAgreementKnightMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierOneConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent supplier one concentration risk.",
        "label": "Supplier One Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierOneConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierThreeConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Three Concentration Risk Member",
        "label": "Supplier 3"
       }
      }
     },
     "localname": "SupplierThreeConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierTwoConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Two Concentration Risk Member",
        "label": "Supplier 2"
       }
      }
     },
     "localname": "SupplierTwoConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Three as defined in financing agreement.",
        "label": "Tranche Three [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Two as defined in financing agreement.",
        "label": "Tranche Two [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_UnderwritersOptionGrantedInPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares available to be purchased per underwriter's option.",
        "label": "Underwriters option granted in period shares"
       }
      }
     },
     "localname": "UnderwritersOptionGrantedInPeriodShares",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_UnderwritingAgreementCantorFitzgeraldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement Cantor Fitzgerald",
        "label": "Underwriting Agreement Cantor Fitzgerald [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementCantorFitzgeraldMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_UnderwritingAgreementGoldmanSachsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement Goldman Sachs",
        "label": "Underwriting Agreement Goldman Sachs [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementGoldmanSachsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_UnderwritingAgreementJPMorganChaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement JP Morgan Chase",
        "label": "Underwriting Agreement JP Morgan Chase [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementJPMorganChaseMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_VitaminsImvexxyAndBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vitamins, IMVEXXY and BIJUVA.",
        "label": "Vitamins, IMVEXXY and BIJUVA [Member]"
       }
      }
     },
     "localname": "VitaminsImvexxyAndBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantGrantedInRelationToFinancingAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a warrant granted in relation to financing agreement.",
        "label": "Warrant Granted In Relation To Financing Agreement",
        "verboseLabel": "Warrant granted in relation to Financing Agreement"
       }
      }
     },
     "localname": "WarrantGrantedInRelationToFinancingAgreement",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item provides the weighted-average contractual remaining life of warrants.",
        "label": "Weighted-average contractual remaining life"
       }
      }
     },
     "localname": "WarrantsAndRightsWeightedAverageContractualRemainingLife",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.",
        "label": "Weighted average exercise price warrants cancelled/forfeited"
       }
      }
     },
     "localname": "WarrantsCancelledForfeitedOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.",
        "label": "Weighted average exercise price warrants granted"
       }
      }
     },
     "localname": "WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which warrant holders can acquire the shares reserved for issuance.",
        "label": "Weighted average exercise price of warrants (in dollars per share)",
        "periodEndLabel": "Weighted average exercise price warrants outstanding ending",
        "periodStartLabel": "Weighted average exercise price warrants outstanding beginning"
       }
      }
     },
     "localname": "WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WarrantsUnvestedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which warrant holders can acquire the shares reserved for issuance on warrants outstanding and unvested.",
        "label": "Weighted average exercise price warrants unvested ending"
       }
      }
     },
     "localname": "WarrantsUnvestedWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WeightedAverageExercisePriceOtherThanOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.",
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOtherThanOptions",
     "nsuri": "http://therapeuticsmd.com/20201231",
     "presentation": [
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r40",
      "r97",
      "r372",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Amounts due to related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r23",
      "r159",
      "r160"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net of allowance for doubtful accounts of $1,117,854 and $904,040, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued sales and marketing costs"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued legal and accounting expense"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll, bonuses and commission costs"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r9",
      "r43",
      "r239"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensated absences"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r197"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r247",
      "r249",
      "r291",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r210",
      "r218",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Warrant granted in relation to Financing Agreement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r249",
      "r281",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r161",
      "r166",
      "r167",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Balance at beginning"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "negatedLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OpeningBalanceOfAllowanceForDoubtfulAccountsIsReconciledToClosingBalanceForExpectedCreditLossesAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r66",
      "r82",
      "r351"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r180",
      "r188"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r139",
      "r148",
      "r154",
      "r164",
      "r328",
      "r331",
      "r339",
      "r405",
      "r418"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r56",
      "r91",
      "r164",
      "r328",
      "r331",
      "r339"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r250",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r35",
      "r436",
      "r437"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r85",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r84",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r340"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r224",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrants exercise price",
        "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Number of warrants issued",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r224",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r207",
      "r408",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - See Note 14"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r201",
      "r203",
      "r206",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at ending (in shares)",
        "periodStartLabel": "Balance at beginning (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - par value $0.001; 600,000,000 and 350,000,000 shares authorized: 299,765,396 and 271,177,076 issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r158",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r158",
      "r336",
      "r337",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r158",
      "r336",
      "r337",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r123",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk and other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "BUSINESS CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r128",
      "r129",
      "r158",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk percentage",
        "verboseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r126",
      "r128",
      "r129",
      "r130",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r158",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68",
      "r389"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r127",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r211",
      "r406",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r45",
      "r213",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Principal repayment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r46",
      "r94",
      "r219",
      "r220",
      "r221",
      "r222",
      "r349",
      "r350",
      "r352",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r349",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt discount",
        "verboseLabel": "Debt Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r212",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r55",
      "r351"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt financing fees on undrawn tranches (Note 8)"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Interest expense limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "R&amp;D credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred income tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120202019And2018AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Contributions under plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Matching contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "EMPLOYEE BENEFIT PLAN"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r82",
      "r195"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation of fixed assets",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r82",
      "r195"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018:"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share, basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted",
        "verboseLabel": "Loss per common share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r301",
      "r321"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r301",
      "r321"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Adjustment in valuation allowances"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r301",
      "r321"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Federal income tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r301",
      "r321"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Permanent and other differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r294",
      "r301"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Excess stock benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r301",
      "r321"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax rate, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r109",
      "r111",
      "r119",
      "r165",
      "r218",
      "r223",
      "r285",
      "r286",
      "r287",
      "r316",
      "r317",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r88",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r181",
      "r184",
      "r187",
      "r191",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r187",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r181",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r187",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "License rights acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r82",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on extinguishment of debt",
        "negatedLabel": "Loss of extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r67",
      "r91",
      "r139",
      "r147",
      "r150",
      "r153",
      "r155",
      "r164",
      "r339"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r82",
      "r192"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Write off of patent and trademark cost",
        "verboseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r194",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r96",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r139",
      "r147",
      "r150",
      "r153",
      "r155",
      "r404",
      "r409",
      "r413",
      "r424"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails",
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails",
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r302",
      "r304",
      "r310",
      "r318",
      "r322",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r110",
      "r111",
      "r138",
      "r300",
      "r319",
      "r323",
      "r425"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r88",
      "r298",
      "r299",
      "r304",
      "r305",
      "r309",
      "r315",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r183",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r183",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedTrademarks": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Trademarks"
       }
      }
     },
     "localname": "IndefiniteLivedTrademarks",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r88",
      "r186",
      "r386",
      "r387",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r179",
      "r185"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r60",
      "r137",
      "r348",
      "r351",
      "r412"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r71",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r79",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r53"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory",
        "totalLabel": "TOTAL INVENTORY"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r54",
      "r88",
      "r116",
      "r173",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "verboseLabel": "Inventory charge"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.",
        "label": "Land and Building [Member]"
       }
      }
     },
     "localname": "LandAndBuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r91",
      "r149",
      "r164",
      "r329",
      "r331",
      "r332",
      "r339"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r91",
      "r164",
      "r339",
      "r407",
      "r420"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r91",
      "r164",
      "r329",
      "r331",
      "r332",
      "r339"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r19",
      "r20",
      "r91",
      "r164",
      "r329",
      "r331",
      "r332",
      "r339"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReflectsOurAggregateFuturePrincipalPaymentsUnderFinancingAgreementForNextFiveYearsAsAmendedByAmendmentNo.8Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term debt",
        "verboseLabel": "TOTAL LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312020And2019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r120",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "THE COMPANY"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Company"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r63",
      "r83",
      "r91",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r139",
      "r147",
      "r150",
      "r153",
      "r155",
      "r164",
      "r339",
      "r410",
      "r423"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing activity"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r147",
      "r150",
      "r153",
      "r155"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Lease impairment"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Short-term operating lease liability (included in Other current liabilities)",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability",
        "verboseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r359",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for amounts included in the measurement of lease liabilities for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets",
        "verboseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r364",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Rental expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss carry forward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails",
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesLossIncomeBeforeTaxesIncludesFollowingComponentsDetails",
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "totalLabel": "TOTAL OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Miscellaneous income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r6",
      "r178"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid costs"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of deferred financing fees"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r250",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other current assets",
        "totalLabel": "TOTAL OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r6",
      "r177",
      "r178"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common stock, net of costs",
        "verboseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Credit Agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r74",
      "r95"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Financing Agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r284"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options and warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r196"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "TOTAL FIXED ASSETS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r198",
      "r421"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Fixed assets, net",
        "totalLabel": "TOTAL FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r88",
      "r198",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Fixed assets, net consist of the following:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Useful life of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r64",
      "r168"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2025"
       }
      }
     },
     "localname": "PurchaseObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2024"
       }
      }
     },
     "localname": "PurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2021"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2022"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Minimum purchase commitment, 2023"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r29",
      "r88",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services.",
        "label": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Recorded Unconditional Purchase Obligation [Line Items]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationTable": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes each recorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.",
        "label": "Recorded Unconditional Purchase Obligation [Table]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r241",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Amount billed"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r241",
      "r370",
      "r373",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r368",
      "r369",
      "r371",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r75",
      "r95"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayment of Credit Agreement"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r297",
      "r442"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r88",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r223",
      "r288",
      "r419",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r109",
      "r111",
      "r165",
      "r285",
      "r286",
      "r287",
      "r316",
      "r317",
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r135",
      "r136",
      "r146",
      "r151",
      "r152",
      "r156",
      "r157",
      "r158",
      "r234",
      "r235",
      "r389"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenue, net",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r61",
      "r91",
      "r135",
      "r136",
      "r146",
      "r151",
      "r152",
      "r156",
      "r157",
      "r158",
      "r164",
      "r339",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r363",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r128",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of calculation of diluted net loss per share allocable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r46",
      "r94",
      "r219",
      "r220",
      "r221",
      "r222",
      "r349",
      "r350",
      "r352",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8:"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "As of December 31, 2020 and 2019, the carrying value of our debt consisted of the following:"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "The components of the net deferred income tax asset as of December 31, 2020, 2019, and 2018 are as follows:"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r181",
      "r186",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312020And2019Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "For financial reporting purposes, (loss) income before taxes includes the following components:"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory consists of the following:"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Other current assets consist of the following:"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueNetByProductMixForYearsEndedDecember3120202019And2018Details",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Summarized quarterly financial data for fiscal years 2020 and 2019 is as follows"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r93",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r265",
      "r270",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule of restricted stock units and performance stock units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r250",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r256",
      "r270",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2020 is as follows:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2020, 2019, and 2018 are set forth in the table below."
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Sales, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Non cash compensation expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited, number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Forfeited, weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted, number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average grant date fair value",
        "terseLabel": "Weighted average grant date fair value, granted",
        "verboseLabel": "Granted, weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance, number of shares",
        "periodStartLabel": "Beginning balance, number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance, weighted average grant date fair value",
        "periodStartLabel": "Beginning balance, weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, warrants outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested/Released, number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Vested/Released, weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Cancelled/Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of shares under warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r257",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of shares under warrants outstanding ending",
        "periodStartLabel": "Number of shares under warrants outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of shares under options, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares under options, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares under options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending",
        "periodStartLabel": "Aggregate intrinsic value, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r258",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares under options, ending",
        "periodStartLabel": "Number of shares under options, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending",
        "periodStartLabel": "Weighted average exercise price, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of shares under options, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r248",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/ScheduleOfRestrictedStockUnitsAndPerformanceStockUnitsDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r88",
      "r250",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Aggregate intrinsic value, warrants outstanding ending",
        "periodStartLabel": "Aggregate intrinsic value, warrants outstanding beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r276",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term (in years)",
        "verboseLabel": "Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, vested and exercisable ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of shares under options, unvested ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r100",
      "r101",
      "r102",
      "r104",
      "r109",
      "r111",
      "r119",
      "r165",
      "r218",
      "r223",
      "r285",
      "r286",
      "r287",
      "r316",
      "r317",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r119",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r246",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r218",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares issued in offerings, net of cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r21",
      "r22",
      "r218",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Issuance of shares from release of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r218",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r218",
      "r223",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Shares issued for exercise of options, net (in shares)",
        "negatedLabel": "Number of shares under options, exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312020IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r218",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares issued in offerings, net of cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r218",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Issuance of shares from release of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r218",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued for exercise of options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r91",
      "r163",
      "r164",
      "r339"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 (Deficit) Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r223",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r347",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r347",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r347",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r347",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement."
       }
      }
     },
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r121",
      "r122",
      "r124",
      "r125",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeasePayment": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.",
        "label": "Variable lease payment"
       }
      }
     },
     "localname": "VariableLeasePayment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ScheduleOfCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312020Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120202019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2020And2019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Warrants expiration date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of deferred financing fees"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25383-109308"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r447": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r448": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r449": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r451": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r452": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r453": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r454": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r455": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r456": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r457": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r458": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r459": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r461": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001387131-21-003140-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-21-003140-xbrl.zip
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M(=H)\38Y'W;/OI3D[<PJZ]7K_^JUNEZK'DSEK-0RIDQ0GX62F\%E1R,7KGD
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M8N.G7*C[T;I#6':R:&Q><W?Z6[I!#8E4@@KYA2+HI]!-?A !MG)MP4R3WBF
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M[1O2G_6' _ZDO]10P3^[HJ*,^G,M_P=02P,$%     @ !)YC4K!]*F=L @
MY!(   L   !E>#$P+3$S+FAT;>V8;8^:0!#'WU]RWV&[2?O*%=!XUP,D0>%.
M4WP(DB;WZ@*ZP$:>"FO/]M-W5\73N^::)FY?5$UDLSMDYC_#;R8!?>"-'./Z
M2A_8IL57;^@YMJ%+VY4=2+6E-[$>^3H%,^_1L;LPS#.J D4N*/!(BBLPQL_
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M'/LR]9*@!Q^S"6/)-<7J%MDHR*](Z/6!(Q'>/2)(11Q)!WOV=UKH76X1?J[
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MR =V.)%]-P]5XK;9T(+H]4YKRYL7BS,9XSBO?6Q4 :U7 ' W"/.$VK8]\#7
M+2)7KA!XK9=S19W*[F,%">I[/*JZ7*]<!R;<C>*W\T+"K.;2O/<?513BPE41
M.)BA?8"93GT5A"O1@;UT]KA7_2!F68C6$I-&UPA_7DAO:9H<R(\W"7>&L(<I
MC0PYAAE#JQ3S]3A/QAC;JC8)$_'[L52)=;3^Z&:JE:!8"M:TY G]ZDOL$$4R
MX@D#NA6YTL%L\GVU+<SVVD2&.@"CXSRU3=$,!PPY!*@R43GG\ $<U>-:<8;/
M^BNV%X^OV(X+M( <,-TW&%!D&ZV+E&GUVV@BI@JY"B&3@.=8F,M$KW#+[7:
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MP.4/P8]7OY.IKGK4N=1)EVH[A BLE@@#X%!U)VR62!0NG):&?X(;%B+%FMO
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MY&T6-&7G-I^\?20HYHGI?Y\HRB8SXEENXC4:X:E'PI-=#@I)RM>#PT)N]Q#
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M)9KUQ>'IT1^$9N\''XX/_C]02P,$%     @ !)YC4N"?V>0!50  7Y(!  L
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M_HZ;?%)GR,F1^1Y/A:$WFJ/K.\X#I3DL$YXM9GBW4 &+U/@P5H.OD%L&E-<
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M\9YU2"_#<=P<1A48[\]M9_=Z<V./SKS)18OG!B_SYH8O1>X.:@*R+.UJT^M
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M,L2QGEU4%'JW+T-:P;[@^[@O%ET>XV=D#<-LKT9HLCQ]:)'+?NFC"Z>DU.2
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MPQHWGPP)%"-IL%:4_$5\]'HD,B$I&R[FBV&K[>DE_42 -.@*I%UF\G %"#P
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M2)/D+^K>I9OY$ XRR:*FR?H@1K#8)L'6KI.L)C1D%(%$]#R'(H>AU1_ZY<2
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M#CZ,\P'0R%YLX< 3<#0GGU$>,F>?471;\_9 LE+N-F>N.&LNK8BKF*0TSH_
MD ?=;S.@Z=)PLX3R6:[R?9L,_4/%WI#N+=8G:)(*^\3)D1(%"A=.\3("U\U
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M<C;O6(6\;Y.F_2X\SM=N@/J),/O&[W_OY?&K/XEHWYS_]A;^\?\!4$L#!!0
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M7RV"Z*+?KIV)T[LK&Z^\^>[G-@5J%QW^(&(=%PN94_>M,/[.(?9D$-B(!1O
M.[D(@<4F]JDQZ$DM>)R9 HH'3(MP#DB1/4,;/[5CX%O"% LF8OOJOR)W3CAB
M9Y/B_TYXK+EO6!S)6$<RY$#4CS49@]A]ICG9R<(4,3><.O!5$FH1P*\L3)C:
M0*.,K&W64\;"5,D$*QM8AS'P9!@G@688@IE4Y,%B0?$5(]R*A!/EV[3ZF_F
MHI:&"Q8,DY 1*ZP?&.4X[%'E55DY'&&FN83F:C1QRD" T#7D%8$.0,K(L%A
M-Q"$5:(3%D"DY$K$"#;FQFE(EXR"B)6\*/%N!7,I?7/JG@4)FP9\7VS9R%3<
MXP+K/-T7)[.9\ 0//5-TU@OA+6Q$MNY!/51]O&4HUP'WY[R,D=3HHY3:&.&
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M'"4Z#3SU/+7B1F4K&Y]9V=&_ %!+ P04    "  $GF-2.TEU=MH'  !2+0
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M^105.Q8O^+H9K],=:G^IFNY>_P]02P,$%     @ !)YC4@9E,*T[!0  _QT
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M@0O5K$/;:!M )'@LP+X%C"EU$L$4PY@(=\%Z<'S"D>?16<BDU)#QK4>Z1%%
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MC73TYV=;1XO%9>D1*"8S.WW,4[0Y<//X,<UX2Y_P9D>^^F3X'U!+ P04
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M>X]*,WQ5E>[K6*>K@B:D=P;)DRT_::'BQY>8)ETWQ)9/'[W]L!&FH/UN)JC
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M*A1Z5C2]XG8"]W#$6VN >D.'79/+?H#;J._1VH2;O+X+5@,5YD/^D^Q "$1
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M9V?GOQ]?-LM^>/KO[[^7?4'MC[[]?OS''W\.?;L)FQT:#\J\** 9P,P%B*8
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MP#B9-LQ"#&F#YA3@SUL '+3QM-4*QFH_FV^#E\QBV :F&_0P'B""NK@1G8%
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MX"WFD4@90((A\6Y92-2D7L- UO6[,D/S=Q!(3D*R3(M]E?5TA\%Z+:P&FB/
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ME&5\5>@[PB4RZ<&H@'70!E$%<AJH0FMTD491*<N?^RX(*7N4CBDU/W4)F5<
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M+D0R@&@NW(RK7S /X$CE <BF/T;3EW!K3M!?.=>-MZ)R%@3K4QT)D "<C!I
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M>*&?X%@/4&S"8BS>Y4KW2+-STL?US,ML4U3AY<%F3:(=<?DZ0[0E74*%Y@Z
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MI].P -L6]4SY',G7K\HJ$<OMN"B;.-#!&1!"-9+==61T#9Y &RD(!\,)F93
M7'*_KU]E+ECV_7VH[:_LV$IA-WHG'B!-G;=&W:L\C=RMNEJJ>L&OY<V2'RU7
MF.8)%SZ:>+DX,R:%D#./3@=?9^#UB:9OZ0:9J8<S[6HC8L2_1$D?F</>-C '
M_'OE]:O?@#>4?24PZ>? &_Y*;$P,Z9')*QDT=C%RT$,[3AREU,(5SE(7K@1+
M+S$JKY[V\45_ 4++=B!? _@_U"1=?WB/)S02HMEJ 8E+"Y.JZL0$-=GW(U)
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M6:/=#\6WU6E3AO\MJVXUM88<K=M7BYN.AI66L0&5[V=XSA#ZQ[C_O%@N6 C
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MX%$W[X9'@Y_&PB'5FD.4<OA%-.&-SK+Q:"F649T67M$TIO29\HZ.?9^:!79
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M"JOU[K@3A30;WW%V8J$\L19.2BP\99"D**G0QCTX,G1WF1\ ;AY[R$CY"$L
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M*\$NSGS^/\'%$6#E^-,OZ<=<[3+\**3KG.,G.%4X3F^FRT#0L&^]:CQIL>&
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MH[0V9P-E[(<0]1(5VC\8PD9TT4A$M3#4*]8&9Y4>I@NER6*-HYG$$.5YNX+
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M@PHMWM&IP<=*>Q6"D/ZBVKH2V@CT TE"%H+O;7LB4BFE$#)&3O7D&5WY$TH
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M'I;.?5@ZW$',+3KVZCEY6A<*YG!4!O%+:<5PMV'B 1-+GS=G#XOJOBPJ7C\
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M@QKJU=RBP*YW\$;"$9@%%P)4VU%D*CP@%2CZH93T!)-Q2YD6,!5W7"O;I1+
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M%AZ0NW69M'/"5R?'O6!K'=?">Z2X] [R=D[C"G%D9E)VGKXKOK:$735A+I:
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MZ&R''L:SX-20V(]^_">I^)NRPDGJ+C.-*"6\@D-'08B>TAZ@[\D_1SU-#C'
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MXWQ*4U8XDE?QTL$L,F0)G0@_;2OYMF@J1[3$^:X@E&Q9:EDL;G;%0K#?!KJ
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M:(@P@\"92?^8.6ZKGS[\ /*V,3NO@7A:&82U?5B9]V!E'EB)[16.]7WD]MB
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M=.5B/U6P.)1 ?_^6XG4U:J=1>$UE:0(S3*S/"%3(E4$M*LU!A@XA@,+=J9*
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ME0,Z9"/PXFX2EV-3#YQ<,RD_$3_S3 "B:\5^O&!)"F@H3(EC<C >G #-5W>
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MF:GM24[+;O,;[1E""@#4%@%'7 ,1+;B:,-DL1FZU>2-B9-">YYN$3\_[X%#
MI_&\PQ(CK-]F[A=2_&"27-R?>78^WU9<:PA^+)A"$ M 1,$,J$;?:]!+U]T5
MX>.]0]0)_ QR"\5!W^2SGW]^\]L/[\[ZR)!'+=Z] E6&% D.&6]V]G4]E;NV
MME0]7N'!(MW*^@R4-AL)H9ZQ_O;F15X^!;8YW-U5P]1P"RT&P(5-X'RYY>L0
MD:9\;FN*W9Q302U_+?9N](;@HXH/UC=Q^[=9J1R6B,>,W=;@#U8YQ7+=!OVV
MXB&5A?TMR0820_%2L?IH9'?8-DW:K_K#%"DM$ZV9N[+]$@3B*Q&I%?KL5:RV
M9&P]*/A7"782N:T:@CQG4)#'].FM>XX)S0ZI)YF11BO@06\VS$-,=5R4X*0'
M$OV/DH"#;L)!X4V)G3.UP#^#/4U6(*#;*19%A*6N6K40X#G=8[6"P3MGJ'IE
MD?WZW=^'X:NN@Z+Z) R86B*TTV7??4Q@$$,7"M-+DWQ P\#83L'(]IMP=U1B
M13^G%N""*O:D*5K ]8"90M?8REJ9P47D-;[2O1$MS_DW:P"C/N?$2V46XBQX
MV_G&>LD=_M? Q4J66:.$KR 4Q*RHD2K9[P#T'X3MV#)@R+AG>7(N(V@AUZ<E
M^@2$N=]>K;^#=)JUPD1UKOZRJ+LT/P[2X7R?SMUH/]LK&-#57U^HD2VT.6+@
M08AJ6O&&:/+$+JG445) <:""X;KE'+7-/'?ZA?8<TL 5]=XTL+Z('9P%VDQD
MWK\AOS 0\"J<WL&(TR.<WL&(T_L/6$"\C:&-^8[X2]]AK,O1$R%"+\\-U\^]
MI>+\9O7$[,!P&:3 ,&Q'V1@A*F L!;>8I9RGQ:%E_DHM9:4XP7)3:FIGJKE?
M2?=S#3ZO*WT9TJJB"-D6W @C_DT;E,9J$-/OP2RWR\#ETB_%6GJ-1%08^.J6
M2+$T4_#:SSDZDF[-C$T9N-[-]$0U[&C?AX5)2Q1O+T=JKDCEK)?*\.<U^/8X
M(/H79]OE ?G"=PV?M6Z-.I=B 35V@>=K.F@CC:$*ZI@K\HP!ER[GY1!9_D#H
M.R#6E(;7W8V!%5X;'<(SAG$)[,Q=2.B2'T/<*LJ60;Z5 Y>B@@C:M_@E6)*O
M)71=QN3?%75B /-,?44+]\/EF :.O-2C(P95(JF6_$0"23@#'IUE=P%QKRIM
M8<OM&&3F1);!I*/,OQ+D=2D?F-KJ)H4?I&;&]JG/WHLP5#3O;>,6C8WB_>A3
M!-MD<P>1^D+PAG0,&VT^8EL;$76F;Z*?+;!S1 +W$4-%SAB?MK^[MQ=SW3H'
M1 DHC42O,1JSU&:$5],VE&&QT1)%?G>%C#^UHM.<7O?;P="BB-A/*._42&*J
M"J_,X)G]@CV>*,)W,3"'5@NH,X_M4XZFGD?_PI%A"@"@!E-*JVADE?31;@W]
MB)"M<?.=*G@^2/&"=T(TD4=_TGEUUN,_)B=6]]L>"$^9##R%'#+PEI@1^=](
MZU(+;MNO\R3<:]-G=^T^-50Z!)&YH-8&!*[47DI>1R$KMY*$"=T)UL_H/M5X
ME%,L] 9/ZU'5VEW_JOR%>4[(]E-2>S)TP*_/W&&ALULBR!2DXX]?<B$85\+>
MT)^_VOT*5&&>U\L$,S+VYR4>,?E9QG29I<T<![7[AZ_8'6LJ>EZJG\"  2I0
M7288U'>1?(T7YT_?-NGUO[/W'+]SNW49W*YK+M;I\<FIKM9U!OSEQ]BXJUAN
MSL8"<FU%/3<>XA0:\_&X4-;@?<,0<R8*4ST:] /I+,JW) #T#Y2I4;B>AG!9
MH6 9*2VY=ZH(-2'V@&L%BW!L68^6:]-WTJS6:T-+>*CYFCZ5)8ZI)C!T[ 'I
M8L85@V'8&"'>G)85 2&R@@)FSJAKYC"@.1A)8G5IMS_"F'E7U"BZFR"ZUEK5
MIICJKSB74(2U*1%C76':CS)$?%'['AD951+)%H8*I&4XYZ*!BHO3N-42'YA1
MQ#9!Q!Q-(VM%%!4J[!1&,[AVJ[KAR,0'(Y&L"TZ)U;XE[3.[=*YCQM>PPSEP
MS8^"MJF"I@%*=YTZB6,IPT]1+NM"^M50O]$A6W%F>V0%_E['%!P6[;4/9;RB
M[:3=?3@338[RNR'RZ_L>/A>H-O)#;$5:3EOJZ(0$RS-#Q6.,>7#15JTY\$H/
M4Z5]'I)#I?GT&9><[Y-,X,EEH0V=\F3I6 +E6:YON/?4.*S=H:B*=)X38]4F
M[X.0U2CNFR#NDBO_--NAEV1B,1G=DTV1$=)F+ '<TM[%R1V?!?,-.M.ODW;J
M!:\UY%/FOJ\^"M0F")0KC?,@5['K=CO8+"6@MKW(8%0,<R,N,*DJ19Y#N6(]
M>#=F#SGK?24:B2E*>J[W=_CV42PW0"P[II^TG$BH"?;,VE:U8@4"%Z'L-]E;
M+RQ/*G-D>77["Q6@7GJ8 %?;0C ):NW@TY1@0K?H)@.9F[PR2;KRTP5#3AV6
M3C-K.O4R#M(&A,9 V*2D=\G:Z7;<H!)#9E-W?5Z\-\3Z1-_H'X9LR*U'5VA9
MS'(DMV"?8B@=4CKMQ3/@;S-<$K79LN*J_%91K;;"V$MI\D>1UI<9510#H)PU
MC $H ^I=.R&L4*?H3NP>Y8JE!PN00CYW!K2[NFWIEG)=;&B_8#R4@[6NO 0"
M FECLARLJV'[Q?YQM6ZM8Q^'PM@.5% 9OI&KP1I3494/5L$A(<J%.%N63L$'
M#=CN,K^^?_O+&R%CIT25NES#W<II*;5A"!'=^OGW8)(^]GMBND0&RAU-[%([
MT6MX.Y[-N!O"Z^=$Y%6$6)$:<TP*-]OGE> &["P%DD)SU,YCG@]L/^?EZ3S\
M !\X_W,AC+WCI-).2FD=ET9UN*ML0)V&3Y]^DIE[0G+%8<0MM@0M4F0R=6DO
MO=X4WT; >0&C]?,.W0ZR]LGKD1><8,@J1'/4L0>LTA8^1%Z7:AO%:9GGR:04
M&A Z*4)P3< ?X5FX-<9<S\.<BO<*X6=GA9:7EGQZ (KFV@GY1=V7ADL[>U3^
M3)YQMS+-A]?/_C.^YEKX^,,1'T_X^,-'CX]_8EK7MTX6!N^>K%[4C 6FZLJ6
M\V2H/R[+*J>*XD76D)93S-^"R%[ULL7T&K'*@KJFECKLM)K*-A'2:WHBW1[Q
MCEU@UR,&[UID5JR58IFPPXJ5YYD9E#NNJ2*+U8N^.03".I9:R\1!]L0YM9H@
M1@-;Q^B@FLBTL;_[7<(ET/33WG=1GK3%=,XWM)MT97)S0:9$")A\4T0_FDE%
M)'%8>&G++ZT]3]3!TGO^YQ([\D5_YV)H%XQ*BN@,FU)0KXK&I7BH(QOR\\&[
MQ7Q7LL$](1OLO4N:V]_V56>+PB2Y,@T@GKCS<1D.-92IO98Y4HM(SPGN/BY[
M<@9V6[-,4#_EQ.XH];)D(<#''$:+*5N$>[OTSY08E>&OMK!:+[[^ 'D2GW.(
MO,H[]W.J'ZCJ6"NY,4L GHUS=5ST@V_E\.>@89QA'O2K?$-=3J+OR_*#H+?)
MW\$C[6H2T. SX&.D_I[+89<^B@$&B<3A6TRJ:C<+ BS-T+-W4NLUS705%\-;
MCSV]I>S6ME8,])X8;PRZ[TY?JH<SMP3#.H"T'SEK^[L'^_AB^.^!'C_0+F=@
MO^:17]C-L82$$V-H$WO1##MC+NX67F3:+<T]%\2 ^[ZA?,G+3#@L7Q#67[O1
MVE\C82V(U4]H(:XL9R8=I' YZ0S"R*QU++O.K4TK[C_%I=T>HVEE25B5VU4K
M!AS+;4J=@_AFP(-KCS/\;F ,ECHOX6\69622"LG#N$*U?^4T ]M'GNB_VHP#
MICS,R!3_+#E^00M*JR#KK>G2SG-V^)-(5LZ[1D7<17UI*HV3H 4F_GYIS7C:
MUI@/F&W .SA.=Q[H@2CW5NB16=$V0V+*=#X7!KP6T_@ZWLF2C3.(F+6@AQ)M
MJHFU($P]JVJ4%L$U(AW8$)@ANG*X[+(/L.8'N]AJN9G7TINHXA"/M(+'G![)
M8VJFE))&+R1=L\9K]8$T0G3+\>25=7#U;SU392VW8:"NY:.?15MO/9.GWT5;
M\Z!OK*^WGEU387<6H*^O!^VH4%WO. 6]?TH\ZK=6T;)'=U#26\^&M'1W&3^;
MGMYZ=I6B'AS&[51U9^- CK:>7:&J96&'E'7XI!W]Z$VT]=:S*]5U=ZQWT=9#
M>GKKV6T5]>"&W$15PWY?0U=W3]EU577H5QV1];,7AV+/IX%"&-*V@D43_+^R
M@D.0K[:>U4W"GF">=X.[WO"0(88;K/(J=UZ!#]%>B<CGQHMZL+M-Z\)_UD,I
MZ5TEYF/Z\=YK:'=Y9QOLEODD0[YKNX_[X/% &6)%(':L5M@%Y3DI;Y?1_G$Z
M2>K7A:Q%P@9#/IH:"K UL@/4T9Y>CGF2%D/^.95=*A-.2 8\:&#"!P8/3V([
MLBOUXS4'E=5V.DJ<(@2'0Y^VO"G=N"V>FFZ7:EE_6+F4<GFT^*Y4',==NR>R
M(K'A!E&'+E54$OD0-@;Q@C"*Z$<.'$9&.,5/.&U"-.@W,)IDF\ ,TP:&1-E9
M,6VK+KV3I5AB-AJ/-I#0&GAZDS QX/>H-,E":)MFWH:Y[X?TR!PYMQI#Z6LH
MF:;) ;M=CKG T0G97 -UA1NN#Q\(LC])E? FF+A2"%8HQ-1]AY4"KUT_;[.*
MB5)V>UY>2O G*'C%\\H.5#%C<RYQ!:%\R 9RWADVF,%R >K;U?22(MI>Q!OY
M8]^:'EN?9)]\>E=2NZ*/N=8<"RY8$6AO,+]VNM*2Y2 "K)>B_CCK)@#]@S\Q
M+OD[0'._$5P@+SJL%7H]WF15P88IU58-[U>JVPL+V2V$8&C_@R]S<MIGR^OV
M#!JX+'$;AQPI8<,<O$?A#VNBC@YP_BE9\; #S?4:ZQ*$PJ. <"K9:TBO)&VZ
M0)3P;*NZ-9Q4&%PP'K7K&)XC^R]>3-IS9L;T:>2Z<<L,--U3G\VC7H%_SC>G
MDFM84$+LF3/8IU[^[E77>1\5PH99<B%2),=6Z>3ZL-AAM>F2[YW7,^FY3[\1
MYKP[AY[JN$#M6MI/6AF^^VLXH&+M^4(\ZQX&RQM)R\,GJ#AW]R\LQD56ND[A
M:X@>I%5BOGKL^OW3J4!"5(3+ZKRCF (7Z/@052&X=:F<E<26<- BVF)E5T.5
ML=-JRX2S>L#5XSM_UC*3H]UEL3(3(@\BT@W;=M*#0F&K#40#:9'S.16+UA[9
MAH+#2,!+UT'0NW;D%'!#D<X+8&TL!@WG5\C Y$78$,.">;RZ%_ J//^.ZEF)
MBB9P.P47US;<6*1BYL0NJNV*@4NNDC@N#=?*T%HGQ+E(I=K]]288&/@ :%AQ
M6:[TD?&&TPX5Y5Q[+.2\PZYT5.\PZY?X<1@OD56PK="]IR^RVJ$LKSRX'07D
MJT9'D&\)9W1 CB>-])5@%^N(N[8G0[0-_-&!ASN.*KH5BL01<M:#^#_DLJ76
M;0M*D'O-- D3-DC4JC7_*W=/TU2+0D!0M(K#VMI)IMZ'&;:;H>VC@Z-D]-*<
MPMK//B> ,].H"V0).\3N(HXL+\G%MY5C\'RX\>B9?G2E"Y>LN>$>([*P%:&B
M]RY,3480M7[#2W[93F#YL&=GV0I=N&4/\N!(<[A3N4L>4O2J"+N;K,H6P8DL
M SID;4-(_%_9A;2C GF;>JOC=2Z]TAG'VUM:U$H/5(&PXC.3">SEB,"Z-P36
MT8C (@36T8C >IC\I&_\SMEXP%^P(GF/BN2)N;;]WH["1DC,?UZS<(;UVM!<
M>4D=EWS"-^[\29S406MM9(KK\+B9C\BI';8YPKAJSKVP%TB>7M5^#VAO+#9H
MN1%AAK5] Y@H%"YE@EZ4Z)-1US6F'B##3/<.'G#TAZX-Z]^.%J"557BQ97E&
MV<P)N%GH9),OC)69*:_]QVS!^,!]?.S0XRCR4// (C00D.IHZ3+0EV#;)G*)
M)U.A9%_;=ERQ_(% =IA"J<<4]033\@9R5-IF*O82YI54L-@L(^#DD%Q%/V*0
M["-U#(J%O^$Z[U8A-KG13CXS?S^\EK]*M>^1B&,Z44@ I-.AEY5%>V1AX#55
M;/%.V#.Z\:VF1?)/*HFQ?:F1,)1#@+B$&0]<DS-*3M56"?6-Q]MU2LELVA%A
M&N7\/+:WPM=@7Y;:ANH# XN,4\P;42K(F%QI2U=D(QE"L6("L"9:2;]=H[>T
MC]VA[W$^$[P_RP.*7C;V>3FX@1/)3=VK2N"X"-*W@FU*S<VM@8F-I-6TK@)6
M"8]#5N"Y0KDC!C"&R=$G>?SJ,]24;S&ZEW#_T??B:!WN'JH9_SZI)@F8Z=MO
M/N9&VX:'^::L=@X;>"\MZ3TJF<HSZF>*33.QTQB'6+AE>QV"*[B7Q<SR'?L;
MS+>;WTJ"VH>@)_ZRM2UOE2!7H!_4,9SKQY2L.VCNAL%0?IEKAU@A]2\GV]49
MFY(S3&"3K%JX*174J01?@NLE\Y. S5TG-=3"PAX"!QN\]A,UB.5/-6E3CL'S
M:]#2D$^Z=VKCJU8*YVXVZ>L/#_6B\E\0N(#"%':W)BO2U1=EWB+/2V8!]AC?
MQUKQ^+IRNRY:<PUMH6UPU&O'YU"<@4+;.8=-.*HP-;;7A>VJ+,YL[!EX['-+
M@R>#I?:FTT[1L^/"P)M?/N %MR5K]8CN@EZ>3H),KJO@DGO)X+JFMN([N$#K
M4DHJ0( *QW4M?<<4<WJ!KG-P<SY^/7X]A IINL+@X4,Q2RHFV(3++&7Z]Z2>
M7[W$G9:/&+>3"MP@OR2MY+S.+R:I"HI!*78HH)FP49U8RV+#?DH!?D 9\MV[
M>3*BM)8"@NK/1U\M#:/IT"OK>8\+G-IEJP;YD=4 0LG.*Z,Y!$:=V8IO>;%]
MG^!BW!JD9H(82'F %L[7Y:<?Q8VI6:X[OMQ:,=>>3&@#FVF6V# DC"B6B67N
M #QJ@0^5!_55]!B^U!\"[PBSQ-9%H/WYV5PD:8+A<E=<CJ*UC1@ NJ?X.I.D
MB^W"IU8_WH2>L0_O@DW$3M[$T!-3L2RO>O Y"P=U'J):+P-! ^=RX*V[6#:U
M;1;N?YB[W'-O>[P:%J58-FH0>;U;-T'EO74R8 DF0&D(?HFX@,G/TVZLDQ5F
M36*_1X@FF$-Q<D*C/=HUM2N=0?W\;N+Q)*Q\=[V5\+\T"V,X3\V-SJ;J7K>?
MEB$4H*8G#;&7]1+TT> 026BNDA1' W"+Q0R8ZT>:^I$'Z'9C5!R/YLB)KT 2
M35+9.LF3X@,H>3.UU:V@-&>F0BO'"[ X+YYY-D213LH$SJ@?;0HZ^>%+BY8"
MB'2=--34A;Q+#KIQ^.\RH<Z6]NX0=3URJ&V"D(*&G&>3C+P\,#%:Z1QT42K1
M)SG'N>LHY04V);?>)?5!?1GE:/E2D4C" 4H!>G;O?GJT?:C'%#GRI6V*"$I_
M<720,*00WME=^(0?N7=!:MM-R8MRSS,BXD-?1C3:.OMS0D:+]=<888!017!D
M*J=M0QL75>;"& U061MV4"UO&)=;M\J!RM9<-(@M48<J?5$N)AEC<GB37TG&
M@"KLO$6GH"CXSE^++?O.7!#$Y;W\_KTF8$Z>[QSN[47;](_#PV]45ZFVPZM/
M[^#,O<S;8;V.R;6E]#'K0S2%]9M3-V[]. <:A?QBA654I @=)%3P(1RX7&#5
MV-DU1T* (.YM#[,IP>,OSPTE@/BE+H%'+GQ=EU/Z,>XE].KH:\%TB7Y?5AF&
M&2Y+1KQB-C'M?>L;D)<@G<BVOS6@O4I0\>+9@"'NNYQ]?&QTO4F@E^,1]$*@
ME^,1]/(@0"]_901U--B<]WNY )]8E*6/=;$WO2;T!1%(#1@+0MYS7S]*HI'A
MBD3YTP\,7\<2!BJRF9IE@Y;+3O3$EFQ=+-YK:>I2<>V2D*>]5;%@V61F&H8S
M_ZM-@G:9(7,K!Z\\ID<N#N JYDDK&\28!\LNM0/6P^"K$Y]]GM)1#G=$(.19
M3DJ('EI320G^%5-=AOB;J'L(N<LP0(L8)I8L,B@+%_L78+P5EV0"SK9]/Q7Q
MV.G 1Q>UR2],'8>E$=,$,_3G1=TC2\3"<WV8K0020BF5UE6G/P-NDY0]6E,@
M54*!Q W.6LZ25:Q! L!2(?G'4*(N+H<E<,%J8<A$B#2E"-8LGEL.&[WP#Y<H
M'5AA>&-%1\PGD/5+,[WAD55>$UR;YJ)E\.ZY@T/ %92$AOV[YG_]D=)J9 [4
M3,*A:T!I7>?7NE=JCUL<IZU,N.;(;%?B"P[+2]V"$9QQ$9:NAKV80]0(5\<T
MM@(6YBP/<R_3MKE"&4=_J.=H;_;W,/;!)I. ],WGEE48$OK^:&:S22I\ 9J3
MCBUV0HS2J'45"W92*@)-I^L)_Y71\WG."7H%/X4+IO40\"[7JAAG+ 'G_D*6
M_3>Y9P@Y+ /P6_8?1"F5KA.1@P](XE?8CH-AT*>".JA0 WY*#$+$.<ANVTAV
M;!!]3A[I  #]:27-\#+7;NQ\(5$">%Y>XLIQG2#BH^CLP365=KIG#^@V2M8:
M&-D3 $I=L]Z[LX*QMO>)![K9>PELJ>E?OZS8,#M5CG:[PI2-'X"QZ*,P!:^<
M^0'3-W/H*ZL[)GL*?(EVVA+:YIT(IX38.U3VE+AB%<2<*\2RP%^0X?'!TWJ2
ML)Y<FXJM0.W#WVH&8=HLE<P32SA=&C5!-YW+4&WR'LWLVMZY7'BBJRZ:H(!M
MU3N9\)8$/%"A)ANK1A $,N4D$G]UA;[=79(6]F/^:HS+WB$NZTZ.=^RMV!?&
MI&-WKXV0A*PHR@O5^0*"\C76* 8;(09R97$!;DB=[PM#<(7S-3W*QR;(A]?^
M@*RM3,EF/,%P;M H$YL@$UC*C99XV!_$$PB/T04A\@OQP09TR @(V!"909P?
M>HL-.7J>!O$\(Z&*]X@O/*Z[IY1N'^C2XY492.V'?_W&#)HTQ3RQ- Q4?)O5
M >N.A)_E2!+E@>=>=UU?7>7>8ZBZQYC&A4EMDS..HPP<Y;@7SEK+E3 0W;J2
MU.&1!VD&F=^R(N.CH,>@,DA452LS2UHEEU*JV2^]N;K8QH<7>C&0 9J+C0B'
M_3Y4O-19]=A?<VE"D?V[13QE%C"(N,@U1]QQ&TR_EQVWL*@P1IUCU(:C:40W
MDQ7_;#DUXL6],UM>QWSAKAZ0.;205!MQG-3BFPK57#6H-<"\(>0)OAA9I9 R
MIN3X,<:Y8JD5YNR;U_ZE$[S&Y JOC;\T_LJL^>(Z=A4;8NB7I$VJ1&.*N4E2
M+M-DN*O&;0?29P$>*;GE8"\#\E.?Q<"K)?42@_SY//N ,_/(2WWNH(+8H#XN
M.?U,A'DP3)2E  E_"_H9Q[CZI#, ;^5LYIF&/RTEIE:]H$G#30^5'3!>LQWZ
M$&T_YS4%]LCM'<MN]QQLB(:DOG7$3C<G*\V2C"U[FR$)-(J)RYI;X)A=T.0B
MR7+]AAIS4M+1I>CU>CH+E[%NPB<[SZ>F7F9H3]HFIZ&]@RK:<%B?;";NB(IC
M"=I(NQ:>3$EOR8XQ!8_])9&H3&<YSVJZ>:]:G,I#X5!*<PX#*9G)HDJ6JW -
MJ!HY0:!#1A "K5[43:&RFW-J4E@I?5A5MN?S(&"3= C;1$\&!!A^(:])]6[3
M:5S::DB]AC FA+=6[5];"&9H.4$T,1Y(O"UJ;0@@C&3=C?4O2OE1DJ>VFP17
M&/J)V?[JLOW$Y3PTT,11=!BND<,N:^&KO+^ U,"9B#6CQ%UUDXJA\)AQJH8
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MV$-**DP&ULT@?+'@+B+&0J!QXY*%DIG2/48ZT7%S$:QX0"YCOWL.[Z"[)3L
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MRE-T=\MY264Z9?5!FADY;@"62$6%$#^MJ2ZR*<ND5_?9;[+LPC+!>FCL(G#
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M4!BAE$0?B=2&E2N_Y7O7N\2Q^XA?E\6M?!5VU&#)R7G_).(!K$, -&(-!OH
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M1,H4K&YP&F?3YAN,0KG4?&<>V,N=>8X[8XTC0W$K2F5>SL$J-40:24:\M%'
M*8*Q-"^(L]V$\L*\ALK&/>-.%3CX"AWB!4H<EAA[C)/"9</4F9DP#88C[X9H
M=NY'0!ZB%+*U0ND.V.@2;N,I[FZJ-.LQ&6LYWO&QTU5(-X9,?K50L9"RHCV3
ML)_8*2C9 F]:HU!"5FY/9+Q M"@N(>+VZ*BMUZ6>B_47_-2J"D=@5UQA0@QQ
M4S[RK1^,='22TY8BCST_<K\40B!]40@-0QJB7M5@VVL7;%A =$O *CYODRH5
M0KS>IS?"''@3MHD@Y4[\C5*?WA8>MU$78K1NX2S R=^GR@A__< WZ-CB.[2U
M!%.[2NINS4Y*7P..KMN;@.HFY$-\H#B4,? "UP;!.U+N_N#N*'I%66!NE5T@
M$D-H'&=<-9N0,Q(X9'X.9]!EBSVJL4X@@:$XQG^(Z@S$Y$C4]6D:&H'%%FR]
M =,ML]%(N@0<L,BM)5>EXEXQ.L\+9@W>S1P%LCOA6KG@KL/M;YI*VM#.HNEJ
M8JKMI&D(^.5RY0H-GYM9(Q2=#</ YP;4_SSV.88K3V=[$]R)7CKDWXLWO[UZ
MN;UW"G('J[- CFE,S9#K#L*$G:2"H7@3J#U\6SW/9@W[\B!U,":F6_::!H1E
M(P*0PZS8ML#0P-HNEW,\BE,)5LH;Z9ZBO*'+O-K "AL]LF&S#)DM$N3UC+UV
M)+4C[:3\5L.^.#X2#!Q\*!I_/F<W^N@$P],G"RH+#3/+)L>Y]K;AQESG58+A
MAEJ F=,/^&_%@<M= H?-<)APC49C\N6LIF@W: #Z*#.+$S(/?::B%HIY410<
M0F*:YN"9<@E5DB%D8+75(_Y'89,I)2O#"'08];) L:[G;8,H<K8M)=#7F:#$
M7Z1O$3)B@W:K6K*F02 6OJ)9))AJI[9$Y:RY) .>EU'L)!@%/9<8W9TZ=AE-
MV(J\S#@:9G?JHLWQJ+I6:V_:AB*W)-,24:&Q@X"9!><U9U72(F,=F?#"DA^0
MXQ,2UYI17=N?:7BYWXM;8$QUVMWJ; Q=6!^,]V+T$^6<*+X4J;G/L8<(NK]P
MC, 1JI<@983UP*,RIW]9<Z_! 4Z?IK9VE-W<H6Y2*1OONJ/DJ>-0A7772ZYO
M$?I!@UCUKMUJI#^LM==61P>')PL^^O9OK^*>:/A'TQH('2D)&<)C(5CNL!^[
MZYT#EL,W?*S8?D2,"$S*N1+:K\CUXL%#P5$0DF.*7SC]*V#N%&ZPM+VZBY:Z
M454)LVR&+UJORY;3#]9N)CMJF2=$Z5_S9N(9 8U5![4BACJB^5WE_)0E=^()
M9JV-B;K4^::8L^G9%2T=\ *6FX;+1]GE=I28&PGT-88]^(0!-579[WD=<M9
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ME!,U(K=I"MLXF@(Q*U!;?A#>^$%>;6&LV;RRBOQ&3;X<8Z"7I(X9A[+&<=[
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MU#H#A(M)U80A1KI<%69,?&Z(F'!F0F"*6'BD['Y8@(+@NPD8TH7PV$DK20Y
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MG=7A%ITB(D(.+%MLMSUL!>CV&A."!)KJBL052<!8.@UC80)7;XNB6HI]@ZH
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M%^BLU^UJ))OZIV^S+Z-#[O5\?D&]<C>ZHP5\=;7U[,V%J2XR<SEJ[,\E$;^
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MEZLIHEZS]0V/?<  $8R/=@L8'A'H&+ZQ)&#\E*V#L7SCLQ#8'A"S4A)$%Z-
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M?^59NRFF85"[I0;4U8IT,,%<6N;,;"= 1:V^V['-T('38G/3F?@H6C9[*6M
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MUU0<[V^WGB&R]]X;X:V%]MXW9WB&A[7W;GC-81WNL/;<$F^KHVIR5>_TNML
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M((F2@DE.7J/ <PP>J8#CJ!XK1.WIM468#),LC>-PJG$I&9LG8+ /C64L'5J
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M>E>F*J*L<NF!-CL)\DO>=+K ,I"ZS!8OC<&6H]P##N\%9K.Z7UV_>R;GXG
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ME%!#N F,] C3.;)I/= =HXQI%U%NAF]U@CT+G3!?$H*>&*$J0@S-TE+KPEF
M-=7,6B2(GU_JT 0' >E%BLT[3R-VDI5W!/&+*BA%$A1.U:#EMXJ<],EP!<,?
M^IX[;1A,M0.="^@G,*"5+F:!*^XEW,.N67&]FLH$<VDFP@,D&EY3@])N.15M
M1@PY$U29<<&MI*')H<H%ZID 5U+SSL"EBM@^T:D4\3,)F'B.3J!S<"]L^HQL
M*@PQ.^'*=IM=7=TX+E[D_6FWU 8UDO$+2,;W!:.^ 36"T>"<_B:NW\ODS]Y8
MX?G:%$:S=OW#/,1"+KR?\-/<^SW(/WD_IMDD?",2]QRI3@BJ0OY%Q5)"Z>^
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MBT6\3TGZDVY>:+)S18)VGZ$$/3OU3T@7.^T-FOMW/Q6$##.2 L/^6;.!]]K
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M9J+:RRC8:WQN^0J-R?KNJ8\.AD%R$4$,GG,G")]1:@5;%7B6<"((QFN#]?B
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MJ19Y)C^[Y7=)X#U ^TX(>K!M$>2J$10#&]Y$\VE41]I P<.1WSH0@#XP/Q_
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M%&/OQ,B>.1(Z\1\F,#]UW/<$&,N#)$!F>A>./3$ZS0(^FSCI>*--XA$3/[D
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MN;M7VEV9-XO$GB?XYE\H(Y9ZEN#)@F;R?* T"'.1Z-R(B$S>CY>NC%SZ(@'
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M8*9NL2YZ(!F6?E6ZN.:N3VM7%]>U"^[L['+&:]8M;0_JD5WD0*F"7_HZB:)
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M8DMSQH&+FD!^#[;3<I&5+6O,/ELB6VST;#$$Y1-X"PZ8-@0M>QF)LIK,299
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M_[Z1(EPJNG(+[I$@"N+M;:Q-3/PYZIX;/:^[!DH203'/ ,SJ[EL!J'@+GD$
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MLJSP:C'-F:B,M':/M#)P4B2^(!=X34US#.&NK9U/3^5OG%M>F.F95Z'$P,S
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M%[<MTS>VW2"X="Q8'4,U1&_K:8UDTQH: ^TVA\:N1-/:C3TQM)<U E1F=6U
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M[TV;VE:ZM>'O5/$?].:<_=1.E>"V#1A[YSZI,E-"0H PA"1?7+(EVPJRY&@
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M42N<0$V2CR63\#=!% Q">%3HPNVAFF8.QFB^%PL*M (P6$MAXEM* %-XM[;
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MBGN+OW/"#\+=GN/ZMC';$RMZ;)%3VK"151C-9;\Y\*M^572HE4NU9E/E7P[
M<T$IC1M'/SJ;4AG'Z%"$KLI$2W7D5NJ]ON-^]*9VL]U[(Y-:WT 2UF0J9O:"
MYTS0K%05>D@UGZNIEB8E:9:7^F"#"7R9L5-MW.-4'_H4:T>;@_6S@[5XW5GL
M*3Z;4UO?F-CAJ Y-]/.,Y3G!\28/KB !JE_QS,VF0FOA+HZQ0FV!K$ MIQ^_
M;G]L_S[=+CN_'N?\;@'$<\^[M&IL6:)'A%07>VPRVLMV)&<\,7AHX'9 6G<D
M3T5"X\CLO[+VR%T2X1^.  T\EQ4BZ YVN@I/%JU]'^6_S*K[V"\:7SL>9E6
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MV+0KOSOIX#F)D((S$'6&J=+3;GQG,K]2: W/$_UC+<D3M#R,XA)QTJ[A@D>
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MY"O5WC%&P/@^],@@KYS "F@ (T= Q0"X4 V&0X74I1 K@08Z,LXC.M!%V%4
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M3+UHY8VRS* )IY' 8TSSOIA,266#F?'EX1PX"Y6$#*>&M7Z82U(_D_,)%O3
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MFU:M?>B:\WA67_\NWCZLIQ(3&=#'!J*/>/A%['#HD.0Z9PM4.$#J>(R^!\E
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M>B\9#3 4HX)D>%8V[X9H,V!OGGP\LA5*?CN=TYEW.+(^AAYK&OND7M("VR"
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M2L+S6&!"J$^?R_<$B[WUX[5X#)\:6XHO8D%*>H(:E3"@R54R"(Z#)HI\%UF
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M&YJP'83B9T,"F,=.N^?#WKM#;OB1@"Z9L1.AZ%WMN_#?./ E:HKL!9;]PHS
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MB;MG6^Z08?G_V?O2YL25I<WOCO!_T/2\YXUS(F1?)/;N.QW!:N,%L,'K%X=
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MU4//MW0D:Q?>D*98[W6R/=[2Q%C%OWTMAMZ5[>?8O<:!CU!QW V.32*OBXL
MP7Y8=V,E(FUZ.9  R:?9++^]$7KNY9@+I-)-50A"5Q0_IW.=>4Q=9)\:U;?=
M:)&00@H2DAO1FQ3HXGR?3'WX6<536I@!5'?^VXT-.8SCV;Q ,9O+LJG<ZH#[
M:Y90Y.8M3KI+Y$GBO9,0O2,^VDA^F![Y87I=K.'S1:9WSF72<;I8ZY56!*=E
MOG$^/\)IQE-\D4XEV63^3_'%#@YK"S4921ZI@WSR4&HRQO?MQU2_G^N?;2'U
MMT)-1O9ERBG%AEF^O-2JN>V^.H:4;%.'KEQSTE0$U43L4GFWY!$T'R_O/"WZ
M)'[TQ[Q,*^)]YWW*"7?/^\C IT,S\+F7J66DM<*=?/58SO[X7:T]5LI4Q+-,
MO=+^VNGWT$,*2[M7HYRPYUS'@O+Y5G\=*Z/>]M/MR9?I:-KA&^/J0$-\\[LJ
M?P*B 4$5QG E?W+M7SO7GO7.YJKU[JO7%V?EX=MAY]J]S:BCOG9^WA.N1IWL
MGUS[GUS[GUS[%HXNED2X!S?6F!BF-(PW,>O.ULI$T:AGND8:^[H!TZ9#OU6<
M!$P:;6D]<PQ3IE31_K%,L SA*SC%94\??;P7QHV6^7F6<N/:&W5C+M[?(I?1
M&? 9>?EKATF0XY).?X'V6)>%(AEE7A::F]$<&PL-\Y5F(U6Z.^^\[8N%Y@8F
MQ\Y"R03')O++>Q'6*%W8./+UVR'8=G(B+A>6=RS(G+_:O*;>=@1E?/UXW>L'
MVEJ[$E$S"UL_ZY5%"BV?W#2AL[T37EE5;2AGYDZX6;L?/=?1_Q.ZNSSA.0FR
MM1/.<'DVDUHN*6(3#VN59U0M'>T#<!4QDB[:- #X;9O;<CN6)\ZNT">K=$\V
MXXW+Y=*]>M?^J :[<;L2+>%K7)\'4XD,FTOO&[$@>.3W+J3,HG,?ZE?%1]5*
M<+>=O0J<PSWW+9HFX2\DXW(EG1D(N@CVVK9Y;F4+>D-98V]H3L-5;Q_3%^>]
MVME[<$/)K@1-R +7Y;9<@N6YPS%D$CL6,:''72Q<9(S1W:34$/<J7P[QN'=K
MU824"UW!J)V!IHCVA 4Z:&G?)2DN+Z=W++H<BM0\!+'Y^4/-ZI^]PO3^K+M6
M^'!7XFW!)C;@>2Y"\=T7*WUR^:RT8YFYD,^DSL?[O=%Y^S3D0^*S.;D: Y]E
M<FPVM]QJVU(-UVJG/A2:S<K+]'P\[)9J[;/:?7<GM5J!15G>3/V^2^/7E5<;
M5&)"]U1VWQ;7[BV:]2F6RF;8='Y[<'1[-%H*73J8 28L2"-=@D& :"^'I$Z\
MI4*>]98]RT4_*Q+\@#B@0&94X-^'<L>+7*^]B/++T  QY)HZ4Z%]=586[XL?
M0_X'8\HF["6,2)OHD[\7L_6V]AE/CT4VQ;&I[0&L_7-(W%:.D=M<4V=Z/LJ]
MOTX&V<9Y]&G-A\5&F\K1/#)/<GQJRTRT# @W=(LV8-_0Q(:)\M$]OS*ORFI]
M'6SJ>(O( RH+OW51<OB)Q2/>\BF>Y=?@S']WZ?AJI[2%'K9$ELUFES=X[J)D
M//\RO4XJUE/_<M)O;KUB?/.*4Z_PQ_.75(-,OH-25S(,4\)3MF9G R?8XR,R
MI0[R=S"C%4_[^A]_?6T^4?:A([@O(Z95@DL@[]XULEK<?;/%?6A3L;^\K]YK
M;T4M9%ZS:23+LYG >X\K@-GY;><7;)O+V]NV=?YMY[5[U;A[NKK@-MTVNCYX
MVUOH]>+2+!?8>4$W#0<_M_'DHHWGG(WGR,:K7"Y5U0RIT,ILO/&<L_'<AG(^
MAXQ8+JC%C6Y<E]QQ@9&FBW&IEZETWKJK27)O5.\<?/L&##B H8M(7-=@>EM?
M1L*.=/LL;^#@/!RPVH->II?WY_?=]MG#<S:_AQ:.3&@+1_EE>F%>?IZU]'=#
MX6"86+M0/ZL5KRK?IX\#IEN8TA7BZKFS\KH"M =L(;"B5PAL\MB7::JK%#YN
MBKG<Q1::GF9[/]"MS-7%M\?)4SO]V$5&M+>]@R'=%QAN$<D1<X!58A^"1TQ7
MT/4)'MV*1]FR,&S1=J>.CP3/MK"0Q%TD_J_@P846'A]-26)#.PIX[-F<NK75
M;/[+MITL[S'))_Y:M9\D4JC14X^^X/-?^^NKMRQLK\R?2VVM58-9JTEAGYO?
MK,<!!Z/_V]&9_Z!GEZB,L/]=P*+B*[5L>,)*GDTXTO K;06YIU_W'&9QO"EN
M^3Q"^8_?#Q)X\9)X0N0_L]W_6V$A!71IA;Y$B'XK#059Q=!$>UZ5CWWWNY8F
M'BO/_#W1C=-_"!I[[((R/&5E4P:,A3DSYF?<R;_E']QE*O+/:K:[FIUT\243
M 4TS]#<R<@W!L#VA$?;YP#N)NQ=&N"9#9 ::/M14"9P$71A-&%&W^LCH5T59
M1-H0?=L,*OJ*JYN+B^: .447HU%BE" CB8*JNQ8\HCBY%EXUO:2@>T^J;VP(
M/)LTYX0R;4*8,J)+R29+DU#%KLAI/5F73?&F=E\6G10K>?4)?C?COIPIT Y]
MFLV?(=3LR4:*5"\CU,*J,++KEU4W'3U&A3QWV&$ )%,BE6+3Z>603 ?4;5B.
M&"!PS4FO'L994\*RHKQWKBU<??#&\VNWTI,B<ZVW<,"[LZB,O"2[NSI)#Y.W
MLZD<F^&7EQ,LY+^Y(H(]"UT*!'T8(O>\T,@]EIYONS(?F7EQXBYF@;LDA;L_
MEDRR?#[-YOGEZ<4]B=N%3PX]IYDL3C$:*SM>FJ]6!'LIW(MH/@4F^7;.XXKQ
M<7%5**4NK[.1>=S9F4\\,V1O#E\O#[]OF64!'_VG:.F0F5TA?K_HG'[\=E-=
M3NXJ&&!]'[WFX04R*]GIYY',<^;OD:3"M[>$>A_<D+@O@SSZC<EU;I]4?6A]
M:F]K&N)[,;YWIP4X9);DV-3&(/MQ>MUT5,(NEQ/<#+D?6R@ZMW>3TX?>(V\F
M;SIKV4![L'O^</JL[>))1YX8\E0B.<D?O]7_"&N-"]DU'D)=4T^$/Q'5/ZLY
MO(CJ^C7+GOR#][^O+<641XBS35T0)1@6=E#=L%[0D!JR+WNNN&X["XZ@MF:^
M&UUUV?1QWV:K*O&^H[6$:^'QX=515>YKJ+IROQ9?7V,H7:)HK[#];<$[YY-L
M,O7M.FC7/\40,_"+[3\X<+SD?E4^NXH%"[6+$/=S9=]'@U&EVF]<7 A!5U8)
MMC"9OYWE,_;Z_]G9=5Y*RC^W?(<FK.P<3H@ENU&?]B[,V\C=3)YFIDC=&K$V
MQ;A2)^63.@'1B>BR9EK^2 PO/H2+UEO>(P^"PREK2($-NW6B[6X[W55AUSO-
MYO,9-AD!/_7+]5FY+!6U1'J-#.CT-ODDB?)P_#",'O!>FI%<C]MVFJC<7<(Q
M,N,M[6#>)<]5%XBQNF2N(,2:?(4?OEYP94L*$F*>\0D[E59!FXA;5O&I+)OE
M8QI0LQ'?;#W"L*V&R>@5C_--+Q(^7^GW?__/R0E3E25%_,DTA3[BGI;T;DEJ
M%YE-^=POYEY0+/1CDCDYL2DCRA_.9>"3/)*3]VFM]GXW>4CF(IO6WB5G8/<S
MB\[ J:S?DT%I,4M64M<[3R%X6?7$2PN;"K\8P$/ZR11TH2-W?S%U='$(I>H:
MT(3+>[_U'_MK\"=268JH%4RX_,NT<)82$N^I;B_C@O.,T*-/.KHDO)UT)'2M
MT-L$92Q,C)5IYNE.\7* ;TG>M<.FR+H]_#''+R/_%L[T_$U)+%Y??[AS)E9@
MQ_EW_>F:^8)?_SY=,_&-ROC3-?.G:V;UKIFO=PI_>F:VMJH_/3-_>F;^K.;K
M9'A7Z)F9';@3C*))2O$"*_0.MF<F8LE22(G>'%+MCHI;+]6+0NLSG>@DE>T,
M1UJG$,_!K-UC678JDV03$0:3'U 73"&&&/"^^/#SX[Z8ERWUD^M%Y<.=Q(;W
MSYJI;([-YY8'" ^CB25BH7)@X>:^>.]6NI\V[WKE0B4=NPQ<@EJW/S;C$9.E
MV$0$].&#;$P).Z<%<'(;-J;,P;#MG&^S;^/!(Y>Y3ZC]""TE\\AN!]Q2DOP"
M+24K&:W[;B#)'H!U&IVSWY)6F^^-]"=M@S&*V[!$=UDHG\_F67YC]/<XG<J]
MMH1$["F,T;*(SK^985N\?!A6<[>ONVSS^,.]WZO-(Q"L.U3%_&D!^;.: PT0
M_MM:0!+KM8#,J:D8ZLEO<]<2?U/H6N.W VGOF-5:\15^\_D4F^-6K[4Z\/:&
M/^T=0=/!-V_OV,5U'.N-AT'R*ME_W]UU7*L]X]]^2_^T9WS;]HSD%MHS[%$,
M]VUIW+NKUZXJR0-MM%A]KD-X\7(VF66Y_#<<:+-R6G>=)-M4%YZD5/>I/[SH
M?84^B>UQ3M2<UM?LD\AOW"=A,TBRHK?E?/^LD)8.LA%BF[*$3^<B3>S^TP@1
M:7)4#O)#W"4OO-U4[C8>?N%?W"LR >7>9*Z_8M-1$B%O>9"8KC"23?3[J<2@
M3TBZ*BB('0UH$D)<:<CHDVK_^&BD(T[3964",S 4J>]^2I=(;YJI,8;4M71H
MB80!&G;B!<9CN+&$4Z8!S0P"_3,C&TQ?%Q#WBRPSEA@:9</9'$:8*4<Z/EJ2
MX[$,/!X$?=5 ;P0^.8$A,LQ0,@>:R*!GD?%9$MK4$"_:,J2>I3"*W)-@8_B-
MG_AO:*>S*<YH"NL./_(*/?%P@/;T?'[*/3T_E9O25X/(<\F)_)=$2/*2#$1#
M'#20NP/$4YA3G%.5T0851>J:%N+:$9UZ9S/-*5/K8:9P&5+53!]3CG5HT-1Z
MB#_4B>?"B/9W\$U@!!,]!_X+7</3XR/7?6,$'3U>TD<27@%<"/@-O,;F=_&4
M*9.KLW2\FS-O!J_-YP%11^/_\AR?YO,_?H]US42W!E8^-P[,BXE:&XX$68?1
M?XW><F\>*50Y>$C<^/SB3;&J_>3=ZU*]N,HKXYXBQ[$<HFXVFPF;++9\HMIZ
M))P?.#=*%BWQ]LXT"W+L)-S>1#ID=.8R"Z;P>>>RL42UR2J]-A[]87JNC"JZ
M-Y0^!\2-A(<9JAHC.[NG5YSN__B(CFL2_?<I^#IQN=.X=>QN-'DA>#@5EA$#
M09S398AW;76"9"GZ"N(AP[ DD<IOL)RM^O9 _\K:$+1N]ZXUHYHZN=2@_OF6
MJCZ[P$ED1?A<\9IL3@B[$>;G4/P9N(TH<"@A2XMX%VKUJN<VU'_\3N9"I0C9
MS?&12-_HLY%F3ZBPXQ.J:KJ$>&KF>&Z29Y6G9+LSFJ3V=#Q!ZUK[;(*RZ-ZS
M@>?"V^PML4BR4$GZ<\>"(J:V50=O&@"GYUJ;@]J8%P0[T1=)A^MLV5CB% <D
M0XK*['CE__[??":;7^CM.=29O1Z9/0DP^OBB_&I]"/8MJ63;9^7S1TG0^#T+
ML8#EK7M9N" D=7)9(@FP*"<D=F.48?XSFDA&NSJU&E9;/ A)%GI$V$]"QS36
M=-&0U(5GI"+W-O249F09\4Z(N0765K%V<7=?@+&68R14X'\#?(1=G^ ,']<U
MU?8Y_:?9_:A]W,DUM<&][>1"A2QD[8,S![H4?G*S]PO\6=_921#@$&6->)-H
M77WT&TF'.ECT#]'JFFYX!!G0R'(VW# )^BC2+;(Q8."TAR/D@@K@^0:ZR3U(
M8>' -;*LJ>>JC55T5SH3QB+/GI<'X'+ U')9AVHI9(HF>?+)69[T?A!9]<A0
M5V0<I1'L;]54!O0?K( ]/L+F[ >XT[B:U_; A=%(08H)/D0]"FS[.TR.U@".
MP-UIZY1E"GH??4=6!?2C!8149/1C41>FLL(R)4$51/3OT@!_HF(!)5BF9NB"
MI* 57 @CT*K7TJ?<U5BL:)\E04&T89E;RS#@62W-,@=,H:>C-9%QW.0WEVCW
M@B?J^-] \)4-H$D"]?<?BR*219'>G[1S7(_:\$/Z_)S84NY^;!9>A50_D^T=
MBG/D6^':ID7H#/=Y4?+W.HY1;.=T9\J*;$Z"C^OLOC#E;JK&PZ2_]^-:L-#U
ME9:DAIZ;1=X7: F6]GEB9<EPC:Z9 ^NH[>RC:EP-S[-[/[#P=:Y_7F,M_)[A
MU_T3>%ZIO88>9LZH]G UR)]??=;OI5V8Y=N1;^$QH%D#:$Z\18G,Q>,V+91M
M[\UZ^2HK7WT\R?MUG^(0;!@U9BW1EMW;:2V2:YE7]:Z5J77OFH/]'E8<0BU<
M"1T?V5)MQEVJ7=]7'A^?MN0(P<KM1S(^G^CX:$6GB$%/0O^;]#M'-L-%=)+\
MW[:)X'P;O%99Q(ZA*9$3QL\"#VG^:7P:NUQ=M&<!YV@LU=1E,/=-SPJ7O@(\
M5EVS^@-(BRJ28)BPTJS?G6,B>W,D/V33/+HW!R!DQ)V;\>.8/V[<-W7C*GLT
M-KVJJ:V-@"(EQ"I#ISK"[<--F3GE//W6W'O6*^J:UQ;8C04A2D=&^D6>5WX;
M</.AH,@DBSOIPNH\X2VW[,,7F#H^"A#" 3(X_><B'^9%Y@_E(NN":H@2XGT%
M_:([L*_P4#8KO>:D<9G<>W!F^7)W>GO7]2EWX-:$':9^=GF>-&\R->. O)LM
M'^5B+V=)M@A+8'<])R-8D%<*'Q\1,;PX03##*=O*$R 3^$$Z/L+&I+# G$3/
M0?8;+4>*LBU8%;$E_ZB)PU03>T@S!\O=ST0B?WYK"Y1>(IW0+/'>*"</2CMX
M5[FV)&E'RU[.^K$S(J7]>((7P\*5]:8P07^X&<ZYA&:8J,'?FY<HV3\W]S!O
M;G'OY05-#]<A!8R[M2#H8%_BTE!NOK;[9NT]=QAU/8L7O/Y]7I0HL&]SD%6W
M!V?;'ZY?=H*3UH-DR9>/9Y.#*/J)Z?QZR(Q9U[#K>9:!]T/0XWP2F;K8QT>K
M5W]T)',L233:25H7DIDU;;SCHY6CASY[+\I69X*+;D21!A*/C^Q((FR&A ]_
MP<]_E,Q!*IG\@9B'C9&D.]5KS;,;KE =6N/+@S(./6O<>[2OT:S<0MT6609Z
MRHDI=0>JIFA]]#WT4?B#M^-KN2'(G>[XCJXY)"L?;4C6QZ"0?A.SA4N^&QG@
MY+L,R>(3ZP[)*KY,;Q[/[][?/C-Z.?\EAV257Z:-MYM>0L_V&E?"V@W(D9EW
M?F4Q=4!@V>T;4G)\A&ZPI!JD[6MA$Z/W:_,-<10&(+!ML<PW;L?53K=9$9;U
MW"U^R?;[%$.1?#)Y-IT*[5=DYTF568-4\^V)7*M9/#LOMZ9*>ONDVJ0?,10^
M,Y]ET_D@/ Q*J,#.SL(ZQ,HYQ,H18KT)+>'\H==H7O1C(%;.(59N:\3B>#:5
M#>WCQ'4/2_N36=J<3-N4<_[NSU,'BLE5BI&:T?WW1T);&($1I,.<4S\M6]V!
M)%J*I/466&]5R[1TR4OV"A$T;3 +VF@-147KOOWP03_DO?@CVWS-RS29?!.O
M[E[/M:X<$Z($$:[DORL. ((0)&Q9IB,8Z(^(3;N6KH.)YNET1RX=.$U.ZSKK
M\(6*WLOT$!THA\@&=)7T-$71QH"12D_>SP!?NIN.*DX"PR58IA9E+F3*XU)A
M-!/RU55G1:X#:F>/5'N"CN@*<9N]-WA5,+>-Q\+9=RN53WLT,G=Q-\IJ#[>%
MT7K8??8V73[?:&R?"_KF+!<B7Y'0J^:O?ATMM#V6E _I&O'9 'N@T^?)PZM8
M?RUVNJXQ'\>8*#X1/,X!T9X[D'$4_Q.VCM26)X9$.)OMS*B>L=VR*3:3V>(T
MD"#V3*_-GB :VF,-<^5K6C'2]5;G[EQ9@RNC8!.[[,?'C. \QU8QLQ*EXSXY
M:'6V26W&-I 6Q(RC314^67H[Z^7D>,19, \EOR,/ 5&_%A=%178,WG!5LW3,
M1(]Z)RWH3]+392YVZ9/ZAIP#A/Q:C!-Q$DG8?M%G,>,\I:XO[XRGXMG'.FIK
M;>F3_HX\A#Y[\#P4%;DQ^3(MY&K#8F=R>:_D-_6SYWS,!:_FLLB8>C=:&:Y?
M5R1INZ^.(892Z.+&#Z,I3("TZ)_H0^*5+'0@<2-+1D$5&X#&Z/E563:ZBF98
MNE0B08.0*(K/-MWNBUZF#VWSHML8B.KCZ^9$_F_'CS".F1$QM:;C:_(3\31R
M20%B\L?O>J-=8;(8]I_[-5,GD>.++U.E(C64HIC6G_@?OQOM\\HM4[J[O:W4
MV\Q5K5"L7=7:M4IK-DC2V5Z@)"@?M66VP2=%#\5S8 MC:MY8:Z3OHT.NGF6'
M7+?X?)7<PB'[CZJ8>)DFY/YG(=^ZOQUUT%'!FIPXF.*NRHZ*4IA4R-R2%BD(
M=VT5,.J@HUGY[4:S%@;SMAMQRG@C3I]:SOSHM6I]5S@'19366\D6%YWT9&,>
M:N]CXZ;7>F[&LNB(LPYV?HB9C6*"&X4[#Y4D_$8D@6NP<Y;>:+U<?BM!W*K?
M$@'3HR4H O2[4BT$_L10:%R5ILDR1W]ZRU[2G^17I"V$=JG8S]X*TU9,L0XJ
M:#.9O\+ /\G2F9$PT9%X9M'K5,N02!U,5QL.9<, 9P #KNXT9+O6D.?@DXC#
M"\FQV72.360WG &^AUAXS(3=%! 8$3658/EL$ [&%J/<G@IRM"GB&6!WXE8R
M+5T%YZ$ UIB@=B4#H) -SG^AI]+D/JD)HBH88DPQ)O>6VBO!^5*TSA&4H<(5
MU<EJUPP+1)^6%%Y'&)5Z<5S"#)O-(EY)!%6SQ!I/V3?A-KUD7()-<AF6SR^_
M9:M?K?R\:KP6]#<)@/5*H$>B*\AZM_AX?C4=7&4Z\8?CYI2B 2>$K]G07K]?
M$>Z6:V9D<2!-8PFX\5DVG4A\L3NV+K4VO5I)EL^EV4PF"*=NFT%NNJ][@?0K
M1+]3@R?Q593+%:.:CEUOT8N$#$D("Y.RH8X!];:'<8=FJ!?+[6&3Z22;SW\U
M';4ZI3962FPJDV1S$2R_U6^.!Q'"T:]537\8:$C$(S&/]+"IRQW+U/2J%.+"
M36^RPN-(*KY/KM]VJ8U\QM_87C$CNDMF>M*^+A0V958@:3Q7+)/DV51R4Y'[
M%6FWZ:5#XBF593D^#G7%S:NKIJ[U)!Q2$)30BQ:HMJ['5\5>,WV32<;O;E&U
M18:589@VDFL" Y 6NAZ$4 ZA9BSQCGR.36<V%<U?AUZ;WJL4CVY6<E.E'W2K
M/*@5=%NWDB$)>G> G,>R]"$IVF@XK[QJS4GBL6<]R><[55[T*NETB?@VB>XB
M]REX%Q$OCBN4Y]/(ZUX^F/>PKM!ZM-K<%DRD\FPFL3R\NEF!*^Y;!;E^)0F&
M9">.)]'54E'C]7J5>TU-7^-62\Y:,2JFY"24)_N5K8M)&(^]QV.7ZJM=I?4I
MMOEU2B?0?P*'6&VA9'-.'W6@'WM& >6%]!5B_E+J?@>E=0$*"*_I$&0H7D@<
M]X)#4I-+L.G<5S/3(M)G\]!<GLNPF6P<ODYZMA9IOAXMNE)YEI*95J7$=<^E
M>)7*+R8P^4T*EP1Z=:C',Y?^C9Z\7R-AOXBO5GE.-(&\\,!BB@HF\RP7(?\2
M0.7U!ZO_FXYH"^'(7(+E^:!9=AL?49 (*<^*D"#9T4;"PW2$A^F(C+16,=*5
MRVSB@8M?N\)^YD4'?YH>>7Y-:@$3IQQ!XFDWVH4K9D'UZF*:XH>OP;OX>XRH
M61U%BE0FL>)3HC/O;@0+.D NDV=S$0KD0\YO7=GR;SFAC:V0))OCDVR&6^[;
MKG5"*W8VY%ZF0N-ARI\E/I+YC8NBH[74+VIWJ+Q,U<GD[>JY<Z\:Z1VL)X9B
M]BM-[;<E?5B6.J&M#-XJB<#/OTP35UTN^9H=5@I<7,@.*[8I'!_EF+!&!<1(
MV<N;Y+/6G]ZDLC]^ERO%=HP]"7N=F=Y0F<)(EQ6&3]F@)6.)P36FR&"655-C
MA..CJJP**M34,X6^+DD0*V,!U@+Q"@"@L P%OPC\'(8?;"'1@O[;1+\UF=8(
M"15!,2?,%8$M9)F:VCTECQ2'L@I)(P' 4HZ/A#Y^"'U!P?=7]!;\QP]!ES7+
M0"($#ME@>HC;&1/1 H#4\/^.!!A? Z)1,C6"RV)/=]%Z&&O-L#J&+,JX*)!\
M',:WX,\'/ \MM&\)NH#HHSO#%^@$&!'0U_"FK1%\09C'UN&]5P;Q9*-70N26
MS:K0Q0&4:^%3'EK#HJ;KN(VB)$!+@SD!CVLT2L@4F"C%ISPX??Y'$#@^YX^W
MTH>F?,"C_"\B8'SNYP!RK-$KZ&AK?7Q^,\"C]@$[YVO#^;43A<?IY5D_>R\O
M4U&K[#A$;R52)VCO]($OBS=G@Y"&+'UM[9=(L GRGS"P('*%>[)NF,='BBPA
MZ21U+;A8Z'H-&45#3-'%2V9Z=,WN5:*_(#"A]K]<'H,4NO AR J-N0&G609!
M[D3[PX#NW8%D_&3^EO\Y/EH(&[8;%FR1O8-JL)EF9 YJHTQI+"<Z.V>:N>6L
M[0%'982Q8!P?B;HP5AFH>R52%H0E%K,A\O,7.C_YGWD1DHSC_-:]_2[L)^A]
MPGG^K])?ML>:??;&Y$$M%J[;ROON!,8246#_?7:QZW)&>G7&0'NO2AT=Z98)
M [AA8*BY[7184PG=@2Q]X&6#\AIJND3P@1?R")*1DFI)8 B6$(%@'0](1Y7P
MCB6]@J$-@22&(:'_+[:%3P^?< D?!MZ+H9LG)TT"2M_0D;WQ(7=G3IQ.NB.3
MPJ$:6%6U#Q?_E3SB%AB-? __^QII=W2J-H^(EU>%<;DN=6[<\3)T(Z&8L#;3
MK+'A$$ ^+N$#Y+.Y9,D&T7Y>?-O9)!@>A8MD]?A(E0!$EA"(F"UT7AQ+IX 3
MVZ=0KS?N 5O61BT#\&QDL+PCOC,) "_L%W\6B1\D?Q: G@?=SCL5LS.]2'4-
M_ ))+Q!]I4A[%D*@(&T6&RCM5.*L?GV>38&''A[57V.;VY1%[IIW(HU&B(O
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MD%8]7W22H;6E=$_'1Z&;\G)^I)TM[K6E4H[$4,F]"<!E*,W= ]K('.4.R$[
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M<(]H'WJ7"F'!,"0S:,>,#/?+N^-Y.BTFP1C)!3A-.C5,(K":=BLZ'G%@F8A
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M4- 'H  8>TNR8;_)+; &F:5+7:VOXOFK\PZV[T:A"R6@W7=,I_ 80&S1[T@
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M9=H.$I 6 BT)D3>LK>>@.M,N_Y=&]+!X!O\B9"9TQSH6S1MR]S91T0;J0Z8
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MUSLQK-G\,-:*CA?T?;Z4;D]K+R>Y-_F\]S J$/IAO4*<\VV@?^#(TAO\X_#
M1O^(MRKX+PA(') .GPV;X[-!9NP.RN)+0TT$-(N)[Z*]&[85N;C0!,3+S?4+
MPJI6W8;+P#KUA-?GS?(34\C4.F$Q6K\M4F@MN("$6A'XXKCZP&_[DB2.INJK
M._/M'/%A)K9+Q^Y)B^W2C<H(8CMDWMC4Q]7H5.Y^9;%=NH.9G-BFCYG5_3+V
M2&SS6Q?;Q?N.$<3V+G5]<G66$J]:F2\MMHO7(I,3V^QQ9C5>=@0<ET^#A!*S
M(M\ 5B:XS"K";I&$T\*%>IE[ASH,O]WB2=7U(8OC.KQ(%@8FN7V4.BYL'7?>
M2XAC*3G93(@#>C]$$&+]52]DK^]3-9G_DX0XH(]$DJYW/DK#Y=B%.);641L*
ML7^?A@A"G)X.ZWWYZ>KQ2OBCA-B_T4.2CKCGV5NT-J5?&W_'W34",J9'NC05
M2=K4_FU >7F2R"*7DB(-S:'=KC5VUTC(GDSR^HFH]F:ND0\7J"-J2&:S<[P5
MBRJ[<'K6!B_"1P1'NQ4B_B-1(3I[K_*WRJAUV>3#"!&9S>Z%R)K'7@D1<\QY
M)?VP$/WCG#=MLXEY7&HSEGJDZ&HS7F>\*DX&UV6ND1UWOH;:3-K-#I3X\&HS
ML61=.+49KQ U*H/1=8-M9;GTUU";NQ,B]CCK*T2?6VUF=ZPV8PW_"L7GNX>W
MYH?<R7P1M9EP8!<(].?K*.R;MQFO$$VZZ7&S]7A1/^M^$;6Y0R'*>^$%;Z V
MXSSXV")DXUHJ.9:L7'@@NJ13 -E,MR7>-12F-]M/LQGL2 \'DF*_0C8N?9Q-
MAU;%L33?6(-B"8?^F:M;U92O1T]<SD=X=J!_ TFQ9\*3.RYX'35\ <]U"4UO
MVVHRWFB-27.E>GZ0Z3^_?F(UN;L0C6..6=\KX4MJ,I8+/YNHR7B%YY%+W]Q+
MK_VL^O*)U>0.A2=SG(G94]T7-;EM24\XQ*\^#LZ&':/YP?M)^J=0DSL+R;(%
M[T*T/?4FXQ6>\X=1X73\JHB/S&=6DSL3'J0F4S'G0;\$>GA<NGH)(R5*F[0X
ML,?7WUMM73..CJYA<N0=_&]+!=K[KU?5AL7LI)1F>G-0OYM!C_M/"LVA/3>%
MO<#VY7RZU:UV4C^].!"EYB _GRJ7N;[YG+X5MB<.[BGLAS@<YWT$XE/[G4NM
M:!(5WEC#J5"ZK/H^>AYU-$TOKBN[4<*</55EV6,/H')O9?;UY&%>F6GY%]VX
MOR](%[GM"<0>*C,_@?C4RFSIE#Q9X8TSZ FES%[4_G4U\SJI/F;7%MX(T<C>
M:C-F/UVS;0C$O#:[R12>!7$TJ)B9[0G$'FHS-E9U%N/IM?\';9A[:@*]A>/1
MHUNYA4U(;T\?DB")'2O>W:0OS6SQ1LW/ M%YNNW@/DA8JNS7"6/JV!-*9=6V
M^"=NP4RL_G>%8,9[D#/D,Y<CO3IJ5IFO(9B[.]/9%\&,!3(KBF#&FCJ_?VB\
MC//:R*CUOXA@[BR+OIE@6C[$O[A-%^G8M>BAN/K:%;/MZ?15,5@V7Y]\)(X2
ML,7.?VY1<3?D*P(:EV1, KO]E59T^UMO\/;T]NZD5W@RG@?/W81H7*20A*,'
M<:,\WIK&0FMVVFK[;K68(WT?2<-3391QTW=)(1(,FU (@^7.IJ ?(*\CR9=E
M]5W_^36ZT:UN/<>D4O]\UCYSBS@D%B++,O;*M]\.D 2A.!7O_]:8"+E63-V!
M1.]Z+M9N)[@GGZ?]W1HKM*^9[YK2UC7W74_#[A1$M4@COK]\3YC@>\+W:W%(
MX"1W/9$RLES@"IJ\O.NI7$ ;74FAG@BPVI?="D4;W6#7!*\CUDN*+G5W/9%[
MTN@K L>WTD,US2*'K,3+N/,Y;RQZJLNM:N-HZ><;UL=R5=@?:N7&,^DY;3Y\
M5&2V.;R\=Z+P&1283EPH$A0XF+,=$;$9=-R.._2M@YIBYXHV:Z6?I5/I%!*L
MU6UJ]JA?9"QYS&5:+_056F@>>>/;&&]:>^Z4IMVQ^*X$] 6;;P6YSS(71(?8
M)='=+BES[(E8MQ=RZ*OD8CGF7,D$QPMS>4%P L?ZEJ9-3]^8^L/%\*0X9/VE
M4K/'Q7RU!L8P 6N*Y;JYK*2/+J-3% ZY\YGE,\V]$$,O=1A+!?HRO1R?BS2C
M\S.W=]VJ47XNF5>CV6T#QV^$N^!D$-)";I_5WOQZ8U!TJ7DU]^UWFN:X/& R
M[667VT5/EL!0I(X9-BLIWW[C-GMB[(?ER34)/=%47?>6V9/+#ZZ6KG#/YX/0
M/F*?K']?FB#BU04=<_NJVW5]Q%R:H[.1CF-B;\:Y5F6%ODE3R7GGS]?S&]_4
M<A>OS=-)IA_>\TM>DN);>J(2MC;4PJXJ(5<_N.^S23;[X&,R;$F*W6C,%4K#
MV6-=UTU1J.#3.B+41*[<!Y/.;-I2HRWX;.A6G1G=/?2ET4<GM&6P]W?@COZ^
M8DNOO8JMZ'Z&9O(LS43J)Q[UXECBBM\FX8:ZOV)R]]>9JQ1?YL+K_E"RDK#V
M7VO]6S, J6/6JX7+YU6YL0A^+$!4?GR_50U>7@CS/$7=5/7^Q_W%]/Y!#A/C
M;4/(8UAKS**]%.XQ= Z9S%QF4]=Y>S%>%?#?XS?7Q5B%V(:H=U@;9,\%J5"Z
M2X_>[YK9->PYIL(FUCS^16[%W*?S',VEO+I\;-/8KY7/6FWLED@9T=P7+KB+
M^]Q#;RBN8^Y7BE+BQGZM]6_-W*>/<]R?;>Z_0+SG.NS^1?G8E#*<1<NR*/Q;
M4[6>*+ERB.N70$0H>]C&G0AKKUD+-#4QE&T27_B[,_$Z^WP=VC1U;6+"]B/$
MC%0+LATSYD&/K9BQ#,/1J1 92T\Q#K!MD>4UG-U;JUQBE=[WH'TTNY>?7,F/
MXG7O+),-;_>"Y'3[-G!-6FS1!N9C$])-B\N2,E-_WO03#-?L6;#'6:"$?Z'7
M:@QU:XBUK2Q^CQ)4LR.+:QG:6+KH^Q>#5;VUE]34W[.I%SW-YL/'?WC@8+OJ
M3X;]J1"+Q9:R:3J79^A">GU-A6D4?;.'D-!P=C7.]$/H<K&JOT4=OKZK-_E'
M\?PB-$[[DE!^IOJPV.QE)HJ]W(44!D4;75-' ^^B5BSM7RO6/'TKU+NMV[>G
M "<O1*W8UNK#C(^AL(/BL#04A[&I5<5A^R"#7IHP(1N\6"GF8XN?)F*3N\@*
MM=0@U"G"_FB\U:5A&Y\59%F:]<0PB$&RMMU ]%[4L=Y0!,HR#OB&:I";NH_E
M9&09145P6MZH\*/PSN?YXWTO>Z/<M1[#.Y_C&>U$%^UVO1G"TB(Q/Y0IT'F.
MI;G\ZN+)+1S+LEL5L\B>YO-85$^%AY+1?PGO:7Y:"=R97YH]3NWZ+&,FFK48
M[R.XM'=(!\F_5>ZTKY[4I_UQJB,$U$KZ^YA^@KE]WS.NNPD1J LQ4+:PROW<
M@@)<RE7'0X=Y1XOQM:Q:1WYL757R;*L?QI5,4J4ELO!$7$PF1V<RF]98Q8DN
M=Z?8C-F"9QBG7FRHULR)TV.UQ=%]Q;4YNKCYT$J3_(T4VA$T;>+L6DI]%IN8
MIY>F"\C98SW!9K:NYPH+"9L-'!@B[7&X=<7NR&R6S>9[>8W[IAO+TRSELBTB
M).JT^4 &[L9IR\8@9M4W4S(F=44W-!.?BLZ17%P\\O3S,71_#TX3N$RE?')=
MO @H@0KRX&P9W&6^<)>D_?8[?\SN@_M6BENMB8)K3SN>6,C$X!L[>:X/RN^M
M@13&F]LG319FW4DX<^D,G6=B*BP.VR>QV)Z6G[3B[6E]/!QEMM,H,:$.>D4/
MAY.F5!/Y7S-VVK[8X<& %Q;LJ4Z!G,!#/:24J/]=;'Z^>- 30RF[Y1?4R1XB
M[4K#-*Y7/\R&*/-2AW,AOL,KU-'"HL 9M=:<Z-8);>17-,&/=LW$'[2=,M1E
M3K*[Y.1\QWFQU34&G8)^.I8^)R=]N]='X60^ +:7&J&-C>.J8PH_?X2C&S3!
MV2JA.!O]770:?R+N6S1#/^JJ?46:XG:@H!<.#] W3=G0"65%JZ0:UN!T!]7]
MVH.2UDLT934=S5/OO$[QHY&F(GJ@3\N39;%SMU\MRK+:A2EZLZM*UN%M6[/B
MQ>6T_G#)G<]\-C=%+*92+I[3E#7BJL@RW+R2OF:3I=ETEL[F?2$;:4_U'(&Z
M2WW,IQ53NRTT!Q\/=X,]HNYR0_&HM,W3N0+Z+Y7SIRT(]1)]F6CT76S'/672
MX^&TR$KRB;!/]%WJBQV=OJD"0[,%7\1(&BL>./"0QDA/$')+!C0<)A1 R^)!
M(>M6DO.8\O9M#+C_AK[NTFSH>:Q^@M7BX0'2BX[+;2O($!K,+0-.NW!1&R-+
MX4UQ)]&$+8R.;^RY?U]6=:.A&D\B(J"]"/?5Z'F+.KT\,Z2/Q['4,M;0?,X<
M*#P)FB)CTQ1\'/W60)K>H&;?IZGB4#65E4FXK1 @B4 CBX_^O:OI+0WP/I"Z
M ^1V3ZB.2/$".-FD\)OJF5!T374'0& =3&EO5HI]3-T.D!AW@;#H3]$ZUL/R
MUA'=)EA%837%4^]6E'UDIQI&N)0;+/*B[*6V(7NDDKRF:M:/X+EDH"*GW;Q\
MVZWG"\]GO0UDV5>&R4HPRUQK20AC,O3YVG89!RU(/%(SQ)W$[MTQHAUE\!](
M.A6QAY0P*$%-1+$E"*E@BN!!\IA*DF*B'XUXPQ UQ>4R*OW# UG5=23]6VX2
MG]!7YC#B\!-(EZC$._Y)CC1D21&AC;!N((J"-&*)<,"AO@(57(O387%8A^IV
MHQ_[9 >BB!D&@1T-V! $:,O"OL;1Q$"5,6B!"EI01):?AB,R^ U B2!Q I&'
MY /1@.BW%/@(4D]"7U,6#Y9 _$P-[?[A4%4.#S#Y0X1%2"</15Y'JEJ@.A/\
M=42+5Z0Z<!YN?EC"5/!&X#F!QQ@,\%=, U#UHC6=PP.8/(5$A.\@MP'K=GC0
M4N:S=4C*P@ :GI.BHGVE&1+R9FPJ "5Y93+S4D:JAI<BZ;/[1]O><$B1B!]=
MV13$W__]GZ,CJ@8 ,#^1INZ+O]"P;Z:H=#&88O87A=.$/ZDT=71D9W0%:>S8
M,S:=:T\G(_/Y-2U4"B^9T%?^W.V,.:@37&AHS&$@Q\CTL/HD+Q8@DD;3R]V3
MX6.U(S<Q;#+\HL <_D3FB^](W5]4 ]D!0BJD<1%-6,[]UK_V:_ KTHL94<N7
M<">B_C(M"1_BJ^P0;H2&/NH@W?UZU!&1B*"O\?([/]'7IIE+,MPB,#<E]]QA
M463>+@%9$IB1:PG(E:U.V#[_5BN\W+\FGG9=GEA"^P598>P( "/=6O-=DLG6
MIJ0>DB7-X"6DM4:NIPTTNHB>1.J$XKL#21Q#W%/O44.2*J3F'AX@I0,*=?YY
MFA+17TGL1#[9!4]",^"\09W7:KQQ>, C)[F'+)E 8>.&_C42K2RQI?/$OB:*
M!'H&?P([9)867)X]>EY'],#A%]*N>#(2&G L"7!>AN?E7M,"!>87I2"?;K8P
M]$$%U*2E_O'B.J [H;O4,?7@\JW=$[-L@;9HRWA]SCX<'M@&P@E L6D WU*6
M7B$41&%A!VUD&>!W@!Z&89T(8E*@#W0UJ0-JVK4BT.&.+=#0!I=TI+4IG?A^
MMG5PNH<BAB!.V386&1R##($(HYK]@66%#-$:;F%)(%TZ,4IVV$')B'BROL@_
MH"Y2$^"QZ:+7# \/YJ>(L80@W";F^L. 48R!;;Z#OT8")9K,TLLV \Z0'6 1
MS*(NF  4-%EL0$*,=3]/%HO^P.>5\"%)04/95'*?T\XE!8(^O1B2S0T#B0IO
MKAUOQPG;SE<J\XA0_CE?\/60<S?+^8H.MY9S)>YRNIDSB;5/8';W_DEK-M^K
MX^SS+"Y<]+0I%-7=(<T:-B_F_?WDL[CI0H'.Y'Q3^AY9W%0HJBUG;1]'M1%?
M:O2X)K\#JL67G65HCLW3&?_L+-D2GAG:<!*WG)$].<^7[CJ/_&6&V07M8LN\
MYM(TDPX0MOFL*XI%]/#'2#AGZQ40 B=&WF[/,57$6MHC=?L^EPQ;MMA>LSD\
M,'7LG* (C5@OMSL2REB_F2C,0N'[A*J6ZK>5(D7\962K%"OE]ZZ:,G883!G<
M)B<>8XZSAP<&UK7P-9BE*RKU)T""B6NR$]9G"WDO1+:[NI5LMS,2>:F)R*O=
M(J?!.P/>*I:-Q]K;M'XB;Y UK.)8 /BZ][GP%>1)(C]>H OY0I3\N-0[/+"B
M&X_P8#Y8 84:-9].A4VGXPB#Y-,M5VI!Q-.?,:F^8%O +.G7-W=V8KW1D@:\
M6"Q?L"^?);$>N*(]3JYS/LEU(FPDP[[]'-V687A#0>\6UX#>]8/;K;>JRG7J
M]*VI,PFEC.R9@4WW-ZSS>0O7+[\&2*Z5'"0][WC34,/@YN93_SAOXD)5\NJZ
M4+KK-CV*@#3(;88TZ#X< IH>Z4A#$,(NGPCAD$%WSH5VTD9J*PMW)SX367G(
M.UHK1,E.X_N]'+%AUAK#Q@Q]Z?_-F'60+0;) D?[_2^AQ9"R2T>?)LCVKR--
M*^%$@Q7%#(G8=5:>G+AL.%L'K_@S3!8CX% 5#&W[&>9;XR6-LL!GG?G^W81_
M5?I?E?Y7I?N+RU^5OK_SW;Y*WQ8$N5=\$DR+8,ARS[@H45#?6-J(+=\:7LA'
M+W16\(-873O):2<W1Z(L9S,?)X/A[.9?R:Z@0$S&-*>7"@9WC,RZ+MF"D%K]
MDJ8;7$%S&I+1;"85JLW\'D$%E[8KUPOWXK&&!@4-JL]!%?9K<Q%9[*OU[)OX
M>OU<9(.D_GVQ<8&KDJ@'JGE,[FY_DKVPDM1;WB8+K396]T?;#USW<-S^O_^3
M9QG6]ZV=;?3MS#Z!!O>+'_1%DPGA KJ<ZWB;M!2VHCSGL7GCU8R*=J-(8K^:
M[<\< HMF 6[ 'JF[>>($U:2M/CB-P0?@:.C;FV>VCER<6'/G-3FPVL#';MTO
M;NNFWBOVZVQZ68;7-.I[*]EK6O,MBOX\9G=ZZTW:?+5S[O-H9]<!("&E+=N5
MNUZ/F[P..O?R_LOHFB+HL^C-P$F@[0.=RT2!IXY=_ZZ%4?T)]*^OE,H9[NZZ
MRS(:\[+_4AJW)HU3C.=U:6I3+V*[;?XCNNBDC?>_UZ(L F<3<M6WD^<@:PD!
M]1C9V=$TKLJ*F0)W/W/8%RBXGN.>%.+CFK3:N>>>3C%T-D3N;EGFXD0ZWH[)
MF"?]#ESVFE(8GTU.U(=1SE^*/Z_KOB9]]\1USVT]: W?FGO?M;6O:U3-&!TM
MT[QY,PM?3PLGX<$SV7W0P]P7T\.^\BF63PK=:HN_U?D_3Y,FY[HS7OW;=H2J
M$+._[@)M#UN>O#7L]NUD/!T*).GH7]V4!Q-#*NC-&0"C\^$ %W^/0-_7)^0>
M1 $^O1<CE>!O"R=^.^Z2"S1]!R&#VD2Q[^5KAKG(>^V'SQLLK$/6/8D4//L+
M[.1Z3OPF)!9LZ"V;$%_O[FR88NOC].E'>@5Z^1<U$$D$*)_31#!?R43XRKMR
M?G8Y;-UQS6;F#U/U"9Y")*+LMXU '+7:&&#G0H4Y(2"Y/34O?H\25+,CBVL9
MJNTX?4L5R=Z(/9'=NK/B<TM(%_*OYZ^.6U<E;?16ER.O2=!]J<Q<#8R<8(23
MHU,<0Z?8]2W8OF#6;Z?J;IV297]DOLC[XL,<I"O3XNCYEO7=%Y\WYMFL2'E[
M)R*KBY2WOTGBM2+;273'9D7\/+_>>;\-_YN>-[H]OG Y.D^MB'B^E)GP]?Z
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M3#9'9[-9NI!;79+VE]Y1>C@MT)OEZ SRI1EF=98V-+U75:4MK1EZTEL_JQ(
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MZ:J<A9O@5H3455$$\I/Z'^2-9UD4'H3*:M@G0&X;?WAPR4](TXC=')7&5U>
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M3N#O0@_Z%')/6#H. MWN4EWHA-@EN>UX2<[Q:F2$H@>_)BU/#D_3;;D"C%<
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MCZHZ2Z,3@6DBZJN4E#XOK3[VTDMQT"A.XD-'0<S -)S[,N%I-9'JK)%.Y.D
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MGS:Y*%DH&E"\_M'IU<?BB_1R4E!^I7#_A?IZSB=BC_]@C57XY'\!4$L#!!0
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M5JYW_=%H9>DN-XI:2VI%1J%'2=N[0G:(M@T36?-'>H@ZO0'IE2$]3;LAN\I
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M>1=^ZE4?TA2*-"JNV'-_NN>Y'_R[?V%UQ^/^9/S:&O8G:_^\M1ZJ_LN([':
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M**LH,]-2@@O8*+=%5QI,CX%6%;Y22M J0TVW)IALL&G3ED8-MZ]$1.[*0Y/
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MS%S!9?EHZ!">$3-YQ-70@#OJBNNI"(> $1"/N@ AK2I.$%[7:=$:;3 H(E;
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M/EVCP,5.AWN6DNY? V12>X]@?N"JK( ')L7I-,54G1P(T$E6E[;] &VS BZ
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M:M&F].O]L)6UGC*(!3:A0T;K;!U-&/2SA6N[ZO8E^B,Z1A=1EA?HMTV0T9O
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M*CE>H#!PH+=,H=  1$ #F+(E"Z:)F.H1*I512]OK&"[?5CK$X<GK'"]Q1D]
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M!9>^=0M[ 2'=:AU$&6TVL^PLRM=I'L2S)3V<SUPJH1KF;(-,.:7F#LYVV#K
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M!%F!L_BU553?K%?:T9:?I&V N^*4S<(0F/:V"WKQ]@VZ$1G]5AMKS2N084S
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MHX/M+H6<X7R11>OR2/!/0191H/.@P"=!'IDM^>M,^%L),W-.ONREUO?.[!U
M:U>R6E9HQUO;0=008I8@LID!NUEG. AG2=MW675]<W5_+-8[)6>P7!<H>[6
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M??J!MEG3 ^J.'_W&V_?XY^1A-OLAN<?@XDP?QLZ"=D%R$%L2=W_5HV36PV'
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MO"NHMQ4X7 ]0=T/T>PPR^YB\.Y38L\,XP?Y&Y-$O<=D%R2$=I=[A58]YE'H
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MME'QZ]I#8^T^Z*VU6J%W#IKO]KG:=8:#:<GS*/_U(L.TF!\FG[O87SL6/^F
M6K'J58W8AD6/>2LM6.';_MHO?2BB3T7U8]].\ZUCTUGT%(4X"???#7>?=$#-
M5_6J]M %MQ_S5IJOPC<'W6_]5)^+_&"* *F9Z[M"D=MY&;I%\4!*-QG/] @/
MPQS5.S ]L?\,WQ?;EW&7!*LT*Z)_T8"0+])-4HA8J56"-\]K#KG_':DFJJ6@
M91B6Y&?_BU;R:-: ]9-O8SSB((Z8*U[.*"%98!]@%C&:4US9>"K)KF_;[@>
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M0>!L:=X@,B'Y =S"?MX, O457<>Q?Q WK<M>RRAWJ_>-PVK((WHDGA5KS3M
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MTQJ+E@K,IE=?G-D.*(;O4*SJLVFHG%%17:0'EKH*L/R&A^I6U.KJ%!1'JZ@
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MS'9=*('RQT[2K#@N<+9J;\&@)E!<VT"?1PF]$8OM $)L5S>)L,QN(T0&\U_
M"+'J%\%J;JW8K0\741(DBRB(K],\*FN:%#C)(S(NO(RD)\/&,^]GD]$X+\6\
MB9C;/I"F9.V0HKPNM7^$FB<<H>H91ZAY"DUGFN>@^D'H[]M'(?HL7R--R;NZ
M(IK6076K!+WC4T'N?^[+-'G0!%B(@?-G3#MM'$[(RR$#Y#E>!5%2_WA+W)'=
MB6UOQE\@-'=23E^]#:"!S1BX-H#5EE!E"C6V2@E$K1T R<^BG"U6T(HBZK)Y
M]F; D%SAI#')!38.@^1RX'V2-YP.*DZ'E2J@*L5=5ZL[_O3[W;O"_HC9!RRG
M7RT)E&0]>-S4<Y _HG40E=>I!M6J9GM,1894:$4L;;(FY^NF"&1XQ91[*00,
M&O:F 6;W14#OWYG2(I%L;^)%FDGR)]DDSRX6G4Z=[>YZ9[9MN#DP36-W'_33
M1SE**[.T]>#*,&LA9;M)[^/H 5#%@DM,8&.)VW7X.-O@*_Q2W#[C^ E_2I/B
M41;+AYMSV3AV=;K=,H;:@C:.W-&/?M,@='M_6 RGYS)NG],=7T]C!2*?>RX.
MH7%EXE#9VX4O(.V' R0M>;!L:]< .V")VW9S,'6ID8,F;\L! 7T_'AY]+\@K
M'>'%E&:@DK?MY%#N4AN'3-T6?@%SOSY YD9/8\3=T@Q8YK:<',Q<8N.@F;O%
M+V#N-X?%W,FRP-E(].W9@LAAH;M#B-PQ!&928Q?T7'6H1YSA@ H>%J-W?#4P
M>;L+56$5]+%$+:Y9MDGJ90X<5E-IZTKU ,AZUT)?7CFD+(TPT!88&NO<->:T
MS!"TZF>[.,%MRR "/Z!HM=X4;!:Y+'D+@^1VBR4@%D(L%CF@+V#8+4Y<D\?3
M)3M:>P-O%^Y@14UZNT\6XO N(9\R9#O(@K@^#CQKUDI4IQ?M3+C=OF[O7'>+
MN[D^&)(. ,UOE2]-H(X-5!M!6RNP3DL:NGZI+:IA:P8@J3DG!Q#[$MPIS('
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MZUU@)Q4O!1@C<A/H47GW)\EX1-*]';*R -L17]G\N!WUL/)H=U:<'XO9K<'
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M2>F6E<7%[69GCAM'EYEJO497EBCXQ8N"D.Z]TJPW8LA .EY(CQ-Z2MR0U-1
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M>74963>W/?-+-MG="# 7&@?[@MC;X^9YRI6.UZK_4ZAY>ZO=:7HADW-EU^%
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M4/WT"?X%G^TG^ .O1.'+_P=02P,$%     @ !)YC4D_F@VE/:@  U[H& !4
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M^N&*A,*XR[>-8!9J*WX<SS_2J39S!I,+-N]8M.5H8CG44L*9YJ%-9QBKTQ)
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M]5<W](*R/A#,50_N#04'@5='BR],TVS@/="CL9_ (2QEH^H(10^/LP<H"QS
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MTV4E-EQ^_A T/]&E6<Y4Q?]G\UQ?>>E!M_-)%+J[G\SIWQ)WP1A46C[: ^$
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M0^;857:U_FB[HV\7*),*A$>O/B:*K>")WZ?+UG/:.!RZR7U DNV/1"$6NJ-
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M[9%8?!!X&K5SVCE"<JIND <X3\OZX !*KG8JA/ =DALDGC_/Z3?EIV)IIY>
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M]-X0GJ6<F2+<NS>,B>>G6SM%L!YJCF';C(8BU($UHU#E4WOT1.*%GS ;9NN
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M+/_B*BJF\CU0C)48$VD,D.Z=KJL<7A6C?*NZ)(Y2];^T(_GX2Y6 ->ISNT*
M\=U:'S8VCD;&$G5\3^.513>+TI<*8D.&2Z7BGP;3)&\6H^UM,('L"<)2PU8^
MO+C2:"1.9Y.H1G!I-7&)5/"%YXE$;:V7.6S 'YD6MNF[Q#.@%"V?,9 *'L(E
M4_25XKZ_[@1%0:93)9SPMLT4<5Q.N:5]G@DL[O:0<SP5T(GV?:1=F6H#OBVZ
M<$6CMV#^]70\&TL$L$]_FU"/511>VV M/0'S'/._9N7[<7X@71UE#!E,I'N<
MYX+]*C56:$<%3M6!2F">YH82Q^V/&8_?;\R;Y"M\@8IMFG(_?G/W6!=J>B+K
MZ#D#<*;,)GNS"T&X-(C"%= 7P!!#$39?DF\/WO+^&HFM'?TV87:_^&M2SQ,G
M4H_8H:SRRI?=+BY<ZS)^_4+)9EM@.BH0]&#$3RK^J[E(FTF29I9J3OUSJ?&*
M2AT/ZQVGN F31+]XD95FL/*GU;H*A%A,J] #D*:]@.(WDDJ19NZ(HXG.-NER
M\9?XH5W73FE76=D.?<TSNFI'+KN93941;Q'85?"[H77B(N%;HR2EF61BL91.
M6;FXEU@55Z]WU2'*;4ONUR^T$V5?7 I\]R'X$^4+^KU%,/$R(8/?2'NP5,+Y
M*)3G5F6OZG>^C])YT.L (+%S3_4>&T"\0<>%"$*_;PUM7(_P 46HAUWR8";)
MI*EBG<!TUJ=8W D'@^@E#R9>8DH6W@NX304N';OL!7@T@,@E=4PS<&9"OT7%
M@(?+BE[HQH1*,:8[S>&H:8O3F&IBNM<SPT6.ST\M)CJ2;SQ>M19Q4R7L3F..
M$DIV;U;@N9*%<ZU@-6Y-?8^/3Z#JO,"W;HT8OU,1<^[B>9@^['E%%$%0Q(DH
MDU/KO/,F+9;W;]4@H\]6]3YV:FBTS^:;0\GM.C3<.V,XLVS=W=_Q(X+M2?!\
MR; -?M*+PCR)&]?X@$L(%:^#I0K00ORLGFRQ%>>/2N@%CT/;A[*)%V^]<M8.
M#:,"6:K2CZ3AM9.H0*8!>?56!"LLR/=DD8(VECCJH7DNI%M\^^0CQZHPCHMM
MG-$;@?R?'I4<<;T/9B/G*G#2(.:DF9V/3:';N3E& \W<_DNK1:6W[A;798PM
MW8^?^I'U-6_J)B+D ;O))G34=T>4AD/6I>'M^LEM'(X!@D-.ZPK)OJ-F'7AI
M^5O']\!^_;KZC"DN,0M7\I,!P; !;6S/Z,TE"'M%,5\S_!BIAQEF=-N8=-W)
MQ8KABVRYJ8/^Q*&U1^S)B#/3OM8LEA>C3K_J/'W\/%-),SZW<9CW-9?]3,]A
MQ?DNY?>?:K(8-6^-7GYA/GH.YSF[;O5RP MS2N%,CJ/A#@<!H1GM6WS1W_7D
M!+O0_:9O8@F')?91MR::@[[(,7V>$STVC3Q"0\YX 1Z"-VZS>9\MX/2 !-^-
M_MDR[=''Z1P]917"FWQV@"2E*9"&G8JFQ,+[ :=H(6!N[SJ^TD<1PG0*OT@?
M(8"[TU O^40=66M9WUJ]F8FQYIAI.^<M"'O$J 8;XV*NH/^!9*?TI=+CH9&7
MI!6E6N4-T_--]/@K%EU$WK[J%)+=;"D^S4<7>SV/5Z%J70[KQ?E =H4B3( ;
M1!K(\M9'%PN'@Q+]&9-/UW^LXM,&'D:ZOPB[BU*.?_S@@.-WB0-4H%'<'7D0
MQK6K!#WIL.MZ?<)B<3?.5"PAR3-M\>&9NN/7+\=,Q^F6)RE.(R5/E5]^P.VX
M(TP.].,C\A R[P8W400'MM]6$$J*G5;6MR^L?>^S:J@ENN=A%^Q>22=K[3UI
MT@HT^XQ1!#RF&,@- 9Q^2CB+VAD^Z#&+Q1J]D+:,X;[E&J[,](^\OMW\5""!
M?^5H'<;&USL>>@':9=?Q^#C=ZC8H.H"]WT/[NC">ZXW,/'D0]>ZRZ:U+0IN7
M[M7QQ2NV<JG>,1AG4??9"VVG02H"@$["JIIKD"TV_3U1W'?PC,6V9U#1E.N>
M0]M1QK;/1M8C#MD.?8\V/!-_,UI&6+'/.QHGLH*:E@B#5*B'4"1I'J*+OSZ)
MF6I(8'@S!WG0D)@ZM0%+4[K>PN9H,WHTH\.*+\?>G"V+'H/9*<=)0[AR<+>J
M]NMXYQO2R;$;.FD.QQ8SUE<>$CNX5X&**_YO0\>$>_1WGW%684L1%BSXA,BO
MP5F$0J6!;5<KQJS*H:I\44T7J0FA.V<.AC(4.S-]UE7(?.>*3&JX2.D&'8#8
ME7(L)66C6TI9E&8DPKUJ7M09[5L4/AKV><WMHR"OVOJ.#71%/BWB9HR;D"Y6
M?6TN]IH\AI;E<;K;!,N9<\/2\)-F*B7D',SMV(6%,=]MWSQT1=R7[NXOY9?M
M/$S?"&J:K6L@/3EC/BDV]<Q"@K?Y#?GXX)P$!]_E1*[S3K,#T_;6G@QO#%0>
MQ=*=INO@[!O^ F*&3"<$G"1HYA!\6)V>[F] CY"3/W^,_WI&K$&W.'?)2LA]
M8M]=_QV<N<> <XL,G-!7_0\WSF"\-D4S(0R]PNU&!3*2JOYEY.%O#72%9$\.
MJ=/'6\URH6<_UL'<R1:.86+NCG0.C$B7K,/@F3X-9P%)_EFM1P,RHH&6U6'.
MCI:-89IFZ.>0Z13*E5YK'#QE!GKD1A+]A.I;:0)/D;CUV]KFDUP=T6M%LU]?
M/)YC>!93<F,LH"DC$"R! Y$X0!;5>,;, MBL(:ZR6O%K;L;$^(W*33W.(BY)
M6 #K<T:+74F[7;I P*E>,J6KKL&6)(]NQ4$QY;"QGCNH6#[0!Z7+&ZH5AD/Q
MLIC1M##SJ'1'M8\&;[*KCG_Q&NT*N>+?K@KXE>(3=J3J"+FXYFFC( \X-\R%
M:(H=*G;,=Y"4J1DO0;EPIK06O6H^Z*M<*);U)/U)\4;>GKJB(Q4XV#FX51K.
M/=;=4(QMKW(L-I=^FS396Z=HZ^UUN$73Z<49OX^KLU4CR=Q=;L'/#TWVK%XC
M2L/B9MI;]8Y/+)IPAZR=Q4N$NIL+MT,;JEG=L)')U\G*V+49O0LI64H>;#%.
MUE]B@"_!"Z6R!'XBB.2',YL2B&L3D!ORNS<4D^F@7XKP$+7+&0PVB<N_-# Q
ME*7^]'#DP\FZ@1;F$ =@"?)(;T2J#7T ;4<_"SE.R%4>?""O8JQ8@G1X<'RR
MH5%FZH#$E3V[]B]7NJ,*-K_<UGA21$/J1/F<=S+:Q9!67O'22%#;/C)2?%LH
M1$]^:LH?_*BLPN]HVWD4J'SR[<:QEP=GO61"ITM'3'<"_04I$$X_ [P,>7?G
M'"9!!A'EP7??6:;OP<:ZP=FQ7M-J(XC-Q ,$G2$GVX(&R9C(0')!X;TB2TEG
M9EF[SQH.K,SU;YG[K+?+9W7;V_-/5>)4W)P_SRSIE4/OM\5]Z=-DCIK4_?%:
MB\Y4F98;-&%=S0$<L4UZ?(M39P<8!N>WQE*S3R@[.<]LV-MZ.]\>ZSP5Q18G
M%W_IQ<SSSRV5684BYJ7P1OFXMOT&I(=O"4QV-33<Z*YW!FJ47'AFT%UT?*6-
MF57LO;W14%$M4G+",ME1X\U(P&=TN40+)$1 #*];.*MWE!#<RB4'YJWJV](Y
MJX]W6B5=[MKIUG6,N=BAQ1U[[?%M/9'DBT76]"MF<@GVT/>@:)0.5]O.;%,#
M4R\JDMB:NM/6MZ5JB:T^6],K%&$N<^?XD\J:.TURC[WB3\XY%8H>"CR)Q-W2
ML2#>K@R:;4_BW'GI42Q_/_/ZO78GVW/OX]1TRO:*G:TJ8UILX!<>N5$0U3<S
M!\"' QI]<IM*0Y$\6X=DH@0_S\Y8HR8K4XKN?UITRVH_71LQ=#S37G*L48Q5
M8)11]D/>C0*]I!_0]Q)1'CI'AA;@3#".9OG*M 3/82Y9HT_V4SSV(%4N+WF?
M+!Z;BJJ^B- 'L=J21N0^<$? ]S3V!!J7_10'@[3!C_FIN#$]>YR+QX0L?!.O
MB-21S.V7OIIE"[&Y[5<9/_@V_-%+;Z6Y>+.#!Q\B@N#3R)J%7)Q<,U@ [XS*
M3;FK48V.<L[PEF%-D=.K^5:RU6S/N3*M!Q:N)JHM^KB"!*5EMCU.T&VX0]^'
MOMQ&A)E0T/G+ 9R!A%UCW-?\TD;[@U^EY[\YB^56F<H^=I8BOVE>9YWWSKO7
M.1^PN<Q[/NU Q'^RO0^X .^\@N<F!ZW!M^X:;C\@W:$"L=8S$D2&"5K9EY-V
M>.E\1B!+)SZ7] Q+!4J)$/*%"-2ODTQ#&1'G@?\)K0@4 =VX5:=*!1[4(LDG
M!NOO0TZ@YQ)AD91&+\C^A3QZGY]*?_"SIP*G8?!E2@\5T'I8[/!;]0+!>H1.
MHA@AN06#DB )O8?QZ0^2V*7+JR(KY 8?9R':%(X]Q.W%MO6%)0ZI1VP5J.RX
M:S_.=Q6B F4N*ZMX]6F+7.P>R=K:OQB6@6E^^H,B3*.H[[BAN!ASK?T'Y>\2
MK8VMM4^FUZE=R:CZVG;NU9>9!C0-[1F_01ZNAU<:)OGDAI2(64:JFVI?AZ\F
M>\I#PNOJI2'AVLS1*M+<CS[$?_1?,Y'82G1<A492A!MP>LV'X:;]4;EC%4[@
M&?*=!>'8:WYYB3M'B[)LG:52%0^[OVD/Z 5MN%"NT03TH0)40#,KC<7$&MW2
M623HC8(<J(A.#]>YM*BNL"7'M#= !:P(""J@!#I(0\/*92J &+;,@7?(8BC5
M$AN<BH KZ-?SO3L06B&P=0RG1V%U1A/(GENWF8[]<NQW-PV[J/[5U5]=_=75
M7UW]TUTEP;Z;$<*GX0R.O ,) :S5.H)MCD,O'E^Z]UDPZET>V+7-<_:JHF,Q
M(9L*"'6U0'=8JZE K\X],)@*=#+C2\F!+NBM5"WT;TN*0+F\C A ]+<9;J@(
MR0OO$ #M4X%R*M#W-H_>Y&<B^;@^=I:B0P7:(3L24%JI(?UF9)B?>!/>B29\
MI[32Q"8+QP;*%TM1E"JIP'8G_%7^TN&_V_GQ+\Z/LV!!/[LRG,'&HJ%A/R&X
MI;_$:2M2D*T%-!O3L**_7SX[+A/EIRI_^7O!"KJ8VVM4_'ZRIGF*17[!N)V/
M>Y57U5$3D_%\;YND&S%M#=D(P*C'"%DYF9I)U+9+TDUT6R"H:72_Z>Z,=-!V
M/;,G=$?-\\*AZFG+B8W+CM_<D<'RB!:^/!0D+.&V@W/TN<IOJ^&\Y@DYVPH]
MIRF;I/HGHGV9498O+^89Z <"GP[4%6SA1QJ,M"S:+N06U&7;E@^>SQTWFAKG
M05US2J,QDOKRVS25Z&,)1-K0BK2A=^@::,/B?9$*M$KL"5L(4H'WYCV4"(=T
M_"Y%0R\*OD+O3P6R-@RHP&_XP0!=O>J)VW2_EH>&J$>$?LH-'!48)B,IKUMO
M@,Z0GB#:!!0)[3,:TBE6LY#G"HJY2R!K],=@M:%M]E5XZK6;.YW.W\2X8JZ(
MU_!Q>^=NSGMG2J:_7::T6P@3\H]4IYF3E/K\;#.7AQM -8@6'[^N/ =>U1=;
M'Q:MM**9K"X>?86:3M*8[+!^4R(D)(HL^9'&_LS]+#YK;&0%Q%47G*8FQC \
M7H>=H0*BVA/.7FYD9-V4[1<JH#SCC][XW-!$SD[%0FR1I_R3KCZ*(QZ@ H+&
M+(?1-G$*@=XDT8\EUW=HP1,'Q_>0(X>IP+[..<#.;MCBC+Q.)9'_I%Q\];C_
M&7[(<I0)T;">"H!-U"F,G52@K5#E%LTN3FCR4^C<11^@X[=G\WZYV"+BKRO^
MNN*O*_X[KR@H*9_1T6ZN>31<M9AF;&):LF>#U'>/EES2C#Q0'B#H9U^&,Z>A
M.]>PP!F\6//E12XAZ4^@V==;$>!$6Q)=D9/$=,HZ0B;, Q$F=]OA0U.3MLYQ
M#&0TR7M%*]7F%=R;,(?U,4(:\4ZDG+JR$(O9LUHB[HFB5?./F(P)WP0KX(?;
M-7(BF[EVIGB^*=$3GSY=,%?RC;2;NGP/WF]X=_A9JP><'7Q*$X?6C3\LHMD7
MJYV[Z5QB,V =O["ANRX6=<Q& 6D9%RA:16_W*;L@/4@?65FT]WUR:R/B!YI[
ML"QOV:LZ9J?8E^)7@2 =CJ,"4?J_V3.LYYS0_^,+3M#]V?GO:/XUCW(<I,W"
M.O4U!Y%EU]6TDYE^9?T=^WFX_"+X[XMA W8$>D/9SY&6*_C6R2*QI?]\:?Q[
M_/64^0=%V9'"O\?;X-^ [WD:*?GO;1]!)_T\0H:-_3F:=H[#RELTQJVK4*_$
MZQ%$(XZ-,L2.M]7B_8>2TGGJ2855SNN=YPH#-'0UG3W!I_'\H2^D$TNWKW<Y
MLIYG7!1)5>(5F7'\:MHF<($POZ"$S5NKNX!M>N(QW@'I6S>BI*2YU&2YQQ %
MN&6\5 C\D+#M#A2:'Z,ZPZ_&==QD\<<+]WK)^H=A&^M40 <D\HUERV%FKN4A
M.MSGR0JRCFQ"\.= )XU$63>$?6_@)XGW!G#;(URRQE9BL75=A?GW.]U\1;SB
M53:ECFMN\5P]4,-[OE3YS?D[0;DZQI?">H7>O-)7Y4S[^QG=4PGMF+TS8!D:
M93B\2XGK-*+\USO!GMS,D?298L>=U_5VF%G5A,"*>@M'O>/M!WD[D:;/9FQ#
M9II7\&)/3,<GBBM8Q$:Z74_%=5Z^ $H4PI0)E^%]56MQM21]/3YTI#!N8(@B
M2C0H[FY[+7,-I*4CW21H6&FFYE+WO;*I<"_G(?!R>.3>;:9/24RD2\BR$2<J
M\ (U![=4WP&A_&M[J,#SVL]]5?ZY"C2FXT)T]NO9@A (XU1 S'$%,F:A_99V
M&'F*[WYZDMX**\[0^-8#B=&LS@[#[^.@*"_.?^"QK&/\5""<3[U2RMY$$!)?
MS5RH-9M[*MF25( 9]Z Y.J,=%2!(T8+OI6%T(A4X/0[?GT-WW-NB0^Q,PBG/
MDB 4MCDJ,'O"OXI&G]-L:)0_^!J$T/I8_\9)*N!$"Y4?/)FT"N"K'D52_=<.
M6T_\U<M?O?R?VHN1%)Y]9N<9KNEJPKWZUOEAKLK+9Y+65FOH3FG'/TZ5ZE?4
M*%HVS-4ZDFT8:WX_6=O0@NB,I@(WND%4@/$I'!\QWW"&Y IA&SOILEJ1CQ)M
M$'<?U]ZSK:]5#+IYN@><2S\P_"J@%WR9@,*?)5X"L1.N6WP3$U\PG8L5?2'W
M-.95AD[NL=WK8.>6?:,JTEF";29,1:4*C>K+10UZ'#JNW16E1"*K3N2)??@\
M^E!I.M 3_ZF4*][1B-O$_?)[5_VJ>J$^+\J]/G1WR7YB0;1N[[7#IC<(4?A7
M;1X'43ADR#R/_Z7#JG%W:J!KW5?:FF3.$JR^LRG)C,$@S=P6P+>,?FF7(P2X
M;EGH6O.1]-,\:YH;5S37=#5+/D1LO2=<=,]>Y9^'+/C2@-A"4\@DPF1;DC)>
M2@6^2:E3@<9W2-)#Q,\I@RVV7BJ LQ6A B>+(T3?9X)6:V@%.;TTG,3SDTJ=
M_\5@(QF!?][->?I_52\*F[/U"Q\Q]*1'0OT5V0CBD5VW2YEGCX*_[IWVIA?!
M<_;]DH@*0"#XW'/",.63'&9?[QSTETF/&WP#/Y=/XV;U]NB;J0!T![Y_E]/Q
MM^ND]^B*?U;#9EZKQZB ,,TID41NFB9;25HKCM'D#,@<AN1&!1[2JF1*G.8-
M?L._ _1MQK]'=^#G&NQ_:=.?G%+-':OK[SIUN24[5?/DQ31^39% T:_;H#$]
MW4'GN7)<0$H>;(HB.T(%1C]S?>6B CD)$F'#./&MDL=J5Z)8?8V-ZQ.,?L27
MSCV?B_^>902:[8E.%2#  VK\=J\L\0YD[LH;IARKJ7^[?VAXC7S_V?K].+_K
M^-R6>".\1!@:*]#?(Z*%(YZ("<U*T-E$JLP7( *VAV$BV)Q@W$)O1J][K3:[
M5.*CFU_*D4:OYB>(93+=JV4&%9D"JE.FI STSD(QJ2BY<\5UH;^="G ]$/#K
MPNUJO-H\P>",LH^;I *#C3$_>$+S2I(_P9GJ(+@%]63=LLD\70@\S_S:Q[J/
MBEV?]ZR0MV;':GQ$M8S]KVJ/?=U$>CONBF=N:#BP>GVD<9J)VW]@0+I./W^:
MMW#,0HD !KZH\ ;^VU7SVW\VCP),_=OJRF\GP0I-?EE(26./ASM@(C$<)'%\
MY QC>*Z?2E\=![;62:K):]^YV#6GW>7(RRHYDR6+PDEM1]]CL=#W)L)[F?=?
M:T2DGWO2IT3D#QBD2.*'(]T3_6SSEY/\A\JP>S8#=2(E)B9*KMC(9N%$KH13
ML:I.K.'KL0L+:IN FKOEB2=AJ9([_"?H]O#8GK'UF>+)^+=&[;R5F1R+D7#[
MI^[:G$XN+:D6;Z%-*X6/#V14[#XH8*C6^<"83.8U(:KLQ-?XZHU^;V>+WS2+
M2X-&Q9PXR%ZNV?/ETP-_-_-Z5TR%.BF9"D3#5RQH =IG?YY>_29><65,M5PN
M5.8M(AXMVF4?TUXQ%X!RI!R_WK,/+&%V-VA\"F% _OMY/GJ1WY[5IP+,_-_)
M@(<+<8]&T=H+__8@9?0F)5"^BDRBW3@[ &]2]Z:! K\IA6(*QR_]^\.89^MH
M6>)(,16 BZ,)VR!<S!3\&Y,A%4#'8T@^__Y(I\8ZY =](1S3Y4)15"<)>2&W
MZ ;1Z_-55$#@WY_&_+]-E$+V-LAQ$@2W ^Q/H7(6+4,,G)TY:;QU\LY3.)W^
MG:(+[:F9FEX^])X3R7\BT*O(G9A^CQ]5,#<5O%[X +GS\=9PQ&0/V2/YH=4$
MQVTJT&2 UVZ1H+S ZAV&!8"["QV*G\[!JP_,@L?1O%C*8#,::P''ZFJO:V'"
M!7K=KT-_8R']<=@'WW&[A5#5@>P(@R/1<28?:E*5#NH$'?:&M[H )(LA!4YW
M:1I^+&Y )]F%1D;L>\=:\B:N;<Y[NCY[9\4DY'8? \!MV7GN$ZXN4L3PZI'2
M+BN[Q^XW9COT'E)X]^2JV@.EGH#G5MFN7;(M9.O;T;R>#KN>VNLZI6CS"I$Q
ML./3\O$_L>7'=8+M27Q/5,/9N&5RP^S^PR1,>5SI?BF(I!&V0ZL$FCH@>$*W
MI[\M-Q4 PS<>&<R/T$J@/^FSE'!'0/@#S=X2X5,7;KD3=5#%/9LO[T5.0\--
M3!;80?;R,?S'J4#S4N)^Q1V)C<QEU'!K: *&B0I487!';$=6_DSHSDL!ET;D
M2#XDQ8%7\)YK):MFE(-7R?;<,^PMA5+A%/[%X8!B^YGS[8M"5GM]E/X@ I96
M#3IKTG+BA5#YI<2Q7WP.\LO7/;V ]VI]Q;Y5&F)Q6H4*W)+ANQ!*B3J!QY<;
MK>.^MU7O&U,!_'[IJCQHB@I\HE& CE!Y2IP\^H_"HT1-+[)!_"/H!YQM>Q>R
MM9DW>@,"D4&_\4:LGL57S<3'86$KCTD@V7#7?-D[LWJU_LHSG&J&UR3;.+W<
MY]X%#7:]['E"\+E2-"OGLJ:W:2_1DFB@;T1F]_LEG 8YOT<N]*]:V&\YJ1VR
MXDO5%$89*"UI)A^HPWSRD8NF2,' S?<'2+9>V)'2S$GAE%R[+GN9V@,J%V(?
MKC<RO0-@BLL9[\F)?A>%C#U@*/83$_D]*246G?Y( CU(+(#5]&[;C&BK[@M1
MD8*G]C3VV_R%0CRLB7*/.+OS 3<Y]<%]%3QL/+0>XG8DCLV+L%^A^QER_&))
MX:Q+!%B\;L,=R:R"C;K63H)#)Y2\/.G6WHL5I-<G=I3J]4F;*A[H="H2%R\J
M'EYK=3G>%OP#.%!LX&]T["YAVVF>H8M0V[7P3KU+I%8!H4,X>R3]\D>\=6ZD
M@J-7RKC']4*7LC;,BJE0TVEP>@,*L[@?N<BE/SY&L*&,39U!"8:-"9[> K2?
MF588Z8*8U$)QF3:[_M!"'W3R!57QEW^":J)9-GJ_/9;Y6U Q1)V@B_L%6/)^
M'99B5> 1#4W^T.T<]6_P0'[KZ8C?R&8R<)OQ?R]9OF/XMXGY8"9"IVYX@1J?
M<CU#DO9CB?WK&ZX7(*]*$/\]I.6PP\\9G%FT'6)/C@J<H@(C]7 JD-5G9/4/
MF#"P5-&SQTB3=_@<13DW3_KO=O[@01O1LRU@R+<ZH:REFJ$W.2^6=PH_SM!*
MA+#\%(U&-YU1[Q>KU:6JWNHOJ,!C##TAIS.)M?9[S69VN-CT^]0%;TZS@H_W
MOTW+!S8K2@5W%(LB7U+.#'$(@ B^,Z(Y5" UJ2C&WI5N>;-<(R!9]&N(6_ [
M[WP])$DNCICIJ5X1.9H:J1-O'23L97U3/][F*HMBM_=@)0(/:3U-KKV/&WYA
MJ?"\OUB ,NW+_;J ?DM%![%C\<W#- 82MHZB MRZ1U8<AE=P%W9>R+8Q5?8;
M;-?=I)6HJON=>:7D&JC?;3>Y#Y<<0155P16K&B-C2Z%F [7&/W"*I")_B/M)
M]I:(7#D$Y32ATKR&/;C8W=2&6)4J6,="8^FE,&VYA69<R:8R;BH%ZWC&*>>^
ML?W0;);A-S$-" -@, 8U;+T';2AT.2\:()%(&CYOHN?I74 Z.ERG+Y$X@^1?
M3HA)->G2T,\>MR)FY5A;;C_1<8%!IZ'/%?@A*9;85<E+;G%N8A;^C9#M(9V>
M_6%C57L]\6:ES8TI\WEO2(.1U>V( >!31H3HQ[3__$+J5SSHI322R9B<:30H
MO7J)?6_9^^DKD846%@FG^[,\FANMYDG21C&PY!T"01)[@6723POW+OI(7Z57
MH<_H5LOU[CN5Y-JZLS,')['=K#-RD1P524;/);[84IC$7'.7[_O;1$]TK2N>
MBUTXHC#59+@VTT><"D7I6YSS)MXB*0^%DNY"#]19/T5CAF6<KFM N[K?T/++
M!-'@$5YB%31CVXU^0>& F9P=OS.X+G/!"!=R=8 *8)03AJQZY3:LBY(^&.5?
M51_*DM@5QDS[HCAG\"01PF!)#EE[9BT\L]PC4@7W_+Y>YD3W)3AG016\S'PX
M/!D>%B#A]V P$EX4@3%!:%?!G>++U-LK[8G&]6D43RH@>^Y94RMEDP-$]-!!
MMTE"PU>'C?1'32O*-6)N!HNM-1JH5\ML@D(AT_D-Q_!ZJ_? G"9V)@-5ZX7:
M6<)9L4T[L?+.Y.GF1_GC[?S+I?U48/H=\I#E1^-M]L-FL(BY4XD>]2:;^I/;
MQM8T(&IW:'\.GTX%,9+H\<K#;2820<45/4>-S9)KO8M+G6-/"IU^670 *L3&
ML?%\[#I+6^[0W&SGH]*2JOXU13:^CGSE@A9?K:C6#6+!!>U,>)T7=!!A3_."
MBKVT?^6"L@ ]7F(G%S\< G>8M,).J'S:%T@4LP E: Z59GRLX\KW!X59V-;J
MR3*<0ZI&GXSA?S),%]FA\=(JH(5&>A+"(?;7(8<<&DZ7X19B[&<A;%..DC]V
M>C]7[1NTEMMKG(DU/B>H_\2#7LCJ<U20-]2O3&;K*WK:G[O5<]?5(0F<D*\*
M/_%D\MQ@EIOX%]=R!3OLLXF"KU_2<*S'KPDG^3&D\UO,WJ:T]@5@/+]5[$*L
M$%_?-KDQV[9IOB1/(!,JS]//.IVEL,C-CD?"%'JG>4AHEN999MN@ICG5 *%(
M38_>Z>[><1AF#"*6]1%LC5X#6T'O!?0-Z]D3%0C8V"G'6'=6_ ?!P&<[]M?V
MWK*QE_@7.F"PH2%%LU4:==?36RH3BO,_Y5L>#W-.OE["S;KQ^>G3V85K"D/0
MWV-Q7Y^"ML^^03588+!_U[$Q=KA_S*'\EW160/G-O/-_)-L]< 2+-93U7<I!
M* TJ=%AZF?<\5E..E2(N$9#32!(G7ZL)BXDCY,1='4ICLIYGDJ*HW@57ABX%
M&U#]&3Y9E\.I7IRM_BMJV&"SKV]P1HUC_!N3QC"CYLJ$BSPWWR]^RPS\5,CV
MHN?T*__PTK-7FF8=#;+%Q"U4N=?M?4N[&K[KG-)ZKI@<9%\QONPH\VC,LW[=
MUSD&.\5.!8*2848S5H(PYZ]-^]ZZ9ZOJ\#0^UG-FZUC7^8=PEC4(UL/O3ATP
M[G<JH<OR=;S>B9$W#WR.5:2*OOOY9M_!5H(J/I:\#2*H/\1-?6CW&I>VUJ '
M[4Q;VX%$2GYL^#NVK4.FD0%7"&<*"PDV4\LMO%97NWN>D[0A+V3"-KR%F6**
MA-HSPIY]/VVX+-:JZ?LV!V.3#JK!Q1+GHM<+Y]\$L)3G$&5X).J?TFBSR#<,
M[@-8THS<$[*O6$7V''[H!\<(O_$SPI>X40'!JN#5=J(1X@(HKG2S5'B8EA\*
MI\T,7TV1'N#90V]EB1EBCM&TB"^ 5POG6L\W$O:ZS=$A ;)^SA%MK.TX4&"
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MXQK:V?7R,JH1GZ\X.FY:M]%U]M-2 2>=4.R-Q:FLN&G(L_F0^^.-J2?LO@_
M*\^I9)G&G-N%+-Y\O."LM\[>W?D]:?D\?6 ?%;#3827* ^[K_!<.G0C!&7XX
M=-IW;("6/;XEL9,(L%DJ<*B>5KO$.'[,"+P*)]CI,%'\%&A(]MR"QG\Z*N#-
MRG:03>PL@B2XC:"HELQ$ #0#8M.E07LX?#OEF$\[%1 <.!K0FR1=%=<VIA=]
MYVKERBN"W'U!LY>IX*XV>2,>HC9EI I:#G_IOBH/9U$O&%_6PMNW*3Z\NNXB
M<M]\U__=V1,5Q@'=SKM'EC^8=JBUL3&WXB56O^?#?+4$])HA1Y=-TOH5=""C
M6[59-=K%*JI)=GQZE2QHNR3-J5.9WBP'.A+YPF_0+2%_U8B&@2'/O\&_-[>#
M"*K+(%*D(9B!9 A]B60_,W3+,+[*T<W-VMO1Y5P7ZS5LX@QL?%5V9Y.13^D,
M5EFJ;;Y9SO+&*0A)6CB8"H %KM)J/PE:3ITS@?RB^K"K*O#D]];\W7>;MYZ@
M:Z8"O[5F)H67@T:[D.RGX%CN(OB&N!?-]]FIP&'F-"K0$QH-P44.0?:X$+^.
M"FK"* C6O],^5">%7^O'#I8&K4CX*95H"]IK3)TQ.)K!/&?LP7Z)&=Q6=71L
M4MN9^ZN]:FW(_<3[YYF\+8EJ=E6WI;2S" N,QS6>Z05[!+\QNEA,!030+8#+
MXW_D&$VKD.E\+OG5[)=)\$#2#23NE9T%UU %A^]E*A">-WQ\1U4GOM#U2J1[
MV5NPH*W7G;P7GK7^9W#M;3B2#L$)NW[<M,C>9>;PE?$[X59O;Q64W_P G'HR
M>W@WE*D8L/RO,XG^?_]XY=%2Z9B$:FW_=+RY:+OL1B=O;8L?7Q$'Q['8:J+$
MU44+F5(JT*@NH7"V@!#=?Q<GI"\7+%U;#X?Z.OD[9_8_+C[>O38]]6HE3O^9
MBZ5MI:$DH':)^;214C%ES =?B8?L& 5:$EU"ZMS8GZ'+MZ/\'Z^A>'*#FF B
M@4H,39SN#9LLM1>BSR=B[-G"Z!;A_VJ?^_]E8(?#ZCLO>YW$K&/Y1=OECF?$
MEK$S+K.8[=NNH(9A5?<:>A5$\RWLDQXE#64Z.@I5UOCHOI+9*LC*4E8_P^$&
MU+Z=MA5N\"5XT4HM-A=^1T\\O(F?"AQOS,N) :=;%OH7B$:&VZ!#1HNJ5$!C
M3O..Q\+#P^!9;??D0Y[0+:/_U%(62M-(POD!@4MX=."6-XG//ZOJ94:5XS-7
M/P$=8>W(%.6Q\Y.94<5=WDGN@>NIBO.?0E?9BC(7??X!%O;^SI2U$>?I0W_]
M1O7?6W+M?-H1T*^C _IG<;I:+PITU 7,[:=8/RPN)DW$/CA8)9&W%)YS?\2T
MM%NFN[59]'7$U6;)B]$3[ D\I^FO$'<B>YW2#W.]F4T<Z0B[!Y.[?]+P"0]Z
M=IB@)(++1_\ZS.$$1PJ+GML,**0&$=[3S'YLO)D]Q(/]J/'BTZE6KD+I&C]/
MX8T^F/6A^-53">/T/">1Y;>T\D=*1_W Y*H*Y*F ?BF2C*\VG[B&BMBKTX-<
MIJ16)]NG)HZW YM9LS%KV9=NIFKCZA[1U_S++?>/,MQ_<%3-+% EI&M# 7)V
M%,EJG%Y$B9]FSHB>BTNQ7- VXLJ@U^ECLRLC0J%Q;&KWF("H[XI,JU+X]3MD
MI(*$2Y$)P9BD:EW+?<[CY&K6%>D8U</9%=;&:Q*7A%Z+23+<LU%C%WN40P7$
MAZC =/I^:@)N:;/E%>FZ8]=]=W%(JR%>O:3M7%V_!WM%"9+-[N'4?LJ7RH7S
MJ\>,V6+;<J:Y"E[.@UZ,V*/*5C!_&@WW,>6854$,OX>_UF2%4E:K0()5J7U?
M9$\%7S=XQW&D>$IU)/5>^\H=J?^GO6L-AWIK^R,VY2QE'&(2(L>(5 :5&)(D
MY31J-G(<S'8FPU1RRF%0"#O*64[%..0T.8OD;#)R&#(5#3-D#,;,.UWOER?[
MNG9=S_-<[_5^V!_O]6&M^_ZMM7[W[_ZO=:V_$4\D?\YIG7M;"<:)OX8_.&Y>
MFR5].V!<=.NB+WA(HO<Z#TE\=7J<;99T _SE)M<ULWY/0)^@QF5..';7F2-T
M+.+??T_J@:+2TF?_1K$*;^=$GE!_=^<T(^[DW/@T63( D.*VQTY)@"'B&HW]
MK,T:<_8B*@%$K@;K,@'GFM68@#V6=#=VWP<L*HW,(*QL\7U!T?;GS$/HR@,"
MJ$&$*4L9/V("Q $+=/=M11IH#I@88"[DL>6\,UU2[EZ:#TLNF^Y&!'CDGDUN
MVG?\_M<3QHN!SI)U)?SL^Y:Q+FKL,-K-$:/ZP31B6Z\$S5'XAKEL/DP=7N=N
M^Q8M6_&6)*,>UE%+^H S8 )X3K3/?)-@23JRG'X7FF;[_?GPI]/I3,#=8PQ-
MP H J3NL)QKLXU\N,D$JHW_QAKW--HUUR;05-Y%+L17+3YZ8>%S]4C:[IL8&
MM2NZ'R,[*_'("K0K.GV"2W H(^(VC,%11!OD7#@8_1-_V%X9LI)[VUORQ@[G
M-RQ]GSDE[T>$ =[6K(JE>WK/J_&:\@OOEY*GE[9BQU47XCHR'QDBN.]K"Y+J
M]^P#OUSPCG98C47OV"J&JNT: _6OW3_E=]R@6M#"0MQYCQ$:0P]B1C!31X<P
MF\27H3PW3A-#%4C30*.(-]K"D>JI.K><92L/XH.MV[90=^EJA9\;S,JLQ*V2
MX0=34S$&^Q"\;OLU8<[7 6&*Z?\'.%C\Q_/!Q9;+:(?Q8E2X^R[%71@ECF"H
MC]H107-\1LNZ*3TI9CS[7+W(IK(^34FU3JG)MF,QG TC9)DV2&=<!<K)8.=Y
MPR;E;/V:[  UG>H^S!A*>#]%E5EPDO!YIXT<*_C_$."O *V-!@L5TDW)5N4$
MDHN8MW^"[S"4Y[U3?<I4892APJ)L0BI.T;CW!7B] M(.JBJZ2Y>N_+Q54)A1
M;!KVM"-IPC2T;'IZ$R[ZV+#>[$2T.D]LAW.[:$>98+'6*.KOHO,3R:G*N>,9
MT*]V)>[LM1R(NE8#3Q_Z,,9:V+YMV( 8XJ=I^<%,V<702:+'ECL;/KCTGS/-
MA]P7K SU+_@,[<+FCK9"F?[?;A:^W@6&*E*2_/T[W+Z*Z#DHO*]92W6V16C2
M WA2]>B]<[+FQ'-']/N.E+(U2J1>UOC-_B<^$34')J"O,\W&*\^XC9B=;"XR
M*X UCQ<$^'H?SCSE]&?XJE7[VUIR2!6OR;%8L8G'[% [^584?W!H=TIPVGB7
M\[C4!WQ9RLT!Y2M&5@<<#EPFGHI3:9)^H)B^BO/1"OK_@=A/<X3\7/1K<UZZ
M$PZI6[+TPJ,21; MJ!\F5HTC_(DU*=>$&IF O#XIXK'4/E?N94[V%^":E:]:
MY'>KJVVS;OB:@J[4/U0]7:HH(@7N<K'[E-V2,-;<3@\TLP,293M\]BWL+27J
MA3(!?^LDMSX_@YOF2C!Z5C+E=L:]*L=:056LPN4Q!R3M0I2ZS/$'!T*(S@^.
MORQ)[;&HQUW_-_9E6%V'&><R\93CN#\NS54HER>R[^4I@-\;V3L*["[_Q3>/
MRW)84?8DE*-P]YF +952N^=P_,6EK8.DB#[E?:'LDYADKQG1 *5707LT3G2=
MDWHZ^%N#4@Y+U&E;, '/JCM &T26;DO^_-<6]J>Y+#E!,P@ ;4F 68HEW!.U
M*87>9=\Y!0/1?Z<5$5: ,[:?85PHPI'AIW_4XM%TN;3 ' ]1CIQCHU5^R1%?
M;IIMZX6/@S# A&]AWF:NLXA)J1&K^MI()J#681B,L9+IG3QU]$;TPIHU]_MU
M#MPPBARUJ/_M9' $@_Z>"5C5!>VR PV$+Q]?\,^=SMR>^<0P>N"NY%O9L3E"
M[1@.EPG&$8JBD 8%[EA!L-+<&Z_UF$H,6F"ISEI],N2,7HE6-L6C3=ZE*7&
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M;2OHT]W4*=I,"6VYJPT4U3#^,.]&?K3%F%H+R*..A[ 3=5S,*>KCFV+E^&U
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M6M&NCIC<6P5MU\RI1OGST"TV9_X)4_\S0A*)GCW%\N !&[Y<W(A%[TL\P*&
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M3+G.6:3*['ALK[/#X9<,,Y;=33<,M@0'&;O4$4'8?W4R7$JX1?RZ4VW-U3_
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MWT*O*D?UMV*<=/!$^_T:M/USC\_H%TM:"KS1=M6ML(EX; GW8"]*Z %-"+G
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ML.SJ%88HDI/R]?#DT@@O+K&8SZP97ZVI]Y,-%YZ^.(W8D R/(995ZZU_"-"
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M_>)<S'37/+3?\+M7R\!5;AN'40"WTL'<5_4Z<1%G#O#Q-+QBPA2JR#%\!&,
M$.GK= GHG/ [1/0M9W]*7,73+A)K;/9R];^;**=&:FW\QK!YG=$1;/VG62/_
M&!DF]E'V/<C&&N+$QZI^'P"7Y9&."T^=^)(8X(Z#&.:V:%P"(O<2$)*)<;@$
M*).U<F+DJJ]<8XNP(:-6&_,6&))VHM-X1:<#^USP(K%_'W@O6R\XY A\>[5
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M[1+>BE#:# RX.>!G$'ZU%W[D0IR3M?5J+,#8V+BKK-7E1KD#FTY&U+V"T!8
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MS:IY/U7D?DC-12KB;IJ;<&@$W%)DU(K<_8G(*NW;,C,CZ2JG+72 MI@:KR/
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M9<D;PEWVT,'E2_LYQ'&O<)ZK*P.Z():&EK###11DTG7:3;%9M7C9-XCIMK7
M(\6RX8T'-53B6_(>[,(@ODBPW""1!SJDW.(N,-Q?U^-<L(O/'.$3F7'_.(-H
M693Q#-XRO_V<.8B]0=J;/$6\C^/]U8B8ZDZ>CAB2TLEC0CC.E/[*/<FT;#2O
MF@@N/3)OTN,#:03'<[/8PL?ZWLCA<%1#RZNTC:[+-HZ]'F59ODR_BD+/  Z!
M!AA>*N/YJJ,B:UJ]]/MU$^NMAS^.JHD/JSQ9=L)]1NHQEQ\+*FM<B]03?ZO%
M]Q9[!E@SC<2.Z]0@IN!$J$W/H_JIM&_]G[9 @3X+3+I22K>,WCL<JR$F#<D5
MV1A<30T701JL;6W-U'FQ\C3)'SAH/CP'   4^IHL%_ZYD[[1\V\O<B<N_*\B
MN><7I6;N25)FTBG4\@SP;3ASOOP?6WW^9X&94:OM&Q6$7[]N;[4S]MBZ?4ZV
MT:,I<952XA&\D(H(P+/ZDQ@@TC]W2\\ JU-?SP")AI1]K$EG &J%]).C61C6
MU?MW\=(S0 37,.GE3@=!ONEWO;<+-9K/<]D025>"6 G>980B4*Z5OOC]!B6E
MZ]S$#"'JF[? <JF?JU+;!6!==NU,+CD\<@2W@?YF4N%67IS%@93$^A>#L7X-
M01^K58K;M[[):MMPD\7T0K3HTFF\<[N36D2K4D.8S@!=NJ0K01 <*FDM@6VW
M/WG7<B\/-2N5N6EOH2-$:2OS8X _VRM3!)/Q^SML'BDX/^\7\]U?%%5XI('_
M6E%;;6,-ESLJ[D*C;].,$#TW'5B864KE8\)BHFQ55)GFX6R<P<CCB/R"Y&-)
M5IQTEP%![* 'AE3J/73EH\:N]%J'X'G%UJV2V0V)BL,ZO=!GXSZA=9P Y*4N
MJO?>IKZ>!#'GGJHK)ZK-./<S0+2:@.9:@JJ07INZJL:(N0>;]0/6"&W\1T'/
M5+ULC6>=WY]*PCDO0U."\S6#-($GK'J=-M<)M&@@!U1/$^=7Y95GJ:SM[E6B
M[\G3<$W!+L9\^$W&E*-P_==GDR<M#6+'=\PP;PMR"?JF7[M)"JW\].X*='J]
MS MNK^RG,:M-L]=>WTW!RE>> 1:,+QHR9@@ 19T..]4*\MJY<TDTVLZET/:1
M;4LZ''8^1H7J-X!&JX[5^#4H9<(;_-]8(&O+(X28)?^JVKKY.%<*6[#J Z/H
M<.U@(6RM]R#Q5>Z%TA&(4\\'V#4XO'7&V*BNL6W277H.IE#)=5N0V2I "RA)
M;9 5R(KLY'\Z";X3%'#Z$;BF1YK.(<=2=$0CQAER>;8M$_I*D1!9S><-BJ.7
M3"0EMCGB^Z>9O%O$&JFN-P"=@(F90(S16@N0X9L-/ZXB/=)71SC=8+8*\?3U
MBTF]C6'.UU*93VRO/K^D7S1LG_S7T@7,#U/@R=4Y\/=YD_,8*3S/%)[\_\L@
M#F#'R."*NOAK/5^YMVJB=Y.8M(NL48413E/[6_ZRM<J)*EW]7Q9S"X,BT08$
M2?I(C)JTAF,AP=N\!:MG<'&P=+0<I0E-O@E6B&Q'7S+N(/-7UGXX+QSD2R.=
M5E ^_F&H$:0P4M+<>$?*R&S>L>@^ZF#8^X=;+.$;K$NG]0(.N':0L$EXEG-U
MMM5D+8E^"6):_[)O>3.[<%C+B)5/,SGC7@ #$\N;2[=N];W('/A]9HI>?4TB
MB8[>,&J.GYU.Q C1,EM%,99;!$*Z.AN_L$]>#\R"M#V\^N3Z[<?LH@-B R]-
M;!^KS"Q/;MH_YWC/"[:/#8]H47#Z70$+C//&-^&4>OCC^&2QV;-I&9]VTN:8
MP%"_L7VB88Y>G&\['*$WD"(>SE-3W7QE4FFA(#[2Y/LK64GZ6&##[Q-MCGOU
MY;I"Q*K##>?+3W3QO![?#69\J24=IR(L[Z4<HA33M'3S4ZUK1R3V.27W:>K1
M<98\T8L_S$;. '1JMR%\\CB#2 7Q+&YH$.]Z%?-..^OTU233=M)T;4J?+QN[
ML8[#X89%5);T_EN6OBV1<9%;.&ME$HV!;VG0"YQ2I+SC] DX<*V#Q<K%,N>U
M[?4B6]C'^SE7PQ]$HK;0&R#KUEW1JYK56GLM8Q,S%WY1: 8EK/,31#TC6NG0
MO/2Z[=BD7H695@U__T\6ZLVE2MF!$"^%5NP^T>9B>?6#CU]"OY#3%3V?F 2Z
M8P2?X)BW#Z&T:(GKRBO5G%H-9.(/YC,3_GI*7^]\G,YEW1V_2N&R$+L1"?CU
M*?:G=!<8:]A!3M@^<<0#Z4[N0MNYO]07HINB"A1=\"O;("'NRK=%RWCQ1 %3
MVVJ'%W+C4%H231EV'EWU2F'9N0<)3/18O-<V[3/X(8VDX^T-"W1TIJ&4^V'6
M\2J[)I0,LW3W,Q42;C8,N]@!N8<+[*WZ6!1^8A%0MM!5@')SM2^/B-8.^]7=
MOV:1 X'+N0>6U&U6^H$:AD!/W_YV%P96&#()A"L,A/W </=RJ;LJWLF8I?Q8
M^M#C:@N"-.";\- 8_NR3Y!./J[DYLBQO>VY2S<B;]9T!*,Y3*C]3J1=&2Q#!
MA-#BFG=SY!%1RM<@Y1>< V$;VU,&+([[QP5N"BQ/IRZ\C0*CJ84V3VC/_Y=,
M )>8HY"09G!"^?D3B0[JJ**-YG#?_P1]MIXX-;9_/ QT4>YE6$[K%,[=.RR-
M4C-[=^&XCW48JMV#@\9U(WU/ES\U%2S;+&JKU,OM' Y*9LF&V?DE.JD//;JD
MY?CYEI"W)1 ;;@$;MS8[ U"F T]>A"J*EL,(]\H[OE:6G0'"]7))M[7_@1,?
MZ&+%$W%G #Q_#YAJ!9+Y'CE1,SVA\DE2:W.%_%7G]]L;L;@$?_P*P=?9MKT3
M6HF'R;#TSOO+T$6&>J=*&[;$\'XFB]]J7?+S"NMJMS(Q88<L''BJ"S^6(63\
MZ&-=#6$Y+5?C)HSW-H>D.GJCJ^K=_"^Y U+0FT]:WI2E;F%E(5L'Y+ NX\I6
M>ZR<SBRX)]D5)=>./3KG7T'(9>+"O>(5M=AGP)?QYHNJ[767IYYR,MN+2,@N
M/OU^65%*"NI:4KBPY/7>$5OW0S&6L+6(1WHR0 ?6KI0Y%REF8!?1IU%OU:)A
M)6YFH_XE5N#^*6ZOC2&,IX3XII?0]1O^R5_[ZALS@)Z>7% 1? B6/T8!(]+S
MJ^BUFB3!6!\G$OFT>@:A+*X7(&4Y/8YHH9>OB+%OL6![XHD*\&BWY&TATJB=
MY+4;-IZ6>)R 5GD#T=(1%79-A,!5(HAV69WV] %)U?A)U.XC^$S&JF/Z<$0?
M)/ 2K0 PZZK/=0;R:,AZ5?\I:'4>([,&O#QNET9BP^EUV1<M6^WX5RE6!8ID
MM5.C;K];;+6U%QP-'1#)2+HC^2E4[6U>NP:V"/,SW^9$%1M244I0ZJ]>AE9^
MU9K(!ZFZZ%+A485%BV -I_)YL465L@(U;U$CQ*N-RT?@NC, 1LD5EX7_0(C&
MMN^JXRB3*J!7Q&EWBS=F-^T=W?T=/24$G'67^<PR*F>HXT3UGM4\_LQ!MBTF
MOF9 "^NZK\ +&^ "1L/66!K3GYP!(E^A@9?=DA=W_8%MU=,5*#12S_J[V&F>
M8]JH^8.AV.[U-XI<*I[G06^+]8S^H:]M",>.QX_F1AW AZT]7!%*XHQM,Y4^
MA+P(VM!Q\6$WHBXMQU+A@I8.@%@92\COS\4:=U!NGP'XA0C6'[_EB'3@*A*;
M/FTK8<=+ES3= ;F&T^7[%@[?U>PY9]@].;RY?Q@6GOI;$1KGS@#PM-S5167E
MJ"FP1;AZ2TNZ:<MWTO3UY&*W9XSWW]$D+UI>?K^OQ'297H(-<%PJO@Z.X$>0
MFM:EXX!T\ Y&U_J7E,DX@=]O]B^4@(<5BP061KW$>\0>HN6XU3_;Y@B9FLA*
M;,9$X'.$".NEW\QL;N/NUNFJD&&)QKG:'776#W[LFAUJNO-$0?SEJ"^X;NJ8
M<EX,:THN,CCRN? #P7KH])$8\,T/Q@#NGB30HR7'FMS],AV7;E1TET"@VZ4/
M:M@AG9P/+?5[#JSB=:G[T3NI+F> AMS(HS, >1*#)4$;S3A5N>>)D%0+4' P
M"O!T]*>HF,D*F;.XJ#JB<G.IQV]66>NN6D5>^XTL$DWX:F!5Q$OG1+L)%?\B
M MBXQMH)A=__\7EZ05LR; DMNC]<'IL9K^S=)2YB6-:A\=]/R7\?)'=:I';=
M)801VQ>=< 9 '"U(7].5\M@TET0B.:Z_J?G>];3,E_(YE93Z?M=5LCTW\;$0
M<@@;/R>)T<5&:*'48KP$M+6UY-8@47],W7\[WW3EN]A0(ID_@.]H'M9-YW@&
M4/4%GW!9G0%P0X O>37G.H&R]@R0TUQ%HI."$3;Y_S?\JG1;>:!//Y!F=$]A
M.S:0.RWY>DN:HY.%9/=[90;JI25BYK8+6=1_9?N_/XI-;]E);](_F+RVA^=R
M]3#B0;XR6;SOZ=KI#>#:N: L3CS'SE?\IVZ V;S:CK_=^<?O)2_G,[7CI:H$
MIZ6E5YO@80SN* :CY"T1 6V;*2F9G".E$V&ECA]2$/#QX?09(&FF QL'F]$^
MA^+.)!*"_S\-@.8Y+=4_.*7-G#\]@9]3LQ^P;N-S!ZEOG7<;)@DDG.J=<[F&
MT_OGLTE]!M@U^IME2"Z-A@RR1&'G:N^MA@L7 7_R-26]SJ6'2\>'<-Q1>MW.
M;[7SRUZ/AW3_7-IU^K@/=;[NHOH60![^1D?5\T1@Y8CQG"$*G@$JM/_3,.%\
M()TI-<(,>6)4-Y-ED,!&?\G-L%S#C9S(M<=[4T:)QRP;TE$G$A:D6P'>8>^@
M]QVL/)+O2-P\3\G9H*Y@R?AY*]H/E,?3Y>,<BYNVSSE[7N;^:UN/J:(-B%>"
M%)JGKE?GKIT!XJ4D"J:_3N6%P9C'Q<R1#^?V)T"4[0+(FW/UFVR\84")9XNI
M[U6929>FL2NZ.-8?AP3I?C.DR6CZPM.I_2!-B6K0YT,W)OT7_F!FX9[ZPA>F
MSB/);*>+TAR_E$B,GK]BSADPXQE@+O\_C0_T=#C^O=O8K_TW +,G].NC9H.(
ME,',[WW'QH@1#ZF!@SAPJIQH>POUE(=+[QY#,1G73=+G$+*&.9"AP45HD[1C
M&!J%-L'QE'J2'_CM3Z./F77X?F%2M)=PG$OY-[KX>O[D0:KH;7#U?/>IH.%T
MY?Q:3H=70"$*M'/3RGI7WU>F*6QK9^=&]D:K4_(<9#%M:2.UE:S[JDGU:6PK
MW4=K/:]"J#&:+1VXT*O8X8Q[1M+*NCJ=KJ]7!N4B=+%.6>;EC=7\#*=H\' 2
M63S/OS_$\UJK,3;W'JZAS_,R=.4)]E&3-QI&I>%%F1J _Y:Z5W(G\J\ R O&
M8X#:K_=^?4^#)$_353BQINB%$YG5#HYM/4>6YY8]_#&;+I*"9HE:.GF0J>3R
M*A;/FR87_:R&6U,,RF'=DF< (][S;+\(_#7S=^L"^]^39?(?"7$D_:_!<Y?Q
MG\G"C_T+=0:8:*J K0P;D("/SP!_:MG&DW'9ZOH\=JQR?3)G(NF4UTH*@>7N
MLA$@)+#'586P"8^__IAV8WTFAUOPCLI3ZB]*V;/J\<$4+]G_M4?&HEI@IB8$
MCZ:E9/-CK_9,1?C>4^B -@)W$.GYP]JX"PG_Y5%T*6Q+*!,I*,"7_^(11PAE
M*^H8+TFP+B%D]=]IF^^VV#]0>3DO"P&[-$:9.Z=LT4*E'!*O-]T@3QEP]6Q;
M>^(L0RE4;TX$_FL?GMA!*RN([ 0R:W=C3 @-;FF[3%M,EYE0O]'S[/!SRJA"
M*\QSP5TE1:ORNSJ3EMV>>?J+OJ(]8^R8.#^#IC]V'#0OC-./V_Y5N-5P'A\0
ML/7]G:'>I:7E0=DFK4M;XM$+++0MSV3(\54$S8X=P=^Z4_L,8)GT-RM4)5KS
M-%6%;FT\7I'O3C56*<X]Z%[ATA(*]&Q^Z4N/ZM"#!J:*C%;%KHWO6WY>'$X!
M!2_\=3:;#PAFF><#$U$_1W5I$&G8W840T8/_'-!^)PF?F]6"4>Y8/SC.\FX@
M>#5L5O;\(:$IFDY#0UBL@Q["V!MZI)D2_/3M#!A4RM"73#FE-V33&V_2KHC6
M?+=Z\0X0>A- %MB[4NL9JF*;M]/L5XC]"FJJG>L"?4DL9GE$UW<TR,G^- FU
M8Y;0Q;];,\D@7?G'8%Y3XSD-#V$C6.Y;5+1S0W-,FQ^GE_FC.3WR9]F'9?*L
M"QK*&VYP.,F4=\U=]W>@&>D=]R4R!:G,)+[Q#&)=Q^C"0<4>JX$''-;+\N,4
MO>PW);;T\$J7>.8FFK45?Z@7A"HI!G?\8=RLU:=Q:KRN#?7&/=@S0%^<\#N$
MZ1D@-M'*I@*N6+U8,4'TD$I3J&L0$[G"FOP^:&QOCD1&^HRZ>)KINU9"4.[D
M$YD^2$."9!3&FN<W- 06\C\0-3?><3^3!/Q@B+?W=I[_,X[@Q(%?DM8J,]:"
M^77@!%]T(#>8WIDH@_']>;6IVDZ2DO!5;U*L7<(]:G6AUSDW^UA._31:C0OJ
MK1M\9W'M:]R59 5$16%_!C!F*]>@1<_V64U&14&;2Z%=O=^N8'/=@^+A:\_W
MN9> ?^I"+U8R[^06UNGM!U<;+AR7:Z9"N9]IG%<PW4P9BQLKF9YDC\X&0,W9
M;J!)H>+_'=+00G-P\U0]+P>IBF4M8;A?&R21(,7)$!F0I0::GP+B7V->IR*:
M7MW)^@Z@R[A4:<#C?.LKK[X?^%]Y@Z--I-B$SZ[F ^E\,[ WLVZ9G'C/!A1\
M'SZ]URI>/@!Q9.JB@<_5R@J$LGBX#O, ;HLH;$R$],!H/N#XPQ2,L9EXR$KT
M2]7V5Q_AQR6R&HZ>E]]T72Z>UY0B=Q7'R$6+#3Q7#K7%K/QK^U9V>4UVY5'0
ML50B5]"="95[CL7F)RHXA0\U;=9:RM2^7Y/T4M:D<O8Y'6K9<YW>?LPX5K=1
M/ QJC @T%>TV)/@2J8.D"0Z9- LG2CBM@ASV,&[]:PHK#,,5G[+(%0\7^RZ+
M!P2*ZJ3=*#",O7BRT+]:$%CU[X!'%;X+K@;W\+[HT85[1J-NUM=-;(8%*H.
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M+3$S+FAT;5!+ 0(4 Q0    (  2>8U*A9;R+[0<  &XG   +
M  "  0L-  !E>#$P+3$T+FAT;5!+ 0(4 Q0    (  2>8U*'2LJB8 (  !\1
M   +              "  2$5  !E>#$P+3$U+FAT;5!+ 0(4 Q0    (  2>
M8U+:7,FFI@<  *X9   +              "  :H7  !E>#$P+3$V+FAT;5!+
M 0(4 Q0    (  2>8U)4-'+CPR,  $SV   +              "  7D?  !E
M>#$P+3(T+FAT;5!+ 0(4 Q0    (  2>8U*A%J"!4BD  (-F 0 +
M      "  65#  !E>#$P+3(U+FAT;5!+ 0(4 Q0    (  2>8U+@G]GD 54
M %^2 0 +              "  >!L  !E>#$P+30Q+FAT;5!+ 0(4 Q0    (
M  2>8U*-;BC < <  +$<   +              "  0K"  !E>#$P+30R+FAT
M;5!+ 0(4 Q0    (  2>8U+]5(U_/@,  )4.   *              "  :/)
M  !E>#(S+3$N:'1M4$L! A0#%     @ !)YC4CM)=7;:!P  4BT   H
M         ( !"<T  &5X,S$M,2YH=&U02P$"% ,4    "  $GF-23(;+'-8'
M  ""+0  "@              @ $+U0  97@S,2TR+FAT;5!+ 0(4 Q0    (
M  2>8U(&93"M.P4  /\=   *              "  0G=  !E>#,R+3$N:'1M
M4$L! A0#%     @ !)YC4H_YE/L_!0  (!X   H              ( !;.(
M &5X,S(M,BYH=&U02P$"% ,4    "  $GF-2!BB#<^(.  !F#P  #P
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M9"TR,#(P,3(S,5]P<F4N>&UL4$L! A0#%     @ !)YC4D3UFC2\5   9X(
M  X              ( !_W\& '1X;60Q,&LP,#$N:G!G4$L! A0#%     @
M!)YC4MO5/YCNIP  #\D   X              ( !Y]0& '1X;60Q,&LP,#(N
9:G!G4$L%!@     7 !< 6@4   %]!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
